<SEC-DOCUMENT>0001628280-23-006041.txt : 20230302
<SEC-HEADER>0001628280-23-006041.hdr.sgml : 20230302
<ACCEPTANCE-DATETIME>20230302160556
ACCESSION NUMBER:		0001628280-23-006041
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		112
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230302
DATE AS OF CHANGE:		20230302

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARDELYX, INC.
		CENTRAL INDEX KEY:			0001437402
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36485
		FILM NUMBER:		23698855

	BUSINESS ADDRESS:	
		STREET 1:		34175 ARDENWOOD BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94555
		BUSINESS PHONE:		510-745-7047

	MAIL ADDRESS:	
		STREET 1:		34175 ARDENWOOD BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94555

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTERYX INC
		DATE OF NAME CHANGE:	20080611
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>ardx-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:9159adf2-88b0-425e-b00c-16d6f1bd5962,g:73dc270f-0b38-43c2-8fc7-c4890fc3e73f,d:8c6ecca27b7b4659bf1d61cfb55de996--><html xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ardx="http://www.ardelyx.com/20221231" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ardx-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl80L2ZyYWc6ZTlhNGMzNjJkYzMxNDUzODk3ZTZkZmNlZWFkZmM5NDcvdGFibGU6MWM2NWYxYzgxNjBiNGEyZmE5ZGI5NTU1OTZhN2Q4YTEvdGFibGVyYW5nZToxYzY1ZjFjODE2MGI0YTJmYTlkYjk1NTU5NmE3ZDhhMV8zLTEtMS0xLTQ2MDEz_481d9a01-a230-4c45-ac25-60ba38525571">0001437402</ix:nonNumeric><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl80L2ZyYWc6ZTlhNGMzNjJkYzMxNDUzODk3ZTZkZmNlZWFkZmM5NDcvdGFibGU6MWM2NWYxYzgxNjBiNGEyZmE5ZGI5NTU1OTZhN2Q4YTEvdGFibGVyYW5nZToxYzY1ZjFjODE2MGI0YTJmYTlkYjk1NTU5NmE3ZDhhMV81LTEtMS0xLTQ2MDEz_9fd85c2d-8d49-4cdd-ae90-22c335b07018">2022</ix:nonNumeric><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl80L2ZyYWc6ZTlhNGMzNjJkYzMxNDUzODk3ZTZkZmNlZWFkZmM5NDcvdGFibGU6MWM2NWYxYzgxNjBiNGEyZmE5ZGI5NTU1OTZhN2Q4YTEvdGFibGVyYW5nZToxYzY1ZjFjODE2MGI0YTJmYTlkYjk1NTU5NmE3ZDhhMV82LTEtMS0xLTQ2MDEz_5bbfdbf6-5369-497f-9c70-7eec45d4c45b">FY</ix:nonNumeric><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl80L2ZyYWc6ZTlhNGMzNjJkYzMxNDUzODk3ZTZkZmNlZWFkZmM5NDcvdGFibGU6MWM2NWYxYzgxNjBiNGEyZmE5ZGI5NTU1OTZhN2Q4YTEvdGFibGVyYW5nZToxYzY1ZjFjODE2MGI0YTJmYTlkYjk1NTU5NmE3ZDhhMV83LTEtMS0xLTQ2MDEz_b926a01f-8799-46ce-9421-d47543ceeaf8">false</ix:nonNumeric><ix:nonNumeric contextRef="i2de3a294b21b459b8c55c13b0a994e24_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzY3Mzg_4835439c-76eb-4d2f-801e-529f6574b0d2">P3Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ardx-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaeca4a04a1754667989d2f2d6e9f8f59_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i9fc42224cc0a42e883f0fb58a584b2a0_I20230228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23bde0040cba4440804b10fdac242262_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ife1a6ddcf0434c3d8408dc580e20d7d8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6d0767c281240d4900cc0d8b9580230_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifee111286a5d4c6e8104da9cafffda38_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c1a31c699a645968b918a7d82fb494c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf3e168c61fd47e8aa38f9a4632206aa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d86efc199f945f69a8db92f44a6eaea_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8defbd8e977443b8e24752f1ecfdee1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80db9f923ef14a778c2d03752079fed3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f9dc553215546f099c0816459c4a6ef_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8955c2eaa96644dfa5eaadbf2a538826_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:CollaborativeDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib046fe75c1ba474da9dd251df8f9addb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:CollaborativeDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45f387fd7df541f5ad7e47ddafdac6b3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:CollaborativeDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i473a2780d03c4c7f8d5e27ab35bdee43_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i559db82cad364aea94a0a0919778a7f7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f9d007b877247ec802a3c602ee3687b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i307df19e90fa4871af799b2b66ba2d31_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c73d82cd653451cb3c69d920ab3d8aa_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c4c2b1d0a9e49ae81d18933f823dba9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ebe0866adef47559cdc2ed65973c005_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63b7a92a09e442b3b15016267ea44e4c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icad9ba2326db486c889dd50988c4fef1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2aa43c785509442dbd5e3673f8823fe4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5a3476a21d74624862c1503a0509e16_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34d8d1400f4a4785ac6e2406ff8e5935_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i271432361a3c43cf9ae96050134ef2c5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0fdfe563b2749f3ad36d74c30c121dd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaeaeaa4c910f4ab5acf339a4968d2a9d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6cbb5f1b5224d25910844cbece963f3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7488244a81d34508944e33dfd4bdc232_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ca2f91dea984f5fa2da91bc632532c1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id70cd43225df4f8fbf5df3ec715b334c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5bd779bf4924020b0765a5cc69ceba5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c1428f4633d41e7a98d5a585209403f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c90b227c4764ac7987b4eef73eeb87d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if786310abbc54aba91f5e0a5b90b7706_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic403adc07fe947369c966ca335e3f7c0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id792a81211054c6a9da992ae71d61ce3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e05fc9654fc4f24b753405c6aae07a3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21472ed42ab040bba0bdd50fdd86e0c6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2954e41000084c28b87d9af1f3c00c87_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i236484790d154382b9ab018143306fb9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a16bb549f604ba4b134dd1fc542e6e0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>ardx:segment</xbrli:measure></xbrli:unit><xbrli:context id="i2de3a294b21b459b8c55c13b0a994e24_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06f6392d8de34129a19422671d121309_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieca82817eeaa4e6a9211772c02ceff0e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">ardx:AccountsReceivableCollaboratorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e0e80bb8eb7493a85b933d3d97f3803_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">ardx:AccountsReceivableCommercialCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia88c0559b8474f5190912f03388fc38d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">ardx:AccountsReceivableCollaboratorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23a66360caef450d9534fe2775f21255_D20150601-20150630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-01</xbrli:startDate><xbrli:endDate>2015-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i8e9b10bffc104601b9077dcc9e1f4fa6_I20150630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d34215ee2e348899b09d93611aa94d9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72b7f1283e114d98b667e2d3b9d78c10_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82f59874748f487e829f759d2d2fe716_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieabaefd41b574aa6b074694d974eb95a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cffd7fcbbc544939e32a7a8f34622be_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91fc450e044e494a99d00262c55ee834_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0604aebc55e7425795ca8e599d946833_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98269013828c4cbf960fd07466f62e00_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ideed1df6eef44d1f8834a64175dd3912_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbbc030abf9e4d3a8044fd67d677deca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">ardx:CorporateBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73a4c3bd901c4931af270d9b6aae48be_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie309689c7e5145568dac251da707114b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i197012cc5c3f4d0186f4f6f49afd9938_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="investment"><xbrli:measure>ardx:investment</xbrli:measure></xbrli:unit><xbrli:context id="ifce32edf589c43559645ca939f8321c0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i800c2d8a407c4f52a90eac1ac7fa9c7f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic862582842b14106872fa00b3bc1a179_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c1965f94e0f45c8ba92675a0a9e37a5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibeba7a62348343fda259cc027ff9efaf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5530fb3f55994ff9b89b29a90019a352_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i215440159e8b42d48ee9a7911b2b27ed_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic020e23db5fa4fd392335d177235faab_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6a449d340e445639849083309b50cfc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b017fd3d9ed45a686ed4da0c90e2b8a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2189793c12b94eb5aea5349640fc8e74_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4045d24f631d4b57b3bad1d73d787f3b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0091d5584e742729920f89400c5a7ec_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63caa9b53ecd4496aa9cbae0e6aebb0f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d651a762ddd4d42b1eb146a2f77667a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41b180661d604a9db63c4cc471ee7d76_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i691c998073704928ab9052cb14232a00_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i733e529140624718b49d4f80ac96a2d6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4139c0b0d3d942078ab8524d3ab1edfb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i663a0605660842e1b03f18928affeeff_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a2ed7629e8644ca88a18430d955a065_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b7cfff0602c4effac77d3fac445e8a0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fb4cf2b13f04f7894360378ff59fdd1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5ac62ac7b5c46bfa5e837d80abb240d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe6734a4d6234308b332b56b6c66f456_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf63c7b0e2bd43fd95a03bb02babbf85_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53e4cddaae814c21930efe5f393ab81c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e79c3ee3bba453c95e397f21030d21e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31e14a2329e641e4a02f507843106a3e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39124c37d91d480fa7bfb56ae5e2f223_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49ea832c4a2441fa815b2b46be792d19_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia22881527d4b49cc88625aa8abc67b5c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13616c69d6954d9dbcff580bb0481727_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cf9501a699e4a90b12f236486a35622_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16228cefd2e34ed3ad2ef7d53b54f81c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i132317a517fe469983d16efc145dde7b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if244d874422d4171840a2bb10d682a60_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if834c52fad8d4fa786b3476c7c479709_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i243d57116a1a4a2abd6f7b0ba194d8ba_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c70318515a54462aad17c07ab4595b2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13f16a403b294350a327194d8765e8ef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie065f8ba75da42ef8bfcb4016909b6aa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa8e2576d88e4d9f819b34c985d539dd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1f7ed33632142769f453e0680a04d95_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if07f3ef040004928a2a337f7a98fc44c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc4e7bf5193a4086bed2f7af56d70ed0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i390e968f8ffa426689dcafbbec33f877_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bc52b266a974dc1bf42493dfd520bfe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0713ee81cc9747f9ae72ce305219dcfb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductIBSRELAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71d12a4b8c5d41dd913f71f3f0c6a002_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ardx:AmerisourceBergenDrugCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cd807982655470294b4c867e9790f9f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ardx:CardinalHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9f614394a884bf3935e5190b6e13cbc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ardx:McKessonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2edca0d9c9d04eb4946163e30a07c874_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerDiscountsAndChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4364f4f8eb794e579c0d74bdcfc9a74d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerRebatesWholesalerAndGPOFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i211614897cb84b21a3db4459c42a8128_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerCopayAndReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbd146d95630481b89a9e53d21e7bfd0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerDiscountsAndChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i378e9c4f2d8d414fb7b08c9fccc9c3c1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerRebatesWholesalerAndGPOFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i375a2ae60c4f4ac8bbe9ccc543f7a1c8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerCopayAndReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4459a35d21754ee897db3e8dbb29305d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerDiscountsAndChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2880e66b0644122b083edc9fd38c11d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerRebatesWholesalerAndGPOFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i855b02ed9cf247be9e99838bb95cb4ba_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerCopayAndReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i955167e463ef48678bbc1d03c4f4d412_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="item"><xbrli:measure>ardx:item</xbrli:measure></xbrli:unit><xbrli:context id="i91c2203d38fd405d99bc3c88353bce51_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5096f6f9abe4dccb2dab386d07f22b0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied48f951c2e54c4c9458741287f35022_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfd7890f2ab641b689a46d3387cd65f5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i317cad6de7604d25be88b176cb33baec_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f143c1e0eb144d6b655d94ab37c1a53_D20171101-20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff763b0fc4f84d4dac40730c49cc1731_I20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i687d24ba9ed84bf19bb4b4b49a494d08_D20171101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife00f72d231640e4becd88f58e11171e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="jpy"><xbrli:measure>iso4217:JPY</xbrli:measure></xbrli:unit><xbrli:context id="if2637e6a1a82402793001d3d295bbbcd_I20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="payment_tranche"><xbrli:measure>ardx:payment_tranche</xbrli:measure></xbrli:unit><xbrli:context id="i59072502f7a54137b0895e14bb4f6df8_I20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dd8313c3e094ef89785a59b13d01eb7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60b13327723642e6932c3f852855047d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id10493b7130846e6b2a4742b479a65fe_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i715636a1b5ae4b288a29b92c2f3a54b3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i274489be58ee4be5a06cb71683dc70e0_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96f5a69e2c1547719e984c8ba3c41ff3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99e3d63e61664f6bbfac5c19cb4294e3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff2fbe5c1eb741e185c1d68735dd7502_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7523c9db4f3440e1bbc8ab0589ca11c5_D20180301-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KnightTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if78e3d93318c461da96ac8c6973a6f76_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KnightTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="cad"><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unit><xbrli:context id="ieba6fa1b17514fa99298840f1171592e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83f16a4b0497447dae41222920314fae_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f4842d33b674e97bec5e1f35f13347e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85d4b734d53646fa9eece46433fcc33e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if72c0334b4964673b5b1e29e363186db_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc0eee8426754521a747a26cbaedb831_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d7903c12c424b3ba490589eb00fd14d_D20150601-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c98abb4d89044e0ab93ab428d564f5f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib952c4e7da01441388aaeecabdfe075a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i236464e64f8d473283dc7641b1f31d01_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8366fe12a3334315af3ed1c7052d20c4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8ee7345370441099ade9119306db79b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d56b583b1d146f7be5316e8e2d710b4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d7bf861c12549a792483e8efc814a9e_D20220601-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:HealthCareRoyaltyPartnersIVLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41ff706f90cc43a59020a70376e95dd2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:HealthCareRoyaltyPartnersIVLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia283d9f31c884152af9cfa5bfc1c18cc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:HealthCareRoyaltyPartnersIVLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38d4c1dcbb354f1cb8f7b983e2aba1a6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:HealthCareRoyaltyPartnersIVLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i933aaacf34f34a61bfa383d7cb1bb60d_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if95076af06f24f2296cea9a5d6d76ff4_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8733e6fccc254fd9bf95445ad142e86f_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95d5e831357142ff915c3c75ead6d520_D20180516-20180516"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-16</xbrli:startDate><xbrli:endDate>2018-05-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c495d34647447ae8783de5a900a3e77_D20191201-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69ee8e8bda5947d3a7b266f55eee864b_D20201009-20201009"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-09</xbrli:startDate><xbrli:endDate>2020-10-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1e9f731799b499eaf4aa779cb305fc6_I20180516"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idaba5dc7a9024a1b89083ce66516cffd_D20220223-20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022AMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-23</xbrli:startDate><xbrli:endDate>2022-02-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ed59bf2f32c4c919325b9d6800e3fad_I20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022BMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i582ccc703db84580ad605cde3180b598_D20220223-20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-23</xbrli:startDate><xbrli:endDate>2022-02-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40c1281552f94064963e3bf9cbecc666_D20220223-20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022BMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-23</xbrli:startDate><xbrli:endDate>2022-02-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62a2e82e4ddc4240896cf7fd6f83fbf6_I20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022AMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id31b250d8a3946278fda76b05ca4b4b1_I20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if668412fafc546cc955d0c29fa2f6c99_I20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f56c96387e743bbb3742ef501488a40_I20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72298d93078c4637ab00517b03176997_I20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0d290137b1441abbf8d0d36c58a8e95_I20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4584120047b3460da4d6b5a0f2eb0808_D20220223-20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-23</xbrli:startDate><xbrli:endDate>2022-02-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddc086b231bc43f99e47143a4bfb2914_D20220223-20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-23</xbrli:startDate><xbrli:endDate>2022-02-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic957e7b2e6404684ab3ce4588e0747ed_D20230209-20230209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermBLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-09</xbrli:startDate><xbrli:endDate>2023-02-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b61195b8cbb43b4945e83216c7f171c_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i829995ddccd34c45973808967c7cab51_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23902f57514345efaefc7f6ed372683f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73c09104400b4fc89c22d500c708517d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a01e0a1633e4784b82496570aa01a7e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a1e94b571de450d80084e08a561e5cc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia25f50b8fef94d1a9bc667f04f3a26ab_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07e35ddf250a487cbae6c8e1f803a4b1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0080f34bc4774f159a2fbc226bec7e75_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ideeb597472c94a98a7ce7e756017a2b2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib44009e3ef8846b299ee2faab0e9ac8c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0921c20fa4634446aebe75988e9825d1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4aa9ee384f104add8be1fdc63cb9f8ce_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74fef4adf9a14a308f8328b9570c5a83_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic44d3449c4204e78b2fb999f07d658ab_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0d3d90e1a504d63bd8c04dc4913b676_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04b8aa4c409143baabd2c14fa0c59341_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60af5b7c588a4c7b92f37d85a0e4d590_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7aeaa47a07574280ba69e0812b3fc9c4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="lease_agreement"><xbrli:measure>ardx:lease_agreement</xbrli:measure></xbrli:unit><xbrli:context id="i26bf80d609da4735913857489e4da748_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:LeaseArrangementsAxis">ardx:FacilityFremontCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i335c2c940aa8413bb90dd9d65c09b3ba_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:LeaseArrangementsAxis">ardx:FacilityOneWalthamMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if84711cbb7fb484d9907b17e292a5c75_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:LeaseArrangementsAxis">ardx:FacilityTwoWalthamMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="renewal_option"><xbrli:measure>ardx:renewal_option</xbrli:measure></xbrli:unit><xbrli:context id="ic02d026a5b904c17807bd479ea7d0b3e_D20210401-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:LeaseArrangementsAxis">ardx:FacilityTwoWalthamMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c53895082604a918d0ac2f036a8236f_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:LeaseArrangementsAxis">ardx:FacilityMilwaukeeWisconsinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i191e1bf76f4b440593cb3aed98e7c4e4_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:LeaseArrangementsAxis">ardx:FacilityMilwaukeeWisconsinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if776a22c61a44a539fe0fe538eb2a3e2_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c0917f6cb2342afb6023949b42688ce_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2020AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4aee40b13b3480c9ac040be86a38b5d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2020AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e194876618f454a8e69ce8891915a74_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2020AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i091722886b334fd9bde76bd765e73617_I20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2021AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i387017f0cb654df1bee8547faa646789_D20210801-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2021AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id010daff3c1947e29d8c5fd89ebaa449_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2021AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieeb64a378b284f01ba441778bf717ff2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2021AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53cfbbd1366348c3a6a036a0048aed7a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2021AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0543a071cf942e590a16ac2b267ca3a_D20230101-20230112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2021AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0edad5a730a244cba8f8a9819262823c_I20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8349613f0ed462d8ac8ec08c2be4b51_I20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2023AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05cd4ea70ed4485589e755e460b69fd1_D20230101-20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2023AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59e25fbea49d4656871685e6d2d6c76e_D20140101-20140630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:TwoThousandEightStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91127df0154643aeaa974e5370a0d08f_I20140618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:TwoThousandFourteenEquityIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-06-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b2b0a1450e146dab1869a3c643a4b54_D20140618-20140618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:TwoThousandFourteenEquityIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-06-18</xbrli:startDate><xbrli:endDate>2014-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib434fa02b7f94f70a56b9427b8d40564_I20161130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:TwoThousandSixteenEmploymentCommencementIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id17ce6206b53406fae2405e677fe43ef_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:TwoThousandSixteenEmploymentCommencementIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43e122158f0e415aa7661317d01ff3be_D20220101-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:TwoThousandSixteenEmploymentCommencementIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i083ca43bb16849a593d6fe2102ad4aca_D20221201-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:TwoThousandSixteenEmploymentCommencementIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5d377e7e91446f9872db311ff7a998d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:TwoThousandSixteenEmploymentCommencementIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i208be3295b5d448a8b943c647170b858_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d035ef039b9449f9a833a4878f300ef_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief16b3cbe3934dc98b9bc68d2856ca35_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5c3b975ccf642298e9ab071e46c4b8e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f8f14f6a5a441a4b8e90c587038294a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad26c62e1f7040819c46ba8aaecbfdf7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5804b276fcba47ec9888f9294a058bd3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c4f587701fb4044879019a9bdf73a97_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic72722bcacf846aeae4e32bdaf25ad95_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0a3fa62b68c4a38948feeb7a5990743_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i759c16cd46934957818cd44b6da608af_D20180701-20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ardx:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a36013712a244a6857a4ef451619a76_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ardx:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0963364402c4d97b8a169943f9ea6a8_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ardx:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i477da3d9a3ff40539adf947d1f500015_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie25852142a964d3188c11071355f91b7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3f407a43bf14aab8924633cd249ade7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i517e23fe4e2f4b29b85b4d380f6c2944_I20140618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-06-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i180188a490a8459b9367c5d5573a5e16_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i248a37dc8c184f47ac596a1ecc3f232f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1fa16bad9884e0e9493c7512c233aa6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8ec837e0d0b46c8864c912515db4ad0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9c65dc81f5a450db626c1aa9194755f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb74b9fdd27048e29f9e1520ac5e595e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b365ae1dfda4e07a8271c22db477bea_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie78b6836511840a480c1026e771997e3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48d97bd1c889443c8fee636ae7505dd3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0ec441698c9479d8b42818e25d70400_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5830a4e62ed14db59de4465b18e9bdb9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i431ed8f3e092438fbec58a56f0b02185_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09a681eff916461fb51eb3329131ce8c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ardx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic11d410599a74593aa714291238376f7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ardx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb22b29792e5485ebf185f5394ba3762_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ardx:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc9a17e7794647c2bf47f0d17f42638a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ardx:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69f5495993474d55b708c186a11429b3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id91a83781eeb4816af435aa999f55171_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac8bff27f31a4cdba6c1c3861745b2ef_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0a0600f40b045c6b35e188f2f71061e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i417d82d19f4a4fbcadb83d9e66e6fd76_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i888d6abdafc14bdab944dd9b5f92fa5f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b6ecc5e16524d9ca5408690716f1a33_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4ad706ca1134370ac1fdd46d324a005_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">ardx:MinimumTaxCreditCarryforwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if221b086648a41aab5554e1ca5f792ec_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">ardx:TaxAuthorityStatesOtherThanCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if59e9efdbe2d42718f4a91fe0b12275c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib44743fdc95f46f182f7c502b1cd9c4d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic04f77eb07ea4224a01520efa0f633d3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1746af5e54554e499e907d7129518fd0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i511c3600481046ab8ea3a0188db062f2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b925d525dc749719f6bd325cefb8a1c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae0dc045d5b541dfa650458342fbe24a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c3c4d25be5c41f2a23bc91cd0c77d25_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b4c067ab6484053a239a2ccd02d90d1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id19674491cd54b0c969b0e9bccb5521e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ardx:CollaborationPartnershipConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:KkcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3fb70f0cf0f4182806a3abc3d5b5b25_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ardx:CollaborationPartnershipConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:KkcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ac81d53477e44f6afab4b4e55da6c0b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ardx:CollaborationPartnershipConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:KkcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2805b962ce1c4f33a04e27034cee3305_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:KnightTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ardx:CollaborationPartnershipConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d1f27a987ea46e4ac5004a0280afb04_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:KnightTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ardx:CollaborationPartnershipConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifda028b327984abab2f5a8dc37dd7bf1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:KnightTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ardx:CollaborationPartnershipConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iceaaa79f1b46468e9d5df39ac4e0e130_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ardx:CollaborationPartnershipConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AmerisourceBergenDrugCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f6e6bcfc89b4e3bbbf5ef1ab1cfa46c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ardx:CollaborationPartnershipConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AmerisourceBergenDrugCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id58e400e1e524590b3c5cd7fe872d7d9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ardx:CollaborationPartnershipConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AmerisourceBergenDrugCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4411bca5f204674a4e725c73570e515_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id664c0aa97b74d6b933633eb24bd7ffa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1833de563c44c0a84b1e4c778b58c6d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i952c9b1adbbf4d96b9b3719a4c54ea85_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba8409a9d3074b558e62a6b388c3ab67_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96a34e4ebc4c41b5b53c6de94e6f9347_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i538aeeb65eb843779d9a0e11b1e50104_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb0f4765d39d45c69282d8ce87f604fc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b5f3274350745bdba9cf5da71e8b2d5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6b3a9fd0ae14ddea562b4e1be92c9ca_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8ac5065cbaa4252992fdf404620572d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if66074aa8b8c4eaf87dfdefd3d2725c2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib374c30529ad46698e71cb3df47baab0_D20220730-20220812"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ardx:StrezsakVersusArdelyxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-30</xbrli:startDate><xbrli:endDate>2022-08-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>ardx:claim</xbrli:measure></xbrli:unit><xbrli:unit id="defendant"><xbrli:measure>ardx:defendant</xbrli:measure></xbrli:unit><xbrli:context id="i4720ecaa980849ecb662496f697442e6_D20220719-20220719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ardx:StrezsakVersusArdelyxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-19</xbrli:startDate><xbrli:endDate>2022-07-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fb81fa2f1994bbf9c437971dd33e52e_D20211207-20220329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ardx:GoVersusRaabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-07</xbrli:startDate><xbrli:endDate>2022-03-29</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_1"></div><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:120%"></span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">____________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGV4dHJlZ2lvbjo4YzEwMzI4ZDE2NDI0NmFjOWQ2ZWQ5NTU4NDQ3N2Y3OV8zNjY1_7cdd28da-6350-4d5b-8192-a4ad30948696">10-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">____________________________________________________</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:18.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:490.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:11pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">(Mark One)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGFibGU6YTZmN2IzZWZlYjZhNGRjZWI4OGVmZDA0OWNmZDhjNjEvdGFibGVyYW5nZTphNmY3YjNlZmViNmE0ZGNlYjg4ZWZkMDQ5Y2ZkOGM2MV8xLTAtMS0xLTQ2MDEz_caba47bb-c0d5-4410-aed2-101da554a496">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">FOR THE FISCAL YEAR ENDED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGV4dHJlZ2lvbjo4YzEwMzI4ZDE2NDI0NmFjOWQ2ZWQ5NTU4NDQ3N2Y3OV8yMjU_0f0ff1f1-dde2-471b-9c4e-485242d38047"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGV4dHJlZ2lvbjo4YzEwMzI4ZDE2NDI0NmFjOWQ2ZWQ5NTU4NDQ3N2Y3OV8yMjU_4b725c36-0b91-4819-89be-1d4c38002690">DECEMBER&#160;31</ix:nonNumeric>, 2022</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:18.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:490.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGFibGU6NTRjM2Y5MjhiYmRiNDYwZWJlMDBhNjBjMjA5ZjFmOWYvdGFibGVyYW5nZTo1NGMzZjkyOGJiZGI0NjBlYmUwMGE2MGMyMDlmMWY5Zl8wLTAtMS0xLTQ2MDEz_de16e466-5d6e-4e37-bb1a-08ea38c3e64f">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;TO&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">COMMISSION FILE NUMBER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGV4dHJlZ2lvbjo4YzEwMzI4ZDE2NDI0NmFjOWQ2ZWQ5NTU4NDQ3N2Y3OV8zNjY4_45480c9b-e842-405d-a7db-e51a3d22322a">001-36485</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">____________________________________________________</span></div><div style="text-align:center"><img src="ardx-20221231_g1.jpg" alt="ardx-20221231_g1.jpg" style="height:100px;margin-bottom:5pt;vertical-align:text-bottom;width:100px"/></div><div style="text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGV4dHJlZ2lvbjo4YzEwMzI4ZDE2NDI0NmFjOWQ2ZWQ5NTU4NDQ3N2Y3OV8zNjY2_7e20bbef-a3a5-4f13-9531-9cfd359dc7da">ARDELYX, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)</span></div><div style="text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">____________________________________________________</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGFibGU6YzUyYzY0M2NlZmFkNDMzZjhmN2RlZDM1NTM2OTI4NGUvdGFibGVyYW5nZTpjNTJjNjQzY2VmYWQ0MzNmOGY3ZGVkMzU1MzY5Mjg0ZV8wLTAtMS0xLTQ2MDEzL3RleHRyZWdpb246YWQzN2VjNWU0MTZmNDE0N2JkMGEyZThiOGZhYTc3NTZfNA_51aa7cf5-0295-4d6d-8a4a-94cce2f434fd">DE</ix:nonNumeric>LAWARE</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGFibGU6YzUyYzY0M2NlZmFkNDMzZjhmN2RlZDM1NTM2OTI4NGUvdGFibGVyYW5nZTpjNTJjNjQzY2VmYWQ0MzNmOGY3ZGVkMzU1MzY5Mjg0ZV8wLTEtMS0xLTQ2MDEz_41d89d68-b02f-446d-a1eb-a67b3b524b67">26-1303944</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">(STATE OR OTHER JURISDICTION OF</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">(I.R.S. EMPLOYER</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">INCORPORATION OR ORGANIZATION)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">IDENTIFICATION NO.)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGV4dHJlZ2lvbjo4YzEwMzI4ZDE2NDI0NmFjOWQ2ZWQ5NTU4NDQ3N2Y3OV8zNjcz_2a861487-69fd-4f84-bb17-53c173abd599">400 FIFTH AVE.</ix:nonNumeric>,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGV4dHJlZ2lvbjo4YzEwMzI4ZDE2NDI0NmFjOWQ2ZWQ5NTU4NDQ3N2Y3OV8zNjY5_d49e5f63-d701-4581-a227-b13a6af28467">SUITE 210</ix:nonNumeric>,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGV4dHJlZ2lvbjo4YzEwMzI4ZDE2NDI0NmFjOWQ2ZWQ5NTU4NDQ3N2Y3OV8zNjU5_fe127b9e-cbb3-4078-828e-fc05cb2e1ac8">WALTHAM</ix:nonNumeric>,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGV4dHJlZ2lvbjo4YzEwMzI4ZDE2NDI0NmFjOWQ2ZWQ5NTU4NDQ3N2Y3OV8zNjc0_ba0bd9f5-9f81-4bdf-92f5-4a73aa1a3104">MA</ix:nonNumeric>SSACHUSETTS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGV4dHJlZ2lvbjo4YzEwMzI4ZDE2NDI0NmFjOWQ2ZWQ5NTU4NDQ3N2Y3OV8zNjcw_f54f35df-c40a-4296-9360-afaedbef1061">02451</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES, INCLUDING ZIP CODE)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGV4dHJlZ2lvbjo4YzEwMzI4ZDE2NDI0NmFjOWQ2ZWQ5NTU4NDQ3N2Y3OV8zNjYw_f1121b9a-7039-49d6-b0b4-08c250c5f06b">510</ix:nonNumeric>)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGV4dHJlZ2lvbjo4YzEwMzI4ZDE2NDI0NmFjOWQ2ZWQ5NTU4NDQ3N2Y3OV8zNjcx_767bb912-6105-427f-891b-3f78aca470b9">745-1700</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">(REGISTRANT&#8217;S TELEPHONE NUMBER, INCLUDING AREA CODE)</span></div><div style="text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">____________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:30.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.966%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Title of Each Class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Name of Each Exchange on Which Registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGFibGU6ZmI0NDA3ZTE1NWFkNDkwYmI3YmYyZGUyM2RjYmQ1N2MvdGFibGVyYW5nZTpmYjQ0MDdlMTU1YWQ0OTBiYjdiZjJkZTIzZGNiZDU3Y18xLTAtMS0xLTQ2MDEz_f44053ec-de4b-4bc7-ad0e-3de3eb8e9ed8">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGFibGU6ZmI0NDA3ZTE1NWFkNDkwYmI3YmYyZGUyM2RjYmQ1N2MvdGFibGVyYW5nZTpmYjQ0MDdlMTU1YWQ0OTBiYjdiZjJkZTIzZGNiZDU3Y18xLTItMS0xLTQ2MDEz_a2d6096c-bfd5-4ef1-b3ea-f2708717aff1">ARDX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGFibGU6ZmI0NDA3ZTE1NWFkNDkwYmI3YmYyZGUyM2RjYmQ1N2MvdGFibGVyYW5nZTpmYjQ0MDdlMTU1YWQ0OTBiYjdiZjJkZTIzZGNiZDU3Y18xLTQtMS0xLTQ2MDEz_68632e21-ae97-482c-abea-502210458ad8">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(g) of the Act: None</span></div><div style="text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">____________________________________________________</span></div><div style="margin-top:3pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes </span><span style="color:#231f20;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGV4dHJlZ2lvbjo4YzEwMzI4ZDE2NDI0NmFjOWQ2ZWQ5NTU4NDQ3N2Y3OV8zNjYx_52cafa01-02e3-45c0-bd47-ffbcb4d283dd">No</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:3pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes </span><span style="color:#231f20;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGV4dHJlZ2lvbjo4YzEwMzI4ZDE2NDI0NmFjOWQ2ZWQ5NTU4NDQ3N2Y3OV8zNjYy_4a3ff91f-2a9d-446a-83e3-f281859bc033">No</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:3pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to such filing requirements for the past 90 days.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGV4dHJlZ2lvbjo4YzEwMzI4ZDE2NDI0NmFjOWQ2ZWQ5NTU4NDQ3N2Y3OV8zNjYz_8822461f-007d-4bfb-9ed8-d2df4fdbf26d">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:3pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">such shorter period that the Registrant was required to submit such files).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGV4dHJlZ2lvbjo4YzEwMzI4ZDE2NDI0NmFjOWQ2ZWQ5NTU4NDQ3N2Y3OV8zNjc1_d78e56c7-209b-4fc6-94d9-e4106dd87f88">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt"><span style="color:#231f20;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">o</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt"><span style="color:#231f20;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">o</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGFibGU6Y2JjM2I1MjZjYjdkNGZkZGIzM2FiYmMwYzQzMmQ0YWEvdGFibGVyYW5nZTpjYmMzYjUyNmNiN2Q0ZmRkYjMzYWJiYzBjNDMyZDRhYV8xLTEtMS0xLTUwOTM4_557951a5-b13f-4a42-81c8-95f0be313eff">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">x</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Small reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGFibGU6Y2JjM2I1MjZjYjdkNGZkZGIzM2FiYmMwYzQzMmQ0YWEvdGFibGVyYW5nZTpjYmMzYjUyNmNiN2Q0ZmRkYjMzYWJiYzBjNDMyZDRhYV8xLTUtMS0xLTQ2MDEz_9729738f-739b-4224-876b-07b58b81b654">x</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt"><span style="color:#231f20;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGFibGU6Y2JjM2I1MjZjYjdkNGZkZGIzM2FiYmMwYzQzMmQ0YWEvdGFibGVyYW5nZTpjYmMzYjUyNmNiN2Q0ZmRkYjMzYWJiYzBjNDMyZDRhYV8yLTUtMS0xLTQ2MDEz_bb8b3998-dec5-4c2e-8fc4-a959fda25b68">o</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:120%"></span></div><div style="margin-top:3pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGV4dHJlZ2lvbjo4YzEwMzI4ZDE2NDI0NmFjOWQ2ZWQ5NTU4NDQ3N2Y3OV8zNjc2_b9bc9ec1-25a2-43c3-8ac2-0c5180f81f0c">o</ix:nonNumeric></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGV4dHJlZ2lvbjo4YzEwMzI4ZDE2NDI0NmFjOWQ2ZWQ5NTU4NDQ3N2Y3OV81NDk3NTU4MTQyOTUz_ee61762c-3639-4a4f-854f-0122b358eada">x</ix:nonNumeric></span></div><div style="margin-top:3pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The aggregate market value of the Registrant&#8217;s common stock held by non-affiliates of the Registrant as of the last business day of the Registrant&#8217;s most recently completed second fiscal quarter, June 30, 2022, based on the last reported sales price of the Registrant&#8217;s common stock on the Nasdaq Global Market of $0.59 per share was</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="iaeca4a04a1754667989d2f2d6e9f8f59_I20220630" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGV4dHJlZ2lvbjo4YzEwMzI4ZDE2NDI0NmFjOWQ2ZWQ5NTU4NDQ3N2Y3OV8zMjY2_effbeeed-9a8c-4e5d-b717-538abec1ee9e">89,227,062</ix:nonFraction></span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:3pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The number of shares of Registrant&#8217;s Common Stock outstanding as of February&#160;28, 2023, was</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> <ix:nonFraction unitRef="shares" contextRef="i9fc42224cc0a42e883f0fb58a584b2a0_I20230228" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGV4dHJlZ2lvbjo4YzEwMzI4ZDE2NDI0NmFjOWQ2ZWQ5NTU4NDQ3N2Y3OV8zMzQ2_ec79c0f0-ea67-4e50-a862-ade8f9cdbd9a">206,492,664</ix:nonFraction></span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE:</span></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGV4dHJlZ2lvbjo4YzEwMzI4ZDE2NDI0NmFjOWQ2ZWQ5NTU4NDQ3N2Y3OV8zNjY0_4990e8e1-aeb3-4d32-b777-9f6372ff7f17" escape="true"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Portions of the Registrant&#8217;s Definitive Proxy Statement for its 2023 Annual Meeting of Stockholders, which will be filed with the Commission within 120 days of December&#160;31, 2022, the close of the Registrant&#8217;s 2022 fiscal year, are incorporated by reference into Part III of this Report</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></ix:nonNumeric></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:120%"></span></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"></span></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_10"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context requires otherwise, in this Annual Report on Form 10-K the terms &#8220;Ardelyx&#8221;, &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and &#8220;the Company&#8221; refer to Ardelyx, Inc.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains forward-looking statements that involve risks and uncertainties. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;due,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;positioned,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the timing of the resubmission of the new drug application (&#8220;NDA&#8221;) for XPHOZAH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (tenapanor) for the control of serum phosphorus in adult patients with chronic kidney disease patients (&#8220;CKD&#8221;) on dialysis to the U.S. Food and Drug Administration (&#8220;FDA&#8221;); </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the development of a label for the commercialization of XPHOZAH and our belief regarding what indication may be included in such a label;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the potential for FDA approval for the NDA for XPHOZAH;  </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to address our operating cash flow requirements with our current cash and short-term investments, cash generated from the sales of IBSRELA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and if approved, sales of XPHOZAH, the potential receipt of anticipated milestone payments from our collaboration partners, the potential receipt of anticipated payments from our Japanese collaboration partner under the second amendment to our License Agreement, with additional financing sources and through the implementation of cash preservation activities to reduce or defer discretionary spending;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans with respect to RDX013 and RDX020; </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">estimates of our expenses, future revenue, capital requirements, our needs for additional financing and our ability to obtain additional capital; and </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other risks and uncertainties, including those under the caption &#8220;Risk Factors.&#8221;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have based these forward-looking statements largely on management&#8217;s current expectations, estimates, forecasts and projections about our business and the industry in which we operate and management&#8217;s beliefs and assumptions, and these forward-looking statements are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. Factors that could cause actual results or conditions to differ from those anticipated by these and other forward-looking statements include those more fully described in the &#8220;ITEM 1A. RISK FACTORS&#8221; section and elsewhere in this Annual Report on Form 10-K. Except as required by law, we assume no obligation to update any forward-looking statement publicly, or to revise any forward-looking statement to reflect events or developments occurring after the date of this Annual Report on Form 10-K, even if new information becomes available in the future. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in any such forward-looking statement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY OF PRINCIPAL RISKS ASSOCIATED WITH OUR BUSINESS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal risks and uncertainties affecting our business include the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred significant losses since our inception and will incur losses in the future, which makes it difficult for us to assess our future viability; although our financial statements have been prepared on a going concern basis, our current level of cash, cash equivalents and short-term investments alone is not sufficient to meet our operating plans for the next twelve months, raising substantial doubt regarding our ability to continue as a going concern. </span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will require additional financing for the foreseeable future as we invest in the commercialization of IBSRELA, and prepare for and commercialize XPHOZAH in the U.S., if approved. The inability to access necessary capital when needed on acceptable terms, or at all, could force us to reduce our efforts to commercialize IBSRELA or, delay or limit the commercialization of XPHOZAH, if approved.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have generated limited revenue from product sales and may never be profitable. </span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are substantially dependent on the successful commercialization of IBSRELA, and there is no guarantee that we will achieve sufficient market acceptance for IBSRELA; secure adequate coverage and reimbursement for IBSRELA; or generate sufficient revenue from product sales of IBSRELA.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are pursuing regulatory approval for XPHOZAH. There can be no assurances that we will be successful in obtaining such regulatory approval.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if we are successful in obtaining regulatory approval for XPHOZAH, there is no guarantee that we will achieve sufficient market acceptance for XPHOZAH; secure adequate coverage and reimbursement for XPHOZAH; or generate sufficient revenue from product sales of XPHOZAH. </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">IBSRELA and/or, if approved and commercialized, XPHOZAH, may cause undesirable side effects or have other properties that could limit the commercial success of the product.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third-party payor coverage and reimbursement status of newly-commercialized products are uncertain. Failure to obtain or maintain adequate coverage and reimbursement for IBSRELA and, if approved, for XPHOZAH could limit our ability to market those products and decrease our ability to generate revenue. </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely completely on third parties to manufacture IBSRELA and XPHOZAH. If they are unable to comply with applicable regulatory requirements, unable to source sufficient raw materials, experience manufacturing or distribution difficulties or are otherwise unable to manufacture sufficient quantities to meet demand, our commercialization of IBSRELA and, if approved and commercialized, of XPHOZAH, and our future development efforts for tenapanor may be materially harmed. </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operating activities may be restricted as a result of covenants related to the indebtedness under our loan and security agreement and we may be required to repay the outstanding indebtedness in an event of default, which could have a materially adverse effect on our business.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The summary risk factors described above should be read together with the text of the full risk factors below in the section entitled &#8220;Risk Factors&#8221; and the other information set forth in this Annual Report on Form 10-K, including our consolidated financial statements and the related notes, as well as in other documents that we file with the U.S. Securities and Exchange Commission. The risks summarized above or described in full below are not the only risks that we face. Additional risks and uncertainties not precisely known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, results of operations, and future growth prospects.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE REGARDING TRADEMARKS</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARDELYX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, IBSRELA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and XPHOZAH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are trademarks of Ardelyx. All other trademarks, trade names and service marks appearing in this Annual Report on Form 10-K are the property of their respective owners.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARDELYX,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM&#160;10-K FOR THE FISCAL&#160;YEAR ENDED December&#160;31, 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.783%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Page</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i8c6ecca27b7b4659bf1d61cfb55de996_13">PART I</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_16">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_16">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8c6ecca27b7b4659bf1d61cfb55de996_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_19">Item&#160;1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_19">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8c6ecca27b7b4659bf1d61cfb55de996_19">18</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_22">Item&#160;1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_22">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8c6ecca27b7b4659bf1d61cfb55de996_22">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_25">Item&#160;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_25">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8c6ecca27b7b4659bf1d61cfb55de996_25">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_28">Item&#160;3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_28">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8c6ecca27b7b4659bf1d61cfb55de996_28">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_31">Item&#160;4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_31">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8c6ecca27b7b4659bf1d61cfb55de996_31">52</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_34">PART&#160;II</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_37">Item&#160;5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_37">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8c6ecca27b7b4659bf1d61cfb55de996_37">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_43">Item&#160;6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_40">[Reserved]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8c6ecca27b7b4659bf1d61cfb55de996_40">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_46">Item&#160;7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_46">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8c6ecca27b7b4659bf1d61cfb55de996_46">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_76">Item&#160;7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_76">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8c6ecca27b7b4659bf1d61cfb55de996_76">70</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_79">Item&#160;8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_79">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8c6ecca27b7b4659bf1d61cfb55de996_79">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_157">Item&#160;9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_157">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8c6ecca27b7b4659bf1d61cfb55de996_157">107</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_160">Item&#160;9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_160">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8c6ecca27b7b4659bf1d61cfb55de996_160">107</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_163">Item&#160;9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_163">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8c6ecca27b7b4659bf1d61cfb55de996_163">108</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_166">Item 9C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_166">Disclosure Regarding Foreign Jurisdictions that Prevent Inspection</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8c6ecca27b7b4659bf1d61cfb55de996_166">108</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_169">PART&#160;III</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_172">Item&#160;10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_172">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8c6ecca27b7b4659bf1d61cfb55de996_172">109</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_175">Item&#160;11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_175">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8c6ecca27b7b4659bf1d61cfb55de996_175">109</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_178">Item&#160;12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_178">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8c6ecca27b7b4659bf1d61cfb55de996_178">109</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_181">Item&#160;13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_181">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8c6ecca27b7b4659bf1d61cfb55de996_181">109</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_184">Item&#160;14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_184">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8c6ecca27b7b4659bf1d61cfb55de996_184">109</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_187">PART&#160;IV</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_190">Item&#160;15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_190">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8c6ecca27b7b4659bf1d61cfb55de996_190">110</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_193">Item&#160;16.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_193">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8c6ecca27b7b4659bf1d61cfb55de996_193">110</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_196">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8c6ecca27b7b4659bf1d61cfb55de996_196">114</a></span></div></td></tr></table></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"></span></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_16"></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1.&#160;&#160;&#160;&#160;BUSINESS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. We developed a unique and innovative platform that enabled the discovery of new biological mechanisms and pathways to develop potent, and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The first molecule we discovered and developed was tenapanor, a targeted, first-in-class, oral, small molecule therapy. Tenapanor, branded as IBSRELA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, is approved in the U.S. for the treatment of adults with irritable bowel syndrome with constipation (&#8220;IBS-C&#8221;). Tenapanor is in development for the control of serum phosphorus in adult patients with chronic kidney disease (&#8220;CKD&#8221;) on dialysis under the brand name XPHOZAH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We also have a developmental stage asset, RDX013, for adult CKD and/or heart failure patients with hyperkalemia, or elevated serum potassium, and a discovery stage asset, RDX020, for adult CKD patients with metabolic acidosis, a serious electrolyte disorder.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since commencing operations in October 2007, substantially all our efforts have been dedicated to our research and development (&#8220;R&amp;D&#8221;) activities, including developing tenapanor and developing our proprietary drug discovery and design platform. We realized our first product sales of IBSRELA (tenapanor) in March 2022. As of December&#160;31, 2022, we had an accumulated deficit of $780.1&#160;million.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur substantial operating losses for the foreseeable future as we invest in the commercialization of IBSRELA, seek to gain approval in the U.S. for XPHOZAH (tenapanor); prepare for and commercialize XPHOZAH in the U.S., if approved; and incur manufacturing and development cost for tenapanor. To date, we have funded our operations from the sale and issuance of common stock and convertible preferred stock, funds from our collaboration partnerships, which includes license fees, milestones and product supply revenue, funds from our loan agreements with our lenders, as well as from sales of IBSRELA.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Commercial Product</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IBSRELA for IBS-C</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our unique discovery platform and deep understanding of the primary mechanism of sodium transport in the intestine resulted in our discovery and development of IBSRELA, a first-in-class, U.S. Food and Drug Administration ("FDA") approved, sodium hydrogen exchange 3 ("NHE3") inhibitor for the treatment of IBS-C in adults. IBSRELA acts locally in the gut and is minimally absorbed. IBS-C is a gastrointestinal ("GI") disorder characterized by both abdominal pain and altered bowel movements, and is estimated to affect 12 million people in the U.S. IBS-C is associated with significantly impaired quality of life, reduced productivity, and substantial economic burden. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We recognized our first sales of IBSRELA in the U.S. in March 2022. For our commercial launch of IBSRELA, we designed a market-responsive commercial strategy and built a commercial organization highly experienced in launching novel therapies into specialty areas. The dynamics of the IBS-C market reflected an established patient base, limited number of competitors all confined to a single mechanism of action, concentrated number of prescribers, and recognized unmet need. In addition, market research indicated a favorable response to the IBSRELA product profile as a novel mechanism therapy. These dynamics enabled a targeted promotional focus on patients currently being managed for IBS-C by the approximately 9,000 high-writing healthcare providers that account for 50% of IBS-C prescriptions. Central to the go to market strategy for IBSRELA is a highly experienced specialty sales force, many with existing relationships across their GI target base, full company engagement, and innovative peer-to-peer and digital initiatives. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect competition for IBSRELA will come largely from the three prescription products indicated for IBS-C: Linzess (linaclotide), Amitiza (lubiprostone) and Trulance (plecanatide). Generic lubiprostone is also available in the U.S. Additionally, over-the-counter products, not indicated for IBS-C, are commonly used to treat the constipation component of IBS-C, alone and in combination with the IBS-C-indicated prescription therapies.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established commercial agreements with Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. ("Fosun Pharma") in China and Knight Therapeutics, Inc. ("Knight") in Canada for IBSRELA for IBS-C. Knight is currently marketing IBSRELA in Canada.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Product Pipeline</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Development Candidate XPHOZAH: A Potential New Approach for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XPHOZAH (tenapanor) is a first-in-class medicine being developed for the control of serum phosphorus, or hyperphosphatemia, in adult patients with CKD on dialysis. XPHOZAH has a unique mechanism of action and acts locally in the gut to inhibit NHE3. This results in the tightening of the epithelial cell junctions, thereby significantly reducing paracellular uptake of phosphate, the primary pathway of phosphate absorption. It is estimated that there are more than 550,000 adult patients with CKD on dialysis in the U.S., and approximately 80% of those patients are being treated with phosphate lowering therapies. Seventy-seven percent of patients treated with phosphate binders to treat hyperphosphatemia were unable to consistently maintain phosphorous levels &lt;=5.5 mg/dL over a six-month period. If approved, XPHOZAH would be the first therapy for phosphate management that blocks phosphorus absorption at the primary site.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, we submitted a new drug application (&#8220;NDA&#8221;) to the FDA for XPHOZAH. The NDA was supported by three Phase 3 trials involving more than 1,200 adult patients that evaluated the use of tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis, with two trials evaluating tenapanor as monotherapy and one trial evaluating tenapanor as part of a dual mechanism approach with phosphate binders. All three Phase 3 trials met their primary and key secondary endpoints.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 28, 2021, we received a Complete Response Letter ("CRL") from the FDA&#8217;s Division of Cardiology and Nephrology (&#8220;Division") regarding our NDA for XPHOZAH. In December 2021, we submitted a Formal Dispute Resolution Request ("FDRR") to the Office of Cardiology, Hematology, Endocrinology and Nephrology ("OCHEN"). At the request of the FDA's Office of New Drugs ("OND"), as part of our second level of appeal of the CRL, a Cardiovascular and Renal Drug Advisory Committee meeting on was held on November 16, 2022 with the committee voting that the benefits of XPHOZAH outweigh its risks nine to four as a monotherapy and ten to two, with one abstention, in combination with phosphate binder therapy. In December 2022, the OND granted our appeal of the CRL for the NDA for XPHOZAH and directed the Division to work with us to develop an appropriate label for the commercialization of XPHOZAH. We believe that a label could reflect an indication for patients whose hyperphosphatemia is insufficiently managed on binder therapy. On February 13, 2023, we participated in a Type A meeting with the Division where we discussed the resubmission of the NDA, and the information to be contained in the resubmitted NDA. We currently expect to resubmit the NDA for XPHOZAH early in the second quarter of 2023. Within thirty (30) days of resubmitting the NDA, we expect to receive notification from the Division as to the classification of the resubmission (Class 1 or Class 2) at which point the expected timing for review will also be known (2-months for a Class 1 and 6-months for a Class 2) as well as a goal review date. We currently believe that the FDA will act upon the XPHOZAH NDA in the second half of 2023, and, if approved, we expect to launch XPHOZAH in the second half of 2023.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established commercial agreements with Kyowa Kirin, Co. Ltd. ("KKC") in Japan, Fosun Pharma in China and Knight in Canada for tenapanor for hyperphosphatemia. In October 2022, KKC submitted an NDA to the Japanese Ministry of Health, Labour and Welfare for tenapanor for the improvement of hyperphosphatemia in adult patients with CKD on dialysis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discovery and Developmental Assets</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a small molecule potassium secretagogue program, RDX013, for the potential treatment of hyperkalemia, or elevated serum potassium. Hyperkalemia is a common problem in patients with heart and kidney disease, particularly in patients taking customary blood pressure medications known as renin-angiotensin-aldosterone system ("RAAS") inhibitors. RDX013 is a novel mechanism agent designed to target the underlying biological mechanisms of potassium secretion to lower elevated potassium. We have completed a Phase 2 dose ranging clinical trial evaluating the safety and efficacy of RDX013 for the treatment of hyperkalemia in CKD patients who are not on dialysis. While the results of the study demonstrated an acceptable safety and tolerability profile for RDX013 and supported proof of concept in its ability to lower serum potassium levels, with statistically significant reductions compared to placebo after eight days of treatment, the study did not meet its primary endpoint of significantly reducing serum potassium levels compared to placebo after four weeks of treatment. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a discovery program targeting the inhibition of bicarbonate exchange inhibitor for the treatment of metabolic acidosis, a highly prevalent comorbidity in CKD patients that is strongly correlated with disease progression and adverse outcomes. We have identified lead compounds that are potent, selective and proprietary inhibitors of bicarbonate secretion. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently expect to meaningfully advance either of these two assets until such time as we have determined our available resources can support additional activities after prioritization of the commercialization of IBSRELA and, if approved, XPHOZAH.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Commercial Strategy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed a portfolio of novel products to address unmet medical needs across gastrointestinal and cardiorenal therapeutic areas and intend to commercialize our products in the U.S. We have established a high quality commercial organization highly experienced in bringing novel products to our customers, including patients, payors and healthcare providers. Our commercial capabilities, including marketing, access, patient services and sales are designed to support our commercialization of IBSRELA, and the commercialization of XPHOZAH, if approved. We have executed ex-U.S. collaborations with established industry leaders to efficiently bring XPHOZAH and IBSRELA to patients in specific territories outside of the U.S. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to evaluate our strategy for the commercialization of IBSRELA and XPHOZAH in other ex-U.S. territories. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration Partners</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have exclusive rights to tenapanor in the U.S. and we have established agreements with KKC in Japan, Fosun Pharma in China and Knight in Canada for the development and commercialization of tenapanor for certain indications in their respective territories. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, we entered into an exclusive license agreement with Knight (&#8220;Knight Agreement&#8221;) for the development, commercialization and distribution of tenapanor in Canada for hyperphosphatemia and IBS-C. In March 2021, Knight announced the commercial availability of IBSRELA in Canada, following its approval by Health Canada in April 2020. Under the terms of the Knight Agreement, Knight paid us a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.3&#160;million non-refundable, one-time payment in March 2018. We may also be eligible to receive approximately CAD 22.2&#160;million for development and commercialization milestones, or approximately $16.3&#160;million at the currency exchange rate on December&#160;31, 2022, of which $0.7&#160;million has been received and recognized as revenue as of December&#160;31, 2022. We are also eligible to receive royalties throughout the term of the agreement, and a transfer price for manufacturing services. The variable consideration related to the remaining development milestone payments has not been included in the transaction price as they were fully constrained at December&#160;31, 2022.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, we entered into an exclusive license agreement with KKC (&#8220;2017 KKC Agreement&#8221;) for the development, commercialization and distribution of tenapanor in Japan for cardiorenal indications. Under the terms of the 2017 KKC Agreement, we received a $30.0&#160;million upfront payment from KKC, and we may be entitled to receive up to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$55.0&#160;million in total development and regulatory milestones, of which $20.0&#160;million has been received and recognized as revenue as of December&#160;31, 2022. We may also be eligible to receive approximately &#165;8.5 billion for commercialization milestones, or approximately $64.6&#160;million at the currency exchange rate on December&#160;31, 2022, as well as reimbursement of costs plus a reasonable overhead for the supply of product and royalties on net sales throughout the term of the agreement. As discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8. Deferred Royalty Obligation Related to the Sale of Future Royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the future royalties and commercial milestone payments we may receive under the 2017 KKC Agreement will be remitted to HealthCare Royalty Partners IV, L.P. pursuant to a Royalty and Sales Milestone Interest Acquisition Agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 11, 2022, we entered into a second amendment to the 2017 KKC Agreement ("2022 Amendment"). Under the terms of the 2022 Amendment, we and KKC agreed to a reduction in the royalty rate payable to us by KKC upon net sales of tenapanor in Japan. The royalty rate was reduced from the high teens to low double digits for a two-year period of time following the first commercial sale in Japan, and then to mid-single digits for the remainder of the royalty term. As discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8. Deferred Royalty Obligation Related to the Sale of Future Royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the future royalties we may receive under the 2017 KKC Agreement will be remitted to HealthCare Royalty Partners IV, L.P. pursuant to a Royalty and Sales Milestone Interest Acquisition Agreement. As consideration for the reduction in the royalty rate, KKC agreed to pay us up to an additional $40.0&#160;million payable in two tranches, with the first payment received in the fourth quarter of 2022 following KKC&#8217;s October 2022 filing with the Japanese Ministry of Health, Labour and Welfare of its application for marketing approval for tenapanor and the second payment due following KKC&#8217;s receipt of regulatory approval to market tenapanor for hyperphosphatemia in Japan. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, we announced that KKC submitted a NDA to the Japanese Ministry of Health, Labour and Welfare for tenapanor for the improvement of hyperphosphatemia in adult patients with CKD on dialysis, which resulted in payment to us from KKC for an aggregate of $35.0 million for milestone payments and payments under the 2022 Amendment. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, we entered into an exclusive license agreement with Fosun Pharma (&#8220;Fosun Agreement&#8221;) for the development and commercialization of tenapanor in China for both hyperphosphatemia and IBS-C. Under the terms of the Fosun Agreement, Fosun paid us a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$12.0&#160;million upfront</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license fee. We may be entitled to receive development and commercialization milestones of up to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$110.0&#160;million, of which $3.0&#160;million has been received and recognized as revenue as of December&#160;31, 2022, as well as reimbursement of cost plus a reasonable overhead for the supply of product and tiered royalties on net sales ranging from the mid-teens to 20%. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Restructurings </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We implemented restructuring plans in August 2021 and October 2021 following the receipt of a CRL from the FDA relating to our NDA for XPHOZAH and following the conclusion of an End of Review Type A meeting with the FDA, respectively. Both restructuring plans were substantially completed in December 2021 and most of the cash payments related to the reduction in workforce were disbursed prior to December 31, 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impacted employees were eligible to receive severance benefits and additional Company funded COBRA premiums, contingent upon an impacted employee&#8217;s execution (and non-revocation) of a separation agreement, which included a general release of claims against us. In connection with restructuring, we incurred restructuring charges of $6.2&#160;million, which were recorded during the twelve months ended December 31, 2021, related to one-time employee termination benefits, including severance payments and other employee-related costs. We did not incur any significant contract termination costs pursuant to restructuring. Of these charges, $2.7&#160;million was recorded in research and development expenses and $3.5&#160;million was recorded in general and administrative expense in the accompanying statements of operations and comprehensive loss. We incurred no restructuring charges during the twelve months ended December&#160;31, 2022. We reported remaining estimated liabilities for the restructuring costs of zero and $0.5&#160;million as accrued compensation and benefits in our Balance Sheet as of December&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Financings</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, we filed a Form S-3 registration statement, which became effective in August 2020 ("2020 Registration Statement"), containing (i) a base prospectus for the offering, issuance and sale by us of up to a maximum aggregate offering price of $250.0 million of our common stock, preferred stock, debt securities, warrants and/or units, from time to time in one or more offerings; and (ii) a prospectus supplement for the offering, issuance and sale by us of up to a maximum aggregate offering price of $100.0 million of our common stock that may be issued and sold, from time to time, under an Open Market Sales Agreement with Jefferies LLC, as sales agent, deemed to be &#8220;at-the-market offerings&#8221; ("2020 Open Market Sales Agreement").&#160;Pursuant to the 2020 Open Market Sales Agreement, Jefferies, as sales agent, received a commission of up to 3.0% of the gross sales price for shares of common stock sold under the 2020 Open Market Sales Agreement. We sold a cumulative total of 23.3 million shares and received the full gross proceeds of $100.0 million at a weighted average sales price of approximately $4.30 per share under the 2020 Open Market Sales Agreement. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we filed an additional prospectus supplement under the 2020 Registration Statement for the offering, issuance and sale by us of up to a maximum aggregate offering price of $150.0 million of our common stock that may be issued and sold, from time to time, under an additional sales agreement we entered into with Jefferies ("2021 Open Market Sales Agreement"), pursuant to which we may, from time to time, sell up to $150.0 million in shares of our common stock through Jefferies. We are not required to sell shares under the 2021 Open Market Sales Agreement. Pursuant to the 2021 Open Market Sales Agreement, Jefferies, as our sales agent, receives a commission of up to 3.0% of the gross sales price for shares of common stock sold under the 2021 Open Market Sales Agreement. As of December&#160;31, 2022, we have sold 79.8 million shares and received gross proceeds of $98.1 million at a weighted average sales price of approximately $1.23 per share under the 2021 Open Market Sales Agreement. During the period January 1, 2023 to January 12, 2023, we received additional gross proceeds of $20.0 million for the sale of an additional 7.7 million shares which were sold at a weighted average sales price of approximately $2.60 per share under the 2021 Open Market Sales Agreement. There have been no other sales under the 2021 Open Market Sales Agreement after December 31, 2022.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, we filed a Form S-3 registration statement, which became effective in January 2023 ("2023 Registration Statement"), containing (i) a base prospectus for the offering, issuance and sale by us of up to a maximum aggregate offering price of $250.0 million of our common stock, preferred stock, debt securities, warrants and/or units, from time to time in one or more offerings; and (ii) a prospectus supplement for the offering, issuance and sale by us of up to a maximum aggregate offering price of $150.0 million of our common stock that may be issued and sold, from time to time, under a sales agreement with Jefferies LLC ("Jefferies"), deemed to be &#8220;at-the-market offerings&#8221; ("2023 Open Market Sales Agreement").&#160;Pursuant to the 2023 Open Market Sales Agreement, Jefferies, as sales agent, may receive a commission of up to 3.0% of the gross sales price for shares of common stock sold under the 2023 Open Market Sales Agreement. There have been no sales of our common stock under the 2023 Open Market Sales Agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had cash, cash equivalents and short-term investments totaling $123.9&#160;million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our ability to obtain and maintain proprietary protection for our drug candidates, manufacturing and process discoveries, and other know-how, to operate without infringing the proprietary rights of others and to prevent others from infringing our proprietary rights. Our policy is to seek to protect our intellectual property by, among other methods, filing U.S. and foreign patent applications related to our proprietary technology and inventions that are important to the development and operation of our business. We also rely on trade secrets and careful monitoring of our proprietary information to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of biopharmaceutical companies like us are generally uncertain and involve complex legal, scientific and factual questions. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Consequently, we do not know whether any of our product candidates will be protectable or remain protected by enforceable patents. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of our issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold may be challenged, circumvented or invalidated by third parties. If third parties prepare and file patent applications in the U.S. that also claim technology or therapeutics to which we have rights, we may have to participate in interference proceedings in the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;) to determine priority of invention, which would result in substantial costs to us even if the eventual outcome is favorable to us.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of individual patents depends upon the legal term of the patents in countries in which they are obtained. In most countries, including the U.S., the patent term is generally 20&#160;years from the earliest date of filing a non-provisional patent application in the applicable country. In the U.S., a patent&#8217;s term may, in certain cases, be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the USPTO in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over a commonly owned patent or a patent naming a common inventor and having an earlier expiration date.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in the U.S., the Hatch-Waxman Act permits a patent term extension of up to five&#160;years beyond the expiration of a U.S. patent as partial compensation for the patent term lost during the FDA regulatory review process occurring while the patent is in force. A patent extension cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of product approval, and only one patent applicable to each regulatory review period may be extended and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. Similar provisions are available in the European Union and certain other foreign jurisdictions to extend the term of a patent that covers an approved drug.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may rely, in some circumstances, on trade secrets to protect our technology. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific collaboration partners, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning the business or financial affairs developed or made known to the individual during the course of the individual&#8217;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees, the agreements provide that all inventions conceived by the individual, and which are related to our current or planned business or research and development or made during the normal working hours, on our premises or using our equipment or proprietary information, are our exclusive property.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tenapanor Patents</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our tenapanor patent portfolio is wholly owned by us. This portfolio includes five issued U.S. patents, three issued patents in each of Israel and Mexico, two issued patents in each of European Patent Organization, Japan, Korea, and Hong Kong and one issued patent in each of the following territories: Australia, Brazil, India, and China. These issued patents cover the composition and certain methods of using tenapanor and are predicted, without extension or adjustment, to expire in December 2029. However, the term of U.S. patent no. 8,541,448 was extended under the Hatch-Waxman Act to August 1, 2033. The portfolio further includes patents covering the use of tenapanor for controlling serum phosphorus that have been issued in the U.S., Europe, Japan, China, Australia, Gulf Co-op countries, Hong Kong, Israel, Korea, Macao, Mexico, New Zealand, Russia, South Africa and Taiwan and are pending in other countries. These patents are predicted, without extension or adjustment, to expire in April 2034.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional U.S. and international patent applications are pending covering additional methods of treatment with tenapanor, and composition of matter and methods of using compounds that we believe may be follow on compounds to tenapanor.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Program Patents</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have patent applications pending in the U.S. and internationally that cover the compositions and methods of using compounds in our RDX013 program.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have relied upon third-party contract manufacturing organizations (&#8220;CMOs&#8221;) to manufacture both the active pharmaceutical ingredient and final drug product dosage forms of our potential drug candidates used as clinical trial material. We expect that we will continue to rely upon CMOs for the manufacture of commercial product for IBSRELA, our clinical trial materials and for our commercial product requirements for XPHOZAH, when and if regulatory approval is received. Our license agreements with Knight, and Fosun Pharma require us to supply final drug product dosage forms of tenapanor for their use in the development and commercialization of tenapanor in each of their respective territories. We are further obligated to supply active pharmaceutical ingredient to KKC to support their development and commercialization of tenapanor in Japan. We expect that we will use CMOs to satisfy our supply obligations to our collaboration partners.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial and burdensome requirements upon companies involved in the clinical development, manufacture, marketing and distribution of drugs. These agencies and other federal, state and local entities regulate research and development activities and the testing, manufacture, quality control, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion, distribution, post-approval monitoring and reporting, sampling, and export and import of our product candidates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the FDA regulates drug products under the Federal Food, Drug, and Cosmetic Act (&#8220;FFDCA&#8221;) and the FDA&#8217;s implementing regulations. If we fail to comply with applicable FDA or other requirements at any time during the drug development process, the approval process or after approval, we may become subject to administrative or judicial sanctions. These sanctions could include the FDA&#8217;s refusal to approve pending applications, license suspension or revocation, withdrawal of an approval, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties or criminal prosecution. Any FDA enforcement action could have a material adverse effect on us. FDA approval is required before any new unapproved drug or dosage form, including a new use of a previously approved drug, can be marketed in the U.S.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process required by the FDA before a drug may be marketed in the U.S. generally involves:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">completion of extensive preclinical laboratory tests, preclinical animal studies and formulation studies, some performed in accordance with the FDA&#8217;s current Good Laboratory Practice (&#8220;GLP&#8221;) regulations;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">submission to the FDA of an Investigational New Drug (&#8220;IND&#8221;) application which must become effective before human clinical trials in the U.S. may begin;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approval by an independent institutional review board, (&#8220;IRB&#8221;) or ethics committee at each clinical trial site before each trial may be initiated;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">performance of adequate and well-controlled human clinical trials in accordance with Good Clinical Practice ("GCP") regulations to establish the safety and efficacy of the drug candidate for each proposed indication;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">submission to the FDA of an NDA;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with current Good Manufacturing Practice (&#8220;cGMP&#8221;) regulations;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of a potential review by an FDA advisory committee, if applicable; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA review and approval of the NDA prior to any commercial marketing, sale or commercial shipment of the drug.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preclinical and clinical testing and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for our product candidates will be granted on a timely basis, if at all. Nonclinical tests include laboratory evaluation of product chemistry, formulation, stability and toxicity, as well as animal studies to assess the characteristics and potential safety and efficacy of the product. The results of preclinical tests, together with manufacturing information, analytical data and a proposed clinical trial protocol and other information, are submitted as part of an IND to the FDA. Additional preclinical testing may continue even after the IND is submitted. The IND automatically becomes effective 30&#160;days after receipt by the FDA, unless the FDA, within the 30-day period, raises concerns or questions relating to the IND and places the clinical trial on a clinical hold, including concerns that human research subjects will be exposed to unreasonable health risks. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. A separate submission to an existing IND must also be made for each successive clinical trial conducted during product development.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve the administration of the investigational drug to human subjects under the supervision of qualified investigators. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, the parameters to be used in monitoring safety and the effectiveness criteria to be used. Each protocol must be submitted to the FDA as part of the IND.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An independent IRB or ethics committee for each medical center proposing to conduct a clinical trial must also review and approve a plan for any clinical trial before it can begin at that center and the IRB must monitor the clinical trial until it is completed. The FDA, the IRB, or the sponsor may suspend or discontinue a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk. Clinical testing also must satisfy extensive GCP requirements, including the requirements for informed consent.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All clinical research performed in the U.S. in support of an NDA must be submitted in advance by the FDA under the IND regulations and procedures described above. However, a sponsor who wishes to conduct a clinical trial outside the U.S. may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of an NDA so long as the clinical trial is conducted in compliance with GCP and if the FDA is able to validate the data from the study through an onsite inspection, if necessary. GCP includes review and approval by an independent ethics committee, such as an IRB, and obtaining and documenting the freely given informed consent of each subject before study initiation. If the applicant seeks approval of an NDA solely on the basis of foreign data, the FDA will only accept such data if they are applicable to the U.S. population and U.S. medical practice, the studies have been performed by clinical investigators of recognized competence, and the data may be considered valid without the need for an on-site inspection by the FDA, or if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an on-site inspection or through other appropriate means.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Trials</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical investigation of a new drug is typically conducted in three or four phases, which may overlap or be combined, and generally proceed as follows.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Clinical trials are initially conducted in a limited population of subjects to test the drug candidate for safety, dose tolerance, absorption, metabolism, distribution and excretion in healthy humans or, on occasion, in patients with severe problems or life-threatening diseases to gain an early indication of its effectiveness.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Clinical trials are generally conducted in a limited patient population to evaluate dosage tolerance and appropriate dosage, identify possible adverse effects and safety risks, and evaluate preliminarily the efficacy of the drug for specific targeted indications in patients with the disease or condition under study.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Clinical trials are typically conducted when Phase 2 clinical trials demonstrate that a dose range of the product candidate is effective and has an acceptable safety profile. Phase 3 clinical trials are commonly referred to as &#8220;pivotal&#8221; studies, which typically denotes a study which presents the data that the FDA or other relevant regulatory agency will use to determine whether or not to approve a drug. Phase 3 clinical trials are generally undertaken with large numbers of patients, such as groups of several hundred to several thousand, to further evaluate dosage, to provide substantial evidence of clinical efficacy and to further test for safety in an expanded and diverse patient population at multiple, geographically dispersed clinical trial sites.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In some cases, the FDA may condition approval of an NDA for a product candidate on the sponsor&#8217;s agreement to conduct additional clinical trials after NDA approval. In other cases, a sponsor may voluntarily conduct additional clinical trials post approval to gain more information about the drug. Such post approval trials are typically referred to as Phase 4 clinical trials.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with clinical trials, companies usually complete additional nonclinical studies and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the drug in commercial quantities in accordance with GMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA, the IRB or the clinical trial sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether or not a trial may move forward at designated check points based on access to certain data from the study. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also suspend or terminate a clinical trial based on evolving business objectives and/or competitive climate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Drug Applications</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of preclinical studies and of the clinical trials, together with other detailed information, including extensive manufacturing information and information on the composition of the drug, are submitted to the FDA in the form of an NDA requesting approval to market the drug for one or more specified indications. The FDA reviews an NDA to determine, among other things, whether a drug is safe and effective for its intended use.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Prescription Drug User Fee Act, the FDA has a goal of responding to standard review NDAs for new molecular entities within ten months after the 60-day filing review period, or six months after the 60-day filing review period for priority review NDAs. For non-new molecular entities, the FDA has a goal of responding within ten months of receipt of standard review NDAs and six months of receipt for priority review NDAs. These timeframes are often extended by FDA requests for additional information or clarification. The FDA may refer the application to an advisory committee for review, evaluation and recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the FDA evaluates the NDA and conducts inspections of manufacturing facilities where the drug product and/or its API will be produced, if deemed necessary, it may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete, and the application is not ready for approval. A Complete Response Letter may require additional clinical data and/or an additional Phase 3 clinical trial(s), and/or other significant, expensive and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. Even if such additional information is submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. The FDA could also approve the NDA with a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) if it is determined that a REMS is necessary to ensure that the drug&#8217;s benefits outweigh its risks and a REMS to mitigate risks, which could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling, development of adequate controls and specifications, or a commitment to conduct one or more post-market studies or clinical trials. Such post-market testing may include Phase 4 clinical trials and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization. The FDA has the authority to prevent or limit </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">further marketing of a drug based on the results of these post-market programs. Once the FDA approves an NDA, or supplement thereto, the FDA may withdraw the approval if ongoing regulatory requirements are not met or if safety problems are identified after the drug reaches the market.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drugs may be marketed only for the FDA approved indications and in accordance with the provisions of the approved labeling. Further, if there are any modifications to the drug, including changes in indications, labeling, or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new NDA or NDA supplement, which may require the applicant to develop additional data or conduct additional preclinical studies and clinical trials.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The testing and approval processes require substantial time, effort and financial resources, and each may take several&#160;years to complete. The FDA may not grant approval on a timely basis, or at all. Even if we believe a clinical trial has demonstrated safety and efficacy of one of our drug candidates for the proposed indication, the results may not be satisfactory to the FDA. Nonclinical and clinical data may be interpreted by the FDA in different ways, which could delay, limit or prevent regulatory approval. We may encounter difficulties or unanticipated costs in our efforts to secure necessary governmental approvals which could delay or preclude us from marketing drugs. The FDA may limit the indications for use or place other conditions on any approvals that could restrict the commercial application of the drugs. After approval, certain changes to the approved drug, such as adding new indications, manufacturing changes, or additional labeling claims are subject to further FDA review and approval. Depending on the nature of the change proposed, an NDA supplement must be filed and approved before the change may be implemented.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Regulatory Requirements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any drugs manufactured or distributed by us or our collaboration partners pursuant to FDA approvals would be subject to continuing regulation by the FDA, including recordkeeping requirements and reporting of adverse experiences associated with the drug. Drug manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies and are subject to periodic announced and unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMP, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Failure to comply with the statutory and regulatory requirements can subject a manufacturer to possible legal or regulatory action, such as warning or untitled letters, suspension of manufacturing, seizure of product, injunctive action or possible civil penalties. We cannot be certain that we or our present or future third-party manufacturers or suppliers will be able to comply with the cGMP regulations and other ongoing FDA regulatory requirements. If we or our present or future third-party manufacturers or suppliers are not able to comply with these requirements, the FDA may, among other things, halt our clinical trials, require us to recall a drug from distribution or withdraw approval of the NDA for that drug.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA closely regulates the post-approval marketing and promotion of drugs, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the Internet. A company can make only those claims relating to safety and efficacy that are in the final label or consistent with the final label. Failure to comply with these requirements can result in, among other things, adverse publicity, warning or untitled letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available drugs for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, impose stringent restrictions on manufacturers&#8217; communications regarding off-label use.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hatch-Waxman Act</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Price Competition and Patent Term Restoration Act, or Hatch-Waxman Act, Section&#160;505 of the FFDCA describes three types of marketing applications that may be submitted to the FDA to request marketing authorization for a new drug. A Section&#160;505(b)(1)&#160;NDA is an application that contains full reports of investigations of safety and efficacy. A Section 505(b)(2)&#160;NDA is an application that contains full reports of investigations of safety and efficacy but where at least some of the information required for approval comes from investigations that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted. This regulatory pathway enables the applicant to rely, in part, on the FDA&#8217;s prior findings of safety and efficacy for an existing product, or published literature, in support of its application. Section&#160;505(j)&#160;establishes an abbreviated approval process for a generic version of approved drug products through the submission of an Abbreviated New Drug Application (&#8220;ANDA&#8221;). An ANDA provides for marketing of a generic drug product that has the same active ingredients, dosage form, strength, route of administration, labeling, performance characteristics and intended use, among other things, to a previously approved product. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ANDAs are termed &#8220;abbreviated&#8221; because they are generally not required to include nonclinical (animal) and clinical (human) data to establish safety and efficacy. Instead, generic applicants must scientifically demonstrate that their product is bioequivalent to, or performs in the same manner as, the innovator drug through in vitro, in vivo, or other testing. The generic version must deliver the same amount of active ingredients into a subject&#8217;s bloodstream in the same amount of time as the innovator drug and can often be substituted by pharmacists under prescriptions written for the reference listed drug. In seeking approval for a drug through an NDA, applicants are required to list with the FDA each patent with claims that cover the applicant&#8217;s drug or a method of using the drug. Upon approval of a drug, each of the patents listed in the application for the drug is then published in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential competitors in support of approval of an ANDA or 505(b)(2)&#160;NDA.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon submission of an ANDA or a 505(b)(2)&#160;NDA, an applicant must certify to the FDA that (1)&#160;no patent information on the drug product that is the subject of the application has been submitted to the FDA; (2)&#160;such patent has expired; (3)&#160;the date on which such patent expires; or (4)&#160;such patent is invalid or will not be infringed upon by the manufacture, use or sale of the drug product for which the application is submitted. Generally, the ANDA or 505(b)(2)&#160;NDA cannot be approved until all listed patents have expired, except where the ANDA or 505(b)(2)&#160;NDA applicant challenges a listed patent through the last type of certification, also known as a Paragraph IV certification. If the applicant does not challenge the listed patents or indicates that it is not seeking approval of a patented method of use, the ANDA or 505(b)(2)&#160;NDA application will not be approved until all of the listed patents claiming the referenced product have expired.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the ANDA or 505(b)(2) NDA applicant has provided a Paragraph IV certification to the FDA, the applicant must send notice of the Paragraph IV certification to the NDA holder and patent owners once the application has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. If the Paragraph IV certification is challenged by an NDA holder or the patent owner(s), the FDA may not approve that application until the earlier of 30 months from the receipt of the notice of the Paragraph IV certification, the expiration of the patent, when the infringement case concerning each such patent was favorably decided in the applicant&#8217;s favor or settled, or such shorter or longer period as may be ordered by a court. This prohibition is generally referred to as the 30-month stay. In instances where an ANDA or 505(b)(2) NDA applicant files a Paragraph IV certification, the NDA holder or patent owner(s) regularly take action to trigger the 30-month stay, recognizing that the related patent litigation may take many months or years to resolve. Thus, approval of an ANDA or 505(b)(2) NDA could be delayed for a significant period of time depending on the patent certification the applicant makes and the reference drug sponsor&#8217;s decision to initiate patent litigation.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Hatch-Waxman Act establishes periods of regulatory exclusivity for certain approved drug products, during which the FDA cannot approve (or in some cases accept) an ANDA or 505(b)(2)&#160;application that relies on the branded reference drug. For example, the holder of an NDA, including a 505(b)(2)&#160;NDA, may obtain five&#160;years of exclusivity upon approval of a new drug containing a new chemical entity (&#8220;NCE&#8221;) that has not been previously approved by the FDA. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the therapeutic activity of the drug substance. During the exclusivity period, the FDA may not accept for review an ANDA or a 505(b)(2)&#160;NDA submitted by another company that contains the previously approved active moiety. However, an ANDA or 505(b)(2)&#160;NDA may be submitted after four&#160;years if it contains a Paragraph IV certification of patent invalidity or non-infringement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Hatch-Waxman Act also provides three&#160;years of marketing exclusivity to the holder of an NDA (including a 505(b)(2)&#160;NDA) for a particular condition of approval, or change to a marketed product, such as a new formulation for a previously approved product, if one or more new clinical studies (other than bioavailability or bioequivalence studies) was essential to the approval of the application and was conducted/sponsored by the applicant. This three-year exclusivity period protects against FDA approval of ANDAs and 505(b)(2)&#160;NDAs for the specific condition of the new drug&#8217;s approval. As a general matter, the three-year exclusivity does not prohibit the FDA from approving ANDAs or 505(b)(2)&#160;NDAs for generic versions of the original, unmodified drug product. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA; however, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and efficacy.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fraud and Abuse Laws</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. the research, manufacturing, distribution, sale and promotion of drug products and medical devices are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including the Centers for Medicare&#160;&amp; Medicaid Services (&#8220;CMS&#8221;) other divisions of the U.S. Department of Health and Human Services (e.g., the Office of Inspector General), the U.S. Department of Justice, state Attorneys General, and other state and local government agencies. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These laws include but are not limited to, the Anti-Kickback Statute, the federal False Claims Act, the federal Physician Payments Sunshine Act, and other state and federal laws and regulations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Anti-Kickback Statute makes it illegal for any person, including a prescription drug manufacturer (or a party acting on its behalf) to knowingly and willfully solicit, receive, offer, or pay any remuneration that is intended to induce the referral of business, including the purchase, order, or prescription of a particular drug, for which payment may be made under a federal healthcare program, such as Medicare or Medicaid. The term remuneration has been interpreted broadly to include anything of value. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution. The exceptions and safe harbors are drawn narrowly and practices that involve remuneration that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the federal Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Additionally, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal False Claims Act prohibits anyone from knowingly presenting, or causing to be presented, for payment to federal programs (including Medicare and Medicaid) claims for items or services, including drugs, that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary items or services. Although we would not submit claims directly to payors, manufacturers can be held liable under these laws if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims by, for example, providing inaccurate billing or coding information to customers or promoting a product off-label. In addition, our activities relating to the reporting of wholesaler or estimated retail prices for our products, the reporting of prices used to calculate Medicaid rebate information and other information affecting federal, state, and third-party reimbursement for our products, and the sale and marketing of our products, are subject to scrutiny under this law. Moreover, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. If the government were to allege that we were, or convict us of, violating these false claims laws, we could be subject to a substantial fine and may suffer a decline in our stock price. In addition, private individuals have the ability to bring actions under the federal False Claims Act.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The civil monetary penalties statute imposes penalties against any person or entity who, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of whether the payor is public or private, knowingly and willfully embezzling or stealing from a health care benefit program, willfully obstructing a criminal investigation of a health care offense and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute, or the specific intent to violate it, to have committed a violation.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the laws described above, the Physician Payments Sunshine Act requires certain drug manufacturers to report payments and other transfer of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) certain non-physician practitioners (physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiologist assistants and certified nurse midwives) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Failure to submit required information may result in significant civil monetary penalties, and additional penalties for knowing failures, for all payments, transfers of value or ownership or investment interests that are not timely, accurately and completely reported in an annual submission. Manufacturers must submit reports by the 90th day of each subsequent calendar year.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many states have also adopted laws similar to the federal laws discussed above. Some of these state prohibitions apply to the referral of patients for healthcare services reimbursed by any insurer, not just federal healthcare programs such as Medicare and Medicaid. There has also been a recent trend of increased regulation of payments made to physicians and other healthcare providers. Certain states mandate implementation of compliance programs, impose restrictions on drug manufacturers&#8217; marketing practices and/or require the tracking and reporting of pricing and marketing information as well as gifts, compensation and other remuneration to physicians. Many of these laws contain ambiguities as to what is required to comply with such laws, which may affect our sales, marketing, and other promotional activities by imposing administrative and compliance burdens on us. In addition, given the lack of clarity with respect to these laws and their implementation, our reporting actions could be subject to the penalty provisions of the pertinent state and perhaps federal, authorities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of any of such laws or any other governmental regulations that apply may result in penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, the curtailment or restructuring of operations, reporting obligations and integrity oversight, exclusion from participation in federal and state healthcare programs and imprisonment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third-Party Coverage and Reimbursement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of pharmaceutical products depend in significant part on the availability of coverage and adequate reimbursement by third-party payors, such as state and federal governments, including Medicare and Medicaid, and commercial managed care providers. In the U.S., no uniform policy of coverage and reimbursement for drug products exists among third-party payors. Accordingly, decisions regarding the extent of coverage and amount of reimbursement to be provided for our product candidates, if approved, will be made on a payor by payor basis. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained. Third-party payors may limit coverage to specific drug products on an approved list, or formulary, which might not include all of the FDA-approved drugs for a particular indication. A decision by a third-party payor not to cover our product candidates could reduce physician utilization of our products once approved and have a material adverse effect on our future sales, results of operations and financial condition. Moreover, a payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is increased uncertainty related to insurance coverage and reimbursement for certain drugs, like XPHOZAH, which, if approved, will be marketed for the control of serum phosphorus in adult patients with CKD on dialysis. In January 2011, CMS implemented a new prospective payment system for dialysis treatment. Under the End Stage Renal Disease (&#8220;ESRD&#8221;) prospective payment system, CMS generally makes a single bundled payment to the dialysis facility for each dialysis treatment that covers all items and services routinely required for dialysis treatments furnished to Medicare beneficiaries in Medicare-certified ESRD facilities or at their home, including the cost of certain routine drugs. The inclusion of oral medications without injectable or intravenous equivalents in the bundled payment was initially delayed until January 1, 2014 and through several subsequent legislative actions was delayed until January 1, 2025. As a result, absent further legislation or regulation on this matter, beginning in 2025, oral ESRD-related drugs without injectable or intravenous equivalents may be included in the ESRD bundle and separate Medicare payment for these drugs will no longer be available, as is the case today under Medicare Part D. While it is too early to project the full impact that bundling may have on XPHOZAH and our business should XPHOZAH be brought into the bundle in 2025, or at any time, we may be unable to sell XPHOZAH, if approved, to dialysis providers on a profitable basis.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare Reform</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March&#160;2010, Congress passed the Patient Protection and Affordable Care Act, a healthcare reform measure (&#8220;ACA&#8221;). The ACA was signed into law and substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacted the pharmaceutical industry.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ACA contained a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement changes and fraud and abuse measures, which have impacted existing government healthcare programs and have resulted in the development of new programs, including Medicare payment for performance initiatives and improvements to the physician quality reporting system and feedback program.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the ACA:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased the minimum level of Medicaid rebates payable by manufacturers of brand-name drugs from 15.1% to 23.1% of the average manufacturer price;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">required collection of rebates for drugs paid by Medicaid managed care organizations;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expanded access to commercial health insurance coverage through new state-based health insurance marketplaces, or exchanges;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">required manufacturers to participate in a coverage gap discount program, under which they must now agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part&#160;D; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">imposed a non-deductible annual fee on pharmaceutical manufacturers or importers who sell &#8220;branded prescription drugs&#8221; to specified federal government programs.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace from February 15, 2021 through August 15, 2021. The executive order instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted in the U.S. since the ACA was enacted. For example, in August 2011, the Budget Control Act of 2011, among other things, included aggregate reductions to Medicare payments to providers, which went into effect on April 1, 2013, and, due to subsequent legislative amendments, will remain in effect through 2032, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022, unless additional Congressional action is taken. In January 2013, the American Taxpayer Relief Act, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. More recently, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, beginning January 1, 2024. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recently, there has also been heightened governmental scrutiny over the manner in which drug manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed bills designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. Most recently, on August 16, 2022, the Inflation Reduction Act of 2022 (the &#8220;IRA&#8221;) was signed into law. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023), and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of the Department of Health and Human Services to implement many of these provisions through guidance, as opposed to regulation, for the initial years. For that and other reasons, it is currently unclear how the IRA will be effectuated. Additionally, individual states have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, and to encourage importation from other countries and bulk purchasing. These new laws and the regulations and policies implementing them, as well as other healthcare reform measures that may be adopted in the future, may have a material adverse effect on our industry generally and on our ability to successfully develop and commercialize our products.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Price Reporting </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid is a joint federal and state program for low-income and disabled beneficiaries. Medicare is a federal program covering individuals age 65 and over as well as those with certain disabilities. As a condition of having federal funds being made available for our covered drugs under Medicaid, we have enrolled in the Medicaid Drug Rebate Program (&#8220;MDRP&#8221;), which requires us to pay a rebate to state Medicaid programs for each unit of our covered drugs dispensed to a Medicaid beneficiary and paid for by a state Medicaid program. Medicaid drug rebates are based on pricing data that we must report on a monthly and quarterly basis to the U.S. Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), the federal agency that administers the MDRP and Medicare programs. For the MDRP, these data include the average manufacturer price (&#8220;AMP&#8221;) and the best price (&#8220;BP&#8221;) for each drug. If we become aware that our MDRP price reporting submission for a prior period was incorrect or has changed as a result of recalculation of the pricing data, we must resubmit the corrected data for up to three years after those data originally were due. Manufacturers who fail to provide information timely or are found to have knowingly submitted false information to the government may be subject to civil monetary penalties and other sanctions, including termination from the MDRP. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal law requires that a manufacturer that participates in the MDRP also participate in the Public Health Service&#8217;s 340B drug pricing program (&#8220;340B program&#8221;) in order for federal funds to be available for the manufacturer&#8217;s drugs under Medicaid and Medicare Part B. We participate in the 340B program, which is administered by the Health Resources and Services Administration (&#8220;HRSA&#8221;), and requires us to charge statutorily defined covered entities no more than the 340B &#8220;ceiling price&#8221; for our covered outpatient drugs used in an outpatient setting. These 340B covered entities include a variety of community health clinics and other entities that receive health services grants from the Public Health Service, as well as hospitals that serve a disproportionate share of low-income patients. The 340B ceiling price is calculated using a statutory formula, which is based on the AMP and rebate amount for the covered outpatient drug as calculated under the MDRP. In general, products subject to Medicaid price reporting and rebate liability are also subject to the 340B ceiling price calculation and discount requirement. We must report 340B ceiling prices to HRSA on a quarterly basis, and HRSA publishes them to 340B covered entities. HRSA has finalized regulations regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities for 340B-eligible drugs. HRSA has also finalized an administrative dispute resolution process through which 340B covered entities may pursue claims against participating manufacturers for overcharges, and through which manufacturers may pursue claims against 340B covered entities for engaging in unlawful diversion or duplicate discounting of 340B drugs.  </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to be eligible to have drug products paid for with federal funds under Medicaid and purchased by certain federal agencies and grantees, manufacturers must also participate in the U.S. Department of Veterans Affairs (&#8220;VA&#8221;) Federal Supply Schedule (&#8220;FSS&#8221;) pricing program. Under the VA/FSS program, manufacturers must report the Non-Federal Average Manufacturer Price (&#8220;Non-FAMP&#8221;) for their covered drugs to the VA and charge certain federal agencies no more than the Federal Ceiling Price, which is calculated based on Non-FAMP using a statutory formula. These four agencies are the VA, the U.S. Department of Defense, the U.S. Coast Guard, and the U.S. Public Health Service (including the Indian Health Service). Manufacturers must also pay rebates on products purchased by military personnel and dependents through the TRICARE retail pharmacy program. Manufacturers who fail to provide timely information or are found to have knowingly submitted false information may be subject to civil monetary penalties. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Individual states continue to consider and have enacted legislation to limit the growth of healthcare costs, including the cost of prescription drugs and combination products. A number of states have either implemented or are considering implementation of drug price transparency legislation. Requirements under such laws include advance notice of planned price increases, reporting price increase amounts and factors considered in taking such increases, wholesale acquisition cost information disclosure to prescribers, purchasers, and state agencies, and new product notice and reporting. Such legislation could limit the price or payment for certain drugs, and a number of states are authorized to impose civil monetary penalties or pursue other enforcement mechanisms against manufacturers who fail to comply with drug price transparency requirements, including the untimely, inaccurate, or incomplete reporting of drug pricing information.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Data Privacy and Security Laws</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous state, federal and foreign laws, including consumer protection laws and regulations, govern the collection, dissemination, use, access to, confidentiality and security of personal information, including health-related information. In the U.S., numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security laws that govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners. Further, certain foreign laws govern the privacy and security of personal data, including health-related data. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. Privacy and security laws, regulations, and other obligations are </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Regulations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to numerous federal, state and local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances. We may incur significant costs to comply with such laws and regulations now or in the future.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of COVID-19</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global COVID-19 pandemic has impacted the operational decisions of companies worldwide. We have undertaken measures to protect our employees, partners, collaborators, and vendors, some of which impact our operations. To date, we have been able to continue our operations with our workforce, most of whom have the ability to work in company-provided offices or remotely, and our pre-existing infrastructure that supports secure access to our internal systems. For a discussion of risks of COVID-19 relating to our business, see &#8220;Part II: Other Information-Item 1A.- Risk Factors- Risks Related to Our Business-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The ongoing effects of the COVID-19 pandemic, or any other outbreak of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">epidemic diseases, or the perception of their effects, could have a material adverse effect on our business, financial condition, results of operations or cash flows</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221; As of the date of issuance of this financial report, we are not aware of any specific event or circumstance that would require updates to our estimates and judgments or revisions to the carrying value of our assets or liabilities. These estimates may change as new events occur and additional information is obtained.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future success of our company depends on our ability to attract, retain, and further develop top talent. In preparation of our launch of IBSRELA in March 2022, we built an experienced commercial team and expanded our internal resources to support a commercial organization. Throughout this transition and expansion of our workforce, we have remained steadfastly committed to our core values, including our goal to develop and maintain an inclusive, diverse, and safe workplace with opportunities for our employees to grow and develop in their careers, supported by strong compensation and benefits.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, we had 133 full-time employees, 43 of whom were engaged directly in development and manufacturing, and 90 in marketing, sales and administrative activities. During 2022, our employee base increased by approximately 47, or 55%. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inclusion and Diversity</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our culture is supported by an unwavering commitment to inclusion and diversity. As of December&#160;31, 2022, approximately 56% of our workforce was female; 43% of our executive leadership team was female and 20% of our employees in managerial roles were female. As of December&#160;31, 2022, minorities represented approximately 38% of our workforce, and 17% of our employees in managerial roles were minorities. We strive to foster a culture where mutual respect, inclusive behavior, and dignity are core to our individual expectations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our success will be significantly impacted by our ability to create and maintain a safe inclusive environment where everyone is empowered to do their best work&#8212;regardless of race, color, national origin, religion, sex, sexual orientation, gender identity and expression, age, or disability. We are united by our desire to serve our patients, and we are proud financial sponsors of the California Life Sciences Association Racial and Social Equity Initiative, a first step in a unified effort for the life sciences industry in California to do more for the under-served and under-represented, focusing on the most critical need to address the inequality for Black, Hispanic, Native American and Pacific Islander populations in California. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Core Values</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fostering and maintaining a strong, healthy culture is a key strategic focus. Our core values reflect who we are and the way our employees interact with one another, our partners and our stockholders. We are dedicated to our core values, recognizing that this dedication will foster an environment where we will be able to realize our vision of advancing patient care. We are Passionate, aware that with integrity and determination, we make a difference for patients. We are Fearless, aware that by challenging convention, we truly innovate. We are Dedicated, aware that working tirelessly together, we are greater than the sum of our parts. We are Inclusive, aware that with respect, grace and humor, we are family. We encourage our employees to live out our core values and to discuss our core values with potential candidates looking to join our team. We believe that this is an important step in helping our culture stay strong and unique.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health, Safety, and Wellness</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The health, safety, and wellness of our employees is a priority in which we have always invested, and will continue to do so. These investments and the prioritization of employee health, safety, and wellness took on particular significance in light of COVID-19. In response to the COVID-19 pandemic, we implemented significant changes that we determined were in the best interest of our employees, as well as the communities in which we operate, in compliance with government regulations. This included having the vast majority of our employees work from home. We have reopened our facilities and employees have returned to our facilities in the manner in which they are comfortable. We will continue to adopt and align our policies to focus on the health, safety and wellness of our employees, and the needs of our business. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation and Benefits</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize that we operate within an industry where there is significant competition for top talent, and we endeavor to provide not only a strong healthy culture, but also important compensation and benefits programs to help meet the needs of our employees. In addition to base compensation, these programs, include annual bonuses, stock awards, an Employee Stock Purchase Plan, 401(k), healthcare and insurance benefits, health savings (funded by the Company) and flexible spending accounts, family leave, family care resources, and flexible work schedules, among many others. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring fair and equitable pay is integral to our commitment to our employees. Our executive team and Board of Directors strongly support this commitment. We conduct pay equity reviews annually to help us understand whether our compensation structure is appropriate and to identify what improvements can be made.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were founded in October 2007 as a Delaware corporation under the name Nteryx. We changed our name to Ardelyx,&#160;Inc. in June&#160;2008. We operate in one business segment, which is the development and commercialization of biopharmaceutical products. Our principal executive offices are located at 400 Fifth Avenue, Suite 210, Waltham, Massachusetts 02415, and our telephone number is (510) 745-1700. Our website address is www.ardelyx.com.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file electronically with the Securities and Exchange Commission (&#8220;SEC&#8221;) our annual reports on Form&#160;10-K, quarterly reports on Form&#160;10-Q and current reports on Form&#160;8-K pursuant to Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934, as amended. We make available on our website at www.ardelyx.com, free of charge, copies of these reports, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The SEC maintains a website that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. The address of that website is www.sec.gov. </span></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_19"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1A.&#160;&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business involves significant risks, some of which are described below. You should carefully consider these risks, as well as other information in this Annual Report on Form 10-K, including our financial statements and the notes thereto and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations, cash flows, the trading price of our common stock and our growth prospects. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Financial Condition and Capital Requirements</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant losses since our inception and will incur losses in the future, which makes it difficult for us to assess our future viability; although our financial statements have been prepared on a going concern basis, our current level of cash and short-term investments alone is not sufficient to meet our operating plans for the next twelve months, raising substantial doubt regarding our ability to continue as a going concern. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, we commenced the commercialization of our first product, IBSRELA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (tenapanor) for the treatment of irritable bowel syndrome with constipation (&#8220;IBS-C&#8221;) in adult patients and have generated limited revenue from product sales to date.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not profitable and have incurred losses in each year since our inception in October 2007, and we do not know whether or when we will become profitable. We continue to incur significant commercialization, development and other expenses related to our ongoing operations. As of December&#160;31, 2022, we had an accumulated deficit of $780.1&#160;million. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur substantial operating losses for the foreseeable future as we commercialize IBSRELA, seek to gain approval for XPHOZAH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(tenapanor) for the control of serum phosphorus in adult patients with chronic kidney disease (&#8220;CKD&#8221;) on dialysis; prepare for, and commercialize XPHOZAH, if approved; incur manufacturing and development cost for tenapanor; and incur manufacturing and development costs for tenapanor. . </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ernst &amp; Young LLP, our independent registered public accounting firm for the fiscal year ended December 31, 2022, has included an explanatory paragraph in their opinion that accompanies our audited financial statements as of the year ended December 31, 2022, indicating our current liquidity position raises substantial doubt about our ability to continue as a going concern. We plan to address our operating cash flow requirements with our current cash and short-term investments, cash generated from the sales of IBSRELA, and if approved, cash generated from the sales of XPHOZAH, our potential receipt of anticipated milestone payments from our collaboration partners, our potential receipt of anticipated payments from our collaboration partner, Kyowa Kirin, Co., Ltd. (&#8220;KKC&#8221;) in connection with the transaction entered into with KKC in April 2022 (&#8220;2022 KKC Amendment&#8221;) which amended our License Agreement entered into with KKC in 2017; with additional financing sources and through the implementation of cash preservation activities to reduce or defer discretionary spending.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no assurances that our efforts to meet our operating cash flow requirements will be successful. If our current cash and short-term investments as well as our plans to meet our operating cash flow requirements are not sufficient to fund necessary expenditures and meet our obligations for at least the next twelve months, our liquidity, financial condition and business prospects will be materially affected. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital. Further, the net losses we incur may fluctuate significantly from quarter-to-quarter and year-to-year, such that a period-to-period comparison of our results of operations may not be a good indication of our future performance. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have substantial net operating loss and tax credit carryforwards for Federal and California income tax purposes. Such net operating losses and tax credits carryforwards may be reduced as a result of certain intercompany restructuring transactions. In addition, the future utilization of such net operating loss and tax credit carryforwards and credits will be subject to limitations, pursuant to Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;).  In general, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a cumulative change of more than 50 percentage points (by value) in its equity ownership by certain stockholders over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss (&#8220;NOL&#8221;) carryforwards and other pre-change tax attributes (such as research and development tax credits) to offset its post-change income or taxes may be limited. We have experienced ownership changes in the past and may experience additional ownership changes in the future, as a result of subsequent changes in our stock ownership, some of which are outside our control. Accordingly, we may not be able to utilize a material portion of our NOL carryforwards, even if we achieve profitability   </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will require additional financing for the foreseeable future as we invest in the commercialization of IBSRELA, and prepare for and commercialize XPHOZAH in the U.S., if approved. The inability to access necessary capital when needed on acceptable terms, or at all, could force us to reduce our efforts to commercialize IBSRELA or delay or limit the commercialization of XPHOZAH, if approved. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, most of our resources have been dedicated to our research and development activities, including developing tenapanor. We believe that we will continue to expend substantial resources for the foreseeable future, including, costs associated with our efforts to commercialize IBSRELA, which we began selling in the U.S. in March 2022; costs associated with our efforts to pursue approval for our NDA for XPHOZAH; conducting pediatric clinical trials for IBSRELA and XPHOZAH, if approved; and manufacturing for IBSRELA and, if approved XPHOZAH. Our future funding requirements will depend on many factors, including, but not limited to:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we are able to generate product revenue from sales of IBSRELA;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether we are successful in securing approval for our NDA for XPHOZAH, and the time and cost associated with securing such approval;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of adequate third-party reimbursement for IBSRELA and, if approved, the sales price and the availability of adequate third-party reimbursement for XPHOZAH;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the manufacturing, selling and marketing costs associated with IBSRELA and, if approved, XPHOZAH; </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain our existing collaboration partnerships and to establish additional collaboration partnerships, in-license/out-license, joint ventures or other similar arrangements and the financial terms of such agreements;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt and amount of any milestones that may be received from our collaboration partners in connection with tenapanor, if any</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt, and amount of revenue, if any, that may be received from KKC in connection with the 2022 KKC Amendment;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt, and amount of royalties we may receive as a result of sales of tenapanor by our collaboration partners in China and Canada, if any;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cash requirements for the discovery and/or development of other potential product candidates, including RDX013 and RDX020;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time and cost necessary to respond to technological and market developments;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of filing, prosecuting, maintaining, defending and enforcing any patent claims and other intellectual property rights, including litigation costs and the outcome of such litigation, including costs of defending any claims of infringement brought by others in connection with the development, manufacture or commercialization of tenapanor or any of our product candidates; and</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the payment of interest and principal related to our loan and security agreement entered into with SLR Investment Corp. in February 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional funds may not be available when we need them on terms that are acceptable to us, or at all. If adequate funds are not available to us on a timely basis, we may be required to limit or reduce our commercialization of IBSRELA, or delay or limit the commercialization of XPHOZAH, if approved, or delay or limit additional clinical trials for tenapanor. Additionally, our inability to access capital on a timely basis and on terms that are acceptable to us may force us to restructure certain aspects of our business or identify and complete one or more strategic collaborations or other transactions in order to fund the commercialization of IBSRELA or XPHOZAH, if approved, through the use of alternative structures.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have generated limited revenue from product sales and may never be profitable. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We began selling IBSRELA in the U.S. in March 2022, and have generated limited revenue from product sales to date. We have no other products approved for sale. We are preparing to resubmit our NDA for XPHOZAH following the U.S. Food and Drug Administration&#8217;s (&#8220;FDA&#8221;) Center for Drug Evaluation and Research, Office of New Drugs (&#8220;OND&#8221;) decision to grant our appeal of the Complete Response Letter (&#8220;CRL&#8221;) for the NDA for XPHOZAH. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurances that our NDA for XPHOZAH will be approved by the FDA. There can be no assurances that we will be successful in increasing the amount of product revenue from sales of IBSRELA. There can be no assurances that we will generate sufficient product revenue from sales of IBSRELA and, if approved, XPHOZAH, to cover our expenses. Our ability to generate product revenue from sales or pursuant to milestone or royalty payments depends heavily on many factors, including but not limited to:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully commercialize IBSRELA;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining market acceptance of IBSRELA as a viable treatment option for IBS-C;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and sustain an adequate level of coverage and reimbursement for IBSRELA by third-party payors;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether we are successful in our efforts to secure approval for our NDA for XPHOZAH;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing and maintaining supply and manufacturing relationships with third parties that can provide an adequate (in amount and quality) supply of product to support the market demand for IBSRELA and, if approved, XPHOZAH;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addressing any competing technological and market developments;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets, and know-how, and our ability to develop, manufacture and commercialize our product candidates and products without infringing intellectual property rights of others; and</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">attracting, hiring, and retaining qualified personnel.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to our commercialization of IBSRELA, and if we are successful in obtaining regulatory approval to market XPHOZAH, our revenue will be dependent, in part, upon the size of the markets in the U.S. and the label for which approval is granted, accepted price for the product, and the ability to get reimbursement at any price. While there is significant uncertainty related to the insurance coverage and reimbursement of newly approved products in general in the U.S., there is additional uncertainty related to insurance coverage and reimbursement for drugs, like XPHOZAH, which, if approved, will be marketed for the control of serum phosphorus in adult patients with CKD on dialysis or for another other related indication. If we are successful in obtaining regulatory approval to market XPHOZAH for such indication, our ability to generate and sustain future revenues from sales of XPHOZAH, may be dependent upon whether and when XPHOZAH, along with other oral end stage renal disease (&#8220;ESRD&#8221;)-related drugs without an injectable or intravenous equivalent, are bundled into the ESRD prospective payment system, and the manner in which such introduction into the ESRD prospective payment system may occur. See &#8220;Third-party payor coverage and reimbursement status of newly approved products are uncertain. Failure to obtain or maintain adequate coverage and reimbursement for IBSRELA and, if approved, XPHOZAH could limit our ability to market those products and decrease our ability to generate revenue&#8221; below. Additionally, if the number of adult patients for IBSRELA or, if approved XPHOZAH, is not as significant as we estimate, the indication approved by regulatory authorities for XPHOZAH is narrower than we expect, coverage and reimbursement for either IBSRELA or XPHOZAH, if approved, are not available in the manner and to the extent we expect, or the reasonably accepted population for treatment is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from the sale of IBSRELA or XPHOZAH, if approved. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our failure to generate adequate revenue from product sales would likely depress our market value and could impair our ability to raise capital, expand our business, discover or develop other product candidates or continue our operations. A decline in the value of our common stock could cause our stockholders to lose all or part of their investment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principal Risks Related to Our Business</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are substantially dependent on the successful commercialization of IBSRELA, and there is no guarantee that we will achieve sufficient market acceptance for IBSRELA, secure adequate coverage and reimbursement for IBSRELA, or generate sufficient revenue from product sales of IBSRELA. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We began selling IBSRELA in the U.S. in March 2022. The overall commercial success of IBSRELA will depend on a number of factors, including the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of the third-party manufacturers we contract with to provide an adequate (in amount and quality) supply of product to support the market demand for IBSRELA;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and sustain an adequate level of coverage and reimbursement for IBSRELA by third-party payors;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of IBSRELA as a treatment for adult patients with IBS-C;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size of the treatable patient population; </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of our sales, market access and marketing efforts; </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether physicians view IBSRELA as a safe and effective treatment for adult patients with IBS-C, which will impact the adoption of IBSRELA by physicians for the treatment of IBS-C;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability, perceived advantages, relative cost, relative safety and relative efficacy of IBSRELA compared to alternative and competing treatments; </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of adverse side effects of IBSRELA;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our potential involvement in lawsuits in connection with enforcing intellectual property rights in and to IBSRELA;</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our potential involvement in third-party interference, opposition, derivation or similar proceedings with respect to our patent rights directed to IBSRELA, and avoiding other challenges to our patent rights and patent infringement claims; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a continued acceptable safety and tolerability profile of IBSRELA following approval.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of potential revenue we may achieve from the commercialization of IBSRELA is subject to these and other factors, and may be unpredictable from quarter-to-quarter. If the number of patients in the market for IBSRELA or the price that the market can bear is not as significant as we estimate, or if we are not able to secure adequate physician and patient acceptance of IBSRELA or adequate coverage and reimbursement for IBSRELA, we may not generate sufficient revenue from sales of IBSRELA. Any failure of IBSRELA to achieve market acceptance, sufficient third-party coverage or reimbursement, or commercial success would adversely affect our results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are pursuing regulatory approval for XPHOZAH. There can be no assurances that we will be successful in obtaining such regulatory approval.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are pursuing regulatory approval for XPHOZAH. To date, we have invested a significant amount of our efforts and financial resources in the research and development of XPHOZAH. On July 28, 2021, we received a CRL from the FDA&#8217;s Division of Cardiology and Nephrology (&#8220;Division&#8221;) regarding our NDA for XPHOZAH. According to the CRL, the Division determined that the magnitude of the treatment effect observed in our Phase 3 clinical trials was small and of unclear clinical significance. Following an End-of-Review Type A meeting (&#8220;End of Review Meeting&#8221;) in October 2021, with the Division, we submitted a Formal Dispute Resolution Request (&#8220;FDRR&#8221;) in December 2021. The FDRR was focused on demonstrating that the data submitted in the NDA supported the clinical significance of the treatment effect of tenapanor in the control of serum phosphorus in adult patients with CKD on dialysis. On February 4, 2022, we received an Appeal Denied Letter ("ADL") from the Office of Cardiology, Hematology, Endocrinology and Nephrology (&#8220;OCHEN&#8221;). On February 18, 2022, we submitted an appeal of the ADL to the OND. In April 2022, we received an interim response from the OND requesting additional input from the Cardiovascular and Renal Drug Advisory Committee (&#8220;CRDAC&#8221;). A CRDAC meeting was held in November 2022 with the Committee voting that the benefits of XPHOZAH outweigh its risks nine to four as a monotherapy and ten to two, with one abstention, in combination with phosphate binder therapy. In December 2022, the OND granted our appeal of the CRL for the NDA for XPHOZAH and directed the Division to work with us to develop an appropriate label for the commercialization of XPHOZAH. We believe that a label could reflect an indication for patients whose hyperphosphatemia is insufficiently managed on binder therapy. On February 13, 2023, we participated in a Type A meeting with the Division where we discussed the resubmission of the NDA, and the information to be contained in the resubmitted NDA. We currently expect to resubmit the NDA for XPHOZAH early in the second quarter of 2023. Within 30 days of resubmitting the NDA, we expect to receive notification from the Division as to the classification of the resubmission (Class 1 or Class 2) at which point the expected timing for review will also be known (2-months for a Class 1 and 6-months for a Class 2) as well as a goal review date. We currently that the FDA will act upon the XPHOZAH NDA in the second half of 2023, and that, if approved, we will launch XPHOZAH in the second half of 2023. There can be no assurances that the granting of our appeal to the CRL and resubmission of our NDA will result in approval of our NDA for XPHOZAH. Even if we are successful in obtaining approval for the NDA, the delay in obtaining such approval may result in delay in the regulatory process for our partners, which could have a material adverse effect on our business and results of operations.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we are successful in obtaining regulatory approval for XPHOZAH, there is no guarantee that we will achieve sufficient market acceptance for XPHOZAH, secure adequate coverage and reimbursement for XPHOZAH or generate sufficient revenue from product sales of XPHOZAH. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be successful in obtaining FDA approval for XPHOZAH, and if we are able to obtain approval, there is no guarantee that we will achieve sufficient market acceptance for XPHOZAH, secure adequate coverage and reimbursement for XPHOZAH or generate sufficient revenue from product sales of XPHOZAH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are successful in obtaining approval for XPHOZAH, the commercial success of XPHOZAH will depend on a number of factors, including the following:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of the third-party manufacturers we contract with to provide an adequate (in amount and quality) supply of product to support the market demand for both IBSRELA and XPHOZAH;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether or not the content and breadth of the label approved by the FDA for XPHOZAH may materially and adversely impact our ability to commercialize the product for the approved indication;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether or when XPHOZAH, along with other oral ESRD-related drugs without an injectable or intravenous equivalent, are bundled into the ESRD prospective payment system, and the manner in which such introduction into the ESRD prospective payment system may occur; </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of adverse side effects of XPHOZAH;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of XPHOZAH as safe, effective and well-tolerated by patients and the medical community, and, the extent to which the issuance of a CRL by the FDA has impacted the potential acceptance of XPHOZAH as safe, effective and well-tolerated;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to manage the commercialization of IBSRELA and XPHOZAH and the complex pricing and reimbursement negotiations that may arise with marketing products containing the same active ingredient at different doses for separate indications;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability, perceived advantages, relative cost, relative safety and relative efficacy of XPHOZAH compared to alternative and competing treatments;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and sustaining an adequate level of coverage and reimbursement for XPHOZAH by third-party payors;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our potential involvement in lawsuits in connection with enforcing intellectual property rights in and to XPHOZAH;</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our potential involvement in third-party interference, opposition, derivation or similar proceedings with respect to our patent rights, and avoiding other challenges to our patent rights and patent infringement claims; and</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a continued acceptable safety and tolerability profile of XPHOZAH following approval. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IBSRELA and/or, if approved and commercialized, XPHOZAH, may cause undesirable side effects or have other properties that could limit the commercial success of the product. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undesirable side effects caused by IBSRELA and/or, if approved, XPHOZAH could cause us or regulatory authorities to interrupt, delay or halt the commercialization of the product. Despite our receipt of marketing approval for IBSRELA and the completion of our Phase 3 clinical program for XPHOZAH, the prevalence and/or severity of side effects caused by IBSRELA and/or, if approved and commercialized, XPHOZAH could result in a number of potentially significant negative consequences could occur, including:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may withdraw their approval of the product or seize the product;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or a collaboration partner may be required to recall the product;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof, including the imposition of a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) which could require creation of a Medication Guide or patient package insert outlining the risks of such side effects for distribution to patients, a communication plan to educate healthcare providers of the drugs&#8217; risks, as well as other elements to assure safe use of the product, such as a patient registry and training and certification of prescribers;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or a collaboration partner may be subject to fines, injunctions or the imposition of civil or criminal penalties;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require the addition of new labeling statements, such as a &#8220;black box&#8221; warning or a contraindication;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could be sued and held liable for harm caused to patients;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product may become less competitive; and</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the foregoing events could prevent us, or a collaboration partner, from achieving or maintaining market acceptance of IBSRELA and/or, if approved, XPHOZAH, and could result in the loss of significant revenue to us, which would materially and adversely affect our results of operations and business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As a company, we have limited experience in the marketing, sale and distribution of pharmaceutical products; and there are significant risks in building and managing a commercial organization. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a company, we have limited experience in building and managing a commercial organization, or in the marketing, sale and distribution of pharmaceutical products. There can be no assurances that we will be successful in our efforts to hire, retain, and incentivize qualified individuals, generate sufficient sales leads, comply with regulatory requirements applicable to the marketing and sale of drug products and effectively manage a geographically dispersed sales and marketing team.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail or are delayed in the development of our internal sales, marketing and distribution capabilities, the commercialization of IBSRELA, and if approved, XPHOZAH could be adversely impacted.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third-party payor coverage and reimbursement status of newly commercialized products are uncertain. Failure to obtain or maintain adequate coverage and reimbursement for IBSRELA and, if approved, XPHOZAH could limit our ability to market those products and decrease our ability to generate revenue.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pricing, coverage and reimbursement of IBSRELA and XPHOZAH, if approved, must be adequate to support a commercial infrastructure. The availability and adequacy of coverage and reimbursement by governmental and private payors are essential for most patients to be able to afford treatments. Sales of IBSRELA and, if approved and commercialized, XPHOZAH, will depend substantially, both domestically and abroad, on the extent to which the costs of the product will be paid for by health maintenance, managed care, pharmacy benefit, and similar healthcare management organizations, or reimbursed by government authorities, private health insurers, and other third-party payors. If coverage and reimbursement are not available, or are available only to limited levels, we, or our collaboration partners, may not be able to successfully commercialize IBSRELA, or XPHOZAH, if approved. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a return on our investment.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the U.S., the principal decisions about coverage and reimbursement for new drugs are typically made by the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), an agency within the United States Department of Health and Human Services responsible for administering the Medicare program, as CMS decides whether and to what extent a new drug will be covered and reimbursed under Medicare. Private payors tend to follow the coverage reimbursement policies established by CMS to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement for products such as ours.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is increased uncertainty related to insurance coverage and reimbursement for drugs, like XPHOZAH, which, if approved, may be marketed for the control of serum phosphorus in adult patients with CKD on dialysis or for another other related indication. In January 2011, CMS implemented a new prospective payment system for dialysis treatment. Under the ESRD prospective payment system, CMS generally makes a single bundled payment to the dialysis facility for each dialysis treatment that covers all items and services routinely required for dialysis treatments furnished to Medicare beneficiaries in Medicare-certified ESRD facilities or at their home, including the cost of certain routine drugs. The inclusion of oral medications without injectable or intravenous equivalents in the bundled payment was initially delayed until January 1, 2014, and through several subsequent legislative actions was delayed until January 1, 2025. As a result, absent further legislation or regulation on this matter, beginning in 2025, oral ESRD-related drugs without injectable or intravenous equivalents may be included in the ESRD bundle and separate Medicare payment for these drugs will no longer be available, as is the case today under Medicare Part D. While it is too early to project the full impact that bundling may have on sales of XPHOZAH, if approved and commercialized, and on our business should XPHOZAH be brought into the bundle in 2025, or at any time, we may be unable to sell XPHOZAH, if approved, to dialysis providers on a profitable basis.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada, Japan, China and other countries has and will continue to put pressure on the pricing and usage of IBSRELA and XPHOZAH, even if regulatory approval is received in such countries. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medicinal products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the U.S., the reimbursement for our products may be reduced compared with the U.S. and may be insufficient to generate commercially reasonable revenue and profits. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, increasing efforts by governmental and third-party payors in the U.S. and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, these caps may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of IBSRELA, and if approved and commercialized, XPHOZAH, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely completely on third parties to manufacture IBSRELA and XPHOZAH. If they are unable to comply with applicable regulatory requirements, unable to source sufficient raw materials, experience manufacturing or distribution difficulties or are otherwise unable to manufacture sufficient quantities to meet demand, our commercialization of IBSRELA and, if approved and commercialized, XPHOZAH and our development efforts for tenapanor may be materially harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have, nor do we plan to acquire, the infrastructure or capability internally to manufacture IBSRELA or XPHOZAH on a commercial scale, or to manufacture our drug supplies for use in the conduct of our nonclinical and clinical studies. The facilities used by our contract manufacturers to manufacture our drug supply are subject to inspection by the FDA. Our ability to control the manufacturing process of our product candidates is limited to the contractual requirements and obligations we impose on our contract manufacturer. Although they are contractually required to do so, we are completely dependent on our contract manufacturing partners for compliance with the regulatory requirements, known as current Good Manufacturing Practice requirements (&#8220;cGMPs&#8221;), for manufacture of both active drug substances and finished drug products.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacture of pharmaceutical products requires significant expertise and capital investment. Manufacturers of pharmaceutical products often encounter difficulties in commercial production. These problems may include difficulties with production costs and yields, quality control, including stability of the product and quality assurance testing, and shortages of qualified personnel, as well as compliance with federal, state and foreign regulations and the challenges associated with complex supply chain management. Even if our contract manufacturers do not experience problems and commercial manufacturing is achieved, their maximum or available manufacturing capacities may be insufficient to meet commercial demand. Finding alternative manufacturers or adding additional manufacturers requires a significant amount of time and involves significant expense. New manufacturers would need to develop and implement the necessary production techniques and processes, which along with their facilities, would need to be inspected and approved by the regulatory authorities in each applicable territory. In addition, the raw materials necessary to make API for our products are acquired from a limited number of sources. Any delay or disruption in the availability of these raw materials could result in production disruptions, delays or higher costs with consequent adverse effects on us.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our contract manufacturers fail to adhere to applicable GMP or other regulatory requirements, experience delays or disruptions in the availability of raw materials or experience manufacturing or distribution problems, we may suffer significant consequences, including the inability to meet our product requirements for our clinical development programs, and if tenapanor is commercialized for any indication, such events could result in product seizures or recalls, loss of product approval, fines and sanctions, reputational damage, shipment delays, inventory shortages, inventory write-offs and other product-related charges and increased manufacturing costs. As a result, or if maximum or available manufacturing capacities are insufficient to meet demand, our development or our commercialization efforts for IBSRELA and/or, if approved, XPHOZAH may be materially harmed.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating activities may be restricted as a result of covenants related to the indebtedness under our loan and security agreement and we may be required to repay the outstanding indebtedness in an event of default, which could have a materially adverse effect on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 23, 2022, we entered into a loan and security agreement with SLR Investment Corp. (&#8220;Lender&#8221;) pursuant to which the Lender agreed to provide us with a loan facility for up to $50.0 million with a maturity date of March 1, 2027, and on August 1, 2022 and February 9, 2023, we entered into amendments to the loan and security agreement (collectively, the &#8220;2022 Loan Agreement.&#8221;). The loan was funded in the amount of $27.5 million on February 23, 2022 and the remaining $22.5 million may be funded by December 20, 2023 upon the satisfaction of both (i) receipt from the FDA of approval of the NDA for XPHOZAH on or prior to November 30, 2023 and (ii) our achievement of certain product revenue milestone targets described in the 2022 Loan Agreement. Until we have repaid all funded indebtedness, the loan and security agreement subjects us to various customary covenants, including requirements as to financial reporting and insurance and restrictions on our ability to dispose of our business or property, to change our line of business, to liquidate or dissolve, to enter into any change in control transaction, to merge or consolidate with any other entity or to acquire all or substantially all the capital stock or property of another entity, to incur additional indebtedness, to incur liens on our property, to pay any dividends or other distributions on capital stock other than dividends payable solely in capital stock, to redeem capital stock, to enter into licensing agreements, to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">engage in transactions with affiliates, and to encumber our intellectual property. Our business may be adversely affected by these restrictions on our ability to operate our business. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are permitted to make interest only payments on the loan facility through March 2024, with principal repayments commencing on April 1, 2024, however, this interest only period will be extended to March 2025 with principal repayments delayed to April 1, 2025 if (i) we secure approval from the FDA for our NDA for XPHOZAH by November 30, 2023 or (ii) we achieve certain product revenue targets described in the 2022 Loan Agreement for the year ended December 31, 2023. In addition, we may be required to repay the outstanding indebtedness under the loan facility if an event of default occurs under the loan and security agreement. An event of default will occur if, among other things, we fail to make payments under the loan and security agreement; we breach any of our covenants under the loan and security agreement, subject to specified cure periods with respect to certain breaches; the Lender determines that a material adverse change has occurred; we or our assets become subject to certain legal proceedings, such as bankruptcy proceedings; we are unable to pay our debts as they become due; or we default on contracts with third parties which would permit the Lender to accelerate the maturity of such indebtedness or that could have a material adverse change on us. We may not have enough available cash or be able to raise additional funds through equity or debt financings to repay such indebtedness at the time any such event of default occurs. In this case, we may be required to limit or reduce our activities necessary to commercialize IBSRELA and/or, if approved, XPHOZAH, or delay or limit clinical trials for tenapanor or other product candidates. The Lender could also exercise its rights as collateral agent to take possession of and to dispose of the collateral securing the term loans, which collateral includes substantially all of our property (excluding intellectual property, which is subject to a negative pledge). Our business, financial condition and results of operations could be materially adversely affected as a result of any of these events.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additional Risks Related to Our Business and Industry</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical drug development involves a lengthy and expensive process with an uncertain outcome. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical studies to demonstrate the safety and efficacy of the product candidates in humans. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. For example, while the results of our Phase 2 clinical trial evaluating RDX013 for the treatment of hyperkalemia demonstrated an acceptable safety and tolerability profile for RDX013 and supported proof of concept in its ability to lower serum potassium levels, with statistically significant reductions compared to placebo after eight days of treatment, the study did not meet its primary endpoint of significantly reducing serum potassium levels compared to placebo after four weeks of treatment. We currently expect that the next step for the program will be to evaluate a new formulation that potentially enhances subject compliance and the efficacy of RDX013 in an additional Phase 2 clinical study at such time as we have determined that our available resources support conducting such an additional clinical study. There can be no assurances that any additional clinical study that we determine to conduct with RDX013 will be successful.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if we conduct additional clinical trials with RDX013 or any other product candidates, we could encounter delays in our future development if any clinical trials are suspended or terminated by us, by the IRBs of the institutions in which the trial is being conducted, or by the FDA or other regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, identifying and qualifying patients to participate in any clinical trials is critical to the success of the clinical trials. The timing of any future clinical trials, including any additional RDX013 clinical trial that we may determine to conduct, will depend, in part, on the speed at which we can recruit patients to participate in testing our product candidates. Patients may be unwilling to participate in our clinical studies because of concerns about adverse events observed with the current standard of care, competitor products and/or other investigational agents, in each case for the same indications and/or similar patient populations. In addition, patients currently receiving treatment with the current standard of care or a competitor product may be reluctant to participate in a clinical trial with an investigational drug, or our inclusion and exclusion criteria for our clinical trials may present challenges in identifying acceptable patients. As a result, the timeline for recruiting patients and conducting clinical trials may be delayed. These delays could result in increased costs, delays in advancing our development of the program, or termination of the clinical studies altogether. Any of these occurrences may significantly harm our business, financial condition and prospects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will rely on third parties to conduct all of our nonclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for additional products or commercialize our product candidates. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have the ability to independently conduct nonclinical studies or clinical trials. We rely on medical institutions, clinical investigators, contract laboratories, and other third parties, such as Contract Research Organizations (&#8220;CROs&#8217;), to conduct clinical trials on our product candidates. The third parties with whom we contract for execution of the clinical trials play a significant role in the conduct of these trials and the subsequent collection and analysis of data. However, these third parties are not our employees, and except for contractual duties and obligations, we control only certain aspects of their activities and have limited ability to control the amount or timing of resources that they devote to our programs. Although we rely, and will continue to rely, on these third parties to conduct our nonclinical studies and our clinical trials, we remain responsible for ensuring that each of our studies and clinical trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards and our reliance on third parties does not relieve us of our regulatory responsibilities. We, and these third parties are required to comply with current GLPs for nonclinical studies, and good clinical practices (&#8220;GCPs&#8221;) for clinical studies. GLPs and GCPs are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area (&#8220;EEA&#8221;) and comparable foreign regulatory authorities for all of our products in nonclinical and clinical development, respectively. Regulatory authorities enforce GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our third-party contractors fail to comply with applicable regulatory requirements, including GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, the European Medicines Agency (&#8220;EMA&#8221;), or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. There can be no assurance that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which could add additional costs and could delay the regulatory approval process. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, and our competitors may discover, develop or commercialize products faster or more successfully than us.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are highly competitive, and we face significant competition from companies in the biotechnology, pharmaceutical and other related markets that are researching and marketing products designed to address diseases that we are currently developing products to treat. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of three prescription products marketed for certain patients with IBS-C, including Linzess (linaclotide), Amitiza (lubiprostone) and Trulance (plecanatide). Generic lubiprostone is also available in the U.S.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XPHOZAH, if approved will compete with phosphate binders. The various types of phosphate binders commercialized in the U.S. include the following: Calcium acetate (several prescription brands including PhosLo and Phoslyra); Lanthanum carbonate (Fosrenol); Sevelamer hydrochloride (Renagel); Sevelamer carbonate (Renvela); Sucroferric oxyhydroxide (Velphoro); and Ferric citrate (Auryxia). All of the listed phosphate binders are available as generics in the U.S., with the exception of Velphoro and Auryxia. Additionally, over-the-counter calcium carbonate, such as Tums and Caltrate, is also used to bind phosphorus.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the currently available phosphate binders, we are aware of at least four other binders in development, including fermagate (Alpharen), an iron-based binder in Phase 3 being developed by Opko Health, Inc., PT20, an iron-based binder in Phase 3 being developed by Shield Therapeutics, AP-301 in Phase 2 being developed by Alebund Pharmaceutical (Hong Kong) Limited, and lanthanum dioxycarbonate (Renazorb), which has demonstrated pharmacodynamic bioequivalence to Fosrenol. Renazorb is being developed by Unicycive Therapeutics, which has announced its plans to file an NDA via the 505(b)(2) pathway in mid-2023. Additionally, Chugai and Alebund are developing EOS789, an inhibitor of phosphate transporters NaPi-2b, PiT-1, and PiT-2, thus far studied in a phase 1 clinical trial. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that our competitors' drugs may be less expensive and more effective than our product candidates, or may render our product candidates obsolete. It is also possible that our competitors will commercialize competing drugs or treatments before we or our collaboration partners can launch any products developed from our product candidates. We also may face increased competition in the future as new companies enter into our target markets. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors have materially greater name recognition and financial, manufacturing, marketing, research and drug development resources than we do. Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. Large pharmaceutical companies in particular have extensive expertise in preclinical and clinical testing and in obtaining regulatory approvals for drugs. In addition, academic institutions, government agencies, and other public and private organizations conducting research may seek patent protection with respect to potentially competitive products or technologies. These organizations may also establish exclusive collaboration partnerships or licensing relationships with our competitors. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may experience difficulties in managing our current activities and growth given our level of managerial, operational, financial and other resources. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have continued to work to optimize our management composition, personnel and systems to support our current activities for future growth, these resources may not be adequate for this purpose. Our need to effectively execute our business strategy requires that we:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manage any commercialization activities in which we may engage effectively;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manage our clinical trials effectively;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manage our internal development efforts effectively while carrying out our contractual obligations to licensors, contractors, collaborators, government agencies and other third parties;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to improve our operational, financial and management controls, reporting systems and procedures; and</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">retain and motivate our remaining employees and potentially identify, recruit, and integrate additional employees. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to maintain or expand our managerial, operational, financial and other resources to the extent required to manage our development and commercialization activities, our business will be materially adversely affected. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of IBSRELA and/or, if approved, XPHOZAH. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and our commercial launch of IBSRELA and will face further risk following the commercial launch of XPHOZAH in the second half of 2023, if approved. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability, and a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for the product;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injury to our reputation;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs to defend the related litigation;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a diversion of management&#8217;s time and our resources;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to trial participants or patients;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory investigations, product recalls or withdrawals, or labeling, marketing or promotional restrictions;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenue; and</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to commercialize or co-promote IBSRELA and/or, if approved, XPHOZAH. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims could prevent or inhibit the commercialization of any products we develop. Although we maintain product liability insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to attract, retain and motivate our executives, senior management and key personnel, our business will suffer. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recruiting and retaining qualified scientific, clinical, medical, manufacturing, and sales and marketing personnel is critical to our success. We are highly dependent on our executives, senior management and certain other key employees. The loss of the services of our executives, senior management or other key employees could impede the achievement of our development and commercial objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executives, senior management and other key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain marketing approval of and commercialize products. We may be unable to hire, train or motivate these key personnel on acceptable terms given the intense competition among numerous biopharmaceutical companies for similar personnel, particularly in our geographic regions. If we are unable to continue to attract and retain high quality personnel, our ability to grow and pursue our business strategy will be limited. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global data protection landscape is rapidly evolving, and we are or may become subject to numerous state, federal and foreign laws, requirements and regulations governing the collection, use, disclosure, retention, and security of personal data, such as information that we may collect in connection with clinical trials in the U.S. and abroad. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business; affect our ability to operate in certain jurisdictions, or to collect, store, transfer use and share personal information; necessitate the acceptance of more onerous obligations in our contracts; result in liability; or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulation, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage to our reputation, any of which could have a material adverse effect on our operations, financial performance and business.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As our operations and business grow, we may become subject to or affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. In the U.S., the Health Insurance Portability and Accountability Act of 1996, as amended, and regulations promulgated thereunder (collectively &#8220;HIPAA&#8221;) imposes, among other things, certain standards relating to the privacy, security, transmission, and breach reporting of individually identifiable health information. We may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under HIPAA. Depending on the facts and circumstances, we could be subject to significant penalties if we violate HIPAA.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain states have also adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. For example, the California Consumer Privacy Act ("CCPA") went into effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that has increased the likelihood of, and risk associated with data breach litigation. Further, the California Privacy Rights Act ("CPRA") generally went into effect on January 1, 2023 and significantly amends the CCPA. It imposes additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It also creates a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. Additional compliance investment and potential business process changes may also be required. Similar laws have passed in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Virginia, Connecticut, Utah and Colorado, and have been proposed in other states and at the federal level, reflecting a trend toward more stringent privacy legislation in the U.S. The enactment of such laws could have potentially conflicting requirements that would make compliance challenging. In the event that we are subject to or affected by HIPAA, the CCPA, the CPRA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the Federal Trade Commission (&#8220;FTC&#8221;) and many state Attorneys General continue to enforce federal and state consumer protection laws against companies for online collection, use, dissemination and security practices that appear to be unfair or deceptive. For example, according to the FTC, failing to take appropriate steps to keep consumers&#8217; personal information secure can constitute unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also or may become subject to rapidly evolving data protection laws, rules and regulations in foreign jurisdictions. For example, in Europe, the European Union General Data Protection Regulation (&#8220;GDPR&#8221;) went into effect in May 2018 and imposes strict requirements for processing the personal data of individuals within the European Economic Area (&#8220;EEA&#8221;). Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater.  Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the U.S.; in July 2020, the Court of Justice of the EU (&#8220;CJEU&#8221;) limited how organizations could lawfully transfer personal data from the EU/EEA to the U.S. by invalidating the Privacy Shield for purposes of international transfers and imposing further restrictions on the use of standard contractual clauses. In March 2022, the U.S. and EU announced a new regulatory regime intended to replace the invalidated regulations; however, this new EU-U.S. Data Privacy Framework has not been implemented beyond an executive order signed by President Biden on October 7, 2022 on Enhancing Safeguards for United States Signals Intelligence Activities. European court and regulatory decisions subsequent to the CJEU decision of July 2020 have taken a restrictive approach to international data transfers. Relatedly, following the United Kingdom&#8217;s withdrawal from the EEA and the European Union, and the expiry of the transition period, companies have had to comply with both the GDPR and the GDPR as incorporated into United Kingdom national law, the latter regime having the ability to separately fine up to the greater of &#163;17.5 million or 4% of global turnover. As we continue to expand into other foreign countries and jurisdictions, we may be subject to additional laws and regulations that may affect how we conduct business.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we work to comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another or other legal obligations with which we must comply. Any failure or perceived failure by us or our employees, representatives, contractors, consultants, CROs, collaborators, or other third parties to comply with such requirements or adequately address privacy and security concerns, even if unfounded, could result in additional cost and liability to us, damage our reputation, and adversely affect our business and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our collaborators, CROs and other contractors and consultants depend on information technology systems, and any failure of these systems could harm our business. Security breaches, loss of data, and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business, results of operations and financial condition. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators, CROs, and other contractors and consultants collect and maintain information in digital form that is necessary to conduct our business, and we are increasingly dependent on information technology systems and infrastructure to operate our business. In the ordinary course of our business, we and our collaborators, CROs and other contractors and consultants collect, store and transmit large amounts of confidential information, including intellectual property, proprietary business information and personal information. It is critical that we and our collaborators, CROs and other contractors and consultants do so in a secure manner to maintain the confidentiality and integrity of such confidential information. We have established physical, electronic and organizational measures designed to safeguard and secure our systems to prevent a data compromise, and rely on commercially available systems, software, tools, and monitoring to provide security for our information technology systems and the processing, transmission and storage of digital information. We have also outsourced elements of our information technology infrastructure, and as a result a number of third-party vendors may or could have access to our confidential information. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our information technology systems and infrastructure, and those of our current and any future collaborators, CROs, contractors and consultants and other third parties on which we rely, are vulnerable to attack, damage and interruption from computer viruses, malware (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ransomware), natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the Internet, phishing attacks and other social engineering schemes, attachments to emails, human error, fraud, denial or degradation of service attacks, sophisticated nation-state and nation-state-supported actors or unauthorized access or use by persons inside our organization, or persons with access to systems inside our organization. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk of a security breach or disruption or data loss, particularly through cyberattacks or cyber intrusion, including by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. In addition, the prevalent use of mobile devices that access confidential information increases the risk of data security breaches, which could lead to the loss of confidential information or other intellectual property. We may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. Even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence. The costs to us to mitigate network security problems, bugs, viruses, worms, malicious software programs and security vulnerabilities could be significant, and while we have implemented security measures to protect our data security and information technology systems, our efforts to address these problems may not be successful, and these problems could result in unexpected interruptions, delays, cessation of service and other harm to our business and our competitive position. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and certain of our service providers are from time to time subject to cyberattacks and security incidents. We do not believe that we have experienced any significant system failure, accident or security breach to date, but if such an event were to occur and cause interruptions in our operations, it could result in a material disruption to our business. In addition, such a breach may require notification to governmental agencies, the media or individuals pursuant to various federal and state privacy and security laws, if applicable. Moreover, if a computer security breach affects our systems or those of our collaborators, CROs or other contractors, or results in the unauthorized release of personally identifiable information, our reputation could be materially damaged. We would also be exposed to a risk of loss or litigation and potential liability, which could materially adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain proper and effective internal controls, our ability to produce accurate and timely financial statements could be impaired, which could harm our operating results, our ability to operate our business and investors&#8217; views of us and could have a material adverse effect on the price of our common stock. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to implement and maintain effective internal controls over financial reporting could result in errors in our financial statements that could result in a restatement of our financial statements and cause us to fail to meet our reporting obligations. If we cannot in the future favorably assess the effectiveness of our internal controls over financial reporting, investor confidence in the reliability of our financial reports may be adversely affected, which could have a material adverse effect on the trading price of our common stock. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have formed in the past, and may form in the future, collaboration partnerships, joint ventures and/or licensing arrangements, and we may not realize the benefits of such collaborations. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have current collaboration partnerships for the commercialization of tenapanor in certain foreign countries, and we may form additional collaboration partnerships, create joint ventures or enter into additional licensing arrangements with third parties in the U.S. and abroad that we believe will complement or augment our existing business. In particular, we have formed collaboration partnerships with KKC for commercialization of tenapanor for hyperphosphatemia in Japan; with Fosun Pharma for commercialization of tenapanor for hyperphosphatemia and IBS-C in China and related territories; and in Canada with Knight for commercialization of tenapanor for IBS-C and hyperphosphatemia. We face significant competition in seeking appropriate collaboration partners, and the process to identify an appropriate partner and negotiate appropriate terms is time-consuming and complex. Any delays in identifying suitable additional collaboration partners and entering into agreements to develop our product candidates could also delay the commercialization of our product candidates, which may reduce their competitiveness even if they reach the market. There is no guarantee that our current collaboration partnerships or any such arrangements we enter into in the future will be successful, or that any collaboration partner will commit sufficient resources to the development, regulatory approval, and commercialization effort for such products, or that such alliances will result in us achieving revenues that justify such transactions. We received a CRL from the FDA regarding our NDA for XPHOZAH. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the OND&#8217;s decision to grant our appeal of the CRL, we are preparing to resubmit our NDA for XPHOZAH. There can be no assurances that the granting of our appeal of the CRL and resubmission of our NDA will result in approval of our NDA for XPHOZAH. Even if we are successful in obtaining approval for the NDA, the delay in obtaining such approval may result in delay in the regulatory process for our partners, which could have a material adverse effect on our business and results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The ongoing effects of the COVID-19 pandemic, or any other outbreak of epidemic diseases, or the perception of their effects, could have a material adverse effect on our business, financial condition, results of operations or cash flows. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outbreaks of epidemic, pandemic, or contagious diseases, such as the current novel coronavirus (&#8220;COVID-19&#8221;) pandemic or, historically, the Ebola virus, Middle East Respiratory Syndrome, Severe Acute Respiratory Syndrome or the H1N1 virus, could disrupt our business. Economic and health conditions related to the COVID-19 pandemic in the U.S. and across most of the globe remain uncertain and continue to evolve. The continuing effects of the coronavirus pandemic may result in delays in the manufacture of tenapanor, or in the delivery of key intermediates or raw materials required to manufacture tenapanor or delays in clinical development activities by us, or our collaboration partners. Such effects could also materially and negatively impact our ability to successfully commercialize IBSRELA and/or, if approved, XPHOZAH, or the ability of our collaboration partners to successfully commercialize such products, if approved for marketing and sale by the foreign regulatory authorities, including our ability, and that of our collaboration partners to educate physicians and patients about the benefits, administration and use of the product. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Although we have reopened our offices and invited our personnel to return to the office, we continue to permit our personnel to work remotely, which could negatively impact productivity, or disrupt, delay, or otherwise adversely impact our business. In addition, this could increase our cyber-security risk, create data accessibility concerns, and make us more susceptible to communication disruptions, any of which could adversely impact our business operations or delay necessary interactions with local and federal regulators, ethics committees, manufacturing sites, research or clinical trial sites and important agencies and contractors. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The FDA and comparable foreign regulatory agencies may continue to experience operational interruptions or delays, which may impact timelines for regulatory submission, trial initiation and regulatory approval. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The full effects of the COVID-19 remain unknown. The extent to which the outbreak may continue to impact our business, including, our commercialization and manufacturing will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as access to physician offices for our commercial and medical teams, business closures or supply chain or business disruptions. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may consider strategic transactions, such as acquisitions of companies, asset purchases, and/or in-licensing of products, product candidates or technologies. In addition, if we are unable to access capital on a timely basis and on terms that are acceptable to us, we may be forced to further restructure certain aspects of our business or identify and complete one or more strategic collaborations or other transactions in order to fund the commercialization of IBSRELA, our continued efforts to seek approval for our NDA for XPHOZAH and/or the development of discovery and developmental assets through the use of alternative structures. Additional potential transactions that we may consider include a variety of different business arrangements, including spin-offs, spin outs, collaboration partnerships, joint ventures, restructurings, divestitures, business combinations and investments. Any such transaction may require us to incur non-recurring or other charges, may increase our near- and long-term expenditures and may pose significant integration challenges or disrupt our management or business, which could adversely affect our operations and financial results. For example, these transactions may entail numerous operational and financial risks, including:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">up-front, milestone and royalty payments, equity investments and financial support of new research and development candidates including increase of personnel, all of which may be substantial;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exposure to unknown liabilities;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruption of our business and diversion of our management&#8217;s time and attention in order to develop acquired products, product candidates or technologies;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incurrence of substantial debt or dilutive issuances of equity securities;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">higher-than-expected acquisition and integration costs;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">write-downs of assets or goodwill or impairment charges;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased amortization expenses;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty and cost in combining the operations and personnel of any acquired businesses with our operations and personnel;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and ownership; and</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to retain key employees of any acquired businesses. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, although there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, any transactions that we do complete may be subject to the foregoing or other risks and could have a material adverse effect on our business, results of operations, financial condition and prospects. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our CMOs manufacture tenapanor API outside of the U.S., and we may seek and obtain approval to commercialize IBSRELA and XPHOZAH outside of the U.S., and as a result a variety of risks associated with international operations could materially adversely affect our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our collaboration partners may decide to seek marketing approval for IBSRELA or XPHOZAH outside the U.S. Additionally, we have contractual agreements with CMOs involving the manufacture of tenapanor API outside of the U.S., and may otherwise engage in business outside of the U.S., including entering into additional contractual agreements with third parties. We are subject to additional risks related to entering these international business markets and relationships, including:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different regulatory requirements for drug approvals in foreign countries;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differing U.S. and foreign drug import and export rules;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced protection for intellectual property rights in foreign countries;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unexpected changes in tariffs, trade barriers and regulatory requirements;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different reimbursement systems, and different competitive drugs;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign taxes, including withholding of payroll taxes;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">workforce uncertainty in countries where labor unrest is more common than in the U.S.;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential liability resulting from development work conducted by these distributors; and</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business involves the use of hazardous materials and we and third-parties with whom we contract must comply with environmental laws and regulations, which can be expensive and restrict how we do business. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and manufacturers and suppliers with whom we may contract are subject to laws and regulations governing the use, manufacture, storage, handling, and disposal of hazardous materials, including the components of our tenapanor and our product candidates. In some cases, these hazardous materials and various wastes resulting from their use are stored at our and our manufacturers&#8217; facilities pending their use and disposal. We cannot eliminate the risk of contamination, which could cause an interruption of our commercialization efforts, and business operations, and could result in environmental damage requiring costly clean-up and resulting in liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. We cannot guarantee that the safety procedures utilized by third-party manufacturers and suppliers with whom we may contract will comply with the standards prescribed by laws and regulations or will eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. We do not currently carry biological or hazardous waste insurance coverage. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be adversely affected by earthquakes or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently occupy a leased facility located in the San Francisco Bay Area, which in the past has experienced severe earthquakes. We do not carry earthquake insurance. Earthquakes or other natural disasters could severely disrupt our operations, and have a material adverse effect on our business, results of operations, financial condition and prospects. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our leased facilities, including our California facility, that damaged critical infrastructure, such as our enterprise financial systems or manufacturing resource planning and enterprise quality systems, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Government Regulation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Despite having received regulatory approval for IBSRELA, and even if we receive regulatory approval for XPHOZAH, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, IBSRELA and, if approved, XPHOZAH could be subject to other restrictions and market withdrawal, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if a drug is approved by the FDA or foreign regulatory authorities, the manufacturing processes, labeling, packaging, distribution, pharmacovigilance, storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCP regulations for any clinical trials that we conduct post-approval. As such, we and our third-party CMOs will be subject to continual review and periodic inspections to assess compliance with regulatory requirements. Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production, and quality control. Regulatory authorities may also impose significant restrictions on a product&#8217;s indicated uses or marketing or impose ongoing requirements for potentially costly post-marketing studies. Furthermore, any new legislation addressing drug safety issues could result in delays or increased costs to assure compliance. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will also be required to report certain adverse reactions and production problems, if any, to the FDA, and to comply with requirements concerning advertising and promotion for our products. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved label. As such, we may not promote our products for indications or uses for which they do not have FDA approval. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">warning or untitled letters or fines;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market or voluntary or mandatory product recalls;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension or revocation of existing regulatory approvals;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension of any of our ongoing clinical trials;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal to approve pending applications or supplements to approved applications submitted by us;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on our or our CMOs&#8217; operations; or</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of products. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize IBSRELA and, if approved, XPHOZAH. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the FDA&#8217;s policies may change, and additional government regulations may be enacted. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the U.S. or abroad. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, or otherwise review and process regulatory submissions in a timely manner, which could negatively impact our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and process regulatory submissions can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. If a prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our CMOs are subject to significant regulation with respect to manufacturing IBSRELA and XPHOZAH. The manufacturing facilities on which we rely may not continue to meet regulatory requirements or may not be able to meet supply demands. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All entities involved in the preparation of product for commercial sale, or product candidates for clinical trials, including our existing contract manufacturers are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical studies must be manufactured in accordance with cGMP regulations. These regulations govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of contaminants or to inadvertent changes in the properties or stability of our products or product candidates that may not be detectable in final product testing. We or our CMOs must supply all necessary </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">documentation in support of an NDA or comparable regulatory filing on a timely basis and must adhere to cGMP regulations enforced by the FDA and other regulatory agencies through their facilities inspection programs. The facilities and quality systems of some or all of our third-party contractors must pass a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of our product candidates. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the manufacture of our product or the associated quality systems for compliance with the regulations applicable to the activities being conducted. Although we oversee the CMOs, we cannot control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with the regulatory requirements. If these facilities do not pass a pre-approval plant inspection, regulatory approval of the products may not be granted or may be substantially delayed until any violations are corrected to the satisfaction of the regulatory authority, if ever. In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory authorities also may, at any time following approval of a product for sale, audit the manufacturing facilities of our third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time consuming for us or a third party to implement, and that may include the temporary or permanent suspension of a clinical study or commercial sales or the temporary or permanent suspension of production or closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or any of our third-party manufacturers fail to maintain regulatory compliance, the FDA or other applicable regulatory authority can impose regulatory sanctions including, among other things, refusal to approve a pending application for a new drug product, withdrawal of an approval, or suspension of production. As a result, our business, financial condition, and results of operations may be materially harmed. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if supply from one approved manufacturer is interrupted, an alternative manufacturer would need to be qualified through an NDA, a supplemental NDA or equivalent foreign regulatory filing, which could result in further delay. The regulatory agencies may also require additional studies if a new manufacturer is relied upon for commercial production. Switching manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These factors could cause us to incur higher costs and could cause the delay or termination of clinical studies, regulatory submissions, required approvals, or commercialization of our product candidates. Furthermore, if our suppliers fail to meet contractual requirements and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical studies may be delayed, or we could lose potential revenue. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply or are found to have failed to comply with FDA and other regulations related to the promotion of our products for unapproved uses, we could be subject to criminal penalties, substantial fines or other sanctions and damage awards. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulations relating to the promotion of products for unapproved uses are complex and subject to substantial interpretation by the FDA and other government agencies. With respect to the commercialization of IBSRELA and/or, if approved, XPHOZAH we will be restricted from marketing the product outside of its approved labeling, also referred to as off-label promotion. However, physicians may nevertheless prescribe an approved product to their patients in a manner that is inconsistent with the approved label, which is an off-label use. We have implemented compliance and training programs designed to ensure that our sales and marketing practices comply with applicable regulations regarding off-label promotion. Notwithstanding these programs, the FDA or other government agencies may allege or find that our practices constitute prohibited promotion of our product candidates for unapproved uses. We also cannot be sure that our employees will comply with company policies and applicable regulations regarding the promotion of products for unapproved uses. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the past several years, a significant number of pharmaceutical and biotechnology companies have been the target of inquiries and investigations by various federal and state regulatory, investigative, prosecutorial and administrative entities in connection with the promotion of products for unapproved uses and other sales practices, including the Department of Justice and various U.S. Attorneys&#8217; Offices, the Office of Inspector General of the Department of Health and Human Services, the FDA, the FTC and various state Attorneys General offices. These investigations have alleged violations of various federal and state laws and regulations, including claims asserting antitrust violations, violations of the FFDCA, the False Claims Act, the Prescription Drug Marketing Act, anti-kickback laws, and other alleged violations in connection with the promotion of products for unapproved uses, pricing and Medicare and/or Medicaid reimbursement. Many of these investigations originate as &#8220;qui tam&#8221; actions under the False Claims Act. Under the False Claims Act, any individual can bring a claim on behalf of the government </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">alleging that a person or entity has presented a false claim, or caused a false claim to be submitted, to the government for payment. The person bringing a qui tam suit is entitled to a share of any recovery or settlement. Qui tam suits, also commonly referred to as &#8220;whistleblower suits,&#8221; are often brought by current or former employees. In a qui tam suit, the government must decide whether to intervene and prosecute the case. If it declines, the individual may pursue the case alone. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA or any other governmental agency initiates an enforcement action against us or if we are the subject of a qui tam suit and it is determined that we violated prohibitions relating to the promotion of products for unapproved uses, we could be subject to substantial civil or criminal fines or damage awards and other sanctions such as consent decrees and corporate integrity agreements pursuant to which our activities would be subject to ongoing scrutiny and monitoring to ensure compliance with applicable laws and regulations. Any such fines, awards or other sanctions would have an adverse effect on our revenue, business, financial prospects and reputation. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IBSRELA and/or, if approved, XPHOZAH may cause or contribute to adverse medical events that we are required to report to regulatory agencies and if we fail to do so we could be subject to sanctions that would materially harm our business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to report certain information about adverse medical events if our products may have caused or contributed to those adverse events. The timing of our obligation to report is triggered by the date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events we become aware of within the prescribed timeframe. We may also fail to appreciate that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our products. If we fail to comply with our reporting obligations, the FDA or a foreign regulatory agency could take action, including criminal prosecution, the imposition of civil monetary penalties, seizure of our products or delay in approval or clearance of future products. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, principal investigators, CROs, collaboration partners, consultants and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk that our employees, independent contractors, principal investigators, CROs, collaboration partners, consultants and vendors may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or unauthorized activities that violate any of the following: FDA regulations, including those laws that require the reporting of true, complete and accurate financial and other information to the FDA; manufacturing standards; or federal and state healthcare fraud and abuse laws and regulations. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. These activities also include the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to obtain regulatory approvals in foreign jurisdictions would prevent us from marketing our products internationally. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market any product in the EEA (which is composed of the 27 Member States of the European Union plus Norway, Iceland and Liechtenstein), and many other foreign jurisdictions, separate regulatory approvals are required. In the EEA, medicinal products can only be commercialized after obtaining a Marketing Authorization (&#8220;MA&#8221;). Before the MA is granted, the EMA or the competent authorities of the Member States of the EEA make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The approval procedures vary among countries and can involve additional clinical testing, and the time required to obtain approval may differ from that required to obtain FDA approval. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one or more foreign regulatory authorities does not ensure approval by regulatory authorities in other foreign countries or by the FDA. However, a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval. We may not be able to file for regulatory approvals or to do so on a timely basis, and even if we do file, we may not receive necessary approvals to commercialize our products in any market. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our collaboration partners are subject to healthcare laws, regulation and enforcement; our failure or the failure of any such collaboration partners to comply with these laws could have a material adverse effect on our results of operations and financial conditions. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaboration partners are subject to additional healthcare statutory and regulatory requirements and enforcement by the federal government and the states and foreign governments in which we conduct our business. The laws that may affect our ability to operate as a commercial organization include:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal false claims laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the false claims statutes;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Civil Monetary Penalties law, which prohibits, among other things, offering or transferring remuneration to a federal healthcare beneficiary that a person knows or should know is likely to influence the beneficiary&#8217;s decision to order or receive items or services reimbursable by the government from a particular provider or supplier;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of these statutes or specific intent to violate them in order to have committed a violation;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal physician sunshine requirements under the ACA, which requires manufacturers of drugs, devices, biologics, and medical supplies to report annually to CMS information related to payments and other transfers of value to physicians, (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician practitioners (physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiologist assistants and certified nurse midwives), and teaching hospitals, and ownership and investment interests held by physicians (as defined by the statute) and their immediate family members;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or pricing information and marketing expenditures; and </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">European and other foreign law equivalents of each of the laws, including reporting requirements detailing interactions with and payments to healthcare providers. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, the exclusion from participation in federal and state healthcare programs and imprisonment, any of which could adversely affect our ability to market our products and adversely impact our financial results. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legislative or regulatory healthcare reforms in the U.S. may make it more difficult and costly for us to obtain regulatory clearance or approval of our product candidates and to produce, market and distribute our products after clearance or approval is obtained. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions governing the regulatory clearance or approval, manufacture, and marketing of regulated products or the reimbursement thereof. In addition, FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business and our products. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of our product candidates. We cannot determine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted or adopted may have on our business in the future. Such changes could, among other things, require:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional clinical trials to be conducted prior to obtaining approval;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes to manufacturing methods;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recall, replacement, or discontinuance of one or more of our products; and</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional record keeping. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these would likely entail substantial time and cost and could materially harm our business and our financial results. In addition, delays in receipt of or failure to receive regulatory clearances or approvals for any future products would harm our business, financial condition and results of operations. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the full impact of recent healthcare reform and other changes in the healthcare industry and in healthcare spending is currently unknown, and may adversely affect our business model. In the U.S., the ACA was enacted in 2010 with a goal of reducing the cost of healthcare and substantially changing the way healthcare is financed by both government and private insurers. Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. The ACA, among other things, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees and taxes on manufacturers of certain branded prescription drugs, and created a new Medicare Part D coverage gap discount program, in which manufacturers must now agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have been proposed and adopted in the U.S. since the ACA was enacted. These new laws, among other things, included aggregate reductions of Medicare payments to providers that will remain in effect through 2032, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022, unless additional action is taken by Congress, additional specific reductions in Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and an increase in the statute of limitations period for the government to recover overpayments to providers from three to five years. More recently, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, beginning January 1, 2024. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recently, there has also been heightened governmental scrutiny over the manner in which drug manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed bills designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. On August 16, 2022, the Inflation Reduction Act of 2022 (the &#8220;IRA&#8221;) was signed into law. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023), and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of the Department of Health and Human Services to implement many of these provisions through guidance, as opposed to regulation, for the initial years. For that and other reasons, it is currently unclear how the IRA will be effectuated. Additionally, individual states have become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, and to encourage importation from other countries and bulk purchasing. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict the reform initiatives that may be adopted in the future or whether initiatives that have been adopted will be repealed or modified. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare may adversely affect the demand for any drug products for which we may obtain regulatory approval, our ability to set a price that we believe is fair for our products, our ability to obtain coverage and reimbursement approval for a product, our ability to generate revenues and achieve or maintain profitability, and the level of taxes that we are required to pay.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs in the U.S., we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, results of operations and financial condition.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:28pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the commercial launch of IBSRELA, we participate in the Medicaid Drug Rebate Program (&#8220;MDRP&#8221;) and other federal and state government pricing programs in the U.S., and we may participate in additional government pricing programs in the future. These programs generally require manufacturers to pay rebates or otherwise provide discounts to government payors in connection with drugs that are dispensed to beneficiaries of these programs. Medicaid drug rebates are based on pricing data that we will be obligated to report on a monthly and quarterly basis to the U.S. Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), the federal agency that administers the MDRP and Medicare programs. For the MDRP, these data include the average manufacturer price (&#8220;AMP&#8221;) and the best price (&#8220;BP&#8221;) for each drug. If we become aware that our MDRP price reporting submission for a prior period was incorrect or has changed as a result of recalculation of the pricing data, we must resubmit the corrected data for up to three years after those data originally were due. In addition, there is increased focus by the Office of Inspector General within the U.S. Department of Health and Human Services on the methodologies used by manufacturers to calculate AMP, and BP, to assess manufacturer compliance with MDRP reporting requirements. If we fail to provide information timely or are found to have knowingly submitted false information to the government, we may be subject to civil monetary penalties and other sanctions, including termination from the MDRP, which would result in payment not being available for our covered drugs under Medicaid. Failure to make necessary disclosures and/or to identify overpayments could result in allegations against us under the Federal False Claims Act and other laws and regulations. </span></div><div style="text-align:justify;text-indent:28pt"><span><br/></span></div><div style="text-align:justify;text-indent:28pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal law requires that a manufacturer that participates in the MDRP also participate in the Public Health Service&#8217;s 340B drug pricing program (&#8220;340B program&#8221;) in order for federal funds to be available for the manufacturer&#8217;s drugs under Medicaid. We participate in the 340B program, which is administered by the Health Resources and Services Administration (&#8220;HRSA&#8221;), and requires us to charge statutorily defined covered entities no more than the 340B &#8220;ceiling price&#8221; for our covered drugs. These 340B covered entities include a variety of community health clinics and other entities that receive health services grants from the Public Health Service, as well as hospitals that serve a disproportionate share of low-income patients. The 340B ceiling price is calculated using a statutory formula, which is based on the AMP and rebate amount for the covered drug as calculated under the MDRP. In general, products subject to Medicaid price reporting and rebate liability are also subject to the 340B ceiling price calculation and discount requirement. We are obligated to report 340B ceiling prices to HRSA on a quarterly basis, and HRSA publishes them to 340B covered entities. HRSA has finalized regulations regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities for 340B-eligible drugs. HRSA has also finalized an administrative dispute resolution process through which 340B covered entities may pursue claims against participating manufacturers for overcharges, and through which manufacturers may pursue claims against 340B covered entities for engaging in unlawful diversion or duplicate discounting of 340B drugs.</span></div><div style="text-align:justify;text-indent:28pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:28pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to be eligible to have drug products paid for with federal funds under Medicaid and purchased by certain federal agencies and grantees, we also participate in the U.S. Department of Veterans Affairs (&#8220;VA&#8221;) Federal Supply Schedule (&#8220;FSS&#8221;) pricing program. Under the VA/FSS program, we are obligated to report the Non-Federal Average Manufacturer Price (&#8220;Non-FAMP&#8221;) for our covered drugs to the VA and charge certain federal agencies no more than the Federal Ceiling Price, which is calculated based on Non-FAMP using a statutory formula. These four agencies are the VA, the U.S. Department of Defense, the U.S. Coast Guard, and the U.S. Public Health Service (including the Indian Health Service). We are also required to pay rebates on products purchased by military personnel and dependents through the TRICARE retail pharmacy program. If we fail to provide timely information or are found to have knowingly submitted false information, we may be subject to civil monetary penalties. </span></div><div style="text-align:justify;text-indent:28pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:28pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Individual states continue to consider and have enacted legislation to limit the growth of healthcare costs, including the cost of prescription drugs and combination products. A number of states have either implemented or are considering implementation of drug price transparency legislation that may prevent or limit our ability to take price increases at certain rates or frequencies. Requirements under such laws include advance notice of planned price increases, reporting price increase amounts and factors considered in taking such increases, wholesale acquisition cost information disclosure to prescribers, purchasers, and state agencies, and new product notice and reporting. Such legislation could limit the price or payment for IBSRELA and, if approved and launched, XPHOZAH, and a number of states are authorized to impose civil monetary penalties or pursue other enforcement mechanisms against manufacturers who fail to comply with drug price transparency requirements, including the untimely, inaccurate, or incomplete reporting of drug pricing information. If we are found to have violated state law requirements, we may become subject to penalties or other enforcement mechanisms, which could have a material adverse effect on our business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:28pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pricing and rebate calculations are complex, vary among products and programs, and are often subject to interpretation by us, governmental or regulatory agencies, and the courts. The terms, scope and complexity of these government pricing programs change frequently, as do interpretations of applicable requirements for pricing and rebate calculations. Responding to current and future changes may increase our costs and the complexity of compliance will be time consuming. Any required refunds to the U.S. government or responding to a government investigation or enforcement action would be expensive and time consuming and could have a material adverse effect on our business, results of operations and financial condition. Price recalculations under the MDRP also may affect the ceiling price at which we are required to offer products under the 340B program. Civil monetary penalties can be applied if we are found to have knowingly submitted any false price or product information to the government, if we fail to submit the required price data on a timely basis, or if we are found to have charged 340B covered entities more than the statutorily mandated ceiling price. In the event that CMS were to terminate our Medicaid rebate agreement, no federal payments would be available under Medicaid or Medicare for IBSRELA or, if approved and launched, XPHOZAH. We cannot offer any assurances that our submissions will not be found to be incomplete or incorrect.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success will depend on our ability to obtain, maintain and protect our intellectual property rights </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success and ability to compete depend in part on our ability to obtain, maintain and enforce issued patents, trademarks and other intellectual property rights and proprietary technology in the U.S. and elsewhere. If we cannot adequately obtain, maintain and enforce our intellectual property rights and proprietary technology, competitors may be able to use our technologies or the goodwill we have acquired in the marketplace and erode or negate any competitive advantage we may have and our ability to compete, which could harm our business and ability to achieve profitability and/or cause us to incur significant expenses.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a combination of contractual provisions, confidentiality procedures and patent, trademark, copyright, trade secret and other intellectual property laws to protect the proprietary aspects of our products, product candidates, brands, technologies, trade secrets, know-how and data. These legal measures afford only limited protection, and competitors or others may gain access to or use our intellectual property rights and proprietary information. Our success will depend, in part, on preserving our trade secrets, maintaining the security of our data and know-how and obtaining, maintaining and enforcing other intellectual property rights. We may not be able to obtain, maintain and/or enforce our intellectual property or other proprietary rights necessary to our business or in a form that provides us with a competitive advantage. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to obtain, maintain and/or enforce intellectual property rights necessary to our business and failure to protect, monitor and control the use of our intellectual property rights could negatively impact our ability to compete and cause us to incur significant expenses. The intellectual property laws and other statutory and contractual arrangements in the U.S. and other jurisdictions we depend upon may not provide sufficient protection in the future to prevent the infringement, use, violation, or misappropriation of our patents, trademarks, data, technology, and other intellectual property rights and products by others; and may not provide an adequate remedy if our intellectual property rights are infringed, misappropriated, or otherwise violated by others.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely in part on our portfolio of issued and pending patent applications in the U.S. and other countries to protect our intellectual property and competitive position. However, it is also possible that we may fail to identify patentable aspects of inventions made in the course of our development, manufacture and commercialization activities before it is too late to obtain patent protection on them. If we fail to timely file for patent protection in any jurisdiction, we may be precluded from doing so at a later date. Although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, suppliers, consultants, advisors, and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. Furthermore, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in any of our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. Moreover, should we become a licensee of a third party&#8217;s patents or patent applications, depending on the terms of any future in-licenses to which we may become a party, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain or enforce the patents, covering technology in-licensed from third parties. Therefore, these patents and patent applications may not be prosecuted, maintained and/or enforced in a manner consistent with the best interests of our business. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of companies, including our patent position, may involve complex legal and factual questions that have been the subject of much litigation in recent years, and, therefore, the scope of any patent claims that we have or may obtain cannot be predicted with certainty. Accordingly, we cannot provide any assurances about which of our patent applications will issue, the breadth of any resulting patent, whether any of the issued patents will be found to be infringed, invalid or unenforceable or will be threatened or challenged by third parties, that any of our issued patents have, or that any of our currently pending or future patent applications that mature into issued patents will include, claims with a scope sufficient to protect our products and services. Our pending and future patent applications may not result in the issuance of patents or, if issued, may not issue in a form that will be advantageous to us. The coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. We cannot offer any assurances that the breadth of our granted patents will be sufficient to stop a competitor from developing, manufacturing and commercializing a product or technologies in a non-infringing manner that would be competitive with one or more of our products or technologies, or otherwise provide us with any competitive advantage. Furthermore, any successful challenge to these patents or any other patents owned by or licensed to us after patent issuance could deprive us of rights necessary for our commercial success. Further, there can be no assurance that we will have adequate resources to enforce our patents.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited lifespan. In the U.S., the natural expiration of a utility patent is generally 20 years from the earliest effective non-provisional filing date. Though an issued patent is presumed valid and enforceable, its issuance is not conclusive as to its validity or its enforceability and it may not provide us with adequate proprietary protection or competitive advantages against competitors with similar products or services. Patents, if issued, may be challenged, deemed unenforceable, invalidated, narrowed or circumvented. Proceedings challenging our patents or patent applications could result in either loss of the patent, or denial of the patent application or loss or reduction in the scope of one or more of the claims of the patent or patent application. Any successful challenge to our patents and patent applications could deprive us of exclusive rights necessary for our commercial success. In addition, defending such challenges in such proceedings may be costly. Thus, any patents that we may own may not provide the anticipated level of, or any, protection against competitors. Furthermore, an adverse decision may result in a third party receiving a patent right sought by us, which in turn could affect our ability to develop, manufacture or commercialize our products or technologies.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our patents and patent applications may in the future be co-owned with third parties. If we are unable to obtain an exclusive license to any such third-party co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products, services and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection for our proprietary rights is uncertain, and we cannot ensure that:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any of our patents, or any of our pending patent applications, if issued, will include claims having a scope sufficient to protect our products or product candidates;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any of our pending patent applications will issue as patents;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We were the first to make the inventions covered by each of our patents and pending patent applications;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We were the first to file patent applications for these inventions;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Others will not develop, manufacture and/or commercialize similar or alternative products or technologies that do not infringe our patents;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any of our challenged patents will be found to ultimately be valid and enforceable;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any patents issued to us will provide a basis for an exclusive market for our commercially viable products or technologies will provide us with any competitive advantages or will not be challenged by third parties;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will develop additional proprietary technologies or products that are separately patentable; or</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our commercial activities or products will not infringe upon the patents of others.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become subject to third-party claims alleging infringement, misappropriation or violation of such third parties&#8217; patents or other intellectual property rights and/or third-party claims seeking to invalidate our patents, which would be costly, time consuming and, if successfully asserted against us, delay or prevent the development, manufacture or commercialization of our products or product candidates. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends, in part, on our ability to develop, manufacture or commercialize our products and product candidates without infringing, misappropriating or otherwise violating the intellectual property rights of third parties. There have been many lawsuits and other proceedings asserting infringement or misappropriation of patents and other intellectual property rights in the pharmaceutical and biotechnology industries, and companies in the industry have used intellectual property litigation to gain a competitive advantage. While we take steps to ensure that we do not infringe upon, misappropriate or otherwise violate the intellectual property rights of others, there can be no assurances that we will not be subject to claims alleging that the manufacture, use or sale of IBSRELA or XPHOZAH or of any other product candidates infringes existing or future third-party patents, or that such claims, if any, will not be successful. Because patent applications can take many years to issue and may be confidential for 18 months or more after filing, and because pending patent claims can be revised before issuance, there may be applications now pending which may later result in issued patents that may be infringed by the manufacture, use or sale of IBSRELA or XPHOZAH or other product candidates. Moreover, we may face patent infringement claims from non-practicing entities that have no relevant product revenue and against whom our own patent portfolio may thus have no deterrent effect. We may be unaware of one or more issued patents that would be infringed by the manufacture, sale or use of IBSRELA or XPHOZAH or our other product candidates. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights. These proceedings could cause us to pay substantial damages, including treble damages and attorney&#8217;s fees if we are found to be willfully infringing a third party&#8217;s patents. We may be required to indemnify future collaboration partners against such claims. We are not aware of any threatened or pending claims related to these matters, but in the future litigation may be necessary to defend against such claims. If a patent infringement suit were brought against us, we could be forced to stop or delay development, manufacturing or sales of the product or product candidate that is the subject of the suit. As a result of patent infringement claims, or in order to avoid potential claims, we may choose to seek, or be required to seek, a license from the third party and would most likely be required to pay license fees or royalties or both. These licenses may not be available on acceptable terms, or at all. Even if we were able to obtain a license, we may be unable to maintain such licenses and the rights may be nonexclusive, which would give our competitors access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or forced to redesign it if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms, or unable to maintain such licenses when granted. Even if we are successful in defending against such claims, such litigation can be expensive and time consuming to litigate and would divert management&#8217;s attention from our core business. Any of these events could harm our business significantly. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also could be ordered to pay substantial damages, including treble damages and attorney&#8217;s fees if we are found to be willfully infringing a third party&#8217;s patents or other intellectual property right. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third party patents are valid and enforceable, and infringed by the use of our products and/or technologies, which could have a negative impact on the commercial success of our current and any future products or technologies. If we were to challenge the validity of any such third party U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. We will have similar burdens to overcome in foreign courts in order to successfully challenge a third party claim of patent infringement. Even if we are successful in defending against such claims, such litigation can be expensive and time consuming to litigate and would divert management&#8217;s attention from our core business. Any of these events could harm our business significantly. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to infringement claims against us, third parties may also raise similar claims before administrative bodies in the U.S. or abroad. Such mechanisms include reexamination, post grant review, inter parties review, derivation or opposition proceedings before the United States Patent and Trademark Office (&#8220;USPTO&#8221;) or other jurisdictional body relating to our intellectual property rights or the intellectual property rights of others. If third parties prepare and file patent applications in the U.S. that also claim technology similar or identical to ours, we may have to participate in interference or derivation proceedings in the USPTO to determine which party is entitled to a patent on the disputed invention. We may also become involved in similar opposition proceedings in the European Patent Office or similar offices in other jurisdictions regarding our intellectual property rights with respect to our products and technology. Since patent applications are confidential for a period of time after filing, we cannot be certain that we were the first to file any patent application related to our product candidates. Such administrative proceedings could result in revocation of or amendment to our patents in such a way that they no longer cover our products or product candidates. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel, and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity and/or unenforceability, we may lose at least part, and perhaps all, of the patent protection on our products or technologies. Such a loss of patent protection would have a material adverse impact on our business, financial condition, results of operations, and prospects.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our intellectual property related to IBSRELA, XPHOZAH, RDX013 or any future product candidates is not adequate or if we are not able to successfully enforce our intellectual property rights, the commercial value of IBSRELA, if approved, XPHOZAH, or other product candidates may be adversely affected and we may not be able to compete effectively in our market.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or license may fail to result in issued patents in the U.S. or in foreign countries. Additionally, our research and development efforts may result in product candidates for which patent protection is limited or not available. Even if patents do successfully issue, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. For example, U.S. patents can be challenged by any person before the new USPTO Patent Trial and Appeals Board at any time before one year after that person is served an infringement complaint based on the patents. Patents granted by the European Patent Office may be similarly opposed by any person within nine months from the publication of the grant. Similar proceedings are available in other jurisdictions, and in the U.S., Europe and other jurisdictions third parties can raise questions of validity with a patent office even before a patent has granted. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our claims. For example, a third party may develop a competitive product that provides therapeutic benefits similar to one or more of our product candidates but has a sufficiently different composition to fall outside the scope of our patent protection. If the breadth or strength of protection provided by the patents and patent applications we hold or pursue with respect to IBSRELA, XPHOZAH, RDX013 or any future product candidates is successfully challenged, then our ability to commercialize such product could be negatively affected, and we may face unexpected competition that could have a material adverse impact on our business. Further, we have reported that we have completed the data analysis from our Phase 2 clinical trial evaluating the safety and efficacy of RDX013 for the treatment of hyperkalemia, and that we currently expect that the next steps for the RDX013 program will be to evaluate a new formulation that potentially enhances subject compliance and the efficacy of RDX013 in an additional Phase 2 clinical study. We currently expect to delay further development of RDX013 until such time as we have determined that our available resources support conducting such additional formulation work and an additional clinical study. As a result of this delay in our development program for RDX013, the period of time during which we or our collaboration partners could market RDX013 under patent protection would be reduced.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even where laws provide protection, costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and the outcome of such litigation would be uncertain. If we or one of our collaboration partners were to initiate legal proceedings against a third party to enforce a patent covering a product or product candidate, the defendant could counterclaim that our patent is invalid and/or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to validity, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability against our intellectual property related to a product or a product candidate, we would lose at least part, and perhaps all, of the patent protection on such product or product candidate. Such a loss of patent protection would have a material adverse impact on our business. Moreover, our competitors could counterclaim that we infringe their intellectual property, and some of our competitors have substantially greater intellectual property portfolios than we do. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on trade secret protection and confidentiality agreements to protect proprietary know-how that may not be patentable, processes for which patents may be difficult to obtain and/or enforce and any other elements of our drug discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. Although we require all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or technology, to assign their inventions to us, and endeavor to execute confidentiality agreements with all such parties, we cannot be certain that we have executed such agreements with all parties who may have helped to develop our intellectual property or who had access to our proprietary information, nor can we be certain that our agreements will not be breached by such consultants, advisors or third parties, or by our former employees. The breach of such agreements by individuals or entities who were actively involved in the discovery and design of our products or potential drug candidates, or in the development of our discovery and design platform could require us to pursue legal action to protect our trade secrets and confidential information, which would be expensive, and the outcome of which would be unpredictable. If we are not successful in prohibiting the continued breach of such agreements, our business could be negatively impacted. We cannot guarantee that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the U.S. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the U.S. and abroad. If we are unable to prevent material disclosure of the intellectual property related to our technologies to third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, results of operations and financial condition. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Although we have obtained patent term extension in the U.S. under the Hatch-Waxman Act, extending the term of marketing exclusivity for tenapanor, if we do not obtain patent term extension in foreign countries under similar legislation, our business may be materially harmed. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the approval by the FDA for our NDA to market tenapanor for IBS-C, we obtained patent term restoration under the Hatch-Waxman Act until August 1, 2033 for U.S. patent no. 8,541,448 covering our approved product or the use thereof. The Hatch-Waxman Act allows a maximum of one patent to be extended per FDA approved product. Patent term extension also may be available in certain foreign countries upon regulatory approval of our product candidates. Despite seeking patent term extension for tenapanor, we may not be granted patent term extension in any foreign country because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the term of extension, as well as the scope of patent protection during any such extension, afforded by the governmental authority could be less than we request. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to obtain patent term extension or restoration in any particular foreign country, or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our product in such foreign country will be shortened and our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced, possibly materially. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The USPTO and various foreign patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions to maintain patent applications and issued patents. Noncompliance with these requirements can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to enforce our intellectual property rights throughout the world. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the U.S. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those relating to life sciences. This could make it difficult for us to stop the infringement of our patents or the misappropriation of our other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Europe&#8217;s planned Unified Patent Court may, in particular, present uncertainties for our ability to protect and enforce our patent rights against competitors in Europe.  In 2012, the European Patent Package (&#8220;EU Patent Package&#8221;) regulations were passed with the goal of providing a single pan-European Unitary Patent and a new European Unified Patent Court (&#8220;UPC&#8221;), for litigation involving European patents. Implementation of the EU Patent Package will likely occur in the first half of 2023. Under the UPC, all European patents, including those issued prior to ratification of the European Patent Package, will by default automatically fall under the jurisdiction of the UPC. The UPC will provide our competitors with a new forum to centrally revoke our European patents, and allow for the possibility of a competitor to obtain pan-European injunctions. It will be several years before we will understand the scope of patent rights that will be recognized and the strength of patent remedies that will be provided by the UPC. Under the EU Patent Package as currently proposed, we will have the right to opt our patents out of the UPC over the first seven years of the court&#8217;s existence, but doing so may preclude us from realizing the benefits of the new unified court.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business. Furthermore, while we intend to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our products. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate. In addition, changes in the law and legal decisions by courts in the U.S. and foreign countries may affect our ability to obtain and enforce adequate intellectual property protection for our technology. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that we or our employees have misappropriated the intellectual property, including know-how or trade secrets, of a third party, or claiming ownership of what we regard as our own intellectual property. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our employees, consultants and contractors were previously employed at or engaged by other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Some of these employees, consultants and contractors, executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment. Although we try to ensure that our employees, consultants and contractors do not use the intellectual property and other proprietary information or know-how or trade secrets of others in their work for us, and do not perform work for us that is in conflict with their obligations to another employer or any other entity, we may be subject to claims that we or these employees, consultants and contractors have used or disclosed such intellectual property, including know-how, trade secrets or other proprietary information. In addition, an employee, advisor or consultant who performs work for us may have obligations to a third party that are in conflict with their obligations to us, and as a result such third party may claim an ownership interest in the intellectual property arising out of work performed for us. We are not aware of any threatened or pending claims related to these matters, but in the future litigation may be necessary to defend against such claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, or access to consultants and contractors. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, while we typically require our employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own, which may result in claims by or against us related to the ownership of such intellectual property. If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our management and scientific personnel. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price may be volatile and our stockholders may not be able to resell shares of our common stock at or above the price they paid. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our common stock is highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. These factors include those discussed in this &#8220;Risk Factors&#8221; section and others such as:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success or lack of success with regards to our commercialization of IBSRELA;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of regulatory decisions regarding our NDA seeking marketing approval for XPHOZAH;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success or lack of success with regards to our commercial launch of XPHOZAH, if approved;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results of regulatory inspections of our facilities or those of our CMOs, or specific label restrictions or patient populations for XPHOZAH&#8217;s use, if approved, or changes or delays in the regulatory review process;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results of regulatory inspections of our facilities or those of our CMOs, or specific label restrictions or patient populations for XPHOZAH&#8217;s use, if approved, or changes or delays in the regulatory review process;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements regarding whether XPHOZAH, if approved, alone or with other oral only medications, will be included in the ESRD prospective payment system, and the time and manner in which such transition is achieved;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements relating to our current or future collaboration partnerships;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of therapeutic innovations or new products by us or our competitors;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse actions taken by regulatory agencies with respect to our product label, our clinical trials, manufacturing supply chain or sales and marketing activities;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes or developments in laws or regulations applicable to our approved products or our product candidates;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our testing and clinical trials;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to meet any of our projected timelines or goals with regard to the commercialization of IBSRELA, the commercial launch of XPHOZAH, if approved, or the clinical development and commercialization of any of our product candidates;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our efforts to acquire or license or discover additional product candidates;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any intellectual property infringement actions in which we may become involved;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our efforts to obtain adequate intellectual property protection for our product candidates;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements concerning our competitors or the pharmaceutical industry in general;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">achievement of expected product sales and profitability;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacture, supply or distribution shortages;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated fluctuations in our operating results;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA or other U.S. or foreign regulatory actions affecting us or our industry or other healthcare reform measures in the U.S.;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in financial estimates or recommendations by securities analysts;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trading volume of our common stock;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of our common stock by us, our executive officers and directors or our stockholders in the future;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of debt securities and sales or licensing of assets;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic and market conditions and overall fluctuations in the U.S. equity markets; and</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the loss of any of our key scientific or management personnel. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock markets in general, and the markets for pharmaceutical, biopharmaceutical and biotechnology stocks in particular, have experienced extreme volatility that may have been unrelated to the operating performance of the issuer. These broad market fluctuations may adversely affect the trading price or liquidity of our common stock. In the past, when the market price of a stock has been volatile, holders of that stock have sometimes instituted securities class action litigation against the issuer. If any of our stockholders were to bring such a lawsuit against us, we could incur substantial costs defending the lawsuit and the attention of our management would be diverted from the operation of our business, which could seriously harm our financial position. Any adverse determination in litigation could also subject us to significant liabilities. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we sell shares of our common stock in future financings, stockholders may experience immediate dilution and, as a result, our stock price may decline. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may from time to time issue additional shares of common stock at a discount from the current trading price of our common stock. As a result, our stockholders would experience immediate dilution upon the purchase of any shares of our common stock sold at such discount. In addition, as opportunities present themselves, we may enter into financing or similar arrangements in the future, including the issuance of debt securities, preferred stock or common stock. If we issue common stock or securities convertible into common stock, our common stockholders would experience additional dilution and, as a result, our stock price may decline. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We incur significant costs as a result of operating as a public company, and our management will devote substantial time to new compliance initiatives. We may fail to comply with the rules that apply to public companies, including Section 404 of the Sarbanes-Oxley Act of 2002, which could result in sanctions or other penalties that would harm our business. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incur significant legal, accounting and other expenses as a public company, including costs resulting from public company reporting obligations under the Securities Exchange Act of 1934, as amended (&#8220;Exchange Act&#8221;) and regulations regarding corporate governance practices. The listing requirements of The Nasdaq Global Market require that we satisfy certain corporate governance requirements relating to director independence, distributing annual and interim reports, stockholder meetings, approvals and voting, soliciting proxies, conflicts of interest and a code of conduct. Our management and other personnel will need to devote a substantial amount of time to ensure that we comply with all of these requirements. Moreover, the reporting requirements, rules and regulations will increase our legal and financial compliance costs and will make some activities more time consuming and costly. Any changes we make to comply with these obligations may not be sufficient to allow us to satisfy our obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors or board committees or to serve as executive officers, or to obtain certain types of insurance, including directors&#8217; and officers&#8217; insurance, on acceptable terms. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to Section 404 of The Sarbanes-Oxley Act of 2002 (&#8220;Section 404&#8221;) and the related rules of the Securities and Exchange Commission (&#8220;SEC&#8221;) which generally require, among other things, our management to report on the effectiveness of our internal control over financial reporting, subject to certain exceptions applicable to non-accelerated filers. Our compliance with Section 404 requires that we incur substantial expense and expend significant management efforts.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the course of our review and testing of our internal controls, we may identify deficiencies and be unable to remediate them before we must provide the required reports. Furthermore, if we have a material weakness in our internal controls over financial reporting, we may not detect errors on a timely basis and our financial statements may be materially misstated. We or our independent registered public accounting firm may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting, which could harm our operating results, cause investors to lose confidence in our reported financial information and cause the trading price of our stock to fall. In addition, as a public company we are required to file accurate and timely quarterly and annual reports with the SEC under the Exchange Act. Any failure to report our financial results on an accurate and timely basis could result in sanctions, lawsuits, delisting of our shares from The Nasdaq Global Market or other adverse consequences that would materially harm our business. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be adversely affected by the global economic environment. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to attract and retain collaboration partners or customers, invest in and grow our business and meet our financial obligations depends on our operating and financial performance, which, in turn, is subject to numerous factors, including the prevailing economic conditions and financial, business and other factors beyond our control, such as the rate of unemployment, the number of uninsured persons in the U.S., presidential elections, other political influences and inflationary pressures. Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets, including the current inflationary environment and rising interest rates. For example, the 2008 global financial crisis caused extreme volatility and disruptions in the capital and credit markets. We cannot anticipate all the ways in which the global economic climate and global financial market conditions could adversely impact our business in the future. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to risks associated with reduced profitability and the potential financial instability of our collaboration partners or customers, many of which may be adversely affected by volatile conditions in the financial markets. For example, unemployment and underemployment, and the resultant loss of insurance, may decrease the demand for healthcare services and pharmaceuticals. If fewer patients are seeking medical care because they do not have insurance coverage, our collaboration partners or customers may experience reductions in revenues, profitability and/or cash flow that could lead them to reduce their support of our programs or financing activities. If collaboration partners or customers are not successful in generating sufficient revenue or are precluded from securing financing, they may not be able to pay, or may delay payment of, accounts receivable that are owed to us. In addition, volatility in the financial markets could cause significant fluctuations in the interest rate and currency markets. We currently do not hedge for these risks. The foregoing events, in turn, could adversely affect our financial condition and liquidity. In addition, if economic challenges in the U.S. result in widespread and prolonged unemployment, either regionally or on a national basis, or if certain provisions of the Patient Protection and ACA, as amended by the Health Care and Education Reconciliation Act, collectively known as the ACA, are repealed, a substantial number of people may become uninsured or underinsured. To the extent economic challenges result in fewer individuals pursuing or being able to afford our product candidates once commercialized, our business, results of operations, financial condition and cash flows could be adversely affected. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could significantly reduce the value of our shares to a potential acquirer or delay or prevent changes in control or changes in our management without the consent of our board of directors. The provisions in our charter documents include the following:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the required approval of at least two-thirds of the shares entitled to vote to remove a director for cause, and the prohibition on removal of directors without cause;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our board of directors to alter our bylaws without obtaining stockholder approval;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the required approval of at least two-thirds of the shares entitled to vote at an election of directors to adopt, amend or repeal our bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the requirement that a special meeting of stockholders may be called only by the chairman of the board of directors, the chief executive officer, the president or the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to obtain control of us. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, these provisions would apply even if we were to receive an offer that some stockholders may consider beneficial. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to the anti-takeover provisions contained in Section 203 of the Delaware General Corporation Law. Under Section 203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other exceptions, the board of directors has approved the transaction. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as permitted by Section 145 of the Delaware General Corporation Law, our amended and restated bylaws and our indemnification agreements that we have entered into with our directors and officers provide that:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such a person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will not be obligated pursuant to our amended and restated bylaws to indemnify a person with respect to proceedings initiated by that person against us or our other indemnities, except with respect to proceedings authorized by our board of directors or brought to enforce a right to indemnification. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The rights conferred in our amended and restated bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not retroactively amend our amended and restated bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not currently intend to pay dividends on our common stock, and, consequently, our stockholders&#8217; ability to achieve a return on their investment will depend on appreciation in the price of our common stock. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently intend to pay any cash dividends on our common stock for the foreseeable future. We currently intend to invest our future earnings, if any, to fund our growth. Additionally, the terms of our loan and security agreements could restrict our ability to pay dividends. Therefore, our stockholders are not likely to receive any dividends on our common stock for the foreseeable future. Since we do not intend to pay dividends, our stockholders&#8217; ability to receive a return on their investment will depend on any future appreciation in the market value of our common stock. There is no guarantee that our common stock will appreciate or even maintain the price at which our holders have purchased it. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The continuing impact of &#8220;Brexit&#8221; may have a negative effect on our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following a national referendum and subsequent legislation the United Kingdom formally withdrew from the European Union, commonly referred to as &#8220;Brexit&#8221; and ratified a trade and cooperation agreement governing its future relationship with the European Union. Among other things, the agreement became effective in  2021, addresses trade, economic arrangements, law enforcement, judicial cooperation and governance. Because the agreement merely sets forth a framework that in many respects requires complex additional bilateral negotiations between the United Kingdom and the European Union significant uncertainty remains about how the precise terms of the relationship between the parties will differ from the terms before withdrawal. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot yet predict the full implications of Brexit, including whether it will increase our operational costs or otherwise have a negative effect on our business, financial condition or results of operations, which could reduce the price of our common stock.</span></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_22"></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1B.&#160;&#160;&#160;&#160;UNRESOLVED STAFF COMMENTS</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_25"></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;2.&#160;&#160;&#160;&#160;PROPERTIES</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our headquarters is currently located in Waltham, Massachusetts and consists of 12,864 square feet of leased office space under a lease agreement that expires in June 2026. In addition, we lease 72,500 square feet of office and laboratory space in Fremont, California under a lease agreement that expires in March 2025 and 4,768 square feet of office space in Milwaukee, Wisconsin under a lease agreement that expires in February 2026. Prior to October 2021, our headquarters were co-located in Fremont, California and Waltham, Massachusetts.</span></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_28"></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;3.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30 and August 12, 2021, two putative securities class action lawsuits were commenced in the U.S. District Court for the Northern District of California naming as defendants Ardelyx and two current officers captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Strezsak v. Ardelyx, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 4:21-cv-05868-HSG, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Siegel v. Ardelyx, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 5:21-cv-06228-HSG (together, the &#8220;Securities Class Actions&#8221;). The complaints allege that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 thereunder, by making false and misleading statements and omissions of material fact related to tenapanor. The plaintiffs seek to represent all persons who purchased or otherwise acquired Ardelyx securities between August 6, 2020, and July 19, 2021. The plaintiffs seek damages and interest, and an award of costs, including attorneys&#8217; fees. On July 19, 2022, the court consolidated the two putative class actions and appointed a lead plaintiff and lead counsel. The lead plaintiff filed an amended complaint on September 29, 2022. Defendants filed a motion to dismiss the amended complaint on December 2, 2022. In January and February 2023, in lieu of filing a response to defendant&#8217;s motion to dismiss, plaintiffs filed a motion seeking leave to further amend their compliant and defendants filed an opposition to the motion for leave to further amend the complaint. A hearing on the motion for leave to further amend the complaint is scheduled for mid-May 2023. We believe the plaintiff&#8217;s claims are without merit and we have not recorded any accrual for a contingent liability associated with these legal proceedings.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2021 and March 29, 2022, two verified shareholders derivative lawsuits were filed in the U.S. District Court for the Northern District of California purportedly on behalf of Ardelyx against certain of Ardelyx&#8217;s executive officers and members of our board of directors, captioned Go v. Raab, et al., Case No. 4:21-cv-09455-HSG, and Morris v. Raab, et al., Case No. 4:22-cv-01988-JSC. The complaints allege that the defendants violated Section 14(a) of the Securities Exchange Act of 1934, as amended, breaches of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement, and waste of corporate assets for personally making and/or causing Ardelyx to make materially false and misleading statements regarding the Company&#8217;s business, operations and prospects. The complaint seeks contribution under Sections 10(b) and 21D of the Securities Exchange Act of 1934, as amended, from two executive officers. On January 19, and April 27, 2022, the court granted the parties&#8217; stipulation to stay the Go and Morris actions, respectively, until resolution of the anticipated motion(s) to dismiss in the Securities Class Actions. On October 25, 2022, the parties filed a stipulation to consolidate and stay the Go and Morris actions, and on October 27, 2022, the court consolidated the Go and Morris action and stayed the consolidated action pending resolution of the anticipated motion(s) to dismiss in the Securities Class Action. We believe the plaintiff&#8217;s claims are without merit and we have not recorded any accrual for a contingent liability associated with these legal proceedings.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be involved in legal proceedings arising in the ordinary course of business. As of December&#160;31, 2022, there is no litigation pending that would reasonably be expected to have a material adverse effect on our results of operations and financial condition, and no contingent liabilities were accrued as of December&#160;31, 2022.</span></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_31"></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-top:12pt;text-align:justify"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;II</span></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_37"></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;5.&#160;&#160;&#160;&#160;MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;19, 2014, our common stock commenced trading on The Nasdaq Global Market under the symbol &#8220;ARDX&#8221;. Prior to that date, there was no public trading market for our common stock. As of December&#160;31, 2022, there were 27 holders of record of our common stock.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our capital stock. We currently intend to retain any future earnings to finance the growth and development of our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance under Equity Compensation Plans</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item regarding executive compensation will be incorporated by reference to the information set forth in the sections titled &#8220;Executive Compensation&#8221; in our Proxy Statement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Proceeds</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_40"></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;6. [RESERVED]</span></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_46"></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;7.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our financial statements and related notes included elsewhere in this report. This discussion and other parts of this report contain forward-looking statements that involve risk and uncertainties, such as statements of our plans, objectives, expectations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and intentions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section of this report entitled &#8220;Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. &#8221; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">These forward-looking statements speak only as of the date hereof. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason. Unless the context requires otherwise, the terms &#8220;Ardelyx&#8221;, &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, and &#8220;our&#8221; refer to Ardelyx, Inc.</span></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_49"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OVERVIEW</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs. We developed a unique and innovative platform that enabled the discovery of new biological mechanisms and pathways to develop potent, and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The first molecule we discovered and developed was tenapanor, a targeted, first-in-class, oral, small molecule therapy. Tenapanor, branded as IBSRELA, is approved in the U.S. for the treatment of adults with irritable bowel syndrome with constipation (&#8220;IBS-C&#8221;). Tenapanor is in development for the control of serum phosphorus, or hyperphosphatemia, in adult patients with chronic kidney disease (&#8220;CKD&#8221;) on dialysis under the brand name XPHOZAH. We also have a development stage asset, RDX013 for adult patients with CKD and/or heart failure with hyperkalemia, or elevated serum potassium, and a discovery stage asset, RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder, in patients with CKD.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since commencing operations in October 2007, substantially all our efforts have been dedicated to our research and development (&#8220;R&amp;D&#8221;) activities, including developing tenapanor and developing our proprietary drug discovery and design platform. We realized our first product sales of IBSRELA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (tenapanor) in March 2022. As of December&#160;31, 2022, we had an accumulated deficit of $780.1&#160;million.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur substantial operating losses for the foreseeable future as we invest in the commercialization of IBSRELA, seek to gain approval in the U.S. for XPHOZAH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (tenapanor); prepare for and commercialize XPHOZAH in the U.S., if approved; and incur manufacturing and development cost for tenapanor. To date, we have funded our operations from the sale and issuance of common stock and convertible preferred stock, funds from our collaboration partnerships, which includes license fees, milestones and product supply revenue, funds from our loan agreements with our lenders, as well as from sales of IBSRELA.</span></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_52"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUR COMMERCIAL PRODUCT</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IBSRELA for IBS-C</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our unique discovery platform and deep understanding of the primary mechanism of sodium transport in the intestine resulted in our discovery and development of IBSRELA, a first-in-class, U.S. Food and Drug Administration (&#8220;FDA") approved, sodium hydrogen exchange 3 ("NHE3") inhibitor for the treatment of IBS-C in adults. IBSRELA acts locally in the gut and is minimally absorbed. IBS-C is a gastrointestinal ("GI") disorder characterized by both abdominal pain and altered bowel movements, and is estimated to affect 12 million people in the U.S. IBS-C is associated with significantly impaired quality of life, reduced productivity, and substantial economic burden. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We recognized our first sales of IBSRELA in the U.S. in March 2022. For our commercial launch of IBSRELA, we designed a market-responsive commercial strategy and built a commercial organization highly experienced in launching novel therapies into specialty areas. The dynamics of the IBS-C market reflect an established patient base, limited number of competitors all confined to a single mechanism of action, concentrated number of prescribers, and recognized unmet need. In addition, market research indicated a favorable response to the IBSRELA product profile as a novel mechanism therapy. These dynamics enabled a targeted promotional focus on patients currently being managed for IBS-C by the approximately 9,000 high-writing healthcare providers that account for 50% of IBS-C prescriptions. Central to the go to market strategy for IBSRELA is a highly experienced specialty sales force, many with existing relationships across their GI target base, full company engagement, and innovative peer-to-peer and digital initiatives. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect competition for IBSRELA will come largely from the three prescription products indicated for IBS-C: Linzess (linaclotide), Amitiza (lubiprostone) and Trulance (plecanatide). Generic lubiprostone is also available in the U.S. Additionally, over-the-counter products, not indicated for IBS-C are commonly used to treat the constipation component of IBS-C, alone and in combination with the IBS-C-indicated prescription therapies.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established commercial agreements with Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. ("Fosun Pharma") in China and Knight Therapeutics, Inc. ("Knight") in Canada for IBSRELA for IBS-C. Knight is currently marketing IBSRELA in Canada.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUR PRODUCT PIPELINE</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Development Candidate XPHOZAH: A Potential New Approach for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XPHOZAH (tenapanor) is a first-in-class medicine being developed for the control of serum phosphorus, or hyperphosphatemia, in adult patients with CKD on dialysis. XPHOZAH has a unique mechanism of action and acts locally in the gut to inhibit NHE3. This results in the tightening of the epithelial cell junctions, thereby significantly reducing paracellular uptake of phosphate, the primary pathway of phosphate absorption. It is estimated that there are more than 550,000 adult patients with CKD on dialysis in the U.S. and approximately 80% of those patients are being treated with phosphate lowering therapies. Seventy-seven percent of patients treated with phosphate binders to treat hyperphosphatemia were unable to consistently maintain phosphorous levels &lt;=5.5 mg/dL over a six-month period. If approved, XPHOZAH would be the first therapy for phosphate management that blocks phosphorus absorption at the primary site of uptake. It is not a phosphate binder.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, we submitted a new drug application ("NDA") to the FDA for XPHOZAH. The NDA was supported by three Phase 3 trials involving more than 1,200 adult patients that evaluated the use of tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis, with two trials evaluating tenapanor as monotherapy and one trial evaluating tenapanor as part of a dual mechanism approach with phosphate binders. All three Phase 3 trials met their primary and key secondary endpoints.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 28, 2021, we received a Complete Response Letter ("CRL") from the FDA&#8217;s Division of Cardiology and Nephrology ("the Division") regarding our NDA for XPHOZAH. In December 2021 we submitted a Formal Dispute Resolution Request ("FDRR") to the Office of Cardiology, Hematology, Endocrinology and Nephrology ("OCHEN"). At the request of the FDA&#8217;s Office of New Drugs ("OND"), as part of our second level of appeal of the CRL, a Cardiovascular and Renal Drug Advisory Committee meeting on was held on November 16, 2022 with the committee voting that the benefits of XPHOZAH outweigh its risks nine to four as a monotherapy and ten to two, with one abstention, in combination with phosphate binder therapy. In December 2022, the OND granted our appeal to the CRL for the NDA for XPHOZAH and directed the Division to work with us to develop an appropriate label for the commercialization of XPHOZAH. We believe that a label could reflect an indication for patients whose hyperphosphatemia is insufficiently managed on binder therapy. On February 13, 2023, we participated in a Type A meeting with the Division where we discussed the resubmission of the NDA, and the information to be contained in the resubmitted NDA. We currently expect to resubmit the NDA for XPHOZAH early in the second quarter of 2023. Within thirty (30) days of resubmitting the NDA, we expect to receive notification from the Division as to the classification of the resubmission (Class 1 or Class 2) at which point the expected timing for review will also be known (2-months for a Class 1 and 6-months for a Class 2) as well as a goal review date. We currently that the FDA will act upon the XPHOZAH NDA in the second half of 2023, and that, if approved, we will launch XPHOZAH in the second half of 2023.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established commercial agreements with Kyowa Kirin, Co. Ltd. ("KKC") in Japan, Fosun Pharma in China and Knight in Canada for tenapanor for hyperphosphatemia. In October 2022, KKC submitted an NDA to the Japanese Ministry of Health, Labour and Welfare for tenapanor for the improvement of hyperphosphatemia in adult patients with CKD on dialysis.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discovery and Developmental Assets</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a small molecule potassium secretagogue program, RDX013, for the potential treatment of hyperkalemia, or elevated serum potassium. Hyperkalemia is a common problem in patients with heart and kidney disease, particularly in patients taking customary blood pressure medications known as renin-angiotensin-aldosterone system ("RAAS") inhibitors. RDX013 is a novel mechanism agent designed to target the underlying biological mechanisms of potassium secretion to lower elevated potassium. We have completed a Phase 2 dose ranging clinical trial evaluating the safety and efficacy of RDX013 for the treatment of hyperkalemia in CKD patients who are not on dialysis. While the results of the study demonstrated an acceptable safety and tolerability profile for RDX013 and supported proof of concept in its ability to lower serum potassium levels, with statistically significant reductions compared to placebo after eight days of treatment, the study did not meet its primary endpoint of significantly reducing serum potassium levels compared to placebo after four weeks of treatment. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a discovery program targeting the inhibition of bicarbonate exchange inhibitor for the treatment of metabolic acidosis, a highly prevalent comorbidity in CKD patients that is strongly correlated with disease progression and adverse outcomes. We have identified lead compounds that are potent, selective and proprietary inhibitors of bicarbonate secretion. </span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently expect to meaningfully advance either of these two assets until such time as we have determined our available resources can support additional activities after prioritization of the commercialization of IBSRELA and, if approved, XPHOZAH.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL OPERATIONS OVERVIEW</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue to date has been generated primarily through license, research and development collaborative agreements with various collaboration partners. We realized our first commercial product sales of IBSRELA beginning in March 2022. In the future, we may generate revenue from a combination of our own product sales and payments in connection with our current or future collaborative partnerships, including license fees, other upfront payments, milestone payments, royalties and payments for drug product and/or drug substance. We expect that any revenue we generate will fluctuate in future periods as a result of, among other factors: the extent to which we are successful in our commercialization of IBSRELA; whether we are able to gain approval from the FDA for our NDA for XPHOZAH; our ability to obtain and sustain an adequate level of coverage and reimbursement for IBSRELA by third-party payors; whether and the extent to which we are successful in our commercialization of XPHOZAH, if approved; the timing and progress of goods and services provided pursuant to our current or future collaborative partnerships; our or our collaborators&#8217; achievement of clinical, regulatory or commercialization milestones, to the extent achieved; the timing and amount of any payments to us relating to the aforementioned milestones; addressing any competing technological and market developments; maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets, and know-how, and our ability to develop, manufacture and commercialize our product candidates and products without infringing intellectual property rights of others; attracting, hiring, and retaining qualified personnel; and the extent to which tenapanor is approved and successfully commercialized by a collaboration partner. If our current collaboration partners or any future collaboration partners fail to obtain regulatory approval for tenapanor, our ability to generate future revenue from our collaborative arrangements, and our results of operations and financial position, would be materially and adversely affected. Our past revenue performance is not necessarily indicative of results to be expected in future periods.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue consists of the cost of commercial goods sold to our Customers and international partners under product supply agreements, as well as royalty expense based on sales of tenapanor. We capitalize inventory costs associated with the production of our products after regulatory approval or when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Otherwise, such costs are expensed as research and development. A portion of the costs of IBSRELA units recognized as revenue during the twelve months ended December&#160;31, 2022 were expensed prior to the fourth quarter of 2021, at which time our intent to commercialize IBSRELA was established and we commenced preparation for the commercial launch of IBSRELA. We believe our cost of revenue for the year ended December&#160;31, 2022 would have been $1.9&#160;million higher if we had not previously expensed certain material and production costs with respect to the units sold. As of December&#160;31, 2022, we had approximately $28.0&#160;million of inventory on hand that was previously expensed as research and development expense and will not be reported as cost of revenue sold in future periods when sales of IBSRELA are recognized as revenue.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue includes payments due to AstraZeneca AB (&#8220;AstraZeneca&#8221;), which under the terms of a termination agreement entered into in 2015 (&#8220;AZ Termination Agreement&#8221;) is entitled to (i) future royalties at a rate of 10% of net sales of tenapanor or other NHE3 products by us or our licensees, and (ii) 20% of non-royalty revenue received from our collaboration partners in connection with the development and commercialization of tenapanor or certain other NHE3 inhibitors. We have agreed to pay AstraZeneca up to a maximum of $75.0&#160;million in the aggregate for (i) and (ii). We recognize these expenses as cost of revenue when we recognize the corresponding revenue that gives rise to payments due to AstraZeneca. To date, we have recognized an aggregate of $15.3&#160;million as cost of revenue under the AZ Termination Agreement. See details in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7, Collaboration and Licensing Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, under AstraZeneca, in the notes to our financial statements, included in Part II, Item 8, of this Annual Report on Form 10-K.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the October 2021 restructuring plan, we eliminated our internal research organization and we do not currently expect to meaningfully advance our discovery efforts with respect to our discovery and developmental assets until such time as we have determined our available resources can support additional activities after prioritization of the commercialization of IBSRELA and, if approved, XPHOZAH. We recognize all research and development expenses as they are incurred to support the discovery, research, development and manufacturing of our product candidates. Research and development expenses include, but are not limited to, the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">external research and development expenses incurred under agreements with consultants, third-party contract research organizations (&#8220;CROs&#8221;) and investigative sites where a substantial portion of our clinical studies are conducted, and with contract manufacturing organizations where our clinical supplies are produced;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses associated with supplies and materials consumed in connection with our research operations;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses associated with producing XPHOZAH prior to FDA approval;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses associated with producing discovery and developmental assets prior to FDA approval;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other costs associated with research, clinical development and regulatory activities;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related expenses, which include salaries, bonuses, benefits, travel and stock-based compensation; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facilities and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities, depreciation and amortization expense, information technology expense and other supplies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses relate to sales and marketing, finance, human resources, legal and other administrative activities, including information technology investments. Selling, general and administrative expenses consist primarily of personnel costs, outside professional services, marketing, advertising and legal expenses, facilities costs not otherwise allocated to research and development and other general and administrative costs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense represents the interest paid on our loan payable.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-cash interest expense related to the sale of future royalties</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash interest expense related to the sale of future royalties represents the imputed interest expense on our deferred royalty obligation related to the sale of future royalties using the effective interest method. As further described in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8. Deferred Royalty Obligation Related to the Sale of Future Royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in June 2022, we and HealthCare Royalty Partners IV, L.P. (&#8220;HCR&#8221;) entered into a Royalty and Sales Milestone Interest Acquisition Agreement (&#8220;HCR Agreement&#8221;). Under the terms of the HCR Agreement, HCR agreed to pay us up to $20.0 million in exchange for the royalty payments and commercial milestone payments (collectively the &#8220;Royalty Interest Payments&#8221;) that we may receive under our 2017 License Agreement with KKC based upon KKC's net sales of tenapanor in Japan for hyperphosphatemia. As part of the HCR Agreement, we received a $10.0 million upfront payment from HCR in June 2022 and recorded it as a deferred royalty obligation on our balance sheet. Non-cash interest expense will be recognized over the life of the HCR Agreement using the effective interest method based on the imputed interest rate derived from estimated amounts and timing of future royalty payments to be received from KKC.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income, net</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net consists of interest income earned on our cash and cash equivalents and available-for-sale investments, the periodic revaluation of the exit fee related to our loan, gains on sales of property and equipment, and currency exchange gains and losses. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for Income Taxes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our provision for income taxes includes current and deferred tax, including foreign withholding taxes paid on payments received from certain collaboration partners. Deferred income taxes reflect the tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Our deferred tax assets continue to be fully offset by a valuation allowance, including deferred tax assets related to our net operating loss carryforwards, which may be subject to annual limitations as a result of ownership changes that may have occurred or could occur in the future.</span></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_58"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING POLICIES AND ESTIMATES</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A detailed discussion of our significant accounting policies can be found in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note&#160;2, Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the notes to our financial statements, included in Part&#160;II, Item&#160;8, of this Annual Report on Form 10-K. Critical accounting policies are those that require significant judgment and/or estimates by management at the time that financial statements are prepared such that materially different results might have been reported if other assumptions had been made. These estimates form the basis for making judgments about the carrying values of assets and liabilities. We base our estimates and judgments on experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ materially from these estimates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider certain accounting policies related to revenue recognition, accrued research and development expenses and stock-based compensation to be critical policies to understanding the judgments and estimates applied in our reported financial results.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales, Net</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for our commercial product sales, net in accordance with Topic 606&#8211;- </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We received approval from the FDA in September 2019 to market IBSRELA in the U.S. We began selling IBSRELA in the U.S. in March 2022. We distribute IBSRELA principally through major wholesalers, specialty pharmacies and group purchasing organizations ("GPOs") (collectively, our "Customers"). Our Customers subsequently sell IBSRELA to pharmacies and patients. Separately, we enter into arrangements with third parties that provide for government-mandated rebates, chargebacks and discounts. Revenue from product sales is recognized when our performance obligations are satisfied, which is when Customers obtain control of our product and occurs upon delivery.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reserves for Variable Consideration</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration which may be settled in the form of off-invoice discounts, chargebacks, or rebates. Variable consideration includes discounts to customers and government programs, wholesaler fees, group purchasing organization administrative fees, patient copay assistance, and estimated product returns. These estimates are based on the amounts earned or to be claimed for related sales and are classified as reductions of gross accounts receivable if settlement is expected to occur through a reduction in the amounts paid by our Customers or a current liability if settlement is expected to occur through a payment from us. Where appropriate, these estimates are based on factors such as industry data and forecasted customer buying and payment patterns, our experience, current contractual and statutory requirements, specific known market events and trends. These reductions to gross sales reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. Variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we adjust these estimates, which would affect product revenue and earnings in the period such variances become known. As we gain more experience, estimates will be more heavily based on the expected utilization from historical data we have accumulated since the IBSRELA product launch.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates: Rebates include wholesaler fees, GPO fees, as well as mandated discounts under the Medicaid Drug Rebate Program ("Medicaid") and the Medicare Coverage Gap Program ("Medicare"). Estimates for rebates are recorded in the same period the related gross revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses on the balance sheets. We estimate our Medicaid and Medicare rebates based upon the estimated payor mix, and statutory discount rates. Our estimates for payor mix are guided by payor information received from specialty pharmacies, expected utilization for wholesaler sales to pharmacies, and available industry payor information. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks: Chargebacks are discounts that occur when certain contracted purchasers purchase directly from our wholesalers at a discounted price. The wholesaler, in turn, charges back the difference between the price initially paid to us by the wholesaler and the discounted price paid to the wholesaler by the contracted purchaser. Amounts for estimated chargebacks are established in the same period that the related gross revenue is recognized, resulting in a reduction of product revenue and accounts receivable. The accrual for wholesaler chargebacks is estimated based on known chargeback rates, known sales to wholesalers, and estimated utilization by types of contracted purchasers.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discounts and Fees: Our payment terms are generally 30 to 60 days. Wholesalers, GPOs and specialty pharmacies are offered various forms of consideration, including off-invoice discounts which may be paid to GPOs and specialty pharmacies. Wholesalers and GPOs may also receive prompt pay discounts for payment within a specified period. We expect discounts to be earned when offered and therefore, we deduct the full amount of these discounts from product sales when revenue is recognized, resulting in a reduction of product revenue and accounts receivable.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Reserves: Patients who have commercial insurance may receive copay assistance when product is dispensed by pharmacies to patients. We estimate the amount of copay assistance provided to eligible patients based on the terms of the program and redemption information provided by third-party claims processing organizations and are recorded in accounts payable and accrued expenses and other current liabilities on the balance sheets. Other reserves include estimated product returns which are recorded in the same period the related gross revenue is recognized, resulting in a reduction of product revenue as well as accounts receivable. We estimate our product returns reserve based upon our experience, and specific known market events and trends. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenue Recognition</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate collaboration revenue primarily from research and collaboration and license agreements with customers. Goods and services in the agreements may include the grant of licenses for the use of our technology,&#160;the provision of services associated with the research and development of product candidates, manufacturing services, and participation in joint steering committees. The terms of these arrangements typically include payment to us of one or more of the following: non-refundable, up-front license fees; research, development, regulatory and commercial milestone payments; reimbursement of research and development services; option payments; reimbursement of certain costs; payments for manufacturing supply services; and future royalties on net sales of licensed products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When two or more contracts are entered into with the same customer at or near the same time, we evaluate the contracts to determine whether the contracts should be accounted for as a single arrangement. Contracts are combined and accounted for as a single arrangement if one or more of the following criteria are met: (i) the contracts are negotiated as a package with a single commercial objective; (ii) the amount of consideration to be paid in one contract depends on the price or performance of the other contract; or (iii) the goods or services promised in the contracts (or some goods or services promised in each of the contracts) are a single performance obligation.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under each of our agreements, management performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including any constraints on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) we satisfy each performance obligation. As part of the accounting for contracts with customers, we develop assumptions that require judgment to determine whether promised goods and services represent distinct performance obligations and the standalone selling price for each performance obligation identified in the contract. This evaluation is subjective and requires us to make judgments about the promised goods and services and whether those goods and services are separable from other aspects of the contract. Further, determining the standalone selling price for performance obligations requires significant judgment, and when an observable price of a promised good or service is not readily available, we consider relevant assumptions to estimate the standalone selling price, including, as applicable, market conditions, development timelines, probabilities of technical and regulatory success, reimbursement rates for personnel costs, forecasted revenues, potential limitations to the selling price of the product and discount rates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply judgment in determining whether a combined performance obligation is satisfied at a point in time or over time, and, if over time, concluding upon the appropriate method of measuring progress to be applied for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, as estimates related to the measure of progress change, related revenue recognition is adjusted accordingly. Changes in our estimated measure of progress are accounted for prospectively as a change in accounting estimate. We recognize collaboration revenue by measuring the progress toward complete satisfaction of the performance obligation using an input measure. In order to recognize revenue over the research and development period, we measure actual costs incurred to date compared to the overall total expected costs to satisfy the performance obligation. Revenues are recognized as the program costs are incurred. We will re-evaluate the estimate of expected costs to satisfy the performance obligation each reporting period and make adjustments for any significant changes. Amounts received prior to satisfying the revenue recognition criteria are recorded as contract liabilities in our balance sheets. If the related performance obligation is expected to be satisfied within the next twelve months, this will be classified in current liabilities. Amounts recognized as revenue prior to receipt are recorded as contract assets in our balance sheets. If we expect to have an unconditional right to receive the consideration in the next twelve months, this will be classified in current assets. A net contract asset or liability is presented for each contract with a customer.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At the inception of each arrangement that includes research and development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved. Milestone payments that are not within the control of us or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achievement of such development milestones and any related constraints, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect earnings in the period of adjustment.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing supply services:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Arrangements that include a promise for the future supply of drug substance or drug product for either clinical development or commercial supply at the customer&#8217;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. If we are entitled to additional payments when the customer exercises these options, any payments are recorded in product supply revenue when the customer obtains control of the goods, which is upon delivery.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and where the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, royalty revenue resulting from licensing arrangements has not been material.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses of intellectual property</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: If a license granted to a customer to use our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from consideration allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we apply judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, to conclude upon the appropriate method of measuring progress for purposes of recognizing revenue related to consideration allocated to the performance obligation.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Customer options, such as options granted to allow a licensee to choose to research, develop and commercialize licensed compounds are evaluated at contract inception in order to determine whether those options provide a material right (i. e., an optional good or service offered for free or at a discount) to the customer. If the customer options represent a material right, the material right is treated as a separate performance obligation at the outset of the arrangement. We allocate the transaction price to material rights based on the standalone selling price, and revenue is recognized when or as the future goods or services are transferred or when the option expires. Customer options that are not material rights do not give rise to a separate performance obligation, and as such, the additional consideration that would result from a customer exercising an option in the future is not included in the transaction price for the current contract. Instead, the option is deemed a marketing offer, and additional option fee payments are recognized or being recognized as revenue when the licensee exercises the option. The exercise of an option that does not represent a material right is treated as a separate contract for accounting purposes.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract modifications:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Contract modifications, defined as changes in the scope or price (or both) of a contract that are approved by the parties to the contract, such as a contract amendment, exist when the parties to a contract approve a modification that either creates new or changes existing enforceable rights and obligations of the parties to the contract. Depending on facts and circumstances, we account for a contract modification as one of the following: (i) a separate contract; (ii) a termination of the existing contract and a creation of a new contract; or (iii) a combination of the preceding treatments. A contract modification is accounted for as a separate contract if the scope of the contract increases because of the addition of promised goods or services that are distinct and the price of the contract increases by an amount of consideration that reflects our standalone selling prices of the additional promised goods or services. When a contract modification is not considered a separate contract and the remaining goods or services are distinct from the goods or services transferred on or before the date of the contract modification, we account for the contract modification as a termination of the existing contract and a creation of a new contract. When a contract modification is not considered a separate contract and the remaining goods or services are not distinct, we account for the contract modification as an add-on to the existing contract and as an adjustment to revenue on a cumulative catch-up basis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive payments from our licensees as established in each contract. Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until we perform our obligations under these arrangements. Where applicable, amounts are recorded as unbilled revenue when our right to consideration is unconditional. We do not assess whether a contract with a customer has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize inventory costs associated with the production of our products after regulatory approval or when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Otherwise, such costs are expensed as research and development. Prior to the regulatory approval of drug product candidates, we incurred expenses for the manufacture of drug product that could potentially be available to support the commercial launch of our products or could be sold to our international partners under product supply agreements. We began to capitalize inventory costs associated with IBSRELA during the fourth quarter of 2021, when our intent to commercialize IBSRELA was established and we commenced preparation for the commercial launch of IBSRELA, which was when it was determined that the inventory had a probable future economic benefit.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is stated at the lower of cost or estimated net realizable value with cost determined under the first-in first-out method. Inventory costs include the cost of materials, third-party contract manufacturing, third-party packaging services, freight, labor costs for personnel involved in the manufacturing process, and indirect overhead costs. We primarily use actual costs to determine the cost basis for inventory. The determination of whether inventory costs will be realizable requires management review of the expiration dates of IBSRELA compared to our forecasted sales. If actual market conditions are less favorable than projected by management, write-downs of inventory may be required, which would be recorded as cost of revenue in the statement of operations and comprehensive loss. As of December&#160;31, 2022, we have not recorded any write-offs for excess and obsolete inventory. The portion of inventory that represents product that is not expected to be sold or used within the next 12 months is classified as non-current on our balance sheets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the process of preparing our financial statements, we are required to estimate our accrued expenses. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us&#160;monthly in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with our service providers and make adjustments if necessary. Examples of estimated accrued research and development expenses include fees paid to:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CROs in connection with clinical studies;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">investigative sites in connection with clinical studies;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">vendors related to product manufacturing, development and distribution of clinical supplies; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">vendors in connection with preclinical development activities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record expenses related to clinical studies and manufacturing development activities based on our estimates of the services received and efforts expended pursuant to contracts with our CROs and manufacturing vendors that conduct and manage these activities on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these contracts depend on factors such as the successful enrollment of subjects and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which each component of a service will be performed, and estimate, with vendor input if appropriate, the resulting level of completion of each component of the service, with such estimates often involving drivers that provide a surrogate measurement of completion such as number of enrolled subjects and/or number of sites activated in the calculation of clinical trial fee accruals. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrued or prepaid expense balance accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, we may report amounts that are too high or too low in any particular period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of stock options and Employee Stock Purchase Plan (&#8220;ESPP&#8221;) shares using the Black-Scholes valuation model. The Black-Scholes model requires the input of highly subjective assumptions which determine the fair value of stock-based awards. These assumptions include:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for our stock-option grants. As such, the expected term is estimated using the simplified method whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option. Beginning in 2021, we estimate the expected term of our options based upon historical exercises and post-vesting termination behavior, which has not resulted in a material difference as compared to using the simplified method.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We use the historic volatility of our own stock over the retrospective period corresponding to the expected remaining term of the options, or the period since our shares were first quoted on The Nasdaq Global Market, if that is shorter, to compute our expected stock price volatility.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The risk-free interest rate assumption is based on zero-coupon U.S. Treasury instruments on the date of grant with a maturity date consistent with the expected term of our stock option grants.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; To date, we have not declared or paid any cash dividends and do not have any plans to do so in the future. Therefore, we use an expected dividend yield of zero.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required, we review our valuation assumptions at each grant date and, as a result, we are likely to change our valuation assumptions used to value employee stock-based awards granted in future periods. Employee and director stock-based compensation costs are to be recognized over the vesting period of the award, and we have elected to use the straight-line attribution method. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. We estimate forfeitures based on historical experience.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units ("RSUs") are measured at the fair value of our common stock on the date of grant and expensed over the period of vesting using the straight-line attribution approach.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance-based RSUs ("PRSUs") are valued at grant-date fair market value. The vesting of the PRSUs is based on performance conditions. Performance conditions include: (i) a specific performance criteria and (ii) the employee&#8217;s continuous employment by the company for a stated period of time in order to earn the right to the related PRSUs to vest. We recognize compensation cost with respect to the vesting of the PRSUs on a ratable basis over the requisite service period, upon the performance conditions being deemed probable of achievement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize restructuring charges related to reorganization plans that have been committed to by management when liabilities have been incurred. In connection with these activities, we record restructuring charges at fair value for, (a) contractual employee termination benefits when obligations are associated to services already rendered, rights to such benefits have vested, and payment of benefits is probable and can be reasonably estimated, (b) one-time employee termination benefits when management has committed to a plan of termination, the plan identifies the employees and their expected termination dates, the details of termination benefits are complete, it is unlikely changes to the plan will be made or the plan will be withdrawn and communication to such employees has occurred, and (c) contract termination costs when a contract is terminated before the end of its term.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One-time employee termination benefits are recognized in their entirety when communication has occurred and future services are not required. If future services are required, the costs are recorded ratably over the remaining period of service. Contract termination costs to be incurred over the remaining contract term without economic benefit are recorded in their entirety when the contract is canceled.</span></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_61"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of the&#160;Years Ended December&#160;31, 2022, 2021 and 2020</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of our total revenue (dollars in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.120%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change <br/>2022 vs. 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change <br/>2021 vs. 2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product supply revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(594)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,031&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative development revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,177)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,187)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,158&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,097&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,571&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,061&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,526&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="12" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) There were no product sales during the prior year period.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fiscal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> compared to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase to total revenues was primarily attributable to $15.6&#160;million of net product sales for IBSRELA to our Customers, as well as aggregate of $35.0 million in milestone payments and payments under the second amendment to the 2017 KKC Agreement which we earned upon KKC's submission of a New Drug Application to the Japanese Ministry of Health, Labour and Welfare for tenapanor for the improvement of hyperphosphatemia in adult patients with CKD on dialysis. We also realized increased product supply revenue in connection with the 2017 KKC Agreement. Partially offsetting these increases was the full recognition of collaborative development revenue for upfront payments associated with the 2019 KKC Agreement through the end of 2021. There were no product sales during 2021 and 2020.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fiscal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> compared to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase to total revenues was primarily attributable to a $5.0 million development milestone which we earned and recognized as licensing revenue during the twelve months ended December 31, 2021 upon the initiation by KKC of Phase 3 clinical studies in Japan to evaluate tenapanor for hyperphosphatemia. The increase was partially offset by lower collaborative development revenue and product supply revenue from KKC during the same period. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of our operating expenses (dollars in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change <br/>2022 vs. 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change <br/>2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,201&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,140&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,053&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,939)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,087&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,917&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,443&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,351&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,526)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,092&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fiscal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> compared to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in cost of revenue was primarily attributable to payments due to AstraZeneca under the AZ Termination Agreement for IBSRELA product sales, net and for the milestone payment we received under the second amendment to the 2017 KKC Agreement, which we earned upon KKC's submission of a New Drug Application to the Japanese Ministry of Health, Labour and Welfare for tenapanor for the improvement of hyperphosphatemia in adult patients with CKD on dialysis. We also incurred $0.5 million for the cost of product shipped for product sales of IBSRELA during the twelve months ended December&#160;31, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fiscal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> compared to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in cost of revenue was attributable to payment to AstraZeneca under the AZ Termination Agreement related to the development milestone we earned upon the initiation by KKC of Phase 3 clinical studies in Japan to evaluate tenapanor for hyperphosphatemia. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of our research and development expenses (dollars in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change <br/>2022 vs. 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change <br/>2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External R&amp;D expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,378&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,747&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,369)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,268&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,911&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,203)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,357&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facilities, equipment and depreciation expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,706)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,201&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,140&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,053&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,939)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,087&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fiscal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> compared to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in our external R&amp;D expenses was primarily the result of lower clinical study costs following the completion of the OPTIMIZE study, lower tenapanor manufacturing expense as we have begun to capitalize costs associated with the production of IBSRELA to inventory, and lower expenses for research following the elimination of our internal research organization in the fourth quarter of 2021. The decrease in our employee-related expenses for the twelve months ended December&#160;31, 2022 is due to lower compensation and benefits expenses for our research and development workforce following restructuring actions in 2021. Similarly, the decrease in facilities, equipment and depreciation expenses is primarily due to a smaller proportion of such expenses being attributed to R&amp;D following the restructuring in 2021. The increase in other expenses is primarily related to disease-related education grants during the twelve months ended December&#160;31, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fiscal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> compared to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in our external R&amp;D expenses was the result of tenapanor manufacturing costs as well as clinical study costs from the advancement of our OPTIMIZE study which were partially offset by lower costs for the PHREEDOM clinical study. The increase in our employee-related expenses was related to compensation and benefits expenses for our research and development workforce. Employee-related expenses for twelve months ended December 31, 2021 include $2.7&#160;million of severance payments and other employee-related costs as discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 14 - Restructuring </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the financial statements included elsewhere in this Annual Report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fiscal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> compared to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in selling, general and administrative expenses for the twelve months ended December&#160;31, 2022 was primarily due to increased costs associated with the commercial launch of IBSRELA during 2022. The changes consisted of headcount and related personnel costs and external spending for disease awareness initiatives, commercial infrastructure and strategy. These increases were partially offset by a reduction in ongoing and one-time costs as a result of the restructuring action carried out during the third quarter of 2021. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fiscal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> compared to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in general and administrative expenses was primarily due to increased costs associated with building and staffing our commercial infrastructure and teams as we prepared for a potential U.S. launch of XPHOZAH. The increase consisted of headcount and related personnel costs and an increase in external spending for disease awareness initiatives, commercial infrastructure and strategy. Selling, general and administrative expenses for the twelve months ended December 31, 2021 include $3.5&#160;million severance payments and other employee-related costs as discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 14 - Restructuring </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the financial statements included elsewhere in this Annual Report.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of our interest expense (dollars in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change <br/>2022 vs. 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change <br/>2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,400)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,502)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,099)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,102&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fiscal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> compared to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in interest expense was due to lower principal outstanding on our loan payable in 2022 than in 2021 due to principal payments made on our 2018 Loan during the fourth quarter of 2021 through February 2022. In February 2022, we repaid the remaining outstanding principal balance of the 2018 Loan in the amount of $25.0&#160;million and entered into the new 2022 Loan in the amount of $27.5&#160;million which has an interest-only payment period through March 31, 2024.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fiscal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> compared to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in interest expense was primarily due to lower interest rates on our variable-rate term loan.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Cash Interest Expense Related to the Sale of Future Royalties</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of our non-cash interest expense related to the sale of future royalties (dollars in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change <br/>2022 vs. 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change <br/>2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense related to the sale of future royalties</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,673)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,673)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) Percent change is not meaningful.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fiscal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> compared to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash interest expense related to the sale of future royalties reflects the recognized amortization of the deferred royalty obligation that we recorded following the receipt of the $10.0&#160;million upfront payment from HCR in June 2022.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income, net</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of our other income (expense), net (dollars in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change <br/>2022 vs. 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change <br/>2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(881)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fiscal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> compared to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in other income, net was primarily due to sales of certain lab equipment and supplies for a net gain of $1.5 million and increased investment income during the twelve months ended December&#160;31, 2022. Partially offsetting these increases were fluctuations related to revaluation of our exit fees. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fiscal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> compared to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in other income, net were primarily due to lower income earned on our investments, which was largely offset by the revaluation of our exit fee related to our term loan agreement following receipt of the FDA CRL on July 28, 2021.</span></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_64"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of our cash, cash equivalents and short-term investments (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:52.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.716%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.688%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change <br/>2022 vs. 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,140&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,428&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,712&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,492)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liquid funds</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,909&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,689&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,220&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had cash and short-term investments of approximately $123.9&#160;million. We have incurred operating losses since inception in 2007 and our accumulated deficit as of December&#160;31, 2022 is $780.1&#160;million. Our current level of cash and short-term investments alone is not sufficient to meet our plans for the next twelve months following the filing of these financial statements on March&#160;2, 2023. These factors raise substantial doubt regarding our ability to continue as a going concern for a period of one year from the issuance of these financial statements. We plan to address our operating cash flow requirements with our current cash and short-term investments, cash generated from product sales of IBSRELA, and if approved, cash generated from sales of XPHOZAH, the potential receipt of anticipated milestone payments from our collaboration partners, the potential receipt of anticipated payments from KKC under the 2022 Amendment, with additional financing sources and through the implementation of cash preservation activities to reduce or defer discretionary spending.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no assurances that our efforts to meet our operating cash flow requirements will be successful. If our current cash and short-term investments as well as our plans to meet our operating cash flow requirements are not sufficient to fund necessary expenditures and meet our obligations for at least the next twelve months following the issuance of these financial statements, our liquidity, financial condition and business prospects will be materially affected. These financial statements have been prepared on a going concern basis and do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary in the event that we can no longer continue as a going concern.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, we filed a Form S-3 registration statement, which became effective in August 2020 ("2020 Registration Statement"), containing (i) a base prospectus for the offering, issuance and sale by us of up to a maximum aggregate offering price of $250.0 million of our common stock, preferred stock, debt securities, warrants and/or units, from time to time in one or more offerings; and (ii) a prospectus supplement for the offering, issuance and sale by us of up to a maximum aggregate offering price of $100.0 million of our common stock that may be issued and sold, from time to time, under an Open Market Sales Agreement with Jefferies LLC ("Jefferies"), as sales agent, deemed to be &#8220;at the market offerings&#8221; "2020 Open Market Sales Agreement").&#160;Pursuant to the 2020 Open Market Sales Agreement, Jefferies received a commission of up to 3.0% of the gross sales price for shares of common stock sold under the 2020 Open Market Sales Agreement. As of December 31, 2021, we had sold 23.3 million shares and received the maximum gross proceeds of $100.0 million pursuant to the 2020 Open Market Sales Agreement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we filed an additional prospectus supplement under the 2020 Registration Statement for the offering, issuance and sale by us of up to a maximum aggregate offering price of $150.0 million of our common stock that may be issued and sold, from time to time, under an additional sales agreement we entered into with Jefferies ("2021 Open Market Sales Agreement"), pursuant to which we may, from time to time, sell up to $150.0 million in shares of our common stock through Jefferies. We are not required to sell shares under the 2021 Open Market Sales Agreement. Pursuant to the 2021 Open Market Sales Agreement, Jefferies, as our sales agent, receives a commission of up to 3.0% of the gross sales price for shares of common stock sold under the 2021 Open Market Sales Agreement. As of December&#160;31, 2022 we have sold 79.8 million shares and received gross proceeds of $98.1 million at a weighted average sales price of approximately $1.23 per share under the 2021 Open Market Sales Agreement. Subsequent to December&#160;31, 2022, we received additional gross proceeds of $20.0 million for the sale of an additional 7.7 million shares which were settled between January 1, 2023 to January 12, 2023 and were sold at a weighted average sales price of approximately $2.60 per share under the 2021 Open Market Sales Agreement. There have been no other sales under the 2021 Open Market Sales Agreement after the January 12, 2023 settlement date.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, we filed a Form S-3 registration statement, which became effective in January 2023 ("2023 Registration Statement"), containing (i) a base prospectus for the offering, issuance and sale by us of up to a maximum aggregate offering price of $250.0 million of our common stock, preferred stock, debt securities, warrants and/or units, from time to time in one or more offerings; and (ii) a prospectus supplement for the offering, issuance and sale by us of up to a maximum aggregate offering price of $150.0 million of our common stock that may be issued and sold, from time to time, under a sales agreement with Jefferies, deemed to be &#8220;at-the-market offerings&#8221; ("2023 Open Market Sales Agreement").&#160;Pursuant to the 2023 Open Market Sales Agreement, Jefferies, as sales agent, may receive a commission of up to 3.0% of the gross sales price for shares of common stock sold under the 2023 Open Market Sales Agreement. There have been no sales of our common stock under the 2023 Open Market Sales Agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we entered into a loan and security agreement (&#8220;2022 Loan Agreement&#8221;) with SLR Investment Corp ("SLR"). The 2022 Loan Agreement provides for a senior secured term loan facility, with $27.5 million funded at closing and an additional $22.5 million that we may borrow on or prior to July 25, 2023; provided that (i) we had received approval by the FDA for our NDA for XPHOZAH by December 31, 2022, and (ii) we have achieved certain product revenue milestone targets described in the 2022 Loan Agreement. In August 2022, we entered into an amendment to the 2022 Loan Agreement with SLR that extended the date by which we must receive approval by the FDA for our NDA for XPHOZAH in order to borrow the additional $22.5 million from December 31, 2022 to March 31, 2023. In February 2023, we further amended the 2022 Loan Agreement (&#8220;2023 Amendment&#8221;) such that, we may borrow the additional $22.5 million under the 2022 Loan Agreement until December 20, 2023; provided that (i) we have received FDA approval for our NDA for XPHOZAH by November 30, 2023, or (ii) we have achieved certain product revenue milestone targets described in the 2023 Amendment. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial funding of $27.5 million was used to repay the 2018 Loan and is funding our ongoing operations. We had $25.0 million principal from the 2018 Loan outstanding as of the closing date. In connection with entering into the 2022 Loan Agreement, we entered into an agreement, whereby we agreed to pay an exit fee in the amount of 2% of the 2022 Loan funded (&#8220;2022 Exit Fee&#8221;) upon (i) any change of control transaction or (ii) our achievement of net revenue from the sale of any products equal to or greater than $100.0 million, measured on a six (6) months basis ("Revenue Milestone"), tested monthly at the end of each month. Notwithstanding the prepayment or termination of the 2022 Loan, the 2022 Exit Fee will expire on February 23, 2032. We concluded that the 2022 Exit Fee is a freestanding derivative which should be accounted for at fair value on a recurring basis. The estimated fair value of the 2022 Exit Fee is recorded as a derivative liability and included in accrued expenses and other current liabilities on the accompanying balance sheets. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, we announced that our collaboration partner, KKC, submitted a New Drug Application to the Japanese Ministry of Health, Labour and Welfare for tenapanor for the improvement of hyperphosphatemia in adult patients with CKD on dialysis. In accordance with the terms of the 2022 Amendment, KKC paid an aggregate of $35.0 million to us in milestone payments and payments associated with the 2022 Amendment during the quarter ended December 31, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary sources of cash have been from the sale and issuance of common stock (in both public offerings and private placements), private placements of convertible preferred stock, funds from our collaboration partnerships, funds from our 2018 Loan Agreement and 2022 Loan Agreement, as well as from sales of IBSRELA. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary uses of cash have been to fund operating expenses, primarily research and development expenditures, as well as pre-commercial and commercial expenses. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future funding requirements will depend on many factors, including, but not limited to:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we are able to generate product revenue from sales of IBSRELA;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether we are successful in securing approval for our NDA for XPHOZAH, and the time and cost associated with securing such approval;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of adequate third-party reimbursement for IBSRELA and, if approved, the sales price and the availability of adequate third-party reimbursement for XPHOZAH;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The manufacturing, selling and marketing costs associated with IBSRELA and, if approved, XPHOZAH; </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain our existing collaboration partnerships and to establish additional collaboration partnerships, in-license/out-license, joint ventures or other similar arrangements and the financial terms of such agreements;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt and amount of any milestones that may be received from our collaboration partners in connection with tenapanor, if any</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt, and amount of revenue, if any, that may be received by KKC in connection with the 2022 KKC Amendment;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt, and amount of royalties we may receive as a result of sales of tenapanor by our collaboration partners in China and Canada, if any;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cash requirements for the discovery and/or development of other potential product candidates, including RDX013 and RDX020;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time and cost necessary to respond to technological and market developments;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of filing, prosecuting, maintaining, defending and enforcing any patent claims and other intellectual property rights, including litigation costs and the outcome of such litigation, including costs of defending any claims of infringement brought by others in connection with the development, manufacture or commercialization of tenapanor or any of our product candidates; and</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the payment of interest and principal related to our loan and security agreement entered into with SLR Investment Corp. in February 2022. </span></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_67"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASH FLOW ACTIVITIES</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods indicated (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change <br/>2022 vs. 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change <br/>2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,044)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152,551)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81,435)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,507&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71,116)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,415&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,948&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,442)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,533)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,390&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(262.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,776&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,658)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,712&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,604)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90,101)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,316&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(227.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,497&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Operating Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fiscal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> compared to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities during the twelve months ended December&#160;31, 2022 decreased by $82.5&#160;million primarily as a result of decreased spending on research and development expenses during the twelve months ended December&#160;31, 2022 as compared to the twelve months ended December 31, 2021, as well net product sales of IBSRELA and $35.0 million of milestone payments and payments under the second amendment to the 2017 KKC Agreement which we earned in 2022 upon KKC's submission of a New Drug Application to the Japanese Ministry of Health, Labour and Welfare for tenapanor for the improvement of hyperphosphatemia in adult patients with CKD on dialysis. Partially offsetting the net loss improvement were changes to our operating assets and liabilities related to expenditures for commercial manufacturing and inventory for the production of IBSRELA. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fiscal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> compared to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities during the year ended December 31, 2021 increased by $71.1 million as a result of our increased net loss for the period. The increased net loss was primarily driven by costs associated with building and staffing our commercial infrastructure and teams as we prepared for the anticipated U.S. launch of XPHOZAH. In addition to the increased net loss, cash flows related to our operating assets and liabilities increased in the amount of $8.7 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Investing Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fiscal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> compared to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities decreased by $32.5&#160;million due to lower investment balances and the timing of our investment maturities, which was partially offset by $1.8&#160;million proceeds from sale of laboratory equipment and supplies during the twelve months ended December&#160;31, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fiscal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> compared to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities increased by $82.4&#160;million as our investment maturities increased to exceed the cost to purchase investments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Financing Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fiscal </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> compared to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities decreased by $7.7&#160;million primarily due to $29.5 million lower proceeds from issuance of common stock under at-the-market offerings and well as increased payments in the amount of $13.6 million to repay the principal outstanding on the 2018 Loan. Partially offsetting these amounts were $27.0 million net proceeds received from the 2022 Loan and $9.6 million net proceeds from the sales of future royalties during the twelve months ended December&#160;31, 2022</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fiscal </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> compared to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities increased by $60.2&#160;million due to net proceeds from issuance of our common stock pursuant to our at-the-market offerings, which were partially offset by principal repayments for our 2018 Loan.</span></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_73"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SMALLER REPORTING COMPANY AND NON-ACCELERATED FILER STATUS</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 28, 2018, the SEC adopted amendments that raise the thresholds in the smaller reporting company ("SRC") definition, whereby we were determined to qualify as a SRC. On March 12, 2020, the SEC amended its rules to allow SRCs that have less than $100.0 million in annual revenue and a public float of less than $700.0 million to qualify as a non-accelerated filer. As a non-accelerated filer, we were not required to obtain an opinion of our independent auditors with respect to our internal controls over financial reporting as of December 31, 2020.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 30, 2022, our public float did not exceed $700.0 million and we had less than $100.0 million in annual revenue, thereby allowing us to qualify as a SRC and a non-accelerated filer as of December 31, 2022. We have determined to avail ourselves of most of the SRC scaled disclosure accommodations and we were not required to obtain an opinion of our independent auditors with respect to our internal controls over financial reporting for the period ended December 31, 2022. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;7A.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to market risks, including interest rate fluctuation exposure through our investments, in the ordinary course of our business. However, the goals of our investment policy are the preservation of capital, fulfillment of liquidity needs and fiduciary control of cash. To achieve our goal of maximizing income without assuming significant market risk, we maintain our excess cash and cash equivalents in money market funds and short-term debt securities. Because of the short-term maturities of our cash equivalents, we do not believe that a decrease in interest rates would have any material negative impact on the fair value of our cash equivalents.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had cash, cash equivalents and short-term investments of $123.9&#160;million, which consist of bank deposits and money market funds, as well as high quality fixed income instruments including corporate bonds, commercial paper, U.S. treasury securities and U.S. government-sponsored agency bonds. The credit rating of our short-term investments must be rated A-1/P-1, or better by Standard and Poor&#8217;s and Moody&#8217;s Investors Service. Asset-backed securities must be rated AAA/Aaa. Money Market funds must be rated AAA/Aaa. Such interest-earning instruments carry a degree of interest rate risk. However, because our investments are high quality and short-term in duration, we believe that our exposure to interest rate risk is not significant and that a 10% movement in market interest rates would not have a significant impact on the total value of our portfolio, as noted above. We do not enter into investments for trading or speculative purposes.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to interest rate fluctuation exposure through our borrowings under the Loan Agreement and our investment in money market accounts which bear a variable interest rate. As of December&#160;31, 2022, borrowings under the 2022 Loan bear interest at a floating per annum rate equal to 7.95% plus the greater of (i) one tenth percent (0.10%) and (ii) the one-month rate published by the Intercontinental Exchange Benchmark Administration Ltd ("ICE") or its successor. A hypothetical increase in one-month ICE of 100 basis points above the current one-month ICE rates would have increased our interest expense by approximately $0.3&#160;million for the year ended December&#160;31, 2022. As of December&#160;31, 2022 we had an aggregate principal amount of $26.7&#160;million outstanding pursuant to our 2022 Loan Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our transactions are denominated in U.S. dollars. However, we do have certain transactions that are denominated in currencies other than the U.S. dollar, primarily Swiss francs and the euro, and we therefore are subject to foreign exchange risk. The fluctuation in the value of the U.S. dollar against other currencies affects the reported amounts of expenses, assets and liabilities associated with a limited number of manufacturing activities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not use derivative financial instruments for speculative trading purposes, nor do we hedge foreign currency exchange rate exposure in a manner that entirely offsets the earnings effects of changes in foreign currency exchange rates. The counterparties to our forward foreign currency exchange contracts are creditworthy commercial banks, which minimizes the risk of counterparty nonperformance.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had no open forward foreign currency exchange contracts.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;8.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARDELYX,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO FINANCIAL STATEMENTS</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:93.043%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.757%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_82">Report of Independent Registered Public Accounting Firm (PCAOB ID: </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl83OS9mcmFnOmRmZWE3NTE1N2VlNzRkYzViMjQ1ZTk5ZDI0Mjg1ZDI4L3RhYmxlOjQwOWFmYmExZTg1YjQ1NWM4OWExNzNmYzljNWQxNDQxL3RhYmxlcmFuZ2U6NDA5YWZiYTFlODViNDU1Yzg5YTE3M2ZjOWM1ZDE0NDFfMC0wLTEtMS00NjAxMy90ZXh0cmVnaW9uOmI5Y2E1ZGZjZWZjNjRhZjY4ZmIxZDQwYmZiNTYyNTM1Xzcx_64daf1b0-8b73-4688-a408-462db0f19e25">42</ix:nonNumeric></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_82">)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8c6ecca27b7b4659bf1d61cfb55de996_82">72</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_85">Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8c6ecca27b7b4659bf1d61cfb55de996_85">74</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_88">Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8c6ecca27b7b4659bf1d61cfb55de996_88">75</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_91">Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8c6ecca27b7b4659bf1d61cfb55de996_91">76</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_94">Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8c6ecca27b7b4659bf1d61cfb55de996_94">77</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_97">Notes&#160;to Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8c6ecca27b7b4659bf1d61cfb55de996_97">78</a></span></div></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">To the Stockholders and the Board of Directors of Ardelyx, Inc.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Opinion on the Financial Statements </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying balance sheets of Ardelyx, Inc. (&#8220;Company&#8221;) as of December 31, 2022 and 2021, the related statements of operations and comprehensive loss, stockholders&#8217; equity, and cash flows for each of the three years in the period ended December 31, 2022, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022, in conformity with U.S. generally accepted accounting principles. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">The Company&#8217;s Ability to Continue as a Going Concern </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered recurring losses from operations and has stated that substantial doubt exists about the Company&#8217;s ability to continue as a going concern. Management's evaluation of the events and conditions and management&#8217;s plans regarding these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Basis for Opinion</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8216;s management. Our responsibility is to express an opinion on the Company&#8216;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Critical Audit Matter</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:17pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:60.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.673%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Estimates of Reserves for Variable Consideration<br/></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Description of the Matter</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 2 to the financial statements, the Company recognizes revenues from product sales at the net sales price (transaction price), which includes estimates of variable consideration relating to off-invoice discounts, chargebacks or rebates, wholesaler fees, group purchasing organization administrative fees, patient copay assistance programs, and estimated product returns. These estimates are based on the amounts earned or to be claimed for related sales which may not be known at the point of sale. Government-mandated rebates under the Medicaid Drug Rebate Program (&#8220;Medicaid&#8221;) and the Medicare Coverage Gap Program (&#8220;Medicare") are estimated based on estimated payor mix and statutory discount rates. Patient copay assistance program amounts are estimated based on terms of the program and redemption information provided by third-party claims processing organizations. Product returns are estimated based on the Company&#8217;s experience and specific known market events and trends. The Company&#8217;s total estimate of reserves for variable consideration was $2.8 million as of December 31, 2022. During 2022, the Company recorded $6.0 million in total reductions to gross commercial product sales as a result of reserves for variable consideration.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing the Company&#8217;s estimates of reserves for variable consideration relating to Medicaid and Medicare claims, patient copay assistance and product returns involved evaluation of management&#8217;s subjective judgments regarding the reasonableness of various assumptions used. The Company has a limited history upon which to base such estimates, and changes in these estimated assumptions may have a material effect on the amount of reserves recorded for variable consideration. </span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To test the Company&#8217;s estimates of reserves for variable consideration relating to Medicaid and Medicare claims, patient copay assistance and product returns,   our audit procedures included, among others, evaluating the methodologies and assumptions used and testing the accuracy and completeness of the underlying data used in the Company&#8217;s analysis. We evaluated the assumptions used by management against third-party industry data and actual trends, evaluated the reasonableness of changes in estimated reserves during the year, and assessed the accuracy of the Company&#8217;s estimates against actual results. We also performed sensitivity analyses   to determine the effect of changes in management&#8217;s assumptions on the amount of reserves recorded for variable consideration, where appropriate. Further, we evaluated the appropriateness of classification and disclosure of the Company&#8217;s reserves for variable consideration in the financial statements.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84Mi9mcmFnOjVmNzUyMmMwYTFiZDRkZTI5MzI0NzA3ZGJjZWFiYWJlL3RleHRyZWdpb246NWY3NTIyYzBhMWJkNGRlMjkzMjQ3MDdkYmNlYWJhYmVfMjc0ODc3OTEwMTcwNA_58ac7c85-312f-4da4-a5f0-c739ab0a60cb">Ernst &amp; Young LLP</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2009.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84Mi9mcmFnOjVmNzUyMmMwYTFiZDRkZTI5MzI0NzA3ZGJjZWFiYWJlL3RleHRyZWdpb246NWY3NTIyYzBhMWJkNGRlMjkzMjQ3MDdkYmNlYWJhYmVfNDA5Mw_d91aaa22-1001-4c04-9f9b-fba2eedc66f1">San Mateo, California</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;2, 2023</span></div><div style="text-align:justify"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARDELYX,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfNC0xLTEtMS00NjAxMw_0d7f054f-9cb6-44b4-9ae4-30eb4f0f04bd">96,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfNC0zLTEtMS00NjAxMw_8b88d738-979c-488f-a6b7-c58a7ecf8c7e">72,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfNS0xLTEtMS00NjAxMw_29e3ed9e-5d96-4433-b92c-ed132b274f74">27,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfNS0zLTEtMS00NjAxMw_caab7591-ea12-4f80-b076-bd66a1e87426">44,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfNi0xLTEtMS00NjAxMw_409e032d-7601-440e-a8e1-04c5846116a2">7,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfNi0zLTEtMS00NjAxMw_6193cf7f-1cc4-45b3-b8a8-d5ffd0516347">502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfNy0xLTEtMS00NjI3Ng_7f616ea7-742b-4964-b249-b96047125793">3,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:InventoryGross" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfNy0zLTEtMS00NjI3Ng_9ad3b4a5-3b86-489a-8c8f-2588bed7169e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid commercial manufacturing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="ardx:PrepaidCommercialManufacturingCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfOC0xLTEtMS00NjI3Ng_ae501e4c-52b5-49cd-8d60-e10da88d21b7">13,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="ardx:PrepaidCommercialManufacturingCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfOC0zLTEtMS00NjI3Ng_7e015129-9dcb-4d0a-869f-b1041912a270">9,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfNy0xLTEtMS00NjAxMw_48236fe1-66d7-49a3-a85f-b5aaa3dd314a">5,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfNy0zLTEtMS00NjAxMw_098676e4-7259-4831-b139-a5618e7db9b9">7,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfOC0xLTEtMS00NjAxMw_5f91b3a8-2b24-4d85-9aad-2935c39b0f7e">153,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfOC0zLTEtMS00NjAxMw_f4edf17d-dff4-42ab-aab9-e447c2395f78">133,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfOS0xLTEtMS00NjAxMw_7648233a-d643-43f2-98ec-59e37788fe6f">1,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfOS0zLTEtMS00NjAxMw_79340bb8-13df-4628-a165-b741f71f846e">2,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMTItMS0xLTEtNTMyNDQ_00d996b8-31df-4738-837d-bc45cd0f7563">25,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:InventoryNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMTItMy0xLTEtNTMyNDQ_fb81aa33-2b67-4160-8cd6-3514fa70741b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMTEtMS0xLTEtNDYwMTM_a27dc45d-f336-49c1-a66c-7e227ca9b498">9,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMTEtMy0xLTEtNDYwMTM_8aa330ae-6a81-4316-b23e-d7120decbb7c">12,752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMTItMS0xLTEtNDYwMTM_25e57799-3439-4ad2-ada2-7c67d8f59047">881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMTItMy0xLTEtNDYwMTM_17c10312-41e9-47c7-9718-d7ee46ae3d85">1,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMTMtMS0xLTEtNDYwMTM_34764d3b-c973-4e7e-b2e9-e6eb8e1476f9">190,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMTMtMy0xLTEtNDYwMTM_0dcaecf0-616c-4ce3-b595-5ab61a38f87e">149,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMTYtMS0xLTEtNDYwMTM_1ed60ae8-4e6d-4896-8a10-17f860c32c82">10,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMTYtMy0xLTEtNDYwMTM_af8028a8-99e7-47bd-b0b4-7878d36f5cd6">4,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMTctMS0xLTEtNDYwMTM_206f91b5-f06a-4257-85df-cfee08d869c2">7,548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMTctMy0xLTEtNDYwMTM_4b9d5507-d3a6-4630-a2c4-2e7247c0025b">5,422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMTgtMS0xLTEtNDYwMTM_2bd5e73b-93e5-4262-aa57-b901dac2b87e">3,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMTgtMy0xLTEtNDYwMTM_5173c1a7-2c8c-4d9a-b2f9-84a5f39371a9">3,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:LoansPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMTktMS0xLTEtNDYwMTM_4b870d9b-43d0-4912-b94e-af8426c4f118">26,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:LoansPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMTktMy0xLTEtNDYwMTM_19580b7a-41b4-4516-80a3-a851ea9cd868">32,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjAtMS0xLTEtNDYwMTM_20e257eb-8b32-4a44-a2e9-e8be375d0387">4,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjAtMy0xLTEtNDYwMTM_4f838a91-361f-4ab0-a3ef-29a6fba0408b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjEtMS0xLTEtNDYwMTM_90296eb7-c1e7-4293-848f-71da3c71d32b">12,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjEtMy0xLTEtNDYwMTM_0514cfdf-945d-478d-be4c-540172586a27">7,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjItMS0xLTEtNDYwMTM_020420ef-80df-42f7-963b-d4ea3bcd8a0f">65,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjItMy0xLTEtNDYwMTM_f37b08eb-4854-4f2f-a723-cd3ad0e647f7">52,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liability, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjMtMS0xLTEtNDYwMTM_096db810-b60e-49f5-85da-fa3254597fa6">5,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjMtMy0xLTEtNDYwMTM_b00dc6cd-5599-4e35-b463-2f893a7b3b52">9,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjUtMS0xLTEtNDYwMTM_757911b5-95d7-4771-9f77-c1e8be246b8a">9,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjUtMy0xLTEtNDYwMTM_5eb349d8-3e3d-48d5-8f31-f27ad22a69cb">4,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred royalty obligation related to the sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="ardx:DeferredRoyaltyObligationNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjgtMS0xLTEtNDYyODA_55bec0ac-2fbd-46d7-8a35-4f1582b87b68">11,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="ardx:DeferredRoyaltyObligationNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjgtMy0xLTEtNDYyODA_1199c445-c9ba-4a54-bd4f-332b0d0f551b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjYtMS0xLTEtNDYwMTM_57a8d13f-a4cd-4c88-80ab-e0dac8d78bda">91,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjYtMy0xLTEtNDYwMTM_2c4d0075-ed17-4d1b-b33f-4c7301238c2a">67,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commitments and contingencies (Note 20)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjctMS0xLTEtNDYwMTM_207e7978-919c-4165-8c7e-93e0d2d78d38"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjctMy0xLTEtNDYwMTM_1929687a-57ce-488e-8cfc-fa02384ddd77"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjktMC0xLTEtNDYwMTMvdGV4dHJlZ2lvbjpiYzU1MmRlNWU5ZDg0MTYxYjg3ZTZhZjU3MTJkOTMxMV8yMQ_6d30f1ea-ff1d-4273-9b0b-5b27c3c1e39c"><ix:nonFraction unitRef="usdPerShare" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjktMC0xLTEtNDYwMTMvdGV4dHJlZ2lvbjpiYzU1MmRlNWU5ZDg0MTYxYjg3ZTZhZjU3MTJkOTMxMV8yMQ_8a619a4a-4611-4438-8e26-062b3dcd6f6a">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjktMC0xLTEtNDYwMTMvdGV4dHJlZ2lvbjpiYzU1MmRlNWU5ZDg0MTYxYjg3ZTZhZjU3MTJkOTMxMV8zNQ_01c2c9dd-9fc6-49c8-ae0f-8d8718a1acf1"><ix:nonFraction unitRef="shares" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjktMC0xLTEtNDYwMTMvdGV4dHJlZ2lvbjpiYzU1MmRlNWU5ZDg0MTYxYjg3ZTZhZjU3MTJkOTMxMV8zNQ_e70668f4-d0c4-4dc2-af87-aaa7e6edb95f">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjktMC0xLTEtNDYwMTMvdGV4dHJlZ2lvbjpiYzU1MmRlNWU5ZDg0MTYxYjg3ZTZhZjU3MTJkOTMxMV81Nw_098d971a-3f1a-476c-8145-2bc8ccbf12a3"><ix:nonFraction unitRef="shares" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjktMC0xLTEtNDYwMTMvdGV4dHJlZ2lvbjpiYzU1MmRlNWU5ZDg0MTYxYjg3ZTZhZjU3MTJkOTMxMV81Nw_319395f9-963c-443f-b6c8-9f63dc8eeacb"><ix:nonFraction unitRef="shares" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjktMC0xLTEtNDYwMTMvdGV4dHJlZ2lvbjpiYzU1MmRlNWU5ZDg0MTYxYjg3ZTZhZjU3MTJkOTMxMV81Nw_8ac71e26-9a21-4808-8107-cf5ac978ba00"><ix:nonFraction unitRef="shares" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjktMC0xLTEtNDYwMTMvdGV4dHJlZ2lvbjpiYzU1MmRlNWU5ZDg0MTYxYjg3ZTZhZjU3MTJkOTMxMV81Nw_df03c550-44fc-4616-a8f0-e5839eeeada1">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2022 and December&#160;31, 2021, respectively.</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjktMS0xLTEtNDYwMTM_79667dfe-abd0-4fb6-b86a-b576ea202099">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjktMy0xLTEtNDYwMTM_9aa8ca09-f9d8-492f-aa5f-2419d606a2ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMzAtMC0xLTEtNDYwMTMvdGV4dHJlZ2lvbjplZmU0ZWQxMWEwZTg0YTA4OGZkOWI3OGE2ZDc0ZTJjOF8xOA_3a8981e4-fb77-4167-80ac-df755548a436"><ix:nonFraction unitRef="usdPerShare" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMzAtMC0xLTEtNDYwMTMvdGV4dHJlZ2lvbjplZmU0ZWQxMWEwZTg0YTA4OGZkOWI3OGE2ZDc0ZTJjOF8xOA_cfba2c1e-ed24-4e31-8175-1609692b7321">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMzAtMC0xLTEtNDYwMTMvdGV4dHJlZ2lvbjplZmU0ZWQxMWEwZTg0YTA4OGZkOWI3OGE2ZDc0ZTJjOF8zMg_16c8f791-a0fc-4524-ae32-4d7f93c0ab07"><ix:nonFraction unitRef="shares" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMzAtMC0xLTEtNDYwMTMvdGV4dHJlZ2lvbjplZmU0ZWQxMWEwZTg0YTA4OGZkOWI3OGE2ZDc0ZTJjOF8zMg_2627f135-59b1-47a6-97e4-671b98b11eb4">300,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMzAtMC0xLTEtNDYwMTMvdGV4dHJlZ2lvbjplZmU0ZWQxMWEwZTg0YTA4OGZkOWI3OGE2ZDc0ZTJjOF81NA_efcf7095-c3be-4f66-aab8-c0e52b0ac7ac"><ix:nonFraction unitRef="shares" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMzAtMC0xLTEtNDYwMTMvdGV4dHJlZ2lvbjplZmU0ZWQxMWEwZTg0YTA4OGZkOWI3OGE2ZDc0ZTJjOF81NA_f0ccaa33-a802-4ce3-87f8-1dedc3ff23bd">198,575,016</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMzAtMC0xLTEtNDYwMTMvdGV4dHJlZ2lvbjplZmU0ZWQxMWEwZTg0YTA4OGZkOWI3OGE2ZDc0ZTJjOF82MQ_7735115f-46e8-4b59-bcd2-38343882648d"><ix:nonFraction unitRef="shares" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMzAtMC0xLTEtNDYwMTMvdGV4dHJlZ2lvbjplZmU0ZWQxMWEwZTg0YTA4OGZkOWI3OGE2ZDc0ZTJjOF82MQ_7ec59e10-49fb-4804-8a71-32401c1be92c">130,182,535</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2022 and December&#160;31, 2021, respectively.</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMzAtMS0xLTEtNDYwMTM_21492d3a-2213-4a87-b8ff-2736415f2f72">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMzAtMy0xLTEtNDYwMTM_d0dc27a0-7fe9-48d3-a334-2ef08a53ace5">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMzEtMS0xLTEtNDYwMTM_07ae289d-cec9-491f-8899-71ee5c570d38">878,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMzEtMy0xLTEtNDYwMTM_a7a2fb0d-9b85-4423-9899-ef7a6ee238e9">795,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMzItMS0xLTEtNDYwMTM_bb1fdc19-4786-45a9-a236-759cb6f59e28">780,137</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMzItMy0xLTEtNDYwMTM_49e407f6-af66-4c5c-9c9f-bb0eb5773ef1">712,930</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMzMtMS0xLTEtNDYwMTM_d8b4f1f5-92a6-4c70-bafc-02888b5a7d87">54</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMzMtMy0xLTEtNDYwMTM_ba9456e6-a67c-4d6f-bcb2-f9b34515aeae">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMzQtMS0xLTEtNDYwMTM_3bc0f2f0-ceaf-458b-bed1-725f2c20711e">98,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMzQtMy0xLTEtNDYwMTM_bf126c13-d547-4db7-b297-5fc102c123fd">82,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMzUtMS0xLTEtNDYwMTM_7460a4c3-9566-498c-b3d7-4e176d8afbdb">190,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMzUtMy0xLTEtNDYwMTM_68f8768b-3d3c-4290-918a-539dce5ee6be">149,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div><div style="margin-top:12pt"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARDELYX,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife1a6ddcf0434c3d8408dc580e20d7d8_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMy0xLTEtMS00NjAxMw_505e4744-ca36-42cb-999f-1f73004f0a84">15,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d0767c281240d4900cc0d8b9580230_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMy0zLTEtMS00NjAxMw_f7ccf8ea-60c7-4ecd-9d09-58c11f190e4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifee111286a5d4c6e8104da9cafffda38_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMy01LTEtMS00NjAxMw_8dd4d981-a7cb-4a49-be83-9cd97bee7b07">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product supply revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c1a31c699a645968b918a7d82fb494c_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfNC0xLTEtMS00NjAxMw_92290435-21dc-4554-beb6-3f1477f1aa35">1,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf3e168c61fd47e8aa38f9a4632206aa_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfNC0zLTEtMS00NjAxMw_6b05d8dd-486d-426a-bbf5-24b2ec3fba96">907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d86efc199f945f69a8db92f44a6eaea_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfNC01LTEtMS00NjAxMw_bb5f37de-a57c-439c-886c-2dc23a560bc9">1,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8defbd8e977443b8e24752f1ecfdee1_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfNS0xLTEtMS00NjAxMw_3b1945ce-6657-44db-b9d3-ed01d522b745">35,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80db9f923ef14a778c2d03752079fed3_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfNS0zLTEtMS00NjAxMw_4f3f2134-f4f7-4326-810a-5b74f2bc0734">5,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9dc553215546f099c0816459c4a6ef_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfNS01LTEtMS00NjAxMw_3a34f2f7-ff82-4baf-9ba6-71277430d87d">706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative development revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8955c2eaa96644dfa5eaadbf2a538826_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfNi0xLTEtMS00NjI5Mw_a633704e-2f0d-4b42-a823-97dbdea65d07">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib046fe75c1ba474da9dd251df8f9addb_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfNi0zLTEtMS00NjI5Mw_352531d9-829a-4dfc-b6cc-82d123e2f569">4,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f387fd7df541f5ad7e47ddafdac6b3_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfNi01LTEtMS00NjI5Mw_be5f6100-7b30-4bd9-9a1a-a945fd016d78">5,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfNi0xLTEtMS00NjAxMw_2e33d68c-8a0c-4768-b8d9-050839a85fad">52,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfNi0zLTEtMS00NjAxMw_ddd66468-166e-408f-8ea1-c3e8195f4d35">10,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfNi01LTEtMS00NjAxMw_f853407b-e563-486e-b7ee-03d926262b54">7,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfOC0xLTEtMS00NjAxMw_3812198f-3277-4d01-9b50-3911d1bd2e10">4,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfOC0zLTEtMS00NjAxMw_27e51fc4-26d2-4f46-b0e5-94c0d5c87d42">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:CostOfRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfOC01LTEtMS00NjAxMw_cd11cc6f-8557-4a02-9c5f-bdc06479f3b6">145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfOS0xLTEtMS00NjAxMw_b3bcfa7c-6737-4ea1-851c-a3b87acc9723">35,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfOS0zLTEtMS00NjAxMw_7c20646c-1844-41de-bcd4-38db5cd3f049">91,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfOS01LTEtMS00NjAxMw_ca902b4b-fdbf-40e5-99d2-b779e4fc6cc5">65,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTAtMS0xLTEtNDYwMTM_b81e4bb9-647e-47ff-8d8b-037d787a2c8a">76,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTAtMy0xLTEtNDYwMTM_09e2836d-9ea1-42db-bfe0-5dded3ad26fc">72,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTAtNS0xLTEtNDYwMTM_1b2bc21c-63d9-4ca1-b7a1-66d815883687">33,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTEtMS0xLTEtNDYwMTM_95d1dc08-016d-441f-8a4d-6fd5ff58ba2b">115,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTEtMy0xLTEtNDYwMTM_835a71f4-3021-43c8-a338-bb279b076afa">164,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTEtNS0xLTEtNDYwMTM_241978bf-d287-4be7-80de-b3235aa826a7">98,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTItMS0xLTEtNDYwMTM_590460d8-2296-4c8e-8f22-e6d0834c7b16">63,759</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTItMy0xLTEtNDYwMTM_8c1f620b-acc9-4a87-9284-d8c1db1bbf33">154,346</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTItNS0xLTEtNDYwMTM_1a0e6423-e3bd-41dd-8c44-23de0d2a0f25">90,780</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTMtMS0xLTEtNDYwMTM_6180aec6-e17e-46d7-9872-4f9f056e4724">3,400</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTMtMy0xLTEtNDYwMTM_82272223-f23c-4f29-a0dc-2ee0fcebab08">4,502</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTMtNS0xLTEtNDYwMTM_2565aa9d-ff52-4fb3-9fd9-ee5e04776258">5,099</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense related to the sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:AmortizationOfAdvanceRoyalty" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTUtMS0xLTEtNDYzMTU_44a0a263-1fec-4a75-ac89-5059af075ab8">1,673</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfAdvanceRoyalty" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTUtMy0xLTEtNDYzMTU_6acf64d6-5d53-4778-80e6-bedbb68973da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfAdvanceRoyalty" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTUtNS0xLTEtNDYzMTU_3b4e6dc6-7ad5-4486-8e0e-2eb6bc89b58e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTQtMS0xLTEtNDYwMTM_a1df38e6-9de4-43c0-88dc-76a91567ffba">1,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTQtMy0xLTEtNDYwMTM_894ada93-b8db-40d2-b1bd-65e545c45697">687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTQtNS0xLTEtNDYwMTM_6ce182af-b7a8-4c8b-9db1-39e4aed309c1">1,568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTUtMS0xLTEtNDYwMTM_762b5636-6430-4d86-9a9a-5f32fdaeb7b5">67,199</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTUtMy0xLTEtNDYwMTM_235b93ef-a640-462f-85c3-51e8a37c86a7">158,161</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTUtNS0xLTEtNDYwMTM_c14e5639-5acb-4625-944f-eafe509abdc5">94,311</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTYtMS0xLTEtNDYwMTM_e4bff21f-5f4c-4337-b9ff-0760b725b62a">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTYtMy0xLTEtNDYwMTM_f066ab96-32c8-411f-9507-3ce6ffd2d7e4">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTYtNS0xLTEtNDYwMTM_5252236c-b032-4c33-8281-88557172541c">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTctMS0xLTEtNDYwMTM_fe265dd0-ee63-496f-8057-c38a08df4b25">67,207</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTctMy0xLTEtNDYwMTM_8f7f2fb8-1aaa-4414-9f94-92aabe9eedfe">158,165</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTctNS0xLTEtNDYwMTM_0ce9e7cf-f818-46bb-b683-73d1265afbd3">94,313</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share of  common stock - basic and diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTgtMS0xLTEtNDYwMTM_3fa663af-cdff-4403-9fc5-53ccccf46ec2"><ix:nonFraction unitRef="usdPerShare" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTgtMS0xLTEtNDYwMTM_89723d78-126a-4aeb-8be9-bede8b76f76d">0.42</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTgtMy0xLTEtNDYwMTM_21963968-0889-467b-aaca-4642d916faad"><ix:nonFraction unitRef="usdPerShare" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTgtMy0xLTEtNDYwMTM_4bfefd32-eedb-43b1-9fda-dccf4f21cae7">1.52</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTgtNS0xLTEtNDYwMTM_25eb1dbe-9231-4907-91ee-77b8abffde9f"><ix:nonFraction unitRef="usdPerShare" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTgtNS0xLTEtNDYwMTM_6bdf6640-2597-4566-bbb9-36d2fa09384c">1.05</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net loss per share - basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTktMS0xLTEtNDYwMTM_7d9faae5-3838-48e0-8f77-74f4d484bebb"><ix:nonFraction unitRef="shares" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTktMS0xLTEtNDYwMTM_de5eca5f-5fab-4d8c-ab34-c46b70859098">158,690,083</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTktMy0xLTEtNDYwMTM_f81abab5-229a-46be-9ade-e2c4cc901961"><ix:nonFraction unitRef="shares" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTktMy0xLTEtNDYwMTM_fb909153-b4c6-48b2-9e66-8b5b1aca7e02">104,205,645</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTktNS0xLTEtNDYwMTM_37683a5e-eb99-40af-a547-5eaf42f4ab80"><ix:nonFraction unitRef="shares" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTktNS0xLTEtNDYwMTM_98c249a6-0e44-4d68-95ad-d9b05eef2fa9">89,582,138</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMjEtMS0xLTEtNDYwMTM_ec10c554-3ade-4b8b-869c-60c8f03409ea">67,207</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMjEtMy0xLTEtNDYwMTM_ccbaaba6-664e-4678-ab06-44434fa0a63a">158,165</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMjEtNS0xLTEtNDYwMTM_11771431-f3eb-42af-826b-bd035c140cba">94,313</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMjItMS0xLTEtNDYwMTM_b7784f3e-d3b3-42fc-9b34-043f7c8c9c02">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMjItMy0xLTEtNDYwMTM_56147f3d-d46a-4d96-b2c1-fbe7dabbd84a">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMjItNS0xLTEtNDYwMTM_c1c484f6-97a0-4a7f-843e-afdaa1e4217c">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMjMtMS0xLTEtNDYwMTM_39e0e964-6132-48b7-960b-04e5b292d753">67,255</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMjMtMy0xLTEtNDYwMTM_c148d6d9-1239-4484-9cae-25a18bca4800">158,167</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMjMtNS0xLTEtNDYwMTM_255f1114-5aeb-424e-8d0b-a65b930c3229">94,337</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARDELYX,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share amounts)</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:24.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>(Loss) Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i473a2780d03c4c7f8d5e27ab35bdee43_I20191231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMi0xLTEtMS00NjAxMw_dc04d7fb-a9c9-4001-841c-9171753a7f87">88,817,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i473a2780d03c4c7f8d5e27ab35bdee43_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMi0zLTEtMS00NjAxMw_ec309802-3f2e-4850-bf16-58388a67ad33">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i559db82cad364aea94a0a0919778a7f7_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMi01LTEtMS00NjAxMw_9807834f-faf2-4b1c-90a2-5b487414e83b">647,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f9d007b877247ec802a3c602ee3687b_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMi03LTEtMS00NjAxMw_0d9ec6f3-fd00-43a3-a0be-786ac1e86b2d">460,452</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i307df19e90fa4871af799b2b66ba2d31_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMi05LTEtMS00NjAxMw_4268d0e7-f542-4f46-b3d6-32781c23530c">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c73d82cd653451cb3c69d920ab3d8aa_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMi0xMS0xLTEtNDYwMTM_1f910577-3b02-4df8-932f-d146b5f89369">186,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c4c2b1d0a9e49ae81d18933f823dba9_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMy0xLTEtMS00NjAxMw_7716f464-9501-49ae-b0e4-2dc1f092c78c">169,931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ebe0866adef47559cdc2ed65973c005_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMy01LTEtMS00NjAxMw_bcaca06c-8549-4487-91fd-5e4e12cc0286">834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMy0xMS0xLTEtNDYwMTM_e61f10e2-59c2-4417-b758-681b1d6e0ddf">834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c4c2b1d0a9e49ae81d18933f823dba9_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfNC0xLTEtMS00NjAxMw_97cc4189-45d8-4ab0-b88c-3e6393a7a312">42,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ebe0866adef47559cdc2ed65973c005_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfNC01LTEtMS00NjAxMw_58edda95-3bd0-4c59-b236-072c8cfbeb0f">310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfNC0xMS0xLTEtNDYwMTM_003c4f24-95f2-42a5-abd9-cec2cbb72125">310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c4c2b1d0a9e49ae81d18933f823dba9_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfNS0xLTEtMS00NjAxMw_b66f826e-0ea5-4ecb-b088-ae82b32a1c01">445,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ebe0866adef47559cdc2ed65973c005_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfNS01LTEtMS00NjAxMw_1893ce97-73db-4665-995c-22d1f00ee70b">1,020</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfNS0xMS0xLTEtNDYwMTM_1b5986e1-a66c-4174-b777-3b630e3551fa">1,020</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c4c2b1d0a9e49ae81d18933f823dba9_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfNi0xLTEtMS00NjAxMw_90f180b3-b503-49da-b7fb-60eb1d61f357">866,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ebe0866adef47559cdc2ed65973c005_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfNy01LTEtMS00NjAxMw_643df924-45c0-42a0-8825-44f8d5fc1fd2">10,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfNy0xMS0xLTEtNDYwMTM_b083b674-e22f-4d96-a4a5-5f9ee37b9f90">10,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized losses on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i63b7a92a09e442b3b15016267ea44e4c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfOC05LTEtMS00NjAxMw_01095698-75af-4c81-b257-3979a96c2ff6">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfOC0xMS0xLTEtNDYwMTM_0544ed1b-3fd4-491e-9542-2e030fd260ba">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in at the market offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c4c2b1d0a9e49ae81d18933f823dba9_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfOS0xLTEtMS00NjAxMw_6c4abd02-7145-4896-bd10-ae06e89c358a">3,257,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ebe0866adef47559cdc2ed65973c005_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfOS01LTEtMS00NjAxMw_731be14d-cdb9-4bc7-8f40-5d49efbe9932">21,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfOS0xMS0xLTEtNDYwMTM_35df095c-6f55-4a0c-bbfc-65b7727a6e17">21,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icad9ba2326db486c889dd50988c4fef1_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTEtNy0xLTEtNDYwMTM_57ecb558-f6e6-4781-855f-cafb1ff3f8d2">94,313</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTEtMTEtMS0xLTQ2MDEz_67999f09-91e5-4e4c-b7d9-9de5b462f46d">94,313</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2aa43c785509442dbd5e3673f8823fe4_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTItMS0xLTEtNDYwMTM_d97bf1b6-9ff9-43d6-9577-e0f74a634fc3">93,599,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aa43c785509442dbd5e3673f8823fe4_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTItMy0xLTEtNDYwMTM_0d1c4760-7dee-4ee2-ba8b-fe8f309ce49b">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5a3476a21d74624862c1503a0509e16_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTItNS0xLTEtNDYwMTM_f91080e4-59b5-4eed-84ea-eabe84125617">680,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34d8d1400f4a4785ac6e2406ff8e5935_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTItNy0xLTEtNDYwMTM_574fdee4-6815-4d6e-8b9f-4bd785cce168">554,765</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i271432361a3c43cf9ae96050134ef2c5_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTItOS0xLTEtNDYwMTM_b18ce75b-7353-473d-8024-e66b8a42562a">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0fdfe563b2749f3ad36d74c30c121dd_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTItMTEtMS0xLTQ2MDEz_17043b71-2b9c-40c9-a236-e5ec806a2f75">126,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaeaeaa4c910f4ab5acf339a4968d2a9d_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTMtMS0xLTEtNDYwMTM_af39a14a-2d48-4e5a-b7c0-ec058c367fdf">386,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6cbb5f1b5224d25910844cbece963f3_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTMtNS0xLTEtNDYwMTM_3b4edaa7-d23f-480b-899d-0b10ebd0b5a9">819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTMtMTEtMS0xLTQ2MDEz_8adbb648-8043-4b59-bc25-423e1a17962b">819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaeaeaa4c910f4ab5acf339a4968d2a9d_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTQtMS0xLTEtNDYwMTM_6b91517f-2c21-4ab8-a50e-76d2f2985fe5">25,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6cbb5f1b5224d25910844cbece963f3_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTQtNS0xLTEtNDYwMTM_ee741453-c354-41a1-8569-21f6f45c9ac1">190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTQtMTEtMS0xLTQ2MDEz_9da56eac-2568-4720-af9a-eaad71d7af88">190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaeaeaa4c910f4ab5acf339a4968d2a9d_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTUtMS0xLTEtNDYwMTM_664b39bf-b3c5-4551-871a-7a16d28a08c8">331,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6cbb5f1b5224d25910844cbece963f3_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTUtNS0xLTEtNDYwMTM_a8da4b1e-44ef-49f8-b6f7-a03f9ffe9faf">584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTUtMTEtMS0xLTQ2MDEz_8f5b4c33-d17c-48a9-92b3-935e9ad82ccf">584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaeaeaa4c910f4ab5acf339a4968d2a9d_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTYtMS0xLTEtNDYwMTM_2c63773f-793e-4312-9819-a59f669a171c">167,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes paid for net share settlement of equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6cbb5f1b5224d25910844cbece963f3_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTctNS0xLTEtNDYwMTM_943e38c1-4e18-4c2f-8e0e-5eefe92c1f92">106</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTctMTEtMS0xLTQ2MDEz_c7036c18-c6af-4468-b6ff-d5e5d4d8edb9">106</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in at the market offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaeaeaa4c910f4ab5acf339a4968d2a9d_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTgtMS0xLTEtNDYwMTM_9c860f94-34b6-46e1-b698-55e63b4f81ac">35,671,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaeaa4c910f4ab5acf339a4968d2a9d_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTgtMy0xLTEtNDYwMTM_eb9ead52-9091-4c64-9905-cdd98a7128ec">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6cbb5f1b5224d25910844cbece963f3_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTgtNS0xLTEtNDYwMTM_29ddbff0-208a-4d17-bf22-11a3314d2189">101,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTgtMTEtMS0xLTQ2MDEz_64e39a5e-8445-4b44-8f50-2aca93d7bc30">101,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6cbb5f1b5224d25910844cbece963f3_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTktNS0xLTEtNDYwMTM_d8f5b481-94a0-45dd-9289-6c384540cd71">12,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTktMTEtMS0xLTQ2MDEz_66847140-6fd7-4da2-b54f-5c84b0ddc12e">12,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized losses on available-for-sale securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7488244a81d34508944e33dfd4bdc232_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjAtOS0xLTEtNDY0MDM_a917c3e7-78e5-435b-919f-e317bb79a298">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjAtMTEtMS0xLTQ2NDAz_7dace226-5741-426c-bb8d-e529d6ab2b88">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ca2f91dea984f5fa2da91bc632532c1_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjAtNy0xLTEtNDYwMTM_f576fa79-7eca-40f6-bf93-47fbd228ab91">158,165</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjAtMTEtMS0xLTQ2MDEz_101a36bc-769e-4adb-890e-a34added8036">158,165</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id70cd43225df4f8fbf5df3ec715b334c_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjEtMS0xLTEtNDYwMTM_3b016bd0-ce18-4f69-b1d8-150f3564399b">130,182,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id70cd43225df4f8fbf5df3ec715b334c_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjEtMy0xLTEtNDYwMTM_17bce5f4-f8ba-45b5-b8cd-bd32ecb2813c">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5bd779bf4924020b0765a5cc69ceba5_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjEtNS0xLTEtNDYwMTM_52a423a0-03e0-4ab7-9885-df458d2ac82d">795,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c1428f4633d41e7a98d5a585209403f_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjEtNy0xLTEtNDYwMTM_1d50b92d-0b72-488f-bd4c-e366a1bad373">712,930</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c90b227c4764ac7987b4eef73eeb87d_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjEtOS0xLTEtNDYwMTM_51ef055f-2f9c-4a1c-84cb-2076db873a47">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjEtMTEtMS0xLTQ2MDEz_9bb11fbc-ec18-4223-b7b6-ba666c71072f">82,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if786310abbc54aba91f5e0a5b90b7706_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjItMS0xLTEtNDYwMTM_3be824f0-fe6e-4d98-8d24-bbdedc2528c4">308,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic403adc07fe947369c966ca335e3f7c0_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjItNS0xLTEtNDYwMTM_b1ca8a34-8e3a-4333-b2b9-0e239b2457b6">195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjItMTEtMS0xLTQ2MDEz_3aaf37ac-4352-4e5e-a063-139ff70d088c">195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if786310abbc54aba91f5e0a5b90b7706_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjMtMS0xLTEtNDYwMTM_73896aee-f187-4af0-81f9-a3bc0eeddf1e">711,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic403adc07fe947369c966ca335e3f7c0_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjMtNS0xLTEtNDYwMTM_1a7ce295-1adc-4933-9e5b-2270a4e2ffcb">390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjMtMTEtMS0xLTQ2MDEz_ade21742-2727-4fd5-bc0b-f4ee5d7c6e68">390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if786310abbc54aba91f5e0a5b90b7706_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjQtMS0xLTEtNDYwMTM_321a998e-3cee-448a-a3e8-add261a8335b">14,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic403adc07fe947369c966ca335e3f7c0_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjQtNS0xLTEtNDYwMTM_f21b2aab-3ba9-4d74-b515-8d63d7a93967">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjQtMTEtMS0xLTQ2MDEz_5d12bdd1-af9c-4c97-b8f4-11a1738aa91e">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if786310abbc54aba91f5e0a5b90b7706_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjUtMS0xLTEtNDYwMTM_d2ae6657-9c56-4e2b-8786-e2ffb6b765ee">3,243,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in at the market offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if786310abbc54aba91f5e0a5b90b7706_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjctMS0xLTEtNDYwMTM_c4cfe0bd-98d8-4a99-86cd-7d368baf335e">64,114,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if786310abbc54aba91f5e0a5b90b7706_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjctMy0xLTEtNDYwMTM_68191ab3-bad1-4c8c-b5a1-a918ad96c7fc">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic403adc07fe947369c966ca335e3f7c0_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjctNS0xLTEtNDYwMTM_21ab3751-821c-4efe-9bd7-e32b7ac65660">71,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjctMTEtMS0xLTQ2MDEz_872f9262-d212-49a8-87da-2adc30e81b4d">71,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic403adc07fe947369c966ca335e3f7c0_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjgtNS0xLTEtNDYwMTM_81f7e92f-9b36-4b8a-ba1e-899af4a0755a">10,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjgtMTEtMS0xLTQ2MDEz_a4b3019f-c6ca-4587-b27c-997dcbcef033">10,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized losses on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id792a81211054c6a9da992ae71d61ce3_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjktOS0xLTEtNDYwMTM_a45dc4e2-f64a-4a30-8c1f-0b91881d7be7">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjktMTEtMS0xLTQ2MDEz_4b5c3b11-d219-4915-95af-25b1809a82b7">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e05fc9654fc4f24b753405c6aae07a3_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMzAtNy0xLTEtNDYwMTM_9b7388cb-67c5-4793-ac26-244fcae83ce6">67,207</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMzAtMTEtMS0xLTQ2MDEz_d6d2cb76-0cf5-4656-b826-327be3e2b73b">67,207</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i21472ed42ab040bba0bdd50fdd86e0c6_I20221231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMzEtMS0xLTEtNDYwMTM_2f92bb7b-fa1f-4fd7-8ed4-15dd5ddda987">198,575,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21472ed42ab040bba0bdd50fdd86e0c6_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMzEtMy0xLTEtNDYwMTM_e95efb3e-669a-4113-9003-a50ca30d0728">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2954e41000084c28b87d9af1f3c00c87_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMzEtNS0xLTEtNDYwMTM_e73c4205-a7d8-4913-bc06-89eb38d2c33e">878,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i236484790d154382b9ab018143306fb9_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMzEtNy0xLTEtNDYwMTM_3bb9a6a8-d303-4629-a345-9c89b2109cf0">780,137</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a16bb549f604ba4b134dd1fc542e6e0_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMzEtOS0xLTEtNDYwMTM_965a1593-ad4c-4649-a059-8ba7187c8b1d">54</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMzEtMTEtMS0xLTQ2MDEz_ae51781b-7abd-41f4-8d96-042e8228f48b">98,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARDELYX,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMi0xLTEtMS00NjAxMw_04792a72-215c-4717-a281-933737108048">67,207</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMi0zLTEtMS00NjAxMw_9311f2f5-70ed-4b32-98e5-a5694658af20">158,165</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMi01LTEtMS00NjAxMw_b45174cb-68b5-4e46-9fb2-db326c36476b">94,313</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfNC0xLTEtMS00NjAxMw_cc690e7e-4b60-4dcd-87c1-b50489cff672">1,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfNC0zLTEtMS00NjAxMw_4bf84a72-18fb-4c1d-8e0b-b8c67ee58ddd">2,807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfNC01LTEtMS00NjAxMw_7d10f70a-7566-482f-b8b5-9eff1b2453d5">2,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfOC0xLTEtMS00NjAxMw_dc42fd05-fcdd-47eb-9ef0-727f90bc32fb">3,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfOC0zLTEtMS00NjAxMw_6a9bac31-96cd-405c-a482-a99faf93a443">3,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfOC01LTEtMS00NjAxMw_e94c63b3-abcf-4352-a088-abeeebf21d46">2,147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfOS0xLTEtMS00NjAxMw_d698e3e3-df08-418a-abc8-81c8e09c075f">10,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfOS0zLTEtMS00NjAxMw_fea01690-4d7c-4af6-9493-c149b2507e56">12,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfOS01LTEtMS00NjAxMw_1b0c6bf2-a545-43f9-88f9-746415ea8f88">10,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in derivative liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTAtMS0xLTEtNDYwMTM_e1fa4215-2a63-4fea-ad7a-4d1a3ffa097a">583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTAtMy0xLTEtNDYwMTM_9db5e511-48a5-43f2-8968-341359a46a53">678</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTAtNS0xLTEtNDYwMTM_f26fba9e-a368-4a4a-a704-0ba9642ac480">407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt refinancing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnRestructuringOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfOC0xLTEtMS00NjUyNg_51b9aeae-29b7-409a-b85f-0234161180e0">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:GainsLossesOnRestructuringOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfOC0zLTEtMS00NjUyNg_9c7b7ea6-1cce-43be-80dd-b500ff3a2094">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:GainsLossesOnRestructuringOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfOC01LTEtMS00NjUyNg_850104bb-67fb-414b-80fe-86ddeff76126">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on sale of equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfOS0xLTEtMS00NjUyNg_a29277c4-2dfd-40c5-ba0a-09cd328aadb4">1,260</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfOS0zLTEtMS00NjUyNg_165fa40a-df75-4adb-b38f-9ebfe5829678">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfOS01LTEtMS00NjUyNg_3c23cb96-34fb-4a8b-862a-c19b098eab47">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTEtMS0xLTEtNDYwMTM_48388a43-1427-4f28-b289-427c8fa25853">1,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTEtMy0xLTEtNDYwMTM_249fed15-9986-4103-ab7c-4ff8cc060bed">283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTEtNS0xLTEtNDYwMTM_3db0cefe-8145-4956-b2f8-111c285bd71f">413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unbilled revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="ardx:IncreaseDecreaseInUnbilledRevenue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTMtMS0xLTEtNDYwMTM_bf719279-fabb-46c8-93df-1445ffd468d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="ardx:IncreaseDecreaseInUnbilledRevenue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTMtMy0xLTEtNDYwMTM_941c9738-b051-4d61-afce-be02f348a31e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" sign="-" name="ardx:IncreaseDecreaseInUnbilledRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTMtNS0xLTEtNDYwMTM_d7ae3a73-a519-480f-9a44-5a6e011313f9">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTQtMS0xLTEtNDYwMTM_59ad8f00-52fa-4cc5-8878-dd1fce29a9eb">7,231</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTQtMy0xLTEtNDYwMTM_7718705e-5e8b-42a1-8a69-cc59ef9bea60">502</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTQtNS0xLTEtNDYwMTM_d53edba1-b6eb-44ed-8cbc-9db2dd6cfa77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTQtMS0xLTEtNDY1NDQ_473e1cbc-c98c-4c91-97f1-dc15e1b495dc">28,346</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTQtMy0xLTEtNDY1NDQ_330f3250-6617-4a34-9593-2f2b2b2ec614">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTQtNS0xLTEtNDY1NDQ_280ca846-3136-4955-8f07-2f92816c1cb8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid commercial manufacturing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="ardx:IncreaseDecreaseInPrepaidCommercialManufacturingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTUtMS0xLTEtNDY1NDQ_4a87605c-bb80-45b8-8d9a-e52796f93700">4,161</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="ardx:IncreaseDecreaseInPrepaidCommercialManufacturingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTUtMy0xLTEtNDY1NDQ_cb7fa451-4639-4546-8663-80799b0f2910">9,406</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="ardx:IncreaseDecreaseInPrepaidCommercialManufacturingExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTUtNS0xLTEtNDY1NDQ_80900117-a811-4496-887e-460ddf7f271e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTUtMS0xLTEtNDYwMTM_81d71ca3-0860-4d5f-a623-b2a78ad81ce4">2,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTUtMy0xLTEtNDYwMTM_8f742b17-da5a-4531-979b-b7f1c305d163">502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTUtNS0xLTEtNDYwMTM_e674962b-a4fc-43d2-affa-c26bc6635361">4,653</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTYtMS0xLTEtNDYwMTM_ef76f930-e2e6-49c0-90cd-b5722c8ab482">6,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTYtMy0xLTEtNDYwMTM_ad40a7bc-b55c-43b8-b89f-15e326d3a354">1,349</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTYtNS0xLTEtNDYwMTM_1f25a241-c678-45d1-8c51-e34f263da690">3,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTctMS0xLTEtNDYwMTM_9ce5cd21-4155-4953-bc39-6748b02c1d88">2,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTctMy0xLTEtNDYwMTM_99b4c0ca-f872-410e-ba2f-cfd55e440760">250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTctNS0xLTEtNDYwMTM_634274e5-9d36-493a-b393-148a4cca6c8b">1,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTgtMS0xLTEtNDYwMTM_c0fd1a2c-df63-4f92-ab44-bc2e7de35edb">3,491</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTgtMy0xLTEtNDYwMTM_fbae1590-77bc-418a-aa8a-3ffda62d9eae">2,853</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTgtNS0xLTEtNDYwMTM_4b41375c-c8f2-43a4-a504-ce869fd56009">2,604</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTktMS0xLTEtNDYwMTM_fa546e1b-3230-46cb-a539-db35fa1061f9">4,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTktMy0xLTEtNDYwMTM_93ccd218-312f-42a0-8255-9fcf29e91542">1,386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTktNS0xLTEtNDYwMTM_0820f7cd-10ab-4f0a-a308-9c1f8362e868">1,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMjAtMS0xLTEtNDYwMTM_c9d3a7b9-c2ec-4ebd-9f69-3bd3dcee6e06">8,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMjAtMy0xLTEtNDYwMTM_f2e47509-3853-4907-bc5a-e4b60a9bff09">550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMjAtNS0xLTEtNDYwMTM_374a5296-776a-4c5d-aff5-4aeceb18e5eb">364</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMjEtMS0xLTEtNDYwMTM_9fc2f5cb-eae6-439d-a216-7e80a2cbcebf">70,044</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMjEtMy0xLTEtNDYwMTM_07b2c3ad-fba7-4c0d-84de-15a3dc3151d4">152,551</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMjEtNS0xLTEtNDYwMTM_6a9b13a4-86d1-427e-b83b-6e4d086f665e">81,435</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from maturities and redemptions of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMjMtMS0xLTEtNDYwMTM_96562ec3-d33b-4f01-9205-83033ebb1490">67,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMjMtMy0xLTEtNDYwMTM_c2b01f0e-1507-44c3-94bd-c7ddc7d61a0f">125,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMjMtNS0xLTEtNDYwMTM_b9d9b02e-e4cb-4f8b-b664-dee6d185c2f5">119,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMjQtMS0xLTEtNDYwMTM_422c9009-2ee4-4f29-a2d0-5f857fd1f22e">50,328</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMjQtMy0xLTEtNDYwMTM_b547d6c2-2084-40ce-8008-d64af48840b5">72,735</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMjQtNS0xLTEtNDYwMTM_bb380152-e985-4fb6-a8a9-4cca0a2f929c">150,852</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMjYtMS0xLTEtNDY1NjQ_027cd806-e7ab-4cd6-b314-c3309108f6b7">1,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMjYtMy0xLTEtNDY1NjQ_d4ed27e6-5a3f-4e82-b824-23a02cf3451e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMjYtNS0xLTEtNDY1NjQ_aeea019d-1165-4d2d-bcc8-8de6d35c4d05">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMjUtMS0xLTEtNDYwMTM_26f9ec35-4579-446a-988f-3386ee6c7817">55</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMjUtMy0xLTEtNDYwMTM_bf59ed11-266b-4dc3-b6d9-ab1e3ab9b657">1,867</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMjUtNS0xLTEtNDYwMTM_0134fd99-8d19-4041-9a73-b8da4839512b">324</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMjYtMS0xLTEtNDYwMTM_0e8b3247-5ce6-43fe-b0f0-0ac01aec4627">18,415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMjYtMy0xLTEtNDYwMTM_cee5d14e-597e-48f1-afca-5ca9dd732aa9">50,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMjYtNS0xLTEtNDYwMTM_157d5916-462f-415c-a331-9d45819e299b">31,442</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from 2022 Loan, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzAtMS0xLTEtNDY1OTU_f6fb0d8b-46b5-400d-a6a8-91d10d2e9197">26,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzAtMy0xLTEtNDY1OTU_18786124-8923-4bcf-a834-5cb18cdcade2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzAtNS0xLTEtNDY1OTU_dcccce43-8602-4f81-ab3c-cdee7fd0c0eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments for 2018 Loan, net of costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:RepaymentsOfSecuredDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzEtMS0xLTEtNDY1NzQ_d1fdb94d-5c52-49ba-94c8-27f8f1715152">33,038</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfSecuredDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzEtMy0xLTEtNDY1NzQ_50381316-2f62-43d3-9096-1e84a958fabb">19,444</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfSecuredDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzEtNS0xLTEtNDY1NzQ_af2e843d-5649-4006-a704-42aec463c9d5">125</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from the sale of future royalties, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="ardx:ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzItMS0xLTEtNDY2MTA_3da08441-b106-43ac-809a-31244a4312aa">9,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="ardx:ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzItMy0xLTEtNDY2MTA_cba05705-cca3-4141-9d2e-074a0e6ef926">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="ardx:ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzItNS0xLTEtNDY2MTA_dfed75eb-b76e-4813-916c-728e6349b21a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock in at the market offering, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzAtMS0xLTEtNDYwMTM_3a420ecb-69ad-456c-b101-97d5be98b7af">71,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzAtMy0xLTEtNDYwMTM_20a6b3b8-2e9b-4bb7-99d2-c1dd5d826093">101,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzAtNS0xLTEtNDYwMTM_b7ac8591-105c-4c5a-b5db-28c0596c9fd7">21,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under equity incentive and stock purchase plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzEtMS0xLTEtNDYwMTM_586a0e57-9d15-4d67-9fa8-2bf45e464ef0">202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzEtMy0xLTEtNDYwMTM_36805d03-3f18-41a5-9658-ad3b10c20f64">1,403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzEtNS0xLTEtNDYwMTM_b2fef871-3678-428e-b8c0-c28814398653">1,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments for taxes related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzQtMS0xLTEtNDY0NDg_9bebf0e4-f1a3-4ac9-91e0-78baac6a74f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzQtMy0xLTEtNDY0NDg_b00ef075-5676-4d95-b96e-88b63d91b052">106</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzQtNS0xLTEtNDY0NDg_0488a7f9-020e-44e6-9d8b-19295e03ec09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzUtMS0xLTEtNDYwMTM_d1e16111-3e21-4b32-b766-bdc47b917295">75,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzUtMy0xLTEtNDYwMTM_dcd094d1-fd05-4406-a51e-bc2022b687cc">82,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzUtNS0xLTEtNDYwMTM_2ee3ff29-c9ba-4043-8285-2aa70ba10156">22,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzYtMS0xLTEtNDYwMTM_7e879894-ae10-4143-8997-4c53b76bd27e">23,712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzYtMy0xLTEtNDYwMTM_eeb5c331-9d19-40aa-89aa-62319c1c529e">18,604</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzYtNS0xLTEtNDYwMTM_357de69e-47cf-4885-83da-923b142b5021">90,101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzctMS0xLTEtNDYwMTM_e28e0a51-2c9e-4974-9439-cbfe6e9e28cb">72,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0fdfe563b2749f3ad36d74c30c121dd_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzctMy0xLTEtNDYwMTM_a470bead-9e3f-43f9-b58d-56787a9f7d5a">91,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c73d82cd653451cb3c69d920ab3d8aa_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzctNS0xLTEtNDYwMTM_b40841ec-eee1-43fe-98d2-0905581d722a">181,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzgtMS0xLTEtNDYwMTM_362b79c9-8db7-4b4e-837c-7a3245ee035d">96,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzgtMy0xLTEtNDYwMTM_3a8da1cb-bca2-49e7-9554-215cc670fc05">72,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0fdfe563b2749f3ad36d74c30c121dd_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzgtNS0xLTEtNDYwMTM_e541ec53-2d6b-4e2a-8583-3c26f9a58320">91,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplementary disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfNDAtMS0xLTEtNDYwMTM_1916af19-c77f-41fb-9b22-7a261106a028">2,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfNDAtMy0xLTEtNDYwMTM_5cde9fe9-45a7-4c98-b124-3436d5a16d6a">3,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfNDAtNS0xLTEtNDYwMTM_2f512cf7-f53f-47fb-899a-267eeebbce8b">4,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfNDEtMS0xLTEtNDYwMTM_a26e2123-53ef-4eb1-a236-ca011609bbaa">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfNDEtMy0xLTEtNDYwMTM_ac0d15d7-6587-4230-8210-6b25b46edd99">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfNDEtNS0xLTEtNDYwMTM_9751abdf-2130-4fb5-8931-f6c067204cd3">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplementary disclosure of non-cash activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfNDMtMS0xLTEtNDYwMTM_36f6217a-3062-4cc7-9cd2-317571aa19e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfNDMtMy0xLTEtNDYwMTM_53a65dc7-4e7f-4723-a055-827cbb9ee972">1,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfNDMtNS0xLTEtNDYwMTM_fdcefd68-7d70-45a4-a447-2387372d3384">450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for services</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:StockIssued1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfNDQtMS0xLTEtNDYwMTM_337f5538-70bc-4e18-9b51-c81d57320a5e">390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:StockIssued1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfNDQtMy0xLTEtNDYwMTM_40de8d0b-046b-4e1e-960d-509aeae5eb25">190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:StockIssued1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfNDQtNS0xLTEtNDYwMTM_def833e0-a25f-43b3-9365-3959c56f6414">310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of derivative in connection with issuance of loan payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="ardx:DerivativeIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfNDgtMS0xLTEtNDY2NDE_7e37e217-dabf-45e6-b583-364a65746267">375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="ardx:DerivativeIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfNDgtMy0xLTEtNDY2NDE_28ef5a7c-36aa-4b05-aeb5-763beeefc96a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="ardx:DerivativeIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfNDgtNS0xLTEtNDY2NDE_2cd005b9-93cd-4690-8eb5-7ccba446e668">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div><div style="margin-top:12pt"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_97"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARDELYX,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO&#160;FINANCIAL STATEMENTS</span></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_100"></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDAvZnJhZzplMjE5NzRhNTgwMTk0NzZiYTI1MzIxZmJiYjBjYTdjOS90ZXh0cmVnaW9uOmUyMTk3NGE1ODAxOTQ3NmJhMjUzMjFmYmJiMGNhN2M5XzcwNg_0ee615a4-80aa-4b28-9cd6-45f0525f0334" continuedAt="i57ba9f1b2561400481d4a9b6ff3b0792" escape="true">ORGANIZATION AND BASIS OF PRESENTATION</ix:nonNumeric></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><ix:continuation id="i57ba9f1b2561400481d4a9b6ff3b0792"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ardelyx, Inc. (&#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) is a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs. We developed a unique and innovative platform that enabled the discovery of new biological mechanisms and pathways to develop potent, and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The first molecule we discovered and developed was tenapanor, a targeted, first-in-class, oral, small molecule therapy. Tenapanor, branded as IBSRELA, is approved in the U.S. for the treatment of adults with irritable bowel syndrome with constipation (&#8220;IBS-C&#8221;). Tenapanor is in development for the control of serum phosphorus in adult patients with chronic kidney disease (&#8220;CKD&#8221;) on dialysis under the brand name XPHOZAH. We also have a development stage asset, RDX013 for adult patients with CKD and/or heart failure with hyperkalemia, or elevated serum potassium, and a discovery phase asset, RDX020 for adult patients with metabolic acidosis, a serious electrolyte disorder, in patients with CKD.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in <ix:nonFraction unitRef="segment" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDAvZnJhZzplMjE5NzRhNTgwMTk0NzZiYTI1MzIxZmJiYjBjYTdjOS90ZXh0cmVnaW9uOmUyMTk3NGE1ODAxOTQ3NmJhMjUzMjFmYmJiMGNhN2M5XzYwMA_dec8cebc-07af-4de9-8080-d756c27b08b7">one</ix:nonFraction> business segment, which is the development and commercialization of biopharmaceutical products.</span></div></ix:continuation><div id="i8c6ecca27b7b4659bf1d61cfb55de996_103"></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzMxOTA2_84ab844c-8ff5-4864-99da-7d418cb8c707" continuedAt="i4b12f51463d8438db0d5944e30c1f5ae" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i4b12f51463d8438db0d5944e30c1f5ae" continuedAt="i8d01250ea5e0479aa0435bb07d75fad4"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzMxODk2_46ceacd6-1441-4aa8-9a53-e3ba52256835" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;).</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzMxOTAy_d3f56543-8f82-4f6c-a679-da8b3c28c2f0" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the amounts reported in the financial statements and accompanying notes thereto. On an ongoing basis, management evaluates its estimates, including those related to recognition of revenue, clinical trial accruals, contract manufacturing accruals, fair value of assets and liabilities, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could materially differ from those estimates.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had cash and short-term investments of approximately $<ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-5" name="us-gaap:InvestmentsAndCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzIzNzQ_759dc7bc-62c3-4ad7-b5ba-da0c9e98e74b">123.9</ix:nonFraction> million. We have incurred operating losses since inception in 2007 and our accumulated deficit as of December&#160;31, 2022 is $<ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzI0Njg_6954659c-e247-46bf-85c0-1d4bed297fb0">780.1</ix:nonFraction>&#160;million. Our current level of cash and short-term investments alone is not sufficient to meet our plans for the next twelve months following the issuance of these financial statements on March&#160;2, 2023. These factors raise substantial doubt regarding our ability to continue as a going concern for a period of one year from the issuance of these financial statements. We plan to address our operating cash flow requirements with our current cash and short-term investments, cash generated from product sales of IBSRELA, and if approved, cash generated from sales of XPHOZAH, our potential receipt of anticipated milestones payments from our collaboration partners, our potential receipt of anticipated payments from our Japanese collaboration partner under the second amendment to our License Agreement, with additional financing sources and through the implementation of cash preservation activities to reduce or defer discretionary spending.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no assurances that our efforts to meet our operating cash flow requirements will be successful. If our current cash and short-term investments as well as our plans to meet our operating cash flow requirements are not sufficient to fund necessary expenditures and meet our obligations for at least the next twelve months following the issuance of these financial statements, our liquidity, financial condition and business prospects will be materially affected. These financial statements have been prepared on a going concern basis and do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary in the event that we can no longer continue as a going concern. </span></div><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzMxOTAz_058cd634-5d3c-408c-b5d6-7f0a3130ca5e" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments purchased with an original maturity date of 90 days or less on the date of purchase to be cash equivalents.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><ix:continuation id="i8d01250ea5e0479aa0435bb07d75fad4" continuedAt="i255d2a1e357b45adaba9b1ca3c3f1181"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="ardx:ShortTermInvestmentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzMxOTA3_8888fedc-6439-4c21-a765-28cd26612bde" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-Term Investments</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments consist of debt securities classified as available-for-sale and have maturities greater than 90&#160;days, but less than one&#160;year, from the date of acquisition. Short-term investments are carried at fair value based upon quoted market prices. Unrealized gains and losses on available-for-sale securities are included in accumulated other comprehensive loss on our balance sheets. The cost of available-for-sale securities sold is based on the specific-identification method.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzMxOTEz_46111201-0f27-41a1-963c-331edeee59a5" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents, short-term investments and accounts receivable. We are exposed to credit risks in the event of default by the counterparties to the extent of the amount recorded in its balance sheet. Cash, cash equivalents and short-term investments are invested through banks and other financial institutions in the U.S.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzMxOTA4_fb937a06-83c9-41e6-a624-7d56d228139c" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage our foreign currency exposures with the use of foreign currency purchases. We primarily conduct business in U.S. dollars; however, a portion of our expense and capital activities are transacted in foreign currencies which are subject to exchange rate fluctuations that can affect cash or earnings. We have been in a loss position and therefore our primary objective is to conserve and manage cash. There are generally two methods by which we may manage the cash flow risk of foreign exchange fluctuations when a contract is signed (i) we can purchase the foreign funds, in full or in part, upon the execution of the contract, or (ii) we can obtain the right to purchase such funds, in full or in part, at the execution of the contract, i.e., obtain a forward contract from an appropriate bank, that can be exercised to obtain the currency of interest at a particular point in time. The derivative instruments that we may use to hedge the exposure shall generally not be designated as cash flow hedges, and as a result, changes in their fair value would be recorded in other income (expense), net, in our statements of operations and comprehensive loss. The fair values of forward foreign currency exchange contracts would be estimated using current exchange rates and interest rates and the current creditworthiness of the counterparties is taken into consideration.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzMxODk4_edaf3b9e-2015-47f3-b873-30ad2b569f53" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets, with ranges generally from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzY3Mzg_4835439c-76eb-4d2f-801e-529f6574b0d2">three</span> to <ix:nonNumeric contextRef="i06f6392d8de34129a19422671d121309_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzY3NDQ_e96f135f-dc23-4aaa-a4b6-9081292a1374">five years</ix:nonNumeric>. Leasehold improvements are amortized over the lesser of the estimated useful lives or the related remaining lease term.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzMxOTE0_81d7c596-21f5-413e-90a7-1b63d350b4be" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of long-lived assets, including property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the asset may not be recoverable. An impairment loss is recognized when the total of estimated future undiscounted cash flows, expected to result from the use of the asset and its eventual disposition, are less than the asset&#8217;s carrying amount. Impairment, if any, would be assessed using discounted cash flows or other appropriate measures of fair value. For the years ending December&#160;31, 2022, 2021 and 2020 we have recognized <ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2Xzc0NzE_15af8d00-f774-4f33-b2ff-e24d7a873b02"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2Xzc0NzE_22fbe075-e505-48fb-b4e5-5f5a6bae7bd8"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2Xzc0NzE_2f75fe73-632b-4152-9605-aa9021b8a4de">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment losses.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzMxOTA5_0c6e296f-4b95-40f1-87ab-f6e3517f48ed" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzIxOTkwMjMzMDczMTY_6a8c2c94-9413-47ce-8f6e-b7e83b1b84c6" continuedAt="i6e3ddfb78c9c4ea19076f2d56b331a9b" escape="true">Accounts Receivable</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6e3ddfb78c9c4ea19076f2d56b331a9b">Accounts receivable is reported net of allowances for returns, chargebacks and contractual off-invoice and prompt-pay discounts offered to our customers. Our estimate of the allowance for doubtful accounts is based on an evaluation of the aging of our receivables. Trade receivable balances are written off against the allowance when it is probable that the receivable will not be collected. To date, we have determined that an allowance for doubtful accounts is not required.</ix:continuation> As of December&#160;31, 2022 our accounts receivable balance was comprised of $<ix:nonFraction unitRef="usd" contextRef="ieca82817eeaa4e6a9211772c02ceff0e_I20221231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzU0OTc1NTg2NTYwMA_ed2be86b-5fbb-4844-82ab-822ea7a32d6e">0.7</ix:nonFraction>&#160;million from our collaboration agreements and $<ix:nonFraction unitRef="usd" contextRef="i3e0e80bb8eb7493a85b933d3d97f3803_I20221231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzU0OTc1NTg2NTYxNQ_4cb28ada-1dc3-4cb5-9943-4d3147a70330">7.0</ix:nonFraction>&#160;million from commercial customers. As of December&#160;31, 2021 our accounts receivable balance was comprised of $<ix:nonFraction unitRef="usd" contextRef="ia88c0559b8474f5190912f03388fc38d_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzU0OTc1NTg2NTYzMA_d28785dd-9a1e-4a4b-9a4f-86c10ed15349">0.5</ix:nonFraction>&#160;million from our collaborators.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><ix:continuation id="i255d2a1e357b45adaba9b1ca3c3f1181" continuedAt="i58ed9fb3d9f24b3e9ca59cf97d5e09ed"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzIxOTkwMjMzMDczMzA_cbde6073-2f03-40ab-a3c4-a4a6de96670c" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize inventory costs associated with the production of our products after regulatory approval or when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Otherwise, such costs are expensed as research and development. Prior to the regulatory approval of drug product candidates, we incurred expenses for the manufacture of drug product that could potentially be available to support the commercial launch of our products or could be sold to our international partners under product supply agreements. We began to capitalize inventory costs associated with IBSRELA during the fourth quarter of 2021, when our intent to commercialize IBSRELA was established and we commenced preparation for the commercial launch of IBSRELA, which was when it was determined that the inventory had a probable future economic benefit.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is stated at the lower of cost or estimated net realizable value with cost determined under the first-in first-out method. Inventory costs include the cost of materials, third-party contract manufacturing, third-party packaging services, freight, labor costs for personnel involved in the manufacturing process, and indirect overhead costs. We primarily use actual costs to determine the cost basis for inventory. The determination of whether inventory costs will be realizable requires management review of the expiration dates of IBSRELA compared to our forecasted sales. If actual market conditions are less favorable than projected by management, write-downs of inventory may be required, which would be recorded as cost of revenue in the statement of operations and comprehensive loss. As of December&#160;31, 2022, we have not recorded any write-offs for excess and obsolete inventory. A portion of inventory that represents product that is not expected to be sold or used within the next 12 months is classified as non-current on our balance sheets.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzMxODky_be7a16e3-4d23-417e-8658-6fad2e4cb409" continuedAt="i2d3a957566a1403983ff7f7fb58f3b88" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales, Net</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for our commercial product sales, net in accordance with Topic 606 - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We received approval from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in September 2019 to market IBSRELA in the U.S.. We began selling IBSRELA in the U.S. in March 2022. We distribute IBSRELA principally through major wholesalers, specialty pharmacies and group purchasing organizations ("GPOs") (collectively, our "Customers"). Our Customers subsequently sell IBSRELA to pharmacies and patients. Separately, we enter into arrangements with third parties that provide for government-mandated rebates, chargebacks and discounts. Revenue from product sales is recognized when our performance obligations are satisfied, which is when Customers obtain control of our product and occurs upon delivery.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reserves for Variable Consideration</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration which may be settled in the form of off-invoice discounts, chargebacks, or rebates. Variable consideration includes discounts to customers and government programs, wholesaler fees, group purchasing organization administrative fees, patient copay assistance programs, and estimated product returns. These estimates are based on the amounts earned or to be claimed for related sales and are classified as reductions of gross accounts receivable if settlement is expected to occur through a reduction in the amounts paid by our customers or a current liability if settlement is expected to occur through a payment from us. Where appropriate, these estimates are based on factors such as industry data and forecasted customer buying and payment patterns, our experience, current contractual and statutory requirements, specific known market events and trends. These reductions to gross sales reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. Variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we adjust these estimates, which would affect product revenue and earnings in the period such variances become known. As we gain more experience, estimates will be more heavily based on the expected utilization from historical data we have accumulated since the IBSRELA product launch.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates: Rebates include wholesaler fees, GPO fees, as well as mandated discounts under the Medicaid Drug Rebate Program ("Medicaid") and the Medicare Coverage Gap Program ("Medicare"). Estimates for rebates are recorded in the same period the related gross revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses on the balance sheets. We estimate our Medicaid and Medicare rebates based upon the estimated payor mix, and statutory discount rates. Our estimates for payor mix are guided by payor information received from specialty pharmacies, expected utilization for wholesaler sales to pharmacies, and available industry payor information. </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><ix:continuation id="i58ed9fb3d9f24b3e9ca59cf97d5e09ed" continuedAt="ib8b7d5b8abcf407c95ca89ef32b74eb2"><ix:continuation id="i2d3a957566a1403983ff7f7fb58f3b88" continuedAt="iad8179fbb01047ee8e2a8a4792bc9f72"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks: Chargebacks are discounts that occur when certain contracted purchasers purchase directly from our wholesalers at a discounted price. The wholesaler, in turn, charges back the difference between the price initially paid to us by the wholesaler and the discounted price paid to the wholesaler by the contracted purchaser. Amounts for estimated chargebacks are established in the same period that the related gross revenue is recognized, resulting in a reduction of product revenue and accounts receivable. The accrual for wholesaler chargebacks is estimated based on known chargeback rates, known sales to wholesalers, and estimated utilization by types of contracted purchasers.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discounts and Fees: Our payment terms are generally <ix:nonNumeric contextRef="i2de3a294b21b459b8c55c13b0a994e24_D20220101-20221231" name="ardx:RevenueGeneralPaymentTerms" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzIxOTkwMjMzMDczMTg_d6fd4281-58e2-4d01-b782-a044db76d9d0">30</ix:nonNumeric> to <ix:nonNumeric contextRef="i06f6392d8de34129a19422671d121309_D20220101-20221231" name="ardx:RevenueGeneralPaymentTerms" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzIxOTkwMjMzMDczMjg_b2a29ae3-ef4d-40ae-b6ba-a07400d2d76a">60</ix:nonNumeric> days. Wholesalers, GPOs and specialty pharmacies are offered various forms of consideration, including off-invoice discounts which may be paid to GPOs and specialty pharmacies. Wholesalers and GPOs may also receive prompt pay discounts for payment within a specified period. We expect discounts to be earned when offered and therefore, we deduct the full amount of these discounts from product sales when revenue is recognized, resulting in a reduction of product revenue and accounts receivable.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Reserves: Patients who have commercial insurance may receive copay assistance when product is dispensed by pharmacies to patients. We estimate the amount of copay assistance provided to eligible patients based on the terms of the program and redemption information provided by third-party claims processing organizations and are recorded in accounts payable and accrued expenses and other current liabilities on the balance sheets. Other reserves include estimated product returns which are recorded in the same period the related gross revenue is recognized, resulting in a reduction of product revenue as well as accounts receivable. We estimate our product returns reserve based upon our experience, and specific known market events and trends. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenue Recognition</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate collaboration revenue primarily from research and collaboration and license agreements with customers. Goods and services in the agreements may include the grant of licenses for the use of our technology,&#160;the provision of services associated with the research and development of product candidates, manufacturing services, and participation in joint steering committees. The terms of these arrangements typically include payment to us of one or more of the following: non-refundable, up-front license fees; research, development, regulatory and commercial milestone payments; reimbursement of research and development services; option payments; reimbursement of certain costs; payments for manufacturing supply services; and future royalties on net sales of licensed products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When two or more contracts are entered into with the same customer at or near the same time, we evaluate the contracts to determine whether the contracts should be accounted for as a single arrangement. Contracts are combined and accounted for as a single arrangement if one or more of the following criteria are met: (i) the contracts are negotiated as a package with a single commercial objective; (ii) the amount of consideration to be paid in one contract depends on the price or performance of the other contract; or (iii) the goods or services promised in the contracts (or some goods or services promised in each of the contracts) are a single performance obligation.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under each of our agreements, management performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including any constraints on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) we satisfy each performance obligation. As part of the accounting for contracts with customers, we develop assumptions that require judgment to determine whether promised goods and services represent distinct performance obligations and the standalone selling price for each performance obligation identified in the contract. This evaluation is subjective and requires us to make judgments about the promised goods and services and whether those goods and services are separable from other aspects of the contract. Further, determining the standalone selling price for performance obligations requires significant judgment, and when an observable price of a promised good or service is not readily available, we consider relevant assumptions to estimate the standalone selling price, including, as applicable, market conditions, development timelines, probabilities of technical and regulatory success, reimbursement rates for personnel costs, forecasted revenues, potential limitations to the selling price of the product and discount rates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply judgment in determining whether a combined performance obligation is satisfied at a point in time or over time, and, if over time, concluding upon the appropriate method of measuring progress to be applied for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, as estimates related to the measure of progress change, related revenue recognition is adjusted accordingly. Changes in our estimated measure of progress are accounted for prospectively as a change in accounting estimate. We recognize collaboration revenue by measuring the progress toward complete satisfaction of the performance obligation using an input measure. In order to recognize revenue over the research and </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><ix:continuation id="ib8b7d5b8abcf407c95ca89ef32b74eb2" continuedAt="i7a451b6a8a7a4b61b4268eb664d0b37c"><ix:continuation id="iad8179fbb01047ee8e2a8a4792bc9f72" continuedAt="i9b44aff313334653a3cb0f343a8a725c"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development period, we measure actual costs incurred to date compared to the overall total expected costs to satisfy the performance obligation. Revenues are recognized as the program costs are incurred. We will re-evaluate the estimate of expected costs to satisfy the performance obligation each reporting period and make adjustments for any significant changes.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to satisfying the revenue recognition criteria are recorded as contract liabilities in our Balance Sheets. If the related performance obligation is expected to be satisfied within the next twelve months it will be classified in current liabilities. Amounts recognized as revenue prior to receipt are recorded as contract assets in our Balance Sheets. If we expect to have an unconditional right to receive the consideration in the next twelve months, it will be classified in current assets. A net contract asset or liability is presented for each contract with a customer.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved. Milestone payments that are not within our control or the control of the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achievement of such development milestones and any related constraints, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect earnings in the period of adjustment.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing supply services:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Arrangements that include a promise for future supply of drug substance or drug product for either clinical development or commercial supply at the customer&#8217;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. If we are entitled to additional payments when the customer exercises these options, any payments are recorded in product supply revenue when the customer obtains control of the goods, which is upon delivery.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and where the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, royalty revenue resulting from licensing arrangements has not been material.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses of intellectual property:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If a license granted to a customer to use our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from consideration allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we apply judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, to conclude upon the appropriate method of measuring progress for purposes of recognizing revenue related to consideration allocated to the performance obligation.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Options:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Customer options, such as options granted to allow a licensee to choose to research, develop and commercialize licensed compounds are evaluated at contract inception in order to determine whether those options provide a material right (i.e., an optional good or service offered for free or at a discount) to the customer. If the customer options represent a material right, the material right is treated as a separate performance obligation at the outset of the arrangement. We allocate the transaction price to material rights based on the standalone selling price, and revenue is recognized when or as the future goods or services are transferred or when the option expires. Customer options that are not material rights do not give rise to a separate performance obligation, and as such, the additional consideration that would result from a customer exercising an option in the future is not included in the transaction price for the current contract. Instead, the option is deemed a marketing offer, and additional option fee payments are recognized or being recognized as revenue when the licensee exercises the option. The exercise of an option that does not represent a material right is treated as a separate contract for accounting purposes.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract modifications:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Contract modifications, defined as changes in the scope or price (or both) of a contract that are approved by the parties to the contract, such as a contract amendment, exist when the parties to a contract approve a modification that either creates new or changes existing enforceable rights and obligations of the parties to the contract. Depending on facts and circumstances, we account for a contract modification as one of the following: (i) a separate contract; (ii) a termination of the existing contract and a creation of a new contract; or (iii) a combination of the preceding treatments. A contract modification is accounted for as a separate contract if the scope of the contract increases because of the addition of promised goods or services that are distinct and the price of the contract increases by an amount of consideration that reflects </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><ix:continuation id="i7a451b6a8a7a4b61b4268eb664d0b37c" continuedAt="i5fb3267b8b93480e97b4ecae55e65a81"><ix:continuation id="i9b44aff313334653a3cb0f343a8a725c"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our standalone selling prices of the additional promised goods or services. When a contract modification is not considered a separate contract and the remaining goods or services are distinct from the goods or services transferred on or before the date of the contract modification, we account for the contract modification as a termination of the existing contract and a creation of a new contract. When a contract modification is not considered a separate contract and the remaining goods or services are not distinct, we account for the contract modification as an add-on to the existing contract and as an adjustment to revenue on a cumulative catch-up basis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive payments from our licensees as established in each contract. Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until we perform our obligations under these arrangements. Where applicable, amounts are recorded as accounts receivable or unbilled revenue when our right to consideration is unconditional. We do not assess whether a contract with a customer has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less.</span></div></ix:continuation><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:CostOfSalesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzIxOTkwMjMzMDczMzM_03b531be-e605-4a04-b817-a68cc6442a86" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue consists of the cost of commercial goods sold to our Customers and international partners under product supply agreements as well as royalty expense based on sales of tenapanor. We capitalize inventory costs associated with the production of our products after regulatory approval or when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Otherwise, such costs are expensed as research and development. A portion of the costs of IBSRELA units recognized as revenue during the twelve months ended December&#160;31, 2022 were expensed prior to the fourth quarter of 2021, at which time our intent to commercialize IBSRELA was established and we commenced preparation for the commercial launch of IBSRELA. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue includes payments due to AstraZeneca, which under the terms of a termination agreement entered into in 2015 ("AZ Termination Agreement") is entitled to (i) future royalties at a rate of <ix:nonFraction unitRef="number" contextRef="i23a66360caef450d9534fe2775f21255_D20150601-20150630" decimals="INF" name="ardx:PercentageOfRoyaltyRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzU0OTc1NTg2NTU2NA_f8f1354e-9995-450c-8bd2-4a412d52d809">10</ix:nonFraction>% of net sales of tenapanor or other NHE3 products by us or our licensees, and (ii) <ix:nonFraction unitRef="number" contextRef="i23a66360caef450d9534fe2775f21255_D20150601-20150630" decimals="INF" name="ardx:PercentageOfNonRoyaltyRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzU0OTc1NTg2NTU2OA_602d4ed0-947c-4d9a-8f19-9596062c8979">20</ix:nonFraction>% of non-royalty revenue received from our collaboration partners as a result of the development and commercialization of tenapanor or certain other NHE3 inhibitors.&#160;We have agreed to pay&#160;AstraZeneca up to a maximum of $<ix:nonFraction unitRef="usd" contextRef="i8e9b10bffc104601b9077dcc9e1f4fa6_I20150630" decimals="-5" name="ardx:CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzU0OTc1NTg2NTU3Mg_0faae7bc-afb8-461d-bd84-aff8c5abb61c">75.0</ix:nonFraction> million in the aggregate for (i) and (ii). We recognize these expenses as cost of revenue when we recognize the corresponding revenue that gives rise to payments due to AstraZeneca. To date, we have recognized an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i1d34215ee2e348899b09d93611aa94d9_I20221231" decimals="-5" name="ardx:CostOfRevenueAggregateAmountRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzU0OTc1NTg2NTU3Ng_190f4fbd-92a5-4a2e-95e4-4a5af75c4dc8">15.3</ix:nonFraction> million as cost of revenue under the AZ Termination Agreement.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzMxOTA0_22c7182a-25f8-4342-b789-c9d9792f67ce" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to expense as incurred and consisted of costs incurred to further our research and development activities and include salaries and related employee benefits, costs associated with clinical trials, costs related to pre-commercialization manufacturing activities such as manufacturing process validation activities and the manufacturing of clinical drug supply, nonclinical research and development activities, regulatory activities, research-related overhead expenses and fees paid to external service providers and contract research and manufacturing organizations that conduct certain research and development activities on our behalf.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="ardx:AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzMxODkz_6c2e8b2b-7b86-4ce9-9bf2-bfdeeda2cbf9" continuedAt="i3000b6a10a9c4b7aa89710534476ea71" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to estimate our accrued expenses at the end of each reporting period. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual costs. The majority of our service providers submit invoices in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with our service providers and make adjustments if necessary. Examples of estimated accrued research and development expenses include fees paid to:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contract research organizations ("CROs") in connection with clinical studies;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">investigative sites in connection with clinical studies;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">vendors related to product manufacturing, development and distribution of clinical supplies; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">vendors in connection with preclinical development activities.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><ix:continuation id="i5fb3267b8b93480e97b4ecae55e65a81" continuedAt="i672ba6308f734219896406feacc6352c"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3000b6a10a9c4b7aa89710534476ea71">We record expenses related to clinical studies and manufacturing development activities based on our estimates of the services received and efforts expended pursuant to contracts with multiple CROs and manufacturing vendors that conduct and manage these activities on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these contracts depend on factors such as the successful enrollment of subjects and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed, enrollment of subjects, number of sites activated and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we will adjust the accrued or prepaid expense balance accordingly.</ix:continuation></span></div><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzMxODk1_c5a8f6a0-1cae-4138-a1c3-15c97c19bccf" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize compensation expense for all stock-based payment awards made to employees, non-employees and directors based on estimated fair values. For employee and non-employee stock options, we determine the grant date fair value of the awards using the Black-Scholes option-pricing model and generally recognize the fair value as stock-based compensation expense on a straight-line basis over the vesting period of the respective awards. For restricted stock and performance-based restricted stock, to the extent they are probable, the compensation cost for these awards is based on the closing price of our common stock on the date of grant and recognized as compensation expense on a straight-line basis over the requisite service period. Stock-based compensation expense is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. As such, our stock-based compensation is reduced for the estimated forfeitures at the date of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:DerivativesReportingOfDerivativeActivity" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzMxOTEw_d24e25e3-954b-4181-8c29-fbfecb2d5e6d" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivatives and Hedging Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for our derivative instruments as either assets or liabilities on the balance sheet and measure them at fair value. Derivatives are adjusted to fair value through other income (expense), net in the statements of operations and comprehensive loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="ardx:NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzIxOTkwMjMzMDczMzQ_d5947480-5811-4ffb-a382-bda155af572a" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-cash Interest Expense on Deferred Royalty Obligation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net proceeds we receive from the sale of certain future royalties are recorded as deferred royalty obligation related to the sale of future royalties on our balance sheets. As we earn royalties and remit those royalties pursuant to the agreement, the balance of the deferred royalty obligation will be effectively repaid over the life of agreement and non-cash interest expense related to the sale of future royalties is recorded using the effective interest method. To determine the amortization of our deferred royalty obligation, we are required to estimate the total amount of future royalty payments we expect to earn. There are a number of factors that could materially affect the amount and timing of royalty payments, most of which are not within our control. We periodically assess the amount of royalty payments we expect to receive which are subject to the agreement and, to the extent that the amount or timing of such payments is materially different than our original estimates, we prospectively adjust the imputed interest rate and the related amortization of the deferred royalty obligation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzMxOTAw_fe77d5fb-1b84-47f5-9cfc-2226c82ffee7" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement is a lease at the inception of the arrangement. Operating leases are included in right-of-use assets, current portion of operating lease liability, and operating lease liability, net of current portion in our balance sheets. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. The operating lease right-of-use assets also include any lease payments made and exclude lease incentives. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise any such options. Lease expense is recognized on a straight-line basis over the expected lease term. We have elected not to separate lease and non-lease components, such as common area maintenance charges, and instead it accounts for these as a single lease component.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzMxOTAx_f2db1f29-992c-48b5-ae14-5f36e92901f6" continuedAt="id5c7be1ba4f74edb9fc1e93b663881fd" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize restructuring charges related to reorganization plans that have been committed to by management when liabilities have been incurred. In connection with these activities, we record restructuring charges at fair value for, (a) contractual employee termination benefits when obligations are associated to services already rendered, rights to such benefits have vested, and payment of benefits is probable and can be reasonably estimated, (b) one-time employee termination benefits </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><ix:continuation id="i672ba6308f734219896406feacc6352c"><ix:continuation id="id5c7be1ba4f74edb9fc1e93b663881fd"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">when management has committed to a plan of termination, the plan identifies the employees and their expected termination dates, the details of termination benefits are complete, it is unlikely changes to the plan will be made or the plan will be withdrawn and communication to such employees has occurred, and (c) contract termination costs when a contract is terminated before the end of its term.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One-time employee termination benefits are recognized in their entirety when communication has occurred and future services are not required. If future services are required, the costs are recorded ratably over the remaining period of service. Contract termination costs to be incurred over the remaining contract term without economic benefit are recorded in their entirety when the contract is canceled.</span></div></ix:continuation><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzMxODk5_5bc21556-85f2-45a1-bd99-f2caecc9b8ef" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration of potential shares of common stock. Diluted net loss per common share in the periods presented is the same as basic net loss per common share, since the effects of potentially dilutive securities are antidilutive due to the net loss for all periods presented.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzMxOTA1_92e37198-0962-4ba6-b677-cc403cb9ca33" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Pronouncements - Recently Adopted</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adopted Accounting Standards Update 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2016-13"), as of December 1, 2021 under the modified retrospective approach. ASU 2016-13 requires an entity to measure and recognize expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities with unrealized credit losses, the standard requires allowances to be recorded through net income instead of directly reducing the amortized cost of the investment under the previous other-than-temporary impairment model. The adoption of this standard did not have a material impact on our financial statements or a significant impact on our internal controls.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were various accounting standards and interpretations issued recently, none of which are expected to a have a material impact on our financial position, operations or cash flows.</span></div></ix:nonNumeric></ix:continuation><div id="i8c6ecca27b7b4659bf1d61cfb55de996_106"></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90ZXh0cmVnaW9uOjc1YjMwNTI2NGY1ODQwZTlhNGIzNTNjMjM2ZmY3YmNlXzI1NzQ_05c1026e-6037-4b46-84e7-db3589e402c9" continuedAt="ica05b7d7a8de4e14b8348773a1913f8f" escape="true">CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS</ix:nonNumeric></span></div><ix:continuation id="ica05b7d7a8de4e14b8348773a1913f8f" continuedAt="ia8332b5dfe5145b89483bb5b67f30aa9"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90ZXh0cmVnaW9uOjc1YjMwNTI2NGY1ODQwZTlhNGIzNTNjMjM2ZmY3YmNlXzI1NzI_2efb7b68-174a-490a-9001-9f5044f8543b" continuedAt="i6ac15c18530640d39ca9d1a5e2434242" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities classified as cash, cash equivalents and short-term investments as of December&#160;31, 2022 and 2021 are summarized below (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72b7f1283e114d98b667e2d3b9d78c10_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzQtMS0xLTEtNDYwMTM_6a152e45-dc6f-415c-b68c-1487f34e7ea4">11,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72b7f1283e114d98b667e2d3b9d78c10_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzQtNy0xLTEtNDYwMTM_cc99f0cb-96d3-4c6d-b111-aa55710c166d">11,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82f59874748f487e829f759d2d2fe716_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzUtMS0xLTEtNDYwMTM_ccb81288-7c8d-4c85-bcb2-0913030255ae">84,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82f59874748f487e829f759d2d2fe716_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzUtNy0xLTEtNDYwMTM_49d5dd72-c0ea-471d-97f7-dc0802935dfc">84,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzctMS0xLTEtNDYwMTM_66c8b2d7-3e7c-4c27-bd4c-5630bcab7bf0">96,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzctNy0xLTEtNDYwMTM_2761c368-7baa-400b-9f0e-623d269d5724">96,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieabaefd41b574aa6b074694d974eb95a_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzktMS0xLTEtNDYwMTM_0066e299-964d-4b44-bf03-fefd3525d365">25,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieabaefd41b574aa6b074694d974eb95a_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzktMy0xLTEtNDYwMTM_c1931767-591a-4e77-97bd-b8bfe657240f">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieabaefd41b574aa6b074694d974eb95a_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzktNS0xLTEtNDYwMTM_8a0f9333-e397-4d52-a2d2-8d9beff1c705">51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieabaefd41b574aa6b074694d974eb95a_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzktNy0xLTEtNDYwMTM_c6dd404c-1221-4cb2-b453-7bcdf290872c">25,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cffd7fcbbc544939e32a7a8f34622be_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzEwLTEtMS0xLTQ2MDEz_f54883e7-8e54-417a-9ac4-412893b09308">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cffd7fcbbc544939e32a7a8f34622be_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzEwLTMtMS0xLTQ2MDEz_20fc28d7-9003-4505-9e40-43e4b5e27190">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cffd7fcbbc544939e32a7a8f34622be_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzEwLTUtMS0xLTQ2MDEz_d5e08417-8326-4f2b-ae01-c5bf9259d9d9">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cffd7fcbbc544939e32a7a8f34622be_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzEwLTctMS0xLTQ2MDEz_7c4ef77b-ae70-4feb-b958-b1966012708b">999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored agency bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91fc450e044e494a99d00262c55ee834_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzExLTEtMS0xLTQ2MDEz_3d2e2826-a4e2-4e76-83e8-f9fa96e09414">1,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91fc450e044e494a99d00262c55ee834_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzExLTMtMS0xLTQ2MDEz_140938d1-3310-4e1d-ad1b-a9169213339e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91fc450e044e494a99d00262c55ee834_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzExLTUtMS0xLTQ2MDEz_27e9c492-a6a2-4c5d-a72f-2023ab5bb26d">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91fc450e044e494a99d00262c55ee834_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzExLTctMS0xLTQ2MDEz_4f72c904-cb05-410f-acae-b9b8695a89d1">1,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzEzLTEtMS0xLTQ2MDEz_4daaf350-76b6-43e9-9501-ea389399f1df">27,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzEzLTMtMS0xLTQ2MDEz_c0552182-8f85-490a-b697-845106966579">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzEzLTUtMS0xLTQ2MDEz_c63f6c92-fbb2-484a-8cd3-bcae900b5952">60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzEzLTctMS0xLTQ2MDEz_26e79629-1a0b-4516-91d3-69f0fb732304">27,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="ardx:InvestmentsAndCashAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzE2LTEtMS0xLTQ2MDEz_f4c3cbce-4832-4dbf-b77f-3cbc6529b8c5">123,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedGains" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzE2LTMtMS0xLTQ2MDEz_0356c4dc-f4a3-4347-8788-0d4553d6063d">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzE2LTUtMS0xLTQ2MDEz_fb2cf6a7-f885-4070-9e4e-99ad5f3eb3da">60</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:InvestmentsAndCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzE2LTctMS0xLTQ2MDEz_35e6b616-f9e2-45c6-af7d-5719e0f81d01">123,909</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><ix:continuation id="ia8332b5dfe5145b89483bb5b67f30aa9"><div style="margin-top:12pt"><ix:continuation id="i6ac15c18530640d39ca9d1a5e2434242"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0604aebc55e7425795ca8e599d946833_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzQtMS0xLTEtNDYwMTM_44be9303-42cb-4e37-87c7-7aaf7df8f982">1,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0604aebc55e7425795ca8e599d946833_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzQtNy0xLTEtNDYwMTM_e1cc4d17-cfbf-48d6-9775-785267689078">1,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98269013828c4cbf960fd07466f62e00_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzUtMS0xLTEtNDYwMTM_01ac6ba2-3e00-40c1-900c-15f5f64cfede">71,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98269013828c4cbf960fd07466f62e00_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzUtNy0xLTEtNDYwMTM_73a7b47a-471c-4f4f-9c4f-fbf7a8bcb6fe">71,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial Paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideed1df6eef44d1f8834a64175dd3912_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzYtMS0xLTEtNDYwMTM_0722f033-4ae4-44c9-a1d0-54dc56c8d03f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideed1df6eef44d1f8834a64175dd3912_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzYtNy0xLTEtNDYwMTM_95445235-10d5-4379-9d79-2410b3823f98">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbbc030abf9e4d3a8044fd67d677deca_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzctMS0xLTEtNDYwMTM_b8a84590-ddee-4fa8-ad3b-448cf3e880bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbbc030abf9e4d3a8044fd67d677deca_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzctNy0xLTEtNDYwMTM_a3afc646-e8b6-4078-9ae2-488037ff98d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzgtMS0xLTEtNDYwMTM_3b62e802-4dfc-489d-bb85-1de218f9be59">72,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzgtNy0xLTEtNDYwMTM_8187ec12-01e0-4c29-8411-d615448561fc">72,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73a4c3bd901c4931af270d9b6aae48be_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzEwLTEtMS0xLTQ2MDEz_34ad630b-8b53-44ea-b9e1-645d1e6c820e">31,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73a4c3bd901c4931af270d9b6aae48be_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzEwLTMtMS0xLTQ2MDEz_15e49619-1ac5-43f2-ada9-23dad2521854">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73a4c3bd901c4931af270d9b6aae48be_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzEwLTUtMS0xLTQ2MDEz_d75198b1-dc0a-4e0b-a088-4e56b9950a00">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73a4c3bd901c4931af270d9b6aae48be_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzEwLTctMS0xLTQ2MDEz_c78937c5-9998-4fe8-bd2e-a6e5d9418b8d">31,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie309689c7e5145568dac251da707114b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzExLTEtMS0xLTQ2MDEz_b406b07c-b147-4eee-aba4-1d3df52eb068">7,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie309689c7e5145568dac251da707114b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzExLTMtMS0xLTQ2MDEz_da4b32d1-92fd-4134-b6c7-09a7d5b8166f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie309689c7e5145568dac251da707114b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzExLTUtMS0xLTQ2MDEz_9478477f-7a64-4f0d-9608-71ea640f90a5">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie309689c7e5145568dac251da707114b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzExLTctMS0xLTQ2MDEz_045e0617-7ba5-4a57-aa20-80417e522232">7,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i197012cc5c3f4d0186f4f6f49afd9938_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzEzLTEtMS0xLTQ2MDEz_f2e7c37b-bb53-4ede-bf53-cbee24756646">5,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i197012cc5c3f4d0186f4f6f49afd9938_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzEzLTMtMS0xLTQ2MDEz_0acbfc77-485e-4d63-a091-cfd1400a3d26">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i197012cc5c3f4d0186f4f6f49afd9938_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzEzLTUtMS0xLTQ2MDEz_8b21c7d1-dff9-496b-90c2-5c16ff2aa1b2">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i197012cc5c3f4d0186f4f6f49afd9938_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzEzLTctMS0xLTQ2MDEz_3d6fa584-56e5-4dd5-8ca0-93796b1f246a">5,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzE0LTEtMS0xLTQ2MDEz_220856ef-22b2-46a7-8911-39ed0fc06a4a">44,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzE0LTMtMS0xLTQ2MDEz_ca1c094d-d504-486e-b2f6-04fa3d4027a6">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzE0LTUtMS0xLTQ2MDEz_e50fac34-c88e-4fa6-9ae8-1f4cfec5e8dd">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzE0LTctMS0xLTQ2MDEz_7b26b488-0f21-4404-bd01-98c881af81c4">44,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="ardx:InvestmentsAndCashAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzE3LTEtMS0xLTQ2MDEz_5ce3578f-4926-4af4-88a6-0f6ab6df9499">116,695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedGains" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzE3LTMtMS0xLTQ2MDEz_af2d6705-9918-40e4-adeb-3d513e496fac">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzE3LTUtMS0xLTQ2MDEz_c008e837-b7cb-4f37-996b-d0463bf478fe">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:InvestmentsAndCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzE3LTctMS0xLTQ2MDEz_79c49458-14b1-4265-b7f4-7dd8dd798dca">116,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of money market funds with original maturities of three months or less at the time of purchase, and the carrying amount is a reasonable approximation of fair value. We invest our cash in high quality securities of financial and commercial institutions. These securities are carried at fair value, which is based on readily available market information, with unrealized gains and losses included in accumulated other comprehensive loss within stockholders&#8217; equity on our balance sheets. We use the specific identification method to determine the amount of realized gains or losses on sales of marketable securities. Realized gains or losses have been insignificant and are included in other income, net, in the statement of operations and comprehensive loss.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the short-term available-for sale securities held as of December&#160;31, 2022 and 2021 had contractual maturities of less than <ix:nonNumeric contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" name="ardx:AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90ZXh0cmVnaW9uOjc1YjMwNTI2NGY1ODQwZTlhNGIzNTNjMjM2ZmY3YmNlXzc2OTY1ODE0MDMwOTc_893b6e37-0dd6-4b6f-9472-efd14569244c"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="ardx:AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90ZXh0cmVnaW9uOjc1YjMwNTI2NGY1ODQwZTlhNGIzNTNjMjM2ZmY3YmNlXzc2OTY1ODE0MDMwOTc_ea0295f9-cdb9-456c-8eb3-695517384fea">one year</ix:nonNumeric></ix:nonNumeric>. Our available-for-sale securities are subject to a periodic impairment review. We consider a debt security to be impaired when its fair value is less than its carrying cost, in which case we would further review the investment to determine whether it is other-than-temporarily impaired. When we evaluate an investment for other-than-temporary impairment, we review factors such as the length of time and extent to which fair value has been below cost basis, the financial condition of the issuer and any changes thereto, intent to sell, and whether it is more likely than not we will be required to sell the investment before the recovery of its cost basis. If an investment is other-than-temporarily impaired or subject to credit losses, we write it down through the statement of operations and comprehensive loss to its fair value and establish that value as a new cost basis for the investment. Our unrealized losses as of December&#160;31, 2022 and 2021 were not material. We determined that none of our available-for-sale securities were other-than-temporarily impaired as of December&#160;31, 2022 and 2021, and <ix:nonFraction unitRef="investment" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90ZXh0cmVnaW9uOjc1YjMwNTI2NGY1ODQwZTlhNGIzNTNjMjM2ZmY3YmNlXzU0OTc1NTgxOTg4Mg_153c0635-56f2-437c-8570-b934d4908d68"><ix:nonFraction unitRef="investment" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90ZXh0cmVnaW9uOjc1YjMwNTI2NGY1ODQwZTlhNGIzNTNjMjM2ZmY3YmNlXzU0OTc1NTgxOTg4Mg_16f14a8d-f699-4d28-9042-2261f4598dfd">no</ix:nonFraction></ix:nonFraction> investment was in a continuous unrealized loss position for more than one year. As such, we believe that it is more likely than not that the investments will be held until maturity or a forecasted recovery of fair value.</span></div></ix:continuation><div id="i8c6ecca27b7b4659bf1d61cfb55de996_109"></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90ZXh0cmVnaW9uOjA2NzI0MDE2MzE1MDQwZjlhOTVmNzhlMWZmMGQxYzZiXzMzMTQ_056acb24-3acb-4a41-8e7a-e0757c073cab" continuedAt="i48017a332f6d45199b105b3725ff390f" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="i48017a332f6d45199b105b3725ff390f" continuedAt="ic3b028ae4d1a46d6b5dec061e30bb354"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1&#160;&#160;&#160;&#8211;&#160;Valuations are based on quoted prices in active markets for identical assets or liabilities and readily accessible to us at the reporting date. </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2&#160;&#160;&#160;&#8211;&#160;&#160;Valuations based on inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 &#160;&#8211;&#160;&#160;Valuations based on unobservable inputs for which there is little or no market data, which require us to develop our own assumptions.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><ix:continuation id="ic3b028ae4d1a46d6b5dec061e30bb354" continuedAt="i274fcc5c710f4870b17b086ce2188d79"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90ZXh0cmVnaW9uOjA2NzI0MDE2MzE1MDQwZjlhOTVmNzhlMWZmMGQxYzZiXzMzMTU_c6a56155-4de6-466e-988c-96788ecbb048" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of our financial assets and liabilities that are measured or disclosed on a recurring basis by level within the fair value hierarchy (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifce32edf589c43559645ca939f8321c0_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzMtMS0xLTEtNDYwMTM_249d1c9f-1da7-4cbb-8a62-2535fbcd0b30">84,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i800c2d8a407c4f52a90eac1ac7fa9c7f_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzMtMy0xLTEtNDYwMTM_822f73ba-0d90-46a2-9948-316727a2b26c">84,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic862582842b14106872fa00b3bc1a179_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzMtNS0xLTEtNDYwMTM_35d52533-5a25-42b2-b87e-b494244c84a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c1965f94e0f45c8ba92675a0a9e37a5_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzMtNy0xLTEtNDYwMTM_4af955b1-2edb-4e08-860c-ac329c624af3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibeba7a62348343fda259cc027ff9efaf_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzQtMS0xLTEtNDYwMTM_f520a4fe-810c-44ca-9a0a-94908cd87a15">25,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5530fb3f55994ff9b89b29a90019a352_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzQtMy0xLTEtNDYwMTM_ff983083-bb53-4b14-ab95-55da18809e26">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i215440159e8b42d48ee9a7911b2b27ed_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzQtNS0xLTEtNDYwMTM_807e6703-368a-4e92-856c-a565d517b065">25,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic020e23db5fa4fd392335d177235faab_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzQtNy0xLTEtNDYwMTM_f8efb0a1-78f8-4ca9-9dd7-67f4c3985b4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored agency bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6a449d340e445639849083309b50cfc_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzYtMS0xLTEtNTE3ODM_ff9b88ef-4cd0-47a6-be75-397c0084bdde">1,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b017fd3d9ed45a686ed4da0c90e2b8a_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzYtMy0xLTEtNTE3ODM_3dceb091-98a2-462c-a05f-aa9db1e352a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2189793c12b94eb5aea5349640fc8e74_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzYtNS0xLTEtNTE3ODM_8ba746dc-3912-4c48-8ddb-c89efac2ee27">1,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4045d24f631d4b57b3bad1d73d787f3b_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzYtNy0xLTEtNTE3ODM_2e7409f1-a55a-452c-b383-180686103641">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0091d5584e742729920f89400c5a7ec_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzUtMS0xLTEtNDYwMTM_d953192c-9267-4368-899a-fb24d283c6c1">999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63caa9b53ecd4496aa9cbae0e6aebb0f_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzUtMy0xLTEtNDYwMTM_aa7c2f2b-0813-4b9e-897a-2c4761ed0ebd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d651a762ddd4d42b1eb146a2f77667a_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzUtNS0xLTEtNDYwMTM_806d0469-dec5-4974-9e32-383e2a1d3328">999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41b180661d604a9db63c4cc471ee7d76_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzUtNy0xLTEtNDYwMTM_e69bb65d-e79e-4875-94e6-c6fb2ed42e2c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i691c998073704928ab9052cb14232a00_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzgtMS0xLTEtNDYwMTM_3ad606eb-0dc0-418c-8a1f-f54c8bf982c4">112,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733e529140624718b49d4f80ac96a2d6_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzgtMy0xLTEtNDYwMTM_e81ef220-f209-420c-9447-1d421d5c51c3">84,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4139c0b0d3d942078ab8524d3ab1edfb_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzgtNS0xLTEtNDYwMTM_a93e5840-ad21-43bb-860a-14020e24fafa">27,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i663a0605660842e1b03f18928affeeff_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzgtNy0xLTEtNDYwMTM_f05081cd-a708-4ba4-b647-1ef959933f7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities for exit fees</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a2ed7629e8644ca88a18430d955a065_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzExLTEtMS0xLTQ2MDEz_e305adda-ac79-4b91-9cad-1e8611bc528f">1,656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b7cfff0602c4effac77d3fac445e8a0_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzExLTMtMS0xLTQ2MDEz_74a93c89-fc99-462d-ac07-7391783d8dc0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb4cf2b13f04f7894360378ff59fdd1_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzExLTUtMS0xLTQ2MDEz_17062dc3-3340-4fc4-9965-7796275555dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5ac62ac7b5c46bfa5e837d80abb240d_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzExLTctMS0xLTQ2MDEz_bba6906a-f66d-48e5-bb6f-af57e1c415a4">1,656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i691c998073704928ab9052cb14232a00_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzEyLTEtMS0xLTQ2MDEz_afab034b-afc4-4c85-960f-879dd5bc8a51">1,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733e529140624718b49d4f80ac96a2d6_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzEyLTMtMS0xLTQ2MDEz_c945f3f3-2c3d-4400-aab2-a238da91d9a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4139c0b0d3d942078ab8524d3ab1edfb_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzEyLTUtMS0xLTQ2MDEz_5c376386-576c-4b5f-9eff-3178a97fcb30">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i663a0605660842e1b03f18928affeeff_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzEyLTctMS0xLTQ2MDEz_52913c66-628e-49af-b8a6-0972c508e134">1,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe6734a4d6234308b332b56b6c66f456_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzMtMS0xLTEtNDYwMTM_d3811811-eb24-4fbb-a6df-b344d08c9945">71,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf63c7b0e2bd43fd95a03bb02babbf85_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzMtMy0xLTEtNDYwMTM_380d24e4-b24d-4b68-aa5a-1b1f50039671">71,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53e4cddaae814c21930efe5f393ab81c_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzMtNS0xLTEtNDYwMTM_2fe969cb-59aa-43e5-b215-91349b63e38a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e79c3ee3bba453c95e397f21030d21e_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzMtNy0xLTEtNDYwMTM_88002b6e-e714-4b32-a467-b75f4826ba5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31e14a2329e641e4a02f507843106a3e_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzQtMS0xLTEtNDYwMTM_aecda001-7313-46cf-b05f-56b627a061d4">31,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39124c37d91d480fa7bfb56ae5e2f223_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzQtMy0xLTEtNDYwMTM_8d679b85-748a-4636-b447-9d99d6b786e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49ea832c4a2441fa815b2b46be792d19_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzQtNS0xLTEtNDYwMTM_b01358d6-65e4-4666-949d-001c7b724a8e">31,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia22881527d4b49cc88625aa8abc67b5c_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzQtNy0xLTEtNDYwMTM_b28a6e7d-51ae-4246-8346-bd44011408fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13616c69d6954d9dbcff580bb0481727_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzUtMS0xLTEtNDYwMTM_1b3a8e0e-4048-45e9-ba27-d5d54e163180">7,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cf9501a699e4a90b12f236486a35622_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzUtMy0xLTEtNDYwMTM_f8158b8f-0175-4ad5-bae1-77c598d88f46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16228cefd2e34ed3ad2ef7d53b54f81c_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzUtNS0xLTEtNDYwMTM_fc120c24-8352-458b-b322-0176f1a39149">7,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i132317a517fe469983d16efc145dde7b_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzUtNy0xLTEtNDYwMTM_c9772b3c-f84a-4b33-b7e2-dad4781a1937">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if244d874422d4171840a2bb10d682a60_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzYtMS0xLTEtNDg1MDY_d65d22ff-142b-4a7f-8aef-8201654b8160">5,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if834c52fad8d4fa786b3476c7c479709_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzYtMy0xLTEtNDg1MDY_69cee13a-b5e5-4614-ae9c-05c69747ed3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i243d57116a1a4a2abd6f7b0ba194d8ba_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzYtNS0xLTEtNDg1MDY_9f84a2a8-ef18-4b90-9518-a5ac6389ed2c">5,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c70318515a54462aad17c07ab4595b2_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzYtNy0xLTEtNDg1MDY_a188c4bd-c3b7-4802-9b7f-c8f7766564e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13f16a403b294350a327194d8765e8ef_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzgtMS0xLTEtNDYwMTM_99ffb22b-baf2-4303-aaa8-82451d9d1395">115,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie065f8ba75da42ef8bfcb4016909b6aa_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzgtMy0xLTEtNDYwMTM_bf253dc3-e4a8-4311-9dad-0f6402b2092d">71,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa8e2576d88e4d9f819b34c985d539dd_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzgtNS0xLTEtNDYwMTM_5d73408a-86d3-4c3c-9f26-e7d75fde10f5">44,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1f7ed33632142769f453e0680a04d95_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzgtNy0xLTEtNDYwMTM_ca3b4265-4a36-4fee-88be-199fb7d18e0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability for exit fee</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07f3ef040004928a2a337f7a98fc44c_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzExLTEtMS0xLTQ2MDEz_91d40288-1504-46a8-9dd7-683ccfa6dbd5">698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc4e7bf5193a4086bed2f7af56d70ed0_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzExLTMtMS0xLTQ2MDEz_c632fb27-a3b3-456b-8a16-bcd11f94c797">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i390e968f8ffa426689dcafbbec33f877_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzExLTUtMS0xLTQ2MDEz_b23918b9-862d-4fbc-8f49-f88aad479b74">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bc52b266a974dc1bf42493dfd520bfe_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzExLTctMS0xLTQ2MDEz_498ed823-cc67-4442-9db1-7259864ff5aa">698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13f16a403b294350a327194d8765e8ef_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzEyLTEtMS0xLTQ2MDEz_39ed4a2b-edd6-4d3f-b629-4b39088aa41a">698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie065f8ba75da42ef8bfcb4016909b6aa_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzEyLTMtMS0xLTQ2MDEz_7a9c1606-760f-49b1-8246-3394853339d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa8e2576d88e4d9f819b34c985d539dd_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzEyLTUtMS0xLTQ2MDEz_1344f907-c34c-409a-8b2f-532b831427a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1f7ed33632142769f453e0680a04d95_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzEyLTctMS0xLTQ2MDEz_9fb1804f-8bfe-4945-a760-222464edfd11">698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where quoted prices are available in an active market, securities are classified as Level 1. We classify money market funds as Level 1. When quoted market prices are not available for the specific security, we estimate fair value by using benchmark yields, reported trades, broker/dealer quotes and issuer spreads. We classify U.S. government-sponsored agency bonds, U.S. treasury notes, corporate bonds, commercial paper, and asset-backed securities as Level 2. In certain cases, where there is limited activity or less transparency around inputs to valuation, securities or derivative liabilities, such as the 2018 Exit Fee and 2022 Exit Fee, as defined and discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 10. Derivative Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, are classified as Level 3.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts reflected in the balance sheets for cash equivalents, short-term investments, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values at both December&#160;31, 2022 and 2021, due to their short-term nature.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our procedures under the expected credit loss model, including an assessment of unrealized losses in our portfolio, we concluded that any unrealized losses on our marketable securities were not attributable to credit and, therefore, we have <ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90ZXh0cmVnaW9uOjA2NzI0MDE2MzE1MDQwZjlhOTVmNzhlMWZmMGQxYzZiXzMwMDI_95aa3fae-08f7-4c1d-8398-af6bb5015407"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90ZXh0cmVnaW9uOjA2NzI0MDE2MzE1MDQwZjlhOTVmNzhlMWZmMGQxYzZiXzMwMDI_b13e4ea4-ae3e-4ba9-a3d5-0d0ebf6bb5c2">no</ix:nonFraction></ix:nonFraction>t recorded an allowance for credit losses for these securities as of December&#160;31, 2022 and 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Debt</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal amount outstanding under our term loan facilities is subject to a variable interest rate. Therefore, we believe the carrying amount of the term loan facility approximates fair value as of December&#160;31, 2022 and 2021. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9. Borrowings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a description of the Level 2 inputs used to estimate the fair value of the liability.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the deferred royalty obligation related to the sale of future royalties approximates its fair value as of December&#160;31, 2022 and is based on our current estimates of future royalties and commercialization milestones expected to be </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div><ix:continuation id="i274fcc5c710f4870b17b086ce2188d79"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">paid to us by Kyowa Kirin Co., Ltd. ("KKC") over the life of the agreement. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8. Deferred Royalty Obligation Related to the Sale of Future Royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a description of the Level 3 inputs used to estimate the fair value of the liability.</span></ix:continuation></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_1558"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTU4L2ZyYWc6MTY0Y2M3ZDZlZWI5NGZkZTg0NjUzZDY0MjlkMWQ2ZDQvdGV4dHJlZ2lvbjoxNjRjYzdkNmVlYjk0ZmRlODQ2NTNkNjQyOWQxZDZkNF8yMTk5MDIzMjU2MzM3_3b3c8c6c-009a-4430-8178-c4a1d52a2701" continuedAt="i7d981dd1d7d947e893613761dde857c9" escape="true">INVENTORY</ix:nonNumeric></span></div><ix:continuation id="i7d981dd1d7d947e893613761dde857c9" continuedAt="i60affa2e18b84ea1ba67265c2f853686"><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We began capitalizing inventory during the fourth quarter of 2021, at which time our intent to commercialize IBSRELA was established and we commenced preparation for the commercial launch of IBSRELA. Inventory as of December&#160;31, 2021 was not material. <ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTU4L2ZyYWc6MTY0Y2M3ZDZlZWI5NGZkZTg0NjUzZDY0MjlkMWQ2ZDQvdGV4dHJlZ2lvbjoxNjRjYzdkNmVlYjk0ZmRlODQ2NTNkNjQyOWQxZDZkNF84Nzk2MDkzMDIzMzE4_c58b8d53-20c0-450b-a644-6eea945955c1" continuedAt="i8bbffd2fe5a4472da7123c22131e9f11" escape="true"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTU4L2ZyYWc6MTY0Y2M3ZDZlZWI5NGZkZTg0NjUzZDY0MjlkMWQ2ZDQvdGV4dHJlZ2lvbjoxNjRjYzdkNmVlYjk0ZmRlODQ2NTNkNjQyOWQxZDZkNF8yMTk5MDIzMjU2MzM4_48fcbe0e-7eff-4194-aba9-4945a745c5ef" continuedAt="i70fed8496c8e4c7a86e2c902734737ea" escape="true">Inventory as of December&#160;31, 2022 consisted of the following (in thousands):</ix:nonNumeric></ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><ix:continuation id="i8bbffd2fe5a4472da7123c22131e9f11"><ix:continuation id="i70fed8496c8e4c7a86e2c902734737ea"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTU4L2ZyYWc6MTY0Y2M3ZDZlZWI5NGZkZTg0NjUzZDY0MjlkMWQ2ZDQvdGFibGU6NTRlMTIwMzBhMGY5NDA3Mzg2OGE4ZDRmOGEwY2E5ZTUvdGFibGVyYW5nZTo1NGUxMjAzMGEwZjk0MDczODY4YThkNGY4YTBjYTllNV8xLTItMS0xLTUwMTE0_5495e3e7-5372-4735-9fd1-1df14b8a394b">22,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTU4L2ZyYWc6MTY0Y2M3ZDZlZWI5NGZkZTg0NjUzZDY0MjlkMWQ2ZDQvdGFibGU6NTRlMTIwMzBhMGY5NDA3Mzg2OGE4ZDRmOGEwY2E5ZTUvdGFibGVyYW5nZTo1NGUxMjAzMGEwZjk0MDczODY4YThkNGY4YTBjYTllNV8yLTItMS0xLTUwMTE0_d46889ea-25a7-4478-9a8e-e70bb2caa258">5,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTU4L2ZyYWc6MTY0Y2M3ZDZlZWI5NGZkZTg0NjUzZDY0MjlkMWQ2ZDQvdGFibGU6NTRlMTIwMzBhMGY5NDA3Mzg2OGE4ZDRmOGEwY2E5ZTUvdGFibGVyYW5nZTo1NGUxMjAzMGEwZjk0MDczODY4YThkNGY4YTBjYTllNV8zLTItMS0xLTUwMTE0_9a4c85b3-983e-4c2d-ab32-ece7ac1720c8">723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTU4L2ZyYWc6MTY0Y2M3ZDZlZWI5NGZkZTg0NjUzZDY0MjlkMWQ2ZDQvdGFibGU6NTRlMTIwMzBhMGY5NDA3Mzg2OGE4ZDRmOGEwY2E5ZTUvdGFibGVyYW5nZTo1NGUxMjAzMGEwZjk0MDczODY4YThkNGY4YTBjYTllNV80LTItMS0xLTUwMTE0_db58c182-4722-4987-bfc0-cc9444b008f9">28,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTU4L2ZyYWc6MTY0Y2M3ZDZlZWI5NGZkZTg0NjUzZDY0MjlkMWQ2ZDQvdGFibGU6NTRlMTIwMzBhMGY5NDA3Mzg2OGE4ZDRmOGEwY2E5ZTUvdGFibGVyYW5nZTo1NGUxMjAzMGEwZjk0MDczODY4YThkNGY4YTBjYTllNV82LTItMS0xLTUwMTE0_1f941a14-0263-4430-8bfd-2692ad54b057">3,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory, non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTU4L2ZyYWc6MTY0Y2M3ZDZlZWI5NGZkZTg0NjUzZDY0MjlkMWQ2ZDQvdGFibGU6NTRlMTIwMzBhMGY5NDA3Mzg2OGE4ZDRmOGEwY2E5ZTUvdGFibGVyYW5nZTo1NGUxMjAzMGEwZjk0MDczODY4YThkNGY4YTBjYTllNV83LTItMS0xLTUwMTE0_047bbf71-30cd-4629-b24a-ab918ad3bce8">25,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTU4L2ZyYWc6MTY0Y2M3ZDZlZWI5NGZkZTg0NjUzZDY0MjlkMWQ2ZDQvdGFibGU6NTRlMTIwMzBhMGY5NDA3Mzg2OGE4ZDRmOGEwY2E5ZTUvdGFibGVyYW5nZTo1NGUxMjAzMGEwZjk0MDczODY4YThkNGY4YTBjYTllNV84LTItMS0xLTUwMTE0_2e71ce33-481e-4d25-9b8d-b86b9a7baaf5">28,346</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i60affa2e18b84ea1ba67265c2f853686">Prepaid commercial manufacturing of $<ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-5" name="ardx:PrepaidCommercialManufacturingCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTU4L2ZyYWc6MTY0Y2M3ZDZlZWI5NGZkZTg0NjUzZDY0MjlkMWQ2ZDQvdGV4dHJlZ2lvbjoxNjRjYzdkNmVlYjk0ZmRlODQ2NTNkNjQyOWQxZDZkNF81NDk3NTU4MTQ2MzE_db3ae23a-b280-40bc-b560-49942620566c">13.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-5" name="ardx:PrepaidCommercialManufacturingCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTU4L2ZyYWc6MTY0Y2M3ZDZlZWI5NGZkZTg0NjUzZDY0MjlkMWQ2ZDQvdGV4dHJlZ2lvbjoxNjRjYzdkNmVlYjk0ZmRlODQ2NTNkNjQyOWQxZDZkNF81NDk3NTU4MTQ2Mzc_edfb73ca-af98-4e6b-bb9e-a5a47434f72f">9.4</ix:nonFraction>&#160;million as of December&#160;31, 2022 and 2021, respectively, consisted of prepayments to third party contract manufacturing organizations for the manufacture of IBSRELA for production orders which we expect work to commence within the next 12 months.</ix:continuation> </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_1564"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGV4dHJlZ2lvbjo1ZDQ1MmY3OWRiNWM0Zjc4YTQyMGZhMjI0MWQ4YmRiZF8yMTk5MDIzMjU2NTAy_d11e92bc-2fe9-4ea8-8227-d6274f5535fc" continuedAt="i68644102a842427795674e325b9735b7" escape="true">PRODUCT REVENUE, NET</ix:nonNumeric></span></div><ix:continuation id="i68644102a842427795674e325b9735b7"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received approval from the FDA in September 2019 to market IBSRELA in the U.S. We began selling IBSRELA in the U.S. in March 2022. We recorded net revenue for IBSRELA of $<ix:nonFraction unitRef="usd" contextRef="i0713ee81cc9747f9ae72ce305219dcfb_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGV4dHJlZ2lvbjo1ZDQ1MmY3OWRiNWM0Zjc4YTQyMGZhMjI0MWQ4YmRiZF81NDk3NTU4MTQ3MjU_98534e3f-422f-4e29-a651-97078101b767">15.6</ix:nonFraction>&#160;million during the twelve months ended December&#160;31, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales to AmerisourceBergen Drug Corporation, Cardinal Health, and McKesson Corporation made up <ix:nonFraction unitRef="number" contextRef="i71d12a4b8c5d41dd913f71f3f0c6a002_D20220101-20221231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGV4dHJlZ2lvbjo1ZDQ1MmY3OWRiNWM0Zjc4YTQyMGZhMjI0MWQ4YmRiZF81NDk3NTU4MTQ4MDQ_61ddbae7-e3dd-49a1-a263-7f2b179e127a">26.8</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i2cd807982655470294b4c867e9790f9f_D20220101-20221231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGV4dHJlZ2lvbjo1ZDQ1MmY3OWRiNWM0Zjc4YTQyMGZhMjI0MWQ4YmRiZF81NDk3NTU4MTQ4MDg_63d92a8c-cbd4-4a8b-bb6a-efaec1928a1b">23.1</ix:nonFraction>%, and <ix:nonFraction unitRef="number" contextRef="ia9f614394a884bf3935e5190b6e13cbc_D20220101-20221231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGV4dHJlZ2lvbjo1ZDQ1MmY3OWRiNWM0Zjc4YTQyMGZhMjI0MWQ4YmRiZF81NDk3NTU4MTQ4MTI_b8a15959-ce6b-49c8-be62-5d750eaeda3f">21.6</ix:nonFraction>%, respectively, of our gross product revenue during the twelve months ended December&#160;31, 2022.</span></div><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="ardx:ScheduleOfGrossToNetSalesAccrualsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGV4dHJlZ2lvbjo1ZDQ1MmY3OWRiNWM0Zjc4YTQyMGZhMjI0MWQ4YmRiZF8yMTk5MDIzMjU2NTAz_fe801b3a-545d-4172-ba90-a2a2043c7926" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Discounts and Chargebacks</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Rebates, Wholesaler and GPO Fees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Copay and Returns</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2edca0d9c9d04eb4946163e30a07c874_I20211231" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesAccruals" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGFibGU6ZGE0ZWYwNDY4YjYxNDg1YmI3MWMwMzYxZTMxN2UxYzcvdGFibGVyYW5nZTpkYTRlZjA0NjhiNjE0ODViYjcxYzAzNjFlMzE3ZTFjN18xLTEtMS0xLTUwMTYz_21cef62b-39d4-4bd8-9007-0fd341911cb9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4364f4f8eb794e579c0d74bdcfc9a74d_I20211231" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesAccruals" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGFibGU6ZGE0ZWYwNDY4YjYxNDg1YmI3MWMwMzYxZTMxN2UxYzcvdGFibGVyYW5nZTpkYTRlZjA0NjhiNjE0ODViYjcxYzAzNjFlMzE3ZTFjN18xLTMtMS0xLTUwMTYz_ef9ed1f6-6313-455c-9401-8b6184f87a9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i211614897cb84b21a3db4459c42a8128_I20211231" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesAccruals" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGFibGU6ZGE0ZWYwNDY4YjYxNDg1YmI3MWMwMzYxZTMxN2UxYzcvdGFibGVyYW5nZTpkYTRlZjA0NjhiNjE0ODViYjcxYzAzNjFlMzE3ZTFjN18xLTUtMS0xLTUwMTYz_cc525eba-c293-42b0-99d5-1477c340fef6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesAccruals" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGFibGU6ZGE0ZWYwNDY4YjYxNDg1YmI3MWMwMzYxZTMxN2UxYzcvdGFibGVyYW5nZTpkYTRlZjA0NjhiNjE0ODViYjcxYzAzNjFlMzE3ZTFjN18xLTctMS0xLTUwMTYz_031d5298-a6f9-47f0-b93a-050c71cf0291">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to 2022 sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbd146d95630481b89a9e53d21e7bfd0_D20220101-20221231" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGFibGU6ZGE0ZWYwNDY4YjYxNDg1YmI3MWMwMzYxZTMxN2UxYzcvdGFibGVyYW5nZTpkYTRlZjA0NjhiNjE0ODViYjcxYzAzNjFlMzE3ZTFjN18yLTEtMS0xLTUwMTYz_c5355d51-b408-4718-b366-336539952994">825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i378e9c4f2d8d414fb7b08c9fccc9c3c1_D20220101-20221231" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGFibGU6ZGE0ZWYwNDY4YjYxNDg1YmI3MWMwMzYxZTMxN2UxYzcvdGFibGVyYW5nZTpkYTRlZjA0NjhiNjE0ODViYjcxYzAzNjFlMzE3ZTFjN18yLTMtMS0xLTUwMTYz_3ce1417a-eda5-4cf0-be58-7df29542d6dc">2,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i375a2ae60c4f4ac8bbe9ccc543f7a1c8_D20220101-20221231" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGFibGU6ZGE0ZWYwNDY4YjYxNDg1YmI3MWMwMzYxZTMxN2UxYzcvdGFibGVyYW5nZTpkYTRlZjA0NjhiNjE0ODViYjcxYzAzNjFlMzE3ZTFjN18yLTUtMS0xLTUwMTYz_25b14907-e21d-4427-8fb7-483fe1d1e0b4">2,502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGFibGU6ZGE0ZWYwNDY4YjYxNDg1YmI3MWMwMzYxZTMxN2UxYzcvdGFibGVyYW5nZTpkYTRlZjA0NjhiNjE0ODViYjcxYzAzNjFlMzE3ZTFjN18yLTctMS0xLTUwMTYz_be5e7bd8-6c1c-4fe5-acc1-cafc248986a7">6,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits/deductions issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbd146d95630481b89a9e53d21e7bfd0_D20220101-20221231" decimals="-3" sign="-" name="ardx:ContractWithCustomerGrossToCreditsOrDeductionsIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGFibGU6ZGE0ZWYwNDY4YjYxNDg1YmI3MWMwMzYxZTMxN2UxYzcvdGFibGVyYW5nZTpkYTRlZjA0NjhiNjE0ODViYjcxYzAzNjFlMzE3ZTFjN18zLTEtMS0xLTUwMTYz_c695f651-7184-4af5-be88-85922d072cc4">683</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i378e9c4f2d8d414fb7b08c9fccc9c3c1_D20220101-20221231" decimals="-3" sign="-" name="ardx:ContractWithCustomerGrossToCreditsOrDeductionsIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGFibGU6ZGE0ZWYwNDY4YjYxNDg1YmI3MWMwMzYxZTMxN2UxYzcvdGFibGVyYW5nZTpkYTRlZjA0NjhiNjE0ODViYjcxYzAzNjFlMzE3ZTFjN18zLTMtMS0xLTUwMTYz_3412b431-12c0-426b-88c5-45ef3273e422">1,277</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i375a2ae60c4f4ac8bbe9ccc543f7a1c8_D20220101-20221231" decimals="-3" sign="-" name="ardx:ContractWithCustomerGrossToCreditsOrDeductionsIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGFibGU6ZGE0ZWYwNDY4YjYxNDg1YmI3MWMwMzYxZTMxN2UxYzcvdGFibGVyYW5nZTpkYTRlZjA0NjhiNjE0ODViYjcxYzAzNjFlMzE3ZTFjN18zLTUtMS0xLTUwMTYz_8f06f1e1-e2d2-4150-a455-ad334f63def1">1,244</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" sign="-" name="ardx:ContractWithCustomerGrossToCreditsOrDeductionsIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGFibGU6ZGE0ZWYwNDY4YjYxNDg1YmI3MWMwMzYxZTMxN2UxYzcvdGFibGVyYW5nZTpkYTRlZjA0NjhiNjE0ODViYjcxYzAzNjFlMzE3ZTFjN18zLTctMS0xLTUwMTYz_c55a79d5-02d3-458c-9357-c9b33d214577">3,204</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4459a35d21754ee897db3e8dbb29305d_I20221231" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesAccruals" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGFibGU6ZGE0ZWYwNDY4YjYxNDg1YmI3MWMwMzYxZTMxN2UxYzcvdGFibGVyYW5nZTpkYTRlZjA0NjhiNjE0ODViYjcxYzAzNjFlMzE3ZTFjN180LTEtMS0xLTUwMTYz_1e86f0d8-134f-49de-a7b4-c36b6771102d">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2880e66b0644122b083edc9fd38c11d_I20221231" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesAccruals" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGFibGU6ZGE0ZWYwNDY4YjYxNDg1YmI3MWMwMzYxZTMxN2UxYzcvdGFibGVyYW5nZTpkYTRlZjA0NjhiNjE0ODViYjcxYzAzNjFlMzE3ZTFjN180LTMtMS0xLTUwMTYz_c2c21d7c-74e7-4401-9842-61fe4aae07e8">1,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855b02ed9cf247be9e99838bb95cb4ba_I20221231" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesAccruals" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGFibGU6ZGE0ZWYwNDY4YjYxNDg1YmI3MWMwMzYxZTMxN2UxYzcvdGFibGVyYW5nZTpkYTRlZjA0NjhiNjE0ODViYjcxYzAzNjFlMzE3ZTFjN180LTUtMS0xLTUwMTYz_a7c7b5d7-f56e-4ab8-a912-0c5733057326">1,258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesAccruals" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGFibGU6ZGE0ZWYwNDY4YjYxNDg1YmI3MWMwMzYxZTMxN2UxYzcvdGFibGVyYW5nZTpkYTRlZjA0NjhiNjE0ODViYjcxYzAzNjFlMzE3ZTFjN180LTctMS0xLTUwMTYz_4a7bce54-65d7-4061-88ea-a09bdff75f68">2,844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="INF" name="ardx:ContractWithCustomerProductSalesGrossToNetAccruals" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGV4dHJlZ2lvbjo1ZDQ1MmY3OWRiNWM0Zjc4YTQyMGZhMjI0MWQ4YmRiZF81NDk3NTU4MTQ4MTY_0aa4aeff-4a6a-4356-803f-3387afb39d20"><ix:nonFraction unitRef="usd" contextRef="ifee111286a5d4c6e8104da9cafffda38_D20200101-20201231" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGV4dHJlZ2lvbjo1ZDQ1MmY3OWRiNWM0Zjc4YTQyMGZhMjI0MWQ4YmRiZF81NDk3NTU4MTQ4MTY_27dd7215-b769-4ef9-b9d9-c86fe6f9d74f"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="INF" name="ardx:ContractWithCustomerProductSalesGrossToNetAccruals" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGV4dHJlZ2lvbjo1ZDQ1MmY3OWRiNWM0Zjc4YTQyMGZhMjI0MWQ4YmRiZF81NDk3NTU4MTQ4MTY_b2a16909-1ec3-4a48-88d7-602d315e02f1"><ix:nonFraction unitRef="usd" contextRef="if6d0767c281240d4900cc0d8b9580230_D20210101-20211231" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGV4dHJlZ2lvbjo1ZDQ1MmY3OWRiNWM0Zjc4YTQyMGZhMjI0MWQ4YmRiZF81NDk3NTU4MTQ4MTY_c76a64ef-54bf-452d-882a-46a851dcda2d">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> product sales or gross-to-net accruals during the twelve months ended December&#160;31, 2021 or 2020.</span></div></ix:continuation><div id="i8c6ecca27b7b4659bf1d61cfb55de996_112"></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzEzNzcz_f8dae5d5-79f3-4491-b29a-df5b77307391" continuedAt="i320799c3679148bfa03296ff4a2385e4" escape="true">COLLABORATION AND LICENSING AGREEMENTS</ix:nonNumeric></span></div><ix:continuation id="i320799c3679148bfa03296ff4a2385e4" continuedAt="if34ec71151f44c89b251d62a62f0d043"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kyowa Kirin Co., Ltd. ("KKC")</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 KKC Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we entered into a research collaboration and option agreement with KKC ("2019 KKC Agreement&#8221;), to undergo research to identify two preclinical study-ready compounds for designation as development compounds, with one compound inhibiting the first undisclosed target (&#8220;Program 1&#8221;) and a second inhibiting the second undisclosed target (&#8220;Program </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><ix:continuation id="if34ec71151f44c89b251d62a62f0d043" continuedAt="ie8d701ea302c4a16bdbbd7c2fef883fc"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2&#8221;). Pursuant to the 2019 KKC Agreement, upon completion of the research and designation by the research steering committee of one or more development candidates (&#8220;DCs&#8221;), KKC has the right to execute <ix:nonFraction unitRef="item" contextRef="i955167e463ef48678bbc1d03c4f4d412_D20191101-20191130" decimals="INF" name="ardx:NumberOfSeparateCollaborativeAgreements" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzY1OA_35e80f2e-cde1-4c2e-89f8-c09570ed6b0a">one</ix:nonFraction> or more separate collaborative agreements relating to the development and commercialization of one or both DCs in certain specified territories.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2019 KKC Agreement, KKC paid us a non-refundable, non-creditable upfront fee of $<ix:nonFraction unitRef="usd" contextRef="i91c2203d38fd405d99bc3c88353bce51_D20191101-20191130" decimals="-5" name="ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTgyOTcxOQ_fff60f5c-6ad6-4001-a639-b0ed67210c86">10.0</ix:nonFraction> million, in two installments as follows: the first installment of $<ix:nonFraction unitRef="usd" contextRef="i91c2203d38fd405d99bc3c88353bce51_D20191101-20191130" decimals="-5" name="ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTgyOTcyNg_18443fba-2df3-40ac-8e4b-17b25dedcc0e">5.0</ix:nonFraction> million within <ix:nonNumeric contextRef="i91c2203d38fd405d99bc3c88353bce51_D20191101-20191130" name="ardx:TermOfPaymentOfLicenseFeeFirstInstallment" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2Xzk4Nw_7f083c79-1467-4736-aeb7-3733ab3369a2">30</ix:nonNumeric> days of November 11, 2019 ("Effective Date"), and the second installment of $<ix:nonFraction unitRef="usd" contextRef="i91c2203d38fd405d99bc3c88353bce51_D20191101-20191130" decimals="-5" name="ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTgyOTczMA_77721edb-b7c4-4462-aa7e-88de361446c6">5.0</ix:nonFraction> million on the first anniversary of the Effective Date. The original term of the 2019 KKC Agreement commenced on the Effective Date and was to end on the earliest of: (i) <ix:nonNumeric contextRef="i91c2203d38fd405d99bc3c88353bce51_D20191101-20191130" name="ardx:TermOfAgreement" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzEzMDY_a861abd3-bad3-46ed-9120-70a3990aef58">two years</ix:nonNumeric> following the Effective Date, (ii) the nomination of a program DC for both programs, (iii) the nomination of one program DC and the decision by the parties to cease research for the other program, or (iv) the decision by the parties to cease research for both programs. We entered into <ix:nonFraction unitRef="segment" contextRef="i91c2203d38fd405d99bc3c88353bce51_D20191101-20191130" decimals="INF" name="ardx:CollaborationAndLicensingAgreementsNumberOfAmendments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2Xzc2OTY1ODE0MTY4ODA_ecbea56e-d7d4-4b78-bbe1-7964e4e748ba">three</ix:nonFraction> amendments to the 2019 KKC Agreement, which have resulted in the extension of the original term. Under the third amendment to the 2019 KKC Agreement entered into on June 28, 2022, the 2019 KKC Agreement ended on February 28, 2023. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assessed the 2019 KKC Agreement in accordance with ASC 606 and concluded that the contract&#8217;s counterparty, KKC, is a customer. We also considered the modification guidance prescribed in ASC 606 and concluded that the 2019 KKC Agreement should be accounted for as a separate contract from the 2017 KKC Agreement, as defined and discussed below.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified various promises in the 2019 KKC Agreement, including the grant of an initial research license, the Program 1 research, the Program 2 research, the right to obtain certain development and commercialization rights with Program 1 in certain territories and the right to obtain development and commercialization rights with Program 2 in certain territories, and participation in a joint steering committee&#160;(&#8220;JSC&#8221;) and determined that KKC could not benefit from either of the research programs without the research license and participation in the JSC. As such, the combined license, research programs and participation in the JSC were deemed to be the highest level of goods and services that can be deemed distinct for each of the Program 1 research and Program 2 research. We concluded that the options to obtain additional development and commercialization rights that are exercisable by KKC under certain circumstances are not performance obligations of the contract at inception because the option fees reflect the standalone selling price of the options, and therefore, the options are not considered to be material rights.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the outset of the 2019 KKC Agreement, we determined that the initial transaction price was $<ix:nonFraction unitRef="usd" contextRef="i91c2203d38fd405d99bc3c88353bce51_D20191101-20191130" decimals="-5" name="ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTgyOTczOQ_fff60f5c-6ad6-4001-a639-b0ed67210c86">10.0</ix:nonFraction> million and that revenue associated with the combined performance obligations should be recognized as services are provided using the input method. Since transfer of control occurs over time, in management&#8217;s judgment this input method is the best measure of progress towards satisfying the performance obligations and reflects a faithful depiction of the transfer of goods and services. Revenue was recognized over the Program 1 and Program 2 research periods which concluded in 2021. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022 and 2021, we recognized <ix:nonFraction unitRef="usd" contextRef="ia5096f6f9abe4dccb2dab386d07f22b0_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzM5Mzg_6e5edc43-e0a0-4b40-9a2e-e8c36bb9ea41">zero</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ied48f951c2e54c4c9458741287f35022_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzM5NDU_77e24472-1170-4e68-8050-cf94932cbc6c">4.2</ix:nonFraction> million, respectively, as revenue under the 2019 KKC Agreement in the statement of operations and comprehensive loss. The transaction price had been fully allocated to revenue as of December&#160;31, 2021 and there was <ix:nonFraction unitRef="usd" contextRef="icfd7890f2ab641b689a46d3387cd65f5_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTgzMDE2Ng_d8dd0d5e-a393-42e3-834f-3c96acf3c15d"><ix:nonFraction unitRef="usd" contextRef="i317cad6de7604d25be88b176cb33baec_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTgzMDE2Ng_fd102e7a-e557-43d5-891e-ef510d815225">no</ix:nonFraction></ix:nonFraction> associated deferred revenue presented on the balance sheet as of December&#160;31, 2022 or 2021. As of December&#160;31, 2022 and 2021, we had no material future obligations under the 2019 KKC Agreement. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 KKC Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, we entered into an exclusive license agreement with KKC (&#8220;2017 KKC Agreement&#8221;), under which we granted KKC an exclusive license to develop and commercialize certain NHE3 inhibitors including tenapanor in Japan for the treatment of cardiorenal diseases and conditions, excluding cancer. We retained the rights to tenapanor outside of Japan, and also retained the rights to tenapanor in Japan for indications other than those stated above. Pursuant to the 2017 KKC Agreement, KKC is responsible for all costs and expenses incurred in the development and commercialization of tenapanor for all licensed indications in Japan. We are responsible for supplying the tenapanor drug substance for KKC&#8217;s use in development and commercialization throughout the term of the 2017 KKC Agreement, provided that KKC may exercise an option to manufacture the tenapanor drug substance under certain conditions. In October 2022, we entered into a Commercial Supply Agreement with KKC to further define the obligations of the parties with respect to the commercial supply of tenapanor drug substance (&#8220;2022 KKC Supply Agreement&#8221;). As detailed below under the heading &#8220;Deferred revenue&#8217; we have received advanced payments from KKC for the manufacturing of tenapanor drug substance that will be used to satisfy KKC needs. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assessed these arrangements in accordance with Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers (Topic 606) and related amendments (&#8220;ASC 606&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and concluded that the contract counterparty, KKC, is a customer. Under the terms of the 2017 KKC Agreement, we received $<ix:nonFraction unitRef="usd" contextRef="i7f143c1e0eb144d6b655d94ab37c1a53_D20171101-20171130" decimals="-5" name="ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTgzMTU4OQ_1fccd503-9b7b-459e-b101-952e69f4aa36">30.0</ix:nonFraction> million in up-front license fees, which was recognized as revenue when the agreement was executed. Based on our assessment, management determined that the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><ix:continuation id="ie8d701ea302c4a16bdbbd7c2fef883fc" continuedAt="ib5237682a9e84223a03c2f7c617d582c"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license and the manufacturing supply services were the material performance obligations at the inception of the 2017 KKC Agreement and, as such, each of the performance obligations is distinct. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2017 KKC Agreement, KKC paid us an up-front license fee of $<ix:nonFraction unitRef="usd" contextRef="i7f143c1e0eb144d6b655d94ab37c1a53_D20171101-20171130" decimals="-5" name="ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTgzMjQwMQ_1fccd503-9b7b-459e-b101-952e69f4aa36">30.0</ix:nonFraction> million,. We may be entitled to receive up to $<ix:nonFraction unitRef="usd" contextRef="iff763b0fc4f84d4dac40730c49cc1731_I20171130" decimals="-5" name="ardx:CollaborativeArrangementPotentialDevelopmentMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTgzMjQwOA_2f212d43-7039-47e6-919e-0b8e6d10b6ec">55.0</ix:nonFraction> million in total development and regulatory milestones, of which $<ix:nonFraction unitRef="usd" contextRef="i687d24ba9ed84bf19bb4b4b49a494d08_D20171101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzcxOTI_42d24670-6ef1-4f08-b05c-c1f8e41b0d49">20.0</ix:nonFraction> million has been received and recognized as revenue as of December&#160;31, 2022. We may also be eligible to receive approximately &#165;<ix:nonFraction unitRef="jpy" contextRef="ife00f72d231640e4becd88f58e11171e_I20221231" decimals="-8" name="ardx:CollaborativeArrangementPotentialCommercializationMilestones" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTgzMjQyOA_13be76eb-3653-4101-9e2a-bf638733a2ef">8.5</ix:nonFraction>&#160;billion for commercialization milestones, or approximately $<ix:nonFraction unitRef="usd" contextRef="ife00f72d231640e4becd88f58e11171e_I20221231" decimals="-5" name="ardx:CollaborativeArrangementPotentialCommercializationMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzcyODk_e59eea0b-6caf-484f-9609-0ac5fc733b27">64.6</ix:nonFraction> million at the currency exchange rate on December&#160;31, 2022, as well as reimbursement of costs plus a reasonable overhead for the supply of product and royalties on net sales throughout the term of the agreement. As discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8. Deferred Royalty Obligation Related to the Sale of Future Royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the future royalties and commercial milestone payments we may receive under the 2017 KKC Agreement will be remitted to HealthCare Royalty Partners IV, L.P. pursuant to a Royalty and Sales Milestone Interest Acquisition Agreement. The variable consideration related to the remaining milestone payments was fully constrained at December&#160;31, 2022 and 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, we entered into a second amendment to the 2017 KKC Agreement ("2022 Amendment"). Under the terms of the 2022 Amendment, we and KKC have agreed to a reduction in the royalty rate payable to us by KKC upon net sales of tenapanor for hyperphosphatemia in Japan. The royalty rate will be reduced from the high teens to low double digits for a two-year period of time following the first commercial sale in Japan, and then to mid-single digits for the remainder of the royalty term. As discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8. Deferred Royalty Obligation Related to the Sale of Future Royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the future commercial milestones and royalties we may receive under the 2017 KKC Agreement will be remitted to HealthCare Royalty Partners IV, L.P. pursuant to a Royalty and Sales Milestone Interest Acquisition Agreement. As consideration for the reduction in the royalty rate, KKC agreed to pay us up to an additional $<ix:nonFraction unitRef="usd" contextRef="if2637e6a1a82402793001d3d295bbbcd_I20220430" decimals="-5" name="ardx:CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2Xzc2OTY1ODE0MjI1NTA_0b3870b7-fe37-4a05-bd8c-ab6ee37df0de">40.0</ix:nonFraction> million payable in <ix:nonFraction unitRef="payment_tranche" contextRef="if2637e6a1a82402793001d3d295bbbcd_I20220430" decimals="INF" name="ardx:CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzQ0OTQ0_abefcc74-3567-452d-8da1-84e585452dbc">two</ix:nonFraction> tranches, with the first payment due following KKC's filing with the Japanese Ministry of Health, Labour and Welfare of its application for marketing approval for tenapanor and the second payment due following KKC&#8217;s receipt of regulatory approval to market tenapanor for hyperphosphatemia in Japan. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, we announced that KKC submitted an NDA to the Japanese Ministry of Health, Labour and Welfare for tenapanor for the improvement of hyperphosphatemia in adult patients with CKD on dialysis, which resulted in payment to us from KKC for an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i59072502f7a54137b0895e14bb4f6df8_I20221031" decimals="-5" name="ardx:RevenueRemainingPerformanceObligationVariableConsiderationAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzQ0OTQ4_b5a66aff-cb85-4d0b-906e-2170d81a8eaf">35.0</ix:nonFraction> million for milestone payments and payments under the 2022 Amendment. We received these payments during the fourth quarter of 2022 and recorded them as licensing revenue on our statement of operations and comprehensive loss. The remaining variable consideration related to the reduction in the royalty rate was fully constrained at December&#160;31, 2022. For the year ended December&#160;31, 2021, $<ix:nonFraction unitRef="usd" contextRef="i4dd8313c3e094ef89785a59b13d01eb7_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTg1NDM4MQ_0fc1244b-3d10-48c4-9984-f78e71accb48">5.0</ix:nonFraction> million of licensing revenue was recorded upon the initiation of phase 3 clinical studies by KKC in Japan to evaluate tenapanor for hyperphosphatemia.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022 and 2021, $<ix:nonFraction unitRef="usd" contextRef="i60b13327723642e6932c3f852855047d_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2Xzc2OTE_d00ecf86-4b7b-4b51-92ed-900fa9a368fb">1.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id10493b7130846e6b2a4742b479a65fe_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2Xzc2OTg_06720236-7375-4ded-bd88-528b0a6662e5">0.9</ix:nonFraction> million, respectively, of product supply revenue was recorded for manufacturing supply of tenapanor and other materials to KKC for product development and clinical trials in Japan, in accordance with our agreement with the 2017 KKC Agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022 and 2021, $<ix:nonFraction unitRef="usd" contextRef="i715636a1b5ae4b288a29b92c2f3a54b3_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2Xzc5OTA_93b889db-f1f2-413e-8502-6a646ae68cbe">35.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4dd8313c3e094ef89785a59b13d01eb7_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2Xzc2OTY1ODE0MjcyNzQ_0fc1244b-3d10-48c4-9984-f78e71accb48">5.0</ix:nonFraction> million, respectively, of licensing revenue was recorded. The 2022 licensing revenue was earned upon KKC's submission of an NDA to the Japanese Ministry of Health, Labour and Welfare for tenapanor for the improvement of hyperphosphatemia in adult patients with CKD on dialysis. The 2021 licensing revenue was recorded upon the initiation of Phase 3 clinical studies by KKC in Japan to evaluate tenapanor for hyperphosphatemia.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. ("Fosun Pharma")</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, we entered into an exclusive license agreement with Fosun Pharma ("Fosun Agreement") for the development, commercialization and distribution of tenapanor in China for both hyperphosphatemia and IBS-C. We assessed these arrangements in accordance with ASC 606 and concluded that the contract counterparty, Fosun Pharma, is a customer. Under the terms of the Fosun Agreement, we received $<ix:nonFraction unitRef="usd" contextRef="i274489be58ee4be5a06cb71683dc70e0_D20171201-20171231" decimals="-5" name="us-gaap:ProceedsFromLicenseFeesReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTgzMzQxMg_39bda077-68ef-43cb-a507-5a555f8cee0e">12.0</ix:nonFraction> million in up-front license fees which was recognized as revenue when the agreement was executed. Based on our assessment, we determined that the license and the manufacturing supply services represented the material performance obligations at the inception of the agreement and, as such, each of the performance obligations are distinct.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be entitled to additional development and commercialization milestones of up to $<ix:nonFraction unitRef="usd" contextRef="i96f5a69e2c1547719e984c8ba3c41ff3_D20220101-20221231" decimals="-5" name="ardx:CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTgzMzQ4Mg_fa058cde-deee-4af6-bf89-7ee0a8a578de">110.0</ix:nonFraction> million, as well as reimbursement of cost plus a reasonable overhead for the supply of product and tiered royalties on net sales ranging from the mid-teens to <ix:nonFraction unitRef="number" contextRef="i96f5a69e2c1547719e984c8ba3c41ff3_D20220101-20221231" decimals="INF" name="ardx:ThresholdPercentageOfSalesForTieredRoyalties" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTgzMzQ4OQ_68eab14d-fee0-4df9-b670-7af175e21c70">20</ix:nonFraction>%. The variable consideration related to the remaining development milestone payments was fully constrained at December&#160;31, 2022 and 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded <ix:nonFraction unitRef="usd" contextRef="i99e3d63e61664f6bbfac5c19cb4294e3_D20210101-20211231" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTgzMzU3OQ_07aa2c1c-2b29-4253-9f45-bd94b63d5ad0"><ix:nonFraction unitRef="usd" contextRef="iff2fbe5c1eb741e185c1d68735dd7502_D20220101-20221231" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTgzMzU3OQ_eba602be-f669-4303-9139-078bbd61f8ce">no</ix:nonFraction></ix:nonFraction> revenue related to the Fosun Agreement during the years ended December&#160;31, 2022 and 2021.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><ix:continuation id="ib5237682a9e84223a03c2f7c617d582c" continuedAt="i9b9fbedae57e4130888599e5d81e60d3"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Knight Therapeutics, Inc. ("Knight")</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, we entered into an exclusive license agreement with Knight Therapeutics, Inc., ("Knight Agreement") for the development, commercialization and distribution of tenapanor in Canada for hyperphosphatemia and IBS-C. We assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Knight, is a customer. Based on our assessment, we determined that the license and the manufacturing supply services were the material performance obligations at the inception of the agreement and, as such, each of the performance obligations are distinct.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Knight Agreement, we received a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i7523c9db4f3440e1bbc8ab0589ca11c5_D20180301-20180331" decimals="-5" name="us-gaap:ProceedsFromLicenseFeesReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzEwNTc3_21bdc5b3-1d69-4ded-9501-ea80048e1e51">2.3</ix:nonFraction> million non-refundable, one-time upfront payment in March 2018 and may be eligible to receive additional development and commercialization milestone payments worth up to CAD<ix:nonFraction unitRef="cad" contextRef="if78e3d93318c461da96ac8c6973a6f76_D20220101-20221231" decimals="-5" name="ardx:CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2Xzc2OTY1ODE0MTQyOTc_a0d0c053-11bd-4b1f-ae9e-fb38bb89b998">22.2</ix:nonFraction>, or approximately $<ix:nonFraction unitRef="usd" contextRef="if78e3d93318c461da96ac8c6973a6f76_D20220101-20221231" decimals="-5" name="ardx:CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTgzMzc0Ng_3bd5a307-1ee9-46e9-bcdb-bf2ab3c8b8ff">16.3</ix:nonFraction> million at the currency exchange rate on December&#160;31, 2022. We are also eligible to receive royalties ranging from the mid-single digits to the low twenties throughout the term of the agreement, and a transfer price for manufacturing services.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The variable consideration related to the remaining development milestone payments were fully constrained at December&#160;31, 2022 and 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022 and 2021, $<ix:nonFraction unitRef="usd" contextRef="ieba6fa1b17514fa99298840f1171592e_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzExMjA1_43889a03-9a0e-4c21-a964-0ff7f1ab2002">31</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="i83f16a4b0497447dae41222920314fae_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzExMjEy_9d6d6f45-424e-499f-88ac-93c451ac9db0">13</ix:nonFraction> thousand of licensing revenue was recorded, respectively, related to the Knight Agreement. For the years ended December&#160;31, 2022 and 2021, <ix:nonFraction unitRef="usd" contextRef="i0f4842d33b674e97bec5e1f35f13347e_D20220101-20221231" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzExMzI4_72a8898a-da10-4c51-bad4-95d5109a2361"><ix:nonFraction unitRef="usd" contextRef="i85d4b734d53646fa9eece46433fcc33e_D20210101-20211231" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzExMzI4_e07ff929-6a76-4231-8c9c-ee1217f6bd66">no</ix:nonFraction></ix:nonFraction> product supply revenue was recorded, respectively, related to the Knight Agreement. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AstraZeneca AB ("AstraZeneca")</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2015, we entered into a termination agreement with AstraZeneca ("AstraZeneca Termination Agreement") pursuant to which we have agreed to pay AstraZeneca (i) future royalties at a royalty rate of <ix:nonFraction unitRef="number" contextRef="i23a66360caef450d9534fe2775f21255_D20150601-20150630" decimals="INF" name="ardx:PercentageOfRoyaltyRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTg0NTUzMg_f8f1354e-9995-450c-8bd2-4a412d52d809">10</ix:nonFraction>% of net sales of tenapanor or other NHE3 products by us or our licensees, and (ii) <ix:nonFraction unitRef="number" contextRef="i23a66360caef450d9534fe2775f21255_D20150601-20150630" decimals="INF" name="ardx:PercentageOfNonRoyaltyRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTg0NTUzNg_602d4ed0-947c-4d9a-8f19-9596062c8979">20</ix:nonFraction>% of non-royalty revenue received from a new collaboration partner should we elect to license, or otherwise provide rights to develop and commercialize tenapanor or another NHE3 inhibitor, up to a maximum of $<ix:nonFraction unitRef="usd" contextRef="i8e9b10bffc104601b9077dcc9e1f4fa6_I20150630" decimals="-5" name="ardx:CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzEzMTg0_1733a871-e164-4593-944b-512c578139c9">75.0</ix:nonFraction> million in aggregate for (i) and (ii). For the years ended December&#160;31, 2022 and 2021, we recognized $<ix:nonFraction unitRef="usd" contextRef="if72c0334b4964673b5b1e29e363186db_D20220101-20221231" decimals="-5" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTg1NTY1MQ_36b185d9-107d-4365-9982-511a1bbfe345">3.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifc0eee8426754521a747a26cbaedb831_D20210101-20211231" decimals="-5" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTg1NTY2Ng_a60bfc01-3133-4ef6-b81d-0f2f68771b2f">1.0</ix:nonFraction> million, respectively, as cost of revenue related to the AstraZeneca Termination Agreement. To date in aggregate, we have recognized $<ix:nonFraction unitRef="usd" contextRef="i1d7903c12c424b3ba490589eb00fd14d_D20150601-20221231" decimals="-5" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTg1NTY4Mg_e14c5961-91f7-47c8-bb48-3510e3197fec">15.3</ix:nonFraction> million of the $<ix:nonFraction unitRef="usd" contextRef="i8e9b10bffc104601b9077dcc9e1f4fa6_I20150630" decimals="-5" name="ardx:CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTg1NTY5OA_1733a871-e164-4593-944b-512c578139c9">75.0</ix:nonFraction> million aggregate maximum related to the AstraZeneca Termination Agreement.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Revenue</span></div><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzEzNzcy_e25552b1-4ad6-4ed4-a97a-8d342c36ea5e" continuedAt="ibc276472b5ef4438bd0c68bcdc61236d" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present changes in our current and non-current deferred revenue balances during the reporting period. The December&#160;31, 2022 deferred revenue current and non-current balances are attributable entirely to prepayments for product supply under the 2017 KKC Agreement, while the December&#160;31, 2021 current deferred revenue balance is attributable to the 2019 KKC Agreement and the December&#160;31, 2021 non-current deferred revenue balance is attributable prepayments for product supply under the 2017 KKC Agreement (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue - current</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at Balance at January 1,</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c98abb4d89044e0ab93ab428d564f5f_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo2YjNlZTkxOWU3NWQ0MWIxYjJhZjZlYTUyY2VjMTJhYS90YWJsZXJhbmdlOjZiM2VlOTE5ZTc1ZDQxYjFiMmFmNmVhNTJjZWMxMmFhXzEtMS0xLTEtNDYwMTM_25439f70-11e0-4407-b0e0-d63117bfd97e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib952c4e7da01441388aaeecabdfe075a_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo2YjNlZTkxOWU3NWQ0MWIxYjJhZjZlYTUyY2VjMTJhYS90YWJsZXJhbmdlOjZiM2VlOTE5ZTc1ZDQxYjFiMmFmNmVhNTJjZWMxMmFhXzEtMy0xLTEtNDYwMTM_b514d168-21b0-47c0-a9c7-1fc8d2ee5053">4,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases due to cash received, excluding amounts recognized as revenue during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i236464e64f8d473283dc7641b1f31d01_D20220101-20221231" decimals="-3" name="ardx:ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenueDuringThePeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo2YjNlZTkxOWU3NWQ0MWIxYjJhZjZlYTUyY2VjMTJhYS90YWJsZXJhbmdlOjZiM2VlOTE5ZTc1ZDQxYjFiMmFmNmVhNTJjZWMxMmFhXzItMS0xLTEtNTM3NTM_fbe55d8f-3c86-4d3c-b054-bf4aea6584fc">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied48f951c2e54c4c9458741287f35022_D20210101-20211231" decimals="-3" name="ardx:ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenueDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo2YjNlZTkxOWU3NWQ0MWIxYjJhZjZlYTUyY2VjMTJhYS90YWJsZXJhbmdlOjZiM2VlOTE5ZTc1ZDQxYjFiMmFmNmVhNTJjZWMxMmFhXzItMy0xLTEtNTM3NTM_51f233a6-c485-4dfd-8d61-9ef26768fe69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases due to amounts reclassified from non-current, to be recognized in the next twelve months</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i236464e64f8d473283dc7641b1f31d01_D20220101-20221231" decimals="-3" name="ardx:ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo2YjNlZTkxOWU3NWQ0MWIxYjJhZjZlYTUyY2VjMTJhYS90YWJsZXJhbmdlOjZiM2VlOTE5ZTc1ZDQxYjFiMmFmNmVhNTJjZWMxMmFhXzMtMS0xLTEtNTM3NTM_a9297b79-deec-4a30-bbb6-eb5489d53aaf">3,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied48f951c2e54c4c9458741287f35022_D20210101-20211231" decimals="-3" name="ardx:ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo2YjNlZTkxOWU3NWQ0MWIxYjJhZjZlYTUyY2VjMTJhYS90YWJsZXJhbmdlOjZiM2VlOTE5ZTc1ZDQxYjFiMmFmNmVhNTJjZWMxMmFhXzMtMy0xLTEtNTM3NTM_9c3a422b-0be6-4fdb-b5b8-7d7b1498d778">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases to amounts invoiced, for which cash has not yet been received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i236464e64f8d473283dc7641b1f31d01_D20220101-20221231" decimals="-3" name="ardx:ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo2YjNlZTkxOWU3NWQ0MWIxYjJhZjZlYTUyY2VjMTJhYS90YWJsZXJhbmdlOjZiM2VlOTE5ZTc1ZDQxYjFiMmFmNmVhNTJjZWMxMmFhXzQtMS0xLTEtNTM3NTM_6de5d365-534a-4d64-9ea6-d0b538a08833">208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied48f951c2e54c4c9458741287f35022_D20210101-20211231" decimals="-3" name="ardx:ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo2YjNlZTkxOWU3NWQ0MWIxYjJhZjZlYTUyY2VjMTJhYS90YWJsZXJhbmdlOjZiM2VlOTE5ZTc1ZDQxYjFiMmFmNmVhNTJjZWMxMmFhXzQtMy0xLTEtNTM3NTM_dcb31873-57b6-4ea9-9898-a1ddd1ce6a4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases due to revenue recognized in the period for which cash has been received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i236464e64f8d473283dc7641b1f31d01_D20220101-20221231" decimals="-3" name="ardx:ContractWithCustomerLiabilityRevenueRecognizedCashReceived" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo2YjNlZTkxOWU3NWQ0MWIxYjJhZjZlYTUyY2VjMTJhYS90YWJsZXJhbmdlOjZiM2VlOTE5ZTc1ZDQxYjFiMmFmNmVhNTJjZWMxMmFhXzItMS0xLTEtNDYwMTM_a9e043d2-3c1b-45c8-9795-f368a2b22381">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied48f951c2e54c4c9458741287f35022_D20210101-20211231" decimals="-3" name="ardx:ContractWithCustomerLiabilityRevenueRecognizedCashReceived" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo2YjNlZTkxOWU3NWQ0MWIxYjJhZjZlYTUyY2VjMTJhYS90YWJsZXJhbmdlOjZiM2VlOTE5ZTc1ZDQxYjFiMmFmNmVhNTJjZWMxMmFhXzItMy0xLTEtNDYwMTM_aa240402-d662-42b2-8952-36e645a4b679">4,177</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31,</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8366fe12a3334315af3ed1c7052d20c4_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo2YjNlZTkxOWU3NWQ0MWIxYjJhZjZlYTUyY2VjMTJhYS90YWJsZXJhbmdlOjZiM2VlOTE5ZTc1ZDQxYjFiMmFmNmVhNTJjZWMxMmFhXzUtMS0xLTEtNDYwMTM_c53d8123-24dc-4171-b375-d85dc0444358">4,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd7890f2ab641b689a46d3387cd65f5_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo2YjNlZTkxOWU3NWQ0MWIxYjJhZjZlYTUyY2VjMTJhYS90YWJsZXJhbmdlOjZiM2VlOTE5ZTc1ZDQxYjFiMmFmNmVhNTJjZWMxMmFhXzUtMy0xLTEtNDYwMTM_58aecaa8-a10f-48b4-abc1-b26f1fa38ee3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><ix:continuation id="i9b9fbedae57e4130888599e5d81e60d3"><ix:continuation id="ibc276472b5ef4438bd0c68bcdc61236d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue - non-current</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at Balance at January 1,</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd7890f2ab641b689a46d3387cd65f5_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo0NTA2ZDMxZmU0Y2Y0MDQwODliNjNjNDFlZDg2YzEwMS90YWJsZXJhbmdlOjQ1MDZkMzFmZTRjZjQwNDA4OWI2M2M0MWVkODZjMTAxXzEtMS0xLTEtNDYwMTM_db465ff0-190b-4f13-80a0-4f5b5f200faf">4,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8ee7345370441099ade9119306db79b_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo0NTA2ZDMxZmU0Y2Y0MDQwODliNjNjNDFlZDg2YzEwMS90YWJsZXJhbmdlOjQ1MDZkMzFmZTRjZjQwNDA4OWI2M2M0MWVkODZjMTAxXzEtMy0xLTEtNDYwMTM_d64fe73e-a4d1-4779-8006-ad7442339890">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases due to cash received during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5096f6f9abe4dccb2dab386d07f22b0_D20220101-20221231" decimals="-3" name="ardx:ContractWithCustomerLiabilityIncreaseForCashReceived" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo0NTA2ZDMxZmU0Y2Y0MDQwODliNjNjNDFlZDg2YzEwMS90YWJsZXJhbmdlOjQ1MDZkMzFmZTRjZjQwNDA4OWI2M2M0MWVkODZjMTAxXzItMS0xLTEtNTM3Njc_d75c17aa-9e32-47c3-8b16-a8b911dab20e">7,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d56b583b1d146f7be5316e8e2d710b4_D20210101-20211231" decimals="-3" name="ardx:ContractWithCustomerLiabilityIncreaseForCashReceived" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo0NTA2ZDMxZmU0Y2Y0MDQwODliNjNjNDFlZDg2YzEwMS90YWJsZXJhbmdlOjQ1MDZkMzFmZTRjZjQwNDA4OWI2M2M0MWVkODZjMTAxXzItMy0xLTEtNTM3Njc_4a5c88ac-5fe6-4dad-8ce6-a5a184ebca38">3,242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases to amounts invoiced, for which cash has not yet been received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5096f6f9abe4dccb2dab386d07f22b0_D20220101-20221231" decimals="-3" name="ardx:ContractWithCustomerLiabilityIncreasesToAmountsInvoicedButCashNotReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo0NTA2ZDMxZmU0Y2Y0MDQwODliNjNjNDFlZDg2YzEwMS90YWJsZXJhbmdlOjQ1MDZkMzFmZTRjZjQwNDA4OWI2M2M0MWVkODZjMTAxXzMtMS0xLTEtNTM3Njc_2ea3290b-0761-4a7c-8eba-28fe5deb84a6">465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d56b583b1d146f7be5316e8e2d710b4_D20210101-20211231" decimals="-3" name="ardx:ContractWithCustomerLiabilityIncreasesToAmountsInvoicedButCashNotReceived" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo0NTA2ZDMxZmU0Y2Y0MDQwODliNjNjNDFlZDg2YzEwMS90YWJsZXJhbmdlOjQ1MDZkMzFmZTRjZjQwNDA4OWI2M2M0MWVkODZjMTAxXzMtMy0xLTEtNTM3Njc_405d6786-1401-4691-a490-491df65884cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase due to unbilled prepayments recorded during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5096f6f9abe4dccb2dab386d07f22b0_D20220101-20221231" decimals="-3" name="ardx:ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo0NTA2ZDMxZmU0Y2Y0MDQwODliNjNjNDFlZDg2YzEwMS90YWJsZXJhbmdlOjQ1MDZkMzFmZTRjZjQwNDA4OWI2M2M0MWVkODZjMTAxXzQtMS0xLTEtNTM3Njc_717e2d5a-c122-4974-9702-93e35e766a4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d56b583b1d146f7be5316e8e2d710b4_D20210101-20211231" decimals="-3" name="ardx:ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo0NTA2ZDMxZmU0Y2Y0MDQwODliNjNjNDFlZDg2YzEwMS90YWJsZXJhbmdlOjQ1MDZkMzFmZTRjZjQwNDA4OWI2M2M0MWVkODZjMTAxXzQtMy0xLTEtNTM3Njc_81a8ba8d-5cdd-4973-8a11-9108871b02b4">1,485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases due to amounts reclassified as current, to be recognized in the next twelve months</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5096f6f9abe4dccb2dab386d07f22b0_D20220101-20221231" decimals="-3" name="ardx:ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo0NTA2ZDMxZmU0Y2Y0MDQwODliNjNjNDFlZDg2YzEwMS90YWJsZXJhbmdlOjQ1MDZkMzFmZTRjZjQwNDA4OWI2M2M0MWVkODZjMTAxXzItMS0xLTEtNDYwMTM_fa558bf9-8646-4d96-9fd4-6d324e13fc28">3,961</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d56b583b1d146f7be5316e8e2d710b4_D20210101-20211231" decimals="-3" name="ardx:ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo0NTA2ZDMxZmU0Y2Y0MDQwODliNjNjNDFlZDg2YzEwMS90YWJsZXJhbmdlOjQ1MDZkMzFmZTRjZjQwNDA4OWI2M2M0MWVkODZjMTAxXzItMy0xLTEtNDYwMTM_d46b1632-86d7-421d-a935-852ff50c7fc3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31,</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i317cad6de7604d25be88b176cb33baec_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo0NTA2ZDMxZmU0Y2Y0MDQwODliNjNjNDFlZDg2YzEwMS90YWJsZXJhbmdlOjQ1MDZkMzFmZTRjZjQwNDA4OWI2M2M0MWVkODZjMTAxXzUtMS0xLTEtNDYwMTM_ab7665e3-f980-4f57-bded-fa14e4346668">9,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c98abb4d89044e0ab93ab428d564f5f_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo0NTA2ZDMxZmU0Y2Y0MDQwODliNjNjNDFlZDg2YzEwMS90YWJsZXJhbmdlOjQ1MDZkMzFmZTRjZjQwNDA4OWI2M2M0MWVkODZjMTAxXzUtMy0xLTEtNDYwMTM_a3999538-9997-4173-a57e-1210a510c897">4,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div style="margin-top:5pt"><span><br/></span></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_1571"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:AssetRetirementObligationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTcxL2ZyYWc6Mzc0MTZhNTgwZjYxNGViM2IxZWQ4ZTExOWU5MzBjYTQvdGV4dHJlZ2lvbjozNzQxNmE1ODBmNjE0ZWIzYjFlZDhlMTE5ZTkzMGNhNF8yMTk5MDIzMjYwMjY2_438f7ee8-33e2-40fc-8315-4b5f2a3bf08f" continuedAt="ie605e742beef4fb3840d8ac3285c3c7d" escape="true">DEFERRED ROYALTY OBLIGATION RELATED TO THE SALE OF FUTURE ROYALTIES</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ie605e742beef4fb3840d8ac3285c3c7d" continuedAt="i0d91a68008e347b481d36956e4d8df3c"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, we and HealthCare Royalty Partners IV, L.P. (&#8220;HCR&#8221;) entered into a Royalty and Sales Milestone Interest Acquisition Agreement (&#8220;HCR Agreement&#8221;). Under the terms of the HCR Agreement, HCR has agreed to pay us up to $<ix:nonFraction unitRef="usd" contextRef="i4d7bf861c12549a792483e8efc814a9e_D20220601-20220630" decimals="-5" name="us-gaap:IncreaseDecreaseInRoyaltiesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTcxL2ZyYWc6Mzc0MTZhNTgwZjYxNGViM2IxZWQ4ZTExOWU5MzBjYTQvdGV4dHJlZ2lvbjozNzQxNmE1ODBmNjE0ZWIzYjFlZDhlMTE5ZTkzMGNhNF81NDk3NTU4MTg1MDg_7ecb26e0-56b5-4c69-b668-eed16ecfeab6">20.0</ix:nonFraction> million in exchange for the royalty payments and commercial milestone payments (collectively the &#8220;Royalty Interest Payments&#8221;) that we may receive under our 2017 License Agreement with KKC based upon KKC's net sales of tenapanor in Japan for hyperphosphatemia. As consideration for the sale of the Royalty Interest Payments, HCR paid to us a $<ix:nonFraction unitRef="usd" contextRef="i41ff706f90cc43a59020a70376e95dd2_I20220630" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTcxL2ZyYWc6Mzc0MTZhNTgwZjYxNGViM2IxZWQ4ZTExOWU5MzBjYTQvdGV4dHJlZ2lvbjozNzQxNmE1ODBmNjE0ZWIzYjFlZDhlMTE5ZTkzMGNhNF81NDk3NTU4MTg1MTU_b5c4c522-9884-456e-9884-0560c843d9c7">10.0</ix:nonFraction> million upfront payment, and we are eligible to receive a $<ix:nonFraction unitRef="usd" contextRef="i41ff706f90cc43a59020a70376e95dd2_I20220630" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTcxL2ZyYWc6Mzc0MTZhNTgwZjYxNGViM2IxZWQ4ZTExOWU5MzBjYTQvdGV4dHJlZ2lvbjozNzQxNmE1ODBmNjE0ZWIzYjFlZDhlMTE5ZTkzMGNhNF81NDk3NTU4MTg1MjI_7fae8822-b041-47b3-952a-08d8a71cf4b5">5.0</ix:nonFraction> million payment following KKC's receipt of regulatory approval to market tenapanor for hyperphosphatemia in Japan, and another $<ix:nonFraction unitRef="usd" contextRef="i41ff706f90cc43a59020a70376e95dd2_I20220630" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTcxL2ZyYWc6Mzc0MTZhNTgwZjYxNGViM2IxZWQ4ZTExOWU5MzBjYTQvdGV4dHJlZ2lvbjozNzQxNmE1ODBmNjE0ZWIzYjFlZDhlMTE5ZTkzMGNhNF81NDk3NTU4MTg1MjY_796a52ab-f433-42be-9258-94870d621641">5.0</ix:nonFraction> million payment in the event net sales by KKC in Japan exceed a certain annual target level by the end of 2025.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The HCR Agreement is effective until terminated by the mutual agreement of the parties and contains customary representations and warranties and customary affirmative and negative covenants, including, among others, requirements as to prosecution, maintenance, defense and enforcement of certain patent rights in Japan, restrictions regarding our ability to forgive, release or reduce any Royalty Interest Payments due to us under the 2017 KKC Agreement, to create or incur any liens with respect to the Royalty Interest Payments, the 2017 KKC Agreement or certain patents, or to sell, license or transfer certain patents in the field and territory described in the 2017 KKC Agreement.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the HCR Agreement contains customary events of default with respect to which we may incur indemnification obligations to HCR for any losses incurred by HCR and related parties as a result of the event of default, subject to a specified limitation of liability cap. Under the HCR Agreement, an event of default will occur if, among other things, any of the representations and warranties included in the HCR Agreement proves not to have been true and correct in all material respects, at the time it was made, we breach any of our covenants under the HCR Agreement, subject to specified cure periods with respect to certain breaches, we are in breach or default under the 2017 KKC Agreement in any manner which is likely to cause a material adverse effect on the Royalty Interest Payments, the occurrence of a termination of the 2017 KKC Agreement under certain circumstances or we or our assets become subject to certain legal proceedings, such as bankruptcy proceedings, or we are unable to pay our debts as they become due.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received the $<ix:nonFraction unitRef="usd" contextRef="i41ff706f90cc43a59020a70376e95dd2_I20220630" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTcxL2ZyYWc6Mzc0MTZhNTgwZjYxNGViM2IxZWQ4ZTExOWU5MzBjYTQvdGV4dHJlZ2lvbjozNzQxNmE1ODBmNjE0ZWIzYjFlZDhlMTE5ZTkzMGNhNF81NDk3NTU4MTg1Mzg_b5c4c522-9884-456e-9884-0560c843d9c7">10.0</ix:nonFraction> million upfront payment from HCR during June 2022 and recorded it as a deferred royalty obligation related to the sale of future royalties ("deferred royalty obligation") on our balance sheet. Due to our ongoing manufacturing obligations under the 2017 KKC Agreement, we account for the proceeds as imputed debt and therefore will recognize royalties received under the arrangement as non-cash royalty revenue. Non-cash interest expense will be recognized over the life of the HCR Agreement using the effective interest method based on the imputed interest rate derived from estimated amounts and timing of future royalty payments to be received from KKC. As part of the sale, we incurred approximately $<ix:nonFraction unitRef="usd" contextRef="ia283d9f31c884152af9cfa5bfc1c18cc_I20221231" decimals="-5" name="ardx:ContractWithCustomerLiabilityTransactionCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTcxL2ZyYWc6Mzc0MTZhNTgwZjYxNGViM2IxZWQ4ZTExOWU5MzBjYTQvdGV4dHJlZ2lvbjozNzQxNmE1ODBmNjE0ZWIzYjFlZDhlMTE5ZTkzMGNhNF81NDk3NTU4MTg1NTU_e2f120f9-6392-44bf-81e6-7504b08b2087">0.4</ix:nonFraction> million in transaction costs, which, along with the deferred royalty obligation, are being amortized to non-cash interest expense over the estimated life of the HCR Agreement using the effective interest method. As future royalties are remitted to us by KKC, and subsequently from us to HCR, the balance of the deferred royalty obligation will be effectively repaid over the life of the HCR Agreement. There are a number of factors that could materially affect the fair value of the deferred royalty obligation. Such factors include, but are not limited to, the amount and timing of potential future royalty payments to be received from KKC under the 2017 KKC agreement, changing standards of care, the introduction of competing products, manufacturing or other delays, intellectual property matters, adverse events that result in governmental health authority imposed restrictions on the use of the drug products, significant changes in foreign exchange rates as the royalties remitted to HCR are made in U.S. dollars while the underlying sales of the products by KKC are made in Japanese yen, and other events or circumstances that could result in reduced royalty payments from KKC, which are not within our control, and all of which would result in a reduction of non-cash royalty revenues and the non-cash interest expense over the life of the deferred royalty obligation. We periodically assess the estimated royalty payments from KKC and, to the extent that the amount or timing of such payments is materially different than our original estimates, we prospectively adjust the imputed interest rate and </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><ix:continuation id="i0d91a68008e347b481d36956e4d8df3c"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the related amortization of the deferred royalty obligation. As of December&#160;31, 2022, our effective interest rate used to amortize the liability is <ix:nonFraction unitRef="number" contextRef="i38d4c1dcbb354f1cb8f7b983e2aba1a6_D20220101-20221231" decimals="3" name="ardx:ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTcxL2ZyYWc6Mzc0MTZhNTgwZjYxNGViM2IxZWQ4ZTExOWU5MzBjYTQvdGV4dHJlZ2lvbjozNzQxNmE1ODBmNjE0ZWIzYjFlZDhlMTE5ZTkzMGNhNF81NDk3NTU4MTg1NzA_630894c9-9b78-4052-be8f-731c2f522741">34.4</ix:nonFraction>%. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the twelve months ended December&#160;31, 2022, we recognized approximately $<ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-5" name="us-gaap:AmortizationOfAdvanceRoyalty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTcxL2ZyYWc6Mzc0MTZhNTgwZjYxNGViM2IxZWQ4ZTExOWU5MzBjYTQvdGV4dHJlZ2lvbjozNzQxNmE1ODBmNjE0ZWIzYjFlZDhlMTE5ZTkzMGNhNF81NDk3NTU4MTg1ODY_8766daef-005d-4e1d-a08c-a37ce3e4ec31">1.7</ix:nonFraction> million of non-cash interest expense for the amortization of the deferred royalty obligation. As of December&#160;31, 2022, we have received <ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="INF" name="us-gaap:ProceedsFromRoyaltiesReceived" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTcxL2ZyYWc6Mzc0MTZhNTgwZjYxNGViM2IxZWQ4ZTExOWU5MzBjYTQvdGV4dHJlZ2lvbjozNzQxNmE1ODBmNjE0ZWIzYjFlZDhlMTE5ZTkzMGNhNF81NDk3NTU4MTg1OTc_ac2d529c-8ce3-4d54-bd99-37625292dfe1">no</ix:nonFraction> royalty payments from KKC and, therefore, the deferred royalty obligation has not begun to be reduced.</span></div></ix:continuation><div id="i8c6ecca27b7b4659bf1d61cfb55de996_115"></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzgxMjM_875d211a-970e-4f72-b939-0df7f451bd19" continuedAt="if4c580f1ce6a4d5d81fdf0871c81f335" escape="true">BORROWINGS</ix:nonNumeric></span></div><ix:continuation id="if4c580f1ce6a4d5d81fdf0871c81f335" continuedAt="id580ddeff2374e03b4441fdcdb81dd7b"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Solar Capital and Western Alliance Bank Loan Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, we entered into a loan and security agreement ("2018 Loan Agreement"), with Solar Capital Ltd. and Western Alliance Bank ("Lenders&#8221;). The 2018 Loan Agreement provided for a $<ix:nonFraction unitRef="usd" contextRef="i933aaacf34f34a61bfa383d7cb1bb60d_I20180531" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg1Njk0MQ_38e81747-f710-4f63-a213-dc6ee12797c1">50.0</ix:nonFraction> million term loan facility with a maturity date of November&#160;1, 2022 ("2018 Term Loan&#8221;). The full amount of the 2018 Term Loan was funded on May&#160;16, 2018. We received net proceeds from the loan of approximately $<ix:nonFraction unitRef="usd" contextRef="if95076af06f24f2296cea9a5d6d76ff4_D20180501-20180531" decimals="-5" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzQ1NDEw_2e8f0fee-8345-4531-a604-acdb1794950a">49.3</ix:nonFraction> million, after deducting the closing fee, legal expenses and issuance costs. In October 2020, we and the Lenders entered into an amendment to the 2018 Loan Agreement (&#8220;2020 Amendment&#8221;) to extend the date through which we were permitted to make interest-only payments on the 2018 Term Loan by <ix:nonNumeric contextRef="i8733e6fccc254fd9bf95445ad142e86f_D20201001-20201031" name="ardx:DebtInstrumentInterestPaymentExtensionTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzQ1NDE0_6d4d00ef-b350-4805-9a0b-12facc48ec16">twelve months</ix:nonNumeric> to December 1, 2021 subject to the repayment terms noted below.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2018 Term Loan bore interest at a floating per annum rate equal to <ix:nonFraction unitRef="number" contextRef="i95d5e831357142ff915c3c75ead6d520_D20180516-20180516" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg1Njk0OA_0b795889-e00c-4602-9633-84cad8aa3317">7.45</ix:nonFraction>% plus the one-month London Inter-bank Offered Rate ("LIBOR"). We were permitted to make interest-only payments on the 2018 Term Loan through June 1, 2020, or until we achieved our primary endpoint in the Phase 3 study of tenapanor for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis prior to June&#160;1, 2020, in which case we would have been permitted to make interest-only payments on the 2018 Term Loan through December 1, 2020. In December 2019, we reported positive topline results for PHREEDOM, a long-term Phase 3 study evaluating the efficacy and safety of tenapanor as monotherapy for the treatment of hyperphosphatemia in adult patients with CKD on dialysis. The Lenders were in agreement that these positive data from the Phase 3 PHREEDOM study achieve the &#8220;Phase 3 Endpoint&#8221; required by the 2018 Term Loan to extend the interest only period by <ix:nonNumeric contextRef="i7c495d34647447ae8783de5a900a3e77_D20191201-20191231" name="ardx:DebtInstrumentInterestPaymentExtensionTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzQ1NDE4_0edac1e0-6c89-4913-9ecd-98e4bee884c9">six months</ix:nonNumeric> to December&#160;1, 2020. Subsequent to the 2020 Amendment, the interest only period was extended an additional <ix:nonNumeric contextRef="i69ee8e8bda5947d3a7b266f55eee864b_D20201009-20201009" name="ardx:DebtInstrumentInterestPaymentExtensionTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzQ1NDIy_f2fd08a7-1edb-40aa-ae4d-5ca52efcbb68">twelve months</ix:nonNumeric> to December 1, 2021. Accordingly, beginning on December&#160;1, 2021 through the maturity date, we would have been required to make monthly payments of interest plus repayment of the 2018 Term Loan in consecutive equal monthly installments of principal. If however, either the FDA did not approve our NDA for tenapanor for control of serum phosphorus in adult patients with CKD on dialysis on or before May 31, 2021 or the FDA issued a Complete Response Letter ("CRL") for tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis, then we would begin principal payments on the earlier of June 1, 2021 or the first day of the month immediately following the date that the FDA issued a CRL to us. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May and July 2021, we and the Lenders entered into additional amendments to the 2018 Loan Agreement (&#8220;the 2021 Amendments&#8221;) which together extended the period of time that we were permitted to make interest-only payments on the 2018 Term Loan to December 1, 2021; provided that if we had not received FDA approval for our NDA for tenapanor for the control of serum phosphorus in adult patients with CDK on dialysis on or before October 25, 2021, the interest-only period would expire and principal repayments would be required to begin on November 1, 2021. If principal repayments were required to begin prior to December 1, 2021 under the 2021 Amendments, then the first such repayment was required to include all payments that would have been due if monthly principal repayment had begun on June 1, 2021. Accordingly, during November 2021, in compliance with the terms of our 2018 Loan Agreement, we began to repay principal on the 2018 Term Loan. As of the Closing Date for the 2022 Loan, as discussed below, we owed $<ix:nonFraction unitRef="usd" contextRef="ia1e9f731799b499eaf4aa779cb305fc6_I20180516" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg1Njg1Nw_51db30e9-a531-4b70-97fa-06771d1ba150">25.0</ix:nonFraction>&#160;million in principal payments from the 2018 Loan, which we repaid in full at that time.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SLR Investment Corp. Loan Agreement </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 23, 2022 (&#8220;Closing Date&#8221;), we entered into a loan and security agreement (&#8220;2022 Loan Agreement&#8221;) with SLR Investment Corp. as collateral agent (&#8220;Agent&#8221;), and the lenders listed in the 2022 Loan Agreement (collectively the &#8220;2022 Lenders&#8221;). The 2022 Loan Agreement provides for a senior secured loan facility, with $<ix:nonFraction unitRef="usd" contextRef="idaba5dc7a9024a1b89083ce66516cffd_D20220223-20220223" decimals="-5" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg0ODk0MQ_41d65aa5-ebaa-40dd-9057-fb2bb35009f8">27.5</ix:nonFraction> million (&#8220;Term A Loan&#8221;) funded on the Closing Date and an additional $<ix:nonFraction unitRef="usd" contextRef="i4ed59bf2f32c4c919325b9d6800e3fad_I20220223" decimals="-5" name="ardx:RemainingFundingBasedOnConditionalMilestoneAchievement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg0ODk0OA_ce424f42-357d-4424-8c2f-aa1784ed1729">22.5</ix:nonFraction> million that we may borrow on or prior to July 25, 2023; provided that (i) we have received approval by the FDA for our NDA for XPHOZAH by December 31, 2022, and (ii) we have achieved certain product revenue milestone targets described in the 2022 Loan Agreement (&#8220;Term B Loan&#8221;, and collectively, the Term A Loan and the Term B Loan, the &#8220;2022 Loan&#8221;). On February 9, 2023, we entered into an amendment to the 2022 Loan Agreement with SLR Investment Corp. that extends the date by which we must receive approval by the FDA for our NDA for the control of serum phosphorus in adult patients with CKD on dialysis in order to borrow the additional $<ix:nonFraction unitRef="usd" contextRef="i4ed59bf2f32c4c919325b9d6800e3fad_I20220223" decimals="-5" name="ardx:RemainingFundingBasedOnConditionalMilestoneAchievement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg0ODk1Mg_ce424f42-357d-4424-8c2f-aa1784ed1729">22.5</ix:nonFraction> million from December 31, 2022 to November 30, 2023 and extended the period during which we are permitted to make interest only payments until March 31, </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><ix:continuation id="id580ddeff2374e03b4441fdcdb81dd7b" continuedAt="i0c428e92a12642ae921746c1e55d0757"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025 if we receive approval by the FDA for our NDA for XPHOZAH on or prior to November 30, 2023 or achieve a defined net product revenue threshold for 2023. The 2022 Term A Loan funds were used to repay the 2018 Loan with the 2018 Lenders. The 2022 Loan has a maturity date of March 1, 2027.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2022 Loan bear interest at a floating per annum rate equal to <ix:nonFraction unitRef="number" contextRef="i582ccc703db84580ad605cde3180b598_D20220223-20220223" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg0ODk3Mg_95769b20-14c7-450c-8733-691ab10522b5">7.95</ix:nonFraction>% plus the greater of (i) one tenth percent (<ix:nonFraction unitRef="number" contextRef="i582ccc703db84580ad605cde3180b598_D20220223-20220223" decimals="INF" name="ardx:DebtInstrumentVariableRateBaseOption" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg0ODk3Ng_cbeadd7d-8a36-48cf-89ff-0d3ab64e8a63">0.10</ix:nonFraction>%) and (ii) the one-month rate published by the Intercontinental Exchange Benchmark Administration Ltd or its successor. We are permitted to make interest-only payments on the 2022 Loan through March 31, 2024 or if certain conditions described above are achieved, through March 31, 2025. Accordingly, beginning on April 1, 2024 or April 1, 2025, we will be required to make monthly payments of interest plus repay the 2022 Loan in consecutive equal monthly installments of principal over <ix:nonNumeric contextRef="idaba5dc7a9024a1b89083ce66516cffd_D20220223-20220223" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzIxOTkwMjMyOTEwMDQ_ff2ee1bc-b2a5-4652-97cb-18a744c88017">36</ix:nonNumeric> months or <ix:nonNumeric contextRef="i40c1281552f94064963e3bf9cbecc666_D20220223-20220223" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzIxOTkwMjMzMDA5NDQ_1e702658-fc24-4704-bff0-6920a6e80b79">24</ix:nonNumeric> months, respectively. We were obligated to pay $<ix:nonFraction unitRef="usd" contextRef="i62a2e82e4ddc4240896cf7fd6f83fbf6_I20220223" decimals="-5" name="ardx:DebtInstrumentClosingFeeAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg0ODk4MA_730aee5b-bcf2-40ae-bfef-9b6157db0dd7">0.2</ix:nonFraction> million, upon the closing of the Term A Loan, and we are obligated to pay $<ix:nonFraction unitRef="usd" contextRef="i4ed59bf2f32c4c919325b9d6800e3fad_I20220223" decimals="-5" name="ardx:LoanAgreementFutureObligationUponFundingOrOtherEvents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg0ODk5Nw_675dba05-ac13-46ad-8dc5-11c3567496a3">0.1</ix:nonFraction> million on the earliest of (i) the funding date of the Term B Loan, (ii) July 25, 2023, and (iii) the prepayment, refinancing, substitution, or replacement of the Term A Loan on or prior to July 25, 2023. We are obligated to pay a final fee equal to <ix:nonFraction unitRef="number" contextRef="id31b250d8a3946278fda76b05ca4b4b1_I20220223" decimals="INF" name="ardx:DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg0OTAwNA_71d25944-b242-4244-af23-391c4409e5e1">4.95</ix:nonFraction>% of the aggregate original principal amount of the 2022 Loan funded upon the earliest to occur of the maturity date, the acceleration of the 2022 Loan, and the prepayment, refinancing, substitution, or replacement of the 2022 Loan. We may voluntarily prepay the outstanding 2022 Loan balance, subject to a prepayment premium of (i) <ix:nonFraction unitRef="number" contextRef="if668412fafc546cc955d0c29fa2f6c99_I20220223" decimals="INF" name="ardx:DebtInstrumentPrepaymentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg0OTAwOA_21cb6047-cb1c-4f0b-b48a-0d3573976766">3</ix:nonFraction>% of the outstanding principal amount of the 2022 Loan if prepaid prior to or on the first anniversary of the Closing Date, (ii) <ix:nonFraction unitRef="number" contextRef="i0f56c96387e743bbb3742ef501488a40_I20220223" decimals="INF" name="ardx:DebtInstrumentPrepaymentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg0OTAxOQ_eb1ea3c3-8a00-4267-af04-487a7d8429ee">2</ix:nonFraction>% of the outstanding principal amount of the 2022 Loan if prepaid after the first anniversary of the Closing Date through and including the second anniversary of the Closing Date, or (iii) <ix:nonFraction unitRef="number" contextRef="i72298d93078c4637ab00517b03176997_I20220223" decimals="INF" name="ardx:DebtInstrumentPrepaymentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg0OTAyMw_02d6028a-5866-4da4-baa3-3ab48733ad82">1</ix:nonFraction>% of the outstanding principal amount of the 2022 Loan if prepaid after the second anniversary of the Closing Date and prior to the maturity date. The 2022 Loan is secured by substantially all of our assets, except for our intellectual property and certain other customary exclusions. Additionally, in connection with the 2022 Loan, we entered into an agreement, whereby we agreed to pay an exit fee in the amount of <ix:nonFraction unitRef="number" contextRef="if0d290137b1441abbf8d0d36c58a8e95_I20220223" decimals="INF" name="ardx:ExitFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg0OTMxNQ_3db56add-e823-4af9-967a-60c729c630a8">2</ix:nonFraction>% of the 2022 Loan funded (&#8220;2022 Exit Fee&#8221;) upon (i) any change of control transaction or (ii) our achievement of net revenue from the sale of any products equal to or greater than $<ix:nonFraction unitRef="usd" contextRef="i4584120047b3460da4d6b5a0f2eb0808_D20220223-20220223" decimals="-5" name="ardx:LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg0OTMxOQ_0f87d771-a37b-4ba4-b9f5-1a0413caf14c">100.0</ix:nonFraction> million, measured on a six (6) months basis, tested monthly at the end of each month. Notwithstanding the prepayment or termination of the 2022 Loan, the 2022 Exit Fee will expire <ix:nonNumeric contextRef="i4584120047b3460da4d6b5a0f2eb0808_D20220223-20220223" name="ardx:LoanAgreementExitFeeTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzIxOTkwMjMyOTEwMDU_9b4b7302-8171-45f4-80f9-49b1e2ddf409">10</ix:nonNumeric> years from the Closing Date.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Loan Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among others, requirements as to financial reporting and insurance and restrictions on our ability to dispose of our business or property, to change our line of business, to liquidate or dissolve, to enter into any change in control transaction, to merge or consolidate with any other entity or to acquire all or substantially all the capital stock or property of another entity, to incur additional indebtedness, to incur liens on our property, to pay any dividends or other distributions on capital stock other than dividends payable solely in capital stock or to redeem capital stock. We have agreed to not allow our cash and cash equivalents to be less than the eighty percent (<ix:nonFraction unitRef="number" contextRef="id31b250d8a3946278fda76b05ca4b4b1_I20220223" decimals="INF" name="ardx:LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg0OTAyNw_bf24e2af-3690-40d8-a663-ae8165d59fa3">80</ix:nonFraction>%) of the outstanding 2022 Term Loan balance for any period in which our net revenue from the sale of any products, calculated on a trailing six (<ix:nonNumeric contextRef="iddc086b231bc43f99e47143a4bfb2914_D20220223-20220223" name="ardx:LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg0OTAzNQ_45e9834d-45a8-4fd0-9347-0a8fe26a271f">6</ix:nonNumeric>) month basis and tested monthly, is less than sixty percent (<ix:nonFraction unitRef="number" contextRef="id31b250d8a3946278fda76b05ca4b4b1_I20220223" decimals="INF" name="ardx:LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg0OTAzMQ_606ea207-3c76-464a-9fbe-5afbc26dc8af">60</ix:nonFraction>%) of the outstanding 2022 Loan balance.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the 2022 Loan Agreement contains customary events of default that entitle the Agent to cause our indebtedness under the 2022 Loan Agreement to become immediately due and payable, and to exercise remedies against us and the collateral securing the 2022 Term Loan, including our cash. Under the 2022 Loan Agreement, an event of default will occur if, among other things, we fail to make payments under the 2022 Loan Agreement, we breach any of our covenants under the 2022 Loan Agreement, subject to specified cure periods with respect to certain breaches, certain Lenders determine that a material adverse change has occurred, we or our assets become subject to certain legal proceedings, such as bankruptcy proceedings, we are unable to pay our debts as they become due or we default on contracts with third parties which would permit the holder of indebtedness to accelerate the maturity of such indebtedness or that could have a material adverse change on us. Upon the occurrence and for the duration of an event of default, an additional default interest rate equal to <ix:nonFraction unitRef="number" contextRef="id31b250d8a3946278fda76b05ca4b4b1_I20220223" decimals="INF" name="ardx:DebtInstrumentInterestRateOnDefaultPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg0OTAzOQ_8f586231-b738-4769-968d-049bb64f604b">4</ix:nonFraction>% per annum will apply to all obligations owed under the 2022 Loan Agreement. We have classified the 2022 Loan balance as a current liability as of December&#160;31, 2022 due to the determination of the existence of substantial doubt about our ability to continue operating as a going concern discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2. Summary of Significant Accounting Policies: Liquidity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and our assessment that the material adverse change clause under the 2022 Loan Agreement is not within our control. The lenders have not invoked the material adverse change clause as of the date of issuance of these financial statements.</span></div></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><ix:continuation id="i0c428e92a12642ae921746c1e55d0757"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 21. Subsequent Events</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on February 9, 2023, we entered into a second amendment (&#8220;Second Amendment&#8221;) to our Loan Agreement with the Lenders. The Second Amendment extends the interest-only term of the loan by twelve months to March 31, 2025 provided that we either (i) receive approval from the FDA for our NDA for the control of serum phosphorus in adult patients with CKD on dialysis on or prior to November 30, 2023 or (ii) achieve certain product revenue milestone targets as described in the Second Amendment for the year ending December 31, 2023. The Second Amendment also extends the period under which we may draw the Term B Loan from July 25, 2023 to December 20, 2023, and amends the milestone that we must achieve in order to draw the Term B Loan by extending the time period for the receipt of approval by the FDA of the NDA for the control of serum phosphorus in adult patients with CKD on dialysis until November 30, 2023. In addition, the Second Amendment replaces the floating per annum interest rate with <ix:nonFraction unitRef="number" contextRef="ic957e7b2e6404684ab3ce4588e0747ed_D20230209-20230209" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg1ODgwMg_8558c00e-26e5-4608-a5f6-1304f05b61fa">7.95</ix:nonFraction>% plus the greater of (a) one percent (<ix:nonFraction unitRef="number" contextRef="ic957e7b2e6404684ab3ce4588e0747ed_D20230209-20230209" decimals="INF" name="ardx:DebtInstrumentVariableRateBaseOption" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg1ODg0Mw_fbd702e0-e7d2-4b62-a06e-090be9e84594">1.00</ix:nonFraction>%) per annum and (b)(i) <ix:nonFraction unitRef="number" contextRef="ic957e7b2e6404684ab3ce4588e0747ed_D20230209-20230209" decimals="5" name="ardx:DebtInstrumentVariableRatePlusOption" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg1ODg2OQ_e0c40463-b1e0-4520-89fa-851f08aecb84">0.022</ix:nonFraction>% plus (ii) 1-month CME Term SOFR reference rate as published by the CME Term SOFR Administrator on the CME Term SOFR Administrator&#8217;s Website.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzgxMjU_f5eaaf7c-1e3e-46b2-9b85-0c93ac2083bf" escape="true"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, our future payment obligations related to the 2022 Loan, excluding interest payments and the 2022 final fee, were as follows (in thousands) and may be condensed to the 24 months ending March 1, 2027 if certain conditions noted above to extend the interest-only period are achieved:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:87.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90YWJsZTpkZTQyOGVlYWE2ZGI0NTZlYTRhZDk5Y2IxMjRhYTdmYi90YWJsZXJhbmdlOmRlNDI4ZWVhYTZkYjQ1NmVhNGFkOTljYjEyNGFhN2ZiXzAtMS0xLTEtNDk0MzQ_9047ed40-c030-40af-ab4f-0bf8aabd9957">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90YWJsZTpkZTQyOGVlYWE2ZGI0NTZlYTRhZDk5Y2IxMjRhYTdmYi90YWJsZXJhbmdlOmRlNDI4ZWVhYTZkYjQ1NmVhNGFkOTljYjEyNGFhN2ZiXzEtMS0xLTEtNDk0MzQ_eb6f2001-0e9a-484f-9234-d605299e6f94">7,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90YWJsZTpkZTQyOGVlYWE2ZGI0NTZlYTRhZDk5Y2IxMjRhYTdmYi90YWJsZXJhbmdlOmRlNDI4ZWVhYTZkYjQ1NmVhNGFkOTljYjEyNGFhN2ZiXzItMS0xLTEtNDk0MzQ_5db5411c-3e99-4862-8525-ffec9b7cd2bc">9,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90YWJsZTpkZTQyOGVlYWE2ZGI0NTZlYTRhZDk5Y2IxMjRhYTdmYi90YWJsZXJhbmdlOmRlNDI4ZWVhYTZkYjQ1NmVhNGFkOTljYjEyNGFhN2ZiXzAtMS0xLTEtNDYwMTM_6f90704c-5285-4205-a395-6a22a142059d">9,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90YWJsZTpkZTQyOGVlYWE2ZGI0NTZlYTRhZDk5Y2IxMjRhYTdmYi90YWJsZXJhbmdlOmRlNDI4ZWVhYTZkYjQ1NmVhNGFkOTljYjEyNGFhN2ZiXzEtMS0xLTEtNDYwMTM_94f8e216-ef31-4732-baa6-1882088d78bd">2,888</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90YWJsZTpkZTQyOGVlYWE2ZGI0NTZlYTRhZDk5Y2IxMjRhYTdmYi90YWJsZXJhbmdlOmRlNDI4ZWVhYTZkYjQ1NmVhNGFkOTljYjEyNGFhN2ZiXzItMS0xLTEtNDYwMTM_29780f48-d1e5-4684-82d3-845ddf9a797b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total repayment obligations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90YWJsZTpkZTQyOGVlYWE2ZGI0NTZlYTRhZDk5Y2IxMjRhYTdmYi90YWJsZXJhbmdlOmRlNDI4ZWVhYTZkYjQ1NmVhNGFkOTljYjEyNGFhN2ZiXzMtMS0xLTEtNDYwMTM_5a7190e2-2466-4e2f-9818-62a8a3887d9c">28,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized discount and debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90YWJsZTpkZTQyOGVlYWE2ZGI0NTZlYTRhZDk5Y2IxMjRhYTdmYi90YWJsZXJhbmdlOmRlNDI4ZWVhYTZkYjQ1NmVhNGFkOTljYjEyNGFhN2ZiXzQtMS0xLTEtNDYwMTM_6f9d8685-b1a8-4390-bb5e-4039a90c96ca">1,110</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unaccreted value of final fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:DebtInstrumentFeeAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90YWJsZTpkZTQyOGVlYWE2ZGI0NTZlYTRhZDk5Y2IxMjRhYTdmYi90YWJsZXJhbmdlOmRlNDI4ZWVhYTZkYjQ1NmVhNGFkOTljYjEyNGFhN2ZiXzUtMS0xLTEtNDYwMTM_f47d23d2-0b17-4fbf-81d5-18b0a26d3854">1,040</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90YWJsZTpkZTQyOGVlYWE2ZGI0NTZlYTRhZDk5Y2IxMjRhYTdmYi90YWJsZXJhbmdlOmRlNDI4ZWVhYTZkYjQ1NmVhNGFkOTljYjEyNGFhN2ZiXzYtMS0xLTEtNDYwMTM_9764e245-b16a-4882-a4d6-7cb0e8e6c154">26,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:LoansPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90YWJsZTpkZTQyOGVlYWE2ZGI0NTZlYTRhZDk5Y2IxMjRhYTdmYi90YWJsZXJhbmdlOmRlNDI4ZWVhYTZkYjQ1NmVhNGFkOTljYjEyNGFhN2ZiXzctMS0xLTEtNDYwMTM_486713dc-0af6-4446-8080-39b791561ea0">26,711</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:LongTermLoansPayable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90YWJsZTpkZTQyOGVlYWE2ZGI0NTZlYTRhZDk5Y2IxMjRhYTdmYi90YWJsZXJhbmdlOmRlNDI4ZWVhYTZkYjQ1NmVhNGFkOTljYjEyNGFhN2ZiXzExLTEtMS0xLTQ5NDM0_3fbbcc08-07e3-46a8-a736-7a010c845a95">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i8c6ecca27b7b4659bf1d61cfb55de996_118"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90ZXh0cmVnaW9uOjIwZjc5ODBmMzZhOTQxZDg4ODQ5NDhkNjFkN2EzZWQwXzI2MzY_42cb87c2-1ffe-468f-b1b5-7050d3973b37" continuedAt="i778e4cbed219486fbee947d83598401a" escape="true">DERIVATIVE LIABILITIES</ix:nonNumeric></span></div><ix:continuation id="i778e4cbed219486fbee947d83598401a" continuedAt="i51f53beb670b438b94495c516c777c14"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Exit Fee</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, in connection with entering into the 2018 Loan Agreement, we entered into an agreement pursuant to which we agreed to pay $<ix:nonFraction unitRef="usd" contextRef="i1b61195b8cbb43b4945e83216c7f171c_I20180531" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90ZXh0cmVnaW9uOjIwZjc5ODBmMzZhOTQxZDg4ODQ5NDhkNjFkN2EzZWQwXzU0OTc1NTgxNzA1OA_c0b7ee30-e558-4eeb-be91-51d3e54aeca3">1.5</ix:nonFraction> million in cash ("2018 Exit Fee") upon any change of control transaction in respect of the Company or if we obtain both (i) FDA approval of XPHOZAH and (ii) FDA approval of IBSRELA, which was obtained on September 12, 2019 (&#8220;2018 Exit Fee Agreement&#8221;). Notwithstanding the February 2022 prepayment of the 2018 Loan, our obligation to pay the 2018 Exit Fee will expire on May 16, 2028. We concluded that the 2018 Exit Fee is a freestanding derivative which should be accounted for at fair value on a recurring basis. The estimated fair value of the 2018 Exit Fee is recorded as a derivative liability and included in accrued expense and other current liabilities on the accompanying balance sheets. As of December&#160;31, 2022 and 2021, the estimated fair value of the 2018 Exit Fee was $<ix:nonFraction unitRef="usd" contextRef="i829995ddccd34c45973808967c7cab51_I20221231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90ZXh0cmVnaW9uOjIwZjc5ODBmMzZhOTQxZDg4ODQ5NDhkNjFkN2EzZWQwXzU0OTc1NTgxNjk2Ng_8d9cbe36-6a99-480e-af0e-7241012850ee">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i23902f57514345efaefc7f6ed372683f_I20211231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90ZXh0cmVnaW9uOjIwZjc5ODBmMzZhOTQxZDg4ODQ5NDhkNjFkN2EzZWQwXzU0OTc1NTgxNjk3MQ_176d214f-c27c-4c17-bc1f-3bc4cd561d3d">0.7</ix:nonFraction> million, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the derivative liability was determined using a discounted cash flow analysis and is classified as a Level 3 measurement within the fair value hierarchy since our valuation utilized significant unobservable inputs. Specifically, the key assumptions included in the calculation of the estimated fair value of the derivative instrument include: (i) our estimates of both the probability and timing of a potential $<ix:nonFraction unitRef="usd" contextRef="i1b61195b8cbb43b4945e83216c7f171c_I20180531" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90ZXh0cmVnaW9uOjIwZjc5ODBmMzZhOTQxZDg4ODQ5NDhkNjFkN2EzZWQwXzE1Nzc_c0b7ee30-e558-4eeb-be91-51d3e54aeca3">1.5</ix:nonFraction> million payment to Solar Capital Ltd. and Western Alliance Bank as a result of the FDA approvals, and (ii) a discount rate which was derived from our estimated cost of debt, adjusted with current LIBOR. Generally, increases or decreases in the probability of occurrence would result in a directionally similar impact in the fair value measurement of the derivative instrument and it is estimated that a <ix:nonFraction unitRef="number" contextRef="i73c09104400b4fc89c22d500c708517d_I20221231" decimals="2" name="ardx:FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90ZXh0cmVnaW9uOjIwZjc5ODBmMzZhOTQxZDg4ODQ5NDhkNjFkN2EzZWQwXzE5NzQ_72e6b105-58d9-4f02-a9c7-911514f87f54">10</ix:nonFraction>% increase (decrease), not to exceed 100%, in the probability of occurrence would result in a fair value fluctuation of no more than $<ix:nonFraction unitRef="usd" contextRef="i73c09104400b4fc89c22d500c708517d_I20221231" decimals="-5" name="ardx:FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90ZXh0cmVnaW9uOjIwZjc5ODBmMzZhOTQxZDg4ODQ5NDhkNjFkN2EzZWQwXzIxMDg_5b4d0a08-d20c-4834-8bf6-cea00d3a8821">0.1</ix:nonFraction> million.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><ix:continuation id="i51f53beb670b438b94495c516c777c14"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2022 Exit Fee</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, in connection with entering into the 2022 Loan Agreement, we entered into an agreement, whereby we agreed to pay an exit fee in the amount of <ix:nonFraction unitRef="number" contextRef="if0d290137b1441abbf8d0d36c58a8e95_I20220223" decimals="INF" name="ardx:ExitFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90ZXh0cmVnaW9uOjIwZjc5ODBmMzZhOTQxZDg4ODQ5NDhkNjFkN2EzZWQwXzU0OTc1NTgxOTEzNA_3db56add-e823-4af9-967a-60c729c630a8">2</ix:nonFraction>% of the 2022 Loan funded (&#8220;2022 Exit Fee&#8221;) upon (i) any change of control transaction or (ii) our achievement of net revenue from the sale of any products equal to or greater than $<ix:nonFraction unitRef="usd" contextRef="i4584120047b3460da4d6b5a0f2eb0808_D20220223-20220223" decimals="-5" name="ardx:LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90ZXh0cmVnaW9uOjIwZjc5ODBmMzZhOTQxZDg4ODQ5NDhkNjFkN2EzZWQwXzU0OTc1NTgxNzQyOQ_327bd6bf-3006-447e-9b75-7c1df664af5c">100.0</ix:nonFraction> million, measured on a six (6) months basis ("Revenue Milestone"), tested monthly at the end of each month. Notwithstanding the prepayment or termination of the 2022 Loan, the 2022 Exit Fee will expire on February 23, 2032. We concluded that the 2022 Exit Fee is a freestanding derivative which should be accounted for at fair value on a recurring basis. The estimated fair value of the 2022 Exit Fee is recorded as a derivative liability and included in accrued expenses and other current liabilities on the accompanying balance sheets. As of December&#160;31, 2022, the estimated fair value of the 2022 Exit Fee is $<ix:nonFraction unitRef="usd" contextRef="i8a01e0a1633e4784b82496570aa01a7e_I20221231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90ZXh0cmVnaW9uOjIwZjc5ODBmMzZhOTQxZDg4ODQ5NDhkNjFkN2EzZWQwXzU0OTc1NTgxOTEzOA_4c06f814-71df-49a2-a810-0ebeada1b8a5">0.4</ix:nonFraction> million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the derivative liability was determined using a discounted cash flow analysis and is classified as a Level 3 measurement within the fair value hierarchy since our valuation utilized significant unobservable inputs. Specifically, the key assumptions included in the calculation of the estimated fair value of the 2022 derivative liability include: (i) our estimates of both the probability and timing of achieving the Revenue Milestone and (ii) the probability and timing of funding the Term B Loan, which is dependent upon (a) approval by the FDA for our NDA for the control of serum phosphorus in adult patients with CKD on dialysis by December 31, 2022, and (b) achievement of certain product revenue milestone targets. Generally, increases or decreases in the probability of occurrence would result in a directionally similar impact in the fair value measurement of the derivative liability and it is estimated that a <ix:nonFraction unitRef="number" contextRef="i3a1e94b571de450d80084e08a561e5cc_I20221231" decimals="2" name="ardx:FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90ZXh0cmVnaW9uOjIwZjc5ODBmMzZhOTQxZDg4ODQ5NDhkNjFkN2EzZWQwXzU0OTc1NTgxOTE0NQ_acbb2be9-db07-4e78-a2a4-6f1aa7265b77">10</ix:nonFraction>% increase (decrease) in the probability of occurrence would not result in a material fair value fluctuation.</span></div><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90ZXh0cmVnaW9uOjIwZjc5ODBmMzZhOTQxZDg4ODQ5NDhkNjFkN2EzZWQwXzI2MzU_c4cb7f11-f40b-4dff-ac05-c45c90de9da0" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of recurring measurements included in Level 3 of the fair value hierarchy are presented as other income, net in our Statements of Operations and were as follows for the years ended December&#160;31, 2022, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1,</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia25f50b8fef94d1a9bc667f04f3a26ab_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90YWJsZTo5Nzk0MWY3ZGYwNzQ0YmI5OWZkYjczMzJhOTBiZmMwOC90YWJsZXJhbmdlOjk3OTQxZjdkZjA3NDRiYjk5ZmRiNzMzMmE5MGJmYzA4XzEtMS0xLTEtNDYwMTM_8ac83932-f642-4b2b-80a9-be62835e71c1">698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e35ddf250a487cbae6c8e1f803a4b1_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90YWJsZTo5Nzk0MWY3ZGYwNzQ0YmI5OWZkYjczMzJhOTBiZmMwOC90YWJsZXJhbmdlOjk3OTQxZjdkZjA3NDRiYjk5ZmRiNzMzMmE5MGJmYzA4XzEtMy0xLTEtNDYwMTM_bd94b863-20f2-4621-b763-31a05a3eae9d">1,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0080f34bc4774f159a2fbc226bec7e75_I20191231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90YWJsZTo5Nzk0MWY3ZGYwNzQ0YmI5OWZkYjczMzJhOTBiZmMwOC90YWJsZXJhbmdlOjk3OTQxZjdkZjA3NDRiYjk5ZmRiNzMzMmE5MGJmYzA4XzEtNS0xLTEtNDYwMTM_2c08ee76-cc8f-4178-84e0-5f793a9ad508">969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Exit Fee addition at fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideeb597472c94a98a7ce7e756017a2b2_D20220101-20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90YWJsZTo5Nzk0MWY3ZGYwNzQ0YmI5OWZkYjczMzJhOTBiZmMwOC90YWJsZXJhbmdlOjk3OTQxZjdkZjA3NDRiYjk5ZmRiNzMzMmE5MGJmYzA4XzItMS0xLTEtNDY3ODk_cfb09343-1fc7-4dcb-861d-30cd7e918311">375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib44009e3ef8846b299ee2faab0e9ac8c_D20210101-20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90YWJsZTo5Nzk0MWY3ZGYwNzQ0YmI5OWZkYjczMzJhOTBiZmMwOC90YWJsZXJhbmdlOjk3OTQxZjdkZjA3NDRiYjk5ZmRiNzMzMmE5MGJmYzA4XzItMy0xLTEtNDY3ODk_3a25380c-375f-48fd-9d03-04d2af75c23c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0921c20fa4634446aebe75988e9825d1_D20200101-20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90YWJsZTo5Nzk0MWY3ZGYwNzQ0YmI5OWZkYjczMzJhOTBiZmMwOC90YWJsZXJhbmdlOjk3OTQxZjdkZjA3NDRiYjk5ZmRiNzMzMmE5MGJmYzA4XzItNS0xLTEtNDY3ODk_759c0e9e-5e02-4e67-9c52-10171353d2a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018 Exit Fee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4aa9ee384f104add8be1fdc63cb9f8ce_D20220101-20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90YWJsZTo5Nzk0MWY3ZGYwNzQ0YmI5OWZkYjczMzJhOTBiZmMwOC90YWJsZXJhbmdlOjk3OTQxZjdkZjA3NDRiYjk5ZmRiNzMzMmE5MGJmYzA4XzQtMS0xLTEtNDY4MDA_c41c5940-a441-4932-9a0e-c70d05aae98d">510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74fef4adf9a14a308f8328b9570c5a83_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90YWJsZTo5Nzk0MWY3ZGYwNzQ0YmI5OWZkYjczMzJhOTBiZmMwOC90YWJsZXJhbmdlOjk3OTQxZjdkZjA3NDRiYjk5ZmRiNzMzMmE5MGJmYzA4XzQtMy0xLTEtNDY4MDA_261274a6-277a-4eb1-95a4-c498c33dc41a">678</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic44d3449c4204e78b2fb999f07d658ab_D20200101-20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90YWJsZTo5Nzk0MWY3ZGYwNzQ0YmI5OWZkYjczMzJhOTBiZmMwOC90YWJsZXJhbmdlOjk3OTQxZjdkZjA3NDRiYjk5ZmRiNzMzMmE5MGJmYzA4XzQtNS0xLTEtNDY4MDA_c4558f57-262d-4350-beb3-db313871186c">407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Exit Fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0d3d90e1a504d63bd8c04dc4913b676_D20220101-20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90YWJsZTo5Nzk0MWY3ZGYwNzQ0YmI5OWZkYjczMzJhOTBiZmMwOC90YWJsZXJhbmdlOjk3OTQxZjdkZjA3NDRiYjk5ZmRiNzMzMmE5MGJmYzA4XzUtMS0xLTEtNDY4MDg_2326f03d-bb1e-4e09-9abd-d9a1cda25adb">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04b8aa4c409143baabd2c14fa0c59341_D20210101-20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90YWJsZTo5Nzk0MWY3ZGYwNzQ0YmI5OWZkYjczMzJhOTBiZmMwOC90YWJsZXJhbmdlOjk3OTQxZjdkZjA3NDRiYjk5ZmRiNzMzMmE5MGJmYzA4XzUtMy0xLTEtNDY4MDg_f09327d6-6a7c-4d06-8d67-b96047dad942">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60af5b7c588a4c7b92f37d85a0e4d590_D20200101-20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90YWJsZTo5Nzk0MWY3ZGYwNzQ0YmI5OWZkYjczMzJhOTBiZmMwOC90YWJsZXJhbmdlOjk3OTQxZjdkZjA3NDRiYjk5ZmRiNzMzMmE5MGJmYzA4XzUtNS0xLTEtNDY4MDg_757063a4-c2bb-4f0b-b931-349a5f9a0051">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of exit fee derivative liabilities at December 31,</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7aeaa47a07574280ba69e0812b3fc9c4_I20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90YWJsZTo5Nzk0MWY3ZGYwNzQ0YmI5OWZkYjczMzJhOTBiZmMwOC90YWJsZXJhbmdlOjk3OTQxZjdkZjA3NDRiYjk5ZmRiNzMzMmE5MGJmYzA4XzMtMS0xLTEtNDYwMTM_66235c55-3678-48fb-ba7c-0c32f8133537">1,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia25f50b8fef94d1a9bc667f04f3a26ab_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90YWJsZTo5Nzk0MWY3ZGYwNzQ0YmI5OWZkYjczMzJhOTBiZmMwOC90YWJsZXJhbmdlOjk3OTQxZjdkZjA3NDRiYjk5ZmRiNzMzMmE5MGJmYzA4XzMtMy0xLTEtNDYwMTM_30632ddd-a8f8-4c61-98c4-76caf4ded6c4">698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e35ddf250a487cbae6c8e1f803a4b1_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90YWJsZTo5Nzk0MWY3ZGYwNzQ0YmI5OWZkYjczMzJhOTBiZmMwOC90YWJsZXJhbmdlOjk3OTQxZjdkZjA3NDRiYjk5ZmRiNzMzMmE5MGJmYzA4XzMtNS0xLTEtNDYwMTM_ddcd123f-7339-4f45-8a5b-b4ea6c597210">1,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i8c6ecca27b7b4659bf1d61cfb55de996_121"></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90ZXh0cmVnaW9uOjA4MzllYzIxNTcxYjQ1NTliN2JjMzRlNjZiNzMxMzgwXzM3Mzk_67dd489e-2368-4589-bfc0-e13724c5552d" continuedAt="i7f882c05c3324a49b583574d4eaf854e" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="i7f882c05c3324a49b583574d4eaf854e" continuedAt="ib15a8bc227434d549a63d3c613ea2964"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have recorded right-of-use operating lease assets under <ix:nonFraction unitRef="lease_agreement" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="INF" name="ardx:NumberOfOperatingLeaseArrangements" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90ZXh0cmVnaW9uOjA4MzllYzIxNTcxYjQ1NTliN2JjMzRlNjZiNzMxMzgwXzc1_29310a97-6c34-486b-8519-85110e53b578">three</ix:nonFraction> lease agreements. We have evaluated our facility leases and determined that, effective upon the adoption of Topic 842, the leases evaluated are all operating leases. We have performed an evaluation of our other contracts with suppliers and collaborators in accordance with Topic 842 and have determined that, except for the facility leases described below, none of our contracts contain a lease. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have recorded a right-of-use operating lease asset located in Fremont, California under a lease agreement entered into in September 2008 that was amended multiple times to add space and to extend the lease term through March 2025. The office space consists of <ix:nonFraction unitRef="sqft" contextRef="i26bf80d609da4735913857489e4da748_I20221231" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90ZXh0cmVnaW9uOjA4MzllYzIxNTcxYjQ1NTliN2JjMzRlNjZiNzMxMzgwXzEyMTc_e7ff74e3-0701-411f-803f-aeeca228fa92">72,500</ix:nonFraction> square feet. We do not have an option to renew the lease at our current Fremont location beyond March 2025.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have recorded a right-of-use operating lease asset located in Waltham, Massachusetts under a lease agreement entered into in October 2018. The office space consisted of <ix:nonFraction unitRef="sqft" contextRef="i335c2c940aa8413bb90dd9d65c09b3ba_I20181031" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90ZXh0cmVnaW9uOjA4MzllYzIxNTcxYjQ1NTliN2JjMzRlNjZiNzMxMzgwXzE1NTU_50214aa7-57de-4d3a-bcfb-dec19c517d2e">3,520</ix:nonFraction> square feet with the lease terminating in September 2021. We did not renew the lease at our original Waltham, Massachusetts facility. During April 2021 and May 2021, we recorded right-of-use operating lease assets for a new facility in Waltham, Massachusetts under a lease agreement entered into during December 2020 with lease commencement dates during April and May 2021. The office space consists of <ix:nonFraction unitRef="sqft" contextRef="if84711cbb7fb484d9907b17e292a5c75_I20210531" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90ZXh0cmVnaW9uOjA4MzllYzIxNTcxYjQ1NTliN2JjMzRlNjZiNzMxMzgwXzE5NjE_8b5aad75-f805-40f4-bdc0-b040eed690ae">12,864</ix:nonFraction> square feet with the lease terminating in June 2026. We have an option to extend the lease term for <ix:nonFraction unitRef="renewal_option" contextRef="if84711cbb7fb484d9907b17e292a5c75_I20210531" decimals="INF" name="ardx:LesseeOperatingLeaseNumberOfRenewalOptions" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90ZXh0cmVnaW9uOjA4MzllYzIxNTcxYjQ1NTliN2JjMzRlNjZiNzMxMzgwXzIwNjQ_7c137da7-231d-46f5-a9f6-d35b70765a2a">one</ix:nonFraction> additional <ix:nonNumeric contextRef="if84711cbb7fb484d9907b17e292a5c75_I20210531" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90ZXh0cmVnaW9uOjA4MzllYzIxNTcxYjQ1NTliN2JjMzRlNjZiNzMxMzgwXzM3NDA_abb358fd-acc5-417f-a42a-cd79af292777">five year</ix:nonNumeric> period. This option to extend the lease term has not been included in the calculation since currently the exercise of the option is uncertain and therefore deemed not probable. We recorded a $<ix:nonFraction unitRef="usd" contextRef="ic02d026a5b904c17807bd479ea7d0b3e_D20210401-20210531" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90ZXh0cmVnaW9uOjA4MzllYzIxNTcxYjQ1NTliN2JjMzRlNjZiNzMxMzgwXzIyNzc_9b510662-eefb-4032-976c-d764c9ef956e">1.6</ix:nonFraction> million right-of-use asset and lease liability for the Waltham lease upon commencement of the lease.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><ix:continuation id="ib15a8bc227434d549a63d3c613ea2964"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have recorded a right-of-use operating lease asset located in Milwaukee, Wisconsin under a lease agreement entered into in October 2020 with a lease commencement date in November 2020. The office space consists of <ix:nonFraction unitRef="sqft" contextRef="i6c53895082604a918d0ac2f036a8236f_I20201130" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90ZXh0cmVnaW9uOjA4MzllYzIxNTcxYjQ1NTliN2JjMzRlNjZiNzMxMzgwXzI1OTA_9a115951-01ce-440d-af2b-dcef36626923">4,768</ix:nonFraction> square feet with the lease terminating in February 2026. We have an option to <ix:nonNumeric contextRef="i191e1bf76f4b440593cb3aed98e7c4e4_D20201101-20201130" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90ZXh0cmVnaW9uOjA4MzllYzIxNTcxYjQ1NTliN2JjMzRlNjZiNzMxMzgwXzM3NDE_75756013-2971-4863-9cf0-30e3b0ccc25c">extend</ix:nonNumeric> the lease term by <ix:nonFraction unitRef="renewal_option" contextRef="i6c53895082604a918d0ac2f036a8236f_I20201130" decimals="INF" name="ardx:LesseeOperatingLeaseNumberOfRenewalOptions" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90ZXh0cmVnaW9uOjA4MzllYzIxNTcxYjQ1NTliN2JjMzRlNjZiNzMxMzgwXzI2OTY_e725197c-d4ec-4c7a-9f1b-51cced5bf0cf">one</ix:nonFraction> additional <ix:nonNumeric contextRef="i6c53895082604a918d0ac2f036a8236f_I20201130" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90ZXh0cmVnaW9uOjA4MzllYzIxNTcxYjQ1NTliN2JjMzRlNjZiNzMxMzgwXzM3NDI_19495bae-4fdc-4c67-9b90-290320ce8767">five-year</ix:nonNumeric> period. This option to extend the lease term has not been included in the calculation since currently the exercise of the option is uncertain and therefore deemed not probable. We recorded a $<ix:nonFraction unitRef="usd" contextRef="i191e1bf76f4b440593cb3aed98e7c4e4_D20201101-20201130" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90ZXh0cmVnaW9uOjA4MzllYzIxNTcxYjQ1NTliN2JjMzRlNjZiNzMxMzgwXzI5MDk_b8f6d63e-2646-4e18-92ef-b4880f42d771">0.4</ix:nonFraction>&#160;million right-of use asset and lease liability for the Milwaukee lease upon commencement of the lease.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our leases are operating leases and each contain customary rent escalation clauses. Certain of the leases have both lease and non-lease components. We have elected to account for each separate lease component and the non-lease components associated with that lease component as a single lease component for all classes of underlying assets. </span></div><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="ardx:ScheduleOfAdditionalDetailsOfLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90ZXh0cmVnaW9uOjA4MzllYzIxNTcxYjQ1NTliN2JjMzRlNjZiNzMxMzgwXzM3NDM_6e5507c6-46dc-431d-a236-42b7b9f5cd01" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides additional details of our facility leases presented in our balance sheets (dollars in thousands):</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:74.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Facilities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZToyZWJkNGU4MDhjNmY0ZTNmYmM1ZjJjOGE0YzRkM2VlMi90YWJsZXJhbmdlOjJlYmQ0ZTgwOGM2ZjRlM2ZiYzVmMmM4YTRjNGQzZWUyXzItMS0xLTEtNDYwMTM_606fdbfa-8aa4-4653-b2e3-683ecfd4822c">9,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZToyZWJkNGU4MDhjNmY0ZTNmYmM1ZjJjOGE0YzRkM2VlMi90YWJsZXJhbmdlOjJlYmQ0ZTgwOGM2ZjRlM2ZiYzVmMmM4YTRjNGQzZWUyXzItMy0xLTEtNDYwMTM_97625e08-ef6c-42c0-a6f1-4dd420240c81">12,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZToyZWJkNGU4MDhjNmY0ZTNmYmM1ZjJjOGE0YzRkM2VlMi90YWJsZXJhbmdlOjJlYmQ0ZTgwOGM2ZjRlM2ZiYzVmMmM4YTRjNGQzZWUyXzQtMS0xLTEtNDYwMTM_3c2c34d0-1715-4abc-a14f-543646fd453a">3,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZToyZWJkNGU4MDhjNmY0ZTNmYmM1ZjJjOGE0YzRkM2VlMi90YWJsZXJhbmdlOjJlYmQ0ZTgwOGM2ZjRlM2ZiYzVmMmM4YTRjNGQzZWUyXzQtMy0xLTEtNDYwMTM_20a076fa-ac3c-4f0a-95b0-c02010feaf13">3,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZToyZWJkNGU4MDhjNmY0ZTNmYmM1ZjJjOGE0YzRkM2VlMi90YWJsZXJhbmdlOjJlYmQ0ZTgwOGM2ZjRlM2ZiYzVmMmM4YTRjNGQzZWUyXzUtMS0xLTEtNDYwMTM_fe59d7cc-1252-45a2-8c5d-03797e8a96b4">5,855</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZToyZWJkNGU4MDhjNmY0ZTNmYmM1ZjJjOGE0YzRkM2VlMi90YWJsZXJhbmdlOjJlYmQ0ZTgwOGM2ZjRlM2ZiYzVmMmM4YTRjNGQzZWUyXzUtMy0xLTEtNDYwMTM_af956ecd-ed2b-4111-98c2-dd9ebbb81a3b">9,748</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZToyZWJkNGU4MDhjNmY0ZTNmYmM1ZjJjOGE0YzRkM2VlMi90YWJsZXJhbmdlOjJlYmQ0ZTgwOGM2ZjRlM2ZiYzVmMmM4YTRjNGQzZWUyXzYtMS0xLTEtNDYwMTM_77f657dd-3a06-4975-8267-6cb66cbd1b98">9,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZToyZWJkNGU4MDhjNmY0ZTNmYmM1ZjJjOGE0YzRkM2VlMi90YWJsZXJhbmdlOjJlYmQ0ZTgwOGM2ZjRlM2ZiYzVmMmM4YTRjNGQzZWUyXzYtMy0xLTEtNDYwMTM_d22f07c0-a8c1-4dda-b509-c5318719d2b3">13,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZToyZWJkNGU4MDhjNmY0ZTNmYmM1ZjJjOGE0YzRkM2VlMi90YWJsZXJhbmdlOjJlYmQ0ZTgwOGM2ZjRlM2ZiYzVmMmM4YTRjNGQzZWUyXzgtMS0xLTEtNDYwMTM_051d1645-4a9f-4568-9578-f8564af6281b">2.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i23bde0040cba4440804b10fdac242262_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZToyZWJkNGU4MDhjNmY0ZTNmYmM1ZjJjOGE0YzRkM2VlMi90YWJsZXJhbmdlOjJlYmQ0ZTgwOGM2ZjRlM2ZiYzVmMmM4YTRjNGQzZWUyXzgtMy0xLTEtNDYwMTM_2c3e680b-8d54-437b-8c1e-4e0f9a8ef6c8">3.4</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZToyZWJkNGU4MDhjNmY0ZTNmYmM1ZjJjOGE0YzRkM2VlMi90YWJsZXJhbmdlOjJlYmQ0ZTgwOGM2ZjRlM2ZiYzVmMmM4YTRjNGQzZWUyXzktMS0xLTEtNDYwMTM_b80cda89-d3ae-4e70-9c9f-e497c25189da">6.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZToyZWJkNGU4MDhjNmY0ZTNmYmM1ZjJjOGE0YzRkM2VlMi90YWJsZXJhbmdlOjJlYmQ0ZTgwOGM2ZjRlM2ZiYzVmMmM4YTRjNGQzZWUyXzktMy0xLTEtNDYwMTM_64a29e68-a9c3-4db0-af5c-dadab61388c2">6.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90ZXh0cmVnaW9uOjA4MzllYzIxNTcxYjQ1NTliN2JjMzRlNjZiNzMxMzgwXzM3NDQ_fd785c54-e756-45f4-87b7-2537e18b9e41" escape="true"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease costs, which are included in operating expenses in our statements of operations, were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZTowMjAzN2ZjNTdiYTQ0ZjAxODg5NGJmM2U4M2JmYWU0ZS90YWJsZXJhbmdlOjAyMDM3ZmM1N2JhNDRmMDE4ODk0YmYzZTgzYmZhZTRlXzItMS0xLTEtNDYwMTM_24bcd240-9215-4b5a-a90d-ec29320ad32e">4,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZTowMjAzN2ZjNTdiYTQ0ZjAxODg5NGJmM2U4M2JmYWU0ZS90YWJsZXJhbmdlOjAyMDM3ZmM1N2JhNDRmMDE4ODk0YmYzZTgzYmZhZTRlXzItMy0xLTEtNDYwMTM_7ac8b677-d87c-4554-a7f3-2f9bbdff341a">3,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZTowMjAzN2ZjNTdiYTQ0ZjAxODg5NGJmM2U4M2JmYWU0ZS90YWJsZXJhbmdlOjAyMDM3ZmM1N2JhNDRmMDE4ODk0YmYzZTgzYmZhZTRlXzItNS0xLTEtNDYwMTM_bd0a4be8-1941-49a0-a5b6-c70072ae7a23">2,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for operating lease</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZTowMjAzN2ZjNTdiYTQ0ZjAxODg5NGJmM2U4M2JmYWU0ZS90YWJsZXJhbmdlOjAyMDM3ZmM1N2JhNDRmMDE4ODk0YmYzZTgzYmZhZTRlXzMtMS0xLTEtNDYwMTM_c2b9ef4a-6625-4735-b2e2-fbc7e1c69fac">4,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZTowMjAzN2ZjNTdiYTQ0ZjAxODg5NGJmM2U4M2JmYWU0ZS90YWJsZXJhbmdlOjAyMDM3ZmM1N2JhNDRmMDE4ODk0YmYzZTgzYmZhZTRlXzMtMy0xLTEtNDYwMTM_db91f2c8-3c40-4131-b022-241dc73b549e">3,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZTowMjAzN2ZjNTdiYTQ0ZjAxODg5NGJmM2U4M2JmYWU0ZS90YWJsZXJhbmdlOjAyMDM3ZmM1N2JhNDRmMDE4ODk0YmYzZTgzYmZhZTRlXzMtNS0xLTEtNDYwMTM_b97ebcf8-5b1e-46c6-9dc0-ca529a204e80">3,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90ZXh0cmVnaW9uOjA4MzllYzIxNTcxYjQ1NTliN2JjMzRlNjZiNzMxMzgwXzM3Mzg_c1f99bec-f871-42f2-a3f0-df314b9cca68" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our undiscounted cash payment obligations for our operating lease liabilities as of December&#160;31, 2022 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:86.436%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZTo3MTk0YWFhY2E2MjU0OWQ1OGYzMWRhMzk4ZTU2OTI0NC90YWJsZXJhbmdlOjcxOTRhYWFjYTYyNTQ5ZDU4ZjMxZGEzOThlNTY5MjQ0XzEtMi0xLTEtNDYwMTM_cba7cae9-a44c-445c-9d81-f47720db1547">4,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZTo3MTk0YWFhY2E2MjU0OWQ1OGYzMWRhMzk4ZTU2OTI0NC90YWJsZXJhbmdlOjcxOTRhYWFjYTYyNTQ5ZDU4ZjMxZGEzOThlNTY5MjQ0XzItMi0xLTEtNDYwMTM_9a44b1a2-80e8-4709-a68b-6036592ff834">4,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZTo3MTk0YWFhY2E2MjU0OWQ1OGYzMWRhMzk4ZTU2OTI0NC90YWJsZXJhbmdlOjcxOTRhYWFjYTYyNTQ5ZDU4ZjMxZGEzOThlNTY5MjQ0XzMtMi0xLTEtNDYwMTM_dffef324-4f2e-4a76-8be7-33ce853ac023">1,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZTo3MTk0YWFhY2E2MjU0OWQ1OGYzMWRhMzk4ZTU2OTI0NC90YWJsZXJhbmdlOjcxOTRhYWFjYTYyNTQ5ZDU4ZjMxZGEzOThlNTY5MjQ0XzQtMi0xLTEtNDYwMTM_4154552c-e214-4731-95b6-338be6a73056">252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="ardx:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZTo3MTk0YWFhY2E2MjU0OWQ1OGYzMWRhMzk4ZTU2OTI0NC90YWJsZXJhbmdlOjcxOTRhYWFjYTYyNTQ5ZDU4ZjMxZGEzOThlNTY5MjQ0XzYtMi0xLTEtNDYwMTM_84416f37-bc85-4e9d-8271-6cb14c0b1947">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted operating lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZTo3MTk0YWFhY2E2MjU0OWQ1OGYzMWRhMzk4ZTU2OTI0NC90YWJsZXJhbmdlOjcxOTRhYWFjYTYyNTQ5ZDU4ZjMxZGEzOThlNTY5MjQ0XzctMi0xLTEtNDYwMTM_c3efc16c-fc29-4572-a443-5e8d1c1b9f22">10,602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imputed interest expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZTo3MTk0YWFhY2E2MjU0OWQ1OGYzMWRhMzk4ZTU2OTI0NC90YWJsZXJhbmdlOjcxOTRhYWFjYTYyNTQ5ZDU4ZjMxZGEzOThlNTY5MjQ0XzgtMi0xLTEtNDYwMTM_31159865-f913-488e-a54d-94ef75b9b199">853</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZTo3MTk0YWFhY2E2MjU0OWQ1OGYzMWRhMzk4ZTU2OTI0NC90YWJsZXJhbmdlOjcxOTRhYWFjYTYyNTQ5ZDU4ZjMxZGEzOThlNTY5MjQ0XzktMi0xLTEtNDYwMTM_92eaaebd-f347-43b4-85c4-f0dbfa52bf59">9,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of operating lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZTo3MTk0YWFhY2E2MjU0OWQ1OGYzMWRhMzk4ZTU2OTI0NC90YWJsZXJhbmdlOjcxOTRhYWFjYTYyNTQ5ZDU4ZjMxZGEzOThlNTY5MjQ0XzEwLTItMS0xLTQ2MDEz_133a522c-c867-42a5-b384-46928b9f7f75">3,894</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZTo3MTk0YWFhY2E2MjU0OWQ1OGYzMWRhMzk4ZTU2OTI0NC90YWJsZXJhbmdlOjcxOTRhYWFjYTYyNTQ5ZDU4ZjMxZGEzOThlNTY5MjQ0XzExLTItMS0xLTQ2MDEz_0718a5bc-0fee-46dc-b807-8c42da92fc46">5,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjQvZnJhZzplZTNjYjU1NjhkYjY0OThiYjQwNWNkMWE1MzhlNjA1Yi90ZXh0cmVnaW9uOmVlM2NiNTU2OGRiNjQ5OGJiNDA1Y2QxYTUzOGU2MDViXzM0OTg_b915cb1e-3e17-46a0-96a8-6b3f0994f800" continuedAt="ied11311814b642d4a0de2542868f143a" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><ix:continuation id="ied11311814b642d4a0de2542868f143a"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, we filed a Form S-3 registration statement, which became effective in August 2020 ("2020 Registration Statement"), containing (i) a base prospectus for the offering, issuance and sale by us of up to a maximum aggregate offering price of $<ix:nonFraction unitRef="usd" contextRef="if776a22c61a44a539fe0fe538eb2a3e2_I20200731" decimals="INF" name="ardx:MaximumAggregateOfferingPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjQvZnJhZzplZTNjYjU1NjhkYjY0OThiYjQwNWNkMWE1MzhlNjA1Yi90ZXh0cmVnaW9uOmVlM2NiNTU2OGRiNjQ5OGJiNDA1Y2QxYTUzOGU2MDViXzI0OQ_796cf922-11cd-4168-ae97-c89ad5c74b47">250.0</ix:nonFraction> million of our common stock, preferred stock, debt securities, warrants and/or units, from time to time in one or more offerings; and (ii) a prospectus supplement for the offering, issuance and sale by us of up to a maximum aggregate offering price of $<ix:nonFraction unitRef="usd" contextRef="i6c0917f6cb2342afb6023949b42688ce_I20200731" decimals="INF" name="ardx:MaximumAggregateOfferingPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjQvZnJhZzplZTNjYjU1NjhkYjY0OThiYjQwNWNkMWE1MzhlNjA1Yi90ZXh0cmVnaW9uOmVlM2NiNTU2OGRiNjQ5OGJiNDA1Y2QxYTUzOGU2MDViXzQ5Ng_c6109666-05d0-4dca-89df-bf664dc34ab0">100.0</ix:nonFraction> million of our common stock that may be issued and sold, from time to time, under a sales agreement with Jefferies LLC ("Jefferies"), deemed to be &#8220;at-the-market offerings&#8221; ("2020 Open Market Sales Agreement").&#160;Pursuant to the 2020 Open Market Sales Agreement, Jefferies, as sales agent, received a commission of up to <ix:nonFraction unitRef="number" contextRef="ib4aee40b13b3480c9ac040be86a38b5d_D20220101-20221231" decimals="INF" name="ardx:StockIssuanceCostCommissionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjQvZnJhZzplZTNjYjU1NjhkYjY0OThiYjQwNWNkMWE1MzhlNjA1Yi90ZXh0cmVnaW9uOmVlM2NiNTU2OGRiNjQ5OGJiNDA1Y2QxYTUzOGU2MDViXzgyOQ_45417bc2-cf95-4bfb-b24a-a8e1b6da33d4">3.0</ix:nonFraction>% of the gross sales price for shares of common stock sold under the 2020 Open Market Sales Agreement. As of December 31, 2021, we had sold <ix:nonFraction unitRef="shares" contextRef="i6e194876618f454a8e69ce8891915a74_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjQvZnJhZzplZTNjYjU1NjhkYjY0OThiYjQwNWNkMWE1MzhlNjA1Yi90ZXh0cmVnaW9uOmVlM2NiNTU2OGRiNjQ5OGJiNDA1Y2QxYTUzOGU2MDViXzExMjI_9f565c9e-9c25-41a5-a10c-2eaaeaa17981">23.3</ix:nonFraction> million shares and received the maximum gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i6e194876618f454a8e69ce8891915a74_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjQvZnJhZzplZTNjYjU1NjhkYjY0OThiYjQwNWNkMWE1MzhlNjA1Yi90ZXh0cmVnaW9uOmVlM2NiNTU2OGRiNjQ5OGJiNDA1Y2QxYTUzOGU2MDViXzExNTQ_ffadf2c5-2a0b-4195-9e81-7169e881457a">100.0</ix:nonFraction> million pursuant to the 2020 Open Market Sales Agreement. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we filed an additional prospectus supplement under the 2020 Registration Statement for the offering, issuance and sale by us of up to a maximum aggregate offering price of $<ix:nonFraction unitRef="usd" contextRef="i091722886b334fd9bde76bd765e73617_I20210831" decimals="INF" name="ardx:MaximumAggregateOfferingPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjQvZnJhZzplZTNjYjU1NjhkYjY0OThiYjQwNWNkMWE1MzhlNjA1Yi90ZXh0cmVnaW9uOmVlM2NiNTU2OGRiNjQ5OGJiNDA1Y2QxYTUzOGU2MDViXzE1MTI_641ece77-6c72-4e61-81d1-a3132a97d6b8">150.0</ix:nonFraction> million of our common stock that may be issued and sold, from time to time, under an additional sales agreement we entered into with Jefferies ("2021 Open Market Sales Agreement"), pursuant to which we may, from time to time, sell up to $<ix:nonFraction unitRef="usd" contextRef="i091722886b334fd9bde76bd765e73617_I20210831" decimals="INF" name="ardx:MaximumAggregateOfferingPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjQvZnJhZzplZTNjYjU1NjhkYjY0OThiYjQwNWNkMWE1MzhlNjA1Yi90ZXh0cmVnaW9uOmVlM2NiNTU2OGRiNjQ5OGJiNDA1Y2QxYTUzOGU2MDViXzE3NDg_641ece77-6c72-4e61-81d1-a3132a97d6b8">150.0</ix:nonFraction> million in shares of our common stock through Jefferies. We are required to sell shares under the 2021 Open Market Sales Agreement. Pursuant to the 2021 Open Market Sales Agreement, Jefferies, as our sales agent, receives a commission of up to <ix:nonFraction unitRef="number" contextRef="i387017f0cb654df1bee8547faa646789_D20210801-20221231" decimals="INF" name="ardx:StockIssuanceCostCommissionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjQvZnJhZzplZTNjYjU1NjhkYjY0OThiYjQwNWNkMWE1MzhlNjA1Yi90ZXh0cmVnaW9uOmVlM2NiNTU2OGRiNjQ5OGJiNDA1Y2QxYTUzOGU2MDViXzE5OTE_2c6849e3-05c1-4c41-9068-3e3d201a3897">3.0</ix:nonFraction>% of the gross sales price for shares of common stock sold under the 2021 Open Market Sales Agreement. During the twelve months ended December&#160;31, 2022, we sold <ix:nonFraction unitRef="shares" contextRef="id010daff3c1947e29d8c5fd89ebaa449_D20221001-20221231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjQvZnJhZzplZTNjYjU1NjhkYjY0OThiYjQwNWNkMWE1MzhlNjA1Yi90ZXh0cmVnaW9uOmVlM2NiNTU2OGRiNjQ5OGJiNDA1Y2QxYTUzOGU2MDViXzU0OTc1NTgyMTE0NA_4c1bbc30-a9fe-474c-a3fe-f0607c5431c0">64.1</ix:nonFraction> million shares and received gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="ieeb64a378b284f01ba441778bf717ff2_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjQvZnJhZzplZTNjYjU1NjhkYjY0OThiYjQwNWNkMWE1MzhlNjA1Yi90ZXh0cmVnaW9uOmVlM2NiNTU2OGRiNjQ5OGJiNDA1Y2QxYTUzOGU2MDViXzU0OTc1NTgxOTg5OA_691bca29-b62c-4a20-96ff-a59b2bb0e3a5">73.1</ix:nonFraction> million at a weighted average sales price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="ieeb64a378b284f01ba441778bf717ff2_D20220101-20221231" decimals="2" name="ardx:SaleOfStockWeightedAveragePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjQvZnJhZzplZTNjYjU1NjhkYjY0OThiYjQwNWNkMWE1MzhlNjA1Yi90ZXh0cmVnaW9uOmVlM2NiNTU2OGRiNjQ5OGJiNDA1Y2QxYTUzOGU2MDViXzU0OTc1NTgxOTkwMg_4732205e-9e7a-4c27-a328-a784059347a4">1.14</ix:nonFraction> per share under the 2021 Open Market Sales Agreement. As of December&#160;31, 2022 we sold a total of <ix:nonFraction unitRef="shares" contextRef="i53cfbbd1366348c3a6a036a0048aed7a_I20221231" decimals="-5" name="ardx:EquitySalesAgreementSharesIssuedSinceInception" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjQvZnJhZzplZTNjYjU1NjhkYjY0OThiYjQwNWNkMWE1MzhlNjA1Yi90ZXh0cmVnaW9uOmVlM2NiNTU2OGRiNjQ5OGJiNDA1Y2QxYTUzOGU2MDViXzIxMTc_90e1911b-f1cd-464f-b243-e0f09c608926">79.8</ix:nonFraction> million shares and received gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i53cfbbd1366348c3a6a036a0048aed7a_I20221231" decimals="-5" name="ardx:EquitySalesAgreementProceedsFromSharesIssuedSinceInception" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjQvZnJhZzplZTNjYjU1NjhkYjY0OThiYjQwNWNkMWE1MzhlNjA1Yi90ZXh0cmVnaW9uOmVlM2NiNTU2OGRiNjQ5OGJiNDA1Y2QxYTUzOGU2MDViXzIxNTg_a5bf7e82-c7ac-42c3-973c-d6a54abd09da">98.1</ix:nonFraction> million at a weighted average sales price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i387017f0cb654df1bee8547faa646789_D20210801-20221231" decimals="2" name="ardx:SaleOfStockWeightedAveragePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjQvZnJhZzplZTNjYjU1NjhkYjY0OThiYjQwNWNkMWE1MzhlNjA1Yi90ZXh0cmVnaW9uOmVlM2NiNTU2OGRiNjQ5OGJiNDA1Y2QxYTUzOGU2MDViXzIyMTI_43daec4d-dcfe-42b9-96f8-690afd8e48b4">1.23</ix:nonFraction> per share under the 2021 Open Market Sales Agreement. During the period January 1, 2023 to January 12, 2023, we received additional gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="ic0543a071cf942e590a16ac2b267ca3a_D20230101-20230112" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjQvZnJhZzplZTNjYjU1NjhkYjY0OThiYjQwNWNkMWE1MzhlNjA1Yi90ZXh0cmVnaW9uOmVlM2NiNTU2OGRiNjQ5OGJiNDA1Y2QxYTUzOGU2MDViXzc2OTY1ODE0MDU4NjY_6cfc0390-2c5d-4ecf-991c-5d9a56ba1d28">20.0</ix:nonFraction> million for the sale of an additional <ix:nonFraction unitRef="shares" contextRef="ic0543a071cf942e590a16ac2b267ca3a_D20230101-20230112" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjQvZnJhZzplZTNjYjU1NjhkYjY0OThiYjQwNWNkMWE1MzhlNjA1Yi90ZXh0cmVnaW9uOmVlM2NiNTU2OGRiNjQ5OGJiNDA1Y2QxYTUzOGU2MDViXzc2OTY1ODE0MDU5MTA_1243993b-1be8-4627-b97d-9cbe3008d5fe">7.7</ix:nonFraction> million shares which were sold at a weighted average sales price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="ic0543a071cf942e590a16ac2b267ca3a_D20230101-20230112" decimals="2" name="ardx:SaleOfStockWeightedAveragePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjQvZnJhZzplZTNjYjU1NjhkYjY0OThiYjQwNWNkMWE1MzhlNjA1Yi90ZXh0cmVnaW9uOmVlM2NiNTU2OGRiNjQ5OGJiNDA1Y2QxYTUzOGU2MDViXzc2OTY1ODE0MDU4NzA_d0c8b514-a191-4622-bd2f-f3445e912e6a">2.60</ix:nonFraction> per share under the 2021 Open Market Sales Agreement. There have been no other sales under the 2021 Open Market Sales Agreement after December 31, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, we filed a Form S-3 registration statement, which became effective in January 2023 ("2023 Registration Statement"), containing (i) a base prospectus for the offering, issuance and sale by us of up to a maximum aggregate offering price of $<ix:nonFraction unitRef="usd" contextRef="i0edad5a730a244cba8f8a9819262823c_I20230131" decimals="INF" name="ardx:MaximumAggregateOfferingPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjQvZnJhZzplZTNjYjU1NjhkYjY0OThiYjQwNWNkMWE1MzhlNjA1Yi90ZXh0cmVnaW9uOmVlM2NiNTU2OGRiNjQ5OGJiNDA1Y2QxYTUzOGU2MDViXzU0OTc1NTgyNDgyMQ_295510a4-7a74-4728-9fbe-ea57ba75958d">250.0</ix:nonFraction> million of our common stock, preferred stock, debt securities, warrants and/or units, from time to time in one or more offerings; and (ii) a prospectus supplement for the offering, issuance and sale by us of up to a maximum aggregate offering price of $<ix:nonFraction unitRef="usd" contextRef="id8349613f0ed462d8ac8ec08c2be4b51_I20230131" decimals="INF" name="ardx:MaximumAggregateOfferingPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjQvZnJhZzplZTNjYjU1NjhkYjY0OThiYjQwNWNkMWE1MzhlNjA1Yi90ZXh0cmVnaW9uOmVlM2NiNTU2OGRiNjQ5OGJiNDA1Y2QxYTUzOGU2MDViXzU0OTc1NTgyNDgyNQ_9be593c4-93f8-4d02-86b5-a3c05b268ffd">150.0</ix:nonFraction> million of our common stock that may be issued and sold, from time to time, under a sales agreement with Jefferies LLC ("Jefferies"), deemed to be &#8220;at-the-market offerings&#8221; ("2023 Open Market Sales Agreement").&#160;Pursuant to the 2023 Open Market Sales Agreement, Jefferies, as sales agent, may receive a commission of up to <ix:nonFraction unitRef="number" contextRef="i05cd4ea70ed4485589e755e460b69fd1_D20230101-20230131" decimals="INF" name="ardx:StockIssuanceCostCommissionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjQvZnJhZzplZTNjYjU1NjhkYjY0OThiYjQwNWNkMWE1MzhlNjA1Yi90ZXh0cmVnaW9uOmVlM2NiNTU2OGRiNjQ5OGJiNDA1Y2QxYTUzOGU2MDViXzU0OTc1NTgyNDgyOQ_afb0af8d-ab5f-4df3-b4be-caea5167842f">3.0</ix:nonFraction>% of the gross sales price for shares of common stock sold under the 2023 Open Market Sales Agreement. There have been no sales of our common stock under the 2023 Open Market Sales Agreement.</span></div></ix:continuation><div id="i8c6ecca27b7b4659bf1d61cfb55de996_127"></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzc3MjI_503777d4-a92c-4a65-80c8-4fa7f3e16aea" continuedAt="i96bbae72e7df49edaf2f0c0ed724f0ab" escape="true">EQUITY INCENTIVE PLANS</ix:nonNumeric></span></div><ix:continuation id="i96bbae72e7df49edaf2f0c0ed724f0ab" continuedAt="i527c4d00d5a643de9e14b5249c5b1935"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2008 Plan</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We granted options under our 2008 Stock Incentive Plan (&#8220;2008 Plan&#8221;) until June&#160;2014 when it was terminated as to future awards, although it continues to govern the terms of options that remain outstanding under the 2008 Plan. The 2008 Plan provided for the granting of incentive and non-qualified stock options, and stock purchase rights to employees, directors and consultants at the discretion of the board of directors. Stock options granted generally vested over a period of <ix:nonNumeric contextRef="i59e25fbea49d4656871685e6d2d6c76e_D20140101-20140630" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzUyNA_bffbe7a0-02d1-4c5d-8e47-2cc1d4675288">four years</ix:nonNumeric> from the date of grant. In connection with the board of directors and stockholders&#8217; approval of the 2014 Plan, all remaining shares available for future award under the 2008 Plan were transferred to 2014 Plan, as discussed below, and the 2008 Plan was terminated.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Plan</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2014 Equity Incentive Award Plan (&#8220;2014 Plan&#8221;) became effective on June&#160;18, 2014. Under the 2014 Plan, <ix:nonFraction unitRef="shares" contextRef="i91127df0154643aeaa974e5370a0d08f_I20140618" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzg5Mg_220d737f-6abe-4a89-8b4b-cba6bcf88b8c">1.4</ix:nonFraction> million shares of common stock were initially reserved for issuance pursuant to a variety of stock-based compensation awards, including stock options, stock appreciation rights ("SARs"), restricted stock awards, service-based restricted stock unit (&#8220;RSU&#8221;) awards, performance-based restricted stock unit (&#8220;PRSU&#8221;) awards, deferred stock awards, deferred stock unit awards, dividend equivalent awards, stock payment awards and performance awards. In addition, <ix:nonFraction unitRef="shares" contextRef="i3b2b0a1450e146dab1869a3c643a4b54_D20140618-20140618" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzEzNDU_a45d47de-419e-4ca6-aafe-1066d1f63a13">35</ix:nonFraction> thousand shares that had been available for future awards under the 2008 Plan as of June&#160;18, 2014, were added to the initial reserve available under the 2014 Plan, bringing the total reserve upon the effective date of the 2014 Plan to <ix:nonFraction unitRef="shares" contextRef="i91127df0154643aeaa974e5370a0d08f_I20140618" decimals="-5" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzE1NzQ_6047eb90-afd4-4ae1-a1ab-6fe5daeed1af">1.5</ix:nonFraction> million shares. The number of shares initially reserved for </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><ix:continuation id="i527c4d00d5a643de9e14b5249c5b1935" continuedAt="ie5aa7211e1ad40fbb2dce81e03c0f4c1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issuance or transfer pursuant to awards under the 2014 Plan will be increased by (i)&#160;the number of shares represented by awards outstanding under 2008 Plan on June&#160;18, 2014, that are either forfeited or lapse unexercised or that are repurchased for the original purchase price thereof, up to a maximum of <ix:nonFraction unitRef="shares" contextRef="i91127df0154643aeaa974e5370a0d08f_I20140618" decimals="-5" name="ardx:IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponInclusionOfForfeitedOrUnexercisedOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzE5MzQ_29436a1f-3f3a-442f-919d-1e78960f4d7f">1.2</ix:nonFraction> million shares, and (ii)&#160;if approved by the administrator of the 2014 Plan, an annual increase on the first day of each fiscal&#160;year ending in 2024 equal to the lesser of (A)&#160;four&#160;percent (<ix:nonFraction unitRef="number" contextRef="i91127df0154643aeaa974e5370a0d08f_I20140618" decimals="INF" name="ardx:IncreaseInSharesReservedForIssuanceOptionForAnnualIncreaseAsPercentageOfSharesOutstanding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzIxMTc_66336035-46c3-459f-84d0-7b348f263916">4.0</ix:nonFraction>%) of the shares of stock outstanding (on an as converted basis) on the last day of the immediately preceding fiscal&#160;year and (B)&#160;such smaller number of shares of stock as determined by our board of directors; provided, however, that no more than <ix:nonFraction unitRef="shares" contextRef="i91127df0154643aeaa974e5370a0d08f_I20140618" decimals="-5" name="ardx:IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponExerciseOfStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzIzNjU_393c5966-8a2f-4878-b828-3e7c02d21815">10.7</ix:nonFraction> million shares of stock may be issued upon the exercise of incentive stock options.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2016 Plan</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November&#160;2016, our board of directors approved the 2016 Employment Commencement Incentive Plan (&#8220;Inducement Plan&#8221;) under which <ix:nonFraction unitRef="shares" contextRef="ib434fa02b7f94f70a56b9427b8d40564_I20161130" decimals="-5" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzI1ODg_f0c9501e-5a1f-4a84-9b9a-5dca9dd7b7b4">1.0</ix:nonFraction> million shares were reserved. In January 2021, January 2022 and December 2022, <ix:nonFraction unitRef="shares" contextRef="id17ce6206b53406fae2405e677fe43ef_D20210101-20210131" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzI2Mzk_eb47b726-b60a-4ee5-b40c-7518b19c6915">0.5</ix:nonFraction>&#160;million, <ix:nonFraction unitRef="shares" contextRef="i43e122158f0e415aa7661317d01ff3be_D20220101-20220131" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzI2NDY_c7a38adf-3a81-44cc-bf61-40a165d64f8b">2.0</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="shares" contextRef="i083ca43bb16849a593d6fe2102ad4aca_D20221201-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzIxOTkwMjMyNjYyMjA_c3e93ada-28eb-483c-b9f3-6549447d4a8f">3.0</ix:nonFraction>&#160;million shares, respectively, were added to the Inducement Plan. As of December&#160;31, 2022, <ix:nonFraction unitRef="shares" contextRef="if5d377e7e91446f9872db311ff7a998d_I20221231" decimals="-5" name="ardx:CommonStockSubjectToIssuedInducementGrantsShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzI3MTY_3834dc15-4d42-4d62-b27c-70c5a0018f03">2.1</ix:nonFraction> million shares of our common stock were subject to inducement grants that were issued pursuant to the Inducement Plan.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzc3MjM_1b471a17-d1cc-41c3-bc5f-32751338c68b" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our stock option activity and related information during the twelve months ended December&#160;31, 2022 is as follows (in thousands, except per share dollar amounts and years):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:39.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.206%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.035%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares&#160;Available for&#160;Grant</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Options&#160;Issued&#160;and&#160;Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual&#160;Term<br/>(in Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic&#160;Value</span></td></tr><tr style="height:32pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number&#160;of&#160;Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise&#160;Price&#160;<br/>per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i208be3295b5d448a8b943c647170b858_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzMtMS0xLTEtNDYwMTM_c35ed0d2-2143-40c2-b91e-35fc81149ce6">4,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzMtMy0xLTEtNDYwMTM_6b5534a1-a27e-4141-926a-66cdc0c14a9c">10,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzMtNS0xLTEtNDYwMTM_e262673b-6679-4491-9ccd-710c4c39a7e2">7.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options authorized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4d035ef039b9449f9a833a4878f300ef_D20220101-20221231" decimals="INF" name="ardx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToAuthorizedInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzQtMS0xLTEtNDYwMTM_87dd0b0b-4b5e-4ba3-8230-5c1480a17c02">10,207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4d035ef039b9449f9a833a4878f300ef_D20220101-20221231" decimals="INF" name="ardx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToGrantedInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzUtMS0xLTEtNDYwMTM_22cf97fc-53c7-4020-9c82-86d78f6d4d17">5,392</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzUtMy0xLTEtNDYwMTM_25a8139e-855b-4bc5-99cd-3826f52d25f3">5,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzUtNS0xLTEtNDYwMTM_72477ea2-8586-4295-bba5-e19c27985d0f">0.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzYtMy0xLTEtNDYwMTM_18db41e5-5589-4141-86cf-9c272a47df72">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzYtNS0xLTEtNDYwMTM_ab979727-3484-4b10-926f-6dad2131e810">0.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4d035ef039b9449f9a833a4878f300ef_D20220101-20221231" decimals="INF" name="ardx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToCanceledInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzctMS0xLTEtNDYwMTM_f4b5af5f-16ff-4b35-89a3-ed8a18d1a0e0">1,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzctMy0xLTEtNDYwMTM_b7c830b3-448d-413b-9677-bfa3b5a4339b">1,832</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzctNS0xLTEtNDYwMTM_91c62ea4-b62e-48cb-a719-f6916d056af8">5.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock for services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4d035ef039b9449f9a833a4878f300ef_D20220101-20221231" decimals="INF" name="ardx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToStockIssuedForServicesInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzgtMS0xLTEtNDYwMTM_bd7d6530-3737-4947-b564-f8ed6c5685a0">712</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief16b3cbe3934dc98b9bc68d2856ca35_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzEwLTEtMS0xLTQ2MDEz_b02bd44e-d054-43d2-ab35-9b9d0e0c3db7">10,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzEwLTMtMS0xLTQ2MDEz_05e0070e-7522-4433-b0b7-94d06c653965">13,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzEwLTUtMS0xLTQ2MDEz_faaee074-5681-49ed-b639-fdf5dccf66da">4.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzEwLTctMS0xLTQ2MDEz_65ed7efc-0726-4c82-b2fa-77884e9806a8">7.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzEwLTktMS0xLTQ2MDEz_219d80cb-0c13-4eed-8c6b-a7c6393edb6f">10,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzExLTMtMS0xLTQ2MDEz_5d36ea73-9b79-4570-8cea-3c32b19b6cfa">13,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzExLTUtMS0xLTQ2MDEz_19973268-2765-4a29-a04d-98185c148f6c">4.83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzExLTctMS0xLTQ2MDEz_a05103a3-31b3-4157-8e16-7b0ee69608f3">7.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzExLTktMS0xLTQ2MDEz_32de5e43-8091-4bb0-8597-45b0c69c5a5c">10,156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzEyLTMtMS0xLTQ2MDEz_6e8b6b40-d7fa-4569-8f31-c785b0ba6d17">8,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzEyLTUtMS0xLTQ2MDEz_2323c280-1a51-4282-8b48-c2933abadc77">6.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzEyLTctMS0xLTQ2MDEz_c442fe69-e518-4ec3-b4cd-7bcd866c75fe">6.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzEyLTktMS0xLTQ2MDEz_ee668e7a-62c6-4719-ac63-b603eba71152">2,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value represents the difference between the total pre-tax value (i.e., the difference between our stock price and the exercise price) of stock options outstanding as of December&#160;31, 2022, based on our common stock closing price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzMyMjg_1ee018f2-5b4f-4572-a537-2df5ec1fd5ab">2.85</ix:nonFraction> per share, which would have been received by the option holders if all their in-the-money options had been exercised as of that date.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intrinsic value of options exercised during the&#160;years ended December&#160;31, 2022, 2021 and 2020, was $<ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzM0NDU_5881d14c-9021-48a1-b572-ef76f56fe1b4">30</ix:nonFraction> thousand, $<ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzM0NDk_1f5de1e1-655c-49a0-9322-9b2678de6670">1.7</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzM0NTc_94312e07-1884-4a56-895b-3e13fd759658">2.7</ix:nonFraction> million, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date estimated fair value of options granted during the&#160;years ended December&#160;31, 2022, 2021 and 2020 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzM1ODg_1c305165-e721-434c-8814-ac91baad5e75">0.63</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzM1OTI_918d098d-571e-4b53-a136-4090045c2a3d">3.92</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzM1OTk_dd1f9f36-9d0d-468a-9ef4-254ef1a593d4">4.82</ix:nonFraction> per share, respectively. <ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzc3MjQ_2e071922-cb37-47fa-8f43-75af93d7678f" continuedAt="i87ac1fe81bfa4ae8b763f214bc811c8f" escape="true">The estimated grant date fair value of employee stock options was calculated using the Black-Scholes option-pricing model, based on the following weighted-average assumptions:</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="i87ac1fe81bfa4ae8b763f214bc811c8f"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4d035ef039b9449f9a833a4878f300ef_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo0MzM3Mjg1M2YyZmI0ZDNjYTdmZTJiZDkyNDIyMTkxNy90YWJsZXJhbmdlOjQzMzcyODUzZjJmYjRkM2NhN2ZlMmJkOTI0MjIxOTE3XzItMS0xLTEtNDYwMTM_0b41406b-7994-4d7c-83ab-30a9e3143e7e">4.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic5c3b975ccf642298e9ab071e46c4b8e_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo0MzM3Mjg1M2YyZmI0ZDNjYTdmZTJiZDkyNDIyMTkxNy90YWJsZXJhbmdlOjQzMzcyODUzZjJmYjRkM2NhN2ZlMmJkOTI0MjIxOTE3XzItMy0xLTEtNDYwMTM_368188f9-08c8-478b-a98a-aeca6d726b07">5.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7f8f14f6a5a441a4b8e90c587038294a_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo0MzM3Mjg1M2YyZmI0ZDNjYTdmZTJiZDkyNDIyMTkxNy90YWJsZXJhbmdlOjQzMzcyODUzZjJmYjRkM2NhN2ZlMmJkOTI0MjIxOTE3XzItNS0xLTEtNDYwMTM_a3a87f5b-5b7b-4daf-b470-0ea70fd1ce69">6.0</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4d035ef039b9449f9a833a4878f300ef_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo0MzM3Mjg1M2YyZmI0ZDNjYTdmZTJiZDkyNDIyMTkxNy90YWJsZXJhbmdlOjQzMzcyODUzZjJmYjRkM2NhN2ZlMmJkOTI0MjIxOTE3XzMtMS0xLTEtNDYwMTM_294313d0-34ac-4478-a1f6-f201496684f9">92.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic5c3b975ccf642298e9ab071e46c4b8e_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo0MzM3Mjg1M2YyZmI0ZDNjYTdmZTJiZDkyNDIyMTkxNy90YWJsZXJhbmdlOjQzMzcyODUzZjJmYjRkM2NhN2ZlMmJkOTI0MjIxOTE3XzMtMy0xLTEtNDYwMTM_9558c00a-703d-4ca0-91ad-e592ede863db">77.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7f8f14f6a5a441a4b8e90c587038294a_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo0MzM3Mjg1M2YyZmI0ZDNjYTdmZTJiZDkyNDIyMTkxNy90YWJsZXJhbmdlOjQzMzcyODUzZjJmYjRkM2NhN2ZlMmJkOTI0MjIxOTE3XzMtNS0xLTEtNDYwMTM_6d70a263-0749-40e7-9051-afed674a4852">83.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4d035ef039b9449f9a833a4878f300ef_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo0MzM3Mjg1M2YyZmI0ZDNjYTdmZTJiZDkyNDIyMTkxNy90YWJsZXJhbmdlOjQzMzcyODUzZjJmYjRkM2NhN2ZlMmJkOTI0MjIxOTE3XzQtMS0xLTEtNDYwMTM_e74af427-00fa-4854-ae0b-7e798749120c">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic5c3b975ccf642298e9ab071e46c4b8e_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo0MzM3Mjg1M2YyZmI0ZDNjYTdmZTJiZDkyNDIyMTkxNy90YWJsZXJhbmdlOjQzMzcyODUzZjJmYjRkM2NhN2ZlMmJkOTI0MjIxOTE3XzQtMy0xLTEtNDYwMTM_21dcf3a6-750e-485a-a0ad-0399945c58cb">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7f8f14f6a5a441a4b8e90c587038294a_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo0MzM3Mjg1M2YyZmI0ZDNjYTdmZTJiZDkyNDIyMTkxNy90YWJsZXJhbmdlOjQzMzcyODUzZjJmYjRkM2NhN2ZlMmJkOTI0MjIxOTE3XzQtNS0xLTEtNDYwMTM_545bed16-517c-4138-b159-dff902f733b8">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4d035ef039b9449f9a833a4878f300ef_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo0MzM3Mjg1M2YyZmI0ZDNjYTdmZTJiZDkyNDIyMTkxNy90YWJsZXJhbmdlOjQzMzcyODUzZjJmYjRkM2NhN2ZlMmJkOTI0MjIxOTE3XzUtMS0xLTEtNDYwMTM_6d0a7a82-915d-43ff-8a21-f7ec860aa828">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic5c3b975ccf642298e9ab071e46c4b8e_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo0MzM3Mjg1M2YyZmI0ZDNjYTdmZTJiZDkyNDIyMTkxNy90YWJsZXJhbmdlOjQzMzcyODUzZjJmYjRkM2NhN2ZlMmJkOTI0MjIxOTE3XzUtMy0xLTEtNDYwMTM_3fdbc56b-8512-42c0-a7a1-ea5d3e4a3d40">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7f8f14f6a5a441a4b8e90c587038294a_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo0MzM3Mjg1M2YyZmI0ZDNjYTdmZTJiZDkyNDIyMTkxNy90YWJsZXJhbmdlOjQzMzcyODUzZjJmYjRkM2NhN2ZlMmJkOTI0MjIxOTE3XzUtNS0xLTEtNDYwMTM_c6d13002-9c4a-46e2-b04d-c5daa12bf407">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><ix:continuation id="ie5aa7211e1ad40fbb2dce81e03c0f4c1" continuedAt="ieeb0e791f0a94a569bf289155a5fe044"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We have limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock-option grants. As such, the expected term was initially estimated using the simplified method whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option. Beginning in 2021, we estimate the expected term of our options based upon historical exercises and post-vesting termination behavior, which has not resulted in a material difference as compared to using the simplified method.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Since January 1, 2017, we use the historic volatility of our own stock over the retrospective period corresponding to the expected remaining term of the options, or the period since our shares were first quoted on The Nasdaq Global Market, if that is shorter, to compute our expected stock price volatility.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The risk-free interest rate assumption is based on the zero-coupon U.S. treasury instruments on the date of grant with a maturity date consistent with the expected term of our stock option grants.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividend Yield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;To date, we have not declared or paid any cash dividends and does not have any plans to do so in the future. Therefore, we use an expected dividend yield of <ix:nonFraction unitRef="number" contextRef="i4d035ef039b9449f9a833a4878f300ef_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzUxNDc_80430830-be96-4cf6-b646-5a972a827c41">zero</ix:nonFraction>.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzc3MjU_c9062d6f-99c5-464b-a587-b7ba7d597552" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our RSUs activity and related information for the twelve months ended December&#160;31, 2022 is as follows (in thousands, except per share dollar amounts): </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant&#160;Date&#160;Fair<br/>Value Per&#160;Share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested restricted stock units at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iad26c62e1f7040819c46ba8aaecbfdf7_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTowZWEzMDZkMTg3Y2E0MGUzOGFmOTQ2YWM1ODA5ZDI2NC90YWJsZXJhbmdlOjBlYTMwNmQxODdjYTQwZTM4YWY5NDZhYzU4MDlkMjY0XzEtMS0xLTEtNDYwMTM_86cedb40-e78d-4728-b11c-081db83bb5c2">3,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iad26c62e1f7040819c46ba8aaecbfdf7_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTowZWEzMDZkMTg3Y2E0MGUzOGFmOTQ2YWM1ODA5ZDI2NC90YWJsZXJhbmdlOjBlYTMwNmQxODdjYTQwZTM4YWY5NDZhYzU4MDlkMjY0XzEtMy0xLTEtNDYwMTM_0e907a1c-8106-45ad-8779-a6f1118d7be2">2.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5804b276fcba47ec9888f9294a058bd3_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTowZWEzMDZkMTg3Y2E0MGUzOGFmOTQ2YWM1ODA5ZDI2NC90YWJsZXJhbmdlOjBlYTMwNmQxODdjYTQwZTM4YWY5NDZhYzU4MDlkMjY0XzItMS0xLTEtNDYwMTM_dec5d11e-99bd-45b0-9ba0-9733126b6f7a">2,195</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5804b276fcba47ec9888f9294a058bd3_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTowZWEzMDZkMTg3Y2E0MGUzOGFmOTQ2YWM1ODA5ZDI2NC90YWJsZXJhbmdlOjBlYTMwNmQxODdjYTQwZTM4YWY5NDZhYzU4MDlkMjY0XzItMy0xLTEtNDYwMTM_eec1228d-d02b-4f93-9dfd-69b8f7ca40f4">0.89</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5804b276fcba47ec9888f9294a058bd3_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTowZWEzMDZkMTg3Y2E0MGUzOGFmOTQ2YWM1ODA5ZDI2NC90YWJsZXJhbmdlOjBlYTMwNmQxODdjYTQwZTM4YWY5NDZhYzU4MDlkMjY0XzMtMS0xLTEtNDYwMTM_05f2a706-80f6-4519-80ad-b71eff390bac">3,956</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5804b276fcba47ec9888f9294a058bd3_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTowZWEzMDZkMTg3Y2E0MGUzOGFmOTQ2YWM1ODA5ZDI2NC90YWJsZXJhbmdlOjBlYTMwNmQxODdjYTQwZTM4YWY5NDZhYzU4MDlkMjY0XzMtMy0xLTEtNDYwMTM_22a3e2df-9416-4d7c-af4b-38e54c74cf66">1.34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5804b276fcba47ec9888f9294a058bd3_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTowZWEzMDZkMTg3Y2E0MGUzOGFmOTQ2YWM1ODA5ZDI2NC90YWJsZXJhbmdlOjBlYTMwNmQxODdjYTQwZTM4YWY5NDZhYzU4MDlkMjY0XzQtMS0xLTEtNDYwMTM_b458f8e9-5fdb-4684-9945-0f720f9fd25e">362</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5804b276fcba47ec9888f9294a058bd3_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTowZWEzMDZkMTg3Y2E0MGUzOGFmOTQ2YWM1ODA5ZDI2NC90YWJsZXJhbmdlOjBlYTMwNmQxODdjYTQwZTM4YWY5NDZhYzU4MDlkMjY0XzQtMy0xLTEtNDYwMTM_a5ee53f7-e5fb-4fe1-adc3-4902855c7814">2.23</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested restricted stock units at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c4f587701fb4044879019a9bdf73a97_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTowZWEzMDZkMTg3Y2E0MGUzOGFmOTQ2YWM1ODA5ZDI2NC90YWJsZXJhbmdlOjBlYTMwNmQxODdjYTQwZTM4YWY5NDZhYzU4MDlkMjY0XzUtMS0xLTEtNDYwMTM_3865c10f-a47e-4e46-a012-2d046b713ecb">1,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5c4f587701fb4044879019a9bdf73a97_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTowZWEzMDZkMTg3Y2E0MGUzOGFmOTQ2YWM1ODA5ZDI2NC90YWJsZXJhbmdlOjBlYTMwNmQxODdjYTQwZTM4YWY5NDZhYzU4MDlkMjY0XzUtMy0xLTEtNDYwMTM_70c0a021-5470-4c8c-91a3-72d3af1609b9">2.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total estimated fair value of RSUs vested during the years ended December&#160;31, 2022, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="i5804b276fcba47ec9888f9294a058bd3_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzU0OTc1NTgyMjU0NA_388f733b-883b-41b5-8e24-773cadc4e830">2.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ic72722bcacf846aeae4e32bdaf25ad95_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzU0OTc1NTgyMjU0OQ_2aace4bb-4d7f-47ef-9224-6ea7f89608b5">0.8</ix:nonFraction> million and <ix:nonFraction unitRef="usd" contextRef="ic0a3fa62b68c4a38948feeb7a5990743_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzU0OTc1NTgyMjU1Ng_e796f68b-9e14-45df-bd6b-501bbd25bdce">zero</ix:nonFraction>, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, we granted <ix:nonFraction unitRef="shares" contextRef="i759c16cd46934957818cd44b6da608af_D20180701-20180731" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzU0NDE_304e8a7c-de16-4c72-b45b-56925895b522">0.9</ix:nonFraction> million PRSUs to our employees that vested upon the achievement of certain performance conditions, subject to the employees&#8217; continued service relationship with us through the achievement date. During 2020, we granted an additional <ix:nonFraction unitRef="shares" contextRef="i6a36013712a244a6857a4ef451619a76_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzU2Njg_712ef473-7ed0-4ab0-9725-39d5e9e13e92">30</ix:nonFraction> thousand PRSUs subject to the same performance conditions. All <ix:nonFraction unitRef="shares" contextRef="ia0963364402c4d97b8a169943f9ea6a8_D20200901-20200930" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzU3MjU_27d8d632-bb39-416f-95bd-2a07caecca50">0.9</ix:nonFraction>&#160;million of these PRSUs vested in September 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuance of Common Stock for Services</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the&#160;years ended December&#160;31, 2022, 2021 and 2020, we issued approximately <ix:nonFraction unitRef="shares" contextRef="i477da3d9a3ff40539adf947d1f500015_D20220101-20221231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzYxMzI_357cff0a-e3be-4517-a04f-508b3a9936a2">0.7</ix:nonFraction> million, <ix:nonFraction unitRef="shares" contextRef="ie25852142a964d3188c11071355f91b7_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzYxMzY_84e45c54-1981-45fb-a33e-1c2c3c4391f4">26</ix:nonFraction> thousand and <ix:nonFraction unitRef="shares" contextRef="ib3f407a43bf14aab8924633cd249ade7_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzYxNDM_f0538039-0ba9-401b-8010-e1b37a9b5892">42</ix:nonFraction> thousand shares, respectively, of common stock to members of the board of directors who elected to receive stock in lieu of their cash fees under our Non-Employee Director Compensation Program. The shares issued during the years ended December&#160;31, 2022, 2021 and 2020 were valued at $<ix:nonFraction unitRef="usd" contextRef="i477da3d9a3ff40539adf947d1f500015_D20220101-20221231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzY0MDE_5f182f22-faca-44f4-9f06-1034cbc5107f">0.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ie25852142a964d3188c11071355f91b7_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzY0MDU_e4773cf2-94da-4ca3-823d-1aac242a5b2d">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib3f407a43bf14aab8924633cd249ade7_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzY0MTI_a6b51eb1-613d-43fa-b183-58608cc9e484">0.3</ix:nonFraction> million for each year, respectively, based on the fair value of the common stock on the date of grant.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adopted the 2014 Employee Stock Purchase Plan (&#8220;ESPP&#8221;) and initially reserved approximately <ix:nonFraction unitRef="shares" contextRef="i517e23fe4e2f4b29b85b4d380f6c2944_I20140618" decimals="-5" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzY2MzQ_12bbc3c7-2d03-407a-a611-b12397b65e93">0.2</ix:nonFraction> million shares of common stock as of its effective date of June&#160;18, 2014. If approved by the administrator of the ESPP, on the first day of each calendar&#160;year, ending in 2024, the number of shares in the reserve will increase by an amount equal to the lesser of (i)&#160;one&#160;percent (<ix:nonFraction unitRef="number" contextRef="i517e23fe4e2f4b29b85b4d380f6c2944_I20140618" decimals="INF" name="ardx:IncreaseInSharesReservedForIssuanceOptionForAnnualIncreaseAsPercentageOfSharesOutstanding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzY5MDg_cc641fec-a929-49dd-8b6b-b145b753b8f7">1.0</ix:nonFraction>%) of the shares of common stock outstanding on the last day of the immediately preceding fiscal&#160;year and (ii)&#160;such number of shares of common stock as determined by the board of directors; provided, however, no more than <ix:nonFraction unitRef="shares" contextRef="i517e23fe4e2f4b29b85b4d380f6c2944_I20140618" decimals="INF" name="ardx:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesUnderEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzcxMzE_65c600b4-1ae5-4185-828a-26884b413fb3">2.2</ix:nonFraction> million shares of our common stock may be issued under the ESPP.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><ix:continuation id="ieeb0e791f0a94a569bf289155a5fe044"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzc3MjY_c0a83a4a-1e29-4edd-8233-6f929beda7ba" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our ESPP activity during the&#160;twelve months ended December&#160;31, 2022 is as follows (in thousands, except per share dollar amounts):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares&#160;Available<br/>for&#160;Grant</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of&#160;Shares<br/>Purchased</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Purchase&#160;Price<br/>per&#160;Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Proceeds</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i180188a490a8459b9367c5d5573a5e16_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZToxZTJhMTc5YzEwZGE0MzNhOTNjMjFjNGMxYzdlY2EzOS90YWJsZXJhbmdlOjFlMmExNzljMTBkYTQzM2E5M2MyMWM0YzFjN2VjYTM5XzItMS0xLTEtNDYwMTM_d5c09586-e645-4560-b4d5-b2c97594932f">899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i180188a490a8459b9367c5d5573a5e16_I20211231" decimals="INF" name="ardx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesStockPurchasePlanPurchasedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZToxZTJhMTc5YzEwZGE0MzNhOTNjMjFjNGMxYzdlY2EzOS90YWJsZXJhbmdlOjFlMmExNzljMTBkYTQzM2E5M2MyMWM0YzFjN2VjYTM5XzItMy0xLTEtNDYwMTM_ef787b4d-7d2f-479d-b6c5-637dbaf4bc8e">1,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares purchased</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i248a37dc8c184f47ac596a1ecc3f232f_D20220101-20221231" decimals="INF" name="ardx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZToxZTJhMTc5YzEwZGE0MzNhOTNjMjFjNGMxYzdlY2EzOS90YWJsZXJhbmdlOjFlMmExNzljMTBkYTQzM2E5M2MyMWM0YzFjN2VjYTM5XzMtMS0xLTEtNDYwMTM_bd747b84-057f-461a-b32c-9f86c5ed5d6d">308</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i248a37dc8c184f47ac596a1ecc3f232f_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZToxZTJhMTc5YzEwZGE0MzNhOTNjMjFjNGMxYzdlY2EzOS90YWJsZXJhbmdlOjFlMmExNzljMTBkYTQzM2E5M2MyMWM0YzFjN2VjYTM5XzMtMy0xLTEtNDYwMTM_142cf22e-728d-4ffd-8a34-dcb4c44da43e">308</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i248a37dc8c184f47ac596a1ecc3f232f_D20220101-20221231" decimals="2" name="ardx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZToxZTJhMTc5YzEwZGE0MzNhOTNjMjFjNGMxYzdlY2EzOS90YWJsZXJhbmdlOjFlMmExNzljMTBkYTQzM2E5M2MyMWM0YzFjN2VjYTM5XzMtNS0xLTEtNDYwMTM_53d184fc-c510-44aa-88ad-280695df0f6a">0.63</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i248a37dc8c184f47ac596a1ecc3f232f_D20220101-20221231" decimals="-3" name="ardx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanGrossProceeds" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZToxZTJhMTc5YzEwZGE0MzNhOTNjMjFjNGMxYzdlY2EzOS90YWJsZXJhbmdlOjFlMmExNzljMTBkYTQzM2E5M2MyMWM0YzFjN2VjYTM5XzMtNy0xLTEtNDYwMTM_47dad088-a08f-495f-bef6-077078610952">195</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1fa16bad9884e0e9493c7512c233aa6_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZToxZTJhMTc5YzEwZGE0MzNhOTNjMjFjNGMxYzdlY2EzOS90YWJsZXJhbmdlOjFlMmExNzljMTBkYTQzM2E5M2MyMWM0YzFjN2VjYTM5XzQtMS0xLTEtNDYwMTM_31c59123-efad-43a5-b495-0371e74791b3">591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1fa16bad9884e0e9493c7512c233aa6_I20221231" decimals="INF" name="ardx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesStockPurchasePlanPurchasedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZToxZTJhMTc5YzEwZGE0MzNhOTNjMjFjNGMxYzdlY2EzOS90YWJsZXJhbmdlOjFlMmExNzljMTBkYTQzM2E5M2MyMWM0YzFjN2VjYTM5XzQtMy0xLTEtNDYwMTM_ef00c3fb-f39b-4dc0-ae21-8109aa543f4f">1,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzc3MTk_a7de4730-d5d8-4df5-a044-bdbfbf07b818" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates the weighted-average assumptions for the Black-Scholes option-pricing model used in determining the fair value of ESPP purchase rights granted to our employees:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i248a37dc8c184f47ac596a1ecc3f232f_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo4Y2U3MGQ5Y2QxYzk0YmVkOGU1ZDE2YTYwMDEwZDA4Yy90YWJsZXJhbmdlOjhjZTcwZDljZDFjOTRiZWQ4ZTVkMTZhNjAwMTBkMDhjXzItMS0xLTEtNDYwMTM_b1c02aef-da07-445a-b2ae-40f47e79ec64">0.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if8ec837e0d0b46c8864c912515db4ad0_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo4Y2U3MGQ5Y2QxYzk0YmVkOGU1ZDE2YTYwMDEwZDA4Yy90YWJsZXJhbmdlOjhjZTcwZDljZDFjOTRiZWQ4ZTVkMTZhNjAwMTBkMDhjXzItMy0xLTEtNDYwMTM_56945d15-672a-460e-8572-9a270e1c1f9f">0.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id9c65dc81f5a450db626c1aa9194755f_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo4Y2U3MGQ5Y2QxYzk0YmVkOGU1ZDE2YTYwMDEwZDA4Yy90YWJsZXJhbmdlOjhjZTcwZDljZDFjOTRiZWQ4ZTVkMTZhNjAwMTBkMDhjXzItNS0xLTEtNDYwMTM_f954c52c-2883-4301-a0c6-64338ea2bd19">0.5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i248a37dc8c184f47ac596a1ecc3f232f_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo4Y2U3MGQ5Y2QxYzk0YmVkOGU1ZDE2YTYwMDEwZDA4Yy90YWJsZXJhbmdlOjhjZTcwZDljZDFjOTRiZWQ4ZTVkMTZhNjAwMTBkMDhjXzMtMS0xLTEtNDYwMTM_1767980e-c7ca-4ae6-8b1b-adbc41efc478">97.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if8ec837e0d0b46c8864c912515db4ad0_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo4Y2U3MGQ5Y2QxYzk0YmVkOGU1ZDE2YTYwMDEwZDA4Yy90YWJsZXJhbmdlOjhjZTcwZDljZDFjOTRiZWQ4ZTVkMTZhNjAwMTBkMDhjXzMtMy0xLTEtNDYwMTM_adefd4e9-31ab-4d57-b9cd-a12a06853a3c">123.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id9c65dc81f5a450db626c1aa9194755f_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo4Y2U3MGQ5Y2QxYzk0YmVkOGU1ZDE2YTYwMDEwZDA4Yy90YWJsZXJhbmdlOjhjZTcwZDljZDFjOTRiZWQ4ZTVkMTZhNjAwMTBkMDhjXzMtNS0xLTEtNDYwMTM_d1909ce2-2006-4021-af5f-b0ac2ab72ff7">79.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i248a37dc8c184f47ac596a1ecc3f232f_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo4Y2U3MGQ5Y2QxYzk0YmVkOGU1ZDE2YTYwMDEwZDA4Yy90YWJsZXJhbmdlOjhjZTcwZDljZDFjOTRiZWQ4ZTVkMTZhNjAwMTBkMDhjXzQtMS0xLTEtNDYwMTM_1ccce258-4e6e-45e6-82ac-b2e5138573ed">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if8ec837e0d0b46c8864c912515db4ad0_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo4Y2U3MGQ5Y2QxYzk0YmVkOGU1ZDE2YTYwMDEwZDA4Yy90YWJsZXJhbmdlOjhjZTcwZDljZDFjOTRiZWQ4ZTVkMTZhNjAwMTBkMDhjXzQtMy0xLTEtNDYwMTM_1833ca10-3c99-4a29-abb7-12f7eaf84aae">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id9c65dc81f5a450db626c1aa9194755f_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo4Y2U3MGQ5Y2QxYzk0YmVkOGU1ZDE2YTYwMDEwZDA4Yy90YWJsZXJhbmdlOjhjZTcwZDljZDFjOTRiZWQ4ZTVkMTZhNjAwMTBkMDhjXzQtNS0xLTEtNDYwMTM_1d67b048-6c1f-42a3-bfb8-43161348a7b5">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i248a37dc8c184f47ac596a1ecc3f232f_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo4Y2U3MGQ5Y2QxYzk0YmVkOGU1ZDE2YTYwMDEwZDA4Yy90YWJsZXJhbmdlOjhjZTcwZDljZDFjOTRiZWQ4ZTVkMTZhNjAwMTBkMDhjXzUtMS0xLTEtNDYwMTM_4235a80f-1e9d-4d8b-94b2-1499f81a6efc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if8ec837e0d0b46c8864c912515db4ad0_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo4Y2U3MGQ5Y2QxYzk0YmVkOGU1ZDE2YTYwMDEwZDA4Yy90YWJsZXJhbmdlOjhjZTcwZDljZDFjOTRiZWQ4ZTVkMTZhNjAwMTBkMDhjXzUtMy0xLTEtNDYwMTM_0382b6ca-f600-44aa-a766-584ca5d13bf1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id9c65dc81f5a450db626c1aa9194755f_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo4Y2U3MGQ5Y2QxYzk0YmVkOGU1ZDE2YTYwMDEwZDA4Yy90YWJsZXJhbmdlOjhjZTcwZDljZDFjOTRiZWQ4ZTVkMTZhNjAwMTBkMDhjXzUtNS0xLTEtNDYwMTM_11bb6e66-94fc-4d0e-88fe-91002d6e8f7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation Expense</span></div><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzc3MjA_080c941e-d1d6-4da1-8814-734b8dafe02b" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for stock options, RSUs, PRSUs and our ESPP are recorded as operating expenses in our statements of operations and comprehensive loss, as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb74b9fdd27048e29f9e1520ac5e595e_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkZWM4MmJkZWE5NWU0NzQyODljYWYwNzc3MmU0Mjg0My90YWJsZXJhbmdlOmRlYzgyYmRlYTk1ZTQ3NDI4OWNhZjA3NzcyZTQyODQzXzItMS0xLTEtNDk4OTQ_9e50782a-2a77-42ff-aa6a-97f602b29feb">7,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b365ae1dfda4e07a8271c22db477bea_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkZWM4MmJkZWE5NWU0NzQyODljYWYwNzc3MmU0Mjg0My90YWJsZXJhbmdlOmRlYzgyYmRlYTk1ZTQ3NDI4OWNhZjA3NzcyZTQyODQzXzItMy0xLTEtNDk4OTQ_371124e5-ed42-4ce1-84ef-371eee84b1a8">7,923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie78b6836511840a480c1026e771997e3_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkZWM4MmJkZWE5NWU0NzQyODljYWYwNzc3MmU0Mjg0My90YWJsZXJhbmdlOmRlYzgyYmRlYTk1ZTQ3NDI4OWNhZjA3NzcyZTQyODQzXzItNS0xLTEtNDk4OTQ_fcbe0a9c-f901-4454-938b-133014862d93">6,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48d97bd1c889443c8fee636ae7505dd3_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkZWM4MmJkZWE5NWU0NzQyODljYWYwNzc3MmU0Mjg0My90YWJsZXJhbmdlOmRlYzgyYmRlYTk1ZTQ3NDI4OWNhZjA3NzcyZTQyODQzXzItMS0xLTEtNDYwMTM_af3058d5-225d-4633-bd3d-25bc2cc3706e">3,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0ec441698c9479d8b42818e25d70400_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkZWM4MmJkZWE5NWU0NzQyODljYWYwNzc3MmU0Mjg0My90YWJsZXJhbmdlOmRlYzgyYmRlYTk1ZTQ3NDI4OWNhZjA3NzcyZTQyODQzXzItMy0xLTEtNDYwMTM_cf613d82-2dc6-4444-a3bd-de81636230f7">4,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5830a4e62ed14db59de4465b18e9bdb9_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkZWM4MmJkZWE5NWU0NzQyODljYWYwNzc3MmU0Mjg0My90YWJsZXJhbmdlOmRlYzgyYmRlYTk1ZTQ3NDI4OWNhZjA3NzcyZTQyODQzXzItNS0xLTEtNDYwMTM_155b1852-8678-490f-91d8-afbf3e154ad7">4,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkZWM4MmJkZWE5NWU0NzQyODljYWYwNzc3MmU0Mjg0My90YWJsZXJhbmdlOmRlYzgyYmRlYTk1ZTQ3NDI4OWNhZjA3NzcyZTQyODQzXzQtMS0xLTEtNDYwMTM_77216b91-5d94-41e7-a2e3-e95d9cb28931">10,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkZWM4MmJkZWE5NWU0NzQyODljYWYwNzc3MmU0Mjg0My90YWJsZXJhbmdlOmRlYzgyYmRlYTk1ZTQ3NDI4OWNhZjA3NzcyZTQyODQzXzQtMy0xLTEtNDYwMTM_fdffd318-05e5-457d-b0ed-99c2d6738597">12,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkZWM4MmJkZWE5NWU0NzQyODljYWYwNzc3MmU0Mjg0My90YWJsZXJhbmdlOmRlYzgyYmRlYTk1ZTQ3NDI4OWNhZjA3NzcyZTQyODQzXzQtNS0xLTEtNDYwMTM_04cd2658-523d-4c9d-a656-d5102b980f40">10,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzc3MjE_4cd81845-61d2-4bb3-b533-79b51b81993e" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our total unrecognized stock-based compensation expense, net of estimated forfeitures, as of December&#160;31, 2022 is as follows (dollars in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:52.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.920%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.922%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrecognized Compensation Expense</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Remaining Vesting Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options grant</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief16b3cbe3934dc98b9bc68d2856ca35_I20221231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZToxNTQ4NjFlODc1MGE0NDkzOTFlZTYxYTExZTdhNDMyZC90YWJsZXJhbmdlOjE1NDg2MWU4NzUwYTQ0OTM5MWVlNjFhMTFlN2E0MzJkXzItMS0xLTEtNDYwMTM_ea3aaaf5-71c2-4a82-bdca-e3c4f733dd2b">9,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4d035ef039b9449f9a833a4878f300ef_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZToxNTQ4NjFlODc1MGE0NDkzOTFlZTYxYTExZTdhNDMyZC90YWJsZXJhbmdlOjE1NDg2MWU4NzUwYTQ0OTM5MWVlNjFhMTFlN2E0MzJkXzItMy0xLTEtNDYwMTM_546381af-d43d-4084-b0b0-c1758b1af528">2.55</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSU grants</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c4f587701fb4044879019a9bdf73a97_I20221231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZToxNTQ4NjFlODc1MGE0NDkzOTFlZTYxYTExZTdhNDMyZC90YWJsZXJhbmdlOjE1NDg2MWU4NzUwYTQ0OTM5MWVlNjFhMTFlN2E0MzJkXzMtMS0xLTEtNDYwMTM_900e639f-de7f-449a-a7b5-73c1c42dcb64">2,937</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5804b276fcba47ec9888f9294a058bd3_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZToxNTQ4NjFlODc1MGE0NDkzOTFlZTYxYTExZTdhNDMyZC90YWJsZXJhbmdlOjE1NDg2MWU4NzUwYTQ0OTM5MWVlNjFhMTFlN2E0MzJkXzMtMy0xLTEtNDYwMTM_0810c5d1-7d3c-4fe0-88ef-ea008ae8990d">2.95</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1fa16bad9884e0e9493c7512c233aa6_I20221231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZToxNTQ4NjFlODc1MGE0NDkzOTFlZTYxYTExZTdhNDMyZC90YWJsZXJhbmdlOjE1NDg2MWU4NzUwYTQ0OTM5MWVlNjFhMTFlN2E0MzJkXzQtMS0xLTEtNDYwMTM_7e9d5a81-ab59-4028-a0ae-2019d87a8d21">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i248a37dc8c184f47ac596a1ecc3f232f_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZToxNTQ4NjFlODc1MGE0NDkzOTFlZTYxYTExZTdhNDMyZC90YWJsZXJhbmdlOjE1NDg2MWU4NzUwYTQ0OTM5MWVlNjFhMTFlN2E0MzJkXzQtMy0xLTEtNDYwMTM_fe9b7a86-962b-496d-a44d-885e8f7c4259">0.2</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i8c6ecca27b7b4659bf1d61cfb55de996_130"></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzAvZnJhZzplNDc3YmQ2ZGE0NjM0ZWQ2Yjk1YTFlNGM2ZmIwMDBhOC90ZXh0cmVnaW9uOmU0NzdiZDZkYTQ2MzRlZDZiOTVhMWU0YzZmYjAwMGE4XzMwMzk_1b953712-f904-4e78-a5fb-1c4427339145" continuedAt="ifa51dfc0be9245aebbc2391909813f1d" escape="true">RESTRUCTURING</ix:nonNumeric></span></div><ix:continuation id="ifa51dfc0be9245aebbc2391909813f1d" continuedAt="i5934eb49f18d4454952d7a035f0a9b57"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, we implemented restructuring plans in August and October following the receipt of a Complete Response Letter (&#8220;CRL&#8221;) from the U.S. FDA relating to our new drug application (&#8220;NDA&#8221;) for XPHOZAH and following the conclusion of an End of Review Type A meeting with the FDA, respectively. Both restructuring plans were substantially completed in December 2021 and most of the cash payments related to the reduction in workforce were disbursed prior to December 31, 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impacted employees were eligible to receive severance benefits and additional Company funded COBRA premiums, contingent upon an impacted employee&#8217;s execution (and non-revocation) of a separation agreement, which included a general release of claims against us. In connection with restructuring, we incurred restructuring charges of $<ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzAvZnJhZzplNDc3YmQ2ZGE0NjM0ZWQ2Yjk1YTFlNGM2ZmIwMDBhOC90ZXh0cmVnaW9uOmU0NzdiZDZkYTQ2MzRlZDZiOTVhMWU0YzZmYjAwMGE4XzIwOTk_66c4fb71-d9c3-4baa-ba4f-ea781e36317b">6.2</ix:nonFraction>&#160;million, which were recorded during the twelve months ended December 31, 2021, related to one-time termination notice and severance payments and other employee-related costs. We did not incur any significant contract termination costs pursuant to restructuring. Of the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><ix:continuation id="i5934eb49f18d4454952d7a035f0a9b57"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">charges, $<ix:nonFraction unitRef="usd" contextRef="i48d97bd1c889443c8fee636ae7505dd3_D20220101-20221231" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzAvZnJhZzplNDc3YmQ2ZGE0NjM0ZWQ2Yjk1YTFlNGM2ZmIwMDBhOC90ZXh0cmVnaW9uOmU0NzdiZDZkYTQ2MzRlZDZiOTVhMWU0YzZmYjAwMGE4XzIzNzI_c97337ee-f621-46bd-89aa-b4ef3e81ba7a">2.7</ix:nonFraction>&#160;million was recorded in research and development expenses, and $<ix:nonFraction unitRef="usd" contextRef="i431ed8f3e092438fbec58a56f0b02185_D20220101-20221231" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzAvZnJhZzplNDc3YmQ2ZGE0NjM0ZWQ2Yjk1YTFlNGM2ZmIwMDBhOC90ZXh0cmVnaW9uOmU0NzdiZDZkYTQ2MzRlZDZiOTVhMWU0YzZmYjAwMGE4XzI0MzA_aff72729-5667-4c63-a5c2-c0aca49e1aaf">3.5</ix:nonFraction>&#160;million was recorded in selling, general and administrative expense in the accompanying statements of operations and comprehensive loss. Most of the cash payments related to the reduction in workforce were disbursed during the twelve months ended December 31, 2021. We reported the remaining estimated restructuring liability of <ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-5" name="us-gaap:RestructuringReserveCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzAvZnJhZzplNDc3YmQ2ZGE0NjM0ZWQ2Yjk1YTFlNGM2ZmIwMDBhOC90ZXh0cmVnaW9uOmU0NzdiZDZkYTQ2MzRlZDZiOTVhMWU0YzZmYjAwMGE4XzU0OTc1NTgxOTI2Mw_38833fa9-7808-4b5b-b24c-8c13857b75f8">zero</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-5" name="us-gaap:RestructuringReserveCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzAvZnJhZzplNDc3YmQ2ZGE0NjM0ZWQ2Yjk1YTFlNGM2ZmIwMDBhOC90ZXh0cmVnaW9uOmU0NzdiZDZkYTQ2MzRlZDZiOTVhMWU0YzZmYjAwMGE4XzI3MzU_2543aad8-c058-4b7b-93d8-6c40f6c64be9">0.5</ix:nonFraction>&#160;million as accrued compensation and benefits in our balance sheet as of December&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in October, 2021, our Board approved, and management has implemented a retention program consisting of cash payments and grants of RSUs to our employees, including our executives, not impacted by the reduction in force.</span></div></ix:continuation><div id="i8c6ecca27b7b4659bf1d61cfb55de996_133"></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzMvZnJhZzo1ZmIwNDYwZjZmMzY0NGM5YTRlZTJmNWExN2I4MzI2Yy90ZXh0cmVnaW9uOjVmYjA0NjBmNmYzNjQ0YzlhNGVlMmY1YTE3YjgzMjZjXzIxOA_7613c9cd-a000-4c50-95be-893f71f20cf2" continuedAt="i48434d44491743a18992550e38df2550" escape="true">PROPERTY AND EQUIPMENT, NET</ix:nonNumeric></span></div><ix:continuation id="i48434d44491743a18992550e38df2550" continuedAt="i0b8b6ee2f5d3409ea54b1ab01cd99a73"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzMvZnJhZzo1ZmIwNDYwZjZmMzY0NGM5YTRlZTJmNWExN2I4MzI2Yy90ZXh0cmVnaW9uOjVmYjA0NjBmNmYzNjQ0YzlhNGVlMmY1YTE3YjgzMjZjXzIxOQ_47096b84-d2ad-4075-a2a4-773a674faae1" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09a681eff916461fb51eb3329131ce8c_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzMvZnJhZzo1ZmIwNDYwZjZmMzY0NGM5YTRlZTJmNWExN2I4MzI2Yy90YWJsZTplMGJlOTZjN2Y0NmE0N2U5ODUxZTE5ZWJhNWEzZmNhMC90YWJsZXJhbmdlOmUwYmU5NmM3ZjQ2YTQ3ZTk4NTFlMTllYmE1YTNmY2EwXzItMS0xLTEtNDYwMTM_7a0f0f16-698b-4680-bbb9-c57bb2ddbfcd">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic11d410599a74593aa714291238376f7_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzMvZnJhZzo1ZmIwNDYwZjZmMzY0NGM5YTRlZTJmNWExN2I4MzI2Yy90YWJsZTplMGJlOTZjN2Y0NmE0N2U5ODUxZTE5ZWJhNWEzZmNhMC90YWJsZXJhbmdlOmUwYmU5NmM3ZjQ2YTQ3ZTk4NTFlMTllYmE1YTNmY2EwXzItMy0xLTEtNDYwMTM_e47af40b-0154-47e4-a709-e2683bed1d95">7,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and furniture</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb22b29792e5485ebf185f5394ba3762_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzMvZnJhZzo1ZmIwNDYwZjZmMzY0NGM5YTRlZTJmNWExN2I4MzI2Yy90YWJsZTplMGJlOTZjN2Y0NmE0N2U5ODUxZTE5ZWJhNWEzZmNhMC90YWJsZXJhbmdlOmUwYmU5NmM3ZjQ2YTQ3ZTk4NTFlMTllYmE1YTNmY2EwXzMtMS0xLTEtNDYwMTM_af928756-6f8a-4dc8-84ba-cf9eee09b46d">2,089</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc9a17e7794647c2bf47f0d17f42638a_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzMvZnJhZzo1ZmIwNDYwZjZmMzY0NGM5YTRlZTJmNWExN2I4MzI2Yy90YWJsZTplMGJlOTZjN2Y0NmE0N2U5ODUxZTE5ZWJhNWEzZmNhMC90YWJsZXJhbmdlOmUwYmU5NmM3ZjQ2YTQ3ZTk4NTFlMTllYmE1YTNmY2EwXzMtMy0xLTEtNDYwMTM_5ab1164b-353f-4a75-8a5c-67d1629fdb81">2,034</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69f5495993474d55b708c186a11429b3_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzMvZnJhZzo1ZmIwNDYwZjZmMzY0NGM5YTRlZTJmNWExN2I4MzI2Yy90YWJsZTplMGJlOTZjN2Y0NmE0N2U5ODUxZTE5ZWJhNWEzZmNhMC90YWJsZXJhbmdlOmUwYmU5NmM3ZjQ2YTQ3ZTk4NTFlMTllYmE1YTNmY2EwXzQtMS0xLTEtNDYwMTM_e289bc3e-86d7-4486-a363-22df92d67da8">8,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id91a83781eeb4816af435aa999f55171_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzMvZnJhZzo1ZmIwNDYwZjZmMzY0NGM5YTRlZTJmNWExN2I4MzI2Yy90YWJsZTplMGJlOTZjN2Y0NmE0N2U5ODUxZTE5ZWJhNWEzZmNhMC90YWJsZXJhbmdlOmUwYmU5NmM3ZjQ2YTQ3ZTk4NTFlMTllYmE1YTNmY2EwXzQtMy0xLTEtNDYwMTM_63190361-28bf-4aa5-85d7-dca7f0802f51">8,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzMvZnJhZzo1ZmIwNDYwZjZmMzY0NGM5YTRlZTJmNWExN2I4MzI2Yy90YWJsZTplMGJlOTZjN2Y0NmE0N2U5ODUxZTE5ZWJhNWEzZmNhMC90YWJsZXJhbmdlOmUwYmU5NmM3ZjQ2YTQ3ZTk4NTFlMTllYmE1YTNmY2EwXzUtMS0xLTEtNDYwMTM_c021fa6b-1d7d-43b8-9043-215ed98da63d">10,880</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzMvZnJhZzo1ZmIwNDYwZjZmMzY0NGM5YTRlZTJmNWExN2I4MzI2Yy90YWJsZTplMGJlOTZjN2Y0NmE0N2U5ODUxZTE5ZWJhNWEzZmNhMC90YWJsZXJhbmdlOmUwYmU5NmM3ZjQ2YTQ3ZTk4NTFlMTllYmE1YTNmY2EwXzUtMy0xLTEtNDYwMTM_b7d1148c-8ea7-48aa-a3bc-1ad6d0419493">18,253</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzMvZnJhZzo1ZmIwNDYwZjZmMzY0NGM5YTRlZTJmNWExN2I4MzI2Yy90YWJsZTplMGJlOTZjN2Y0NmE0N2U5ODUxZTE5ZWJhNWEzZmNhMC90YWJsZXJhbmdlOmUwYmU5NmM3ZjQ2YTQ3ZTk4NTFlMTllYmE1YTNmY2EwXzYtMS0xLTEtNDYwMTM_74250d1c-8c4b-4ee4-bfe2-3df6399e06c3">9,657</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzMvZnJhZzo1ZmIwNDYwZjZmMzY0NGM5YTRlZTJmNWExN2I4MzI2Yy90YWJsZTplMGJlOTZjN2Y0NmE0N2U5ODUxZTE5ZWJhNWEzZmNhMC90YWJsZXJhbmdlOmUwYmU5NmM3ZjQ2YTQ3ZTk4NTFlMTllYmE1YTNmY2EwXzYtMy0xLTEtNDYwMTM_a301dc78-565c-4c20-80c5-fbcafd796b5f">15,891</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzMvZnJhZzo1ZmIwNDYwZjZmMzY0NGM5YTRlZTJmNWExN2I4MzI2Yy90YWJsZTplMGJlOTZjN2Y0NmE0N2U5ODUxZTE5ZWJhNWEzZmNhMC90YWJsZXJhbmdlOmUwYmU5NmM3ZjQ2YTQ3ZTk4NTFlMTllYmE1YTNmY2EwXzctMS0xLTEtNDYwMTM_07ec0bd1-b961-48ba-8cea-550b4da4f126">1,223</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzMvZnJhZzo1ZmIwNDYwZjZmMzY0NGM5YTRlZTJmNWExN2I4MzI2Yy90YWJsZTplMGJlOTZjN2Y0NmE0N2U5ODUxZTE5ZWJhNWEzZmNhMC90YWJsZXJhbmdlOmUwYmU5NmM3ZjQ2YTQ3ZTk4NTFlMTllYmE1YTNmY2EwXzctMy0xLTEtNDYwMTM_26f91363-eb2b-46f5-91c1-bba430a93a4e">2,362</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized depreciation expense in the amount of $<ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzMvZnJhZzo1ZmIwNDYwZjZmMzY0NGM5YTRlZTJmNWExN2I4MzI2Yy90ZXh0cmVnaW9uOjVmYjA0NjBmNmYzNjQ0YzlhNGVlMmY1YTE3YjgzMjZjXzE1Ng_6c5861f8-cdc2-4c45-a826-61498482d2d3">0.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzMvZnJhZzo1ZmIwNDYwZjZmMzY0NGM5YTRlZTJmNWExN2I4MzI2Yy90ZXh0cmVnaW9uOjVmYjA0NjBmNmYzNjQ0YzlhNGVlMmY1YTE3YjgzMjZjXzE2MA_d6721bab-5a1d-4c44-9f0d-f2dad7e73c5c">1.4</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzMvZnJhZzo1ZmIwNDYwZjZmMzY0NGM5YTRlZTJmNWExN2I4MzI2Yy90ZXh0cmVnaW9uOjVmYjA0NjBmNmYzNjQ0YzlhNGVlMmY1YTE3YjgzMjZjXzE2OA_74ffe3b0-7cd5-478b-a5a8-21a8a9e2b247">1.8</ix:nonFraction> million for the&#160;years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0b8b6ee2f5d3409ea54b1ab01cd99a73">During the year ended December 31, 2022, following the elimination of our internal research organization in the fourth quarter of 2021, we sold laboratory equipment with total net carrying value of $<ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentDisposals" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzMvZnJhZzo1ZmIwNDYwZjZmMzY0NGM5YTRlZTJmNWExN2I4MzI2Yy90ZXh0cmVnaW9uOjVmYjA0NjBmNmYzNjQ0YzlhNGVlMmY1YTE3YjgzMjZjXzU0OTc1NTgxNDU3Nw_4205bb80-e134-4074-a42a-0363d7befe3f">0.5</ix:nonFraction> million and received cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzMvZnJhZzo1ZmIwNDYwZjZmMzY0NGM5YTRlZTJmNWExN2I4MzI2Yy90ZXh0cmVnaW9uOjVmYjA0NjBmNmYzNjQ0YzlhNGVlMmY1YTE3YjgzMjZjXzU0OTc1NTgxNDU5Mg_eae15ad3-0b45-4839-acee-846a9e46562c">1.8</ix:nonFraction> million, resulting in a gain of $<ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-5" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzMvZnJhZzo1ZmIwNDYwZjZmMzY0NGM5YTRlZTJmNWExN2I4MzI2Yy90ZXh0cmVnaW9uOjVmYjA0NjBmNmYzNjQ0YzlhNGVlMmY1YTE3YjgzMjZjXzU0OTc1NTgxNDYwNw_dcbb6983-2ed7-46a7-81d4-43b0a2004ba9">1.3</ix:nonFraction> million which has been reported within other income, net on our statement of operations and comprehensive loss.</ix:continuation> </span></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_136"></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzYvZnJhZzpjZWQ5MWEzYWM4ODE0M2U0YjczNGFiYTExZWEzMjFjNS90ZXh0cmVnaW9uOmNlZDkxYTNhYzg4MTQzZTRiNzM0YWJhMTFlYTMyMWM1XzE0Nw_095d6099-96b9-4389-b64c-e56426c87cba" continuedAt="icb3ffd89c7284f0c97e1a9cba23b56b3" escape="true">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</ix:nonNumeric></span></div><ix:continuation id="icb3ffd89c7284f0c97e1a9cba23b56b3"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzYvZnJhZzpjZWQ5MWEzYWM4ODE0M2U0YjczNGFiYTExZWEzMjFjNS90ZXh0cmVnaW9uOmNlZDkxYTNhYzg4MTQzZTRiNzM0YWJhMTFlYTMyMWM1XzE0OA_44881a31-2d7c-4885-aeec-b60d5a755c32" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consist of the following (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:75.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.191%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payments due to AstraZeneca </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="ardx:AccruedPaymentsDueToRelatedParty" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzYvZnJhZzpjZWQ5MWEzYWM4ODE0M2U0YjczNGFiYTExZWEzMjFjNS90YWJsZTplM2Y5M2ZmODQ5YjU0OTM5YWZlNzE3ZDQwNWQ3MzM4YS90YWJsZXJhbmdlOmUzZjkzZmY4NDliNTQ5MzlhZmU3MTdkNDA1ZDczMzhhXzItMS0xLTEtNTMzNDE_460b2140-0612-4925-93b1-8c19f1b67e1c">3,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="ardx:AccruedPaymentsDueToRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzYvZnJhZzpjZWQ5MWEzYWM4ODE0M2U0YjczNGFiYTExZWEzMjFjNS90YWJsZTplM2Y5M2ZmODQ5YjU0OTM5YWZlNzE3ZDQwNWQ3MzM4YS90YWJsZXJhbmdlOmUzZjkzZmY4NDliNTQ5MzlhZmU3MTdkNDA1ZDczMzhhXzItMy0xLTEtNTMzNDE_054483b2-6628-444e-a514-c5b2dcb2ec40">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued gross to net revenue liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="ardx:AccruedGrossToNetRevenueLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzYvZnJhZzpjZWQ5MWEzYWM4ODE0M2U0YjczNGFiYTExZWEzMjFjNS90YWJsZTplM2Y5M2ZmODQ5YjU0OTM5YWZlNzE3ZDQwNWQ3MzM4YS90YWJsZXJhbmdlOmUzZjkzZmY4NDliNTQ5MzlhZmU3MTdkNDA1ZDczMzhhXzItMS0xLTEtNDYwMTM_71b3e949-ff87-4460-b3f3-03abaeb4a7d1">1,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="ardx:AccruedGrossToNetRevenueLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzYvZnJhZzpjZWQ5MWEzYWM4ODE0M2U0YjczNGFiYTExZWEzMjFjNS90YWJsZTplM2Y5M2ZmODQ5YjU0OTM5YWZlNzE3ZDQwNWQ3MzM4YS90YWJsZXJhbmdlOmUzZjkzZmY4NDliNTQ5MzlhZmU3MTdkNDA1ZDczMzhhXzItMy0xLTEtNDYwMTM_50ca88d8-a532-4b6f-91db-27b65252006b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued contract manufacturing expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="ardx:AccruedContractManufacturingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzYvZnJhZzpjZWQ5MWEzYWM4ODE0M2U0YjczNGFiYTExZWEzMjFjNS90YWJsZTplM2Y5M2ZmODQ5YjU0OTM5YWZlNzE3ZDQwNWQ3MzM4YS90YWJsZXJhbmdlOmUzZjkzZmY4NDliNTQ5MzlhZmU3MTdkNDA1ZDczMzhhXzMtMS0xLTEtNDYwMTM_f9875057-d7b7-41d3-9e5f-1e61b77a7d3c">1,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="ardx:AccruedContractManufacturingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzYvZnJhZzpjZWQ5MWEzYWM4ODE0M2U0YjczNGFiYTExZWEzMjFjNS90YWJsZTplM2Y5M2ZmODQ5YjU0OTM5YWZlNzE3ZDQwNWQ3MzM4YS90YWJsZXJhbmdlOmUzZjkzZmY4NDliNTQ5MzlhZmU3MTdkNDA1ZDczMzhhXzMtMy0xLTEtNDYwMTM_473eae0f-9b6d-407e-81ae-be3311363f58">2,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability for exit fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="ardx:DerivativeLiabilityForExitFees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzYvZnJhZzpjZWQ5MWEzYWM4ODE0M2U0YjczNGFiYTExZWEzMjFjNS90YWJsZTplM2Y5M2ZmODQ5YjU0OTM5YWZlNzE3ZDQwNWQ3MzM4YS90YWJsZXJhbmdlOmUzZjkzZmY4NDliNTQ5MzlhZmU3MTdkNDA1ZDczMzhhXzQtMS0xLTEtNDYwMTM_bf859605-0eb5-494f-baea-56e38749bcd8">1,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="ardx:DerivativeLiabilityForExitFees" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzYvZnJhZzpjZWQ5MWEzYWM4ODE0M2U0YjczNGFiYTExZWEzMjFjNS90YWJsZTplM2Y5M2ZmODQ5YjU0OTM5YWZlNzE3ZDQwNWQ3MzM4YS90YWJsZXJhbmdlOmUzZjkzZmY4NDliNTQ5MzlhZmU3MTdkNDA1ZDczMzhhXzQtMy0xLTEtNDYwMTM_5301d8c4-beb0-465b-822c-63152b7a2420">698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued non-clinical research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="ardx:AccruedNonClinicalResearchAndDevelopmentExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzYvZnJhZzpjZWQ5MWEzYWM4ODE0M2U0YjczNGFiYTExZWEzMjFjNS90YWJsZTplM2Y5M2ZmODQ5YjU0OTM5YWZlNzE3ZDQwNWQ3MzM4YS90YWJsZXJhbmdlOmUzZjkzZmY4NDliNTQ5MzlhZmU3MTdkNDA1ZDczMzhhXzYtMS0xLTEtNTUxMzc_67e726a4-fe5d-4e9d-b3ae-8fb4867a8617">1,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="ardx:AccruedNonClinicalResearchAndDevelopmentExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzYvZnJhZzpjZWQ5MWEzYWM4ODE0M2U0YjczNGFiYTExZWEzMjFjNS90YWJsZTplM2Y5M2ZmODQ5YjU0OTM5YWZlNzE3ZDQwNWQ3MzM4YS90YWJsZXJhbmdlOmUzZjkzZmY4NDliNTQ5MzlhZmU3MTdkNDA1ZDczMzhhXzYtMy0xLTEtNTUxMzc_10d75e05-0754-4b6c-bd99-7656fe2fe39f">265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional and consulting services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="ardx:AccruedProfessionalAndConsultantFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzYvZnJhZzpjZWQ5MWEzYWM4ODE0M2U0YjczNGFiYTExZWEzMjFjNS90YWJsZTplM2Y5M2ZmODQ5YjU0OTM5YWZlNzE3ZDQwNWQ3MzM4YS90YWJsZXJhbmdlOmUzZjkzZmY4NDliNTQ5MzlhZmU3MTdkNDA1ZDczMzhhXzUtMS0xLTEtNDYwMTM_5e051f10-c741-4f6a-8b4a-46764449f503">808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="ardx:AccruedProfessionalAndConsultantFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzYvZnJhZzpjZWQ5MWEzYWM4ODE0M2U0YjczNGFiYTExZWEzMjFjNS90YWJsZTplM2Y5M2ZmODQ5YjU0OTM5YWZlNzE3ZDQwNWQ3MzM4YS90YWJsZXJhbmdlOmUzZjkzZmY4NDliNTQ5MzlhZmU3MTdkNDA1ZDczMzhhXzUtMy0xLTEtNDYwMTM_87c9b855-0893-4ae4-8535-235edc5b49b6">597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued sales and marketing expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="ardx:AccruedSalesAndMarketingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzYvZnJhZzpjZWQ5MWEzYWM4ODE0M2U0YjczNGFiYTExZWEzMjFjNS90YWJsZTplM2Y5M2ZmODQ5YjU0OTM5YWZlNzE3ZDQwNWQ3MzM4YS90YWJsZXJhbmdlOmUzZjkzZmY4NDliNTQ5MzlhZmU3MTdkNDA1ZDczMzhhXzctMS0xLTEtNTE0ODU_67959593-7f6d-4025-aa4f-659c476d2dd8">587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="ardx:AccruedSalesAndMarketingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzYvZnJhZzpjZWQ5MWEzYWM4ODE0M2U0YjczNGFiYTExZWEzMjFjNS90YWJsZTplM2Y5M2ZmODQ5YjU0OTM5YWZlNzE3ZDQwNWQ3MzM4YS90YWJsZXJhbmdlOmUzZjkzZmY4NDliNTQ5MzlhZmU3MTdkNDA1ZDczMzhhXzctMy0xLTEtNTE0ODU_7d101a95-004e-47bb-998a-1ac1e8d8a245">256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="ardx:AccruedClinicalExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzYvZnJhZzpjZWQ5MWEzYWM4ODE0M2U0YjczNGFiYTExZWEzMjFjNS90YWJsZTplM2Y5M2ZmODQ5YjU0OTM5YWZlNzE3ZDQwNWQ3MzM4YS90YWJsZXJhbmdlOmUzZjkzZmY4NDliNTQ5MzlhZmU3MTdkNDA1ZDczMzhhXzYtMS0xLTEtNDYwMTM_04163c03-8102-4839-8dc3-2c34e1cd1226">223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="ardx:AccruedClinicalExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzYvZnJhZzpjZWQ5MWEzYWM4ODE0M2U0YjczNGFiYTExZWEzMjFjNS90YWJsZTplM2Y5M2ZmODQ5YjU0OTM5YWZlNzE3ZDQwNWQ3MzM4YS90YWJsZXJhbmdlOmUzZjkzZmY4NDliNTQ5MzlhZmU3MTdkNDA1ZDczMzhhXzYtMy0xLTEtNDYwMTM_d854b1dc-ca02-4a46-a1a5-09830e801e1f">2,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzYvZnJhZzpjZWQ5MWEzYWM4ODE0M2U0YjczNGFiYTExZWEzMjFjNS90YWJsZTplM2Y5M2ZmODQ5YjU0OTM5YWZlNzE3ZDQwNWQ3MzM4YS90YWJsZXJhbmdlOmUzZjkzZmY4NDliNTQ5MzlhZmU3MTdkNDA1ZDczMzhhXzgtMS0xLTEtNDYwMTM_380efa5e-d812-46c6-9f43-abd7e32ca4d3">885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzYvZnJhZzpjZWQ5MWEzYWM4ODE0M2U0YjczNGFiYTExZWEzMjFjNS90YWJsZTplM2Y5M2ZmODQ5YjU0OTM5YWZlNzE3ZDQwNWQ3MzM4YS90YWJsZXJhbmdlOmUzZjkzZmY4NDliNTQ5MzlhZmU3MTdkNDA1ZDczMzhhXzgtMy0xLTEtNDYwMTM_faa056f1-d3f8-4897-a1d9-1cf3fd430543">474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzYvZnJhZzpjZWQ5MWEzYWM4ODE0M2U0YjczNGFiYTExZWEzMjFjNS90YWJsZTplM2Y5M2ZmODQ5YjU0OTM5YWZlNzE3ZDQwNWQ3MzM4YS90YWJsZXJhbmdlOmUzZjkzZmY4NDliNTQ5MzlhZmU3MTdkNDA1ZDczMzhhXzktMS0xLTEtNDYwMTM_b672bfae-71cb-43ea-adf8-ac26e30e2d95">12,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzYvZnJhZzpjZWQ5MWEzYWM4ODE0M2U0YjczNGFiYTExZWEzMjFjNS90YWJsZTplM2Y5M2ZmODQ5YjU0OTM5YWZlNzE3ZDQwNWQ3MzM4YS90YWJsZXJhbmdlOmUzZjkzZmY4NDliNTQ5MzlhZmU3MTdkNDA1ZDczMzhhXzktMy0xLTEtNDYwMTM_5f269faa-c0b3-4caf-9569-07a46ae0e086">7,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_139"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90ZXh0cmVnaW9uOjU5ZTk3ZjNhMDkyMDQ4ODRhZTE0NWMzZmVmZTIxMmUwXzU4NzU_92d47264-eb6c-43f0-8e59-ced343b1323b" continuedAt="i48516fd466804aceb6bade1454c092c9" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="i48516fd466804aceb6bade1454c092c9" continuedAt="i7076e93dbffa400c8cc1a958480de863"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90ZXh0cmVnaW9uOjU5ZTk3ZjNhMDkyMDQ4ODRhZTE0NWMzZmVmZTIxMmUwXzU4NzY_f82fd51c-5fb8-4fa8-adec-45052490b636" escape="true"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of our provision for income taxes for the years ended December&#160;31, 2022, 2021 and 2020, are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1NjIxZTQwNDlmZWU0OGI4YjUzMDcwZDFhYWVhNGEwNi90YWJsZXJhbmdlOjU2MjFlNDA0OWZlZTQ4YjhiNTMwNzBkMWFhZWE0YTA2XzMtMS0xLTEtNDYwMTM_49a27cf2-12df-40b1-9a58-0d854f8766ce">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1NjIxZTQwNDlmZWU0OGI4YjUzMDcwZDFhYWVhNGEwNi90YWJsZXJhbmdlOjU2MjFlNDA0OWZlZTQ4YjhiNTMwNzBkMWFhZWE0YTA2XzMtMy0xLTEtNDYwMTM_0bdb320b-081e-478b-9c7f-4dd6ee941da8">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1NjIxZTQwNDlmZWU0OGI4YjUzMDcwZDFhYWVhNGEwNi90YWJsZXJhbmdlOjU2MjFlNDA0OWZlZTQ4YjhiNTMwNzBkMWFhZWE0YTA2XzMtNS0xLTEtNDYwMTM_54f5b0c4-ed9d-4bb1-b370-6560ebd74e86">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1NjIxZTQwNDlmZWU0OGI4YjUzMDcwZDFhYWVhNGEwNi90YWJsZXJhbmdlOjU2MjFlNDA0OWZlZTQ4YjhiNTMwNzBkMWFhZWE0YTA2XzQtMS0xLTEtNDYwMTM_8bc088de-da90-45d7-9b86-f00a76d36d73">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1NjIxZTQwNDlmZWU0OGI4YjUzMDcwZDFhYWVhNGEwNi90YWJsZXJhbmdlOjU2MjFlNDA0OWZlZTQ4YjhiNTMwNzBkMWFhZWE0YTA2XzQtMy0xLTEtNDYwMTM_5f0cd6c4-44db-4378-b465-378ced6f5e6e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1NjIxZTQwNDlmZWU0OGI4YjUzMDcwZDFhYWVhNGEwNi90YWJsZXJhbmdlOjU2MjFlNDA0OWZlZTQ4YjhiNTMwNzBkMWFhZWE0YTA2XzQtNS0xLTEtNDYwMTM_3d8a9775-e3c9-43f1-9f62-1932900a2e6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1NjIxZTQwNDlmZWU0OGI4YjUzMDcwZDFhYWVhNGEwNi90YWJsZXJhbmdlOjU2MjFlNDA0OWZlZTQ4YjhiNTMwNzBkMWFhZWE0YTA2XzUtMS0xLTEtNDYwMTM_bb3f7ed6-5d6c-4710-98bf-4120c05a50b6">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1NjIxZTQwNDlmZWU0OGI4YjUzMDcwZDFhYWVhNGEwNi90YWJsZXJhbmdlOjU2MjFlNDA0OWZlZTQ4YjhiNTMwNzBkMWFhZWE0YTA2XzUtMy0xLTEtNDYwMTM_8aa52c94-d75a-4357-ba5b-04425cdff54e">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1NjIxZTQwNDlmZWU0OGI4YjUzMDcwZDFhYWVhNGEwNi90YWJsZXJhbmdlOjU2MjFlNDA0OWZlZTQ4YjhiNTMwNzBkMWFhZWE0YTA2XzUtNS0xLTEtNDYwMTM_d2cb90ea-9ca7-4bba-91cf-c9981aa1548c">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1NjIxZTQwNDlmZWU0OGI4YjUzMDcwZDFhYWVhNGEwNi90YWJsZXJhbmdlOjU2MjFlNDA0OWZlZTQ4YjhiNTMwNzBkMWFhZWE0YTA2XzctMS0xLTEtNDYwMTM_7f0005b0-f264-42fa-a049-dc21263c0ff1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1NjIxZTQwNDlmZWU0OGI4YjUzMDcwZDFhYWVhNGEwNi90YWJsZXJhbmdlOjU2MjFlNDA0OWZlZTQ4YjhiNTMwNzBkMWFhZWE0YTA2XzctMy0xLTEtNDYwMTM_0ea6f032-c0ed-49a3-a37b-33221067012f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1NjIxZTQwNDlmZWU0OGI4YjUzMDcwZDFhYWVhNGEwNi90YWJsZXJhbmdlOjU2MjFlNDA0OWZlZTQ4YjhiNTMwNzBkMWFhZWE0YTA2XzctNS0xLTEtNDYwMTM_4158b94c-2059-4a81-8be5-f9773459a57e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1NjIxZTQwNDlmZWU0OGI4YjUzMDcwZDFhYWVhNGEwNi90YWJsZXJhbmdlOjU2MjFlNDA0OWZlZTQ4YjhiNTMwNzBkMWFhZWE0YTA2XzgtMS0xLTEtNDYwMTM_b131d60a-b28e-4683-850f-ad4b1a147aaa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1NjIxZTQwNDlmZWU0OGI4YjUzMDcwZDFhYWVhNGEwNi90YWJsZXJhbmdlOjU2MjFlNDA0OWZlZTQ4YjhiNTMwNzBkMWFhZWE0YTA2XzgtMy0xLTEtNDYwMTM_6e08490e-145e-4cfc-bd4d-95e75d49a465">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1NjIxZTQwNDlmZWU0OGI4YjUzMDcwZDFhYWVhNGEwNi90YWJsZXJhbmdlOjU2MjFlNDA0OWZlZTQ4YjhiNTMwNzBkMWFhZWE0YTA2XzgtNS0xLTEtNDYwMTM_1124980d-fb6a-49f4-880c-e8a4b975328b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1NjIxZTQwNDlmZWU0OGI4YjUzMDcwZDFhYWVhNGEwNi90YWJsZXJhbmdlOjU2MjFlNDA0OWZlZTQ4YjhiNTMwNzBkMWFhZWE0YTA2XzktMS0xLTEtNDYwMTM_bb27ce59-365e-4749-a8b6-da2ba4d79448">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1NjIxZTQwNDlmZWU0OGI4YjUzMDcwZDFhYWVhNGEwNi90YWJsZXJhbmdlOjU2MjFlNDA0OWZlZTQ4YjhiNTMwNzBkMWFhZWE0YTA2XzktMy0xLTEtNDYwMTM_0e59a48f-f269-4991-ae49-c92850a26282">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1NjIxZTQwNDlmZWU0OGI4YjUzMDcwZDFhYWVhNGEwNi90YWJsZXJhbmdlOjU2MjFlNDA0OWZlZTQ4YjhiNTMwNzBkMWFhZWE0YTA2XzktNS0xLTEtNDYwMTM_c0b5fe95-65ed-4310-99fa-988f377fb456">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:18pt"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90ZXh0cmVnaW9uOjU5ZTk3ZjNhMDkyMDQ4ODRhZTE0NWMzZmVmZTIxMmUwXzU4Nzc_bee845ac-66e5-43d4-a218-99decd71b171" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the statutory federal income tax rate to our effective tax rate is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax at the federal statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzItMS0xLTEtNTY3ODU_eb823943-54a5-425a-ba94-66bc7ecd7072">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzItMy0xLTEtNTY3ODU_7a9613eb-134d-406c-9101-522a68cc17e5">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzItNS0xLTEtNTY3ODU_3caab700-aa21-4b46-92f4-38fc48e72c8d">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzUtMS0xLTEtNDYwMTM_c0f5288f-3be5-4ed8-8976-62b150ac50d8">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzUtMy0xLTEtNDYwMTM_18c0420e-f4b9-470f-9b82-876bc26e4c73">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzUtNS0xLTEtNDYwMTM_1eaaaf5d-5f85-4b01-bcfc-e7a29beb70fc">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzYtMS0xLTEtNDYwMTM_4641fe0d-519d-43a5-a90f-54eb2234e62a">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzYtMy0xLTEtNDYwMTM_49880835-1147-4494-9914-afc2f7b2d93f">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzYtNS0xLTEtNDYwMTM_dac23bbb-dbe5-4af7-b3dc-2fbadde642c7">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive compensation disallowed under IRC Sec 162(m)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="3" sign="-" name="ardx:EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitExecutiveCompensationDisallowedIRCSec162mPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzctMS0xLTEtNDYwMTM_dc531326-b7c0-45cd-9096-5efd30699378">1.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="3" sign="-" name="ardx:EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitExecutiveCompensationDisallowedIRCSec162mPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzctMy0xLTEtNDYwMTM_9c9a1e46-c6fb-4fad-9495-dc67eb81dedf">1.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="3" sign="-" name="ardx:EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitExecutiveCompensationDisallowedIRCSec162mPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzctNS0xLTEtNDYwMTM_d8d58d90-f04c-4ebe-8db5-cd8e659a5cc8">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzktMS0xLTEtNTY4MDk_b13d4189-caac-48c9-82d1-e80aa6b40836">2.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzktMy0xLTEtNTY4MDk_c468a1c0-fd20-4a87-8bbd-8d8ad83540f9">1.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzktNS0xLTEtNTY4MDk_5e8936b3-9eb7-4901-923a-8a2ad59872ba">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzctMS0xLTEtNTY4Mzk_28757fde-a1c0-449f-89b5-c28fa772a53a">0.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzctMy0xLTEtNTY4Mzk_6e14027e-eb48-4ae4-bd79-e11b463c19cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzctNS0xLTEtNTY4Mzk_9a6acc23-8f14-4caf-9439-bb0a4cc5ca88">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzktMS0xLTEtNTY3OTg_b549af3b-6795-4ed9-9f41-6ca2370bb9ed">19.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzktMy0xLTEtNTY3OTg_a6c39229-e4a0-4643-be39-d01479c5c620">20.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzktNS0xLTEtNTY3OTg_262980a8-13c6-458d-9bbe-c31678c26c93">22.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzktMS0xLTEtNDYwMTM_91bb650d-d929-4e73-bea6-5779f3b6fd28">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzktMy0xLTEtNDYwMTM_4744c2bb-8cc5-4a9e-854c-2081d3bed155">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzktNS0xLTEtNDYwMTM_6f0f0c8b-a8c1-4985-94c0-96af5029f0b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. <ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90ZXh0cmVnaW9uOjU5ZTk3ZjNhMDkyMDQ4ODRhZTE0NWMzZmVmZTIxMmUwXzU4Nzg_481dbc74-dfbf-4263-8f14-26adbc3108f3" continuedAt="i63646721ad6d4b838c2b5fa71f6122b4" escape="true">Significant components of our deferred tax assets are as follows as of December&#160;31, 2022 and 2021 (in thousands):</ix:nonNumeric></span><ix:continuation id="i63646721ad6d4b838c2b5fa71f6122b4"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization and depreciation</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="ardx:DeferredTaxAssetsAmortizationAndDepreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1ZThiNmFlMjQxZGY0ZTE3Yjc5ODVlMzdiZDIzYzNiNC90YWJsZXJhbmdlOjVlOGI2YWUyNDFkZjRlMTdiNzk4NWUzN2JkMjNjM2I0XzMtMS0xLTEtNDYwMTM_84719549-9a01-45e1-a10a-c318f8d45f69">64,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="ardx:DeferredTaxAssetsAmortizationAndDepreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1ZThiNmFlMjQxZGY0ZTE3Yjc5ODVlMzdiZDIzYzNiNC90YWJsZXJhbmdlOjVlOGI2YWUyNDFkZjRlMTdiNzk4NWUzN2JkMjNjM2I0XzMtMy0xLTEtNDYwMTM_13d52ca1-4b04-4dbf-a815-594cb802b569">61,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1ZThiNmFlMjQxZGY0ZTE3Yjc5ODVlMzdiZDIzYzNiNC90YWJsZXJhbmdlOjVlOGI2YWUyNDFkZjRlMTdiNzk4NWUzN2JkMjNjM2I0XzQtMS0xLTEtNDYwMTM_0f732002-e4b8-4050-aecf-df5aa36de912">86,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1ZThiNmFlMjQxZGY0ZTE3Yjc5ODVlMzdiZDIzYzNiNC90YWJsZXJhbmdlOjVlOGI2YWUyNDFkZjRlMTdiNzk4NWUzN2JkMjNjM2I0XzQtMy0xLTEtNDYwMTM_f81a7d7c-792b-4880-a3bd-8df2c6dc8505">74,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1ZThiNmFlMjQxZGY0ZTE3Yjc5ODVlMzdiZDIzYzNiNC90YWJsZXJhbmdlOjVlOGI2YWUyNDFkZjRlMTdiNzk4NWUzN2JkMjNjM2I0XzUtMS0xLTEtNDYwMTM_b10ae403-4e3e-46a8-9b19-83f7e7c29d6b">14,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1ZThiNmFlMjQxZGY0ZTE3Yjc5ODVlMzdiZDIzYzNiNC90YWJsZXJhbmdlOjVlOGI2YWUyNDFkZjRlMTdiNzk4NWUzN2JkMjNjM2I0XzUtMy0xLTEtNDYwMTM_778c5d1f-fb65-47dc-8a69-d568572f1c02">13,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1ZThiNmFlMjQxZGY0ZTE3Yjc5ODVlMzdiZDIzYzNiNC90YWJsZXJhbmdlOjVlOGI2YWUyNDFkZjRlMTdiNzk4NWUzN2JkMjNjM2I0XzYtMS0xLTEtNDYwMTM_fa9c04e2-4916-4ebe-a29f-09c1db05d401">5,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1ZThiNmFlMjQxZGY0ZTE3Yjc5ODVlMzdiZDIzYzNiNC90YWJsZXJhbmdlOjVlOGI2YWUyNDFkZjRlMTdiNzk4NWUzN2JkMjNjM2I0XzYtMy0xLTEtNDYwMTM_ae0c4669-7b63-47fe-9193-08134926f50d">4,054</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1ZThiNmFlMjQxZGY0ZTE3Yjc5ODVlMzdiZDIzYzNiNC90YWJsZXJhbmdlOjVlOGI2YWUyNDFkZjRlMTdiNzk4NWUzN2JkMjNjM2I0XzgtMS0xLTEtNDYwMTM_d203a4b5-905a-4031-9c9e-e90022dc974a">7,486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1ZThiNmFlMjQxZGY0ZTE3Yjc5ODVlMzdiZDIzYzNiNC90YWJsZXJhbmdlOjVlOGI2YWUyNDFkZjRlMTdiNzk4NWUzN2JkMjNjM2I0XzgtMy0xLTEtNDYwMTM_e25583f3-759e-42b1-b1f3-5e84c472f0e0">3,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1ZThiNmFlMjQxZGY0ZTE3Yjc5ODVlMzdiZDIzYzNiNC90YWJsZXJhbmdlOjVlOGI2YWUyNDFkZjRlMTdiNzk4NWUzN2JkMjNjM2I0XzktMS0xLTEtNDYwMTM_ca18cd21-9d8c-473f-9f9a-ba41c7cddf4e">177,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1ZThiNmFlMjQxZGY0ZTE3Yjc5ODVlMzdiZDIzYzNiNC90YWJsZXJhbmdlOjVlOGI2YWUyNDFkZjRlMTdiNzk4NWUzN2JkMjNjM2I0XzktMy0xLTEtNDYwMTM_83694f0f-c21c-44dd-b6ea-7044325cbaaa">157,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1ZThiNmFlMjQxZGY0ZTE3Yjc5ODVlMzdiZDIzYzNiNC90YWJsZXJhbmdlOjVlOGI2YWUyNDFkZjRlMTdiNzk4NWUzN2JkMjNjM2I0XzEwLTEtMS0xLTQ2MDEz_ec3364ec-4269-4ec1-ad23-15bb52198bd7">175,670</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1ZThiNmFlMjQxZGY0ZTE3Yjc5ODVlMzdiZDIzYzNiNC90YWJsZXJhbmdlOjVlOGI2YWUyNDFkZjRlMTdiNzk4NWUzN2JkMjNjM2I0XzEwLTMtMS0xLTQ2MDEz_5bdbcbe3-49a8-47a4-b1e4-65e08829d5d4">155,141</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets net of valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1ZThiNmFlMjQxZGY0ZTE3Yjc5ODVlMzdiZDIzYzNiNC90YWJsZXJhbmdlOjVlOGI2YWUyNDFkZjRlMTdiNzk4NWUzN2JkMjNjM2I0XzExLTEtMS0xLTQ2MDEz_61974c8f-6816-4c23-9a24-9709b233accc">2,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1ZThiNmFlMjQxZGY0ZTE3Yjc5ODVlMzdiZDIzYzNiNC90YWJsZXJhbmdlOjVlOGI2YWUyNDFkZjRlMTdiNzk4NWUzN2JkMjNjM2I0XzExLTMtMS0xLTQ2MDEz_46dbfc83-8449-4b88-b5d7-0ea166de84db">2,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="ardx:DeferredTaxLiabilitiesRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1ZThiNmFlMjQxZGY0ZTE3Yjc5ODVlMzdiZDIzYzNiNC90YWJsZXJhbmdlOjVlOGI2YWUyNDFkZjRlMTdiNzk4NWUzN2JkMjNjM2I0XzEzLTEtMS0xLTQ2MDEz_173072bb-8f03-40c2-b806-cd7b90b1b9a5">2,129</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="ardx:DeferredTaxLiabilitiesRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1ZThiNmFlMjQxZGY0ZTE3Yjc5ODVlMzdiZDIzYzNiNC90YWJsZXJhbmdlOjVlOGI2YWUyNDFkZjRlMTdiNzk4NWUzN2JkMjNjM2I0XzEzLTMtMS0xLTQ2MDEz_d4089fc0-7104-433a-a38e-750b7f83927b">2,689</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1ZThiNmFlMjQxZGY0ZTE3Yjc5ODVlMzdiZDIzYzNiNC90YWJsZXJhbmdlOjVlOGI2YWUyNDFkZjRlMTdiNzk4NWUzN2JkMjNjM2I0XzE1LTEtMS0xLTQ2MDEz_e0a44173-32e6-4480-be9a-cf080a1c1c43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1ZThiNmFlMjQxZGY0ZTE3Yjc5ODVlMzdiZDIzYzNiNC90YWJsZXJhbmdlOjVlOGI2YWUyNDFkZjRlMTdiNzk4NWUzN2JkMjNjM2I0XzE1LTMtMS0xLTQ2MDEz_ab8a8810-dd4b-4d21-8edb-905725b89c1e">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1ZThiNmFlMjQxZGY0ZTE3Yjc5ODVlMzdiZDIzYzNiNC90YWJsZXJhbmdlOjVlOGI2YWUyNDFkZjRlMTdiNzk4NWUzN2JkMjNjM2I0XzE2LTEtMS0xLTQ2MDEz_bb7b0271-4058-4aa1-a94a-87c55360fbe4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1ZThiNmFlMjQxZGY0ZTE3Yjc5ODVlMzdiZDIzYzNiNC90YWJsZXJhbmdlOjVlOGI2YWUyNDFkZjRlMTdiNzk4NWUzN2JkMjNjM2I0XzE2LTMtMS0xLTQ2MDEz_f10011bc-c0c0-40d4-81ab-d71d6e5bd120">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realization of deferred tax assets is dependent on future taxable income, if any, the timing and the amount of which are uncertain. We assess the available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit use of the existing deferred tax assets. A significant component of objective negative evidence evaluated was our cumulative loss incurred over the three-year period ended December&#160;31, 2022. Such objective evidence limits the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><ix:continuation id="i7076e93dbffa400c8cc1a958480de863"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ability to consider other subjective evidence, such as our projections for future growth. On the basis of this evaluation, as of December&#160;31, 2022, December&#160;31, 2021 and December&#160;31, 2020, a full valuation allowance has been recorded against our net deferred tax asset. The valuation allowance increased by $<ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90ZXh0cmVnaW9uOjU5ZTk3ZjNhMDkyMDQ4ODRhZTE0NWMzZmVmZTIxMmUwXzU0OTc1NTgyMTc4NA_e2e9d509-0d1b-401f-95e8-907e98a1aa74">20.5</ix:nonFraction>&#160;million in 2022 primarily due to increases in net operating losses. The amount of the deferred tax asset considered realizable, however, could be adjusted if estimates of future taxable income during the carryforward period are reduced or increased or if objective negative evidence in the form of cumulative losses is no longer present and additional weight is given to subjective evidence such as our projections for growth.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had net operating loss carryforwards for federal income tax purposes of approximately $<ix:nonFraction unitRef="usd" contextRef="iac8bff27f31a4cdba6c1c3861745b2ef_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90ZXh0cmVnaW9uOjU5ZTk3ZjNhMDkyMDQ4ODRhZTE0NWMzZmVmZTIxMmUwXzE3MTA_b27f25f0-616a-4761-9cbf-29b20e8976e4">433.6</ix:nonFraction> million, of which approximately $<ix:nonFraction unitRef="usd" contextRef="iac8bff27f31a4cdba6c1c3861745b2ef_I20221231" decimals="-5" name="ardx:OperatingLossCarryforwardsWithoutExpiration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90ZXh0cmVnaW9uOjU5ZTk3ZjNhMDkyMDQ4ODRhZTE0NWMzZmVmZTIxMmUwXzE3Mzc_293da095-f4d8-4bc3-9b0b-48c1f5d67695">283.4</ix:nonFraction> million can be carried forward indefinitely and the remaining net operating losses expire beginning in 2030, if not utilized. Federal research and development tax credit carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="if0a0600f40b045c6b35e188f2f71061e_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90ZXh0cmVnaW9uOjU5ZTk3ZjNhMDkyMDQ4ODRhZTE0NWMzZmVmZTIxMmUwXzE5MzM_8b46af5d-f250-4ddb-9090-9dd24db64215">17.2</ix:nonFraction> million that expire beginning in 2027, if not utilized, and foreign tax credit carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="i417d82d19f4a4fbcadb83d9e66e6fd76_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90ZXh0cmVnaW9uOjU5ZTk3ZjNhMDkyMDQ4ODRhZTE0NWMzZmVmZTIxMmUwXzIwMzg_8b7ee59a-a3ae-4607-9a2c-d96d63873e85">1.2</ix:nonFraction> million that expire in 2027, if not utilized.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we had net operating loss carryforwards for California income tax purposes of approximately $<ix:nonFraction unitRef="usd" contextRef="i888d6abdafc14bdab944dd9b5f92fa5f_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90ZXh0cmVnaW9uOjU5ZTk3ZjNhMDkyMDQ4ODRhZTE0NWMzZmVmZTIxMmUwXzIxODQ_aa9fba54-c586-4fa8-9cfc-dfc0213b0d8d">89.8</ix:nonFraction>&#160;million that expire beginning of 2030, if not utilized, and state research and development tax credit carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="i4b6ecc5e16524d9ca5408690716f1a33_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90ZXh0cmVnaW9uOjU5ZTk3ZjNhMDkyMDQ4ODRhZTE0NWMzZmVmZTIxMmUwXzIzMTI_5ad2ac56-7b2e-4560-85f0-54f96cd0834b">8.6</ix:nonFraction> million which can be carried forward indefinitely. We had approximately $<ix:nonFraction unitRef="usd" contextRef="ib4ad706ca1134370ac1fdd46d324a005_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90ZXh0cmVnaW9uOjU5ZTk3ZjNhMDkyMDQ4ODRhZTE0NWMzZmVmZTIxMmUwXzIzNzk_911fa412-c8db-49b8-b75a-4b6a4f2f11ee">0.1</ix:nonFraction> million of minimum tax credit carryovers for California income tax purposes. The minimum tax credits have no expiration date. We had other state net operating losses of approximately $<ix:nonFraction unitRef="usd" contextRef="if221b086648a41aab5554e1ca5f792ec_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90ZXh0cmVnaW9uOjU5ZTk3ZjNhMDkyMDQ4ODRhZTE0NWMzZmVmZTIxMmUwXzI1NTc_2b34f183-b49b-4038-80a8-4167c03db414">19.0</ix:nonFraction> million that begin to expire in 2031.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future utilization of net operating loss and tax credit carryforwards and credits may be subject to an annual limitation, pursuant to Internal Revenue Code Sections 382 and 383, as a result of ownership changes that may have occurred previously or that could occur in the future. Due to the existence of the valuation allowance, limitations under Section 382 and 383 will not impact our effective tax rate.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Tax Cuts and Jobs Act of 2017, research and development costs are no longer fully deductible and are required to be capitalized and amortized for U.S. tax purposes effective January 1, 2022. The mandatory capitalization requirement did not have a material impact on our deferred tax assets and did not result in a cash tax liability as we have historically elected to capitalized research and development expenses for tax purposes.</span></div><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90ZXh0cmVnaW9uOjU5ZTk3ZjNhMDkyMDQ4ODRhZTE0NWMzZmVmZTIxMmUwXzU4Nzk_27f95387-93d6-458d-913e-7ce4d4364a55" escape="true"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo0ODZlYTQ2YzFhNDM0MTA2YmM3YWVmYjZiNjVjODk2MS90YWJsZXJhbmdlOjQ4NmVhNDZjMWE0MzQxMDZiYzdhZWZiNmI2NWM4OTYxXzItMS0xLTEtNDYwMTM_b4f9e622-3026-46a6-8e53-9bf4cde63440">24,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0fdfe563b2749f3ad36d74c30c121dd_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo0ODZlYTQ2YzFhNDM0MTA2YmM3YWVmYjZiNjVjODk2MS90YWJsZXJhbmdlOjQ4NmVhNDZjMWE0MzQxMDZiYzdhZWZiNmI2NWM4OTYxXzItMy0xLTEtNDYwMTM_b2e91cf1-aaf6-488c-ab7b-f4326db6b655">23,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c73d82cd653451cb3c69d920ab3d8aa_I20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo0ODZlYTQ2YzFhNDM0MTA2YmM3YWVmYjZiNjVjODk2MS90YWJsZXJhbmdlOjQ4NmVhNDZjMWE0MzQxMDZiYzdhZWZiNmI2NWM4OTYxXzItNS0xLTEtNDYwMTM_6f182dad-6920-40d5-9292-826922e15890">24,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo0ODZlYTQ2YzFhNDM0MTA2YmM3YWVmYjZiNjVjODk2MS90YWJsZXJhbmdlOjQ4NmVhNDZjMWE0MzQxMDZiYzdhZWZiNmI2NWM4OTYxXzMtMS0xLTEtNTQ0NTA_3d702717-80d6-4ec0-8a12-5cf1836ba095">460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo0ODZlYTQ2YzFhNDM0MTA2YmM3YWVmYjZiNjVjODk2MS90YWJsZXJhbmdlOjQ4NmVhNDZjMWE0MzQxMDZiYzdhZWZiNmI2NWM4OTYxXzMtMy0xLTEtNTQ0NTA_23b9ecff-3ede-4de9-ad72-dd6f6ded4582">1,613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo0ODZlYTQ2YzFhNDM0MTA2YmM3YWVmYjZiNjVjODk2MS90YWJsZXJhbmdlOjQ4NmVhNDZjMWE0MzQxMDZiYzdhZWZiNmI2NWM4OTYxXzMtNS0xLTEtNTQ0NTA_56024be4-9018-4c3c-b5cc-b7df1360e572">474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtractions related to lapse of statute of limitation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo0ODZlYTQ2YzFhNDM0MTA2YmM3YWVmYjZiNjVjODk2MS90YWJsZXJhbmdlOjQ4NmVhNDZjMWE0MzQxMDZiYzdhZWZiNmI2NWM4OTYxXzQtMS0xLTEtNTQ0NTk_0993d36b-2baa-46aa-a58e-f7aacbd908e4">811</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo0ODZlYTQ2YzFhNDM0MTA2YmM3YWVmYjZiNjVjODk2MS90YWJsZXJhbmdlOjQ4NmVhNDZjMWE0MzQxMDZiYzdhZWZiNmI2NWM4OTYxXzQtMy0xLTEtNTQ0NTk_2dc607b2-1c2b-46dc-b1b5-bac564c76325">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo0ODZlYTQ2YzFhNDM0MTA2YmM3YWVmYjZiNjVjODk2MS90YWJsZXJhbmdlOjQ4NmVhNDZjMWE0MzQxMDZiYzdhZWZiNmI2NWM4OTYxXzQtNS0xLTEtNTQ0NTk_748a07a0-e3f0-46b8-ae24-042414faa7eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtractions based on tax positions related to prior year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo0ODZlYTQ2YzFhNDM0MTA2YmM3YWVmYjZiNjVjODk2MS90YWJsZXJhbmdlOjQ4NmVhNDZjMWE0MzQxMDZiYzdhZWZiNmI2NWM4OTYxXzMtMS0xLTEtNDYwMTM_6d4f074b-23e8-4400-9d9b-888423fdf3b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo0ODZlYTQ2YzFhNDM0MTA2YmM3YWVmYjZiNjVjODk2MS90YWJsZXJhbmdlOjQ4NmVhNDZjMWE0MzQxMDZiYzdhZWZiNmI2NWM4OTYxXzMtMy0xLTEtNDYwMTM_3224d9c6-9679-4c2d-a174-884a6211074b">811</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo0ODZlYTQ2YzFhNDM0MTA2YmM3YWVmYjZiNjVjODk2MS90YWJsZXJhbmdlOjQ4NmVhNDZjMWE0MzQxMDZiYzdhZWZiNmI2NWM4OTYxXzMtNS0xLTEtNDYwMTM_b851480b-2e33-416b-87bf-c6f33668c9e9">1,388</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo0ODZlYTQ2YzFhNDM0MTA2YmM3YWVmYjZiNjVjODk2MS90YWJsZXJhbmdlOjQ4NmVhNDZjMWE0MzQxMDZiYzdhZWZiNmI2NWM4OTYxXzUtMS0xLTEtNDYwMTM_81d46404-25a8-4a8c-8478-120e237ea96c">24,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23bde0040cba4440804b10fdac242262_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo0ODZlYTQ2YzFhNDM0MTA2YmM3YWVmYjZiNjVjODk2MS90YWJsZXJhbmdlOjQ4NmVhNDZjMWE0MzQxMDZiYzdhZWZiNmI2NWM4OTYxXzUtMy0xLTEtNDYwMTM_b9c79786-6663-4506-978c-048090d396c1">24,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0fdfe563b2749f3ad36d74c30c121dd_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo0ODZlYTQ2YzFhNDM0MTA2YmM3YWVmYjZiNjVjODk2MS90YWJsZXJhbmdlOjQ4NmVhNDZjMWE0MzQxMDZiYzdhZWZiNmI2NWM4OTYxXzUtNS0xLTEtNDYwMTM_667393f2-231a-4a3a-ba5f-f393859a2e4b">23,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize a tax benefit from an uncertain tax position when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. Income tax positions must meet a more likely than not recognition at the effective date to be recognized. None of our unrecognized tax benefits would impact the effective tax rate if recognized, because the benefit would be offset by an increase in the valuation allowance.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected to include interest and penalties as a component of tax expense. During the years ended December&#160;31, 2022, 2021 and 2020, we did not recognize accrued interest and penalties related to unrecognized tax benefits. Although the timing and outcome of an income tax audit is highly uncertain, we do not anticipate that the amount of existing unrecognized tax benefits will significantly change during the next 12 months.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file a U.S. federal income tax return and income tax returns in various state and local jurisdictions. Due to our net operating loss and tax credit carryforwards, the income tax returns remain open to U.S. federal and state tax examinations. We are not currently under examination in any tax jurisdiction.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_142"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="ardx:GeographicInformationAndConcentrationsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90ZXh0cmVnaW9uOjNiZjdlNzRjMWU3NzQyZTZiYmM3N2FmYWI2YjA3ODg0XzExNjg_6e6358f2-2501-47d2-8e57-b2891e7f8ec8" continuedAt="i50a1542c3a204094ac62dd24402ea975" escape="true">GEOGRAPHIC INFORMATION AND CONCENTRATIONS</ix:nonNumeric></span></div><ix:continuation id="i50a1542c3a204094ac62dd24402ea975" continuedAt="i52ad704e16c04a86ac99b5076b4c16ca"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are attributed to geographical areas based on the location at which we earned revenue for product sales of IBSRELA or the domicile of our collaboration partners. <ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90ZXh0cmVnaW9uOjNiZjdlNzRjMWU3NzQyZTZiYmM3N2FmYWI2YjA3ODg0XzExNjk_ba0b36f2-cec6-429b-a84c-ded3d346763f" continuedAt="i3cc430bb77ee47088158725d56c94284" escape="true">A summary of our revenue by geographic areas for the years ended December&#160;31, 2022, 2021 and 2020, is as follows (in thousands):</ix:nonNumeric></span><ix:continuation id="i3cc430bb77ee47088158725d56c94284" continuedAt="i2b00e104533d4c2499e79af8d56ad3a4"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if59e9efdbe2d42718f4a91fe0b12275c_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90YWJsZTphY2Y1MDVlNjUyODA0MDNlODlkYWVmOGIzNWViZjczOC90YWJsZXJhbmdlOmFjZjUwNWU2NTI4MDQwM2U4OWRhZWY4YjM1ZWJmNzM4XzItMS0xLTEtNDYwMTM_2757d0d3-f3fd-40d2-837c-bb2e0d744139">15,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib44743fdc95f46f182f7c502b1cd9c4d_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90YWJsZTphY2Y1MDVlNjUyODA0MDNlODlkYWVmOGIzNWViZjczOC90YWJsZXJhbmdlOmFjZjUwNWU2NTI4MDQwM2U4OWRhZWY4YjM1ZWJmNzM4XzItMy0xLTEtNDYwMTM_61aa4aae-83c5-452d-9bfa-1893b26c7794">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic04f77eb07ea4224a01520efa0f633d3_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90YWJsZTphY2Y1MDVlNjUyODA0MDNlODlkYWVmOGIzNWViZjczOC90YWJsZXJhbmdlOmFjZjUwNWU2NTI4MDQwM2U4OWRhZWY4YjM1ZWJmNzM4XzItNS0xLTEtNDYwMTM_f1af9784-8f1e-4b9b-a840-e44b65515e06">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1746af5e54554e499e907d7129518fd0_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90YWJsZTphY2Y1MDVlNjUyODA0MDNlODlkYWVmOGIzNWViZjczOC90YWJsZXJhbmdlOmFjZjUwNWU2NTI4MDQwM2U4OWRhZWY4YjM1ZWJmNzM4XzQtMS0xLTEtNTIxMjg_1037f081-012e-4373-a9b4-d223af043d8f">36,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i511c3600481046ab8ea3a0188db062f2_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90YWJsZTphY2Y1MDVlNjUyODA0MDNlODlkYWVmOGIzNWViZjczOC90YWJsZXJhbmdlOmFjZjUwNWU2NTI4MDQwM2U4OWRhZWY4YjM1ZWJmNzM4XzQtMy0xLTEtNTIxMjg_86f7a467-fb3f-4c32-8790-971dce2ef0d5">10,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b925d525dc749719f6bd325cefb8a1c_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90YWJsZTphY2Y1MDVlNjUyODA0MDNlODlkYWVmOGIzNWViZjczOC90YWJsZXJhbmdlOmFjZjUwNWU2NTI4MDQwM2U4OWRhZWY4YjM1ZWJmNzM4XzQtNS0xLTEtNTIxMjg_89a88fdd-8951-4824-82bc-8e4fc8eb5c4a">6,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">North America (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae0dc045d5b541dfa650458342fbe24a_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90YWJsZTphY2Y1MDVlNjUyODA0MDNlODlkYWVmOGIzNWViZjczOC90YWJsZXJhbmdlOmFjZjUwNWU2NTI4MDQwM2U4OWRhZWY4YjM1ZWJmNzM4XzQtMS0xLTEtNDYwMTM_f26e99b0-eb33-4219-8122-3373147080e5">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c3c4d25be5c41f2a23bc91cd0c77d25_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90YWJsZTphY2Y1MDVlNjUyODA0MDNlODlkYWVmOGIzNWViZjczOC90YWJsZXJhbmdlOmFjZjUwNWU2NTI4MDQwM2U4OWRhZWY4YjM1ZWJmNzM4XzQtMy0xLTEtNDYwMTM_8139c73f-59e0-46c4-9e9d-8c5d25ca604e">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b4c067ab6484053a239a2ccd02d90d1_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90YWJsZTphY2Y1MDVlNjUyODA0MDNlODlkYWVmOGIzNWViZjczOC90YWJsZXJhbmdlOmFjZjUwNWU2NTI4MDQwM2U4OWRhZWY4YjM1ZWJmNzM4XzQtNS0xLTEtNDYwMTM_69ae8791-f3de-4524-a1d1-b547918c0def">806</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90YWJsZTphY2Y1MDVlNjUyODA0MDNlODlkYWVmOGIzNWViZjczOC90YWJsZXJhbmdlOmFjZjUwNWU2NTI4MDQwM2U4OWRhZWY4YjM1ZWJmNzM4XzYtMS0xLTEtNDYwMTM_f51791b1-2610-4405-bb5e-4fff7b42d0a9">52,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90YWJsZTphY2Y1MDVlNjUyODA0MDNlODlkYWVmOGIzNWViZjczOC90YWJsZXJhbmdlOmFjZjUwNWU2NTI4MDQwM2U4OWRhZWY4YjM1ZWJmNzM4XzYtMy0xLTEtNDYwMTM_9ec7f179-c0cb-4358-bd43-5285fcb4a297">10,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90YWJsZTphY2Y1MDVlNjUyODA0MDNlODlkYWVmOGIzNWViZjczOC90YWJsZXJhbmdlOmFjZjUwNWU2NTI4MDQwM2U4OWRhZWY4YjM1ZWJmNzM4XzYtNS0xLTEtNDYwMTM_f89aaa2e-9d80-49a8-adc5-ed5e8e732049">7,571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:continuation id="i2b00e104533d4c2499e79af8d56ad3a4"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Revenues from the United States are comprised of amounts earned from sales of IBSRELA.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Revenues from Asia Pacific are primarily comprised of amounts earned in accordance with the 2017 KKC Agreement and the 2019 KKC Agreement.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Revenues from North America are comprised of amounts earned from Canada in accordance with the Knight Agreement.</span></div></ix:continuation><div style="margin-top:12pt;text-indent:18pt"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90ZXh0cmVnaW9uOjNiZjdlNzRjMWU3NzQyZTZiYmM3N2FmYWI2YjA3ODg0XzExNzA_c666187c-a9f5-476e-ae41-54d159f723c2" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from Customers and collaboration partnerships accounting for more than 10% of total revenues during the years ended December&#160;31, 2022, 2021 and 2020 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KKC</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id19674491cd54b0c969b0e9bccb5521e_D20220101-20221231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90YWJsZTozYjZkNTI3Y2FiOWM0OTg5OWEzZjkyNWY4ZTAwNjExOC90YWJsZXJhbmdlOjNiNmQ1MjdjYWI5YzQ5ODk5YTNmOTI1ZjhlMDA2MTE4XzItMS0xLTEtNDYwMTM_74142af4-0b18-48e9-adbb-1e4eb43839ca">70.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id3fb70f0cf0f4182806a3abc3d5b5b25_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90YWJsZTozYjZkNTI3Y2FiOWM0OTg5OWEzZjkyNWY4ZTAwNjExOC90YWJsZXJhbmdlOjNiNmQ1MjdjYWI5YzQ5ODk5YTNmOTI1ZjhlMDA2MTE4XzItMy0xLTEtNDYwMTM_792cffa8-6cde-4507-95b6-45fdca60b801">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8ac81d53477e44f6afab4b4e55da6c0b_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90YWJsZTozYjZkNTI3Y2FiOWM0OTg5OWEzZjkyNWY4ZTAwNjExOC90YWJsZXJhbmdlOjNiNmQ1MjdjYWI5YzQ5ODk5YTNmOTI1ZjhlMDA2MTE4XzItNS0xLTEtNDYwMTM_e82c921d-fccc-4074-9191-3683880a1b02">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Knight</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2805b962ce1c4f33a04e27034cee3305_D20220101-20221231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90YWJsZTozYjZkNTI3Y2FiOWM0OTg5OWEzZjkyNWY4ZTAwNjExOC90YWJsZXJhbmdlOjNiNmQ1MjdjYWI5YzQ5ODk5YTNmOTI1ZjhlMDA2MTE4XzMtMS0xLTEtNDYwMTM_197798f4-cd83-47c9-a48f-f3e6d2a5833d">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2d1f27a987ea46e4ac5004a0280afb04_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90YWJsZTozYjZkNTI3Y2FiOWM0OTg5OWEzZjkyNWY4ZTAwNjExOC90YWJsZXJhbmdlOjNiNmQ1MjdjYWI5YzQ5ODk5YTNmOTI1ZjhlMDA2MTE4XzMtMy0xLTEtNDYwMTM_b7ed3997-e1f3-4466-8404-c6b8c1c52077">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifda028b327984abab2f5a8dc37dd7bf1_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90YWJsZTozYjZkNTI3Y2FiOWM0OTg5OWEzZjkyNWY4ZTAwNjExOC90YWJsZXJhbmdlOjNiNmQ1MjdjYWI5YzQ5ODk5YTNmOTI1ZjhlMDA2MTE4XzMtNS0xLTEtNDYwMTM_fe1f5f76-8d30-4fa6-9cd7-149328c2dc93">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Drug Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iceaaa79f1b46468e9d5df39ac4e0e130_D20220101-20221231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90YWJsZTozYjZkNTI3Y2FiOWM0OTg5OWEzZjkyNWY4ZTAwNjExOC90YWJsZXJhbmdlOjNiNmQ1MjdjYWI5YzQ5ODk5YTNmOTI1ZjhlMDA2MTE4XzUtMS0xLTEtNDYwMTM_ccd39d62-3527-4a81-9428-3403b9e9f6fe">11.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7f6e6bcfc89b4e3bbbf5ef1ab1cfa46c_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90YWJsZTozYjZkNTI3Y2FiOWM0OTg5OWEzZjkyNWY4ZTAwNjExOC90YWJsZXJhbmdlOjNiNmQ1MjdjYWI5YzQ5ODk5YTNmOTI1ZjhlMDA2MTE4XzUtMy0xLTEtNDYwMTM_9cdf3c23-f6f9-4348-ba2c-9d1c69635d0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id58e400e1e524590b3c5cd7fe872d7d9_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90YWJsZTozYjZkNTI3Y2FiOWM0OTg5OWEzZjkyNWY4ZTAwNjExOC90YWJsZXJhbmdlOjNiNmQ1MjdjYWI5YzQ5ODk5YTNmOTI1ZjhlMDA2MTE4XzUtNS0xLTEtNDYwMTM_6724d253-9d95-4ce5-a1a6-537a075fc644">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i52ad704e16c04a86ac99b5076b4c16ca">Historically, we have not experienced credit losses from our accounts receivable. We have not recorded a reserve for credit losses as of December&#160;31, 2022 and 2021.</ix:continuation> </span></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_145"></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90ZXh0cmVnaW9uOjhhZTY1ODUzMmEwMjQ3NTdhZjRlZDk3ZTA2MWVmZjdkXzEzMjk_7e812903-4c3e-4056-a7a5-70d68c475c18" continuedAt="ia3dfb03e6d014291959f00716a25197e" escape="true">NET LOSS PER SHARE</ix:nonNumeric></span></div><ix:continuation id="ia3dfb03e6d014291959f00716a25197e" continuedAt="i714a46e6be7a4dd1847dd72b4ad07e35"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, less shares subject to repurchase, and excludes any dilutive effects of stock-based awards and warrants. Diluted net loss per common share is computed giving effect to all potential dilutive common shares, including common stock issuable upon exercise of stock options, and unvested restricted common stock and stock units. As we had net losses for the&#160;years ended December&#160;31, 2022, 2021 and 2020, all potential common shares were determined to be anti-dilutive. </span></div><div style="margin-top:12pt;text-indent:18pt"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90ZXh0cmVnaW9uOjhhZTY1ODUzMmEwMjQ3NTdhZjRlZDk3ZTA2MWVmZjdkXzEzMzA_09d5db2f-14ac-482d-803c-e7633bcdd7c8" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of net loss per common share (in thousands, except per share dollar amounts):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTo2ZDNmZTIyY2U4NTM0MjBlYmVjODllYWUwZmU0ZGU3NC90YWJsZXJhbmdlOjZkM2ZlMjJjZTg1MzQyMGViZWM4OWVhZTBmZTRkZTc0XzMtMS0xLTEtNDYwMTM_6e924cce-a135-4e5e-b390-4b4605679b15">67,207</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTo2ZDNmZTIyY2U4NTM0MjBlYmVjODllYWUwZmU0ZGU3NC90YWJsZXJhbmdlOjZkM2ZlMjJjZTg1MzQyMGViZWM4OWVhZTBmZTRkZTc0XzMtMy0xLTEtNDYwMTM_a36fe0de-4290-4a21-8c15-e8ed7de840d9">158,165</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTo2ZDNmZTIyY2U4NTM0MjBlYmVjODllYWUwZmU0ZGU3NC90YWJsZXJhbmdlOjZkM2ZlMjJjZTg1MzQyMGViZWM4OWVhZTBmZTRkZTc0XzMtNS0xLTEtNDYwMTM_c2931176-5c46-4ce5-90ee-7110edb1dddf">94,313</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - basic and diluted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTo2ZDNmZTIyY2U4NTM0MjBlYmVjODllYWUwZmU0ZGU3NC90YWJsZXJhbmdlOjZkM2ZlMjJjZTg1MzQyMGViZWM4OWVhZTBmZTRkZTc0XzUtMS0xLTEtNDYwMTM_12291c73-949d-4c4c-89bd-b33c52c3ad53"><ix:nonFraction unitRef="shares" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTo2ZDNmZTIyY2U4NTM0MjBlYmVjODllYWUwZmU0ZGU3NC90YWJsZXJhbmdlOjZkM2ZlMjJjZTg1MzQyMGViZWM4OWVhZTBmZTRkZTc0XzUtMS0xLTEtNDYwMTM_7fdf098b-ae33-4f0c-adc7-341f02b5ae61">158,690</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTo2ZDNmZTIyY2U4NTM0MjBlYmVjODllYWUwZmU0ZGU3NC90YWJsZXJhbmdlOjZkM2ZlMjJjZTg1MzQyMGViZWM4OWVhZTBmZTRkZTc0XzUtMy0xLTEtNDYwMTM_1391c730-7703-4054-b088-ea1659f82f30"><ix:nonFraction unitRef="shares" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTo2ZDNmZTIyY2U4NTM0MjBlYmVjODllYWUwZmU0ZGU3NC90YWJsZXJhbmdlOjZkM2ZlMjJjZTg1MzQyMGViZWM4OWVhZTBmZTRkZTc0XzUtMy0xLTEtNDYwMTM_6aca9ca3-ac69-4160-b7a7-185503b94cf3">104,206</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTo2ZDNmZTIyY2U4NTM0MjBlYmVjODllYWUwZmU0ZGU3NC90YWJsZXJhbmdlOjZkM2ZlMjJjZTg1MzQyMGViZWM4OWVhZTBmZTRkZTc0XzUtNS0xLTEtNDYwMTM_19185182-a45e-4201-a348-52c514403105"><ix:nonFraction unitRef="shares" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTo2ZDNmZTIyY2U4NTM0MjBlYmVjODllYWUwZmU0ZGU3NC90YWJsZXJhbmdlOjZkM2ZlMjJjZTg1MzQyMGViZWM4OWVhZTBmZTRkZTc0XzUtNS0xLTEtNDYwMTM_2f510e28-a546-4bce-9ec0-f920c7c65587">89,582</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTo2ZDNmZTIyY2U4NTM0MjBlYmVjODllYWUwZmU0ZGU3NC90YWJsZXJhbmdlOjZkM2ZlMjJjZTg1MzQyMGViZWM4OWVhZTBmZTRkZTc0XzYtMS0xLTEtNDYwMTM_413d6136-69ca-4656-9909-d71b5ec3efcf"><ix:nonFraction unitRef="usdPerShare" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTo2ZDNmZTIyY2U4NTM0MjBlYmVjODllYWUwZmU0ZGU3NC90YWJsZXJhbmdlOjZkM2ZlMjJjZTg1MzQyMGViZWM4OWVhZTBmZTRkZTc0XzYtMS0xLTEtNDYwMTM_b9dc3948-e8cf-4c7c-84fe-f10de92917e1">0.42</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTo2ZDNmZTIyY2U4NTM0MjBlYmVjODllYWUwZmU0ZGU3NC90YWJsZXJhbmdlOjZkM2ZlMjJjZTg1MzQyMGViZWM4OWVhZTBmZTRkZTc0XzYtMy0xLTEtNDYwMTM_a6067273-b87b-4269-bb28-8e87d9b24da3"><ix:nonFraction unitRef="usdPerShare" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTo2ZDNmZTIyY2U4NTM0MjBlYmVjODllYWUwZmU0ZGU3NC90YWJsZXJhbmdlOjZkM2ZlMjJjZTg1MzQyMGViZWM4OWVhZTBmZTRkZTc0XzYtMy0xLTEtNDYwMTM_f1049434-647e-4602-87c3-3bc04d88a8ee">1.52</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTo2ZDNmZTIyY2U4NTM0MjBlYmVjODllYWUwZmU0ZGU3NC90YWJsZXJhbmdlOjZkM2ZlMjJjZTg1MzQyMGViZWM4OWVhZTBmZTRkZTc0XzYtNS0xLTEtNDYwMTM_9a373f0f-72a1-48e5-9e4d-70dac6a629bc"><ix:nonFraction unitRef="usdPerShare" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTo2ZDNmZTIyY2U4NTM0MjBlYmVjODllYWUwZmU0ZGU3NC90YWJsZXJhbmdlOjZkM2ZlMjJjZTg1MzQyMGViZWM4OWVhZTBmZTRkZTc0XzYtNS0xLTEtNDYwMTM_a8afb13b-07e5-4e18-96d8-677c9226c3d9">1.05</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><ix:continuation id="i714a46e6be7a4dd1847dd72b4ad07e35"><ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90ZXh0cmVnaW9uOjhhZTY1ODUzMmEwMjQ3NTdhZjRlZDk3ZTA2MWVmZjdkXzEzMzE_08c3006d-950c-42d4-ba87-f2f4f190df69" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the&#160;years ended December&#160;31, 2022, 2021 and 2020, the total numbers of securities that could potentially dilute net income per share in the future that were not considered in the diluted net loss per share calculations because the effect would have been anti-dilutive were as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib4411bca5f204674a4e725c73570e515_D20220101-20221231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTowZGVhZGU4NGY2ZWI0M2ZlYWY1ZjU4YzJmZTA2YTk0OS90YWJsZXJhbmdlOjBkZWFkZTg0ZjZlYjQzZmVhZjVmNThjMmZlMDZhOTQ5XzItMS0xLTEtNDYwMTM_3bacc153-477c-4d1e-b8c9-892b7b272f96">13,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id664c0aa97b74d6b933633eb24bd7ffa_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTowZGVhZGU4NGY2ZWI0M2ZlYWY1ZjU4YzJmZTA2YTk0OS90YWJsZXJhbmdlOjBkZWFkZTg0ZjZlYjQzZmVhZjVmNThjMmZlMDZhOTQ5XzItMy0xLTEtNDYwMTM_0921cddf-c47f-45f9-bcbc-9112a5f68744">11,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia1833de563c44c0a84b1e4c778b58c6d_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTowZGVhZGU4NGY2ZWI0M2ZlYWY1ZjU4YzJmZTA2YTk0OS90YWJsZXJhbmdlOjBkZWFkZTg0ZjZlYjQzZmVhZjVmNThjMmZlMDZhOTQ5XzItNS0xLTEtNDYwMTM_9ae88707-ba42-4786-ba42-24666cad3555">9,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i952c9b1adbbf4d96b9b3719a4c54ea85_D20220101-20221231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTowZGVhZGU4NGY2ZWI0M2ZlYWY1ZjU4YzJmZTA2YTk0OS90YWJsZXJhbmdlOjBkZWFkZTg0ZjZlYjQzZmVhZjVmNThjMmZlMDZhOTQ5XzMtMS0xLTEtNDYwMTM_10d07bd7-ea31-4448-9051-b7799864a8ab">2,694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iba8409a9d3074b558e62a6b388c3ab67_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTowZGVhZGU4NGY2ZWI0M2ZlYWY1ZjU4YzJmZTA2YTk0OS90YWJsZXJhbmdlOjBkZWFkZTg0ZjZlYjQzZmVhZjVmNThjMmZlMDZhOTQ5XzMtMy0xLTEtNDYwMTM_50f80741-c9de-49b7-ac50-562949d36799">1,602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i96a34e4ebc4c41b5b53c6de94e6f9347_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTowZGVhZGU4NGY2ZWI0M2ZlYWY1ZjU4YzJmZTA2YTk0OS90YWJsZXJhbmdlOjBkZWFkZTg0ZjZlYjQzZmVhZjVmNThjMmZlMDZhOTQ5XzMtNS0xLTEtNDYwMTM_1f7f7920-74d4-4664-8089-b194c1090fc1">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP shares issuable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i538aeeb65eb843779d9a0e11b1e50104_D20220101-20221231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTowZGVhZGU4NGY2ZWI0M2ZlYWY1ZjU4YzJmZTA2YTk0OS90YWJsZXJhbmdlOjBkZWFkZTg0ZjZlYjQzZmVhZjVmNThjMmZlMDZhOTQ5XzQtMS0xLTEtNDYwMTM_3ea57153-7129-4d92-a826-8d9279fc0358">166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieb0f4765d39d45c69282d8ce87f604fc_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTowZGVhZGU4NGY2ZWI0M2ZlYWY1ZjU4YzJmZTA2YTk0OS90YWJsZXJhbmdlOjBkZWFkZTg0ZjZlYjQzZmVhZjVmNThjMmZlMDZhOTQ5XzQtMy0xLTEtNDYwMTM_415de0d5-891d-40e3-8b02-15e0dd875321">207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1b5f3274350745bdba9cf5da71e8b2d5_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTowZGVhZGU4NGY2ZWI0M2ZlYWY1ZjU4YzJmZTA2YTk0OS90YWJsZXJhbmdlOjBkZWFkZTg0ZjZlYjQzZmVhZjVmNThjMmZlMDZhOTQ5XzQtNS0xLTEtNDYwMTM_29b34cae-a5e8-43e1-9459-133b17db0cd8">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia6b3a9fd0ae14ddea562b4e1be92c9ca_D20220101-20221231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTowZGVhZGU4NGY2ZWI0M2ZlYWY1ZjU4YzJmZTA2YTk0OS90YWJsZXJhbmdlOjBkZWFkZTg0ZjZlYjQzZmVhZjVmNThjMmZlMDZhOTQ5XzUtMS0xLTEtNDYwMTM_2e10a545-f368-4608-9147-6878ebcc5c2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia8ac5065cbaa4252992fdf404620572d_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTowZGVhZGU4NGY2ZWI0M2ZlYWY1ZjU4YzJmZTA2YTk0OS90YWJsZXJhbmdlOjBkZWFkZTg0ZjZlYjQzZmVhZjVmNThjMmZlMDZhOTQ5XzUtMy0xLTEtNDYwMTM_6614038e-6f56-490e-87dc-7dc1a9c69220">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if66074aa8b8c4eaf87dfdefd3d2725c2_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTowZGVhZGU4NGY2ZWI0M2ZlYWY1ZjU4YzJmZTA2YTk0OS90YWJsZXJhbmdlOjBkZWFkZTg0ZjZlYjQzZmVhZjVmNThjMmZlMDZhOTQ5XzUtNS0xLTEtNDYwMTM_54525f1f-ae2d-4081-94d7-a459b00d729c">932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTowZGVhZGU4NGY2ZWI0M2ZlYWY1ZjU4YzJmZTA2YTk0OS90YWJsZXJhbmdlOjBkZWFkZTg0ZjZlYjQzZmVhZjVmNThjMmZlMDZhOTQ5XzctMS0xLTEtNDYwMTM_4110e04e-ba53-47e1-adee-5c04a9ca2078">16,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTowZGVhZGU4NGY2ZWI0M2ZlYWY1ZjU4YzJmZTA2YTk0OS90YWJsZXJhbmdlOjBkZWFkZTg0ZjZlYjQzZmVhZjVmNThjMmZlMDZhOTQ5XzctMy0xLTEtNDYwMTM_25b999c8-7c42-4d43-a1ab-2f311582e02f">13,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTowZGVhZGU4NGY2ZWI0M2ZlYWY1ZjU4YzJmZTA2YTk0OS90YWJsZXJhbmdlOjBkZWFkZTg0ZjZlYjQzZmVhZjVmNThjMmZlMDZhOTQ5XzctNS0xLTEtNDYwMTM_17fe7a61-392f-4361-8c75-3a8b276e6391">10,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of potential common shares that would have been included in diluted income per share had it not been for the anti-dilutive effect caused by the net loss, computed by converting these securities using the treasury stock method during the years ended December&#160;31, 2022, 2021 and 2020, was approximately <ix:nonFraction unitRef="shares" contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" decimals="-5" name="ardx:PotentialCommonSharesAntiDilutiveEffectOnSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90ZXh0cmVnaW9uOjhhZTY1ODUzMmEwMjQ3NTdhZjRlZDk3ZTA2MWVmZjdkXzEzMDI_4492d663-7c46-4405-85b6-8468576747e0">0.6</ix:nonFraction> million, <ix:nonFraction unitRef="shares" contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231" decimals="-5" name="ardx:PotentialCommonSharesAntiDilutiveEffectOnSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90ZXh0cmVnaW9uOjhhZTY1ODUzMmEwMjQ3NTdhZjRlZDk3ZTA2MWVmZjdkXzEzMDY_471be0d6-0838-4c4f-885f-c1aeea012850">1.1</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231" decimals="-5" name="ardx:PotentialCommonSharesAntiDilutiveEffectOnSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90ZXh0cmVnaW9uOjhhZTY1ODUzMmEwMjQ3NTdhZjRlZDk3ZTA2MWVmZjdkXzEzMTM_ea6ca218-04a7-474d-affe-d8954072cce7">2.1</ix:nonFraction> million, respectively.</span></div></ix:continuation><div id="i8c6ecca27b7b4659bf1d61cfb55de996_148"></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">20.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDgvZnJhZzo3ZWYwMmVhMWYxNjk0N2RjYjVhYmEyYjU0MzhiYmZkNC90ZXh0cmVnaW9uOjdlZjAyZWExZjE2OTQ3ZGNiNWFiYTJiNTQzOGJiZmQ0XzE0MTU_dfdddd7f-6264-4cc1-82dc-10b26b16c5f0" continuedAt="i9916b7d32cd94e19943dc764f98bf4fa" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i9916b7d32cd94e19943dc764f98bf4fa" continuedAt="i4f40b2d58ac34c328d40fc91baa21761"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Guarantees and Indemnifications</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We indemnify each of our officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at our request in such capacity, as permitted under Delaware law and in accordance with our certificate of incorporation and bylaws. The term of the indemnification period lasts as long as an officer or director may be subject to any proceeding arising out of acts or omissions of such officer or director in such capacity.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maximum amount of potential future indemnification is unlimited; however, we currently hold director and officer liability insurance, which allows the transfer of risk associated with our exposure and may enable us to recover a portion of any future amounts paid. We believe that the fair value of these indemnification obligations is minimal. Accordingly, we have not recognized any liabilities relating to these obligations for any period presented.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings and Claims</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30 and August 12, 2021, <ix:nonFraction unitRef="claim" contextRef="ib374c30529ad46698e71cb3df47baab0_D20220730-20220812" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDgvZnJhZzo3ZWYwMmVhMWYxNjk0N2RjYjVhYmEyYjU0MzhiYmZkNC90ZXh0cmVnaW9uOjdlZjAyZWExZjE2OTQ3ZGNiNWFiYTJiNTQzOGJiZmQ0XzIxOTkwMjMyNzE1NTU_5b17b913-b5e1-42b8-bff7-3f315ab6dd9e">two</ix:nonFraction> putative securities class action lawsuits were commenced in the U.S. District Court for the Northern District of California naming as defendants Ardelyx and <ix:nonFraction unitRef="defendant" contextRef="ib374c30529ad46698e71cb3df47baab0_D20220730-20220812" decimals="INF" name="us-gaap:LossContingencyNumberOfDefendants" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDgvZnJhZzo3ZWYwMmVhMWYxNjk0N2RjYjVhYmEyYjU0MzhiYmZkNC90ZXh0cmVnaW9uOjdlZjAyZWExZjE2OTQ3ZGNiNWFiYTJiNTQzOGJiZmQ0XzIxOTkwMjMyNzE1NjU_96035cd3-b08c-451c-be8d-598dca32dce4">two</ix:nonFraction> current officers captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Strezsak v. Ardelyx, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 4:21-cv-05868-HSG, and Siegel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> v. Ardelyx, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 5:21-cv-06228-HSG (together, the &#8220;Securities Class Actions&#8221;). The complaints allege that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 thereunder, by making false and misleading statements and omissions of material fact related to tenapanor. The plaintiffs seek to represent all persons who purchased or otherwise acquired Ardelyx securities between August 6, 2020, and July 19, 2021. The plaintiffs seek damages and interest, and an award of costs, including attorneys&#8217; fees. On July 19, 2022, the court consolidated the <ix:nonFraction unitRef="claim" contextRef="i4720ecaa980849ecb662496f697442e6_D20220719-20220719" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDgvZnJhZzo3ZWYwMmVhMWYxNjk0N2RjYjVhYmEyYjU0MzhiYmZkNC90ZXh0cmVnaW9uOjdlZjAyZWExZjE2OTQ3ZGNiNWFiYTJiNTQzOGJiZmQ0XzIxOTkwMjMyNzE1NzQ_67c282d2-3734-46bd-b6da-28ae4efee47e">two</ix:nonFraction> putative class actions and appointed a lead plaintiff and lead counsel. The lead plaintiff filed an amended complaint on September 29, 2022. Defendants filed a motion to dismiss the amended complaint on December 2, 2022. In January and February 2023, in lieu of filing a response to defendant&#8217;s motion to dismiss, plaintiffs filed a motion seeking leave to further amend their compliant and defendants filed an opposition to the motion for leave to further amend the complaint. A hearing on the motion for leave to further amend the complaint is scheduled for mid-May 2023. We believe the plaintiff&#8217;s claims are without merit and we have not recorded any accrual for a contingent liability associated with these legal proceedings.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2021 and March 29, 2022, <ix:nonFraction unitRef="claim" contextRef="i1fb81fa2f1994bbf9c437971dd33e52e_D20211207-20220329" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDgvZnJhZzo3ZWYwMmVhMWYxNjk0N2RjYjVhYmEyYjU0MzhiYmZkNC90ZXh0cmVnaW9uOjdlZjAyZWExZjE2OTQ3ZGNiNWFiYTJiNTQzOGJiZmQ0XzIxOTkwMjMyNzE1NzM_f62b9b45-5c16-41a3-866b-ab0e4611ce09">two</ix:nonFraction> verified shareholders derivative lawsuits were filed in the U.S. District Court for the Northern District of California purportedly on behalf of Ardelyx against certain of Ardelyx&#8217;s executive officers and members of our board of directors, captioned Go v. Raab, et al., Case No. 4:21-cv-09455-HSG, and Morris v. Raab, et al., Case No. 4:22-cv-01988-JSC. The complaints allege that the defendants violations of Section 14(a) of the Securities Exchange Act of 1934, as amended, breaches of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement, and waste of corporate assets, for personally making and/or causing Ardelyx to make materially false and misleading statements regarding the Company&#8217;s business, operations and prospects. The complaint seeks contribution under Sections 10(b) and 21D of the Securities Exchange Act of 1934 from <ix:nonFraction unitRef="defendant" contextRef="i1fb81fa2f1994bbf9c437971dd33e52e_D20211207-20220329" decimals="INF" name="us-gaap:LossContingencyNumberOfDefendants" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDgvZnJhZzo3ZWYwMmVhMWYxNjk0N2RjYjVhYmEyYjU0MzhiYmZkNC90ZXh0cmVnaW9uOjdlZjAyZWExZjE2OTQ3ZGNiNWFiYTJiNTQzOGJiZmQ0XzIxOTkwMjMyNzE1OTY_8da0e31f-ec50-45b0-9398-ca2515e9dc94">two</ix:nonFraction> executive officers. On January 19, and April 27, 2022, the court granted the parties&#8217; stipulation to stay the Go and Morris actions, respectively, until resolution of the anticipated motion(s) to dismiss in the Securities Class Actions. On October 25, 2022, the parties filed a stipulation to consolidate and stay the Go and Morris actions, </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><ix:continuation id="i4f40b2d58ac34c328d40fc91baa21761"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and on October 27, 2022, the court consolidated the Go and Morris action and stayed the consolidated action pending resolution of the anticipated motion(s) to dismiss in the Securities Class Action. We believe the plaintiff&#8217;s claims are without merit and we have not recorded any accrual for a contingent liability associated with these legal proceedings.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be involved in legal proceedings arising in the ordinary course of business. As of December&#160;31, 2022, there is no litigation pending that would reasonably be expected to have a material adverse effect on our results of operations and financial condition, and <ix:nonFraction unitRef="usd" contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231" decimals="INF" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDgvZnJhZzo3ZWYwMmVhMWYxNjk0N2RjYjVhYmEyYjU0MzhiYmZkNC90ZXh0cmVnaW9uOjdlZjAyZWExZjE2OTQ3ZGNiNWFiYTJiNTQzOGJiZmQ0XzIxOTkwMjMyNzE1ODg_0050fad5-e88b-4e23-bdf9-8b261cda5ae8">no</ix:nonFraction> contingent liabilities were accrued as of December&#160;31, 2022.</span></div></ix:continuation><div id="i8c6ecca27b7b4659bf1d61cfb55de996_154"></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">21.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTQvZnJhZzozMDdmYTE5YmM4YmQ0ZjE0OGRlYmViNzQ5NjVjM2JhMC90ZXh0cmVnaW9uOjMwN2ZhMTliYzhiZDRmMTQ4ZGViZWI3NDk2NWMzYmEwXzU2MzI_78ca9ae4-40bd-427e-a0f8-32e05f9e7d56" continuedAt="ief69b7e9d0284d41aacf4924e4fb784b" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><ix:continuation id="ief69b7e9d0284d41aacf4924e4fb784b"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, we filed a Form S-3 registration statement, which became effective in January 2023 ("2023 Registration Statement"), containing (i) a base prospectus for the offering, issuance and sale by us of up to a maximum aggregate offering price of $<ix:nonFraction unitRef="usd" contextRef="i0edad5a730a244cba8f8a9819262823c_I20230131" decimals="INF" name="ardx:MaximumAggregateOfferingPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTQvZnJhZzozMDdmYTE5YmM4YmQ0ZjE0OGRlYmViNzQ5NjVjM2JhMC90ZXh0cmVnaW9uOjMwN2ZhMTliYzhiZDRmMTQ4ZGViZWI3NDk2NWMzYmEwXzU0OTc1NTgyNTQyNg_295510a4-7a74-4728-9fbe-ea57ba75958d">250.0</ix:nonFraction> million of our common stock, preferred stock, debt securities, warrants and/or units, from time to time in one or more offerings; and (ii) a prospectus supplement for the offering, issuance and sale by us of up to a maximum aggregate offering price of $<ix:nonFraction unitRef="usd" contextRef="id8349613f0ed462d8ac8ec08c2be4b51_I20230131" decimals="INF" name="ardx:MaximumAggregateOfferingPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTQvZnJhZzozMDdmYTE5YmM4YmQ0ZjE0OGRlYmViNzQ5NjVjM2JhMC90ZXh0cmVnaW9uOjMwN2ZhMTliYzhiZDRmMTQ4ZGViZWI3NDk2NWMzYmEwXzU0OTc1NTgyNTY3NA_9be593c4-93f8-4d02-86b5-a3c05b268ffd">150.0</ix:nonFraction> million of our common stock that may be issued and sold, from time to time, under a sales agreement with Jefferies LLC ("Jefferies"), deemed to be &#8220;at-the-market offerings&#8221; ("2023 Open Market Sales Agreement").&#160;Pursuant to the 2023 Open Market Sales Agreement, Jefferies, as sales agent, may receive a commission of up to <ix:nonFraction unitRef="number" contextRef="i05cd4ea70ed4485589e755e460b69fd1_D20230101-20230131" decimals="INF" name="ardx:StockIssuanceCostCommissionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTQvZnJhZzozMDdmYTE5YmM4YmQ0ZjE0OGRlYmViNzQ5NjVjM2JhMC90ZXh0cmVnaW9uOjMwN2ZhMTliYzhiZDRmMTQ4ZGViZWI3NDk2NWMzYmEwXzU0OTc1NTgyNTk5Ng_afb0af8d-ab5f-4df3-b4be-caea5167842f">3.0</ix:nonFraction>% of the gross sales price for shares of common stock sold under the 2023 Open Market Sales Agreement. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 9, 2023, we entered into a second amendment (&#8220;Second Amendment&#8221;) to our Loan Agreement with the Lenders. The Second Amendment extends the interest-only term of the loan by twelve months to March 31, 2025 provided that we either (i) receive approval from the FDA for our NDA for the control of serum phosphorus in adult patients with CKD on dialysis on or prior to November 30, 2023 or (ii) achieve certain product revenue milestone targets as described in the Second Amendment for the year ending December 31, 2023. The Second Amendment also extends the period under which we may draw the Term B Loan from July 25, 2023 to December 20, 2023, and amends the milestone that we must achieve in order to draw the Term B Loan by extending the time period for the receipt of approval by the FDA of the NDA for the control of serum phosphorus in adult patients with CKD on dialysis until November 30, 2023. In addition, the Second Amendment replaces the floating per annum interest rate with <ix:nonFraction unitRef="number" contextRef="ic957e7b2e6404684ab3ce4588e0747ed_D20230209-20230209" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTQvZnJhZzozMDdmYTE5YmM4YmQ0ZjE0OGRlYmViNzQ5NjVjM2JhMC90ZXh0cmVnaW9uOjMwN2ZhMTliYzhiZDRmMTQ4ZGViZWI3NDk2NWMzYmEwXzIxOTkwMjMyNjk3NTY_8558c00e-26e5-4608-a5f6-1304f05b61fa">7.95</ix:nonFraction>% plus the greater of (a) one percent (<ix:nonFraction unitRef="number" contextRef="ic957e7b2e6404684ab3ce4588e0747ed_D20230209-20230209" decimals="INF" name="ardx:DebtInstrumentVariableRateBaseOption" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTQvZnJhZzozMDdmYTE5YmM4YmQ0ZjE0OGRlYmViNzQ5NjVjM2JhMC90ZXh0cmVnaW9uOjMwN2ZhMTliYzhiZDRmMTQ4ZGViZWI3NDk2NWMzYmEwXzIxOTkwMjMyNjk3NjM_fbd702e0-e7d2-4b62-a06e-090be9e84594">1.00</ix:nonFraction>%) per annum and (b)(i) <ix:nonFraction unitRef="number" contextRef="ic957e7b2e6404684ab3ce4588e0747ed_D20230209-20230209" decimals="5" name="ardx:DebtInstrumentVariableRatePlusOption" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTQvZnJhZzozMDdmYTE5YmM4YmQ0ZjE0OGRlYmViNzQ5NjVjM2JhMC90ZXh0cmVnaW9uOjMwN2ZhMTliYzhiZDRmMTQ4ZGViZWI3NDk2NWMzYmEwXzIxOTkwMjMyNjk3NzA_e0c40463-b1e0-4520-89fa-851f08aecb84">0.022</ix:nonFraction>% plus (ii) 1-month CME Term SOFR reference rate as published by the CME Term SOFR Administrator on the CME Term SOFR Administrator&#8217;s Website.</span></div></ix:continuation><div id="i8c6ecca27b7b4659bf1d61cfb55de996_157"></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9.&#160;&#160;&#160;&#160;CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_160"></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9A.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conclusions Regarding the Effectiveness of Disclosure Controls and Procedures</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, management, with the participation of our Chief Executive Officer ("CEO") and Chief Financial and Operations Officer ("CFOO"), performed an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;of the Exchange Act. Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#8217;s rules&#160;and forms, and that such information is accumulated and communicated to our management, including the CEO and the CFOO, to allow timely decisions regarding required disclosures.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on this evaluation, our CEO and CFOO concluded that, as of December&#160;31, 2022, the design and operation of our disclosure controls and procedures were effective at a reasonable assurance level.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process designed by, or under the supervision of, our CEO and CFO, and effected by our Board of Directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pertain to the maintenance of records that accurately and fairly reflect in reasonable detail the transactions and dispositions of the assets of our company;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Provide reasonable assurances regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material adverse effect on our financial statements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management assessed our internal control over financial reporting as of December&#160;31, 2022, the end of the period covered by this Annual Report on Form&#160;10-K. Management based its assessment on criteria established in &#8220;Internal Control&#8212;Integrated Framework (2013)&#8221; issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on management&#8217;s assessment of our internal control over financial reporting, management concluded that, as of December&#160;31, 2022, our internal control over financial reporting was effective.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended December&#160;31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_163"></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9B.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_166"></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9C.&#160;&#160;&#160;&#160;DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_169"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;III</span></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_172"></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;10.&#160;&#160;&#160;&#160;DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item will be contained in our definitive proxy statement to be filed with the Securities and Exchange Commission on Schedule 14A in connection with our 2023 Annual Meeting of Stockholders (&#8220;Proxy Statement&#8221;), which will be filed not later than 120&#160;days after the end of our fiscal&#160;year ended December&#160;31, 2022, under the headings &#8220;Executive Officers,&#8221; &#8220;Election of Directors,&#8221; &#8220;Corporate Governance,&#8221; and &#8220; Section&#160;16(a)&#160;Beneficial Ownership Reporting Compliance,&#8221; and is incorporated herein by reference.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a Code of Business Conduct and Ethics that applies to our officers, directors and employees which is available on our website at www.ardelyx.com. The Code of Business Conduct and Ethics is intended to qualify as a &#8220;code of ethics&#8221; within the meaning of Section 406 of the Sarbanes-Oxley Act of 2002 and Item 406 of Regulation S-K. If we make any amendment to, or waiver from, a provision of our Code of Conduct that we are required to disclose under SEC rules, we intend to satisfy that disclosure requirement by posting such information to our website at www.ardelyx.com. The contents of our websites are not intended to be incorporated by reference into this Form 10-K or in any other report or document we file with the SEC, and any references to our websites are intended to be inactive textual references only.</span></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_175"></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;11.&#160;&#160;&#160;&#160;EXECUTIVE COMPENSATION</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item regarding executive compensation will be incorporated by reference to the information set forth in the sections titled &#8220;Executive Compensation&#8221; in our Proxy Statement.</span></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_178"></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;12.&#160;&#160;&#160;&#160;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item regarding security ownership of certain beneficial owners and management will be incorporated by reference to the information set forth in the section titled &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Equity Compensation Plan Information&#8221; in our Proxy Statement.</span></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_181"></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;13.&#160;&#160;&#160;&#160;CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item regarding certain relationships and related transactions and director independence will be incorporated by reference to the information set forth in the sections titled &#8220;Certain Relationships and Related Party Transactions&#8221; and &#8220;Election of Directors&#8221;, respectively, in our Proxy Statement.</span></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_184"></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;14.&#160;&#160;&#160;&#160;PRINCIPAL ACCOUNTING FEES AND SERVICES</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item regarding principal accountant fees and services will be incorporated by reference to the information set forth in the section titled &#8220;Principal Accountant Fees and Services&#8221; in our Proxy Statement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_187"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;IV</span></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_190"></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;15.&#160;&#160;&#160;&#160;EXHIBITS, FINANCIAL STATEMENT SCHEDULES</span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">The following documents are filed as part of this report:</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Financial Statements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Index to Financial Statements at Item&#160;8 herein.</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Financial Statement Schedules</span></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All schedules are omitted because they are not applicable or the required information is shown in the financial statements or notes thereto.</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Exhibits</span></div><div style="margin-top:12pt;text-align:justify;text-indent:90pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the Exhibit&#160;Index immediately following this page.</span></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_193"></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16.&#160;&#160;&#160;&#160;FORM 10-K SUMMARY</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:12pt"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;Index</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.747%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.365%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Incorporated&#160;by&#160;Reference</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Filed<br/>Herewith</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000119312514247380/d748616dex31.htm">Amended and Restated Certificate of Incorporation</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6/24/2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000119312514247380/d748616dex32.htm">Amended and Restated Bylaws</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6/24/2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reference is made to Exhibits 3.1 and 3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000119312514240520/d704770dex42.htm">Form&#160;of Common Stock Certificate</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6/18/2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000155837021002500/ardx-20201231xex4d4.htm">Description of the Registrant&#8217;s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3/8/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1(a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000119312515288082/d948397dex101.htm">Termination Agreement, dated June&#160;2, 2015, by and between AstraZeneca AB and Ardelyx,&#160;Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8/12/2015</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1(b)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000119312516493375/d133887dex101d.htm">Amendment No. 1 to Termination Agreement and to Manufacturing and Supply Agreement, dated November&#160;2, 2015 by and between AstraZeneca AB and Ardelyx,&#160;Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3/4/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1(d)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2(a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000119312514204985/d704770dex104a.htm">Lease, dated August&#160;8, 2008, by and between 34175 Ardenwood Venture, LLC and Ardelyx,&#160;Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5/19/2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.4(a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2(b)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000119312514204985/d704770dex104b.htm">First Amendment to Lease, dated December&#160;20, 2012, by and between 34175 Ardenwood Venture, LLC and Ardelyx,&#160;Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5/19/2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.4(b)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2(c)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000119312514336840/d786507dex101.htm">Second Amendment to Lease, dated September&#160;5, 2014, by and between Ardelyx,&#160;Inc. and 34175 Ardenwood Venture, LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9/9/2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2(d)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000119312516675135/d201246dex103.htm">Third Amendment to Lease, dated April&#160;28, 2016, by and between Ardelyx,&#160;Inc. and 34175 Ardenwood Venture, LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8/8/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2(e)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ardenwoodventurellc-leasea.htm">Fourth Amendment to Lease, dated May 25, 2021, by and between Ardelyx,&#160;Inc. and 34175 Ardenwood Venture, LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2(f)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000162828021011446/ardenwoodleasefifthamendme.htm">Fifth Amendment to Lease, dated May 25, 2021, by and between Ardelyx,&#160;Inc. and 34175 Ardenwood Venture, LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6/1/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000155837021002500/ardx-20201231xex10d31.htm">Lease Agreement, dated December 30, 2020, by and between Ardelyx, Inc. and Prospect Fifth Ave, LLC.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3/8/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.4(a)#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000119312514204985/d704770dex105a.htm">Ardelyx,&#160;Inc. 2008 Stock Incentive Plan, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5/19/2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.5(a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.747%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.365%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Incorporated&#160;by&#160;Reference</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Filed<br/>Herewith</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.4(b)#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000119312514204985/d704770dex105b.htm">Form&#160;of Stock Option Grant Notice and Stock Option Agreement under the 2008 Stock Incentive Plan, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5/19/2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.5(b)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.4(c)#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000119312514204985/d704770dex105c.htm">Form&#160;of Restricted Stock Purchase Grant Notice and Restricted Stock Purchase Agreement under the 2008 Stock Incentive Plan, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5/19/2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.5(c)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.5(a)#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1437402/000119312514267896/d758186dex993.htm">Ardelyx,&#160;Inc. 2014 Equity Incentive Award Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7/14/2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.5(b)#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000119312514229371/d704770dex106b.htm">Form&#160;of Stock Option Grant Notice and Stock Option Agreement under the 2014 Equity Incentive Award Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6/9/2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.6(b)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.5(c)#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000119312514229371/d704770dex106c.htm">Form&#160;of Restricted Stock Award Agreement and Restricted Stock Unit Award Grant Notice under the 2014 Equity Incentive Award Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6/9/2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.6(c)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.6#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000119312514267896/d758186dex996.htm">Ardelyx,&#160;Inc. 2014 Employee Stock Purchase Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7/14/2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.7(a)#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000119312516764653/d276142dex991.htm">Ardelyx,&#160;Inc. 2016 Employment Commencement Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11/10/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.7(b)#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000119312516764653/d276142dex992.htm">Form&#160;of Stock Option Grant Notice and Stock Option Agreement under the 2016 Employment Commencement Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11/10/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.7(c)#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000119312516764653/d276142dex993.htm">Form&#160;of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2016 Employment Commencement Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11/10/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.7(d)#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000119312516764653/d276142dex994.htm">Form&#160;of Restricted Stock Award Grant Notice and Restricted Stock Award Agreement under the 2016 Employment Commencement Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11/10/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000119312515250831/d44646dex991.htm">Registration Rights Agreement by and among Ardelyx,&#160;Inc. and the investors signatory thereto, dated June&#160;2, 2015</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7/13/2015</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000119312516675135/d201246dex102.htm">Registration Rights Agreement by and among Ardelyx,&#160;Inc. and the investors signatory thereto, dated July&#160;14, 2016</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8/8/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.10#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000119312514229371/d704770dex107.htm">Form&#160;of Indemnification Agreement for directors and officers</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6/9/2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.11#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000119312514229371/d704770dex108.htm">Amended and Restated Executive Employment Agreement, dated June&#160;6, 2014, by and between Ardelyx,&#160;Inc. and Michael Raab</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6/9/2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.12#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000119312514229371/d704770dex1013.htm">Offer Letter, dated December&#160;28, 2009, by and between Ardelyx,&#160;Inc. and David Rosenbaum, Ph.D.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6/9/2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.13(a)#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000155837018004307/ardx-20180331ex101b83033.htm">Second Amended and Restated Change in Control and Severance Agreement by and between Ardelyx, Inc. and David P. Rosenbaum, Ph.D.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5/8/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.13(b)#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000162828022004226/amendmentnumberone_drosenb.htm">Amendment Number One to Second Amended and Restated Change in Control Severance Agreement and Retention Agreement dated December 1, 2021 between Ardelyx, Inc. and David Rosenbaum</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2/28/2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.14#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000119312514229371/d704770dex1014.htm">Offer Letter, dated November&#160;21, 2012, by and between Ardelyx,&#160;Inc. and Elizabeth Grammer,&#160;Esq.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6/9/2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.15#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000155837018004307/ardx-20180331ex100e97155.htm">Second Amended and Restated Change in Control and Severance Agreement by and between Ardelyx, Inc. and Elizabeth Grammer.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5/8/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.0</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.16#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000155837020009636/ardx-20200630xex10d1.htm">Offer Letter, dated April 27, 2020, by and between Ardelyx, Inc. and Susan Rodriguez</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8/6/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.17#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000155837020009636/ardx-20200630xex10d2.htm">Change in Control Severance Agreement dated June 2, 2020, by and between Ardelyx, Inc. and Susan Rodriguez</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8/6/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.18#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000155837020009636/ardx-20200630xex10d3.htm">Offer Letter, dated June 2, 2020, by and between Ardelyx, Inc. and Justin Renz</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8/6/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.19#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000155837020009636/ardx-20200630xex10d4.htm">Change in Control Severance Agreement, dated June 8, 2020, by and between Ardelyx, Inc. and Justin Renz</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8/6/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.20(a)#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000119312514229371/d704770dex1021.htm">Non-Employee&#160;Director Compensation Program</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6/9/2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.20(b)#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000119312517077089/d133384d8k.htm">Description of amendments to Non-Employee&#160;Director Compensation Program</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3/9/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.20(c)#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000155837019004249/ardx-20190331ex101320fc2.htm">Amended and Restated Non-Employee Director Compensation Program.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5/7/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.747%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.365%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Incorporated&#160;by&#160;Reference</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Filed<br/>Herewith</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.20(d)#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000162828022021047/secondamendedandrestatedno.htm">Second Amended and Restated Non-Employee Director Compensation Program</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8/4/2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.21(a)&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000155837018002056/ardx-20171231ex10353fabf.htm">License Agreement, dated November 27, 2017, by and between Kyowa Hakko Kirin Co. , Ltd. and Ardelyx, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3/14/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.35</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.21(b)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="kyowakirincoltdfkakyowahak.htm">Amendment Number 1 to License Agreement, dated as of November 27, 2017, by and among Ardelyx, Inc., and Kyowa Kirin Co., Ltd.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.21(c)&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000162828022008924/a2ndamendmenttokkc-ardxlic.htm">Amendment Number 2 to License Agreement, dated as of April 11, 2022, by and among Ardelyx, Inc., </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000162828022008924/a2ndamendmenttokkc-ardxlic.htm">and Kyowa Kirin Co., Ltd.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4/11/2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.22&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000155837018002056/ardx-20171231ex103695c56.htm">License Agreement, dated December 11, 2017, by and between Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. and Ardelyx, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3/14/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.36</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.23&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000162828022021047/hcr-ardelyxxroyaltyandmile.htm">Royalty and Sales Milestone Interest Acquisition Agreement dated June 29, 2022, by and between Ardelyx, Inc. and Healthcare Royalty Partners IV, L.P.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8/4/2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.24(a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000162828022012630/slrloanandsecurityagreemen.htm">Loan and Security Agreement dated February 23, 2022, by and between Ardelyx, Inc. and SLR Investment Corp.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5/5/2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.24(b)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000162828022021047/slr-ardelyxxfirstamendment.htm">First Amendment to the Loan and Security Agreement dated August 1, 2022, by and between Ardelyx, Inc. and SLR Investment Corp.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8/4/2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.24(c)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="slr-ardelyxxsecondamendmen.htm">Second Amendment to the Loan and Security Agreement dated February 9, 2023, by and between Ardelyx, Inc. and SLR Investment Corp.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.25</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000162828022012630/slrexitfeeagreement-ex102.htm">Exit Fee Agreement dated February 23, 2022, by and between Ardelyx, Inc. and SLR Investment Corp.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5/5/2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.26</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000155837018006606/ardx-20180630ex102467e2d.htm">Exit Fee Agreement, dated May 16, 2018, by and between the Company and Solar Capital Ltd. and Western Alliance Bank. &#160;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8/7/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.27(a)&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000155837020009636/ardx-20200630xex10d5.htm">Manufacturing Services Agreement, dated May 18, 2020, between Ardelyx, Inc. and Patheon Pharmaceuticals Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8/6/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.27(b)&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ardelyx_psgxmsaamendment1.htm">First Amendment to the Manufacturing Services Agreement dated February 27, 2023, between Ardelyx, Inc. and Patheon Pharmaceuticals Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.29</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000162828021017192/salesagencyagreementaugust.htm">Open Market Sales Agreement, dated August 31, 2021 between Ardelyx, Inc. and Jefferies LLC.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8/13/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000119312523010411/d429337dex12.htm">Open Market Sales Agreement, dated January 18, 2023 between Ardelyx, Inc. and Jefferies LLC.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S-3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1/19/2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="consentofindependentregist.htm">Consent of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ardx-20221231xex311.htm">Certification of Principal Executive Officer Required Under Rule&#160;13a-14(a)&#160;and&#160;15d-14(a)&#160;of the Securities Exchange Act of 1934, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ardx-20221231xex312.htm">Certification of Principal Financial Officer Required Under Rule&#160;13a-14(a)&#160;and&#160;15d-14(a)&#160;of the Securities Exchange Act of 1934, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ardx-20221231xex321.htm">Certification of Principal Executive Officer and Principal Financial Officer Required Under Rule 13a&#8209;14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C &#167;1350</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;Confidential treatment granted as to portions of this Exhibit. The confidential portions of this Exhibit&#160;have been omitted and are marked by asterisks.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8224;&#8224;&#160;&#160;&#160;&#160;Certain portions of this exhibit have been redacted pursuant to Item 601(b)(10) of Regulation S-K. A copy of the omitted portions will be furnished supplementally to the Securities and Exchange Commission upon request.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#&#160;&#160;&#160;&#160;Indicates management contract or compensatory plan.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><div id="i8c6ecca27b7b4659bf1d61cfb55de996_196"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.969%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ardelyx, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: March 2, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Robert Felsch</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Robert Felsch<br/>Senior Vice President and Chief Accounting Officer<br/>(Principal Accounting Officer)</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each person whose individual signature appears below hereby authorizes and appoints Michael Raab, Justin Renz, and Robert Felsch, and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this annual report on Form&#160;10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c6ecca27b7b4659bf1d61cfb55de996_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:33.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.568%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.016%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Date</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Michael Raab</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President, Chief Executive Officer and Director</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Principal Executive Officer)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 2, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Michael Raab</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Justin Renz</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial and Operations Officer </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Principal Financial Officer)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 2, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Justin Renz</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Robert Felsch</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Accounting Officer </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Principal Accounting Officer)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 2, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Robert Felsch</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ David Mott</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chairman of the Board of Directors</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 2, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">David Mott</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Robert Bazemore</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 2, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Robert Bazemore</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ William Bertrand,&#160;Jr.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 2, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">William Bertrand,&#160;Jr., J.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Muna Bhanji</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 2, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Muna Bhanji, R.Ph</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Geoffrey A. Block</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 2, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Geoffrey A. Block, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Onaiza Cadoret-Manier</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 2, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Onaiza Cadoret-Manier</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Jan M. Lundberg</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 2, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jan M. Lundberg, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Richard Rodgers</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 2, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Richard Rodgers</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2(E)
<SEQUENCE>2
<FILENAME>ardenwoodventurellc-leasea.htm
<DESCRIPTION>EX-10.2(E)
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i25c2734c472b4edc952431f138cca6d3_1"></div><div style="min-height:76.32pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Ex. 10.2(e)</font></div></div><div style="margin-top:3.15pt;padding-left:69.92pt;padding-right:69.92pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">FOURTH AMENDMENT TO LEASE</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6.95pt;padding-right:6pt;text-align:justify;text-indent:34.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">THIS FOURTH AMENDMENT TO LEASE (this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">&#34;Fourth Amendment&#34;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> is entered into as of this ll</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.47pt;font-weight:400;line-height:100%;position:relative;top:-4.02pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> day of May, 2018 (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">&#34;Execution Date&#34;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> by and between 34175 ARDENWOOD VENTURE, LLC, a Delaware limited liability company </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">(&#34;Landlord&#34;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> and ARDELYX, INC., a Delaware corporation </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">(&#34;Tenant,&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> formerly known as Nteryx, Inc.).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:69.67pt;padding-right:69.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">RECITALS</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:6.15pt;padding-right:5.55pt;text-align:justify;text-indent:35.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:19.13pt">WHEREAS, Landlord and Tenant entered into that certain Lease dated as of August 8, 2008, as amended by that certain First Amendment to Lease dated as of December 20, 2012, as further amended by that certain Second Amendment to Lease dated as of September 5, 2014, and as further amended by that certain Third Amendment to Lease dated as of April 28, 20I6 (collectively, and as the same may have been further amended, amended and restated, supplemented or modified from time to time, the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">&#34;Existing Lease&#34;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> whereby Tenant leases certain premises (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">&#34;Existing Premises&#34;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> from Landlord at 34175 Ardenwood Boulevard in Fremont, California (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">&#34;Building&#34;)&#58;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:75.95pt;text-indent:-34.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:24.67pt">WHEREAS, Tenant desires to amend its notice address under the Lease&#59; and</font></div><div style="margin-top:11.65pt;padding-left:6.05pt;padding-right:6.1pt;text-align:justify;text-indent:34.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:117%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:117%;padding-left:20.46pt">WHEREAS, Landlord and Tenant desire to modify and amend the Existing Lease only in the respects and on the conditions hereinafter stated.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:69.42pt;padding-right:69.42pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">AGREEMENT</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:5.65pt;padding-right:6pt;text-align:justify;text-indent:35.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">NOW, THEREFORE, Landlord and Tenant, in consideration of the mutual promises contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, agree as follows&#58;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:5.2pt;padding-right:6.1pt;text-align:justify;text-indent:1.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">I. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Definitions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> For purposes of this Fourth Amendment, capitalized terms shall have the meanings ascribed to them in the Existing Lease unless otherwise defined herein. The Existing Lease, as amended by this Fourth Amendment, is referred to collectively herein as the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">&#34;Lease.&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> From and after the date hereof, the term &#34;Lease,&#34; as used in the Existing Lease, shall mean the Existing Lease, as amended by this Fourth Amendment.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5.05pt;padding-right:6.45pt;text-align:justify;text-indent:0.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:114%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:114%;padding-left:22.28pt;text-decoration:underline">Notices.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:114%"> Notwithstanding anything in the Lease to the contrary, notices delivered to Tenant pursuant to the Lease should be sent to&#58;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:109.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Ardelyx, Inc.</font></div><div style="margin-top:0.45pt;padding-left:109.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">34175 Ardenwood Blvd.</font></div><div style="margin-top:0.15pt;padding-left:109.55pt;padding-right:209.05pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Fremont, California 94555 Attn&#58; Director of Facilities</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:109.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">With a copy to&#58;</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:109.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Ardelyx, Inc.</font></div><div style="margin-top:0.15pt;padding-left:109.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">34175 Ardenwood Blvd.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i25c2734c472b4edc952431f138cca6d3_4"></div><hr style="page-break-after:always"><div style="min-height:74.88pt;width:100%"><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div><div style="margin-top:3.7pt;padding-left:111.7pt;padding-right:209.05pt;text-indent:0.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:117%">Fremont, California 94555 Attn&#58; General Counsel</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:111.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">And a copy to&#58;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:111.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:114%">Solar Capital Ltd.</font></div><div style="padding-left:111.35pt;padding-right:226.2pt;text-indent:0.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:117%">500 Park Avenue, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">3,d </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:117%">Floor New York, NY 10022 Attn&#58; Anthony Storino</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:6.6pt;padding-right:6pt;text-align:justify;text-indent:0.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:20.33pt;text-decoration:underline">Broker.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> Tenant represents and warrants that it has not dealt with any broker or agent in the negotiation for or the obtaining of this Fourth Amendment, and agrees to reimburse, indenmify, save, defend (at Landlord's option and with counsel reasonably acceptable to Landlord, at Tenant's sole cost and expense) and hold harmless the Landlord Parties for, from and against any and all cost or liability for compensation claimed by any such broker or agent, other than Broker, employed or engaged by it or claiming to have been employed or engaged by it.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:6.35pt;padding-right:5.9pt;text-align:justify;text-indent:0.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:20.78pt;text-decoration:underline">No Default.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> Tenant represents, warrants and covenants that, to the best of Tenant's knowledge, Landlord and Tenant are not in default of any of their respective obligations under the Existing Lease and no event has occurred that, with the passage of time or the giving of notice (or both) would constitute a default by either Landlord or Tenant thereunder.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:5.9pt;padding-right:5.9pt;text-align:justify;text-indent:0.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:21.13pt;text-decoration:underline">Effect of Amendment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> Except as modified by this Fourth Amendment, the Existing Lease and all the covenants, agreements, terms, provisions and conditions thereof shall remain in full force and effect and are hereby ratified and affirmed. In the event of any conflict between the tenns contained in this Fourth Amendment and the Existing Lease, the terms herein contained shall supersede and control the obligations and liabilities of the parties.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5.7pt;padding-right:5.8pt;text-align:justify;text-indent:0.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:21.43pt;text-decoration:underline">Successors and Assigns.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> Each of the covenants, conditions and agreements contained in this Fourth Amendment shall inure to the benefit of and shall apply to and be binding upon the parties hereto and their respective heirs, legatees, devisees, executors, administrators and permitted successors and assigns and sublessees. Nothing in this Section shall in any way alter the provisions of the Lease restricting assignment or subletting.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5.3pt;padding-right:5.85pt;text-align:justify;text-indent:0.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:118%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:118%;padding-left:21.78pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:118%">. This Fourth Amendment becomes effective only upon execution and delivery hereof by Landlord and Tenant. The captions of the paragraphs and subparagraphs in this Fourth Amendment are inserted and included solely for convenience and shall not be considered or given any effect in construing the provisions hereof. All exhibits hereto are incorporated herein by reference. Submission of this instrument for examination or signature by Tenant does not constitute a reservation of or option for a lease, and shall not be effective as a lease, lease amendment or otherwise until execution by and delivery to both Landlord and Tenant.</font></div><div style="margin-top:11.25pt;padding-left:5.15pt;padding-right:5.95pt;text-align:justify;text-indent:0.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:117%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:117%;padding-left:22.03pt;text-decoration:underline">Authority.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:117%"> Tenant guarantees, warrants and represents that the individual or individuals signing this Fourth Amendment have the power, authority and legal capacity to sign this Fourth Amendment on behalf of and to bind all entities, corporations, partnerships, limited liability </font></div><div style="height:97.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.749%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></div></div><div id="i25c2734c472b4edc952431f138cca6d3_7"></div><hr style="page-break-after:always"><div style="min-height:76.32pt;width:100%"><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:7.55pt;text-indent:-0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:119%">companies, joint venturers or other organizations and entities on whose behalf such individual or individuals have signed.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:7pt;padding-right:6pt;text-align:justify;text-indent:0.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;padding-left:20.7pt;text-decoration:underline">Counterparts&#58; Facsimile and PDF Signatures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">. This Fourth Amendment may be executed in one or more counterparts, each of which, when taken together, shall constitute one and the same document. A facsimile or portable document format (PDF) signature on this Fourth Amendment shall be equivalent to, and have the same force and effect as, an original signature.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:69.97pt;padding-right:69.97pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="height:97.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.749%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:76.32pt;width:100%"><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="margin-top:3.5pt;padding-left:7.15pt;padding-right:5.15pt;text-indent:34.75pt"><font style="color:#464b4b;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:119%">IN WITNESS WHEREOF, Landlord and Tenant have executed this Fourth Amendment as of the date and year first above written.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:6.6pt"><font style="color:#464b4b;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">LANDLORD&#58;</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:6.7pt"><font style="color:#464b4b;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">34175 ARDENWOOD VENTURE, LLC,</font></div><div style="margin-top:0.7pt;padding-left:6.8pt"><font style="color:#464b4b;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware </font><font style="color:#313636;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">limited </font><font style="color:#464b4b;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">liability company</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:6.6pt"><font style="color:#464b4b;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:333%">By&#58; &#47;s&#47; Kevin M. Simonsen&#160;&#160;&#160;&#160;</font></div><div style="padding-left:6.95pt"><font style="color:#464b4b;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:132%">Name&#58; Kevin M. Simonsen</font></div><div style="padding-left:6.45pt"><font style="color:#464b4b;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">Title&#58; Sr. Vice President, Sr. Counsel</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:6.4pt"><font style="color:#464b4b;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">TENANT&#58;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:6pt"><font style="color:#464b4b;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ARDELYX, INC.,</font></div><div style="margin-top:1.1pt;padding-left:6.05pt"><font style="color:#464b4b;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware corporation</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.9pt"><font style="color:#464b4b;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:383%">By&#58; &#47;s&#47; Mark Kaufmann&#160;&#160;&#160;&#160;</font></div><div style="padding-left:5.85pt"><font style="color:#464b4b;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Mark Kaufmann</font></div><div style="padding-left:5.75pt"><font style="color:#464b4b;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Title&#58; Chief Financial Officer</font></div><div style="height:97.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.749%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.21(B)
<SEQUENCE>3
<FILENAME>kyowakirincoltdfkakyowahak.htm
<DESCRIPTION>EX-10.21(B)
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i93c4c483ad284e629ac7b3795cb186cf_1"></div><div style="min-height:90.72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Ex. 10.21(b)</font></div></div><div style="margin-top:4.45pt;padding-left:145.67pt;padding-right:145.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">AMENDMENT </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NO. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">to</font></div><div style="margin-top:0.85pt;padding-left:145.82pt;padding-right:145.82pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">LICENSE AGREEMENT</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6.15pt;padding-right:5.4pt;text-indent:34.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">This FIRST AMENDMENT (the &#8221;Amendment&#8221;), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">effective as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">date last </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">signed </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">below </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">(the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:110%">&#8221;Amendment </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Date&#8221;), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">amends that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">certain </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">License </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:110%">Agreement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">dated November </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">27, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">2017 (together with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">all </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">exhibits, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">amendments </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">attachments </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">thereto, the &#34;Original Agreement&#8221;) by and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Kyowa Kirin Co., </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">Ltd. (f&#47;k&#47;a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:110%">Kyowa </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">Hakko Kirin </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Co., </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">Ltd.), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:110%">Japanese corporation </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:110%">a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">place </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">of business at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">1&#8212;9&#8212; 2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Otemachi, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:110%">Chiyoda&#8212;ku, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Tokyo 100-0004, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:110%">Japan (&#34;KKC&#34;), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Ardelyx, Inc., </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">Delaware </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:110%">corporation </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">having its principal </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">place of business at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">34175 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">Ardenwood </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Boulevard, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">Fremont, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">California </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">United </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">States of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">America </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">94555 (&#34;Ardelyx&#34;). </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">KKC </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">and Ardelyx shall each be hereinafter referred </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:110%">as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">a &#34;Party&#34; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">and collectively </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:110%">as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">the &#8221;Parties&#8221;. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">Capitalized </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">terms used but not otherwise defined </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">herein </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">shall have the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">meanings </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">ascribed to them </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Original Agreement.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:40.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:127%">WHEREAS, KKC </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:127%">has no further need for Licensed </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:127%">Product </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">supply </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:127%">from </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:127%">Ardelyx </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:127%">and desires only</font></div><div style="padding-left:5.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:129%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:129%">receive API </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:129%">supply </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:129%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:129%">accordance </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:129%">with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:129%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:129%">Original Agreement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:129%">and the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:129%">MSA&#59; and</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:40.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">the Parties wish </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">amend the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Original Agreement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">to reflect the foregoing&#59;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%">NOW, THEREFORE, in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:121%">consideration ofthe </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:121%">premises </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:121%">the terms and conditions </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%">contained</font></div><div style="padding-left:6.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%">herein, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%">Parties </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">agree </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:122%">as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">follows&#58;</font></div><div><font><br></font></div><div style="padding-left:5.3pt;padding-right:6pt;text-indent:35.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%;padding-left:23.5pt">Development </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Product </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">Supply. The </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Parties </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">agree that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ardelyx </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">shall have </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">no further </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">obligation </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">supply </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">KKC, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">and KKC shall have </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">no </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">further </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">obligation </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">to purchase </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">from </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ardelyx, any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">Development Product </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Supply pursuant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Section 5.01(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Original Agreement. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">KKC acknowledges </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">agrees that&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">Ardelyx has </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">fulfilled all of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">its </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">obligations </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">respect </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">Development </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Product </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">Supply </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">under the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Original Agreement, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">as amended </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">Amendment, and that (b) other </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%">provisions </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">which </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">expressly </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">survive </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">termination </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">expiration, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">all </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">Ardelyx's obligations under the Original </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Agreement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">respect </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">Development Product Supply </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">expire </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">automatically </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">on the Amendment </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">Date. Notwithstanding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">foregoing, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">if </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">KKC </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">requests </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">Ardelyx </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">supply </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">KKC </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">the Lead </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">Licensed Product and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">placebos </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">are </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">manufactured for the US market </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">order for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">KKC </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">to conduct </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">the CMC </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%">Development </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">of the Lead Licensed </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Product and placebos </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">KKC in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Territory, the Parties </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">shall discuss KKC&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">request in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%">good </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">faith.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.85pt;text-indent:35.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;padding-left:23.73pt">Amendment. In </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">connection </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">with the foregoing, Exhibit F </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Original </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Agreement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">hereby </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">amended to delete </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the tables listed </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">under clauses (i)-(iii) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">insert </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the following </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">language in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">their </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">place&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">&#8221;As </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">set forth </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">Exhibit C </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSA </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">dated </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 9, 2018, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">amended.&#34;</font></div><div style="margin-top:8.15pt;padding-left:5pt;padding-right:7.45pt;text-indent:35.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:111%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:111%;padding-left:24.03pt">Commercial Product </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:111%">Supply. KKC </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:111%">has elected to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:111%">assume </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:111%">responsibility </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:111%">for Manufacture </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:111%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:111%">Licensed </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:111%">Products and does </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:111%">not desire </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%">Ardelyx </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:111%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%">provide Temporary </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:111%">Commercial </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:111%">Product </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:111%">Supply </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%">pursuant </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:111%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:111%;text-decoration:underline">Section 5.01(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:111%"> of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%">Original </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:111%">Agreement. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:111%">The Parties </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:111%">therefore </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:111%">agree </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:111%">that&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:111%">(a) Ardelyx shall have </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:111%">no </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%">obligation </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:111%">to supply </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%">Temporary </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:111%">Commercial </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:111%">Product Supply, and (b) each </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:111%">occurrence </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:111%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:111%">the term &#8221;Temporary </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%">Commercial </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:111%">Product Supply&#8221; throughout </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%">the Original Agreement is hereby omitted and surrounding language adjusted </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:111%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:111%">reflect </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%">such omission.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.3pt;text-indent:34.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%;padding-left:24.65pt">Third </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Party </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">Manufacturers. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">The Parties acknowledge </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">Ardelyx may </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">its </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">discretion </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">provide </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">assistance to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">KKC in engaging </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">one or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:110%">more </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">Ardelyx&#8217;s Third </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Party </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">contractors </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:110%">(each </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:110%">an &#34;Ardelyx </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">Contractor&#8221;) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">perform Manufacturing activities </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">KCC. The Parties agree </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">that, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">connection </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">with KKC&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">engagement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Ardelyx Contractor, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">each </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:110%">Party </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">will </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:110%">use </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Commercially </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">Reasonable Efforts </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">avoid </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">interference </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">with the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">other </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">Party&#8216;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:110%">own </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">supply requirements </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">from </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:110%">Ardelyx Contractor.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:146.85pt;padding-right:146.85pt;text-align:center"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:90.72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:4.35pt;padding-left:7.3pt;padding-right:5.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:118%">Without </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:118%">limiting </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:118%">the foregoing, KKC </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">shall obtain </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:118%">Ardelyx&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:118%">prior </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:118%">written approval </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:118%">any Manufacturing </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:118%">services </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:118%">to be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">scheduled </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:118%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">the same </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:118%">physical </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">location </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:118%">being used </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:118%">Manufacture </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:118%">Ardelyx&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:118%">own </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:118%">supply </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:118%">requirements by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:118%">such Ardelyx Contractor.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:6.75pt;padding-right:7.95pt;text-indent:35.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:114%;padding-left:22.05pt">Miscellaneous. This Amendment shall be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:114%">governed </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">and construed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:114%">accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:114%">the laws of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:114%">State </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">of New </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:114%">York, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">without </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">giving </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">effect to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:114%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">conflict </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:114%">of law </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">rules thereof that would </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">require </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:114%">application of the laws </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">of any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:114%">other jurisdiction. Except </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:114%">as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:114%">expressly amended hereby, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:114%">Original </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Agreement remains </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:114%">unchanged and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">full force </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:114%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">effect. The </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:114%">Original </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Agreement together </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:114%">with this Amendment shall be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">construed </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">as a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">single instrument. This Amendment may </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:114%">be executed </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:114%">number </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:114%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:114%">counterparts, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">each of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:114%">which shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">be deemed </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:114%">an </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">original </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:114%">and all of which taken together shall be deemed </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">constitute </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:114%">one </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:114%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:114%">same </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">instrument.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:146.25pt;padding-right:146.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">***</font></div><div><font><br></font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:42.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:124%">IN </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:124%">WITNESS WHEREOF, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:124%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:124%">Parties </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:124%">have </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:124%">caused </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:124%">this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:124%">First </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:124%">Amendment </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:124%">to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:124%">License </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:124%">Agreement to</font></div><div style="padding-left:7.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">be executed by their duly </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">authorized </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%">representatives </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:122%">Amendment Date.</font></div><div><font><br></font></div><div style="padding-left:42.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">Kyowa </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirin </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">Co., </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Ltd.   &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">Ardelyx, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inc.</font></div><div style="padding-left:42.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Yasou Fujii</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Michael Raab</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-right:58.65pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:2pt;font-weight:400;line-height:100%">-</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:2pt;font-weight:400;line-height:100%">&#47;s</font></div><div><font><br></font></div><div style="margin-top:0.25pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:2.5pt;font-weight:400;line-height:100%"> &#47;</font></div><div style="padding-left:41.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Yasuo Fujii                                              Name&#58; Michael Raab</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Title&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">Executive </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officer, Director,&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; CEO</font></div><div style="margin-top:4.05pt;padding-left:42.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">Business Development </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Department</font></div><div style="margin-top:4.7pt;padding-left:42.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">Date&#58; June 17, 2020&#160;&#160;&#160;&#160;Date&#58; June 23, 2020</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:146.85pt;padding-right:146.85pt;text-align:center"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.24(C)
<SEQUENCE>4
<FILENAME>slr-ardelyxxsecondamendmen.htm
<DESCRIPTION>EX-10.24(C)
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i00feeb34fcce477bb1d889b44fc2f07b_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ex. 10.24(c)</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">THIS SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) is entered into as of February 9, 2023, by and among SLR INVESTMENT CORP., a Maryland corporation with an office located at 500 Park Avenue, 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Floor, New York, NY 10022 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SLR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), as collateral agent (in such capacity, together with its successors and assigns, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Collateral Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), the Lenders listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule&#160;1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> thereto or otherwise a party thereto from time to time including SLR in its capacity as a Lender (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), and ARDELYX, INC., a Delaware corporation with offices located at 400 Fifth Avenue, Suite 210, Waltham, MA 02451 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;Collateral Agent, Borrower and Lenders have entered into that certain Loan and Security Agreement dated as of February 23, 2022 (as amended, supplemented or otherwise modified from time to time, including but not limited to that certain First Amendment to Loan and Security Agreement dated as of August 1, 2022, collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loan Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) pursuant to which Lenders have provided to Borrower certain loans in accordance with the terms and conditions thereof&#59; and </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;Borrower, Collateral Agent and the Required Lenders have agreed to amend the defined term &#8220;Term B Milestone&#8221;, subject to, and in accordance with, the terms and conditions set forth herein, and in reliance upon the representations and warranties set forth herein.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Agreement</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;NOW, THEREFORE, in consideration of the promises, covenants and agreements contained herein, and other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Borrower, the Required Lenders and Collateral Agent hereby agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:28.5pt">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Capitalized terms used but not defined in this Amendment shall have the meanings given to them in the Loan Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:28.5pt">Amendments to Loan Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:23.5pt">Section 13.1 (Definitions).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  The following terms and their respective definitions hereby are added or amended and restated in their entirety, as applicable, to Section 1.4 of the Loan Agreement as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1-Month CME Term SOFR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is the 1-month CME Term SOFR reference rate as published by the CME Term SOFR Administrator on the CME Term SOFR Administrator&#8217;s Website.</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means April 1, 2024&#59; provided, that upon acheivement of the Interest-Only Extension Milestone, the Amortization Date shall automatically be extended to April 1, 2025.</font></div><div style="padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Applicable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a per annum interest rate equal to the greater of (a) one percent (1.00%) per annum and (b)(i) 0.022% plus (ii) 1-month CME Term SOFR reference rate as published by the CME Term SOFR Administrator on the CME Term SOFR Administrator&#8217;s Website (or on any successor or substitute page of the CME Term SOFR Administrator, or any successor to or substitute for the CME Term SOFR Administrator, as determined by Collateral Agent in a manner consistent with other loans in Collateral Agent&#8217;s portfolio), which determination by Collateral Agent shall be conclusive in the absence of manifest error&#59; provided that if, at any time, Lenders notify Collateral Agent that Lenders have determined that (x) Lenders are unable to determine or ascertain such rate, or (y) the applicable regulator has made public statements to the effect that the rate published by the CME Term SOFR Administrator is no longer used for determining interest rates for loans, then the Applicable Rate shall be equal to an alternate benchmark rate and spread agreed between Collateral Agent and Borrowers, giving due consideration to (i) market convention or (ii) selection, endorsement or recommendation by a Relevant Governmental Body.  Such alternative benchmark rate and spread shall be binding unless the Required Lenders object within five (5) days following notification of such amendment.</font></div><div style="padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:118.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:11pt;padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CME Term SOFR Administrator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is CME Group Benchmark Administration Limited, as administrator of the forward-looking term SOFR, or any successor administrator of 1-Month CME Term SOFR selected by the Collateral Agent in its reasonable discretion.</font></div><div style="margin-bottom:11pt;padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CME Term SOFR Administrator&#8217;s Website</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">is</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the website of the CME Group Benchmark Administrator at&#160;</font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">http&#58;&#47;&#47;www.cmegroup.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, or any successor source.</font></div><div style="margin-top:11pt;padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest-Only Extension Milestone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is Collateral Agent&#8217;s receipt of satisfactory evidence that Borrower has either (i) received FDA approval of Tenapanor for use in certain patients with Hyperphosphatemia on or prior to November 30, 2023 or (ii) achieved a minimum of Seventy-Five Million Dollars ($75,000,000) in Net Product Revenue calculated for Borrower&#8217;s fiscal year ending December 31, 2023.</font></div><div style="margin-top:11pt;padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Term B Draw Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is the period commencing on the date of the occurrence of the Term B Milestone and ending on December 20, 2023.  </font></div><div style="margin-top:11pt;padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Term B Milestone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is Collateral Agent&#8217;s receipt of satisfactory evidence that Borrower (i) has received FDA approval of Tenapanor for use in certain patients with Hyperphosphatemia on or prior to November 30, 2023 and (ii) has achieved a minimum of Thirty Million Dollars ($30,000,000) in Net Product Revenue calculated on a trailing six (6) month basis.</font></div><div style="padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:23.5pt">Section 13.1 (Definitions).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  The following term and its definitions hereby is deleted from Section 1.4 of the Loan Agreement&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SOFR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:23.5pt">Section 2.2 (Term Loans).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Section 2.2(b) of the Loan Agreement is hereby amended and restated to read as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Repayment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Borrower shall make monthly payments of interest only commencing on the first (1st) Payment Date following the Funding Date of each Term Loan, and continuing on the Payment Date of each successive month thereafter through and including the Payment Date immediately preceding the Amortization Date.  Borrower agrees to pay, on the Funding Date of each Term Loan, any initial partial monthly interest payment otherwise due for the period between the Funding Date of such Term Loan and the first Payment Date after such Funding Date.  Commencing on the Amortization Date, and continuing on the Payment Date of each month thereafter, Borrower shall (i) make monthly payments of interest, to each Lender in accordance with its Pro Rata Share, as calculated by Collateral Agent (which calculations shall be deemed correct absent manifest error) based upon the effective rate of interest applicable to the Term Loan, as determined in Section 2.3(a) plus (ii) make consecutive equal monthly payments of principal to each Lender in accordance with its Pro Rata Share in accordance with their respective Pro Rata Shares, as calculated by Collateral Agent (which calculations shall be deemed correct absent manifest error) based upon&#58; (A) the respective principal amounts of such Lender&#8217;s Term Loans outstanding, and (B) a repayment schedule equal to (I) if the Amortization Date is April 1, 2024, thirty-six (36) months and (II) if the Amortization Date is April 1, 2025, twenty-four (24) months.  All unpaid principal and accrued and unpaid interest with respect to each such Term Loan is due and payable in full on the Maturity Date.  The Term Loans may only be prepaid in accordance with Sections 2.2(c) and 2.2(d).&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:28.5pt">Limitation of Amendment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt">The amendment set forth in Section 2 above is effective for the purposes set forth herein and shall be limited precisely as written and shall not be deemed to (a) be a consent to any amendment, waiver or modification of any other term or condition of any Loan Document, or (b) otherwise prejudice any right, remedy or obligation which Lenders or Borrower may now have or may have in the future under or in connection with any Loan Document, as amended hereby.</font></div><div style="height:118.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;2</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt">This Amendment shall be construed in connection with and as part of the Loan Documents and all terms, conditions, representations, warranties, covenants and agreements set forth in the Loan Documents are hereby ratified and confirmed and shall remain in full force and effect.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:28.5pt">Representations and Warranties.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  To induce Collateral Agent and the Required Lenders to enter into this Amendment, Borrower hereby represents and warrants to Collateral Agent and the Required Lenders as follows&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt">Immediately after giving effect to this Amendment (a) the representations and warranties contained in the Loan Documents are true, accurate and complete in all material respects as of the date hereof (except to the extent such representations and warranties relate to an earlier date, in which case they are true and correct in all material respects as of such date) and (b) no Event of Default has occurred and is continuing&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt">Borrower has the power and due authority to execute and deliver this Amendment and to perform its obligations under the Loan Agreement, as amended by this Amendment&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt">The organizational documents of Borrower delivered to Collateral Agent on the Effective Date, and updated pursuant to subsequent deliveries by or on behalf of the Borrower to the Collateral Agent, remain true, accurate and complete and have not been amended, supplemented or restated and are and continue to be in full force and effect&#59;  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt">The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not contravene (i) any material law or regulation binding on or affecting Borrower, (ii) any material contractual restriction with a Person binding on Borrower, (iii) any applicable order, judgment or decree of any court or other governmental or public body or authority, or subdivision thereof, binding on Borrower, or (iv) the organizational documents of Borrower&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt">The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not require any order, consent, approval, license, authorization or validation of, or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision thereof, binding on Borrower, except as already has been obtained or made&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt">This Amendment has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors&#8217; rights. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:28.5pt">Loan Document.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Borrower, Lenders and Collateral Agent agree that this Amendment shall be a Loan Document.  Except as expressly set forth herein, the Loan Agreement and the other Loan Documents shall continue in full force and effect without alteration or amendment.  This Amendment and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:28.5pt">Release by Borrower.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:23.5pt">FOR GOOD AND VALUABLE CONSIDERATION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, Borrower hereby forever relieves, releases, and discharges Collateral Agent and each Lender and their respective present or former employees, officers, directors, agents, representatives, attorneys, and each of them, from any and all claims, debts, liabilities, demands, obligations, promises, acts, agreements, costs and expenses, actions and causes of action, of every type, kind, nature, description or character whatsoever, whether known or unknown, suspected or unsuspected, absolute or contingent, arising out of or in any manner whatsoever connected with or related to facts, circumstances, issues, controversies or claims existing or arising from the Effective Date through and including the date of execution of this Amendment solely to the extent such claims arise out of or are in any manner whatsoever connected with or related to the Loan Documents, the Recitals hereto, any instruments, agreements or documents executed in connection with any of the foregoing or the origination, negotiation, administration, servicing and&#47;or enforcement of any of the foregoing (collectively &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Released Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt">By entering into this release, Borrower recognizes that no facts or representations are ever absolutely certain and it may hereafter discover facts in addition to or different from those which it presently knows </font></div><div style="height:118.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;3</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">or believes to be true, but that it is the intention of Borrower hereby to fully, finally and forever settle and release all matters, disputes and differences, known or unknown, suspected or unsuspected in relation to the Released Claims&#59; accordingly, if Borrower should subsequently discover that any fact that it relied upon in entering into this release was untrue, or that any understanding of the facts was incorrect, Borrower shall not be entitled to set aside this release by reason thereof, regardless of any claim of mistake of fact or law or any other circumstances whatsoever.  Borrower acknowledges that it is not relying upon and has not relied upon any representation or statement made by Collateral Agent or Lenders with respect to the facts underlying this release or with regard to any of such party&#8217;s rights or asserted rights.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt">This release may be pleaded as a full and complete defense and&#47;or as a cross-complaint or counterclaim against any action, suit, or other proceeding that may be instituted, prosecuted or attempted in breach of this release.  Borrower acknowledges that the release contained herein constitutes a material inducement to Collateral Agent and the Lenders to enter into this Amendment, and that Collateral Agent and the Lenders would not have done so but for Collateral Agent&#8217;s and the Lenders&#8217; expectation that such release is valid and enforceable in all events.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:28.5pt">Effectiveness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. This Amendment shall be deemed effective as of the date hereof upon (i) the due execution and delivery of this Amendment by each party hereto, (ii) the due execution and delivery to Collateral Agent and Lenders of a certificate of Borrower in substantially the form of Annex I hereto executed by the Secretary of Borrower with appropriate insertions and attachments, and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii) Borrower&#8217;s payment of a non-refundable amendment fee, fully earned as of the date hereof, in an amount equal to Fifty-Five Thousand Dollars ($55,000) to be shared among the Lenders in accordance with their respective Pro Rata Shares. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:28.5pt">Counterparts.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  This Amendment may be executed in any number of counterparts, each of which shall be deemed an original, and all of which, taken together, shall constitute one and the same instrument.  Delivery by electronic transmission (e.g. &#8220;.pdf&#8221;) of an executed counterpart of this Amendment shall be effective as a manually executed counterpart signature thereof.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:28.5pt">Electronic Execution.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  The words &#8220;execution,&#8221; &#8220;execute&#8221;, &#8220;signed,&#8221; &#8220;signature,&#8221; and words of like import in or related to any document to be signed in connection with this Amendment and the transactions contemplated hereby (including without limitation assignments, assumptions, amendments, waivers and consents) shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by the Collateral Agent, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:23.5pt">Governing Law.   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">THIS AMENDMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL IN ALL RESPECTS BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK (WITHOUT REGARD TO THE CONFLICT OF LAWS PRINCIPLES THAT WOULD RESULT IN THE APPLICATION OF ANY LAW OTHER THAN THE LAW OF SUCH STATE), INCLUDING ALL MATTERS OF CONSTRUCTION, VALIDITY AND PERFORMANCE, REGARDLESS OF THE LOCATION OF THE COLLATERAL, PROVIDED, HOWEVER, THAT IF THE LAWS OF ANY JURISDICTION OTHER THAN NEW YORK SHALL GOVERN IN REGARD TO THE VALIDITY, PERFECTION OR EFFECT OF PERFECTION OF ANY LIEN OR IN REGARD TO PROCEDURAL MATTERS AFFECTING ENFORCEMENT OF ANY LIENS IN COLLATERAL, SUCH LAWS OF SUCH OTHER JURISDICTIONS SHALL CONTINUE TO APPLY TO THAT EXTENT.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Balance of Page Intentionally Left Blank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#93;</font></div><div style="height:118.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;4</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="i00feeb34fcce477bb1d889b44fc2f07b_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, the parties hereto have caused this Second Amendment to Loan and Security Agreement to be executed as of the date first set forth above.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.006%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BORROWER&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARDELYX, INC.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By &#47;s&#47; Justin Renz</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58; Justin Renz</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; Chief Financial and Operations Officer</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">COLLATERAL AGENT AND LENDER&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SLR INVESTMENT CORP.</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By &#47;s&#47; Anthony J. Storino</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58; Anthony J. Storino</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; Authorized Signatory</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LENDERS&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SLR SENIOR INVESTMENT CORP.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SCP PRIVATE CREDIT INCOME FUND SPV, LLC</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SCP PRIVATE CREDIT INCOME BDC SPV LLC</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SCP PRIVATE CORPORATE LENDING FUND SPV LLC</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SCP SF DEBT FUND L.P.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SLR HC FUND SPV, LLC</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SLR HC BDC LLC</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By &#47;s&#47; Anthony J. Storino</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58; Anthony J. Storino</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; Authorized Signatory </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Signature Page to Second Amendment to Loan and Security Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#93;</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="i00feeb34fcce477bb1d889b44fc2f07b_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Annex I</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CORPORATE BORROWING CERTIFICATE</font></div><div style="margin-top:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BORROWER&#58;   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARDELYX, INC.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DATE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58; February 7, 2023</font></div><div style="padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LENDER&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SLR INVESTMENT CORP., as Collateral Agent and Lender <br></font></div><div style="margin-top:11pt;padding-right:3.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I hereby certify, solely in my capacity as an officer of Borrower and not in my individual capacity, as follows, as of the date set forth above&#58;</font></div><div style="margin-top:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;I am the Secretary or other officer of Borrower. My title is as set forth below.</font></div><div style="margin-top:11pt;padding-right:3.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;Borrower&#8217;s exact legal name is set forth above. Borrower is a corporation existing under the laws of the State of Delaware.</font></div><div style="margin-top:11pt;padding-right:3.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;Attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, respectively, are true, correct and complete copies of (i) Borrower&#8217;s Certificate of Incorporation (including amendments), as filed with the Secretary of State of the state in which Borrower is incorporated as set forth in paragraph 2 above&#59; and (ii) Borrower&#8217;s Bylaws. Neither such Certificate of Incorporation nor such Bylaws have been amended, annulled, rescinded, revoked or supplemented, and such Certificate of Incorporation and such Bylaws remain in full force and effect as of the date hereof.</font></div><div style="margin-top:11pt;padding-right:3.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;The following resolutions were duly and validly adopted by Borrower&#8217;s board of directors (or a duly authorized committee thereof) at a duly held meeting of such directors (or pursuant to a unanimous written consent or other authorized corporate action). Such resolutions are in full force and effect as of the date hereof and have not been in any way modified, repealed, rescinded, amended or revoked, and the Lenders may rely on them until each Lender receives written notice of revocation from Borrower.</font></div><div style="margin-bottom:249.65pt;margin-top:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Balance of Page Intentionally Left Blank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#93;</font></div><div style="margin-top:11pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:15pt;margin-top:11pt;padding-left:36pt;padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RESOLVED, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">any one </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">of the following officers or employees of Borrower, whose names, titles and signatures are below, may act on behalf of Borrower&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.716%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.716%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.099%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Name</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Title</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Signature</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Authorized to Add or Remove </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Signatories</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael Raab</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer </font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael Raab</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Justin Renz</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial &#38; Operating Officer</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Justin Renz</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9633;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9633;</font></td></tr></table></div><div style="margin-top:16pt;padding-left:36pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RESOLVED FURTHER, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">any one </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">of the persons designated above with a checked box beside his or her name may, from time to time, add or remove any individuals to and from the above list of persons authorized to act on behalf of Borrower.</font></div><div style="margin-top:11pt;padding-left:36pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RESOLVED FURTHER, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">that such individuals may, on behalf of Borrower&#58;</font></div><div style="margin-top:11pt;padding-left:36pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Borrow Money</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Borrow money from the Lenders.</font></div><div style="margin-top:11pt;padding-left:36pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Execute Loan Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Execute any loan documents any Lender requires, including that certain Second Amendment to Loan and Security Agreement dated on or about even date herewith.</font></div><div style="margin-top:11pt;padding-left:36pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Security</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Grant Collateral Agent a security interest in any of Borrower&#8217;s assets (excluding intellectual property).</font></div><div style="margin-top:11pt;padding-left:36pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Negotiate Items</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Negotiate or discount all drafts, trade acceptances, promissory notes, or other indebtedness in which Borrower has an interest and receive cash or otherwise use the proceeds.</font></div><div style="margin-top:11pt;padding-left:36pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pay Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Pay fees under the Loan Agreement or any other Loan Document.</font></div><div style="margin-top:11pt;padding-left:36pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Further Acts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Designate other individuals to request advances, pay fees and costs and execute other documents or agreements (including documents or agreement that waive Borrower&#8217;s right to a jury trial) they believe to be necessary to effectuate such resolutions.</font></div><div style="margin-top:11pt;padding-left:36pt;padding-right:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RESOLVED FURTHER, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">that all acts authorized by the above resolutions and any prior acts relating thereto are ratified.</font></div><div style="margin-bottom:182.95pt;margin-top:11pt;padding-left:183.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Balance of Page Intentionally Left Blank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11pt;padding-right:3.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;The persons listed above are Borrower&#8217;s officers or employees with their titles and signatures shown next to their names.</font></div><div style="margin-top:11pt;padding-left:255.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">By&#58; &#47;s&#47; Justin Renz&#160;&#160;&#160;&#160;<br>Name&#58; Justin Renz<br>Title&#58; Chief Financial and Operating Officer</font></div><div style="margin-top:11pt;padding-left:3.6pt;padding-right:3.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">*** If the Secretary or other certifying officer executing above is designated by the resolutions set forth in paragraph 4 as one of the authorized signing officers, this Certificate must also be signed by a second authorized officer or director of Borrower.</font></div><div style="margin-top:11pt;padding-right:3.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I, the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">CEO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> of Borrower, hereby certify as to paragraphs 1 through 5 above, as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">February 9, 2023</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> on the date set</font></div><div style="margin-top:11pt;padding-left:3.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">forth above.</font></div><div style="margin-top:11pt;padding-left:255.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">By&#58; &#47;s&#47; Michael Raab&#160;&#160;&#160;&#160; </font></div><div style="margin-bottom:423.6pt;margin-top:11pt;padding-left:255.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name&#58; Michael Raab<br>Title&#58; Chief Executive Officer</font></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:center"><font><br></font></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT A</font></div><div style="margin-top:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Certificate of Incorporation (including amendments)</font></div><div style="margin-top:11pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="i00feeb34fcce477bb1d889b44fc2f07b_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT B</font></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Bylaws  </font></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><font><br></font></div><div style="margin-bottom:6pt;margin-top:11pt;text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.27(B)
<SEQUENCE>5
<FILENAME>ardelyx_psgxmsaamendment1.htm
<DESCRIPTION>EX-10.27(B)
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ic0342eb7484342fbb50d4697a65699a0_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:2pt;padding-right:1.45pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ex. 10.27(b)</font></div><div><font><br></font></div></div><div style="margin-bottom:2pt;padding-right:1.45pt;text-align:justify"><font><br></font></div><div style="margin-bottom:2pt;padding-right:1.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div style="margin-bottom:2pt;padding-right:1.45pt;text-align:justify"><font><br></font></div><div style="margin-bottom:2pt;padding-left:0.72pt;padding-right:0.72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">First Amendment to Manufacturing Services Agreement</font></div><div style="margin-bottom:2pt;padding-left:0.72pt;padding-right:0.72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Between Ardelyx, Inc. and Patheon Pharmaceuticals Inc.</font></div><div style="margin-bottom:2pt;padding-left:0.72pt;padding-right:0.72pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;padding-right:18.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">THIS AMENDMENT NO. 1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amendment 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) is entered into by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Ardelyx, Inc. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware corporation with a principal place of business at 400 5th Ave., Suite 210, Waltham, MA 02451, USA (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Client</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patheon Pharmaceuticals Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, located at 2110 East Galbraith Road, Cincinnati, OH 45237, USA  (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patheon</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  </font></div><div style="margin-bottom:12pt;padding-right:18.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Patheon and Client entered into that certain Manufacturing Services Agreement dated May 18, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MSA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; </font></div><div style="margin-bottom:12pt;padding-right:18.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AND WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Patheon and Client wish to amend the MSA as set forth in this Amendment. All capitalized terms used but not defined in this Amendment shall have the respective meanings set forth in the MSA&#59;</font></div><div style="margin-bottom:12pt;padding-right:18.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NOW, THEREFORE, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">in consideration of the foregoing recitals that are hereby incorporated by reference hereunder and made a part of this Amendment 1 as if expressly set forth below,  the promises and agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the Parties wish to amend the MSA as follows&#58;</font></div><div style="margin-bottom:12pt;padding-right:18.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt">The Amendment 1 shall take effect as of the date last signed below (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amendment Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-right:18.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt">Appendix 1 &#8220;Commercial Supply Pricing&#8221; of the MSA is deleted in its entirety and shall be replaced as set forth in Exhibit 1 hereto.</font></div><div style="margin-bottom:12pt;padding-right:18.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt">Section 2.2(a) of the MSA is hereby augmented such that, as of the Amendment Effective Date, the Minimum &#91;***&#93; Requirement will be based on &#91;***&#93;.  The Parties agree that a &#91;***&#93; shall count as &#91;***&#93; for purposes of calculating &#91;***&#93; contemplated in such Section 2.2(a).</font></div><div style="margin-bottom:12pt;padding-right:18.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt">Except as expressly provided in this Amendment 1, the MSA shall remain unchanged.</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:89.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:2pt;padding-right:1.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:2pt;padding-right:1.45pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ex. 10.27(b)</font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-right:18.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> the Parties hereto have executed or caused this Amendment 1 to be executed by their respective officers or other representatives duly authorized as of the Amendment Effective Date.</font></div><div style="margin-bottom:8pt;padding-left:36pt;padding-right:18.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Ardelyx, Inc.&#160;&#160;&#160;&#160;</font></div><div style="padding-left:36pt;padding-right:18.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  &#47;s&#47; Justin Renz&#160;&#160;&#160;&#160;</font></div><div style="padding-left:36pt;padding-right:18.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Print Name&#58; Justin Renz&#160;&#160;&#160;&#160;</font></div><div style="padding-left:36pt;padding-right:18.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;  Chief Financial and Operations Manager </font></div><div style="margin-bottom:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58; 1&#47;24&#47;2023</font></div><div style="margin-bottom:8pt;padding-left:36pt;padding-right:18.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patheon Pharmaceuticals Inc.</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  &#47;s&#47; Alan Bensman</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Print Name&#58;  Alan Bensman</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;  General Manager, Cincinnati</font></div><div style="margin-bottom:8pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58;  2&#47;27&#47;2023</font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:89.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:2pt;padding-right:1.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:2pt;padding-right:1.45pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ex. 10.27(b)</font></div><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXHIBIT 1</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commercial Supply Pricing</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="height:89.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:2pt;padding-right:1.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>consentofindependentregist.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i4629f24467fe4c0fa30ca68b4fb53221_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Registration Statement on Form S-8 (No. 333-197408) pertaining to the 2008 Stock Incentive Plan, as amended, the 2014 Equity Incentive Award Plan and the 2014 Employee Stock Purchase Plan of Ardelyx, Inc.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Registration Statements on Form S-8 (Nos. 333-202663 and 333-230156) pertaining to the 2014 Equity Incentive Award Plan and the 2014 Employee Stock Purchase Plan of Ardelyx, Inc.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Registration Statements on Form S-3 (Nos. 333-205630, 333-213085, 333-239764 and 333-269297) of Ardelyx, Inc.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Registration Statements on Form S-8 (Nos. 333-210079, 333-216154, 333-223694 and 333-237057) pertaining to the 2014 Equity Incentive Award Plan of Ardelyx, Inc.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Registration Statement on Form S-8 (No. 333-214538) pertaining to the 2016 Employment Commencement Incentive Plan of Ardelyx, Inc.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Registration Statement on Form S-8 (No. 333-254187) pertaining to the 2014 Equity Incentive Award Plan, the 2014 Employee Stock Purchase Plan and the 2016 Employment Commencement Incentive Plan of Ardelyx, Inc.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Registration Statement on Form S-8 (333-263145) pertaining to the 2014 Equity Incentive Award Plan and the 2016 Employment Commencement Incentive Plan of Ardelyx, Inc.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">of our report dated March&#160;2, 2023, with respect to the financial statements of Ardelyx, Inc. included in this Annual Report (Form 10-K) of Ardelyx, Inc. for the year ended December&#160;31, 2022.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Mateo, California</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">March&#160;2, 2023</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>ardx-20221231xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i1ad2b5d527154cd1a048b514ee7a4f15_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael Raab, certify that&#58;</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of Ardelyx, Inc.&#59;</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.691%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March 2, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Michael Raab</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Michael Raab<br>President, Chief Executive Officer and Director<br>(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>ardx-20221231xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i4ce2b74aed734a59bc7e3d4aa00ec73c_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Justin Renz, certify that&#58;</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of Ardelyx, Inc.&#59;</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.691%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March 2, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Justin Renz</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Justin Renz<br>Chief Financial &#38; Operations Officer<br>(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>ardx-20221231xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i08da5d98ea33438fa24d92c7a32e8c65_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Ardelyx, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ending December&#160;31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), Michael Raab, President and Chief Executive Officer of the Company, and Justin Renz, Chief Financial &#38; Operations Officer of the Company, respectively, do each hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.691%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March 2, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Michael Raab</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Michael Raab<br>President, Chief Executive Officer and Director<br>(Principal Executive Officer)</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March 2, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Justin Renz</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Justin Renz<br>Chief Financial &#38; Operations Officer<br>(Principal Financial Officer)</font></td></tr></table></div><div style="margin-top:10pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>ardx-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:9159adf2-88b0-425e-b00c-16d6f1bd5962,g:73dc270f-0b38-43c2-8fc7-c4890fc3e73f-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ardx="http://www.ardelyx.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.ardelyx.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ardx-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ardx-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ardx-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ardx-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.ardelyx.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.ardelyx.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETS" roleURI="http://www.ardelyx.com/role/BALANCESHEETS">
        <link:definition>0000003 - Statement - BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETSParenthetical" roleURI="http://www.ardelyx.com/role/BALANCESHEETSParenthetical">
        <link:definition>0000004 - Statement - BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>0000005 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.ardelyx.com/role/STATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>0000006 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STATEMENTSOFCASHFLOWS" roleURI="http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS">
        <link:definition>0000007 - Statement - STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentation" roleURI="http://www.ardelyx.com/role/OrganizationandBasisofPresentation">
        <link:definition>0000008 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.ardelyx.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandShortTermInvestments" roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestments">
        <link:definition>0000010 - Disclosure - Cash, Cash Equivalents and Short-Term Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.ardelyx.com/role/FairValueMeasurements">
        <link:definition>0000011 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.ardelyx.com/role/Inventory">
        <link:definition>0000012 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenueNet" roleURI="http://www.ardelyx.com/role/ProductRevenueNet">
        <link:definition>0000013 - Disclosure - Product Revenue, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicensingAgreements" roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreements">
        <link:definition>0000014 - Disclosure - Collaboration and Licensing Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyalties" roleURI="http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyalties">
        <link:definition>0000015 - Disclosure - Deferred Royalty Obligation Related To The Sale Of Future Royalties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Borrowings" roleURI="http://www.ardelyx.com/role/Borrowings">
        <link:definition>0000016 - Disclosure - Borrowings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeLiabilities" roleURI="http://www.ardelyx.com/role/DerivativeLiabilities">
        <link:definition>0000017 - Disclosure - Derivative Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.ardelyx.com/role/Leases">
        <link:definition>0000018 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.ardelyx.com/role/StockholdersEquity">
        <link:definition>0000019 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlans" roleURI="http://www.ardelyx.com/role/EquityIncentivePlans">
        <link:definition>0000020 - Disclosure - Equity Incentive Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Restructuring" roleURI="http://www.ardelyx.com/role/Restructuring">
        <link:definition>0000021 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNet" roleURI="http://www.ardelyx.com/role/PropertyandEquipmentNet">
        <link:definition>0000022 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilities" roleURI="http://www.ardelyx.com/role/AccruedExpensesandOtherCurrentLiabilities">
        <link:definition>0000023 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.ardelyx.com/role/IncomeTaxes">
        <link:definition>0000024 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeographicInformationandConcentrations" roleURI="http://www.ardelyx.com/role/GeographicInformationandConcentrations">
        <link:definition>0000025 - Disclosure - Geographic Information and Concentrations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.ardelyx.com/role/NetLossPerShare">
        <link:definition>0000026 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.ardelyx.com/role/CommitmentsandContingencies">
        <link:definition>0000027 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.ardelyx.com/role/SubsequentEvents">
        <link:definition>0000028 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000029 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandShortTermInvestmentsTables" roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsTables">
        <link:definition>0000030 - Disclosure - Cash, Cash Equivalents and Short-Term Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.ardelyx.com/role/FairValueMeasurementsTables">
        <link:definition>0000031 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.ardelyx.com/role/InventoryTables">
        <link:definition>0000032 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenueNetTables" roleURI="http://www.ardelyx.com/role/ProductRevenueNetTables">
        <link:definition>0000033 - Disclosure - Product Revenue, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicensingAgreementsTables" roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsTables">
        <link:definition>0000034 - Disclosure - Collaboration and Licensing Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsTables" roleURI="http://www.ardelyx.com/role/BorrowingsTables">
        <link:definition>0000035 - Disclosure - Borrowings (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeLiabilitiesTables" roleURI="http://www.ardelyx.com/role/DerivativeLiabilitiesTables">
        <link:definition>0000036 - Disclosure - Derivative Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.ardelyx.com/role/LeasesTables">
        <link:definition>0000037 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansTables" roleURI="http://www.ardelyx.com/role/EquityIncentivePlansTables">
        <link:definition>0000038 - Disclosure - Equity Incentive Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetTables" roleURI="http://www.ardelyx.com/role/PropertyandEquipmentNetTables">
        <link:definition>0000039 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesTables" roleURI="http://www.ardelyx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables">
        <link:definition>0000040 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.ardelyx.com/role/IncomeTaxesTables">
        <link:definition>0000041 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeographicInformationandConcentrationsTables" roleURI="http://www.ardelyx.com/role/GeographicInformationandConcentrationsTables">
        <link:definition>0000042 - Disclosure - Geographic Information and Concentrations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.ardelyx.com/role/NetLossPerShareTables">
        <link:definition>0000043 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationDetails" roleURI="http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails">
        <link:definition>0000044 - Disclosure - Organization and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesLiquidityDetails" roleURI="http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesLiquidityDetails">
        <link:definition>0000045 - Disclosure - Summary of Significant Accounting Policies - Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAccountsReceivableDetails" roleURI="http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails">
        <link:definition>0000046 - Disclosure - Summary of Significant Accounting Policies - Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesProductSalesNetDetails" roleURI="http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesProductSalesNetDetails">
        <link:definition>0000047 - Disclosure - Summary of Significant Accounting Policies - Product Sales Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>0000048 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails" roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails">
        <link:definition>0000049 - Disclosure - Cash, Cash Equivalents and Short-Term Investments - Securities Classified as Cash and Short-Term Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandShortTermInvestmentsNarrativeDetails" roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsNarrativeDetails">
        <link:definition>0000050 - Disclosure - Cash, Cash Equivalents and Short-Term Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" roleURI="http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails">
        <link:definition>0000051 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Measured on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.ardelyx.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>0000052 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryScheduleDetails" roleURI="http://www.ardelyx.com/role/InventoryScheduleDetails">
        <link:definition>0000053 - Disclosure - Inventory - Schedule (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryNarrativeDetails" roleURI="http://www.ardelyx.com/role/InventoryNarrativeDetails">
        <link:definition>0000054 - Disclosure - Inventory - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenueNetNarrativeDetails" roleURI="http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails">
        <link:definition>0000055 - Disclosure - Product Revenue, Net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenueNetGrosstoNetSalesAccrualsDetails" roleURI="http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails">
        <link:definition>0000056 - Disclosure - Product Revenue, Net - Gross-to-Net Sales Accruals (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicensingAgreementsNarrativeDetails" roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails">
        <link:definition>0000057 - Disclosure - Collaboration and Licensing Agreements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicensingAgreementsDeferredRevenueDetails" roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails">
        <link:definition>0000058 - Disclosure - Collaboration and Licensing Agreements - Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails" roleURI="http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails">
        <link:definition>0000059 - Disclosure - Deferred Royalty Obligation Related To The Sale Of Future Royalties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsNarrativeDetails" roleURI="http://www.ardelyx.com/role/BorrowingsNarrativeDetails">
        <link:definition>0000060 - Disclosure - Borrowings - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsFuturePaymentObligationsDetails" roleURI="http://www.ardelyx.com/role/BorrowingsFuturePaymentObligationsDetails">
        <link:definition>0000061 - Disclosure - Borrowings - Future Payment Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsFuturePaymentObligationsDetails_1" roleURI="http://www.ardelyx.com/role/BorrowingsFuturePaymentObligationsDetails_1">
        <link:definition>0000061 - Disclosure - Borrowings - Future Payment Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeLiabilitiesNarrativeDetails" roleURI="http://www.ardelyx.com/role/DerivativeLiabilitiesNarrativeDetails">
        <link:definition>0000062 - Disclosure - Derivative Liabilities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeLiabilitiesChangesinFairValueDetails" roleURI="http://www.ardelyx.com/role/DerivativeLiabilitiesChangesinFairValueDetails">
        <link:definition>0000063 - Disclosure - Derivative Liabilities - Changes in Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.ardelyx.com/role/LeasesNarrativeDetails">
        <link:definition>0000064 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalLeaseInformationDetails" roleURI="http://www.ardelyx.com/role/LeasesAdditionalLeaseInformationDetails">
        <link:definition>0000065 - Disclosure - Leases - Additional Lease Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseCostsDetails" roleURI="http://www.ardelyx.com/role/LeasesLeaseCostsDetails">
        <link:definition>0000066 - Disclosure - Leases - Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesUndiscountedCashPaymentObligationsDetails" roleURI="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails">
        <link:definition>0000067 - Disclosure - Leases - Undiscounted Cash Payment Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesUndiscountedCashPaymentObligationsDetails_1" roleURI="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1">
        <link:definition>0000067 - Disclosure - Leases - Undiscounted Cash Payment Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://www.ardelyx.com/role/StockholdersEquityDetails">
        <link:definition>0000068 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansNarrativeDetails" roleURI="http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails">
        <link:definition>0000069 - Disclosure - Equity Incentive Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansStockOptionsDetails" roleURI="http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails">
        <link:definition>0000070 - Disclosure - Equity Incentive Plans - Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansValuationAssumptionsforStockOptionsDetails" roleURI="http://www.ardelyx.com/role/EquityIncentivePlansValuationAssumptionsforStockOptionsDetails">
        <link:definition>0000071 - Disclosure - Equity Incentive Plans - Valuation Assumptions for Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansRestrictedStockUnitsDetails" roleURI="http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails">
        <link:definition>0000072 - Disclosure - Equity Incentive Plans - Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansEmployeeStockPurchasePlanDetails" roleURI="http://www.ardelyx.com/role/EquityIncentivePlansEmployeeStockPurchasePlanDetails">
        <link:definition>0000073 - Disclosure - Equity Incentive Plans - Employee Stock Purchase Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansValuationAssumptionsforESPPDetails" roleURI="http://www.ardelyx.com/role/EquityIncentivePlansValuationAssumptionsforESPPDetails">
        <link:definition>0000074 - Disclosure - Equity Incentive Plans - Valuation Assumptions for ESPP (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansStockBasedCompensationDetails" roleURI="http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails">
        <link:definition>0000075 - Disclosure - Equity Incentive Plans - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansUnrecognizedStockBasedCompensationDetails" roleURI="http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails">
        <link:definition>0000076 - Disclosure - Equity Incentive Plans - Unrecognized Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringDetails" roleURI="http://www.ardelyx.com/role/RestructuringDetails">
        <link:definition>0000077 - Disclosure - Restructuring (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetBalancesDetails" roleURI="http://www.ardelyx.com/role/PropertyandEquipmentNetBalancesDetails">
        <link:definition>0000078 - Disclosure - Property and Equipment, Net - Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetNarrativeDetails" roleURI="http://www.ardelyx.com/role/PropertyandEquipmentNetNarrativeDetails">
        <link:definition>0000079 - Disclosure - Property and Equipment, Net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesDetails" roleURI="http://www.ardelyx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails">
        <link:definition>0000080 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofProvisionforIncomeTaxesDetails" roleURI="http://www.ardelyx.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails">
        <link:definition>0000081 - Disclosure - Income Taxes - Components of Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofEffectiveTaxRateDetails" roleURI="http://www.ardelyx.com/role/IncomeTaxesReconciliationofEffectiveTaxRateDetails">
        <link:definition>0000082 - Disclosure - Income Taxes - Reconciliation of Effective Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofDeferredTaxAssetsDetails" roleURI="http://www.ardelyx.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails">
        <link:definition>0000083 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.ardelyx.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>0000084 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" roleURI="http://www.ardelyx.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails">
        <link:definition>0000085 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeographicInformationandConcentrationsRevenuebyGeographicalAreaDetails" roleURI="http://www.ardelyx.com/role/GeographicInformationandConcentrationsRevenuebyGeographicalAreaDetails">
        <link:definition>0000086 - Disclosure - Geographic Information and Concentrations - Revenue by Geographical Area (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeographicInformationandConcentrationsConcentrationRiskDetails" roleURI="http://www.ardelyx.com/role/GeographicInformationandConcentrationsConcentrationRiskDetails">
        <link:definition>0000087 - Disclosure - Geographic Information and Concentrations - Concentration Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareComputationofNetLossPerCommonShareDetails" roleURI="http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails">
        <link:definition>0000088 - Disclosure - Net Loss Per Share - Computation of Net Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAntiDilutiveSecuritiesandPotentialCommonSharesDetails" roleURI="http://www.ardelyx.com/role/NetLossPerShareAntiDilutiveSecuritiesandPotentialCommonSharesDetails">
        <link:definition>0000089 - Disclosure - Net Loss Per Share - Anti-Dilutive Securities and Potential Common Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.ardelyx.com/role/CommitmentsandContingenciesDetails">
        <link:definition>0000090 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.ardelyx.com/role/SubsequentEventsDetails">
        <link:definition>0000091 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ardx_DeferredTaxLiabilitiesRightOfUseAsset" abstract="false" name="DeferredTaxLiabilitiesRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_KyowaKirinCo.LtdMember" abstract="true" name="KyowaKirinCo.LtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_EquitySalesAgreementProceedsFromSharesIssuedSinceInception" abstract="false" name="EquitySalesAgreementProceedsFromSharesIssuedSinceInception" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_EquitySalesAgreementSharesIssuedSinceInception" abstract="false" name="EquitySalesAgreementSharesIssuedSinceInception" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ardx_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_ContractWithCustomerLiabilityIncreaseForCashReceived" abstract="false" name="ContractWithCustomerLiabilityIncreaseForCashReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember" abstract="true" name="LicenseAgreementDevelopmentCommercializationDistributionInChinaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum" abstract="false" name="LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_AccountsReceivableCommercialCustomerMember" abstract="true" name="AccountsReceivableCommercialCustomerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_TermOfPaymentOfLicenseFeeFirstInstallment" abstract="false" name="TermOfPaymentOfLicenseFeeFirstInstallment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ardx_ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenueDuringThePeriod" abstract="false" name="ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenueDuringThePeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_KkcMember" abstract="true" name="KkcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_ContractWithCustomerLiabilityTransactionCosts" abstract="false" name="ContractWithCustomerLiabilityTransactionCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember" abstract="true" name="OpenMarketSalesAgreement2021AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_PercentageOfNonRoyaltyRevenue" abstract="false" name="PercentageOfNonRoyaltyRevenue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_ExitFee2022Member" abstract="true" name="ExitFee2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_RevenueGeneralPaymentTerms" abstract="false" name="RevenueGeneralPaymentTerms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ardx_AccruedProfessionalAndConsultantFeesCurrent" abstract="false" name="AccruedProfessionalAndConsultantFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_TermOfAgreement" abstract="false" name="TermOfAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ardx_LoanAgreementExitFeeTerm" abstract="false" name="LoanAgreementExitFeeTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents" abstract="false" name="LoanAgreementFutureObligationUponFundingOrOtherEvents" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_AccruedClinicalExpenses" abstract="false" name="AccruedClinicalExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember" abstract="true" name="OpenMarketSalesAgreement2023AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_ExitFeePercentage" abstract="false" name="ExitFeePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum" abstract="false" name="AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ardx_PercentageOfRoyaltyRevenue" abstract="false" name="PercentageOfRoyaltyRevenue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" abstract="false" name="FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_TwoThousandFourteenEquityIncentiveAwardPlanMember" abstract="true" name="TwoThousandFourteenEquityIncentiveAwardPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees" abstract="false" name="CollaborationAndLicensingAgreementsUpfrontLicenseFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_ExitFee2018Member" abstract="true" name="ExitFee2018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_SharesAvailableForGrantRollForward" abstract="true" name="SharesAvailableForGrantRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ardx_CollaborativeArrangementPotentialCommercializationMilestones" abstract="false" name="CollaborativeArrangementPotentialCommercializationMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_PrepaidCommercialManufacturingCurrent" abstract="false" name="PrepaidCommercialManufacturingCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward" abstract="true" name="ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches" abstract="false" name="CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ardx_GoVersusRaabMember" abstract="true" name="GoVersusRaabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_CollaborativeArrangementPotentialDevelopmentMilestones" abstract="false" name="CollaborativeArrangementPotentialDevelopmentMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum" abstract="false" name="LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_ContractWithCustomerDiscountsAndChargebacksMember" abstract="true" name="ContractWithCustomerDiscountsAndChargebacksMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_AccruedGrossToNetRevenueLiabilities" abstract="false" name="AccruedGrossToNetRevenueLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_IncomeTaxDisclosureLineItems" abstract="true" name="IncomeTaxDisclosureLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod" abstract="false" name="ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_NumberOfSeparateCollaborativeAgreements" abstract="false" name="NumberOfSeparateCollaborativeAgreements" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ardx_OperatingLossCarryforwardsWithoutExpiration" abstract="false" name="OperatingLossCarryforwardsWithoutExpiration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToAuthorizedInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToAuthorizedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ardx_PotentialCommonSharesAntiDilutiveEffectOnSecurities" abstract="false" name="PotentialCommonSharesAntiDilutiveEffectOnSecurities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ardx_AccruedNonClinicalResearchAndDevelopmentExpenses" abstract="false" name="AccruedNonClinicalResearchAndDevelopmentExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_DebtInstrumentInterestPaymentExtensionTerm" abstract="false" name="DebtInstrumentInterestPaymentExtensionTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ardx_TwoThousandSixteenEmploymentCommencementIncentivePlanMember" abstract="true" name="TwoThousandSixteenEmploymentCommencementIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward" abstract="true" name="ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ardx_EmployeeStockPurchasePlanSharesAvailableRollForward" abstract="true" name="EmployeeStockPurchasePlanSharesAvailableRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsPurchases" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsPurchases" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ardx_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment" abstract="false" name="CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod" abstract="false" name="LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ardx_StockOptionsWeightedAverageRemainingContractualTermAbstract" abstract="true" name="StockOptionsWeightedAverageRemainingContractualTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ardx_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_MinimumTaxCreditCarryforwardMember" abstract="true" name="MinimumTaxCreditCarryforwardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember" abstract="true" name="LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_DebtInstrumentVariableRateBaseOption" abstract="false" name="DebtInstrumentVariableRateBaseOption" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember" abstract="true" name="ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate" abstract="false" name="CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_TaxAuthorityStatesOtherThanCaliforniaMember" abstract="true" name="TaxAuthorityStatesOtherThanCaliforniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock" abstract="false" name="ScheduleOfGrossToNetSalesAccrualsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ardx_DebtInstrumentVariableRatePlusOption" abstract="false" name="DebtInstrumentVariableRatePlusOption" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_DeferredRoyaltyObligationNoncurrent" abstract="false" name="DeferredRoyaltyObligationNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponInclusionOfForfeitedOrUnexercisedOptions" abstract="false" name="IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponInclusionOfForfeitedOrUnexercisedOptions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ardx_ContractWithCustomerCopayAndReturnsMember" abstract="true" name="ContractWithCustomerCopayAndReturnsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_DeferredTaxAssetsAmortizationAndDepreciation" abstract="false" name="DeferredTaxAssetsAmortizationAndDepreciation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_FacilityFremontCaliforniaMember" abstract="true" name="FacilityFremontCaliforniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_AstraZenecaTerminationAgreementMember" abstract="true" name="AstraZenecaTerminationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_StockIssuanceCostCommissionPercent" abstract="false" name="StockIssuanceCostCommissionPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation" abstract="false" name="FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_InvestmentsAndCashAmortizedCost" abstract="false" name="InvestmentsAndCashAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts" abstract="false" name="ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived" abstract="false" name="ContractWithCustomerLiabilityRevenueRecognizedCashReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_DerivativeLiabilityForExitFees" abstract="false" name="DerivativeLiabilityForExitFees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock" abstract="false" name="AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ardx_GrossToNetSalesAccrualAndReserveClassificationDomain" abstract="true" name="GrossToNetSalesAccrualAndReserveClassificationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_DebtInstrumentInterestRateOnDefaultPercentage" abstract="false" name="DebtInstrumentInterestRateOnDefaultPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_FacilityMilwaukeeWisconsinMember" abstract="true" name="FacilityMilwaukeeWisconsinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToGrantedInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToGrantedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ardx_KnightTherapeuticsIncMember" abstract="true" name="KnightTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_TermLoan2022AMember" abstract="true" name="TermLoan2022AMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_OfficeEquipmentAndFurnitureMember" abstract="true" name="OfficeEquipmentAndFurnitureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember" abstract="true" name="OpenMarketSalesAgreement2020AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_RemainingFundingBasedOnConditionalMilestoneAchievement" abstract="false" name="RemainingFundingBasedOnConditionalMilestoneAchievement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponExerciseOfStockOptions" abstract="false" name="IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponExerciseOfStockOptions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ardx_FacilityOneWalthamMassachusettsMember" abstract="true" name="FacilityOneWalthamMassachusettsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage" abstract="false" name="DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_ContractWithCustomerRebatesWholesalerAndGPOFeesMember" abstract="true" name="ContractWithCustomerRebatesWholesalerAndGPOFeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_IncreaseDecreaseInUnbilledRevenue" abstract="false" name="IncreaseDecreaseInUnbilledRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward" abstract="true" name="ContractWithCustomerGrossToNetSalesAccrualRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ardx_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitExecutiveCompensationDisallowedIRCSec162mPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitExecutiveCompensationDisallowedIRCSec162mPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_RevenueRemainingPerformanceObligationVariableConsiderationAmount" abstract="false" name="RevenueRemainingPerformanceObligationVariableConsiderationAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_ProductIBSRELAMember" abstract="true" name="ProductIBSRELAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToCanceledInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToCanceledInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ardx_CostOfRevenueAggregateAmountRecognized" abstract="false" name="CostOfRevenueAggregateAmountRecognized" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesUnderEmployeeStockPurchasePlan" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesUnderEmployeeStockPurchasePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ardx_AccruedPaymentsDueToRelatedParty" abstract="false" name="AccruedPaymentsDueToRelatedParty" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_CollaborationPartnershipConcentrationRiskMember" abstract="true" name="CollaborationPartnershipConcentrationRiskMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_LesseeOperatingLeaseNumberOfRenewalOptions" abstract="false" name="LesseeOperatingLeaseNumberOfRenewalOptions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ardx_EmployeeStockPurchasePlanSharesPurchasedRollForward" abstract="true" name="EmployeeStockPurchasePlanSharesPurchasedRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ardx_CollaborativeDevelopmentMember" abstract="true" name="CollaborativeDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" abstract="false" name="CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued" abstract="false" name="ContractWithCustomerGrossToCreditsOrDeductionsIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_ThresholdPercentageOfSalesForTieredRoyalties" abstract="false" name="ThresholdPercentageOfSalesForTieredRoyalties" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded" abstract="false" name="ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_DebtInstrumentClosingFeeAmount" abstract="false" name="DebtInstrumentClosingFeeAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_HealthCareRoyaltyPartnersIVLPMember" abstract="true" name="HealthCareRoyaltyPartnersIVLPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_CommonStockSubjectToIssuedInducementGrantsShares" abstract="false" name="CommonStockSubjectToIssuedInducementGrantsShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense" abstract="false" name="IncreaseDecreaseInPrepaidCommercialManufacturingExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_MaximumAggregateOfferingPrice" abstract="false" name="MaximumAggregateOfferingPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_ContractWithCustomerProductSalesGrossToNetAccruals" abstract="false" name="ContractWithCustomerProductSalesGrossToNetAccruals" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_GrossToNetSalesAccrualAndReserveClassificationAxis" abstract="true" name="GrossToNetSalesAccrualAndReserveClassificationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToStockIssuedForServicesInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToStockIssuedForServicesInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ardx_CardinalHealthMember" abstract="true" name="CardinalHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_FacilityTwoWalthamMassachusettsMember" abstract="true" name="FacilityTwoWalthamMassachusettsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_IncomeTaxDisclosureTable" abstract="true" name="IncomeTaxDisclosureTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent" abstract="false" name="ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_TwoThousandEightStockIncentivePlanMember" abstract="true" name="TwoThousandEightStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_TermLoan2022BMember" abstract="true" name="TermLoan2022BMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_StrezsakVersusArdelyxIncMember" abstract="true" name="StrezsakVersusArdelyxIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses" abstract="false" name="CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_StockOptionsAggregateIntrinsicValueAbstract" abstract="true" name="StockOptionsAggregateIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock" abstract="false" name="ScheduleOfAdditionalDetailsOfLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ardx_ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived" abstract="false" name="ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_PerformanceBasedRestrictedStockUnitsMember" abstract="true" name="PerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_CollaborationAndLicensingAgreementsNumberOfAmendments" abstract="false" name="CollaborationAndLicensingAgreementsNumberOfAmendments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ardx_AmerisourceBergenDrugCorporationMember" abstract="true" name="AmerisourceBergenDrugCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths" abstract="false" name="ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_TermLoan2018Member" abstract="true" name="TermLoan2018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_CollaborationAndLicensingAgreementsAbstract" abstract="true" name="CollaborationAndLicensingAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" abstract="false" name="CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_ProductSupplyRevenueMember" abstract="true" name="ProductSupplyRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanGrossProceeds" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanGrossProceeds" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum" abstract="false" name="LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains" abstract="false" name="CashCashEquivalentsAndInvestmentsGrossUnrealizedGains" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_NumberOfOperatingLeaseArrangements" abstract="false" name="NumberOfOperatingLeaseArrangements" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember" abstract="true" name="LicenseAgreementDevelopmentCommercializationDistributionInJapanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_AccruedContractManufacturingCosts" abstract="false" name="AccruedContractManufacturingCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock" abstract="false" name="NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ardx_IncreaseInSharesReservedForIssuanceOptionForAnnualIncreaseAsPercentageOfSharesOutstanding" abstract="false" name="IncreaseInSharesReservedForIssuanceOptionForAnnualIncreaseAsPercentageOfSharesOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_GeographicInformationAndConcentrationsTextBlock" abstract="false" name="GeographicInformationAndConcentrationsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ardx_ContractWithCustomerLiabilityIncreasesToAmountsInvoicedButCashNotReceived" abstract="false" name="ContractWithCustomerLiabilityIncreasesToAmountsInvoicedButCashNotReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_TermBLoanMember" abstract="true" name="TermBLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_DerivativeIssued" abstract="false" name="DerivativeIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_McKessonCorporationMember" abstract="true" name="McKessonCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_AccruedSalesAndMarketingExpenses" abstract="false" name="AccruedSalesAndMarketingExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment" abstract="false" name="CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_AstrazenecaMember" abstract="true" name="AstrazenecaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths" abstract="false" name="ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_LeaseArrangementsDomain" abstract="true" name="LeaseArrangementsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_ShortTermInvestmentsPolicyTextBlock" abstract="false" name="ShortTermInvestmentsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ardx_ResearchCollaborationAndOptionAgreementMember" abstract="true" name="ResearchCollaborationAndOptionAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_TermLoan2022Member" abstract="true" name="TermLoan2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_AccountsReceivableCollaboratorMember" abstract="true" name="AccountsReceivableCollaboratorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_SaleOfStockWeightedAveragePricePerShare" abstract="false" name="SaleOfStockWeightedAveragePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ardx_ContractWithCustomerGrossToNetSalesAccruals" abstract="false" name="ContractWithCustomerGrossToNetSalesAccruals" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_LeaseArrangementsAxis" abstract="true" name="LeaseArrangementsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="ardx_CorporateBondsMember" abstract="true" name="CorporateBondsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_DebtInstrumentPrepaymentFeePercentage" abstract="false" name="DebtInstrumentPrepaymentFeePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesStockPurchasePlanPurchasedNumber" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesStockPurchasePlanPurchasedNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>ardx-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:9159adf2-88b0-425e-b00c-16d6f1bd5962,g:73dc270f-0b38-43c2-8fc7-c4890fc3e73f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ardelyx.com/role/BALANCESHEETS" xlink:type="simple" xlink:href="ardx-20221231.xsd#BALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/BALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_752232db-68c6-4bb5-ad70-44c04e276607" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_d9ae2012-7dfb-4b4f-ba7a-306c5f7bd188" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_752232db-68c6-4bb5-ad70-44c04e276607" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_d9ae2012-7dfb-4b4f-ba7a-306c5f7bd188" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f7adbc3d-76d4-4ccb-8251-68e73f1792bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_752232db-68c6-4bb5-ad70-44c04e276607" xlink:to="loc_us-gaap_LiabilitiesCurrent_f7adbc3d-76d4-4ccb-8251-68e73f1792bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DeferredRoyaltyObligationNoncurrent_43af41bf-f26c-46fe-8f80-aeb90d623c8e" xlink:href="ardx-20221231.xsd#ardx_DeferredRoyaltyObligationNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_752232db-68c6-4bb5-ad70-44c04e276607" xlink:to="loc_ardx_DeferredRoyaltyObligationNoncurrent_43af41bf-f26c-46fe-8f80-aeb90d623c8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_05bb81aa-eeb7-49d7-8cf2-35c66e7f16a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_752232db-68c6-4bb5-ad70-44c04e276607" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_05bb81aa-eeb7-49d7-8cf2-35c66e7f16a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_494cb974-0a5d-49fa-9489-4ae2a391b0bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9dd11946-a480-4046-b420-7b2dc129979a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_494cb974-0a5d-49fa-9489-4ae2a391b0bb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9dd11946-a480-4046-b420-7b2dc129979a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_8387a3a5-803c-48a7-9eb2-7a2c012f67c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_494cb974-0a5d-49fa-9489-4ae2a391b0bb" xlink:to="loc_us-gaap_InventoryNoncurrent_8387a3a5-803c-48a7-9eb2-7a2c012f67c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a09ad119-4ddd-47aa-8926-e9bcdcc49a33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_494cb974-0a5d-49fa-9489-4ae2a391b0bb" xlink:to="loc_us-gaap_AssetsCurrent_a09ad119-4ddd-47aa-8926-e9bcdcc49a33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8319135a-1b58-4991-9b35-b29447fd1e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_494cb974-0a5d-49fa-9489-4ae2a391b0bb" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8319135a-1b58-4991-9b35-b29447fd1e77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_75b4c378-db65-4469-84da-e4dc91ee87a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_494cb974-0a5d-49fa-9489-4ae2a391b0bb" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_75b4c378-db65-4469-84da-e4dc91ee87a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_896137a1-397f-4ded-b29b-9a19747d157f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PrepaidCommercialManufacturingCurrent_8197ffea-80a4-4283-8f46-9889fe5fc192" xlink:href="ardx-20221231.xsd#ardx_PrepaidCommercialManufacturingCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_896137a1-397f-4ded-b29b-9a19747d157f" xlink:to="loc_ardx_PrepaidCommercialManufacturingCurrent_8197ffea-80a4-4283-8f46-9889fe5fc192" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8b6a1996-3465-4b23-93a8-53536a0fa641" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_896137a1-397f-4ded-b29b-9a19747d157f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8b6a1996-3465-4b23-93a8-53536a0fa641" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_a531eac9-865c-4648-a56e-7ec17279e72a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_896137a1-397f-4ded-b29b-9a19747d157f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_a531eac9-865c-4648-a56e-7ec17279e72a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0eb9b47f-ebc1-427b-9e6e-5802116b0e41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_896137a1-397f-4ded-b29b-9a19747d157f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0eb9b47f-ebc1-427b-9e6e-5802116b0e41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_0a72ac38-b015-4394-bb7e-1f9d39ad7f27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_896137a1-397f-4ded-b29b-9a19747d157f" xlink:to="loc_us-gaap_InventoryGross_0a72ac38-b015-4394-bb7e-1f9d39ad7f27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8ecd6fac-05d2-4b2e-bd85-7088744342d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_896137a1-397f-4ded-b29b-9a19747d157f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_8ecd6fac-05d2-4b2e-bd85-7088744342d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ca94eaff-71c9-4b1f-9f18-20208f3553a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_02abce08-3e49-439c-b60b-6623e0735410" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ca94eaff-71c9-4b1f-9f18-20208f3553a6" xlink:to="loc_us-gaap_AccountsPayableCurrent_02abce08-3e49-439c-b60b-6623e0735410" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_783ece09-0c03-47da-b9a5-0f2f566309e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ca94eaff-71c9-4b1f-9f18-20208f3553a6" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_783ece09-0c03-47da-b9a5-0f2f566309e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_a4ebf6c8-6d73-4b07-9240-f0266da1e53b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ca94eaff-71c9-4b1f-9f18-20208f3553a6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_a4ebf6c8-6d73-4b07-9240-f0266da1e53b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableCurrent_5b470377-2bd6-46ab-91d4-71b4cd070c84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ca94eaff-71c9-4b1f-9f18-20208f3553a6" xlink:to="loc_us-gaap_LoansPayableCurrent_5b470377-2bd6-46ab-91d4-71b4cd070c84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d576408d-6fc4-44e9-97dc-273d20dbe81b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ca94eaff-71c9-4b1f-9f18-20208f3553a6" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d576408d-6fc4-44e9-97dc-273d20dbe81b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_e14b8e2f-3421-4c3f-a284-dea3da3b6119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ca94eaff-71c9-4b1f-9f18-20208f3553a6" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_e14b8e2f-3421-4c3f-a284-dea3da3b6119" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3b044984-434a-4427-8c82-184bd0b8cb8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_191226cc-bf5c-49c8-ae7b-6a45ebe12727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3b044984-434a-4427-8c82-184bd0b8cb8d" xlink:to="loc_us-gaap_PreferredStockValue_191226cc-bf5c-49c8-ae7b-6a45ebe12727" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_7d11f3b5-3c67-4265-9d5e-1ed3692f40f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3b044984-434a-4427-8c82-184bd0b8cb8d" xlink:to="loc_us-gaap_CommonStockValue_7d11f3b5-3c67-4265-9d5e-1ed3692f40f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_49498f13-cad9-4b7f-918e-d342505ba596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3b044984-434a-4427-8c82-184bd0b8cb8d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_49498f13-cad9-4b7f-918e-d342505ba596" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cbf0e902-d600-4b8f-bb42-fe739b59a3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3b044984-434a-4427-8c82-184bd0b8cb8d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cbf0e902-d600-4b8f-bb42-fe739b59a3ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_14163b04-45ba-4667-886a-58f9e6f20aae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3b044984-434a-4427-8c82-184bd0b8cb8d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_14163b04-45ba-4667-886a-58f9e6f20aae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_cf542912-9bc9-4472-8e8c-13f1cb5454e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_39ad0b33-b93e-480e-96af-bdc7892649a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cf542912-9bc9-4472-8e8c-13f1cb5454e1" xlink:to="loc_us-gaap_Liabilities_39ad0b33-b93e-480e-96af-bdc7892649a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_acb9b8dc-dea9-4c7f-8bc5-8dde0072cd57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cf542912-9bc9-4472-8e8c-13f1cb5454e1" xlink:to="loc_us-gaap_CommitmentsAndContingencies_acb9b8dc-dea9-4c7f-8bc5-8dde0072cd57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7bfc5951-1ee2-4f78-ab76-1f7dd15fb835" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cf542912-9bc9-4472-8e8c-13f1cb5454e1" xlink:to="loc_us-gaap_StockholdersEquity_7bfc5951-1ee2-4f78-ab76-1f7dd15fb835" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="ardx-20221231.xsd#STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cf8564ec-08bd-492e-aeb9-921af5fcc3e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d6bf99fa-c9c4-43b0-a9f0-c5d114fef526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cf8564ec-08bd-492e-aeb9-921af5fcc3e1" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_d6bf99fa-c9c4-43b0-a9f0-c5d114fef526" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b6ac81a3-cee5-4c84-be89-74e0958be33a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cf8564ec-08bd-492e-aeb9-921af5fcc3e1" xlink:to="loc_us-gaap_InterestExpense_b6ac81a3-cee5-4c84-be89-74e0958be33a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfAdvanceRoyalty_3cb3f539-3bfc-4481-8252-851a1de323ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfAdvanceRoyalty"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cf8564ec-08bd-492e-aeb9-921af5fcc3e1" xlink:to="loc_us-gaap_AmortizationOfAdvanceRoyalty_3cb3f539-3bfc-4481-8252-851a1de323ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1f4afce2-b176-43f6-b4fc-381f48a6ae76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cf8564ec-08bd-492e-aeb9-921af5fcc3e1" xlink:to="loc_us-gaap_OperatingIncomeLoss_1f4afce2-b176-43f6-b4fc-381f48a6ae76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_cdcb6dfb-98ce-450e-acae-cba475dda8d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_656dd7a6-d405-4732-83d4-5edd495cbd4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_cdcb6dfb-98ce-450e-acae-cba475dda8d4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_656dd7a6-d405-4732-83d4-5edd495cbd4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_174e23cd-9e3e-46be-8385-bf026eb58697" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_cdcb6dfb-98ce-450e-acae-cba475dda8d4" xlink:to="loc_us-gaap_CostsAndExpenses_174e23cd-9e3e-46be-8385-bf026eb58697" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_265bd918-c542-4c5c-9703-b21a515c7f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_41e65ac3-3d75-4b41-8e4f-b8941be1feee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_265bd918-c542-4c5c-9703-b21a515c7f1e" xlink:to="loc_us-gaap_CostOfRevenue_41e65ac3-3d75-4b41-8e4f-b8941be1feee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_82b31983-3be8-496c-958f-acb44d17633d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_265bd918-c542-4c5c-9703-b21a515c7f1e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_82b31983-3be8-496c-958f-acb44d17633d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1ce1a93e-3ee1-4963-98b1-7b823934333d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_265bd918-c542-4c5c-9703-b21a515c7f1e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1ce1a93e-3ee1-4963-98b1-7b823934333d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1eff59c2-7013-4dfe-9b23-c17a60318bba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_adc27e6e-c1d8-4444-986d-8df761352035" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_1eff59c2-7013-4dfe-9b23-c17a60318bba" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_adc27e6e-c1d8-4444-986d-8df761352035" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a80ed956-5a8e-4ac0-a708-62ee5283312d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_1eff59c2-7013-4dfe-9b23-c17a60318bba" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a80ed956-5a8e-4ac0-a708-62ee5283312d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_31292a85-c69f-495d-a204-989577989c32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_56a8e727-fb22-4205-bf00-3821dafb80fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_31292a85-c69f-495d-a204-989577989c32" xlink:to="loc_us-gaap_NetIncomeLoss_56a8e727-fb22-4205-bf00-3821dafb80fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_277313c7-e5b6-4118-a10e-c30665dfb19e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_31292a85-c69f-495d-a204-989577989c32" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_277313c7-e5b6-4118-a10e-c30665dfb19e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="ardx-20221231.xsd#STATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_096888e5-6053-46fe-8616-ff966c751375" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_61a5e7b6-0a1c-41ca-b73b-902e3ee77793" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_096888e5-6053-46fe-8616-ff966c751375" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_61a5e7b6-0a1c-41ca-b73b-902e3ee77793" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_795051eb-d0f4-4cf5-a790-fd9f0d208beb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_096888e5-6053-46fe-8616-ff966c751375" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_795051eb-d0f4-4cf5-a790-fd9f0d208beb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_40657bc4-90f7-4721-b158-dddc260a00e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_096888e5-6053-46fe-8616-ff966c751375" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_40657bc4-90f7-4721-b158-dddc260a00e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts_f57ca8c7-1cf2-49a2-923b-554a7ff279eb" xlink:href="ardx-20221231.xsd#ardx_ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_096888e5-6053-46fe-8616-ff966c751375" xlink:to="loc_ardx_ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts_f57ca8c7-1cf2-49a2-923b-554a7ff279eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_8e7be3ee-3840-425e-956d-828942082a74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_096888e5-6053-46fe-8616-ff966c751375" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_8e7be3ee-3840-425e-956d-828942082a74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt_c96f97aa-c3ed-4f80-8b33-ed9b46626ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_096888e5-6053-46fe-8616-ff966c751375" xlink:to="loc_us-gaap_RepaymentsOfSecuredDebt_c96f97aa-c3ed-4f80-8b33-ed9b46626ceb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3b4b2b70-dafd-421a-92f3-ee4277bc8662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_762ec127-b9e7-49bd-8544-be1cd508249e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3b4b2b70-dafd-421a-92f3-ee4277bc8662" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_762ec127-b9e7-49bd-8544-be1cd508249e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_72816ea6-f842-4ced-b4fe-e18e937a3c36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3b4b2b70-dafd-421a-92f3-ee4277bc8662" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_72816ea6-f842-4ced-b4fe-e18e937a3c36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_27f78cc3-971e-4bf4-8622-42731ce78d96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3b4b2b70-dafd-421a-92f3-ee4277bc8662" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_27f78cc3-971e-4bf4-8622-42731ce78d96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b93994c7-2843-48f7-a4b0-ee0a0315cd7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_d5733b2f-2345-4fa9-8fa8-22032ce59ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b93994c7-2843-48f7-a4b0-ee0a0315cd7e" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_d5733b2f-2345-4fa9-8fa8-22032ce59ceb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_e8da245e-8931-4a39-a3bd-9408504b01c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b93994c7-2843-48f7-a4b0-ee0a0315cd7e" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_e8da245e-8931-4a39-a3bd-9408504b01c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_f3001972-115b-47d0-85cd-1d5b790e5a46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b93994c7-2843-48f7-a4b0-ee0a0315cd7e" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_f3001972-115b-47d0-85cd-1d5b790e5a46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_c90e0c1f-fe63-4c81-9c63-aa14d1a65fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b93994c7-2843-48f7-a4b0-ee0a0315cd7e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_c90e0c1f-fe63-4c81-9c63-aa14d1a65fc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3c4e3317-f07e-441c-9a83-126e195f83a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b93994c7-2843-48f7-a4b0-ee0a0315cd7e" xlink:to="loc_us-gaap_NetIncomeLoss_3c4e3317-f07e-441c-9a83-126e195f83a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_d9dd89c1-b8f3-4b37-9821-e46486dee0b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b93994c7-2843-48f7-a4b0-ee0a0315cd7e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_d9dd89c1-b8f3-4b37-9821-e46486dee0b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_IncreaseDecreaseInUnbilledRevenue_4f0300cc-c35b-49b2-bb43-650a2af0f113" xlink:href="ardx-20221231.xsd#ardx_IncreaseDecreaseInUnbilledRevenue"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b93994c7-2843-48f7-a4b0-ee0a0315cd7e" xlink:to="loc_ardx_IncreaseDecreaseInUnbilledRevenue_4f0300cc-c35b-49b2-bb43-650a2af0f113" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_c0d5927b-3011-4668-b018-e44dd970d484" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b93994c7-2843-48f7-a4b0-ee0a0315cd7e" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_c0d5927b-3011-4668-b018-e44dd970d484" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c332c271-79e2-4ce3-8757-67186373642d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b93994c7-2843-48f7-a4b0-ee0a0315cd7e" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c332c271-79e2-4ce3-8757-67186373642d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense_70317863-eaff-477a-ba0b-b739cd857c62" xlink:href="ardx-20221231.xsd#ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b93994c7-2843-48f7-a4b0-ee0a0315cd7e" xlink:to="loc_ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense_70317863-eaff-477a-ba0b-b739cd857c62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_8c8e86bb-063f-40f2-8b88-5ce04079b409" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b93994c7-2843-48f7-a4b0-ee0a0315cd7e" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_8c8e86bb-063f-40f2-8b88-5ce04079b409" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_bbdb317f-c8eb-4211-90dc-e90460528301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b93994c7-2843-48f7-a4b0-ee0a0315cd7e" xlink:to="loc_us-gaap_ShareBasedCompensation_bbdb317f-c8eb-4211-90dc-e90460528301" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_7cf3d0a0-2541-422d-81bb-b9cb70975f85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b93994c7-2843-48f7-a4b0-ee0a0315cd7e" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_7cf3d0a0-2541-422d-81bb-b9cb70975f85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_21666435-5d19-4eb4-b151-18b5ee054289" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b93994c7-2843-48f7-a4b0-ee0a0315cd7e" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_21666435-5d19-4eb4-b151-18b5ee054289" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_a83cbdfc-237f-4a78-b064-4771d233822b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b93994c7-2843-48f7-a4b0-ee0a0315cd7e" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_a83cbdfc-237f-4a78-b064-4771d233822b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f757206d-e67c-49c4-a137-ebe346f463de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b93994c7-2843-48f7-a4b0-ee0a0315cd7e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f757206d-e67c-49c4-a137-ebe346f463de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_b42f5c33-0711-4062-89bd-f77490d62072" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b93994c7-2843-48f7-a4b0-ee0a0315cd7e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_b42f5c33-0711-4062-89bd-f77490d62072" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt_0c62f76a-7eb1-4873-95cd-63bbae5a18cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <link:calculationArc order="18" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b93994c7-2843-48f7-a4b0-ee0a0315cd7e" xlink:to="loc_us-gaap_GainsLossesOnRestructuringOfDebt_0c62f76a-7eb1-4873-95cd-63bbae5a18cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a72117d8-db4e-4da0-8d72-e67097b49d18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_0fb5b4f7-8dcc-4c5c-8aca-7d2874d1b161" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a72117d8-db4e-4da0-8d72-e67097b49d18" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_0fb5b4f7-8dcc-4c5c-8aca-7d2874d1b161" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_1c606366-4a8d-4d86-bf6f-01b7d5fba061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a72117d8-db4e-4da0-8d72-e67097b49d18" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_1c606366-4a8d-4d86-bf6f-01b7d5fba061" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_5801b434-2f70-4d1f-97d0-b4915ffa4d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a72117d8-db4e-4da0-8d72-e67097b49d18" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_5801b434-2f70-4d1f-97d0-b4915ffa4d5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b14fb174-b881-40f6-8f2b-8d16046e48c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a72117d8-db4e-4da0-8d72-e67097b49d18" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b14fb174-b881-40f6-8f2b-8d16046e48c9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4fcb86ce-343f-4139-9d5e-b360f22e0cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_646952b4-5dd7-49e6-bada-2173af1c857b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4fcb86ce-343f-4139-9d5e-b360f22e0cb6" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_646952b4-5dd7-49e6-bada-2173af1c857b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3d59efe2-8146-4b34-88f7-86c266a3d37e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4fcb86ce-343f-4139-9d5e-b360f22e0cb6" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3d59efe2-8146-4b34-88f7-86c266a3d37e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8b993a1a-1dd0-4bef-bc7e-66114e650ace" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4fcb86ce-343f-4139-9d5e-b360f22e0cb6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8b993a1a-1dd0-4bef-bc7e-66114e650ace" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_InvestmentsAndCashAmortizedCost_0f684894-a155-43ad-b570-ab1e6db2cf98" xlink:href="ardx-20221231.xsd#ardx_InvestmentsAndCashAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains_24a26e6b-8a6e-4b20-a949-690c0cd52335" xlink:href="ardx-20221231.xsd#ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ardx_InvestmentsAndCashAmortizedCost_0f684894-a155-43ad-b570-ab1e6db2cf98" xlink:to="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains_24a26e6b-8a6e-4b20-a949-690c0cd52335" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses_b20f9dd9-8746-4e5d-85e3-f5bbff73b6d1" xlink:href="ardx-20221231.xsd#ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ardx_InvestmentsAndCashAmortizedCost_0f684894-a155-43ad-b570-ab1e6db2cf98" xlink:to="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses_b20f9dd9-8746-4e5d-85e3-f5bbff73b6d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_9ba0d2f7-0a13-4b23-9cd7-1d8ff3092fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndCash"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ardx_InvestmentsAndCashAmortizedCost_0f684894-a155-43ad-b570-ab1e6db2cf98" xlink:to="loc_us-gaap_InvestmentsAndCash_9ba0d2f7-0a13-4b23-9cd7-1d8ff3092fa2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/InventoryScheduleDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#InventoryScheduleDetails"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/InventoryScheduleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_2ba60253-5a8f-434b-b512-fd8d3d1f63f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_3d44c79e-32c2-420c-ad33-be304323b330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_2ba60253-5a8f-434b-b512-fd8d3d1f63f9" xlink:to="loc_us-gaap_InventoryRawMaterials_3d44c79e-32c2-420c-ad33-be304323b330" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_1b0db3dc-c93b-411e-ba92-fb95ef5880ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_2ba60253-5a8f-434b-b512-fd8d3d1f63f9" xlink:to="loc_us-gaap_InventoryWorkInProcess_1b0db3dc-c93b-411e-ba92-fb95ef5880ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_5c12ad0e-1d17-48e4-a5e2-d9c66110ef42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_2ba60253-5a8f-434b-b512-fd8d3d1f63f9" xlink:to="loc_us-gaap_InventoryFinishedGoods_5c12ad0e-1d17-48e4-a5e2-d9c66110ef42" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/BorrowingsFuturePaymentObligationsDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#BorrowingsFuturePaymentObligationsDetails"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/BorrowingsFuturePaymentObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_83605214-6dc0-4220-800d-1c6ea51d6901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_318cc562-7ecb-4fad-8ca5-858d7199b4b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_83605214-6dc0-4220-800d-1c6ea51d6901" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_318cc562-7ecb-4fad-8ca5-858d7199b4b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_96a8d621-0aa3-4a89-8d63-ccde0cfb854d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_83605214-6dc0-4220-800d-1c6ea51d6901" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_96a8d621-0aa3-4a89-8d63-ccde0cfb854d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_bdb055c4-a89e-4bab-a40a-4600db06a629" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_83605214-6dc0-4220-800d-1c6ea51d6901" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_bdb055c4-a89e-4bab-a40a-4600db06a629" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_0f42f94b-33e2-48e5-92b0-c33f3f03f651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_b11d1793-e756-4d5e-8114-de29e3489ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_0f42f94b-33e2-48e5-92b0-c33f3f03f651" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_b11d1793-e756-4d5e-8114-de29e3489ae3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_7ecc2c1e-41ce-4dfe-8ad2-c9d3c116c026" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_0f42f94b-33e2-48e5-92b0-c33f3f03f651" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_7ecc2c1e-41ce-4dfe-8ad2-c9d3c116c026" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_9c24e1a9-e7c4-4ff2-834e-953fec806501" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_0f42f94b-33e2-48e5-92b0-c33f3f03f651" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_9c24e1a9-e7c4-4ff2-834e-953fec806501" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_723b1f65-e378-43eb-9e1a-1a5e7df779d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_0f42f94b-33e2-48e5-92b0-c33f3f03f651" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_723b1f65-e378-43eb-9e1a-1a5e7df779d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_f03d7c1a-5133-4dc5-b79e-b4c2766c0e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_0f42f94b-33e2-48e5-92b0-c33f3f03f651" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_f03d7c1a-5133-4dc5-b79e-b4c2766c0e0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_3cf8d280-7497-4806-a0ea-5b04e089ea83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_0f42f94b-33e2-48e5-92b0-c33f3f03f651" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_3cf8d280-7497-4806-a0ea-5b04e089ea83" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/BorrowingsFuturePaymentObligationsDetails_1" xlink:type="simple" xlink:href="ardx-20221231.xsd#BorrowingsFuturePaymentObligationsDetails_1"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/BorrowingsFuturePaymentObligationsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_3b1a214f-e66b-49f0-92c5-ea38a137a812" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableCurrent_46306bbe-a5f3-45fa-a8a5-ae35042b37a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_3b1a214f-e66b-49f0-92c5-ea38a137a812" xlink:to="loc_us-gaap_LoansPayableCurrent_46306bbe-a5f3-45fa-a8a5-ae35042b37a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLoansPayable_daef736b-1934-489c-a4d7-885a33e6bf31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermLoansPayable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_3b1a214f-e66b-49f0-92c5-ea38a137a812" xlink:to="loc_us-gaap_LongTermLoansPayable_daef736b-1934-489c-a4d7-885a33e6bf31" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#LeasesUndiscountedCashPaymentObligationsDetails"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_1de54a17-8ced-4cb9-9063-2b4de8002a24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_337e545a-9921-4400-9413-dd15dbfe2b69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_1de54a17-8ced-4cb9-9063-2b4de8002a24" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_337e545a-9921-4400-9413-dd15dbfe2b69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b12f7960-b246-4710-aa3a-36c76f811e59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_1de54a17-8ced-4cb9-9063-2b4de8002a24" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b12f7960-b246-4710-aa3a-36c76f811e59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4f4eea55-fd61-45ce-8a5e-d022206c809e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d6fb2618-9b41-4b48-828e-8fba541adfde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4f4eea55-fd61-45ce-8a5e-d022206c809e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d6fb2618-9b41-4b48-828e-8fba541adfde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_0d128227-0105-4f8f-a1ac-540e8c639b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4f4eea55-fd61-45ce-8a5e-d022206c809e" xlink:to="loc_us-gaap_OperatingLeaseLiability_0d128227-0105-4f8f-a1ac-540e8c639b5d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1" xlink:type="simple" xlink:href="ardx-20221231.xsd#LeasesUndiscountedCashPaymentObligationsDetails_1"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_44ea0895-96d9-49c7-acdc-eee9b7f5f561" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_fd713e6a-0833-4179-8e59-3245b4fb81f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_44ea0895-96d9-49c7-acdc-eee9b7f5f561" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_fd713e6a-0833-4179-8e59-3245b4fb81f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_098682ee-81d7-4040-bd5b-5f5ff4db2570" xlink:href="ardx-20221231.xsd#ardx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_44ea0895-96d9-49c7-acdc-eee9b7f5f561" xlink:to="loc_ardx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_098682ee-81d7-4040-bd5b-5f5ff4db2570" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_fcd114b0-e1e6-4c81-a39f-d4ebb9d4da62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_44ea0895-96d9-49c7-acdc-eee9b7f5f561" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_fcd114b0-e1e6-4c81-a39f-d4ebb9d4da62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7ed98bbd-b41b-4fac-b2ae-1c1e525d60a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_44ea0895-96d9-49c7-acdc-eee9b7f5f561" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7ed98bbd-b41b-4fac-b2ae-1c1e525d60a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_59cd8b7f-f919-413d-8efd-6fbc3f2dfbf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_44ea0895-96d9-49c7-acdc-eee9b7f5f561" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_59cd8b7f-f919-413d-8efd-6fbc3f2dfbf9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/PropertyandEquipmentNetBalancesDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#PropertyandEquipmentNetBalancesDetails"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/PropertyandEquipmentNetBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a2e0f5f1-ad09-4a96-a2f4-694c711d2134" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_3822b3b7-2328-420f-a800-d5ae9ce3bdac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_a2e0f5f1-ad09-4a96-a2f4-694c711d2134" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_3822b3b7-2328-420f-a800-d5ae9ce3bdac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4516eb1a-32fc-401e-b5ba-cb5b75338fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_a2e0f5f1-ad09-4a96-a2f4-694c711d2134" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4516eb1a-32fc-401e-b5ba-cb5b75338fcb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#AccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_5b4c1f4f-b448-49bf-b2ef-d7d55d5dc00c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AccruedProfessionalAndConsultantFeesCurrent_8ad040ab-68f6-493e-b951-893a1d1f341f" xlink:href="ardx-20221231.xsd#ardx_AccruedProfessionalAndConsultantFeesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_5b4c1f4f-b448-49bf-b2ef-d7d55d5dc00c" xlink:to="loc_ardx_AccruedProfessionalAndConsultantFeesCurrent_8ad040ab-68f6-493e-b951-893a1d1f341f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AccruedNonClinicalResearchAndDevelopmentExpenses_61531746-b97c-4d4d-aafe-bc955d1a0a3f" xlink:href="ardx-20221231.xsd#ardx_AccruedNonClinicalResearchAndDevelopmentExpenses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_5b4c1f4f-b448-49bf-b2ef-d7d55d5dc00c" xlink:to="loc_ardx_AccruedNonClinicalResearchAndDevelopmentExpenses_61531746-b97c-4d4d-aafe-bc955d1a0a3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AccruedPaymentsDueToRelatedParty_f596af2f-e3e9-43b6-8363-85345b089fc2" xlink:href="ardx-20221231.xsd#ardx_AccruedPaymentsDueToRelatedParty"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_5b4c1f4f-b448-49bf-b2ef-d7d55d5dc00c" xlink:to="loc_ardx_AccruedPaymentsDueToRelatedParty_f596af2f-e3e9-43b6-8363-85345b089fc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AccruedContractManufacturingCosts_c0e759cc-01cc-4c11-873f-6bc1bcbf325c" xlink:href="ardx-20221231.xsd#ardx_AccruedContractManufacturingCosts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_5b4c1f4f-b448-49bf-b2ef-d7d55d5dc00c" xlink:to="loc_ardx_AccruedContractManufacturingCosts_c0e759cc-01cc-4c11-873f-6bc1bcbf325c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_1f1d1bda-4a82-4f93-90c1-38748e10ec5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_5b4c1f4f-b448-49bf-b2ef-d7d55d5dc00c" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_1f1d1bda-4a82-4f93-90c1-38748e10ec5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AccruedClinicalExpenses_5ff1cf9b-dad5-4344-8ad6-8b53fb6fa724" xlink:href="ardx-20221231.xsd#ardx_AccruedClinicalExpenses"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_5b4c1f4f-b448-49bf-b2ef-d7d55d5dc00c" xlink:to="loc_ardx_AccruedClinicalExpenses_5ff1cf9b-dad5-4344-8ad6-8b53fb6fa724" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AccruedSalesAndMarketingExpenses_c1cca70a-d28b-4fd6-bd5b-c39720ca4402" xlink:href="ardx-20221231.xsd#ardx_AccruedSalesAndMarketingExpenses"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_5b4c1f4f-b448-49bf-b2ef-d7d55d5dc00c" xlink:to="loc_ardx_AccruedSalesAndMarketingExpenses_c1cca70a-d28b-4fd6-bd5b-c39720ca4402" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AccruedGrossToNetRevenueLiabilities_6132ee5c-8680-4442-bfc1-b3561ebf7ddd" xlink:href="ardx-20221231.xsd#ardx_AccruedGrossToNetRevenueLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_5b4c1f4f-b448-49bf-b2ef-d7d55d5dc00c" xlink:to="loc_ardx_AccruedGrossToNetRevenueLiabilities_6132ee5c-8680-4442-bfc1-b3561ebf7ddd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DerivativeLiabilityForExitFees_b8627d1c-aeb1-439e-9c17-e50ea5bdd08a" xlink:href="ardx-20221231.xsd#ardx_DerivativeLiabilityForExitFees"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_5b4c1f4f-b448-49bf-b2ef-d7d55d5dc00c" xlink:to="loc_ardx_DerivativeLiabilityForExitFees_b8627d1c-aeb1-439e-9c17-e50ea5bdd08a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#IncomeTaxesComponentsofProvisionforIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_dd8f2e4a-21a1-4b37-9447-d7d93df2deb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_42b08261-2ff7-475c-9b09-6f20273f6716" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_dd8f2e4a-21a1-4b37-9447-d7d93df2deb9" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_42b08261-2ff7-475c-9b09-6f20273f6716" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ab3fddb7-e717-485b-9f39-54dae3061a77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_dd8f2e4a-21a1-4b37-9447-d7d93df2deb9" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ab3fddb7-e717-485b-9f39-54dae3061a77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_21f5d729-0004-4117-8f47-fa2c91bcce2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1cd04983-55ac-44b7-a0e5-bb84c1bb4336" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_21f5d729-0004-4117-8f47-fa2c91bcce2b" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1cd04983-55ac-44b7-a0e5-bb84c1bb4336" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_d31b81e5-ab79-46f8-8967-04c77ccac067" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_21f5d729-0004-4117-8f47-fa2c91bcce2b" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_d31b81e5-ab79-46f8-8967-04c77ccac067" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9f11de54-f06b-49da-a6d3-0916fc5ea5cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_4417fba8-116e-4627-8483-1742ea9b76a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9f11de54-f06b-49da-a6d3-0916fc5ea5cb" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_4417fba8-116e-4627-8483-1742ea9b76a8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/IncomeTaxesReconciliationofEffectiveTaxRateDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#IncomeTaxesReconciliationofEffectiveTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/IncomeTaxesReconciliationofEffectiveTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_247148b0-c8fc-4d65-af07-3c66f96bc33a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitExecutiveCompensationDisallowedIRCSec162mPercent_eff33cbf-58fa-4dca-9751-e21f03e731c5" xlink:href="ardx-20221231.xsd#ardx_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitExecutiveCompensationDisallowedIRCSec162mPercent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_247148b0-c8fc-4d65-af07-3c66f96bc33a" xlink:to="loc_ardx_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitExecutiveCompensationDisallowedIRCSec162mPercent_eff33cbf-58fa-4dca-9751-e21f03e731c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_51095a41-1c8d-43c5-b7b9-b15713ba622e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_247148b0-c8fc-4d65-af07-3c66f96bc33a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_51095a41-1c8d-43c5-b7b9-b15713ba622e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_d1653594-5799-4ac2-a884-5b1d662d85ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_247148b0-c8fc-4d65-af07-3c66f96bc33a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_d1653594-5799-4ac2-a884-5b1d662d85ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_07f844de-af8b-4ed0-aa7f-0a4cc8df462f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_247148b0-c8fc-4d65-af07-3c66f96bc33a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_07f844de-af8b-4ed0-aa7f-0a4cc8df462f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0fad4a01-25b0-4d35-8cca-f17a3579aa0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_247148b0-c8fc-4d65-af07-3c66f96bc33a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0fad4a01-25b0-4d35-8cca-f17a3579aa0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_38679621-2ac9-4e11-a93d-53f8a582d6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_247148b0-c8fc-4d65-af07-3c66f96bc33a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_38679621-2ac9-4e11-a93d-53f8a582d6f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_523dc07c-cca0-4d88-9d37-7e85f5d4ff65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_247148b0-c8fc-4d65-af07-3c66f96bc33a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_523dc07c-cca0-4d88-9d37-7e85f5d4ff65" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#IncomeTaxesComponentsofDeferredTaxAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_448a434d-6d4c-41d6-9ca0-1f37d1243648" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_01eaa792-32f0-400d-8f4e-6382daf28f19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_448a434d-6d4c-41d6-9ca0-1f37d1243648" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_01eaa792-32f0-400d-8f4e-6382daf28f19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_13596a37-7ca2-4fca-8c44-8ae64ce80a47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_448a434d-6d4c-41d6-9ca0-1f37d1243648" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_13596a37-7ca2-4fca-8c44-8ae64ce80a47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DeferredTaxLiabilitiesRightOfUseAsset_3a85d6fe-c96a-42ab-9114-77f455c23022" xlink:href="ardx-20221231.xsd#ardx_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_448a434d-6d4c-41d6-9ca0-1f37d1243648" xlink:to="loc_ardx_DeferredTaxLiabilitiesRightOfUseAsset_3a85d6fe-c96a-42ab-9114-77f455c23022" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_d1dcc750-c895-4ace-81cb-9db8a01a1acd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_ee3ea8fd-59a6-495d-aa4d-3049dbd6681d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_d1dcc750-c895-4ace-81cb-9db8a01a1acd" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_ee3ea8fd-59a6-495d-aa4d-3049dbd6681d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_95dc9423-54b2-4523-ad3c-b2c2f128b0f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_d1dcc750-c895-4ace-81cb-9db8a01a1acd" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_95dc9423-54b2-4523-ad3c-b2c2f128b0f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_aa80d690-fa2f-44b5-87fa-e6c62aa70728" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_ee0c2c00-3114-4366-ac13-b7077a14dcce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_aa80d690-fa2f-44b5-87fa-e6c62aa70728" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_ee0c2c00-3114-4366-ac13-b7077a14dcce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DeferredTaxAssetsAmortizationAndDepreciation_1f578aa6-3b3b-4585-9b9f-e304d371858a" xlink:href="ardx-20221231.xsd#ardx_DeferredTaxAssetsAmortizationAndDepreciation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_aa80d690-fa2f-44b5-87fa-e6c62aa70728" xlink:to="loc_ardx_DeferredTaxAssetsAmortizationAndDepreciation_1f578aa6-3b3b-4585-9b9f-e304d371858a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_de4cd477-a3dd-4574-87e0-b0249eaecf4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_aa80d690-fa2f-44b5-87fa-e6c62aa70728" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_de4cd477-a3dd-4574-87e0-b0249eaecf4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_27e7dd88-9d2b-41cf-9a5b-872814ada8c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_aa80d690-fa2f-44b5-87fa-e6c62aa70728" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_27e7dd88-9d2b-41cf-9a5b-872814ada8c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_ee84c7b5-49c9-40a0-8223-7e5b885dc606" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_aa80d690-fa2f-44b5-87fa-e6c62aa70728" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_ee84c7b5-49c9-40a0-8223-7e5b885dc606" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>ardx-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:9159adf2-88b0-425e-b00c-16d6f1bd5962,g:73dc270f-0b38-43c2-8fc7-c4890fc3e73f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="ardx-20221231.xsd#STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended" id="i9d6071e6e0fd466ba88cb115fba646cc_STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ee678115-c8f9-4c91-913a-e6a0673f325e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_330c0519-ab34-4fbb-a901-15c3928d4a35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ee678115-c8f9-4c91-913a-e6a0673f325e" xlink:to="loc_us-gaap_RevenuesAbstract_330c0519-ab34-4fbb-a901-15c3928d4a35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_39ac2e44-063f-4b77-b9bf-a0670dbcac89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_330c0519-ab34-4fbb-a901-15c3928d4a35" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_39ac2e44-063f-4b77-b9bf-a0670dbcac89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_4868d582-01a4-4c94-a4d0-6313fece0319" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ee678115-c8f9-4c91-913a-e6a0673f325e" xlink:to="loc_us-gaap_OperatingExpensesAbstract_4868d582-01a4-4c94-a4d0-6313fece0319" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_72a6fa7f-7afd-4906-97ae-255b35949f30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4868d582-01a4-4c94-a4d0-6313fece0319" xlink:to="loc_us-gaap_CostOfRevenue_72a6fa7f-7afd-4906-97ae-255b35949f30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f8f861cc-d41a-4ea9-a9b0-98b06a6bfc80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4868d582-01a4-4c94-a4d0-6313fece0319" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f8f861cc-d41a-4ea9-a9b0-98b06a6bfc80" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_4f90ea8d-b670-40ac-9dbe-39d91cfb4b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4868d582-01a4-4c94-a4d0-6313fece0319" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_4f90ea8d-b670-40ac-9dbe-39d91cfb4b2d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_6d4b8899-577b-4784-b64f-99c09f78c112" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4868d582-01a4-4c94-a4d0-6313fece0319" xlink:to="loc_us-gaap_CostsAndExpenses_6d4b8899-577b-4784-b64f-99c09f78c112" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_13214e1a-9520-4819-b230-89a168b82d19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ee678115-c8f9-4c91-913a-e6a0673f325e" xlink:to="loc_us-gaap_OperatingIncomeLoss_13214e1a-9520-4819-b230-89a168b82d19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_58f3096d-a307-4862-a6b6-e95a8766ffd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ee678115-c8f9-4c91-913a-e6a0673f325e" xlink:to="loc_us-gaap_InterestExpense_58f3096d-a307-4862-a6b6-e95a8766ffd1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfAdvanceRoyalty_c38644fd-0daa-428e-98ad-2e75f06d822d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfAdvanceRoyalty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ee678115-c8f9-4c91-913a-e6a0673f325e" xlink:to="loc_us-gaap_AmortizationOfAdvanceRoyalty_c38644fd-0daa-428e-98ad-2e75f06d822d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_15d62242-4ebc-4066-8db1-5393cf57c623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ee678115-c8f9-4c91-913a-e6a0673f325e" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_15d62242-4ebc-4066-8db1-5393cf57c623" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fc2254f3-68cf-4847-b174-1d2fe69f5d13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ee678115-c8f9-4c91-913a-e6a0673f325e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fc2254f3-68cf-4847-b174-1d2fe69f5d13" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_846cf955-8dc5-40bc-b5ff-84eb19091b28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ee678115-c8f9-4c91-913a-e6a0673f325e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_846cf955-8dc5-40bc-b5ff-84eb19091b28" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6bc51903-3993-490b-be98-55520387ba3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ee678115-c8f9-4c91-913a-e6a0673f325e" xlink:to="loc_us-gaap_NetIncomeLoss_6bc51903-3993-490b-be98-55520387ba3e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9484a781-b4cc-4de4-a6c1-fffc570940e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ee678115-c8f9-4c91-913a-e6a0673f325e" xlink:to="loc_us-gaap_EarningsPerShareBasic_9484a781-b4cc-4de4-a6c1-fffc570940e6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_934ae123-5e5c-40cc-bf1c-f6832d3f979e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ee678115-c8f9-4c91-913a-e6a0673f325e" xlink:to="loc_us-gaap_EarningsPerShareDiluted_934ae123-5e5c-40cc-bf1c-f6832d3f979e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b22fd885-eb20-49a1-ad59-60a3626c63a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ee678115-c8f9-4c91-913a-e6a0673f325e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b22fd885-eb20-49a1-ad59-60a3626c63a7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_73d59cd8-efee-4d34-9c9d-e6b886ac8d18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ee678115-c8f9-4c91-913a-e6a0673f325e" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_73d59cd8-efee-4d34-9c9d-e6b886ac8d18" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_947e653b-6135-4ca7-9192-03c874ec9aba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ee678115-c8f9-4c91-913a-e6a0673f325e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_947e653b-6135-4ca7-9192-03c874ec9aba" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_85aec0fb-cd48-49fb-8109-9888ee828fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_085c7654-94f6-4049-b51f-967e92bb832d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_947e653b-6135-4ca7-9192-03c874ec9aba" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_085c7654-94f6-4049-b51f-967e92bb832d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_00a16ea4-41a2-4ec3-8b14-9ee07334bfab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_947e653b-6135-4ca7-9192-03c874ec9aba" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_00a16ea4-41a2-4ec3-8b14-9ee07334bfab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_aaaedf1b-53f7-4000-bbe9-d5db3dcba245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_ee678115-c8f9-4c91-913a-e6a0673f325e" xlink:to="loc_us-gaap_StatementTable_aaaedf1b-53f7-4000-bbe9-d5db3dcba245" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6cad257f-14bf-462a-85f3-9ef85914afc6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_aaaedf1b-53f7-4000-bbe9-d5db3dcba245" xlink:to="loc_srt_ProductOrServiceAxis_6cad257f-14bf-462a-85f3-9ef85914afc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6cad257f-14bf-462a-85f3-9ef85914afc6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_6cad257f-14bf-462a-85f3-9ef85914afc6" xlink:to="loc_srt_ProductsAndServicesDomain_6cad257f-14bf-462a-85f3-9ef85914afc6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_483bd195-fd4b-4348-ac6f-16c9439400e7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_6cad257f-14bf-462a-85f3-9ef85914afc6" xlink:to="loc_srt_ProductsAndServicesDomain_483bd195-fd4b-4348-ac6f-16c9439400e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_fe97a50a-3310-4fef-bc66-ba4c9e530be8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_483bd195-fd4b-4348-ac6f-16c9439400e7" xlink:to="loc_us-gaap_ProductMember_fe97a50a-3310-4fef-bc66-ba4c9e530be8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ProductSupplyRevenueMember_d116de79-d286-4165-8ee4-c77ab889b2f4" xlink:href="ardx-20221231.xsd#ardx_ProductSupplyRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_483bd195-fd4b-4348-ac6f-16c9439400e7" xlink:to="loc_ardx_ProductSupplyRevenueMember_d116de79-d286-4165-8ee4-c77ab889b2f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_cca562d7-da45-4f94-9e85-55b32e826651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_483bd195-fd4b-4348-ac6f-16c9439400e7" xlink:to="loc_us-gaap_LicenseMember_cca562d7-da45-4f94-9e85-55b32e826651" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeDevelopmentMember_aba31cf5-ab60-4545-aa9f-571df42c1fae" xlink:href="ardx-20221231.xsd#ardx_CollaborativeDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_483bd195-fd4b-4348-ac6f-16c9439400e7" xlink:to="loc_ardx_CollaborativeDevelopmentMember_aba31cf5-ab60-4545-aa9f-571df42c1fae" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/STATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="ardx-20221231.xsd#STATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/STATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="ic695dbb27d2141d4afffd502eacc4a69_STATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_29d9d99e-8228-4131-abf5-226586936ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_90073137-ed71-4b17-9484-445e6e933899" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_29d9d99e-8228-4131-abf5-226586936ff2" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_90073137-ed71-4b17-9484-445e6e933899" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_be9e9685-953a-4099-a514-fa4a004f2128" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_90073137-ed71-4b17-9484-445e6e933899" xlink:to="loc_us-gaap_SharesOutstanding_be9e9685-953a-4099-a514-fa4a004f2128" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_89b5e691-646c-4838-bae1-3d9767871f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_90073137-ed71-4b17-9484-445e6e933899" xlink:to="loc_us-gaap_StockholdersEquity_89b5e691-646c-4838-bae1-3d9767871f2e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_74dfb508-d597-4e44-96bc-7f71bad63a07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_90073137-ed71-4b17-9484-445e6e933899" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_74dfb508-d597-4e44-96bc-7f71bad63a07" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_8ff75dae-96cf-4e85-a706-ce172f20940f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_90073137-ed71-4b17-9484-445e6e933899" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_8ff75dae-96cf-4e85-a706-ce172f20940f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_7e03e904-187d-4061-b05b-8c740c61c44d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_90073137-ed71-4b17-9484-445e6e933899" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_7e03e904-187d-4061-b05b-8c740c61c44d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_18066e62-4294-4bfb-80bc-109e87a4f91a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_90073137-ed71-4b17-9484-445e6e933899" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_18066e62-4294-4bfb-80bc-109e87a4f91a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_dd9643e1-6930-4470-9a6e-32a447a6ad71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_90073137-ed71-4b17-9484-445e6e933899" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_dd9643e1-6930-4470-9a6e-32a447a6ad71" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_79e948df-a5a9-424d-84e6-a26c2ae7894b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_90073137-ed71-4b17-9484-445e6e933899" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_79e948df-a5a9-424d-84e6-a26c2ae7894b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_623b5583-c8f7-4824-9c3d-285544e742a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_90073137-ed71-4b17-9484-445e6e933899" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_623b5583-c8f7-4824-9c3d-285544e742a1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_da078c1a-c608-4dcc-aace-d0fd472574a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_90073137-ed71-4b17-9484-445e6e933899" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_da078c1a-c608-4dcc-aace-d0fd472574a5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1621ca0c-d6c3-4ec4-906f-a647df21cf41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_90073137-ed71-4b17-9484-445e6e933899" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1621ca0c-d6c3-4ec4-906f-a647df21cf41" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e9788343-3a2b-4b70-ad26-549f3fbd80d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_90073137-ed71-4b17-9484-445e6e933899" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e9788343-3a2b-4b70-ad26-549f3fbd80d5" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fd3690e1-9251-4a21-8350-fd5a71e305ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_90073137-ed71-4b17-9484-445e6e933899" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fd3690e1-9251-4a21-8350-fd5a71e305ae" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_cff8071f-db66-4d6f-a961-686d06ea68b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_90073137-ed71-4b17-9484-445e6e933899" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_cff8071f-db66-4d6f-a961-686d06ea68b2" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9272234b-8e55-475d-8ee3-5b1f2ff64a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_90073137-ed71-4b17-9484-445e6e933899" xlink:to="loc_us-gaap_NetIncomeLoss_9272234b-8e55-475d-8ee3-5b1f2ff64a6f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_69080bba-f2f2-461f-9486-7a5c4e80fe95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d62982dd-3ff7-4fc9-b7f0-a1ddf06af18c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b09d8f49-41e2-4c37-8c05-19f84df9825f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_29d9d99e-8228-4131-abf5-226586936ff2" xlink:to="loc_us-gaap_StatementTable_b09d8f49-41e2-4c37-8c05-19f84df9825f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_39478a9c-e5a0-4139-b23e-b9d3326aefbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b09d8f49-41e2-4c37-8c05-19f84df9825f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_39478a9c-e5a0-4139-b23e-b9d3326aefbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_39478a9c-e5a0-4139-b23e-b9d3326aefbd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_39478a9c-e5a0-4139-b23e-b9d3326aefbd" xlink:to="loc_us-gaap_EquityComponentDomain_39478a9c-e5a0-4139-b23e-b9d3326aefbd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a02f2a06-29b1-48b6-a556-5cccc51621e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_39478a9c-e5a0-4139-b23e-b9d3326aefbd" xlink:to="loc_us-gaap_EquityComponentDomain_a02f2a06-29b1-48b6-a556-5cccc51621e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_015a72ff-d151-4f23-bb87-6ea6bf02a0fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a02f2a06-29b1-48b6-a556-5cccc51621e0" xlink:to="loc_us-gaap_CommonStockMember_015a72ff-d151-4f23-bb87-6ea6bf02a0fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_948cd317-9a59-4863-a76d-49424feb40f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a02f2a06-29b1-48b6-a556-5cccc51621e0" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_948cd317-9a59-4863-a76d-49424feb40f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_af06d53c-557b-4141-8161-09b0a66d9ead" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a02f2a06-29b1-48b6-a556-5cccc51621e0" xlink:to="loc_us-gaap_RetainedEarningsMember_af06d53c-557b-4141-8161-09b0a66d9ead" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c7b63c67-5599-4e10-965e-5310387ecead" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a02f2a06-29b1-48b6-a556-5cccc51621e0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c7b63c67-5599-4e10-965e-5310387ecead" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#SummaryofSignificantAccountingPoliciesAccountsReceivableDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails" xlink:type="extended" id="ib5526ce0647f4f8ba93fc8f426156262_SummaryofSignificantAccountingPoliciesAccountsReceivableDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8354bcda-62a7-47d7-a48a-b8d0ac2f29dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_e635f0e9-2b4b-451b-aa79-020736be2e87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8354bcda-62a7-47d7-a48a-b8d0ac2f29dd" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_e635f0e9-2b4b-451b-aa79-020736be2e87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_526ee5d1-9a20-4da7-a1a7-42071967cb56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8354bcda-62a7-47d7-a48a-b8d0ac2f29dd" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_526ee5d1-9a20-4da7-a1a7-42071967cb56" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_412ceb56-06bb-4ffa-9755-b847a35c2a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_526ee5d1-9a20-4da7-a1a7-42071967cb56" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_412ceb56-06bb-4ffa-9755-b847a35c2a9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_412ceb56-06bb-4ffa-9755-b847a35c2a9b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_412ceb56-06bb-4ffa-9755-b847a35c2a9b" xlink:to="loc_us-gaap_ReceivableTypeDomain_412ceb56-06bb-4ffa-9755-b847a35c2a9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_316a51bc-d621-4a52-97ab-d72369276fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_412ceb56-06bb-4ffa-9755-b847a35c2a9b" xlink:to="loc_us-gaap_ReceivableTypeDomain_316a51bc-d621-4a52-97ab-d72369276fc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AccountsReceivableCollaboratorMember_14ca9b05-8a43-4f40-ad5e-c3158dff3727" xlink:href="ardx-20221231.xsd#ardx_AccountsReceivableCollaboratorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_316a51bc-d621-4a52-97ab-d72369276fc1" xlink:to="loc_ardx_AccountsReceivableCollaboratorMember_14ca9b05-8a43-4f40-ad5e-c3158dff3727" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AccountsReceivableCommercialCustomerMember_3af7d142-cdd3-499d-b6c3-4f2725145390" xlink:href="ardx-20221231.xsd#ardx_AccountsReceivableCommercialCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_316a51bc-d621-4a52-97ab-d72369276fc1" xlink:to="loc_ardx_AccountsReceivableCommercialCustomerMember_3af7d142-cdd3-499d-b6c3-4f2725145390" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="i01d40bd1489c48869b626367989dc14e_SummaryofSignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f0d64bcb-3325-4583-b9ca-e751eefd00fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_670a8e6c-9dd5-423d-b519-64597020fa3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f0d64bcb-3325-4583-b9ca-e751eefd00fa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_670a8e6c-9dd5-423d-b519-64597020fa3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_7359899d-a55b-4249-a33e-3c2660159ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f0d64bcb-3325-4583-b9ca-e751eefd00fa" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_7359899d-a55b-4249-a33e-3c2660159ef2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_RevenueGeneralPaymentTerms_fa513bdb-8624-4b28-98e5-2db7759a7d16" xlink:href="ardx-20221231.xsd#ardx_RevenueGeneralPaymentTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f0d64bcb-3325-4583-b9ca-e751eefd00fa" xlink:to="loc_ardx_RevenueGeneralPaymentTerms_fa513bdb-8624-4b28-98e5-2db7759a7d16" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PercentageOfRoyaltyRevenue_4444674a-ed06-4950-a848-eefa2d3b3a0f" xlink:href="ardx-20221231.xsd#ardx_PercentageOfRoyaltyRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f0d64bcb-3325-4583-b9ca-e751eefd00fa" xlink:to="loc_ardx_PercentageOfRoyaltyRevenue_4444674a-ed06-4950-a848-eefa2d3b3a0f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PercentageOfNonRoyaltyRevenue_31bba6ca-20dc-4c4d-bca3-f5936fee9cab" xlink:href="ardx-20221231.xsd#ardx_PercentageOfNonRoyaltyRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f0d64bcb-3325-4583-b9ca-e751eefd00fa" xlink:to="loc_ardx_PercentageOfNonRoyaltyRevenue_31bba6ca-20dc-4c4d-bca3-f5936fee9cab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_cf383755-f3ee-4095-9241-bb34ee8bdd1c" xlink:href="ardx-20221231.xsd#ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f0d64bcb-3325-4583-b9ca-e751eefd00fa" xlink:to="loc_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_cf383755-f3ee-4095-9241-bb34ee8bdd1c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CostOfRevenueAggregateAmountRecognized_530f3c64-b6f6-4d93-a55e-b67d63ca992e" xlink:href="ardx-20221231.xsd#ardx_CostOfRevenueAggregateAmountRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f0d64bcb-3325-4583-b9ca-e751eefd00fa" xlink:to="loc_ardx_CostOfRevenueAggregateAmountRecognized_530f3c64-b6f6-4d93-a55e-b67d63ca992e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_201c9e88-7a5d-4ab0-91a8-c641d6a7901d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f0d64bcb-3325-4583-b9ca-e751eefd00fa" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_201c9e88-7a5d-4ab0-91a8-c641d6a7901d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_053edd1b-c166-47c0-a2b7-da6a3b2634af" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_201c9e88-7a5d-4ab0-91a8-c641d6a7901d" xlink:to="loc_srt_CounterpartyNameAxis_053edd1b-c166-47c0-a2b7-da6a3b2634af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_053edd1b-c166-47c0-a2b7-da6a3b2634af_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_053edd1b-c166-47c0-a2b7-da6a3b2634af" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_053edd1b-c166-47c0-a2b7-da6a3b2634af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a4d8e7b1-0652-4bcc-8b36-0bc0674c62c8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_053edd1b-c166-47c0-a2b7-da6a3b2634af" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a4d8e7b1-0652-4bcc-8b36-0bc0674c62c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AstrazenecaMember_2d6357ef-3baa-4c5a-8ea6-e5b2f497ef91" xlink:href="ardx-20221231.xsd#ardx_AstrazenecaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a4d8e7b1-0652-4bcc-8b36-0bc0674c62c8" xlink:to="loc_ardx_AstrazenecaMember_2d6357ef-3baa-4c5a-8ea6-e5b2f497ef91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3bc8d87d-aab9-4bb7-99da-f417c257716c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_201c9e88-7a5d-4ab0-91a8-c641d6a7901d" xlink:to="loc_srt_RangeAxis_3bc8d87d-aab9-4bb7-99da-f417c257716c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3bc8d87d-aab9-4bb7-99da-f417c257716c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3bc8d87d-aab9-4bb7-99da-f417c257716c" xlink:to="loc_srt_RangeMember_3bc8d87d-aab9-4bb7-99da-f417c257716c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_33a29281-059b-43cd-8401-f358d504fd00" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3bc8d87d-aab9-4bb7-99da-f417c257716c" xlink:to="loc_srt_RangeMember_33a29281-059b-43cd-8401-f358d504fd00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_05618426-b5ce-48ed-bc38-59a75cc43cfa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_33a29281-059b-43cd-8401-f358d504fd00" xlink:to="loc_srt_MinimumMember_05618426-b5ce-48ed-bc38-59a75cc43cfa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8ecafed1-48f7-489b-8461-8b8bfbf3dee1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_33a29281-059b-43cd-8401-f358d504fd00" xlink:to="loc_srt_MaximumMember_8ecafed1-48f7-489b-8461-8b8bfbf3dee1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5e9f5f6d-140f-4c1e-ac2e-9b87ebedd593" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_201c9e88-7a5d-4ab0-91a8-c641d6a7901d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5e9f5f6d-140f-4c1e-ac2e-9b87ebedd593" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5e9f5f6d-140f-4c1e-ac2e-9b87ebedd593_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5e9f5f6d-140f-4c1e-ac2e-9b87ebedd593" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5e9f5f6d-140f-4c1e-ac2e-9b87ebedd593_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76a7ba8c-02d0-44d3-a6dc-7f4385836252" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5e9f5f6d-140f-4c1e-ac2e-9b87ebedd593" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76a7ba8c-02d0-44d3-a6dc-7f4385836252" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AstraZenecaTerminationAgreementMember_9f98da45-e29d-4b75-8bd6-7ea7ad3211a5" xlink:href="ardx-20221231.xsd#ardx_AstraZenecaTerminationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76a7ba8c-02d0-44d3-a6dc-7f4385836252" xlink:to="loc_ardx_AstraZenecaTerminationAgreementMember_9f98da45-e29d-4b75-8bd6-7ea7ad3211a5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails" xlink:type="extended" id="i1ff384b194c14216ab52702aaca50f50_CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e95773ec-5ff5-4947-bab6-70003b04f7dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_00aa799e-aaee-45dd-a111-08bfc57ea7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e95773ec-5ff5-4947-bab6-70003b04f7dc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_00aa799e-aaee-45dd-a111-08bfc57ea7dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d74d43b0-6391-4c62-b5af-ad6687e18a71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_00aa799e-aaee-45dd-a111-08bfc57ea7dd" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d74d43b0-6391-4c62-b5af-ad6687e18a71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_991f6a3f-b865-4d88-a85c-f42d3eb207d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e95773ec-5ff5-4947-bab6-70003b04f7dc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_991f6a3f-b865-4d88-a85c-f42d3eb207d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fbdd5a6c-ef3f-4a21-8f34-af62101d01ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_991f6a3f-b865-4d88-a85c-f42d3eb207d9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fbdd5a6c-ef3f-4a21-8f34-af62101d01ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8c8696e8-c5ee-458d-b142-c746c5cd580c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_991f6a3f-b865-4d88-a85c-f42d3eb207d9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8c8696e8-c5ee-458d-b142-c746c5cd580c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7f6f48ca-68f0-425c-a161-27f8e099a4be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_991f6a3f-b865-4d88-a85c-f42d3eb207d9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7f6f48ca-68f0-425c-a161-27f8e099a4be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ce2d5b9e-00f5-4334-b6ed-3f8f0c7bf051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_991f6a3f-b865-4d88-a85c-f42d3eb207d9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ce2d5b9e-00f5-4334-b6ed-3f8f0c7bf051" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_InvestmentsAndCashAmortizedCost_4b6b11b4-08dd-4f9e-9db5-063a16938904" xlink:href="ardx-20221231.xsd#ardx_InvestmentsAndCashAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e95773ec-5ff5-4947-bab6-70003b04f7dc" xlink:to="loc_ardx_InvestmentsAndCashAmortizedCost_4b6b11b4-08dd-4f9e-9db5-063a16938904" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains_8fb752cf-c34b-4be2-a6ff-d625d41b0572" xlink:href="ardx-20221231.xsd#ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e95773ec-5ff5-4947-bab6-70003b04f7dc" xlink:to="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains_8fb752cf-c34b-4be2-a6ff-d625d41b0572" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses_3224b89d-7f3d-4047-a4b8-64dddb8a1bb5" xlink:href="ardx-20221231.xsd#ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e95773ec-5ff5-4947-bab6-70003b04f7dc" xlink:to="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses_3224b89d-7f3d-4047-a4b8-64dddb8a1bb5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_1ee52ede-87e1-4be5-93ca-586475fe6979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e95773ec-5ff5-4947-bab6-70003b04f7dc" xlink:to="loc_us-gaap_InvestmentsAndCash_1ee52ede-87e1-4be5-93ca-586475fe6979" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c45cf9dc-1050-4b64-b413-52c892ee7c86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e95773ec-5ff5-4947-bab6-70003b04f7dc" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c45cf9dc-1050-4b64-b413-52c892ee7c86" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_bcdcaaba-c3fb-4873-8b3e-cbda66158881" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c45cf9dc-1050-4b64-b413-52c892ee7c86" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_bcdcaaba-c3fb-4873-8b3e-cbda66158881" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_bcdcaaba-c3fb-4873-8b3e-cbda66158881_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_bcdcaaba-c3fb-4873-8b3e-cbda66158881" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_bcdcaaba-c3fb-4873-8b3e-cbda66158881_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ed9dc261-93eb-4319-9bc5-172664e4a3e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_bcdcaaba-c3fb-4873-8b3e-cbda66158881" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ed9dc261-93eb-4319-9bc5-172664e4a3e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_6f2b5655-5dbf-409e-b281-e05eebc9ca8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ed9dc261-93eb-4319-9bc5-172664e4a3e4" xlink:to="loc_us-gaap_CashMember_6f2b5655-5dbf-409e-b281-e05eebc9ca8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_e6c1790f-b470-4e58-83c3-7490b95c1e49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ed9dc261-93eb-4319-9bc5-172664e4a3e4" xlink:to="loc_us-gaap_MoneyMarketFundsMember_e6c1790f-b470-4e58-83c3-7490b95c1e49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_91b6df5c-71d9-4404-996e-62dea127bd15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ed9dc261-93eb-4319-9bc5-172664e4a3e4" xlink:to="loc_us-gaap_CommercialPaperMember_91b6df5c-71d9-4404-996e-62dea127bd15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CorporateBondsMember_a765aac7-07bb-4c3c-b287-b3a65e43d1f8" xlink:href="ardx-20221231.xsd#ardx_CorporateBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ed9dc261-93eb-4319-9bc5-172664e4a3e4" xlink:to="loc_ardx_CorporateBondsMember_a765aac7-07bb-4c3c-b287-b3a65e43d1f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_898f96e6-07ee-4cd0-ab83-b9d5e71cf68f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c45cf9dc-1050-4b64-b413-52c892ee7c86" xlink:to="loc_us-gaap_FinancialInstrumentAxis_898f96e6-07ee-4cd0-ab83-b9d5e71cf68f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_898f96e6-07ee-4cd0-ab83-b9d5e71cf68f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_898f96e6-07ee-4cd0-ab83-b9d5e71cf68f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_898f96e6-07ee-4cd0-ab83-b9d5e71cf68f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eef6a71b-7246-4152-8bd7-643619f71ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_898f96e6-07ee-4cd0-ab83-b9d5e71cf68f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eef6a71b-7246-4152-8bd7-643619f71ce8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_a0919206-0ab4-434d-94d2-aa6abc1ed1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eef6a71b-7246-4152-8bd7-643619f71ce8" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_a0919206-0ab4-434d-94d2-aa6abc1ed1f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_5397f66f-3a0f-4ea4-ad6a-2a5d3f954f20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eef6a71b-7246-4152-8bd7-643619f71ce8" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_5397f66f-3a0f-4ea4-ad6a-2a5d3f954f20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_d4a6e79e-41a3-4bd7-8227-a810eea1bf2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eef6a71b-7246-4152-8bd7-643619f71ce8" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_d4a6e79e-41a3-4bd7-8227-a810eea1bf2d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_410c42a7-870e-44dc-9350-a2a4cc699cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eef6a71b-7246-4152-8bd7-643619f71ce8" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_410c42a7-870e-44dc-9350-a2a4cc699cfe" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="extended" id="ia37ca8206dc94da2b6e9fcfca6b410e6_FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_010043cb-e043-4492-8264-693f9dfe53cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_0cf9d423-a155-4e60-bac4-578170af875a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_010043cb-e043-4492-8264-693f9dfe53cc" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_0cf9d423-a155-4e60-bac4-578170af875a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_d0c0db04-b1a9-49bb-82ba-4bf7ac419b73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0cf9d423-a155-4e60-bac4-578170af875a" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_d0c0db04-b1a9-49bb-82ba-4bf7ac419b73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_41e8014e-4653-4b5e-9cb4-957386853ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_010043cb-e043-4492-8264-693f9dfe53cc" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_41e8014e-4653-4b5e-9cb4-957386853ac6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_7121bd52-67d8-4aef-bac3-e94ef168c6b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_41e8014e-4653-4b5e-9cb4-957386853ac6" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_7121bd52-67d8-4aef-bac3-e94ef168c6b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6ddbf0e5-8b56-48bc-b42b-64bfde3e348e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_010043cb-e043-4492-8264-693f9dfe53cc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6ddbf0e5-8b56-48bc-b42b-64bfde3e348e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0d90397e-097f-441a-9b99-1476169b8caf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6ddbf0e5-8b56-48bc-b42b-64bfde3e348e" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0d90397e-097f-441a-9b99-1476169b8caf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0d90397e-097f-441a-9b99-1476169b8caf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0d90397e-097f-441a-9b99-1476169b8caf" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0d90397e-097f-441a-9b99-1476169b8caf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e5e6b756-49fd-493d-812c-da46b1cf73fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0d90397e-097f-441a-9b99-1476169b8caf" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e5e6b756-49fd-493d-812c-da46b1cf73fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_38f96ce6-a488-48d5-b921-479278d6728e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e5e6b756-49fd-493d-812c-da46b1cf73fa" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_38f96ce6-a488-48d5-b921-479278d6728e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c5d9c6cc-57a6-4268-bab8-b18ad9c9c9af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6ddbf0e5-8b56-48bc-b42b-64bfde3e348e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c5d9c6cc-57a6-4268-bab8-b18ad9c9c9af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c5d9c6cc-57a6-4268-bab8-b18ad9c9c9af_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c5d9c6cc-57a6-4268-bab8-b18ad9c9c9af" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c5d9c6cc-57a6-4268-bab8-b18ad9c9c9af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f0118d97-a814-40af-af58-f58d5754b679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c5d9c6cc-57a6-4268-bab8-b18ad9c9c9af" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f0118d97-a814-40af-af58-f58d5754b679" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_429839fa-b262-4144-8b92-0f19fcfd6ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f0118d97-a814-40af-af58-f58d5754b679" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_429839fa-b262-4144-8b92-0f19fcfd6ef9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_31d8e350-50ce-4cea-912c-7c73c4e9918e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f0118d97-a814-40af-af58-f58d5754b679" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_31d8e350-50ce-4cea-912c-7c73c4e9918e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2cbeca36-36e3-447a-bdce-fefb2cd555a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f0118d97-a814-40af-af58-f58d5754b679" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2cbeca36-36e3-447a-bdce-fefb2cd555a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_4aa22267-c2d6-43a5-b510-dff96943f3d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6ddbf0e5-8b56-48bc-b42b-64bfde3e348e" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_4aa22267-c2d6-43a5-b510-dff96943f3d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_4aa22267-c2d6-43a5-b510-dff96943f3d7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_4aa22267-c2d6-43a5-b510-dff96943f3d7" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_4aa22267-c2d6-43a5-b510-dff96943f3d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_65ef96b0-759b-4225-b986-4152af2ddca4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_4aa22267-c2d6-43a5-b510-dff96943f3d7" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_65ef96b0-759b-4225-b986-4152af2ddca4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_57bee55c-0310-400a-b13c-d02efc644ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_65ef96b0-759b-4225-b986-4152af2ddca4" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_57bee55c-0310-400a-b13c-d02efc644ba7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_b849591b-d807-4478-b378-2b9b690b890f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6ddbf0e5-8b56-48bc-b42b-64bfde3e348e" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_b849591b-d807-4478-b378-2b9b690b890f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b849591b-d807-4478-b378-2b9b690b890f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_b849591b-d807-4478-b378-2b9b690b890f" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b849591b-d807-4478-b378-2b9b690b890f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_06ebbd81-db6b-43ea-9d94-cbac5b193577" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_b849591b-d807-4478-b378-2b9b690b890f" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_06ebbd81-db6b-43ea-9d94-cbac5b193577" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_9f035aec-a876-4fa4-8bbe-a0e255636a61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_06ebbd81-db6b-43ea-9d94-cbac5b193577" xlink:to="loc_us-gaap_MoneyMarketFundsMember_9f035aec-a876-4fa4-8bbe-a0e255636a61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_fc852a3e-6cdd-40a2-8b52-1d86282d3c69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_06ebbd81-db6b-43ea-9d94-cbac5b193577" xlink:to="loc_us-gaap_CommercialPaperMember_fc852a3e-6cdd-40a2-8b52-1d86282d3c69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_d289e19c-6d63-4638-9f57-9b28e27d879e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_06ebbd81-db6b-43ea-9d94-cbac5b193577" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_d289e19c-6d63-4638-9f57-9b28e27d879e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_b156c8ee-b8c1-415f-bf9c-fc85ce6b4a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_06ebbd81-db6b-43ea-9d94-cbac5b193577" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_b156c8ee-b8c1-415f-bf9c-fc85ce6b4a8e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_54c84b7d-d9f5-4b8e-9487-bb499e585e66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_06ebbd81-db6b-43ea-9d94-cbac5b193577" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_54c84b7d-d9f5-4b8e-9487-bb499e585e66" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#ProductRevenueNetNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails" xlink:type="extended" id="ie8b3228bd49a40d49c29ec8be8649c17_ProductRevenueNetNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_eeafd150-d909-4089-8543-7e3133eface0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0f6a3081-8eba-422a-90c2-6a80b69e91ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_eeafd150-d909-4089-8543-7e3133eface0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0f6a3081-8eba-422a-90c2-6a80b69e91ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_bb75afeb-f71f-471e-a93b-5522e9b9d0b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_eeafd150-d909-4089-8543-7e3133eface0" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_bb75afeb-f71f-471e-a93b-5522e9b9d0b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerProductSalesGrossToNetAccruals_27a05eb2-df8a-40ef-a58c-a772a78c6039" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerProductSalesGrossToNetAccruals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_eeafd150-d909-4089-8543-7e3133eface0" xlink:to="loc_ardx_ContractWithCustomerProductSalesGrossToNetAccruals_27a05eb2-df8a-40ef-a58c-a772a78c6039" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b247828b-484c-4f10-a9ea-c408dfa0d78c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_eeafd150-d909-4089-8543-7e3133eface0" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b247828b-484c-4f10-a9ea-c408dfa0d78c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4d6059a9-2651-43b8-9110-b08b8806d91d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b247828b-484c-4f10-a9ea-c408dfa0d78c" xlink:to="loc_srt_ProductOrServiceAxis_4d6059a9-2651-43b8-9110-b08b8806d91d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4d6059a9-2651-43b8-9110-b08b8806d91d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4d6059a9-2651-43b8-9110-b08b8806d91d" xlink:to="loc_srt_ProductsAndServicesDomain_4d6059a9-2651-43b8-9110-b08b8806d91d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c682e7d3-3e23-4e02-b56d-011745fd0b1d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4d6059a9-2651-43b8-9110-b08b8806d91d" xlink:to="loc_srt_ProductsAndServicesDomain_c682e7d3-3e23-4e02-b56d-011745fd0b1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ProductIBSRELAMember_64fcf76c-1d8e-4f78-af7a-340c7ac94cff" xlink:href="ardx-20221231.xsd#ardx_ProductIBSRELAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c682e7d3-3e23-4e02-b56d-011745fd0b1d" xlink:to="loc_ardx_ProductIBSRELAMember_64fcf76c-1d8e-4f78-af7a-340c7ac94cff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_bdd0fa00-d3a3-47c7-8b3e-cbb68a850589" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c682e7d3-3e23-4e02-b56d-011745fd0b1d" xlink:to="loc_us-gaap_ProductMember_bdd0fa00-d3a3-47c7-8b3e-cbb68a850589" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_070028b0-082e-41f1-8fcb-b05ad26cfa70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b247828b-484c-4f10-a9ea-c408dfa0d78c" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_070028b0-082e-41f1-8fcb-b05ad26cfa70" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_070028b0-082e-41f1-8fcb-b05ad26cfa70_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_070028b0-082e-41f1-8fcb-b05ad26cfa70" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_070028b0-082e-41f1-8fcb-b05ad26cfa70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_998e1898-0546-45c9-ae79-981e187ebcca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_070028b0-082e-41f1-8fcb-b05ad26cfa70" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_998e1898-0546-45c9-ae79-981e187ebcca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueProductLineMember_5eaaecbd-7fde-40dd-8604-04957e87325e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_998e1898-0546-45c9-ae79-981e187ebcca" xlink:to="loc_us-gaap_SalesRevenueProductLineMember_5eaaecbd-7fde-40dd-8604-04957e87325e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_6ad3fbd6-c447-4ad7-a2d3-9fa96c27767f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b247828b-484c-4f10-a9ea-c408dfa0d78c" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_6ad3fbd6-c447-4ad7-a2d3-9fa96c27767f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_6ad3fbd6-c447-4ad7-a2d3-9fa96c27767f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_6ad3fbd6-c447-4ad7-a2d3-9fa96c27767f" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_6ad3fbd6-c447-4ad7-a2d3-9fa96c27767f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_014b503e-5c3d-4053-8e95-0b5c447d7efb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_6ad3fbd6-c447-4ad7-a2d3-9fa96c27767f" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_014b503e-5c3d-4053-8e95-0b5c447d7efb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_3bad6929-0529-4bd9-a9fe-6951700de37d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_014b503e-5c3d-4053-8e95-0b5c447d7efb" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_3bad6929-0529-4bd9-a9fe-6951700de37d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_b24515eb-7f43-4d6b-99e1-b747d2c68ee0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b247828b-484c-4f10-a9ea-c408dfa0d78c" xlink:to="loc_srt_MajorCustomersAxis_b24515eb-7f43-4d6b-99e1-b747d2c68ee0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b24515eb-7f43-4d6b-99e1-b747d2c68ee0_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_b24515eb-7f43-4d6b-99e1-b747d2c68ee0" xlink:to="loc_srt_NameOfMajorCustomerDomain_b24515eb-7f43-4d6b-99e1-b747d2c68ee0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_4a541c2e-dfeb-499e-be87-7dc17bfab2bd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_b24515eb-7f43-4d6b-99e1-b747d2c68ee0" xlink:to="loc_srt_NameOfMajorCustomerDomain_4a541c2e-dfeb-499e-be87-7dc17bfab2bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AmerisourceBergenDrugCorporationMember_af739f30-ebac-4ebc-b2a0-44c513a1c127" xlink:href="ardx-20221231.xsd#ardx_AmerisourceBergenDrugCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_4a541c2e-dfeb-499e-be87-7dc17bfab2bd" xlink:to="loc_ardx_AmerisourceBergenDrugCorporationMember_af739f30-ebac-4ebc-b2a0-44c513a1c127" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CardinalHealthMember_56492d1c-2581-45d6-bda6-90383ae3856a" xlink:href="ardx-20221231.xsd#ardx_CardinalHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_4a541c2e-dfeb-499e-be87-7dc17bfab2bd" xlink:to="loc_ardx_CardinalHealthMember_56492d1c-2581-45d6-bda6-90383ae3856a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_McKessonCorporationMember_ee907502-4b9a-4b8c-b6f0-1331e53279f0" xlink:href="ardx-20221231.xsd#ardx_McKessonCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_4a541c2e-dfeb-499e-be87-7dc17bfab2bd" xlink:to="loc_ardx_McKessonCorporationMember_ee907502-4b9a-4b8c-b6f0-1331e53279f0" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#ProductRevenueNetGrosstoNetSalesAccrualsDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails" xlink:type="extended" id="ie2b71d8ae6784edfbc1a6538d89fecaf_ProductRevenueNetGrosstoNetSalesAccrualsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_01d044ff-d857-4455-8f93-fa7819f1e69a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_994ce6b5-774f-4dfb-9cf1-b7f7d4cc091b" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_01d044ff-d857-4455-8f93-fa7819f1e69a" xlink:to="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_994ce6b5-774f-4dfb-9cf1-b7f7d4cc091b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesAccruals_c5093e67-f1d7-4f6e-b096-5585ebca5f45" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerGrossToNetSalesAccruals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_994ce6b5-774f-4dfb-9cf1-b7f7d4cc091b" xlink:to="loc_ardx_ContractWithCustomerGrossToNetSalesAccruals_c5093e67-f1d7-4f6e-b096-5585ebca5f45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod_d767bf8d-0a80-4f05-8b3b-b80dd2951168" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_994ce6b5-774f-4dfb-9cf1-b7f7d4cc091b" xlink:to="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod_d767bf8d-0a80-4f05-8b3b-b80dd2951168" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued_b29c913d-623c-4fcc-8ce0-2c6e629da6e8" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_994ce6b5-774f-4dfb-9cf1-b7f7d4cc091b" xlink:to="loc_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued_b29c913d-623c-4fcc-8ce0-2c6e629da6e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesAccruals_78731271-7b09-4e94-97e2-66421afec68c" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerGrossToNetSalesAccruals"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_28472aab-70bd-468d-84b6-98fdafb06e40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_01d044ff-d857-4455-8f93-fa7819f1e69a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_28472aab-70bd-468d-84b6-98fdafb06e40" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis_b04c7035-40bc-4139-89d8-62420282d828" xlink:href="ardx-20221231.xsd#ardx_GrossToNetSalesAccrualAndReserveClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_28472aab-70bd-468d-84b6-98fdafb06e40" xlink:to="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis_b04c7035-40bc-4139-89d8-62420282d828" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_b04c7035-40bc-4139-89d8-62420282d828_default" xlink:href="ardx-20221231.xsd#ardx_GrossToNetSalesAccrualAndReserveClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis_b04c7035-40bc-4139-89d8-62420282d828" xlink:to="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_b04c7035-40bc-4139-89d8-62420282d828_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_5e35b3c2-c590-4a75-8f09-ad26761cff9b" xlink:href="ardx-20221231.xsd#ardx_GrossToNetSalesAccrualAndReserveClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis_b04c7035-40bc-4139-89d8-62420282d828" xlink:to="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_5e35b3c2-c590-4a75-8f09-ad26761cff9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerDiscountsAndChargebacksMember_6ba4a612-9313-4421-8737-bb29d6561bea" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerDiscountsAndChargebacksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_5e35b3c2-c590-4a75-8f09-ad26761cff9b" xlink:to="loc_ardx_ContractWithCustomerDiscountsAndChargebacksMember_6ba4a612-9313-4421-8737-bb29d6561bea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerRebatesWholesalerAndGPOFeesMember_51b6cb35-c317-49a0-b69b-9a41eacaa90c" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerRebatesWholesalerAndGPOFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_5e35b3c2-c590-4a75-8f09-ad26761cff9b" xlink:to="loc_ardx_ContractWithCustomerRebatesWholesalerAndGPOFeesMember_51b6cb35-c317-49a0-b69b-9a41eacaa90c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerCopayAndReturnsMember_cdf91a9f-69b3-4ca6-89ac-664f6d00cd93" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerCopayAndReturnsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_5e35b3c2-c590-4a75-8f09-ad26761cff9b" xlink:to="loc_ardx_ContractWithCustomerCopayAndReturnsMember_cdf91a9f-69b3-4ca6-89ac-664f6d00cd93" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#CollaborationandLicensingAgreementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails" xlink:type="extended" id="i1e1f877373fa417f961f4c66d0ab4270_CollaborationandLicensingAgreementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_NumberOfSeparateCollaborativeAgreements_cf093b36-e000-49e6-9bfd-c26c9635018e" xlink:href="ardx-20221231.xsd#ardx_NumberOfSeparateCollaborativeAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:to="loc_ardx_NumberOfSeparateCollaborativeAgreements_cf093b36-e000-49e6-9bfd-c26c9635018e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees_abbeed16-a0f5-4c0f-b4de-8c0ad58248a7" xlink:href="ardx-20221231.xsd#ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:to="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees_abbeed16-a0f5-4c0f-b4de-8c0ad58248a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment_37c89bd8-fc3d-4b28-aa54-c6108f32093b" xlink:href="ardx-20221231.xsd#ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:to="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment_37c89bd8-fc3d-4b28-aa54-c6108f32093b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermOfPaymentOfLicenseFeeFirstInstallment_e099868b-43a7-468f-98ee-9f132313c9cc" xlink:href="ardx-20221231.xsd#ardx_TermOfPaymentOfLicenseFeeFirstInstallment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:to="loc_ardx_TermOfPaymentOfLicenseFeeFirstInstallment_e099868b-43a7-468f-98ee-9f132313c9cc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment_488187dd-59a6-45e9-a38d-163533c11c44" xlink:href="ardx-20221231.xsd#ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:to="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment_488187dd-59a6-45e9-a38d-163533c11c44" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermOfAgreement_d9143395-4f30-4ade-bdc6-ba0cb1101d8d" xlink:href="ardx-20221231.xsd#ardx_TermOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:to="loc_ardx_TermOfAgreement_d9143395-4f30-4ade-bdc6-ba0cb1101d8d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsNumberOfAmendments_55f09cdb-c9b0-495a-af47-1d54767efe57" xlink:href="ardx-20221231.xsd#ardx_CollaborationAndLicensingAgreementsNumberOfAmendments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:to="loc_ardx_CollaborationAndLicensingAgreementsNumberOfAmendments_55f09cdb-c9b0-495a-af47-1d54767efe57" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cfc1e05b-e6d5-4730-8273-2ed7f60cfebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cfc1e05b-e6d5-4730-8273-2ed7f60cfebe" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4c3903be-3918-40d0-8781-5038552e99ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4c3903be-3918-40d0-8781-5038552e99ac" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialDevelopmentMilestones_b74d2d9f-221c-4ca8-9c29-39017d6d6136" xlink:href="ardx-20221231.xsd#ardx_CollaborativeArrangementPotentialDevelopmentMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:to="loc_ardx_CollaborativeArrangementPotentialDevelopmentMilestones_b74d2d9f-221c-4ca8-9c29-39017d6d6136" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialCommercializationMilestones_53465d49-764f-4e1a-99eb-18ba39109349" xlink:href="ardx-20221231.xsd#ardx_CollaborativeArrangementPotentialCommercializationMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:to="loc_ardx_CollaborativeArrangementPotentialCommercializationMilestones_53465d49-764f-4e1a-99eb-18ba39109349" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate_22676d3c-037c-490f-9720-0bf61d3d0c39" xlink:href="ardx-20221231.xsd#ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:to="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate_22676d3c-037c-490f-9720-0bf61d3d0c39" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches_2b7b87c3-1de3-48f5-b0c5-d9fe286f0a7c" xlink:href="ardx-20221231.xsd#ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:to="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches_2b7b87c3-1de3-48f5-b0c5-d9fe286f0a7c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_RevenueRemainingPerformanceObligationVariableConsiderationAmount_75572e06-f00e-416a-980e-5127035ed597" xlink:href="ardx-20221231.xsd#ardx_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:to="loc_ardx_RevenueRemainingPerformanceObligationVariableConsiderationAmount_75572e06-f00e-416a-980e-5127035ed597" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived_09544d01-42a0-478e-b313-8c85a1e261ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLicenseFeesReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:to="loc_us-gaap_ProceedsFromLicenseFeesReceived_09544d01-42a0-478e-b313-8c85a1e261ea" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones_8807f334-0ee8-4542-a4c5-63af43722efc" xlink:href="ardx-20221231.xsd#ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:to="loc_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones_8807f334-0ee8-4542-a4c5-63af43722efc" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ThresholdPercentageOfSalesForTieredRoyalties_acdc1dde-cfec-4fd4-82dd-6007c8083a09" xlink:href="ardx-20221231.xsd#ardx_ThresholdPercentageOfSalesForTieredRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:to="loc_ardx_ThresholdPercentageOfSalesForTieredRoyalties_acdc1dde-cfec-4fd4-82dd-6007c8083a09" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PercentageOfRoyaltyRevenue_a53ecf24-dd69-4290-9c9b-d915aa2b7d4a" xlink:href="ardx-20221231.xsd#ardx_PercentageOfRoyaltyRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:to="loc_ardx_PercentageOfRoyaltyRevenue_a53ecf24-dd69-4290-9c9b-d915aa2b7d4a" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PercentageOfNonRoyaltyRevenue_9782294c-9b36-41af-93af-43ec0282b593" xlink:href="ardx-20221231.xsd#ardx_PercentageOfNonRoyaltyRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:to="loc_ardx_PercentageOfNonRoyaltyRevenue_9782294c-9b36-41af-93af-43ec0282b593" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_9900b028-56f5-44f0-bbcc-7229a3cf6395" xlink:href="ardx-20221231.xsd#ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:to="loc_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_9900b028-56f5-44f0-bbcc-7229a3cf6395" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_1bc9aa15-ca5d-4cc5-9941-126ce2d73efa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:to="loc_us-gaap_CostOfRevenue_1bc9aa15-ca5d-4cc5-9941-126ce2d73efa" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1f7a92c-dc45-4a6c-9524-35148054b3c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1f7a92c-dc45-4a6c-9524-35148054b3c8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_54a98e64-fb76-45d5-b82a-22c5911672fa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1f7a92c-dc45-4a6c-9524-35148054b3c8" xlink:to="loc_srt_CounterpartyNameAxis_54a98e64-fb76-45d5-b82a-22c5911672fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_54a98e64-fb76-45d5-b82a-22c5911672fa_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_54a98e64-fb76-45d5-b82a-22c5911672fa" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_54a98e64-fb76-45d5-b82a-22c5911672fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3057b31-143a-4cf4-a748-d592d08c63f5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_54a98e64-fb76-45d5-b82a-22c5911672fa" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3057b31-143a-4cf4-a748-d592d08c63f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_KyowaKirinCo.LtdMember_4f0f1c18-8106-4eb2-bac1-5959e70be6ad" xlink:href="ardx-20221231.xsd#ardx_KyowaKirinCo.LtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3057b31-143a-4cf4-a748-d592d08c63f5" xlink:to="loc_ardx_KyowaKirinCo.LtdMember_4f0f1c18-8106-4eb2-bac1-5959e70be6ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember_1d08bb62-0621-465b-b30f-f043d80ba86e" xlink:href="ardx-20221231.xsd#ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3057b31-143a-4cf4-a748-d592d08c63f5" xlink:to="loc_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember_1d08bb62-0621-465b-b30f-f043d80ba86e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_KnightTherapeuticsIncMember_357068a0-3452-46ae-8c11-aef065d92175" xlink:href="ardx-20221231.xsd#ardx_KnightTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3057b31-143a-4cf4-a748-d592d08c63f5" xlink:to="loc_ardx_KnightTherapeuticsIncMember_357068a0-3452-46ae-8c11-aef065d92175" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AstrazenecaMember_c3d66f68-385f-4f2e-ade1-bdd3e7c25f84" xlink:href="ardx-20221231.xsd#ardx_AstrazenecaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3057b31-143a-4cf4-a748-d592d08c63f5" xlink:to="loc_ardx_AstrazenecaMember_c3d66f68-385f-4f2e-ade1-bdd3e7c25f84" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b21568ca-8139-4f5b-a3f6-345f2a559692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1f7a92c-dc45-4a6c-9524-35148054b3c8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b21568ca-8139-4f5b-a3f6-345f2a559692" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b21568ca-8139-4f5b-a3f6-345f2a559692_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b21568ca-8139-4f5b-a3f6-345f2a559692" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b21568ca-8139-4f5b-a3f6-345f2a559692_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_48c099d3-5f11-42b6-9c04-4bb502068ade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b21568ca-8139-4f5b-a3f6-345f2a559692" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_48c099d3-5f11-42b6-9c04-4bb502068ade" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ResearchCollaborationAndOptionAgreementMember_18cf112d-8fec-4723-89eb-a7ec63a9dab1" xlink:href="ardx-20221231.xsd#ardx_ResearchCollaborationAndOptionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_48c099d3-5f11-42b6-9c04-4bb502068ade" xlink:to="loc_ardx_ResearchCollaborationAndOptionAgreementMember_18cf112d-8fec-4723-89eb-a7ec63a9dab1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_8957eeac-776f-474a-ac57-d60f02c2ca53" xlink:href="ardx-20221231.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_48c099d3-5f11-42b6-9c04-4bb502068ade" xlink:to="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_8957eeac-776f-474a-ac57-d60f02c2ca53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember_8997f392-afac-407b-b7ad-d30dfd2a48ac" xlink:href="ardx-20221231.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_48c099d3-5f11-42b6-9c04-4bb502068ade" xlink:to="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember_8997f392-afac-407b-b7ad-d30dfd2a48ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember_16aec2f4-a5ad-4793-88c9-905eaf8fddd3" xlink:href="ardx-20221231.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_48c099d3-5f11-42b6-9c04-4bb502068ade" xlink:to="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember_16aec2f4-a5ad-4793-88c9-905eaf8fddd3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AstraZenecaTerminationAgreementMember_710d7a28-3d19-44f7-914b-3f6563521a58" xlink:href="ardx-20221231.xsd#ardx_AstraZenecaTerminationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_48c099d3-5f11-42b6-9c04-4bb502068ade" xlink:to="loc_ardx_AstraZenecaTerminationAgreementMember_710d7a28-3d19-44f7-914b-3f6563521a58" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d2079138-8928-4a51-b465-26e5f2efff45" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1f7a92c-dc45-4a6c-9524-35148054b3c8" xlink:to="loc_srt_RangeAxis_d2079138-8928-4a51-b465-26e5f2efff45" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d2079138-8928-4a51-b465-26e5f2efff45_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d2079138-8928-4a51-b465-26e5f2efff45" xlink:to="loc_srt_RangeMember_d2079138-8928-4a51-b465-26e5f2efff45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9dd45925-6a8a-49e5-9615-69ccca627661" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d2079138-8928-4a51-b465-26e5f2efff45" xlink:to="loc_srt_RangeMember_9dd45925-6a8a-49e5-9615-69ccca627661" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_40d48220-d752-4163-921f-533749ddfe6a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9dd45925-6a8a-49e5-9615-69ccca627661" xlink:to="loc_srt_MinimumMember_40d48220-d752-4163-921f-533749ddfe6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_20cf87b8-56d2-41b3-992d-44438e0c66d9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1f7a92c-dc45-4a6c-9524-35148054b3c8" xlink:to="loc_srt_ProductOrServiceAxis_20cf87b8-56d2-41b3-992d-44438e0c66d9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_20cf87b8-56d2-41b3-992d-44438e0c66d9_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_20cf87b8-56d2-41b3-992d-44438e0c66d9" xlink:to="loc_srt_ProductsAndServicesDomain_20cf87b8-56d2-41b3-992d-44438e0c66d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_87acdd16-db40-4b43-8fbe-3b1cb66bb8b6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_20cf87b8-56d2-41b3-992d-44438e0c66d9" xlink:to="loc_srt_ProductsAndServicesDomain_87acdd16-db40-4b43-8fbe-3b1cb66bb8b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_63ae7f5e-4fd0-419e-a87f-e01a4c4fd179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_87acdd16-db40-4b43-8fbe-3b1cb66bb8b6" xlink:to="loc_us-gaap_LicenseMember_63ae7f5e-4fd0-419e-a87f-e01a4c4fd179" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ProductSupplyRevenueMember_1c4a5246-5647-4e1d-bcc7-69f15006a9b1" xlink:href="ardx-20221231.xsd#ardx_ProductSupplyRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_87acdd16-db40-4b43-8fbe-3b1cb66bb8b6" xlink:to="loc_ardx_ProductSupplyRevenueMember_1c4a5246-5647-4e1d-bcc7-69f15006a9b1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#CollaborationandLicensingAgreementsDeferredRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails" xlink:type="extended" id="i232b23183d984a28be34c5ee7f5f0bbd_CollaborationandLicensingAgreementsDeferredRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_532ec4e3-83aa-461f-89fa-8aff7e5f098c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_d891b463-1311-417d-8290-6541967bf8ea" xlink:href="ardx-20221231.xsd#ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_532ec4e3-83aa-461f-89fa-8aff7e5f098c" xlink:to="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_d891b463-1311-417d-8290-6541967bf8ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a996c261-c61c-4569-9238-cd8cc7e7dc17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_d891b463-1311-417d-8290-6541967bf8ea" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a996c261-c61c-4569-9238-cd8cc7e7dc17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenueDuringThePeriod_92eed5e0-77b4-471e-854b-724e863624c9" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenueDuringThePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_d891b463-1311-417d-8290-6541967bf8ea" xlink:to="loc_ardx_ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenueDuringThePeriod_92eed5e0-77b4-471e-854b-724e863624c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths_f70ff0e6-ed16-48f2-87d0-a4da6d4e62d4" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_d891b463-1311-417d-8290-6541967bf8ea" xlink:to="loc_ardx_ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths_f70ff0e6-ed16-48f2-87d0-a4da6d4e62d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived_ae82bfbe-29e4-4fb9-aaba-71bd27dd5907" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_d891b463-1311-417d-8290-6541967bf8ea" xlink:to="loc_ardx_ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived_ae82bfbe-29e4-4fb9-aaba-71bd27dd5907" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived_130b6f41-4e21-4f77-8cf6-e5d2f64633c2" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_d891b463-1311-417d-8290-6541967bf8ea" xlink:to="loc_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived_130b6f41-4e21-4f77-8cf6-e5d2f64633c2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cdb2e25e-390f-4c28-aa04-685910ff7045" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_aaf82a02-ca24-407a-b07c-34b9c838fb8f" xlink:href="ardx-20221231.xsd#ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_532ec4e3-83aa-461f-89fa-8aff7e5f098c" xlink:to="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_aaf82a02-ca24-407a-b07c-34b9c838fb8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f424f1db-f936-41e3-9447-19c222bcfa3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_aaf82a02-ca24-407a-b07c-34b9c838fb8f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f424f1db-f936-41e3-9447-19c222bcfa3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityIncreaseForCashReceived_2fd58ab2-77bb-4c7f-acb2-3639098fdb7a" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerLiabilityIncreaseForCashReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_aaf82a02-ca24-407a-b07c-34b9c838fb8f" xlink:to="loc_ardx_ContractWithCustomerLiabilityIncreaseForCashReceived_2fd58ab2-77bb-4c7f-acb2-3639098fdb7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityIncreasesToAmountsInvoicedButCashNotReceived_a4e0463a-2776-40c5-a59d-0da3c5b2c104" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerLiabilityIncreasesToAmountsInvoicedButCashNotReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_aaf82a02-ca24-407a-b07c-34b9c838fb8f" xlink:to="loc_ardx_ContractWithCustomerLiabilityIncreasesToAmountsInvoicedButCashNotReceived_a4e0463a-2776-40c5-a59d-0da3c5b2c104" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded_0b4bac31-8bd9-47d8-90e9-f6cf3ae40e7c" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_aaf82a02-ca24-407a-b07c-34b9c838fb8f" xlink:to="loc_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded_0b4bac31-8bd9-47d8-90e9-f6cf3ae40e7c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths_ae827b5f-228e-452c-a4dc-2b394d7a4ba7" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_aaf82a02-ca24-407a-b07c-34b9c838fb8f" xlink:to="loc_ardx_ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths_ae827b5f-228e-452c-a4dc-2b394d7a4ba7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c3fd408d-fb15-4103-8735-e2ce64791261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_81e406b5-bb34-4c3b-8800-a0e14f00498a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_532ec4e3-83aa-461f-89fa-8aff7e5f098c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_81e406b5-bb34-4c3b-8800-a0e14f00498a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_70236168-9f87-478e-a99c-56ba2cc37aef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_81e406b5-bb34-4c3b-8800-a0e14f00498a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_70236168-9f87-478e-a99c-56ba2cc37aef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_70236168-9f87-478e-a99c-56ba2cc37aef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_70236168-9f87-478e-a99c-56ba2cc37aef" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_70236168-9f87-478e-a99c-56ba2cc37aef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_acedbac2-0aea-41b8-8473-11e8392188f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_70236168-9f87-478e-a99c-56ba2cc37aef" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_acedbac2-0aea-41b8-8473-11e8392188f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ResearchCollaborationAndOptionAgreementMember_80d9b80d-417a-4512-afbb-db387be4cdd9" xlink:href="ardx-20221231.xsd#ardx_ResearchCollaborationAndOptionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_acedbac2-0aea-41b8-8473-11e8392188f3" xlink:to="loc_ardx_ResearchCollaborationAndOptionAgreementMember_80d9b80d-417a-4512-afbb-db387be4cdd9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_16c6af70-c48b-4620-9bb0-bc68fc2e5ad9" xlink:href="ardx-20221231.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_acedbac2-0aea-41b8-8473-11e8392188f3" xlink:to="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_16c6af70-c48b-4620-9bb0-bc68fc2e5ad9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails" xlink:type="extended" id="id06b2258351d4742ae929e5765c79d0d_DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_971aea4c-a115-4c21-a473-ce4920667276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInRoyaltiesPayable_a3b4b843-5fc7-4b9a-893f-9f480d925cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInRoyaltiesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_971aea4c-a115-4c21-a473-ce4920667276" xlink:to="loc_us-gaap_IncreaseDecreaseInRoyaltiesPayable_a3b4b843-5fc7-4b9a-893f-9f480d925cbe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_439a4daa-632c-429a-81bf-847c65c015dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_971aea4c-a115-4c21-a473-ce4920667276" xlink:to="loc_us-gaap_ContractWithCustomerLiability_439a4daa-632c-429a-81bf-847c65c015dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_64506ec9-9c92-4155-a790-a8949397367f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_971aea4c-a115-4c21-a473-ce4920667276" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_64506ec9-9c92-4155-a790-a8949397367f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityTransactionCosts_d378d9c5-aa1e-4d88-a48a-c7267eaa9ceb" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerLiabilityTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_971aea4c-a115-4c21-a473-ce4920667276" xlink:to="loc_ardx_ContractWithCustomerLiabilityTransactionCosts_d378d9c5-aa1e-4d88-a48a-c7267eaa9ceb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent_aa8b13a3-d914-4be3-81aa-1c6b218b62e7" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_971aea4c-a115-4c21-a473-ce4920667276" xlink:to="loc_ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent_aa8b13a3-d914-4be3-81aa-1c6b218b62e7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfAdvanceRoyalty_c11872e8-f3d2-4687-bbc6-44765c8b910c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfAdvanceRoyalty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_971aea4c-a115-4c21-a473-ce4920667276" xlink:to="loc_us-gaap_AmortizationOfAdvanceRoyalty_c11872e8-f3d2-4687-bbc6-44765c8b910c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRoyaltiesReceived_92d0fc4e-57fd-4440-8494-9a1052911b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRoyaltiesReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_971aea4c-a115-4c21-a473-ce4920667276" xlink:to="loc_us-gaap_ProceedsFromRoyaltiesReceived_92d0fc4e-57fd-4440-8494-9a1052911b5a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_46b8ed4b-59c6-4067-abd0-413682fef906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_971aea4c-a115-4c21-a473-ce4920667276" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_46b8ed4b-59c6-4067-abd0-413682fef906" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e0613c09-ec99-4f46-bd3f-93850822bb97" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_46b8ed4b-59c6-4067-abd0-413682fef906" xlink:to="loc_srt_CounterpartyNameAxis_e0613c09-ec99-4f46-bd3f-93850822bb97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e0613c09-ec99-4f46-bd3f-93850822bb97_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_e0613c09-ec99-4f46-bd3f-93850822bb97" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e0613c09-ec99-4f46-bd3f-93850822bb97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e9a08716-300a-40dd-bb2d-d8cd51e9aa24" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_e0613c09-ec99-4f46-bd3f-93850822bb97" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e9a08716-300a-40dd-bb2d-d8cd51e9aa24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_HealthCareRoyaltyPartnersIVLPMember_954c9a76-c5a5-49ec-85d4-4deef4a112f8" xlink:href="ardx-20221231.xsd#ardx_HealthCareRoyaltyPartnersIVLPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e9a08716-300a-40dd-bb2d-d8cd51e9aa24" xlink:to="loc_ardx_HealthCareRoyaltyPartnersIVLPMember_954c9a76-c5a5-49ec-85d4-4deef4a112f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_91239905-2bd1-4a53-9971-b99ae5479369" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_46b8ed4b-59c6-4067-abd0-413682fef906" xlink:to="loc_srt_ProductOrServiceAxis_91239905-2bd1-4a53-9971-b99ae5479369" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_91239905-2bd1-4a53-9971-b99ae5479369_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_91239905-2bd1-4a53-9971-b99ae5479369" xlink:to="loc_srt_ProductsAndServicesDomain_91239905-2bd1-4a53-9971-b99ae5479369_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_70be2c69-533a-4bd4-b7ef-672a04b71684" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_91239905-2bd1-4a53-9971-b99ae5479369" xlink:to="loc_srt_ProductsAndServicesDomain_70be2c69-533a-4bd4-b7ef-672a04b71684" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_ab4738e0-d350-4715-a24c-6979ae60657a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_70be2c69-533a-4bd4-b7ef-672a04b71684" xlink:to="loc_us-gaap_LicenseMember_ab4738e0-d350-4715-a24c-6979ae60657a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#BorrowingsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/BorrowingsNarrativeDetails" xlink:type="extended" id="i1d7e65a10d554ee7a56ddf43bbd6fca9_BorrowingsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_289a289e-2d13-4fdb-b2f6-b190fd5e984b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_a154e4b7-871b-4319-90ac-fd43837317c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_289a289e-2d13-4fdb-b2f6-b190fd5e984b" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_a154e4b7-871b-4319-90ac-fd43837317c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_5f985130-776f-4671-9caf-bd23c9b42e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_289a289e-2d13-4fdb-b2f6-b190fd5e984b" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_5f985130-776f-4671-9caf-bd23c9b42e2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7db8b1b7-3486-43ad-9abf-4b93ac3a4a54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_289a289e-2d13-4fdb-b2f6-b190fd5e984b" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7db8b1b7-3486-43ad-9abf-4b93ac3a4a54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentInterestPaymentExtensionTerm_a5e0393c-d7e7-48c1-8026-7494d025dad7" xlink:href="ardx-20221231.xsd#ardx_DebtInstrumentInterestPaymentExtensionTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_289a289e-2d13-4fdb-b2f6-b190fd5e984b" xlink:to="loc_ardx_DebtInstrumentInterestPaymentExtensionTerm_a5e0393c-d7e7-48c1-8026-7494d025dad7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_d04752ed-c1c6-4f83-b3e1-ddf1c2c7175f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_289a289e-2d13-4fdb-b2f6-b190fd5e984b" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_d04752ed-c1c6-4f83-b3e1-ddf1c2c7175f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement_48e55624-1c06-4548-94e5-8a9117151c4b" xlink:href="ardx-20221231.xsd#ardx_RemainingFundingBasedOnConditionalMilestoneAchievement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_289a289e-2d13-4fdb-b2f6-b190fd5e984b" xlink:to="loc_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement_48e55624-1c06-4548-94e5-8a9117151c4b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentVariableRateBaseOption_577bb58b-fb10-4565-b3de-02e971b35a9f" xlink:href="ardx-20221231.xsd#ardx_DebtInstrumentVariableRateBaseOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_289a289e-2d13-4fdb-b2f6-b190fd5e984b" xlink:to="loc_ardx_DebtInstrumentVariableRateBaseOption_577bb58b-fb10-4565-b3de-02e971b35a9f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_84c3b247-7133-4207-98bc-01c09bd62c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_289a289e-2d13-4fdb-b2f6-b190fd5e984b" xlink:to="loc_us-gaap_DebtInstrumentTerm_84c3b247-7133-4207-98bc-01c09bd62c2f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentClosingFeeAmount_acc69c92-179d-44c8-8649-3530af54624b" xlink:href="ardx-20221231.xsd#ardx_DebtInstrumentClosingFeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_289a289e-2d13-4fdb-b2f6-b190fd5e984b" xlink:to="loc_ardx_DebtInstrumentClosingFeeAmount_acc69c92-179d-44c8-8649-3530af54624b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents_d05aaf9d-bf29-41cc-9c18-8bab8ed1130c" xlink:href="ardx-20221231.xsd#ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_289a289e-2d13-4fdb-b2f6-b190fd5e984b" xlink:to="loc_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents_d05aaf9d-bf29-41cc-9c18-8bab8ed1130c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage_0427294f-5c52-4900-aae4-885ca3a85707" xlink:href="ardx-20221231.xsd#ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_289a289e-2d13-4fdb-b2f6-b190fd5e984b" xlink:to="loc_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage_0427294f-5c52-4900-aae4-885ca3a85707" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentPrepaymentFeePercentage_7939b700-67c9-4aff-868e-95a348fdbcc6" xlink:href="ardx-20221231.xsd#ardx_DebtInstrumentPrepaymentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_289a289e-2d13-4fdb-b2f6-b190fd5e984b" xlink:to="loc_ardx_DebtInstrumentPrepaymentFeePercentage_7939b700-67c9-4aff-868e-95a348fdbcc6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFeePercentage_3ff24217-0a7b-41aa-a7b6-ee2883e8d3a8" xlink:href="ardx-20221231.xsd#ardx_ExitFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_289a289e-2d13-4fdb-b2f6-b190fd5e984b" xlink:to="loc_ardx_ExitFeePercentage_3ff24217-0a7b-41aa-a7b6-ee2883e8d3a8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum_afc93d89-31e2-409b-8786-e9f2478dfa2d" xlink:href="ardx-20221231.xsd#ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_289a289e-2d13-4fdb-b2f6-b190fd5e984b" xlink:to="loc_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum_afc93d89-31e2-409b-8786-e9f2478dfa2d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementExitFeeTerm_d48031ed-1e42-4045-a4f3-a435ea73ce5a" xlink:href="ardx-20221231.xsd#ardx_LoanAgreementExitFeeTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_289a289e-2d13-4fdb-b2f6-b190fd5e984b" xlink:to="loc_ardx_LoanAgreementExitFeeTerm_d48031ed-1e42-4045-a4f3-a435ea73ce5a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum_3d73dbb4-be78-46ba-b4a8-0736f157b96d" xlink:href="ardx-20221231.xsd#ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_289a289e-2d13-4fdb-b2f6-b190fd5e984b" xlink:to="loc_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum_3d73dbb4-be78-46ba-b4a8-0736f157b96d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod_de7679e2-367c-44aa-9088-d11fff84baba" xlink:href="ardx-20221231.xsd#ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_289a289e-2d13-4fdb-b2f6-b190fd5e984b" xlink:to="loc_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod_de7679e2-367c-44aa-9088-d11fff84baba" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum_c84dad74-e623-4bb1-a048-cccfe44156ae" xlink:href="ardx-20221231.xsd#ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_289a289e-2d13-4fdb-b2f6-b190fd5e984b" xlink:to="loc_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum_c84dad74-e623-4bb1-a048-cccfe44156ae" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentInterestRateOnDefaultPercentage_e587fe90-7ccd-4e85-bf98-b08b2eacabb7" xlink:href="ardx-20221231.xsd#ardx_DebtInstrumentInterestRateOnDefaultPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_289a289e-2d13-4fdb-b2f6-b190fd5e984b" xlink:to="loc_ardx_DebtInstrumentInterestRateOnDefaultPercentage_e587fe90-7ccd-4e85-bf98-b08b2eacabb7" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentVariableRatePlusOption_5e6d6405-dd13-4efc-b85d-7248ff22b574" xlink:href="ardx-20221231.xsd#ardx_DebtInstrumentVariableRatePlusOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_289a289e-2d13-4fdb-b2f6-b190fd5e984b" xlink:to="loc_ardx_DebtInstrumentVariableRatePlusOption_5e6d6405-dd13-4efc-b85d-7248ff22b574" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9fbf9a0d-ac1b-4001-b8ba-95942f745b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_289a289e-2d13-4fdb-b2f6-b190fd5e984b" xlink:to="loc_us-gaap_DebtInstrumentTable_9fbf9a0d-ac1b-4001-b8ba-95942f745b3d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_bf195f4f-ed16-47ac-bb3e-b612f13a5a77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9fbf9a0d-ac1b-4001-b8ba-95942f745b3d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_bf195f4f-ed16-47ac-bb3e-b612f13a5a77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bf195f4f-ed16-47ac-bb3e-b612f13a5a77_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bf195f4f-ed16-47ac-bb3e-b612f13a5a77" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bf195f4f-ed16-47ac-bb3e-b612f13a5a77_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2633fc82-c7f5-4da6-9117-106ca42d5ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bf195f4f-ed16-47ac-bb3e-b612f13a5a77" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2633fc82-c7f5-4da6-9117-106ca42d5ebb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_feda9bb7-0fdd-43be-aadf-d06a49a6f704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2633fc82-c7f5-4da6-9117-106ca42d5ebb" xlink:to="loc_us-gaap_LoansPayableMember_feda9bb7-0fdd-43be-aadf-d06a49a6f704" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_55f4d29d-7907-496a-852c-29f3531d6556" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9fbf9a0d-ac1b-4001-b8ba-95942f745b3d" xlink:to="loc_us-gaap_DebtInstrumentAxis_55f4d29d-7907-496a-852c-29f3531d6556" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_55f4d29d-7907-496a-852c-29f3531d6556_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_55f4d29d-7907-496a-852c-29f3531d6556" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_55f4d29d-7907-496a-852c-29f3531d6556_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_51acc923-bfab-46c4-b60d-2c116bff89f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_55f4d29d-7907-496a-852c-29f3531d6556" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_51acc923-bfab-46c4-b60d-2c116bff89f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2018Member_d064b2af-da08-4963-8593-4ae78a71b3e3" xlink:href="ardx-20221231.xsd#ardx_TermLoan2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51acc923-bfab-46c4-b60d-2c116bff89f3" xlink:to="loc_ardx_TermLoan2018Member_d064b2af-da08-4963-8593-4ae78a71b3e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2022Member_0077c070-8ee6-4704-9496-4c95a3a66566" xlink:href="ardx-20221231.xsd#ardx_TermLoan2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51acc923-bfab-46c4-b60d-2c116bff89f3" xlink:to="loc_ardx_TermLoan2022Member_0077c070-8ee6-4704-9496-4c95a3a66566" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2022AMember_d176fac4-6deb-4f08-b080-43f0a1baf1ae" xlink:href="ardx-20221231.xsd#ardx_TermLoan2022AMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_TermLoan2022Member_0077c070-8ee6-4704-9496-4c95a3a66566" xlink:to="loc_ardx_TermLoan2022AMember_d176fac4-6deb-4f08-b080-43f0a1baf1ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2022BMember_053f00b1-e043-46bc-b1c3-85bb3b272189" xlink:href="ardx-20221231.xsd#ardx_TermLoan2022BMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_TermLoan2022Member_0077c070-8ee6-4704-9496-4c95a3a66566" xlink:to="loc_ardx_TermLoan2022BMember_053f00b1-e043-46bc-b1c3-85bb3b272189" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_c74baf6d-e62f-45c6-9b40-eb62c73cb7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9fbf9a0d-ac1b-4001-b8ba-95942f745b3d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_c74baf6d-e62f-45c6-9b40-eb62c73cb7d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c74baf6d-e62f-45c6-9b40-eb62c73cb7d9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_c74baf6d-e62f-45c6-9b40-eb62c73cb7d9" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c74baf6d-e62f-45c6-9b40-eb62c73cb7d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_4f130da2-3bd0-4d91-b13d-270032ed1c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_c74baf6d-e62f-45c6-9b40-eb62c73cb7d9" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_4f130da2-3bd0-4d91-b13d-270032ed1c3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_143737c6-1159-4fed-86be-85998722f987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_4f130da2-3bd0-4d91-b13d-270032ed1c3b" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_143737c6-1159-4fed-86be-85998722f987" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_4a3ca441-9030-42e3-b5f5-e8c3346a706d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_4f130da2-3bd0-4d91-b13d-270032ed1c3b" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_4a3ca441-9030-42e3-b5f5-e8c3346a706d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_9a8babd7-15d1-4bca-92e6-29b4f46d5725" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_4f130da2-3bd0-4d91-b13d-270032ed1c3b" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_9a8babd7-15d1-4bca-92e6-29b4f46d5725" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_e206454a-296b-43f0-8ba0-15beabb806ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9fbf9a0d-ac1b-4001-b8ba-95942f745b3d" xlink:to="loc_us-gaap_VariableRateAxis_e206454a-296b-43f0-8ba0-15beabb806ba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_e206454a-296b-43f0-8ba0-15beabb806ba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_e206454a-296b-43f0-8ba0-15beabb806ba" xlink:to="loc_us-gaap_VariableRateDomain_e206454a-296b-43f0-8ba0-15beabb806ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_076d7bab-d6db-4c59-b32c-c69993ff02f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_e206454a-296b-43f0-8ba0-15beabb806ba" xlink:to="loc_us-gaap_VariableRateDomain_076d7bab-d6db-4c59-b32c-c69993ff02f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_6db58d5e-d410-4556-8876-5f73299e3603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_076d7bab-d6db-4c59-b32c-c69993ff02f1" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_6db58d5e-d410-4556-8876-5f73299e3603" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_7b854758-e2a1-4cd3-afef-46967b08b222" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9fbf9a0d-ac1b-4001-b8ba-95942f745b3d" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_7b854758-e2a1-4cd3-afef-46967b08b222" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7b854758-e2a1-4cd3-afef-46967b08b222_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_7b854758-e2a1-4cd3-afef-46967b08b222" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7b854758-e2a1-4cd3-afef-46967b08b222_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_41900f1b-fcee-4437-bd1d-be0beda44da7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_7b854758-e2a1-4cd3-afef-46967b08b222" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_41900f1b-fcee-4437-bd1d-be0beda44da7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2022Member_e1bfe80e-c3a5-4eb6-ac85-57ed2fc61d2f" xlink:href="ardx-20221231.xsd#ardx_ExitFee2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_41900f1b-fcee-4437-bd1d-be0beda44da7" xlink:to="loc_ardx_ExitFee2022Member_e1bfe80e-c3a5-4eb6-ac85-57ed2fc61d2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8eee3a1f-48e4-4bd9-ab24-16c7fca2f48c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9fbf9a0d-ac1b-4001-b8ba-95942f745b3d" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8eee3a1f-48e4-4bd9-ab24-16c7fca2f48c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8eee3a1f-48e4-4bd9-ab24-16c7fca2f48c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8eee3a1f-48e4-4bd9-ab24-16c7fca2f48c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8eee3a1f-48e4-4bd9-ab24-16c7fca2f48c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3549ff01-940b-46a1-ac1c-9a369264f789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8eee3a1f-48e4-4bd9-ab24-16c7fca2f48c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3549ff01-940b-46a1-ac1c-9a369264f789" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_7ced733d-046b-4e5e-b070-8cb250657d93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3549ff01-940b-46a1-ac1c-9a369264f789" xlink:to="loc_us-gaap_SubsequentEventMember_7ced733d-046b-4e5e-b070-8cb250657d93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_31950f3a-a9d1-432c-97bc-ad76e5fe63ba" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9fbf9a0d-ac1b-4001-b8ba-95942f745b3d" xlink:to="loc_srt_RangeAxis_31950f3a-a9d1-432c-97bc-ad76e5fe63ba" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_31950f3a-a9d1-432c-97bc-ad76e5fe63ba_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_31950f3a-a9d1-432c-97bc-ad76e5fe63ba" xlink:to="loc_srt_RangeMember_31950f3a-a9d1-432c-97bc-ad76e5fe63ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d1e070a2-960c-41be-910a-ddaa7bee43b1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_31950f3a-a9d1-432c-97bc-ad76e5fe63ba" xlink:to="loc_srt_RangeMember_d1e070a2-960c-41be-910a-ddaa7bee43b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_93f501a6-8090-4157-aecc-ca74aca364a9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d1e070a2-960c-41be-910a-ddaa7bee43b1" xlink:to="loc_srt_MaximumMember_93f501a6-8090-4157-aecc-ca74aca364a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6b295747-fd84-4bb9-bc1d-117388349d2f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d1e070a2-960c-41be-910a-ddaa7bee43b1" xlink:to="loc_srt_MinimumMember_6b295747-fd84-4bb9-bc1d-117388349d2f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/DerivativeLiabilitiesNarrativeDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#DerivativeLiabilitiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/DerivativeLiabilitiesNarrativeDetails" xlink:type="extended" id="i96d9e8a1677e4a06804c6f229243a0ac_DerivativeLiabilitiesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_39625854-aa93-4f55-b6d5-f5c665e95237" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_63692980-23c7-447e-ae78-0464f6d281fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_39625854-aa93-4f55-b6d5-f5c665e95237" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_63692980-23c7-447e-ae78-0464f6d281fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4e2b35d3-7d1a-4514-afd1-c4eb9b65119e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_39625854-aa93-4f55-b6d5-f5c665e95237" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4e2b35d3-7d1a-4514-afd1-c4eb9b65119e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage_bb0bc6cf-2aad-4f39-bd99-4d736ad47329" xlink:href="ardx-20221231.xsd#ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_39625854-aa93-4f55-b6d5-f5c665e95237" xlink:to="loc_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage_bb0bc6cf-2aad-4f39-bd99-4d736ad47329" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation_3ae8167b-f387-4ead-825c-6790bcba0f73" xlink:href="ardx-20221231.xsd#ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_39625854-aa93-4f55-b6d5-f5c665e95237" xlink:to="loc_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation_3ae8167b-f387-4ead-825c-6790bcba0f73" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFeePercentage_9d1b7b14-a699-457f-93c0-a39202d10346" xlink:href="ardx-20221231.xsd#ardx_ExitFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_39625854-aa93-4f55-b6d5-f5c665e95237" xlink:to="loc_ardx_ExitFeePercentage_9d1b7b14-a699-457f-93c0-a39202d10346" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum_caee716d-ade6-46ad-98a1-b091c7cedab2" xlink:href="ardx-20221231.xsd#ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_39625854-aa93-4f55-b6d5-f5c665e95237" xlink:to="loc_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum_caee716d-ade6-46ad-98a1-b091c7cedab2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_38ee0716-1ee2-4faf-8525-3bacb08d762e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_39625854-aa93-4f55-b6d5-f5c665e95237" xlink:to="loc_us-gaap_DerivativeTable_38ee0716-1ee2-4faf-8525-3bacb08d762e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_c114349f-5f2b-48ab-83b0-5c8091c97622" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_38ee0716-1ee2-4faf-8525-3bacb08d762e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_c114349f-5f2b-48ab-83b0-5c8091c97622" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c114349f-5f2b-48ab-83b0-5c8091c97622_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c114349f-5f2b-48ab-83b0-5c8091c97622" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c114349f-5f2b-48ab-83b0-5c8091c97622_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0b4aedcc-79e4-4d4c-8120-eedc6b94104c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c114349f-5f2b-48ab-83b0-5c8091c97622" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0b4aedcc-79e4-4d4c-8120-eedc6b94104c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2018Member_e2f3af52-98ad-4a9f-9f54-090eb7948651" xlink:href="ardx-20221231.xsd#ardx_ExitFee2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0b4aedcc-79e4-4d4c-8120-eedc6b94104c" xlink:to="loc_ardx_ExitFee2018Member_e2f3af52-98ad-4a9f-9f54-090eb7948651" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2022Member_0558f3f6-9f53-4b76-a42a-18c7819950f1" xlink:href="ardx-20221231.xsd#ardx_ExitFee2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0b4aedcc-79e4-4d4c-8120-eedc6b94104c" xlink:to="loc_ardx_ExitFee2022Member_0558f3f6-9f53-4b76-a42a-18c7819950f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_69408013-8577-4b19-9ee7-810d6ed0d257" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_38ee0716-1ee2-4faf-8525-3bacb08d762e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_69408013-8577-4b19-9ee7-810d6ed0d257" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_69408013-8577-4b19-9ee7-810d6ed0d257_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_69408013-8577-4b19-9ee7-810d6ed0d257" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_69408013-8577-4b19-9ee7-810d6ed0d257_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_04c5b081-59e6-4530-b67f-44bc5c9c6bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_69408013-8577-4b19-9ee7-810d6ed0d257" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_04c5b081-59e6-4530-b67f-44bc5c9c6bfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_afd92e5c-585c-462c-9966-293bae29727e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_04c5b081-59e6-4530-b67f-44bc5c9c6bfd" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_afd92e5c-585c-462c-9966-293bae29727e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/DerivativeLiabilitiesChangesinFairValueDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#DerivativeLiabilitiesChangesinFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/DerivativeLiabilitiesChangesinFairValueDetails" xlink:type="extended" id="i6c6bc870ba4e486e9db74a1133b1de8f_DerivativeLiabilitiesChangesinFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_89c98d90-6c4a-4e3d-a7fd-97c5c928597b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6f920f88-5bdb-4b28-99c5-4244666087f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_89c98d90-6c4a-4e3d-a7fd-97c5c928597b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6f920f88-5bdb-4b28-99c5-4244666087f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ff5e1eb4-95a5-4ed2-ba12-ea0e9cc1df6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6f920f88-5bdb-4b28-99c5-4244666087f4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ff5e1eb4-95a5-4ed2-ba12-ea0e9cc1df6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_81de456c-3e2c-43c8-b9b9-7e6e4bd8d72d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6f920f88-5bdb-4b28-99c5-4244666087f4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_81de456c-3e2c-43c8-b9b9-7e6e4bd8d72d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_27c1d7f3-3501-49f6-9170-83e04200469b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6f920f88-5bdb-4b28-99c5-4244666087f4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_27c1d7f3-3501-49f6-9170-83e04200469b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_099b712b-451f-4732-b9c9-ac9d707cd87b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_71290e82-8ff2-4682-a18e-2aa28c6b3c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_89c98d90-6c4a-4e3d-a7fd-97c5c928597b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_71290e82-8ff2-4682-a18e-2aa28c6b3c0a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_fee6be95-72ee-49a0-8f61-ff13fd0a9896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_71290e82-8ff2-4682-a18e-2aa28c6b3c0a" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_fee6be95-72ee-49a0-8f61-ff13fd0a9896" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_fee6be95-72ee-49a0-8f61-ff13fd0a9896_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_fee6be95-72ee-49a0-8f61-ff13fd0a9896" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_fee6be95-72ee-49a0-8f61-ff13fd0a9896_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_f57463ed-3c25-401b-aad5-66873332185e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_fee6be95-72ee-49a0-8f61-ff13fd0a9896" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_f57463ed-3c25-401b-aad5-66873332185e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_bd3bf8b4-28d2-4c58-b796-5d971705984f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_f57463ed-3c25-401b-aad5-66873332185e" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_bd3bf8b4-28d2-4c58-b796-5d971705984f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_4e5948f8-26e0-480b-8713-ba628916cefb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_71290e82-8ff2-4682-a18e-2aa28c6b3c0a" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_4e5948f8-26e0-480b-8713-ba628916cefb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4e5948f8-26e0-480b-8713-ba628916cefb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4e5948f8-26e0-480b-8713-ba628916cefb" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4e5948f8-26e0-480b-8713-ba628916cefb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_78da1cba-da3b-4758-acbc-419306f7c6b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4e5948f8-26e0-480b-8713-ba628916cefb" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_78da1cba-da3b-4758-acbc-419306f7c6b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2018Member_f44491a0-0960-405f-80df-ed1e8c1472c0" xlink:href="ardx-20221231.xsd#ardx_ExitFee2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_78da1cba-da3b-4758-acbc-419306f7c6b1" xlink:to="loc_ardx_ExitFee2018Member_f44491a0-0960-405f-80df-ed1e8c1472c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2022Member_0304bdee-eb4f-4240-870e-3af91c6a2618" xlink:href="ardx-20221231.xsd#ardx_ExitFee2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_78da1cba-da3b-4758-acbc-419306f7c6b1" xlink:to="loc_ardx_ExitFee2022Member_0304bdee-eb4f-4240-870e-3af91c6a2618" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/LeasesNarrativeDetails" xlink:type="extended" id="ic99f4a5ee49a488daa73f74f25f4f9b9_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_693bcafa-6d1c-4765-a720-af61dd228110" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_NumberOfOperatingLeaseArrangements_6b930160-5e3a-4c8c-85b2-1059bbc9eb49" xlink:href="ardx-20221231.xsd#ardx_NumberOfOperatingLeaseArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_693bcafa-6d1c-4765-a720-af61dd228110" xlink:to="loc_ardx_NumberOfOperatingLeaseArrangements_6b930160-5e3a-4c8c-85b2-1059bbc9eb49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_e29472f3-be4c-4b08-a3fd-91f0443648e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_693bcafa-6d1c-4765-a720-af61dd228110" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_e29472f3-be4c-4b08-a3fd-91f0443648e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LesseeOperatingLeaseNumberOfRenewalOptions_c73a6619-c33e-4f2f-8742-5e1a64568edb" xlink:href="ardx-20221231.xsd#ardx_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_693bcafa-6d1c-4765-a720-af61dd228110" xlink:to="loc_ardx_LesseeOperatingLeaseNumberOfRenewalOptions_c73a6619-c33e-4f2f-8742-5e1a64568edb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_93568818-51de-46b4-b9ab-8d9cb41dac96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_693bcafa-6d1c-4765-a720-af61dd228110" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_93568818-51de-46b4-b9ab-8d9cb41dac96" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_df4bcd97-f23d-4235-bb40-e26d2a680220" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_693bcafa-6d1c-4765-a720-af61dd228110" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_df4bcd97-f23d-4235-bb40-e26d2a680220" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_abb02449-0bda-4f13-862b-781a4a827a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_693bcafa-6d1c-4765-a720-af61dd228110" xlink:to="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_abb02449-0bda-4f13-862b-781a4a827a4b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_439c2851-8491-4ed2-9228-ed84aeb626ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_693bcafa-6d1c-4765-a720-af61dd228110" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_439c2851-8491-4ed2-9228-ed84aeb626ed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LeaseArrangementsAxis_4e1b2f40-06d7-4881-bfad-61f7aef1cea8" xlink:href="ardx-20221231.xsd#ardx_LeaseArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_439c2851-8491-4ed2-9228-ed84aeb626ed" xlink:to="loc_ardx_LeaseArrangementsAxis_4e1b2f40-06d7-4881-bfad-61f7aef1cea8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LeaseArrangementsDomain_4e1b2f40-06d7-4881-bfad-61f7aef1cea8_default" xlink:href="ardx-20221231.xsd#ardx_LeaseArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ardx_LeaseArrangementsAxis_4e1b2f40-06d7-4881-bfad-61f7aef1cea8" xlink:to="loc_ardx_LeaseArrangementsDomain_4e1b2f40-06d7-4881-bfad-61f7aef1cea8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LeaseArrangementsDomain_fb10c3dd-5aad-41f2-9935-3188400d18d8" xlink:href="ardx-20221231.xsd#ardx_LeaseArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ardx_LeaseArrangementsAxis_4e1b2f40-06d7-4881-bfad-61f7aef1cea8" xlink:to="loc_ardx_LeaseArrangementsDomain_fb10c3dd-5aad-41f2-9935-3188400d18d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FacilityFremontCaliforniaMember_e9dc5b1b-9ab1-4f78-a9ff-937b86daf567" xlink:href="ardx-20221231.xsd#ardx_FacilityFremontCaliforniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_LeaseArrangementsDomain_fb10c3dd-5aad-41f2-9935-3188400d18d8" xlink:to="loc_ardx_FacilityFremontCaliforniaMember_e9dc5b1b-9ab1-4f78-a9ff-937b86daf567" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FacilityOneWalthamMassachusettsMember_fd754999-2f75-490e-8066-2d14a507ea05" xlink:href="ardx-20221231.xsd#ardx_FacilityOneWalthamMassachusettsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_LeaseArrangementsDomain_fb10c3dd-5aad-41f2-9935-3188400d18d8" xlink:to="loc_ardx_FacilityOneWalthamMassachusettsMember_fd754999-2f75-490e-8066-2d14a507ea05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FacilityTwoWalthamMassachusettsMember_e363b6d4-51ba-4ff3-9424-711b9a7c0074" xlink:href="ardx-20221231.xsd#ardx_FacilityTwoWalthamMassachusettsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_LeaseArrangementsDomain_fb10c3dd-5aad-41f2-9935-3188400d18d8" xlink:to="loc_ardx_FacilityTwoWalthamMassachusettsMember_e363b6d4-51ba-4ff3-9424-711b9a7c0074" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FacilityMilwaukeeWisconsinMember_749b9e9c-1363-48f1-96cb-7a96278165d1" xlink:href="ardx-20221231.xsd#ardx_FacilityMilwaukeeWisconsinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_LeaseArrangementsDomain_fb10c3dd-5aad-41f2-9935-3188400d18d8" xlink:to="loc_ardx_FacilityMilwaukeeWisconsinMember_749b9e9c-1363-48f1-96cb-7a96278165d1" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/StockholdersEquityDetails" xlink:type="extended" id="i2dc2cdd8c0ba4c3baa7373198df57821_StockholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_f63ab666-021c-4bc6-a3bd-112e44a715b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_MaximumAggregateOfferingPrice_571530fd-c0fc-4351-80c9-8192fdf68a50" xlink:href="ardx-20221231.xsd#ardx_MaximumAggregateOfferingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_f63ab666-021c-4bc6-a3bd-112e44a715b6" xlink:to="loc_ardx_MaximumAggregateOfferingPrice_571530fd-c0fc-4351-80c9-8192fdf68a50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_StockIssuanceCostCommissionPercent_3acb3936-818e-43d9-8b2f-564ed996890f" xlink:href="ardx-20221231.xsd#ardx_StockIssuanceCostCommissionPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_f63ab666-021c-4bc6-a3bd-112e44a715b6" xlink:to="loc_ardx_StockIssuanceCostCommissionPercent_3acb3936-818e-43d9-8b2f-564ed996890f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fb3599f3-59e0-466c-9107-afa55bf1a7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_f63ab666-021c-4bc6-a3bd-112e44a715b6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fb3599f3-59e0-466c-9107-afa55bf1a7b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a3168424-bd78-4f65-9a35-3dc38c122ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_f63ab666-021c-4bc6-a3bd-112e44a715b6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a3168424-bd78-4f65-9a35-3dc38c122ef5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_SaleOfStockWeightedAveragePricePerShare_4da0ccf0-4fea-446d-bd9f-6736e1971883" xlink:href="ardx-20221231.xsd#ardx_SaleOfStockWeightedAveragePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_f63ab666-021c-4bc6-a3bd-112e44a715b6" xlink:to="loc_ardx_SaleOfStockWeightedAveragePricePerShare_4da0ccf0-4fea-446d-bd9f-6736e1971883" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EquitySalesAgreementSharesIssuedSinceInception_493bd82a-da7b-45b2-b419-44c795716622" xlink:href="ardx-20221231.xsd#ardx_EquitySalesAgreementSharesIssuedSinceInception"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_f63ab666-021c-4bc6-a3bd-112e44a715b6" xlink:to="loc_ardx_EquitySalesAgreementSharesIssuedSinceInception_493bd82a-da7b-45b2-b419-44c795716622" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EquitySalesAgreementProceedsFromSharesIssuedSinceInception_2618fb88-4e91-4802-9ddd-8203bb645b7b" xlink:href="ardx-20221231.xsd#ardx_EquitySalesAgreementProceedsFromSharesIssuedSinceInception"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_f63ab666-021c-4bc6-a3bd-112e44a715b6" xlink:to="loc_ardx_EquitySalesAgreementProceedsFromSharesIssuedSinceInception_2618fb88-4e91-4802-9ddd-8203bb645b7b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c0ff6d91-fb0a-4717-ac28-83e23caacbe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_f63ab666-021c-4bc6-a3bd-112e44a715b6" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c0ff6d91-fb0a-4717-ac28-83e23caacbe1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_453e8783-1f96-4c6e-bb57-6da8e6ab91d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c0ff6d91-fb0a-4717-ac28-83e23caacbe1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_453e8783-1f96-4c6e-bb57-6da8e6ab91d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_453e8783-1f96-4c6e-bb57-6da8e6ab91d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_453e8783-1f96-4c6e-bb57-6da8e6ab91d5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_453e8783-1f96-4c6e-bb57-6da8e6ab91d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c3c5f800-e928-4e3c-8ea7-4a4dfc6d8c67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_453e8783-1f96-4c6e-bb57-6da8e6ab91d5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c3c5f800-e928-4e3c-8ea7-4a4dfc6d8c67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember_997d2e97-55d1-4a24-985d-9ebefc3c7bf0" xlink:href="ardx-20221231.xsd#ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c3c5f800-e928-4e3c-8ea7-4a4dfc6d8c67" xlink:to="loc_ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember_997d2e97-55d1-4a24-985d-9ebefc3c7bf0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember_e76d2981-6519-454c-b2f0-6eca41f94bbd" xlink:href="ardx-20221231.xsd#ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c3c5f800-e928-4e3c-8ea7-4a4dfc6d8c67" xlink:to="loc_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember_e76d2981-6519-454c-b2f0-6eca41f94bbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember_2d387bf5-26a6-4b43-ba5c-f30a473a10f9" xlink:href="ardx-20221231.xsd#ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c3c5f800-e928-4e3c-8ea7-4a4dfc6d8c67" xlink:to="loc_ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember_2d387bf5-26a6-4b43-ba5c-f30a473a10f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_76ff2984-8a9f-45ef-a9ef-58356e69d040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c0ff6d91-fb0a-4717-ac28-83e23caacbe1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_76ff2984-8a9f-45ef-a9ef-58356e69d040" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_76ff2984-8a9f-45ef-a9ef-58356e69d040_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_76ff2984-8a9f-45ef-a9ef-58356e69d040" xlink:to="loc_us-gaap_ClassOfStockDomain_76ff2984-8a9f-45ef-a9ef-58356e69d040_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0842aefd-ab99-4699-b0f8-b6c0c587d994" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_76ff2984-8a9f-45ef-a9ef-58356e69d040" xlink:to="loc_us-gaap_ClassOfStockDomain_0842aefd-ab99-4699-b0f8-b6c0c587d994" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_152b5991-2a70-4d9a-b16d-2ee996d347fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0842aefd-ab99-4699-b0f8-b6c0c587d994" xlink:to="loc_us-gaap_CommonClassAMember_152b5991-2a70-4d9a-b16d-2ee996d347fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f781fe23-5bd7-47fc-81de-c8057a67498b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c0ff6d91-fb0a-4717-ac28-83e23caacbe1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f781fe23-5bd7-47fc-81de-c8057a67498b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f781fe23-5bd7-47fc-81de-c8057a67498b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f781fe23-5bd7-47fc-81de-c8057a67498b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f781fe23-5bd7-47fc-81de-c8057a67498b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fce66702-4641-430e-9b43-7c332625dedb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f781fe23-5bd7-47fc-81de-c8057a67498b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fce66702-4641-430e-9b43-7c332625dedb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_1918457e-43b3-426c-9f8a-078b46ea3923" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_fce66702-4641-430e-9b43-7c332625dedb" xlink:to="loc_us-gaap_SubsequentEventMember_1918457e-43b3-426c-9f8a-078b46ea3923" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#EquityIncentivePlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails" xlink:type="extended" id="ib9412bb5e20245cb996879f1cc17c933_EquityIncentivePlansNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bab7eba-971b-4781-b0f9-4e025c950112" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f58245df-7fa3-4fef-8bb8-09a13f723a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bab7eba-971b-4781-b0f9-4e025c950112" xlink:to="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f58245df-7fa3-4fef-8bb8-09a13f723a5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_52a7a28f-e48c-4492-8591-e0e608ef34cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f58245df-7fa3-4fef-8bb8-09a13f723a5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_52a7a28f-e48c-4492-8591-e0e608ef34cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0da22a2d-b207-40f2-9ddb-14ecbff700a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f58245df-7fa3-4fef-8bb8-09a13f723a5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0da22a2d-b207-40f2-9ddb-14ecbff700a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_b5453240-6c03-49f5-b04c-7d05b8a653f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f58245df-7fa3-4fef-8bb8-09a13f723a5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_b5453240-6c03-49f5-b04c-7d05b8a653f6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b07a22e3-b4ca-4825-b3dd-69f7cfdd3235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f58245df-7fa3-4fef-8bb8-09a13f723a5c" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b07a22e3-b4ca-4825-b3dd-69f7cfdd3235" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponInclusionOfForfeitedOrUnexercisedOptions_6b0b7d95-2297-4679-bf99-7bba4aac909f" xlink:href="ardx-20221231.xsd#ardx_IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponInclusionOfForfeitedOrUnexercisedOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f58245df-7fa3-4fef-8bb8-09a13f723a5c" xlink:to="loc_ardx_IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponInclusionOfForfeitedOrUnexercisedOptions_6b0b7d95-2297-4679-bf99-7bba4aac909f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_IncreaseInSharesReservedForIssuanceOptionForAnnualIncreaseAsPercentageOfSharesOutstanding_473b1796-f35e-4457-8a01-003f0aaa4177" xlink:href="ardx-20221231.xsd#ardx_IncreaseInSharesReservedForIssuanceOptionForAnnualIncreaseAsPercentageOfSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f58245df-7fa3-4fef-8bb8-09a13f723a5c" xlink:to="loc_ardx_IncreaseInSharesReservedForIssuanceOptionForAnnualIncreaseAsPercentageOfSharesOutstanding_473b1796-f35e-4457-8a01-003f0aaa4177" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponExerciseOfStockOptions_b39b7aec-488f-4fd3-aae5-6f81679cb3e4" xlink:href="ardx-20221231.xsd#ardx_IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponExerciseOfStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f58245df-7fa3-4fef-8bb8-09a13f723a5c" xlink:to="loc_ardx_IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponExerciseOfStockOptions_b39b7aec-488f-4fd3-aae5-6f81679cb3e4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CommonStockSubjectToIssuedInducementGrantsShares_fb28e987-9815-4815-9452-57313382a031" xlink:href="ardx-20221231.xsd#ardx_CommonStockSubjectToIssuedInducementGrantsShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f58245df-7fa3-4fef-8bb8-09a13f723a5c" xlink:to="loc_ardx_CommonStockSubjectToIssuedInducementGrantsShares_fb28e987-9815-4815-9452-57313382a031" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_927d034f-7e32-4685-a119-83181dfe9c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f58245df-7fa3-4fef-8bb8-09a13f723a5c" xlink:to="loc_us-gaap_SharePrice_927d034f-7e32-4685-a119-83181dfe9c6e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_61678f2c-299d-4065-b85d-f55f865cc7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f58245df-7fa3-4fef-8bb8-09a13f723a5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_61678f2c-299d-4065-b85d-f55f865cc7a5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ff34e7ea-505a-4cc7-8b58-18079477faa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f58245df-7fa3-4fef-8bb8-09a13f723a5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ff34e7ea-505a-4cc7-8b58-18079477faa7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6c3d1a0a-b246-4268-8edd-b43fdc1bad09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f58245df-7fa3-4fef-8bb8-09a13f723a5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6c3d1a0a-b246-4268-8edd-b43fdc1bad09" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_b7e3e855-9a23-4bad-bbae-f877546f03df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f58245df-7fa3-4fef-8bb8-09a13f723a5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_b7e3e855-9a23-4bad-bbae-f877546f03df" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3e6e5a0b-3c2e-4e73-be88-14d3d6c39b81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f58245df-7fa3-4fef-8bb8-09a13f723a5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3e6e5a0b-3c2e-4e73-be88-14d3d6c39b81" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8c2912ab-a87c-4722-b392-8d46ecc788d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f58245df-7fa3-4fef-8bb8-09a13f723a5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8c2912ab-a87c-4722-b392-8d46ecc788d9" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_b2774deb-b6e9-4f7f-b2e3-d7d13cae97a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f58245df-7fa3-4fef-8bb8-09a13f723a5c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_b2774deb-b6e9-4f7f-b2e3-d7d13cae97a2" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_36353fdb-11d8-4215-b9ba-ec158bc22483" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f58245df-7fa3-4fef-8bb8-09a13f723a5c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_36353fdb-11d8-4215-b9ba-ec158bc22483" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesUnderEmployeeStockPurchasePlan_22894912-46d3-47c6-8cfd-552305cd7530" xlink:href="ardx-20221231.xsd#ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesUnderEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f58245df-7fa3-4fef-8bb8-09a13f723a5c" xlink:to="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesUnderEmployeeStockPurchasePlan_22894912-46d3-47c6-8cfd-552305cd7530" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_540a20d6-6e69-4ac1-9de3-e94996d3d92b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bab7eba-971b-4781-b0f9-4e025c950112" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_540a20d6-6e69-4ac1-9de3-e94996d3d92b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_e3a96d09-acca-4abf-9475-e36d8b25edb0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_540a20d6-6e69-4ac1-9de3-e94996d3d92b" xlink:to="loc_srt_TitleOfIndividualAxis_e3a96d09-acca-4abf-9475-e36d8b25edb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e3a96d09-acca-4abf-9475-e36d8b25edb0_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_e3a96d09-acca-4abf-9475-e36d8b25edb0" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e3a96d09-acca-4abf-9475-e36d8b25edb0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_46c9dd1a-fa06-4630-b04c-ac84813a2e0b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_e3a96d09-acca-4abf-9475-e36d8b25edb0" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_46c9dd1a-fa06-4630-b04c-ac84813a2e0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_37541c2c-758f-4200-b92f-750eff1a0533" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_46c9dd1a-fa06-4630-b04c-ac84813a2e0b" xlink:to="loc_srt_DirectorMember_37541c2c-758f-4200-b92f-750eff1a0533" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c063edb6-c0f5-42c7-bffd-17b6881db268" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_540a20d6-6e69-4ac1-9de3-e94996d3d92b" xlink:to="loc_us-gaap_AwardTypeAxis_c063edb6-c0f5-42c7-bffd-17b6881db268" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c063edb6-c0f5-42c7-bffd-17b6881db268_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c063edb6-c0f5-42c7-bffd-17b6881db268" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c063edb6-c0f5-42c7-bffd-17b6881db268_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83d25548-555b-4595-8d3f-b67e01384e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c063edb6-c0f5-42c7-bffd-17b6881db268" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83d25548-555b-4595-8d3f-b67e01384e4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_235163fc-465e-49ba-861c-c18da3faff42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83d25548-555b-4595-8d3f-b67e01384e4d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_235163fc-465e-49ba-861c-c18da3faff42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PerformanceBasedRestrictedStockUnitsMember_cc17c4e5-ae96-4145-b980-ff42e9ca0b45" xlink:href="ardx-20221231.xsd#ardx_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83d25548-555b-4595-8d3f-b67e01384e4d" xlink:to="loc_ardx_PerformanceBasedRestrictedStockUnitsMember_cc17c4e5-ae96-4145-b980-ff42e9ca0b45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_9cafaad3-b6b4-40ee-a7dd-80dc63fe8b18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83d25548-555b-4595-8d3f-b67e01384e4d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_9cafaad3-b6b4-40ee-a7dd-80dc63fe8b18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_c7a49909-5b1f-45d7-bbff-0ea06bd9d37f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_540a20d6-6e69-4ac1-9de3-e94996d3d92b" xlink:to="loc_us-gaap_PlanNameAxis_c7a49909-5b1f-45d7-bbff-0ea06bd9d37f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c7a49909-5b1f-45d7-bbff-0ea06bd9d37f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_c7a49909-5b1f-45d7-bbff-0ea06bd9d37f" xlink:to="loc_us-gaap_PlanNameDomain_c7a49909-5b1f-45d7-bbff-0ea06bd9d37f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_40d62965-623b-4985-96cc-81774857d97e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_c7a49909-5b1f-45d7-bbff-0ea06bd9d37f" xlink:to="loc_us-gaap_PlanNameDomain_40d62965-623b-4985-96cc-81774857d97e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TwoThousandEightStockIncentivePlanMember_817e7acd-f515-4759-9653-f497e2da5995" xlink:href="ardx-20221231.xsd#ardx_TwoThousandEightStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_40d62965-623b-4985-96cc-81774857d97e" xlink:to="loc_ardx_TwoThousandEightStockIncentivePlanMember_817e7acd-f515-4759-9653-f497e2da5995" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TwoThousandFourteenEquityIncentiveAwardPlanMember_fb213dd7-89eb-49ea-867c-29689df9e847" xlink:href="ardx-20221231.xsd#ardx_TwoThousandFourteenEquityIncentiveAwardPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_40d62965-623b-4985-96cc-81774857d97e" xlink:to="loc_ardx_TwoThousandFourteenEquityIncentiveAwardPlanMember_fb213dd7-89eb-49ea-867c-29689df9e847" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TwoThousandSixteenEmploymentCommencementIncentivePlanMember_a03fcd1c-3c51-4c9f-b834-cf6c421a08e3" xlink:href="ardx-20221231.xsd#ardx_TwoThousandSixteenEmploymentCommencementIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_40d62965-623b-4985-96cc-81774857d97e" xlink:to="loc_ardx_TwoThousandSixteenEmploymentCommencementIncentivePlanMember_a03fcd1c-3c51-4c9f-b834-cf6c421a08e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EmployeeStockPurchasePlanMember_d9f17018-831d-4b0a-8a11-b792072993be" xlink:href="ardx-20221231.xsd#ardx_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_40d62965-623b-4985-96cc-81774857d97e" xlink:to="loc_ardx_EmployeeStockPurchasePlanMember_d9f17018-831d-4b0a-8a11-b792072993be" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#EquityIncentivePlansStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails" xlink:type="extended" id="i876556d15cbd4ae8b5c57579a6d11cf9_EquityIncentivePlansStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4f90cc5b-355d-4289-a51c-4cebbda26ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_SharesAvailableForGrantRollForward_e5d45748-f93c-40d4-bbc5-2be295427405" xlink:href="ardx-20221231.xsd#ardx_SharesAvailableForGrantRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4f90cc5b-355d-4289-a51c-4cebbda26ddb" xlink:to="loc_ardx_SharesAvailableForGrantRollForward_e5d45748-f93c-40d4-bbc5-2be295427405" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4fadacc4-c5c3-4fc0-9ea8-e0c80d6c8b16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_SharesAvailableForGrantRollForward_e5d45748-f93c-40d4-bbc5-2be295427405" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4fadacc4-c5c3-4fc0-9ea8-e0c80d6c8b16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToAuthorizedInPeriod_4b86b04a-bf34-413a-98df-1d501fb392a8" xlink:href="ardx-20221231.xsd#ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToAuthorizedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_SharesAvailableForGrantRollForward_e5d45748-f93c-40d4-bbc5-2be295427405" xlink:to="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToAuthorizedInPeriod_4b86b04a-bf34-413a-98df-1d501fb392a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToGrantedInPeriod_a61ccdfe-56e6-4e9e-9a94-7aa230777639" xlink:href="ardx-20221231.xsd#ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToGrantedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_SharesAvailableForGrantRollForward_e5d45748-f93c-40d4-bbc5-2be295427405" xlink:to="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToGrantedInPeriod_a61ccdfe-56e6-4e9e-9a94-7aa230777639" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToCanceledInPeriod_738cda17-b094-489b-a923-aac6401ece23" xlink:href="ardx-20221231.xsd#ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToCanceledInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_SharesAvailableForGrantRollForward_e5d45748-f93c-40d4-bbc5-2be295427405" xlink:to="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToCanceledInPeriod_738cda17-b094-489b-a923-aac6401ece23" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToStockIssuedForServicesInPeriod_90829926-9b89-4c89-9a3b-1191724788c9" xlink:href="ardx-20221231.xsd#ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToStockIssuedForServicesInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_SharesAvailableForGrantRollForward_e5d45748-f93c-40d4-bbc5-2be295427405" xlink:to="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToStockIssuedForServicesInPeriod_90829926-9b89-4c89-9a3b-1191724788c9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3e1647f3-1e85-431f-bf61-c991055073fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_82e8c1c1-1c56-42c0-b7de-a2d59efb12e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4f90cc5b-355d-4289-a51c-4cebbda26ddb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_82e8c1c1-1c56-42c0-b7de-a2d59efb12e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b1083c52-6306-4da6-9494-38a31dc07022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_82e8c1c1-1c56-42c0-b7de-a2d59efb12e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b1083c52-6306-4da6-9494-38a31dc07022" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_cfbf1b02-433d-4177-97cc-81a25b95928f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_82e8c1c1-1c56-42c0-b7de-a2d59efb12e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_cfbf1b02-433d-4177-97cc-81a25b95928f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_da025575-263e-4628-b47a-9a74ea512637" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_82e8c1c1-1c56-42c0-b7de-a2d59efb12e7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_da025575-263e-4628-b47a-9a74ea512637" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1117ad07-1406-47f3-9da6-2db6dc045a31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_82e8c1c1-1c56-42c0-b7de-a2d59efb12e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1117ad07-1406-47f3-9da6-2db6dc045a31" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4c45373f-099b-40c7-999a-a523f15f7ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_5d16601d-6c83-42a9-a7f7-6a5a90b797e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4f90cc5b-355d-4289-a51c-4cebbda26ddb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_5d16601d-6c83-42a9-a7f7-6a5a90b797e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_f8d844a5-9fb6-4909-bfa3-eeece62e3949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4f90cc5b-355d-4289-a51c-4cebbda26ddb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_f8d844a5-9fb6-4909-bfa3-eeece62e3949" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3c68c64b-cf22-4117-bcd5-dbd044cbfdbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4f90cc5b-355d-4289-a51c-4cebbda26ddb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3c68c64b-cf22-4117-bcd5-dbd044cbfdbf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_fb34090f-36a2-476f-940d-11c810dc7f69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3c68c64b-cf22-4117-bcd5-dbd044cbfdbf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_fb34090f-36a2-476f-940d-11c810dc7f69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_911f9076-58ca-4606-9d83-5e8f82cd7c52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3c68c64b-cf22-4117-bcd5-dbd044cbfdbf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_911f9076-58ca-4606-9d83-5e8f82cd7c52" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_241ae984-7049-49e5-93d4-21a9b5f09473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3c68c64b-cf22-4117-bcd5-dbd044cbfdbf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_241ae984-7049-49e5-93d4-21a9b5f09473" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4df37603-5676-4d77-858a-1cd2f77b7b25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3c68c64b-cf22-4117-bcd5-dbd044cbfdbf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4df37603-5676-4d77-858a-1cd2f77b7b25" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_725a6d10-1acf-460f-80ed-2b37203bbfb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_4647c9bf-e426-4057-9761-f4d4c799c00a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4f90cc5b-355d-4289-a51c-4cebbda26ddb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_4647c9bf-e426-4057-9761-f4d4c799c00a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3fc8476f-f2e5-4998-8e3e-13fd7f0a2436" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4f90cc5b-355d-4289-a51c-4cebbda26ddb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3fc8476f-f2e5-4998-8e3e-13fd7f0a2436" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_StockOptionsWeightedAverageRemainingContractualTermAbstract_058878bd-7160-4657-92ff-9716c4a6465f" xlink:href="ardx-20221231.xsd#ardx_StockOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4f90cc5b-355d-4289-a51c-4cebbda26ddb" xlink:to="loc_ardx_StockOptionsWeightedAverageRemainingContractualTermAbstract_058878bd-7160-4657-92ff-9716c4a6465f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c15a4917-9a0d-4aac-bdbc-516399be6e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_StockOptionsWeightedAverageRemainingContractualTermAbstract_058878bd-7160-4657-92ff-9716c4a6465f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c15a4917-9a0d-4aac-bdbc-516399be6e2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_589a5956-edaa-42ac-83e9-1507a176713b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_StockOptionsWeightedAverageRemainingContractualTermAbstract_058878bd-7160-4657-92ff-9716c4a6465f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_589a5956-edaa-42ac-83e9-1507a176713b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_70586958-406e-45c8-915a-c07adc5b6207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_StockOptionsWeightedAverageRemainingContractualTermAbstract_058878bd-7160-4657-92ff-9716c4a6465f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_70586958-406e-45c8-915a-c07adc5b6207" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_StockOptionsAggregateIntrinsicValueAbstract_b18dce39-a43e-4eed-aa2b-2b919e5962fd" xlink:href="ardx-20221231.xsd#ardx_StockOptionsAggregateIntrinsicValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4f90cc5b-355d-4289-a51c-4cebbda26ddb" xlink:to="loc_ardx_StockOptionsAggregateIntrinsicValueAbstract_b18dce39-a43e-4eed-aa2b-2b919e5962fd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1bad0ff6-1e8e-4b7d-9ae4-542a4624ddb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_StockOptionsAggregateIntrinsicValueAbstract_b18dce39-a43e-4eed-aa2b-2b919e5962fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1bad0ff6-1e8e-4b7d-9ae4-542a4624ddb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_75142d1f-e263-4697-8558-1d4b99bc0142" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_StockOptionsAggregateIntrinsicValueAbstract_b18dce39-a43e-4eed-aa2b-2b919e5962fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_75142d1f-e263-4697-8558-1d4b99bc0142" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_04dba744-e55c-4d8a-8ce1-5d688a416949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_StockOptionsAggregateIntrinsicValueAbstract_b18dce39-a43e-4eed-aa2b-2b919e5962fd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_04dba744-e55c-4d8a-8ce1-5d688a416949" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9ddbfe0a-1191-490f-a34d-1f8c10b65a40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4f90cc5b-355d-4289-a51c-4cebbda26ddb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9ddbfe0a-1191-490f-a34d-1f8c10b65a40" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4877e3cd-dc6e-4869-add5-39c25d193c36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9ddbfe0a-1191-490f-a34d-1f8c10b65a40" xlink:to="loc_us-gaap_AwardTypeAxis_4877e3cd-dc6e-4869-add5-39c25d193c36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4877e3cd-dc6e-4869-add5-39c25d193c36_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4877e3cd-dc6e-4869-add5-39c25d193c36" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4877e3cd-dc6e-4869-add5-39c25d193c36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d4ddddca-b4ef-4c83-a929-3d153bd382ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4877e3cd-dc6e-4869-add5-39c25d193c36" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d4ddddca-b4ef-4c83-a929-3d153bd382ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_fa73869a-99de-4239-863c-3ad77b19a42c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d4ddddca-b4ef-4c83-a929-3d153bd382ee" xlink:to="loc_us-gaap_EmployeeStockOptionMember_fa73869a-99de-4239-863c-3ad77b19a42c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansValuationAssumptionsforStockOptionsDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#EquityIncentivePlansValuationAssumptionsforStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansValuationAssumptionsforStockOptionsDetails" xlink:type="extended" id="i9b2c878780524b7ca14c87f05ca0348a_EquityIncentivePlansValuationAssumptionsforStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed134030-dadf-4cab-ab27-5d3350324fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0a535f41-50af-4204-986a-5353180e64b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed134030-dadf-4cab-ab27-5d3350324fb0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0a535f41-50af-4204-986a-5353180e64b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b5e9d3cd-3242-4c7d-9fe2-c346c133e590" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed134030-dadf-4cab-ab27-5d3350324fb0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b5e9d3cd-3242-4c7d-9fe2-c346c133e590" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_56652d95-b09b-489b-a185-9622df0faf30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed134030-dadf-4cab-ab27-5d3350324fb0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_56652d95-b09b-489b-a185-9622df0faf30" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_59f5b076-1fe3-49f1-bdb1-89418431149b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed134030-dadf-4cab-ab27-5d3350324fb0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_59f5b076-1fe3-49f1-bdb1-89418431149b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_759eef25-7145-4d00-a93f-94d5a8972b70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed134030-dadf-4cab-ab27-5d3350324fb0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_759eef25-7145-4d00-a93f-94d5a8972b70" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_01f0c420-f228-4615-984e-433a994ac7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_759eef25-7145-4d00-a93f-94d5a8972b70" xlink:to="loc_us-gaap_AwardTypeAxis_01f0c420-f228-4615-984e-433a994ac7c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_01f0c420-f228-4615-984e-433a994ac7c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_01f0c420-f228-4615-984e-433a994ac7c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_01f0c420-f228-4615-984e-433a994ac7c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_718eb1d6-74d9-4ea9-95b0-a91f9e2cdfde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_01f0c420-f228-4615-984e-433a994ac7c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_718eb1d6-74d9-4ea9-95b0-a91f9e2cdfde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_dfb5b6c7-f920-472e-ba8a-90c46740c0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_718eb1d6-74d9-4ea9-95b0-a91f9e2cdfde" xlink:to="loc_us-gaap_EmployeeStockOptionMember_dfb5b6c7-f920-472e-ba8a-90c46740c0b6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#EquityIncentivePlansRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails" xlink:type="extended" id="i8cc05af3d8a74e2aa5d7675631a1bcc4_EquityIncentivePlansRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_55098dac-b9c4-4878-bcc2-0df168d26ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_756204f1-9b69-4390-9aee-0df5ab131dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_55098dac-b9c4-4878-bcc2-0df168d26ea1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_756204f1-9b69-4390-9aee-0df5ab131dbd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3354d59d-2c72-4a58-ae07-a15a9a6cc17c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_756204f1-9b69-4390-9aee-0df5ab131dbd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3354d59d-2c72-4a58-ae07-a15a9a6cc17c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3a38ad8d-6f57-40ea-874e-d9a2a0ca23e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_756204f1-9b69-4390-9aee-0df5ab131dbd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3a38ad8d-6f57-40ea-874e-d9a2a0ca23e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ccdcfb1f-0b7d-413e-94d8-7b22e8caf856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_756204f1-9b69-4390-9aee-0df5ab131dbd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ccdcfb1f-0b7d-413e-94d8-7b22e8caf856" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c4241dfd-a9d7-45fc-a92f-ec200a323d77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_756204f1-9b69-4390-9aee-0df5ab131dbd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c4241dfd-a9d7-45fc-a92f-ec200a323d77" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_41c64dd2-d3a8-4653-ae76-ab602704f499" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c24050ce-146b-4dfc-b476-3524c45260dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_55098dac-b9c4-4878-bcc2-0df168d26ea1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c24050ce-146b-4dfc-b476-3524c45260dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7e5d8fb4-6e8d-4491-85b7-6d952ee7e76c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c24050ce-146b-4dfc-b476-3524c45260dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7e5d8fb4-6e8d-4491-85b7-6d952ee7e76c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1334db81-579c-4ffe-bd07-2904152f4e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c24050ce-146b-4dfc-b476-3524c45260dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1334db81-579c-4ffe-bd07-2904152f4e7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_15b71e3e-886f-4fa2-b69a-864605f4a03d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c24050ce-146b-4dfc-b476-3524c45260dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_15b71e3e-886f-4fa2-b69a-864605f4a03d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e4174be3-a470-4216-a1d8-5cadb1ed6f38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c24050ce-146b-4dfc-b476-3524c45260dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e4174be3-a470-4216-a1d8-5cadb1ed6f38" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1da34b40-c61b-4e48-87a7-80b1daeb02ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a91a0f81-b8e5-41ec-8d68-cf1410bbf2f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_55098dac-b9c4-4878-bcc2-0df168d26ea1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a91a0f81-b8e5-41ec-8d68-cf1410bbf2f3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e4671064-9dbb-44b6-aae2-3610f8bb6a17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a91a0f81-b8e5-41ec-8d68-cf1410bbf2f3" xlink:to="loc_us-gaap_AwardTypeAxis_e4671064-9dbb-44b6-aae2-3610f8bb6a17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e4671064-9dbb-44b6-aae2-3610f8bb6a17_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e4671064-9dbb-44b6-aae2-3610f8bb6a17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e4671064-9dbb-44b6-aae2-3610f8bb6a17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_00ae4b97-35c5-4159-943a-ac4de4d0b449" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e4671064-9dbb-44b6-aae2-3610f8bb6a17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_00ae4b97-35c5-4159-943a-ac4de4d0b449" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8faa6be5-4816-48e1-8a3c-b577ea33dc78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_00ae4b97-35c5-4159-943a-ac4de4d0b449" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8faa6be5-4816-48e1-8a3c-b577ea33dc78" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#EquityIncentivePlansEmployeeStockPurchasePlanDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansEmployeeStockPurchasePlanDetails" xlink:type="extended" id="i7aebd09dd9bd4ee4b4915c9e129de66d_EquityIncentivePlansEmployeeStockPurchasePlanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ce6ae36f-e434-4a6f-a102-eb0c64014c95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EmployeeStockPurchasePlanSharesAvailableRollForward_c787bfcc-2c4a-4690-a51c-ec9a5b362717" xlink:href="ardx-20221231.xsd#ardx_EmployeeStockPurchasePlanSharesAvailableRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ce6ae36f-e434-4a6f-a102-eb0c64014c95" xlink:to="loc_ardx_EmployeeStockPurchasePlanSharesAvailableRollForward_c787bfcc-2c4a-4690-a51c-ec9a5b362717" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4e7af3a2-42bf-40a9-8b13-c726ba92687c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_EmployeeStockPurchasePlanSharesAvailableRollForward_c787bfcc-2c4a-4690-a51c-ec9a5b362717" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4e7af3a2-42bf-40a9-8b13-c726ba92687c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsPurchases_141ba8e8-8e65-42b5-bb1b-d592f50e854d" xlink:href="ardx-20221231.xsd#ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsPurchases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_EmployeeStockPurchasePlanSharesAvailableRollForward_c787bfcc-2c4a-4690-a51c-ec9a5b362717" xlink:to="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsPurchases_141ba8e8-8e65-42b5-bb1b-d592f50e854d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_de8800ff-cb6f-4094-a4fd-291b605574cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EmployeeStockPurchasePlanSharesPurchasedRollForward_0d6eb861-2150-4a31-8d46-d5b8e6084882" xlink:href="ardx-20221231.xsd#ardx_EmployeeStockPurchasePlanSharesPurchasedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ce6ae36f-e434-4a6f-a102-eb0c64014c95" xlink:to="loc_ardx_EmployeeStockPurchasePlanSharesPurchasedRollForward_0d6eb861-2150-4a31-8d46-d5b8e6084882" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesStockPurchasePlanPurchasedNumber_23df0ff5-60cd-4ac0-ac8f-cea4c3b061cb" xlink:href="ardx-20221231.xsd#ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesStockPurchasePlanPurchasedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_EmployeeStockPurchasePlanSharesPurchasedRollForward_0d6eb861-2150-4a31-8d46-d5b8e6084882" xlink:to="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesStockPurchasePlanPurchasedNumber_23df0ff5-60cd-4ac0-ac8f-cea4c3b061cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_2a688349-c2aa-47fa-80b4-dd8d12075e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_EmployeeStockPurchasePlanSharesPurchasedRollForward_0d6eb861-2150-4a31-8d46-d5b8e6084882" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_2a688349-c2aa-47fa-80b4-dd8d12075e8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesStockPurchasePlanPurchasedNumber_8609bc2c-f5c4-422c-91ff-4129f5d3b117" xlink:href="ardx-20221231.xsd#ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesStockPurchasePlanPurchasedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare_c41ee6f1-a6f8-4cb1-b545-cc8388ff5914" xlink:href="ardx-20221231.xsd#ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ce6ae36f-e434-4a6f-a102-eb0c64014c95" xlink:to="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare_c41ee6f1-a6f8-4cb1-b545-cc8388ff5914" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanGrossProceeds_6da3844a-c94c-4320-98cc-2c6f7da4077b" xlink:href="ardx-20221231.xsd#ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanGrossProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ce6ae36f-e434-4a6f-a102-eb0c64014c95" xlink:to="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanGrossProceeds_6da3844a-c94c-4320-98cc-2c6f7da4077b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a206eb91-5168-4f46-8794-178ac453debb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ce6ae36f-e434-4a6f-a102-eb0c64014c95" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a206eb91-5168-4f46-8794-178ac453debb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_72b1de21-3275-47a0-b1f0-6581ce881902" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a206eb91-5168-4f46-8794-178ac453debb" xlink:to="loc_us-gaap_PlanNameAxis_72b1de21-3275-47a0-b1f0-6581ce881902" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_72b1de21-3275-47a0-b1f0-6581ce881902_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_72b1de21-3275-47a0-b1f0-6581ce881902" xlink:to="loc_us-gaap_PlanNameDomain_72b1de21-3275-47a0-b1f0-6581ce881902_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_bbb63140-f8e1-4049-b95d-27780f3f4db8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_72b1de21-3275-47a0-b1f0-6581ce881902" xlink:to="loc_us-gaap_PlanNameDomain_bbb63140-f8e1-4049-b95d-27780f3f4db8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EmployeeStockPurchasePlanMember_e57408b3-6eac-4c4b-938e-cf763a2c81ca" xlink:href="ardx-20221231.xsd#ardx_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_bbb63140-f8e1-4049-b95d-27780f3f4db8" xlink:to="loc_ardx_EmployeeStockPurchasePlanMember_e57408b3-6eac-4c4b-938e-cf763a2c81ca" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansValuationAssumptionsforESPPDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#EquityIncentivePlansValuationAssumptionsforESPPDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansValuationAssumptionsforESPPDetails" xlink:type="extended" id="i560aa37394dd4ab199ab6038c222d090_EquityIncentivePlansValuationAssumptionsforESPPDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_86fc0be5-1ac3-411f-b44c-77dd993e40bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4feb738f-0818-4fd3-b9f9-3e2d494fc4df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_86fc0be5-1ac3-411f-b44c-77dd993e40bd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4feb738f-0818-4fd3-b9f9-3e2d494fc4df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_86eae2f7-4d8d-434b-8138-970f496a8cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_86fc0be5-1ac3-411f-b44c-77dd993e40bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_86eae2f7-4d8d-434b-8138-970f496a8cd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_75c88651-22ab-4773-a87b-db44a4fa7fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_86fc0be5-1ac3-411f-b44c-77dd993e40bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_75c88651-22ab-4773-a87b-db44a4fa7fb1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a7a9fb1e-173d-444e-b2e5-3e0481c2d285" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_86fc0be5-1ac3-411f-b44c-77dd993e40bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a7a9fb1e-173d-444e-b2e5-3e0481c2d285" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_849040e3-66bd-4de0-88fb-c41633831903" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_86fc0be5-1ac3-411f-b44c-77dd993e40bd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_849040e3-66bd-4de0-88fb-c41633831903" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_32d878bb-7977-4070-8aa5-b0033feb30e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_849040e3-66bd-4de0-88fb-c41633831903" xlink:to="loc_us-gaap_PlanNameAxis_32d878bb-7977-4070-8aa5-b0033feb30e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_32d878bb-7977-4070-8aa5-b0033feb30e0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_32d878bb-7977-4070-8aa5-b0033feb30e0" xlink:to="loc_us-gaap_PlanNameDomain_32d878bb-7977-4070-8aa5-b0033feb30e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7fe43479-e893-470a-b378-678c8398537f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_32d878bb-7977-4070-8aa5-b0033feb30e0" xlink:to="loc_us-gaap_PlanNameDomain_7fe43479-e893-470a-b378-678c8398537f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EmployeeStockPurchasePlanMember_5d30dbbe-8386-4eef-8a59-779a44379ac4" xlink:href="ardx-20221231.xsd#ardx_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7fe43479-e893-470a-b378-678c8398537f" xlink:to="loc_ardx_EmployeeStockPurchasePlanMember_5d30dbbe-8386-4eef-8a59-779a44379ac4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#EquityIncentivePlansStockBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails" xlink:type="extended" id="ic255f9a60dd948adb4c39a324be5dfd3_EquityIncentivePlansStockBasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_07fa9425-4df5-402c-9575-a41348762d55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1e54ae58-6713-41ca-91b8-3b58d8748cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_07fa9425-4df5-402c-9575-a41348762d55" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1e54ae58-6713-41ca-91b8-3b58d8748cdb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_04417ac8-a6c6-4013-a6bb-c164ed327475" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_07fa9425-4df5-402c-9575-a41348762d55" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_04417ac8-a6c6-4013-a6bb-c164ed327475" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2089961c-0e02-4e9c-b236-4dc54b48c362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_04417ac8-a6c6-4013-a6bb-c164ed327475" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2089961c-0e02-4e9c-b236-4dc54b48c362" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2089961c-0e02-4e9c-b236-4dc54b48c362_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2089961c-0e02-4e9c-b236-4dc54b48c362" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2089961c-0e02-4e9c-b236-4dc54b48c362_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_643eb763-7570-4c20-8233-5f3fc0ac1c55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2089961c-0e02-4e9c-b236-4dc54b48c362" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_643eb763-7570-4c20-8233-5f3fc0ac1c55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_7e3d26aa-44af-4740-b962-17825c622301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_643eb763-7570-4c20-8233-5f3fc0ac1c55" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_7e3d26aa-44af-4740-b962-17825c622301" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7dd9d1b3-0bdd-4d42-afee-b827e9055942" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_643eb763-7570-4c20-8233-5f3fc0ac1c55" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7dd9d1b3-0bdd-4d42-afee-b827e9055942" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails" xlink:type="extended" id="if6e50d2162f0466a8ad295889fc1b4ab_EquityIncentivePlansUnrecognizedStockBasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f0c3e8-6bb1-47c1-adb9-7801e85de4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3b640e92-d8bb-49f9-a065-bc2c4fd1f34f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f0c3e8-6bb1-47c1-adb9-7801e85de4e3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3b640e92-d8bb-49f9-a065-bc2c4fd1f34f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5af3972b-b1cd-43c0-8f11-6d942e3a77e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f0c3e8-6bb1-47c1-adb9-7801e85de4e3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5af3972b-b1cd-43c0-8f11-6d942e3a77e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4f89a1f3-b8ff-48ef-90cf-2617ad5a815b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f0c3e8-6bb1-47c1-adb9-7801e85de4e3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4f89a1f3-b8ff-48ef-90cf-2617ad5a815b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d408d773-60d7-4317-98cf-777799de37c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4f89a1f3-b8ff-48ef-90cf-2617ad5a815b" xlink:to="loc_us-gaap_PlanNameAxis_d408d773-60d7-4317-98cf-777799de37c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d408d773-60d7-4317-98cf-777799de37c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_d408d773-60d7-4317-98cf-777799de37c7" xlink:to="loc_us-gaap_PlanNameDomain_d408d773-60d7-4317-98cf-777799de37c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_bb4aacee-6034-4271-9ebb-7e87ccc65ced" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_d408d773-60d7-4317-98cf-777799de37c7" xlink:to="loc_us-gaap_PlanNameDomain_bb4aacee-6034-4271-9ebb-7e87ccc65ced" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EmployeeStockPurchasePlanMember_0394e5cc-fa53-4812-afe9-81975bea3bd9" xlink:href="ardx-20221231.xsd#ardx_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_bb4aacee-6034-4271-9ebb-7e87ccc65ced" xlink:to="loc_ardx_EmployeeStockPurchasePlanMember_0394e5cc-fa53-4812-afe9-81975bea3bd9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_12a2d913-1b62-4936-8beb-5491d1135866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4f89a1f3-b8ff-48ef-90cf-2617ad5a815b" xlink:to="loc_us-gaap_AwardTypeAxis_12a2d913-1b62-4936-8beb-5491d1135866" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_12a2d913-1b62-4936-8beb-5491d1135866_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_12a2d913-1b62-4936-8beb-5491d1135866" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_12a2d913-1b62-4936-8beb-5491d1135866_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9076ac3c-1577-4a5e-be69-8dda51a6988f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_12a2d913-1b62-4936-8beb-5491d1135866" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9076ac3c-1577-4a5e-be69-8dda51a6988f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_672c6012-2e7e-4391-ab7e-52589e7c3c08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9076ac3c-1577-4a5e-be69-8dda51a6988f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_672c6012-2e7e-4391-ab7e-52589e7c3c08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_706a06c5-ca56-4f0f-9705-d2f1a9a43d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9076ac3c-1577-4a5e-be69-8dda51a6988f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_706a06c5-ca56-4f0f-9705-d2f1a9a43d2c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/RestructuringDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#RestructuringDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/RestructuringDetails" xlink:type="extended" id="i992d304242c04a6899f4f74b8bbcde1b_RestructuringDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_75ced200-6e12-4d30-b0a0-8716b7453667" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_1ce3d273-d144-4655-adb4-9b7cd3e6ce41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_75ced200-6e12-4d30-b0a0-8716b7453667" xlink:to="loc_us-gaap_RestructuringCharges_1ce3d273-d144-4655-adb4-9b7cd3e6ce41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveCurrent_09f8e274-53c6-4e06-ab4c-05f3807c5e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_75ced200-6e12-4d30-b0a0-8716b7453667" xlink:to="loc_us-gaap_RestructuringReserveCurrent_09f8e274-53c6-4e06-ab4c-05f3807c5e0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_37db8736-d548-4e3f-9f94-fc4dbf131ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_75ced200-6e12-4d30-b0a0-8716b7453667" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_37db8736-d548-4e3f-9f94-fc4dbf131ff7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c1c3e68f-7615-4081-a53c-df78c6bc24f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_37db8736-d548-4e3f-9f94-fc4dbf131ff7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c1c3e68f-7615-4081-a53c-df78c6bc24f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c1c3e68f-7615-4081-a53c-df78c6bc24f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c1c3e68f-7615-4081-a53c-df78c6bc24f9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c1c3e68f-7615-4081-a53c-df78c6bc24f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_33caf570-7f45-4a2a-ad7d-fbdad0d07c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c1c3e68f-7615-4081-a53c-df78c6bc24f9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_33caf570-7f45-4a2a-ad7d-fbdad0d07c9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_aa7079ba-a1cc-4d9a-a4b5-331a65182dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_33caf570-7f45-4a2a-ad7d-fbdad0d07c9c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_aa7079ba-a1cc-4d9a-a4b5-331a65182dd5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_20965baf-6c5b-4268-a7af-fc8ffc7366e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_33caf570-7f45-4a2a-ad7d-fbdad0d07c9c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_20965baf-6c5b-4268-a7af-fc8ffc7366e0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/PropertyandEquipmentNetBalancesDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#PropertyandEquipmentNetBalancesDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/PropertyandEquipmentNetBalancesDetails" xlink:type="extended" id="i0f4b0c2c9ffb45a8abce2060251ab9ef_PropertyandEquipmentNetBalancesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c2345e30-7812-4069-a8a9-164d37aa3ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_00407546-8913-4ee8-9d00-dfe5de1efc17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c2345e30-7812-4069-a8a9-164d37aa3ff8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_00407546-8913-4ee8-9d00-dfe5de1efc17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f3895e46-227b-4e00-b7bc-e4be679bc9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c2345e30-7812-4069-a8a9-164d37aa3ff8" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f3895e46-227b-4e00-b7bc-e4be679bc9a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_72ebd1e3-1950-4545-94b0-8d7f77a49769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c2345e30-7812-4069-a8a9-164d37aa3ff8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_72ebd1e3-1950-4545-94b0-8d7f77a49769" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_741b8667-afe0-452e-9d55-85e480022c57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c2345e30-7812-4069-a8a9-164d37aa3ff8" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_741b8667-afe0-452e-9d55-85e480022c57" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cb56546f-1c81-464c-9015-21f66cfafc67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_741b8667-afe0-452e-9d55-85e480022c57" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cb56546f-1c81-464c-9015-21f66cfafc67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cb56546f-1c81-464c-9015-21f66cfafc67_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cb56546f-1c81-464c-9015-21f66cfafc67" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cb56546f-1c81-464c-9015-21f66cfafc67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_65e9ef6f-d26b-42f3-b51e-d51866027158" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cb56546f-1c81-464c-9015-21f66cfafc67" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_65e9ef6f-d26b-42f3-b51e-d51866027158" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LaboratoryEquipmentMember_0e48c14c-0f08-4b43-a0e6-c6f2c7e01b33" xlink:href="ardx-20221231.xsd#ardx_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_65e9ef6f-d26b-42f3-b51e-d51866027158" xlink:to="loc_ardx_LaboratoryEquipmentMember_0e48c14c-0f08-4b43-a0e6-c6f2c7e01b33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_OfficeEquipmentAndFurnitureMember_f4a84db9-be63-48d5-b159-a89eaa49ac58" xlink:href="ardx-20221231.xsd#ardx_OfficeEquipmentAndFurnitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_65e9ef6f-d26b-42f3-b51e-d51866027158" xlink:to="loc_ardx_OfficeEquipmentAndFurnitureMember_f4a84db9-be63-48d5-b159-a89eaa49ac58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_a8a46d80-0de2-4e7c-b023-717ebd1c8b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_65e9ef6f-d26b-42f3-b51e-d51866027158" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_a8a46d80-0de2-4e7c-b023-717ebd1c8b6d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="ifafc01817e3a4a0f96821b7fc0d1fea8_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ardx_IncomeTaxDisclosureLineItems_a535559f-1d41-4398-8a99-141fd47efa51" xlink:href="ardx-20221231.xsd#ardx_IncomeTaxDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_00287ef5-fa3c-454e-a15f-c9a69e3b260c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_IncomeTaxDisclosureLineItems_a535559f-1d41-4398-8a99-141fd47efa51" xlink:to="loc_us-gaap_OperatingLossCarryforwards_00287ef5-fa3c-454e-a15f-c9a69e3b260c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_8f7961ca-8432-4e17-b506-abb61610e12b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_IncomeTaxDisclosureLineItems_a535559f-1d41-4398-8a99-141fd47efa51" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_8f7961ca-8432-4e17-b506-abb61610e12b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_OperatingLossCarryforwardsWithoutExpiration_0316e6aa-c182-4585-a69c-8478d3751438" xlink:href="ardx-20221231.xsd#ardx_OperatingLossCarryforwardsWithoutExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_IncomeTaxDisclosureLineItems_a535559f-1d41-4398-8a99-141fd47efa51" xlink:to="loc_ardx_OperatingLossCarryforwardsWithoutExpiration_0316e6aa-c182-4585-a69c-8478d3751438" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_0e11eb7a-b303-40f1-90f1-7f0e44cc014c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_IncomeTaxDisclosureLineItems_a535559f-1d41-4398-8a99-141fd47efa51" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_0e11eb7a-b303-40f1-90f1-7f0e44cc014c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_IncomeTaxDisclosureTable_4bc2de47-8a60-4c3d-8730-0562f98157b2" xlink:href="ardx-20221231.xsd#ardx_IncomeTaxDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ardx_IncomeTaxDisclosureLineItems_a535559f-1d41-4398-8a99-141fd47efa51" xlink:to="loc_ardx_IncomeTaxDisclosureTable_4bc2de47-8a60-4c3d-8730-0562f98157b2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_3af502a5-3b70-4370-af2e-95ee47958f80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ardx_IncomeTaxDisclosureTable_4bc2de47-8a60-4c3d-8730-0562f98157b2" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_3af502a5-3b70-4370-af2e-95ee47958f80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_3af502a5-3b70-4370-af2e-95ee47958f80_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_3af502a5-3b70-4370-af2e-95ee47958f80" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_3af502a5-3b70-4370-af2e-95ee47958f80_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_25fd9571-2910-4971-910a-5cb7a957b276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_3af502a5-3b70-4370-af2e-95ee47958f80" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_25fd9571-2910-4971-910a-5cb7a957b276" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_68f760ab-4e43-4217-8fad-75e58616b680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_25fd9571-2910-4971-910a-5cb7a957b276" xlink:to="loc_us-gaap_DomesticCountryMember_68f760ab-4e43-4217-8fad-75e58616b680" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_ffbc49e7-8cd2-4ca6-be6c-b08833a303af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_25fd9571-2910-4971-910a-5cb7a957b276" xlink:to="loc_us-gaap_ForeignCountryMember_ffbc49e7-8cd2-4ca6-be6c-b08833a303af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_48a21601-471f-4d0c-82a6-ff24e276ddf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_25fd9571-2910-4971-910a-5cb7a957b276" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_48a21601-471f-4d0c-82a6-ff24e276ddf2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_ad974fa8-7d9f-45d4-b040-81ee619ee2c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ardx_IncomeTaxDisclosureTable_4bc2de47-8a60-4c3d-8730-0562f98157b2" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_ad974fa8-7d9f-45d4-b040-81ee619ee2c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_ad974fa8-7d9f-45d4-b040-81ee619ee2c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_ad974fa8-7d9f-45d4-b040-81ee619ee2c3" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_ad974fa8-7d9f-45d4-b040-81ee619ee2c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_b9d829e1-6c59-49c3-908f-399db3103d11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_ad974fa8-7d9f-45d4-b040-81ee619ee2c3" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_b9d829e1-6c59-49c3-908f-399db3103d11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_6fc78369-fdc5-40a8-a47c-5b2aa7d9c3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_b9d829e1-6c59-49c3-908f-399db3103d11" xlink:to="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_6fc78369-fdc5-40a8-a47c-5b2aa7d9c3dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TaxAuthorityStatesOtherThanCaliforniaMember_f82c9495-d4ee-456b-9749-a678512bf927" xlink:href="ardx-20221231.xsd#ardx_TaxAuthorityStatesOtherThanCaliforniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_b9d829e1-6c59-49c3-908f-399db3103d11" xlink:to="loc_ardx_TaxAuthorityStatesOtherThanCaliforniaMember_f82c9495-d4ee-456b-9749-a678512bf927" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_132b2551-a7a8-446d-a1e9-d485cd04ad24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ardx_IncomeTaxDisclosureTable_4bc2de47-8a60-4c3d-8730-0562f98157b2" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_132b2551-a7a8-446d-a1e9-d485cd04ad24" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_132b2551-a7a8-446d-a1e9-d485cd04ad24_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_132b2551-a7a8-446d-a1e9-d485cd04ad24" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_132b2551-a7a8-446d-a1e9-d485cd04ad24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_8404e880-63d8-4c14-9bce-dc63f8665238" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_132b2551-a7a8-446d-a1e9-d485cd04ad24" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_8404e880-63d8-4c14-9bce-dc63f8665238" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_b23ad8f2-517e-4a4c-9d90-ee64bc897cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_8404e880-63d8-4c14-9bce-dc63f8665238" xlink:to="loc_us-gaap_ResearchMember_b23ad8f2-517e-4a4c-9d90-ee64bc897cf3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_MinimumTaxCreditCarryforwardMember_516c8762-7276-4b8e-8e7e-bc36f3b9aa0e" xlink:href="ardx-20221231.xsd#ardx_MinimumTaxCreditCarryforwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_8404e880-63d8-4c14-9bce-dc63f8665238" xlink:to="loc_ardx_MinimumTaxCreditCarryforwardMember_516c8762-7276-4b8e-8e7e-bc36f3b9aa0e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/GeographicInformationandConcentrationsRevenuebyGeographicalAreaDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#GeographicInformationandConcentrationsRevenuebyGeographicalAreaDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/GeographicInformationandConcentrationsRevenuebyGeographicalAreaDetails" xlink:type="extended" id="iffe669f7e8bc4a72bfe20994148b0dbe_GeographicInformationandConcentrationsRevenuebyGeographicalAreaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_718c4a95-6c1d-42d9-b434-129e31353a37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1397ba9e-57d8-40d7-ad00-c09a63346e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_718c4a95-6c1d-42d9-b434-129e31353a37" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1397ba9e-57d8-40d7-ad00-c09a63346e7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_e9cf9487-e4b6-4989-92f6-4f96d6eca650" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_718c4a95-6c1d-42d9-b434-129e31353a37" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_e9cf9487-e4b6-4989-92f6-4f96d6eca650" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_09f77312-b0ca-4ccf-b3d8-9f09e93a228b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_e9cf9487-e4b6-4989-92f6-4f96d6eca650" xlink:to="loc_srt_StatementGeographicalAxis_09f77312-b0ca-4ccf-b3d8-9f09e93a228b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_09f77312-b0ca-4ccf-b3d8-9f09e93a228b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_09f77312-b0ca-4ccf-b3d8-9f09e93a228b" xlink:to="loc_srt_SegmentGeographicalDomain_09f77312-b0ca-4ccf-b3d8-9f09e93a228b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ca0a1faa-18c4-41c8-8e90-242a03846373" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_09f77312-b0ca-4ccf-b3d8-9f09e93a228b" xlink:to="loc_srt_SegmentGeographicalDomain_ca0a1faa-18c4-41c8-8e90-242a03846373" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_115168f4-66b7-4973-ba02-d1e9f4fc2029" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ca0a1faa-18c4-41c8-8e90-242a03846373" xlink:to="loc_country_US_115168f4-66b7-4973-ba02-d1e9f4fc2029" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_c47f10a9-32ab-4029-a090-858486691cc8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AsiaPacificMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ca0a1faa-18c4-41c8-8e90-242a03846373" xlink:to="loc_srt_AsiaPacificMember_c47f10a9-32ab-4029-a090-858486691cc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_5cb3ea89-6131-4402-b9d7-3d0afd744bdb" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ca0a1faa-18c4-41c8-8e90-242a03846373" xlink:to="loc_country_CA_5cb3ea89-6131-4402-b9d7-3d0afd744bdb" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/GeographicInformationandConcentrationsConcentrationRiskDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#GeographicInformationandConcentrationsConcentrationRiskDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/GeographicInformationandConcentrationsConcentrationRiskDetails" xlink:type="extended" id="i50d2540706844876a2c48189fa7a4992_GeographicInformationandConcentrationsConcentrationRiskDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_9d9d43cd-2084-46c4-8866-de5f0cbcfd31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_1c02b2dc-32c5-437c-86ca-b579b2ea8bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9d9d43cd-2084-46c4-8866-de5f0cbcfd31" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_1c02b2dc-32c5-437c-86ca-b579b2ea8bd2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_571d585a-8591-47d3-a1b6-c8ee1b301fae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9d9d43cd-2084-46c4-8866-de5f0cbcfd31" xlink:to="loc_us-gaap_ConcentrationRiskTable_571d585a-8591-47d3-a1b6-c8ee1b301fae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a797424e-c829-4ee2-8983-64a0143f3ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_571d585a-8591-47d3-a1b6-c8ee1b301fae" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a797424e-c829-4ee2-8983-64a0143f3ee7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a797424e-c829-4ee2-8983-64a0143f3ee7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a797424e-c829-4ee2-8983-64a0143f3ee7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a797424e-c829-4ee2-8983-64a0143f3ee7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ef027fe0-bf6b-4b1a-9db4-075fb7f0b53c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a797424e-c829-4ee2-8983-64a0143f3ee7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ef027fe0-bf6b-4b1a-9db4-075fb7f0b53c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_06050cc0-fed5-431c-a264-4613b27771da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ef027fe0-bf6b-4b1a-9db4-075fb7f0b53c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_06050cc0-fed5-431c-a264-4613b27771da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_2bd0de90-c9d9-4585-a4b3-4546bb592baf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_571d585a-8591-47d3-a1b6-c8ee1b301fae" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_2bd0de90-c9d9-4585-a4b3-4546bb592baf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_2bd0de90-c9d9-4585-a4b3-4546bb592baf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_2bd0de90-c9d9-4585-a4b3-4546bb592baf" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_2bd0de90-c9d9-4585-a4b3-4546bb592baf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_ace6caf6-4b62-49ef-990c-08dbd0e91c46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_2bd0de90-c9d9-4585-a4b3-4546bb592baf" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_ace6caf6-4b62-49ef-990c-08dbd0e91c46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationPartnershipConcentrationRiskMember_fd85d758-3f83-42ff-9867-4ed3bb5135e0" xlink:href="ardx-20221231.xsd#ardx_CollaborationPartnershipConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_ace6caf6-4b62-49ef-990c-08dbd0e91c46" xlink:to="loc_ardx_CollaborationPartnershipConcentrationRiskMember_fd85d758-3f83-42ff-9867-4ed3bb5135e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_cbd9d7be-6d38-4dde-96ae-bdd7fc2dfd90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_571d585a-8591-47d3-a1b6-c8ee1b301fae" xlink:to="loc_us-gaap_TypeOfArrangementAxis_cbd9d7be-6d38-4dde-96ae-bdd7fc2dfd90" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cbd9d7be-6d38-4dde-96ae-bdd7fc2dfd90_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cbd9d7be-6d38-4dde-96ae-bdd7fc2dfd90" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cbd9d7be-6d38-4dde-96ae-bdd7fc2dfd90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2769415a-7fb1-4dd2-a6df-c6eb801e3582" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cbd9d7be-6d38-4dde-96ae-bdd7fc2dfd90" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2769415a-7fb1-4dd2-a6df-c6eb801e3582" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_KkcMember_f5ba93ab-d210-4a1a-a3f9-66bcd744e73c" xlink:href="ardx-20221231.xsd#ardx_KkcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2769415a-7fb1-4dd2-a6df-c6eb801e3582" xlink:to="loc_ardx_KkcMember_f5ba93ab-d210-4a1a-a3f9-66bcd744e73c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_KnightTherapeuticsIncMember_f4f9c75b-6995-4159-bb87-48616a38c286" xlink:href="ardx-20221231.xsd#ardx_KnightTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2769415a-7fb1-4dd2-a6df-c6eb801e3582" xlink:to="loc_ardx_KnightTherapeuticsIncMember_f4f9c75b-6995-4159-bb87-48616a38c286" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AmerisourceBergenDrugCorporationMember_e850c466-9203-4182-8c3f-d657b6c4b461" xlink:href="ardx-20221231.xsd#ardx_AmerisourceBergenDrugCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2769415a-7fb1-4dd2-a6df-c6eb801e3582" xlink:to="loc_ardx_AmerisourceBergenDrugCorporationMember_e850c466-9203-4182-8c3f-d657b6c4b461" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/NetLossPerShareAntiDilutiveSecuritiesandPotentialCommonSharesDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#NetLossPerShareAntiDilutiveSecuritiesandPotentialCommonSharesDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/NetLossPerShareAntiDilutiveSecuritiesandPotentialCommonSharesDetails" xlink:type="extended" id="iac6562e2114b479abe842afd900b6de0_NetLossPerShareAntiDilutiveSecuritiesandPotentialCommonSharesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2102d69b-48bb-47f1-a6a4-755c052eb03e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c7b974df-a0bf-4de6-96ff-a5cdd47df061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2102d69b-48bb-47f1-a6a4-755c052eb03e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c7b974df-a0bf-4de6-96ff-a5cdd47df061" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PotentialCommonSharesAntiDilutiveEffectOnSecurities_2acb87c0-b08c-4250-b7fd-be61e6de87cd" xlink:href="ardx-20221231.xsd#ardx_PotentialCommonSharesAntiDilutiveEffectOnSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2102d69b-48bb-47f1-a6a4-755c052eb03e" xlink:to="loc_ardx_PotentialCommonSharesAntiDilutiveEffectOnSecurities_2acb87c0-b08c-4250-b7fd-be61e6de87cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_77344a0e-348f-4e5c-b3ce-a628d741d321" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2102d69b-48bb-47f1-a6a4-755c052eb03e" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_77344a0e-348f-4e5c-b3ce-a628d741d321" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d4bb5dbd-db94-4ce1-90ad-cacf7536de45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_77344a0e-348f-4e5c-b3ce-a628d741d321" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d4bb5dbd-db94-4ce1-90ad-cacf7536de45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d4bb5dbd-db94-4ce1-90ad-cacf7536de45_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d4bb5dbd-db94-4ce1-90ad-cacf7536de45" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d4bb5dbd-db94-4ce1-90ad-cacf7536de45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1486c113-4759-4f8a-a2c1-ca218d66595b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d4bb5dbd-db94-4ce1-90ad-cacf7536de45" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1486c113-4759-4f8a-a2c1-ca218d66595b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5fdb2ea8-4008-4e22-afdc-b341e5bd3a80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1486c113-4759-4f8a-a2c1-ca218d66595b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5fdb2ea8-4008-4e22-afdc-b341e5bd3a80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_aa9eb04c-1b8b-4a2e-9a7a-81a65c0d632b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1486c113-4759-4f8a-a2c1-ca218d66595b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_aa9eb04c-1b8b-4a2e-9a7a-81a65c0d632b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EmployeeStockPurchasePlanMember_f74c8feb-d0e2-4355-b0eb-2d8f77247dd1" xlink:href="ardx-20221231.xsd#ardx_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1486c113-4759-4f8a-a2c1-ca218d66595b" xlink:to="loc_ardx_EmployeeStockPurchasePlanMember_f74c8feb-d0e2-4355-b0eb-2d8f77247dd1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_1464cd55-3e2f-4250-b353-1c15be65a3fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1486c113-4759-4f8a-a2c1-ca218d66595b" xlink:to="loc_us-gaap_WarrantMember_1464cd55-3e2f-4250-b353-1c15be65a3fa" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="ifd73e5d58693429887b54368c316eb73_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_c7270121-6d99-4dcb-8dea-c5240d5bd881" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_a3ea2c6f-b492-459e-a62e-4c3b111f0378" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_c7270121-6d99-4dcb-8dea-c5240d5bd881" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_a3ea2c6f-b492-459e-a62e-4c3b111f0378" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfDefendants_56883498-c4b5-42e6-a12e-7dfe75dd5e42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfDefendants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_c7270121-6d99-4dcb-8dea-c5240d5bd881" xlink:to="loc_us-gaap_LossContingencyNumberOfDefendants_56883498-c4b5-42e6-a12e-7dfe75dd5e42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_49f10407-152f-42ef-9090-b2817c2da5f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_c7270121-6d99-4dcb-8dea-c5240d5bd881" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_49f10407-152f-42ef-9090-b2817c2da5f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_fc8c5b55-087b-452d-8687-eaddbb22a99f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_c7270121-6d99-4dcb-8dea-c5240d5bd881" xlink:to="loc_us-gaap_LossContingenciesTable_fc8c5b55-087b-452d-8687-eaddbb22a99f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_c3f63811-eb7b-4f05-8fbd-6e75313c69f7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_fc8c5b55-087b-452d-8687-eaddbb22a99f" xlink:to="loc_srt_LitigationCaseAxis_c3f63811-eb7b-4f05-8fbd-6e75313c69f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_c3f63811-eb7b-4f05-8fbd-6e75313c69f7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_c3f63811-eb7b-4f05-8fbd-6e75313c69f7" xlink:to="loc_srt_LitigationCaseTypeDomain_c3f63811-eb7b-4f05-8fbd-6e75313c69f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_b23cd93c-96e2-4277-aace-ecb27c8b8c24" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_c3f63811-eb7b-4f05-8fbd-6e75313c69f7" xlink:to="loc_srt_LitigationCaseTypeDomain_b23cd93c-96e2-4277-aace-ecb27c8b8c24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_StrezsakVersusArdelyxIncMember_caf5fd9a-6eff-49bc-9b0e-96e8dcb822ab" xlink:href="ardx-20221231.xsd#ardx_StrezsakVersusArdelyxIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_b23cd93c-96e2-4277-aace-ecb27c8b8c24" xlink:to="loc_ardx_StrezsakVersusArdelyxIncMember_caf5fd9a-6eff-49bc-9b0e-96e8dcb822ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_GoVersusRaabMember_46b79874-b07b-4e41-a377-5baf45df3632" xlink:href="ardx-20221231.xsd#ardx_GoVersusRaabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_b23cd93c-96e2-4277-aace-ecb27c8b8c24" xlink:to="loc_ardx_GoVersusRaabMember_46b79874-b07b-4e41-a377-5baf45df3632" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/SubsequentEventsDetails" xlink:type="extended" id="if16a60124a9540b29b71d77190a96aa6_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_a35f36f0-f3b3-4da2-ba22-0cfdb1f56498" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_MaximumAggregateOfferingPrice_1d9888ad-2b2e-4645-b414-ccbf152f250e" xlink:href="ardx-20221231.xsd#ardx_MaximumAggregateOfferingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_a35f36f0-f3b3-4da2-ba22-0cfdb1f56498" xlink:to="loc_ardx_MaximumAggregateOfferingPrice_1d9888ad-2b2e-4645-b414-ccbf152f250e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_StockIssuanceCostCommissionPercent_403543ce-bc5e-4ced-8fb9-e6d744d4816e" xlink:href="ardx-20221231.xsd#ardx_StockIssuanceCostCommissionPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_a35f36f0-f3b3-4da2-ba22-0cfdb1f56498" xlink:to="loc_ardx_StockIssuanceCostCommissionPercent_403543ce-bc5e-4ced-8fb9-e6d744d4816e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_029d064d-0652-4202-90b8-1fc06aece5f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_a35f36f0-f3b3-4da2-ba22-0cfdb1f56498" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_029d064d-0652-4202-90b8-1fc06aece5f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentVariableRateBaseOption_33bb26bb-05d6-460e-b7eb-4487bf6dfc0e" xlink:href="ardx-20221231.xsd#ardx_DebtInstrumentVariableRateBaseOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_a35f36f0-f3b3-4da2-ba22-0cfdb1f56498" xlink:to="loc_ardx_DebtInstrumentVariableRateBaseOption_33bb26bb-05d6-460e-b7eb-4487bf6dfc0e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentVariableRatePlusOption_c775de21-5e4c-4b26-a7b0-a32e3a689bb4" xlink:href="ardx-20221231.xsd#ardx_DebtInstrumentVariableRatePlusOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_a35f36f0-f3b3-4da2-ba22-0cfdb1f56498" xlink:to="loc_ardx_DebtInstrumentVariableRatePlusOption_c775de21-5e4c-4b26-a7b0-a32e3a689bb4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_625be18f-e99d-4f8b-967e-c8003ebccaa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_a35f36f0-f3b3-4da2-ba22-0cfdb1f56498" xlink:to="loc_us-gaap_SubsequentEventTable_625be18f-e99d-4f8b-967e-c8003ebccaa5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_77c2ecdb-e8c3-4b8b-a7fa-655621a29c13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_625be18f-e99d-4f8b-967e-c8003ebccaa5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_77c2ecdb-e8c3-4b8b-a7fa-655621a29c13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_77c2ecdb-e8c3-4b8b-a7fa-655621a29c13_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_77c2ecdb-e8c3-4b8b-a7fa-655621a29c13" xlink:to="loc_us-gaap_ClassOfStockDomain_77c2ecdb-e8c3-4b8b-a7fa-655621a29c13_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_851c5c22-a140-4b4b-a040-ac11f3d3c8a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_77c2ecdb-e8c3-4b8b-a7fa-655621a29c13" xlink:to="loc_us-gaap_ClassOfStockDomain_851c5c22-a140-4b4b-a040-ac11f3d3c8a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_607b960c-6aff-4a9b-b70e-b6f2bc4c4f08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_851c5c22-a140-4b4b-a040-ac11f3d3c8a1" xlink:to="loc_us-gaap_CommonClassAMember_607b960c-6aff-4a9b-b70e-b6f2bc4c4f08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_983aea83-7558-4feb-a656-82f2937595cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_625be18f-e99d-4f8b-967e-c8003ebccaa5" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_983aea83-7558-4feb-a656-82f2937595cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_983aea83-7558-4feb-a656-82f2937595cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_983aea83-7558-4feb-a656-82f2937595cf" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_983aea83-7558-4feb-a656-82f2937595cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_bb4e4107-7813-4681-8bda-31e2c5865f00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_983aea83-7558-4feb-a656-82f2937595cf" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_bb4e4107-7813-4681-8bda-31e2c5865f00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5160c79c-107d-4e15-a3b4-186637e9a3b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_bb4e4107-7813-4681-8bda-31e2c5865f00" xlink:to="loc_us-gaap_SubsequentEventMember_5160c79c-107d-4e15-a3b4-186637e9a3b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_73319e3b-07c7-4a50-a8e5-793304835676" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_625be18f-e99d-4f8b-967e-c8003ebccaa5" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_73319e3b-07c7-4a50-a8e5-793304835676" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_73319e3b-07c7-4a50-a8e5-793304835676_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_73319e3b-07c7-4a50-a8e5-793304835676" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_73319e3b-07c7-4a50-a8e5-793304835676_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fe044b64-adc1-4059-99a7-3194bbed299e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_73319e3b-07c7-4a50-a8e5-793304835676" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fe044b64-adc1-4059-99a7-3194bbed299e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember_435c3398-7d96-46d8-b49a-6c4a79a6e960" xlink:href="ardx-20221231.xsd#ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fe044b64-adc1-4059-99a7-3194bbed299e" xlink:to="loc_ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember_435c3398-7d96-46d8-b49a-6c4a79a6e960" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_57d213d4-ef95-4d28-875e-cc2a06bf6115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_625be18f-e99d-4f8b-967e-c8003ebccaa5" xlink:to="loc_us-gaap_DebtInstrumentAxis_57d213d4-ef95-4d28-875e-cc2a06bf6115" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_57d213d4-ef95-4d28-875e-cc2a06bf6115_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_57d213d4-ef95-4d28-875e-cc2a06bf6115" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_57d213d4-ef95-4d28-875e-cc2a06bf6115_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7a3bf491-9978-4aeb-a4db-c81c592ad685" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_57d213d4-ef95-4d28-875e-cc2a06bf6115" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7a3bf491-9978-4aeb-a4db-c81c592ad685" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermBLoanMember_fbc481b6-6f33-408b-9c80-ec8dfcc512e9" xlink:href="ardx-20221231.xsd#ardx_TermBLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7a3bf491-9978-4aeb-a4db-c81c592ad685" xlink:to="loc_ardx_TermBLoanMember_fbc481b6-6f33-408b-9c80-ec8dfcc512e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f6896fea-2fc3-472c-921e-27fa83547eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_625be18f-e99d-4f8b-967e-c8003ebccaa5" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f6896fea-2fc3-472c-921e-27fa83547eb1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f6896fea-2fc3-472c-921e-27fa83547eb1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f6896fea-2fc3-472c-921e-27fa83547eb1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f6896fea-2fc3-472c-921e-27fa83547eb1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c0f6b464-bcb6-495a-b6bd-9924f40493e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f6896fea-2fc3-472c-921e-27fa83547eb1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c0f6b464-bcb6-495a-b6bd-9924f40493e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_c589f811-a310-4cea-a6e8-e10ae0092cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c0f6b464-bcb6-495a-b6bd-9924f40493e1" xlink:to="loc_us-gaap_LoansPayableMember_c589f811-a310-4cea-a6e8-e10ae0092cbf" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>ardx-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:9159adf2-88b0-425e-b00c-16d6f1bd5962,g:73dc270f-0b38-43c2-8fc7-c4890fc3e73f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04e884c8-97ba-40e9-9b63-a504fff1e243_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_c7bbe3d8-48a4-486f-8ad8-c1453666931f_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_50952939-3db7-49f5-8638-c6345283807a_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted operating lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_2737d027-0986-4031-89ae-48191e5ea7bc_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitExecutiveCompensationDisallowedIRCSec162mPercent_785b9eef-30d3-4317-a8a7-242402fe54d3_terseLabel_en-US" xlink:label="lab_ardx_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitExecutiveCompensationDisallowedIRCSec162mPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive compensation disallowed under IRC Sec 162(m)</link:label>
    <link:label id="lab_ardx_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitExecutiveCompensationDisallowedIRCSec162mPercent_label_en-US" xlink:label="lab_ardx_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitExecutiveCompensationDisallowedIRCSec162mPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Executive Compensation Disallowed IRC Sec 162m, Percent</link:label>
    <link:label id="lab_ardx_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitExecutiveCompensationDisallowedIRCSec162mPercent_documentation_en-US" xlink:label="lab_ardx_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitExecutiveCompensationDisallowedIRCSec162mPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Executive Compensation Disallowed IRC Sec 162m, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitExecutiveCompensationDisallowedIRCSec162mPercent" xlink:href="ardx-20221231.xsd#ardx_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitExecutiveCompensationDisallowedIRCSec162mPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitExecutiveCompensationDisallowedIRCSec162mPercent" xlink:to="lab_ardx_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitExecutiveCompensationDisallowedIRCSec162mPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_830bb476-8ef8-4562-9e81-a7aeff2db8b2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal outstanding</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_5c786116-0cc5-46c6-87da-c4e73789e838_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total repayment obligations</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_cfd4deb7-da55-45c3-a0aa-1a6248e15694_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CommonStockSubjectToIssuedInducementGrantsShares_320cc1d4-7523-4860-ae73-a52a7f7dd8c8_terseLabel_en-US" xlink:label="lab_ardx_CommonStockSubjectToIssuedInducementGrantsShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of common stock subject to issued inducement grants</link:label>
    <link:label id="lab_ardx_CommonStockSubjectToIssuedInducementGrantsShares_label_en-US" xlink:label="lab_ardx_CommonStockSubjectToIssuedInducementGrantsShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Subject To Issued Inducement Grants, Shares</link:label>
    <link:label id="lab_ardx_CommonStockSubjectToIssuedInducementGrantsShares_documentation_en-US" xlink:label="lab_ardx_CommonStockSubjectToIssuedInducementGrantsShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Subject To Issued Inducement Grants, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CommonStockSubjectToIssuedInducementGrantsShares" xlink:href="ardx-20221231.xsd#ardx_CommonStockSubjectToIssuedInducementGrantsShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CommonStockSubjectToIssuedInducementGrantsShares" xlink:to="lab_ardx_CommonStockSubjectToIssuedInducementGrantsShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_DebtInstrumentInterestRateOnDefaultPercentage_5a618256-6874-42e9-9038-8a60541edee0_terseLabel_en-US" xlink:label="lab_ardx_DebtInstrumentInterestRateOnDefaultPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional default interest rate</link:label>
    <link:label id="lab_ardx_DebtInstrumentInterestRateOnDefaultPercentage_label_en-US" xlink:label="lab_ardx_DebtInstrumentInterestRateOnDefaultPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate On Default, Percentage</link:label>
    <link:label id="lab_ardx_DebtInstrumentInterestRateOnDefaultPercentage_documentation_en-US" xlink:label="lab_ardx_DebtInstrumentInterestRateOnDefaultPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of additional default interest rate on the event of default.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentInterestRateOnDefaultPercentage" xlink:href="ardx-20221231.xsd#ardx_DebtInstrumentInterestRateOnDefaultPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_DebtInstrumentInterestRateOnDefaultPercentage" xlink:to="lab_ardx_DebtInstrumentInterestRateOnDefaultPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_1c2057a8-82bd-4eb8-bc97-52fa2587e38c_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office space area (sq ft)</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_a8dccbfb-6185-47d9-8888-30657ecf16f1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_c5a6a3ad-cea9-4fce-a880-bfbcb9bb26ee_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_900261aa-e1a2-416f-ba5d-b5d107d20dc9_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized losses on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_0d8f5a3f-0922-461c-8777-6e512a577bee_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized losses on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_f5570634-ada1-4852-982c-7918f48d00c0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_8e6b494f-6c4d-44c8-974d-1bc6092f5ee9_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_b054e28d-49ad-48ce-be12-79267a8aa018_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock_8dc3ef70-2832-4a4a-bb1e-2e9c3595d762_terseLabel_en-US" xlink:label="lab_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Additional Details of the Leases</link:label>
    <link:label id="lab_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock_label_en-US" xlink:label="lab_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Additional Details of Leases [Table Text Block]</link:label>
    <link:label id="lab_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock_documentation_en-US" xlink:label="lab_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The tabular disclosure of additional details of the leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock" xlink:href="ardx-20221231.xsd#ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock" xlink:to="lab_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_FacilityMilwaukeeWisconsinMember_88511a33-f850-4067-8208-d33cb1fe7480_terseLabel_en-US" xlink:label="lab_ardx_FacilityMilwaukeeWisconsinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milwaukee facility</link:label>
    <link:label id="lab_ardx_FacilityMilwaukeeWisconsinMember_label_en-US" xlink:label="lab_ardx_FacilityMilwaukeeWisconsinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility, Milwaukee Wisconsin [Member]</link:label>
    <link:label id="lab_ardx_FacilityMilwaukeeWisconsinMember_documentation_en-US" xlink:label="lab_ardx_FacilityMilwaukeeWisconsinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility, Milwaukee Wisconsin</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FacilityMilwaukeeWisconsinMember" xlink:href="ardx-20221231.xsd#ardx_FacilityMilwaukeeWisconsinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_FacilityMilwaukeeWisconsinMember" xlink:to="lab_ardx_FacilityMilwaukeeWisconsinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_4550e555-9ff4-48b0-9f14-bd2143cff27e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_4640f4f0-ecf5-4915-b94b-fa617b50e524_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_5ce836d6-eb12-4ef0-8f37-1e1cc8ba3df5_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_da7e2b13-4e63-408d-97e3-0c29b0b1ec89_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_3daf3556-00b2-40e0-85f0-e11930b64b81_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Securities Classified as Cash, Cash Equivalents and Short-Term Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfDefendants_382753fd-5ff3-481e-b201-6bbc61ee7d9d_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfDefendants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of defendants</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfDefendants_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfDefendants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Defendants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfDefendants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfDefendants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfDefendants" xlink:to="lab_us-gaap_LossContingencyNumberOfDefendants" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_EmployeeStockPurchasePlanSharesAvailableRollForward_2c85dd06-8c3f-4b6c-a1eb-baceaaa2452f_terseLabel_en-US" xlink:label="lab_ardx_EmployeeStockPurchasePlanSharesAvailableRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares&#160;Available for&#160;Grant</link:label>
    <link:label id="lab_ardx_EmployeeStockPurchasePlanSharesAvailableRollForward_label_en-US" xlink:label="lab_ardx_EmployeeStockPurchasePlanSharesAvailableRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Shares Available [Roll Forward]</link:label>
    <link:label id="lab_ardx_EmployeeStockPurchasePlanSharesAvailableRollForward_documentation_en-US" xlink:label="lab_ardx_EmployeeStockPurchasePlanSharesAvailableRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Shares Available</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EmployeeStockPurchasePlanSharesAvailableRollForward" xlink:href="ardx-20221231.xsd#ardx_EmployeeStockPurchasePlanSharesAvailableRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_EmployeeStockPurchasePlanSharesAvailableRollForward" xlink:to="lab_ardx_EmployeeStockPurchasePlanSharesAvailableRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9cd59a45-9b37-4813-902c-b4ffd079bb98_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_141cffa8-2917-4efa-ac01-15c3450b843b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating per annum rate (percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_1c341dec-aa72-46fe-afea-744f4be132fb_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_16ca337c-58c7-4258-82f8-ef434244d369_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e017a18c-1490-43b4-a06c-c6797c683618_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8a7a26bb-1a65-48fd-874d-18c9eb2b550b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_18d6cdd1-65be-4fd1-a6f2-14617517f919_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_a717c877-0174-4c45-81dc-65e72654d377_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon vesting of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0a20d52a-7263-44c4-b5a5-7f81b306d139_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_3d227698-e4f1-48e9-8a4b-70dfb22999c8_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cecd08a4-55bf-442e-a578-c4117c9050ba_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_c202fd43-bc01-430e-95f2-1d58eff33946_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtractions related to lapse of statute of limitation</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_0a03d0e0-b737-46b9-be91-89b6f2b7529d_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_3fc837b0-9988-409d-9271-3b4829e09f1e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After second anniversary to maturity date</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_8c99297f-b644-48ee-9ce1-78c569cdaca1_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerCopayAndReturnsMember_40f60dc1-ad60-452b-85fe-d8f89eaee7cd_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerCopayAndReturnsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Copay and Returns</link:label>
    <link:label id="lab_ardx_ContractWithCustomerCopayAndReturnsMember_label_en-US" xlink:label="lab_ardx_ContractWithCustomerCopayAndReturnsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Copay And Returns [Member]</link:label>
    <link:label id="lab_ardx_ContractWithCustomerCopayAndReturnsMember_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerCopayAndReturnsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Copay and Returns</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerCopayAndReturnsMember" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerCopayAndReturnsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerCopayAndReturnsMember" xlink:to="lab_ardx_ContractWithCustomerCopayAndReturnsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_cba48d9f-c337-47e3-978a-bfeb67c2fc05_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_6e22fcdb-2fbd-4c6e-92d2-1533bc2836df_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_82a5a5e4-bf10-4e94-b282-d52ac5632c0b_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_70934f56-1a14-46d8-a6aa-8f4b1d8ca77f_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_43f68aef-d04c-453c-a638-ef5a668174de_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5b83dc0c-d51d-49f0-b1b3-89384e111bd1_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_10b4b1e5-99e1-4ba2-b60e-6e5442672c15_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Valuation Assumptions for Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0162191d-8c32-43e1-b28f-94f42f1ca835_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities not included in computation of diluted net loss per share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_cfe656c7-4693-48c4-9993-35a980bb742a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Debt Payment Obligations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_552597bc-0853-4dd2-ae06-5311f90dbd65_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_93f7b667-7f93-4075-8f06-093826ab13d2_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undiscounted cash payment obligations</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_0be634df-5ced-4cbc-97d9-46542a236503_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_b015084d-1e5d-489b-b576-93c2c5cdb99f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_6d0ebb62-9a07-41f5-ad07-2738d179a7ee_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsNumberOfAmendments_445f5747-3f6c-4c53-952d-a546b204b40c_terseLabel_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsNumberOfAmendments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of amendments</link:label>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsNumberOfAmendments_label_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsNumberOfAmendments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Licensing Agreements, Number Of Amendments</link:label>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsNumberOfAmendments_documentation_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsNumberOfAmendments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Licensing Agreements, Number Of Amendments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsNumberOfAmendments" xlink:href="ardx-20221231.xsd#ardx_CollaborationAndLicensingAgreementsNumberOfAmendments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborationAndLicensingAgreementsNumberOfAmendments" xlink:to="lab_ardx_CollaborationAndLicensingAgreementsNumberOfAmendments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_e88237a8-3947-4507-89ac-5e2a82834577_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_FacilityOneWalthamMassachusettsMember_ec3566df-5537-4a8c-8a8c-bb37d2baaaf0_terseLabel_en-US" xlink:label="lab_ardx_FacilityOneWalthamMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Original Waltham facility</link:label>
    <link:label id="lab_ardx_FacilityOneWalthamMassachusettsMember_label_en-US" xlink:label="lab_ardx_FacilityOneWalthamMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility One, Waltham Massachusetts [Member]</link:label>
    <link:label id="lab_ardx_FacilityOneWalthamMassachusettsMember_documentation_en-US" xlink:label="lab_ardx_FacilityOneWalthamMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility One, Waltham Massachusetts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FacilityOneWalthamMassachusettsMember" xlink:href="ardx-20221231.xsd#ardx_FacilityOneWalthamMassachusettsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_FacilityOneWalthamMassachusettsMember" xlink:to="lab_ardx_FacilityOneWalthamMassachusettsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_e87a57d8-3401-46f6-8d84-163e15d0fbce_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions based on tax positions related to current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_e6d258b8-ae9e-4527-91e5-23c08edb8a11_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_04ce900a-a7d8-4d13-9593-3d8bf96532fc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_6aff4a3d-28fd-46a3-b9ab-f28b42916da9_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerGrossToNetSalesAccruals_2057c1d3-9085-4c5c-91ac-4ca00e7f1afb_periodStartLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToNetSalesAccruals" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_ardx_ContractWithCustomerGrossToNetSalesAccruals_41ae6030-83f1-4c3b-836b-9837ee8f5436_periodEndLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToNetSalesAccruals" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_ardx_ContractWithCustomerGrossToNetSalesAccruals_label_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToNetSalesAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Gross To Net Sales Accruals</link:label>
    <link:label id="lab_ardx_ContractWithCustomerGrossToNetSalesAccruals_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToNetSalesAccruals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Gross To Net Sales Accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesAccruals" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerGrossToNetSalesAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerGrossToNetSalesAccruals" xlink:to="lab_ardx_ContractWithCustomerGrossToNetSalesAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate_87d173be-ac9e-44fb-9911-1608562527d2_terseLabel_en-US" xlink:label="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fee receivable for reduction in royalty rate</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate_label_en-US" xlink:label="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate_documentation_en-US" xlink:label="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate" xlink:href="ardx-20221231.xsd#ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate" xlink:to="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f4499008-edc4-48ae-8d10-aa5f316dffab_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments, Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_d65d2b7c-97b4-49f5-abc2-fadf0862bb5d_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityIncreasesToAmountsInvoicedButCashNotReceived_b9705a43-143f-41fd-88b3-0e559c4a7ab2_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityIncreasesToAmountsInvoicedButCashNotReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases to amounts invoiced, for which cash has not yet been received</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityIncreasesToAmountsInvoicedButCashNotReceived_label_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityIncreasesToAmountsInvoicedButCashNotReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Increases To Amounts Invoiced, But Cash Not Received</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityIncreasesToAmountsInvoicedButCashNotReceived_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityIncreasesToAmountsInvoicedButCashNotReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Increases To Amounts Invoiced, But Cash Not Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityIncreasesToAmountsInvoicedButCashNotReceived" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerLiabilityIncreasesToAmountsInvoicedButCashNotReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerLiabilityIncreasesToAmountsInvoicedButCashNotReceived" xlink:to="lab_ardx_ContractWithCustomerLiabilityIncreasesToAmountsInvoicedButCashNotReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_KyowaKirinCo.LtdMember_edabc572-8b45-48a4-ad44-3b40692adb68_terseLabel_en-US" xlink:label="lab_ardx_KyowaKirinCo.LtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kyowa Kirin Co. Ltd</link:label>
    <link:label id="lab_ardx_KyowaKirinCo.LtdMember_label_en-US" xlink:label="lab_ardx_KyowaKirinCo.LtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kyowa Kirin Co. Ltd [Member]</link:label>
    <link:label id="lab_ardx_KyowaKirinCo.LtdMember_documentation_en-US" xlink:label="lab_ardx_KyowaKirinCo.LtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to Kyowa Kirin Co., Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_KyowaKirinCo.LtdMember" xlink:href="ardx-20221231.xsd#ardx_KyowaKirinCo.LtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_KyowaKirinCo.LtdMember" xlink:to="lab_ardx_KyowaKirinCo.LtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_7f6a5404-b522-45a4-8f76-b78379a3f77e_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplementary disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_01a51c70-bbde-4ba2-8b51-b29d831f45ee_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options canceled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum_68bd07f6-197b-47f1-a492-f6bb4e44a5aa_terseLabel_en-US" xlink:label="lab_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan agreement covenant, net product revenue as percentage of outstanding loan balance, minimum</link:label>
    <link:label id="lab_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum_label_en-US" xlink:label="lab_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Covenant, Net Product Revenue As Percentage Of Outstanding Loan Balance, Minimum</link:label>
    <link:label id="lab_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum_documentation_en-US" xlink:label="lab_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Covenant, Net Product Revenue As Percentage Of Outstanding Loan Balance, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum" xlink:href="ardx-20221231.xsd#ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum" xlink:to="lab_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_5fae1a73-b34b-45dd-b016-a8ebd8ec31c3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_9a73811e-6dfd-4e64-a8ec-f2fae8afee2a_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_DeferredTaxAssetsAmortizationAndDepreciation_9adda878-3b5d-458d-b15d-18b28f1e2f39_terseLabel_en-US" xlink:label="lab_ardx_DeferredTaxAssetsAmortizationAndDepreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and depreciation</link:label>
    <link:label id="lab_ardx_DeferredTaxAssetsAmortizationAndDepreciation_label_en-US" xlink:label="lab_ardx_DeferredTaxAssetsAmortizationAndDepreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Amortization and Depreciation</link:label>
    <link:label id="lab_ardx_DeferredTaxAssetsAmortizationAndDepreciation_documentation_en-US" xlink:label="lab_ardx_DeferredTaxAssetsAmortizationAndDepreciation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from amortization and depreciation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DeferredTaxAssetsAmortizationAndDepreciation" xlink:href="ardx-20221231.xsd#ardx_DeferredTaxAssetsAmortizationAndDepreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_DeferredTaxAssetsAmortizationAndDepreciation" xlink:to="lab_ardx_DeferredTaxAssetsAmortizationAndDepreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_856601f1-5dfb-4525-88d7-30d7be3ad64d_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfAdvanceRoyalty_dd497836-907c-41ea-877a-660f62badc10_negatedLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfAdvanceRoyalty" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense related to the sale of future royalties</link:label>
    <link:label id="lab_us-gaap_AmortizationOfAdvanceRoyalty_dfa36abc-1557-44c7-85c9-ba8bdc422e42_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfAdvanceRoyalty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of the deferred royalty obligation</link:label>
    <link:label id="lab_us-gaap_AmortizationOfAdvanceRoyalty_label_en-US" xlink:label="lab_us-gaap_AmortizationOfAdvanceRoyalty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Advance Royalty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfAdvanceRoyalty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfAdvanceRoyalty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfAdvanceRoyalty" xlink:to="lab_us-gaap_AmortizationOfAdvanceRoyalty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_f01fd849-10f6-4f5f-8418-802ca34fea8e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement_6c1e9aa3-dcd8-46ab-b444-4a20f1b3b7a6_terseLabel_en-US" xlink:label="lab_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining funding based on milestone achievement</link:label>
    <link:label id="lab_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement_label_en-US" xlink:label="lab_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining Funding Based On Conditional Milestone Achievement</link:label>
    <link:label id="lab_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement_documentation_en-US" xlink:label="lab_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining Funding Based On Conditional Milestone Achievement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement" xlink:href="ardx-20221231.xsd#ardx_RemainingFundingBasedOnConditionalMilestoneAchievement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement" xlink:to="lab_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_fe7494e9-9ad0-4bf2-a698-f54014ad495d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialCommercializationMilestones_c428c22d-2b41-46e6-bf21-3aa3e2474066_terseLabel_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialCommercializationMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential commercialization milestones</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialCommercializationMilestones_label_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialCommercializationMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Potential Commercialization Milestones</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialCommercializationMilestones_documentation_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialCommercializationMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Potential Commercialization Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialCommercializationMilestones" xlink:href="ardx-20221231.xsd#ardx_CollaborativeArrangementPotentialCommercializationMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborativeArrangementPotentialCommercializationMilestones" xlink:to="lab_ardx_CollaborativeArrangementPotentialCommercializationMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_77f822fb-7750-477f-a517-da248fd40b32_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesStockPurchasePlanPurchasedNumber_e16835f4-ae67-4ea9-9985-428d32b98580_periodStartLabel_en-US" xlink:label="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesStockPurchasePlanPurchasedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased, beginning (shares)</link:label>
    <link:label id="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesStockPurchasePlanPurchasedNumber_acb5b447-575b-486b-9ec3-a12abc7e0e40_periodEndLabel_en-US" xlink:label="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesStockPurchasePlanPurchasedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased, ending (shares)</link:label>
    <link:label id="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesStockPurchasePlanPurchasedNumber_label_en-US" xlink:label="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesStockPurchasePlanPurchasedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Employees Stock Purchase Plan, Purchased, Number</link:label>
    <link:label id="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesStockPurchasePlanPurchasedNumber_documentation_en-US" xlink:label="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesStockPurchasePlanPurchasedNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Employees Stock Purchase Plan, Purchased, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesStockPurchasePlanPurchasedNumber" xlink:href="ardx-20221231.xsd#ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesStockPurchasePlanPurchasedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesStockPurchasePlanPurchasedNumber" xlink:to="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesStockPurchasePlanPurchasedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_e32ce21b-18a9-4a6c-ab10-74d90f2bdcaf_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options issued and outstanding (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_896444db-a7ca-40c9-a044-10f7ca27547a_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_NumberOfOperatingLeaseArrangements_d6c07959-5f0c-42cd-881e-09718fa8c1ab_terseLabel_en-US" xlink:label="lab_ardx_NumberOfOperatingLeaseArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of lease agreements</link:label>
    <link:label id="lab_ardx_NumberOfOperatingLeaseArrangements_label_en-US" xlink:label="lab_ardx_NumberOfOperatingLeaseArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Lease Arrangements</link:label>
    <link:label id="lab_ardx_NumberOfOperatingLeaseArrangements_documentation_en-US" xlink:label="lab_ardx_NumberOfOperatingLeaseArrangements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of operating lease arrangements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_NumberOfOperatingLeaseArrangements" xlink:href="ardx-20221231.xsd#ardx_NumberOfOperatingLeaseArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_NumberOfOperatingLeaseArrangements" xlink:to="lab_ardx_NumberOfOperatingLeaseArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_668fad7d-e058-4f0d-90e3-c39c0b10c1f6_verboseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of significant accounting policies</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4ec027c8-689a-4784-8663-cf3338f0344a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_0d6260ae-c360-4db7-96fd-094da03d4259_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_c9cdb090-f9a8-4994-b09d-5414d18541b7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_65a74439-a03a-4765-ba8f-d3b20433cd9e_negatedLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion of operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d598cb12-8690-45ef-9bee-108c668fd9b1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod_836ea829-53a2-40da-8895-1ca26676436f_terseLabel_en-US" xlink:label="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan agreement, covenant, cash and cash equivalents as percentage of outstanding loan balance, calculation period</link:label>
    <link:label id="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod_label_en-US" xlink:label="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Covenant, Cash And Cash Equivalents As Percentage Of Outstanding Loan Balance, Calculation Period</link:label>
    <link:label id="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod_documentation_en-US" xlink:label="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Covenant, Cash And Cash Equivalents As Percentage Of Outstanding Loan Balance, Calculation Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod" xlink:href="ardx-20221231.xsd#ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod" xlink:to="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_ea02759b-c538-42f3-9700-5bcf60b18999_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_PotentialCommonSharesAntiDilutiveEffectOnSecurities_aa5fe1aa-0e0c-4231-a208-09a32f3fba6e_terseLabel_en-US" xlink:label="lab_ardx_PotentialCommonSharesAntiDilutiveEffectOnSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential common shares that would have been included if not for anti-dilutive effect of securities</link:label>
    <link:label id="lab_ardx_PotentialCommonSharesAntiDilutiveEffectOnSecurities_label_en-US" xlink:label="lab_ardx_PotentialCommonSharesAntiDilutiveEffectOnSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Common Shares, Anti-Dilutive Effect On Securities</link:label>
    <link:label id="lab_ardx_PotentialCommonSharesAntiDilutiveEffectOnSecurities_documentation_en-US" xlink:label="lab_ardx_PotentialCommonSharesAntiDilutiveEffectOnSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Common Shares, Anti-Dilutive Effect On Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PotentialCommonSharesAntiDilutiveEffectOnSecurities" xlink:href="ardx-20221231.xsd#ardx_PotentialCommonSharesAntiDilutiveEffectOnSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_PotentialCommonSharesAntiDilutiveEffectOnSecurities" xlink:to="lab_ardx_PotentialCommonSharesAntiDilutiveEffectOnSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_132f129d-d3d0-4400-9827-ea7506b1c0b6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_700f485a-767b-40a3-a4ae-5038c79619ef_terseLabel_en-US" xlink:label="lab_ardx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_ardx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_ardx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Four</link:label>
    <link:label id="lab_ardx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_ardx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="ardx-20221231.xsd#ardx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_ardx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4617875a-4e62-49d0-92e6-f11aef40f69b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options canceled (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_4ed32e16-c6d3-4008-b62d-907723f50492_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_DebtInstrumentClosingFeeAmount_73df4032-e967-4456-bb26-b01bb8827202_terseLabel_en-US" xlink:label="lab_ardx_DebtInstrumentClosingFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing fee</link:label>
    <link:label id="lab_ardx_DebtInstrumentClosingFeeAmount_label_en-US" xlink:label="lab_ardx_DebtInstrumentClosingFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Closing Fee Amount</link:label>
    <link:label id="lab_ardx_DebtInstrumentClosingFeeAmount_documentation_en-US" xlink:label="lab_ardx_DebtInstrumentClosingFeeAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Closing Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentClosingFeeAmount" xlink:href="ardx-20221231.xsd#ardx_DebtInstrumentClosingFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_DebtInstrumentClosingFeeAmount" xlink:to="lab_ardx_DebtInstrumentClosingFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_2298d98d-63a4-4fc8-bcd8-fd7c7ddf724c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses_1c5e4922-a39c-4b31-a9b8-497fb39fe4c5_negatedTerseLabel_en-US" xlink:label="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and investments, Gross Unrealized Losses</link:label>
    <link:label id="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses_label_en-US" xlink:label="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Cash Equivalents And Investments Gross Unrealized Losses</link:label>
    <link:label id="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses_documentation_en-US" xlink:label="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and investments gross unrealized losses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses" xlink:href="ardx-20221231.xsd#ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses" xlink:to="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_eb25a588-4d6e-4206-a8fd-35d66f20f3f1_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a7ba605f-9b21-48d0-b78b-a278d7da0734_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining life (years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_0efa3dee-07e5-4712-a79a-705ee67b54ed_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3f45e086-1bb1-4add-a153-1feee83be42b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0eec624c-4ce5-4816-87c5-094e97e76d0a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_PercentageOfRoyaltyRevenue_75c0ff31-307e-4d8e-b26c-c8d2943482ef_terseLabel_en-US" xlink:label="lab_ardx_PercentageOfRoyaltyRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of royalty revenue</link:label>
    <link:label id="lab_ardx_PercentageOfRoyaltyRevenue_label_en-US" xlink:label="lab_ardx_PercentageOfRoyaltyRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Royalty Revenue</link:label>
    <link:label id="lab_ardx_PercentageOfRoyaltyRevenue_documentation_en-US" xlink:label="lab_ardx_PercentageOfRoyaltyRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents percentage of royalty revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PercentageOfRoyaltyRevenue" xlink:href="ardx-20221231.xsd#ardx_PercentageOfRoyaltyRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_PercentageOfRoyaltyRevenue" xlink:to="lab_ardx_PercentageOfRoyaltyRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_AccruedNonClinicalResearchAndDevelopmentExpenses_8e6983c8-90fa-4355-9a7b-d6aed5925585_terseLabel_en-US" xlink:label="lab_ardx_AccruedNonClinicalResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued non-clinical research and development expenses</link:label>
    <link:label id="lab_ardx_AccruedNonClinicalResearchAndDevelopmentExpenses_label_en-US" xlink:label="lab_ardx_AccruedNonClinicalResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Non-Clinical Research And Development Expenses</link:label>
    <link:label id="lab_ardx_AccruedNonClinicalResearchAndDevelopmentExpenses_documentation_en-US" xlink:label="lab_ardx_AccruedNonClinicalResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Non-Clinical Research And Development Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AccruedNonClinicalResearchAndDevelopmentExpenses" xlink:href="ardx-20221231.xsd#ardx_AccruedNonClinicalResearchAndDevelopmentExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_AccruedNonClinicalResearchAndDevelopmentExpenses" xlink:to="lab_ardx_AccruedNonClinicalResearchAndDevelopmentExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_fcbdb1d4-213e-4182-89d9-017ab9cad50c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in at the market offering</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_2d0c56c1-b1a4-49a4-acd7-f99b0ab1cdb4_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_47f799b4-8062-4e57-bbc2-782574cebaa4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RisksAndUncertaintiesAbstract_label_en-US" xlink:label="lab_us-gaap_RisksAndUncertaintiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract" xlink:to="lab_us-gaap_RisksAndUncertaintiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_StockOptionsAggregateIntrinsicValueAbstract_d431eaf5-b83e-44b6-909a-b8ed1e017082_terseLabel_en-US" xlink:label="lab_ardx_StockOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic&#160;Value</link:label>
    <link:label id="lab_ardx_StockOptionsAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_ardx_StockOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_ardx_StockOptionsAggregateIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_ardx_StockOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_StockOptionsAggregateIntrinsicValueAbstract" xlink:href="ardx-20221231.xsd#ardx_StockOptionsAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_StockOptionsAggregateIntrinsicValueAbstract" xlink:to="lab_ardx_StockOptionsAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_3a0f2e91-8c91-47b7-8e52-d4a1b6f1b530_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_12ad88c6-d3a6-4380-90e4-e68798add733_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Sales, Net and Reserves for Variable Consideration and Collaboration Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_4f75e72d-8df9-43aa-8e40-80f6f47e09b2_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_5bb43fe7-744e-4ba0-b11c-2d4b603884c5_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_ee01d06d-b407-42fc-9876-74dc16b97107_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_66447bdc-467f-415f-adf5-a0131d95e3c6_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_17d7faf7-b384-424a-8243-ad9f68e166aa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise&#160;Price&#160; per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_0678a6ff-8a21-41a7-8c3e-5ef35b8da172_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_15028810-7b15-4aeb-8cd9-243652f37c7e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of RSUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_bae48d3b-1f4a-4147-b985-6ddde58115b9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CardinalHealthMember_3ba1a0d5-8a30-4c72-9e1c-f44cc3f5b68e_terseLabel_en-US" xlink:label="lab_ardx_CardinalHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health</link:label>
    <link:label id="lab_ardx_CardinalHealthMember_label_en-US" xlink:label="lab_ardx_CardinalHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health [Member]</link:label>
    <link:label id="lab_ardx_CardinalHealthMember_documentation_en-US" xlink:label="lab_ardx_CardinalHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CardinalHealthMember" xlink:href="ardx-20221231.xsd#ardx_CardinalHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CardinalHealthMember" xlink:to="lab_ardx_CardinalHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_4a9f0c00-61d2-4719-8f7a-f57cef41a379_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_AccountsReceivableCommercialCustomerMember_434d2288-8ff3-45ec-8c50-33253151862a_terseLabel_en-US" xlink:label="lab_ardx_AccountsReceivableCommercialCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial customers</link:label>
    <link:label id="lab_ardx_AccountsReceivableCommercialCustomerMember_label_en-US" xlink:label="lab_ardx_AccountsReceivableCommercialCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Commercial Customer [Member]</link:label>
    <link:label id="lab_ardx_AccountsReceivableCommercialCustomerMember_documentation_en-US" xlink:label="lab_ardx_AccountsReceivableCommercialCustomerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Commercial Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AccountsReceivableCommercialCustomerMember" xlink:href="ardx-20221231.xsd#ardx_AccountsReceivableCommercialCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_AccountsReceivableCommercialCustomerMember" xlink:to="lab_ardx_AccountsReceivableCommercialCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_aea6cfbf-8e97-4341-901a-a9911b5225a2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested balance, beginning (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_79287fa4-f698-44c5-9f17-63e759920309_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested balance, ending (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_c997f0de-0533-4b5d-a403-a681ba53ab83_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsPurchases_dc145011-d07f-4e36-b70c-dc8a81d67213_negatedTerseLabel_en-US" xlink:label="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsPurchases" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares purchased (shares)</link:label>
    <link:label id="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsPurchases_label_en-US" xlink:label="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Options, Purchases</link:label>
    <link:label id="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsPurchases_documentation_en-US" xlink:label="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsPurchases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents share based compensation arrangement by share based payment award number of shares available for grants options, purchase during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsPurchases" xlink:href="ardx-20221231.xsd#ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsPurchases" xlink:to="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_d764ccaf-cf18-4e9a-9d67-55f412fee049_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_a7c28588-4e4a-493f-8cc4-f436c1df4ab8_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_5249487b-5dd7-4d24-a3e0-392daf5b9074_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_db9bc08f-ddea-440a-8623-b83b9ed60c42_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_49e847d4-1589-4c87-8d79-adc7d0773da6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtractions based on tax positions related to prior year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_ae3fe53d-aa30-4ef5-b952-ed5aef0532b8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_d5ad210e-60ca-4446-a73a-faca2e512864_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9c000d5e-2fca-4115-b12f-9686608e6f56_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableCurrent_dd4a44fc-f121-43ca-93f3-601bfd079957_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LoansPayableCurrent_2e8cb8d3-b732-4fa5-822c-3fde2bfbe921_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LoansPayableCurrent_label_en-US" xlink:label="lab_us-gaap_LoansPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableCurrent" xlink:to="lab_us-gaap_LoansPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityIncreaseForCashReceived_298f93d3-8422-45be-af42-cf767480591d_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityIncreaseForCashReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases due to cash received during the period</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityIncreaseForCashReceived_label_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityIncreaseForCashReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Increase For Cash Received</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityIncreaseForCashReceived_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityIncreaseForCashReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Increase For Cash Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityIncreaseForCashReceived" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerLiabilityIncreaseForCashReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerLiabilityIncreaseForCashReceived" xlink:to="lab_ardx_ContractWithCustomerLiabilityIncreaseForCashReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityTransactionCosts_79ae8ffb-11f7-44d9-a6a1-2af483276dcb_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityTransactionCosts_label_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Transaction Costs</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityTransactionCosts_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityTransactionCosts" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerLiabilityTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerLiabilityTransactionCosts" xlink:to="lab_ardx_ContractWithCustomerLiabilityTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_d4a98377-6e7d-4e7e-ba9c-f941eec11b4b_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_d62018bd-6e58-43bd-bc0c-97e6d66f91d9_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis_9880f8f0-d0a6-4101-8034-8cdf12c729e5_terseLabel_en-US" xlink:label="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross To Net Sales Accrual And Reserve Classification [Axis]</link:label>
    <link:label id="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis_label_en-US" xlink:label="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross To Net Sales Accrual And Reserve Classification [Axis]</link:label>
    <link:label id="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis_documentation_en-US" xlink:label="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross To Net Sales Accrual And Reserve Classification</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis" xlink:href="ardx-20221231.xsd#ardx_GrossToNetSalesAccrualAndReserveClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis" xlink:to="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ProductIBSRELAMember_73ff53a4-df72-4dfe-8ede-8954d3379f42_terseLabel_en-US" xlink:label="lab_ardx_ProductIBSRELAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IBSRELA</link:label>
    <link:label id="lab_ardx_ProductIBSRELAMember_label_en-US" xlink:label="lab_ardx_ProductIBSRELAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, IBSRELA [Member]</link:label>
    <link:label id="lab_ardx_ProductIBSRELAMember_documentation_en-US" xlink:label="lab_ardx_ProductIBSRELAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, IBSRELA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ProductIBSRELAMember" xlink:href="ardx-20221231.xsd#ardx_ProductIBSRELAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ProductIBSRELAMember" xlink:to="lab_ardx_ProductIBSRELAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_7f1f0261-7d5a-4713-ba15-1c747ca799c7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_09269c5d-4122-4d32-85e0-af694670c538_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Revenue Balances</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_6b5a78de-3f11-41f3-843f-f0774986ff35_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_41ae8665-f324-4396-b863-b790ff8f198f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare_b5bf5c77-98fe-4387-8243-987185e54bf0_terseLabel_en-US" xlink:label="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Price per Share (in dollars per share)</link:label>
    <link:label id="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare_label_en-US" xlink:label="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award, Purchased Price of Share</link:label>
    <link:label id="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare_documentation_en-US" xlink:label="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the purchase price per share of shares issued to employees under the plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare" xlink:href="ardx-20221231.xsd#ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare" xlink:to="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_AmerisourceBergenDrugCorporationMember_c17162a5-7865-4707-a1fa-d18add9e0846_terseLabel_en-US" xlink:label="lab_ardx_AmerisourceBergenDrugCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Drug Corporation</link:label>
    <link:label id="lab_ardx_AmerisourceBergenDrugCorporationMember_label_en-US" xlink:label="lab_ardx_AmerisourceBergenDrugCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Drug Corporation [Member]</link:label>
    <link:label id="lab_ardx_AmerisourceBergenDrugCorporationMember_documentation_en-US" xlink:label="lab_ardx_AmerisourceBergenDrugCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Drug Corporation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AmerisourceBergenDrugCorporationMember" xlink:href="ardx-20221231.xsd#ardx_AmerisourceBergenDrugCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_AmerisourceBergenDrugCorporationMember" xlink:to="lab_ardx_AmerisourceBergenDrugCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_2d318b32-48b3-48ff-a88b-89ee52d0da71_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones_3ecf3b41-d100-45ba-87b9-d28f4a74ea75_terseLabel_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development and commercialization milestones</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones_label_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Potential Development And Commercialization Milestones</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones_documentation_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount of future development and commercialization milestone under collaborative arrangements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" xlink:href="ardx-20221231.xsd#ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" xlink:to="lab_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_b21f01e1-5dd4-439c-939d-84adbd1b1b10_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_4f9915b4-c0b4-4431-b720-d5d4d8881535_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_1227599a-dd51-4818-babf-5215cb0ba92a_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_f1f8ff2e-3fae-4d6e-aec8-dcf905043411_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_86039e69-4a52-4b3b-9b96-4b4122e2fcd5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_310c34a2-4d24-4dc6-a12c-f56846d78df6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponInclusionOfForfeitedOrUnexercisedOptions_e2d0f646-b32d-4ca3-9604-bf66751d711f_terseLabel_en-US" xlink:label="lab_ardx_IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponInclusionOfForfeitedOrUnexercisedOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential increase to shares reserved for inclusion of forfeited or unexercised options from prior plan</link:label>
    <link:label id="lab_ardx_IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponInclusionOfForfeitedOrUnexercisedOptions_label_en-US" xlink:label="lab_ardx_IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponInclusionOfForfeitedOrUnexercisedOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase In Shares Reserved For Issuance, Maximum Shares To Be Issued Upon Inclusion Of Forfeited Or Unexercised Options</link:label>
    <link:label id="lab_ardx_IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponInclusionOfForfeitedOrUnexercisedOptions_documentation_en-US" xlink:label="lab_ardx_IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponInclusionOfForfeitedOrUnexercisedOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase In Shares Reserved For Issuance, Maximum Shares To Be Issued Upon Inclusion Of Forfeited Or Unexercised Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponInclusionOfForfeitedOrUnexercisedOptions" xlink:href="ardx-20221231.xsd#ardx_IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponInclusionOfForfeitedOrUnexercisedOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponInclusionOfForfeitedOrUnexercisedOptions" xlink:to="lab_ardx_IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponInclusionOfForfeitedOrUnexercisedOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LeaseArrangementsAxis_a1da0532-3624-47c2-b474-faf57aea18b0_terseLabel_en-US" xlink:label="lab_ardx_LeaseArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Axis]</link:label>
    <link:label id="lab_ardx_LeaseArrangementsAxis_label_en-US" xlink:label="lab_ardx_LeaseArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Axis]</link:label>
    <link:label id="lab_ardx_LeaseArrangementsAxis_documentation_en-US" xlink:label="lab_ardx_LeaseArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LeaseArrangementsAxis" xlink:href="ardx-20221231.xsd#ardx_LeaseArrangementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LeaseArrangementsAxis" xlink:to="lab_ardx_LeaseArrangementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_e77ee4dc-faeb-4db0-97bf-e8be9254c64b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_afdbe4a4-3d42-463f-8f0f-948d674aad52_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_b2247aa0-02af-45c4-b4aa-6915ace6816f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_ef7f521b-6982-4546-a30d-89aa5f7f7e71_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CorporateBondsMember_57915a08-b44b-46d7-b49d-fa7ca8685893_terseLabel_en-US" xlink:label="lab_ardx_CorporateBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_ardx_CorporateBondsMember_label_en-US" xlink:label="lab_ardx_CorporateBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bonds [Member]</link:label>
    <link:label id="lab_ardx_CorporateBondsMember_documentation_en-US" xlink:label="lab_ardx_CorporateBondsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bonds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CorporateBondsMember" xlink:href="ardx-20221231.xsd#ardx_CorporateBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CorporateBondsMember" xlink:to="lab_ardx_CorporateBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_85c4c336-6b60-4031-b786-f8110d67054c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_39688862-bcf5-4ed9-9342-d8a71511078c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fb8e65f1-1a8a-427b-a6c2-0b2f08216b1a_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_0aa801f9-83f3-4c16-b443-23a1bf334a74_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d82b2502-01b8-4e97-9a0b-9f3bf4afba50_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_0e3a3df1-a705-49ce-9ff9-0a6e168b5903_terseLabel_en-US" xlink:label="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross To Net Sales Accrual And Reserve Classification [Domain]</link:label>
    <link:label id="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_label_en-US" xlink:label="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross To Net Sales Accrual And Reserve Classification [Domain]</link:label>
    <link:label id="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_documentation_en-US" xlink:label="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross To Net Sales Accrual And Reserve Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain" xlink:href="ardx-20221231.xsd#ardx_GrossToNetSalesAccrualAndReserveClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain" xlink:to="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_a7cbf444-5d84-4c3b-9276-2ec5d2297f83_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_38a3a92e-d3b0-4eda-a3b5-534df7be4364_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_f4dfb278-ef55-4d6f-a818-f03936f9d64f_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2a2866c6-5da5-4be5-b88a-cdea9707f2c6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Valuation Assumptions for Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_FacilityTwoWalthamMassachusettsMember_1790cb02-bf92-40dd-be6c-deeb3819bad2_terseLabel_en-US" xlink:label="lab_ardx_FacilityTwoWalthamMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Waltham facility</link:label>
    <link:label id="lab_ardx_FacilityTwoWalthamMassachusettsMember_label_en-US" xlink:label="lab_ardx_FacilityTwoWalthamMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Two, Waltham Massachusetts [Member]</link:label>
    <link:label id="lab_ardx_FacilityTwoWalthamMassachusettsMember_documentation_en-US" xlink:label="lab_ardx_FacilityTwoWalthamMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Two, Waltham Massachusetts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FacilityTwoWalthamMassachusettsMember" xlink:href="ardx-20221231.xsd#ardx_FacilityTwoWalthamMassachusettsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_FacilityTwoWalthamMassachusettsMember" xlink:to="lab_ardx_FacilityTwoWalthamMassachusettsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_c08081fa-6634-475d-86e0-04c415db83f0_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_667aa6b5-41e1-4009-98ca-4f8249e96e8b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_11ba8af0-38d2-42b2-a672-15b5a26266a2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Provision for Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a134c9f1-d44e-48b9-a997-ba5d387556d5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_9ba02852-5532-453a-a8e3-8ddd85eb5d63_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_93d81c59-9ea3-458f-87ff-48ad970a9445_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average Remaining Vesting Period (Years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a75017e8-08ba-46fb-a2b2-787f1fbafbfe_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_TermLoan2022Member_ea5f8fee-20de-49a9-99ef-804794052035_terseLabel_en-US" xlink:label="lab_ardx_TermLoan2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Term Loan</link:label>
    <link:label id="lab_ardx_TermLoan2022Member_label_en-US" xlink:label="lab_ardx_TermLoan2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan 2022 [Member]</link:label>
    <link:label id="lab_ardx_TermLoan2022Member_documentation_en-US" xlink:label="lab_ardx_TermLoan2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2022Member" xlink:href="ardx-20221231.xsd#ardx_TermLoan2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_TermLoan2022Member" xlink:to="lab_ardx_TermLoan2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_d469f0a4-2f16-4558-8909-386b1eb38bb5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_0c674f15-ffd7-47ec-848b-e571e4030150_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_33c7f01d-6090-4561-8c91-66790dd934e8_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_299bb750-8540-4840-bbd0-69555fe9f16d_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in at the market offering (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0ace38d0-d99c-4400-877b-5e7e937a3471_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock sold and issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_02097395-48ed-4fe1-a374-6ee8ef1c2d90_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_dd8e56b1-ae9a-4d21-8dce-d28d5903e74f_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Short-Term Investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e3d24fb1-5f0f-41fa-9706-59d245dd8ae9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToAuthorizedInPeriod_997a8a99-1dec-451f-b4ec-e3d11b3dfb78_terseLabel_en-US" xlink:label="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToAuthorizedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for grant, effect of authorized (shares)</link:label>
    <link:label id="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToAuthorizedInPeriod_label_en-US" xlink:label="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToAuthorizedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Available For Grant, Increase Due To Authorized In Period</link:label>
    <link:label id="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToAuthorizedInPeriod_documentation_en-US" xlink:label="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToAuthorizedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award number of shares available for grant options authorized.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToAuthorizedInPeriod" xlink:href="ardx-20221231.xsd#ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToAuthorizedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToAuthorizedInPeriod" xlink:to="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToAuthorizedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_a6a1bde2-a8d8-4a29-bd20-7db26e6a0514_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_faef6e25-cbb0-42ba-916f-90a3f45b29a4_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_960eaa9b-108a-410e-a406-bc28998a729f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_6a7d78eb-9fa6-4e57-b06a-9a6356cee229_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToStockIssuedForServicesInPeriod_ccd26563-16f4-4beb-aa60-90596295db6f_negatedTerseLabel_en-US" xlink:label="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToStockIssuedForServicesInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for grant, effect of shares issued for services (shares)</link:label>
    <link:label id="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToStockIssuedForServicesInPeriod_label_en-US" xlink:label="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToStockIssuedForServicesInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Available For Grant, Decrease Due To Stock Issued For Services In Period</link:label>
    <link:label id="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToStockIssuedForServicesInPeriod_documentation_en-US" xlink:label="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToStockIssuedForServicesInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Available For Grant, Decrease Due To Stock Issued For Services In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToStockIssuedForServicesInPeriod" xlink:href="ardx-20221231.xsd#ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToStockIssuedForServicesInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToStockIssuedForServicesInPeriod" xlink:to="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToStockIssuedForServicesInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_IncreaseInSharesReservedForIssuanceOptionForAnnualIncreaseAsPercentageOfSharesOutstanding_bc821b8c-bac2-4820-8d56-db6e799be97a_terseLabel_en-US" xlink:label="lab_ardx_IncreaseInSharesReservedForIssuanceOptionForAnnualIncreaseAsPercentageOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential increase in shares reserved as a percentage of shares outstanding</link:label>
    <link:label id="lab_ardx_IncreaseInSharesReservedForIssuanceOptionForAnnualIncreaseAsPercentageOfSharesOutstanding_label_en-US" xlink:label="lab_ardx_IncreaseInSharesReservedForIssuanceOptionForAnnualIncreaseAsPercentageOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase In Shares Reserved For Issuance, Option For Annual Increase As Percentage Of Shares Outstanding</link:label>
    <link:label id="lab_ardx_IncreaseInSharesReservedForIssuanceOptionForAnnualIncreaseAsPercentageOfSharesOutstanding_documentation_en-US" xlink:label="lab_ardx_IncreaseInSharesReservedForIssuanceOptionForAnnualIncreaseAsPercentageOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase In Shares Reserved For Issuance, Option For Annual Increase As Percentage Of Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_IncreaseInSharesReservedForIssuanceOptionForAnnualIncreaseAsPercentageOfSharesOutstanding" xlink:href="ardx-20221231.xsd#ardx_IncreaseInSharesReservedForIssuanceOptionForAnnualIncreaseAsPercentageOfSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_IncreaseInSharesReservedForIssuanceOptionForAnnualIncreaseAsPercentageOfSharesOutstanding" xlink:to="lab_ardx_IncreaseInSharesReservedForIssuanceOptionForAnnualIncreaseAsPercentageOfSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1d9b14c5-ae3e-45d8-afdf-2fa74ad8aebd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_bcbecd30-3d27-4d58-bb25-2074ac50ebd4_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from loan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_85df5aec-b1ad-4950-bc99-3e8b01d7fa2b_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_68f704ba-fda3-4d0f-82a7-15c557af987b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_2967dd73-88bb-4a37-9f55-b455a2e62525_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_PrepaidCommercialManufacturingCurrent_3067372e-70f2-42ad-9323-24d949b4c0f8_terseLabel_en-US" xlink:label="lab_ardx_PrepaidCommercialManufacturingCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid commercial manufacturing</link:label>
    <link:label id="lab_ardx_PrepaidCommercialManufacturingCurrent_label_en-US" xlink:label="lab_ardx_PrepaidCommercialManufacturingCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Commercial Manufacturing, Current</link:label>
    <link:label id="lab_ardx_PrepaidCommercialManufacturingCurrent_documentation_en-US" xlink:label="lab_ardx_PrepaidCommercialManufacturingCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Commercial Manufacturing, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PrepaidCommercialManufacturingCurrent" xlink:href="ardx-20221231.xsd#ardx_PrepaidCommercialManufacturingCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_PrepaidCommercialManufacturingCurrent" xlink:to="lab_ardx_PrepaidCommercialManufacturingCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_36272fff-bb75-4fc3-b813-925f5b2a7a1c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_4fb81681-9d5f-4658-8f95-a75836c9d10c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from 2022 Loan, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4a11e440-9f82-4b51-a60a-ea292714ca7d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_b4c1c935-d76e-4abb-bb89-36bec263f9a9_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_MinimumTaxCreditCarryforwardMember_21cbf3e6-e22a-4192-a27f-bd4725b0084d_terseLabel_en-US" xlink:label="lab_ardx_MinimumTaxCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum tax credit carryforwards</link:label>
    <link:label id="lab_ardx_MinimumTaxCreditCarryforwardMember_label_en-US" xlink:label="lab_ardx_MinimumTaxCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Tax Credit Carryforward [Member]</link:label>
    <link:label id="lab_ardx_MinimumTaxCreditCarryforwardMember_documentation_en-US" xlink:label="lab_ardx_MinimumTaxCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_MinimumTaxCreditCarryforwardMember" xlink:href="ardx-20221231.xsd#ardx_MinimumTaxCreditCarryforwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_MinimumTaxCreditCarryforwardMember" xlink:to="lab_ardx_MinimumTaxCreditCarryforwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_8a39ba50-2c61-46ed-b50b-f8f727c2b14b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_f50d1a96-d854-4def-b9e6-ec52ddcbb216_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock closing price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_22522ec3-50e7-4bca-8b9a-cfe5960a81ab_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_b30f266f-c3e3-4855-8196-1cca048b4d77_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_fb9615b8-8aed-4286-866a-4f1ea49d8a66_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_TermOfAgreement_834550f2-4f16-458e-96db-ff956d00380a_terseLabel_en-US" xlink:label="lab_ardx_TermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of agreement</link:label>
    <link:label id="lab_ardx_TermOfAgreement_label_en-US" xlink:label="lab_ardx_TermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Of Agreement</link:label>
    <link:label id="lab_ardx_TermOfAgreement_documentation_en-US" xlink:label="lab_ardx_TermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermOfAgreement" xlink:href="ardx-20221231.xsd#ardx_TermOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_TermOfAgreement" xlink:to="lab_ardx_TermOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_b16f43ee-5960-4620-813a-1784efba9110_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, non-current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_8e6d0376-26fa-4378-916c-0439045ce732_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_86f01e4b-16f6-4c7d-915f-a491518b188a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_4dd19cb0-62fb-49cf-bc64-8ed9a03749be_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CA_e7f2f61d-f70d-450a-bb39-9b389441fbcf_terseLabel_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">North America</link:label>
    <link:label id="lab_country_CA_label_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CANADA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CA" xlink:to="lab_country_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_3cf59386-ea79-43a0-bf1c-6cc2fd0b52e9_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LesseeOperatingLeaseNumberOfRenewalOptions_5b350e57-5bde-474d-8c3e-5216d0b4fd47_terseLabel_en-US" xlink:label="lab_ardx_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options to extend</link:label>
    <link:label id="lab_ardx_LesseeOperatingLeaseNumberOfRenewalOptions_label_en-US" xlink:label="lab_ardx_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Options</link:label>
    <link:label id="lab_ardx_LesseeOperatingLeaseNumberOfRenewalOptions_documentation_en-US" xlink:label="lab_ardx_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:href="ardx-20221231.xsd#ardx_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:to="lab_ardx_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_cb93321d-3223-45e8-b8db-614157f51710_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_90eae3f2-0562-4449-a136-18a006a630c3_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_a9062303-b088-47c3-b9b9-ac7b94b621be_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credit</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_51e73eb6-34c0-41e7-8124-cf3e7246d45e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cee2fff3-c459-4195-b5d8-7838a2b709eb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_d6321c2b-6554-49e4-95ba-547cc472cb40_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_e2d13efa-6aa4-4c73-b0d8-61434217d5a4_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ad29c9b2-55d4-446f-a1c6-8a110f0251e5_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax provision</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_DebtInstrumentPrepaymentFeePercentage_ee2190d6-5131-4ccc-b52a-e982e15625b7_terseLabel_en-US" xlink:label="lab_ardx_DebtInstrumentPrepaymentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment premium (as a percent)</link:label>
    <link:label id="lab_ardx_DebtInstrumentPrepaymentFeePercentage_label_en-US" xlink:label="lab_ardx_DebtInstrumentPrepaymentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Fee, Percentage</link:label>
    <link:label id="lab_ardx_DebtInstrumentPrepaymentFeePercentage_documentation_en-US" xlink:label="lab_ardx_DebtInstrumentPrepaymentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of fee payable on prepayment of debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentPrepaymentFeePercentage" xlink:href="ardx-20221231.xsd#ardx_DebtInstrumentPrepaymentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_DebtInstrumentPrepaymentFeePercentage" xlink:to="lab_ardx_DebtInstrumentPrepaymentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_50edc62e-a6a1-4495-9939-9edc3b2eee4a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_e30b9137-1355-413c-a9bf-a981ac024ff0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum_599fbb64-d385-4564-a3ef-918134462e83_terseLabel_en-US" xlink:label="lab_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term securities, contractual maturities, maximum</link:label>
    <link:label id="lab_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum_label_en-US" xlink:label="lab_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-For-Sale Securities, Debt Securities, Current, Contractual Maturities, Maximum</link:label>
    <link:label id="lab_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum_documentation_en-US" xlink:label="lab_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-For-Sale Securities, Debt Securities, Current, Contractual Maturities, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum" xlink:href="ardx-20221231.xsd#ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum" xlink:to="lab_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_c002f2c7-20d5-4fc5-b62f-f932409ef22a_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_b5d8d79a-cb65-4c8e-9664-3591617dc4c6_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreed amount for exit fee upon change of control or regulatory approval</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:to="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_a0e00086-bbcc-404f-b587-7b6d1b5f017e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_2c1ef732-778b-4e9a-a87c-b235f4d3b94b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_05b526b8-b2dd-47d9-80bf-604f54e03eb1_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ThresholdPercentageOfSalesForTieredRoyalties_0a32e4fe-d4dd-4b58-a515-9369d9d69ee9_terseLabel_en-US" xlink:label="lab_ardx_ThresholdPercentageOfSalesForTieredRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold percentage of net sales for tiered royalties</link:label>
    <link:label id="lab_ardx_ThresholdPercentageOfSalesForTieredRoyalties_label_en-US" xlink:label="lab_ardx_ThresholdPercentageOfSalesForTieredRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold Percentage of Sales For Tiered Royalties</link:label>
    <link:label id="lab_ardx_ThresholdPercentageOfSalesForTieredRoyalties_documentation_en-US" xlink:label="lab_ardx_ThresholdPercentageOfSalesForTieredRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the threshold percentage of net sales for tiered royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ThresholdPercentageOfSalesForTieredRoyalties" xlink:href="ardx-20221231.xsd#ardx_ThresholdPercentageOfSalesForTieredRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ThresholdPercentageOfSalesForTieredRoyalties" xlink:to="lab_ardx_ThresholdPercentageOfSalesForTieredRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_974dbd1f-35e9-4964-b541-33980c4c81e4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_c9e5d937-f59e-4b00-a6d5-1073d1e51a17_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of exit fee derivative liabilities, beginning</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_063aea94-264e-4c89-accf-3178256d24e3_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of exit fee derivative liabilities, ending</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_cd1d94ac-a98b-4978-a32c-44337b55504e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk (percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_4b8efd60-050a-4ad4-97bb-5ed644e44809_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares added to initial reserve</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember_ae95e0e7-188d-46ae-8418-444864d2a3b8_terseLabel_en-US" xlink:label="lab_ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Open Market Sales Agreement</link:label>
    <link:label id="lab_ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember_label_en-US" xlink:label="lab_ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Market Sales Agreement 2020, At The Market Offering [Member]</link:label>
    <link:label id="lab_ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Market Sales Agreement 2020, At The Market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember" xlink:href="ardx-20221231.xsd#ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember" xlink:to="lab_ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_PerformanceBasedRestrictedStockUnitsMember_1dd83a69-8084-4822-aabf-69130903934d_verboseLabel_en-US" xlink:label="lab_ardx_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PRSUs</link:label>
    <link:label id="lab_ardx_PerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_ardx_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_ardx_PerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_ardx_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This member stands for performance-based restricted stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PerformanceBasedRestrictedStockUnitsMember" xlink:href="ardx-20221231.xsd#ardx_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_PerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_ardx_PerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_df2befcd-8fa3-4717-bd0f-55e59e4a229f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in continuous unrealized loss position for more than one year</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_00dc808f-3058-454b-92e3-8163547a00df_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Unaccreted value of final fee</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFeeAmount" xlink:to="lab_us-gaap_DebtInstrumentFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_b0a38854-c57b-4cbf-9c30-7186b34026b7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_AccruedPaymentsDueToRelatedParty_744ef4b8-d0a5-4cc7-aac2-bd66a8f8e6ad_terseLabel_en-US" xlink:label="lab_ardx_AccruedPaymentsDueToRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payments due to AstraZeneca</link:label>
    <link:label id="lab_ardx_AccruedPaymentsDueToRelatedParty_label_en-US" xlink:label="lab_ardx_AccruedPaymentsDueToRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Payments Due To Related Party</link:label>
    <link:label id="lab_ardx_AccruedPaymentsDueToRelatedParty_documentation_en-US" xlink:label="lab_ardx_AccruedPaymentsDueToRelatedParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Payments Due To Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AccruedPaymentsDueToRelatedParty" xlink:href="ardx-20221231.xsd#ardx_AccruedPaymentsDueToRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_AccruedPaymentsDueToRelatedParty" xlink:to="lab_ardx_AccruedPaymentsDueToRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_5ec8e81b-7992-4fd6-9c58-351c02fd2141_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_bca0d97d-f911-4d98-8347-7af8a61eed66_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share of common stock - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_131925eb-46ce-4438-80b4-f0a7661075c3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember_77648655-8386-407e-a6dd-dd3697baa0a9_terseLabel_en-US" xlink:label="lab_ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Open Market Sales Agreement</link:label>
    <link:label id="lab_ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember_label_en-US" xlink:label="lab_ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Market Sales Agreement 2023, At The Market Offering [Member]</link:label>
    <link:label id="lab_ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Market Sales Agreement 2023, At The Market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember" xlink:href="ardx-20221231.xsd#ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember" xlink:to="lab_ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LoanAgreementExitFeeTerm_7d02aa85-3acd-4deb-a71d-083c31c5560f_terseLabel_en-US" xlink:label="lab_ardx_LoanAgreementExitFeeTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit fee, term (in years)</link:label>
    <link:label id="lab_ardx_LoanAgreementExitFeeTerm_label_en-US" xlink:label="lab_ardx_LoanAgreementExitFeeTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Exit Fee, Term</link:label>
    <link:label id="lab_ardx_LoanAgreementExitFeeTerm_documentation_en-US" xlink:label="lab_ardx_LoanAgreementExitFeeTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Exit Fee, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementExitFeeTerm" xlink:href="ardx-20221231.xsd#ardx_LoanAgreementExitFeeTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LoanAgreementExitFeeTerm" xlink:to="lab_ardx_LoanAgreementExitFeeTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_AccruedSalesAndMarketingExpenses_1ec5a93e-0b65-4f47-8e3d-cbfa30e3b7ff_terseLabel_en-US" xlink:label="lab_ardx_AccruedSalesAndMarketingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued sales and marketing expenses</link:label>
    <link:label id="lab_ardx_AccruedSalesAndMarketingExpenses_label_en-US" xlink:label="lab_ardx_AccruedSalesAndMarketingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Sales And Marketing Expenses</link:label>
    <link:label id="lab_ardx_AccruedSalesAndMarketingExpenses_documentation_en-US" xlink:label="lab_ardx_AccruedSalesAndMarketingExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of accrued sales and marketing expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AccruedSalesAndMarketingExpenses" xlink:href="ardx-20221231.xsd#ardx_AccruedSalesAndMarketingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_AccruedSalesAndMarketingExpenses" xlink:to="lab_ardx_AccruedSalesAndMarketingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5db76161-c5b6-4555-8472-a888cae1a7b6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_23444951-13a8-461c-9ff2-48e613f365e5_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_f621cd65-fa2e-4b1c-bda7-deec5438fef3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value of RSUs vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_c23e095e-914d-4a78-b26f-8426f8acdc24_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_ae51747f-b854-41d8-8a82-d379ab4abe58_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_b6e3ca7e-c1a5-4216-9621-3c2e66bb5f7a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_f1c82384-28e7-4f0e-a907-5349fdff4ab9_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_8faef2ae-146f-4baf-bb17-7a3be5bbb56e_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_427ffe3f-914f-403c-adfb-258a9a52c9ed_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_98fae73f-de2e-4c6a-a053-22990aeda315_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_60e5c824-563c-4fc2-b47b-23fb51f83212_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_eb59d781-dbe6-4b57-89da-56c48b831724_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_215984f1-faa1-402b-88fd-c736bf904de7_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board of directors</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember_5f86c937-7f92-40ff-93a6-c4645c15728f_terseLabel_en-US" xlink:label="lab_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fosun Pharma</link:label>
    <link:label id="lab_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember_label_en-US" xlink:label="lab_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shanghai Fosun Pharmaceutical Industrial Development [Member]</link:label>
    <link:label id="lab_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember_documentation_en-US" xlink:label="lab_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents Shanghai Fosun Pharmaceutical Industrial Development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember" xlink:href="ardx-20221231.xsd#ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember" xlink:to="lab_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8588584f-ed55-4469-9815-f0352d7825fa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths_0d0829b5-c5e1-4cbf-b971-6f38794723b4_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases due to amounts reclassified from non-current, to be recognized in the next twelve months</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths_label_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Revenue To Be Recognized In Next Twelve Months</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Revenue To Be Recognized In Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths" xlink:to="lab_ardx_ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_2469761b-da71-4adf-9b81-ca5f904638a3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit loss on available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_a6ab392b-7b4c-404d-bec5-db859403631a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_461091ba-5282-4f84-8c85-e0ab86380be9_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember_3c9f6c1d-da0a-4423-9e1a-7a538d285e7d_terseLabel_en-US" xlink:label="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Knight Agreement</link:label>
    <link:label id="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember_label_en-US" xlink:label="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Development Commercialization Distribution In Canada [Member]</link:label>
    <link:label id="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember_documentation_en-US" xlink:label="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement for the development, commercialization and distribution fo tenapanor in Canada. The Knight Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember" xlink:href="ardx-20221231.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember" xlink:to="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d616cae3-6414-4160-8f39-a1b86f96dc5b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6e95de90-351e-4fc1-9a3f-248c47ab99ce_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_4e327ec0-624d-46c1-863c-844336b263cd_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2ecf6a03-f900-41ab-be18-9e880e6d89c2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Fair Value of Derivative Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_4a0c2860-5b84-4e5f-a222-7ea04447cfca_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_f5c535f7-abe6-4dd4-8fe0-edd1ceb63133_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_EmployeeStockPurchasePlanSharesPurchasedRollForward_ddaf4d0e-168e-40d5-b6f9-7e01bd81c771_terseLabel_en-US" xlink:label="lab_ardx_EmployeeStockPurchasePlanSharesPurchasedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of&#160;Shares Purchased</link:label>
    <link:label id="lab_ardx_EmployeeStockPurchasePlanSharesPurchasedRollForward_label_en-US" xlink:label="lab_ardx_EmployeeStockPurchasePlanSharesPurchasedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Shares Purchased [Roll Forward]</link:label>
    <link:label id="lab_ardx_EmployeeStockPurchasePlanSharesPurchasedRollForward_documentation_en-US" xlink:label="lab_ardx_EmployeeStockPurchasePlanSharesPurchasedRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Shares Purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EmployeeStockPurchasePlanSharesPurchasedRollForward" xlink:href="ardx-20221231.xsd#ardx_EmployeeStockPurchasePlanSharesPurchasedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_EmployeeStockPurchasePlanSharesPurchasedRollForward" xlink:to="lab_ardx_EmployeeStockPurchasePlanSharesPurchasedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_33ecbf84-60c1-4465-818b-025709136b7d_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_AccruedGrossToNetRevenueLiabilities_c8c108eb-dcfa-47c7-af69-2c26971198e9_terseLabel_en-US" xlink:label="lab_ardx_AccruedGrossToNetRevenueLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued gross to net revenue liabilities</link:label>
    <link:label id="lab_ardx_AccruedGrossToNetRevenueLiabilities_label_en-US" xlink:label="lab_ardx_AccruedGrossToNetRevenueLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Gross To Net Revenue Liabilities</link:label>
    <link:label id="lab_ardx_AccruedGrossToNetRevenueLiabilities_documentation_en-US" xlink:label="lab_ardx_AccruedGrossToNetRevenueLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Gross To Net Revenue Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AccruedGrossToNetRevenueLiabilities" xlink:href="ardx-20221231.xsd#ardx_AccruedGrossToNetRevenueLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_AccruedGrossToNetRevenueLiabilities" xlink:to="lab_ardx_AccruedGrossToNetRevenueLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_b643cc47-056b-4e3c-8fc8-70ab8ac9625a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_07fb55d9-5b7e-43e6-bbcc-8a6c76bcbddb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation Recognized</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_6ac23c46-437a-4053-a057-7d02b237059a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_7988361d-aa4e-4201-82f1-b8fd4d2340df_verboseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Lease Costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4e1f106f-95aa-46ed-84c0-a089de1f46a1_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for grant, beginning (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_859ec7b7-f5c3-42e2-a61a-4b7ac28283e2_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for grant, ending (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_4998964c-97f6-4f60-ac27-e12d28c8ca75_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_7b31d30b-162b-418d-a56d-b10de918a99d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_30e17c3b-fbb7-42f4-ac3c-ed2321be9d59_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_8f26ab37-3821-46b1-b7fe-aa8297ad828b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_EmployeeStockPurchasePlanMember_e3ef676a-ac20-4530-b2bb-0be07e397d0a_terseLabel_en-US" xlink:label="lab_ardx_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_ardx_EmployeeStockPurchasePlanMember_a289b62a-254b-4230-8420-e7004207141f_verboseLabel_en-US" xlink:label="lab_ardx_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP shares issuable</link:label>
    <link:label id="lab_ardx_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_ardx_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_ardx_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_ardx_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EmployeeStockPurchasePlanMember" xlink:href="ardx-20221231.xsd#ardx_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_EmployeeStockPurchasePlanMember" xlink:to="lab_ardx_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_848acb59-d0ad-465d-9828-b772ad7767ad_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_24409e6a-3687-4a44-93cc-9462fec501d9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of lease extension</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_e53a0855-ca99-433c-af00-22306ed25811_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_4001f927-e187-42d1-9c90-960dccb5d5bd_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_6f94c8fe-3304-47b6-806e-b935798cab46_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_e55dc326-352d-4436-aae2-b47a2f622012_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_884597e4-929f-46b8-a6a8-2e7b82e20e78_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_SaleOfStockWeightedAveragePricePerShare_50fc224c-e6e1-44a7-b36f-2662d625318d_terseLabel_en-US" xlink:label="lab_ardx_SaleOfStockWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average share price (in dollars per share)</link:label>
    <link:label id="lab_ardx_SaleOfStockWeightedAveragePricePerShare_label_en-US" xlink:label="lab_ardx_SaleOfStockWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Weighted-Average Price Per Share</link:label>
    <link:label id="lab_ardx_SaleOfStockWeightedAveragePricePerShare_documentation_en-US" xlink:label="lab_ardx_SaleOfStockWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Weighted-Average Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_SaleOfStockWeightedAveragePricePerShare" xlink:href="ardx-20221231.xsd#ardx_SaleOfStockWeightedAveragePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_SaleOfStockWeightedAveragePricePerShare" xlink:to="lab_ardx_SaleOfStockWeightedAveragePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_d46bed54-d146-4c05-b18a-b5f28ff98835_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CostOfRevenueAggregateAmountRecognized_120e2957-cd72-4c0c-bc72-3f1173f69209_terseLabel_en-US" xlink:label="lab_ardx_CostOfRevenueAggregateAmountRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate cost of revenue recognized</link:label>
    <link:label id="lab_ardx_CostOfRevenueAggregateAmountRecognized_label_en-US" xlink:label="lab_ardx_CostOfRevenueAggregateAmountRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Revenue, Aggregate Amount Recognized</link:label>
    <link:label id="lab_ardx_CostOfRevenueAggregateAmountRecognized_documentation_en-US" xlink:label="lab_ardx_CostOfRevenueAggregateAmountRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue, aggregate amount recognized.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CostOfRevenueAggregateAmountRecognized" xlink:href="ardx-20221231.xsd#ardx_CostOfRevenueAggregateAmountRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CostOfRevenueAggregateAmountRecognized" xlink:to="lab_ardx_CostOfRevenueAggregateAmountRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_4d236149-8b4b-4b11-9289-da38b65cfc92_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod_c3ae514b-1876-45cc-9362-fc813b886eaf_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Activity related to 2022 sales</link:label>
    <link:label id="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod_label_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Gross To Net Sales, Accrual Activity During Current Period</link:label>
    <link:label id="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Gross To Net Sales, Accrual Activity During Current Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod" xlink:to="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_AstraZenecaTerminationAgreementMember_5d673c21-6055-489a-af99-26f510b6e8c7_terseLabel_en-US" xlink:label="lab_ardx_AstraZenecaTerminationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AZ Termination Agreement</link:label>
    <link:label id="lab_ardx_AstraZenecaTerminationAgreementMember_label_en-US" xlink:label="lab_ardx_AstraZenecaTerminationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca Termination Agreement [Member]</link:label>
    <link:label id="lab_ardx_AstraZenecaTerminationAgreementMember_documentation_en-US" xlink:label="lab_ardx_AstraZenecaTerminationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca Termination Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AstraZenecaTerminationAgreementMember" xlink:href="ardx-20221231.xsd#ardx_AstraZenecaTerminationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_AstraZenecaTerminationAgreementMember" xlink:to="lab_ardx_AstraZenecaTerminationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_206b1250-023a-435c-aabd-3969422b2603_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Geographic Areas</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_25f4f6c4-eb97-409c-be5c-e0064a7ff0db_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_1e2a9f44-5b77-4229-8582-d67de9eb334f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_a9d86296-b18a-4962-9916-a53588df8d98_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_5e64a1f4-2f00-45c1-9057-87b0a2a4d69f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_f56c8e46-f825-4395-9e34-5c5e62f4d3ea_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_92d2c7e4-c6d1-40f0-81d1-501316ac3f5e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_FacilityFremontCaliforniaMember_956ba212-14b3-4c8a-8c51-dced10fec3cc_terseLabel_en-US" xlink:label="lab_ardx_FacilityFremontCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fremont facility</link:label>
    <link:label id="lab_ardx_FacilityFremontCaliforniaMember_label_en-US" xlink:label="lab_ardx_FacilityFremontCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility, Fremont California [Member]</link:label>
    <link:label id="lab_ardx_FacilityFremontCaliforniaMember_documentation_en-US" xlink:label="lab_ardx_FacilityFremontCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility, Fremont California</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FacilityFremontCaliforniaMember" xlink:href="ardx-20221231.xsd#ardx_FacilityFremontCaliforniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_FacilityFremontCaliforniaMember" xlink:to="lab_ardx_FacilityFremontCaliforniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock_23a501f3-e247-4c83-b454-e6188c922a47_terseLabel_en-US" xlink:label="lab_ardx_NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash Interest Expense on Deferred Royalty Obligation</link:label>
    <link:label id="lab_ardx_NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock_label_en-US" xlink:label="lab_ardx_NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Interest Expense On Deferred Royalty Obligation [Policy Text Block]</link:label>
    <link:label id="lab_ardx_NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock_documentation_en-US" xlink:label="lab_ardx_NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Interest Expense On Deferred Royalty Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock" xlink:href="ardx-20221231.xsd#ardx_NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock" xlink:to="lab_ardx_NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_6cb37893-fc4e-4305-81e8-2aa93593dbe2_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_bdd6d7ec-4fa4-4806-b07d-a9d5acef92df_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fed83d28-bc76-4444-bc9e-5852c5501261_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_f00b0537-aeb6-4480-9ddc-bf7a161ac19b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_b0401e1e-0899-427f-8195-8241a8661aaf_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liabilities for exit fees</link:label>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_f759098e-c9b0-462d-a02f-9e9064b84b21_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit fee derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments, Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:to="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fa8f893c-e281-4e01-88dc-efff091674a5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested balance, beginning (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bd0f0afd-2bac-4415-a45f-82277394665f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested balance, ending (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_IncreaseDecreaseInUnbilledRevenue_6c77dc60-d8fe-45dc-affa-315dd0af1172_negatedLabel_en-US" xlink:label="lab_ardx_IncreaseDecreaseInUnbilledRevenue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled revenue</link:label>
    <link:label id="lab_ardx_IncreaseDecreaseInUnbilledRevenue_label_en-US" xlink:label="lab_ardx_IncreaseDecreaseInUnbilledRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Unbilled Revenue</link:label>
    <link:label id="lab_ardx_IncreaseDecreaseInUnbilledRevenue_documentation_en-US" xlink:label="lab_ardx_IncreaseDecreaseInUnbilledRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of increase or decrease in unbilled revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_IncreaseDecreaseInUnbilledRevenue" xlink:href="ardx-20221231.xsd#ardx_IncreaseDecreaseInUnbilledRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_IncreaseDecreaseInUnbilledRevenue" xlink:to="lab_ardx_IncreaseDecreaseInUnbilledRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_3ed2ed3f-b76c-43f1-8e3e-f17583babb60_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_a30a3f60-1dcb-4c6b-9ab9-4bee3931e70b_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_2342c66d-3511-4af8-9530-6415c99a7d4e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_c08f3c95-2292-4e05-ac92-3a32ba5bacb9_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_PercentageOfNonRoyaltyRevenue_539a0961-1d67-448e-9677-12784bb4b8c1_terseLabel_en-US" xlink:label="lab_ardx_PercentageOfNonRoyaltyRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of non royalty revenue</link:label>
    <link:label id="lab_ardx_PercentageOfNonRoyaltyRevenue_label_en-US" xlink:label="lab_ardx_PercentageOfNonRoyaltyRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Non-Royalty Revenue</link:label>
    <link:label id="lab_ardx_PercentageOfNonRoyaltyRevenue_documentation_en-US" xlink:label="lab_ardx_PercentageOfNonRoyaltyRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents percentage of non-royalty revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PercentageOfNonRoyaltyRevenue" xlink:href="ardx-20221231.xsd#ardx_PercentageOfNonRoyaltyRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_PercentageOfNonRoyaltyRevenue" xlink:to="lab_ardx_PercentageOfNonRoyaltyRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_1d32bb1d-cac6-4e5b-b155-2924e0d6cfb9_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5c5f2953-143b-4a39-a0c5-a460fcd2f5d1_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments, Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_c6be58e4-a71d-4bec-a350-130edb8e91b4_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_9cfe1893-b88b-4f8c-bfa2-cd76ec62edd6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_1c5892e9-4417-43e1-ba52-5fb59fea2f7a_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1b48ad3b-f075-43ce-816d-88dcd2241631_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive (Loss) Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_GeographicInformationAndConcentrationsTextBlock_21a2a101-f8e6-43d0-a49e-a4cbbd738148_terseLabel_en-US" xlink:label="lab_ardx_GeographicInformationAndConcentrationsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Information and Concentrations</link:label>
    <link:label id="lab_ardx_GeographicInformationAndConcentrationsTextBlock_label_en-US" xlink:label="lab_ardx_GeographicInformationAndConcentrationsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Information And Concentrations [Text Block]</link:label>
    <link:label id="lab_ardx_GeographicInformationAndConcentrationsTextBlock_documentation_en-US" xlink:label="lab_ardx_GeographicInformationAndConcentrationsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The entire disclosure on geographic information and concentrations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_GeographicInformationAndConcentrationsTextBlock" xlink:href="ardx-20221231.xsd#ardx_GeographicInformationAndConcentrationsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_GeographicInformationAndConcentrationsTextBlock" xlink:to="lab_ardx_GeographicInformationAndConcentrationsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_b4d788e7-4515-4761-9f20-714325f7388e_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_e62b8af8-30bf-4337-8d88-c432b4ff2d54_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_571fa2fb-64c7-495d-85db-c1f2dab6acaf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_b14d67a5-4530-49ce-8dbb-e0069fc18107_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_f5576c35-7dca-4aad-b23f-5b35642220b1_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_a108e858-33aa-43c3-88b3-ee1f2e0e1521_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_ee2084e9-110c-46c7-8114-5c32882cbb03_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_150c3202-8b13-49ab-a816-10c810df1ef9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_249e6036-558c-4d41-bb81-0c25e65c43fa_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_4dee0a18-9549-465f-b0ac-1f4fc78b9c3c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_664b9e67-f41b-439c-b38a-093f040fc2d8_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ProductSupplyRevenueMember_fe98ba75-619f-4da1-b8d2-9bf100522989_terseLabel_en-US" xlink:label="lab_ardx_ProductSupplyRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product supply revenue</link:label>
    <link:label id="lab_ardx_ProductSupplyRevenueMember_label_en-US" xlink:label="lab_ardx_ProductSupplyRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Supply Revenue [Member]</link:label>
    <link:label id="lab_ardx_ProductSupplyRevenueMember_documentation_en-US" xlink:label="lab_ardx_ProductSupplyRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Supply Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ProductSupplyRevenueMember" xlink:href="ardx-20221231.xsd#ardx_ProductSupplyRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ProductSupplyRevenueMember" xlink:to="lab_ardx_ProductSupplyRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_4ab20f3c-c730-44e4-9ff9-c20d2efb6515_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ExitFeePercentage_0ef80aa1-3b2f-41c9-81f7-2aa0fe816ccb_terseLabel_en-US" xlink:label="lab_ardx_ExitFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit fee (percent)</link:label>
    <link:label id="lab_ardx_ExitFeePercentage_label_en-US" xlink:label="lab_ardx_ExitFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit Fee, Percentage</link:label>
    <link:label id="lab_ardx_ExitFeePercentage_documentation_en-US" xlink:label="lab_ardx_ExitFeePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit Fee, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFeePercentage" xlink:href="ardx-20221231.xsd#ardx_ExitFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ExitFeePercentage" xlink:to="lab_ardx_ExitFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0972c1f7-b299-4681-9b04-78e107c6f969_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_4e2299a4-b96f-4c8f-a167-6b7d47d5840d_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_2d008329-4ba2-4862-a522-75118bb9d280_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_ec0d8265-35a7-439d-af56-365310e4ec9f_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_53e4dcdc-0524-4867-a16e-9d18bb03f669_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_75879d87-0c8c-48a3-8cc3-ecdb3fbb68aa_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_EquitySalesAgreementProceedsFromSharesIssuedSinceInception_4b210758-d3af-4c05-9a1b-fca2f370aac5_terseLabel_en-US" xlink:label="lab_ardx_EquitySalesAgreementProceedsFromSharesIssuedSinceInception" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total of gross proceeds</link:label>
    <link:label id="lab_ardx_EquitySalesAgreementProceedsFromSharesIssuedSinceInception_label_en-US" xlink:label="lab_ardx_EquitySalesAgreementProceedsFromSharesIssuedSinceInception" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Sales Agreement, Proceeds From Shares Issued Since Inception</link:label>
    <link:label id="lab_ardx_EquitySalesAgreementProceedsFromSharesIssuedSinceInception_documentation_en-US" xlink:label="lab_ardx_EquitySalesAgreementProceedsFromSharesIssuedSinceInception" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Sales Agreement, Proceeds From Shares Issued Since Inception</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EquitySalesAgreementProceedsFromSharesIssuedSinceInception" xlink:href="ardx-20221231.xsd#ardx_EquitySalesAgreementProceedsFromSharesIssuedSinceInception"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_EquitySalesAgreementProceedsFromSharesIssuedSinceInception" xlink:to="lab_ardx_EquitySalesAgreementProceedsFromSharesIssuedSinceInception" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_54f16c2b-ce8d-43be-83ae-44a5d6a8df31_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d91250c1-76ad-4c5c-a0e6-60b58ba4715b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_f2e48b9c-ea14-4f5e-9a4b-dac89325723f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, fair value</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_StockIssuanceCostCommissionPercent_2259b34c-5a6f-4adc-9124-a326fb02000a_terseLabel_en-US" xlink:label="lab_ardx_StockIssuanceCostCommissionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering sales commission (percent)</link:label>
    <link:label id="lab_ardx_StockIssuanceCostCommissionPercent_label_en-US" xlink:label="lab_ardx_StockIssuanceCostCommissionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Cost, Commission, Percent</link:label>
    <link:label id="lab_ardx_StockIssuanceCostCommissionPercent_documentation_en-US" xlink:label="lab_ardx_StockIssuanceCostCommissionPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of commission given on gross proceeds from sale of securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_StockIssuanceCostCommissionPercent" xlink:href="ardx-20221231.xsd#ardx_StockIssuanceCostCommissionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_StockIssuanceCostCommissionPercent" xlink:to="lab_ardx_StockIssuanceCostCommissionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_c8aa3df9-2cd8-4fd3-90b2-8da53bb7432d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9e3ad2bf-a443-487a-aff9-3b6891f89eb0_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_07166141-37cb-4b53-9f6b-b0a1ba660952_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_7f02618b-25ac-4781-b860-f4e245369208_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_b6f37f6d-1c4f-437b-9902-b86b988d4f33_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_d12923b8-d019-446f-b6bc-ac9d941424b3_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_095c76e5-2edc-4ded-b271-497a0d968d58_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fbf2aa54-b2b0-4f62-af7f-842ce1aa71d4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_414f5f54-9f37-49e5-934b-0cefe3bf8ee2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_e2f90eb8-efc2-497a-8b8c-4071a0cbf181_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c43c87fe-4d6d-45e4-872d-675d97bd9a84_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_7461f29c-1473-48d0-aee3-27dd9cef7b40_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_AccruedContractManufacturingCosts_ae5b7c56-495d-40ed-8e95-0348f277c747_terseLabel_en-US" xlink:label="lab_ardx_AccruedContractManufacturingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued contract manufacturing expenses</link:label>
    <link:label id="lab_ardx_AccruedContractManufacturingCosts_label_en-US" xlink:label="lab_ardx_AccruedContractManufacturingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Contract Manufacturing Costs</link:label>
    <link:label id="lab_ardx_AccruedContractManufacturingCosts_documentation_en-US" xlink:label="lab_ardx_AccruedContractManufacturingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued contract manufacturing costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AccruedContractManufacturingCosts" xlink:href="ardx-20221231.xsd#ardx_AccruedContractManufacturingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_AccruedContractManufacturingCosts" xlink:to="lab_ardx_AccruedContractManufacturingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5c8fa5fe-4d4c-48f5-bb68-b5f3755e346d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_AuditInformationAbstract_label_en-US" xlink:label="lab_ardx_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_ardx_AuditInformationAbstract_documentation_en-US" xlink:label="lab_ardx_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AuditInformationAbstract" xlink:href="ardx-20221231.xsd#ardx_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_AuditInformationAbstract" xlink:to="lab_ardx_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_11324a65-9dc7-4bfa-b877-caf22523b9f6_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_b561f7d5-ac34-463b-9053-f2c9bb85a30d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_733aa764-6ee2-4a0f-a529-626a7e02e4f8_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment loss of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_9b08fa3c-0744-4500-bae9-402876b24cf2_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborativeDevelopmentMember_d84f62ac-c19f-410c-8378-c4f12d53dcd4_terseLabel_en-US" xlink:label="lab_ardx_CollaborativeDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative development revenue</link:label>
    <link:label id="lab_ardx_CollaborativeDevelopmentMember_label_en-US" xlink:label="lab_ardx_CollaborativeDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Development [Member]</link:label>
    <link:label id="lab_ardx_CollaborativeDevelopmentMember_documentation_en-US" xlink:label="lab_ardx_CollaborativeDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeDevelopmentMember" xlink:href="ardx-20221231.xsd#ardx_CollaborativeDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborativeDevelopmentMember" xlink:to="lab_ardx_CollaborativeDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_fef7d9c4-7ea1-495a-8e2f-a10598ea2325_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6fab9736-5531-45b3-a14f-e839ce6d396c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_TaxAuthorityStatesOtherThanCaliforniaMember_c0f38e92-86da-4db3-abfa-eb10082b3cd8_terseLabel_en-US" xlink:label="lab_ardx_TaxAuthorityStatesOtherThanCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other states</link:label>
    <link:label id="lab_ardx_TaxAuthorityStatesOtherThanCaliforniaMember_label_en-US" xlink:label="lab_ardx_TaxAuthorityStatesOtherThanCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Authority, States Other Than California [Member]</link:label>
    <link:label id="lab_ardx_TaxAuthorityStatesOtherThanCaliforniaMember_documentation_en-US" xlink:label="lab_ardx_TaxAuthorityStatesOtherThanCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Authority, States Other Than California</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TaxAuthorityStatesOtherThanCaliforniaMember" xlink:href="ardx-20221231.xsd#ardx_TaxAuthorityStatesOtherThanCaliforniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_TaxAuthorityStatesOtherThanCaliforniaMember" xlink:to="lab_ardx_TaxAuthorityStatesOtherThanCaliforniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts_f015db2d-9eb4-49ea-9418-6649f6174b4c_terseLabel_en-US" xlink:label="lab_ardx_ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the sale of future royalties, net of issuance costs</link:label>
    <link:label id="lab_ardx_ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts_label_en-US" xlink:label="lab_ardx_ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Future Royalties, Net Of Issuance Costs</link:label>
    <link:label id="lab_ardx_ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts_documentation_en-US" xlink:label="lab_ardx_ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Future Royalties, Net Of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts" xlink:href="ardx-20221231.xsd#ardx_ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts" xlink:to="lab_ardx_ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_947374fe-d317-44a1-9e34-280d328292e8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_842a4daf-0b35-4b8a-b93a-f973709ea19a_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in computing net loss per share - diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ed5c468e-00d6-48b5-af37-3624da6d3fd1_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_af146c5b-eb0c-45c1-8ba5-41db6c0931b7_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage_ce01914e-1ef1-48e2-96ec-337227e241f5_terseLabel_en-US" xlink:label="lab_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final fee due upon maturity, acceleration, prepayment, or termination (percent)</link:label>
    <link:label id="lab_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage_label_en-US" xlink:label="lab_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fee Due Upon Maturity, Acceleration, Prepayment, Termination, Percentage</link:label>
    <link:label id="lab_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage_documentation_en-US" xlink:label="lab_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fee Due Upon Maturity, Acceleration, Prepayment, Termination, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage" xlink:href="ardx-20221231.xsd#ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage" xlink:to="lab_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_c733d886-4fec-47f1-a0a7-c656ae51dbac_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Current Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_AstrazenecaMember_e46320f1-a767-4c15-a122-6b6fe6781822_terseLabel_en-US" xlink:label="lab_ardx_AstrazenecaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca</link:label>
    <link:label id="lab_ardx_AstrazenecaMember_label_en-US" xlink:label="lab_ardx_AstrazenecaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Astrazeneca [Member]</link:label>
    <link:label id="lab_ardx_AstrazenecaMember_documentation_en-US" xlink:label="lab_ardx_AstrazenecaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to AstraZeneca.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AstrazenecaMember" xlink:href="ardx-20221231.xsd#ardx_AstrazenecaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_AstrazenecaMember" xlink:to="lab_ardx_AstrazenecaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_TermOfPaymentOfLicenseFeeFirstInstallment_7fb62cdb-1bb5-4df1-bb8a-95c140154e45_terseLabel_en-US" xlink:label="lab_ardx_TermOfPaymentOfLicenseFeeFirstInstallment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of payment of license fee, first installment</link:label>
    <link:label id="lab_ardx_TermOfPaymentOfLicenseFeeFirstInstallment_label_en-US" xlink:label="lab_ardx_TermOfPaymentOfLicenseFeeFirstInstallment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Of Payment Of License Fee, First Installment</link:label>
    <link:label id="lab_ardx_TermOfPaymentOfLicenseFeeFirstInstallment_documentation_en-US" xlink:label="lab_ardx_TermOfPaymentOfLicenseFeeFirstInstallment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of payment of first installment fee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermOfPaymentOfLicenseFeeFirstInstallment" xlink:href="ardx-20221231.xsd#ardx_TermOfPaymentOfLicenseFeeFirstInstallment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_TermOfPaymentOfLicenseFeeFirstInstallment" xlink:to="lab_ardx_TermOfPaymentOfLicenseFeeFirstInstallment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3485dfab-ebb4-4843-8399-b279f8112fcb_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_75fadf53-4a65-4295-b1c8-b5daedc3c8c2_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage_5344a164-d9ba-4f22-bff4-d85b73158894_terseLabel_en-US" xlink:label="lab_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value analysis, percentage change in probability of occurrence</link:label>
    <link:label id="lab_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage_label_en-US" xlink:label="lab_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Sensitivity Analysis, Change In Probability Of Occurrence, Percentage</link:label>
    <link:label id="lab_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage_documentation_en-US" xlink:label="lab_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Sensitivity Analysis, Change In Probability Of Occurrence, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" xlink:href="ardx-20221231.xsd#ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" xlink:to="lab_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_TwoThousandFourteenEquityIncentiveAwardPlanMember_92a7b8bb-9930-4f74-8a69-bac2c311d58c_terseLabel_en-US" xlink:label="lab_ardx_TwoThousandFourteenEquityIncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Plan</link:label>
    <link:label id="lab_ardx_TwoThousandFourteenEquityIncentiveAwardPlanMember_label_en-US" xlink:label="lab_ardx_TwoThousandFourteenEquityIncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Fourteen Equity Incentive Award Plan [Member]</link:label>
    <link:label id="lab_ardx_TwoThousandFourteenEquityIncentiveAwardPlanMember_documentation_en-US" xlink:label="lab_ardx_TwoThousandFourteenEquityIncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Equity Incentive Award Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TwoThousandFourteenEquityIncentiveAwardPlanMember" xlink:href="ardx-20221231.xsd#ardx_TwoThousandFourteenEquityIncentiveAwardPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_TwoThousandFourteenEquityIncentiveAwardPlanMember" xlink:to="lab_ardx_TwoThousandFourteenEquityIncentiveAwardPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_EquitySalesAgreementSharesIssuedSinceInception_c7ba3957-23a2-4980-afef-4092861a0124_terseLabel_en-US" xlink:label="lab_ardx_EquitySalesAgreementSharesIssuedSinceInception" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total of shares sold</link:label>
    <link:label id="lab_ardx_EquitySalesAgreementSharesIssuedSinceInception_label_en-US" xlink:label="lab_ardx_EquitySalesAgreementSharesIssuedSinceInception" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Sales Agreement, Shares Issued Since Inception</link:label>
    <link:label id="lab_ardx_EquitySalesAgreementSharesIssuedSinceInception_documentation_en-US" xlink:label="lab_ardx_EquitySalesAgreementSharesIssuedSinceInception" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Sales Agreement, Shares Issued Since Inception</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EquitySalesAgreementSharesIssuedSinceInception" xlink:href="ardx-20221231.xsd#ardx_EquitySalesAgreementSharesIssuedSinceInception"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_EquitySalesAgreementSharesIssuedSinceInception" xlink:to="lab_ardx_EquitySalesAgreementSharesIssuedSinceInception" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9e0c7ad4-6df6-4bf7-98c5-9a2ed834f303_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_RevenueRemainingPerformanceObligationVariableConsiderationAmount_10c46adb-f01e-41c4-ac09-a61530ee2921_terseLabel_en-US" xlink:label="lab_ardx_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from milestone payments</link:label>
    <link:label id="lab_ardx_RevenueRemainingPerformanceObligationVariableConsiderationAmount_label_en-US" xlink:label="lab_ardx_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount</link:label>
    <link:label id="lab_ardx_RevenueRemainingPerformanceObligationVariableConsiderationAmount_documentation_en-US" xlink:label="lab_ardx_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:href="ardx-20221231.xsd#ardx_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:to="lab_ardx_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches_ed42a1e3-7716-42d5-807a-fcbaaf25ff3e_terseLabel_en-US" xlink:label="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of payment tranches for fee receivable for reduction in royalty rate</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches_label_en-US" xlink:label="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate, Number Of Payment Tranches</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches_documentation_en-US" xlink:label="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate, Number Of Payment Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches" xlink:href="ardx-20221231.xsd#ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches" xlink:to="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_df8c9a90-e0c6-40c9-a772-202d49da7d87_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_1d3ec82d-3911-4faf-90ee-9bcd9ff2509d_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_NumberOfSeparateCollaborativeAgreements_864d3a6d-99fc-4fd3-a312-88177221b8ef_terseLabel_en-US" xlink:label="lab_ardx_NumberOfSeparateCollaborativeAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of separate collaborative agreements</link:label>
    <link:label id="lab_ardx_NumberOfSeparateCollaborativeAgreements_label_en-US" xlink:label="lab_ardx_NumberOfSeparateCollaborativeAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Separate Collaborative Agreements</link:label>
    <link:label id="lab_ardx_NumberOfSeparateCollaborativeAgreements_documentation_en-US" xlink:label="lab_ardx_NumberOfSeparateCollaborativeAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of separate collaborative agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_NumberOfSeparateCollaborativeAgreements" xlink:href="ardx-20221231.xsd#ardx_NumberOfSeparateCollaborativeAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_NumberOfSeparateCollaborativeAgreements" xlink:to="lab_ardx_NumberOfSeparateCollaborativeAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_4b5961ed-1554-4c0d-86bc-1d08886291b6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value; 300,000,000 shares authorized; 198,575,016 and 130,182,535 shares issued and outstanding as of December&#160;31, 2022 and December&#160;31, 2021, respectively.</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_3552d87b-356d-4725-9f59-3ec212f35e09_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_SharesAvailableForGrantRollForward_78b7e2ba-c10a-4027-8a01-1f8eddd056cd_terseLabel_en-US" xlink:label="lab_ardx_SharesAvailableForGrantRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares&#160;Available for&#160;Grant</link:label>
    <link:label id="lab_ardx_SharesAvailableForGrantRollForward_label_en-US" xlink:label="lab_ardx_SharesAvailableForGrantRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Available For Grant [Roll Forward]</link:label>
    <link:label id="lab_ardx_SharesAvailableForGrantRollForward_documentation_en-US" xlink:label="lab_ardx_SharesAvailableForGrantRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Available For Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_SharesAvailableForGrantRollForward" xlink:href="ardx-20221231.xsd#ardx_SharesAvailableForGrantRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_SharesAvailableForGrantRollForward" xlink:to="lab_ardx_SharesAvailableForGrantRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment_5c0864d7-94d4-4ea2-90bd-f34c20e1f8a0_terseLabel_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second installment of upfront license fees</link:label>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment_label_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Licensing Agreements, Upfront License Fees, Second Installment</link:label>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment_documentation_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Licensing Agreements, Upfront License Fees, Second Installment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment" xlink:href="ardx-20221231.xsd#ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment" xlink:to="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_02b66c7c-3eef-4724-9adf-d8493ce9916d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AsiaPacificMember_490c78e6-cc9d-421d-a1ac-75d28d580e76_terseLabel_en-US" xlink:label="lab_srt_AsiaPacificMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia Pacific</link:label>
    <link:label id="lab_srt_AsiaPacificMember_label_en-US" xlink:label="lab_srt_AsiaPacificMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia Pacific [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AsiaPacificMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AsiaPacificMember" xlink:to="lab_srt_AsiaPacificMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_TermLoan2018Member_1a5f89d5-8824-4223-b7c5-42c0779aef50_terseLabel_en-US" xlink:label="lab_ardx_TermLoan2018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Term Loan</link:label>
    <link:label id="lab_ardx_TermLoan2018Member_label_en-US" xlink:label="lab_ardx_TermLoan2018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan 2018 [Member]</link:label>
    <link:label id="lab_ardx_TermLoan2018Member_documentation_en-US" xlink:label="lab_ardx_TermLoan2018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan 2018</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2018Member" xlink:href="ardx-20221231.xsd#ardx_TermLoan2018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_TermLoan2018Member" xlink:to="lab_ardx_TermLoan2018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f46ba7a4-a486-45c1-91e6-fc321aec2823_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Anti-Dilutive Securities Not Considered in Diluted Net Loss Per Common Share Calculation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerProductSalesGrossToNetAccruals_3dec67af-e345-46f8-abcc-764a25c6d390_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerProductSalesGrossToNetAccruals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer product sales gross to net accruals</link:label>
    <link:label id="lab_ardx_ContractWithCustomerProductSalesGrossToNetAccruals_label_en-US" xlink:label="lab_ardx_ContractWithCustomerProductSalesGrossToNetAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer Product Sales Gross To Net Accruals</link:label>
    <link:label id="lab_ardx_ContractWithCustomerProductSalesGrossToNetAccruals_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerProductSalesGrossToNetAccruals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer Product Sales Gross To Net Accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerProductSalesGrossToNetAccruals" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerProductSalesGrossToNetAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerProductSalesGrossToNetAccruals" xlink:to="lab_ardx_ContractWithCustomerProductSalesGrossToNetAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_06042126-5f56-40db-b342-04ebf9638a60_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Financial Assets and Liabilities Measured on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_b30ade8e-3992-467f-9a42-8d1e3249d4a5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanGrossProceeds_9e13b565-21b2-4726-8165-1c63408616b2_terseLabel_en-US" xlink:label="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross&#160;Proceeds</link:label>
    <link:label id="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanGrossProceeds_label_en-US" xlink:label="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Employee Stock Purchase Plan, Gross Proceeds</link:label>
    <link:label id="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanGrossProceeds_documentation_en-US" xlink:label="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of gross proceeds received from shares issued to employees under the plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanGrossProceeds" xlink:href="ardx-20221231.xsd#ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanGrossProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanGrossProceeds" xlink:to="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanGrossProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6b6371f9-55a6-45ae-8045-d5a224d6fc32_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_99413023-7886-4f1a-865a-c35364d523f2_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember_6faddb18-a86b-450b-85d3-6e143ba8f47f_terseLabel_en-US" xlink:label="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fosun Agreement</link:label>
    <link:label id="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember_label_en-US" xlink:label="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Development Commercialization Distribution In China [Member]</link:label>
    <link:label id="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember_documentation_en-US" xlink:label="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement for the development, commercialization and distribution of tenapanor in China. The Fosun Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember" xlink:href="ardx-20221231.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember" xlink:to="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_DerivativeIssued_b7f44604-143d-4f03-a70e-c6076619bee0_terseLabel_en-US" xlink:label="lab_ardx_DerivativeIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of derivative in connection with issuance of loan payable</link:label>
    <link:label id="lab_ardx_DerivativeIssued_label_en-US" xlink:label="lab_ardx_DerivativeIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Issued</link:label>
    <link:label id="lab_ardx_DerivativeIssued_documentation_en-US" xlink:label="lab_ardx_DerivativeIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the non-cash issuance of derivative in connection with issuance of loan payable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DerivativeIssued" xlink:href="ardx-20221231.xsd#ardx_DerivativeIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_DerivativeIssued" xlink:to="lab_ardx_DerivativeIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f8d1b48a-c069-4ae9-bc4e-35e3a6b24d65_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ba077727-36e4-4b90-be91-7d25724135db_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_479b5aee-699a-48a3-ace2-250604f7a3d3_terseLabel_en-US" xlink:label="lab_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue - non-current</link:label>
    <link:label id="lab_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_label_en-US" xlink:label="lab_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer Liability, Noncurrent, Rollforward [Roll Forward]</link:label>
    <link:label id="lab_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_documentation_en-US" xlink:label="lab_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer Liability, Noncurrent, Rollforward</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward" xlink:href="ardx-20221231.xsd#ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward" xlink:to="lab_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenueDuringThePeriod_8eb0eee9-f8d2-4606-a350-2fd24746ea1e_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenueDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases due to cash received, excluding amounts recognized as revenue during the period</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenueDuringThePeriod_label_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenueDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Increases Due To Cash Received, Excluding Amounts Recognized As Revenue During The Period</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenueDuringThePeriod_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenueDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Increases Due To Cash Received, Excluding Amounts Recognized As Revenue During The Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenueDuringThePeriod" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenueDuringThePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenueDuringThePeriod" xlink:to="lab_ardx_ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenueDuringThePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock_924d4e1e-3634-4e1a-b211-ac6160b74525_terseLabel_en-US" xlink:label="lab_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Chargebacks, Discounts and Reserve Balances</link:label>
    <link:label id="lab_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock_label_en-US" xlink:label="lab_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Gross To Net Sales Accruals [Table Text Block]</link:label>
    <link:label id="lab_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock_documentation_en-US" xlink:label="lab_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Gross To Net Sales Accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock" xlink:href="ardx-20221231.xsd#ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock" xlink:to="lab_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableMember_430a5af6-364c-4776-aa08-9751b8b1e1b0_verboseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_3fb682a8-ec28-4eda-943f-b46b40d7d800_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_640568f5-61f9-4791-9413-b0bba5bea711_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_33a65a85-e730-49e8-a660-1171c9ec7db0_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_TermLoan2022AMember_e9aa263e-6931-437a-a1ec-aee490200594_terseLabel_en-US" xlink:label="lab_ardx_TermLoan2022AMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A</link:label>
    <link:label id="lab_ardx_TermLoan2022AMember_label_en-US" xlink:label="lab_ardx_TermLoan2022AMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan 2022 A [Member]</link:label>
    <link:label id="lab_ardx_TermLoan2022AMember_documentation_en-US" xlink:label="lab_ardx_TermLoan2022AMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan 2022 A</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2022AMember" xlink:href="ardx-20221231.xsd#ardx_TermLoan2022AMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_TermLoan2022AMember" xlink:to="lab_ardx_TermLoan2022AMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum_f29baa76-a05f-4480-96c4-71d551ea0759_terseLabel_en-US" xlink:label="lab_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit fee, net product revenue threshold</link:label>
    <link:label id="lab_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum_label_en-US" xlink:label="lab_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Exit Fee, Net Product Revenue Threshold Metric, Trailing Six Month Basis, Minimum</link:label>
    <link:label id="lab_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum_documentation_en-US" xlink:label="lab_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Exit Fee, Net Product Revenue Threshold Metric, Trailing Six Month Basis, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum" xlink:href="ardx-20221231.xsd#ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum" xlink:to="lab_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRoyaltiesReceived_a206967e-7479-4a53-80a4-f87bfbaf5bc5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRoyaltiesReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from royalties received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRoyaltiesReceived_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRoyaltiesReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Royalties Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRoyaltiesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRoyaltiesReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRoyaltiesReceived" xlink:to="lab_us-gaap_ProceedsFromRoyaltiesReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_d11e2548-8530-426f-860e-2ea000487f5d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_79c899a6-c11b-46dc-8595-a6d48f077290_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Exit Fee addition at fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded_f325b499-cf13-496c-8f7f-e0f74b025d88_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase due to unbilled prepayments recorded during the period</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded_label_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Increase Due To Unbilled Prepayments Recorded</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Increase Due To Unbilled Prepayments Recorded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded" xlink:to="lab_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_0a63dc80-7d4e-4ada-b0bc-f566a1eeae97_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_41b7799c-5fcb-4f85-aeb7-7788899ab80b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vest and expected to vest (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_eef697e8-05c6-41a5-9674-2a7bd9342f08_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_dcb79610-71d1-4587-8eec-439b0220e20b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_6b890c38-f866-463b-bca6-191cc65cc180_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_97cd9e7c-025a-4001-a5ed-677583881c57_terseLabel_en-US" xlink:label="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 KKC Agreement</link:label>
    <link:label id="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_label_en-US" xlink:label="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Development Commercialization Distribution In Japan [Member]</link:label>
    <link:label id="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_documentation_en-US" xlink:label="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement for the development, commercialization and distribution of tenapanor in Japan. The 2017 KKC Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember" xlink:href="ardx-20221231.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember" xlink:to="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_41ea44b3-25bb-45b2-a71a-d9e3a8b451ab_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CaliforniaFranchiseTaxBoardMember_8e444e82-45e8-42d5-b2c8-968bed6c8435_terseLabel_en-US" xlink:label="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California</link:label>
    <link:label id="lab_us-gaap_CaliforniaFranchiseTaxBoardMember_label_en-US" xlink:label="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Franchise Tax Board [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:to="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8cbb3309-8b64-44d3-842c-e0500ee99c55_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_341a2901-502c-4cb1-8d11-e41e2572943c_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_861a889e-afc0-440f-9d06-92a56bc72798_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_644187b9-eafc-485a-8c76-b0cd68686332_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in derivative liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Derivative Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_55e350d8-2c8c-4875-baf3-026f822fcc97_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_fbc46864-557c-49c0-bcd8-aa0a4396be90_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_2cea5387-e594-48fb-9c18-9fdcae91d451_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of lawsuits</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3a258a4e-65af-46d0-8161-7074bc3261af_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_2857cef1-c04b-44f4-bee8-9ac4bfe26c83_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_5d03fae9-8c0f-4226-9a94-f8e6653b0b99_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_4f933c5c-a9d1-487d-93fe-0e7befe7d93a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plans</link:label>
    <link:label id="lab_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="lab_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_5688cb2e-7a60-49fe-bb5e-47e1bd323040_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under equity incentive and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_DebtInstrumentVariableRatePlusOption_dff566c3-b4de-4986-afd9-277d6ab32329_terseLabel_en-US" xlink:label="lab_ardx_DebtInstrumentVariableRatePlusOption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Addition plus to floating per annum rate (percent)</link:label>
    <link:label id="lab_ardx_DebtInstrumentVariableRatePlusOption_label_en-US" xlink:label="lab_ardx_DebtInstrumentVariableRatePlusOption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Variable Rate, Plus Option</link:label>
    <link:label id="lab_ardx_DebtInstrumentVariableRatePlusOption_documentation_en-US" xlink:label="lab_ardx_DebtInstrumentVariableRatePlusOption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Variable Rate, Plus Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentVariableRatePlusOption" xlink:href="ardx-20221231.xsd#ardx_DebtInstrumentVariableRatePlusOption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_DebtInstrumentVariableRatePlusOption" xlink:to="lab_ardx_DebtInstrumentVariableRatePlusOption" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveCurrent_9aeb6e7f-6e27-4657-aed4-f7ed9fc7df97_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated restructuring liability</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveCurrent_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveCurrent" xlink:to="lab_us-gaap_RestructuringReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_646aac9a-8a55-46ff-8eb2-98cb42754e21_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments, Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_6c8c92d6-5bee-4638-af86-eb5b063e8ba4_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_26020d2f-161f-4bb0-8341-3b6e5aff9767_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember_39ff88d1-330b-41c5-9bb7-7aea1f93c622_terseLabel_en-US" xlink:label="lab_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Open Market Sales Agreement</link:label>
    <link:label id="lab_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember_label_en-US" xlink:label="lab_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Market Sales Agreement 2021, At The Market Offering [Member]</link:label>
    <link:label id="lab_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Market Sales Agreement 2021, At The Market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember" xlink:href="ardx-20221231.xsd#ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember" xlink:to="lab_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_f668ae42-2e61-4a16-ac99-0cb33aa5a097_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponExerciseOfStockOptions_4b712317-0435-4cc2-b8b8-7c5724b4aaab_terseLabel_en-US" xlink:label="lab_ardx_IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum shares to be issued upon exercise of incentive stock options</link:label>
    <link:label id="lab_ardx_IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponExerciseOfStockOptions_label_en-US" xlink:label="lab_ardx_IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase In Shares Reserved For Issuance, Maximum Shares To Be Issued Upon Exercise Of Stock Options</link:label>
    <link:label id="lab_ardx_IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponExerciseOfStockOptions_documentation_en-US" xlink:label="lab_ardx_IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase In Shares Reserved For Issuance, Maximum Shares To Be Issued Upon Exercise Of Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponExerciseOfStockOptions" xlink:href="ardx-20221231.xsd#ardx_IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponExerciseOfStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponExerciseOfStockOptions" xlink:to="lab_ardx_IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponExerciseOfStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToCanceledInPeriod_9b421fb1-964c-4213-98cf-fff980674368_terseLabel_en-US" xlink:label="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToCanceledInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for grant, effect of canceled (shares)</link:label>
    <link:label id="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToCanceledInPeriod_label_en-US" xlink:label="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToCanceledInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Available For Grant, Increase Due To Canceled In Period</link:label>
    <link:label id="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToCanceledInPeriod_documentation_en-US" xlink:label="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToCanceledInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Available For Grant, Increase Due To Canceled In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToCanceledInPeriod" xlink:href="ardx-20221231.xsd#ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToCanceledInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToCanceledInPeriod" xlink:to="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToCanceledInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_57357ff1-2de1-434b-809d-1aa12177e87a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future payment obligations</link:label>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:to="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0b79a916-9dee-4d38-923a-69e9c29bbd72_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_IncomeTaxDisclosureTable_5886448a-74fc-4f69-a647-114cbc337e72_terseLabel_en-US" xlink:label="lab_ardx_IncomeTaxDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Table]</link:label>
    <link:label id="lab_ardx_IncomeTaxDisclosureTable_label_en-US" xlink:label="lab_ardx_IncomeTaxDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Table]</link:label>
    <link:label id="lab_ardx_IncomeTaxDisclosureTable_documentation_en-US" xlink:label="lab_ardx_IncomeTaxDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_IncomeTaxDisclosureTable" xlink:href="ardx-20221231.xsd#ardx_IncomeTaxDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_IncomeTaxDisclosureTable" xlink:to="lab_ardx_IncomeTaxDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_27c8f20c-e82c-4e21-bd1e-905dbd3ae0ef_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_da7ca1ca-e994-44e9-8b76-b06f3a02c302_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_64efe6ee-f402-485e-a13c-af4e119c543e_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_36d11400-4a42-46fd-b729-e418073c06ab_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax at the federal statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ResearchCollaborationAndOptionAgreementMember_c665176e-cd7c-487c-8212-5e8cf7d8e61e_terseLabel_en-US" xlink:label="lab_ardx_ResearchCollaborationAndOptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 KKC Agreement</link:label>
    <link:label id="lab_ardx_ResearchCollaborationAndOptionAgreementMember_label_en-US" xlink:label="lab_ardx_ResearchCollaborationAndOptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration And Option Agreement [Member]</link:label>
    <link:label id="lab_ardx_ResearchCollaborationAndOptionAgreementMember_documentation_en-US" xlink:label="lab_ardx_ResearchCollaborationAndOptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pertaining to the research collaboration and option agreement for research associated with identifying two pre-clinical compounds. The 2019 KKC AGreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ResearchCollaborationAndOptionAgreementMember" xlink:href="ardx-20221231.xsd#ardx_ResearchCollaborationAndOptionAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ResearchCollaborationAndOptionAgreementMember" xlink:to="lab_ardx_ResearchCollaborationAndOptionAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_451452d0-778e-4031-bc45-7375079b2823_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_OfficeEquipmentAndFurnitureMember_96617ccc-b426-4cb9-8335-e62768645938_terseLabel_en-US" xlink:label="lab_ardx_OfficeEquipmentAndFurnitureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office equipment and furniture</link:label>
    <link:label id="lab_ardx_OfficeEquipmentAndFurnitureMember_label_en-US" xlink:label="lab_ardx_OfficeEquipmentAndFurnitureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment And Furniture [Member]</link:label>
    <link:label id="lab_ardx_OfficeEquipmentAndFurnitureMember_documentation_en-US" xlink:label="lab_ardx_OfficeEquipmentAndFurnitureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment And Furniture [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_OfficeEquipmentAndFurnitureMember" xlink:href="ardx-20221231.xsd#ardx_OfficeEquipmentAndFurnitureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_OfficeEquipmentAndFurnitureMember" xlink:to="lab_ardx_OfficeEquipmentAndFurnitureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_9ec791b8-856d-4392-88ae-63b15932a821_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_a74f35b9-7db4-4e4d-ba4c-239cd346cbf8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialDevelopmentMilestones_674e60cc-9114-4872-bccf-7d51c968d89a_terseLabel_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development milestones</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialDevelopmentMilestones_label_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Potential Development Milestones</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialDevelopmentMilestones_documentation_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Potential Development Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialDevelopmentMilestones" xlink:href="ardx-20221231.xsd#ardx_CollaborativeArrangementPotentialDevelopmentMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborativeArrangementPotentialDevelopmentMilestones" xlink:to="lab_ardx_CollaborativeArrangementPotentialDevelopmentMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_25b5be15-45b0-4f5d-880b-ff81bf104bdc_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options issued and outstanding balance, beginning (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ddfc9f00-037f-489c-9b1b-5188cb34c0ef_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options issued and outstanding balance, ending (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_7efab01c-173d-4e12-851a-845b39d111bc_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Unamortized discount and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_c2295835-9b7b-40d2-ab73-ba00bebe78f8_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_8751dceb-a48a-4aeb-8977-1a87f473c7f8_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived_fce9e8df-60ff-4013-9a85-e109dd39aebc_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases to amounts invoiced, for which cash has not yet been received</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived_label_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Revenue Invoiced But Cash Not Received</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Revenue Invoiced But Cash Not Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived" xlink:to="lab_ardx_ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_258b819b-6729-45fb-adcd-4a858337285f_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dd585a0d-e21d-4e6c-938d-13bd4aa0e048_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8f8342ef-5191-4f72-99f0-5d10c7e9eda3_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LeaseArrangementsDomain_ab9b6b7c-5e61-4a63-8573-4c00a5690364_terseLabel_en-US" xlink:label="lab_ardx_LeaseArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Domain]</link:label>
    <link:label id="lab_ardx_LeaseArrangementsDomain_label_en-US" xlink:label="lab_ardx_LeaseArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Domain]</link:label>
    <link:label id="lab_ardx_LeaseArrangementsDomain_documentation_en-US" xlink:label="lab_ardx_LeaseArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LeaseArrangementsDomain" xlink:href="ardx-20221231.xsd#ardx_LeaseArrangementsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LeaseArrangementsDomain" xlink:to="lab_ardx_LeaseArrangementsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_55590798-423e-4083-838a-dbee36f3f953_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_6068c2ee-1133-49a4-a060-2582d96f2ace_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_13f4e845-d1df-4d29-a92f-06057b9f4f22_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_8dc7e7eb-96f8-444d-8563-dbb6c50a2890_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_b67b6042-9597-4cb5-99f1-1e49db0880f7_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for operating lease</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract_4dc4b57e-beec-449d-9ae9-2ae6e446ec27_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facilities - right-of-use assets and lease liabilities</link:label>
    <link:label id="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_64249dc1-da8a-4ccb-807f-a1c57be3f68a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in estimated fair value:</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_924c86ee-159b-4ace-88b6-eaa195127e54_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_fdbb0e15-cbf1-4d8e-9113-cc9e491deda2_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_f9b40bcb-18c5-4330-9ace-80a41cbaf315_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisposals_3b5325fe-bbc9-4a95-a8ad-71627c234c2a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisposals_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Disposals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1060b991-fc65-4a24-85ed-398326e76c32_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_5644c388-6779-45da-aab7-3dc402115190_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f5148d77-80db-43b0-bab4-3b826eff42e5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8c5691fa-1e26-4207-ae11-2af6958be2a4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_2852344d-1701-4afc-b971-3b5c20ee7be4_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_d571bb49-1925-4a0c-a363-5420357c42a8_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_4532731f-8919-4eb8-93ae-dfc69525945b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_ce597da6-8b10-43df-bc80-3e83d0100e6b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_HealthCareRoyaltyPartnersIVLPMember_142d1e22-b08c-44e4-a4b2-8823b276dbcb_terseLabel_en-US" xlink:label="lab_ardx_HealthCareRoyaltyPartnersIVLPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare royalty partners IV, L.P</link:label>
    <link:label id="lab_ardx_HealthCareRoyaltyPartnersIVLPMember_label_en-US" xlink:label="lab_ardx_HealthCareRoyaltyPartnersIVLPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HealthCare Royalty Partners IV, L.P [Member]</link:label>
    <link:label id="lab_ardx_HealthCareRoyaltyPartnersIVLPMember_documentation_en-US" xlink:label="lab_ardx_HealthCareRoyaltyPartnersIVLPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HealthCare Royalty Partners IV, L.P</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_HealthCareRoyaltyPartnersIVLPMember" xlink:href="ardx-20221231.xsd#ardx_HealthCareRoyaltyPartnersIVLPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_HealthCareRoyaltyPartnersIVLPMember" xlink:to="lab_ardx_HealthCareRoyaltyPartnersIVLPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborationPartnershipConcentrationRiskMember_f3d32555-bb34-4124-a033-85efe5b2c035_terseLabel_en-US" xlink:label="lab_ardx_CollaborationPartnershipConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration partnership concentration risk</link:label>
    <link:label id="lab_ardx_CollaborationPartnershipConcentrationRiskMember_label_en-US" xlink:label="lab_ardx_CollaborationPartnershipConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Partnership Concentration Risk [Member]</link:label>
    <link:label id="lab_ardx_CollaborationPartnershipConcentrationRiskMember_documentation_en-US" xlink:label="lab_ardx_CollaborationPartnershipConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Partnership Concentration Risk</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationPartnershipConcentrationRiskMember" xlink:href="ardx-20221231.xsd#ardx_CollaborationPartnershipConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborationPartnershipConcentrationRiskMember" xlink:to="lab_ardx_CollaborationPartnershipConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_StockOptionsWeightedAverageRemainingContractualTermAbstract_dba51a28-0d57-475a-9d31-6bd8ccf5dad3_terseLabel_en-US" xlink:label="lab_ardx_StockOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual&#160;Term (in Years)</link:label>
    <link:label id="lab_ardx_StockOptionsWeightedAverageRemainingContractualTermAbstract_label_en-US" xlink:label="lab_ardx_StockOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options, Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label id="lab_ardx_StockOptionsWeightedAverageRemainingContractualTermAbstract_documentation_en-US" xlink:label="lab_ardx_StockOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_StockOptionsWeightedAverageRemainingContractualTermAbstract" xlink:href="ardx-20221231.xsd#ardx_StockOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_StockOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="lab_ardx_StockOptionsWeightedAverageRemainingContractualTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_4c4a9b4e-33aa-444d-9f2e-0cf5df1f521a_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_afbee73d-c6b0-443e-aa0b-09d76f4def5f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_104a53ce-f211-40bc-bbb5-3e1ab173e689_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_AccruedProfessionalAndConsultantFeesCurrent_2d94f611-82a2-47b3-ac27-67307c7f8e74_terseLabel_en-US" xlink:label="lab_ardx_AccruedProfessionalAndConsultantFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional and consulting services</link:label>
    <link:label id="lab_ardx_AccruedProfessionalAndConsultantFeesCurrent_label_en-US" xlink:label="lab_ardx_AccruedProfessionalAndConsultantFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional And Consultant Fees Current</link:label>
    <link:label id="lab_ardx_AccruedProfessionalAndConsultantFeesCurrent_documentation_en-US" xlink:label="lab_ardx_AccruedProfessionalAndConsultantFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional and consultant fees current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AccruedProfessionalAndConsultantFeesCurrent" xlink:href="ardx-20221231.xsd#ardx_AccruedProfessionalAndConsultantFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_AccruedProfessionalAndConsultantFeesCurrent" xlink:to="lab_ardx_AccruedProfessionalAndConsultantFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerRebatesWholesalerAndGPOFeesMember_f3db23e4-5869-4a05-955e-f65628a8101d_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerRebatesWholesalerAndGPOFeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates, Wholesaler and GPO Fees</link:label>
    <link:label id="lab_ardx_ContractWithCustomerRebatesWholesalerAndGPOFeesMember_label_en-US" xlink:label="lab_ardx_ContractWithCustomerRebatesWholesalerAndGPOFeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Rebates, Wholesaler And GPO Fees [Member]</link:label>
    <link:label id="lab_ardx_ContractWithCustomerRebatesWholesalerAndGPOFeesMember_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerRebatesWholesalerAndGPOFeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Rebates, Wholesaler And GPO Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerRebatesWholesalerAndGPOFeesMember" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerRebatesWholesalerAndGPOFeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerRebatesWholesalerAndGPOFeesMember" xlink:to="lab_ardx_ContractWithCustomerRebatesWholesalerAndGPOFeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_4e97bd98-7c55-411d-a0c3-2c61d32bab73_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_32a5b58f-f93b-4711-9523-26f4bd882567_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_dcae0d20-66b1-4fb7-a799-086f738c9c90_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_dc451fef-13d8-4294-ba35-087d6f4a2192_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetRetirementObligationDisclosureTextBlock_d8b15bdb-aad4-4ea1-8a84-43aa9a4b3709_terseLabel_en-US" xlink:label="lab_us-gaap_AssetRetirementObligationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Royalty Obligation Related To The Sale Of Future Royalties</link:label>
    <link:label id="lab_us-gaap_AssetRetirementObligationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AssetRetirementObligationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Retirement Obligation Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetRetirementObligationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetRetirementObligationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetRetirementObligationDisclosureTextBlock" xlink:to="lab_us-gaap_AssetRetirementObligationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ShortTermInvestmentsPolicyTextBlock_0a67db4b-e3f2-46f7-859a-a9cbbecb1b8f_terseLabel_en-US" xlink:label="lab_ardx_ShortTermInvestmentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments</link:label>
    <link:label id="lab_ardx_ShortTermInvestmentsPolicyTextBlock_label_en-US" xlink:label="lab_ardx_ShortTermInvestmentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Investments [Policy Text Block]</link:label>
    <link:label id="lab_ardx_ShortTermInvestmentsPolicyTextBlock_documentation_en-US" xlink:label="lab_ardx_ShortTermInvestmentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short term investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShortTermInvestmentsPolicyTextBlock" xlink:href="ardx-20221231.xsd#ardx_ShortTermInvestmentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ShortTermInvestmentsPolicyTextBlock" xlink:to="lab_ardx_ShortTermInvestmentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_5385a97c-0c31-4121-b2f0-9065da7dedf9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_fa0b0233-e528-46d9-93ed-2fda465f93dd_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_e164d09a-d76e-46f1-9309-d2a6c8cfa503_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_da0ce4d3-21a1-427b-965e-16edb6b671e8_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_ae2406c2-3404-4fb3-bbfe-469d65acd94b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7e1dd66b-984c-48a4-9144-e4944e651901_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_b62e91d5-61a8-4d5a-a4a0-33c606d0e08c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_cd128101-4f41-4b24-9115-4ed409082c43_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares purchased (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_e6311b10-2c26-48eb-88ad-caf8d2c472d2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_OperatingLossCarryforwardsWithoutExpiration_30dfcacb-14cb-44cc-b41a-5a6280a15e22_terseLabel_en-US" xlink:label="lab_ardx_OperatingLossCarryforwardsWithoutExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards, indefinite</link:label>
    <link:label id="lab_ardx_OperatingLossCarryforwardsWithoutExpiration_label_en-US" xlink:label="lab_ardx_OperatingLossCarryforwardsWithoutExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Without Expiration</link:label>
    <link:label id="lab_ardx_OperatingLossCarryforwardsWithoutExpiration_documentation_en-US" xlink:label="lab_ardx_OperatingLossCarryforwardsWithoutExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws indefinitely.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_OperatingLossCarryforwardsWithoutExpiration" xlink:href="ardx-20221231.xsd#ardx_OperatingLossCarryforwardsWithoutExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_OperatingLossCarryforwardsWithoutExpiration" xlink:to="lab_ardx_OperatingLossCarryforwardsWithoutExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_36d63a0d-6a1c-44f8-9183-528d8b99a455_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_8ae8e230-7c24-4072-901e-19122f7947ef_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_39fb49c8-fc03-428a-8f2d-52ca42819a05_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Compensation Expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5e9ebcab-2b0b-4f40-b578-26313098277f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of&#160;Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_bfcce62f-da16-4394-aeed-e1b5b2ebe3ac_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Customers and Collaboration Partnerships</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_9dd02175-bf97-42a2-bafb-d3abd6dc0556_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_868506d1-d9f8-4c64-a26f-4f84cec10c2f_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_KnightTherapeuticsIncMember_45336a72-5d8e-4cca-82a1-794e12cc3581_terseLabel_en-US" xlink:label="lab_ardx_KnightTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Knight</link:label>
    <link:label id="lab_ardx_KnightTherapeuticsIncMember_label_en-US" xlink:label="lab_ardx_KnightTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Knight Therapeutics Inc [Member]</link:label>
    <link:label id="lab_ardx_KnightTherapeuticsIncMember_documentation_en-US" xlink:label="lab_ardx_KnightTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Knight Therapeutics Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_KnightTherapeuticsIncMember" xlink:href="ardx-20221231.xsd#ardx_KnightTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_KnightTherapeuticsIncMember" xlink:to="lab_ardx_KnightTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_26b6f10a-9fc5-452b-aa94-e9c8b9eb7b41_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options issued and outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_1e8e119a-0f7f-413f-8e8b-38125385741e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_9f0f3034-46a5-409b-bad6-027241893e2c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_987f73a2-8117-4899-bbb3-99fa9575dd2d_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_StrezsakVersusArdelyxIncMember_3a225de0-6968-430e-a6ab-7151b6add81b_terseLabel_en-US" xlink:label="lab_ardx_StrezsakVersusArdelyxIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strezsak v. Ardelyx, Inc.</link:label>
    <link:label id="lab_ardx_StrezsakVersusArdelyxIncMember_label_en-US" xlink:label="lab_ardx_StrezsakVersusArdelyxIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strezsak Versus Ardelyx, Inc. [Member]</link:label>
    <link:label id="lab_ardx_StrezsakVersusArdelyxIncMember_documentation_en-US" xlink:label="lab_ardx_StrezsakVersusArdelyxIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strezsak Versus Ardelyx, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_StrezsakVersusArdelyxIncMember" xlink:href="ardx-20221231.xsd#ardx_StrezsakVersusArdelyxIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_StrezsakVersusArdelyxIncMember" xlink:to="lab_ardx_StrezsakVersusArdelyxIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDescriptionAbstract_173b900e-dd41-407b-b959-3ad25da481fc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional details</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDescriptionAbstract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Description [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="lab_us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_37de39a6-c7a5-463d-b972-a5b3dcf446f0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_612e9128-2425-4f2a-b484-cdb5dc7e5c84_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_3114703e-7bb8-4a1a-bcc8-ccc15aaec650_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_f36fbfc8-b3d3-48c6-96e9-84541f1c3e90_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_312b663d-3660-4cb7-ae5a-b4ef46ea1892_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loans</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_c99ac183-1e1c-463c-8fed-bc7ea77d894d_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_3768e079-e93c-4834-94a3-d9d2b6802efd_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government-sponsored agency bonds</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_3d23d185-36c9-4c57-904d-f4482de4d138_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsAbstract_3bff9f51-a320-4004-a71e-a177b18cbc99_terseLabel_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Licensing Agreements</link:label>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsAbstract_label_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Licensing Agreements [Abstract]</link:label>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsAbstract_documentation_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsAbstract" xlink:href="ardx-20221231.xsd#ardx_CollaborationAndLicensingAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborationAndLicensingAgreementsAbstract" xlink:to="lab_ardx_CollaborationAndLicensingAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_43e19772-4e22-4280-b815-0c385526d917_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_dbf47fe5-0fab-4d95-9a89-dc7ead638c58_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b5fe6540-9397-4e10-affd-5918d55ac933_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b6f68c15-59a3-474a-a459-b54bf0c16d55_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments, Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_8025b93b-b5c2-4712-94e4-9e8b000b3f26_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Stock Purchase Plan Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_82e24dfa-8cec-4935-949c-b0eff25d28cd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_e856bf9d-543d-4d06-81c5-a39f5be1125b_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_5cabaa89-2974-478e-8877-462d238d80da_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_1858d244-4442-461d-a166-c549c1c31435_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_17e8d65a-1b52-4b6b-a508-31f3c324f7f2_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_f245a836-fdfa-4d39-aed4-729a4d57379b_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_ff23dcab-d96d-4902-974f-033d9136de89_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_0e4fd169-dc40-499a-9407-4dffcd62b6d9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_21a62d25-efa4-4b0b-98be-a23c8f914954_terseLabel_en-US" xlink:label="lab_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue - current</link:label>
    <link:label id="lab_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_label_en-US" xlink:label="lab_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer Liability, Current, Rollforward [Roll Forward]</link:label>
    <link:label id="lab_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_documentation_en-US" xlink:label="lab_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer Liability, Current, Rollforward</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward" xlink:href="ardx-20221231.xsd#ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward" xlink:to="lab_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_TwoThousandEightStockIncentivePlanMember_c970eb0c-257b-40c6-befa-b2d6d8ff462b_terseLabel_en-US" xlink:label="lab_ardx_TwoThousandEightStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2008 Plan</link:label>
    <link:label id="lab_ardx_TwoThousandEightStockIncentivePlanMember_label_en-US" xlink:label="lab_ardx_TwoThousandEightStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Eight Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_ardx_TwoThousandEightStockIncentivePlanMember_documentation_en-US" xlink:label="lab_ardx_TwoThousandEightStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Eight Stock Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TwoThousandEightStockIncentivePlanMember" xlink:href="ardx-20221231.xsd#ardx_TwoThousandEightStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_TwoThousandEightStockIncentivePlanMember" xlink:to="lab_ardx_TwoThousandEightStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_f4779f8c-769d-4903-8dea-dbcaa60ee62c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_40c0efb8-036d-4904-836a-8be57646228b_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_94270ee4-0c69-4dfc-a6e8-ad6aba40ee7f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueProductLineMember_a6446ba1-2799-4e73-b7f9-bf4c860de475_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueProductLineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross product revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueProductLineMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueProductLineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Product and Service Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueProductLineMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueProductLineMember" xlink:to="lab_us-gaap_SalesRevenueProductLineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesUnderEmployeeStockPurchasePlan_645e683e-8436-4c9d-8d41-6d4ca607cd8d_terseLabel_en-US" xlink:label="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesUnderEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum shares to be issued under ESPP</link:label>
    <link:label id="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesUnderEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesUnderEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Number Of Shares Under Employee Stock Purchase Plan</link:label>
    <link:label id="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesUnderEmployeeStockPurchasePlan_documentation_en-US" xlink:label="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesUnderEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Number Of Shares Under Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesUnderEmployeeStockPurchasePlan" xlink:href="ardx-20221231.xsd#ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesUnderEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesUnderEmployeeStockPurchasePlan" xlink:to="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesUnderEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_68f84594-d017-4925-837c-79a5ac62544b_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants to purchase common stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAndCash_cf9d4709-4cf9-446f-85d9-c9dddc5e7881_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAndCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and short-term investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsAndCash_c938e341-1ed9-4e3e-be7d-41e340255e1d_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAndCash" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and investments, Fair Value</link:label>
    <link:label id="lab_us-gaap_InvestmentsAndCash_label_en-US" xlink:label="lab_us-gaap_InvestmentsAndCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments and Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAndCash" xlink:to="lab_us-gaap_InvestmentsAndCash" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_84aa549c-1e3b-4ee7-8c91-1fd0f6748290_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_76b58004-66df-4960-afb6-2ebb37242d24_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock in at the market offering, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_f2e6600c-5b64-4616-bb9f-b3fb51a9772a_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a6564453-dfbb-4a05-989a-494749602e8e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in computing net loss per share - basic</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_33ca7974-0346-44e5-a837-463af29198d9_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_AccountsReceivableCollaboratorMember_a37ac04b-efb0-4124-8d50-167afe2a3b0d_terseLabel_en-US" xlink:label="lab_ardx_AccountsReceivableCollaboratorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborators</link:label>
    <link:label id="lab_ardx_AccountsReceivableCollaboratorMember_label_en-US" xlink:label="lab_ardx_AccountsReceivableCollaboratorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Collaborator [Member]</link:label>
    <link:label id="lab_ardx_AccountsReceivableCollaboratorMember_documentation_en-US" xlink:label="lab_ardx_AccountsReceivableCollaboratorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Collaborator</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AccountsReceivableCollaboratorMember" xlink:href="ardx-20221231.xsd#ardx_AccountsReceivableCollaboratorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_AccountsReceivableCollaboratorMember" xlink:to="lab_ardx_AccountsReceivableCollaboratorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_e7005cf8-76c0-4067-bc01-c3c14945ae20_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_DeferredRoyaltyObligationNoncurrent_90261963-d46b-4104-aa36-57b472df1037_terseLabel_en-US" xlink:label="lab_ardx_DeferredRoyaltyObligationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred royalty obligation related to the sale of future royalties</link:label>
    <link:label id="lab_ardx_DeferredRoyaltyObligationNoncurrent_label_en-US" xlink:label="lab_ardx_DeferredRoyaltyObligationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Royalty Obligation, Noncurrent</link:label>
    <link:label id="lab_ardx_DeferredRoyaltyObligationNoncurrent_documentation_en-US" xlink:label="lab_ardx_DeferredRoyaltyObligationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Royalty Obligation, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DeferredRoyaltyObligationNoncurrent" xlink:href="ardx-20221231.xsd#ardx_DeferredRoyaltyObligationNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_DeferredRoyaltyObligationNoncurrent" xlink:to="lab_ardx_DeferredRoyaltyObligationNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation_9c66e3de-886c-4836-a4e2-01516e790f5a_terseLabel_en-US" xlink:label="lab_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value analysis, effect on fair value based on 10% change in probability of occurrence</link:label>
    <link:label id="lab_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation_label_en-US" xlink:label="lab_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Sensitivity Analysis, Ten Percent Change In Probability Of Occurrence, Effect On Valuation</link:label>
    <link:label id="lab_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation_documentation_en-US" xlink:label="lab_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Sensitivity Analysis, Ten Percent Change In Probability Of Occurrence, Effect On Valuation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation" xlink:href="ardx-20221231.xsd#ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation" xlink:to="lab_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_24076a57-3925-489a-a174-862b8c3f6a53_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Total Unrecognized Stock-Based Compensation Expense, Net of Estimated Forfeitures</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_82153ee0-f18b-4b6f-a9d8-4d6c8aa4d066_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liabilities</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerDiscountsAndChargebacksMember_565d32cd-52bc-48e0-a6d1-37c0d652d879_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerDiscountsAndChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounts and Chargebacks</link:label>
    <link:label id="lab_ardx_ContractWithCustomerDiscountsAndChargebacksMember_label_en-US" xlink:label="lab_ardx_ContractWithCustomerDiscountsAndChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Discounts And Chargebacks [Member]</link:label>
    <link:label id="lab_ardx_ContractWithCustomerDiscountsAndChargebacksMember_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerDiscountsAndChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Discounts And Chargebacks</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerDiscountsAndChargebacksMember" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerDiscountsAndChargebacksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerDiscountsAndChargebacksMember" xlink:to="lab_ardx_ContractWithCustomerDiscountsAndChargebacksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_869d0228-7d0d-413b-b21a-efab57c5d542_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_3972120e-4691-4f1f-9b8a-24057e5fd818_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_82e966d8-79b4-47eb-896d-0844ed9c54e8_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_88678e25-51de-49e2-9e81-14c60c75b176_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c1640d2e-85d5-4571-8bd1-3b8cb6663b09_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options issued and outstanding balance, beginning (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6ac96f5f-0e4d-4b94-996f-4aa5267f8670_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options issued and outstanding balance, ending (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_eaa49b31-f498-4727-89a0-396e4cf19107_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing revenue</link:label>
    <link:label id="lab_us-gaap_LicenseMember_6e31cb15-41ae-47bc-bbe9-0afad34b94be_verboseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnRestructuringOfDebt_4b7a9c12-3ee4-4a95-adf3-e462a76e99fd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt refinancing costs</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnRestructuringOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (Losses) on Restructuring of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:to="lab_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_3c90537a-2b22-4bf7-9219-394db63496f4_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for services</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_7145c5bd-9d16-4d8e-b936-1db047481be9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of December&#160;31, 2022 and December&#160;31, 2021, respectively.</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths_16b21913-f79c-4f1b-a77a-c06848c4b742_negatedTerseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decreases due to amounts reclassified as current, to be recognized in the next twelve months</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths_label_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Decrease In Revenue, To Be Recognized In Next Twelve Months</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Decrease In Revenue, To Be Recognized In Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths" xlink:to="lab_ardx_ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_bd371a33-51cb-482b-ba15-21ada1a6647a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for services</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_1ec9d8c4-f119-4c04-b5d9-024c4f338cd1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments:</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_e1dec14c-8bb9-4eb9-a6ba-f36400723e43_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_TermBLoanMember_9915cafd-1cc7-4358-a1b8-8c155ee250a2_terseLabel_en-US" xlink:label="lab_ardx_TermBLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term B Loan</link:label>
    <link:label id="lab_ardx_TermBLoanMember_label_en-US" xlink:label="lab_ardx_TermBLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term B Loan [Member]</link:label>
    <link:label id="lab_ardx_TermBLoanMember_documentation_en-US" xlink:label="lab_ardx_TermBLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term B Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermBLoanMember" xlink:href="ardx-20221231.xsd#ardx_TermBLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_TermBLoanMember" xlink:to="lab_ardx_TermBLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_IncomeTaxDisclosureLineItems_4ce90f08-bfb6-4d1d-ab88-0a6782a90274_terseLabel_en-US" xlink:label="lab_ardx_IncomeTaxDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Line Items]</link:label>
    <link:label id="lab_ardx_IncomeTaxDisclosureLineItems_label_en-US" xlink:label="lab_ardx_IncomeTaxDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Line Items]</link:label>
    <link:label id="lab_ardx_IncomeTaxDisclosureLineItems_documentation_en-US" xlink:label="lab_ardx_IncomeTaxDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_IncomeTaxDisclosureLineItems" xlink:href="ardx-20221231.xsd#ardx_IncomeTaxDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_IncomeTaxDisclosureLineItems" xlink:to="lab_ardx_IncomeTaxDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_acd28379-aaad-4902-9b15-d8afe0eacba4_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees_3abc7d5d-f1ec-426c-8cec-5be7e9ae74ca_terseLabel_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront license fees</link:label>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees_label_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Licensing Agreements, Upfront License Fees</link:label>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees_documentation_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Licensing Agreements, Upfront License Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees" xlink:href="ardx-20221231.xsd#ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees" xlink:to="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_2c08a70a-dcc7-4d5e-9098-b84fd339e5af_terseLabel_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential payment per agreement</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_label_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Potential Payment Per Termination Agreement, Maximum</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_documentation_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Potential Payment Per Termination Agreement, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" xlink:href="ardx-20221231.xsd#ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" xlink:to="lab_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7f5e1655-c67e-4961-b750-ff64a01f489a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9668ea39-b7a9-4f28-9065-237223743b71_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_0255e497-2366-4157-a847-30bf72dc0ace_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a4c12d82-108f-4198-9a4a-602d7f08e0a2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_12f1286e-dc5d-4b40-9ffe-b40784867c45_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_e7622b81-dd74-46e0-9218-65d81af69929_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_be4c0313-2210-4019-822e-a07ff8c35100_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_66aaae91-185d-433b-a361-aca246a3839f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_21458d50-2288-40ec-949d-07415b084cb0_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_2bd7056a-4f9e-434d-8a92-d0ea7846a7ad_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_24561318-cfc3-4ba6-bcc4-c53a9fcd597f_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_797d5345-e32e-450a-bd0b-2a13a2a344ff_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Revenue, Net</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents_f02dfb65-3daa-411e-ae3e-ed3bf890feab_terseLabel_en-US" xlink:label="lab_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future obligation upon loan funding or other events</link:label>
    <link:label id="lab_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents_label_en-US" xlink:label="lab_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Future Obligation Upon Funding Or Other Events</link:label>
    <link:label id="lab_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents_documentation_en-US" xlink:label="lab_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Future Obligation Upon Funding Or Other Events</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents" xlink:href="ardx-20221231.xsd#ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents" xlink:to="lab_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_2da2acdf-7bc5-40e0-933a-3e659bcede4c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After first anniversary through second anniversary of closing date</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9c495a31-15c8-4ca8-ae43-3cb3cfe6743f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_9f86649c-f459-4bac-a63a-7a422c0816b9_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_59cbd1e7-cf5a-4614-b8ff-6d4a4245f6a3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for taxes related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_eb7713ed-ecd3-4a83-bd24-926631f47afb_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_16ff704b-3e1c-497f-ad97-0e2121fbaeef_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInRoyaltiesPayable_46c4603f-061f-4cd2-beca-59fa74414731_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty payments and commercial milestone payments</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInRoyaltiesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Royalties Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInRoyaltiesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_57213ded-ac45-44d1-8ac4-9fec53b17aab_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_17eac41d-f5d8-429d-92b6-9864a75e8196_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_TwoThousandSixteenEmploymentCommencementIncentivePlanMember_bd46f78a-6559-4b5d-a674-794709dd4ff3_terseLabel_en-US" xlink:label="lab_ardx_TwoThousandSixteenEmploymentCommencementIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement Plan</link:label>
    <link:label id="lab_ardx_TwoThousandSixteenEmploymentCommencementIncentivePlanMember_label_en-US" xlink:label="lab_ardx_TwoThousandSixteenEmploymentCommencementIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Sixteen Employment Commencement Incentive Plan [Member]</link:label>
    <link:label id="lab_ardx_TwoThousandSixteenEmploymentCommencementIncentivePlanMember_documentation_en-US" xlink:label="lab_ardx_TwoThousandSixteenEmploymentCommencementIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Employment commencement incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TwoThousandSixteenEmploymentCommencementIncentivePlanMember" xlink:href="ardx-20221231.xsd#ardx_TwoThousandSixteenEmploymentCommencementIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_TwoThousandSixteenEmploymentCommencementIncentivePlanMember" xlink:to="lab_ardx_TwoThousandSixteenEmploymentCommencementIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_efec9dbd-7886-47fe-a48c-b19192d06b6c_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_56a27fa6-c711-4f85-be25-3f226b816af8_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_192ffa6b-01ae-485c-8ebd-49355d0c0957_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued_c8036b22-494d-41fb-aa2b-a204f58d0337_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credits/deductions issued</link:label>
    <link:label id="lab_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued_label_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Gross To Credits Or Deductions Issued</link:label>
    <link:label id="lab_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Gross To Credits Or Deductions Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued" xlink:to="lab_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_AccruedClinicalExpenses_ddceada5-d491-418e-a7dc-f03b6230c3d3_terseLabel_en-US" xlink:label="lab_ardx_AccruedClinicalExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical expenses</link:label>
    <link:label id="lab_ardx_AccruedClinicalExpenses_label_en-US" xlink:label="lab_ardx_AccruedClinicalExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Expenses</link:label>
    <link:label id="lab_ardx_AccruedClinicalExpenses_documentation_en-US" xlink:label="lab_ardx_AccruedClinicalExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AccruedClinicalExpenses" xlink:href="ardx-20221231.xsd#ardx_AccruedClinicalExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_AccruedClinicalExpenses" xlink:to="lab_ardx_AccruedClinicalExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_22d10d71-92fe-4261-91fa-fa920a98e47a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_2830aca4-41c9-4845-8318-d95034f63208_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_285ec6e9-548f-4468-a4fb-4fd95eb0d770_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior to first anniversary of closing date</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_8f6b555a-c4e3-4655-bddb-2d1708f684dc_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5dcf5358-48a3-438b-b788-a2a085a40d78_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imputed interest expenses</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains_fb505517-6e58-4f9f-b943-10b9fb0c7771_terseLabel_en-US" xlink:label="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and investments, Gross Unrealized Gains</link:label>
    <link:label id="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains_label_en-US" xlink:label="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Cash Equivalents And Investments Gross Unrealized Gains</link:label>
    <link:label id="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains_documentation_en-US" xlink:label="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and investments gross unrealized gains.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains" xlink:href="ardx-20221231.xsd#ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains" xlink:to="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_1995299f-dd27-42a6-8548-0da6a4f7e908_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share of common stock - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_1d148b61-b591-4607-bb09-ede1258f513d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToGrantedInPeriod_fefc7e50-eeaa-4922-99d4-ef7a05930d41_negatedTerseLabel_en-US" xlink:label="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToGrantedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for grant, effect of granted (shares)</link:label>
    <link:label id="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToGrantedInPeriod_label_en-US" xlink:label="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToGrantedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Available For Grant, Decrease Due To Granted In Period</link:label>
    <link:label id="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToGrantedInPeriod_documentation_en-US" xlink:label="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToGrantedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Available For Grant, Decrease Due To Granted In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToGrantedInPeriod" xlink:href="ardx-20221231.xsd#ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToGrantedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToGrantedInPeriod" xlink:to="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToGrantedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_d265f14d-d1ac-4d03-a193-4225831a37d7_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvanceRoyaltiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdvanceRoyaltiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance Royalties [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvanceRoyaltiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvanceRoyaltiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvanceRoyaltiesAbstract" xlink:to="lab_us-gaap_AdvanceRoyaltiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_f592f252-840f-44ef-aa57-60e681efdae4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent_d3aba1d9-865a-46c6-888b-0744a9529b43_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization, effective interest rate, percent</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent_label_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Amortization, Effective Interest Rate, Percent</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Amortization, Effective Interest Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent" xlink:to="lab_ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ea644f12-f026-43d8-adc6-d0c2b3b36b9a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_87c2e175-dfe1-4e7c-af1f-9fd2d2ff88c0_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on disposition of property plant equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_49cf78bb-94ab-47ab-a0e3-2b1a74e18d92_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_fd762e9f-43b7-4a31-b7b1-16716ba2f605_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum_1d9cf5f6-d4db-49e7-9e16-bdf8e82e2f94_terseLabel_en-US" xlink:label="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan agreement covenant, cash and cash equivalents as percentage of outstanding loan balance, minimum</link:label>
    <link:label id="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum_label_en-US" xlink:label="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Covenant, Cash And Cash Equivalents As Percentage Of Outstanding Loan Balance, Minimum</link:label>
    <link:label id="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum_documentation_en-US" xlink:label="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Covenant, Cash And Cash Equivalents As Percentage Of Outstanding Loan Balance, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum" xlink:href="ardx-20221231.xsd#ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum" xlink:to="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense_34359795-88a1-4e00-b651-15bc67783e89_negatedLabel_en-US" xlink:label="lab_ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid commercial manufacturing</link:label>
    <link:label id="lab_ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense_label_en-US" xlink:label="lab_ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Prepaid Commercial Manufacturing Expense</link:label>
    <link:label id="lab_ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense_documentation_en-US" xlink:label="lab_ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Prepaid Commercial Manufacturing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense" xlink:href="ardx-20221231.xsd#ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense" xlink:to="lab_ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_56c75603-66e4-4937-a4d1-41022a6b18e9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_235f9001-c650-493e-a1dc-c555a2a1a953_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a8146149-8410-4fb4-a5a5-4f77b4f7bf05_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_8f6be3bd-4743-48ba-bf54-4bcd182c524f_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_TermLoan2022BMember_1273332c-96b8-4ad9-abca-6a0f86e25e6d_terseLabel_en-US" xlink:label="lab_ardx_TermLoan2022BMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B</link:label>
    <link:label id="lab_ardx_TermLoan2022BMember_label_en-US" xlink:label="lab_ardx_TermLoan2022BMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan 2022 B [Member]</link:label>
    <link:label id="lab_ardx_TermLoan2022BMember_documentation_en-US" xlink:label="lab_ardx_TermLoan2022BMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan 2022 B</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2022BMember" xlink:href="ardx-20221231.xsd#ardx_TermLoan2022BMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_TermLoan2022BMember" xlink:to="lab_ardx_TermLoan2022BMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_d72c36af-eaf6-41e3-bee6-ff4e4ce20166_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_ef07f063-7e21-4a8f-8833-ec231507e466_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_4578ecbc-264a-4342-a0c8-ac0cca032958_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets net of valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_a72cda97-8250-4528-9928-98bc0238c087_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of the provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_98a62573-76d6-4171-90db-2a51a64fc623_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_1b6460de-a011-48bc-a381-1f6ae0029e6f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_RevenueGeneralPaymentTerms_57566744-c0b3-496f-a120-168e79340eb9_terseLabel_en-US" xlink:label="lab_ardx_RevenueGeneralPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment terms</link:label>
    <link:label id="lab_ardx_RevenueGeneralPaymentTerms_label_en-US" xlink:label="lab_ardx_RevenueGeneralPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, General Payment Terms</link:label>
    <link:label id="lab_ardx_RevenueGeneralPaymentTerms_documentation_en-US" xlink:label="lab_ardx_RevenueGeneralPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, General Payment Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_RevenueGeneralPaymentTerms" xlink:href="ardx-20221231.xsd#ardx_RevenueGeneralPaymentTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_RevenueGeneralPaymentTerms" xlink:to="lab_ardx_RevenueGeneralPaymentTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_df5fa012-b4d8-4846-af9b-6268d1c1f940_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for services (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_9e4f2074-9777-4b3d-831b-23b3eeefae29_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for services (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_9be67580-1af4-446c-b8e5-89b504b0928f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment to be received</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_9340ab26-7f5f-4a86-b2d7-6160cc10f6ce_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_b5319d2e-d66c-49e9-ae26-95503f9a835d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_99ac7032-9079-41d5-a0ea-5060353ebc3c_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Undiscounted Cash Payment Obligations for Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_777f375c-055f-4d31-a734-d9ddce7eb758_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_7e76b835-aed0-4e4a-8c05-927ac3641cb7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_8aea9ecf-9cb2-4ed1-bd6f-03b055918fb2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_203ba003-0f3d-4167-a6ca-bb42285bf8d9_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_1d9abd4d-fb85-4d51-9cc8-efa8c8111706_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_InvestmentsAndCashAmortizedCost_85bf6ce4-6c3e-4172-893e-3dda02be6ded_totalLabel_en-US" xlink:label="lab_ardx_InvestmentsAndCashAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and investments, Cost</link:label>
    <link:label id="lab_ardx_InvestmentsAndCashAmortizedCost_label_en-US" xlink:label="lab_ardx_InvestmentsAndCashAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments And Cash, Amortized Cost</link:label>
    <link:label id="lab_ardx_InvestmentsAndCashAmortizedCost_documentation_en-US" xlink:label="lab_ardx_InvestmentsAndCashAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments And Cash, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_InvestmentsAndCashAmortizedCost" xlink:href="ardx-20221231.xsd#ardx_InvestmentsAndCashAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_InvestmentsAndCashAmortizedCost" xlink:to="lab_ardx_InvestmentsAndCashAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_0d91e240-ce27-4bc8-a22a-7c36263cf254_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_627638d9-ac93-427c-810f-5ceaa0941844_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_f367964a-03d6-463e-8d0b-f4eaffa5b2b3_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_990440c5-0d8f-47b6-9abe-e51c542591d4_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_afa96756-b5f0-4cb8-b7dd-82b3a83a84e5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_McKessonCorporationMember_341e66bf-ec07-4375-bd54-0d86c88ab039_terseLabel_en-US" xlink:label="lab_ardx_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation</link:label>
    <link:label id="lab_ardx_McKessonCorporationMember_label_en-US" xlink:label="lab_ardx_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation [Member]</link:label>
    <link:label id="lab_ardx_McKessonCorporationMember_documentation_en-US" xlink:label="lab_ardx_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_McKessonCorporationMember" xlink:href="ardx-20221231.xsd#ardx_McKessonCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_McKessonCorporationMember" xlink:to="lab_ardx_McKessonCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_GoVersusRaabMember_a1a86bb7-b184-4411-85e2-ca7dfd2071bf_terseLabel_en-US" xlink:label="lab_ardx_GoVersusRaabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Go v. Raab</link:label>
    <link:label id="lab_ardx_GoVersusRaabMember_label_en-US" xlink:label="lab_ardx_GoVersusRaabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Go Versus Raab [Member]</link:label>
    <link:label id="lab_ardx_GoVersusRaabMember_documentation_en-US" xlink:label="lab_ardx_GoVersusRaabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Go Versus Raab</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_GoVersusRaabMember" xlink:href="ardx-20221231.xsd#ardx_GoVersusRaabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_GoVersusRaabMember" xlink:to="lab_ardx_GoVersusRaabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_6d76547e-1701-4e2e-b68e-d2859dd9357d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_5eeb705c-b664-4426-80d8-2f9ee9850b3b_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1ebea83b-4acd-4718-bab8-00cbf2453490_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_185b6b04-1e40-4942-b3c9-b38d1719f8f9_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Existence of option to extend</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Existence of Option to Extend [true false]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="lab_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_3a80eb77-e384-4946-95e0-819745718840_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-Sale Debt Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_5b4b3084-7cc6-48f0-b44e-8c270cc76c89_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities and redemptions of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_ce18203c-de69-4d34-bf4b-1ffe15ac90e0_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, non-current</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_f08c30c5-5050-4e3a-9206-2c92e0fde4cc_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government-sponsored agency bonds</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_093296bc-2a11-4775-8f61-bec91fdd0656_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_79fc63f9-6139-4713-9f30-54438816b502_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c3465437-496b-4de9-bdf9-0511db2d1001_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_129cd9cd-c762-4f83-a136-f6c494581aa8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6e5f58d2-479f-4cf5-b1fb-f9cc4a1f005d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ebc81675-9f59-4a1a-a995-d8520b54f8ad_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_dbff252b-c29c-4ec6-8a7e-043f08a06da8_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0561f943-f190-49c2-b58e-99b73ca2ef43_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares initially authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_f9c8419a-42f5-48c5-b44f-ffabe0e3bf3c_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:to="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_8005832f-c80c-4f4b-b8fe-d1ca40548ee8_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross-to-net sales accruals and reserves</link:label>
    <link:label id="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_label_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Gross To Net Sales Accrual [Roll Forward]</link:label>
    <link:label id="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Gross To Net Sales Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward" xlink:to="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_8d92f7fb-e3c5-44ff-8f24-2b9e38399b3c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLicenseFeesReceived_f2d9526f-1940-4139-aecb-a9f70f5aae43_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLicenseFeesReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLicenseFeesReceived_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLicenseFeesReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from License Fees Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLicenseFeesReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="lab_us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_b50b8ed9-25c3-4fee-921a-dfcff9c3f196_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock_6e4ab784-fcd1-44d2-a85f-ecec788bf02b_terseLabel_en-US" xlink:label="lab_ardx_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research and Development Expenses</link:label>
    <link:label id="lab_ardx_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock_label_en-US" xlink:label="lab_ardx_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research and Development Expenses Policy [Policy Text Block]</link:label>
    <link:label id="lab_ardx_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_ardx_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development expenses policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock" xlink:href="ardx-20221231.xsd#ardx_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock" xlink:to="lab_ardx_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2b129313-4aea-4fb5-83c9-7f5ce6b58c73_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Fair Value of Derivative Liability</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_fdae39f2-5895-4cd2-ba6b-94414190aa9a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Effective Tax Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2f2fb07d-ba54-4f16-b11c-437022f89f9f_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_DeferredTaxLiabilitiesRightOfUseAsset_379c5edc-3364-4f9b-aa41-2a344fb1e091_negatedLabel_en-US" xlink:label="lab_ardx_DeferredTaxLiabilitiesRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset</link:label>
    <link:label id="lab_ardx_DeferredTaxLiabilitiesRightOfUseAsset_label_en-US" xlink:label="lab_ardx_DeferredTaxLiabilitiesRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Right Of Use Asset</link:label>
    <link:label id="lab_ardx_DeferredTaxLiabilitiesRightOfUseAsset_documentation_en-US" xlink:label="lab_ardx_DeferredTaxLiabilitiesRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of deferred tax liability attributable to taxable temporary differences from right of use asset.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DeferredTaxLiabilitiesRightOfUseAsset" xlink:href="ardx-20221231.xsd#ardx_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="lab_ardx_DeferredTaxLiabilitiesRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_6b1fef57-b4b2-4991-ac5f-91f376b8d2e6_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_4bc001b0-89c5-4e1b-a579-a9771968394f_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_22b854d1-bd94-4ba3-8c27-bc10c5b75081_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSecuredDebt_c6749e10-98ae-4d8d-889d-78538d86546b_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for 2018 Loan, net of costs</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSecuredDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSecuredDebt" xlink:to="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_92cb4848-f048-453e-9d39-76177d31a116_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_efb87ad7-1c7c-487a-8841-f811cea374be_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f6408df6-2cd5-4bab-82a5-22e646bdce43_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant&#160;Date&#160;Fair Value Per&#160;Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_ed291da5-4535-48df-9022-d4135fc3b39b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid for net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2dff25b5-9483-410b-85be-e8041a862e47_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_19c5556c-efe4-4ea5-bd55-7847b83cb011_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Licensing Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived_fc1b13ca-5bb1-44aa-9c18-ab9afae490ef_negatedTerseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decreases due to revenue recognized in the period for which cash has been received</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived_label_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer Liability Revenue Recognized Cash Received</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived" xlink:to="lab_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_0f432276-408a-427b-ad24-7ce32e37e000_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ExitFee2018Member_0978b01a-ebb4-4959-8f1d-9aa56af86320_terseLabel_en-US" xlink:label="lab_ardx_ExitFee2018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Exit Fee</link:label>
    <link:label id="lab_ardx_ExitFee2018Member_label_en-US" xlink:label="lab_ardx_ExitFee2018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit Fee 2018 [Member]</link:label>
    <link:label id="lab_ardx_ExitFee2018Member_documentation_en-US" xlink:label="lab_ardx_ExitFee2018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit Fee 2018</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2018Member" xlink:href="ardx-20221231.xsd#ardx_ExitFee2018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ExitFee2018Member" xlink:to="lab_ardx_ExitFee2018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_46c876c3-89b2-48ac-b55e-e2763b0293d2_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_13f064c6-077c-4126-b976-544c8b914369_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_116a9b7e-2823-4334-8c48-abd18f980b9c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_150df6f8-f0cd-4b29-a25b-57ac9124626e_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_beb55b52-ed2f-4358-b968-80845da430bd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_b223e6b7-2a5e-4963-b159-5ac944f9cf93_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_d7e6c2d9-f784-4c04-b942-d41d274f2b4a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_DerivativeLiabilityForExitFees_20d66012-f4b6-44f9-9f04-9672dfdc4de4_terseLabel_en-US" xlink:label="lab_ardx_DerivativeLiabilityForExitFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability for exit fees</link:label>
    <link:label id="lab_ardx_DerivativeLiabilityForExitFees_label_en-US" xlink:label="lab_ardx_DerivativeLiabilityForExitFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability for Exit Fees</link:label>
    <link:label id="lab_ardx_DerivativeLiabilityForExitFees_documentation_en-US" xlink:label="lab_ardx_DerivativeLiabilityForExitFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of derivative liability for exit fee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DerivativeLiabilityForExitFees" xlink:href="ardx-20221231.xsd#ardx_DerivativeLiabilityForExitFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_DerivativeLiabilityForExitFees" xlink:to="lab_ardx_DerivativeLiabilityForExitFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8346e54f-8330-4c54-8df5-5bbdf4e81701_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_DebtInstrumentInterestPaymentExtensionTerm_8c166998-9176-4d5d-92c2-6a4f60b8069d_terseLabel_en-US" xlink:label="lab_ardx_DebtInstrumentInterestPaymentExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest-only payment extension term (in months)</link:label>
    <link:label id="lab_ardx_DebtInstrumentInterestPaymentExtensionTerm_label_en-US" xlink:label="lab_ardx_DebtInstrumentInterestPaymentExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Payment Extension Term</link:label>
    <link:label id="lab_ardx_DebtInstrumentInterestPaymentExtensionTerm_documentation_en-US" xlink:label="lab_ardx_DebtInstrumentInterestPaymentExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of interest payment of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentInterestPaymentExtensionTerm" xlink:href="ardx-20221231.xsd#ardx_DebtInstrumentInterestPaymentExtensionTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_DebtInstrumentInterestPaymentExtensionTerm" xlink:to="lab_ardx_DebtInstrumentInterestPaymentExtensionTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_e53a8aae-acf4-47ed-86b2-a1cabfbb6123_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents:</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ExitFee2022Member_667068a4-ea0c-471a-a819-92da3393fb90_terseLabel_en-US" xlink:label="lab_ardx_ExitFee2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Exit Fee</link:label>
    <link:label id="lab_ardx_ExitFee2022Member_label_en-US" xlink:label="lab_ardx_ExitFee2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit Fee 2022 [Member]</link:label>
    <link:label id="lab_ardx_ExitFee2022Member_documentation_en-US" xlink:label="lab_ardx_ExitFee2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit Fee 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2022Member" xlink:href="ardx-20221231.xsd#ardx_ExitFee2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ExitFee2022Member" xlink:to="lab_ardx_ExitFee2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_abaef5d7-1ec7-4e05-80c1-07894227c29a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_584bcb7f-a7c7-4a5d-bdcc-10a8d830c903_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2f7e1a7d-3102-4431-9ee2-d1da20fd01ba_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ddf49e17-58f2-44a3-a026-47c01dbec856_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplementary disclosure of non-cash activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_3c05d720-4797-479c-8201-7656ae0196d8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_d801dba7-8753-42c7-997e-b1621533115a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Noncurrent Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Noncurrent [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_56adba55-192a-43f7-a150-c0a88c9c99f8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant-date estimated fair value of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_5213243e-c7d0-434b-a790-8d233b2cee52_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermLoansPayable_d6338487-91a7-4475-b38c-2535910c4835_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermLoansPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of current portion</link:label>
    <link:label id="lab_us-gaap_LongTermLoansPayable_label_en-US" xlink:label="lab_us-gaap_LongTermLoansPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLoansPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermLoansPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermLoansPayable" xlink:to="lab_us-gaap_LongTermLoansPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_KkcMember_a4adcda5-60eb-4a6d-8f01-c7e77d03a6e0_terseLabel_en-US" xlink:label="lab_ardx_KkcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KKC</link:label>
    <link:label id="lab_ardx_KkcMember_label_en-US" xlink:label="lab_ardx_KkcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kkc [Member]</link:label>
    <link:label id="lab_ardx_KkcMember_documentation_en-US" xlink:label="lab_ardx_KkcMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to KKC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_KkcMember" xlink:href="ardx-20221231.xsd#ardx_KkcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_KkcMember" xlink:to="lab_ardx_KkcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_DebtInstrumentVariableRateBaseOption_97ad6e62-9b42-4be6-9616-479862f79c21_terseLabel_en-US" xlink:label="lab_ardx_DebtInstrumentVariableRateBaseOption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Addition to floating per annum rate (percent)</link:label>
    <link:label id="lab_ardx_DebtInstrumentVariableRateBaseOption_label_en-US" xlink:label="lab_ardx_DebtInstrumentVariableRateBaseOption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Variable Rate, Base Option</link:label>
    <link:label id="lab_ardx_DebtInstrumentVariableRateBaseOption_documentation_en-US" xlink:label="lab_ardx_DebtInstrumentVariableRateBaseOption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Variable Rate, Base Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentVariableRateBaseOption" xlink:href="ardx-20221231.xsd#ardx_DebtInstrumentVariableRateBaseOption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_DebtInstrumentVariableRateBaseOption" xlink:to="lab_ardx_DebtInstrumentVariableRateBaseOption" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_db5f0847-6315-4312-b5e3-e0e1b4a0b84f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_42c6fc83-e300-4467-ab35-02e30bc08501_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_2106e7ce-62c4-4d48-a518-79330beaf791_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_304ecead-966f-42f7-9b61-15ef29767e35_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LaboratoryEquipmentMember_948877da-0df0-4d2d-94e1-2611f65266be_terseLabel_en-US" xlink:label="lab_ardx_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_ardx_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_ardx_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_ardx_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_ardx_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LaboratoryEquipmentMember" xlink:href="ardx-20221231.xsd#ardx_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LaboratoryEquipmentMember" xlink:to="lab_ardx_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_c9d3b309-e1ca-48a8-9bd6-d21257a349e0_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Computation of Net Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_794c1ea1-2d6a-4361-8aa1-b4f517a09372_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesReportingOfDerivativeActivity_9348fba0-2998-4ffd-8a0c-d8b7790a1a6d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesReportingOfDerivativeActivity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives and Hedging Activities</link:label>
    <link:label id="lab_us-gaap_DerivativesReportingOfDerivativeActivity_label_en-US" xlink:label="lab_us-gaap_DerivativesReportingOfDerivativeActivity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Reporting of Derivative Activity [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesReportingOfDerivativeActivity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesReportingOfDerivativeActivity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesReportingOfDerivativeActivity" xlink:to="lab_us-gaap_DerivativesReportingOfDerivativeActivity" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_MaximumAggregateOfferingPrice_b5baaae9-b231-4ef2-a94d-6243682ba742_terseLabel_en-US" xlink:label="lab_ardx_MaximumAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum aggregate offering price</link:label>
    <link:label id="lab_ardx_MaximumAggregateOfferingPrice_label_en-US" xlink:label="lab_ardx_MaximumAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Aggregate Offering Price</link:label>
    <link:label id="lab_ardx_MaximumAggregateOfferingPrice_documentation_en-US" xlink:label="lab_ardx_MaximumAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of maximum aggregate offering price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_MaximumAggregateOfferingPrice" xlink:href="ardx-20221231.xsd#ardx_MaximumAggregateOfferingPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_MaximumAggregateOfferingPrice" xlink:to="lab_ardx_MaximumAggregateOfferingPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment_95b3bfb8-23f4-4248-9d8f-1a922bcee237_terseLabel_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First installment of upfront license fees</link:label>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment_label_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Licensing Agreements, Upfront License Fees, First Installment</link:label>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment_documentation_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Licensing Agreements, Upfront License Fees, First Installment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment" xlink:href="ardx-20221231.xsd#ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment" xlink:to="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_59916392-81d1-423a-a592-7311fe44a480_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>ardx-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:9159adf2-88b0-425e-b00c-16d6f1bd5962,g:73dc270f-0b38-43c2-8fc7-c4890fc3e73f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ardelyx.com/role/Cover" xlink:type="simple" xlink:href="ardx-20221231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_5b362809-dff2-4bcf-984c-0fa46d0d9710" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b44dec3e-e0b4-498c-9544-502af421d4c5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b362809-dff2-4bcf-984c-0fa46d0d9710" xlink:to="loc_dei_DocumentType_b44dec3e-e0b4-498c-9544-502af421d4c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_96b22396-6aab-4fb8-b2c4-8c5d633c2c7e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b362809-dff2-4bcf-984c-0fa46d0d9710" xlink:to="loc_dei_DocumentAnnualReport_96b22396-6aab-4fb8-b2c4-8c5d633c2c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_0e4e58e9-e778-4a91-831a-eb4b72e630bd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b362809-dff2-4bcf-984c-0fa46d0d9710" xlink:to="loc_dei_DocumentPeriodEndDate_0e4e58e9-e778-4a91-831a-eb4b72e630bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_31da19fe-9442-4fd5-a2db-f8673dff81df" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b362809-dff2-4bcf-984c-0fa46d0d9710" xlink:to="loc_dei_CurrentFiscalYearEndDate_31da19fe-9442-4fd5-a2db-f8673dff81df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_f2e47eb9-720b-4bf8-ae4a-ce676d12832f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b362809-dff2-4bcf-984c-0fa46d0d9710" xlink:to="loc_dei_DocumentTransitionReport_f2e47eb9-720b-4bf8-ae4a-ce676d12832f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_cd731c46-c4e2-4400-bef2-b705743bce18" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b362809-dff2-4bcf-984c-0fa46d0d9710" xlink:to="loc_dei_EntityFileNumber_cd731c46-c4e2-4400-bef2-b705743bce18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_3e3fe3cc-f3e7-4951-bff4-bb0767396d35" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b362809-dff2-4bcf-984c-0fa46d0d9710" xlink:to="loc_dei_EntityRegistrantName_3e3fe3cc-f3e7-4951-bff4-bb0767396d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_657003fc-d834-4e77-9bb9-2717af6a234a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b362809-dff2-4bcf-984c-0fa46d0d9710" xlink:to="loc_dei_EntityIncorporationStateCountryCode_657003fc-d834-4e77-9bb9-2717af6a234a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_e6751db9-70c8-4df6-82f9-a6e39293fb3c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b362809-dff2-4bcf-984c-0fa46d0d9710" xlink:to="loc_dei_EntityTaxIdentificationNumber_e6751db9-70c8-4df6-82f9-a6e39293fb3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_c04bee0c-324e-4afd-a277-8842b867f37b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b362809-dff2-4bcf-984c-0fa46d0d9710" xlink:to="loc_dei_EntityAddressAddressLine1_c04bee0c-324e-4afd-a277-8842b867f37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_35e42808-bece-43b0-9366-7bff3efc7d4c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b362809-dff2-4bcf-984c-0fa46d0d9710" xlink:to="loc_dei_EntityAddressAddressLine2_35e42808-bece-43b0-9366-7bff3efc7d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_7ae40f4f-c78e-4c93-a06c-3e61133a58e0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b362809-dff2-4bcf-984c-0fa46d0d9710" xlink:to="loc_dei_EntityAddressCityOrTown_7ae40f4f-c78e-4c93-a06c-3e61133a58e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_b54dd104-e28a-4e22-aa2a-49eaf89bbca1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b362809-dff2-4bcf-984c-0fa46d0d9710" xlink:to="loc_dei_EntityAddressStateOrProvince_b54dd104-e28a-4e22-aa2a-49eaf89bbca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_0ca5898b-8a27-4606-aaea-a3135b1c2a7b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b362809-dff2-4bcf-984c-0fa46d0d9710" xlink:to="loc_dei_EntityAddressPostalZipCode_0ca5898b-8a27-4606-aaea-a3135b1c2a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ea8c7922-7def-4ca2-93de-5b1a6ef61294" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b362809-dff2-4bcf-984c-0fa46d0d9710" xlink:to="loc_dei_CityAreaCode_ea8c7922-7def-4ca2-93de-5b1a6ef61294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_de25f5ea-2844-4600-a90b-d766c339b39d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b362809-dff2-4bcf-984c-0fa46d0d9710" xlink:to="loc_dei_LocalPhoneNumber_de25f5ea-2844-4600-a90b-d766c339b39d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_b299ac80-7102-47d0-bfc3-8c62c8e43b22" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b362809-dff2-4bcf-984c-0fa46d0d9710" xlink:to="loc_dei_Security12bTitle_b299ac80-7102-47d0-bfc3-8c62c8e43b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_4d85412a-47ac-45eb-9925-a029522ddd77" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b362809-dff2-4bcf-984c-0fa46d0d9710" xlink:to="loc_dei_TradingSymbol_4d85412a-47ac-45eb-9925-a029522ddd77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_118bfd7d-bcb6-4e7d-9f44-bec1e54a3e5c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b362809-dff2-4bcf-984c-0fa46d0d9710" xlink:to="loc_dei_SecurityExchangeName_118bfd7d-bcb6-4e7d-9f44-bec1e54a3e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_4dbb723e-66f9-4ed1-a9e8-5c692581c7f5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b362809-dff2-4bcf-984c-0fa46d0d9710" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_4dbb723e-66f9-4ed1-a9e8-5c692581c7f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_b36a93bf-f3f7-4f55-ac27-d14306a9fad8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b362809-dff2-4bcf-984c-0fa46d0d9710" xlink:to="loc_dei_EntityVoluntaryFilers_b36a93bf-f3f7-4f55-ac27-d14306a9fad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_acfad2bb-78d5-4eb5-aac9-91385dca41be" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b362809-dff2-4bcf-984c-0fa46d0d9710" xlink:to="loc_dei_EntityCurrentReportingStatus_acfad2bb-78d5-4eb5-aac9-91385dca41be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_8c0f2056-5996-4324-9cfc-faebbe590564" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b362809-dff2-4bcf-984c-0fa46d0d9710" xlink:to="loc_dei_EntityInteractiveDataCurrent_8c0f2056-5996-4324-9cfc-faebbe590564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_de18c2c4-599a-4638-8a5d-66c3e463fcbd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b362809-dff2-4bcf-984c-0fa46d0d9710" xlink:to="loc_dei_EntityFilerCategory_de18c2c4-599a-4638-8a5d-66c3e463fcbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_21e51f3d-3b47-4ab3-8d3c-7ddf9cc70efc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b362809-dff2-4bcf-984c-0fa46d0d9710" xlink:to="loc_dei_EntitySmallBusiness_21e51f3d-3b47-4ab3-8d3c-7ddf9cc70efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_7b4a8005-4353-476a-85c0-967109b27afd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b362809-dff2-4bcf-984c-0fa46d0d9710" xlink:to="loc_dei_EntityEmergingGrowthCompany_7b4a8005-4353-476a-85c0-967109b27afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_965b2f14-6a6b-4f1f-9ffb-85ce459ff61e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b362809-dff2-4bcf-984c-0fa46d0d9710" xlink:to="loc_dei_IcfrAuditorAttestationFlag_965b2f14-6a6b-4f1f-9ffb-85ce459ff61e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_6c8e6684-a81a-4e32-b0d0-80ec747bc25d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b362809-dff2-4bcf-984c-0fa46d0d9710" xlink:to="loc_dei_EntityShellCompany_6c8e6684-a81a-4e32-b0d0-80ec747bc25d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_c7c7ff00-5aca-4e15-a6a1-b2e029c8f38e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b362809-dff2-4bcf-984c-0fa46d0d9710" xlink:to="loc_dei_EntityPublicFloat_c7c7ff00-5aca-4e15-a6a1-b2e029c8f38e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_7d0f480f-28f8-4532-b090-c49601af9cf3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b362809-dff2-4bcf-984c-0fa46d0d9710" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_7d0f480f-28f8-4532-b090-c49601af9cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_7ff1a3bf-c545-45be-bbcd-c03263a5192a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b362809-dff2-4bcf-984c-0fa46d0d9710" xlink:to="loc_dei_EntityCentralIndexKey_7ff1a3bf-c545-45be-bbcd-c03263a5192a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_f8116305-98d0-458d-a320-94295514ba67" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b362809-dff2-4bcf-984c-0fa46d0d9710" xlink:to="loc_dei_DocumentFiscalYearFocus_f8116305-98d0-458d-a320-94295514ba67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_d38d00b8-d8b4-4bf3-a9e6-7b63eb9ef141" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b362809-dff2-4bcf-984c-0fa46d0d9710" xlink:to="loc_dei_DocumentFiscalPeriodFocus_d38d00b8-d8b4-4bf3-a9e6-7b63eb9ef141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_8a0fe6be-3fd5-474d-a3f3-89c381178d4b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b362809-dff2-4bcf-984c-0fa46d0d9710" xlink:to="loc_dei_AmendmentFlag_8a0fe6be-3fd5-474d-a3f3-89c381178d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_216aa7a7-4112-4a9d-87ab-0496921cf9bd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b362809-dff2-4bcf-984c-0fa46d0d9710" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_216aa7a7-4112-4a9d-87ab-0496921cf9bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/AuditInformation" xlink:type="simple" xlink:href="ardx-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AuditInformationAbstract_9dcb3bbd-3efe-48b6-b485-e503d785a5ad" xlink:href="ardx-20221231.xsd#ardx_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_124e2b0d-ba35-4f62-970f-97a993ce88b6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_AuditInformationAbstract_9dcb3bbd-3efe-48b6-b485-e503d785a5ad" xlink:to="loc_dei_AuditorName_124e2b0d-ba35-4f62-970f-97a993ce88b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_bbd0bc1c-4f62-4503-b590-37849bee8f9f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_AuditInformationAbstract_9dcb3bbd-3efe-48b6-b485-e503d785a5ad" xlink:to="loc_dei_AuditorLocation_bbd0bc1c-4f62-4503-b590-37849bee8f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_dbd73a46-6db3-4c74-bf23-42b75418baec" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_AuditInformationAbstract_9dcb3bbd-3efe-48b6-b485-e503d785a5ad" xlink:to="loc_dei_AuditorFirmId_dbd73a46-6db3-4c74-bf23-42b75418baec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/BALANCESHEETS" xlink:type="simple" xlink:href="ardx-20221231.xsd#BALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/BALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_32eaab9e-4dfe-4240-ad3b-c7a17dbd2c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_e742f1c6-f254-4b81-a4af-784600cfbf7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_32eaab9e-4dfe-4240-ad3b-c7a17dbd2c9b" xlink:to="loc_us-gaap_AssetsAbstract_e742f1c6-f254-4b81-a4af-784600cfbf7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_62cf6d8f-fc05-4631-bb2c-8a92d9130ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e742f1c6-f254-4b81-a4af-784600cfbf7d" xlink:to="loc_us-gaap_AssetsCurrentAbstract_62cf6d8f-fc05-4631-bb2c-8a92d9130ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e68a224f-9b9a-4ded-96d1-5309e0178597" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_62cf6d8f-fc05-4631-bb2c-8a92d9130ec1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e68a224f-9b9a-4ded-96d1-5309e0178597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_cca68a3b-9570-41e1-95d9-5c5761135256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_62cf6d8f-fc05-4631-bb2c-8a92d9130ec1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_cca68a3b-9570-41e1-95d9-5c5761135256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_9bea57c4-f3f9-4dea-8fb8-e92f3d6d198c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_62cf6d8f-fc05-4631-bb2c-8a92d9130ec1" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_9bea57c4-f3f9-4dea-8fb8-e92f3d6d198c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_d909d93b-6bca-4c8d-8075-c831bf53bb39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_62cf6d8f-fc05-4631-bb2c-8a92d9130ec1" xlink:to="loc_us-gaap_InventoryGross_d909d93b-6bca-4c8d-8075-c831bf53bb39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PrepaidCommercialManufacturingCurrent_42635f00-60bc-4b6e-be0f-6e914073e311" xlink:href="ardx-20221231.xsd#ardx_PrepaidCommercialManufacturingCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_62cf6d8f-fc05-4631-bb2c-8a92d9130ec1" xlink:to="loc_ardx_PrepaidCommercialManufacturingCurrent_42635f00-60bc-4b6e-be0f-6e914073e311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9d579945-016c-4572-afdc-a02f10c9da49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_62cf6d8f-fc05-4631-bb2c-8a92d9130ec1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9d579945-016c-4572-afdc-a02f10c9da49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5e53b53c-db1f-4333-8bd8-98cb790a7fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_62cf6d8f-fc05-4631-bb2c-8a92d9130ec1" xlink:to="loc_us-gaap_AssetsCurrent_5e53b53c-db1f-4333-8bd8-98cb790a7fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_91f72d19-df4b-46f1-b2e1-affa10a0f95c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e742f1c6-f254-4b81-a4af-784600cfbf7d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_91f72d19-df4b-46f1-b2e1-affa10a0f95c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_17d03b8f-4c94-4238-805e-76207be388b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e742f1c6-f254-4b81-a4af-784600cfbf7d" xlink:to="loc_us-gaap_InventoryNoncurrent_17d03b8f-4c94-4238-805e-76207be388b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_db039f56-6ed0-4996-ae83-15f303fd4336" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e742f1c6-f254-4b81-a4af-784600cfbf7d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_db039f56-6ed0-4996-ae83-15f303fd4336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c6a30510-86e4-4226-b179-5caf8bfd441f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e742f1c6-f254-4b81-a4af-784600cfbf7d" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c6a30510-86e4-4226-b179-5caf8bfd441f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e2ff6dbe-1723-4d8c-8b7a-4d52807274ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e742f1c6-f254-4b81-a4af-784600cfbf7d" xlink:to="loc_us-gaap_Assets_e2ff6dbe-1723-4d8c-8b7a-4d52807274ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_41de17a7-a691-4ac3-9a00-f67013196ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_32eaab9e-4dfe-4240-ad3b-c7a17dbd2c9b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_41de17a7-a691-4ac3-9a00-f67013196ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_6d138d5f-3b0d-4916-9a46-7098e68d0027" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_41de17a7-a691-4ac3-9a00-f67013196ccd" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_6d138d5f-3b0d-4916-9a46-7098e68d0027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_17e7d104-5177-4392-88b1-a09889feb972" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6d138d5f-3b0d-4916-9a46-7098e68d0027" xlink:to="loc_us-gaap_AccountsPayableCurrent_17e7d104-5177-4392-88b1-a09889feb972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_adaa4659-b712-4e66-b71d-e84ba57d5b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6d138d5f-3b0d-4916-9a46-7098e68d0027" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_adaa4659-b712-4e66-b71d-e84ba57d5b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_dee6cb0d-98ec-4236-ba75-80e1a83f980f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6d138d5f-3b0d-4916-9a46-7098e68d0027" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_dee6cb0d-98ec-4236-ba75-80e1a83f980f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableCurrent_468f398b-8cce-47f1-b871-280ec7077647" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6d138d5f-3b0d-4916-9a46-7098e68d0027" xlink:to="loc_us-gaap_LoansPayableCurrent_468f398b-8cce-47f1-b871-280ec7077647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8a0248d8-5d7e-4bfa-a405-a3c6bf0a1e10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6d138d5f-3b0d-4916-9a46-7098e68d0027" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8a0248d8-5d7e-4bfa-a405-a3c6bf0a1e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_7a55f245-59a3-4037-8a3c-09372ccadbf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6d138d5f-3b0d-4916-9a46-7098e68d0027" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_7a55f245-59a3-4037-8a3c-09372ccadbf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_aca44ed4-f576-4d07-b667-7b91d7793948" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6d138d5f-3b0d-4916-9a46-7098e68d0027" xlink:to="loc_us-gaap_LiabilitiesCurrent_aca44ed4-f576-4d07-b667-7b91d7793948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_39fab345-13cb-4d6e-ae49-0b43c7386c96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_41de17a7-a691-4ac3-9a00-f67013196ccd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_39fab345-13cb-4d6e-ae49-0b43c7386c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_4224c974-eada-4722-960e-b09dedc502bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_41de17a7-a691-4ac3-9a00-f67013196ccd" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_4224c974-eada-4722-960e-b09dedc502bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DeferredRoyaltyObligationNoncurrent_ab7dd2ea-61b9-4455-9521-d9198ab3af87" xlink:href="ardx-20221231.xsd#ardx_DeferredRoyaltyObligationNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_41de17a7-a691-4ac3-9a00-f67013196ccd" xlink:to="loc_ardx_DeferredRoyaltyObligationNoncurrent_ab7dd2ea-61b9-4455-9521-d9198ab3af87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_39692c23-a5e6-4d85-8bab-dfa945e97ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_41de17a7-a691-4ac3-9a00-f67013196ccd" xlink:to="loc_us-gaap_Liabilities_39692c23-a5e6-4d85-8bab-dfa945e97ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_60534fd5-da1c-41df-a6d7-43dd0227f883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_41de17a7-a691-4ac3-9a00-f67013196ccd" xlink:to="loc_us-gaap_CommitmentsAndContingencies_60534fd5-da1c-41df-a6d7-43dd0227f883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_adb6a27a-3b35-4971-b1d4-49e2d692ba71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_41de17a7-a691-4ac3-9a00-f67013196ccd" xlink:to="loc_us-gaap_StockholdersEquityAbstract_adb6a27a-3b35-4971-b1d4-49e2d692ba71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_ba0162cd-d158-4bfe-9706-2257839a036c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_adb6a27a-3b35-4971-b1d4-49e2d692ba71" xlink:to="loc_us-gaap_PreferredStockValue_ba0162cd-d158-4bfe-9706-2257839a036c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b3e5596a-16ad-47f0-8471-dd55c5194686" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_adb6a27a-3b35-4971-b1d4-49e2d692ba71" xlink:to="loc_us-gaap_CommonStockValue_b3e5596a-16ad-47f0-8471-dd55c5194686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f292554d-2d98-40eb-9b6e-a341d0e1814f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_adb6a27a-3b35-4971-b1d4-49e2d692ba71" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f292554d-2d98-40eb-9b6e-a341d0e1814f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8b80f9f2-c048-4fe6-b16e-91b6de51fd1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_adb6a27a-3b35-4971-b1d4-49e2d692ba71" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8b80f9f2-c048-4fe6-b16e-91b6de51fd1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_dfe919ff-075b-4499-87ca-f65d75046bea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_adb6a27a-3b35-4971-b1d4-49e2d692ba71" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_dfe919ff-075b-4499-87ca-f65d75046bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d7f22768-8786-45d6-93cf-c8d0be383ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_adb6a27a-3b35-4971-b1d4-49e2d692ba71" xlink:to="loc_us-gaap_StockholdersEquity_d7f22768-8786-45d6-93cf-c8d0be383ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_369c3d09-a9a9-4df3-971b-64cf20ea41bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_41de17a7-a691-4ac3-9a00-f67013196ccd" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_369c3d09-a9a9-4df3-971b-64cf20ea41bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/BALANCESHEETSParenthetical" xlink:type="simple" xlink:href="ardx-20221231.xsd#BALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/BALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_35d68e87-cec9-4dea-8462-6d5a57e751b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_78a1ba91-c4dd-4284-b006-fb9e1cd9d633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_35d68e87-cec9-4dea-8462-6d5a57e751b4" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_78a1ba91-c4dd-4284-b006-fb9e1cd9d633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_5b7a5a64-5a7b-4ae3-917b-f2b33f0f7a13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_35d68e87-cec9-4dea-8462-6d5a57e751b4" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_5b7a5a64-5a7b-4ae3-917b-f2b33f0f7a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_7968b33e-ca1f-4d4a-b417-e880ce3cf6f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_35d68e87-cec9-4dea-8462-6d5a57e751b4" xlink:to="loc_us-gaap_PreferredStockSharesIssued_7968b33e-ca1f-4d4a-b417-e880ce3cf6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_6593f945-2245-4951-8e6f-7869f39b878c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_35d68e87-cec9-4dea-8462-6d5a57e751b4" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_6593f945-2245-4951-8e6f-7869f39b878c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_f50b72e4-8708-4008-ab42-f93c8b5af028" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_35d68e87-cec9-4dea-8462-6d5a57e751b4" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_f50b72e4-8708-4008-ab42-f93c8b5af028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_daafdcfb-697e-42b1-9848-5ff339b19d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_35d68e87-cec9-4dea-8462-6d5a57e751b4" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_daafdcfb-697e-42b1-9848-5ff339b19d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_991cbdcb-b639-4521-b15a-92dc5d085e6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_35d68e87-cec9-4dea-8462-6d5a57e751b4" xlink:to="loc_us-gaap_CommonStockSharesIssued_991cbdcb-b639-4521-b15a-92dc5d085e6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_79130722-962e-4e9b-ab41-4c8c3fc5e1ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_35d68e87-cec9-4dea-8462-6d5a57e751b4" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_79130722-962e-4e9b-ab41-4c8c3fc5e1ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="ardx-20221231.xsd#STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_2640e87f-a391-4519-b070-110a132847ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_aaaedf1b-53f7-4000-bbe9-d5db3dcba245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2640e87f-a391-4519-b070-110a132847ce" xlink:to="loc_us-gaap_StatementTable_aaaedf1b-53f7-4000-bbe9-d5db3dcba245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6cad257f-14bf-462a-85f3-9ef85914afc6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_aaaedf1b-53f7-4000-bbe9-d5db3dcba245" xlink:to="loc_srt_ProductOrServiceAxis_6cad257f-14bf-462a-85f3-9ef85914afc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_483bd195-fd4b-4348-ac6f-16c9439400e7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_6cad257f-14bf-462a-85f3-9ef85914afc6" xlink:to="loc_srt_ProductsAndServicesDomain_483bd195-fd4b-4348-ac6f-16c9439400e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_fe97a50a-3310-4fef-bc66-ba4c9e530be8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_483bd195-fd4b-4348-ac6f-16c9439400e7" xlink:to="loc_us-gaap_ProductMember_fe97a50a-3310-4fef-bc66-ba4c9e530be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ProductSupplyRevenueMember_d116de79-d286-4165-8ee4-c77ab889b2f4" xlink:href="ardx-20221231.xsd#ardx_ProductSupplyRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_483bd195-fd4b-4348-ac6f-16c9439400e7" xlink:to="loc_ardx_ProductSupplyRevenueMember_d116de79-d286-4165-8ee4-c77ab889b2f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_cca562d7-da45-4f94-9e85-55b32e826651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_483bd195-fd4b-4348-ac6f-16c9439400e7" xlink:to="loc_us-gaap_LicenseMember_cca562d7-da45-4f94-9e85-55b32e826651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeDevelopmentMember_aba31cf5-ab60-4545-aa9f-571df42c1fae" xlink:href="ardx-20221231.xsd#ardx_CollaborativeDevelopmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_483bd195-fd4b-4348-ac6f-16c9439400e7" xlink:to="loc_ardx_CollaborativeDevelopmentMember_aba31cf5-ab60-4545-aa9f-571df42c1fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ee678115-c8f9-4c91-913a-e6a0673f325e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_aaaedf1b-53f7-4000-bbe9-d5db3dcba245" xlink:to="loc_us-gaap_StatementLineItems_ee678115-c8f9-4c91-913a-e6a0673f325e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_330c0519-ab34-4fbb-a901-15c3928d4a35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ee678115-c8f9-4c91-913a-e6a0673f325e" xlink:to="loc_us-gaap_RevenuesAbstract_330c0519-ab34-4fbb-a901-15c3928d4a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_39ac2e44-063f-4b77-b9bf-a0670dbcac89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_330c0519-ab34-4fbb-a901-15c3928d4a35" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_39ac2e44-063f-4b77-b9bf-a0670dbcac89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_4868d582-01a4-4c94-a4d0-6313fece0319" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ee678115-c8f9-4c91-913a-e6a0673f325e" xlink:to="loc_us-gaap_OperatingExpensesAbstract_4868d582-01a4-4c94-a4d0-6313fece0319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_72a6fa7f-7afd-4906-97ae-255b35949f30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4868d582-01a4-4c94-a4d0-6313fece0319" xlink:to="loc_us-gaap_CostOfRevenue_72a6fa7f-7afd-4906-97ae-255b35949f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f8f861cc-d41a-4ea9-a9b0-98b06a6bfc80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4868d582-01a4-4c94-a4d0-6313fece0319" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f8f861cc-d41a-4ea9-a9b0-98b06a6bfc80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_4f90ea8d-b670-40ac-9dbe-39d91cfb4b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4868d582-01a4-4c94-a4d0-6313fece0319" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_4f90ea8d-b670-40ac-9dbe-39d91cfb4b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_6d4b8899-577b-4784-b64f-99c09f78c112" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4868d582-01a4-4c94-a4d0-6313fece0319" xlink:to="loc_us-gaap_CostsAndExpenses_6d4b8899-577b-4784-b64f-99c09f78c112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_13214e1a-9520-4819-b230-89a168b82d19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ee678115-c8f9-4c91-913a-e6a0673f325e" xlink:to="loc_us-gaap_OperatingIncomeLoss_13214e1a-9520-4819-b230-89a168b82d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_58f3096d-a307-4862-a6b6-e95a8766ffd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ee678115-c8f9-4c91-913a-e6a0673f325e" xlink:to="loc_us-gaap_InterestExpense_58f3096d-a307-4862-a6b6-e95a8766ffd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfAdvanceRoyalty_c38644fd-0daa-428e-98ad-2e75f06d822d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfAdvanceRoyalty"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ee678115-c8f9-4c91-913a-e6a0673f325e" xlink:to="loc_us-gaap_AmortizationOfAdvanceRoyalty_c38644fd-0daa-428e-98ad-2e75f06d822d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_15d62242-4ebc-4066-8db1-5393cf57c623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ee678115-c8f9-4c91-913a-e6a0673f325e" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_15d62242-4ebc-4066-8db1-5393cf57c623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fc2254f3-68cf-4847-b174-1d2fe69f5d13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ee678115-c8f9-4c91-913a-e6a0673f325e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fc2254f3-68cf-4847-b174-1d2fe69f5d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_846cf955-8dc5-40bc-b5ff-84eb19091b28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ee678115-c8f9-4c91-913a-e6a0673f325e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_846cf955-8dc5-40bc-b5ff-84eb19091b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6bc51903-3993-490b-be98-55520387ba3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ee678115-c8f9-4c91-913a-e6a0673f325e" xlink:to="loc_us-gaap_NetIncomeLoss_6bc51903-3993-490b-be98-55520387ba3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9484a781-b4cc-4de4-a6c1-fffc570940e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ee678115-c8f9-4c91-913a-e6a0673f325e" xlink:to="loc_us-gaap_EarningsPerShareBasic_9484a781-b4cc-4de4-a6c1-fffc570940e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_934ae123-5e5c-40cc-bf1c-f6832d3f979e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ee678115-c8f9-4c91-913a-e6a0673f325e" xlink:to="loc_us-gaap_EarningsPerShareDiluted_934ae123-5e5c-40cc-bf1c-f6832d3f979e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b22fd885-eb20-49a1-ad59-60a3626c63a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ee678115-c8f9-4c91-913a-e6a0673f325e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b22fd885-eb20-49a1-ad59-60a3626c63a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_73d59cd8-efee-4d34-9c9d-e6b886ac8d18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ee678115-c8f9-4c91-913a-e6a0673f325e" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_73d59cd8-efee-4d34-9c9d-e6b886ac8d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_947e653b-6135-4ca7-9192-03c874ec9aba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ee678115-c8f9-4c91-913a-e6a0673f325e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_947e653b-6135-4ca7-9192-03c874ec9aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_85aec0fb-cd48-49fb-8109-9888ee828fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_947e653b-6135-4ca7-9192-03c874ec9aba" xlink:to="loc_us-gaap_NetIncomeLoss_85aec0fb-cd48-49fb-8109-9888ee828fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_085c7654-94f6-4049-b51f-967e92bb832d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_947e653b-6135-4ca7-9192-03c874ec9aba" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_085c7654-94f6-4049-b51f-967e92bb832d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_00a16ea4-41a2-4ec3-8b14-9ee07334bfab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_947e653b-6135-4ca7-9192-03c874ec9aba" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_00a16ea4-41a2-4ec3-8b14-9ee07334bfab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/STATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="ardx-20221231.xsd#STATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/STATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0f0667f2-fa1c-41b3-b52d-d429577c67a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b09d8f49-41e2-4c37-8c05-19f84df9825f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0f0667f2-fa1c-41b3-b52d-d429577c67a6" xlink:to="loc_us-gaap_StatementTable_b09d8f49-41e2-4c37-8c05-19f84df9825f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_39478a9c-e5a0-4139-b23e-b9d3326aefbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b09d8f49-41e2-4c37-8c05-19f84df9825f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_39478a9c-e5a0-4139-b23e-b9d3326aefbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a02f2a06-29b1-48b6-a556-5cccc51621e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_39478a9c-e5a0-4139-b23e-b9d3326aefbd" xlink:to="loc_us-gaap_EquityComponentDomain_a02f2a06-29b1-48b6-a556-5cccc51621e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_015a72ff-d151-4f23-bb87-6ea6bf02a0fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a02f2a06-29b1-48b6-a556-5cccc51621e0" xlink:to="loc_us-gaap_CommonStockMember_015a72ff-d151-4f23-bb87-6ea6bf02a0fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_948cd317-9a59-4863-a76d-49424feb40f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a02f2a06-29b1-48b6-a556-5cccc51621e0" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_948cd317-9a59-4863-a76d-49424feb40f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_af06d53c-557b-4141-8161-09b0a66d9ead" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a02f2a06-29b1-48b6-a556-5cccc51621e0" xlink:to="loc_us-gaap_RetainedEarningsMember_af06d53c-557b-4141-8161-09b0a66d9ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c7b63c67-5599-4e10-965e-5310387ecead" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a02f2a06-29b1-48b6-a556-5cccc51621e0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c7b63c67-5599-4e10-965e-5310387ecead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_29d9d99e-8228-4131-abf5-226586936ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b09d8f49-41e2-4c37-8c05-19f84df9825f" xlink:to="loc_us-gaap_StatementLineItems_29d9d99e-8228-4131-abf5-226586936ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_90073137-ed71-4b17-9484-445e6e933899" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_29d9d99e-8228-4131-abf5-226586936ff2" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_90073137-ed71-4b17-9484-445e6e933899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_be9e9685-953a-4099-a514-fa4a004f2128" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_90073137-ed71-4b17-9484-445e6e933899" xlink:to="loc_us-gaap_SharesOutstanding_be9e9685-953a-4099-a514-fa4a004f2128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_89b5e691-646c-4838-bae1-3d9767871f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_90073137-ed71-4b17-9484-445e6e933899" xlink:to="loc_us-gaap_StockholdersEquity_89b5e691-646c-4838-bae1-3d9767871f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_74dfb508-d597-4e44-96bc-7f71bad63a07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_90073137-ed71-4b17-9484-445e6e933899" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_74dfb508-d597-4e44-96bc-7f71bad63a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_8ff75dae-96cf-4e85-a706-ce172f20940f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_90073137-ed71-4b17-9484-445e6e933899" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_8ff75dae-96cf-4e85-a706-ce172f20940f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_7e03e904-187d-4061-b05b-8c740c61c44d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_90073137-ed71-4b17-9484-445e6e933899" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_7e03e904-187d-4061-b05b-8c740c61c44d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_18066e62-4294-4bfb-80bc-109e87a4f91a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_90073137-ed71-4b17-9484-445e6e933899" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_18066e62-4294-4bfb-80bc-109e87a4f91a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_dd9643e1-6930-4470-9a6e-32a447a6ad71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_90073137-ed71-4b17-9484-445e6e933899" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_dd9643e1-6930-4470-9a6e-32a447a6ad71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_79e948df-a5a9-424d-84e6-a26c2ae7894b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_90073137-ed71-4b17-9484-445e6e933899" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_79e948df-a5a9-424d-84e6-a26c2ae7894b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_623b5583-c8f7-4824-9c3d-285544e742a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_90073137-ed71-4b17-9484-445e6e933899" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_623b5583-c8f7-4824-9c3d-285544e742a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_da078c1a-c608-4dcc-aace-d0fd472574a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_90073137-ed71-4b17-9484-445e6e933899" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_da078c1a-c608-4dcc-aace-d0fd472574a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1621ca0c-d6c3-4ec4-906f-a647df21cf41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_90073137-ed71-4b17-9484-445e6e933899" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1621ca0c-d6c3-4ec4-906f-a647df21cf41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e9788343-3a2b-4b70-ad26-549f3fbd80d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_90073137-ed71-4b17-9484-445e6e933899" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_e9788343-3a2b-4b70-ad26-549f3fbd80d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fd3690e1-9251-4a21-8350-fd5a71e305ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_90073137-ed71-4b17-9484-445e6e933899" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fd3690e1-9251-4a21-8350-fd5a71e305ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_cff8071f-db66-4d6f-a961-686d06ea68b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_90073137-ed71-4b17-9484-445e6e933899" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_cff8071f-db66-4d6f-a961-686d06ea68b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9272234b-8e55-475d-8ee3-5b1f2ff64a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_90073137-ed71-4b17-9484-445e6e933899" xlink:to="loc_us-gaap_NetIncomeLoss_9272234b-8e55-475d-8ee3-5b1f2ff64a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_69080bba-f2f2-461f-9486-7a5c4e80fe95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_90073137-ed71-4b17-9484-445e6e933899" xlink:to="loc_us-gaap_SharesOutstanding_69080bba-f2f2-461f-9486-7a5c4e80fe95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d62982dd-3ff7-4fc9-b7f0-a1ddf06af18c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_29d9d99e-8228-4131-abf5-226586936ff2" xlink:to="loc_us-gaap_StockholdersEquity_d62982dd-3ff7-4fc9-b7f0-a1ddf06af18c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="ardx-20221231.xsd#STATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_4371b02d-081e-49da-a3c7-d96d577af360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_49ac77d8-4611-4b0c-bd6c-e749207aeedc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4371b02d-081e-49da-a3c7-d96d577af360" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_49ac77d8-4611-4b0c-bd6c-e749207aeedc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5bf642bc-fb36-4ecc-ab97-40c3ce3b1fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_49ac77d8-4611-4b0c-bd6c-e749207aeedc" xlink:to="loc_us-gaap_NetIncomeLoss_5bf642bc-fb36-4ecc-ab97-40c3ce3b1fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4b507516-c7b2-4801-95c1-070ad871ba42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_49ac77d8-4611-4b0c-bd6c-e749207aeedc" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4b507516-c7b2-4801-95c1-070ad871ba42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_906e95b9-a22f-40f2-b6e1-be6e6586c6fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4b507516-c7b2-4801-95c1-070ad871ba42" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_906e95b9-a22f-40f2-b6e1-be6e6586c6fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_1d343523-048c-437f-a01e-fa1d06734378" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4b507516-c7b2-4801-95c1-070ad871ba42" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_1d343523-048c-437f-a01e-fa1d06734378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_285214e8-b126-4d59-ba1f-121b8b107ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4b507516-c7b2-4801-95c1-070ad871ba42" xlink:to="loc_us-gaap_ShareBasedCompensation_285214e8-b126-4d59-ba1f-121b8b107ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_de647a7a-b53b-4083-8a78-613395c4c5a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4b507516-c7b2-4801-95c1-070ad871ba42" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_de647a7a-b53b-4083-8a78-613395c4c5a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt_7bc7606f-d25d-4170-9d00-918acb1bea9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4b507516-c7b2-4801-95c1-070ad871ba42" xlink:to="loc_us-gaap_GainsLossesOnRestructuringOfDebt_7bc7606f-d25d-4170-9d00-918acb1bea9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_21c2e8b6-1d76-4883-b269-15cb574195e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4b507516-c7b2-4801-95c1-070ad871ba42" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_21c2e8b6-1d76-4883-b269-15cb574195e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_075eed8e-d82c-4a9d-a832-df31ae86bac2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4b507516-c7b2-4801-95c1-070ad871ba42" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_075eed8e-d82c-4a9d-a832-df31ae86bac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_303c91ff-a7c5-4ff4-9e7c-76681899c707" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4b507516-c7b2-4801-95c1-070ad871ba42" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_303c91ff-a7c5-4ff4-9e7c-76681899c707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_IncreaseDecreaseInUnbilledRevenue_dac150d2-a469-46af-b34f-296dc6e0f48b" xlink:href="ardx-20221231.xsd#ardx_IncreaseDecreaseInUnbilledRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_303c91ff-a7c5-4ff4-9e7c-76681899c707" xlink:to="loc_ardx_IncreaseDecreaseInUnbilledRevenue_dac150d2-a469-46af-b34f-296dc6e0f48b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_26f32a90-cc69-4198-9dbc-df30f6f57217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_303c91ff-a7c5-4ff4-9e7c-76681899c707" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_26f32a90-cc69-4198-9dbc-df30f6f57217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_272f8085-89c6-468d-a9c3-006d835e8153" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_303c91ff-a7c5-4ff4-9e7c-76681899c707" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_272f8085-89c6-468d-a9c3-006d835e8153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense_c41556fb-ed7d-4787-9ae9-c4ec50c65c7c" xlink:href="ardx-20221231.xsd#ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_303c91ff-a7c5-4ff4-9e7c-76681899c707" xlink:to="loc_ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense_c41556fb-ed7d-4787-9ae9-c4ec50c65c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_145dff38-3c51-475e-9870-3f9cd7ff1159" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_303c91ff-a7c5-4ff4-9e7c-76681899c707" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_145dff38-3c51-475e-9870-3f9cd7ff1159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8778dda3-debc-44f9-b0f6-a7ed3b059545" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_303c91ff-a7c5-4ff4-9e7c-76681899c707" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8778dda3-debc-44f9-b0f6-a7ed3b059545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_07f30838-f9a7-4ea2-ad80-3f820d97d043" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_303c91ff-a7c5-4ff4-9e7c-76681899c707" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_07f30838-f9a7-4ea2-ad80-3f820d97d043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_c3a848e8-088e-4941-baa5-15a0b95f87ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_303c91ff-a7c5-4ff4-9e7c-76681899c707" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_c3a848e8-088e-4941-baa5-15a0b95f87ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1b850d40-7f4e-43ad-aae8-b18825ff1080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_303c91ff-a7c5-4ff4-9e7c-76681899c707" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1b850d40-7f4e-43ad-aae8-b18825ff1080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_8ddb1dd2-e23e-490c-a362-27f1f41fe87b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_303c91ff-a7c5-4ff4-9e7c-76681899c707" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_8ddb1dd2-e23e-490c-a362-27f1f41fe87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b8024fe-94f5-4c5a-9511-7af461c9c410" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_49ac77d8-4611-4b0c-bd6c-e749207aeedc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b8024fe-94f5-4c5a-9511-7af461c9c410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d1ab02d0-8f2a-464d-bbbc-28e990d930c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4371b02d-081e-49da-a3c7-d96d577af360" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d1ab02d0-8f2a-464d-bbbc-28e990d930c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_a4b0d877-3081-41ab-951f-5b6f6275230c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d1ab02d0-8f2a-464d-bbbc-28e990d930c9" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_a4b0d877-3081-41ab-951f-5b6f6275230c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_416beb02-64cc-48be-a8b0-9c0e1a167821" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d1ab02d0-8f2a-464d-bbbc-28e990d930c9" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_416beb02-64cc-48be-a8b0-9c0e1a167821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_2bfbe7d3-0911-43a3-9840-5b6addb3f69d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d1ab02d0-8f2a-464d-bbbc-28e990d930c9" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_2bfbe7d3-0911-43a3-9840-5b6addb3f69d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e5b20e15-529b-424c-98b3-7e4cf1da69c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d1ab02d0-8f2a-464d-bbbc-28e990d930c9" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e5b20e15-529b-424c-98b3-7e4cf1da69c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_74bd919a-35b6-43e3-accb-a72291b6f0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d1ab02d0-8f2a-464d-bbbc-28e990d930c9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_74bd919a-35b6-43e3-accb-a72291b6f0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7e547a0e-b06e-4460-a505-a96c3e23f808" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4371b02d-081e-49da-a3c7-d96d577af360" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7e547a0e-b06e-4460-a505-a96c3e23f808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_15751905-f8a1-40bc-8914-526ced5e1a64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7e547a0e-b06e-4460-a505-a96c3e23f808" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_15751905-f8a1-40bc-8914-526ced5e1a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt_ad89e4d5-dd33-42fa-98d6-4ed67a2b316b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7e547a0e-b06e-4460-a505-a96c3e23f808" xlink:to="loc_us-gaap_RepaymentsOfSecuredDebt_ad89e4d5-dd33-42fa-98d6-4ed67a2b316b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts_cd6d3cec-c851-4b0c-abd2-1176db5ac0b8" xlink:href="ardx-20221231.xsd#ardx_ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7e547a0e-b06e-4460-a505-a96c3e23f808" xlink:to="loc_ardx_ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts_cd6d3cec-c851-4b0c-abd2-1176db5ac0b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d78b6778-ab23-474f-ad20-60aa4eee83f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7e547a0e-b06e-4460-a505-a96c3e23f808" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d78b6778-ab23-474f-ad20-60aa4eee83f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_c63c36fb-71c0-4860-b844-01dae1a419de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7e547a0e-b06e-4460-a505-a96c3e23f808" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_c63c36fb-71c0-4860-b844-01dae1a419de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d7489127-2abc-43d7-b6cd-512f2d797ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7e547a0e-b06e-4460-a505-a96c3e23f808" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d7489127-2abc-43d7-b6cd-512f2d797ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3d6ae411-83a5-4261-9a1c-347058e28e04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7e547a0e-b06e-4460-a505-a96c3e23f808" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3d6ae411-83a5-4261-9a1c-347058e28e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f711102d-4a02-4681-b18d-cc1ac9e6e9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4371b02d-081e-49da-a3c7-d96d577af360" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f711102d-4a02-4681-b18d-cc1ac9e6e9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f1f9fff9-0fc9-4cfc-9bbf-ad1a18cb1fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4371b02d-081e-49da-a3c7-d96d577af360" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f1f9fff9-0fc9-4cfc-9bbf-ad1a18cb1fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1573a435-5bd9-46b9-a986-088211adb988" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4371b02d-081e-49da-a3c7-d96d577af360" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1573a435-5bd9-46b9-a986-088211adb988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_bc758cc8-6686-4da7-88b8-3fa88fce293d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4371b02d-081e-49da-a3c7-d96d577af360" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_bc758cc8-6686-4da7-88b8-3fa88fce293d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_84e919e4-2fed-4906-ad6c-398614f8edb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_bc758cc8-6686-4da7-88b8-3fa88fce293d" xlink:to="loc_us-gaap_InterestPaidNet_84e919e4-2fed-4906-ad6c-398614f8edb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_d7d9fe6e-b600-467d-9e34-6d79ffade5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_bc758cc8-6686-4da7-88b8-3fa88fce293d" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_d7d9fe6e-b600-467d-9e34-6d79ffade5e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_40be7e8e-ef66-4efd-8d90-680718b09d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4371b02d-081e-49da-a3c7-d96d577af360" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_40be7e8e-ef66-4efd-8d90-680718b09d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_94eddc22-60fa-4180-ab74-b983c6b73016" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_40be7e8e-ef66-4efd-8d90-680718b09d5f" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_94eddc22-60fa-4180-ab74-b983c6b73016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_10574506-73fe-4d28-8ccc-2720e947f563" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_40be7e8e-ef66-4efd-8d90-680718b09d5f" xlink:to="loc_us-gaap_StockIssued1_10574506-73fe-4d28-8ccc-2720e947f563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DerivativeIssued_84e7f290-d52f-494b-b06f-dda89c79faf1" xlink:href="ardx-20221231.xsd#ardx_DerivativeIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_40be7e8e-ef66-4efd-8d90-680718b09d5f" xlink:to="loc_ardx_DerivativeIssued_84e7f290-d52f-494b-b06f-dda89c79faf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="ardx-20221231.xsd#OrganizationandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/OrganizationandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a85b33cb-9810-4fd8-8184-a34e3f653a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_85e3506f-84e4-4dda-9fbe-637056a4a4a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a85b33cb-9810-4fd8-8184-a34e3f653a0d" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_85e3506f-84e4-4dda-9fbe-637056a4a4a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="ardx-20221231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e496400b-e3bc-4a83-9acc-156fae70a9aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_3f525ddc-5014-4eaa-a1c0-dc3f7e25c221" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e496400b-e3bc-4a83-9acc-156fae70a9aa" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_3f525ddc-5014-4eaa-a1c0-dc3f7e25c221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestments" xlink:type="simple" xlink:href="ardx-20221231.xsd#CashCashEquivalentsandShortTermInvestments"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_8406d4fb-40a2-4ed9-86bd-d73b4199ea84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_c5d42e6d-1230-4d96-9ee1-178f8528a185" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_8406d4fb-40a2-4ed9-86bd-d73b4199ea84" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_c5d42e6d-1230-4d96-9ee1-178f8528a185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="ardx-20221231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a2fa7ca5-159a-4f5b-b154-c589194c155d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_b5cbabeb-2b8d-407f-8fb9-b1f3465c31cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a2fa7ca5-159a-4f5b-b154-c589194c155d" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_b5cbabeb-2b8d-407f-8fb9-b1f3465c31cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/Inventory" xlink:type="simple" xlink:href="ardx-20221231.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_a9c6a86c-9877-483b-bc1c-07cdb2fad4c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_b7cf17a8-58fd-40a9-8a2d-ce50952516b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a9c6a86c-9877-483b-bc1c-07cdb2fad4c7" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_b7cf17a8-58fd-40a9-8a2d-ce50952516b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/ProductRevenueNet" xlink:type="simple" xlink:href="ardx-20221231.xsd#ProductRevenueNet"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/ProductRevenueNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1db8ef7c-552f-44da-8316-e9a815b152c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_fa3c44f3-a8fc-4fa0-b4a7-a3a5b10c9dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1db8ef7c-552f-44da-8316-e9a815b152c9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_fa3c44f3-a8fc-4fa0-b4a7-a3a5b10c9dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreements" xlink:type="simple" xlink:href="ardx-20221231.xsd#CollaborationandLicensingAgreements"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CollaborationandLicensingAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsAbstract_40f71fa0-cda0-4ca9-b131-8efb417afd03" xlink:href="ardx-20221231.xsd#ardx_CollaborationAndLicensingAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_3106df85-1296-4958-9e11-8d1f90abbf90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_CollaborationAndLicensingAgreementsAbstract_40f71fa0-cda0-4ca9-b131-8efb417afd03" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_3106df85-1296-4958-9e11-8d1f90abbf90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyalties" xlink:type="simple" xlink:href="ardx-20221231.xsd#DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyalties"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyalties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvanceRoyaltiesAbstract_a0443e33-be0e-42a3-b898-438bf70e1d25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvanceRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetRetirementObligationDisclosureTextBlock_2589963e-b63a-4de9-8be0-8e5c041aa1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetRetirementObligationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdvanceRoyaltiesAbstract_a0443e33-be0e-42a3-b898-438bf70e1d25" xlink:to="loc_us-gaap_AssetRetirementObligationDisclosureTextBlock_2589963e-b63a-4de9-8be0-8e5c041aa1b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/Borrowings" xlink:type="simple" xlink:href="ardx-20221231.xsd#Borrowings"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/Borrowings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_832615a4-99c3-47f9-957a-093854c1ca02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_170c0c7c-5211-4374-97c4-d07b4d300d17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_832615a4-99c3-47f9-957a-093854c1ca02" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_170c0c7c-5211-4374-97c4-d07b4d300d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/DerivativeLiabilities" xlink:type="simple" xlink:href="ardx-20221231.xsd#DerivativeLiabilities"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/DerivativeLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3f36274c-296f-41eb-bb39-865815e3c364" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_c7eafa22-1450-46d8-9776-8af1c300a70e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3f36274c-296f-41eb-bb39-865815e3c364" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_c7eafa22-1450-46d8-9776-8af1c300a70e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/Leases" xlink:type="simple" xlink:href="ardx-20221231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_7b19e579-c4c5-4483-b61b-fec7316a3efb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_9794ab4a-dc2f-4634-948a-f03fd0d2ccf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7b19e579-c4c5-4483-b61b-fec7316a3efb" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_9794ab4a-dc2f-4634-948a-f03fd0d2ccf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/StockholdersEquity" xlink:type="simple" xlink:href="ardx-20221231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_5304ad89-5d93-4c14-91e7-c7d5b68f56b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0e1757e1-a650-46e6-81ad-ed9330489f55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_5304ad89-5d93-4c14-91e7-c7d5b68f56b5" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0e1757e1-a650-46e6-81ad-ed9330489f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlans" xlink:type="simple" xlink:href="ardx-20221231.xsd#EquityIncentivePlans"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_48e3c202-3d1d-42ab-860c-f0b5ee7f58ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0db87f93-8112-4ff2-902c-e749a70301d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_48e3c202-3d1d-42ab-860c-f0b5ee7f58ea" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0db87f93-8112-4ff2-902c-e749a70301d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/Restructuring" xlink:type="simple" xlink:href="ardx-20221231.xsd#Restructuring"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/Restructuring" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_ee95c6ae-7f78-48c7-9364-69532294fcd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_766b2b99-364e-416a-8368-218e50b80abd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_ee95c6ae-7f78-48c7-9364-69532294fcd7" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_766b2b99-364e-416a-8368-218e50b80abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/PropertyandEquipmentNet" xlink:type="simple" xlink:href="ardx-20221231.xsd#PropertyandEquipmentNet"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_fe099d4e-4ed3-458f-ad36-820e6c90e835" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1837e145-5b57-4f46-a73b-b90074b63997" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_fe099d4e-4ed3-458f-ad36-820e6c90e835" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1837e145-5b57-4f46-a73b-b90074b63997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="simple" xlink:href="ardx-20221231.xsd#AccruedExpensesandOtherCurrentLiabilities"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_ffff1bd5-5f4f-4e3b-9927-b10c45c2e00f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_0db28182-6f63-4665-afa9-a139b2d9df42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_ffff1bd5-5f4f-4e3b-9927-b10c45c2e00f" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_0db28182-6f63-4665-afa9-a139b2d9df42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/IncomeTaxes" xlink:type="simple" xlink:href="ardx-20221231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_eaa10843-b7e2-4d27-8e27-47625d6c1918" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_e6593d05-14d1-4a16-a701-4ae7c35b9bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_eaa10843-b7e2-4d27-8e27-47625d6c1918" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_e6593d05-14d1-4a16-a701-4ae7c35b9bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/GeographicInformationandConcentrations" xlink:type="simple" xlink:href="ardx-20221231.xsd#GeographicInformationandConcentrations"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/GeographicInformationandConcentrations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_b7ebb040-aa92-4354-be08-17b21faa3532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_GeographicInformationAndConcentrationsTextBlock_ae7a3ab3-f088-46fb-83e2-f70d0e1e7eee" xlink:href="ardx-20221231.xsd#ardx_GeographicInformationAndConcentrationsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_b7ebb040-aa92-4354-be08-17b21faa3532" xlink:to="loc_ardx_GeographicInformationAndConcentrationsTextBlock_ae7a3ab3-f088-46fb-83e2-f70d0e1e7eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/NetLossPerShare" xlink:type="simple" xlink:href="ardx-20221231.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7470a96f-7b94-4b8f-af98-1290f2c366ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_175b1e49-9684-4acb-9d36-fb9796c1d964" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7470a96f-7b94-4b8f-af98-1290f2c366ae" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_175b1e49-9684-4acb-9d36-fb9796c1d964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="ardx-20221231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9829608f-162e-450b-b00c-c6a9210409ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_45329d99-ea0a-4bf4-a940-9fd36350f76b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9829608f-162e-450b-b00c-c6a9210409ce" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_45329d99-ea0a-4bf4-a940-9fd36350f76b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/SubsequentEvents" xlink:type="simple" xlink:href="ardx-20221231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_bd2d004c-77ed-4c50-8eb2-142cdee7f936" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_567699fc-5697-4478-b699-0c3701c826ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_bd2d004c-77ed-4c50-8eb2-142cdee7f936" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_567699fc-5697-4478-b699-0c3701c826ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="ardx-20221231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_82406c27-2db1-42db-80fd-fb960f240b08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ea9b7c25-6c35-44a8-9f9a-a7278d3b7147" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82406c27-2db1-42db-80fd-fb960f240b08" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ea9b7c25-6c35-44a8-9f9a-a7278d3b7147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_6515a55d-a399-46a5-b58f-97c1df71d15f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82406c27-2db1-42db-80fd-fb960f240b08" xlink:to="loc_us-gaap_UseOfEstimates_6515a55d-a399-46a5-b58f-97c1df71d15f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_579c8819-0aa8-428d-88cb-fde74e137239" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82406c27-2db1-42db-80fd-fb960f240b08" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_579c8819-0aa8-428d-88cb-fde74e137239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShortTermInvestmentsPolicyTextBlock_01b05fb9-b1f8-454f-869d-be2a046cfd0f" xlink:href="ardx-20221231.xsd#ardx_ShortTermInvestmentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82406c27-2db1-42db-80fd-fb960f240b08" xlink:to="loc_ardx_ShortTermInvestmentsPolicyTextBlock_01b05fb9-b1f8-454f-869d-be2a046cfd0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_ae12a7f2-2611-444d-9baf-c41adb9e1dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82406c27-2db1-42db-80fd-fb960f240b08" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_ae12a7f2-2611-444d-9baf-c41adb9e1dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_a923c39f-4f8b-4e6b-9da6-5b074ae186df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82406c27-2db1-42db-80fd-fb960f240b08" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_a923c39f-4f8b-4e6b-9da6-5b074ae186df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_a37973d8-50ff-4766-9584-62546e23e542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82406c27-2db1-42db-80fd-fb960f240b08" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_a37973d8-50ff-4766-9584-62546e23e542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_73f63758-4b99-4318-b4cf-202e64557afe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82406c27-2db1-42db-80fd-fb960f240b08" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_73f63758-4b99-4318-b4cf-202e64557afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_c5e75541-b7d6-4ff3-88f9-842e2d39210e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82406c27-2db1-42db-80fd-fb960f240b08" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_c5e75541-b7d6-4ff3-88f9-842e2d39210e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_8d764baa-5528-49cd-b73c-3519e929aca2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82406c27-2db1-42db-80fd-fb960f240b08" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_8d764baa-5528-49cd-b73c-3519e929aca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_86d25ad6-77a8-4f7e-bd79-379e5174a7ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82406c27-2db1-42db-80fd-fb960f240b08" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_86d25ad6-77a8-4f7e-bd79-379e5174a7ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_46355982-17e0-4751-8891-547ba8edaa7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82406c27-2db1-42db-80fd-fb960f240b08" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_46355982-17e0-4751-8891-547ba8edaa7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_e8e8df77-c509-4d88-9a66-4b0b0c886fff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82406c27-2db1-42db-80fd-fb960f240b08" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_e8e8df77-c509-4d88-9a66-4b0b0c886fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_7abd575e-7042-4715-9e88-1e08730c4542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82406c27-2db1-42db-80fd-fb960f240b08" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_7abd575e-7042-4715-9e88-1e08730c4542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock_367735b1-0ed5-4719-bd5b-c5eef576d8b8" xlink:href="ardx-20221231.xsd#ardx_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82406c27-2db1-42db-80fd-fb960f240b08" xlink:to="loc_ardx_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock_367735b1-0ed5-4719-bd5b-c5eef576d8b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_de60439a-a45a-4c7d-b233-60d6bc26075c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82406c27-2db1-42db-80fd-fb960f240b08" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_de60439a-a45a-4c7d-b233-60d6bc26075c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesReportingOfDerivativeActivity_5521154b-c084-4fc2-afef-d7a5ac7e2db9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesReportingOfDerivativeActivity"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82406c27-2db1-42db-80fd-fb960f240b08" xlink:to="loc_us-gaap_DerivativesReportingOfDerivativeActivity_5521154b-c084-4fc2-afef-d7a5ac7e2db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock_1e1bbe24-9ff1-4f27-b380-6981f76ed4de" xlink:href="ardx-20221231.xsd#ardx_NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82406c27-2db1-42db-80fd-fb960f240b08" xlink:to="loc_ardx_NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock_1e1bbe24-9ff1-4f27-b380-6981f76ed4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_e866b553-3170-4fc9-b068-e63062cdb137" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82406c27-2db1-42db-80fd-fb960f240b08" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_e866b553-3170-4fc9-b068-e63062cdb137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_4ca946bd-97ed-478d-a6ef-2b727190b8b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82406c27-2db1-42db-80fd-fb960f240b08" xlink:to="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_4ca946bd-97ed-478d-a6ef-2b727190b8b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_78c98e7b-73da-4c3f-b84f-a30ac6f55ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82406c27-2db1-42db-80fd-fb960f240b08" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_78c98e7b-73da-4c3f-b84f-a30ac6f55ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_336d8e95-394b-4d89-a9b8-a8510853e15d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82406c27-2db1-42db-80fd-fb960f240b08" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_336d8e95-394b-4d89-a9b8-a8510853e15d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsTables" xlink:type="simple" xlink:href="ardx-20221231.xsd#CashCashEquivalentsandShortTermInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_d1c5b504-bc57-4b0d-a5cb-f3544dd1a147" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_b9c70bf5-8c22-4445-a8a2-c8d904974243" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_d1c5b504-bc57-4b0d-a5cb-f3544dd1a147" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_b9c70bf5-8c22-4445-a8a2-c8d904974243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="ardx-20221231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1fbc8803-8ca2-45c3-9237-5e210902b764" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_857b6a05-171a-4d2e-82d1-5addf0cee5dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1fbc8803-8ca2-45c3-9237-5e210902b764" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_857b6a05-171a-4d2e-82d1-5addf0cee5dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/InventoryTables" xlink:type="simple" xlink:href="ardx-20221231.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_16a8bb91-0cda-4480-8228-03a4c712e14f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_0cfc82f6-892d-4182-afc3-f121214a9679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_16a8bb91-0cda-4480-8228-03a4c712e14f" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_0cfc82f6-892d-4182-afc3-f121214a9679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_57e27ba2-ad21-4e7c-a404-18ce5601ae7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_16a8bb91-0cda-4480-8228-03a4c712e14f" xlink:to="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_57e27ba2-ad21-4e7c-a404-18ce5601ae7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/ProductRevenueNetTables" xlink:type="simple" xlink:href="ardx-20221231.xsd#ProductRevenueNetTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/ProductRevenueNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_14202388-b22f-4a29-9bf9-b9d8a2becf61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock_e9f3cd0e-4b93-419b-aea6-5261857529b6" xlink:href="ardx-20221231.xsd#ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_14202388-b22f-4a29-9bf9-b9d8a2becf61" xlink:to="loc_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock_e9f3cd0e-4b93-419b-aea6-5261857529b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsTables" xlink:type="simple" xlink:href="ardx-20221231.xsd#CollaborationandLicensingAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsAbstract_3a409e87-f09b-485f-a8e8-4e1361b2bdc8" xlink:href="ardx-20221231.xsd#ardx_CollaborationAndLicensingAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_27d031c5-c109-4ae7-a06b-163c4b28e3a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_CollaborationAndLicensingAgreementsAbstract_3a409e87-f09b-485f-a8e8-4e1361b2bdc8" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_27d031c5-c109-4ae7-a06b-163c4b28e3a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/BorrowingsTables" xlink:type="simple" xlink:href="ardx-20221231.xsd#BorrowingsTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/BorrowingsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1f7ae5c0-c0f5-4bc0-ab05-19cc7fdd497e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_4219d47b-972e-4b74-8313-7d88e048c8dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1f7ae5c0-c0f5-4bc0-ab05-19cc7fdd497e" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_4219d47b-972e-4b74-8313-7d88e048c8dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/DerivativeLiabilitiesTables" xlink:type="simple" xlink:href="ardx-20221231.xsd#DerivativeLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/DerivativeLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9098371a-6f92-4e7d-bee2-5bf49ca623ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_00979bc0-b000-476d-a5b6-34a6e45f004d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9098371a-6f92-4e7d-bee2-5bf49ca623ea" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_00979bc0-b000-476d-a5b6-34a6e45f004d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/LeasesTables" xlink:type="simple" xlink:href="ardx-20221231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_80b3460c-2352-49f9-85bd-513933d5d6e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock_ff50ea8c-bb43-43c5-a9af-d1b73c05db5b" xlink:href="ardx-20221231.xsd#ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_80b3460c-2352-49f9-85bd-513933d5d6e6" xlink:to="loc_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock_ff50ea8c-bb43-43c5-a9af-d1b73c05db5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_aeb60932-e67a-4bbb-bf36-546ba5c7fba5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_80b3460c-2352-49f9-85bd-513933d5d6e6" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_aeb60932-e67a-4bbb-bf36-546ba5c7fba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1c465cbb-b75d-4234-adb7-54939ac23757" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_80b3460c-2352-49f9-85bd-513933d5d6e6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1c465cbb-b75d-4234-adb7-54939ac23757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansTables" xlink:type="simple" xlink:href="ardx-20221231.xsd#EquityIncentivePlansTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cc177bf6-2231-4631-87ae-7e612a2b6b64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_830859a9-3b27-4b90-9679-d5e84a6de315" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cc177bf6-2231-4631-87ae-7e612a2b6b64" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_830859a9-3b27-4b90-9679-d5e84a6de315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4804f58b-c273-4610-b09c-4f8f666acc84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cc177bf6-2231-4631-87ae-7e612a2b6b64" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4804f58b-c273-4610-b09c-4f8f666acc84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_284c89ce-17a0-4ac1-9375-a0895df9fd46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cc177bf6-2231-4631-87ae-7e612a2b6b64" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_284c89ce-17a0-4ac1-9375-a0895df9fd46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_6937100a-71ae-48db-a086-366603c089e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cc177bf6-2231-4631-87ae-7e612a2b6b64" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_6937100a-71ae-48db-a086-366603c089e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_b4ba27e6-ee9b-43ac-8002-50a7dc2cbac4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cc177bf6-2231-4631-87ae-7e612a2b6b64" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_b4ba27e6-ee9b-43ac-8002-50a7dc2cbac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_f0e96251-b309-4062-a30a-33e5d2c93d26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cc177bf6-2231-4631-87ae-7e612a2b6b64" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_f0e96251-b309-4062-a30a-33e5d2c93d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_6a6bddd8-9427-40c5-9d30-567829028499" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cc177bf6-2231-4631-87ae-7e612a2b6b64" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_6a6bddd8-9427-40c5-9d30-567829028499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/PropertyandEquipmentNetTables" xlink:type="simple" xlink:href="ardx-20221231.xsd#PropertyandEquipmentNetTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_116773c7-3586-4dda-839a-cdf0f04f1802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_b50d0501-73eb-4ddc-ab1d-12defe7a169c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_116773c7-3586-4dda-839a-cdf0f04f1802" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_b50d0501-73eb-4ddc-ab1d-12defe7a169c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="simple" xlink:href="ardx-20221231.xsd#AccruedExpensesandOtherCurrentLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_014df023-3f9a-4e04-bbba-2b272e7868de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_9a1472a2-44f6-4cc6-9272-c85c38b2d4b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_014df023-3f9a-4e04-bbba-2b272e7868de" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_9a1472a2-44f6-4cc6-9272-c85c38b2d4b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="ardx-20221231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5e0274bb-53a7-458a-bd20-f97925cd6e17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_6f4c3585-998e-49b4-995a-ec6794ed778c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5e0274bb-53a7-458a-bd20-f97925cd6e17" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_6f4c3585-998e-49b4-995a-ec6794ed778c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_ac17426f-552d-450b-8ea5-77e7902205c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5e0274bb-53a7-458a-bd20-f97925cd6e17" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_ac17426f-552d-450b-8ea5-77e7902205c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_ff859610-d055-423f-9106-2516ed260ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5e0274bb-53a7-458a-bd20-f97925cd6e17" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_ff859610-d055-423f-9106-2516ed260ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_1f9fe70f-e5dd-4704-9cac-255ba093d741" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5e0274bb-53a7-458a-bd20-f97925cd6e17" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_1f9fe70f-e5dd-4704-9cac-255ba093d741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/GeographicInformationandConcentrationsTables" xlink:type="simple" xlink:href="ardx-20221231.xsd#GeographicInformationandConcentrationsTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/GeographicInformationandConcentrationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_0deb4cf3-604a-4507-848b-7042fdfe6175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_82933540-a714-4ce4-8a6c-cc9850544fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_0deb4cf3-604a-4507-848b-7042fdfe6175" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_82933540-a714-4ce4-8a6c-cc9850544fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_bea6472c-c394-4c34-a27f-544f19deef2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_0deb4cf3-604a-4507-848b-7042fdfe6175" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_bea6472c-c394-4c34-a27f-544f19deef2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="ardx-20221231.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1940e752-95e0-49bf-b80c-f378586c7f31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_a09e830c-eef6-43fb-80f4-1636bd51ac65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1940e752-95e0-49bf-b80c-f378586c7f31" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_a09e830c-eef6-43fb-80f4-1636bd51ac65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1c8577d9-bf14-4458-a4f2-0a6802dfc040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1940e752-95e0-49bf-b80c-f378586c7f31" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1c8577d9-bf14-4458-a4f2-0a6802dfc040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#OrganizationandBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0897c260-176e-4e9a-af8a-16f945fde511" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_707c461d-2b3e-4e81-bbea-1f46315d2412" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0897c260-176e-4e9a-af8a-16f945fde511" xlink:to="loc_us-gaap_NumberOfOperatingSegments_707c461d-2b3e-4e81-bbea-1f46315d2412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesLiquidityDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#SummaryofSignificantAccountingPoliciesLiquidityDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesLiquidityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9c66382f-ca5f-40aa-8000-fbb3fdaeec1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_36538a47-3252-4880-8614-aa07308aa3fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndCash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9c66382f-ca5f-40aa-8000-fbb3fdaeec1c" xlink:to="loc_us-gaap_InvestmentsAndCash_36538a47-3252-4880-8614-aa07308aa3fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6e6016df-8352-49a3-866d-3e1fac3b613a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9c66382f-ca5f-40aa-8000-fbb3fdaeec1c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6e6016df-8352-49a3-866d-3e1fac3b613a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#SummaryofSignificantAccountingPoliciesAccountsReceivableDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_763971c7-ef89-468b-89ac-3385922c6afb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_526ee5d1-9a20-4da7-a1a7-42071967cb56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_763971c7-ef89-468b-89ac-3385922c6afb" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_526ee5d1-9a20-4da7-a1a7-42071967cb56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_412ceb56-06bb-4ffa-9755-b847a35c2a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_526ee5d1-9a20-4da7-a1a7-42071967cb56" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_412ceb56-06bb-4ffa-9755-b847a35c2a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_316a51bc-d621-4a52-97ab-d72369276fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_412ceb56-06bb-4ffa-9755-b847a35c2a9b" xlink:to="loc_us-gaap_ReceivableTypeDomain_316a51bc-d621-4a52-97ab-d72369276fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AccountsReceivableCollaboratorMember_14ca9b05-8a43-4f40-ad5e-c3158dff3727" xlink:href="ardx-20221231.xsd#ardx_AccountsReceivableCollaboratorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_316a51bc-d621-4a52-97ab-d72369276fc1" xlink:to="loc_ardx_AccountsReceivableCollaboratorMember_14ca9b05-8a43-4f40-ad5e-c3158dff3727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AccountsReceivableCommercialCustomerMember_3af7d142-cdd3-499d-b6c3-4f2725145390" xlink:href="ardx-20221231.xsd#ardx_AccountsReceivableCommercialCustomerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_316a51bc-d621-4a52-97ab-d72369276fc1" xlink:to="loc_ardx_AccountsReceivableCommercialCustomerMember_3af7d142-cdd3-499d-b6c3-4f2725145390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8354bcda-62a7-47d7-a48a-b8d0ac2f29dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_526ee5d1-9a20-4da7-a1a7-42071967cb56" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8354bcda-62a7-47d7-a48a-b8d0ac2f29dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_e635f0e9-2b4b-451b-aa79-020736be2e87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8354bcda-62a7-47d7-a48a-b8d0ac2f29dd" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_e635f0e9-2b4b-451b-aa79-020736be2e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesProductSalesNetDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#SummaryofSignificantAccountingPoliciesProductSalesNetDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesProductSalesNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_617b532e-dcfd-4e07-9240-ea351b2b84ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_dd5c0419-e494-426d-ba8a-b0131e408995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_201c9e88-7a5d-4ab0-91a8-c641d6a7901d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd5c0419-e494-426d-ba8a-b0131e408995" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_201c9e88-7a5d-4ab0-91a8-c641d6a7901d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_053edd1b-c166-47c0-a2b7-da6a3b2634af" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_201c9e88-7a5d-4ab0-91a8-c641d6a7901d" xlink:to="loc_srt_CounterpartyNameAxis_053edd1b-c166-47c0-a2b7-da6a3b2634af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a4d8e7b1-0652-4bcc-8b36-0bc0674c62c8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_053edd1b-c166-47c0-a2b7-da6a3b2634af" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a4d8e7b1-0652-4bcc-8b36-0bc0674c62c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AstrazenecaMember_2d6357ef-3baa-4c5a-8ea6-e5b2f497ef91" xlink:href="ardx-20221231.xsd#ardx_AstrazenecaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a4d8e7b1-0652-4bcc-8b36-0bc0674c62c8" xlink:to="loc_ardx_AstrazenecaMember_2d6357ef-3baa-4c5a-8ea6-e5b2f497ef91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3bc8d87d-aab9-4bb7-99da-f417c257716c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_201c9e88-7a5d-4ab0-91a8-c641d6a7901d" xlink:to="loc_srt_RangeAxis_3bc8d87d-aab9-4bb7-99da-f417c257716c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_33a29281-059b-43cd-8401-f358d504fd00" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3bc8d87d-aab9-4bb7-99da-f417c257716c" xlink:to="loc_srt_RangeMember_33a29281-059b-43cd-8401-f358d504fd00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_05618426-b5ce-48ed-bc38-59a75cc43cfa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_33a29281-059b-43cd-8401-f358d504fd00" xlink:to="loc_srt_MinimumMember_05618426-b5ce-48ed-bc38-59a75cc43cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8ecafed1-48f7-489b-8461-8b8bfbf3dee1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_33a29281-059b-43cd-8401-f358d504fd00" xlink:to="loc_srt_MaximumMember_8ecafed1-48f7-489b-8461-8b8bfbf3dee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5e9f5f6d-140f-4c1e-ac2e-9b87ebedd593" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_201c9e88-7a5d-4ab0-91a8-c641d6a7901d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5e9f5f6d-140f-4c1e-ac2e-9b87ebedd593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76a7ba8c-02d0-44d3-a6dc-7f4385836252" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5e9f5f6d-140f-4c1e-ac2e-9b87ebedd593" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76a7ba8c-02d0-44d3-a6dc-7f4385836252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AstraZenecaTerminationAgreementMember_9f98da45-e29d-4b75-8bd6-7ea7ad3211a5" xlink:href="ardx-20221231.xsd#ardx_AstraZenecaTerminationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76a7ba8c-02d0-44d3-a6dc-7f4385836252" xlink:to="loc_ardx_AstraZenecaTerminationAgreementMember_9f98da45-e29d-4b75-8bd6-7ea7ad3211a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f0d64bcb-3325-4583-b9ca-e751eefd00fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_201c9e88-7a5d-4ab0-91a8-c641d6a7901d" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f0d64bcb-3325-4583-b9ca-e751eefd00fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_670a8e6c-9dd5-423d-b519-64597020fa3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f0d64bcb-3325-4583-b9ca-e751eefd00fa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_670a8e6c-9dd5-423d-b519-64597020fa3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_7359899d-a55b-4249-a33e-3c2660159ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f0d64bcb-3325-4583-b9ca-e751eefd00fa" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_7359899d-a55b-4249-a33e-3c2660159ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_RevenueGeneralPaymentTerms_fa513bdb-8624-4b28-98e5-2db7759a7d16" xlink:href="ardx-20221231.xsd#ardx_RevenueGeneralPaymentTerms"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f0d64bcb-3325-4583-b9ca-e751eefd00fa" xlink:to="loc_ardx_RevenueGeneralPaymentTerms_fa513bdb-8624-4b28-98e5-2db7759a7d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PercentageOfRoyaltyRevenue_4444674a-ed06-4950-a848-eefa2d3b3a0f" xlink:href="ardx-20221231.xsd#ardx_PercentageOfRoyaltyRevenue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f0d64bcb-3325-4583-b9ca-e751eefd00fa" xlink:to="loc_ardx_PercentageOfRoyaltyRevenue_4444674a-ed06-4950-a848-eefa2d3b3a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PercentageOfNonRoyaltyRevenue_31bba6ca-20dc-4c4d-bca3-f5936fee9cab" xlink:href="ardx-20221231.xsd#ardx_PercentageOfNonRoyaltyRevenue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f0d64bcb-3325-4583-b9ca-e751eefd00fa" xlink:to="loc_ardx_PercentageOfNonRoyaltyRevenue_31bba6ca-20dc-4c4d-bca3-f5936fee9cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_cf383755-f3ee-4095-9241-bb34ee8bdd1c" xlink:href="ardx-20221231.xsd#ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f0d64bcb-3325-4583-b9ca-e751eefd00fa" xlink:to="loc_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_cf383755-f3ee-4095-9241-bb34ee8bdd1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CostOfRevenueAggregateAmountRecognized_530f3c64-b6f6-4d93-a55e-b67d63ca992e" xlink:href="ardx-20221231.xsd#ardx_CostOfRevenueAggregateAmountRecognized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f0d64bcb-3325-4583-b9ca-e751eefd00fa" xlink:to="loc_ardx_CostOfRevenueAggregateAmountRecognized_530f3c64-b6f6-4d93-a55e-b67d63ca992e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_fa5c499c-729c-4585-871c-ef20c9d24511" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c45cf9dc-1050-4b64-b413-52c892ee7c86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_fa5c499c-729c-4585-871c-ef20c9d24511" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c45cf9dc-1050-4b64-b413-52c892ee7c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_bcdcaaba-c3fb-4873-8b3e-cbda66158881" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c45cf9dc-1050-4b64-b413-52c892ee7c86" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_bcdcaaba-c3fb-4873-8b3e-cbda66158881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ed9dc261-93eb-4319-9bc5-172664e4a3e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_bcdcaaba-c3fb-4873-8b3e-cbda66158881" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ed9dc261-93eb-4319-9bc5-172664e4a3e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_6f2b5655-5dbf-409e-b281-e05eebc9ca8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ed9dc261-93eb-4319-9bc5-172664e4a3e4" xlink:to="loc_us-gaap_CashMember_6f2b5655-5dbf-409e-b281-e05eebc9ca8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_e6c1790f-b470-4e58-83c3-7490b95c1e49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ed9dc261-93eb-4319-9bc5-172664e4a3e4" xlink:to="loc_us-gaap_MoneyMarketFundsMember_e6c1790f-b470-4e58-83c3-7490b95c1e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_91b6df5c-71d9-4404-996e-62dea127bd15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ed9dc261-93eb-4319-9bc5-172664e4a3e4" xlink:to="loc_us-gaap_CommercialPaperMember_91b6df5c-71d9-4404-996e-62dea127bd15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CorporateBondsMember_a765aac7-07bb-4c3c-b287-b3a65e43d1f8" xlink:href="ardx-20221231.xsd#ardx_CorporateBondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ed9dc261-93eb-4319-9bc5-172664e4a3e4" xlink:to="loc_ardx_CorporateBondsMember_a765aac7-07bb-4c3c-b287-b3a65e43d1f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_898f96e6-07ee-4cd0-ab83-b9d5e71cf68f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c45cf9dc-1050-4b64-b413-52c892ee7c86" xlink:to="loc_us-gaap_FinancialInstrumentAxis_898f96e6-07ee-4cd0-ab83-b9d5e71cf68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eef6a71b-7246-4152-8bd7-643619f71ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_898f96e6-07ee-4cd0-ab83-b9d5e71cf68f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eef6a71b-7246-4152-8bd7-643619f71ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_a0919206-0ab4-434d-94d2-aa6abc1ed1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eef6a71b-7246-4152-8bd7-643619f71ce8" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_a0919206-0ab4-434d-94d2-aa6abc1ed1f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_5397f66f-3a0f-4ea4-ad6a-2a5d3f954f20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eef6a71b-7246-4152-8bd7-643619f71ce8" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_5397f66f-3a0f-4ea4-ad6a-2a5d3f954f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_d4a6e79e-41a3-4bd7-8227-a810eea1bf2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eef6a71b-7246-4152-8bd7-643619f71ce8" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_d4a6e79e-41a3-4bd7-8227-a810eea1bf2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_410c42a7-870e-44dc-9350-a2a4cc699cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eef6a71b-7246-4152-8bd7-643619f71ce8" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_410c42a7-870e-44dc-9350-a2a4cc699cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e95773ec-5ff5-4947-bab6-70003b04f7dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c45cf9dc-1050-4b64-b413-52c892ee7c86" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e95773ec-5ff5-4947-bab6-70003b04f7dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_00aa799e-aaee-45dd-a111-08bfc57ea7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e95773ec-5ff5-4947-bab6-70003b04f7dc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_00aa799e-aaee-45dd-a111-08bfc57ea7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d74d43b0-6391-4c62-b5af-ad6687e18a71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_00aa799e-aaee-45dd-a111-08bfc57ea7dd" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d74d43b0-6391-4c62-b5af-ad6687e18a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_991f6a3f-b865-4d88-a85c-f42d3eb207d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e95773ec-5ff5-4947-bab6-70003b04f7dc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_991f6a3f-b865-4d88-a85c-f42d3eb207d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fbdd5a6c-ef3f-4a21-8f34-af62101d01ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_991f6a3f-b865-4d88-a85c-f42d3eb207d9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fbdd5a6c-ef3f-4a21-8f34-af62101d01ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8c8696e8-c5ee-458d-b142-c746c5cd580c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_991f6a3f-b865-4d88-a85c-f42d3eb207d9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8c8696e8-c5ee-458d-b142-c746c5cd580c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7f6f48ca-68f0-425c-a161-27f8e099a4be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_991f6a3f-b865-4d88-a85c-f42d3eb207d9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7f6f48ca-68f0-425c-a161-27f8e099a4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ce2d5b9e-00f5-4334-b6ed-3f8f0c7bf051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_991f6a3f-b865-4d88-a85c-f42d3eb207d9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ce2d5b9e-00f5-4334-b6ed-3f8f0c7bf051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_InvestmentsAndCashAmortizedCost_4b6b11b4-08dd-4f9e-9db5-063a16938904" xlink:href="ardx-20221231.xsd#ardx_InvestmentsAndCashAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e95773ec-5ff5-4947-bab6-70003b04f7dc" xlink:to="loc_ardx_InvestmentsAndCashAmortizedCost_4b6b11b4-08dd-4f9e-9db5-063a16938904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains_8fb752cf-c34b-4be2-a6ff-d625d41b0572" xlink:href="ardx-20221231.xsd#ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e95773ec-5ff5-4947-bab6-70003b04f7dc" xlink:to="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains_8fb752cf-c34b-4be2-a6ff-d625d41b0572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses_3224b89d-7f3d-4047-a4b8-64dddb8a1bb5" xlink:href="ardx-20221231.xsd#ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e95773ec-5ff5-4947-bab6-70003b04f7dc" xlink:to="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses_3224b89d-7f3d-4047-a4b8-64dddb8a1bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_1ee52ede-87e1-4be5-93ca-586475fe6979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndCash"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e95773ec-5ff5-4947-bab6-70003b04f7dc" xlink:to="loc_us-gaap_InvestmentsAndCash_1ee52ede-87e1-4be5-93ca-586475fe6979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsNarrativeDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#CashCashEquivalentsandShortTermInvestmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_6b4a33f9-41d5-44e5-9659-4edf5064099d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_a7d35a8a-8ad5-48e7-8415-6b70e7107e45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_6b4a33f9-41d5-44e5-9659-4edf5064099d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_a7d35a8a-8ad5-48e7-8415-6b70e7107e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum_22df1edc-c02d-46f6-9641-5d3a950f0551" xlink:href="ardx-20221231.xsd#ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_a7d35a8a-8ad5-48e7-8415-6b70e7107e45" xlink:to="loc_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum_22df1edc-c02d-46f6-9641-5d3a950f0551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_bd56cefa-2391-46d4-8358-56e31374845c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_a7d35a8a-8ad5-48e7-8415-6b70e7107e45" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_bd56cefa-2391-46d4-8358-56e31374845c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_acbf22ac-3027-418c-ad66-c32b988f7203" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6ddbf0e5-8b56-48bc-b42b-64bfde3e348e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_acbf22ac-3027-418c-ad66-c32b988f7203" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6ddbf0e5-8b56-48bc-b42b-64bfde3e348e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0d90397e-097f-441a-9b99-1476169b8caf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6ddbf0e5-8b56-48bc-b42b-64bfde3e348e" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0d90397e-097f-441a-9b99-1476169b8caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e5e6b756-49fd-493d-812c-da46b1cf73fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0d90397e-097f-441a-9b99-1476169b8caf" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e5e6b756-49fd-493d-812c-da46b1cf73fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_38f96ce6-a488-48d5-b921-479278d6728e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e5e6b756-49fd-493d-812c-da46b1cf73fa" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_38f96ce6-a488-48d5-b921-479278d6728e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c5d9c6cc-57a6-4268-bab8-b18ad9c9c9af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6ddbf0e5-8b56-48bc-b42b-64bfde3e348e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c5d9c6cc-57a6-4268-bab8-b18ad9c9c9af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f0118d97-a814-40af-af58-f58d5754b679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c5d9c6cc-57a6-4268-bab8-b18ad9c9c9af" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f0118d97-a814-40af-af58-f58d5754b679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_429839fa-b262-4144-8b92-0f19fcfd6ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f0118d97-a814-40af-af58-f58d5754b679" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_429839fa-b262-4144-8b92-0f19fcfd6ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_31d8e350-50ce-4cea-912c-7c73c4e9918e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f0118d97-a814-40af-af58-f58d5754b679" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_31d8e350-50ce-4cea-912c-7c73c4e9918e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2cbeca36-36e3-447a-bdce-fefb2cd555a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f0118d97-a814-40af-af58-f58d5754b679" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2cbeca36-36e3-447a-bdce-fefb2cd555a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_4aa22267-c2d6-43a5-b510-dff96943f3d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6ddbf0e5-8b56-48bc-b42b-64bfde3e348e" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_4aa22267-c2d6-43a5-b510-dff96943f3d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_65ef96b0-759b-4225-b986-4152af2ddca4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_4aa22267-c2d6-43a5-b510-dff96943f3d7" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_65ef96b0-759b-4225-b986-4152af2ddca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_57bee55c-0310-400a-b13c-d02efc644ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_65ef96b0-759b-4225-b986-4152af2ddca4" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_57bee55c-0310-400a-b13c-d02efc644ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_b849591b-d807-4478-b378-2b9b690b890f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6ddbf0e5-8b56-48bc-b42b-64bfde3e348e" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_b849591b-d807-4478-b378-2b9b690b890f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_06ebbd81-db6b-43ea-9d94-cbac5b193577" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_b849591b-d807-4478-b378-2b9b690b890f" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_06ebbd81-db6b-43ea-9d94-cbac5b193577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_9f035aec-a876-4fa4-8bbe-a0e255636a61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_06ebbd81-db6b-43ea-9d94-cbac5b193577" xlink:to="loc_us-gaap_MoneyMarketFundsMember_9f035aec-a876-4fa4-8bbe-a0e255636a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_fc852a3e-6cdd-40a2-8b52-1d86282d3c69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_06ebbd81-db6b-43ea-9d94-cbac5b193577" xlink:to="loc_us-gaap_CommercialPaperMember_fc852a3e-6cdd-40a2-8b52-1d86282d3c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_d289e19c-6d63-4638-9f57-9b28e27d879e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_06ebbd81-db6b-43ea-9d94-cbac5b193577" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_d289e19c-6d63-4638-9f57-9b28e27d879e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_b156c8ee-b8c1-415f-bf9c-fc85ce6b4a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_06ebbd81-db6b-43ea-9d94-cbac5b193577" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_b156c8ee-b8c1-415f-bf9c-fc85ce6b4a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_54c84b7d-d9f5-4b8e-9487-bb499e585e66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_06ebbd81-db6b-43ea-9d94-cbac5b193577" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_54c84b7d-d9f5-4b8e-9487-bb499e585e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_010043cb-e043-4492-8264-693f9dfe53cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6ddbf0e5-8b56-48bc-b42b-64bfde3e348e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_010043cb-e043-4492-8264-693f9dfe53cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_0cf9d423-a155-4e60-bac4-578170af875a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_010043cb-e043-4492-8264-693f9dfe53cc" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_0cf9d423-a155-4e60-bac4-578170af875a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_d0c0db04-b1a9-49bb-82ba-4bf7ac419b73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0cf9d423-a155-4e60-bac4-578170af875a" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_d0c0db04-b1a9-49bb-82ba-4bf7ac419b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_41e8014e-4653-4b5e-9cb4-957386853ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_010043cb-e043-4492-8264-693f9dfe53cc" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_41e8014e-4653-4b5e-9cb4-957386853ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_7121bd52-67d8-4aef-bac3-e94ef168c6b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_41e8014e-4653-4b5e-9cb4-957386853ac6" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_7121bd52-67d8-4aef-bac3-e94ef168c6b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d81ac9c8-b7ca-4351-91ec-f331807fc8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_ffb4ea18-b1d3-4bab-8ef4-ba9ce08da939" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d81ac9c8-b7ca-4351-91ec-f331807fc8fb" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_ffb4ea18-b1d3-4bab-8ef4-ba9ce08da939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/InventoryScheduleDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#InventoryScheduleDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/InventoryScheduleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_8a19406d-745f-4d9c-93bb-d4fef93fb6e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_ac65c59d-214a-48f0-9e3e-a2bc447c227c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8a19406d-745f-4d9c-93bb-d4fef93fb6e1" xlink:to="loc_us-gaap_InventoryRawMaterials_ac65c59d-214a-48f0-9e3e-a2bc447c227c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_7d387c11-7774-49c6-b708-e72d3ba16644" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8a19406d-745f-4d9c-93bb-d4fef93fb6e1" xlink:to="loc_us-gaap_InventoryWorkInProcess_7d387c11-7774-49c6-b708-e72d3ba16644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_e3091385-3afb-466d-9b8e-be2d74bea5f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8a19406d-745f-4d9c-93bb-d4fef93fb6e1" xlink:to="loc_us-gaap_InventoryFinishedGoods_e3091385-3afb-466d-9b8e-be2d74bea5f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_e6ce149f-ca89-4ad6-9919-0063f4c8f33b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8a19406d-745f-4d9c-93bb-d4fef93fb6e1" xlink:to="loc_us-gaap_InventoryGross_e6ce149f-ca89-4ad6-9919-0063f4c8f33b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_46c5a5e6-cc27-4fe0-b1e3-24740823eac1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8a19406d-745f-4d9c-93bb-d4fef93fb6e1" xlink:to="loc_us-gaap_InventoryNoncurrent_46c5a5e6-cc27-4fe0-b1e3-24740823eac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_cc9e3037-c892-4c2d-ba53-8b3c5873d5cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8a19406d-745f-4d9c-93bb-d4fef93fb6e1" xlink:to="loc_us-gaap_InventoryNet_cc9e3037-c892-4c2d-ba53-8b3c5873d5cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/InventoryNarrativeDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#InventoryNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/InventoryNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_ad246595-f4df-405c-9662-e8a80a9ae1e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PrepaidCommercialManufacturingCurrent_c1fce502-9d19-4bd0-96f3-1b3680da4e86" xlink:href="ardx-20221231.xsd#ardx_PrepaidCommercialManufacturingCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_ad246595-f4df-405c-9662-e8a80a9ae1e1" xlink:to="loc_ardx_PrepaidCommercialManufacturingCurrent_c1fce502-9d19-4bd0-96f3-1b3680da4e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#ProductRevenueNetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_08bf402f-071f-4c79-9516-8a29f5349232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b247828b-484c-4f10-a9ea-c408dfa0d78c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_08bf402f-071f-4c79-9516-8a29f5349232" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b247828b-484c-4f10-a9ea-c408dfa0d78c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4d6059a9-2651-43b8-9110-b08b8806d91d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b247828b-484c-4f10-a9ea-c408dfa0d78c" xlink:to="loc_srt_ProductOrServiceAxis_4d6059a9-2651-43b8-9110-b08b8806d91d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c682e7d3-3e23-4e02-b56d-011745fd0b1d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4d6059a9-2651-43b8-9110-b08b8806d91d" xlink:to="loc_srt_ProductsAndServicesDomain_c682e7d3-3e23-4e02-b56d-011745fd0b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ProductIBSRELAMember_64fcf76c-1d8e-4f78-af7a-340c7ac94cff" xlink:href="ardx-20221231.xsd#ardx_ProductIBSRELAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c682e7d3-3e23-4e02-b56d-011745fd0b1d" xlink:to="loc_ardx_ProductIBSRELAMember_64fcf76c-1d8e-4f78-af7a-340c7ac94cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_bdd0fa00-d3a3-47c7-8b3e-cbb68a850589" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c682e7d3-3e23-4e02-b56d-011745fd0b1d" xlink:to="loc_us-gaap_ProductMember_bdd0fa00-d3a3-47c7-8b3e-cbb68a850589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_070028b0-082e-41f1-8fcb-b05ad26cfa70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b247828b-484c-4f10-a9ea-c408dfa0d78c" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_070028b0-082e-41f1-8fcb-b05ad26cfa70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_998e1898-0546-45c9-ae79-981e187ebcca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_070028b0-082e-41f1-8fcb-b05ad26cfa70" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_998e1898-0546-45c9-ae79-981e187ebcca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueProductLineMember_5eaaecbd-7fde-40dd-8604-04957e87325e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_998e1898-0546-45c9-ae79-981e187ebcca" xlink:to="loc_us-gaap_SalesRevenueProductLineMember_5eaaecbd-7fde-40dd-8604-04957e87325e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_6ad3fbd6-c447-4ad7-a2d3-9fa96c27767f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b247828b-484c-4f10-a9ea-c408dfa0d78c" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_6ad3fbd6-c447-4ad7-a2d3-9fa96c27767f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_014b503e-5c3d-4053-8e95-0b5c447d7efb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_6ad3fbd6-c447-4ad7-a2d3-9fa96c27767f" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_014b503e-5c3d-4053-8e95-0b5c447d7efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_3bad6929-0529-4bd9-a9fe-6951700de37d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_014b503e-5c3d-4053-8e95-0b5c447d7efb" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_3bad6929-0529-4bd9-a9fe-6951700de37d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_b24515eb-7f43-4d6b-99e1-b747d2c68ee0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b247828b-484c-4f10-a9ea-c408dfa0d78c" xlink:to="loc_srt_MajorCustomersAxis_b24515eb-7f43-4d6b-99e1-b747d2c68ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_4a541c2e-dfeb-499e-be87-7dc17bfab2bd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_b24515eb-7f43-4d6b-99e1-b747d2c68ee0" xlink:to="loc_srt_NameOfMajorCustomerDomain_4a541c2e-dfeb-499e-be87-7dc17bfab2bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AmerisourceBergenDrugCorporationMember_af739f30-ebac-4ebc-b2a0-44c513a1c127" xlink:href="ardx-20221231.xsd#ardx_AmerisourceBergenDrugCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_4a541c2e-dfeb-499e-be87-7dc17bfab2bd" xlink:to="loc_ardx_AmerisourceBergenDrugCorporationMember_af739f30-ebac-4ebc-b2a0-44c513a1c127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CardinalHealthMember_56492d1c-2581-45d6-bda6-90383ae3856a" xlink:href="ardx-20221231.xsd#ardx_CardinalHealthMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_4a541c2e-dfeb-499e-be87-7dc17bfab2bd" xlink:to="loc_ardx_CardinalHealthMember_56492d1c-2581-45d6-bda6-90383ae3856a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_McKessonCorporationMember_ee907502-4b9a-4b8c-b6f0-1331e53279f0" xlink:href="ardx-20221231.xsd#ardx_McKessonCorporationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_4a541c2e-dfeb-499e-be87-7dc17bfab2bd" xlink:to="loc_ardx_McKessonCorporationMember_ee907502-4b9a-4b8c-b6f0-1331e53279f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_eeafd150-d909-4089-8543-7e3133eface0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b247828b-484c-4f10-a9ea-c408dfa0d78c" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_eeafd150-d909-4089-8543-7e3133eface0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0f6a3081-8eba-422a-90c2-6a80b69e91ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_eeafd150-d909-4089-8543-7e3133eface0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0f6a3081-8eba-422a-90c2-6a80b69e91ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_bb75afeb-f71f-471e-a93b-5522e9b9d0b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_eeafd150-d909-4089-8543-7e3133eface0" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_bb75afeb-f71f-471e-a93b-5522e9b9d0b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerProductSalesGrossToNetAccruals_27a05eb2-df8a-40ef-a58c-a772a78c6039" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerProductSalesGrossToNetAccruals"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_eeafd150-d909-4089-8543-7e3133eface0" xlink:to="loc_ardx_ContractWithCustomerProductSalesGrossToNetAccruals_27a05eb2-df8a-40ef-a58c-a772a78c6039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#ProductRevenueNetGrosstoNetSalesAccrualsDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e606dddb-295e-422d-8118-17e81c850f17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_28472aab-70bd-468d-84b6-98fdafb06e40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e606dddb-295e-422d-8118-17e81c850f17" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_28472aab-70bd-468d-84b6-98fdafb06e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis_b04c7035-40bc-4139-89d8-62420282d828" xlink:href="ardx-20221231.xsd#ardx_GrossToNetSalesAccrualAndReserveClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_28472aab-70bd-468d-84b6-98fdafb06e40" xlink:to="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis_b04c7035-40bc-4139-89d8-62420282d828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_5e35b3c2-c590-4a75-8f09-ad26761cff9b" xlink:href="ardx-20221231.xsd#ardx_GrossToNetSalesAccrualAndReserveClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis_b04c7035-40bc-4139-89d8-62420282d828" xlink:to="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_5e35b3c2-c590-4a75-8f09-ad26761cff9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerDiscountsAndChargebacksMember_6ba4a612-9313-4421-8737-bb29d6561bea" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerDiscountsAndChargebacksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_5e35b3c2-c590-4a75-8f09-ad26761cff9b" xlink:to="loc_ardx_ContractWithCustomerDiscountsAndChargebacksMember_6ba4a612-9313-4421-8737-bb29d6561bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerRebatesWholesalerAndGPOFeesMember_51b6cb35-c317-49a0-b69b-9a41eacaa90c" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerRebatesWholesalerAndGPOFeesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_5e35b3c2-c590-4a75-8f09-ad26761cff9b" xlink:to="loc_ardx_ContractWithCustomerRebatesWholesalerAndGPOFeesMember_51b6cb35-c317-49a0-b69b-9a41eacaa90c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerCopayAndReturnsMember_cdf91a9f-69b3-4ca6-89ac-664f6d00cd93" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerCopayAndReturnsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_5e35b3c2-c590-4a75-8f09-ad26761cff9b" xlink:to="loc_ardx_ContractWithCustomerCopayAndReturnsMember_cdf91a9f-69b3-4ca6-89ac-664f6d00cd93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_01d044ff-d857-4455-8f93-fa7819f1e69a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_28472aab-70bd-468d-84b6-98fdafb06e40" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_01d044ff-d857-4455-8f93-fa7819f1e69a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_994ce6b5-774f-4dfb-9cf1-b7f7d4cc091b" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_01d044ff-d857-4455-8f93-fa7819f1e69a" xlink:to="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_994ce6b5-774f-4dfb-9cf1-b7f7d4cc091b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesAccruals_c5093e67-f1d7-4f6e-b096-5585ebca5f45" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerGrossToNetSalesAccruals"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_994ce6b5-774f-4dfb-9cf1-b7f7d4cc091b" xlink:to="loc_ardx_ContractWithCustomerGrossToNetSalesAccruals_c5093e67-f1d7-4f6e-b096-5585ebca5f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod_d767bf8d-0a80-4f05-8b3b-b80dd2951168" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_994ce6b5-774f-4dfb-9cf1-b7f7d4cc091b" xlink:to="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod_d767bf8d-0a80-4f05-8b3b-b80dd2951168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued_b29c913d-623c-4fcc-8ce0-2c6e629da6e8" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_994ce6b5-774f-4dfb-9cf1-b7f7d4cc091b" xlink:to="loc_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued_b29c913d-623c-4fcc-8ce0-2c6e629da6e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesAccruals_78731271-7b09-4e94-97e2-66421afec68c" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerGrossToNetSalesAccruals"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_994ce6b5-774f-4dfb-9cf1-b7f7d4cc091b" xlink:to="loc_ardx_ContractWithCustomerGrossToNetSalesAccruals_78731271-7b09-4e94-97e2-66421afec68c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#CollaborationandLicensingAgreementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsAbstract_16d18d10-10fe-4b57-b5a2-3faa53c844ea" xlink:href="ardx-20221231.xsd#ardx_CollaborationAndLicensingAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1f7a92c-dc45-4a6c-9524-35148054b3c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_CollaborationAndLicensingAgreementsAbstract_16d18d10-10fe-4b57-b5a2-3faa53c844ea" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1f7a92c-dc45-4a6c-9524-35148054b3c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_54a98e64-fb76-45d5-b82a-22c5911672fa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1f7a92c-dc45-4a6c-9524-35148054b3c8" xlink:to="loc_srt_CounterpartyNameAxis_54a98e64-fb76-45d5-b82a-22c5911672fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3057b31-143a-4cf4-a748-d592d08c63f5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_54a98e64-fb76-45d5-b82a-22c5911672fa" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3057b31-143a-4cf4-a748-d592d08c63f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_KyowaKirinCo.LtdMember_4f0f1c18-8106-4eb2-bac1-5959e70be6ad" xlink:href="ardx-20221231.xsd#ardx_KyowaKirinCo.LtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3057b31-143a-4cf4-a748-d592d08c63f5" xlink:to="loc_ardx_KyowaKirinCo.LtdMember_4f0f1c18-8106-4eb2-bac1-5959e70be6ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember_1d08bb62-0621-465b-b30f-f043d80ba86e" xlink:href="ardx-20221231.xsd#ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3057b31-143a-4cf4-a748-d592d08c63f5" xlink:to="loc_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember_1d08bb62-0621-465b-b30f-f043d80ba86e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_KnightTherapeuticsIncMember_357068a0-3452-46ae-8c11-aef065d92175" xlink:href="ardx-20221231.xsd#ardx_KnightTherapeuticsIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3057b31-143a-4cf4-a748-d592d08c63f5" xlink:to="loc_ardx_KnightTherapeuticsIncMember_357068a0-3452-46ae-8c11-aef065d92175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AstrazenecaMember_c3d66f68-385f-4f2e-ade1-bdd3e7c25f84" xlink:href="ardx-20221231.xsd#ardx_AstrazenecaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3057b31-143a-4cf4-a748-d592d08c63f5" xlink:to="loc_ardx_AstrazenecaMember_c3d66f68-385f-4f2e-ade1-bdd3e7c25f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b21568ca-8139-4f5b-a3f6-345f2a559692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1f7a92c-dc45-4a6c-9524-35148054b3c8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b21568ca-8139-4f5b-a3f6-345f2a559692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_48c099d3-5f11-42b6-9c04-4bb502068ade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b21568ca-8139-4f5b-a3f6-345f2a559692" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_48c099d3-5f11-42b6-9c04-4bb502068ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ResearchCollaborationAndOptionAgreementMember_18cf112d-8fec-4723-89eb-a7ec63a9dab1" xlink:href="ardx-20221231.xsd#ardx_ResearchCollaborationAndOptionAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_48c099d3-5f11-42b6-9c04-4bb502068ade" xlink:to="loc_ardx_ResearchCollaborationAndOptionAgreementMember_18cf112d-8fec-4723-89eb-a7ec63a9dab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_8957eeac-776f-474a-ac57-d60f02c2ca53" xlink:href="ardx-20221231.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_48c099d3-5f11-42b6-9c04-4bb502068ade" xlink:to="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_8957eeac-776f-474a-ac57-d60f02c2ca53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember_8997f392-afac-407b-b7ad-d30dfd2a48ac" xlink:href="ardx-20221231.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_48c099d3-5f11-42b6-9c04-4bb502068ade" xlink:to="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember_8997f392-afac-407b-b7ad-d30dfd2a48ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember_16aec2f4-a5ad-4793-88c9-905eaf8fddd3" xlink:href="ardx-20221231.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_48c099d3-5f11-42b6-9c04-4bb502068ade" xlink:to="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember_16aec2f4-a5ad-4793-88c9-905eaf8fddd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AstraZenecaTerminationAgreementMember_710d7a28-3d19-44f7-914b-3f6563521a58" xlink:href="ardx-20221231.xsd#ardx_AstraZenecaTerminationAgreementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_48c099d3-5f11-42b6-9c04-4bb502068ade" xlink:to="loc_ardx_AstraZenecaTerminationAgreementMember_710d7a28-3d19-44f7-914b-3f6563521a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d2079138-8928-4a51-b465-26e5f2efff45" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1f7a92c-dc45-4a6c-9524-35148054b3c8" xlink:to="loc_srt_RangeAxis_d2079138-8928-4a51-b465-26e5f2efff45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9dd45925-6a8a-49e5-9615-69ccca627661" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d2079138-8928-4a51-b465-26e5f2efff45" xlink:to="loc_srt_RangeMember_9dd45925-6a8a-49e5-9615-69ccca627661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_40d48220-d752-4163-921f-533749ddfe6a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9dd45925-6a8a-49e5-9615-69ccca627661" xlink:to="loc_srt_MinimumMember_40d48220-d752-4163-921f-533749ddfe6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_20cf87b8-56d2-41b3-992d-44438e0c66d9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1f7a92c-dc45-4a6c-9524-35148054b3c8" xlink:to="loc_srt_ProductOrServiceAxis_20cf87b8-56d2-41b3-992d-44438e0c66d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_87acdd16-db40-4b43-8fbe-3b1cb66bb8b6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_20cf87b8-56d2-41b3-992d-44438e0c66d9" xlink:to="loc_srt_ProductsAndServicesDomain_87acdd16-db40-4b43-8fbe-3b1cb66bb8b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_63ae7f5e-4fd0-419e-a87f-e01a4c4fd179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_87acdd16-db40-4b43-8fbe-3b1cb66bb8b6" xlink:to="loc_us-gaap_LicenseMember_63ae7f5e-4fd0-419e-a87f-e01a4c4fd179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ProductSupplyRevenueMember_1c4a5246-5647-4e1d-bcc7-69f15006a9b1" xlink:href="ardx-20221231.xsd#ardx_ProductSupplyRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_87acdd16-db40-4b43-8fbe-3b1cb66bb8b6" xlink:to="loc_ardx_ProductSupplyRevenueMember_1c4a5246-5647-4e1d-bcc7-69f15006a9b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a1f7a92c-dc45-4a6c-9524-35148054b3c8" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_NumberOfSeparateCollaborativeAgreements_cf093b36-e000-49e6-9bfd-c26c9635018e" xlink:href="ardx-20221231.xsd#ardx_NumberOfSeparateCollaborativeAgreements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:to="loc_ardx_NumberOfSeparateCollaborativeAgreements_cf093b36-e000-49e6-9bfd-c26c9635018e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees_abbeed16-a0f5-4c0f-b4de-8c0ad58248a7" xlink:href="ardx-20221231.xsd#ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:to="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees_abbeed16-a0f5-4c0f-b4de-8c0ad58248a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment_37c89bd8-fc3d-4b28-aa54-c6108f32093b" xlink:href="ardx-20221231.xsd#ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:to="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment_37c89bd8-fc3d-4b28-aa54-c6108f32093b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermOfPaymentOfLicenseFeeFirstInstallment_e099868b-43a7-468f-98ee-9f132313c9cc" xlink:href="ardx-20221231.xsd#ardx_TermOfPaymentOfLicenseFeeFirstInstallment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:to="loc_ardx_TermOfPaymentOfLicenseFeeFirstInstallment_e099868b-43a7-468f-98ee-9f132313c9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment_488187dd-59a6-45e9-a38d-163533c11c44" xlink:href="ardx-20221231.xsd#ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:to="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment_488187dd-59a6-45e9-a38d-163533c11c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermOfAgreement_d9143395-4f30-4ade-bdc6-ba0cb1101d8d" xlink:href="ardx-20221231.xsd#ardx_TermOfAgreement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:to="loc_ardx_TermOfAgreement_d9143395-4f30-4ade-bdc6-ba0cb1101d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsNumberOfAmendments_55f09cdb-c9b0-495a-af47-1d54767efe57" xlink:href="ardx-20221231.xsd#ardx_CollaborationAndLicensingAgreementsNumberOfAmendments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:to="loc_ardx_CollaborationAndLicensingAgreementsNumberOfAmendments_55f09cdb-c9b0-495a-af47-1d54767efe57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cfc1e05b-e6d5-4730-8273-2ed7f60cfebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cfc1e05b-e6d5-4730-8273-2ed7f60cfebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4c3903be-3918-40d0-8781-5038552e99ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4c3903be-3918-40d0-8781-5038552e99ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialDevelopmentMilestones_b74d2d9f-221c-4ca8-9c29-39017d6d6136" xlink:href="ardx-20221231.xsd#ardx_CollaborativeArrangementPotentialDevelopmentMilestones"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:to="loc_ardx_CollaborativeArrangementPotentialDevelopmentMilestones_b74d2d9f-221c-4ca8-9c29-39017d6d6136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialCommercializationMilestones_53465d49-764f-4e1a-99eb-18ba39109349" xlink:href="ardx-20221231.xsd#ardx_CollaborativeArrangementPotentialCommercializationMilestones"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:to="loc_ardx_CollaborativeArrangementPotentialCommercializationMilestones_53465d49-764f-4e1a-99eb-18ba39109349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate_22676d3c-037c-490f-9720-0bf61d3d0c39" xlink:href="ardx-20221231.xsd#ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:to="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate_22676d3c-037c-490f-9720-0bf61d3d0c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches_2b7b87c3-1de3-48f5-b0c5-d9fe286f0a7c" xlink:href="ardx-20221231.xsd#ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:to="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches_2b7b87c3-1de3-48f5-b0c5-d9fe286f0a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_RevenueRemainingPerformanceObligationVariableConsiderationAmount_75572e06-f00e-416a-980e-5127035ed597" xlink:href="ardx-20221231.xsd#ardx_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:to="loc_ardx_RevenueRemainingPerformanceObligationVariableConsiderationAmount_75572e06-f00e-416a-980e-5127035ed597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived_09544d01-42a0-478e-b313-8c85a1e261ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLicenseFeesReceived"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:to="loc_us-gaap_ProceedsFromLicenseFeesReceived_09544d01-42a0-478e-b313-8c85a1e261ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones_8807f334-0ee8-4542-a4c5-63af43722efc" xlink:href="ardx-20221231.xsd#ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:to="loc_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones_8807f334-0ee8-4542-a4c5-63af43722efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ThresholdPercentageOfSalesForTieredRoyalties_acdc1dde-cfec-4fd4-82dd-6007c8083a09" xlink:href="ardx-20221231.xsd#ardx_ThresholdPercentageOfSalesForTieredRoyalties"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:to="loc_ardx_ThresholdPercentageOfSalesForTieredRoyalties_acdc1dde-cfec-4fd4-82dd-6007c8083a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PercentageOfRoyaltyRevenue_a53ecf24-dd69-4290-9c9b-d915aa2b7d4a" xlink:href="ardx-20221231.xsd#ardx_PercentageOfRoyaltyRevenue"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:to="loc_ardx_PercentageOfRoyaltyRevenue_a53ecf24-dd69-4290-9c9b-d915aa2b7d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PercentageOfNonRoyaltyRevenue_9782294c-9b36-41af-93af-43ec0282b593" xlink:href="ardx-20221231.xsd#ardx_PercentageOfNonRoyaltyRevenue"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:to="loc_ardx_PercentageOfNonRoyaltyRevenue_9782294c-9b36-41af-93af-43ec0282b593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_9900b028-56f5-44f0-bbcc-7229a3cf6395" xlink:href="ardx-20221231.xsd#ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:to="loc_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_9900b028-56f5-44f0-bbcc-7229a3cf6395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_1bc9aa15-ca5d-4cc5-9941-126ce2d73efa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0c35a723-abe5-4756-b03f-e620ecb573fc" xlink:to="loc_us-gaap_CostOfRevenue_1bc9aa15-ca5d-4cc5-9941-126ce2d73efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#CollaborationandLicensingAgreementsDeferredRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsAbstract_cc6dab4d-a5ae-421f-988d-16cdebadde53" xlink:href="ardx-20221231.xsd#ardx_CollaborationAndLicensingAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_81e406b5-bb34-4c3b-8800-a0e14f00498a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_CollaborationAndLicensingAgreementsAbstract_cc6dab4d-a5ae-421f-988d-16cdebadde53" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_81e406b5-bb34-4c3b-8800-a0e14f00498a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_70236168-9f87-478e-a99c-56ba2cc37aef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_81e406b5-bb34-4c3b-8800-a0e14f00498a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_70236168-9f87-478e-a99c-56ba2cc37aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_acedbac2-0aea-41b8-8473-11e8392188f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_70236168-9f87-478e-a99c-56ba2cc37aef" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_acedbac2-0aea-41b8-8473-11e8392188f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ResearchCollaborationAndOptionAgreementMember_80d9b80d-417a-4512-afbb-db387be4cdd9" xlink:href="ardx-20221231.xsd#ardx_ResearchCollaborationAndOptionAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_acedbac2-0aea-41b8-8473-11e8392188f3" xlink:to="loc_ardx_ResearchCollaborationAndOptionAgreementMember_80d9b80d-417a-4512-afbb-db387be4cdd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_16c6af70-c48b-4620-9bb0-bc68fc2e5ad9" xlink:href="ardx-20221231.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_acedbac2-0aea-41b8-8473-11e8392188f3" xlink:to="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_16c6af70-c48b-4620-9bb0-bc68fc2e5ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_532ec4e3-83aa-461f-89fa-8aff7e5f098c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_81e406b5-bb34-4c3b-8800-a0e14f00498a" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_532ec4e3-83aa-461f-89fa-8aff7e5f098c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_d891b463-1311-417d-8290-6541967bf8ea" xlink:href="ardx-20221231.xsd#ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_532ec4e3-83aa-461f-89fa-8aff7e5f098c" xlink:to="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_d891b463-1311-417d-8290-6541967bf8ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a996c261-c61c-4569-9238-cd8cc7e7dc17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_d891b463-1311-417d-8290-6541967bf8ea" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a996c261-c61c-4569-9238-cd8cc7e7dc17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenueDuringThePeriod_92eed5e0-77b4-471e-854b-724e863624c9" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenueDuringThePeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_d891b463-1311-417d-8290-6541967bf8ea" xlink:to="loc_ardx_ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenueDuringThePeriod_92eed5e0-77b4-471e-854b-724e863624c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths_f70ff0e6-ed16-48f2-87d0-a4da6d4e62d4" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_d891b463-1311-417d-8290-6541967bf8ea" xlink:to="loc_ardx_ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths_f70ff0e6-ed16-48f2-87d0-a4da6d4e62d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived_ae82bfbe-29e4-4fb9-aaba-71bd27dd5907" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_d891b463-1311-417d-8290-6541967bf8ea" xlink:to="loc_ardx_ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived_ae82bfbe-29e4-4fb9-aaba-71bd27dd5907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived_130b6f41-4e21-4f77-8cf6-e5d2f64633c2" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_d891b463-1311-417d-8290-6541967bf8ea" xlink:to="loc_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived_130b6f41-4e21-4f77-8cf6-e5d2f64633c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cdb2e25e-390f-4c28-aa04-685910ff7045" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_d891b463-1311-417d-8290-6541967bf8ea" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cdb2e25e-390f-4c28-aa04-685910ff7045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_aaf82a02-ca24-407a-b07c-34b9c838fb8f" xlink:href="ardx-20221231.xsd#ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_532ec4e3-83aa-461f-89fa-8aff7e5f098c" xlink:to="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_aaf82a02-ca24-407a-b07c-34b9c838fb8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f424f1db-f936-41e3-9447-19c222bcfa3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_aaf82a02-ca24-407a-b07c-34b9c838fb8f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f424f1db-f936-41e3-9447-19c222bcfa3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityIncreaseForCashReceived_2fd58ab2-77bb-4c7f-acb2-3639098fdb7a" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerLiabilityIncreaseForCashReceived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_aaf82a02-ca24-407a-b07c-34b9c838fb8f" xlink:to="loc_ardx_ContractWithCustomerLiabilityIncreaseForCashReceived_2fd58ab2-77bb-4c7f-acb2-3639098fdb7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityIncreasesToAmountsInvoicedButCashNotReceived_a4e0463a-2776-40c5-a59d-0da3c5b2c104" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerLiabilityIncreasesToAmountsInvoicedButCashNotReceived"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_aaf82a02-ca24-407a-b07c-34b9c838fb8f" xlink:to="loc_ardx_ContractWithCustomerLiabilityIncreasesToAmountsInvoicedButCashNotReceived_a4e0463a-2776-40c5-a59d-0da3c5b2c104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded_0b4bac31-8bd9-47d8-90e9-f6cf3ae40e7c" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_aaf82a02-ca24-407a-b07c-34b9c838fb8f" xlink:to="loc_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded_0b4bac31-8bd9-47d8-90e9-f6cf3ae40e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths_ae827b5f-228e-452c-a4dc-2b394d7a4ba7" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_aaf82a02-ca24-407a-b07c-34b9c838fb8f" xlink:to="loc_ardx_ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths_ae827b5f-228e-452c-a4dc-2b394d7a4ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c3fd408d-fb15-4103-8735-e2ce64791261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_aaf82a02-ca24-407a-b07c-34b9c838fb8f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c3fd408d-fb15-4103-8735-e2ce64791261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvanceRoyaltiesAbstract_0c30385a-f543-4d1c-83e1-b4bb115bb6e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvanceRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_46b8ed4b-59c6-4067-abd0-413682fef906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdvanceRoyaltiesAbstract_0c30385a-f543-4d1c-83e1-b4bb115bb6e4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_46b8ed4b-59c6-4067-abd0-413682fef906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e0613c09-ec99-4f46-bd3f-93850822bb97" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_46b8ed4b-59c6-4067-abd0-413682fef906" xlink:to="loc_srt_CounterpartyNameAxis_e0613c09-ec99-4f46-bd3f-93850822bb97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e9a08716-300a-40dd-bb2d-d8cd51e9aa24" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_e0613c09-ec99-4f46-bd3f-93850822bb97" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e9a08716-300a-40dd-bb2d-d8cd51e9aa24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_HealthCareRoyaltyPartnersIVLPMember_954c9a76-c5a5-49ec-85d4-4deef4a112f8" xlink:href="ardx-20221231.xsd#ardx_HealthCareRoyaltyPartnersIVLPMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e9a08716-300a-40dd-bb2d-d8cd51e9aa24" xlink:to="loc_ardx_HealthCareRoyaltyPartnersIVLPMember_954c9a76-c5a5-49ec-85d4-4deef4a112f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_91239905-2bd1-4a53-9971-b99ae5479369" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_46b8ed4b-59c6-4067-abd0-413682fef906" xlink:to="loc_srt_ProductOrServiceAxis_91239905-2bd1-4a53-9971-b99ae5479369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_70be2c69-533a-4bd4-b7ef-672a04b71684" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_91239905-2bd1-4a53-9971-b99ae5479369" xlink:to="loc_srt_ProductsAndServicesDomain_70be2c69-533a-4bd4-b7ef-672a04b71684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_ab4738e0-d350-4715-a24c-6979ae60657a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_70be2c69-533a-4bd4-b7ef-672a04b71684" xlink:to="loc_us-gaap_LicenseMember_ab4738e0-d350-4715-a24c-6979ae60657a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_971aea4c-a115-4c21-a473-ce4920667276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_46b8ed4b-59c6-4067-abd0-413682fef906" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_971aea4c-a115-4c21-a473-ce4920667276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInRoyaltiesPayable_a3b4b843-5fc7-4b9a-893f-9f480d925cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInRoyaltiesPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_971aea4c-a115-4c21-a473-ce4920667276" xlink:to="loc_us-gaap_IncreaseDecreaseInRoyaltiesPayable_a3b4b843-5fc7-4b9a-893f-9f480d925cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_439a4daa-632c-429a-81bf-847c65c015dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_971aea4c-a115-4c21-a473-ce4920667276" xlink:to="loc_us-gaap_ContractWithCustomerLiability_439a4daa-632c-429a-81bf-847c65c015dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_64506ec9-9c92-4155-a790-a8949397367f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_971aea4c-a115-4c21-a473-ce4920667276" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_64506ec9-9c92-4155-a790-a8949397367f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityTransactionCosts_d378d9c5-aa1e-4d88-a48a-c7267eaa9ceb" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerLiabilityTransactionCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_971aea4c-a115-4c21-a473-ce4920667276" xlink:to="loc_ardx_ContractWithCustomerLiabilityTransactionCosts_d378d9c5-aa1e-4d88-a48a-c7267eaa9ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent_aa8b13a3-d914-4be3-81aa-1c6b218b62e7" xlink:href="ardx-20221231.xsd#ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_971aea4c-a115-4c21-a473-ce4920667276" xlink:to="loc_ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent_aa8b13a3-d914-4be3-81aa-1c6b218b62e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfAdvanceRoyalty_c11872e8-f3d2-4687-bbc6-44765c8b910c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfAdvanceRoyalty"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_971aea4c-a115-4c21-a473-ce4920667276" xlink:to="loc_us-gaap_AmortizationOfAdvanceRoyalty_c11872e8-f3d2-4687-bbc6-44765c8b910c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRoyaltiesReceived_92d0fc4e-57fd-4440-8494-9a1052911b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRoyaltiesReceived"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_971aea4c-a115-4c21-a473-ce4920667276" xlink:to="loc_us-gaap_ProceedsFromRoyaltiesReceived_92d0fc4e-57fd-4440-8494-9a1052911b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#BorrowingsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/BorrowingsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_48482a34-e1d9-400d-b77f-8b2c80712ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9fbf9a0d-ac1b-4001-b8ba-95942f745b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_48482a34-e1d9-400d-b77f-8b2c80712ac3" xlink:to="loc_us-gaap_DebtInstrumentTable_9fbf9a0d-ac1b-4001-b8ba-95942f745b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_bf195f4f-ed16-47ac-bb3e-b612f13a5a77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9fbf9a0d-ac1b-4001-b8ba-95942f745b3d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_bf195f4f-ed16-47ac-bb3e-b612f13a5a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2633fc82-c7f5-4da6-9117-106ca42d5ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bf195f4f-ed16-47ac-bb3e-b612f13a5a77" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2633fc82-c7f5-4da6-9117-106ca42d5ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_feda9bb7-0fdd-43be-aadf-d06a49a6f704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2633fc82-c7f5-4da6-9117-106ca42d5ebb" xlink:to="loc_us-gaap_LoansPayableMember_feda9bb7-0fdd-43be-aadf-d06a49a6f704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_55f4d29d-7907-496a-852c-29f3531d6556" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9fbf9a0d-ac1b-4001-b8ba-95942f745b3d" xlink:to="loc_us-gaap_DebtInstrumentAxis_55f4d29d-7907-496a-852c-29f3531d6556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_51acc923-bfab-46c4-b60d-2c116bff89f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_55f4d29d-7907-496a-852c-29f3531d6556" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_51acc923-bfab-46c4-b60d-2c116bff89f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2018Member_d064b2af-da08-4963-8593-4ae78a71b3e3" xlink:href="ardx-20221231.xsd#ardx_TermLoan2018Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51acc923-bfab-46c4-b60d-2c116bff89f3" xlink:to="loc_ardx_TermLoan2018Member_d064b2af-da08-4963-8593-4ae78a71b3e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2022Member_0077c070-8ee6-4704-9496-4c95a3a66566" xlink:href="ardx-20221231.xsd#ardx_TermLoan2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_51acc923-bfab-46c4-b60d-2c116bff89f3" xlink:to="loc_ardx_TermLoan2022Member_0077c070-8ee6-4704-9496-4c95a3a66566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2022AMember_d176fac4-6deb-4f08-b080-43f0a1baf1ae" xlink:href="ardx-20221231.xsd#ardx_TermLoan2022AMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_TermLoan2022Member_0077c070-8ee6-4704-9496-4c95a3a66566" xlink:to="loc_ardx_TermLoan2022AMember_d176fac4-6deb-4f08-b080-43f0a1baf1ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2022BMember_053f00b1-e043-46bc-b1c3-85bb3b272189" xlink:href="ardx-20221231.xsd#ardx_TermLoan2022BMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_TermLoan2022Member_0077c070-8ee6-4704-9496-4c95a3a66566" xlink:to="loc_ardx_TermLoan2022BMember_053f00b1-e043-46bc-b1c3-85bb3b272189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_c74baf6d-e62f-45c6-9b40-eb62c73cb7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9fbf9a0d-ac1b-4001-b8ba-95942f745b3d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_c74baf6d-e62f-45c6-9b40-eb62c73cb7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_4f130da2-3bd0-4d91-b13d-270032ed1c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_c74baf6d-e62f-45c6-9b40-eb62c73cb7d9" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_4f130da2-3bd0-4d91-b13d-270032ed1c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_143737c6-1159-4fed-86be-85998722f987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_4f130da2-3bd0-4d91-b13d-270032ed1c3b" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_143737c6-1159-4fed-86be-85998722f987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_4a3ca441-9030-42e3-b5f5-e8c3346a706d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_4f130da2-3bd0-4d91-b13d-270032ed1c3b" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_4a3ca441-9030-42e3-b5f5-e8c3346a706d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_9a8babd7-15d1-4bca-92e6-29b4f46d5725" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_4f130da2-3bd0-4d91-b13d-270032ed1c3b" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_9a8babd7-15d1-4bca-92e6-29b4f46d5725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_e206454a-296b-43f0-8ba0-15beabb806ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9fbf9a0d-ac1b-4001-b8ba-95942f745b3d" xlink:to="loc_us-gaap_VariableRateAxis_e206454a-296b-43f0-8ba0-15beabb806ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_076d7bab-d6db-4c59-b32c-c69993ff02f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_e206454a-296b-43f0-8ba0-15beabb806ba" xlink:to="loc_us-gaap_VariableRateDomain_076d7bab-d6db-4c59-b32c-c69993ff02f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_6db58d5e-d410-4556-8876-5f73299e3603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_076d7bab-d6db-4c59-b32c-c69993ff02f1" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_6db58d5e-d410-4556-8876-5f73299e3603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_7b854758-e2a1-4cd3-afef-46967b08b222" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9fbf9a0d-ac1b-4001-b8ba-95942f745b3d" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_7b854758-e2a1-4cd3-afef-46967b08b222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_41900f1b-fcee-4437-bd1d-be0beda44da7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_7b854758-e2a1-4cd3-afef-46967b08b222" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_41900f1b-fcee-4437-bd1d-be0beda44da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2022Member_e1bfe80e-c3a5-4eb6-ac85-57ed2fc61d2f" xlink:href="ardx-20221231.xsd#ardx_ExitFee2022Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_41900f1b-fcee-4437-bd1d-be0beda44da7" xlink:to="loc_ardx_ExitFee2022Member_e1bfe80e-c3a5-4eb6-ac85-57ed2fc61d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8eee3a1f-48e4-4bd9-ab24-16c7fca2f48c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9fbf9a0d-ac1b-4001-b8ba-95942f745b3d" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8eee3a1f-48e4-4bd9-ab24-16c7fca2f48c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3549ff01-940b-46a1-ac1c-9a369264f789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8eee3a1f-48e4-4bd9-ab24-16c7fca2f48c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3549ff01-940b-46a1-ac1c-9a369264f789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_7ced733d-046b-4e5e-b070-8cb250657d93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3549ff01-940b-46a1-ac1c-9a369264f789" xlink:to="loc_us-gaap_SubsequentEventMember_7ced733d-046b-4e5e-b070-8cb250657d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_31950f3a-a9d1-432c-97bc-ad76e5fe63ba" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9fbf9a0d-ac1b-4001-b8ba-95942f745b3d" xlink:to="loc_srt_RangeAxis_31950f3a-a9d1-432c-97bc-ad76e5fe63ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d1e070a2-960c-41be-910a-ddaa7bee43b1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_31950f3a-a9d1-432c-97bc-ad76e5fe63ba" xlink:to="loc_srt_RangeMember_d1e070a2-960c-41be-910a-ddaa7bee43b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_93f501a6-8090-4157-aecc-ca74aca364a9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d1e070a2-960c-41be-910a-ddaa7bee43b1" xlink:to="loc_srt_MaximumMember_93f501a6-8090-4157-aecc-ca74aca364a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6b295747-fd84-4bb9-bc1d-117388349d2f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d1e070a2-960c-41be-910a-ddaa7bee43b1" xlink:to="loc_srt_MinimumMember_6b295747-fd84-4bb9-bc1d-117388349d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_289a289e-2d13-4fdb-b2f6-b190fd5e984b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9fbf9a0d-ac1b-4001-b8ba-95942f745b3d" xlink:to="loc_us-gaap_DebtInstrumentLineItems_289a289e-2d13-4fdb-b2f6-b190fd5e984b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_a154e4b7-871b-4319-90ac-fd43837317c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_289a289e-2d13-4fdb-b2f6-b190fd5e984b" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_a154e4b7-871b-4319-90ac-fd43837317c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_5f985130-776f-4671-9caf-bd23c9b42e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_289a289e-2d13-4fdb-b2f6-b190fd5e984b" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_5f985130-776f-4671-9caf-bd23c9b42e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7db8b1b7-3486-43ad-9abf-4b93ac3a4a54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_289a289e-2d13-4fdb-b2f6-b190fd5e984b" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7db8b1b7-3486-43ad-9abf-4b93ac3a4a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentInterestPaymentExtensionTerm_a5e0393c-d7e7-48c1-8026-7494d025dad7" xlink:href="ardx-20221231.xsd#ardx_DebtInstrumentInterestPaymentExtensionTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_289a289e-2d13-4fdb-b2f6-b190fd5e984b" xlink:to="loc_ardx_DebtInstrumentInterestPaymentExtensionTerm_a5e0393c-d7e7-48c1-8026-7494d025dad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_d04752ed-c1c6-4f83-b3e1-ddf1c2c7175f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_289a289e-2d13-4fdb-b2f6-b190fd5e984b" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_d04752ed-c1c6-4f83-b3e1-ddf1c2c7175f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement_48e55624-1c06-4548-94e5-8a9117151c4b" xlink:href="ardx-20221231.xsd#ardx_RemainingFundingBasedOnConditionalMilestoneAchievement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_289a289e-2d13-4fdb-b2f6-b190fd5e984b" xlink:to="loc_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement_48e55624-1c06-4548-94e5-8a9117151c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentVariableRateBaseOption_577bb58b-fb10-4565-b3de-02e971b35a9f" xlink:href="ardx-20221231.xsd#ardx_DebtInstrumentVariableRateBaseOption"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_289a289e-2d13-4fdb-b2f6-b190fd5e984b" xlink:to="loc_ardx_DebtInstrumentVariableRateBaseOption_577bb58b-fb10-4565-b3de-02e971b35a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_84c3b247-7133-4207-98bc-01c09bd62c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_289a289e-2d13-4fdb-b2f6-b190fd5e984b" xlink:to="loc_us-gaap_DebtInstrumentTerm_84c3b247-7133-4207-98bc-01c09bd62c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentClosingFeeAmount_acc69c92-179d-44c8-8649-3530af54624b" xlink:href="ardx-20221231.xsd#ardx_DebtInstrumentClosingFeeAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_289a289e-2d13-4fdb-b2f6-b190fd5e984b" xlink:to="loc_ardx_DebtInstrumentClosingFeeAmount_acc69c92-179d-44c8-8649-3530af54624b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents_d05aaf9d-bf29-41cc-9c18-8bab8ed1130c" xlink:href="ardx-20221231.xsd#ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_289a289e-2d13-4fdb-b2f6-b190fd5e984b" xlink:to="loc_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents_d05aaf9d-bf29-41cc-9c18-8bab8ed1130c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage_0427294f-5c52-4900-aae4-885ca3a85707" xlink:href="ardx-20221231.xsd#ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_289a289e-2d13-4fdb-b2f6-b190fd5e984b" xlink:to="loc_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage_0427294f-5c52-4900-aae4-885ca3a85707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentPrepaymentFeePercentage_7939b700-67c9-4aff-868e-95a348fdbcc6" xlink:href="ardx-20221231.xsd#ardx_DebtInstrumentPrepaymentFeePercentage"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_289a289e-2d13-4fdb-b2f6-b190fd5e984b" xlink:to="loc_ardx_DebtInstrumentPrepaymentFeePercentage_7939b700-67c9-4aff-868e-95a348fdbcc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFeePercentage_3ff24217-0a7b-41aa-a7b6-ee2883e8d3a8" xlink:href="ardx-20221231.xsd#ardx_ExitFeePercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_289a289e-2d13-4fdb-b2f6-b190fd5e984b" xlink:to="loc_ardx_ExitFeePercentage_3ff24217-0a7b-41aa-a7b6-ee2883e8d3a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum_afc93d89-31e2-409b-8786-e9f2478dfa2d" xlink:href="ardx-20221231.xsd#ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_289a289e-2d13-4fdb-b2f6-b190fd5e984b" xlink:to="loc_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum_afc93d89-31e2-409b-8786-e9f2478dfa2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementExitFeeTerm_d48031ed-1e42-4045-a4f3-a435ea73ce5a" xlink:href="ardx-20221231.xsd#ardx_LoanAgreementExitFeeTerm"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_289a289e-2d13-4fdb-b2f6-b190fd5e984b" xlink:to="loc_ardx_LoanAgreementExitFeeTerm_d48031ed-1e42-4045-a4f3-a435ea73ce5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum_3d73dbb4-be78-46ba-b4a8-0736f157b96d" xlink:href="ardx-20221231.xsd#ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_289a289e-2d13-4fdb-b2f6-b190fd5e984b" xlink:to="loc_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum_3d73dbb4-be78-46ba-b4a8-0736f157b96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod_de7679e2-367c-44aa-9088-d11fff84baba" xlink:href="ardx-20221231.xsd#ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_289a289e-2d13-4fdb-b2f6-b190fd5e984b" xlink:to="loc_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod_de7679e2-367c-44aa-9088-d11fff84baba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum_c84dad74-e623-4bb1-a048-cccfe44156ae" xlink:href="ardx-20221231.xsd#ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_289a289e-2d13-4fdb-b2f6-b190fd5e984b" xlink:to="loc_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum_c84dad74-e623-4bb1-a048-cccfe44156ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentInterestRateOnDefaultPercentage_e587fe90-7ccd-4e85-bf98-b08b2eacabb7" xlink:href="ardx-20221231.xsd#ardx_DebtInstrumentInterestRateOnDefaultPercentage"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_289a289e-2d13-4fdb-b2f6-b190fd5e984b" xlink:to="loc_ardx_DebtInstrumentInterestRateOnDefaultPercentage_e587fe90-7ccd-4e85-bf98-b08b2eacabb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentVariableRatePlusOption_5e6d6405-dd13-4efc-b85d-7248ff22b574" xlink:href="ardx-20221231.xsd#ardx_DebtInstrumentVariableRatePlusOption"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_289a289e-2d13-4fdb-b2f6-b190fd5e984b" xlink:to="loc_ardx_DebtInstrumentVariableRatePlusOption_5e6d6405-dd13-4efc-b85d-7248ff22b574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/BorrowingsFuturePaymentObligationsDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#BorrowingsFuturePaymentObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/BorrowingsFuturePaymentObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4f37314f-8367-4537-813d-c6aca3e1b121" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_b9c5a92c-e8de-418e-8730-00ff808b2cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4f37314f-8367-4537-813d-c6aca3e1b121" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_b9c5a92c-e8de-418e-8730-00ff808b2cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_ba5e6ecd-c49f-44d5-8228-f997acb174e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_b9c5a92c-e8de-418e-8730-00ff808b2cf3" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_ba5e6ecd-c49f-44d5-8228-f997acb174e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_16dcecd3-fc93-4458-9298-9d8bd453b5fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_b9c5a92c-e8de-418e-8730-00ff808b2cf3" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_16dcecd3-fc93-4458-9298-9d8bd453b5fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_f1260e4e-e8d4-4cf7-a871-2ff09e76fb01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_b9c5a92c-e8de-418e-8730-00ff808b2cf3" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_f1260e4e-e8d4-4cf7-a871-2ff09e76fb01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_7ccd96ea-7f0a-475d-ab53-2cfd0ca43e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_b9c5a92c-e8de-418e-8730-00ff808b2cf3" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_7ccd96ea-7f0a-475d-ab53-2cfd0ca43e8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_a4dc5a4f-d3d2-48a5-8d30-d62150f3ebca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_b9c5a92c-e8de-418e-8730-00ff808b2cf3" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_a4dc5a4f-d3d2-48a5-8d30-d62150f3ebca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_c5e6d976-f289-4098-a162-f1f282ea286f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_b9c5a92c-e8de-418e-8730-00ff808b2cf3" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_c5e6d976-f289-4098-a162-f1f282ea286f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_31f79c32-f340-4caf-8b6c-2e18da5637b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_b9c5a92c-e8de-418e-8730-00ff808b2cf3" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_31f79c32-f340-4caf-8b6c-2e18da5637b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_806e42ff-e3ef-4813-9575-3473ccaf566f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_b9c5a92c-e8de-418e-8730-00ff808b2cf3" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_806e42ff-e3ef-4813-9575-3473ccaf566f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_25d4aa15-1014-48cb-9533-2414f976dad1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_b9c5a92c-e8de-418e-8730-00ff808b2cf3" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_25d4aa15-1014-48cb-9533-2414f976dad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_fac3a9b3-fa0f-4ea9-9916-9ae7a860df85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_b9c5a92c-e8de-418e-8730-00ff808b2cf3" xlink:to="loc_us-gaap_LongTermDebt_fac3a9b3-fa0f-4ea9-9916-9ae7a860df85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableCurrent_0596f619-3114-43e6-a103-77c4e1de54f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_b9c5a92c-e8de-418e-8730-00ff808b2cf3" xlink:to="loc_us-gaap_LoansPayableCurrent_0596f619-3114-43e6-a103-77c4e1de54f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLoansPayable_2c9d685b-603e-457c-9cb9-96f4ad7caca0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermLoansPayable"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_b9c5a92c-e8de-418e-8730-00ff808b2cf3" xlink:to="loc_us-gaap_LongTermLoansPayable_2c9d685b-603e-457c-9cb9-96f4ad7caca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/BorrowingsFuturePaymentObligationsDetails_1" xlink:type="simple" xlink:href="ardx-20221231.xsd#BorrowingsFuturePaymentObligationsDetails_1"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/BorrowingsFuturePaymentObligationsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ardelyx.com/role/DerivativeLiabilitiesNarrativeDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#DerivativeLiabilitiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/DerivativeLiabilitiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9206854c-48ce-49d8-8f24-aabf80e1100c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_38ee0716-1ee2-4faf-8525-3bacb08d762e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9206854c-48ce-49d8-8f24-aabf80e1100c" xlink:to="loc_us-gaap_DerivativeTable_38ee0716-1ee2-4faf-8525-3bacb08d762e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_c114349f-5f2b-48ab-83b0-5c8091c97622" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_38ee0716-1ee2-4faf-8525-3bacb08d762e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_c114349f-5f2b-48ab-83b0-5c8091c97622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0b4aedcc-79e4-4d4c-8120-eedc6b94104c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c114349f-5f2b-48ab-83b0-5c8091c97622" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0b4aedcc-79e4-4d4c-8120-eedc6b94104c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2018Member_e2f3af52-98ad-4a9f-9f54-090eb7948651" xlink:href="ardx-20221231.xsd#ardx_ExitFee2018Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0b4aedcc-79e4-4d4c-8120-eedc6b94104c" xlink:to="loc_ardx_ExitFee2018Member_e2f3af52-98ad-4a9f-9f54-090eb7948651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2022Member_0558f3f6-9f53-4b76-a42a-18c7819950f1" xlink:href="ardx-20221231.xsd#ardx_ExitFee2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0b4aedcc-79e4-4d4c-8120-eedc6b94104c" xlink:to="loc_ardx_ExitFee2022Member_0558f3f6-9f53-4b76-a42a-18c7819950f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_69408013-8577-4b19-9ee7-810d6ed0d257" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_38ee0716-1ee2-4faf-8525-3bacb08d762e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_69408013-8577-4b19-9ee7-810d6ed0d257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_04c5b081-59e6-4530-b67f-44bc5c9c6bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_69408013-8577-4b19-9ee7-810d6ed0d257" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_04c5b081-59e6-4530-b67f-44bc5c9c6bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_afd92e5c-585c-462c-9966-293bae29727e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_04c5b081-59e6-4530-b67f-44bc5c9c6bfd" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_afd92e5c-585c-462c-9966-293bae29727e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_39625854-aa93-4f55-b6d5-f5c665e95237" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_38ee0716-1ee2-4faf-8525-3bacb08d762e" xlink:to="loc_us-gaap_DerivativeLineItems_39625854-aa93-4f55-b6d5-f5c665e95237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_63692980-23c7-447e-ae78-0464f6d281fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_39625854-aa93-4f55-b6d5-f5c665e95237" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_63692980-23c7-447e-ae78-0464f6d281fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4e2b35d3-7d1a-4514-afd1-c4eb9b65119e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_39625854-aa93-4f55-b6d5-f5c665e95237" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4e2b35d3-7d1a-4514-afd1-c4eb9b65119e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage_bb0bc6cf-2aad-4f39-bd99-4d736ad47329" xlink:href="ardx-20221231.xsd#ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_39625854-aa93-4f55-b6d5-f5c665e95237" xlink:to="loc_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage_bb0bc6cf-2aad-4f39-bd99-4d736ad47329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation_3ae8167b-f387-4ead-825c-6790bcba0f73" xlink:href="ardx-20221231.xsd#ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_39625854-aa93-4f55-b6d5-f5c665e95237" xlink:to="loc_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation_3ae8167b-f387-4ead-825c-6790bcba0f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFeePercentage_9d1b7b14-a699-457f-93c0-a39202d10346" xlink:href="ardx-20221231.xsd#ardx_ExitFeePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_39625854-aa93-4f55-b6d5-f5c665e95237" xlink:to="loc_ardx_ExitFeePercentage_9d1b7b14-a699-457f-93c0-a39202d10346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum_caee716d-ade6-46ad-98a1-b091c7cedab2" xlink:href="ardx-20221231.xsd#ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_39625854-aa93-4f55-b6d5-f5c665e95237" xlink:to="loc_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum_caee716d-ade6-46ad-98a1-b091c7cedab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/DerivativeLiabilitiesChangesinFairValueDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#DerivativeLiabilitiesChangesinFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/DerivativeLiabilitiesChangesinFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8836a681-4791-4a06-b1ad-2d26a2ef1d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_71290e82-8ff2-4682-a18e-2aa28c6b3c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8836a681-4791-4a06-b1ad-2d26a2ef1d1d" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_71290e82-8ff2-4682-a18e-2aa28c6b3c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_fee6be95-72ee-49a0-8f61-ff13fd0a9896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_71290e82-8ff2-4682-a18e-2aa28c6b3c0a" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_fee6be95-72ee-49a0-8f61-ff13fd0a9896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_f57463ed-3c25-401b-aad5-66873332185e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_fee6be95-72ee-49a0-8f61-ff13fd0a9896" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_f57463ed-3c25-401b-aad5-66873332185e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_bd3bf8b4-28d2-4c58-b796-5d971705984f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_f57463ed-3c25-401b-aad5-66873332185e" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_bd3bf8b4-28d2-4c58-b796-5d971705984f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_4e5948f8-26e0-480b-8713-ba628916cefb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_71290e82-8ff2-4682-a18e-2aa28c6b3c0a" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_4e5948f8-26e0-480b-8713-ba628916cefb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_78da1cba-da3b-4758-acbc-419306f7c6b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4e5948f8-26e0-480b-8713-ba628916cefb" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_78da1cba-da3b-4758-acbc-419306f7c6b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2018Member_f44491a0-0960-405f-80df-ed1e8c1472c0" xlink:href="ardx-20221231.xsd#ardx_ExitFee2018Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_78da1cba-da3b-4758-acbc-419306f7c6b1" xlink:to="loc_ardx_ExitFee2018Member_f44491a0-0960-405f-80df-ed1e8c1472c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2022Member_0304bdee-eb4f-4240-870e-3af91c6a2618" xlink:href="ardx-20221231.xsd#ardx_ExitFee2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_78da1cba-da3b-4758-acbc-419306f7c6b1" xlink:to="loc_ardx_ExitFee2022Member_0304bdee-eb4f-4240-870e-3af91c6a2618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_89c98d90-6c4a-4e3d-a7fd-97c5c928597b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_71290e82-8ff2-4682-a18e-2aa28c6b3c0a" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_89c98d90-6c4a-4e3d-a7fd-97c5c928597b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6f920f88-5bdb-4b28-99c5-4244666087f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_89c98d90-6c4a-4e3d-a7fd-97c5c928597b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6f920f88-5bdb-4b28-99c5-4244666087f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ff5e1eb4-95a5-4ed2-ba12-ea0e9cc1df6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6f920f88-5bdb-4b28-99c5-4244666087f4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ff5e1eb4-95a5-4ed2-ba12-ea0e9cc1df6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_81de456c-3e2c-43c8-b9b9-7e6e4bd8d72d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6f920f88-5bdb-4b28-99c5-4244666087f4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_81de456c-3e2c-43c8-b9b9-7e6e4bd8d72d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_27c1d7f3-3501-49f6-9170-83e04200469b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6f920f88-5bdb-4b28-99c5-4244666087f4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_27c1d7f3-3501-49f6-9170-83e04200469b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_099b712b-451f-4732-b9c9-ac9d707cd87b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6f920f88-5bdb-4b28-99c5-4244666087f4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_099b712b-451f-4732-b9c9-ac9d707cd87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_4a8ace9b-9bb3-47d6-87b8-563dbdcfc744" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_439c2851-8491-4ed2-9228-ed84aeb626ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4a8ace9b-9bb3-47d6-87b8-563dbdcfc744" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_439c2851-8491-4ed2-9228-ed84aeb626ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LeaseArrangementsAxis_4e1b2f40-06d7-4881-bfad-61f7aef1cea8" xlink:href="ardx-20221231.xsd#ardx_LeaseArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_439c2851-8491-4ed2-9228-ed84aeb626ed" xlink:to="loc_ardx_LeaseArrangementsAxis_4e1b2f40-06d7-4881-bfad-61f7aef1cea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LeaseArrangementsDomain_fb10c3dd-5aad-41f2-9935-3188400d18d8" xlink:href="ardx-20221231.xsd#ardx_LeaseArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_LeaseArrangementsAxis_4e1b2f40-06d7-4881-bfad-61f7aef1cea8" xlink:to="loc_ardx_LeaseArrangementsDomain_fb10c3dd-5aad-41f2-9935-3188400d18d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FacilityFremontCaliforniaMember_e9dc5b1b-9ab1-4f78-a9ff-937b86daf567" xlink:href="ardx-20221231.xsd#ardx_FacilityFremontCaliforniaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_LeaseArrangementsDomain_fb10c3dd-5aad-41f2-9935-3188400d18d8" xlink:to="loc_ardx_FacilityFremontCaliforniaMember_e9dc5b1b-9ab1-4f78-a9ff-937b86daf567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FacilityOneWalthamMassachusettsMember_fd754999-2f75-490e-8066-2d14a507ea05" xlink:href="ardx-20221231.xsd#ardx_FacilityOneWalthamMassachusettsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_LeaseArrangementsDomain_fb10c3dd-5aad-41f2-9935-3188400d18d8" xlink:to="loc_ardx_FacilityOneWalthamMassachusettsMember_fd754999-2f75-490e-8066-2d14a507ea05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FacilityTwoWalthamMassachusettsMember_e363b6d4-51ba-4ff3-9424-711b9a7c0074" xlink:href="ardx-20221231.xsd#ardx_FacilityTwoWalthamMassachusettsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_LeaseArrangementsDomain_fb10c3dd-5aad-41f2-9935-3188400d18d8" xlink:to="loc_ardx_FacilityTwoWalthamMassachusettsMember_e363b6d4-51ba-4ff3-9424-711b9a7c0074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FacilityMilwaukeeWisconsinMember_749b9e9c-1363-48f1-96cb-7a96278165d1" xlink:href="ardx-20221231.xsd#ardx_FacilityMilwaukeeWisconsinMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_LeaseArrangementsDomain_fb10c3dd-5aad-41f2-9935-3188400d18d8" xlink:to="loc_ardx_FacilityMilwaukeeWisconsinMember_749b9e9c-1363-48f1-96cb-7a96278165d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_693bcafa-6d1c-4765-a720-af61dd228110" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_439c2851-8491-4ed2-9228-ed84aeb626ed" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_693bcafa-6d1c-4765-a720-af61dd228110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_NumberOfOperatingLeaseArrangements_6b930160-5e3a-4c8c-85b2-1059bbc9eb49" xlink:href="ardx-20221231.xsd#ardx_NumberOfOperatingLeaseArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_693bcafa-6d1c-4765-a720-af61dd228110" xlink:to="loc_ardx_NumberOfOperatingLeaseArrangements_6b930160-5e3a-4c8c-85b2-1059bbc9eb49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_e29472f3-be4c-4b08-a3fd-91f0443648e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_693bcafa-6d1c-4765-a720-af61dd228110" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_e29472f3-be4c-4b08-a3fd-91f0443648e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LesseeOperatingLeaseNumberOfRenewalOptions_c73a6619-c33e-4f2f-8742-5e1a64568edb" xlink:href="ardx-20221231.xsd#ardx_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_693bcafa-6d1c-4765-a720-af61dd228110" xlink:to="loc_ardx_LesseeOperatingLeaseNumberOfRenewalOptions_c73a6619-c33e-4f2f-8742-5e1a64568edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_93568818-51de-46b4-b9ab-8d9cb41dac96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_693bcafa-6d1c-4765-a720-af61dd228110" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_93568818-51de-46b4-b9ab-8d9cb41dac96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_df4bcd97-f23d-4235-bb40-e26d2a680220" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_693bcafa-6d1c-4765-a720-af61dd228110" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_df4bcd97-f23d-4235-bb40-e26d2a680220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_abb02449-0bda-4f13-862b-781a4a827a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_693bcafa-6d1c-4765-a720-af61dd228110" xlink:to="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_abb02449-0bda-4f13-862b-781a4a827a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/LeasesAdditionalLeaseInformationDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#LeasesAdditionalLeaseInformationDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/LeasesAdditionalLeaseInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f6eba095-b3d2-401f-a593-4f4728f613d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_6736d812-8b8c-44f4-ad2c-ea005aa799c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f6eba095-b3d2-401f-a593-4f4728f613d8" xlink:to="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_6736d812-8b8c-44f4-ad2c-ea005aa799c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2aa5c730-1e30-4e3f-8f01-82cb68110da5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_6736d812-8b8c-44f4-ad2c-ea005aa799c2" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2aa5c730-1e30-4e3f-8f01-82cb68110da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f12b60ce-0044-4e96-8d98-627c0483bb73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_6736d812-8b8c-44f4-ad2c-ea005aa799c2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f12b60ce-0044-4e96-8d98-627c0483bb73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0da8c206-ad94-443b-97b6-6a35d0d927d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_6736d812-8b8c-44f4-ad2c-ea005aa799c2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0da8c206-ad94-443b-97b6-6a35d0d927d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_191bd1da-2b12-479a-8023-2b54dee14dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_6736d812-8b8c-44f4-ad2c-ea005aa799c2" xlink:to="loc_us-gaap_OperatingLeaseLiability_191bd1da-2b12-479a-8023-2b54dee14dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract_1d307396-cb42-455a-b175-5d5ec6eb83f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f6eba095-b3d2-401f-a593-4f4728f613d8" xlink:to="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract_1d307396-cb42-455a-b175-5d5ec6eb83f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_98ce73a6-6b39-42a8-965e-482b914d2faa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract_1d307396-cb42-455a-b175-5d5ec6eb83f0" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_98ce73a6-6b39-42a8-965e-482b914d2faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ca54289d-d0a5-4053-99e0-518b09ebd80c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract_1d307396-cb42-455a-b175-5d5ec6eb83f0" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ca54289d-d0a5-4053-99e0-518b09ebd80c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/LeasesLeaseCostsDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#LeasesLeaseCostsDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/LeasesLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_7ae933f0-4ada-40dc-b65d-b0759b68e94a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_0b4510b9-40cf-40a1-94b3-17d4d66b491b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7ae933f0-4ada-40dc-b65d-b0759b68e94a" xlink:to="loc_us-gaap_LeaseCostAbstract_0b4510b9-40cf-40a1-94b3-17d4d66b491b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_27cf432e-5692-48f0-aaf4-e6e45a7c45fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_0b4510b9-40cf-40a1-94b3-17d4d66b491b" xlink:to="loc_us-gaap_OperatingLeaseCost_27cf432e-5692-48f0-aaf4-e6e45a7c45fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_5d00a6f2-409c-48a0-81c6-7cdb98010883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_0b4510b9-40cf-40a1-94b3-17d4d66b491b" xlink:to="loc_us-gaap_OperatingLeasePayments_5d00a6f2-409c-48a0-81c6-7cdb98010883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#LeasesUndiscountedCashPaymentObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_64fc30b1-1e01-4f84-824f-2ca2acfc8ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e4e44c36-3f06-4f1a-8ff7-67788f61749d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_64fc30b1-1e01-4f84-824f-2ca2acfc8ffa" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e4e44c36-3f06-4f1a-8ff7-67788f61749d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_09a7146a-6f3e-4f17-b063-2c23f6c1dbd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e4e44c36-3f06-4f1a-8ff7-67788f61749d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_09a7146a-6f3e-4f17-b063-2c23f6c1dbd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9285ea87-a403-4c02-bb90-924bf0b331ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e4e44c36-3f06-4f1a-8ff7-67788f61749d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9285ea87-a403-4c02-bb90-924bf0b331ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9a7b2445-08bb-47ef-b86d-432b273de2fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e4e44c36-3f06-4f1a-8ff7-67788f61749d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9a7b2445-08bb-47ef-b86d-432b273de2fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5db1134f-0f41-4678-a8fc-f1002915ba16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e4e44c36-3f06-4f1a-8ff7-67788f61749d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5db1134f-0f41-4678-a8fc-f1002915ba16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_2872c1e7-ac65-47cc-9561-2b63790df3f6" xlink:href="ardx-20221231.xsd#ardx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e4e44c36-3f06-4f1a-8ff7-67788f61749d" xlink:to="loc_ardx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_2872c1e7-ac65-47cc-9561-2b63790df3f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_efc9b47c-5b34-47ee-a051-29cc28bc6b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e4e44c36-3f06-4f1a-8ff7-67788f61749d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_efc9b47c-5b34-47ee-a051-29cc28bc6b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_54955253-93e1-4952-a8bd-562fa4f5507b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e4e44c36-3f06-4f1a-8ff7-67788f61749d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_54955253-93e1-4952-a8bd-562fa4f5507b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_72dc2dea-1746-4132-87ef-cd7c0e7ad339" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e4e44c36-3f06-4f1a-8ff7-67788f61749d" xlink:to="loc_us-gaap_OperatingLeaseLiability_72dc2dea-1746-4132-87ef-cd7c0e7ad339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_646efcc3-c703-40fe-bedf-16427c61c104" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e4e44c36-3f06-4f1a-8ff7-67788f61749d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_646efcc3-c703-40fe-bedf-16427c61c104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_fe3940e0-3aa8-46f1-b0c1-287e9ae96eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e4e44c36-3f06-4f1a-8ff7-67788f61749d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_fe3940e0-3aa8-46f1-b0c1-287e9ae96eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1" xlink:type="simple" xlink:href="ardx-20221231.xsd#LeasesUndiscountedCashPaymentObligationsDetails_1"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ardelyx.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_1188fef2-9445-4e09-8732-856ee3336d50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c0ff6d91-fb0a-4717-ac28-83e23caacbe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_1188fef2-9445-4e09-8732-856ee3336d50" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c0ff6d91-fb0a-4717-ac28-83e23caacbe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_453e8783-1f96-4c6e-bb57-6da8e6ab91d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c0ff6d91-fb0a-4717-ac28-83e23caacbe1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_453e8783-1f96-4c6e-bb57-6da8e6ab91d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c3c5f800-e928-4e3c-8ea7-4a4dfc6d8c67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_453e8783-1f96-4c6e-bb57-6da8e6ab91d5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c3c5f800-e928-4e3c-8ea7-4a4dfc6d8c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember_997d2e97-55d1-4a24-985d-9ebefc3c7bf0" xlink:href="ardx-20221231.xsd#ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c3c5f800-e928-4e3c-8ea7-4a4dfc6d8c67" xlink:to="loc_ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember_997d2e97-55d1-4a24-985d-9ebefc3c7bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember_e76d2981-6519-454c-b2f0-6eca41f94bbd" xlink:href="ardx-20221231.xsd#ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c3c5f800-e928-4e3c-8ea7-4a4dfc6d8c67" xlink:to="loc_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember_e76d2981-6519-454c-b2f0-6eca41f94bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember_2d387bf5-26a6-4b43-ba5c-f30a473a10f9" xlink:href="ardx-20221231.xsd#ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c3c5f800-e928-4e3c-8ea7-4a4dfc6d8c67" xlink:to="loc_ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember_2d387bf5-26a6-4b43-ba5c-f30a473a10f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_76ff2984-8a9f-45ef-a9ef-58356e69d040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c0ff6d91-fb0a-4717-ac28-83e23caacbe1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_76ff2984-8a9f-45ef-a9ef-58356e69d040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0842aefd-ab99-4699-b0f8-b6c0c587d994" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_76ff2984-8a9f-45ef-a9ef-58356e69d040" xlink:to="loc_us-gaap_ClassOfStockDomain_0842aefd-ab99-4699-b0f8-b6c0c587d994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_152b5991-2a70-4d9a-b16d-2ee996d347fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0842aefd-ab99-4699-b0f8-b6c0c587d994" xlink:to="loc_us-gaap_CommonClassAMember_152b5991-2a70-4d9a-b16d-2ee996d347fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f781fe23-5bd7-47fc-81de-c8057a67498b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c0ff6d91-fb0a-4717-ac28-83e23caacbe1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f781fe23-5bd7-47fc-81de-c8057a67498b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fce66702-4641-430e-9b43-7c332625dedb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f781fe23-5bd7-47fc-81de-c8057a67498b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fce66702-4641-430e-9b43-7c332625dedb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_1918457e-43b3-426c-9f8a-078b46ea3923" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_fce66702-4641-430e-9b43-7c332625dedb" xlink:to="loc_us-gaap_SubsequentEventMember_1918457e-43b3-426c-9f8a-078b46ea3923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_f63ab666-021c-4bc6-a3bd-112e44a715b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c0ff6d91-fb0a-4717-ac28-83e23caacbe1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_f63ab666-021c-4bc6-a3bd-112e44a715b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_MaximumAggregateOfferingPrice_571530fd-c0fc-4351-80c9-8192fdf68a50" xlink:href="ardx-20221231.xsd#ardx_MaximumAggregateOfferingPrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_f63ab666-021c-4bc6-a3bd-112e44a715b6" xlink:to="loc_ardx_MaximumAggregateOfferingPrice_571530fd-c0fc-4351-80c9-8192fdf68a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_StockIssuanceCostCommissionPercent_3acb3936-818e-43d9-8b2f-564ed996890f" xlink:href="ardx-20221231.xsd#ardx_StockIssuanceCostCommissionPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_f63ab666-021c-4bc6-a3bd-112e44a715b6" xlink:to="loc_ardx_StockIssuanceCostCommissionPercent_3acb3936-818e-43d9-8b2f-564ed996890f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fb3599f3-59e0-466c-9107-afa55bf1a7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_f63ab666-021c-4bc6-a3bd-112e44a715b6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fb3599f3-59e0-466c-9107-afa55bf1a7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a3168424-bd78-4f65-9a35-3dc38c122ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_f63ab666-021c-4bc6-a3bd-112e44a715b6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a3168424-bd78-4f65-9a35-3dc38c122ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_SaleOfStockWeightedAveragePricePerShare_4da0ccf0-4fea-446d-bd9f-6736e1971883" xlink:href="ardx-20221231.xsd#ardx_SaleOfStockWeightedAveragePricePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_f63ab666-021c-4bc6-a3bd-112e44a715b6" xlink:to="loc_ardx_SaleOfStockWeightedAveragePricePerShare_4da0ccf0-4fea-446d-bd9f-6736e1971883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EquitySalesAgreementSharesIssuedSinceInception_493bd82a-da7b-45b2-b419-44c795716622" xlink:href="ardx-20221231.xsd#ardx_EquitySalesAgreementSharesIssuedSinceInception"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_f63ab666-021c-4bc6-a3bd-112e44a715b6" xlink:to="loc_ardx_EquitySalesAgreementSharesIssuedSinceInception_493bd82a-da7b-45b2-b419-44c795716622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EquitySalesAgreementProceedsFromSharesIssuedSinceInception_2618fb88-4e91-4802-9ddd-8203bb645b7b" xlink:href="ardx-20221231.xsd#ardx_EquitySalesAgreementProceedsFromSharesIssuedSinceInception"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_f63ab666-021c-4bc6-a3bd-112e44a715b6" xlink:to="loc_ardx_EquitySalesAgreementProceedsFromSharesIssuedSinceInception_2618fb88-4e91-4802-9ddd-8203bb645b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#EquityIncentivePlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4ce174a6-2c9b-4189-b924-25d3b6b2ae21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_540a20d6-6e69-4ac1-9de3-e94996d3d92b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4ce174a6-2c9b-4189-b924-25d3b6b2ae21" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_540a20d6-6e69-4ac1-9de3-e94996d3d92b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_e3a96d09-acca-4abf-9475-e36d8b25edb0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_540a20d6-6e69-4ac1-9de3-e94996d3d92b" xlink:to="loc_srt_TitleOfIndividualAxis_e3a96d09-acca-4abf-9475-e36d8b25edb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_46c9dd1a-fa06-4630-b04c-ac84813a2e0b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_e3a96d09-acca-4abf-9475-e36d8b25edb0" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_46c9dd1a-fa06-4630-b04c-ac84813a2e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_37541c2c-758f-4200-b92f-750eff1a0533" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_46c9dd1a-fa06-4630-b04c-ac84813a2e0b" xlink:to="loc_srt_DirectorMember_37541c2c-758f-4200-b92f-750eff1a0533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c063edb6-c0f5-42c7-bffd-17b6881db268" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_540a20d6-6e69-4ac1-9de3-e94996d3d92b" xlink:to="loc_us-gaap_AwardTypeAxis_c063edb6-c0f5-42c7-bffd-17b6881db268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83d25548-555b-4595-8d3f-b67e01384e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c063edb6-c0f5-42c7-bffd-17b6881db268" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83d25548-555b-4595-8d3f-b67e01384e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_235163fc-465e-49ba-861c-c18da3faff42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83d25548-555b-4595-8d3f-b67e01384e4d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_235163fc-465e-49ba-861c-c18da3faff42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PerformanceBasedRestrictedStockUnitsMember_cc17c4e5-ae96-4145-b980-ff42e9ca0b45" xlink:href="ardx-20221231.xsd#ardx_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83d25548-555b-4595-8d3f-b67e01384e4d" xlink:to="loc_ardx_PerformanceBasedRestrictedStockUnitsMember_cc17c4e5-ae96-4145-b980-ff42e9ca0b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_9cafaad3-b6b4-40ee-a7dd-80dc63fe8b18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83d25548-555b-4595-8d3f-b67e01384e4d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_9cafaad3-b6b4-40ee-a7dd-80dc63fe8b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_c7a49909-5b1f-45d7-bbff-0ea06bd9d37f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_540a20d6-6e69-4ac1-9de3-e94996d3d92b" xlink:to="loc_us-gaap_PlanNameAxis_c7a49909-5b1f-45d7-bbff-0ea06bd9d37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_40d62965-623b-4985-96cc-81774857d97e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_c7a49909-5b1f-45d7-bbff-0ea06bd9d37f" xlink:to="loc_us-gaap_PlanNameDomain_40d62965-623b-4985-96cc-81774857d97e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TwoThousandEightStockIncentivePlanMember_817e7acd-f515-4759-9653-f497e2da5995" xlink:href="ardx-20221231.xsd#ardx_TwoThousandEightStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_40d62965-623b-4985-96cc-81774857d97e" xlink:to="loc_ardx_TwoThousandEightStockIncentivePlanMember_817e7acd-f515-4759-9653-f497e2da5995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TwoThousandFourteenEquityIncentiveAwardPlanMember_fb213dd7-89eb-49ea-867c-29689df9e847" xlink:href="ardx-20221231.xsd#ardx_TwoThousandFourteenEquityIncentiveAwardPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_40d62965-623b-4985-96cc-81774857d97e" xlink:to="loc_ardx_TwoThousandFourteenEquityIncentiveAwardPlanMember_fb213dd7-89eb-49ea-867c-29689df9e847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TwoThousandSixteenEmploymentCommencementIncentivePlanMember_a03fcd1c-3c51-4c9f-b834-cf6c421a08e3" xlink:href="ardx-20221231.xsd#ardx_TwoThousandSixteenEmploymentCommencementIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_40d62965-623b-4985-96cc-81774857d97e" xlink:to="loc_ardx_TwoThousandSixteenEmploymentCommencementIncentivePlanMember_a03fcd1c-3c51-4c9f-b834-cf6c421a08e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EmployeeStockPurchasePlanMember_d9f17018-831d-4b0a-8a11-b792072993be" xlink:href="ardx-20221231.xsd#ardx_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_40d62965-623b-4985-96cc-81774857d97e" xlink:to="loc_ardx_EmployeeStockPurchasePlanMember_d9f17018-831d-4b0a-8a11-b792072993be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bab7eba-971b-4781-b0f9-4e025c950112" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_540a20d6-6e69-4ac1-9de3-e94996d3d92b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bab7eba-971b-4781-b0f9-4e025c950112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f58245df-7fa3-4fef-8bb8-09a13f723a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bab7eba-971b-4781-b0f9-4e025c950112" xlink:to="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f58245df-7fa3-4fef-8bb8-09a13f723a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_52a7a28f-e48c-4492-8591-e0e608ef34cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f58245df-7fa3-4fef-8bb8-09a13f723a5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_52a7a28f-e48c-4492-8591-e0e608ef34cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0da22a2d-b207-40f2-9ddb-14ecbff700a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f58245df-7fa3-4fef-8bb8-09a13f723a5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0da22a2d-b207-40f2-9ddb-14ecbff700a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_b5453240-6c03-49f5-b04c-7d05b8a653f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f58245df-7fa3-4fef-8bb8-09a13f723a5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_b5453240-6c03-49f5-b04c-7d05b8a653f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b07a22e3-b4ca-4825-b3dd-69f7cfdd3235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f58245df-7fa3-4fef-8bb8-09a13f723a5c" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b07a22e3-b4ca-4825-b3dd-69f7cfdd3235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponInclusionOfForfeitedOrUnexercisedOptions_6b0b7d95-2297-4679-bf99-7bba4aac909f" xlink:href="ardx-20221231.xsd#ardx_IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponInclusionOfForfeitedOrUnexercisedOptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f58245df-7fa3-4fef-8bb8-09a13f723a5c" xlink:to="loc_ardx_IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponInclusionOfForfeitedOrUnexercisedOptions_6b0b7d95-2297-4679-bf99-7bba4aac909f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_IncreaseInSharesReservedForIssuanceOptionForAnnualIncreaseAsPercentageOfSharesOutstanding_473b1796-f35e-4457-8a01-003f0aaa4177" xlink:href="ardx-20221231.xsd#ardx_IncreaseInSharesReservedForIssuanceOptionForAnnualIncreaseAsPercentageOfSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f58245df-7fa3-4fef-8bb8-09a13f723a5c" xlink:to="loc_ardx_IncreaseInSharesReservedForIssuanceOptionForAnnualIncreaseAsPercentageOfSharesOutstanding_473b1796-f35e-4457-8a01-003f0aaa4177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponExerciseOfStockOptions_b39b7aec-488f-4fd3-aae5-6f81679cb3e4" xlink:href="ardx-20221231.xsd#ardx_IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponExerciseOfStockOptions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f58245df-7fa3-4fef-8bb8-09a13f723a5c" xlink:to="loc_ardx_IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponExerciseOfStockOptions_b39b7aec-488f-4fd3-aae5-6f81679cb3e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CommonStockSubjectToIssuedInducementGrantsShares_fb28e987-9815-4815-9452-57313382a031" xlink:href="ardx-20221231.xsd#ardx_CommonStockSubjectToIssuedInducementGrantsShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f58245df-7fa3-4fef-8bb8-09a13f723a5c" xlink:to="loc_ardx_CommonStockSubjectToIssuedInducementGrantsShares_fb28e987-9815-4815-9452-57313382a031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_927d034f-7e32-4685-a119-83181dfe9c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f58245df-7fa3-4fef-8bb8-09a13f723a5c" xlink:to="loc_us-gaap_SharePrice_927d034f-7e32-4685-a119-83181dfe9c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_61678f2c-299d-4065-b85d-f55f865cc7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f58245df-7fa3-4fef-8bb8-09a13f723a5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_61678f2c-299d-4065-b85d-f55f865cc7a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ff34e7ea-505a-4cc7-8b58-18079477faa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f58245df-7fa3-4fef-8bb8-09a13f723a5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ff34e7ea-505a-4cc7-8b58-18079477faa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6c3d1a0a-b246-4268-8edd-b43fdc1bad09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f58245df-7fa3-4fef-8bb8-09a13f723a5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6c3d1a0a-b246-4268-8edd-b43fdc1bad09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_b7e3e855-9a23-4bad-bbae-f877546f03df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f58245df-7fa3-4fef-8bb8-09a13f723a5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_b7e3e855-9a23-4bad-bbae-f877546f03df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3e6e5a0b-3c2e-4e73-be88-14d3d6c39b81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f58245df-7fa3-4fef-8bb8-09a13f723a5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3e6e5a0b-3c2e-4e73-be88-14d3d6c39b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8c2912ab-a87c-4722-b392-8d46ecc788d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f58245df-7fa3-4fef-8bb8-09a13f723a5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8c2912ab-a87c-4722-b392-8d46ecc788d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_b2774deb-b6e9-4f7f-b2e3-d7d13cae97a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f58245df-7fa3-4fef-8bb8-09a13f723a5c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_b2774deb-b6e9-4f7f-b2e3-d7d13cae97a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_36353fdb-11d8-4215-b9ba-ec158bc22483" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f58245df-7fa3-4fef-8bb8-09a13f723a5c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_36353fdb-11d8-4215-b9ba-ec158bc22483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesUnderEmployeeStockPurchasePlan_22894912-46d3-47c6-8cfd-552305cd7530" xlink:href="ardx-20221231.xsd#ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesUnderEmployeeStockPurchasePlan"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_f58245df-7fa3-4fef-8bb8-09a13f723a5c" xlink:to="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesUnderEmployeeStockPurchasePlan_22894912-46d3-47c6-8cfd-552305cd7530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#EquityIncentivePlansStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_985d8505-1c3c-48ca-98bc-272278905cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9ddbfe0a-1191-490f-a34d-1f8c10b65a40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_985d8505-1c3c-48ca-98bc-272278905cdc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9ddbfe0a-1191-490f-a34d-1f8c10b65a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4877e3cd-dc6e-4869-add5-39c25d193c36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9ddbfe0a-1191-490f-a34d-1f8c10b65a40" xlink:to="loc_us-gaap_AwardTypeAxis_4877e3cd-dc6e-4869-add5-39c25d193c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d4ddddca-b4ef-4c83-a929-3d153bd382ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4877e3cd-dc6e-4869-add5-39c25d193c36" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d4ddddca-b4ef-4c83-a929-3d153bd382ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_fa73869a-99de-4239-863c-3ad77b19a42c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d4ddddca-b4ef-4c83-a929-3d153bd382ee" xlink:to="loc_us-gaap_EmployeeStockOptionMember_fa73869a-99de-4239-863c-3ad77b19a42c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4f90cc5b-355d-4289-a51c-4cebbda26ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9ddbfe0a-1191-490f-a34d-1f8c10b65a40" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4f90cc5b-355d-4289-a51c-4cebbda26ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_SharesAvailableForGrantRollForward_e5d45748-f93c-40d4-bbc5-2be295427405" xlink:href="ardx-20221231.xsd#ardx_SharesAvailableForGrantRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4f90cc5b-355d-4289-a51c-4cebbda26ddb" xlink:to="loc_ardx_SharesAvailableForGrantRollForward_e5d45748-f93c-40d4-bbc5-2be295427405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4fadacc4-c5c3-4fc0-9ea8-e0c80d6c8b16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_SharesAvailableForGrantRollForward_e5d45748-f93c-40d4-bbc5-2be295427405" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4fadacc4-c5c3-4fc0-9ea8-e0c80d6c8b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToAuthorizedInPeriod_4b86b04a-bf34-413a-98df-1d501fb392a8" xlink:href="ardx-20221231.xsd#ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToAuthorizedInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_SharesAvailableForGrantRollForward_e5d45748-f93c-40d4-bbc5-2be295427405" xlink:to="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToAuthorizedInPeriod_4b86b04a-bf34-413a-98df-1d501fb392a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToGrantedInPeriod_a61ccdfe-56e6-4e9e-9a94-7aa230777639" xlink:href="ardx-20221231.xsd#ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToGrantedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_SharesAvailableForGrantRollForward_e5d45748-f93c-40d4-bbc5-2be295427405" xlink:to="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToGrantedInPeriod_a61ccdfe-56e6-4e9e-9a94-7aa230777639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToCanceledInPeriod_738cda17-b094-489b-a923-aac6401ece23" xlink:href="ardx-20221231.xsd#ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToCanceledInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_SharesAvailableForGrantRollForward_e5d45748-f93c-40d4-bbc5-2be295427405" xlink:to="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToCanceledInPeriod_738cda17-b094-489b-a923-aac6401ece23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToStockIssuedForServicesInPeriod_90829926-9b89-4c89-9a3b-1191724788c9" xlink:href="ardx-20221231.xsd#ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToStockIssuedForServicesInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_SharesAvailableForGrantRollForward_e5d45748-f93c-40d4-bbc5-2be295427405" xlink:to="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToStockIssuedForServicesInPeriod_90829926-9b89-4c89-9a3b-1191724788c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3e1647f3-1e85-431f-bf61-c991055073fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_SharesAvailableForGrantRollForward_e5d45748-f93c-40d4-bbc5-2be295427405" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3e1647f3-1e85-431f-bf61-c991055073fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_82e8c1c1-1c56-42c0-b7de-a2d59efb12e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4f90cc5b-355d-4289-a51c-4cebbda26ddb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_82e8c1c1-1c56-42c0-b7de-a2d59efb12e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b1083c52-6306-4da6-9494-38a31dc07022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_82e8c1c1-1c56-42c0-b7de-a2d59efb12e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b1083c52-6306-4da6-9494-38a31dc07022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_cfbf1b02-433d-4177-97cc-81a25b95928f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_82e8c1c1-1c56-42c0-b7de-a2d59efb12e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_cfbf1b02-433d-4177-97cc-81a25b95928f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_da025575-263e-4628-b47a-9a74ea512637" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_82e8c1c1-1c56-42c0-b7de-a2d59efb12e7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_da025575-263e-4628-b47a-9a74ea512637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1117ad07-1406-47f3-9da6-2db6dc045a31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_82e8c1c1-1c56-42c0-b7de-a2d59efb12e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1117ad07-1406-47f3-9da6-2db6dc045a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4c45373f-099b-40c7-999a-a523f15f7ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_82e8c1c1-1c56-42c0-b7de-a2d59efb12e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4c45373f-099b-40c7-999a-a523f15f7ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_5d16601d-6c83-42a9-a7f7-6a5a90b797e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4f90cc5b-355d-4289-a51c-4cebbda26ddb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_5d16601d-6c83-42a9-a7f7-6a5a90b797e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_f8d844a5-9fb6-4909-bfa3-eeece62e3949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4f90cc5b-355d-4289-a51c-4cebbda26ddb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_f8d844a5-9fb6-4909-bfa3-eeece62e3949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3c68c64b-cf22-4117-bcd5-dbd044cbfdbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4f90cc5b-355d-4289-a51c-4cebbda26ddb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3c68c64b-cf22-4117-bcd5-dbd044cbfdbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_fb34090f-36a2-476f-940d-11c810dc7f69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3c68c64b-cf22-4117-bcd5-dbd044cbfdbf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_fb34090f-36a2-476f-940d-11c810dc7f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_911f9076-58ca-4606-9d83-5e8f82cd7c52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3c68c64b-cf22-4117-bcd5-dbd044cbfdbf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_911f9076-58ca-4606-9d83-5e8f82cd7c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_241ae984-7049-49e5-93d4-21a9b5f09473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3c68c64b-cf22-4117-bcd5-dbd044cbfdbf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_241ae984-7049-49e5-93d4-21a9b5f09473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4df37603-5676-4d77-858a-1cd2f77b7b25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3c68c64b-cf22-4117-bcd5-dbd044cbfdbf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4df37603-5676-4d77-858a-1cd2f77b7b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_725a6d10-1acf-460f-80ed-2b37203bbfb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3c68c64b-cf22-4117-bcd5-dbd044cbfdbf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_725a6d10-1acf-460f-80ed-2b37203bbfb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_4647c9bf-e426-4057-9761-f4d4c799c00a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4f90cc5b-355d-4289-a51c-4cebbda26ddb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_4647c9bf-e426-4057-9761-f4d4c799c00a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3fc8476f-f2e5-4998-8e3e-13fd7f0a2436" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4f90cc5b-355d-4289-a51c-4cebbda26ddb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3fc8476f-f2e5-4998-8e3e-13fd7f0a2436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_StockOptionsWeightedAverageRemainingContractualTermAbstract_058878bd-7160-4657-92ff-9716c4a6465f" xlink:href="ardx-20221231.xsd#ardx_StockOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4f90cc5b-355d-4289-a51c-4cebbda26ddb" xlink:to="loc_ardx_StockOptionsWeightedAverageRemainingContractualTermAbstract_058878bd-7160-4657-92ff-9716c4a6465f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c15a4917-9a0d-4aac-bdbc-516399be6e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_StockOptionsWeightedAverageRemainingContractualTermAbstract_058878bd-7160-4657-92ff-9716c4a6465f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c15a4917-9a0d-4aac-bdbc-516399be6e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_589a5956-edaa-42ac-83e9-1507a176713b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_StockOptionsWeightedAverageRemainingContractualTermAbstract_058878bd-7160-4657-92ff-9716c4a6465f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_589a5956-edaa-42ac-83e9-1507a176713b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_70586958-406e-45c8-915a-c07adc5b6207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_StockOptionsWeightedAverageRemainingContractualTermAbstract_058878bd-7160-4657-92ff-9716c4a6465f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_70586958-406e-45c8-915a-c07adc5b6207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_StockOptionsAggregateIntrinsicValueAbstract_b18dce39-a43e-4eed-aa2b-2b919e5962fd" xlink:href="ardx-20221231.xsd#ardx_StockOptionsAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4f90cc5b-355d-4289-a51c-4cebbda26ddb" xlink:to="loc_ardx_StockOptionsAggregateIntrinsicValueAbstract_b18dce39-a43e-4eed-aa2b-2b919e5962fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1bad0ff6-1e8e-4b7d-9ae4-542a4624ddb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_StockOptionsAggregateIntrinsicValueAbstract_b18dce39-a43e-4eed-aa2b-2b919e5962fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1bad0ff6-1e8e-4b7d-9ae4-542a4624ddb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_75142d1f-e263-4697-8558-1d4b99bc0142" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_StockOptionsAggregateIntrinsicValueAbstract_b18dce39-a43e-4eed-aa2b-2b919e5962fd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_75142d1f-e263-4697-8558-1d4b99bc0142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_04dba744-e55c-4d8a-8ce1-5d688a416949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_StockOptionsAggregateIntrinsicValueAbstract_b18dce39-a43e-4eed-aa2b-2b919e5962fd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_04dba744-e55c-4d8a-8ce1-5d688a416949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansValuationAssumptionsforStockOptionsDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#EquityIncentivePlansValuationAssumptionsforStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansValuationAssumptionsforStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9479b998-dfc0-4563-9937-a95dd37cdc1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_759eef25-7145-4d00-a93f-94d5a8972b70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9479b998-dfc0-4563-9937-a95dd37cdc1e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_759eef25-7145-4d00-a93f-94d5a8972b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_01f0c420-f228-4615-984e-433a994ac7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_759eef25-7145-4d00-a93f-94d5a8972b70" xlink:to="loc_us-gaap_AwardTypeAxis_01f0c420-f228-4615-984e-433a994ac7c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_718eb1d6-74d9-4ea9-95b0-a91f9e2cdfde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_01f0c420-f228-4615-984e-433a994ac7c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_718eb1d6-74d9-4ea9-95b0-a91f9e2cdfde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_dfb5b6c7-f920-472e-ba8a-90c46740c0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_718eb1d6-74d9-4ea9-95b0-a91f9e2cdfde" xlink:to="loc_us-gaap_EmployeeStockOptionMember_dfb5b6c7-f920-472e-ba8a-90c46740c0b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed134030-dadf-4cab-ab27-5d3350324fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_759eef25-7145-4d00-a93f-94d5a8972b70" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed134030-dadf-4cab-ab27-5d3350324fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0a535f41-50af-4204-986a-5353180e64b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed134030-dadf-4cab-ab27-5d3350324fb0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0a535f41-50af-4204-986a-5353180e64b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b5e9d3cd-3242-4c7d-9fe2-c346c133e590" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed134030-dadf-4cab-ab27-5d3350324fb0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b5e9d3cd-3242-4c7d-9fe2-c346c133e590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_56652d95-b09b-489b-a185-9622df0faf30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed134030-dadf-4cab-ab27-5d3350324fb0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_56652d95-b09b-489b-a185-9622df0faf30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_59f5b076-1fe3-49f1-bdb1-89418431149b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ed134030-dadf-4cab-ab27-5d3350324fb0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_59f5b076-1fe3-49f1-bdb1-89418431149b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#EquityIncentivePlansRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_acf2afd6-1ecd-4efa-a603-16123a5c9954" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a91a0f81-b8e5-41ec-8d68-cf1410bbf2f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_acf2afd6-1ecd-4efa-a603-16123a5c9954" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a91a0f81-b8e5-41ec-8d68-cf1410bbf2f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e4671064-9dbb-44b6-aae2-3610f8bb6a17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a91a0f81-b8e5-41ec-8d68-cf1410bbf2f3" xlink:to="loc_us-gaap_AwardTypeAxis_e4671064-9dbb-44b6-aae2-3610f8bb6a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_00ae4b97-35c5-4159-943a-ac4de4d0b449" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e4671064-9dbb-44b6-aae2-3610f8bb6a17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_00ae4b97-35c5-4159-943a-ac4de4d0b449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8faa6be5-4816-48e1-8a3c-b577ea33dc78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_00ae4b97-35c5-4159-943a-ac4de4d0b449" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8faa6be5-4816-48e1-8a3c-b577ea33dc78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_55098dac-b9c4-4878-bcc2-0df168d26ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a91a0f81-b8e5-41ec-8d68-cf1410bbf2f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_55098dac-b9c4-4878-bcc2-0df168d26ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_756204f1-9b69-4390-9aee-0df5ab131dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_55098dac-b9c4-4878-bcc2-0df168d26ea1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_756204f1-9b69-4390-9aee-0df5ab131dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3354d59d-2c72-4a58-ae07-a15a9a6cc17c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_756204f1-9b69-4390-9aee-0df5ab131dbd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3354d59d-2c72-4a58-ae07-a15a9a6cc17c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3a38ad8d-6f57-40ea-874e-d9a2a0ca23e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_756204f1-9b69-4390-9aee-0df5ab131dbd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3a38ad8d-6f57-40ea-874e-d9a2a0ca23e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ccdcfb1f-0b7d-413e-94d8-7b22e8caf856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_756204f1-9b69-4390-9aee-0df5ab131dbd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ccdcfb1f-0b7d-413e-94d8-7b22e8caf856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c4241dfd-a9d7-45fc-a92f-ec200a323d77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_756204f1-9b69-4390-9aee-0df5ab131dbd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c4241dfd-a9d7-45fc-a92f-ec200a323d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_41c64dd2-d3a8-4653-ae76-ab602704f499" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_756204f1-9b69-4390-9aee-0df5ab131dbd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_41c64dd2-d3a8-4653-ae76-ab602704f499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c24050ce-146b-4dfc-b476-3524c45260dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_55098dac-b9c4-4878-bcc2-0df168d26ea1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c24050ce-146b-4dfc-b476-3524c45260dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7e5d8fb4-6e8d-4491-85b7-6d952ee7e76c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c24050ce-146b-4dfc-b476-3524c45260dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7e5d8fb4-6e8d-4491-85b7-6d952ee7e76c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1334db81-579c-4ffe-bd07-2904152f4e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c24050ce-146b-4dfc-b476-3524c45260dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1334db81-579c-4ffe-bd07-2904152f4e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_15b71e3e-886f-4fa2-b69a-864605f4a03d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c24050ce-146b-4dfc-b476-3524c45260dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_15b71e3e-886f-4fa2-b69a-864605f4a03d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e4174be3-a470-4216-a1d8-5cadb1ed6f38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c24050ce-146b-4dfc-b476-3524c45260dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e4174be3-a470-4216-a1d8-5cadb1ed6f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1da34b40-c61b-4e48-87a7-80b1daeb02ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c24050ce-146b-4dfc-b476-3524c45260dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1da34b40-c61b-4e48-87a7-80b1daeb02ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#EquityIncentivePlansEmployeeStockPurchasePlanDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansEmployeeStockPurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6b2a87cf-440f-4445-b49a-500e8c2b75dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a206eb91-5168-4f46-8794-178ac453debb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6b2a87cf-440f-4445-b49a-500e8c2b75dc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a206eb91-5168-4f46-8794-178ac453debb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_72b1de21-3275-47a0-b1f0-6581ce881902" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a206eb91-5168-4f46-8794-178ac453debb" xlink:to="loc_us-gaap_PlanNameAxis_72b1de21-3275-47a0-b1f0-6581ce881902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_bbb63140-f8e1-4049-b95d-27780f3f4db8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_72b1de21-3275-47a0-b1f0-6581ce881902" xlink:to="loc_us-gaap_PlanNameDomain_bbb63140-f8e1-4049-b95d-27780f3f4db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EmployeeStockPurchasePlanMember_e57408b3-6eac-4c4b-938e-cf763a2c81ca" xlink:href="ardx-20221231.xsd#ardx_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_bbb63140-f8e1-4049-b95d-27780f3f4db8" xlink:to="loc_ardx_EmployeeStockPurchasePlanMember_e57408b3-6eac-4c4b-938e-cf763a2c81ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ce6ae36f-e434-4a6f-a102-eb0c64014c95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a206eb91-5168-4f46-8794-178ac453debb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ce6ae36f-e434-4a6f-a102-eb0c64014c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EmployeeStockPurchasePlanSharesAvailableRollForward_c787bfcc-2c4a-4690-a51c-ec9a5b362717" xlink:href="ardx-20221231.xsd#ardx_EmployeeStockPurchasePlanSharesAvailableRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ce6ae36f-e434-4a6f-a102-eb0c64014c95" xlink:to="loc_ardx_EmployeeStockPurchasePlanSharesAvailableRollForward_c787bfcc-2c4a-4690-a51c-ec9a5b362717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4e7af3a2-42bf-40a9-8b13-c726ba92687c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_EmployeeStockPurchasePlanSharesAvailableRollForward_c787bfcc-2c4a-4690-a51c-ec9a5b362717" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4e7af3a2-42bf-40a9-8b13-c726ba92687c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsPurchases_141ba8e8-8e65-42b5-bb1b-d592f50e854d" xlink:href="ardx-20221231.xsd#ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsPurchases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_EmployeeStockPurchasePlanSharesAvailableRollForward_c787bfcc-2c4a-4690-a51c-ec9a5b362717" xlink:to="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsPurchases_141ba8e8-8e65-42b5-bb1b-d592f50e854d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_de8800ff-cb6f-4094-a4fd-291b605574cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_EmployeeStockPurchasePlanSharesAvailableRollForward_c787bfcc-2c4a-4690-a51c-ec9a5b362717" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_de8800ff-cb6f-4094-a4fd-291b605574cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EmployeeStockPurchasePlanSharesPurchasedRollForward_0d6eb861-2150-4a31-8d46-d5b8e6084882" xlink:href="ardx-20221231.xsd#ardx_EmployeeStockPurchasePlanSharesPurchasedRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ce6ae36f-e434-4a6f-a102-eb0c64014c95" xlink:to="loc_ardx_EmployeeStockPurchasePlanSharesPurchasedRollForward_0d6eb861-2150-4a31-8d46-d5b8e6084882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesStockPurchasePlanPurchasedNumber_23df0ff5-60cd-4ac0-ac8f-cea4c3b061cb" xlink:href="ardx-20221231.xsd#ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesStockPurchasePlanPurchasedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_EmployeeStockPurchasePlanSharesPurchasedRollForward_0d6eb861-2150-4a31-8d46-d5b8e6084882" xlink:to="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesStockPurchasePlanPurchasedNumber_23df0ff5-60cd-4ac0-ac8f-cea4c3b061cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_2a688349-c2aa-47fa-80b4-dd8d12075e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_EmployeeStockPurchasePlanSharesPurchasedRollForward_0d6eb861-2150-4a31-8d46-d5b8e6084882" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_2a688349-c2aa-47fa-80b4-dd8d12075e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesStockPurchasePlanPurchasedNumber_8609bc2c-f5c4-422c-91ff-4129f5d3b117" xlink:href="ardx-20221231.xsd#ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesStockPurchasePlanPurchasedNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_EmployeeStockPurchasePlanSharesPurchasedRollForward_0d6eb861-2150-4a31-8d46-d5b8e6084882" xlink:to="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesStockPurchasePlanPurchasedNumber_8609bc2c-f5c4-422c-91ff-4129f5d3b117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare_c41ee6f1-a6f8-4cb1-b545-cc8388ff5914" xlink:href="ardx-20221231.xsd#ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ce6ae36f-e434-4a6f-a102-eb0c64014c95" xlink:to="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare_c41ee6f1-a6f8-4cb1-b545-cc8388ff5914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanGrossProceeds_6da3844a-c94c-4320-98cc-2c6f7da4077b" xlink:href="ardx-20221231.xsd#ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanGrossProceeds"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ce6ae36f-e434-4a6f-a102-eb0c64014c95" xlink:to="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanGrossProceeds_6da3844a-c94c-4320-98cc-2c6f7da4077b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansValuationAssumptionsforESPPDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#EquityIncentivePlansValuationAssumptionsforESPPDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansValuationAssumptionsforESPPDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8c7e5ee7-0797-468f-a149-8d9b48ba3a7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_849040e3-66bd-4de0-88fb-c41633831903" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8c7e5ee7-0797-468f-a149-8d9b48ba3a7c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_849040e3-66bd-4de0-88fb-c41633831903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_32d878bb-7977-4070-8aa5-b0033feb30e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_849040e3-66bd-4de0-88fb-c41633831903" xlink:to="loc_us-gaap_PlanNameAxis_32d878bb-7977-4070-8aa5-b0033feb30e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7fe43479-e893-470a-b378-678c8398537f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_32d878bb-7977-4070-8aa5-b0033feb30e0" xlink:to="loc_us-gaap_PlanNameDomain_7fe43479-e893-470a-b378-678c8398537f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EmployeeStockPurchasePlanMember_5d30dbbe-8386-4eef-8a59-779a44379ac4" xlink:href="ardx-20221231.xsd#ardx_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7fe43479-e893-470a-b378-678c8398537f" xlink:to="loc_ardx_EmployeeStockPurchasePlanMember_5d30dbbe-8386-4eef-8a59-779a44379ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_86fc0be5-1ac3-411f-b44c-77dd993e40bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_849040e3-66bd-4de0-88fb-c41633831903" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_86fc0be5-1ac3-411f-b44c-77dd993e40bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4feb738f-0818-4fd3-b9f9-3e2d494fc4df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_86fc0be5-1ac3-411f-b44c-77dd993e40bd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4feb738f-0818-4fd3-b9f9-3e2d494fc4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_86eae2f7-4d8d-434b-8138-970f496a8cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_86fc0be5-1ac3-411f-b44c-77dd993e40bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_86eae2f7-4d8d-434b-8138-970f496a8cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_75c88651-22ab-4773-a87b-db44a4fa7fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_86fc0be5-1ac3-411f-b44c-77dd993e40bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_75c88651-22ab-4773-a87b-db44a4fa7fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a7a9fb1e-173d-444e-b2e5-3e0481c2d285" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_86fc0be5-1ac3-411f-b44c-77dd993e40bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a7a9fb1e-173d-444e-b2e5-3e0481c2d285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#EquityIncentivePlansStockBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ac03a57f-9dd2-4974-a131-22b77249cb39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_04417ac8-a6c6-4013-a6bb-c164ed327475" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ac03a57f-9dd2-4974-a131-22b77249cb39" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_04417ac8-a6c6-4013-a6bb-c164ed327475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2089961c-0e02-4e9c-b236-4dc54b48c362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_04417ac8-a6c6-4013-a6bb-c164ed327475" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2089961c-0e02-4e9c-b236-4dc54b48c362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_643eb763-7570-4c20-8233-5f3fc0ac1c55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2089961c-0e02-4e9c-b236-4dc54b48c362" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_643eb763-7570-4c20-8233-5f3fc0ac1c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_7e3d26aa-44af-4740-b962-17825c622301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_643eb763-7570-4c20-8233-5f3fc0ac1c55" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_7e3d26aa-44af-4740-b962-17825c622301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7dd9d1b3-0bdd-4d42-afee-b827e9055942" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_643eb763-7570-4c20-8233-5f3fc0ac1c55" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7dd9d1b3-0bdd-4d42-afee-b827e9055942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_07fa9425-4df5-402c-9575-a41348762d55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_04417ac8-a6c6-4013-a6bb-c164ed327475" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_07fa9425-4df5-402c-9575-a41348762d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1e54ae58-6713-41ca-91b8-3b58d8748cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_07fa9425-4df5-402c-9575-a41348762d55" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1e54ae58-6713-41ca-91b8-3b58d8748cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d4920f59-4e53-4c27-aefc-8cd6fe51f3ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4f89a1f3-b8ff-48ef-90cf-2617ad5a815b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d4920f59-4e53-4c27-aefc-8cd6fe51f3ee" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4f89a1f3-b8ff-48ef-90cf-2617ad5a815b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d408d773-60d7-4317-98cf-777799de37c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4f89a1f3-b8ff-48ef-90cf-2617ad5a815b" xlink:to="loc_us-gaap_PlanNameAxis_d408d773-60d7-4317-98cf-777799de37c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_bb4aacee-6034-4271-9ebb-7e87ccc65ced" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_d408d773-60d7-4317-98cf-777799de37c7" xlink:to="loc_us-gaap_PlanNameDomain_bb4aacee-6034-4271-9ebb-7e87ccc65ced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EmployeeStockPurchasePlanMember_0394e5cc-fa53-4812-afe9-81975bea3bd9" xlink:href="ardx-20221231.xsd#ardx_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_bb4aacee-6034-4271-9ebb-7e87ccc65ced" xlink:to="loc_ardx_EmployeeStockPurchasePlanMember_0394e5cc-fa53-4812-afe9-81975bea3bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_12a2d913-1b62-4936-8beb-5491d1135866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4f89a1f3-b8ff-48ef-90cf-2617ad5a815b" xlink:to="loc_us-gaap_AwardTypeAxis_12a2d913-1b62-4936-8beb-5491d1135866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9076ac3c-1577-4a5e-be69-8dda51a6988f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_12a2d913-1b62-4936-8beb-5491d1135866" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9076ac3c-1577-4a5e-be69-8dda51a6988f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_672c6012-2e7e-4391-ab7e-52589e7c3c08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9076ac3c-1577-4a5e-be69-8dda51a6988f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_672c6012-2e7e-4391-ab7e-52589e7c3c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_706a06c5-ca56-4f0f-9705-d2f1a9a43d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9076ac3c-1577-4a5e-be69-8dda51a6988f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_706a06c5-ca56-4f0f-9705-d2f1a9a43d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f0c3e8-6bb1-47c1-adb9-7801e85de4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4f89a1f3-b8ff-48ef-90cf-2617ad5a815b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f0c3e8-6bb1-47c1-adb9-7801e85de4e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3b640e92-d8bb-49f9-a065-bc2c4fd1f34f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f0c3e8-6bb1-47c1-adb9-7801e85de4e3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3b640e92-d8bb-49f9-a065-bc2c4fd1f34f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5af3972b-b1cd-43c0-8f11-6d942e3a77e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f0c3e8-6bb1-47c1-adb9-7801e85de4e3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5af3972b-b1cd-43c0-8f11-6d942e3a77e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/RestructuringDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#RestructuringDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/RestructuringDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_dc145330-daad-4f20-aeba-1be363cdad96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_37db8736-d548-4e3f-9f94-fc4dbf131ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_dc145330-daad-4f20-aeba-1be363cdad96" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_37db8736-d548-4e3f-9f94-fc4dbf131ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c1c3e68f-7615-4081-a53c-df78c6bc24f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_37db8736-d548-4e3f-9f94-fc4dbf131ff7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c1c3e68f-7615-4081-a53c-df78c6bc24f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_33caf570-7f45-4a2a-ad7d-fbdad0d07c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c1c3e68f-7615-4081-a53c-df78c6bc24f9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_33caf570-7f45-4a2a-ad7d-fbdad0d07c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_aa7079ba-a1cc-4d9a-a4b5-331a65182dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_33caf570-7f45-4a2a-ad7d-fbdad0d07c9c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_aa7079ba-a1cc-4d9a-a4b5-331a65182dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_20965baf-6c5b-4268-a7af-fc8ffc7366e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_33caf570-7f45-4a2a-ad7d-fbdad0d07c9c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_20965baf-6c5b-4268-a7af-fc8ffc7366e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_75ced200-6e12-4d30-b0a0-8716b7453667" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_37db8736-d548-4e3f-9f94-fc4dbf131ff7" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_75ced200-6e12-4d30-b0a0-8716b7453667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_1ce3d273-d144-4655-adb4-9b7cd3e6ce41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_75ced200-6e12-4d30-b0a0-8716b7453667" xlink:to="loc_us-gaap_RestructuringCharges_1ce3d273-d144-4655-adb4-9b7cd3e6ce41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveCurrent_09f8e274-53c6-4e06-ab4c-05f3807c5e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_75ced200-6e12-4d30-b0a0-8716b7453667" xlink:to="loc_us-gaap_RestructuringReserveCurrent_09f8e274-53c6-4e06-ab4c-05f3807c5e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/PropertyandEquipmentNetBalancesDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#PropertyandEquipmentNetBalancesDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/PropertyandEquipmentNetBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_09e729c0-312e-4f4c-9d91-57af601c1b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_741b8667-afe0-452e-9d55-85e480022c57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_09e729c0-312e-4f4c-9d91-57af601c1b3b" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_741b8667-afe0-452e-9d55-85e480022c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cb56546f-1c81-464c-9015-21f66cfafc67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_741b8667-afe0-452e-9d55-85e480022c57" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cb56546f-1c81-464c-9015-21f66cfafc67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_65e9ef6f-d26b-42f3-b51e-d51866027158" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cb56546f-1c81-464c-9015-21f66cfafc67" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_65e9ef6f-d26b-42f3-b51e-d51866027158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LaboratoryEquipmentMember_0e48c14c-0f08-4b43-a0e6-c6f2c7e01b33" xlink:href="ardx-20221231.xsd#ardx_LaboratoryEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_65e9ef6f-d26b-42f3-b51e-d51866027158" xlink:to="loc_ardx_LaboratoryEquipmentMember_0e48c14c-0f08-4b43-a0e6-c6f2c7e01b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_OfficeEquipmentAndFurnitureMember_f4a84db9-be63-48d5-b159-a89eaa49ac58" xlink:href="ardx-20221231.xsd#ardx_OfficeEquipmentAndFurnitureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_65e9ef6f-d26b-42f3-b51e-d51866027158" xlink:to="loc_ardx_OfficeEquipmentAndFurnitureMember_f4a84db9-be63-48d5-b159-a89eaa49ac58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_a8a46d80-0de2-4e7c-b023-717ebd1c8b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_65e9ef6f-d26b-42f3-b51e-d51866027158" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_a8a46d80-0de2-4e7c-b023-717ebd1c8b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c2345e30-7812-4069-a8a9-164d37aa3ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_741b8667-afe0-452e-9d55-85e480022c57" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c2345e30-7812-4069-a8a9-164d37aa3ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_00407546-8913-4ee8-9d00-dfe5de1efc17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c2345e30-7812-4069-a8a9-164d37aa3ff8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_00407546-8913-4ee8-9d00-dfe5de1efc17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f3895e46-227b-4e00-b7bc-e4be679bc9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c2345e30-7812-4069-a8a9-164d37aa3ff8" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f3895e46-227b-4e00-b7bc-e4be679bc9a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_72ebd1e3-1950-4545-94b0-8d7f77a49769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c2345e30-7812-4069-a8a9-164d37aa3ff8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_72ebd1e3-1950-4545-94b0-8d7f77a49769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/PropertyandEquipmentNetNarrativeDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#PropertyandEquipmentNetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/PropertyandEquipmentNetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_3aa188f2-45d4-4177-83b4-9ce7b926a37e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_ba6170a0-ed4b-4e0e-bdf5-c9b77d402d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_3aa188f2-45d4-4177-83b4-9ce7b926a37e" xlink:to="loc_us-gaap_Depreciation_ba6170a0-ed4b-4e0e-bdf5-c9b77d402d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals_88e2ffea-1fa5-46cd-87ce-abaa88b559a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_3aa188f2-45d4-4177-83b4-9ce7b926a37e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisposals_88e2ffea-1fa5-46cd-87ce-abaa88b559a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_6649608d-b58a-4527-a833-8fc23176fc61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_3aa188f2-45d4-4177-83b4-9ce7b926a37e" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_6649608d-b58a-4527-a833-8fc23176fc61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_aa9ef8fa-74ff-424d-a992-32a782f04e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_3aa188f2-45d4-4177-83b4-9ce7b926a37e" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_aa9ef8fa-74ff-424d-a992-32a782f04e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#AccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_410ccaef-85ac-405a-b0bd-fdde0e22c812" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AccruedPaymentsDueToRelatedParty_407428e6-ab06-4890-bb47-51112f7aaf64" xlink:href="ardx-20221231.xsd#ardx_AccruedPaymentsDueToRelatedParty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_410ccaef-85ac-405a-b0bd-fdde0e22c812" xlink:to="loc_ardx_AccruedPaymentsDueToRelatedParty_407428e6-ab06-4890-bb47-51112f7aaf64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AccruedGrossToNetRevenueLiabilities_056ed985-77fe-478f-9c8f-1867e4ce34d8" xlink:href="ardx-20221231.xsd#ardx_AccruedGrossToNetRevenueLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_410ccaef-85ac-405a-b0bd-fdde0e22c812" xlink:to="loc_ardx_AccruedGrossToNetRevenueLiabilities_056ed985-77fe-478f-9c8f-1867e4ce34d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AccruedContractManufacturingCosts_5455880e-1ef6-436b-8cda-0b240abcceaf" xlink:href="ardx-20221231.xsd#ardx_AccruedContractManufacturingCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_410ccaef-85ac-405a-b0bd-fdde0e22c812" xlink:to="loc_ardx_AccruedContractManufacturingCosts_5455880e-1ef6-436b-8cda-0b240abcceaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DerivativeLiabilityForExitFees_ddf4f12e-1aa1-427f-b82f-563636e6e485" xlink:href="ardx-20221231.xsd#ardx_DerivativeLiabilityForExitFees"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_410ccaef-85ac-405a-b0bd-fdde0e22c812" xlink:to="loc_ardx_DerivativeLiabilityForExitFees_ddf4f12e-1aa1-427f-b82f-563636e6e485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AccruedNonClinicalResearchAndDevelopmentExpenses_3bfef43b-98b2-45f4-bec5-3de0b656b856" xlink:href="ardx-20221231.xsd#ardx_AccruedNonClinicalResearchAndDevelopmentExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_410ccaef-85ac-405a-b0bd-fdde0e22c812" xlink:to="loc_ardx_AccruedNonClinicalResearchAndDevelopmentExpenses_3bfef43b-98b2-45f4-bec5-3de0b656b856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AccruedProfessionalAndConsultantFeesCurrent_7a51e3da-fa91-45ed-9db5-fbfba9a62f95" xlink:href="ardx-20221231.xsd#ardx_AccruedProfessionalAndConsultantFeesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_410ccaef-85ac-405a-b0bd-fdde0e22c812" xlink:to="loc_ardx_AccruedProfessionalAndConsultantFeesCurrent_7a51e3da-fa91-45ed-9db5-fbfba9a62f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AccruedSalesAndMarketingExpenses_c86b655d-1dd1-4be7-8069-0f5d74a859e6" xlink:href="ardx-20221231.xsd#ardx_AccruedSalesAndMarketingExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_410ccaef-85ac-405a-b0bd-fdde0e22c812" xlink:to="loc_ardx_AccruedSalesAndMarketingExpenses_c86b655d-1dd1-4be7-8069-0f5d74a859e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AccruedClinicalExpenses_464b8ea5-7cbe-4a2a-ad57-389952bbcff1" xlink:href="ardx-20221231.xsd#ardx_AccruedClinicalExpenses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_410ccaef-85ac-405a-b0bd-fdde0e22c812" xlink:to="loc_ardx_AccruedClinicalExpenses_464b8ea5-7cbe-4a2a-ad57-389952bbcff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_af9a39c4-dd61-4940-a60b-dea9c02047eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_410ccaef-85ac-405a-b0bd-fdde0e22c812" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_af9a39c4-dd61-4940-a60b-dea9c02047eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_55f48c9d-31ff-47d8-809a-96ccbde238e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_410ccaef-85ac-405a-b0bd-fdde0e22c812" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_55f48c9d-31ff-47d8-809a-96ccbde238e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#IncomeTaxesComponentsofProvisionforIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_93bd18e5-4c1a-48a4-a225-2dab47aaf036" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_b5401a1a-ce1e-4fdc-9e61-eafc40898be0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_93bd18e5-4c1a-48a4-a225-2dab47aaf036" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_b5401a1a-ce1e-4fdc-9e61-eafc40898be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3c433123-5394-4623-ba56-0f80605ae011" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_b5401a1a-ce1e-4fdc-9e61-eafc40898be0" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3c433123-5394-4623-ba56-0f80605ae011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1854a269-e9af-418e-93f1-9b08e2555e76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3c433123-5394-4623-ba56-0f80605ae011" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1854a269-e9af-418e-93f1-9b08e2555e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_1a7197d4-54c1-4ed4-b797-05d4b9d72035" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3c433123-5394-4623-ba56-0f80605ae011" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_1a7197d4-54c1-4ed4-b797-05d4b9d72035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_58aeb6b5-b81e-4e0e-a0bf-bfab9383afa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3c433123-5394-4623-ba56-0f80605ae011" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_58aeb6b5-b81e-4e0e-a0bf-bfab9383afa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_816f05f7-1fca-457d-a201-b716257c0d24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_b5401a1a-ce1e-4fdc-9e61-eafc40898be0" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_816f05f7-1fca-457d-a201-b716257c0d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_ed42f13a-2737-469c-9c0c-f8383ca78283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_816f05f7-1fca-457d-a201-b716257c0d24" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_ed42f13a-2737-469c-9c0c-f8383ca78283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_339d55de-1514-41ed-81cc-5b1398a572e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_816f05f7-1fca-457d-a201-b716257c0d24" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_339d55de-1514-41ed-81cc-5b1398a572e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_affc8805-1cf1-4654-9a05-1e59596da178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_b5401a1a-ce1e-4fdc-9e61-eafc40898be0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_affc8805-1cf1-4654-9a05-1e59596da178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/IncomeTaxesReconciliationofEffectiveTaxRateDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#IncomeTaxesReconciliationofEffectiveTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/IncomeTaxesReconciliationofEffectiveTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_51cb6480-7f53-48c7-a64c-c0344c6f528d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_4e67f5d0-1037-48e8-8b76-78b3b2a969fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_51cb6480-7f53-48c7-a64c-c0344c6f528d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_4e67f5d0-1037-48e8-8b76-78b3b2a969fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_4c5b8adf-63ef-4aeb-af2a-680ea742a1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_51cb6480-7f53-48c7-a64c-c0344c6f528d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_4c5b8adf-63ef-4aeb-af2a-680ea742a1b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_b2e2b5a9-0cdb-4a71-a2ad-61d95f1b4a89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_51cb6480-7f53-48c7-a64c-c0344c6f528d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_b2e2b5a9-0cdb-4a71-a2ad-61d95f1b4a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitExecutiveCompensationDisallowedIRCSec162mPercent_7b09570d-2410-4dd2-bb90-6a56d945b817" xlink:href="ardx-20221231.xsd#ardx_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitExecutiveCompensationDisallowedIRCSec162mPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_51cb6480-7f53-48c7-a64c-c0344c6f528d" xlink:to="loc_ardx_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitExecutiveCompensationDisallowedIRCSec162mPercent_7b09570d-2410-4dd2-bb90-6a56d945b817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_74ac3c1e-42ee-4efa-83a6-842c660f36ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_51cb6480-7f53-48c7-a64c-c0344c6f528d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_74ac3c1e-42ee-4efa-83a6-842c660f36ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_382e5c3c-592d-4a49-a071-5b7aa3f15b47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_51cb6480-7f53-48c7-a64c-c0344c6f528d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_382e5c3c-592d-4a49-a071-5b7aa3f15b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_ed2e411e-570c-48db-8b3d-01a3bda43552" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_51cb6480-7f53-48c7-a64c-c0344c6f528d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_ed2e411e-570c-48db-8b3d-01a3bda43552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_71b089f9-ceeb-4f58-ae0e-acd5574585c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_51cb6480-7f53-48c7-a64c-c0344c6f528d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_71b089f9-ceeb-4f58-ae0e-acd5574585c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#IncomeTaxesComponentsofDeferredTaxAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_16a3a59f-11a3-4e5b-a082-6e5ba5654bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_8b338fdd-9f65-4407-9d3d-4f448822fb1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_16a3a59f-11a3-4e5b-a082-6e5ba5654bc5" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_8b338fdd-9f65-4407-9d3d-4f448822fb1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DeferredTaxAssetsAmortizationAndDepreciation_072c5ccc-f4ef-4fa0-abf2-856733bea46f" xlink:href="ardx-20221231.xsd#ardx_DeferredTaxAssetsAmortizationAndDepreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_8b338fdd-9f65-4407-9d3d-4f448822fb1f" xlink:to="loc_ardx_DeferredTaxAssetsAmortizationAndDepreciation_072c5ccc-f4ef-4fa0-abf2-856733bea46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_278c07ad-212b-4c2a-a23e-bdf6cf2211d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_8b338fdd-9f65-4407-9d3d-4f448822fb1f" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_278c07ad-212b-4c2a-a23e-bdf6cf2211d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_70a97a96-ab85-4c01-922d-47dc922a54db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_8b338fdd-9f65-4407-9d3d-4f448822fb1f" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_70a97a96-ab85-4c01-922d-47dc922a54db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_8c628ed4-5789-4365-a571-b53849a4d1fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_8b338fdd-9f65-4407-9d3d-4f448822fb1f" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_8c628ed4-5789-4365-a571-b53849a4d1fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_75fecc05-ac42-4f1e-b083-30444dd98ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_8b338fdd-9f65-4407-9d3d-4f448822fb1f" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_75fecc05-ac42-4f1e-b083-30444dd98ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1031a43b-2caf-4e7f-9b67-dff7f0bb5c89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_8b338fdd-9f65-4407-9d3d-4f448822fb1f" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_1031a43b-2caf-4e7f-9b67-dff7f0bb5c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2502c16c-347d-4c57-b89b-53595363ca1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_8b338fdd-9f65-4407-9d3d-4f448822fb1f" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2502c16c-347d-4c57-b89b-53595363ca1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_34191333-cb94-4179-8cc8-19c5996843a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_8b338fdd-9f65-4407-9d3d-4f448822fb1f" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_34191333-cb94-4179-8cc8-19c5996843a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_903d1985-f0fc-42cd-bc4b-a321c49a5f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_16a3a59f-11a3-4e5b-a082-6e5ba5654bc5" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_903d1985-f0fc-42cd-bc4b-a321c49a5f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DeferredTaxLiabilitiesRightOfUseAsset_ea6c1add-8594-4ecc-b7d4-69bde0596f99" xlink:href="ardx-20221231.xsd#ardx_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_903d1985-f0fc-42cd-bc4b-a321c49a5f6a" xlink:to="loc_ardx_DeferredTaxLiabilitiesRightOfUseAsset_ea6c1add-8594-4ecc-b7d4-69bde0596f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_e253e218-0095-49b2-a5e4-88742c3831bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_903d1985-f0fc-42cd-bc4b-a321c49a5f6a" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_e253e218-0095-49b2-a5e4-88742c3831bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_0fcefa77-f148-4015-a092-d751b7442aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_16a3a59f-11a3-4e5b-a082-6e5ba5654bc5" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_0fcefa77-f148-4015-a092-d751b7442aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ea31a614-bb13-4a03-be0a-c9b877627800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_IncomeTaxDisclosureTable_4bc2de47-8a60-4c3d-8730-0562f98157b2" xlink:href="ardx-20221231.xsd#ardx_IncomeTaxDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ea31a614-bb13-4a03-be0a-c9b877627800" xlink:to="loc_ardx_IncomeTaxDisclosureTable_4bc2de47-8a60-4c3d-8730-0562f98157b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_3af502a5-3b70-4370-af2e-95ee47958f80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_IncomeTaxDisclosureTable_4bc2de47-8a60-4c3d-8730-0562f98157b2" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_3af502a5-3b70-4370-af2e-95ee47958f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_25fd9571-2910-4971-910a-5cb7a957b276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_3af502a5-3b70-4370-af2e-95ee47958f80" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_25fd9571-2910-4971-910a-5cb7a957b276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_68f760ab-4e43-4217-8fad-75e58616b680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_25fd9571-2910-4971-910a-5cb7a957b276" xlink:to="loc_us-gaap_DomesticCountryMember_68f760ab-4e43-4217-8fad-75e58616b680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_ffbc49e7-8cd2-4ca6-be6c-b08833a303af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_25fd9571-2910-4971-910a-5cb7a957b276" xlink:to="loc_us-gaap_ForeignCountryMember_ffbc49e7-8cd2-4ca6-be6c-b08833a303af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_48a21601-471f-4d0c-82a6-ff24e276ddf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_25fd9571-2910-4971-910a-5cb7a957b276" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_48a21601-471f-4d0c-82a6-ff24e276ddf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_ad974fa8-7d9f-45d4-b040-81ee619ee2c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_IncomeTaxDisclosureTable_4bc2de47-8a60-4c3d-8730-0562f98157b2" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_ad974fa8-7d9f-45d4-b040-81ee619ee2c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_b9d829e1-6c59-49c3-908f-399db3103d11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_ad974fa8-7d9f-45d4-b040-81ee619ee2c3" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_b9d829e1-6c59-49c3-908f-399db3103d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_6fc78369-fdc5-40a8-a47c-5b2aa7d9c3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_b9d829e1-6c59-49c3-908f-399db3103d11" xlink:to="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_6fc78369-fdc5-40a8-a47c-5b2aa7d9c3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TaxAuthorityStatesOtherThanCaliforniaMember_f82c9495-d4ee-456b-9749-a678512bf927" xlink:href="ardx-20221231.xsd#ardx_TaxAuthorityStatesOtherThanCaliforniaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_b9d829e1-6c59-49c3-908f-399db3103d11" xlink:to="loc_ardx_TaxAuthorityStatesOtherThanCaliforniaMember_f82c9495-d4ee-456b-9749-a678512bf927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_132b2551-a7a8-446d-a1e9-d485cd04ad24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_IncomeTaxDisclosureTable_4bc2de47-8a60-4c3d-8730-0562f98157b2" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_132b2551-a7a8-446d-a1e9-d485cd04ad24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_8404e880-63d8-4c14-9bce-dc63f8665238" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_132b2551-a7a8-446d-a1e9-d485cd04ad24" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_8404e880-63d8-4c14-9bce-dc63f8665238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_b23ad8f2-517e-4a4c-9d90-ee64bc897cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_8404e880-63d8-4c14-9bce-dc63f8665238" xlink:to="loc_us-gaap_ResearchMember_b23ad8f2-517e-4a4c-9d90-ee64bc897cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_MinimumTaxCreditCarryforwardMember_516c8762-7276-4b8e-8e7e-bc36f3b9aa0e" xlink:href="ardx-20221231.xsd#ardx_MinimumTaxCreditCarryforwardMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_8404e880-63d8-4c14-9bce-dc63f8665238" xlink:to="loc_ardx_MinimumTaxCreditCarryforwardMember_516c8762-7276-4b8e-8e7e-bc36f3b9aa0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_IncomeTaxDisclosureLineItems_a535559f-1d41-4398-8a99-141fd47efa51" xlink:href="ardx-20221231.xsd#ardx_IncomeTaxDisclosureLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_IncomeTaxDisclosureTable_4bc2de47-8a60-4c3d-8730-0562f98157b2" xlink:to="loc_ardx_IncomeTaxDisclosureLineItems_a535559f-1d41-4398-8a99-141fd47efa51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_00287ef5-fa3c-454e-a15f-c9a69e3b260c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_IncomeTaxDisclosureLineItems_a535559f-1d41-4398-8a99-141fd47efa51" xlink:to="loc_us-gaap_OperatingLossCarryforwards_00287ef5-fa3c-454e-a15f-c9a69e3b260c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_8f7961ca-8432-4e17-b506-abb61610e12b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_IncomeTaxDisclosureLineItems_a535559f-1d41-4398-8a99-141fd47efa51" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_8f7961ca-8432-4e17-b506-abb61610e12b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_OperatingLossCarryforwardsWithoutExpiration_0316e6aa-c182-4585-a69c-8478d3751438" xlink:href="ardx-20221231.xsd#ardx_OperatingLossCarryforwardsWithoutExpiration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_IncomeTaxDisclosureLineItems_a535559f-1d41-4398-8a99-141fd47efa51" xlink:to="loc_ardx_OperatingLossCarryforwardsWithoutExpiration_0316e6aa-c182-4585-a69c-8478d3751438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_0e11eb7a-b303-40f1-90f1-7f0e44cc014c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_IncomeTaxDisclosureLineItems_a535559f-1d41-4398-8a99-141fd47efa51" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_0e11eb7a-b303-40f1-90f1-7f0e44cc014c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_888b22b4-4e27-4711-bbc0-12a65c2a52c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_7c7127c8-6855-4856-987b-9b7ca8bfa7d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_888b22b4-4e27-4711-bbc0-12a65c2a52c2" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_7c7127c8-6855-4856-987b-9b7ca8bfa7d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_6ac3e03c-d17b-45e8-9f93-8e5b71afb3d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_7c7127c8-6855-4856-987b-9b7ca8bfa7d4" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_6ac3e03c-d17b-45e8-9f93-8e5b71afb3d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_3daf9482-2dd1-4f1f-bdf5-1a3beac367e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_7c7127c8-6855-4856-987b-9b7ca8bfa7d4" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_3daf9482-2dd1-4f1f-bdf5-1a3beac367e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_4aa68b06-fe72-4f26-aa2d-0c824a6842a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_7c7127c8-6855-4856-987b-9b7ca8bfa7d4" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_4aa68b06-fe72-4f26-aa2d-0c824a6842a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_a302b47a-fe5a-44d6-ad6f-d35353e1fb50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_7c7127c8-6855-4856-987b-9b7ca8bfa7d4" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_a302b47a-fe5a-44d6-ad6f-d35353e1fb50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_4993671e-a38d-46a9-938d-74e02c464596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_7c7127c8-6855-4856-987b-9b7ca8bfa7d4" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_4993671e-a38d-46a9-938d-74e02c464596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/GeographicInformationandConcentrationsRevenuebyGeographicalAreaDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#GeographicInformationandConcentrationsRevenuebyGeographicalAreaDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/GeographicInformationandConcentrationsRevenuebyGeographicalAreaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_bf4d41ad-d235-47e0-8edf-afb82805b6ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_e9cf9487-e4b6-4989-92f6-4f96d6eca650" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_bf4d41ad-d235-47e0-8edf-afb82805b6ee" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_e9cf9487-e4b6-4989-92f6-4f96d6eca650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_09f77312-b0ca-4ccf-b3d8-9f09e93a228b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_e9cf9487-e4b6-4989-92f6-4f96d6eca650" xlink:to="loc_srt_StatementGeographicalAxis_09f77312-b0ca-4ccf-b3d8-9f09e93a228b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ca0a1faa-18c4-41c8-8e90-242a03846373" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_09f77312-b0ca-4ccf-b3d8-9f09e93a228b" xlink:to="loc_srt_SegmentGeographicalDomain_ca0a1faa-18c4-41c8-8e90-242a03846373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_115168f4-66b7-4973-ba02-d1e9f4fc2029" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ca0a1faa-18c4-41c8-8e90-242a03846373" xlink:to="loc_country_US_115168f4-66b7-4973-ba02-d1e9f4fc2029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_c47f10a9-32ab-4029-a090-858486691cc8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AsiaPacificMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ca0a1faa-18c4-41c8-8e90-242a03846373" xlink:to="loc_srt_AsiaPacificMember_c47f10a9-32ab-4029-a090-858486691cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_5cb3ea89-6131-4402-b9d7-3d0afd744bdb" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ca0a1faa-18c4-41c8-8e90-242a03846373" xlink:to="loc_country_CA_5cb3ea89-6131-4402-b9d7-3d0afd744bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_718c4a95-6c1d-42d9-b434-129e31353a37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_e9cf9487-e4b6-4989-92f6-4f96d6eca650" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_718c4a95-6c1d-42d9-b434-129e31353a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1397ba9e-57d8-40d7-ad00-c09a63346e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_718c4a95-6c1d-42d9-b434-129e31353a37" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1397ba9e-57d8-40d7-ad00-c09a63346e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/GeographicInformationandConcentrationsConcentrationRiskDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#GeographicInformationandConcentrationsConcentrationRiskDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/GeographicInformationandConcentrationsConcentrationRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_6cb332cf-49ab-4b25-b7c9-774861503860" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_571d585a-8591-47d3-a1b6-c8ee1b301fae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_6cb332cf-49ab-4b25-b7c9-774861503860" xlink:to="loc_us-gaap_ConcentrationRiskTable_571d585a-8591-47d3-a1b6-c8ee1b301fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a797424e-c829-4ee2-8983-64a0143f3ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_571d585a-8591-47d3-a1b6-c8ee1b301fae" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a797424e-c829-4ee2-8983-64a0143f3ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ef027fe0-bf6b-4b1a-9db4-075fb7f0b53c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a797424e-c829-4ee2-8983-64a0143f3ee7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ef027fe0-bf6b-4b1a-9db4-075fb7f0b53c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_06050cc0-fed5-431c-a264-4613b27771da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ef027fe0-bf6b-4b1a-9db4-075fb7f0b53c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_06050cc0-fed5-431c-a264-4613b27771da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_2bd0de90-c9d9-4585-a4b3-4546bb592baf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_571d585a-8591-47d3-a1b6-c8ee1b301fae" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_2bd0de90-c9d9-4585-a4b3-4546bb592baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_ace6caf6-4b62-49ef-990c-08dbd0e91c46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_2bd0de90-c9d9-4585-a4b3-4546bb592baf" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_ace6caf6-4b62-49ef-990c-08dbd0e91c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationPartnershipConcentrationRiskMember_fd85d758-3f83-42ff-9867-4ed3bb5135e0" xlink:href="ardx-20221231.xsd#ardx_CollaborationPartnershipConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_ace6caf6-4b62-49ef-990c-08dbd0e91c46" xlink:to="loc_ardx_CollaborationPartnershipConcentrationRiskMember_fd85d758-3f83-42ff-9867-4ed3bb5135e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_cbd9d7be-6d38-4dde-96ae-bdd7fc2dfd90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_571d585a-8591-47d3-a1b6-c8ee1b301fae" xlink:to="loc_us-gaap_TypeOfArrangementAxis_cbd9d7be-6d38-4dde-96ae-bdd7fc2dfd90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2769415a-7fb1-4dd2-a6df-c6eb801e3582" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cbd9d7be-6d38-4dde-96ae-bdd7fc2dfd90" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2769415a-7fb1-4dd2-a6df-c6eb801e3582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_KkcMember_f5ba93ab-d210-4a1a-a3f9-66bcd744e73c" xlink:href="ardx-20221231.xsd#ardx_KkcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2769415a-7fb1-4dd2-a6df-c6eb801e3582" xlink:to="loc_ardx_KkcMember_f5ba93ab-d210-4a1a-a3f9-66bcd744e73c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_KnightTherapeuticsIncMember_f4f9c75b-6995-4159-bb87-48616a38c286" xlink:href="ardx-20221231.xsd#ardx_KnightTherapeuticsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2769415a-7fb1-4dd2-a6df-c6eb801e3582" xlink:to="loc_ardx_KnightTherapeuticsIncMember_f4f9c75b-6995-4159-bb87-48616a38c286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AmerisourceBergenDrugCorporationMember_e850c466-9203-4182-8c3f-d657b6c4b461" xlink:href="ardx-20221231.xsd#ardx_AmerisourceBergenDrugCorporationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2769415a-7fb1-4dd2-a6df-c6eb801e3582" xlink:to="loc_ardx_AmerisourceBergenDrugCorporationMember_e850c466-9203-4182-8c3f-d657b6c4b461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_9d9d43cd-2084-46c4-8866-de5f0cbcfd31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_571d585a-8591-47d3-a1b6-c8ee1b301fae" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_9d9d43cd-2084-46c4-8866-de5f0cbcfd31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_1c02b2dc-32c5-437c-86ca-b579b2ea8bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9d9d43cd-2084-46c4-8866-de5f0cbcfd31" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_1c02b2dc-32c5-437c-86ca-b579b2ea8bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#NetLossPerShareComputationofNetLossPerCommonShareDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_124b61d5-3eaf-49f6-b3a7-213a0d4407f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_ec27a72a-bff5-45ea-9b99-6bef25c7dc2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_124b61d5-3eaf-49f6-b3a7-213a0d4407f2" xlink:to="loc_us-gaap_NetIncomeLossAbstract_ec27a72a-bff5-45ea-9b99-6bef25c7dc2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_59c7a1b3-e105-445a-bc9d-b869f0db1d42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_ec27a72a-bff5-45ea-9b99-6bef25c7dc2d" xlink:to="loc_us-gaap_NetIncomeLoss_59c7a1b3-e105-445a-bc9d-b869f0db1d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_0d242ace-47ef-4980-9911-c9d490e83c95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_124b61d5-3eaf-49f6-b3a7-213a0d4407f2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_0d242ace-47ef-4980-9911-c9d490e83c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_62ddf0e9-db98-4884-8c3c-dea8a0cdb7b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_0d242ace-47ef-4980-9911-c9d490e83c95" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_62ddf0e9-db98-4884-8c3c-dea8a0cdb7b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a763661c-aedc-426c-997c-acf3c0aa589d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_0d242ace-47ef-4980-9911-c9d490e83c95" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a763661c-aedc-426c-997c-acf3c0aa589d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_00ec09e9-1bbf-4622-ad55-0e0a7c2c5a43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_124b61d5-3eaf-49f6-b3a7-213a0d4407f2" xlink:to="loc_us-gaap_EarningsPerShareBasic_00ec09e9-1bbf-4622-ad55-0e0a7c2c5a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_e254ca4e-b93e-4a0c-9aa6-a34143c96cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_124b61d5-3eaf-49f6-b3a7-213a0d4407f2" xlink:to="loc_us-gaap_EarningsPerShareDiluted_e254ca4e-b93e-4a0c-9aa6-a34143c96cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/NetLossPerShareAntiDilutiveSecuritiesandPotentialCommonSharesDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#NetLossPerShareAntiDilutiveSecuritiesandPotentialCommonSharesDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/NetLossPerShareAntiDilutiveSecuritiesandPotentialCommonSharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e3f62a62-a16e-415e-b350-296db53de39b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_77344a0e-348f-4e5c-b3ce-a628d741d321" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e3f62a62-a16e-415e-b350-296db53de39b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_77344a0e-348f-4e5c-b3ce-a628d741d321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d4bb5dbd-db94-4ce1-90ad-cacf7536de45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_77344a0e-348f-4e5c-b3ce-a628d741d321" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d4bb5dbd-db94-4ce1-90ad-cacf7536de45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1486c113-4759-4f8a-a2c1-ca218d66595b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d4bb5dbd-db94-4ce1-90ad-cacf7536de45" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1486c113-4759-4f8a-a2c1-ca218d66595b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5fdb2ea8-4008-4e22-afdc-b341e5bd3a80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1486c113-4759-4f8a-a2c1-ca218d66595b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5fdb2ea8-4008-4e22-afdc-b341e5bd3a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_aa9eb04c-1b8b-4a2e-9a7a-81a65c0d632b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1486c113-4759-4f8a-a2c1-ca218d66595b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_aa9eb04c-1b8b-4a2e-9a7a-81a65c0d632b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EmployeeStockPurchasePlanMember_f74c8feb-d0e2-4355-b0eb-2d8f77247dd1" xlink:href="ardx-20221231.xsd#ardx_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1486c113-4759-4f8a-a2c1-ca218d66595b" xlink:to="loc_ardx_EmployeeStockPurchasePlanMember_f74c8feb-d0e2-4355-b0eb-2d8f77247dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_1464cd55-3e2f-4250-b353-1c15be65a3fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1486c113-4759-4f8a-a2c1-ca218d66595b" xlink:to="loc_us-gaap_WarrantMember_1464cd55-3e2f-4250-b353-1c15be65a3fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2102d69b-48bb-47f1-a6a4-755c052eb03e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_77344a0e-348f-4e5c-b3ce-a628d741d321" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2102d69b-48bb-47f1-a6a4-755c052eb03e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c7b974df-a0bf-4de6-96ff-a5cdd47df061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2102d69b-48bb-47f1-a6a4-755c052eb03e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c7b974df-a0bf-4de6-96ff-a5cdd47df061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PotentialCommonSharesAntiDilutiveEffectOnSecurities_2acb87c0-b08c-4250-b7fd-be61e6de87cd" xlink:href="ardx-20221231.xsd#ardx_PotentialCommonSharesAntiDilutiveEffectOnSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2102d69b-48bb-47f1-a6a4-755c052eb03e" xlink:to="loc_ardx_PotentialCommonSharesAntiDilutiveEffectOnSecurities_2acb87c0-b08c-4250-b7fd-be61e6de87cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_89a5fd4c-9ba7-4a13-bdb8-313780d596c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_fc8c5b55-087b-452d-8687-eaddbb22a99f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_89a5fd4c-9ba7-4a13-bdb8-313780d596c6" xlink:to="loc_us-gaap_LossContingenciesTable_fc8c5b55-087b-452d-8687-eaddbb22a99f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_c3f63811-eb7b-4f05-8fbd-6e75313c69f7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_fc8c5b55-087b-452d-8687-eaddbb22a99f" xlink:to="loc_srt_LitigationCaseAxis_c3f63811-eb7b-4f05-8fbd-6e75313c69f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_b23cd93c-96e2-4277-aace-ecb27c8b8c24" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_c3f63811-eb7b-4f05-8fbd-6e75313c69f7" xlink:to="loc_srt_LitigationCaseTypeDomain_b23cd93c-96e2-4277-aace-ecb27c8b8c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_StrezsakVersusArdelyxIncMember_caf5fd9a-6eff-49bc-9b0e-96e8dcb822ab" xlink:href="ardx-20221231.xsd#ardx_StrezsakVersusArdelyxIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_b23cd93c-96e2-4277-aace-ecb27c8b8c24" xlink:to="loc_ardx_StrezsakVersusArdelyxIncMember_caf5fd9a-6eff-49bc-9b0e-96e8dcb822ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_GoVersusRaabMember_46b79874-b07b-4e41-a377-5baf45df3632" xlink:href="ardx-20221231.xsd#ardx_GoVersusRaabMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_b23cd93c-96e2-4277-aace-ecb27c8b8c24" xlink:to="loc_ardx_GoVersusRaabMember_46b79874-b07b-4e41-a377-5baf45df3632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_c7270121-6d99-4dcb-8dea-c5240d5bd881" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_fc8c5b55-087b-452d-8687-eaddbb22a99f" xlink:to="loc_us-gaap_LossContingenciesLineItems_c7270121-6d99-4dcb-8dea-c5240d5bd881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_a3ea2c6f-b492-459e-a62e-4c3b111f0378" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_c7270121-6d99-4dcb-8dea-c5240d5bd881" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_a3ea2c6f-b492-459e-a62e-4c3b111f0378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfDefendants_56883498-c4b5-42e6-a12e-7dfe75dd5e42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfDefendants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_c7270121-6d99-4dcb-8dea-c5240d5bd881" xlink:to="loc_us-gaap_LossContingencyNumberOfDefendants_56883498-c4b5-42e6-a12e-7dfe75dd5e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_49f10407-152f-42ef-9090-b2817c2da5f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_c7270121-6d99-4dcb-8dea-c5240d5bd881" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_49f10407-152f-42ef-9090-b2817c2da5f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="ardx-20221231.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_baa1d558-120d-4f9c-a16d-6f3d1c63019e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_625be18f-e99d-4f8b-967e-c8003ebccaa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_baa1d558-120d-4f9c-a16d-6f3d1c63019e" xlink:to="loc_us-gaap_SubsequentEventTable_625be18f-e99d-4f8b-967e-c8003ebccaa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_77c2ecdb-e8c3-4b8b-a7fa-655621a29c13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_625be18f-e99d-4f8b-967e-c8003ebccaa5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_77c2ecdb-e8c3-4b8b-a7fa-655621a29c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_851c5c22-a140-4b4b-a040-ac11f3d3c8a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_77c2ecdb-e8c3-4b8b-a7fa-655621a29c13" xlink:to="loc_us-gaap_ClassOfStockDomain_851c5c22-a140-4b4b-a040-ac11f3d3c8a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_607b960c-6aff-4a9b-b70e-b6f2bc4c4f08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_851c5c22-a140-4b4b-a040-ac11f3d3c8a1" xlink:to="loc_us-gaap_CommonClassAMember_607b960c-6aff-4a9b-b70e-b6f2bc4c4f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_983aea83-7558-4feb-a656-82f2937595cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_625be18f-e99d-4f8b-967e-c8003ebccaa5" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_983aea83-7558-4feb-a656-82f2937595cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_bb4e4107-7813-4681-8bda-31e2c5865f00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_983aea83-7558-4feb-a656-82f2937595cf" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_bb4e4107-7813-4681-8bda-31e2c5865f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5160c79c-107d-4e15-a3b4-186637e9a3b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_bb4e4107-7813-4681-8bda-31e2c5865f00" xlink:to="loc_us-gaap_SubsequentEventMember_5160c79c-107d-4e15-a3b4-186637e9a3b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_73319e3b-07c7-4a50-a8e5-793304835676" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_625be18f-e99d-4f8b-967e-c8003ebccaa5" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_73319e3b-07c7-4a50-a8e5-793304835676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fe044b64-adc1-4059-99a7-3194bbed299e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_73319e3b-07c7-4a50-a8e5-793304835676" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fe044b64-adc1-4059-99a7-3194bbed299e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember_435c3398-7d96-46d8-b49a-6c4a79a6e960" xlink:href="ardx-20221231.xsd#ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fe044b64-adc1-4059-99a7-3194bbed299e" xlink:to="loc_ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember_435c3398-7d96-46d8-b49a-6c4a79a6e960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_57d213d4-ef95-4d28-875e-cc2a06bf6115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_625be18f-e99d-4f8b-967e-c8003ebccaa5" xlink:to="loc_us-gaap_DebtInstrumentAxis_57d213d4-ef95-4d28-875e-cc2a06bf6115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7a3bf491-9978-4aeb-a4db-c81c592ad685" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_57d213d4-ef95-4d28-875e-cc2a06bf6115" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7a3bf491-9978-4aeb-a4db-c81c592ad685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermBLoanMember_fbc481b6-6f33-408b-9c80-ec8dfcc512e9" xlink:href="ardx-20221231.xsd#ardx_TermBLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7a3bf491-9978-4aeb-a4db-c81c592ad685" xlink:to="loc_ardx_TermBLoanMember_fbc481b6-6f33-408b-9c80-ec8dfcc512e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f6896fea-2fc3-472c-921e-27fa83547eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_625be18f-e99d-4f8b-967e-c8003ebccaa5" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f6896fea-2fc3-472c-921e-27fa83547eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c0f6b464-bcb6-495a-b6bd-9924f40493e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f6896fea-2fc3-472c-921e-27fa83547eb1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c0f6b464-bcb6-495a-b6bd-9924f40493e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_c589f811-a310-4cea-a6e8-e10ae0092cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c0f6b464-bcb6-495a-b6bd-9924f40493e1" xlink:to="loc_us-gaap_LoansPayableMember_c589f811-a310-4cea-a6e8-e10ae0092cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_a35f36f0-f3b3-4da2-ba22-0cfdb1f56498" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_625be18f-e99d-4f8b-967e-c8003ebccaa5" xlink:to="loc_us-gaap_SubsequentEventLineItems_a35f36f0-f3b3-4da2-ba22-0cfdb1f56498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_MaximumAggregateOfferingPrice_1d9888ad-2b2e-4645-b414-ccbf152f250e" xlink:href="ardx-20221231.xsd#ardx_MaximumAggregateOfferingPrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_a35f36f0-f3b3-4da2-ba22-0cfdb1f56498" xlink:to="loc_ardx_MaximumAggregateOfferingPrice_1d9888ad-2b2e-4645-b414-ccbf152f250e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_StockIssuanceCostCommissionPercent_403543ce-bc5e-4ced-8fb9-e6d744d4816e" xlink:href="ardx-20221231.xsd#ardx_StockIssuanceCostCommissionPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_a35f36f0-f3b3-4da2-ba22-0cfdb1f56498" xlink:to="loc_ardx_StockIssuanceCostCommissionPercent_403543ce-bc5e-4ced-8fb9-e6d744d4816e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_029d064d-0652-4202-90b8-1fc06aece5f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_a35f36f0-f3b3-4da2-ba22-0cfdb1f56498" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_029d064d-0652-4202-90b8-1fc06aece5f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentVariableRateBaseOption_33bb26bb-05d6-460e-b7eb-4487bf6dfc0e" xlink:href="ardx-20221231.xsd#ardx_DebtInstrumentVariableRateBaseOption"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_a35f36f0-f3b3-4da2-ba22-0cfdb1f56498" xlink:to="loc_ardx_DebtInstrumentVariableRateBaseOption_33bb26bb-05d6-460e-b7eb-4487bf6dfc0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentVariableRatePlusOption_c775de21-5e4c-4b26-a7b0-a32e3a689bb4" xlink:href="ardx-20221231.xsd#ardx_DebtInstrumentVariableRatePlusOption"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_a35f36f0-f3b3-4da2-ba22-0cfdb1f56498" xlink:to="loc_ardx_DebtInstrumentVariableRatePlusOption_c775de21-5e4c-4b26-a7b0-a32e3a689bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ardx-20221231_g1.jpg
<TEXT>
begin 644 ardx-20221231_g1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !N &X# 2(  A$! Q$!_\0
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&444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583747442192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARDELYX, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-1303944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">400 FIFTH AVE.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">SUITE 210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">WALTHAM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">745-1700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ARDX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89,227,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,492,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001437402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Portions of the Registrant&#8217;s Definitive Proxy Statement for its 2023 Annual Meeting of Stockholders, which will be filed with the Commission within 120 days of December&#160;31, 2022, the close of the Registrant&#8217;s 2022 fiscal year, are incorporated by reference into Part III of this Report</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583747341520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Mateo, California<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583752751072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 96,140<span></span>
</td>
<td class="nump">$ 72,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">27,769<span></span>
</td>
<td class="nump">44,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">7,733<span></span>
</td>
<td class="nump">502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory</a></td>
<td class="nump">3,282<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_PrepaidCommercialManufacturingCurrent', window );">Prepaid commercial manufacturing</a></td>
<td class="nump">13,567<span></span>
</td>
<td class="nump">9,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,112<span></span>
</td>
<td class="nump">7,052<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">153,603<span></span>
</td>
<td class="nump">133,649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,223<span></span>
</td>
<td class="nump">2,362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, non-current</a></td>
<td class="nump">25,064<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">9,295<span></span>
</td>
<td class="nump">12,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">881<span></span>
</td>
<td class="nump">1,150<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">190,066<span></span>
</td>
<td class="nump">149,913<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">10,859<span></span>
</td>
<td class="nump">4,277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">7,548<span></span>
</td>
<td class="nump">5,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="nump">3,894<span></span>
</td>
<td class="nump">3,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">26,711<span></span>
</td>
<td class="nump">32,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">4,211<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">12,380<span></span>
</td>
<td class="nump">7,366<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">65,603<span></span>
</td>
<td class="nump">52,821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">5,855<span></span>
</td>
<td class="nump">9,748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="nump">9,025<span></span>
</td>
<td class="nump">4,727<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_DeferredRoyaltyObligationNoncurrent', window );">Deferred royalty obligation related to the sale of future royalties</a></td>
<td class="nump">11,254<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">91,737<span></span>
</td>
<td class="nump">67,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of December&#160;31, 2022 and December&#160;31, 2021, respectively.</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 300,000,000 shares authorized; 198,575,016 and 130,182,535 shares issued and outstanding as of December&#160;31, 2022 and December&#160;31, 2021, respectively.</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">878,500<span></span>
</td>
<td class="nump">795,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(780,137)<span></span>
</td>
<td class="num">(712,930)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(54)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">98,329<span></span>
</td>
<td class="nump">82,617<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 190,066<span></span>
</td>
<td class="nump">$ 149,913<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_DeferredRoyaltyObligationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Royalty Obligation, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_DeferredRoyaltyObligationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_PrepaidCommercialManufacturingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Commercial Manufacturing, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_PrepaidCommercialManufacturingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583753139584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">198,575,016<span></span>
</td>
<td class="nump">130,182,535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">198,575,016<span></span>
</td>
<td class="nump">130,182,535<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583748641136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 52,158,000<span></span>
</td>
<td class="nump">$ 10,097,000<span></span>
</td>
<td class="nump">$ 7,571,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">4,117,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">145,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">35,201,000<span></span>
</td>
<td class="nump">91,140,000<span></span>
</td>
<td class="nump">65,053,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">76,599,000<span></span>
</td>
<td class="nump">72,303,000<span></span>
</td>
<td class="nump">33,153,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">115,917,000<span></span>
</td>
<td class="nump">164,443,000<span></span>
</td>
<td class="nump">98,351,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(63,759,000)<span></span>
</td>
<td class="num">(154,346,000)<span></span>
</td>
<td class="num">(90,780,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(3,400,000)<span></span>
</td>
<td class="num">(4,502,000)<span></span>
</td>
<td class="num">(5,099,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfAdvanceRoyalty', window );">Non-cash interest expense related to the sale of future royalties</a></td>
<td class="num">(1,673,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">1,633,000<span></span>
</td>
<td class="nump">687,000<span></span>
</td>
<td class="nump">1,568,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="num">(67,199,000)<span></span>
</td>
<td class="num">(158,161,000)<span></span>
</td>
<td class="num">(94,311,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (67,207,000)<span></span>
</td>
<td class="num">$ (158,165,000)<span></span>
</td>
<td class="num">$ (94,313,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of common stock - basic (in dollars per share)</a></td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="num">$ (1.52)<span></span>
</td>
<td class="num">$ (1.05)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of common stock - diluted (in dollars per share)</a></td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="num">$ (1.52)<span></span>
</td>
<td class="num">$ (1.05)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in computing net loss per share - basic</a></td>
<td class="nump">158,690,083<span></span>
</td>
<td class="nump">104,205,645<span></span>
</td>
<td class="nump">89,582,138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in computing net loss per share - diluted</a></td>
<td class="nump">158,690,083<span></span>
</td>
<td class="nump">104,205,645<span></span>
</td>
<td class="nump">89,582,138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (67,207,000)<span></span>
</td>
<td class="num">$ (158,165,000)<span></span>
</td>
<td class="num">$ (94,313,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized losses on available-for-sale securities</a></td>
<td class="num">(48,000)<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
<td class="num">(24,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(67,255,000)<span></span>
</td>
<td class="num">(158,167,000)<span></span>
</td>
<td class="num">(94,337,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">15,600,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ardx_ProductSupplyRevenueMember', window );">Product supply revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,527,000<span></span>
</td>
<td class="nump">907,000<span></span>
</td>
<td class="nump">1,501,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">Licensing revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">35,031,000<span></span>
</td>
<td class="nump">5,013,000<span></span>
</td>
<td class="nump">706,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ardx_CollaborativeDevelopmentMember', window );">Collaborative development revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,177,000<span></span>
</td>
<td class="nump">$ 5,364,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfAdvanceRoyalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense charged against earnings for the periodic recognition of the advance royalties. These royalties are paid in one accounting period, but are deducted from earnings over time through amortization. For example, royalties that are required to be paid in advance of production from a mineral, oil, or gas property and amortized over the period of right to produce these items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfAdvanceRoyalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ardx_ProductSupplyRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ardx_ProductSupplyRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ardx_CollaborativeDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ardx_CollaborativeDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583749129888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss) Income</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,817,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 186,655<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 647,078<span></span>
</td>
<td class="num">$ (460,452)<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="nump">310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">445,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of options</a></td>
<td class="nump">1,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">866,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in at the market offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,257,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in at the market offering</a></td>
<td class="nump">21,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">10,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized losses on available-for-sale securities</a></td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(94,313)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(94,313)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,599,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">126,112<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">680,872<span></span>
</td>
<td class="num">(554,765)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">386,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="nump">190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">331,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of options</a></td>
<td class="nump">584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid for net share settlement of equity awards</a></td>
<td class="num">(106)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(106)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in at the market offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,671,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in at the market offering</a></td>
<td class="nump">101,146<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">101,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">12,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized losses on available-for-sale securities</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(158,165)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(158,165)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,182,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">82,617<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">795,540<span></span>
</td>
<td class="num">(712,930)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">711,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="nump">$ 390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options (in shares)</a></td>
<td class="nump">14,000<span></span>
</td>
<td class="nump">14,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of options</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,243,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in at the market offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,114,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in at the market offering</a></td>
<td class="nump">71,625<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">71,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">10,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized losses on available-for-sale securities</a></td>
<td class="num">(48)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(67,207)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(67,207)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198,575,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 98,329<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 878,500<span></span>
</td>
<td class="num">$ (780,137)<span></span>
</td>
<td class="num">$ (54)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583747506672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (67,207)<span></span>
</td>
<td class="num">$ (158,165)<span></span>
</td>
<td class="num">$ (94,313)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">1,144<span></span>
</td>
<td class="nump">2,807<span></span>
</td>
<td class="nump">2,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash lease expense</a></td>
<td class="nump">3,457<span></span>
</td>
<td class="nump">3,085<span></span>
</td>
<td class="nump">2,147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">10,750<span></span>
</td>
<td class="nump">12,039<span></span>
</td>
<td class="nump">10,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Change in derivative liabilities</a></td>
<td class="nump">583<span></span>
</td>
<td class="num">(678)<span></span>
</td>
<td class="nump">407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnRestructuringOfDebt', window );">Debt refinancing costs</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Gain on sale of equipment</a></td>
<td class="num">(1,260)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Non-cash interest expense</a></td>
<td class="nump">1,962<span></span>
</td>
<td class="nump">283<span></span>
</td>
<td class="nump">413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_IncreaseDecreaseInUnbilledRevenue', window );">Unbilled revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(7,231)<span></span>
</td>
<td class="num">(502)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(28,346)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense', window );">Prepaid commercial manufacturing</a></td>
<td class="num">(4,161)<span></span>
</td>
<td class="num">(9,406)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">2,299<span></span>
</td>
<td class="nump">502<span></span>
</td>
<td class="num">(4,653)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">6,582<span></span>
</td>
<td class="num">(1,349)<span></span>
</td>
<td class="nump">3,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and benefits</a></td>
<td class="nump">2,126<span></span>
</td>
<td class="num">(250)<span></span>
</td>
<td class="nump">1,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(3,491)<span></span>
</td>
<td class="num">(2,853)<span></span>
</td>
<td class="num">(2,604)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued and other liabilities</a></td>
<td class="nump">4,138<span></span>
</td>
<td class="nump">1,386<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">8,509<span></span>
</td>
<td class="nump">550<span></span>
</td>
<td class="num">(364)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(70,044)<span></span>
</td>
<td class="num">(152,551)<span></span>
</td>
<td class="num">(81,435)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities and redemptions of investments</a></td>
<td class="nump">67,000<span></span>
</td>
<td class="nump">125,550<span></span>
</td>
<td class="nump">119,734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of investments</a></td>
<td class="num">(50,328)<span></span>
</td>
<td class="num">(72,735)<span></span>
</td>
<td class="num">(150,852)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">1,798<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(55)<span></span>
</td>
<td class="num">(1,867)<span></span>
</td>
<td class="num">(324)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">18,415<span></span>
</td>
<td class="nump">50,948<span></span>
</td>
<td class="num">(31,442)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from 2022 Loan, net of issuance costs</a></td>
<td class="nump">26,971<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfSecuredDebt', window );">Payments for 2018 Loan, net of costs</a></td>
<td class="num">(33,038)<span></span>
</td>
<td class="num">(19,444)<span></span>
</td>
<td class="num">(125)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts', window );">Proceeds from the sale of future royalties, net of issuance costs</a></td>
<td class="nump">9,581<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in at the market offering, net of issuance costs</a></td>
<td class="nump">71,625<span></span>
</td>
<td class="nump">101,146<span></span>
</td>
<td class="nump">21,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">202<span></span>
</td>
<td class="nump">1,403<span></span>
</td>
<td class="nump">1,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments for taxes related to net share settlement of equity awards</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(106)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">75,341<span></span>
</td>
<td class="nump">82,999<span></span>
</td>
<td class="nump">22,776<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">23,712<span></span>
</td>
<td class="num">(18,604)<span></span>
</td>
<td class="num">(90,101)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">72,428<span></span>
</td>
<td class="nump">91,032<span></span>
</td>
<td class="nump">181,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">96,140<span></span>
</td>
<td class="nump">72,428<span></span>
</td>
<td class="nump">91,032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplementary disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">2,901<span></span>
</td>
<td class="nump">3,469<span></span>
</td>
<td class="nump">4,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplementary disclosure of non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,604<span></span>
</td>
<td class="nump">450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of common stock for services</a></td>
<td class="nump">390<span></span>
</td>
<td class="nump">190<span></span>
</td>
<td class="nump">310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_DerivativeIssued', window );">Issuance of derivative in connection with issuance of loan payable</a></td>
<td class="nump">$ 375<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_DerivativeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the non-cash issuance of derivative in connection with issuance of loan payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_DerivativeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Prepaid Commercial Manufacturing Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_IncreaseDecreaseInUnbilledRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase or decrease in unbilled revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_IncreaseDecreaseInUnbilledRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Sale Of Future Royalties, Net Of Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2443-110228<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnRestructuringOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 60<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6402221&amp;loc=d3e15743-112638<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnRestructuringOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583750765584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text">ORGANIZATION AND BASIS OF PRESENTATION<div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ardelyx, Inc. (&#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) is a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs. We developed a unique and innovative platform that enabled the discovery of new biological mechanisms and pathways to develop potent, and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The first molecule we discovered and developed was tenapanor, a targeted, first-in-class, oral, small molecule therapy. Tenapanor, branded as IBSRELA, is approved in the U.S. for the treatment of adults with irritable bowel syndrome with constipation (&#8220;IBS-C&#8221;). Tenapanor is in development for the control of serum phosphorus in adult patients with chronic kidney disease (&#8220;CKD&#8221;) on dialysis under the brand name XPHOZAH. We also have a development stage asset, RDX013 for adult patients with CKD and/or heart failure with hyperkalemia, or elevated serum potassium, and a discovery phase asset, RDX020 for adult patients with metabolic acidosis, a serious electrolyte disorder, in patients with CKD.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in one business segment, which is the development and commercialization of biopharmaceutical products.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI https://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583755670704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the amounts reported in the financial statements and accompanying notes thereto. On an ongoing basis, management evaluates its estimates, including those related to recognition of revenue, clinical trial accruals, contract manufacturing accruals, fair value of assets and liabilities, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could materially differ from those estimates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had cash and short-term investments of approximately $123.9 million. We have incurred operating losses since inception in 2007 and our accumulated deficit as of December&#160;31, 2022 is $780.1&#160;million. Our current level of cash and short-term investments alone is not sufficient to meet our plans for the next twelve months following the issuance of these financial statements on March&#160;2, 2023. These factors raise substantial doubt regarding our ability to continue as a going concern for a period of one year from the issuance of these financial statements. We plan to address our operating cash flow requirements with our current cash and short-term investments, cash generated from product sales of IBSRELA, and if approved, cash generated from sales of XPHOZAH, our potential receipt of anticipated milestones payments from our collaboration partners, our potential receipt of anticipated payments from our Japanese collaboration partner under the second amendment to our License Agreement, with additional financing sources and through the implementation of cash preservation activities to reduce or defer discretionary spending.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no assurances that our efforts to meet our operating cash flow requirements will be successful. If our current cash and short-term investments as well as our plans to meet our operating cash flow requirements are not sufficient to fund necessary expenditures and meet our obligations for at least the next twelve months following the issuance of these financial statements, our liquidity, financial condition and business prospects will be materially affected. These financial statements have been prepared on a going concern basis and do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary in the event that we can no longer continue as a going concern. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments purchased with an original maturity date of 90 days or less on the date of purchase to be cash equivalents.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-Term Investments</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments consist of debt securities classified as available-for-sale and have maturities greater than 90&#160;days, but less than one&#160;year, from the date of acquisition. Short-term investments are carried at fair value based upon quoted market prices. Unrealized gains and losses on available-for-sale securities are included in accumulated other comprehensive loss on our balance sheets. The cost of available-for-sale securities sold is based on the specific-identification method.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents, short-term investments and accounts receivable. We are exposed to credit risks in the event of default by the counterparties to the extent of the amount recorded in its balance sheet. Cash, cash equivalents and short-term investments are invested through banks and other financial institutions in the U.S.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage our foreign currency exposures with the use of foreign currency purchases. We primarily conduct business in U.S. dollars; however, a portion of our expense and capital activities are transacted in foreign currencies which are subject to exchange rate fluctuations that can affect cash or earnings. We have been in a loss position and therefore our primary objective is to conserve and manage cash. There are generally two methods by which we may manage the cash flow risk of foreign exchange fluctuations when a contract is signed (i) we can purchase the foreign funds, in full or in part, upon the execution of the contract, or (ii) we can obtain the right to purchase such funds, in full or in part, at the execution of the contract, i.e., obtain a forward contract from an appropriate bank, that can be exercised to obtain the currency of interest at a particular point in time. The derivative instruments that we may use to hedge the exposure shall generally not be designated as cash flow hedges, and as a result, changes in their fair value would be recorded in other income (expense), net, in our statements of operations and comprehensive loss. The fair values of forward foreign currency exchange contracts would be estimated using current exchange rates and interest rates and the current creditworthiness of the counterparties is taken into consideration.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets, with ranges generally from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzY3Mzg_4835439c-76eb-4d2f-801e-529f6574b0d2">three</span> to five years. Leasehold improvements are amortized over the lesser of the estimated useful lives or the related remaining lease term.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of long-lived assets, including property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the asset may not be recoverable. An impairment loss is recognized when the total of estimated future undiscounted cash flows, expected to result from the use of the asset and its eventual disposition, are less than the asset&#8217;s carrying amount. Impairment, if any, would be assessed using discounted cash flows or other appropriate measures of fair value. For the years ending December&#160;31, 2022, 2021 and 2020 we have recognized no impairment losses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable is reported net of allowances for returns, chargebacks and contractual off-invoice and prompt-pay discounts offered to our customers. Our estimate of the allowance for doubtful accounts is based on an evaluation of the aging of our receivables. Trade receivable balances are written off against the allowance when it is probable that the receivable will not be collected. To date, we have determined that an allowance for doubtful accounts is not required. As of December&#160;31, 2022 our accounts receivable balance was comprised of $0.7&#160;million from our collaboration agreements and $7.0&#160;million from commercial customers. As of December&#160;31, 2021 our accounts receivable balance was comprised of $0.5&#160;million from our collaborators.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize inventory costs associated with the production of our products after regulatory approval or when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Otherwise, such costs are expensed as research and development. Prior to the regulatory approval of drug product candidates, we incurred expenses for the manufacture of drug product that could potentially be available to support the commercial launch of our products or could be sold to our international partners under product supply agreements. We began to capitalize inventory costs associated with IBSRELA during the fourth quarter of 2021, when our intent to commercialize IBSRELA was established and we commenced preparation for the commercial launch of IBSRELA, which was when it was determined that the inventory had a probable future economic benefit.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is stated at the lower of cost or estimated net realizable value with cost determined under the first-in first-out method. Inventory costs include the cost of materials, third-party contract manufacturing, third-party packaging services, freight, labor costs for personnel involved in the manufacturing process, and indirect overhead costs. We primarily use actual costs to determine the cost basis for inventory. The determination of whether inventory costs will be realizable requires management review of the expiration dates of IBSRELA compared to our forecasted sales. If actual market conditions are less favorable than projected by management, write-downs of inventory may be required, which would be recorded as cost of revenue in the statement of operations and comprehensive loss. As of December&#160;31, 2022, we have not recorded any write-offs for excess and obsolete inventory. A portion of inventory that represents product that is not expected to be sold or used within the next 12 months is classified as non-current on our balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales, Net</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for our commercial product sales, net in accordance with Topic 606 - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We received approval from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in September 2019 to market IBSRELA in the U.S.. We began selling IBSRELA in the U.S. in March 2022. We distribute IBSRELA principally through major wholesalers, specialty pharmacies and group purchasing organizations ("GPOs") (collectively, our "Customers"). Our Customers subsequently sell IBSRELA to pharmacies and patients. Separately, we enter into arrangements with third parties that provide for government-mandated rebates, chargebacks and discounts. Revenue from product sales is recognized when our performance obligations are satisfied, which is when Customers obtain control of our product and occurs upon delivery.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reserves for Variable Consideration</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration which may be settled in the form of off-invoice discounts, chargebacks, or rebates. Variable consideration includes discounts to customers and government programs, wholesaler fees, group purchasing organization administrative fees, patient copay assistance programs, and estimated product returns. These estimates are based on the amounts earned or to be claimed for related sales and are classified as reductions of gross accounts receivable if settlement is expected to occur through a reduction in the amounts paid by our customers or a current liability if settlement is expected to occur through a payment from us. Where appropriate, these estimates are based on factors such as industry data and forecasted customer buying and payment patterns, our experience, current contractual and statutory requirements, specific known market events and trends. These reductions to gross sales reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. Variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we adjust these estimates, which would affect product revenue and earnings in the period such variances become known. As we gain more experience, estimates will be more heavily based on the expected utilization from historical data we have accumulated since the IBSRELA product launch.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates: Rebates include wholesaler fees, GPO fees, as well as mandated discounts under the Medicaid Drug Rebate Program ("Medicaid") and the Medicare Coverage Gap Program ("Medicare"). Estimates for rebates are recorded in the same period the related gross revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses on the balance sheets. We estimate our Medicaid and Medicare rebates based upon the estimated payor mix, and statutory discount rates. Our estimates for payor mix are guided by payor information received from specialty pharmacies, expected utilization for wholesaler sales to pharmacies, and available industry payor information. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks: Chargebacks are discounts that occur when certain contracted purchasers purchase directly from our wholesalers at a discounted price. The wholesaler, in turn, charges back the difference between the price initially paid to us by the wholesaler and the discounted price paid to the wholesaler by the contracted purchaser. Amounts for estimated chargebacks are established in the same period that the related gross revenue is recognized, resulting in a reduction of product revenue and accounts receivable. The accrual for wholesaler chargebacks is estimated based on known chargeback rates, known sales to wholesalers, and estimated utilization by types of contracted purchasers.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discounts and Fees: Our payment terms are generally 30 to 60 days. Wholesalers, GPOs and specialty pharmacies are offered various forms of consideration, including off-invoice discounts which may be paid to GPOs and specialty pharmacies. Wholesalers and GPOs may also receive prompt pay discounts for payment within a specified period. We expect discounts to be earned when offered and therefore, we deduct the full amount of these discounts from product sales when revenue is recognized, resulting in a reduction of product revenue and accounts receivable.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Reserves: Patients who have commercial insurance may receive copay assistance when product is dispensed by pharmacies to patients. We estimate the amount of copay assistance provided to eligible patients based on the terms of the program and redemption information provided by third-party claims processing organizations and are recorded in accounts payable and accrued expenses and other current liabilities on the balance sheets. Other reserves include estimated product returns which are recorded in the same period the related gross revenue is recognized, resulting in a reduction of product revenue as well as accounts receivable. We estimate our product returns reserve based upon our experience, and specific known market events and trends. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenue Recognition</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate collaboration revenue primarily from research and collaboration and license agreements with customers. Goods and services in the agreements may include the grant of licenses for the use of our technology,&#160;the provision of services associated with the research and development of product candidates, manufacturing services, and participation in joint steering committees. The terms of these arrangements typically include payment to us of one or more of the following: non-refundable, up-front license fees; research, development, regulatory and commercial milestone payments; reimbursement of research and development services; option payments; reimbursement of certain costs; payments for manufacturing supply services; and future royalties on net sales of licensed products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When two or more contracts are entered into with the same customer at or near the same time, we evaluate the contracts to determine whether the contracts should be accounted for as a single arrangement. Contracts are combined and accounted for as a single arrangement if one or more of the following criteria are met: (i) the contracts are negotiated as a package with a single commercial objective; (ii) the amount of consideration to be paid in one contract depends on the price or performance of the other contract; or (iii) the goods or services promised in the contracts (or some goods or services promised in each of the contracts) are a single performance obligation.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under each of our agreements, management performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including any constraints on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) we satisfy each performance obligation. As part of the accounting for contracts with customers, we develop assumptions that require judgment to determine whether promised goods and services represent distinct performance obligations and the standalone selling price for each performance obligation identified in the contract. This evaluation is subjective and requires us to make judgments about the promised goods and services and whether those goods and services are separable from other aspects of the contract. Further, determining the standalone selling price for performance obligations requires significant judgment, and when an observable price of a promised good or service is not readily available, we consider relevant assumptions to estimate the standalone selling price, including, as applicable, market conditions, development timelines, probabilities of technical and regulatory success, reimbursement rates for personnel costs, forecasted revenues, potential limitations to the selling price of the product and discount rates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply judgment in determining whether a combined performance obligation is satisfied at a point in time or over time, and, if over time, concluding upon the appropriate method of measuring progress to be applied for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, as estimates related to the measure of progress change, related revenue recognition is adjusted accordingly. Changes in our estimated measure of progress are accounted for prospectively as a change in accounting estimate. We recognize collaboration revenue by measuring the progress toward complete satisfaction of the performance obligation using an input measure. In order to recognize revenue over the research and </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development period, we measure actual costs incurred to date compared to the overall total expected costs to satisfy the performance obligation. Revenues are recognized as the program costs are incurred. We will re-evaluate the estimate of expected costs to satisfy the performance obligation each reporting period and make adjustments for any significant changes.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to satisfying the revenue recognition criteria are recorded as contract liabilities in our Balance Sheets. If the related performance obligation is expected to be satisfied within the next twelve months it will be classified in current liabilities. Amounts recognized as revenue prior to receipt are recorded as contract assets in our Balance Sheets. If we expect to have an unconditional right to receive the consideration in the next twelve months, it will be classified in current assets. A net contract asset or liability is presented for each contract with a customer.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved. Milestone payments that are not within our control or the control of the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achievement of such development milestones and any related constraints, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect earnings in the period of adjustment.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing supply services:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Arrangements that include a promise for future supply of drug substance or drug product for either clinical development or commercial supply at the customer&#8217;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. If we are entitled to additional payments when the customer exercises these options, any payments are recorded in product supply revenue when the customer obtains control of the goods, which is upon delivery.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and where the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, royalty revenue resulting from licensing arrangements has not been material.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses of intellectual property:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If a license granted to a customer to use our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from consideration allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we apply judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, to conclude upon the appropriate method of measuring progress for purposes of recognizing revenue related to consideration allocated to the performance obligation.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Options:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Customer options, such as options granted to allow a licensee to choose to research, develop and commercialize licensed compounds are evaluated at contract inception in order to determine whether those options provide a material right (i.e., an optional good or service offered for free or at a discount) to the customer. If the customer options represent a material right, the material right is treated as a separate performance obligation at the outset of the arrangement. We allocate the transaction price to material rights based on the standalone selling price, and revenue is recognized when or as the future goods or services are transferred or when the option expires. Customer options that are not material rights do not give rise to a separate performance obligation, and as such, the additional consideration that would result from a customer exercising an option in the future is not included in the transaction price for the current contract. Instead, the option is deemed a marketing offer, and additional option fee payments are recognized or being recognized as revenue when the licensee exercises the option. The exercise of an option that does not represent a material right is treated as a separate contract for accounting purposes.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract modifications:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Contract modifications, defined as changes in the scope or price (or both) of a contract that are approved by the parties to the contract, such as a contract amendment, exist when the parties to a contract approve a modification that either creates new or changes existing enforceable rights and obligations of the parties to the contract. Depending on facts and circumstances, we account for a contract modification as one of the following: (i) a separate contract; (ii) a termination of the existing contract and a creation of a new contract; or (iii) a combination of the preceding treatments. A contract modification is accounted for as a separate contract if the scope of the contract increases because of the addition of promised goods or services that are distinct and the price of the contract increases by an amount of consideration that reflects </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our standalone selling prices of the additional promised goods or services. When a contract modification is not considered a separate contract and the remaining goods or services are distinct from the goods or services transferred on or before the date of the contract modification, we account for the contract modification as a termination of the existing contract and a creation of a new contract. When a contract modification is not considered a separate contract and the remaining goods or services are not distinct, we account for the contract modification as an add-on to the existing contract and as an adjustment to revenue on a cumulative catch-up basis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive payments from our licensees as established in each contract. Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until we perform our obligations under these arrangements. Where applicable, amounts are recorded as accounts receivable or unbilled revenue when our right to consideration is unconditional. We do not assess whether a contract with a customer has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue consists of the cost of commercial goods sold to our Customers and international partners under product supply agreements as well as royalty expense based on sales of tenapanor. We capitalize inventory costs associated with the production of our products after regulatory approval or when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Otherwise, such costs are expensed as research and development. A portion of the costs of IBSRELA units recognized as revenue during the twelve months ended December&#160;31, 2022 were expensed prior to the fourth quarter of 2021, at which time our intent to commercialize IBSRELA was established and we commenced preparation for the commercial launch of IBSRELA. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue includes payments due to AstraZeneca, which under the terms of a termination agreement entered into in 2015 ("AZ Termination Agreement") is entitled to (i) future royalties at a rate of 10% of net sales of tenapanor or other NHE3 products by us or our licensees, and (ii) 20% of non-royalty revenue received from our collaboration partners as a result of the development and commercialization of tenapanor or certain other NHE3 inhibitors.&#160;We have agreed to pay&#160;AstraZeneca up to a maximum of $75.0 million in the aggregate for (i) and (ii). We recognize these expenses as cost of revenue when we recognize the corresponding revenue that gives rise to payments due to AstraZeneca. To date, we have recognized an aggregate of $15.3 million as cost of revenue under the AZ Termination Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to expense as incurred and consisted of costs incurred to further our research and development activities and include salaries and related employee benefits, costs associated with clinical trials, costs related to pre-commercialization manufacturing activities such as manufacturing process validation activities and the manufacturing of clinical drug supply, nonclinical research and development activities, regulatory activities, research-related overhead expenses and fees paid to external service providers and contract research and manufacturing organizations that conduct certain research and development activities on our behalf.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to estimate our accrued expenses at the end of each reporting period. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual costs. The majority of our service providers submit invoices in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with our service providers and make adjustments if necessary. Examples of estimated accrued research and development expenses include fees paid to:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contract research organizations ("CROs") in connection with clinical studies;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">investigative sites in connection with clinical studies;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">vendors related to product manufacturing, development and distribution of clinical supplies; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">vendors in connection with preclinical development activities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record expenses related to clinical studies and manufacturing development activities based on our estimates of the services received and efforts expended pursuant to contracts with multiple CROs and manufacturing vendors that conduct and manage these activities on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these contracts depend on factors such as the successful enrollment of subjects and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed, enrollment of subjects, number of sites activated and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we will adjust the accrued or prepaid expense balance accordingly.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize compensation expense for all stock-based payment awards made to employees, non-employees and directors based on estimated fair values. For employee and non-employee stock options, we determine the grant date fair value of the awards using the Black-Scholes option-pricing model and generally recognize the fair value as stock-based compensation expense on a straight-line basis over the vesting period of the respective awards. For restricted stock and performance-based restricted stock, to the extent they are probable, the compensation cost for these awards is based on the closing price of our common stock on the date of grant and recognized as compensation expense on a straight-line basis over the requisite service period. Stock-based compensation expense is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. As such, our stock-based compensation is reduced for the estimated forfeitures at the date of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivatives and Hedging Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for our derivative instruments as either assets or liabilities on the balance sheet and measure them at fair value. Derivatives are adjusted to fair value through other income (expense), net in the statements of operations and comprehensive loss.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-cash Interest Expense on Deferred Royalty Obligation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net proceeds we receive from the sale of certain future royalties are recorded as deferred royalty obligation related to the sale of future royalties on our balance sheets. As we earn royalties and remit those royalties pursuant to the agreement, the balance of the deferred royalty obligation will be effectively repaid over the life of agreement and non-cash interest expense related to the sale of future royalties is recorded using the effective interest method. To determine the amortization of our deferred royalty obligation, we are required to estimate the total amount of future royalty payments we expect to earn. There are a number of factors that could materially affect the amount and timing of royalty payments, most of which are not within our control. We periodically assess the amount of royalty payments we expect to receive which are subject to the agreement and, to the extent that the amount or timing of such payments is materially different than our original estimates, we prospectively adjust the imputed interest rate and the related amortization of the deferred royalty obligation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement is a lease at the inception of the arrangement. Operating leases are included in right-of-use assets, current portion of operating lease liability, and operating lease liability, net of current portion in our balance sheets. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. The operating lease right-of-use assets also include any lease payments made and exclude lease incentives. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise any such options. Lease expense is recognized on a straight-line basis over the expected lease term. We have elected not to separate lease and non-lease components, such as common area maintenance charges, and instead it accounts for these as a single lease component.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize restructuring charges related to reorganization plans that have been committed to by management when liabilities have been incurred. In connection with these activities, we record restructuring charges at fair value for, (a) contractual employee termination benefits when obligations are associated to services already rendered, rights to such benefits have vested, and payment of benefits is probable and can be reasonably estimated, (b) one-time employee termination benefits </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">when management has committed to a plan of termination, the plan identifies the employees and their expected termination dates, the details of termination benefits are complete, it is unlikely changes to the plan will be made or the plan will be withdrawn and communication to such employees has occurred, and (c) contract termination costs when a contract is terminated before the end of its term.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One-time employee termination benefits are recognized in their entirety when communication has occurred and future services are not required. If future services are required, the costs are recorded ratably over the remaining period of service. Contract termination costs to be incurred over the remaining contract term without economic benefit are recorded in their entirety when the contract is canceled.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration of potential shares of common stock. Diluted net loss per common share in the periods presented is the same as basic net loss per common share, since the effects of potentially dilutive securities are antidilutive due to the net loss for all periods presented.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Pronouncements - Recently Adopted</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adopted Accounting Standards Update 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2016-13"), as of December 1, 2021 under the modified retrospective approach. ASU 2016-13 requires an entity to measure and recognize expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities with unrealized credit losses, the standard requires allowances to be recorded through net income instead of directly reducing the amortized cost of the investment under the previous other-than-temporary impairment model. The adoption of this standard did not have a material impact on our financial statements or a significant impact on our internal controls.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were various accounting standards and interpretations issued recently, none of which are expected to a have a material impact on our financial position, operations or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583752645920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Short-Term Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock', window );">Cash, Cash Equivalents and Short-Term Investments</a></td>
<td class="text">CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS<div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities classified as cash, cash equivalents and short-term investments as of December&#160;31, 2022 and 2021 are summarized below (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,140&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,140&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored agency bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,823&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,963&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,909&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial Paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,428&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,428&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,261&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,695&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,689&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of money market funds with original maturities of three months or less at the time of purchase, and the carrying amount is a reasonable approximation of fair value. We invest our cash in high quality securities of financial and commercial institutions. These securities are carried at fair value, which is based on readily available market information, with unrealized gains and losses included in accumulated other comprehensive loss within stockholders&#8217; equity on our balance sheets. We use the specific identification method to determine the amount of realized gains or losses on sales of marketable securities. Realized gains or losses have been insignificant and are included in other income, net, in the statement of operations and comprehensive loss.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the short-term available-for sale securities held as of December&#160;31, 2022 and 2021 had contractual maturities of less than one year. Our available-for-sale securities are subject to a periodic impairment review. We consider a debt security to be impaired when its fair value is less than its carrying cost, in which case we would further review the investment to determine whether it is other-than-temporarily impaired. When we evaluate an investment for other-than-temporary impairment, we review factors such as the length of time and extent to which fair value has been below cost basis, the financial condition of the issuer and any changes thereto, intent to sell, and whether it is more likely than not we will be required to sell the investment before the recovery of its cost basis. If an investment is other-than-temporarily impaired or subject to credit losses, we write it down through the statement of operations and comprehensive loss to its fair value and establish that value as a new cost basis for the investment. Our unrealized losses as of December&#160;31, 2022 and 2021 were not material. We determined that none of our available-for-sale securities were other-than-temporarily impaired as of December&#160;31, 2022 and 2021, and no investment was in a continuous unrealized loss position for more than one year. As such, we believe that it is more likely than not that the investments will be held until maturity or a forecasted recovery of fair value.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583750735856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1&#160;&#160;&#160;&#8211;&#160;Valuations are based on quoted prices in active markets for identical assets or liabilities and readily accessible to us at the reporting date. </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2&#160;&#160;&#160;&#8211;&#160;&#160;Valuations based on inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 &#160;&#8211;&#160;&#160;Valuations based on unobservable inputs for which there is little or no market data, which require us to develop our own assumptions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of our financial assets and liabilities that are measured or disclosed on a recurring basis by level within the fair value hierarchy (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored agency bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,082&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,313&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,769&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities for exit fees</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,656&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,656&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,656&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,656&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,436&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,261&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability for exit fee</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where quoted prices are available in an active market, securities are classified as Level 1. We classify money market funds as Level 1. When quoted market prices are not available for the specific security, we estimate fair value by using benchmark yields, reported trades, broker/dealer quotes and issuer spreads. We classify U.S. government-sponsored agency bonds, U.S. treasury notes, corporate bonds, commercial paper, and asset-backed securities as Level 2. In certain cases, where there is limited activity or less transparency around inputs to valuation, securities or derivative liabilities, such as the 2018 Exit Fee and 2022 Exit Fee, as defined and discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 10. Derivative Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, are classified as Level 3.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts reflected in the balance sheets for cash equivalents, short-term investments, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values at both December&#160;31, 2022 and 2021, due to their short-term nature.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our procedures under the expected credit loss model, including an assessment of unrealized losses in our portfolio, we concluded that any unrealized losses on our marketable securities were not attributable to credit and, therefore, we have not recorded an allowance for credit losses for these securities as of December&#160;31, 2022 and 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Debt</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal amount outstanding under our term loan facilities is subject to a variable interest rate. Therefore, we believe the carrying amount of the term loan facility approximates fair value as of December&#160;31, 2022 and 2021. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9. Borrowings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a description of the Level 2 inputs used to estimate the fair value of the liability.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the deferred royalty obligation related to the sale of future royalties approximates its fair value as of December&#160;31, 2022 and is based on our current estimates of future royalties and commercialization milestones expected to be </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">paid to us by Kyowa Kirin Co., Ltd. ("KKC") over the life of the agreement. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8. Deferred Royalty Obligation Related to the Sale of Future Royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a description of the Level 3 inputs used to estimate the fair value of the liability.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583750600576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">INVENTORY<div style="margin-bottom:3pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We began capitalizing inventory during the fourth quarter of 2021, at which time our intent to commercialize IBSRELA was established and we commenced preparation for the commercial launch of IBSRELA. Inventory as of December&#160;31, 2021 was not material. Inventory as of December&#160;31, 2022 consisted of the following (in thousands):</span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,299&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,346&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory, non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,064&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28,346</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Prepaid commercial manufacturing of $13.6&#160;million and $9.4&#160;million as of December&#160;31, 2022 and 2021, respectively, consisted of prepayments to third party contract manufacturing organizations for the manufacture of IBSRELA for production orders which we expect work to commence within the next 12 months.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583749110656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Product Revenue, Net</a></td>
<td class="text">PRODUCT REVENUE, NET<div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received approval from the FDA in September 2019 to market IBSRELA in the U.S. We began selling IBSRELA in the U.S. in March 2022. We recorded net revenue for IBSRELA of $15.6&#160;million during the twelve months ended December&#160;31, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales to AmerisourceBergen Drug Corporation, Cardinal Health, and McKesson Corporation made up 26.8%, 23.1%, and 21.6%, respectively, of our gross product revenue during the twelve months ended December&#160;31, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Discounts and Chargebacks</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Rebates, Wholesaler and GPO Fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Copay and Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to 2022 sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,048&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits/deductions issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(683)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,277)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,244)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,204)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,444&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,258&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,844&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no product sales or gross-to-net accruals during the twelve months ended December&#160;31, 2021 or 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583750735856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Licensing Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_CollaborationAndLicensingAgreementsAbstract', window );"><strong>Collaboration and Licensing Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and Licensing Agreements</a></td>
<td class="text">COLLABORATION AND LICENSING AGREEMENTS<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kyowa Kirin Co., Ltd. ("KKC")</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 KKC Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we entered into a research collaboration and option agreement with KKC ("2019 KKC Agreement&#8221;), to undergo research to identify two preclinical study-ready compounds for designation as development compounds, with one compound inhibiting the first undisclosed target (&#8220;Program 1&#8221;) and a second inhibiting the second undisclosed target (&#8220;Program </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2&#8221;). Pursuant to the 2019 KKC Agreement, upon completion of the research and designation by the research steering committee of one or more development candidates (&#8220;DCs&#8221;), KKC has the right to execute one or more separate collaborative agreements relating to the development and commercialization of one or both DCs in certain specified territories.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2019 KKC Agreement, KKC paid us a non-refundable, non-creditable upfront fee of $10.0 million, in two installments as follows: the first installment of $5.0 million within 30 days of November 11, 2019 ("Effective Date"), and the second installment of $5.0 million on the first anniversary of the Effective Date. The original term of the 2019 KKC Agreement commenced on the Effective Date and was to end on the earliest of: (i) two years following the Effective Date, (ii) the nomination of a program DC for both programs, (iii) the nomination of one program DC and the decision by the parties to cease research for the other program, or (iv) the decision by the parties to cease research for both programs. We entered into three amendments to the 2019 KKC Agreement, which have resulted in the extension of the original term. Under the third amendment to the 2019 KKC Agreement entered into on June 28, 2022, the 2019 KKC Agreement ended on February 28, 2023. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assessed the 2019 KKC Agreement in accordance with ASC 606 and concluded that the contract&#8217;s counterparty, KKC, is a customer. We also considered the modification guidance prescribed in ASC 606 and concluded that the 2019 KKC Agreement should be accounted for as a separate contract from the 2017 KKC Agreement, as defined and discussed below.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified various promises in the 2019 KKC Agreement, including the grant of an initial research license, the Program 1 research, the Program 2 research, the right to obtain certain development and commercialization rights with Program 1 in certain territories and the right to obtain development and commercialization rights with Program 2 in certain territories, and participation in a joint steering committee&#160;(&#8220;JSC&#8221;) and determined that KKC could not benefit from either of the research programs without the research license and participation in the JSC. As such, the combined license, research programs and participation in the JSC were deemed to be the highest level of goods and services that can be deemed distinct for each of the Program 1 research and Program 2 research. We concluded that the options to obtain additional development and commercialization rights that are exercisable by KKC under certain circumstances are not performance obligations of the contract at inception because the option fees reflect the standalone selling price of the options, and therefore, the options are not considered to be material rights.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the outset of the 2019 KKC Agreement, we determined that the initial transaction price was $10.0 million and that revenue associated with the combined performance obligations should be recognized as services are provided using the input method. Since transfer of control occurs over time, in management&#8217;s judgment this input method is the best measure of progress towards satisfying the performance obligations and reflects a faithful depiction of the transfer of goods and services. Revenue was recognized over the Program 1 and Program 2 research periods which concluded in 2021. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022 and 2021, we recognized zero and $4.2 million, respectively, as revenue under the 2019 KKC Agreement in the statement of operations and comprehensive loss. The transaction price had been fully allocated to revenue as of December&#160;31, 2021 and there was no associated deferred revenue presented on the balance sheet as of December&#160;31, 2022 or 2021. As of December&#160;31, 2022 and 2021, we had no material future obligations under the 2019 KKC Agreement. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 KKC Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, we entered into an exclusive license agreement with KKC (&#8220;2017 KKC Agreement&#8221;), under which we granted KKC an exclusive license to develop and commercialize certain NHE3 inhibitors including tenapanor in Japan for the treatment of cardiorenal diseases and conditions, excluding cancer. We retained the rights to tenapanor outside of Japan, and also retained the rights to tenapanor in Japan for indications other than those stated above. Pursuant to the 2017 KKC Agreement, KKC is responsible for all costs and expenses incurred in the development and commercialization of tenapanor for all licensed indications in Japan. We are responsible for supplying the tenapanor drug substance for KKC&#8217;s use in development and commercialization throughout the term of the 2017 KKC Agreement, provided that KKC may exercise an option to manufacture the tenapanor drug substance under certain conditions. In October 2022, we entered into a Commercial Supply Agreement with KKC to further define the obligations of the parties with respect to the commercial supply of tenapanor drug substance (&#8220;2022 KKC Supply Agreement&#8221;). As detailed below under the heading &#8220;Deferred revenue&#8217; we have received advanced payments from KKC for the manufacturing of tenapanor drug substance that will be used to satisfy KKC needs. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assessed these arrangements in accordance with Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers (Topic 606) and related amendments (&#8220;ASC 606&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and concluded that the contract counterparty, KKC, is a customer. Under the terms of the 2017 KKC Agreement, we received $30.0 million in up-front license fees, which was recognized as revenue when the agreement was executed. Based on our assessment, management determined that the </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license and the manufacturing supply services were the material performance obligations at the inception of the 2017 KKC Agreement and, as such, each of the performance obligations is distinct. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2017 KKC Agreement, KKC paid us an up-front license fee of $30.0 million,. We may be entitled to receive up to $55.0 million in total development and regulatory milestones, of which $20.0 million has been received and recognized as revenue as of December&#160;31, 2022. We may also be eligible to receive approximately &#165;8.5&#160;billion for commercialization milestones, or approximately $64.6 million at the currency exchange rate on December&#160;31, 2022, as well as reimbursement of costs plus a reasonable overhead for the supply of product and royalties on net sales throughout the term of the agreement. As discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8. Deferred Royalty Obligation Related to the Sale of Future Royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the future royalties and commercial milestone payments we may receive under the 2017 KKC Agreement will be remitted to HealthCare Royalty Partners IV, L.P. pursuant to a Royalty and Sales Milestone Interest Acquisition Agreement. The variable consideration related to the remaining milestone payments was fully constrained at December&#160;31, 2022 and 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, we entered into a second amendment to the 2017 KKC Agreement ("2022 Amendment"). Under the terms of the 2022 Amendment, we and KKC have agreed to a reduction in the royalty rate payable to us by KKC upon net sales of tenapanor for hyperphosphatemia in Japan. The royalty rate will be reduced from the high teens to low double digits for a two-year period of time following the first commercial sale in Japan, and then to mid-single digits for the remainder of the royalty term. As discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8. Deferred Royalty Obligation Related to the Sale of Future Royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the future commercial milestones and royalties we may receive under the 2017 KKC Agreement will be remitted to HealthCare Royalty Partners IV, L.P. pursuant to a Royalty and Sales Milestone Interest Acquisition Agreement. As consideration for the reduction in the royalty rate, KKC agreed to pay us up to an additional $40.0 million payable in two tranches, with the first payment due following KKC's filing with the Japanese Ministry of Health, Labour and Welfare of its application for marketing approval for tenapanor and the second payment due following KKC&#8217;s receipt of regulatory approval to market tenapanor for hyperphosphatemia in Japan. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, we announced that KKC submitted an NDA to the Japanese Ministry of Health, Labour and Welfare for tenapanor for the improvement of hyperphosphatemia in adult patients with CKD on dialysis, which resulted in payment to us from KKC for an aggregate of $35.0 million for milestone payments and payments under the 2022 Amendment. We received these payments during the fourth quarter of 2022 and recorded them as licensing revenue on our statement of operations and comprehensive loss. The remaining variable consideration related to the reduction in the royalty rate was fully constrained at December&#160;31, 2022. For the year ended December&#160;31, 2021, $5.0 million of licensing revenue was recorded upon the initiation of phase 3 clinical studies by KKC in Japan to evaluate tenapanor for hyperphosphatemia.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022 and 2021, $1.5 million and $0.9 million, respectively, of product supply revenue was recorded for manufacturing supply of tenapanor and other materials to KKC for product development and clinical trials in Japan, in accordance with our agreement with the 2017 KKC Agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022 and 2021, $35.0 million and $5.0 million, respectively, of licensing revenue was recorded. The 2022 licensing revenue was earned upon KKC's submission of an NDA to the Japanese Ministry of Health, Labour and Welfare for tenapanor for the improvement of hyperphosphatemia in adult patients with CKD on dialysis. The 2021 licensing revenue was recorded upon the initiation of Phase 3 clinical studies by KKC in Japan to evaluate tenapanor for hyperphosphatemia.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. ("Fosun Pharma")</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, we entered into an exclusive license agreement with Fosun Pharma ("Fosun Agreement") for the development, commercialization and distribution of tenapanor in China for both hyperphosphatemia and IBS-C. We assessed these arrangements in accordance with ASC 606 and concluded that the contract counterparty, Fosun Pharma, is a customer. Under the terms of the Fosun Agreement, we received $12.0 million in up-front license fees which was recognized as revenue when the agreement was executed. Based on our assessment, we determined that the license and the manufacturing supply services represented the material performance obligations at the inception of the agreement and, as such, each of the performance obligations are distinct.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be entitled to additional development and commercialization milestones of up to $110.0 million, as well as reimbursement of cost plus a reasonable overhead for the supply of product and tiered royalties on net sales ranging from the mid-teens to 20%. The variable consideration related to the remaining development milestone payments was fully constrained at December&#160;31, 2022 and 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded no revenue related to the Fosun Agreement during the years ended December&#160;31, 2022 and 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Knight Therapeutics, Inc. ("Knight")</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, we entered into an exclusive license agreement with Knight Therapeutics, Inc., ("Knight Agreement") for the development, commercialization and distribution of tenapanor in Canada for hyperphosphatemia and IBS-C. We assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Knight, is a customer. Based on our assessment, we determined that the license and the manufacturing supply services were the material performance obligations at the inception of the agreement and, as such, each of the performance obligations are distinct.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Knight Agreement, we received a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.3 million non-refundable, one-time upfront payment in March 2018 and may be eligible to receive additional development and commercialization milestone payments worth up to CAD22.2, or approximately $16.3 million at the currency exchange rate on December&#160;31, 2022. We are also eligible to receive royalties ranging from the mid-single digits to the low twenties throughout the term of the agreement, and a transfer price for manufacturing services.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The variable consideration related to the remaining development milestone payments were fully constrained at December&#160;31, 2022 and 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022 and 2021, $31 thousand and $13 thousand of licensing revenue was recorded, respectively, related to the Knight Agreement. For the years ended December&#160;31, 2022 and 2021, no product supply revenue was recorded, respectively, related to the Knight Agreement. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AstraZeneca AB ("AstraZeneca")</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2015, we entered into a termination agreement with AstraZeneca ("AstraZeneca Termination Agreement") pursuant to which we have agreed to pay AstraZeneca (i) future royalties at a royalty rate of 10% of net sales of tenapanor or other NHE3 products by us or our licensees, and (ii) 20% of non-royalty revenue received from a new collaboration partner should we elect to license, or otherwise provide rights to develop and commercialize tenapanor or another NHE3 inhibitor, up to a maximum of $75.0 million in aggregate for (i) and (ii). For the years ended December&#160;31, 2022 and 2021, we recognized $3.6 million and $1.0 million, respectively, as cost of revenue related to the AstraZeneca Termination Agreement. To date in aggregate, we have recognized $15.3 million of the $75.0 million aggregate maximum related to the AstraZeneca Termination Agreement.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present changes in our current and non-current deferred revenue balances during the reporting period. The December&#160;31, 2022 deferred revenue current and non-current balances are attributable entirely to prepayments for product supply under the 2017 KKC Agreement, while the December&#160;31, 2021 current deferred revenue balance is attributable to the 2019 KKC Agreement and the December&#160;31, 2021 non-current deferred revenue balance is attributable prepayments for product supply under the 2017 KKC Agreement (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue - current</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at Balance at January 1,</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases due to cash received, excluding amounts recognized as revenue during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases due to amounts reclassified from non-current, to be recognized in the next twelve months</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,961&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases to amounts invoiced, for which cash has not yet been received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases due to revenue recognized in the period for which cash has been received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,177)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31,</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,211&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue - non-current</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at Balance at January 1,</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,727&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases due to cash received during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases to amounts invoiced, for which cash has not yet been received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase due to unbilled prepayments recorded during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases due to amounts reclassified as current, to be recognized in the next twelve months</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,961)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31,</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,025&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,727&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborationAndLicensingAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborationAndLicensingAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583750723984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Royalty Obligation Related To The Sale Of Future Royalties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvanceRoyaltiesAbstract', window );"><strong>Advance Royalties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetRetirementObligationDisclosureTextBlock', window );">Deferred Royalty Obligation Related To The Sale Of Future Royalties</a></td>
<td class="text">DEFERRED ROYALTY OBLIGATION RELATED TO THE SALE OF FUTURE ROYALTIES<div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, we and HealthCare Royalty Partners IV, L.P. (&#8220;HCR&#8221;) entered into a Royalty and Sales Milestone Interest Acquisition Agreement (&#8220;HCR Agreement&#8221;). Under the terms of the HCR Agreement, HCR has agreed to pay us up to $20.0 million in exchange for the royalty payments and commercial milestone payments (collectively the &#8220;Royalty Interest Payments&#8221;) that we may receive under our 2017 License Agreement with KKC based upon KKC's net sales of tenapanor in Japan for hyperphosphatemia. As consideration for the sale of the Royalty Interest Payments, HCR paid to us a $10.0 million upfront payment, and we are eligible to receive a $5.0 million payment following KKC's receipt of regulatory approval to market tenapanor for hyperphosphatemia in Japan, and another $5.0 million payment in the event net sales by KKC in Japan exceed a certain annual target level by the end of 2025.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The HCR Agreement is effective until terminated by the mutual agreement of the parties and contains customary representations and warranties and customary affirmative and negative covenants, including, among others, requirements as to prosecution, maintenance, defense and enforcement of certain patent rights in Japan, restrictions regarding our ability to forgive, release or reduce any Royalty Interest Payments due to us under the 2017 KKC Agreement, to create or incur any liens with respect to the Royalty Interest Payments, the 2017 KKC Agreement or certain patents, or to sell, license or transfer certain patents in the field and territory described in the 2017 KKC Agreement.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the HCR Agreement contains customary events of default with respect to which we may incur indemnification obligations to HCR for any losses incurred by HCR and related parties as a result of the event of default, subject to a specified limitation of liability cap. Under the HCR Agreement, an event of default will occur if, among other things, any of the representations and warranties included in the HCR Agreement proves not to have been true and correct in all material respects, at the time it was made, we breach any of our covenants under the HCR Agreement, subject to specified cure periods with respect to certain breaches, we are in breach or default under the 2017 KKC Agreement in any manner which is likely to cause a material adverse effect on the Royalty Interest Payments, the occurrence of a termination of the 2017 KKC Agreement under certain circumstances or we or our assets become subject to certain legal proceedings, such as bankruptcy proceedings, or we are unable to pay our debts as they become due.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received the $10.0 million upfront payment from HCR during June 2022 and recorded it as a deferred royalty obligation related to the sale of future royalties ("deferred royalty obligation") on our balance sheet. Due to our ongoing manufacturing obligations under the 2017 KKC Agreement, we account for the proceeds as imputed debt and therefore will recognize royalties received under the arrangement as non-cash royalty revenue. Non-cash interest expense will be recognized over the life of the HCR Agreement using the effective interest method based on the imputed interest rate derived from estimated amounts and timing of future royalty payments to be received from KKC. As part of the sale, we incurred approximately $0.4 million in transaction costs, which, along with the deferred royalty obligation, are being amortized to non-cash interest expense over the estimated life of the HCR Agreement using the effective interest method. As future royalties are remitted to us by KKC, and subsequently from us to HCR, the balance of the deferred royalty obligation will be effectively repaid over the life of the HCR Agreement. There are a number of factors that could materially affect the fair value of the deferred royalty obligation. Such factors include, but are not limited to, the amount and timing of potential future royalty payments to be received from KKC under the 2017 KKC agreement, changing standards of care, the introduction of competing products, manufacturing or other delays, intellectual property matters, adverse events that result in governmental health authority imposed restrictions on the use of the drug products, significant changes in foreign exchange rates as the royalties remitted to HCR are made in U.S. dollars while the underlying sales of the products by KKC are made in Japanese yen, and other events or circumstances that could result in reduced royalty payments from KKC, which are not within our control, and all of which would result in a reduction of non-cash royalty revenues and the non-cash interest expense over the life of the deferred royalty obligation. We periodically assess the estimated royalty payments from KKC and, to the extent that the amount or timing of such payments is materially different than our original estimates, we prospectively adjust the imputed interest rate and </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the related amortization of the deferred royalty obligation. As of December&#160;31, 2022, our effective interest rate used to amortize the liability is 34.4%. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the twelve months ended December&#160;31, 2022, we recognized approximately $1.7 million of non-cash interest expense for the amortization of the deferred royalty obligation. As of December&#160;31, 2022, we have received no royalty payments from KKC and, therefore, the deferred royalty obligation has not begun to be reduced.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvanceRoyaltiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvanceRoyaltiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetRetirementObligationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an asset retirement obligation and the associated long-lived asset. An asset retirement obligation is a legal obligation associated with the disposal or retirement from service of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6392692&amp;loc=d3e7569-110849<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2175671<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6392692&amp;loc=d3e7535-110849<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetRetirementObligationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583751638496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Borrowings</a></td>
<td class="text">BORROWINGS<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Solar Capital and Western Alliance Bank Loan Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, we entered into a loan and security agreement ("2018 Loan Agreement"), with Solar Capital Ltd. and Western Alliance Bank ("Lenders&#8221;). The 2018 Loan Agreement provided for a $50.0 million term loan facility with a maturity date of November&#160;1, 2022 ("2018 Term Loan&#8221;). The full amount of the 2018 Term Loan was funded on May&#160;16, 2018. We received net proceeds from the loan of approximately $49.3 million, after deducting the closing fee, legal expenses and issuance costs. In October 2020, we and the Lenders entered into an amendment to the 2018 Loan Agreement (&#8220;2020 Amendment&#8221;) to extend the date through which we were permitted to make interest-only payments on the 2018 Term Loan by twelve months to December 1, 2021 subject to the repayment terms noted below.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2018 Term Loan bore interest at a floating per annum rate equal to 7.45% plus the one-month London Inter-bank Offered Rate ("LIBOR"). We were permitted to make interest-only payments on the 2018 Term Loan through June 1, 2020, or until we achieved our primary endpoint in the Phase 3 study of tenapanor for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis prior to June&#160;1, 2020, in which case we would have been permitted to make interest-only payments on the 2018 Term Loan through December 1, 2020. In December 2019, we reported positive topline results for PHREEDOM, a long-term Phase 3 study evaluating the efficacy and safety of tenapanor as monotherapy for the treatment of hyperphosphatemia in adult patients with CKD on dialysis. The Lenders were in agreement that these positive data from the Phase 3 PHREEDOM study achieve the &#8220;Phase 3 Endpoint&#8221; required by the 2018 Term Loan to extend the interest only period by six months to December&#160;1, 2020. Subsequent to the 2020 Amendment, the interest only period was extended an additional twelve months to December 1, 2021. Accordingly, beginning on December&#160;1, 2021 through the maturity date, we would have been required to make monthly payments of interest plus repayment of the 2018 Term Loan in consecutive equal monthly installments of principal. If however, either the FDA did not approve our NDA for tenapanor for control of serum phosphorus in adult patients with CKD on dialysis on or before May 31, 2021 or the FDA issued a Complete Response Letter ("CRL") for tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis, then we would begin principal payments on the earlier of June 1, 2021 or the first day of the month immediately following the date that the FDA issued a CRL to us. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May and July 2021, we and the Lenders entered into additional amendments to the 2018 Loan Agreement (&#8220;the 2021 Amendments&#8221;) which together extended the period of time that we were permitted to make interest-only payments on the 2018 Term Loan to December 1, 2021; provided that if we had not received FDA approval for our NDA for tenapanor for the control of serum phosphorus in adult patients with CDK on dialysis on or before October 25, 2021, the interest-only period would expire and principal repayments would be required to begin on November 1, 2021. If principal repayments were required to begin prior to December 1, 2021 under the 2021 Amendments, then the first such repayment was required to include all payments that would have been due if monthly principal repayment had begun on June 1, 2021. Accordingly, during November 2021, in compliance with the terms of our 2018 Loan Agreement, we began to repay principal on the 2018 Term Loan. As of the Closing Date for the 2022 Loan, as discussed below, we owed $25.0&#160;million in principal payments from the 2018 Loan, which we repaid in full at that time.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SLR Investment Corp. Loan Agreement </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 23, 2022 (&#8220;Closing Date&#8221;), we entered into a loan and security agreement (&#8220;2022 Loan Agreement&#8221;) with SLR Investment Corp. as collateral agent (&#8220;Agent&#8221;), and the lenders listed in the 2022 Loan Agreement (collectively the &#8220;2022 Lenders&#8221;). The 2022 Loan Agreement provides for a senior secured loan facility, with $27.5 million (&#8220;Term A Loan&#8221;) funded on the Closing Date and an additional $22.5 million that we may borrow on or prior to July 25, 2023; provided that (i) we have received approval by the FDA for our NDA for XPHOZAH by December 31, 2022, and (ii) we have achieved certain product revenue milestone targets described in the 2022 Loan Agreement (&#8220;Term B Loan&#8221;, and collectively, the Term A Loan and the Term B Loan, the &#8220;2022 Loan&#8221;). On February 9, 2023, we entered into an amendment to the 2022 Loan Agreement with SLR Investment Corp. that extends the date by which we must receive approval by the FDA for our NDA for the control of serum phosphorus in adult patients with CKD on dialysis in order to borrow the additional $22.5 million from December 31, 2022 to November 30, 2023 and extended the period during which we are permitted to make interest only payments until March 31, </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025 if we receive approval by the FDA for our NDA for XPHOZAH on or prior to November 30, 2023 or achieve a defined net product revenue threshold for 2023. The 2022 Term A Loan funds were used to repay the 2018 Loan with the 2018 Lenders. The 2022 Loan has a maturity date of March 1, 2027.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2022 Loan bear interest at a floating per annum rate equal to 7.95% plus the greater of (i) one tenth percent (0.10%) and (ii) the one-month rate published by the Intercontinental Exchange Benchmark Administration Ltd or its successor. We are permitted to make interest-only payments on the 2022 Loan through March 31, 2024 or if certain conditions described above are achieved, through March 31, 2025. Accordingly, beginning on April 1, 2024 or April 1, 2025, we will be required to make monthly payments of interest plus repay the 2022 Loan in consecutive equal monthly installments of principal over 36 months or 24 months, respectively. We were obligated to pay $0.2 million, upon the closing of the Term A Loan, and we are obligated to pay $0.1 million on the earliest of (i) the funding date of the Term B Loan, (ii) July 25, 2023, and (iii) the prepayment, refinancing, substitution, or replacement of the Term A Loan on or prior to July 25, 2023. We are obligated to pay a final fee equal to 4.95% of the aggregate original principal amount of the 2022 Loan funded upon the earliest to occur of the maturity date, the acceleration of the 2022 Loan, and the prepayment, refinancing, substitution, or replacement of the 2022 Loan. We may voluntarily prepay the outstanding 2022 Loan balance, subject to a prepayment premium of (i) 3% of the outstanding principal amount of the 2022 Loan if prepaid prior to or on the first anniversary of the Closing Date, (ii) 2% of the outstanding principal amount of the 2022 Loan if prepaid after the first anniversary of the Closing Date through and including the second anniversary of the Closing Date, or (iii) 1% of the outstanding principal amount of the 2022 Loan if prepaid after the second anniversary of the Closing Date and prior to the maturity date. The 2022 Loan is secured by substantially all of our assets, except for our intellectual property and certain other customary exclusions. Additionally, in connection with the 2022 Loan, we entered into an agreement, whereby we agreed to pay an exit fee in the amount of 2% of the 2022 Loan funded (&#8220;2022 Exit Fee&#8221;) upon (i) any change of control transaction or (ii) our achievement of net revenue from the sale of any products equal to or greater than $100.0 million, measured on a six (6) months basis, tested monthly at the end of each month. Notwithstanding the prepayment or termination of the 2022 Loan, the 2022 Exit Fee will expire 10 years from the Closing Date.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Loan Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among others, requirements as to financial reporting and insurance and restrictions on our ability to dispose of our business or property, to change our line of business, to liquidate or dissolve, to enter into any change in control transaction, to merge or consolidate with any other entity or to acquire all or substantially all the capital stock or property of another entity, to incur additional indebtedness, to incur liens on our property, to pay any dividends or other distributions on capital stock other than dividends payable solely in capital stock or to redeem capital stock. We have agreed to not allow our cash and cash equivalents to be less than the eighty percent (80%) of the outstanding 2022 Term Loan balance for any period in which our net revenue from the sale of any products, calculated on a trailing six (6) month basis and tested monthly, is less than sixty percent (60%) of the outstanding 2022 Loan balance.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the 2022 Loan Agreement contains customary events of default that entitle the Agent to cause our indebtedness under the 2022 Loan Agreement to become immediately due and payable, and to exercise remedies against us and the collateral securing the 2022 Term Loan, including our cash. Under the 2022 Loan Agreement, an event of default will occur if, among other things, we fail to make payments under the 2022 Loan Agreement, we breach any of our covenants under the 2022 Loan Agreement, subject to specified cure periods with respect to certain breaches, certain Lenders determine that a material adverse change has occurred, we or our assets become subject to certain legal proceedings, such as bankruptcy proceedings, we are unable to pay our debts as they become due or we default on contracts with third parties which would permit the holder of indebtedness to accelerate the maturity of such indebtedness or that could have a material adverse change on us. Upon the occurrence and for the duration of an event of default, an additional default interest rate equal to 4% per annum will apply to all obligations owed under the 2022 Loan Agreement. We have classified the 2022 Loan balance as a current liability as of December&#160;31, 2022 due to the determination of the existence of substantial doubt about our ability to continue operating as a going concern discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2. Summary of Significant Accounting Policies: Liquidity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and our assessment that the material adverse change clause under the 2022 Loan Agreement is not within our control. The lenders have not invoked the material adverse change clause as of the date of issuance of these financial statements.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 21. Subsequent Events</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on February 9, 2023, we entered into a second amendment (&#8220;Second Amendment&#8221;) to our Loan Agreement with the Lenders. The Second Amendment extends the interest-only term of the loan by twelve months to March 31, 2025 provided that we either (i) receive approval from the FDA for our NDA for the control of serum phosphorus in adult patients with CKD on dialysis on or prior to November 30, 2023 or (ii) achieve certain product revenue milestone targets as described in the Second Amendment for the year ending December 31, 2023. The Second Amendment also extends the period under which we may draw the Term B Loan from July 25, 2023 to December 20, 2023, and amends the milestone that we must achieve in order to draw the Term B Loan by extending the time period for the receipt of approval by the FDA of the NDA for the control of serum phosphorus in adult patients with CKD on dialysis until November 30, 2023. In addition, the Second Amendment replaces the floating per annum interest rate with 7.95% plus the greater of (a) one percent (1.00%) per annum and (b)(i) 0.022% plus (ii) 1-month CME Term SOFR reference rate as published by the CME Term SOFR Administrator on the CME Term SOFR Administrator&#8217;s Website.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, our future payment obligations related to the 2022 Loan, excluding interest payments and the 2022 final fee, were as follows (in thousands) and may be condensed to the 24 months ending March 1, 2027 if certain conditions noted above to extend the interest-only period are achieved:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,888&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total repayment obligations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,861&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized discount and debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,110)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unaccreted value of final fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,040)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,711&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,711)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583750544416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Liabilities</a></td>
<td class="text">DERIVATIVE LIABILITIES<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Exit Fee</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, in connection with entering into the 2018 Loan Agreement, we entered into an agreement pursuant to which we agreed to pay $1.5 million in cash ("2018 Exit Fee") upon any change of control transaction in respect of the Company or if we obtain both (i) FDA approval of XPHOZAH and (ii) FDA approval of IBSRELA, which was obtained on September 12, 2019 (&#8220;2018 Exit Fee Agreement&#8221;). Notwithstanding the February 2022 prepayment of the 2018 Loan, our obligation to pay the 2018 Exit Fee will expire on May 16, 2028. We concluded that the 2018 Exit Fee is a freestanding derivative which should be accounted for at fair value on a recurring basis. The estimated fair value of the 2018 Exit Fee is recorded as a derivative liability and included in accrued expense and other current liabilities on the accompanying balance sheets. As of December&#160;31, 2022 and 2021, the estimated fair value of the 2018 Exit Fee was $1.2 million and $0.7 million, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the derivative liability was determined using a discounted cash flow analysis and is classified as a Level 3 measurement within the fair value hierarchy since our valuation utilized significant unobservable inputs. Specifically, the key assumptions included in the calculation of the estimated fair value of the derivative instrument include: (i) our estimates of both the probability and timing of a potential $1.5 million payment to Solar Capital Ltd. and Western Alliance Bank as a result of the FDA approvals, and (ii) a discount rate which was derived from our estimated cost of debt, adjusted with current LIBOR. Generally, increases or decreases in the probability of occurrence would result in a directionally similar impact in the fair value measurement of the derivative instrument and it is estimated that a 10% increase (decrease), not to exceed 100%, in the probability of occurrence would result in a fair value fluctuation of no more than $0.1 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2022 Exit Fee</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, in connection with entering into the 2022 Loan Agreement, we entered into an agreement, whereby we agreed to pay an exit fee in the amount of 2% of the 2022 Loan funded (&#8220;2022 Exit Fee&#8221;) upon (i) any change of control transaction or (ii) our achievement of net revenue from the sale of any products equal to or greater than $100.0 million, measured on a six (6) months basis ("Revenue Milestone"), tested monthly at the end of each month. Notwithstanding the prepayment or termination of the 2022 Loan, the 2022 Exit Fee will expire on February 23, 2032. We concluded that the 2022 Exit Fee is a freestanding derivative which should be accounted for at fair value on a recurring basis. The estimated fair value of the 2022 Exit Fee is recorded as a derivative liability and included in accrued expenses and other current liabilities on the accompanying balance sheets. As of December&#160;31, 2022, the estimated fair value of the 2022 Exit Fee is $0.4 million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the derivative liability was determined using a discounted cash flow analysis and is classified as a Level 3 measurement within the fair value hierarchy since our valuation utilized significant unobservable inputs. Specifically, the key assumptions included in the calculation of the estimated fair value of the 2022 derivative liability include: (i) our estimates of both the probability and timing of achieving the Revenue Milestone and (ii) the probability and timing of funding the Term B Loan, which is dependent upon (a) approval by the FDA for our NDA for the control of serum phosphorus in adult patients with CKD on dialysis by December 31, 2022, and (b) achievement of certain product revenue milestone targets. Generally, increases or decreases in the probability of occurrence would result in a directionally similar impact in the fair value measurement of the derivative liability and it is estimated that a 10% increase (decrease) in the probability of occurrence would not result in a material fair value fluctuation.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of recurring measurements included in Level 3 of the fair value hierarchy are presented as other income, net in our Statements of Operations and were as follows for the years ended December&#160;31, 2022, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1,</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Exit Fee addition at fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018 Exit Fee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(678)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Exit Fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of exit fee derivative liabilities at December 31,</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,656&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI https://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583750466064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">LEASES<div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have recorded right-of-use operating lease assets under three lease agreements. We have evaluated our facility leases and determined that, effective upon the adoption of Topic 842, the leases evaluated are all operating leases. We have performed an evaluation of our other contracts with suppliers and collaborators in accordance with Topic 842 and have determined that, except for the facility leases described below, none of our contracts contain a lease. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have recorded a right-of-use operating lease asset located in Fremont, California under a lease agreement entered into in September 2008 that was amended multiple times to add space and to extend the lease term through March 2025. The office space consists of 72,500 square feet. We do not have an option to renew the lease at our current Fremont location beyond March 2025.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have recorded a right-of-use operating lease asset located in Waltham, Massachusetts under a lease agreement entered into in October 2018. The office space consisted of 3,520 square feet with the lease terminating in September 2021. We did not renew the lease at our original Waltham, Massachusetts facility. During April 2021 and May 2021, we recorded right-of-use operating lease assets for a new facility in Waltham, Massachusetts under a lease agreement entered into during December 2020 with lease commencement dates during April and May 2021. The office space consists of 12,864 square feet with the lease terminating in June 2026. We have an option to extend the lease term for one additional five year period. This option to extend the lease term has not been included in the calculation since currently the exercise of the option is uncertain and therefore deemed not probable. We recorded a $1.6 million right-of-use asset and lease liability for the Waltham lease upon commencement of the lease.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have recorded a right-of-use operating lease asset located in Milwaukee, Wisconsin under a lease agreement entered into in October 2020 with a lease commencement date in November 2020. The office space consists of 4,768 square feet with the lease terminating in February 2026. We have an option to extend the lease term by one additional five-year period. This option to extend the lease term has not been included in the calculation since currently the exercise of the option is uncertain and therefore deemed not probable. We recorded a $0.4&#160;million right-of use asset and lease liability for the Milwaukee lease upon commencement of the lease.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our leases are operating leases and each contain customary rent escalation clauses. Certain of the leases have both lease and non-lease components. We have elected to account for each separate lease component and the non-lease components associated with that lease component as a single lease component for all classes of underlying assets. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides additional details of our facility leases presented in our balance sheets (dollars in thousands):</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:74.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Facilities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,752&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,894&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,855&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,748&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,749&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease costs, which are included in operating expenses in our statements of operations, were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.057%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,257&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,671&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,608&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for operating lease</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our undiscounted cash payment obligations for our operating lease liabilities as of December&#160;31, 2022 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:86.436%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted operating lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,602&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imputed interest expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(853)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,749&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of operating lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,894)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,855&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583750550592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY<div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, we filed a Form S-3 registration statement, which became effective in August 2020 ("2020 Registration Statement"), containing (i) a base prospectus for the offering, issuance and sale by us of up to a maximum aggregate offering price of $250.0 million of our common stock, preferred stock, debt securities, warrants and/or units, from time to time in one or more offerings; and (ii) a prospectus supplement for the offering, issuance and sale by us of up to a maximum aggregate offering price of $100.0 million of our common stock that may be issued and sold, from time to time, under a sales agreement with Jefferies LLC ("Jefferies"), deemed to be &#8220;at-the-market offerings&#8221; ("2020 Open Market Sales Agreement").&#160;Pursuant to the 2020 Open Market Sales Agreement, Jefferies, as sales agent, received a commission of up to 3.0% of the gross sales price for shares of common stock sold under the 2020 Open Market Sales Agreement. As of December 31, 2021, we had sold 23.3 million shares and received the maximum gross proceeds of $100.0 million pursuant to the 2020 Open Market Sales Agreement. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we filed an additional prospectus supplement under the 2020 Registration Statement for the offering, issuance and sale by us of up to a maximum aggregate offering price of $150.0 million of our common stock that may be issued and sold, from time to time, under an additional sales agreement we entered into with Jefferies ("2021 Open Market Sales Agreement"), pursuant to which we may, from time to time, sell up to $150.0 million in shares of our common stock through Jefferies. We are required to sell shares under the 2021 Open Market Sales Agreement. Pursuant to the 2021 Open Market Sales Agreement, Jefferies, as our sales agent, receives a commission of up to 3.0% of the gross sales price for shares of common stock sold under the 2021 Open Market Sales Agreement. During the twelve months ended December&#160;31, 2022, we sold 64.1 million shares and received gross proceeds of $73.1 million at a weighted average sales price of approximately $1.14 per share under the 2021 Open Market Sales Agreement. As of December&#160;31, 2022 we sold a total of 79.8 million shares and received gross proceeds of $98.1 million at a weighted average sales price of approximately $1.23 per share under the 2021 Open Market Sales Agreement. During the period January 1, 2023 to January 12, 2023, we received additional gross proceeds of $20.0 million for the sale of an additional 7.7 million shares which were sold at a weighted average sales price of approximately $2.60 per share under the 2021 Open Market Sales Agreement. There have been no other sales under the 2021 Open Market Sales Agreement after December 31, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, we filed a Form S-3 registration statement, which became effective in January 2023 ("2023 Registration Statement"), containing (i) a base prospectus for the offering, issuance and sale by us of up to a maximum aggregate offering price of $250.0 million of our common stock, preferred stock, debt securities, warrants and/or units, from time to time in one or more offerings; and (ii) a prospectus supplement for the offering, issuance and sale by us of up to a maximum aggregate offering price of $150.0 million of our common stock that may be issued and sold, from time to time, under a sales agreement with Jefferies LLC ("Jefferies"), deemed to be &#8220;at-the-market offerings&#8221; ("2023 Open Market Sales Agreement").&#160;Pursuant to the 2023 Open Market Sales Agreement, Jefferies, as sales agent, may receive a commission of up to 3.0% of the gross sales price for shares of common stock sold under the 2023 Open Market Sales Agreement. There have been no sales of our common stock under the 2023 Open Market Sales Agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583750473920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity Incentive Plans</a></td>
<td class="text">EQUITY INCENTIVE PLANS<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2008 Plan</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We granted options under our 2008 Stock Incentive Plan (&#8220;2008 Plan&#8221;) until June&#160;2014 when it was terminated as to future awards, although it continues to govern the terms of options that remain outstanding under the 2008 Plan. The 2008 Plan provided for the granting of incentive and non-qualified stock options, and stock purchase rights to employees, directors and consultants at the discretion of the board of directors. Stock options granted generally vested over a period of four years from the date of grant. In connection with the board of directors and stockholders&#8217; approval of the 2014 Plan, all remaining shares available for future award under the 2008 Plan were transferred to 2014 Plan, as discussed below, and the 2008 Plan was terminated.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Plan</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2014 Equity Incentive Award Plan (&#8220;2014 Plan&#8221;) became effective on June&#160;18, 2014. Under the 2014 Plan, 1.4 million shares of common stock were initially reserved for issuance pursuant to a variety of stock-based compensation awards, including stock options, stock appreciation rights ("SARs"), restricted stock awards, service-based restricted stock unit (&#8220;RSU&#8221;) awards, performance-based restricted stock unit (&#8220;PRSU&#8221;) awards, deferred stock awards, deferred stock unit awards, dividend equivalent awards, stock payment awards and performance awards. In addition, 35 thousand shares that had been available for future awards under the 2008 Plan as of June&#160;18, 2014, were added to the initial reserve available under the 2014 Plan, bringing the total reserve upon the effective date of the 2014 Plan to 1.5 million shares. The number of shares initially reserved for </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issuance or transfer pursuant to awards under the 2014 Plan will be increased by (i)&#160;the number of shares represented by awards outstanding under 2008 Plan on June&#160;18, 2014, that are either forfeited or lapse unexercised or that are repurchased for the original purchase price thereof, up to a maximum of 1.2 million shares, and (ii)&#160;if approved by the administrator of the 2014 Plan, an annual increase on the first day of each fiscal&#160;year ending in 2024 equal to the lesser of (A)&#160;four&#160;percent (4.0%) of the shares of stock outstanding (on an as converted basis) on the last day of the immediately preceding fiscal&#160;year and (B)&#160;such smaller number of shares of stock as determined by our board of directors; provided, however, that no more than 10.7 million shares of stock may be issued upon the exercise of incentive stock options.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2016 Plan</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November&#160;2016, our board of directors approved the 2016 Employment Commencement Incentive Plan (&#8220;Inducement Plan&#8221;) under which 1.0 million shares were reserved. In January 2021, January 2022 and December 2022, 0.5&#160;million, 2.0&#160;million and 3.0&#160;million shares, respectively, were added to the Inducement Plan. As of December&#160;31, 2022, 2.1 million shares of our common stock were subject to inducement grants that were issued pursuant to the Inducement Plan.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our stock option activity and related information during the twelve months ended December&#160;31, 2022 is as follows (in thousands, except per share dollar amounts and years):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:39.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.035%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares&#160;Available for&#160;Grant</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Options&#160;Issued&#160;and&#160;Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual&#160;Term<br/>(in Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic&#160;Value</span></td></tr><tr style="height:32pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number&#160;of&#160;Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise&#160;Price&#160;<br/>per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,974&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options authorized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,392)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,832)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock for services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(712)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,909&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,963&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,963&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,283&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value represents the difference between the total pre-tax value (i.e., the difference between our stock price and the exercise price) of stock options outstanding as of December&#160;31, 2022, based on our common stock closing price of $2.85 per share, which would have been received by the option holders if all their in-the-money options had been exercised as of that date.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intrinsic value of options exercised during the&#160;years ended December&#160;31, 2022, 2021 and 2020, was $30 thousand, $1.7&#160;million, and $2.7 million, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date estimated fair value of options granted during the&#160;years ended December&#160;31, 2022, 2021 and 2020 was $0.63, $3.92 and $4.82 per share, respectively. The estimated grant date fair value of employee stock options was calculated using the Black-Scholes option-pricing model, based on the following weighted-average assumptions:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We have limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock-option grants. As such, the expected term was initially estimated using the simplified method whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option. Beginning in 2021, we estimate the expected term of our options based upon historical exercises and post-vesting termination behavior, which has not resulted in a material difference as compared to using the simplified method.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Since January 1, 2017, we use the historic volatility of our own stock over the retrospective period corresponding to the expected remaining term of the options, or the period since our shares were first quoted on The Nasdaq Global Market, if that is shorter, to compute our expected stock price volatility.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The risk-free interest rate assumption is based on the zero-coupon U.S. treasury instruments on the date of grant with a maturity date consistent with the expected term of our stock option grants.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividend Yield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;To date, we have not declared or paid any cash dividends and does not have any plans to do so in the future. Therefore, we use an expected dividend yield of zero.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our RSUs activity and related information for the twelve months ended December&#160;31, 2022 is as follows (in thousands, except per share dollar amounts): </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant&#160;Date&#160;Fair<br/>Value Per&#160;Share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested restricted stock units at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,529&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.04&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,195&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,956)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(362)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested restricted stock units at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,406&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total estimated fair value of RSUs vested during the years ended December&#160;31, 2022, 2021 and 2020 was $2.6 million, $0.8 million and zero, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, we granted 0.9 million PRSUs to our employees that vested upon the achievement of certain performance conditions, subject to the employees&#8217; continued service relationship with us through the achievement date. During 2020, we granted an additional 30 thousand PRSUs subject to the same performance conditions. All 0.9&#160;million of these PRSUs vested in September 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuance of Common Stock for Services</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the&#160;years ended December&#160;31, 2022, 2021 and 2020, we issued approximately 0.7 million, 26 thousand and 42 thousand shares, respectively, of common stock to members of the board of directors who elected to receive stock in lieu of their cash fees under our Non-Employee Director Compensation Program. The shares issued during the years ended December&#160;31, 2022, 2021 and 2020 were valued at $0.4 million, $0.2 million and $0.3 million for each year, respectively, based on the fair value of the common stock on the date of grant.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adopted the 2014 Employee Stock Purchase Plan (&#8220;ESPP&#8221;) and initially reserved approximately 0.2 million shares of common stock as of its effective date of June&#160;18, 2014. If approved by the administrator of the ESPP, on the first day of each calendar&#160;year, ending in 2024, the number of shares in the reserve will increase by an amount equal to the lesser of (i)&#160;one&#160;percent (1.0%) of the shares of common stock outstanding on the last day of the immediately preceding fiscal&#160;year and (ii)&#160;such number of shares of common stock as determined by the board of directors; provided, however, no more than 2.2 million shares of our common stock may be issued under the ESPP.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our ESPP activity during the&#160;twelve months ended December&#160;31, 2022 is as follows (in thousands, except per share dollar amounts):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares&#160;Available<br/>for&#160;Grant</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of&#160;Shares<br/>Purchased</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Purchase&#160;Price<br/>per&#160;Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Proceeds</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,048&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares purchased</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(308)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,356&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates the weighted-average assumptions for the Black-Scholes option-pricing model used in determining the fair value of ESPP purchase rights granted to our employees:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation Expense</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for stock options, RSUs, PRSUs and our ESPP are recorded as operating expenses in our statements of operations and comprehensive loss, as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,525&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,923&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,750&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,039&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,583&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our total unrecognized stock-based compensation expense, net of estimated forfeitures, as of December&#160;31, 2022 is as follows (dollars in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:52.125%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.920%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.922%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrecognized Compensation Expense</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Remaining Vesting Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options grant</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,434&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.55</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSU grants</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,937&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.95</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583750600576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text">RESTRUCTURING<div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, we implemented restructuring plans in August and October following the receipt of a Complete Response Letter (&#8220;CRL&#8221;) from the U.S. FDA relating to our new drug application (&#8220;NDA&#8221;) for XPHOZAH and following the conclusion of an End of Review Type A meeting with the FDA, respectively. Both restructuring plans were substantially completed in December 2021 and most of the cash payments related to the reduction in workforce were disbursed prior to December 31, 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impacted employees were eligible to receive severance benefits and additional Company funded COBRA premiums, contingent upon an impacted employee&#8217;s execution (and non-revocation) of a separation agreement, which included a general release of claims against us. In connection with restructuring, we incurred restructuring charges of $6.2&#160;million, which were recorded during the twelve months ended December 31, 2021, related to one-time termination notice and severance payments and other employee-related costs. We did not incur any significant contract termination costs pursuant to restructuring. Of the </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">charges, $2.7&#160;million was recorded in research and development expenses, and $3.5&#160;million was recorded in selling, general and administrative expense in the accompanying statements of operations and comprehensive loss. Most of the cash payments related to the reduction in workforce were disbursed during the twelve months ended December 31, 2021. We reported the remaining estimated restructuring liability of zero and $0.5&#160;million as accrued compensation and benefits in our balance sheet as of December&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in October, 2021, our Board approved, and management has implemented a retention program consisting of cash payments and grants of RSUs to our employees, including our executives, not impacted by the reduction in force.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI https://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583750660368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">PROPERTY AND EQUIPMENT, NET<div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,474&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and furniture</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,089&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,034&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,880&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,253&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,657)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,891)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,362&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized depreciation expense in the amount of $0.7 million, $1.4 million, and $1.8 million for the&#160;years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div>During the year ended December 31, 2022, following the elimination of our internal research organization in the fourth quarter of 2021, we sold laboratory equipment with total net carrying value of $0.5 million and received cash proceeds of $1.8 million, resulting in a gain of $1.3 million which has been reported within other income, net on our statement of operations and comprehensive loss.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583750515552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES<div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consist of the following (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:75.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.191%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payments due to AstraZeneca </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,385&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued gross to net revenue liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued contract manufacturing expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability for exit fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued non-clinical research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional and consulting services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued sales and marketing expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,380&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,366&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583750574304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">INCOME TAXES<div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of our provision for income taxes for the years ended December&#160;31, 2022, 2021 and 2020, are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the statutory federal income tax rate to our effective tax rate is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax at the federal statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive compensation disallowed under IRC Sec 162(m)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets are as follows as of December&#160;31, 2022 and 2021 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization and depreciation</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,054&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,867&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,799&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,835&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(175,670)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155,141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets net of valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,129&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,694&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,129)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,689)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realization of deferred tax assets is dependent on future taxable income, if any, the timing and the amount of which are uncertain. We assess the available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit use of the existing deferred tax assets. A significant component of objective negative evidence evaluated was our cumulative loss incurred over the three-year period ended December&#160;31, 2022. Such objective evidence limits the </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ability to consider other subjective evidence, such as our projections for future growth. On the basis of this evaluation, as of December&#160;31, 2022, December&#160;31, 2021 and December&#160;31, 2020, a full valuation allowance has been recorded against our net deferred tax asset. The valuation allowance increased by $20.5&#160;million in 2022 primarily due to increases in net operating losses. The amount of the deferred tax asset considered realizable, however, could be adjusted if estimates of future taxable income during the carryforward period are reduced or increased or if objective negative evidence in the form of cumulative losses is no longer present and additional weight is given to subjective evidence such as our projections for growth.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had net operating loss carryforwards for federal income tax purposes of approximately $433.6 million, of which approximately $283.4 million can be carried forward indefinitely and the remaining net operating losses expire beginning in 2030, if not utilized. Federal research and development tax credit carryforwards of approximately $17.2 million that expire beginning in 2027, if not utilized, and foreign tax credit carryforwards of approximately $1.2 million that expire in 2027, if not utilized.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we had net operating loss carryforwards for California income tax purposes of approximately $89.8&#160;million that expire beginning of 2030, if not utilized, and state research and development tax credit carryforwards of approximately $8.6 million which can be carried forward indefinitely. We had approximately $0.1 million of minimum tax credit carryovers for California income tax purposes. The minimum tax credits have no expiration date. We had other state net operating losses of approximately $19.0 million that begin to expire in 2031.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future utilization of net operating loss and tax credit carryforwards and credits may be subject to an annual limitation, pursuant to Internal Revenue Code Sections 382 and 383, as a result of ownership changes that may have occurred previously or that could occur in the future. Due to the existence of the valuation allowance, limitations under Section 382 and 383 will not impact our effective tax rate.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Tax Cuts and Jobs Act of 2017, research and development costs are no longer fully deductible and are required to be capitalized and amortized for U.S. tax purposes effective January 1, 2022. The mandatory capitalization requirement did not have a material impact on our deferred tax assets and did not result in a cash tax liability as we have historically elected to capitalized research and development expenses for tax purposes.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,426&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,538&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtractions related to lapse of statute of limitation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(811)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtractions based on tax positions related to prior year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(811)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,388)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,075&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,426&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,624&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize a tax benefit from an uncertain tax position when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. Income tax positions must meet a more likely than not recognition at the effective date to be recognized. None of our unrecognized tax benefits would impact the effective tax rate if recognized, because the benefit would be offset by an increase in the valuation allowance.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected to include interest and penalties as a component of tax expense. During the years ended December&#160;31, 2022, 2021 and 2020, we did not recognize accrued interest and penalties related to unrecognized tax benefits. Although the timing and outcome of an income tax audit is highly uncertain, we do not anticipate that the amount of existing unrecognized tax benefits will significantly change during the next 12 months.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file a U.S. federal income tax return and income tax returns in various state and local jurisdictions. Due to our net operating loss and tax credit carryforwards, the income tax returns remain open to U.S. federal and state tax examinations. We are not currently under examination in any tax jurisdiction.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583750571872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geographic Information and Concentrations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_GeographicInformationAndConcentrationsTextBlock', window );">Geographic Information and Concentrations</a></td>
<td class="text">GEOGRAPHIC INFORMATION AND CONCENTRATIONS<div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are attributed to geographical areas based on the location at which we earned revenue for product sales of IBSRELA or the domicile of our collaboration partners. A summary of our revenue by geographic areas for the years ended December&#160;31, 2022, 2021 and 2020, is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">North America (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">806&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,158&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,097&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,571&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Revenues from the United States are comprised of amounts earned from sales of IBSRELA.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Revenues from Asia Pacific are primarily comprised of amounts earned in accordance with the 2017 KKC Agreement and the 2019 KKC Agreement.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Revenues from North America are comprised of amounts earned from Canada in accordance with the Knight Agreement.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from Customers and collaboration partnerships accounting for more than 10% of total revenues during the years ended December&#160;31, 2022, 2021 and 2020 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KKC</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Knight</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Drug Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div>Historically, we have not experienced credit losses from our accounts receivable. We have not recorded a reserve for credit losses as of December&#160;31, 2022 and 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_GeographicInformationAndConcentrationsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure on geographic information and concentrations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_GeographicInformationAndConcentrationsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583749110656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">NET LOSS PER SHARE<div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, less shares subject to repurchase, and excludes any dilutive effects of stock-based awards and warrants. Diluted net loss per common share is computed giving effect to all potential dilutive common shares, including common stock issuable upon exercise of stock options, and unvested restricted common stock and stock units. As we had net losses for the&#160;years ended December&#160;31, 2022, 2021 and 2020, all potential common shares were determined to be anti-dilutive. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of net loss per common share (in thousands, except per share dollar amounts):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(67,207)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(158,165)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(94,313)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - basic and diluted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">158,690&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104,206&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89,582&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.42)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.52)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.05)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the&#160;years ended December&#160;31, 2022, 2021 and 2020, the total numbers of securities that could potentially dilute net income per share in the future that were not considered in the diluted net loss per share calculations because the effect would have been anti-dilutive were as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,871&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,247&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP shares issuable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,382&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,680&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,299&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of potential common shares that would have been included in diluted income per share had it not been for the anti-dilutive effect caused by the net loss, computed by converting these securities using the treasury stock method during the years ended December&#160;31, 2022, 2021 and 2020, was approximately 0.6 million, 1.1 million and 2.1 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583747403552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Guarantees and Indemnifications</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We indemnify each of our officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at our request in such capacity, as permitted under Delaware law and in accordance with our certificate of incorporation and bylaws. The term of the indemnification period lasts as long as an officer or director may be subject to any proceeding arising out of acts or omissions of such officer or director in such capacity.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maximum amount of potential future indemnification is unlimited; however, we currently hold director and officer liability insurance, which allows the transfer of risk associated with our exposure and may enable us to recover a portion of any future amounts paid. We believe that the fair value of these indemnification obligations is minimal. Accordingly, we have not recognized any liabilities relating to these obligations for any period presented.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings and Claims</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30 and August 12, 2021, two putative securities class action lawsuits were commenced in the U.S. District Court for the Northern District of California naming as defendants Ardelyx and two current officers captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Strezsak v. Ardelyx, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 4:21-cv-05868-HSG, and Siegel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> v. Ardelyx, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 5:21-cv-06228-HSG (together, the &#8220;Securities Class Actions&#8221;). The complaints allege that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 thereunder, by making false and misleading statements and omissions of material fact related to tenapanor. The plaintiffs seek to represent all persons who purchased or otherwise acquired Ardelyx securities between August 6, 2020, and July 19, 2021. The plaintiffs seek damages and interest, and an award of costs, including attorneys&#8217; fees. On July 19, 2022, the court consolidated the two putative class actions and appointed a lead plaintiff and lead counsel. The lead plaintiff filed an amended complaint on September 29, 2022. Defendants filed a motion to dismiss the amended complaint on December 2, 2022. In January and February 2023, in lieu of filing a response to defendant&#8217;s motion to dismiss, plaintiffs filed a motion seeking leave to further amend their compliant and defendants filed an opposition to the motion for leave to further amend the complaint. A hearing on the motion for leave to further amend the complaint is scheduled for mid-May 2023. We believe the plaintiff&#8217;s claims are without merit and we have not recorded any accrual for a contingent liability associated with these legal proceedings.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2021 and March 29, 2022, two verified shareholders derivative lawsuits were filed in the U.S. District Court for the Northern District of California purportedly on behalf of Ardelyx against certain of Ardelyx&#8217;s executive officers and members of our board of directors, captioned Go v. Raab, et al., Case No. 4:21-cv-09455-HSG, and Morris v. Raab, et al., Case No. 4:22-cv-01988-JSC. The complaints allege that the defendants violations of Section 14(a) of the Securities Exchange Act of 1934, as amended, breaches of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement, and waste of corporate assets, for personally making and/or causing Ardelyx to make materially false and misleading statements regarding the Company&#8217;s business, operations and prospects. The complaint seeks contribution under Sections 10(b) and 21D of the Securities Exchange Act of 1934 from two executive officers. On January 19, and April 27, 2022, the court granted the parties&#8217; stipulation to stay the Go and Morris actions, respectively, until resolution of the anticipated motion(s) to dismiss in the Securities Class Actions. On October 25, 2022, the parties filed a stipulation to consolidate and stay the Go and Morris actions, </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and on October 27, 2022, the court consolidated the Go and Morris action and stayed the consolidated action pending resolution of the anticipated motion(s) to dismiss in the Securities Class Action. We believe the plaintiff&#8217;s claims are without merit and we have not recorded any accrual for a contingent liability associated with these legal proceedings.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be involved in legal proceedings arising in the ordinary course of business. As of December&#160;31, 2022, there is no litigation pending that would reasonably be expected to have a material adverse effect on our results of operations and financial condition, and no contingent liabilities were accrued as of December&#160;31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583749110656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">SUBSEQUENT EVENTS<div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, we filed a Form S-3 registration statement, which became effective in January 2023 ("2023 Registration Statement"), containing (i) a base prospectus for the offering, issuance and sale by us of up to a maximum aggregate offering price of $250.0 million of our common stock, preferred stock, debt securities, warrants and/or units, from time to time in one or more offerings; and (ii) a prospectus supplement for the offering, issuance and sale by us of up to a maximum aggregate offering price of $150.0 million of our common stock that may be issued and sold, from time to time, under a sales agreement with Jefferies LLC ("Jefferies"), deemed to be &#8220;at-the-market offerings&#8221; ("2023 Open Market Sales Agreement").&#160;Pursuant to the 2023 Open Market Sales Agreement, Jefferies, as sales agent, may receive a commission of up to 3.0% of the gross sales price for shares of common stock sold under the 2023 Open Market Sales Agreement. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 9, 2023, we entered into a second amendment (&#8220;Second Amendment&#8221;) to our Loan Agreement with the Lenders. The Second Amendment extends the interest-only term of the loan by twelve months to March 31, 2025 provided that we either (i) receive approval from the FDA for our NDA for the control of serum phosphorus in adult patients with CKD on dialysis on or prior to November 30, 2023 or (ii) achieve certain product revenue milestone targets as described in the Second Amendment for the year ending December 31, 2023. The Second Amendment also extends the period under which we may draw the Term B Loan from July 25, 2023 to December 20, 2023, and amends the milestone that we must achieve in order to draw the Term B Loan by extending the time period for the receipt of approval by the FDA of the NDA for the control of serum phosphorus in adult patients with CKD on dialysis until November 30, 2023. In addition, the Second Amendment replaces the floating per annum interest rate with 7.95% plus the greater of (a) one percent (1.00%) per annum and (b)(i) 0.022% plus (ii) 1-month CME Term SOFR reference rate as published by the CME Term SOFR Administrator on the CME Term SOFR Administrator&#8217;s Website.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583748628208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the amounts reported in the financial statements and accompanying notes thereto. On an ongoing basis, management evaluates its estimates, including those related to recognition of revenue, clinical trial accruals, contract manufacturing accruals, fair value of assets and liabilities, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could materially differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments purchased with an original maturity date of 90 days or less on the date of purchase to be cash equivalents.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ShortTermInvestmentsPolicyTextBlock', window );">Short-Term Investments</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-Term Investments</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments consist of debt securities classified as available-for-sale and have maturities greater than 90&#160;days, but less than one&#160;year, from the date of acquisition. Short-term investments are carried at fair value based upon quoted market prices. Unrealized gains and losses on available-for-sale securities are included in accumulated other comprehensive loss on our balance sheets. The cost of available-for-sale securities sold is based on the specific-identification method.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents, short-term investments and accounts receivable. We are exposed to credit risks in the event of default by the counterparties to the extent of the amount recorded in its balance sheet. Cash, cash equivalents and short-term investments are invested through banks and other financial institutions in the U.S.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage our foreign currency exposures with the use of foreign currency purchases. We primarily conduct business in U.S. dollars; however, a portion of our expense and capital activities are transacted in foreign currencies which are subject to exchange rate fluctuations that can affect cash or earnings. We have been in a loss position and therefore our primary objective is to conserve and manage cash. There are generally two methods by which we may manage the cash flow risk of foreign exchange fluctuations when a contract is signed (i) we can purchase the foreign funds, in full or in part, upon the execution of the contract, or (ii) we can obtain the right to purchase such funds, in full or in part, at the execution of the contract, i.e., obtain a forward contract from an appropriate bank, that can be exercised to obtain the currency of interest at a particular point in time. The derivative instruments that we may use to hedge the exposure shall generally not be designated as cash flow hedges, and as a result, changes in their fair value would be recorded in other income (expense), net, in our statements of operations and comprehensive loss. The fair values of forward foreign currency exchange contracts would be estimated using current exchange rates and interest rates and the current creditworthiness of the counterparties is taken into consideration.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets, with ranges generally from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzY3Mzg_4835439c-76eb-4d2f-801e-529f6574b0d2">three</span> to five years. Leasehold improvements are amortized over the lesser of the estimated useful lives or the related remaining lease term.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of long-lived assets, including property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the asset may not be recoverable. An impairment loss is recognized when the total of estimated future undiscounted cash flows, expected to result from the use of the asset and its eventual disposition, are less than the asset&#8217;s carrying amount. Impairment, if any, would be assessed using discounted cash flows or other appropriate measures of fair value. For the years ending December&#160;31, 2022, 2021 and 2020 we have recognized no impairment losses.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text">Accounts ReceivableAccounts receivable is reported net of allowances for returns, chargebacks and contractual off-invoice and prompt-pay discounts offered to our customers. Our estimate of the allowance for doubtful accounts is based on an evaluation of the aging of our receivables. Trade receivable balances are written off against the allowance when it is probable that the receivable will not be collected. To date, we have determined that an allowance for doubtful accounts is not required.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize inventory costs associated with the production of our products after regulatory approval or when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Otherwise, such costs are expensed as research and development. Prior to the regulatory approval of drug product candidates, we incurred expenses for the manufacture of drug product that could potentially be available to support the commercial launch of our products or could be sold to our international partners under product supply agreements. We began to capitalize inventory costs associated with IBSRELA during the fourth quarter of 2021, when our intent to commercialize IBSRELA was established and we commenced preparation for the commercial launch of IBSRELA, which was when it was determined that the inventory had a probable future economic benefit.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is stated at the lower of cost or estimated net realizable value with cost determined under the first-in first-out method. Inventory costs include the cost of materials, third-party contract manufacturing, third-party packaging services, freight, labor costs for personnel involved in the manufacturing process, and indirect overhead costs. We primarily use actual costs to determine the cost basis for inventory. The determination of whether inventory costs will be realizable requires management review of the expiration dates of IBSRELA compared to our forecasted sales. If actual market conditions are less favorable than projected by management, write-downs of inventory may be required, which would be recorded as cost of revenue in the statement of operations and comprehensive loss. As of December&#160;31, 2022, we have not recorded any write-offs for excess and obsolete inventory. A portion of inventory that represents product that is not expected to be sold or used within the next 12 months is classified as non-current on our balance sheets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Product Sales, Net and Reserves for Variable Consideration and Collaboration Revenue Recognition</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales, Net</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for our commercial product sales, net in accordance with Topic 606 - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We received approval from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in September 2019 to market IBSRELA in the U.S.. We began selling IBSRELA in the U.S. in March 2022. We distribute IBSRELA principally through major wholesalers, specialty pharmacies and group purchasing organizations ("GPOs") (collectively, our "Customers"). Our Customers subsequently sell IBSRELA to pharmacies and patients. Separately, we enter into arrangements with third parties that provide for government-mandated rebates, chargebacks and discounts. Revenue from product sales is recognized when our performance obligations are satisfied, which is when Customers obtain control of our product and occurs upon delivery.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reserves for Variable Consideration</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration which may be settled in the form of off-invoice discounts, chargebacks, or rebates. Variable consideration includes discounts to customers and government programs, wholesaler fees, group purchasing organization administrative fees, patient copay assistance programs, and estimated product returns. These estimates are based on the amounts earned or to be claimed for related sales and are classified as reductions of gross accounts receivable if settlement is expected to occur through a reduction in the amounts paid by our customers or a current liability if settlement is expected to occur through a payment from us. Where appropriate, these estimates are based on factors such as industry data and forecasted customer buying and payment patterns, our experience, current contractual and statutory requirements, specific known market events and trends. These reductions to gross sales reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. Variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we adjust these estimates, which would affect product revenue and earnings in the period such variances become known. As we gain more experience, estimates will be more heavily based on the expected utilization from historical data we have accumulated since the IBSRELA product launch.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates: Rebates include wholesaler fees, GPO fees, as well as mandated discounts under the Medicaid Drug Rebate Program ("Medicaid") and the Medicare Coverage Gap Program ("Medicare"). Estimates for rebates are recorded in the same period the related gross revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses on the balance sheets. We estimate our Medicaid and Medicare rebates based upon the estimated payor mix, and statutory discount rates. Our estimates for payor mix are guided by payor information received from specialty pharmacies, expected utilization for wholesaler sales to pharmacies, and available industry payor information. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks: Chargebacks are discounts that occur when certain contracted purchasers purchase directly from our wholesalers at a discounted price. The wholesaler, in turn, charges back the difference between the price initially paid to us by the wholesaler and the discounted price paid to the wholesaler by the contracted purchaser. Amounts for estimated chargebacks are established in the same period that the related gross revenue is recognized, resulting in a reduction of product revenue and accounts receivable. The accrual for wholesaler chargebacks is estimated based on known chargeback rates, known sales to wholesalers, and estimated utilization by types of contracted purchasers.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discounts and Fees: Our payment terms are generally 30 to 60 days. Wholesalers, GPOs and specialty pharmacies are offered various forms of consideration, including off-invoice discounts which may be paid to GPOs and specialty pharmacies. Wholesalers and GPOs may also receive prompt pay discounts for payment within a specified period. We expect discounts to be earned when offered and therefore, we deduct the full amount of these discounts from product sales when revenue is recognized, resulting in a reduction of product revenue and accounts receivable.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Reserves: Patients who have commercial insurance may receive copay assistance when product is dispensed by pharmacies to patients. We estimate the amount of copay assistance provided to eligible patients based on the terms of the program and redemption information provided by third-party claims processing organizations and are recorded in accounts payable and accrued expenses and other current liabilities on the balance sheets. Other reserves include estimated product returns which are recorded in the same period the related gross revenue is recognized, resulting in a reduction of product revenue as well as accounts receivable. We estimate our product returns reserve based upon our experience, and specific known market events and trends. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenue Recognition</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate collaboration revenue primarily from research and collaboration and license agreements with customers. Goods and services in the agreements may include the grant of licenses for the use of our technology,&#160;the provision of services associated with the research and development of product candidates, manufacturing services, and participation in joint steering committees. The terms of these arrangements typically include payment to us of one or more of the following: non-refundable, up-front license fees; research, development, regulatory and commercial milestone payments; reimbursement of research and development services; option payments; reimbursement of certain costs; payments for manufacturing supply services; and future royalties on net sales of licensed products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When two or more contracts are entered into with the same customer at or near the same time, we evaluate the contracts to determine whether the contracts should be accounted for as a single arrangement. Contracts are combined and accounted for as a single arrangement if one or more of the following criteria are met: (i) the contracts are negotiated as a package with a single commercial objective; (ii) the amount of consideration to be paid in one contract depends on the price or performance of the other contract; or (iii) the goods or services promised in the contracts (or some goods or services promised in each of the contracts) are a single performance obligation.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under each of our agreements, management performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including any constraints on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) we satisfy each performance obligation. As part of the accounting for contracts with customers, we develop assumptions that require judgment to determine whether promised goods and services represent distinct performance obligations and the standalone selling price for each performance obligation identified in the contract. This evaluation is subjective and requires us to make judgments about the promised goods and services and whether those goods and services are separable from other aspects of the contract. Further, determining the standalone selling price for performance obligations requires significant judgment, and when an observable price of a promised good or service is not readily available, we consider relevant assumptions to estimate the standalone selling price, including, as applicable, market conditions, development timelines, probabilities of technical and regulatory success, reimbursement rates for personnel costs, forecasted revenues, potential limitations to the selling price of the product and discount rates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply judgment in determining whether a combined performance obligation is satisfied at a point in time or over time, and, if over time, concluding upon the appropriate method of measuring progress to be applied for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, as estimates related to the measure of progress change, related revenue recognition is adjusted accordingly. Changes in our estimated measure of progress are accounted for prospectively as a change in accounting estimate. We recognize collaboration revenue by measuring the progress toward complete satisfaction of the performance obligation using an input measure. In order to recognize revenue over the research and </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development period, we measure actual costs incurred to date compared to the overall total expected costs to satisfy the performance obligation. Revenues are recognized as the program costs are incurred. We will re-evaluate the estimate of expected costs to satisfy the performance obligation each reporting period and make adjustments for any significant changes.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to satisfying the revenue recognition criteria are recorded as contract liabilities in our Balance Sheets. If the related performance obligation is expected to be satisfied within the next twelve months it will be classified in current liabilities. Amounts recognized as revenue prior to receipt are recorded as contract assets in our Balance Sheets. If we expect to have an unconditional right to receive the consideration in the next twelve months, it will be classified in current assets. A net contract asset or liability is presented for each contract with a customer.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved. Milestone payments that are not within our control or the control of the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achievement of such development milestones and any related constraints, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect earnings in the period of adjustment.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing supply services:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Arrangements that include a promise for future supply of drug substance or drug product for either clinical development or commercial supply at the customer&#8217;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. If we are entitled to additional payments when the customer exercises these options, any payments are recorded in product supply revenue when the customer obtains control of the goods, which is upon delivery.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and where the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, royalty revenue resulting from licensing arrangements has not been material.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses of intellectual property:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If a license granted to a customer to use our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from consideration allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we apply judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, to conclude upon the appropriate method of measuring progress for purposes of recognizing revenue related to consideration allocated to the performance obligation.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Options:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Customer options, such as options granted to allow a licensee to choose to research, develop and commercialize licensed compounds are evaluated at contract inception in order to determine whether those options provide a material right (i.e., an optional good or service offered for free or at a discount) to the customer. If the customer options represent a material right, the material right is treated as a separate performance obligation at the outset of the arrangement. We allocate the transaction price to material rights based on the standalone selling price, and revenue is recognized when or as the future goods or services are transferred or when the option expires. Customer options that are not material rights do not give rise to a separate performance obligation, and as such, the additional consideration that would result from a customer exercising an option in the future is not included in the transaction price for the current contract. Instead, the option is deemed a marketing offer, and additional option fee payments are recognized or being recognized as revenue when the licensee exercises the option. The exercise of an option that does not represent a material right is treated as a separate contract for accounting purposes.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract modifications:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Contract modifications, defined as changes in the scope or price (or both) of a contract that are approved by the parties to the contract, such as a contract amendment, exist when the parties to a contract approve a modification that either creates new or changes existing enforceable rights and obligations of the parties to the contract. Depending on facts and circumstances, we account for a contract modification as one of the following: (i) a separate contract; (ii) a termination of the existing contract and a creation of a new contract; or (iii) a combination of the preceding treatments. A contract modification is accounted for as a separate contract if the scope of the contract increases because of the addition of promised goods or services that are distinct and the price of the contract increases by an amount of consideration that reflects </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our standalone selling prices of the additional promised goods or services. When a contract modification is not considered a separate contract and the remaining goods or services are distinct from the goods or services transferred on or before the date of the contract modification, we account for the contract modification as a termination of the existing contract and a creation of a new contract. When a contract modification is not considered a separate contract and the remaining goods or services are not distinct, we account for the contract modification as an add-on to the existing contract and as an adjustment to revenue on a cumulative catch-up basis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive payments from our licensees as established in each contract. Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until we perform our obligations under these arrangements. Where applicable, amounts are recorded as accounts receivable or unbilled revenue when our right to consideration is unconditional. We do not assess whether a contract with a customer has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Revenue</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue consists of the cost of commercial goods sold to our Customers and international partners under product supply agreements as well as royalty expense based on sales of tenapanor. We capitalize inventory costs associated with the production of our products after regulatory approval or when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Otherwise, such costs are expensed as research and development. A portion of the costs of IBSRELA units recognized as revenue during the twelve months ended December&#160;31, 2022 were expensed prior to the fourth quarter of 2021, at which time our intent to commercialize IBSRELA was established and we commenced preparation for the commercial launch of IBSRELA. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue includes payments due to AstraZeneca, which under the terms of a termination agreement entered into in 2015 ("AZ Termination Agreement") is entitled to (i) future royalties at a rate of 10% of net sales of tenapanor or other NHE3 products by us or our licensees, and (ii) 20% of non-royalty revenue received from our collaboration partners as a result of the development and commercialization of tenapanor or certain other NHE3 inhibitors.&#160;We have agreed to pay&#160;AstraZeneca up to a maximum of $75.0 million in the aggregate for (i) and (ii). We recognize these expenses as cost of revenue when we recognize the corresponding revenue that gives rise to payments due to AstraZeneca. To date, we have recognized an aggregate of $15.3 million as cost of revenue under the AZ Termination Agreement.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to expense as incurred and consisted of costs incurred to further our research and development activities and include salaries and related employee benefits, costs associated with clinical trials, costs related to pre-commercialization manufacturing activities such as manufacturing process validation activities and the manufacturing of clinical drug supply, nonclinical research and development activities, regulatory activities, research-related overhead expenses and fees paid to external service providers and contract research and manufacturing organizations that conduct certain research and development activities on our behalf.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock', window );">Accrued Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to estimate our accrued expenses at the end of each reporting period. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual costs. The majority of our service providers submit invoices in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with our service providers and make adjustments if necessary. Examples of estimated accrued research and development expenses include fees paid to:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contract research organizations ("CROs") in connection with clinical studies;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">investigative sites in connection with clinical studies;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">vendors related to product manufacturing, development and distribution of clinical supplies; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">vendors in connection with preclinical development activities.</span></div>We record expenses related to clinical studies and manufacturing development activities based on our estimates of the services received and efforts expended pursuant to contracts with multiple CROs and manufacturing vendors that conduct and manage these activities on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these contracts depend on factors such as the successful enrollment of subjects and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed, enrollment of subjects, number of sites activated and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we will adjust the accrued or prepaid expense balance accordingly.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize compensation expense for all stock-based payment awards made to employees, non-employees and directors based on estimated fair values. For employee and non-employee stock options, we determine the grant date fair value of the awards using the Black-Scholes option-pricing model and generally recognize the fair value as stock-based compensation expense on a straight-line basis over the vesting period of the respective awards. For restricted stock and performance-based restricted stock, to the extent they are probable, the compensation cost for these awards is based on the closing price of our common stock on the date of grant and recognized as compensation expense on a straight-line basis over the requisite service period. Stock-based compensation expense is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. As such, our stock-based compensation is reduced for the estimated forfeitures at the date of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesReportingOfDerivativeActivity', window );">Derivatives and Hedging Activities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivatives and Hedging Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for our derivative instruments as either assets or liabilities on the balance sheet and measure them at fair value. Derivatives are adjusted to fair value through other income (expense), net in the statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock', window );">Non-cash Interest Expense on Deferred Royalty Obligation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-cash Interest Expense on Deferred Royalty Obligation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net proceeds we receive from the sale of certain future royalties are recorded as deferred royalty obligation related to the sale of future royalties on our balance sheets. As we earn royalties and remit those royalties pursuant to the agreement, the balance of the deferred royalty obligation will be effectively repaid over the life of agreement and non-cash interest expense related to the sale of future royalties is recorded using the effective interest method. To determine the amortization of our deferred royalty obligation, we are required to estimate the total amount of future royalty payments we expect to earn. There are a number of factors that could materially affect the amount and timing of royalty payments, most of which are not within our control. We periodically assess the amount of royalty payments we expect to receive which are subject to the agreement and, to the extent that the amount or timing of such payments is materially different than our original estimates, we prospectively adjust the imputed interest rate and the related amortization of the deferred royalty obligation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement is a lease at the inception of the arrangement. Operating leases are included in right-of-use assets, current portion of operating lease liability, and operating lease liability, net of current portion in our balance sheets. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. The operating lease right-of-use assets also include any lease payments made and exclude lease incentives. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise any such options. Lease expense is recognized on a straight-line basis over the expected lease term. We have elected not to separate lease and non-lease components, such as common area maintenance charges, and instead it accounts for these as a single lease component.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock', window );">Restructuring</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize restructuring charges related to reorganization plans that have been committed to by management when liabilities have been incurred. In connection with these activities, we record restructuring charges at fair value for, (a) contractual employee termination benefits when obligations are associated to services already rendered, rights to such benefits have vested, and payment of benefits is probable and can be reasonably estimated, (b) one-time employee termination benefits </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">when management has committed to a plan of termination, the plan identifies the employees and their expected termination dates, the details of termination benefits are complete, it is unlikely changes to the plan will be made or the plan will be withdrawn and communication to such employees has occurred, and (c) contract termination costs when a contract is terminated before the end of its term.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One-time employee termination benefits are recognized in their entirety when communication has occurred and future services are not required. If future services are required, the costs are recorded ratably over the remaining period of service. Contract termination costs to be incurred over the remaining contract term without economic benefit are recorded in their entirety when the contract is canceled.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration of potential shares of common stock. Diluted net loss per common share in the periods presented is the same as basic net loss per common share, since the effects of potentially dilutive securities are antidilutive due to the net loss for all periods presented.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Pronouncements - Recently Adopted</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adopted Accounting Standards Update 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2016-13"), as of December 1, 2021 under the modified retrospective approach. ASU 2016-13 requires an entity to measure and recognize expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities with unrealized credit losses, the standard requires allowances to be recorded through net income instead of directly reducing the amortized cost of the investment under the previous other-than-temporary impairment model. The adoption of this standard did not have a material impact on our financial statements or a significant impact on our internal controls.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were various accounting standards and interpretations issued recently, none of which are expected to a have a material impact on our financial position, operations or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Cash Interest Expense On Deferred Royalty Obligation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ShortTermInvestmentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short term investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ShortTermInvestmentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI https://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesReportingOfDerivativeActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for derivatives entered into for trading purposes and those entered into for purposes other than trading including where and when derivative financial instruments and derivative commodity instruments and their related gains or losses are reported in the entity's statements of financial position, cash flows, and results of operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesReportingOfDerivativeActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583750550592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Short-Term Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Securities Classified as Cash, Cash Equivalents and Short-Term Investments</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities classified as cash, cash equivalents and short-term investments as of December&#160;31, 2022 and 2021 are summarized below (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,140&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,140&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored agency bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,823&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,963&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,909&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial Paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,428&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,428&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,261&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,695&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,689&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583750501104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value of Financial Assets and Liabilities Measured on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of our financial assets and liabilities that are measured or disclosed on a recurring basis by level within the fair value hierarchy (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored agency bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,082&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,313&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,769&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities for exit fees</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,656&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,656&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,656&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,656&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,436&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,261&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability for exit fee</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583747313632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Current Inventory</a></td>
<td class="text">Inventory as of December&#160;31, 2022 consisted of the following (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,299&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,346&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory, non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,064&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28,346</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock', window );">Schedule of Noncurrent Inventory</a></td>
<td class="text">Inventory as of December&#160;31, 2022 consisted of the following (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,299&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,346&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory, non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,064&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28,346</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle including inventoried costs relating to long-term contracts or programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583750660368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock', window );">Schedule of Chargebacks, Discounts and Reserve Balances</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Discounts and Chargebacks</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Rebates, Wholesaler and GPO Fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Copay and Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to 2022 sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,048&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits/deductions issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(683)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,277)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,244)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,204)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,444&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,258&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,844&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Gross To Net Sales Accruals</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583750606688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Licensing Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_CollaborationAndLicensingAgreementsAbstract', window );"><strong>Collaboration and Licensing Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Deferred Revenue Balances</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present changes in our current and non-current deferred revenue balances during the reporting period. The December&#160;31, 2022 deferred revenue current and non-current balances are attributable entirely to prepayments for product supply under the 2017 KKC Agreement, while the December&#160;31, 2021 current deferred revenue balance is attributable to the 2019 KKC Agreement and the December&#160;31, 2021 non-current deferred revenue balance is attributable prepayments for product supply under the 2017 KKC Agreement (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue - current</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at Balance at January 1,</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases due to cash received, excluding amounts recognized as revenue during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases due to amounts reclassified from non-current, to be recognized in the next twelve months</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,961&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases to amounts invoiced, for which cash has not yet been received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases due to revenue recognized in the period for which cash has been received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,177)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31,</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,211&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue - non-current</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at Balance at January 1,</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,727&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases due to cash received during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases to amounts invoiced, for which cash has not yet been received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase due to unbilled prepayments recorded during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases due to amounts reclassified as current, to be recognized in the next twelve months</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,961)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31,</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,025&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,727&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborationAndLicensingAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborationAndLicensingAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583747532560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Debt Payment Obligations</a></td>
<td class="text"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, our future payment obligations related to the 2022 Loan, excluding interest payments and the 2022 final fee, were as follows (in thousands) and may be condensed to the 24 months ending March 1, 2027 if certain conditions noted above to extend the interest-only period are achieved:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,888&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total repayment obligations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,861&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized discount and debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,110)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unaccreted value of final fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,040)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,711&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,711)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583750800256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Changes in Fair Value of Derivative Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of recurring measurements included in Level 3 of the fair value hierarchy are presented as other income, net in our Statements of Operations and were as follows for the years ended December&#160;31, 2022, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1,</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Exit Fee addition at fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018 Exit Fee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(678)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Exit Fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of exit fee derivative liabilities at December 31,</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,656&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583747562096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock', window );">Summary of Additional Details of the Leases</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides additional details of our facility leases presented in our balance sheets (dollars in thousands):</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:74.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Facilities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,752&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,894&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,855&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,748&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,749&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Lease Costs</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease costs, which are included in operating expenses in our statements of operations, were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.057%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,257&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,671&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,608&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for operating lease</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Undiscounted Cash Payment Obligations for Operating Lease Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our undiscounted cash payment obligations for our operating lease liabilities as of December&#160;31, 2022 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:86.436%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted operating lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,602&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imputed interest expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(853)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,749&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of operating lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,894)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,855&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of additional details of the leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583750243264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our stock option activity and related information during the twelve months ended December&#160;31, 2022 is as follows (in thousands, except per share dollar amounts and years):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:39.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.035%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares&#160;Available for&#160;Grant</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Options&#160;Issued&#160;and&#160;Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual&#160;Term<br/>(in Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic&#160;Value</span></td></tr><tr style="height:32pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number&#160;of&#160;Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise&#160;Price&#160;<br/>per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,974&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options authorized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,392)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,832)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock for services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(712)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,909&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,963&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,963&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,283&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions for Stock Options</a></td>
<td class="text">The estimated grant date fair value of employee stock options was calculated using the Black-Scholes option-pricing model, based on the following weighted-average assumptions:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Stock Units Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our RSUs activity and related information for the twelve months ended December&#160;31, 2022 is as follows (in thousands, except per share dollar amounts): </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant&#160;Date&#160;Fair<br/>Value Per&#160;Share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested restricted stock units at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,529&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.04&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,195&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,956)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(362)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested restricted stock units at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,406&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock', window );">Schedule of Employee Stock Purchase Plan Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our ESPP activity during the&#160;twelve months ended December&#160;31, 2022 is as follows (in thousands, except per share dollar amounts):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares&#160;Available<br/>for&#160;Grant</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of&#160;Shares<br/>Purchased</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Purchase&#160;Price<br/>per&#160;Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Proceeds</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,048&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares purchased</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(308)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,356&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions for Employee Stock Purchase Plan</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates the weighted-average assumptions for the Black-Scholes option-pricing model used in determining the fair value of ESPP purchase rights granted to our employees:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Recognized</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for stock options, RSUs, PRSUs and our ESPP are recorded as operating expenses in our statements of operations and comprehensive loss, as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,525&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,923&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,750&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,039&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,583&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock', window );">Schedule of Total Unrecognized Stock-Based Compensation Expense, Net of Estimated Forfeitures</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our total unrecognized stock-based compensation expense, net of estimated forfeitures, as of December&#160;31, 2022 is as follows (dollars in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:52.125%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.920%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.922%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrecognized Compensation Expense</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Remaining Vesting Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options grant</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,434&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.55</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSU grants</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,937&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.95</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of employee stock purchase plan activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583750515552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,474&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and furniture</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,089&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,034&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,880&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,253&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,657)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,891)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,362&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583750600576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consist of the following (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:75.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.191%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payments due to AstraZeneca </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,385&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued gross to net revenue liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued contract manufacturing expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability for exit fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued non-clinical research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional and consulting services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued sales and marketing expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,380&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,366&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583747506240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Provision for Income Taxes</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of our provision for income taxes for the years ended December&#160;31, 2022, 2021 and 2020, are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Effective Tax Rate</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the statutory federal income tax rate to our effective tax rate is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax at the federal statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive compensation disallowed under IRC Sec 162(m)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of Deferred Tax Assets</a></td>
<td class="text">Significant components of our deferred tax assets are as follows as of December&#160;31, 2022 and 2021 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization and depreciation</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,054&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,867&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,799&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,835&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(175,670)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155,141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets net of valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,129&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,694&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,129)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,689)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Reconciliation of Unrecognized Tax Benefits</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,426&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,538&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtractions related to lapse of statute of limitation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(811)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtractions based on tax positions related to prior year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(811)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,388)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,075&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,426&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,624&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI https://asc.fasb.org/extlink&amp;oid=126976462&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583749100784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geographic Information and Concentrations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Revenue by Geographic Areas</a></td>
<td class="text">A summary of our revenue by geographic areas for the years ended December&#160;31, 2022, 2021 and 2020, is as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">North America (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">806&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,158&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,097&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,571&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Revenues from the United States are comprised of amounts earned from sales of IBSRELA.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Revenues from Asia Pacific are primarily comprised of amounts earned in accordance with the 2017 KKC Agreement and the 2019 KKC Agreement.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Revenues from North America are comprised of amounts earned from Canada in accordance with the Knight Agreement.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Customers and Collaboration Partnerships</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from Customers and collaboration partnerships accounting for more than 10% of total revenues during the years ended December&#160;31, 2022, 2021 and 2020 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KKC</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Knight</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Drug Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583747393904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Net Loss Per Common Share</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of net loss per common share (in thousands, except per share dollar amounts):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(67,207)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(158,165)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(94,313)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - basic and diluted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">158,690&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104,206&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89,582&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.42)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.52)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.05)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Anti-Dilutive Securities Not Considered in Diluted Net Loss Per Common Share Calculation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the&#160;years ended December&#160;31, 2022, 2021 and 2020, the total numbers of securities that could potentially dilute net income per share in the future that were not considered in the diluted net loss per share calculations because the effect would have been anti-dilutive were as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,871&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,247&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP shares issuable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,382&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,680&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,299&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583750473920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583753683904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Liquidity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Cash and short-term investments</a></td>
<td class="nump">$ 123,909<span></span>
</td>
<td class="nump">$ 116,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (780,137)<span></span>
</td>
<td class="num">$ (712,930)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of investments and unrestricted cash as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583749246608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Accounts Receivable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 7,733<span></span>
</td>
<td class="nump">$ 502<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=ardx_AccountsReceivableCollaboratorMember', window );">Collaborators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=ardx_AccountsReceivableCommercialCustomerMember', window );">Commercial customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=ardx_AccountsReceivableCollaboratorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=ardx_AccountsReceivableCollaboratorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=ardx_AccountsReceivableCommercialCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=ardx_AccountsReceivableCommercialCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583750221968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment loss of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_RevenueGeneralPaymentTerms', window );">Payment terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_RevenueGeneralPaymentTerms', window );">Payment terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ardx_AstrazenecaMember', window );">AstraZeneca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_CostOfRevenueAggregateAmountRecognized', window );">Aggregate cost of revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ardx_AstrazenecaMember', window );">AstraZeneca | AZ Termination Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_PercentageOfRoyaltyRevenue', window );">Percentage of royalty revenue</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_PercentageOfNonRoyaltyRevenue', window );">Percentage of non royalty revenue</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum', window );">Maximum potential payment per agreement</a></td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Potential Payment Per Termination Agreement, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CostOfRevenueAggregateAmountRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of revenue, aggregate amount recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CostOfRevenueAggregateAmountRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_PercentageOfNonRoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of non-royalty revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_PercentageOfNonRoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_PercentageOfRoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of royalty revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_PercentageOfRoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_RevenueGeneralPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, General Payment Terms</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_RevenueGeneralPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ardx_AstrazenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ardx_AstrazenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ardx_AstraZenecaTerminationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ardx_AstraZenecaTerminationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583743891920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Short-Term Investments - Securities Classified as Cash and Short-Term Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 96,140<span></span>
</td>
<td class="nump">$ 72,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Short-term investments, Cost</a></td>
<td class="nump">27,823<span></span>
</td>
<td class="nump">44,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Short-term investments, Gross Unrealized Gains</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Short-term investments, Gross Unrealized Losses</a></td>
<td class="num">(60)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments, Fair Value</a></td>
<td class="nump">27,769<span></span>
</td>
<td class="nump">44,261<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_InvestmentsAndCashAmortizedCost', window );">Total cash equivalents and investments, Cost</a></td>
<td class="nump">123,963<span></span>
</td>
<td class="nump">116,695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains', window );">Total cash equivalents and investments, Gross Unrealized Gains</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses', window );">Total cash equivalents and investments, Gross Unrealized Losses</a></td>
<td class="num">(60)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Total cash equivalents and investments, Fair Value</a></td>
<td class="nump">123,909<span></span>
</td>
<td class="nump">116,689<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Short-term investments, Cost</a></td>
<td class="nump">25,336<span></span>
</td>
<td class="nump">31,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Short-term investments, Gross Unrealized Gains</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Short-term investments, Gross Unrealized Losses</a></td>
<td class="num">(51)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments, Fair Value</a></td>
<td class="nump">25,291<span></span>
</td>
<td class="nump">31,935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Short-term investments, Cost</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">7,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Short-term investments, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Short-term investments, Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments, Fair Value</a></td>
<td class="nump">999<span></span>
</td>
<td class="nump">7,022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government-sponsored agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Short-term investments, Cost</a></td>
<td class="nump">1,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Short-term investments, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Short-term investments, Gross Unrealized Losses</a></td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments, Fair Value</a></td>
<td class="nump">1,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Short-term investments, Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Short-term investments, Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Short-term investments, Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,304<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">11,827<span></span>
</td>
<td class="nump">1,253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 84,313<span></span>
</td>
<td class="nump">71,175<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=ardx_CorporateBondsMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, cash equivalents and investments gross unrealized gains.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, cash equivalents and investments gross unrealized losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_InvestmentsAndCashAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investments And Cash, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_InvestmentsAndCashAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of investments and unrestricted cash as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=ardx_CorporateBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=ardx_CorporateBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583750554736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Short-Term Investments - Narrative (Details) - investment<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Available-for-Sale Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum', window );">Short-term securities, contractual maturities, maximum</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Investment in continuous unrealized loss position for more than one year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available-For-Sale Securities, Debt Securities, Current, Contractual Maturities, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583744694512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Assets and Liabilities Measured on a Recurring Basis (Details) - Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">$ 112,082<span></span>
</td>
<td class="nump">$ 115,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">1,656<span></span>
</td>
<td class="nump">698<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">84,313<span></span>
</td>
<td class="nump">71,175<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">25,291<span></span>
</td>
<td class="nump">31,935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. government-sponsored agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">1,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">999<span></span>
</td>
<td class="nump">7,022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,304<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Derivative liabilities for exit fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">1,656<span></span>
</td>
<td class="nump">698<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">84,313<span></span>
</td>
<td class="nump">71,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">84,313<span></span>
</td>
<td class="nump">71,175<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | U.S. government-sponsored agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Derivative liabilities for exit fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">27,769<span></span>
</td>
<td class="nump">44,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">25,291<span></span>
</td>
<td class="nump">31,935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | U.S. government-sponsored agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">1,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">999<span></span>
</td>
<td class="nump">7,022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,304<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Derivative liabilities for exit fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">1,656<span></span>
</td>
<td class="nump">698<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | U.S. government-sponsored agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Derivative liabilities for exit fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">$ 1,656<span></span>
</td>
<td class="nump">$ 698<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583751405792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for credit loss on available-for-sale debt securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583743821568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Schedule (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 22,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">5,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory</a></td>
<td class="nump">3,282<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, non-current</a></td>
<td class="nump">25,064<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
<td class="nump">$ 28,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583751397440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_PrepaidCommercialManufacturingCurrent', window );">Prepaid commercial manufacturing</a></td>
<td class="nump">$ 13,567<span></span>
</td>
<td class="nump">$ 9,406<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_PrepaidCommercialManufacturingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Commercial Manufacturing, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_PrepaidCommercialManufacturingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583748493888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue, Net - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 52,158,000<span></span>
</td>
<td class="nump">$ 10,097,000<span></span>
</td>
<td class="nump">$ 7,571,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerProductSalesGrossToNetAccruals', window );">Contract with customer product sales gross to net accruals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Gross product revenue | Customer | AmerisourceBergen Drug Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (percent)</a></td>
<td class="nump">26.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Gross product revenue | Customer | Cardinal Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (percent)</a></td>
<td class="nump">23.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Gross product revenue | Customer | McKesson Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (percent)</a></td>
<td class="nump">21.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ardx_ProductIBSRELAMember', window );">IBSRELA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 15,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 15,600,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerProductSalesGrossToNetAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer Product Sales Gross To Net Accruals</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerProductSalesGrossToNetAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ardx_AmerisourceBergenDrugCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ardx_AmerisourceBergenDrugCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ardx_CardinalHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ardx_CardinalHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ardx_McKessonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ardx_McKessonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ardx_ProductIBSRELAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ardx_ProductIBSRELAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583749228496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue, Net - Gross-to-Net Sales Accruals (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward', window );"><strong>Gross-to-net sales accruals and reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccruals', window );">Beginning balance</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod', window );">Activity related to 2022 sales</a></td>
<td class="nump">6,048<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued', window );">Credits/deductions issued</a></td>
<td class="num">(3,204)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccruals', window );">Ending balance</a></td>
<td class="nump">2,844<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis=ardx_ContractWithCustomerDiscountsAndChargebacksMember', window );">Discounts and Chargebacks</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward', window );"><strong>Gross-to-net sales accruals and reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccruals', window );">Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod', window );">Activity related to 2022 sales</a></td>
<td class="nump">825<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued', window );">Credits/deductions issued</a></td>
<td class="num">(683)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccruals', window );">Ending balance</a></td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis=ardx_ContractWithCustomerRebatesWholesalerAndGPOFeesMember', window );">Rebates, Wholesaler and GPO Fees</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward', window );"><strong>Gross-to-net sales accruals and reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccruals', window );">Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod', window );">Activity related to 2022 sales</a></td>
<td class="nump">2,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued', window );">Credits/deductions issued</a></td>
<td class="num">(1,277)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccruals', window );">Ending balance</a></td>
<td class="nump">1,444<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis=ardx_ContractWithCustomerCopayAndReturnsMember', window );">Copay and Returns</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward', window );"><strong>Gross-to-net sales accruals and reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccruals', window );">Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod', window );">Activity related to 2022 sales</a></td>
<td class="nump">2,502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued', window );">Credits/deductions issued</a></td>
<td class="num">(1,244)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccruals', window );">Ending balance</a></td>
<td class="nump">$ 1,258<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Gross To Credits Or Deductions Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Gross To Net Sales, Accrual Activity During Current Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Gross To Net Sales Accrual</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerGrossToNetSalesAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Gross To Net Sales Accruals</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerGrossToNetSalesAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis=ardx_ContractWithCustomerDiscountsAndChargebacksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_GrossToNetSalesAccrualAndReserveClassificationAxis=ardx_ContractWithCustomerDiscountsAndChargebacksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis=ardx_ContractWithCustomerRebatesWholesalerAndGPOFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_GrossToNetSalesAccrualAndReserveClassificationAxis=ardx_ContractWithCustomerRebatesWholesalerAndGPOFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis=ardx_ContractWithCustomerCopayAndReturnsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_GrossToNetSalesAccrualAndReserveClassificationAxis=ardx_ContractWithCustomerCopayAndReturnsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583741545056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Licensing Agreements - Narrative (Details)<br> $ in Millions, &#165; in Billions</strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1">50 Months Ended</th>
<th class="th" colspan="1">91 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2019 </div>
<div>USD ($) </div>
<div>item </div>
<div>segment</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>JPY (&#165;)</div>
</th>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>USD ($) </div>
<div>payment_tranche</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,158,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,097,000<span></span>
</td>
<td class="nump">$ 7,571,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,211,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,211,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,117,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">145,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">Licensing revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,031,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,013,000<span></span>
</td>
<td class="nump">706,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ardx_ProductSupplyRevenueMember', window );">Product supply revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,527,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">907,000<span></span>
</td>
<td class="nump">1,501,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_ResearchCollaborationAndOptionAgreementMember', window );">2019 KKC Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 4,177,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember', window );">2017 KKC Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,211,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,211,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember', window );">2017 KKC Agreement | Licensing revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember', window );">2017 KKC Agreement | Product supply revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember', window );">Fosun Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember', window );">Knight Agreement | Licensing revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember', window );">Knight Agreement | Product supply revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ardx_KyowaKirinCo.LtdMember', window );">Kyowa Kirin Co. Ltd | 2019 KKC Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees', window );">Upfront license fees</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment', window );">First installment of upfront license fees</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_TermOfPaymentOfLicenseFeeFirstInstallment', window );">Term of payment of license fee, first installment</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment', window );">Second installment of upfront license fees</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_TermOfAgreement', window );">Term of agreement</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_CollaborationAndLicensingAgreementsNumberOfAmendments', window );">Number of amendments | segment</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ardx_KyowaKirinCo.LtdMember', window );">Kyowa Kirin Co. Ltd | 2019 KKC Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_NumberOfSeparateCollaborativeAgreements', window );">Number of separate collaborative agreements | item</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ardx_KyowaKirinCo.LtdMember', window );">Kyowa Kirin Co. Ltd | 2017 KKC Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees', window );">Upfront license fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_CollaborativeArrangementPotentialDevelopmentMilestones', window );">Potential development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_CollaborativeArrangementPotentialCommercializationMilestones', window );">Potential commercialization milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,600,000<span></span>
</td>
<td class="nump">&#165; 8.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate', window );">Fee receivable for reduction in royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches', window );">Number of payment tranches for fee receivable for reduction in royalty rate | payment_tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ardx_KyowaKirinCo.LtdMember', window );">Kyowa Kirin Co. Ltd | 2017 KKC Agreement | Licensing revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_RevenueRemainingPerformanceObligationVariableConsiderationAmount', window );">Proceeds from milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember', window );">Fosun Pharma | Fosun Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones', window );">Potential development and commercialization milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ThresholdPercentageOfSalesForTieredRoyalties', window );">Threshold percentage of net sales for tiered royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ardx_KnightTherapeuticsIncMember', window );">Knight | Knight Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones', window );">Potential development and commercialization milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,300,000<span></span>
</td>
<td class="nump">$ 22.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ardx_AstrazenecaMember', window );">AstraZeneca | AZ Termination Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_PercentageOfRoyaltyRevenue', window );">Percentage of royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_PercentageOfNonRoyaltyRevenue', window );">Percentage of non royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum', window );">Maximum potential payment per agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborationAndLicensingAgreementsNumberOfAmendments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration And Licensing Agreements, Number Of Amendments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborationAndLicensingAgreementsNumberOfAmendments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration And Licensing Agreements, Upfront License Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration And Licensing Agreements, Upfront License Fees, First Installment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration And Licensing Agreements, Upfront License Fees, Second Installment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate, Number Of Payment Tranches</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborativeArrangementPotentialCommercializationMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Potential Commercialization Milestones</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborativeArrangementPotentialCommercializationMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of future development and commercialization milestone under collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborativeArrangementPotentialDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Potential Development Milestones</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborativeArrangementPotentialDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Potential Payment Per Termination Agreement, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_NumberOfSeparateCollaborativeAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of separate collaborative agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_NumberOfSeparateCollaborativeAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_PercentageOfNonRoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of non-royalty revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_PercentageOfNonRoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_PercentageOfRoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of royalty revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_PercentageOfRoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_RevenueRemainingPerformanceObligationVariableConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Variable Consideration Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_RevenueRemainingPerformanceObligationVariableConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_TermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_TermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_TermOfPaymentOfLicenseFeeFirstInstallment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of payment of first installment fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_TermOfPaymentOfLicenseFeeFirstInstallment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ThresholdPercentageOfSalesForTieredRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the threshold percentage of net sales for tiered royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ThresholdPercentageOfSalesForTieredRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ardx_ProductSupplyRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ardx_ProductSupplyRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ardx_ResearchCollaborationAndOptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ardx_ResearchCollaborationAndOptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ardx_KyowaKirinCo.LtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ardx_KyowaKirinCo.LtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ardx_KnightTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ardx_KnightTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ardx_AstrazenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ardx_AstrazenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ardx_AstraZenecaTerminationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ardx_AstraZenecaTerminationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583748852432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Licensing Agreements - Deferred Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward', window );"><strong>Deferred revenue - current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Beginning balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Ending balance</a></td>
<td class="nump">4,211<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward', window );"><strong>Deferred revenue - non-current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Beginning balance</a></td>
<td class="nump">4,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Ending balance</a></td>
<td class="nump">9,025<span></span>
</td>
<td class="nump">4,727<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_ResearchCollaborationAndOptionAgreementMember', window );">2019 KKC Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward', window );"><strong>Deferred revenue - current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenueDuringThePeriod', window );">Increases due to cash received, excluding amounts recognized as revenue during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths', window );">Increases due to amounts reclassified from non-current, to be recognized in the next twelve months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived', window );">Increases to amounts invoiced, for which cash has not yet been received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived', window );">Decreases due to revenue recognized in the period for which cash has been received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,177)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward', window );"><strong>Deferred revenue - non-current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Beginning balance</a></td>
<td class="nump">4,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerLiabilityIncreaseForCashReceived', window );">Increases due to cash received during the period</a></td>
<td class="nump">7,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerLiabilityIncreasesToAmountsInvoicedButCashNotReceived', window );">Increases to amounts invoiced, for which cash has not yet been received</a></td>
<td class="nump">465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded', window );">Increase due to unbilled prepayments recorded during the period</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths', window );">Decreases due to amounts reclassified as current, to be recognized in the next twelve months</a></td>
<td class="num">(3,961)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Ending balance</a></td>
<td class="nump">9,025<span></span>
</td>
<td class="nump">4,727<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember', window );">2017 KKC Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward', window );"><strong>Deferred revenue - current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenueDuringThePeriod', window );">Increases due to cash received, excluding amounts recognized as revenue during the period</a></td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths', window );">Increases due to amounts reclassified from non-current, to be recognized in the next twelve months</a></td>
<td class="nump">3,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived', window );">Increases to amounts invoiced, for which cash has not yet been received</a></td>
<td class="nump">208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived', window );">Decreases due to revenue recognized in the period for which cash has been received</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Ending balance</a></td>
<td class="nump">4,211<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward', window );"><strong>Deferred revenue - non-current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Beginning balance</a></td>
<td class="nump">$ 4,727<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerLiabilityIncreaseForCashReceived', window );">Increases due to cash received during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerLiabilityIncreasesToAmountsInvoicedButCashNotReceived', window );">Increases to amounts invoiced, for which cash has not yet been received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded', window );">Increase due to unbilled prepayments recorded during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths', window );">Decreases due to amounts reclassified as current, to be recognized in the next twelve months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,727<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Contract With Customer Liability, Current, Rollforward</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Contract With Customer Liability, Noncurrent, Rollforward</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Decrease In Revenue, To Be Recognized In Next Twelve Months</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Increase Due To Unbilled Prepayments Recorded</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerLiabilityIncreaseForCashReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Increase For Cash Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerLiabilityIncreaseForCashReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenueDuringThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Increases Due To Cash Received, Excluding Amounts Recognized As Revenue During The Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenueDuringThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerLiabilityIncreasesToAmountsInvoicedButCashNotReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Increases To Amounts Invoiced, But Cash Not Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerLiabilityIncreasesToAmountsInvoicedButCashNotReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Revenue Invoiced But Cash Not Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Revenue To Be Recognized In Next Twelve Months</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ardx_ResearchCollaborationAndOptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ardx_ResearchCollaborationAndOptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583749201200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Royalty Obligation Related To The Sale Of Future Royalties (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfAdvanceRoyalty', window );">Amortization of the deferred royalty obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,673,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRoyaltiesReceived', window );">Proceeds from royalties received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ardx_HealthCareRoyaltyPartnersIVLPMember', window );">Healthcare royalty partners IV, L.P | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRoyaltiesPayable', window );">Royalty payments and commercial milestone payments</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Upfront payment</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Payment to be received</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerLiabilityTransactionCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent', window );">Amortization, effective interest rate, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Amortization, Effective Interest Rate, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerLiabilityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerLiabilityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfAdvanceRoyalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense charged against earnings for the periodic recognition of the advance royalties. These royalties are paid in one accounting period, but are deducted from earnings over time through amortization. For example, royalties that are required to be paid in advance of production from a mineral, oil, or gas property and amortized over the period of right to produce these items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfAdvanceRoyalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRoyaltiesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligations due for compensation payments related to the use of copyrights, patents, trade names, licenses, technology. Royalty payments are also paid by the lease holders for oil, gas, and mineral extraction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRoyaltiesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRoyaltiesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRoyaltiesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ardx_HealthCareRoyaltyPartnersIVLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ardx_HealthCareRoyaltyPartnersIVLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583744110864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 23, 2022</div></th>
<th class="th"><div>Oct. 09, 2020</div></th>
<th class="th"><div>May 16, 2018</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Term Loans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,861,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2022Member', window );">2022 Exit Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Term Loans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ExitFeePercentage', window );">Exit fee (percent)</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum', window );">Exit fee, net product revenue threshold</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_LoanAgreementExitFeeTerm', window );">Exit fee, term (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Loan Agreement | 2018 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Term Loans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net proceeds from loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_DebtInstrumentInterestPaymentExtensionTerm', window );">Interest-only payment extension term (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Loan Agreement | 2018 Term Loan | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Term Loans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Floating per annum rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Loan Agreement | 2022 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Term Loans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage', window );">Final fee due upon maturity, acceleration, prepayment, or termination (percent)</a></td>
<td class="nump">4.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum', window );">Loan agreement covenant, cash and cash equivalents as percentage of outstanding loan balance, minimum</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod', window );">Loan agreement, covenant, cash and cash equivalents as percentage of outstanding loan balance, calculation period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum', window );">Loan agreement covenant, net product revenue as percentage of outstanding loan balance, minimum</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_DebtInstrumentInterestRateOnDefaultPercentage', window );">Additional default interest rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Loan Agreement | 2022 Term Loan | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Term Loans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Floating per annum rate (percent)</a></td>
<td class="nump">7.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_DebtInstrumentVariableRateBaseOption', window );">Addition to floating per annum rate (percent)</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Loan Agreement | 2022 Term Loan | Prior to first anniversary of closing date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Term Loans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_DebtInstrumentPrepaymentFeePercentage', window );">Prepayment premium (as a percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Loan Agreement | 2022 Term Loan | After first anniversary through second anniversary of closing date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Term Loans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_DebtInstrumentPrepaymentFeePercentage', window );">Prepayment premium (as a percent)</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Loan Agreement | 2022 Term Loan | After second anniversary to maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Term Loans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_DebtInstrumentPrepaymentFeePercentage', window );">Prepayment premium (as a percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Loan Agreement | Term Loan A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Term Loans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net proceeds from loan</a></td>
<td class="nump">$ 27,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Payment term</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_DebtInstrumentClosingFeeAmount', window );">Closing fee</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Loan Agreement | Term Loan B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Term Loans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement', window );">Remaining funding based on milestone achievement</a></td>
<td class="nump">$ 22,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Payment term</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents', window );">Future obligation upon loan funding or other events</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_DebtInstrumentClosingFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Closing Fee Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_DebtInstrumentClosingFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Fee Due Upon Maturity, Acceleration, Prepayment, Termination, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_DebtInstrumentInterestPaymentExtensionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of interest payment of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_DebtInstrumentInterestPaymentExtensionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_DebtInstrumentInterestRateOnDefaultPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of additional default interest rate on the event of default.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_DebtInstrumentInterestRateOnDefaultPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_DebtInstrumentPrepaymentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of fee payable on prepayment of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_DebtInstrumentPrepaymentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_DebtInstrumentVariableRateBaseOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Variable Rate, Base Option</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_DebtInstrumentVariableRateBaseOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ExitFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exit Fee, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ExitFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loan Agreement, Covenant, Cash And Cash Equivalents As Percentage Of Outstanding Loan Balance, Calculation Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loan Agreement, Covenant, Cash And Cash Equivalents As Percentage Of Outstanding Loan Balance, Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loan Agreement, Covenant, Net Product Revenue As Percentage Of Outstanding Loan Balance, Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loan Agreement, Exit Fee, Net Product Revenue Threshold Metric, Trailing Six Month Basis, Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_LoanAgreementExitFeeTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loan Agreement, Exit Fee, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_LoanAgreementExitFeeTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loan Agreement, Future Obligation Upon Funding Or Other Events</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining Funding Based On Conditional Milestone Achievement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_RemainingFundingBasedOnConditionalMilestoneAchievement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ardx_TermLoan2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ardx_TermLoan2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ardx_TermLoan2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ardx_TermLoan2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ardx_TermLoan2022AMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ardx_TermLoan2022AMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ardx_TermLoan2022BMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ardx_TermLoan2022BMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583749220944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Borrowings - Future Payment Obligations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Future payment obligations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">7,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">9,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2026</a></td>
<td class="nump">9,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2027</a></td>
<td class="nump">2,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total repayment obligations</a></td>
<td class="nump">28,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: Unamortized discount and debt issuance costs</a></td>
<td class="num">(1,110)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Less: Unaccreted value of final fee</a></td>
<td class="num">(1,040)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">26,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Less: Current portion of long-term debt</a></td>
<td class="num">(26,711)<span></span>
</td>
<td class="num">$ (32,264)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermLoansPayable', window );">Long-term debt, net of current portion</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583744513728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Liabilities - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Feb. 23, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2018Member', window );">2018 Exit Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Agreed amount for exit fee upon change of control or regulatory approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2018Member', window );">2018 Exit Fee | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage', window );">Fair value analysis, percentage change in probability of occurrence</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation', window );">Fair value analysis, effect on fair value based on 10% change in probability of occurrence</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2022Member', window );">2022 Exit Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ExitFeePercentage', window );">Exit fee (percent)</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum', window );">Exit fee, net product revenue threshold</a></td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2022Member', window );">2022 Exit Fee | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage', window );">Fair value analysis, percentage change in probability of occurrence</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ExitFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exit Fee, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ExitFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Sensitivity Analysis, Change In Probability Of Occurrence, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Sensitivity Analysis, Ten Percent Change In Probability Of Occurrence, Effect On Valuation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loan Agreement, Exit Fee, Net Product Revenue Threshold Metric, Trailing Six Month Basis, Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583854024688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liabilities - Changes in Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2018Member', window );">2018 Exit Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Change in Fair Value of Derivative Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value of exit fee derivative liabilities, beginning</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value of exit fee derivative liabilities, ending</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2022Member', window );">2022 Exit Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Change in Fair Value of Derivative Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value of exit fee derivative liabilities, ending</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember', window );">Exit fee derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Change in Fair Value of Derivative Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value of exit fee derivative liabilities, beginning</a></td>
<td class="nump">698<span></span>
</td>
<td class="nump">1,376<span></span>
</td>
<td class="nump">$ 969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">2022 Exit Fee addition at fair value</a></td>
<td class="nump">375<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value of exit fee derivative liabilities, ending</a></td>
<td class="nump">1,656<span></span>
</td>
<td class="nump">698<span></span>
</td>
<td class="nump">1,376<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember', window );">Exit fee derivative liability | 2018 Exit Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Change in Fair Value of Derivative Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in estimated fair value:</a></td>
<td class="nump">510<span></span>
</td>
<td class="num">(678)<span></span>
</td>
<td class="nump">407<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember', window );">Exit fee derivative liability | 2022 Exit Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Change in Fair Value of Derivative Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in estimated fair value:</a></td>
<td class="nump">$ 73<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583748414080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>renewal_option</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>renewal_option</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>lease_agreement</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_NumberOfOperatingLeaseArrangements', window );">Number of lease agreements | lease_agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,604<span></span>
</td>
<td class="nump">$ 450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_LeaseArrangementsAxis=ardx_FacilityFremontCaliforniaMember', window );">Fremont facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Office space area (sq ft)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_LeaseArrangementsAxis=ardx_FacilityOneWalthamMassachusettsMember', window );">Original Waltham facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Office space area (sq ft)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,520<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_LeaseArrangementsAxis=ardx_FacilityTwoWalthamMassachusettsMember', window );">Waltham facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Office space area (sq ft)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_LesseeOperatingLeaseNumberOfRenewalOptions', window );">Number of options to extend | renewal_option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Term of lease extension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_LeaseArrangementsAxis=ardx_FacilityMilwaukeeWisconsinMember', window );">Milwaukee facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Office space area (sq ft)</a></td>
<td class="nump">4,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_LesseeOperatingLeaseNumberOfRenewalOptions', window );">Number of options to extend | renewal_option</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Term of lease extension</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations | $</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Existence of option to extend</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_LesseeOperatingLeaseNumberOfRenewalOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Renewal Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_LesseeOperatingLeaseNumberOfRenewalOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_NumberOfOperatingLeaseArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of operating lease arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_NumberOfOperatingLeaseArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_LeaseArrangementsAxis=ardx_FacilityFremontCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_LeaseArrangementsAxis=ardx_FacilityFremontCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_LeaseArrangementsAxis=ardx_FacilityOneWalthamMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_LeaseArrangementsAxis=ardx_FacilityOneWalthamMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_LeaseArrangementsAxis=ardx_FacilityTwoWalthamMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_LeaseArrangementsAxis=ardx_FacilityTwoWalthamMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_LeaseArrangementsAxis=ardx_FacilityMilwaukeeWisconsinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_LeaseArrangementsAxis=ardx_FacilityMilwaukeeWisconsinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583751801456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Additional Lease Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract', window );"><strong>Facilities - right-of-use assets and lease liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 9,295<span></span>
</td>
<td class="nump">$ 12,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liabilities</a></td>
<td class="nump">3,894<span></span>
</td>
<td class="nump">3,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">5,855<span></span>
</td>
<td class="nump">9,748<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 9,749<span></span>
</td>
<td class="nump">$ 13,240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract', window );"><strong>Additional details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining life (years)</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">6.80%<span></span>
</td>
<td class="nump">6.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAndLiabilitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescriptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583747411984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="nump">$ 4,257<span></span>
</td>
<td class="nump">$ 3,671<span></span>
</td>
<td class="nump">$ 2,608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating lease</a></td>
<td class="nump">$ 4,292<span></span>
</td>
<td class="nump">$ 3,438<span></span>
</td>
<td class="nump">$ 3,065<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583743821024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Undiscounted Cash Payment Obligations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Undiscounted cash payment obligations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 4,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">4,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">1,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted operating lease payments</a></td>
<td class="nump">10,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Imputed interest expenses</a></td>
<td class="num">(853)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">9,749<span></span>
</td>
<td class="nump">$ 13,240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Current portion of operating lease liability</a></td>
<td class="num">(3,894)<span></span>
</td>
<td class="num">(3,492)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">$ 5,855<span></span>
</td>
<td class="nump">$ 9,748<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, to be Paid, after Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583748252528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br> $ / shares in Units, shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">17 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 12, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,625,000<span></span>
</td>
<td class="nump">$ 101,146,000<span></span>
</td>
<td class="nump">$ 21,047,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_MaximumAggregateOfferingPrice', window );">Maximum aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common stock | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_MaximumAggregateOfferingPrice', window );">Maximum aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember', window );">2020 Open Market Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_StockIssuanceCostCommissionPercent', window );">Offering sales commission (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock sold and issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember', window );">2020 Open Market Sales Agreement | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_MaximumAggregateOfferingPrice', window );">Maximum aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember', window );">2021 Open Market Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_StockIssuanceCostCommissionPercent', window );">Offering sales commission (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock sold and issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_SaleOfStockWeightedAveragePricePerShare', window );">Weighted-average share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_EquitySalesAgreementSharesIssuedSinceInception', window );">Total of shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79.8<span></span>
</td>
<td class="nump">79.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_EquitySalesAgreementProceedsFromSharesIssuedSinceInception', window );">Total of gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98,100,000<span></span>
</td>
<td class="nump">$ 98,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember', window );">2021 Open Market Sales Agreement | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock sold and issued (in shares)</a></td>
<td class="nump">7.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_SaleOfStockWeightedAveragePricePerShare', window );">Weighted-average share price (in dollars per share)</a></td>
<td class="nump">$ 2.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember', window );">2021 Open Market Sales Agreement | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_MaximumAggregateOfferingPrice', window );">Maximum aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember', window );">2023 Open Market Sales Agreement | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_StockIssuanceCostCommissionPercent', window );">Offering sales commission (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember', window );">2023 Open Market Sales Agreement | Common stock | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_MaximumAggregateOfferingPrice', window );">Maximum aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_EquitySalesAgreementProceedsFromSharesIssuedSinceInception">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Sales Agreement, Proceeds From Shares Issued Since Inception</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_EquitySalesAgreementProceedsFromSharesIssuedSinceInception</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_EquitySalesAgreementSharesIssuedSinceInception">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Sales Agreement, Shares Issued Since Inception</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_EquitySalesAgreementSharesIssuedSinceInception</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_MaximumAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of maximum aggregate offering price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_MaximumAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_SaleOfStockWeightedAveragePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Weighted-Average Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_SaleOfStockWeightedAveragePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_StockIssuanceCostCommissionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of commission given on gross proceeds from sale of securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_StockIssuanceCostCommissionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583741565728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 18, 2014</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jul. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Nov. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Equity Incentive Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common stock closing price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date estimated fair value of options granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.63<span></span>
</td>
<td class="nump">$ 3.92<span></span>
</td>
<td class="nump">$ 4.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 390<span></span>
</td>
<td class="nump">$ 190<span></span>
</td>
<td class="nump">$ 310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ardx_TwoThousandFourteenEquityIncentiveAwardPlanMember', window );">2014 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Equity Incentive Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares initially authorized (in shares)</a></td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of shares added to initial reserve</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponInclusionOfForfeitedOrUnexercisedOptions', window );">Potential increase to shares reserved for inclusion of forfeited or unexercised options from prior plan</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_IncreaseInSharesReservedForIssuanceOptionForAnnualIncreaseAsPercentageOfSharesOutstanding', window );">Potential increase in shares reserved as a percentage of shares outstanding</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponExerciseOfStockOptions', window );">Maximum shares to be issued upon exercise of incentive stock options</a></td>
<td class="nump">10,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ardx_TwoThousandSixteenEmploymentCommencementIncentivePlanMember', window );">Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Equity Incentive Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of shares added to initial reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_CommonStockSubjectToIssuedInducementGrantsShares', window );">Share of common stock subject to issued inducement grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ardx_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Equity Incentive Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_IncreaseInSharesReservedForIssuanceOptionForAnnualIncreaseAsPercentageOfSharesOutstanding', window );">Potential increase in shares reserved as a percentage of shares outstanding</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesUnderEmployeeStockPurchasePlan', window );">Maximum shares to be issued under ESPP</a></td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Equity Incentive Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | 2008 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Equity Incentive Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ardx_PerformanceBasedRestrictedStockUnitsMember', window );">PRSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Equity Incentive Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Equity Incentive Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Estimated fair value of RSUs vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,195,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,956,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Board of directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Equity Incentive Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
<td class="nump">42,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CommonStockSubjectToIssuedInducementGrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Subject To Issued Inducement Grants, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CommonStockSubjectToIssuedInducementGrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase In Shares Reserved For Issuance, Maximum Shares To Be Issued Upon Exercise Of Stock Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponInclusionOfForfeitedOrUnexercisedOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase In Shares Reserved For Issuance, Maximum Shares To Be Issued Upon Inclusion Of Forfeited Or Unexercised Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponInclusionOfForfeitedOrUnexercisedOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_IncreaseInSharesReservedForIssuanceOptionForAnnualIncreaseAsPercentageOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase In Shares Reserved For Issuance, Option For Annual Increase As Percentage Of Shares Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_IncreaseInSharesReservedForIssuanceOptionForAnnualIncreaseAsPercentageOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesUnderEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Number Of Shares Under Employee Stock Purchase Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesUnderEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ardx_TwoThousandFourteenEquityIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ardx_TwoThousandFourteenEquityIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ardx_TwoThousandSixteenEmploymentCommencementIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ardx_TwoThousandSixteenEmploymentCommencementIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ardx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ardx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ardx_TwoThousandEightStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ardx_TwoThousandEightStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ardx_PerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ardx_PerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583744617152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Stock Options (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number&#160;of&#160;Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options issued and outstanding balance, beginning (shares)</a></td>
<td class="nump">10,417,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (shares)</a></td>
<td class="nump">5,392,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (shares)</a></td>
<td class="num">(14,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options canceled (shares)</a></td>
<td class="num">(1,832,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options issued and outstanding balance, ending (shares)</a></td>
<td class="nump">13,963,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested and expected to vest (shares)</a></td>
<td class="nump">13,963,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable (shares)</a></td>
<td class="nump">8,283,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise&#160;Price&#160; per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options issued and outstanding balance, beginning (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 7.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in dollars per share) | $ / shares</a></td>
<td class="nump">0.96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">0.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options canceled (in dollars per share) | $ / shares</a></td>
<td class="nump">5.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options issued and outstanding balance, ending (in dollars per share) | $ / shares</a></td>
<td class="nump">4.83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options vested and expected to vest (in dollars per share) | $ / shares</a></td>
<td class="nump">4.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_StockOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual&#160;Term (in Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options issued and outstanding (in years)</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Options vest and expected to vest (in years)</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable (in years)</a></td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_StockOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic&#160;Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options issued and outstanding | $</a></td>
<td class="nump">$ 10,156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options vested and expected to vest | $</a></td>
<td class="nump">10,156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable | $</a></td>
<td class="nump">$ 2,727<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_SharesAvailableForGrantRollForward', window );"><strong>Shares&#160;Available for&#160;Grant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant, beginning (shares)</a></td>
<td class="nump">4,974,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToAuthorizedInPeriod', window );">Shares available for grant, effect of authorized (shares)</a></td>
<td class="nump">10,207,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToGrantedInPeriod', window );">Shares available for grant, effect of granted (shares)</a></td>
<td class="num">(5,392,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToCanceledInPeriod', window );">Shares available for grant, effect of canceled (shares)</a></td>
<td class="nump">1,832,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToStockIssuedForServicesInPeriod', window );">Shares available for grant, effect of shares issued for services (shares)</a></td>
<td class="num">(712,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant, ending (shares)</a></td>
<td class="nump">10,909,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToGrantedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Available For Grant, Decrease Due To Granted In Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToGrantedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToStockIssuedForServicesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Available For Grant, Decrease Due To Stock Issued For Services In Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToStockIssuedForServicesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToAuthorizedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of shares available for grant options authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToAuthorizedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToCanceledInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Available For Grant, Increase Due To Canceled In Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToCanceledInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_SharesAvailableForGrantRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Available For Grant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_SharesAvailableForGrantRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_StockOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Options, Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_StockOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_StockOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Options, Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_StockOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583748836160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Valuation Assumptions for Stock Options (Details) - Stock options<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">92.10%<span></span>
</td>
<td class="nump">77.00%<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">4.70%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583748844032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Restricted Stock Units (Details) - RSUs<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number&#160;of RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested balance, beginning (shares) | shares</a></td>
<td class="nump">3,529,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (shares) | shares</a></td>
<td class="nump">2,195,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (shares) | shares</a></td>
<td class="num">(3,956,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (shares) | shares</a></td>
<td class="num">(362,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested balance, ending (shares) | shares</a></td>
<td class="nump">1,406,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant&#160;Date&#160;Fair Value Per&#160;Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested balance, beginning (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">0.89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">1.34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">2.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested balance, ending (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.17<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583744526384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Employee Stock Purchase Plan (Details) - ESPP<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_EmployeeStockPurchasePlanSharesAvailableRollForward', window );"><strong>Shares&#160;Available for&#160;Grant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant, beginning (shares)</a></td>
<td class="nump">899,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsPurchases', window );">Shares purchased (shares)</a></td>
<td class="num">(308,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant, ending (shares)</a></td>
<td class="nump">591,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_EmployeeStockPurchasePlanSharesPurchasedRollForward', window );"><strong>Number&#160;of&#160;Shares Purchased</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesStockPurchasePlanPurchasedNumber', window );">Purchased, beginning (shares)</a></td>
<td class="nump">1,048,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares purchased (shares)</a></td>
<td class="nump">308,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesStockPurchasePlanPurchasedNumber', window );">Purchased, ending (shares)</a></td>
<td class="nump">1,356,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare', window );">Purchase Price per Share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanGrossProceeds', window );">Gross&#160;Proceeds | $</a></td>
<td class="nump">$ 195<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_EmployeeStockPurchasePlanSharesAvailableRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Purchase Plan, Shares Available</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_EmployeeStockPurchasePlanSharesAvailableRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_EmployeeStockPurchasePlanSharesPurchasedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Purchase Plan, Shares Purchased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_EmployeeStockPurchasePlanSharesPurchasedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of gross proceeds received from shares issued to employees under the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesStockPurchasePlanPurchasedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Employees Stock Purchase Plan, Purchased, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesStockPurchasePlanPurchasedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents share based compensation arrangement by share based payment award number of shares available for grants options, purchase during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the purchase price per share of shares issued to employees under the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ardx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ardx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583751181744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Valuation Assumptions for ESPP (Details) - ESPP<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">97.20%<span></span>
</td>
<td class="nump">123.00%<span></span>
</td>
<td class="nump">79.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ardx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ardx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583750122016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Stock-Based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 10,750<span></span>
</td>
<td class="nump">$ 12,039<span></span>
</td>
<td class="nump">$ 10,583<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">7,525<span></span>
</td>
<td class="nump">7,923<span></span>
</td>
<td class="nump">6,522<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 3,225<span></span>
</td>
<td class="nump">$ 4,116<span></span>
</td>
<td class="nump">$ 4,061<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583750123296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Unrecognized Stock-Based Compensation (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized Compensation Expense</a></td>
<td class="nump">$ 9,434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Average Remaining Vesting Period (Years)</a></td>
<td class="text">2 years 6 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized Compensation Expense</a></td>
<td class="nump">$ 2,937<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Average Remaining Vesting Period (Years)</a></td>
<td class="text">2 years 11 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ardx_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized Compensation Expense</a></td>
<td class="nump">$ 22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Average Remaining Vesting Period (Years)</a></td>
<td class="text">2 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ardx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ardx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583749263520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveCurrent', window );">Estimated restructuring liability</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583744598304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Balances (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 10,880<span></span>
</td>
<td class="nump">$ 18,253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(9,657)<span></span>
</td>
<td class="num">(15,891)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">1,223<span></span>
</td>
<td class="nump">2,362<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ardx_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">7,474<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ardx_OfficeEquipmentAndFurnitureMember', window );">Office equipment and furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,089<span></span>
</td>
<td class="nump">2,034<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 8,745<span></span>
</td>
<td class="nump">$ 8,745<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ardx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ardx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ardx_OfficeEquipmentAndFurnitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ardx_OfficeEquipmentAndFurnitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583748761696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisposals', window );">Sale of property, plant and equipment</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">1,798<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on disposition of property plant equipment</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisposals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisposals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583854012448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_AccruedPaymentsDueToRelatedParty', window );">Accrued payments due to AstraZeneca</a></td>
<td class="nump">$ 3,385<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_AccruedGrossToNetRevenueLiabilities', window );">Accrued gross to net revenue liabilities</a></td>
<td class="nump">1,991<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_AccruedContractManufacturingCosts', window );">Accrued contract manufacturing expenses</a></td>
<td class="nump">1,657<span></span>
</td>
<td class="nump">2,485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_DerivativeLiabilityForExitFees', window );">Derivative liability for exit fees</a></td>
<td class="nump">1,656<span></span>
</td>
<td class="nump">698<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_AccruedNonClinicalResearchAndDevelopmentExpenses', window );">Accrued non-clinical research and development expenses</a></td>
<td class="nump">1,188<span></span>
</td>
<td class="nump">265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_AccruedProfessionalAndConsultantFeesCurrent', window );">Accrued professional and consulting services</a></td>
<td class="nump">808<span></span>
</td>
<td class="nump">597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_AccruedSalesAndMarketingExpenses', window );">Accrued sales and marketing expenses</a></td>
<td class="nump">587<span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_AccruedClinicalExpenses', window );">Accrued clinical expenses</a></td>
<td class="nump">223<span></span>
</td>
<td class="nump">2,522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">885<span></span>
</td>
<td class="nump">474<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 12,380<span></span>
</td>
<td class="nump">$ 7,366<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_AccruedClinicalExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_AccruedClinicalExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_AccruedContractManufacturingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued contract manufacturing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_AccruedContractManufacturingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_AccruedGrossToNetRevenueLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Gross To Net Revenue Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_AccruedGrossToNetRevenueLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_AccruedNonClinicalResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Non-Clinical Research And Development Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_AccruedNonClinicalResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_AccruedPaymentsDueToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Payments Due To Related Party</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_AccruedPaymentsDueToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_AccruedProfessionalAndConsultantFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued professional and consultant fees current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_AccruedProfessionalAndConsultantFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_AccruedSalesAndMarketingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued sales and marketing expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_AccruedSalesAndMarketingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_DerivativeLiabilityForExitFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of derivative liability for exit fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_DerivativeLiabilityForExitFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583751490624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Provision for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583854011808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Effective Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax at the federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitExecutiveCompensationDisallowedIRCSec162mPercent', window );">Executive compensation disallowed under IRC Sec 162(m)</a></td>
<td class="num">(1.60%)<span></span>
</td>
<td class="num">(1.10%)<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Stock based compensation</a></td>
<td class="num">(2.30%)<span></span>
</td>
<td class="num">(1.30%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.80%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(19.70%)<span></span>
</td>
<td class="num">(20.00%)<span></span>
</td>
<td class="num">(22.30%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax provision</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitExecutiveCompensationDisallowedIRCSec162mPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Executive Compensation Disallowed IRC Sec 162m, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitExecutiveCompensationDisallowedIRCSec162mPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126970579&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583749235984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_DeferredTaxAssetsAmortizationAndDepreciation', window );">Amortization and depreciation</a></td>
<td class="nump">$ 64,111<span></span>
</td>
<td class="nump">$ 61,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">86,547<span></span>
</td>
<td class="nump">74,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Tax credits</a></td>
<td class="nump">14,411<span></span>
</td>
<td class="nump">13,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">5,244<span></span>
</td>
<td class="nump">4,054<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">7,486<span></span>
</td>
<td class="nump">3,867<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">177,799<span></span>
</td>
<td class="nump">157,835<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(175,670)<span></span>
</td>
<td class="num">(155,141)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets net of valuation allowance</a></td>
<td class="nump">2,129<span></span>
</td>
<td class="nump">2,694<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_DeferredTaxLiabilitiesRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="num">(2,129)<span></span>
</td>
<td class="num">(2,689)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_DeferredTaxAssetsAmortizationAndDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from amortization and depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_DeferredTaxAssetsAmortizationAndDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583749044448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">$ 20.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">433.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_OperatingLossCarryforwardsWithoutExpiration', window );">Net operating loss carryforwards, indefinite</a></td>
<td class="nump">283.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research and development tax credit</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">17.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | California</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">89.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | California | Research and development tax credit</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">8.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | California | Minimum tax credit carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Other states</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 19.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Disclosure [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_OperatingLossCarryforwardsWithoutExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws indefinitely.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_OperatingLossCarryforwardsWithoutExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=ardx_MinimumTaxCreditCarryforwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=ardx_MinimumTaxCreditCarryforwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=ardx_TaxAuthorityStatesOtherThanCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=ardx_TaxAuthorityStatesOtherThanCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583751277584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at beginning of year</a></td>
<td class="nump">$ 24,426<span></span>
</td>
<td class="nump">$ 23,624<span></span>
</td>
<td class="nump">$ 24,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to current year</a></td>
<td class="nump">460<span></span>
</td>
<td class="nump">1,613<span></span>
</td>
<td class="nump">474<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Subtractions related to lapse of statute of limitation</a></td>
<td class="num">(811)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Subtractions based on tax positions related to prior year</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(811)<span></span>
</td>
<td class="num">(1,388)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at end of year</a></td>
<td class="nump">$ 24,075<span></span>
</td>
<td class="nump">$ 24,426<span></span>
</td>
<td class="nump">$ 23,624<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583750132560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geographic Information and Concentrations - Revenue by Geographical Area (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 52,158<span></span>
</td>
<td class="nump">$ 10,097<span></span>
</td>
<td class="nump">$ 7,571<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">15,600<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember', window );">Asia Pacific</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">36,527<span></span>
</td>
<td class="nump">10,084<span></span>
</td>
<td class="nump">6,765<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">North America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 806<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AsiaPacificMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583744607520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geographic Information and Concentrations - Concentration Risk (Details) - Revenue - Collaboration partnership concentration risk<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">KKC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (percent)</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">89.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Knight</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (percent)</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">AmerisourceBergen Drug Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (percent)</a></td>
<td class="nump">11.10%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=ardx_CollaborationPartnershipConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=ardx_CollaborationPartnershipConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ardx_KkcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ardx_KkcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ardx_KnightTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ardx_KnightTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ardx_AmerisourceBergenDrugCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ardx_AmerisourceBergenDrugCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583748846672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Computation of Net Loss Per Common Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (67,207)<span></span>
</td>
<td class="num">$ (158,165)<span></span>
</td>
<td class="num">$ (94,313)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding - basic (in shares)</a></td>
<td class="nump">158,690,083<span></span>
</td>
<td class="nump">104,205,645<span></span>
</td>
<td class="nump">89,582,138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding - diluted (in shares)</a></td>
<td class="nump">158,690,083<span></span>
</td>
<td class="nump">104,205,645<span></span>
</td>
<td class="nump">89,582,138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic (in dollars per share)</a></td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="num">$ (1.52)<span></span>
</td>
<td class="num">$ (1.05)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - diluted (in dollars per share)</a></td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="num">$ (1.52)<span></span>
</td>
<td class="num">$ (1.05)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583749204928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Anti-Dilutive Securities and Potential Common Shares (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities not included in computation of diluted net loss per share</a></td>
<td class="nump">16,382<span></span>
</td>
<td class="nump">13,680<span></span>
</td>
<td class="nump">10,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_PotentialCommonSharesAntiDilutiveEffectOnSecurities', window );">Potential common shares that would have been included if not for anti-dilutive effect of securities</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities not included in computation of diluted net loss per share</a></td>
<td class="nump">13,522<span></span>
</td>
<td class="nump">11,871<span></span>
</td>
<td class="nump">9,247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities not included in computation of diluted net loss per share</a></td>
<td class="nump">2,694<span></span>
</td>
<td class="nump">1,602<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ardx_EmployeeStockPurchasePlanMember', window );">ESPP shares issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities not included in computation of diluted net loss per share</a></td>
<td class="nump">166<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities not included in computation of diluted net loss per share</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">932<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_PotentialCommonSharesAntiDilutiveEffectOnSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Common Shares, Anti-Dilutive Effect On Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_PotentialCommonSharesAntiDilutiveEffectOnSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ardx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ardx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583750193280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 12, 2022 </div>
<div>defendant </div>
<div>claim</div>
</th>
<th class="th">
<div>Jul. 19, 2022 </div>
<div>claim</div>
</th>
<th class="th">
<div>Mar. 29, 2022 </div>
<div>claim </div>
<div>defendant</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Contingent liabilities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ardx_StrezsakVersusArdelyxIncMember', window );">Strezsak v. Ardelyx, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of lawsuits | claim</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfDefendants', window );">Number of defendants | defendant</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ardx_GoVersusRaabMember', window );">Go v. Raab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of lawsuits | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfDefendants', window );">Number of defendants | defendant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14615-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfDefendants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of defendants named in a legal action.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfDefendants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=ardx_StrezsakVersusArdelyxIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=ardx_StrezsakVersusArdelyxIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=ardx_GoVersusRaabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=ardx_GoVersusRaabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140583748636048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 09, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | Term B Loan | Term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Floating per annum rate (percent)</a></td>
<td class="nump">7.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_DebtInstrumentVariableRateBaseOption', window );">Addition to floating per annum rate (percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_DebtInstrumentVariableRatePlusOption', window );">Addition plus to floating per annum rate (percent)</a></td>
<td class="nump">0.022%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | 2023 Open Market Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_StockIssuanceCostCommissionPercent', window );">Offering sales commission (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_MaximumAggregateOfferingPrice', window );">Maximum aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common stock | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_MaximumAggregateOfferingPrice', window );">Maximum aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common stock | Subsequent event | 2023 Open Market Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_MaximumAggregateOfferingPrice', window );">Maximum aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_DebtInstrumentVariableRateBaseOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Variable Rate, Base Option</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_DebtInstrumentVariableRateBaseOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_DebtInstrumentVariableRatePlusOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Variable Rate, Plus Option</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_DebtInstrumentVariableRatePlusOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_MaximumAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of maximum aggregate offering price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_MaximumAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_StockIssuanceCostCommissionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of commission given on gross proceeds from sale of securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_StockIssuanceCostCommissionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ardx_TermBLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ardx_TermBLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>ardx-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ardx="http://www.ardelyx.com/20221231"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ardx-20221231.xsd" xlink:type="simple"/>
    <context id="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iaeca4a04a1754667989d2f2d6e9f8f59_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9fc42224cc0a42e883f0fb58a584b2a0_I20230228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <instant>2023-02-28</instant>
        </period>
    </context>
    <context id="i776a810ab6f5478f91b8fbb19a6855bb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i23bde0040cba4440804b10fdac242262_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ife1a6ddcf0434c3d8408dc580e20d7d8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if6d0767c281240d4900cc0d8b9580230_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifee111286a5d4c6e8104da9cafffda38_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7c1a31c699a645968b918a7d82fb494c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibf3e168c61fd47e8aa38f9a4632206aa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6d86efc199f945f69a8db92f44a6eaea_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id8defbd8e977443b8e24752f1ecfdee1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i80db9f923ef14a778c2d03752079fed3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8f9dc553215546f099c0816459c4a6ef_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8955c2eaa96644dfa5eaadbf2a538826_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:CollaborativeDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib046fe75c1ba474da9dd251df8f9addb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:CollaborativeDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i45f387fd7df541f5ad7e47ddafdac6b3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:CollaborativeDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i473a2780d03c4c7f8d5e27ab35bdee43_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i559db82cad364aea94a0a0919778a7f7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4f9d007b877247ec802a3c602ee3687b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i307df19e90fa4871af799b2b66ba2d31_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3c73d82cd653451cb3c69d920ab3d8aa_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0c4c2b1d0a9e49ae81d18933f823dba9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6ebe0866adef47559cdc2ed65973c005_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i63b7a92a09e442b3b15016267ea44e4c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icad9ba2326db486c889dd50988c4fef1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2aa43c785509442dbd5e3673f8823fe4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia5a3476a21d74624862c1503a0509e16_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i34d8d1400f4a4785ac6e2406ff8e5935_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i271432361a3c43cf9ae96050134ef2c5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if0fdfe563b2749f3ad36d74c30c121dd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaeaeaa4c910f4ab5acf339a4968d2a9d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id6cbb5f1b5224d25910844cbece963f3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7488244a81d34508944e33dfd4bdc232_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7ca2f91dea984f5fa2da91bc632532c1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id70cd43225df4f8fbf5df3ec715b334c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie5bd779bf4924020b0765a5cc69ceba5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3c1428f4633d41e7a98d5a585209403f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7c90b227c4764ac7987b4eef73eeb87d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if786310abbc54aba91f5e0a5b90b7706_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic403adc07fe947369c966ca335e3f7c0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id792a81211054c6a9da992ae71d61ce3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3e05fc9654fc4f24b753405c6aae07a3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i21472ed42ab040bba0bdd50fdd86e0c6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2954e41000084c28b87d9af1f3c00c87_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i236484790d154382b9ab018143306fb9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7a16bb549f604ba4b134dd1fc542e6e0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2de3a294b21b459b8c55c13b0a994e24_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i06f6392d8de34129a19422671d121309_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ieca82817eeaa4e6a9211772c02ceff0e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">ardx:AccountsReceivableCollaboratorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3e0e80bb8eb7493a85b933d3d97f3803_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">ardx:AccountsReceivableCommercialCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia88c0559b8474f5190912f03388fc38d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">ardx:AccountsReceivableCollaboratorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i23a66360caef450d9534fe2775f21255_D20150601-20150630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-01</startDate>
            <endDate>2015-06-30</endDate>
        </period>
    </context>
    <context id="i8e9b10bffc104601b9077dcc9e1f4fa6_I20150630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-06-30</instant>
        </period>
    </context>
    <context id="i1d34215ee2e348899b09d93611aa94d9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i72b7f1283e114d98b667e2d3b9d78c10_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i82f59874748f487e829f759d2d2fe716_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ieabaefd41b574aa6b074694d974eb95a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5cffd7fcbbc544939e32a7a8f34622be_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i91fc450e044e494a99d00262c55ee834_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0604aebc55e7425795ca8e599d946833_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i98269013828c4cbf960fd07466f62e00_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ideed1df6eef44d1f8834a64175dd3912_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idbbc030abf9e4d3a8044fd67d677deca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">ardx:CorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i73a4c3bd901c4931af270d9b6aae48be_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie309689c7e5145568dac251da707114b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i197012cc5c3f4d0186f4f6f49afd9938_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifce32edf589c43559645ca939f8321c0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i800c2d8a407c4f52a90eac1ac7fa9c7f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic862582842b14106872fa00b3bc1a179_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8c1965f94e0f45c8ba92675a0a9e37a5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibeba7a62348343fda259cc027ff9efaf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5530fb3f55994ff9b89b29a90019a352_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i215440159e8b42d48ee9a7911b2b27ed_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic020e23db5fa4fd392335d177235faab_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie6a449d340e445639849083309b50cfc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4b017fd3d9ed45a686ed4da0c90e2b8a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2189793c12b94eb5aea5349640fc8e74_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4045d24f631d4b57b3bad1d73d787f3b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic0091d5584e742729920f89400c5a7ec_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i63caa9b53ecd4496aa9cbae0e6aebb0f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2d651a762ddd4d42b1eb146a2f77667a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i41b180661d604a9db63c4cc471ee7d76_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i691c998073704928ab9052cb14232a00_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i733e529140624718b49d4f80ac96a2d6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4139c0b0d3d942078ab8524d3ab1edfb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i663a0605660842e1b03f18928affeeff_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6a2ed7629e8644ca88a18430d955a065_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0b7cfff0602c4effac77d3fac445e8a0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9fb4cf2b13f04f7894360378ff59fdd1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib5ac62ac7b5c46bfa5e837d80abb240d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibe6734a4d6234308b332b56b6c66f456_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icf63c7b0e2bd43fd95a03bb02babbf85_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i53e4cddaae814c21930efe5f393ab81c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2e79c3ee3bba453c95e397f21030d21e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i31e14a2329e641e4a02f507843106a3e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i39124c37d91d480fa7bfb56ae5e2f223_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i49ea832c4a2441fa815b2b46be792d19_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia22881527d4b49cc88625aa8abc67b5c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i13616c69d6954d9dbcff580bb0481727_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0cf9501a699e4a90b12f236486a35622_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i16228cefd2e34ed3ad2ef7d53b54f81c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i132317a517fe469983d16efc145dde7b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if244d874422d4171840a2bb10d682a60_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if834c52fad8d4fa786b3476c7c479709_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i243d57116a1a4a2abd6f7b0ba194d8ba_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6c70318515a54462aad17c07ab4595b2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i13f16a403b294350a327194d8765e8ef_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie065f8ba75da42ef8bfcb4016909b6aa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifa8e2576d88e4d9f819b34c985d539dd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id1f7ed33632142769f453e0680a04d95_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if07f3ef040004928a2a337f7a98fc44c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icc4e7bf5193a4086bed2f7af56d70ed0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i390e968f8ffa426689dcafbbec33f877_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9bc52b266a974dc1bf42493dfd520bfe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0713ee81cc9747f9ae72ce305219dcfb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductIBSRELAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i71d12a4b8c5d41dd913f71f3f0c6a002_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ardx:AmerisourceBergenDrugCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2cd807982655470294b4c867e9790f9f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ardx:CardinalHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia9f614394a884bf3935e5190b6e13cbc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ardx:McKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2edca0d9c9d04eb4946163e30a07c874_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerDiscountsAndChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4364f4f8eb794e579c0d74bdcfc9a74d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerRebatesWholesalerAndGPOFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i211614897cb84b21a3db4459c42a8128_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerCopayAndReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icbd146d95630481b89a9e53d21e7bfd0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerDiscountsAndChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i378e9c4f2d8d414fb7b08c9fccc9c3c1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerRebatesWholesalerAndGPOFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i375a2ae60c4f4ac8bbe9ccc543f7a1c8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerCopayAndReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4459a35d21754ee897db3e8dbb29305d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerDiscountsAndChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if2880e66b0644122b083edc9fd38c11d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerRebatesWholesalerAndGPOFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i855b02ed9cf247be9e99838bb95cb4ba_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerCopayAndReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i955167e463ef48678bbc1d03c4f4d412_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="i91c2203d38fd405d99bc3c88353bce51_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="ia5096f6f9abe4dccb2dab386d07f22b0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ied48f951c2e54c4c9458741287f35022_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icfd7890f2ab641b689a46d3387cd65f5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i317cad6de7604d25be88b176cb33baec_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7f143c1e0eb144d6b655d94ab37c1a53_D20171101-20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="iff763b0fc4f84d4dac40730c49cc1731_I20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-30</instant>
        </period>
    </context>
    <context id="i687d24ba9ed84bf19bb4b4b49a494d08_D20171101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ife00f72d231640e4becd88f58e11171e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if2637e6a1a82402793001d3d295bbbcd_I20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="i59072502f7a54137b0895e14bb4f6df8_I20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="i4dd8313c3e094ef89785a59b13d01eb7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i60b13327723642e6932c3f852855047d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id10493b7130846e6b2a4742b479a65fe_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i715636a1b5ae4b288a29b92c2f3a54b3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i274489be58ee4be5a06cb71683dc70e0_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i96f5a69e2c1547719e984c8ba3c41ff3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i99e3d63e61664f6bbfac5c19cb4294e3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iff2fbe5c1eb741e185c1d68735dd7502_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7523c9db4f3440e1bbc8ab0589ca11c5_D20180301-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KnightTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="if78e3d93318c461da96ac8c6973a6f76_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KnightTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ieba6fa1b17514fa99298840f1171592e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i83f16a4b0497447dae41222920314fae_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0f4842d33b674e97bec5e1f35f13347e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i85d4b734d53646fa9eece46433fcc33e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if72c0334b4964673b5b1e29e363186db_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifc0eee8426754521a747a26cbaedb831_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1d7903c12c424b3ba490589eb00fd14d_D20150601-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7c98abb4d89044e0ab93ab428d564f5f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib952c4e7da01441388aaeecabdfe075a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i236464e64f8d473283dc7641b1f31d01_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8366fe12a3334315af3ed1c7052d20c4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib8ee7345370441099ade9119306db79b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0d56b583b1d146f7be5316e8e2d710b4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4d7bf861c12549a792483e8efc814a9e_D20220601-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:HealthCareRoyaltyPartnersIVLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i41ff706f90cc43a59020a70376e95dd2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:HealthCareRoyaltyPartnersIVLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia283d9f31c884152af9cfa5bfc1c18cc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:HealthCareRoyaltyPartnersIVLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i38d4c1dcbb354f1cb8f7b983e2aba1a6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:HealthCareRoyaltyPartnersIVLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i933aaacf34f34a61bfa383d7cb1bb60d_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="if95076af06f24f2296cea9a5d6d76ff4_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="i8733e6fccc254fd9bf95445ad142e86f_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="i95d5e831357142ff915c3c75ead6d520_D20180516-20180516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-16</startDate>
            <endDate>2018-05-16</endDate>
        </period>
    </context>
    <context id="i7c495d34647447ae8783de5a900a3e77_D20191201-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i69ee8e8bda5947d3a7b266f55eee864b_D20201009-20201009">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-09</startDate>
            <endDate>2020-10-09</endDate>
        </period>
    </context>
    <context id="ia1e9f731799b499eaf4aa779cb305fc6_I20180516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-16</instant>
        </period>
    </context>
    <context id="idaba5dc7a9024a1b89083ce66516cffd_D20220223-20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022AMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-23</startDate>
            <endDate>2022-02-23</endDate>
        </period>
    </context>
    <context id="i4ed59bf2f32c4c919325b9d6800e3fad_I20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022BMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-23</instant>
        </period>
    </context>
    <context id="i582ccc703db84580ad605cde3180b598_D20220223-20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-23</startDate>
            <endDate>2022-02-23</endDate>
        </period>
    </context>
    <context id="i40c1281552f94064963e3bf9cbecc666_D20220223-20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022BMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-23</startDate>
            <endDate>2022-02-23</endDate>
        </period>
    </context>
    <context id="i62a2e82e4ddc4240896cf7fd6f83fbf6_I20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022AMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-23</instant>
        </period>
    </context>
    <context id="id31b250d8a3946278fda76b05ca4b4b1_I20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-23</instant>
        </period>
    </context>
    <context id="if668412fafc546cc955d0c29fa2f6c99_I20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-23</instant>
        </period>
    </context>
    <context id="i0f56c96387e743bbb3742ef501488a40_I20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-23</instant>
        </period>
    </context>
    <context id="i72298d93078c4637ab00517b03176997_I20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-23</instant>
        </period>
    </context>
    <context id="if0d290137b1441abbf8d0d36c58a8e95_I20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-23</instant>
        </period>
    </context>
    <context id="i4584120047b3460da4d6b5a0f2eb0808_D20220223-20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-23</startDate>
            <endDate>2022-02-23</endDate>
        </period>
    </context>
    <context id="iddc086b231bc43f99e47143a4bfb2914_D20220223-20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-23</startDate>
            <endDate>2022-02-23</endDate>
        </period>
    </context>
    <context id="ic957e7b2e6404684ab3ce4588e0747ed_D20230209-20230209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermBLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-09</startDate>
            <endDate>2023-02-09</endDate>
        </period>
    </context>
    <context id="i1b61195b8cbb43b4945e83216c7f171c_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="i829995ddccd34c45973808967c7cab51_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i23902f57514345efaefc7f6ed372683f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i73c09104400b4fc89c22d500c708517d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8a01e0a1633e4784b82496570aa01a7e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3a1e94b571de450d80084e08a561e5cc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia25f50b8fef94d1a9bc667f04f3a26ab_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i07e35ddf250a487cbae6c8e1f803a4b1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0080f34bc4774f159a2fbc226bec7e75_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ideeb597472c94a98a7ce7e756017a2b2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib44009e3ef8846b299ee2faab0e9ac8c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0921c20fa4634446aebe75988e9825d1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4aa9ee384f104add8be1fdc63cb9f8ce_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i74fef4adf9a14a308f8328b9570c5a83_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic44d3449c4204e78b2fb999f07d658ab_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia0d3d90e1a504d63bd8c04dc4913b676_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i04b8aa4c409143baabd2c14fa0c59341_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i60af5b7c588a4c7b92f37d85a0e4d590_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7aeaa47a07574280ba69e0812b3fc9c4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i26bf80d609da4735913857489e4da748_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:LeaseArrangementsAxis">ardx:FacilityFremontCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i335c2c940aa8413bb90dd9d65c09b3ba_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:LeaseArrangementsAxis">ardx:FacilityOneWalthamMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="if84711cbb7fb484d9907b17e292a5c75_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:LeaseArrangementsAxis">ardx:FacilityTwoWalthamMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="ic02d026a5b904c17807bd479ea7d0b3e_D20210401-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:LeaseArrangementsAxis">ardx:FacilityTwoWalthamMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="i6c53895082604a918d0ac2f036a8236f_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:LeaseArrangementsAxis">ardx:FacilityMilwaukeeWisconsinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="i191e1bf76f4b440593cb3aed98e7c4e4_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:LeaseArrangementsAxis">ardx:FacilityMilwaukeeWisconsinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="if776a22c61a44a539fe0fe538eb2a3e2_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i6c0917f6cb2342afb6023949b42688ce_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2020AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="ib4aee40b13b3480c9ac040be86a38b5d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2020AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6e194876618f454a8e69ce8891915a74_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2020AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i091722886b334fd9bde76bd765e73617_I20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2021AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="i387017f0cb654df1bee8547faa646789_D20210801-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2021AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id010daff3c1947e29d8c5fd89ebaa449_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2021AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ieeb64a378b284f01ba441778bf717ff2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2021AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i53cfbbd1366348c3a6a036a0048aed7a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2021AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic0543a071cf942e590a16ac2b267ca3a_D20230101-20230112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2021AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-12</endDate>
        </period>
    </context>
    <context id="i0edad5a730a244cba8f8a9819262823c_I20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="id8349613f0ed462d8ac8ec08c2be4b51_I20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2023AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="i05cd4ea70ed4485589e755e460b69fd1_D20230101-20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2023AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="i59e25fbea49d4656871685e6d2d6c76e_D20140101-20140630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:TwoThousandEightStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-06-30</endDate>
        </period>
    </context>
    <context id="i91127df0154643aeaa974e5370a0d08f_I20140618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:TwoThousandFourteenEquityIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-06-18</instant>
        </period>
    </context>
    <context id="i3b2b0a1450e146dab1869a3c643a4b54_D20140618-20140618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:TwoThousandFourteenEquityIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-06-18</startDate>
            <endDate>2014-06-18</endDate>
        </period>
    </context>
    <context id="ib434fa02b7f94f70a56b9427b8d40564_I20161130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:TwoThousandSixteenEmploymentCommencementIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-11-30</instant>
        </period>
    </context>
    <context id="id17ce6206b53406fae2405e677fe43ef_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:TwoThousandSixteenEmploymentCommencementIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i43e122158f0e415aa7661317d01ff3be_D20220101-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:TwoThousandSixteenEmploymentCommencementIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="i083ca43bb16849a593d6fe2102ad4aca_D20221201-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:TwoThousandSixteenEmploymentCommencementIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if5d377e7e91446f9872db311ff7a998d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:TwoThousandSixteenEmploymentCommencementIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i208be3295b5d448a8b943c647170b858_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4d035ef039b9449f9a833a4878f300ef_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ief16b3cbe3934dc98b9bc68d2856ca35_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic5c3b975ccf642298e9ab071e46c4b8e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7f8f14f6a5a441a4b8e90c587038294a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iad26c62e1f7040819c46ba8aaecbfdf7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5804b276fcba47ec9888f9294a058bd3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5c4f587701fb4044879019a9bdf73a97_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic72722bcacf846aeae4e32bdaf25ad95_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic0a3fa62b68c4a38948feeb7a5990743_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i759c16cd46934957818cd44b6da608af_D20180701-20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ardx:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="i6a36013712a244a6857a4ef451619a76_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ardx:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia0963364402c4d97b8a169943f9ea6a8_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ardx:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i477da3d9a3ff40539adf947d1f500015_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie25852142a964d3188c11071355f91b7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib3f407a43bf14aab8924633cd249ade7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i517e23fe4e2f4b29b85b4d380f6c2944_I20140618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-06-18</instant>
        </period>
    </context>
    <context id="i180188a490a8459b9367c5d5573a5e16_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i248a37dc8c184f47ac596a1ecc3f232f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id1fa16bad9884e0e9493c7512c233aa6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if8ec837e0d0b46c8864c912515db4ad0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id9c65dc81f5a450db626c1aa9194755f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ieb74b9fdd27048e29f9e1520ac5e595e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2b365ae1dfda4e07a8271c22db477bea_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie78b6836511840a480c1026e771997e3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i48d97bd1c889443c8fee636ae7505dd3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib0ec441698c9479d8b42818e25d70400_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5830a4e62ed14db59de4465b18e9bdb9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i431ed8f3e092438fbec58a56f0b02185_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i09a681eff916461fb51eb3329131ce8c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ardx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic11d410599a74593aa714291238376f7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ardx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibb22b29792e5485ebf185f5394ba3762_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ardx:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icc9a17e7794647c2bf47f0d17f42638a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ardx:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i69f5495993474d55b708c186a11429b3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id91a83781eeb4816af435aa999f55171_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iac8bff27f31a4cdba6c1c3861745b2ef_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if0a0600f40b045c6b35e188f2f71061e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i417d82d19f4a4fbcadb83d9e66e6fd76_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i888d6abdafc14bdab944dd9b5f92fa5f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4b6ecc5e16524d9ca5408690716f1a33_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib4ad706ca1134370ac1fdd46d324a005_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">ardx:MinimumTaxCreditCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if221b086648a41aab5554e1ca5f792ec_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">ardx:TaxAuthorityStatesOtherThanCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if59e9efdbe2d42718f4a91fe0b12275c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib44743fdc95f46f182f7c502b1cd9c4d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic04f77eb07ea4224a01520efa0f633d3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1746af5e54554e499e907d7129518fd0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i511c3600481046ab8ea3a0188db062f2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1b925d525dc749719f6bd325cefb8a1c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iae0dc045d5b541dfa650458342fbe24a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9c3c4d25be5c41f2a23bc91cd0c77d25_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5b4c067ab6484053a239a2ccd02d90d1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id19674491cd54b0c969b0e9bccb5521e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ardx:CollaborationPartnershipConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:KkcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id3fb70f0cf0f4182806a3abc3d5b5b25_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ardx:CollaborationPartnershipConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:KkcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8ac81d53477e44f6afab4b4e55da6c0b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ardx:CollaborationPartnershipConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:KkcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2805b962ce1c4f33a04e27034cee3305_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ardx:CollaborationPartnershipConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:KnightTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2d1f27a987ea46e4ac5004a0280afb04_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ardx:CollaborationPartnershipConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:KnightTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifda028b327984abab2f5a8dc37dd7bf1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ardx:CollaborationPartnershipConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:KnightTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iceaaa79f1b46468e9d5df39ac4e0e130_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ardx:CollaborationPartnershipConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AmerisourceBergenDrugCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7f6e6bcfc89b4e3bbbf5ef1ab1cfa46c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ardx:CollaborationPartnershipConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AmerisourceBergenDrugCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id58e400e1e524590b3c5cd7fe872d7d9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ardx:CollaborationPartnershipConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AmerisourceBergenDrugCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib4411bca5f204674a4e725c73570e515_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id664c0aa97b74d6b933633eb24bd7ffa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia1833de563c44c0a84b1e4c778b58c6d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i952c9b1adbbf4d96b9b3719a4c54ea85_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iba8409a9d3074b558e62a6b388c3ab67_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i96a34e4ebc4c41b5b53c6de94e6f9347_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i538aeeb65eb843779d9a0e11b1e50104_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ieb0f4765d39d45c69282d8ce87f604fc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1b5f3274350745bdba9cf5da71e8b2d5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia6b3a9fd0ae14ddea562b4e1be92c9ca_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia8ac5065cbaa4252992fdf404620572d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if66074aa8b8c4eaf87dfdefd3d2725c2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib374c30529ad46698e71cb3df47baab0_D20220730-20220812">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ardx:StrezsakVersusArdelyxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-30</startDate>
            <endDate>2022-08-12</endDate>
        </period>
    </context>
    <context id="i4720ecaa980849ecb662496f697442e6_D20220719-20220719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ardx:StrezsakVersusArdelyxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-19</startDate>
            <endDate>2022-07-19</endDate>
        </period>
    </context>
    <context id="i1fb81fa2f1994bbf9c437971dd33e52e_D20211207-20220329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ardx:GoVersusRaabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-07</startDate>
            <endDate>2022-03-29</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>ardx:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="investment">
        <measure>ardx:investment</measure>
    </unit>
    <unit id="item">
        <measure>ardx:item</measure>
    </unit>
    <unit id="jpy">
        <measure>iso4217:JPY</measure>
    </unit>
    <unit id="payment_tranche">
        <measure>ardx:payment_tranche</measure>
    </unit>
    <unit id="cad">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="lease_agreement">
        <measure>ardx:lease_agreement</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="renewal_option">
        <measure>ardx:renewal_option</measure>
    </unit>
    <unit id="claim">
        <measure>ardx:claim</measure>
    </unit>
    <unit id="defendant">
        <measure>ardx:defendant</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl80L2ZyYWc6ZTlhNGMzNjJkYzMxNDUzODk3ZTZkZmNlZWFkZmM5NDcvdGFibGU6MWM2NWYxYzgxNjBiNGEyZmE5ZGI5NTU1OTZhN2Q4YTEvdGFibGVyYW5nZToxYzY1ZjFjODE2MGI0YTJmYTlkYjk1NTU5NmE3ZDhhMV8zLTEtMS0xLTQ2MDEz_481d9a01-a230-4c45-ac25-60ba38525571">0001437402</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl80L2ZyYWc6ZTlhNGMzNjJkYzMxNDUzODk3ZTZkZmNlZWFkZmM5NDcvdGFibGU6MWM2NWYxYzgxNjBiNGEyZmE5ZGI5NTU1OTZhN2Q4YTEvdGFibGVyYW5nZToxYzY1ZjFjODE2MGI0YTJmYTlkYjk1NTU5NmE3ZDhhMV81LTEtMS0xLTQ2MDEz_9fd85c2d-8d49-4cdd-ae90-22c335b07018">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl80L2ZyYWc6ZTlhNGMzNjJkYzMxNDUzODk3ZTZkZmNlZWFkZmM5NDcvdGFibGU6MWM2NWYxYzgxNjBiNGEyZmE5ZGI5NTU1OTZhN2Q4YTEvdGFibGVyYW5nZToxYzY1ZjFjODE2MGI0YTJmYTlkYjk1NTU5NmE3ZDhhMV82LTEtMS0xLTQ2MDEz_5bbfdbf6-5369-497f-9c70-7eec45d4c45b">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl80L2ZyYWc6ZTlhNGMzNjJkYzMxNDUzODk3ZTZkZmNlZWFkZmM5NDcvdGFibGU6MWM2NWYxYzgxNjBiNGEyZmE5ZGI5NTU1OTZhN2Q4YTEvdGFibGVyYW5nZToxYzY1ZjFjODE2MGI0YTJmYTlkYjk1NTU5NmE3ZDhhMV83LTEtMS0xLTQ2MDEz_b926a01f-8799-46ce-9421-d47543ceeaf8">false</dei:AmendmentFlag>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i2de3a294b21b459b8c55c13b0a994e24_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzY3Mzg_4835439c-76eb-4d2f-801e-529f6574b0d2">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <dei:DocumentType
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGV4dHJlZ2lvbjo4YzEwMzI4ZDE2NDI0NmFjOWQ2ZWQ5NTU4NDQ3N2Y3OV8zNjY1_7cdd28da-6350-4d5b-8192-a4ad30948696">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGFibGU6YTZmN2IzZWZlYjZhNGRjZWI4OGVmZDA0OWNmZDhjNjEvdGFibGVyYW5nZTphNmY3YjNlZmViNmE0ZGNlYjg4ZWZkMDQ5Y2ZkOGM2MV8xLTAtMS0xLTQ2MDEz_caba47bb-c0d5-4410-aed2-101da554a496">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGV4dHJlZ2lvbjo4YzEwMzI4ZDE2NDI0NmFjOWQ2ZWQ5NTU4NDQ3N2Y3OV8yMjU_0f0ff1f1-dde2-471b-9c4e-485242d38047">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGV4dHJlZ2lvbjo4YzEwMzI4ZDE2NDI0NmFjOWQ2ZWQ5NTU4NDQ3N2Y3OV8yMjU_4b725c36-0b91-4819-89be-1d4c38002690">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGFibGU6NTRjM2Y5MjhiYmRiNDYwZWJlMDBhNjBjMjA5ZjFmOWYvdGFibGVyYW5nZTo1NGMzZjkyOGJiZGI0NjBlYmUwMGE2MGMyMDlmMWY5Zl8wLTAtMS0xLTQ2MDEz_de16e466-5d6e-4e37-bb1a-08ea38c3e64f">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGV4dHJlZ2lvbjo4YzEwMzI4ZDE2NDI0NmFjOWQ2ZWQ5NTU4NDQ3N2Y3OV8zNjY4_45480c9b-e842-405d-a7db-e51a3d22322a">001-36485</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGV4dHJlZ2lvbjo4YzEwMzI4ZDE2NDI0NmFjOWQ2ZWQ5NTU4NDQ3N2Y3OV8zNjY2_7e20bbef-a3a5-4f13-9531-9cfd359dc7da">ARDELYX, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGFibGU6YzUyYzY0M2NlZmFkNDMzZjhmN2RlZDM1NTM2OTI4NGUvdGFibGVyYW5nZTpjNTJjNjQzY2VmYWQ0MzNmOGY3ZGVkMzU1MzY5Mjg0ZV8wLTAtMS0xLTQ2MDEzL3RleHRyZWdpb246YWQzN2VjNWU0MTZmNDE0N2JkMGEyZThiOGZhYTc3NTZfNA_51aa7cf5-0295-4d6d-8a4a-94cce2f434fd">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGFibGU6YzUyYzY0M2NlZmFkNDMzZjhmN2RlZDM1NTM2OTI4NGUvdGFibGVyYW5nZTpjNTJjNjQzY2VmYWQ0MzNmOGY3ZGVkMzU1MzY5Mjg0ZV8wLTEtMS0xLTQ2MDEz_41d89d68-b02f-446d-a1eb-a67b3b524b67">26-1303944</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGV4dHJlZ2lvbjo4YzEwMzI4ZDE2NDI0NmFjOWQ2ZWQ5NTU4NDQ3N2Y3OV8zNjcz_2a861487-69fd-4f84-bb17-53c173abd599">400 FIFTH AVE.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGV4dHJlZ2lvbjo4YzEwMzI4ZDE2NDI0NmFjOWQ2ZWQ5NTU4NDQ3N2Y3OV8zNjY5_d49e5f63-d701-4581-a227-b13a6af28467">SUITE 210</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGV4dHJlZ2lvbjo4YzEwMzI4ZDE2NDI0NmFjOWQ2ZWQ5NTU4NDQ3N2Y3OV8zNjU5_fe127b9e-cbb3-4078-828e-fc05cb2e1ac8">WALTHAM</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGV4dHJlZ2lvbjo4YzEwMzI4ZDE2NDI0NmFjOWQ2ZWQ5NTU4NDQ3N2Y3OV8zNjc0_ba0bd9f5-9f81-4bdf-92f5-4a73aa1a3104">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGV4dHJlZ2lvbjo4YzEwMzI4ZDE2NDI0NmFjOWQ2ZWQ5NTU4NDQ3N2Y3OV8zNjcw_f54f35df-c40a-4296-9360-afaedbef1061">02451</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGV4dHJlZ2lvbjo4YzEwMzI4ZDE2NDI0NmFjOWQ2ZWQ5NTU4NDQ3N2Y3OV8zNjYw_f1121b9a-7039-49d6-b0b4-08c250c5f06b">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGV4dHJlZ2lvbjo4YzEwMzI4ZDE2NDI0NmFjOWQ2ZWQ5NTU4NDQ3N2Y3OV8zNjcx_767bb912-6105-427f-891b-3f78aca470b9">745-1700</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGFibGU6ZmI0NDA3ZTE1NWFkNDkwYmI3YmYyZGUyM2RjYmQ1N2MvdGFibGVyYW5nZTpmYjQ0MDdlMTU1YWQ0OTBiYjdiZjJkZTIzZGNiZDU3Y18xLTAtMS0xLTQ2MDEz_f44053ec-de4b-4bc7-ad0e-3de3eb8e9ed8">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGFibGU6ZmI0NDA3ZTE1NWFkNDkwYmI3YmYyZGUyM2RjYmQ1N2MvdGFibGVyYW5nZTpmYjQ0MDdlMTU1YWQ0OTBiYjdiZjJkZTIzZGNiZDU3Y18xLTItMS0xLTQ2MDEz_a2d6096c-bfd5-4ef1-b3ea-f2708717aff1">ARDX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGFibGU6ZmI0NDA3ZTE1NWFkNDkwYmI3YmYyZGUyM2RjYmQ1N2MvdGFibGVyYW5nZTpmYjQ0MDdlMTU1YWQ0OTBiYjdiZjJkZTIzZGNiZDU3Y18xLTQtMS0xLTQ2MDEz_68632e21-ae97-482c-abea-502210458ad8">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGV4dHJlZ2lvbjo4YzEwMzI4ZDE2NDI0NmFjOWQ2ZWQ5NTU4NDQ3N2Y3OV8zNjYx_52cafa01-02e3-45c0-bd47-ffbcb4d283dd">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGV4dHJlZ2lvbjo4YzEwMzI4ZDE2NDI0NmFjOWQ2ZWQ5NTU4NDQ3N2Y3OV8zNjYy_4a3ff91f-2a9d-446a-83e3-f281859bc033">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGV4dHJlZ2lvbjo4YzEwMzI4ZDE2NDI0NmFjOWQ2ZWQ5NTU4NDQ3N2Y3OV8zNjYz_8822461f-007d-4bfb-9ed8-d2df4fdbf26d">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGV4dHJlZ2lvbjo4YzEwMzI4ZDE2NDI0NmFjOWQ2ZWQ5NTU4NDQ3N2Y3OV8zNjc1_d78e56c7-209b-4fc6-94d9-e4106dd87f88">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGFibGU6Y2JjM2I1MjZjYjdkNGZkZGIzM2FiYmMwYzQzMmQ0YWEvdGFibGVyYW5nZTpjYmMzYjUyNmNiN2Q0ZmRkYjMzYWJiYzBjNDMyZDRhYV8xLTEtMS0xLTUwOTM4_557951a5-b13f-4a42-81c8-95f0be313eff">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGFibGU6Y2JjM2I1MjZjYjdkNGZkZGIzM2FiYmMwYzQzMmQ0YWEvdGFibGVyYW5nZTpjYmMzYjUyNmNiN2Q0ZmRkYjMzYWJiYzBjNDMyZDRhYV8xLTUtMS0xLTQ2MDEz_9729738f-739b-4224-876b-07b58b81b654">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGFibGU6Y2JjM2I1MjZjYjdkNGZkZGIzM2FiYmMwYzQzMmQ0YWEvdGFibGVyYW5nZTpjYmMzYjUyNmNiN2Q0ZmRkYjMzYWJiYzBjNDMyZDRhYV8yLTUtMS0xLTQ2MDEz_bb8b3998-dec5-4c2e-8fc4-a959fda25b68">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGV4dHJlZ2lvbjo4YzEwMzI4ZDE2NDI0NmFjOWQ2ZWQ5NTU4NDQ3N2Y3OV8zNjc2_b9bc9ec1-25a2-43c3-8ac2-0c5180f81f0c">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGV4dHJlZ2lvbjo4YzEwMzI4ZDE2NDI0NmFjOWQ2ZWQ5NTU4NDQ3N2Y3OV81NDk3NTU4MTQyOTUz_ee61762c-3639-4a4f-854f-0122b358eada">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="iaeca4a04a1754667989d2f2d6e9f8f59_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGV4dHJlZ2lvbjo4YzEwMzI4ZDE2NDI0NmFjOWQ2ZWQ5NTU4NDQ3N2Y3OV8zMjY2_effbeeed-9a8c-4e5d-b717-538abec1ee9e"
      unitRef="usd">89227062</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i9fc42224cc0a42e883f0fb58a584b2a0_I20230228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGV4dHJlZ2lvbjo4YzEwMzI4ZDE2NDI0NmFjOWQ2ZWQ5NTU4NDQ3N2Y3OV8zMzQ2_ec79c0f0-ea67-4e50-a862-ade8f9cdbd9a"
      unitRef="shares">206492664</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xL2ZyYWc6OGMxMDMyOGQxNjQyNDZhYzlkNmVkOTU1ODQ0NzdmNzkvdGV4dHJlZ2lvbjo4YzEwMzI4ZDE2NDI0NmFjOWQ2ZWQ5NTU4NDQ3N2Y3OV8zNjY0_4990e8e1-aeb3-4d32-b777-9f6372ff7f17">&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Portions of the Registrant&#x2019;s Definitive Proxy Statement for its 2023 Annual Meeting of Stockholders, which will be filed with the Commission within 120 days of December&#160;31, 2022, the close of the Registrant&#x2019;s 2022 fiscal year, are incorporated by reference into Part III of this Report&lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl83OS9mcmFnOmRmZWE3NTE1N2VlNzRkYzViMjQ1ZTk5ZDI0Mjg1ZDI4L3RhYmxlOjQwOWFmYmExZTg1YjQ1NWM4OWExNzNmYzljNWQxNDQxL3RhYmxlcmFuZ2U6NDA5YWZiYTFlODViNDU1Yzg5YTE3M2ZjOWM1ZDE0NDFfMC0wLTEtMS00NjAxMy90ZXh0cmVnaW9uOmI5Y2E1ZGZjZWZjNjRhZjY4ZmIxZDQwYmZiNTYyNTM1Xzcx_64daf1b0-8b73-4688-a408-462db0f19e25">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84Mi9mcmFnOjVmNzUyMmMwYTFiZDRkZTI5MzI0NzA3ZGJjZWFiYWJlL3RleHRyZWdpb246NWY3NTIyYzBhMWJkNGRlMjkzMjQ3MDdkYmNlYWJhYmVfMjc0ODc3OTEwMTcwNA_58ac7c85-312f-4da4-a5f0-c739ab0a60cb">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84Mi9mcmFnOjVmNzUyMmMwYTFiZDRkZTI5MzI0NzA3ZGJjZWFiYWJlL3RleHRyZWdpb246NWY3NTIyYzBhMWJkNGRlMjkzMjQ3MDdkYmNlYWJhYmVfNDA5Mw_d91aaa22-1001-4c04-9f9b-fba2eedc66f1">San Mateo, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfNC0xLTEtMS00NjAxMw_0d7f054f-9cb6-44b4-9ae4-30eb4f0f04bd"
      unitRef="usd">96140000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfNC0zLTEtMS00NjAxMw_8b88d738-979c-488f-a6b7-c58a7ecf8c7e"
      unitRef="usd">72428000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfNS0xLTEtMS00NjAxMw_29e3ed9e-5d96-4433-b92c-ed132b274f74"
      unitRef="usd">27769000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfNS0zLTEtMS00NjAxMw_caab7591-ea12-4f80-b076-bd66a1e87426"
      unitRef="usd">44261000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfNi0xLTEtMS00NjAxMw_409e032d-7601-440e-a8e1-04c5846116a2"
      unitRef="usd">7733000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfNi0zLTEtMS00NjAxMw_6193cf7f-1cc4-45b3-b8a8-d5ffd0516347"
      unitRef="usd">502000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryGross
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfNy0xLTEtMS00NjI3Ng_7f616ea7-742b-4964-b249-b96047125793"
      unitRef="usd">3282000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfNy0zLTEtMS00NjI3Ng_9ad3b4a5-3b86-489a-8c8f-2588bed7169e"
      unitRef="usd">0</us-gaap:InventoryGross>
    <ardx:PrepaidCommercialManufacturingCurrent
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfOC0xLTEtMS00NjI3Ng_ae501e4c-52b5-49cd-8d60-e10da88d21b7"
      unitRef="usd">13567000</ardx:PrepaidCommercialManufacturingCurrent>
    <ardx:PrepaidCommercialManufacturingCurrent
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfOC0zLTEtMS00NjI3Ng_7e015129-9dcb-4d0a-869f-b1041912a270"
      unitRef="usd">9406000</ardx:PrepaidCommercialManufacturingCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfNy0xLTEtMS00NjAxMw_48236fe1-66d7-49a3-a85f-b5aaa3dd314a"
      unitRef="usd">5112000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfNy0zLTEtMS00NjAxMw_098676e4-7259-4831-b139-a5618e7db9b9"
      unitRef="usd">7052000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfOC0xLTEtMS00NjAxMw_5f91b3a8-2b24-4d85-9aad-2935c39b0f7e"
      unitRef="usd">153603000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfOC0zLTEtMS00NjAxMw_f4edf17d-dff4-42ab-aab9-e447c2395f78"
      unitRef="usd">133649000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfOS0xLTEtMS00NjAxMw_7648233a-d643-43f2-98ec-59e37788fe6f"
      unitRef="usd">1223000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfOS0zLTEtMS00NjAxMw_79340bb8-13df-4628-a165-b741f71f846e"
      unitRef="usd">2362000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:InventoryNoncurrent
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMTItMS0xLTEtNTMyNDQ_00d996b8-31df-4738-837d-bc45cd0f7563"
      unitRef="usd">25064000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMTItMy0xLTEtNTMyNDQ_fb81aa33-2b67-4160-8cd6-3514fa70741b"
      unitRef="usd">0</us-gaap:InventoryNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMTEtMS0xLTEtNDYwMTM_a27dc45d-f336-49c1-a66c-7e227ca9b498"
      unitRef="usd">9295000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMTEtMy0xLTEtNDYwMTM_8aa330ae-6a81-4316-b23e-d7120decbb7c"
      unitRef="usd">12752000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMTItMS0xLTEtNDYwMTM_25e57799-3439-4ad2-ada2-7c67d8f59047"
      unitRef="usd">881000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMTItMy0xLTEtNDYwMTM_17c10312-41e9-47c7-9718-d7ee46ae3d85"
      unitRef="usd">1150000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMTMtMS0xLTEtNDYwMTM_34764d3b-c973-4e7e-b2e9-e6eb8e1476f9"
      unitRef="usd">190066000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMTMtMy0xLTEtNDYwMTM_0dcaecf0-616c-4ce3-b595-5ab61a38f87e"
      unitRef="usd">149913000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMTYtMS0xLTEtNDYwMTM_1ed60ae8-4e6d-4896-8a10-17f860c32c82"
      unitRef="usd">10859000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMTYtMy0xLTEtNDYwMTM_af8028a8-99e7-47bd-b0b4-7878d36f5cd6"
      unitRef="usd">4277000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMTctMS0xLTEtNDYwMTM_206f91b5-f06a-4257-85df-cfee08d869c2"
      unitRef="usd">7548000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMTctMy0xLTEtNDYwMTM_4b9d5507-d3a6-4630-a2c4-2e7247c0025b"
      unitRef="usd">5422000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMTgtMS0xLTEtNDYwMTM_2bd5e73b-93e5-4262-aa57-b901dac2b87e"
      unitRef="usd">3894000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMTgtMy0xLTEtNDYwMTM_5173c1a7-2c8c-4d9a-b2f9-84a5f39371a9"
      unitRef="usd">3492000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LoansPayableCurrent
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMTktMS0xLTEtNDYwMTM_4b870d9b-43d0-4912-b94e-af8426c4f118"
      unitRef="usd">26711000</us-gaap:LoansPayableCurrent>
    <us-gaap:LoansPayableCurrent
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMTktMy0xLTEtNDYwMTM_19580b7a-41b4-4516-80a3-a851ea9cd868"
      unitRef="usd">32264000</us-gaap:LoansPayableCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjAtMS0xLTEtNDYwMTM_20e257eb-8b32-4a44-a2e9-e8be375d0387"
      unitRef="usd">4211000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjAtMy0xLTEtNDYwMTM_4f838a91-361f-4ab0-a3ef-29a6fba0408b"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjEtMS0xLTEtNDYwMTM_90296eb7-c1e7-4293-848f-71da3c71d32b"
      unitRef="usd">12380000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjEtMy0xLTEtNDYwMTM_0514cfdf-945d-478d-be4c-540172586a27"
      unitRef="usd">7366000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:LiabilitiesCurrent
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjItMS0xLTEtNDYwMTM_020420ef-80df-42f7-963b-d4ea3bcd8a0f"
      unitRef="usd">65603000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjItMy0xLTEtNDYwMTM_f37b08eb-4854-4f2f-a723-cd3ad0e647f7"
      unitRef="usd">52821000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjMtMS0xLTEtNDYwMTM_096db810-b60e-49f5-85da-fa3254597fa6"
      unitRef="usd">5855000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjMtMy0xLTEtNDYwMTM_b00dc6cd-5599-4e35-b463-2f893a7b3b52"
      unitRef="usd">9748000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjUtMS0xLTEtNDYwMTM_757911b5-95d7-4771-9f77-c1e8be246b8a"
      unitRef="usd">9025000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjUtMy0xLTEtNDYwMTM_5eb349d8-3e3d-48d5-8f31-f27ad22a69cb"
      unitRef="usd">4727000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <ardx:DeferredRoyaltyObligationNoncurrent
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjgtMS0xLTEtNDYyODA_55bec0ac-2fbd-46d7-8a35-4f1582b87b68"
      unitRef="usd">11254000</ardx:DeferredRoyaltyObligationNoncurrent>
    <ardx:DeferredRoyaltyObligationNoncurrent
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjgtMy0xLTEtNDYyODA_1199c445-c9ba-4a54-bd4f-332b0d0f551b"
      unitRef="usd">0</ardx:DeferredRoyaltyObligationNoncurrent>
    <us-gaap:Liabilities
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjYtMS0xLTEtNDYwMTM_57a8d13f-a4cd-4c88-80ab-e0dac8d78bda"
      unitRef="usd">91737000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjYtMy0xLTEtNDYwMTM_2c4d0075-ed17-4d1b-b33f-4c7301238c2a"
      unitRef="usd">67296000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjctMS0xLTEtNDYwMTM_207e7978-919c-4165-8c7e-93e0d2d78d38"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjctMy0xLTEtNDYwMTM_1929687a-57ce-488e-8cfc-fa02384ddd77"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjktMC0xLTEtNDYwMTMvdGV4dHJlZ2lvbjpiYzU1MmRlNWU5ZDg0MTYxYjg3ZTZhZjU3MTJkOTMxMV8yMQ_6d30f1ea-ff1d-4273-9b0b-5b27c3c1e39c"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjktMC0xLTEtNDYwMTMvdGV4dHJlZ2lvbjpiYzU1MmRlNWU5ZDg0MTYxYjg3ZTZhZjU3MTJkOTMxMV8yMQ_8a619a4a-4611-4438-8e26-062b3dcd6f6a"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjktMC0xLTEtNDYwMTMvdGV4dHJlZ2lvbjpiYzU1MmRlNWU5ZDg0MTYxYjg3ZTZhZjU3MTJkOTMxMV8zNQ_01c2c9dd-9fc6-49c8-ae0f-8d8718a1acf1"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjktMC0xLTEtNDYwMTMvdGV4dHJlZ2lvbjpiYzU1MmRlNWU5ZDg0MTYxYjg3ZTZhZjU3MTJkOTMxMV8zNQ_e70668f4-d0c4-4dc2-af87-aaa7e6edb95f"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjktMC0xLTEtNDYwMTMvdGV4dHJlZ2lvbjpiYzU1MmRlNWU5ZDg0MTYxYjg3ZTZhZjU3MTJkOTMxMV81Nw_098d971a-3f1a-476c-8145-2bc8ccbf12a3"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjktMC0xLTEtNDYwMTMvdGV4dHJlZ2lvbjpiYzU1MmRlNWU5ZDg0MTYxYjg3ZTZhZjU3MTJkOTMxMV81Nw_319395f9-963c-443f-b6c8-9f63dc8eeacb"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjktMC0xLTEtNDYwMTMvdGV4dHJlZ2lvbjpiYzU1MmRlNWU5ZDg0MTYxYjg3ZTZhZjU3MTJkOTMxMV81Nw_8ac71e26-9a21-4808-8107-cf5ac978ba00"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjktMC0xLTEtNDYwMTMvdGV4dHJlZ2lvbjpiYzU1MmRlNWU5ZDg0MTYxYjg3ZTZhZjU3MTJkOTMxMV81Nw_df03c550-44fc-4616-a8f0-e5839eeeada1"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjktMS0xLTEtNDYwMTM_79667dfe-abd0-4fb6-b86a-b576ea202099"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMjktMy0xLTEtNDYwMTM_9aa8ca09-f9d8-492f-aa5f-2419d606a2ba"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMzAtMC0xLTEtNDYwMTMvdGV4dHJlZ2lvbjplZmU0ZWQxMWEwZTg0YTA4OGZkOWI3OGE2ZDc0ZTJjOF8xOA_3a8981e4-fb77-4167-80ac-df755548a436"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMzAtMC0xLTEtNDYwMTMvdGV4dHJlZ2lvbjplZmU0ZWQxMWEwZTg0YTA4OGZkOWI3OGE2ZDc0ZTJjOF8xOA_cfba2c1e-ed24-4e31-8175-1609692b7321"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMzAtMC0xLTEtNDYwMTMvdGV4dHJlZ2lvbjplZmU0ZWQxMWEwZTg0YTA4OGZkOWI3OGE2ZDc0ZTJjOF8zMg_16c8f791-a0fc-4524-ae32-4d7f93c0ab07"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMzAtMC0xLTEtNDYwMTMvdGV4dHJlZ2lvbjplZmU0ZWQxMWEwZTg0YTA4OGZkOWI3OGE2ZDc0ZTJjOF8zMg_2627f135-59b1-47a6-97e4-671b98b11eb4"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMzAtMC0xLTEtNDYwMTMvdGV4dHJlZ2lvbjplZmU0ZWQxMWEwZTg0YTA4OGZkOWI3OGE2ZDc0ZTJjOF81NA_efcf7095-c3be-4f66-aab8-c0e52b0ac7ac"
      unitRef="shares">198575016</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMzAtMC0xLTEtNDYwMTMvdGV4dHJlZ2lvbjplZmU0ZWQxMWEwZTg0YTA4OGZkOWI3OGE2ZDc0ZTJjOF81NA_f0ccaa33-a802-4ce3-87f8-1dedc3ff23bd"
      unitRef="shares">198575016</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMzAtMC0xLTEtNDYwMTMvdGV4dHJlZ2lvbjplZmU0ZWQxMWEwZTg0YTA4OGZkOWI3OGE2ZDc0ZTJjOF82MQ_7735115f-46e8-4b59-bcd2-38343882648d"
      unitRef="shares">130182535</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMzAtMC0xLTEtNDYwMTMvdGV4dHJlZ2lvbjplZmU0ZWQxMWEwZTg0YTA4OGZkOWI3OGE2ZDc0ZTJjOF82MQ_7ec59e10-49fb-4804-8a71-32401c1be92c"
      unitRef="shares">130182535</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMzAtMS0xLTEtNDYwMTM_21492d3a-2213-4a87-b8ff-2736415f2f72"
      unitRef="usd">20000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMzAtMy0xLTEtNDYwMTM_d0dc27a0-7fe9-48d3-a334-2ef08a53ace5"
      unitRef="usd">13000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMzEtMS0xLTEtNDYwMTM_07ae289d-cec9-491f-8899-71ee5c570d38"
      unitRef="usd">878500000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMzEtMy0xLTEtNDYwMTM_a7a2fb0d-9b85-4423-9899-ef7a6ee238e9"
      unitRef="usd">795540000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMzItMS0xLTEtNDYwMTM_bb1fdc19-4786-45a9-a236-759cb6f59e28"
      unitRef="usd">-780137000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMzItMy0xLTEtNDYwMTM_49e407f6-af66-4c5c-9c9f-bb0eb5773ef1"
      unitRef="usd">-712930000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMzMtMS0xLTEtNDYwMTM_d8b4f1f5-92a6-4c70-bafc-02888b5a7d87"
      unitRef="usd">-54000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMzMtMy0xLTEtNDYwMTM_ba9456e6-a67c-4d6f-bcb2-f9b34515aeae"
      unitRef="usd">-6000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMzQtMS0xLTEtNDYwMTM_3bc0f2f0-ceaf-458b-bed1-725f2c20711e"
      unitRef="usd">98329000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMzQtMy0xLTEtNDYwMTM_bf126c13-d547-4db7-b297-5fc102c123fd"
      unitRef="usd">82617000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMzUtMS0xLTEtNDYwMTM_7460a4c3-9566-498c-b3d7-4e176d8afbdb"
      unitRef="usd">190066000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84NS9mcmFnOjBhNzYwYTJiYWEwNDQ0ZTE5YWVlZjAzODdiZWY5ZGZkL3RhYmxlOjFjYzg5NjkzYTNiMDQ3Nzc4ODYzMjBlYzM2ZGE2YzhlL3RhYmxlcmFuZ2U6MWNjODk2OTNhM2IwNDc3Nzg4NjMyMGVjMzZkYTZjOGVfMzUtMy0xLTEtNDYwMTM_68f8768b-3d3c-4290-918a-539dce5ee6be"
      unitRef="usd">149913000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ife1a6ddcf0434c3d8408dc580e20d7d8_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMy0xLTEtMS00NjAxMw_505e4744-ca36-42cb-999f-1f73004f0a84"
      unitRef="usd">15600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if6d0767c281240d4900cc0d8b9580230_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMy0zLTEtMS00NjAxMw_f7ccf8ea-60c7-4ecd-9d09-58c11f190e4b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifee111286a5d4c6e8104da9cafffda38_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMy01LTEtMS00NjAxMw_8dd4d981-a7cb-4a49-be83-9cd97bee7b07"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c1a31c699a645968b918a7d82fb494c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfNC0xLTEtMS00NjAxMw_92290435-21dc-4554-beb6-3f1477f1aa35"
      unitRef="usd">1527000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf3e168c61fd47e8aa38f9a4632206aa_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfNC0zLTEtMS00NjAxMw_6b05d8dd-486d-426a-bbf5-24b2ec3fba96"
      unitRef="usd">907000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d86efc199f945f69a8db92f44a6eaea_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfNC01LTEtMS00NjAxMw_bb5f37de-a57c-439c-886c-2dc23a560bc9"
      unitRef="usd">1501000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id8defbd8e977443b8e24752f1ecfdee1_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfNS0xLTEtMS00NjAxMw_3b1945ce-6657-44db-b9d3-ed01d522b745"
      unitRef="usd">35031000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i80db9f923ef14a778c2d03752079fed3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfNS0zLTEtMS00NjAxMw_4f3f2134-f4f7-4326-810a-5b74f2bc0734"
      unitRef="usd">5013000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8f9dc553215546f099c0816459c4a6ef_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfNS01LTEtMS00NjAxMw_3a34f2f7-ff82-4baf-9ba6-71277430d87d"
      unitRef="usd">706000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8955c2eaa96644dfa5eaadbf2a538826_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfNi0xLTEtMS00NjI5Mw_a633704e-2f0d-4b42-a823-97dbdea65d07"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib046fe75c1ba474da9dd251df8f9addb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfNi0zLTEtMS00NjI5Mw_352531d9-829a-4dfc-b6cc-82d123e2f569"
      unitRef="usd">4177000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i45f387fd7df541f5ad7e47ddafdac6b3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfNi01LTEtMS00NjI5Mw_be5f6100-7b30-4bd9-9a1a-a945fd016d78"
      unitRef="usd">5364000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfNi0xLTEtMS00NjAxMw_2e33d68c-8a0c-4768-b8d9-050839a85fad"
      unitRef="usd">52158000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfNi0zLTEtMS00NjAxMw_ddd66468-166e-408f-8ea1-c3e8195f4d35"
      unitRef="usd">10097000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfNi01LTEtMS00NjAxMw_f853407b-e563-486e-b7ee-03d926262b54"
      unitRef="usd">7571000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfOC0xLTEtMS00NjAxMw_3812198f-3277-4d01-9b50-3911d1bd2e10"
      unitRef="usd">4117000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfOC0zLTEtMS00NjAxMw_27e51fc4-26d2-4f46-b0e5-94c0d5c87d42"
      unitRef="usd">1000000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfOC01LTEtMS00NjAxMw_cd11cc6f-8557-4a02-9c5f-bdc06479f3b6"
      unitRef="usd">145000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfOS0xLTEtMS00NjAxMw_b3bcfa7c-6737-4ea1-851c-a3b87acc9723"
      unitRef="usd">35201000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfOS0zLTEtMS00NjAxMw_7c20646c-1844-41de-bcd4-38db5cd3f049"
      unitRef="usd">91140000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfOS01LTEtMS00NjAxMw_ca902b4b-fdbf-40e5-99d2-b779e4fc6cc5"
      unitRef="usd">65053000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTAtMS0xLTEtNDYwMTM_b81e4bb9-647e-47ff-8d8b-037d787a2c8a"
      unitRef="usd">76599000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTAtMy0xLTEtNDYwMTM_09e2836d-9ea1-42db-bfe0-5dded3ad26fc"
      unitRef="usd">72303000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTAtNS0xLTEtNDYwMTM_1b2bc21c-63d9-4ca1-b7a1-66d815883687"
      unitRef="usd">33153000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTEtMS0xLTEtNDYwMTM_95d1dc08-016d-441f-8a4d-6fd5ff58ba2b"
      unitRef="usd">115917000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTEtMy0xLTEtNDYwMTM_835a71f4-3021-43c8-a338-bb279b076afa"
      unitRef="usd">164443000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTEtNS0xLTEtNDYwMTM_241978bf-d287-4be7-80de-b3235aa826a7"
      unitRef="usd">98351000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTItMS0xLTEtNDYwMTM_590460d8-2296-4c8e-8f22-e6d0834c7b16"
      unitRef="usd">-63759000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTItMy0xLTEtNDYwMTM_8c1f620b-acc9-4a87-9284-d8c1db1bbf33"
      unitRef="usd">-154346000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTItNS0xLTEtNDYwMTM_1a0e6423-e3bd-41dd-8c44-23de0d2a0f25"
      unitRef="usd">-90780000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTMtMS0xLTEtNDYwMTM_6180aec6-e17e-46d7-9872-4f9f056e4724"
      unitRef="usd">3400000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTMtMy0xLTEtNDYwMTM_82272223-f23c-4f29-a0dc-2ee0fcebab08"
      unitRef="usd">4502000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTMtNS0xLTEtNDYwMTM_2565aa9d-ff52-4fb3-9fd9-ee5e04776258"
      unitRef="usd">5099000</us-gaap:InterestExpense>
    <us-gaap:AmortizationOfAdvanceRoyalty
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTUtMS0xLTEtNDYzMTU_44a0a263-1fec-4a75-ac89-5059af075ab8"
      unitRef="usd">1673000</us-gaap:AmortizationOfAdvanceRoyalty>
    <us-gaap:AmortizationOfAdvanceRoyalty
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTUtMy0xLTEtNDYzMTU_6acf64d6-5d53-4778-80e6-bedbb68973da"
      unitRef="usd">0</us-gaap:AmortizationOfAdvanceRoyalty>
    <us-gaap:AmortizationOfAdvanceRoyalty
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTUtNS0xLTEtNDYzMTU_3b4e6dc6-7ad5-4486-8e0e-2eb6bc89b58e"
      unitRef="usd">0</us-gaap:AmortizationOfAdvanceRoyalty>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTQtMS0xLTEtNDYwMTM_a1df38e6-9de4-43c0-88dc-76a91567ffba"
      unitRef="usd">1633000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTQtMy0xLTEtNDYwMTM_894ada93-b8db-40d2-b1bd-65e545c45697"
      unitRef="usd">687000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTQtNS0xLTEtNDYwMTM_6ce182af-b7a8-4c8b-9db1-39e4aed309c1"
      unitRef="usd">1568000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTUtMS0xLTEtNDYwMTM_762b5636-6430-4d86-9a9a-5f32fdaeb7b5"
      unitRef="usd">-67199000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTUtMy0xLTEtNDYwMTM_235b93ef-a640-462f-85c3-51e8a37c86a7"
      unitRef="usd">-158161000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTUtNS0xLTEtNDYwMTM_c14e5639-5acb-4625-944f-eafe509abdc5"
      unitRef="usd">-94311000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTYtMS0xLTEtNDYwMTM_e4bff21f-5f4c-4337-b9ff-0760b725b62a"
      unitRef="usd">8000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTYtMy0xLTEtNDYwMTM_f066ab96-32c8-411f-9507-3ce6ffd2d7e4"
      unitRef="usd">4000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTYtNS0xLTEtNDYwMTM_5252236c-b032-4c33-8281-88557172541c"
      unitRef="usd">2000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTctMS0xLTEtNDYwMTM_fe265dd0-ee63-496f-8057-c38a08df4b25"
      unitRef="usd">-67207000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTctMy0xLTEtNDYwMTM_8f7f2fb8-1aaa-4414-9f94-92aabe9eedfe"
      unitRef="usd">-158165000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTctNS0xLTEtNDYwMTM_0ce9e7cf-f818-46bb-b683-73d1265afbd3"
      unitRef="usd">-94313000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTgtMS0xLTEtNDYwMTM_3fa663af-cdff-4403-9fc5-53ccccf46ec2"
      unitRef="usdPerShare">-0.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTgtMS0xLTEtNDYwMTM_89723d78-126a-4aeb-8be9-bede8b76f76d"
      unitRef="usdPerShare">-0.42</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTgtMy0xLTEtNDYwMTM_21963968-0889-467b-aaca-4642d916faad"
      unitRef="usdPerShare">-1.52</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTgtMy0xLTEtNDYwMTM_4bfefd32-eedb-43b1-9fda-dccf4f21cae7"
      unitRef="usdPerShare">-1.52</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTgtNS0xLTEtNDYwMTM_25eb1dbe-9231-4907-91ee-77b8abffde9f"
      unitRef="usdPerShare">-1.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTgtNS0xLTEtNDYwMTM_6bdf6640-2597-4566-bbb9-36d2fa09384c"
      unitRef="usdPerShare">-1.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTktMS0xLTEtNDYwMTM_7d9faae5-3838-48e0-8f77-74f4d484bebb"
      unitRef="shares">158690083</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTktMS0xLTEtNDYwMTM_de5eca5f-5fab-4d8c-ab34-c46b70859098"
      unitRef="shares">158690083</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTktMy0xLTEtNDYwMTM_f81abab5-229a-46be-9ade-e2c4cc901961"
      unitRef="shares">104205645</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTktMy0xLTEtNDYwMTM_fb909153-b4c6-48b2-9e66-8b5b1aca7e02"
      unitRef="shares">104205645</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTktNS0xLTEtNDYwMTM_37683a5e-eb99-40af-a547-5eaf42f4ab80"
      unitRef="shares">89582138</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMTktNS0xLTEtNDYwMTM_98c249a6-0e44-4d68-95ad-d9b05eef2fa9"
      unitRef="shares">89582138</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMjEtMS0xLTEtNDYwMTM_ec10c554-3ade-4b8b-869c-60c8f03409ea"
      unitRef="usd">-67207000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMjEtMy0xLTEtNDYwMTM_ccbaaba6-664e-4678-ab06-44434fa0a63a"
      unitRef="usd">-158165000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMjEtNS0xLTEtNDYwMTM_11771431-f3eb-42af-826b-bd035c140cba"
      unitRef="usd">-94313000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMjItMS0xLTEtNDYwMTM_b7784f3e-d3b3-42fc-9b34-043f7c8c9c02"
      unitRef="usd">-48000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMjItMy0xLTEtNDYwMTM_56147f3d-d46a-4d96-b2c1-fbe7dabbd84a"
      unitRef="usd">-2000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMjItNS0xLTEtNDYwMTM_c1c484f6-97a0-4a7f-843e-afdaa1e4217c"
      unitRef="usd">-24000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMjMtMS0xLTEtNDYwMTM_39e0e964-6132-48b7-960b-04e5b292d753"
      unitRef="usd">-67255000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMjMtMy0xLTEtNDYwMTM_c148d6d9-1239-4484-9cae-25a18bca4800"
      unitRef="usd">-158167000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl84OC9mcmFnOmI2N2Y1YTA4OWFiYTQzMWM4Zjg3OGRlNDE3MWNmZjcxL3RhYmxlOmVhYmVkM2QzMjU0YzRjYjFiZmI3YmIyZTc4ZDNkNTU4L3RhYmxlcmFuZ2U6ZWFiZWQzZDMyNTRjNGNiMWJmYjdiYjJlNzhkM2Q1NThfMjMtNS0xLTEtNDYwMTM_255f1114-5aeb-424e-8d0b-a65b930c3229"
      unitRef="usd">-94337000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i473a2780d03c4c7f8d5e27ab35bdee43_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMi0xLTEtMS00NjAxMw_dc04d7fb-a9c9-4001-841c-9171753a7f87"
      unitRef="shares">88817741</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i473a2780d03c4c7f8d5e27ab35bdee43_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMi0zLTEtMS00NjAxMw_ec309802-3f2e-4850-bf16-58388a67ad33"
      unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i559db82cad364aea94a0a0919778a7f7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMi01LTEtMS00NjAxMw_9807834f-faf2-4b1c-90a2-5b487414e83b"
      unitRef="usd">647078000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4f9d007b877247ec802a3c602ee3687b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMi03LTEtMS00NjAxMw_0d9ec6f3-fd00-43a3-a0be-786ac1e86b2d"
      unitRef="usd">-460452000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i307df19e90fa4871af799b2b66ba2d31_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMi05LTEtMS00NjAxMw_4268d0e7-f542-4f46-b3d6-32781c23530c"
      unitRef="usd">20000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3c73d82cd653451cb3c69d920ab3d8aa_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMi0xMS0xLTEtNDYwMTM_1f910577-3b02-4df8-932f-d146b5f89369"
      unitRef="usd">186655000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i0c4c2b1d0a9e49ae81d18933f823dba9_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMy0xLTEtMS00NjAxMw_7716f464-9501-49ae-b0e4-2dc1f092c78c"
      unitRef="shares">169931</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i6ebe0866adef47559cdc2ed65973c005_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMy01LTEtMS00NjAxMw_bcaca06c-8549-4487-91fd-5e4e12cc0286"
      unitRef="usd">834000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMy0xMS0xLTEtNDYwMTM_e61f10e2-59c2-4417-b758-681b1d6e0ddf"
      unitRef="usd">834000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="i0c4c2b1d0a9e49ae81d18933f823dba9_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfNC0xLTEtMS00NjAxMw_97cc4189-45d8-4ab0-b88c-3e6393a7a312"
      unitRef="shares">42403</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="i6ebe0866adef47559cdc2ed65973c005_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfNC01LTEtMS00NjAxMw_58edda95-3bd0-4c59-b236-072c8cfbeb0f"
      unitRef="usd">310000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfNC0xMS0xLTEtNDYwMTM_003c4f24-95f2-42a5-abd9-cec2cbb72125"
      unitRef="usd">310000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i0c4c2b1d0a9e49ae81d18933f823dba9_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfNS0xLTEtMS00NjAxMw_b66f826e-0ea5-4ecb-b088-ae82b32a1c01"
      unitRef="shares">445942</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6ebe0866adef47559cdc2ed65973c005_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfNS01LTEtMS00NjAxMw_1893ce97-73db-4665-995c-22d1f00ee70b"
      unitRef="usd">1020000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfNS0xMS0xLTEtNDYwMTM_1b5986e1-a66c-4174-b777-3b630e3551fa"
      unitRef="usd">1020000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i0c4c2b1d0a9e49ae81d18933f823dba9_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfNi0xLTEtMS00NjAxMw_90f180b3-b503-49da-b7fb-60eb1d61f357"
      unitRef="shares">866528</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6ebe0866adef47559cdc2ed65973c005_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfNy01LTEtMS00NjAxMw_643df924-45c0-42a0-8825-44f8d5fc1fd2"
      unitRef="usd">10583000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfNy0xMS0xLTEtNDYwMTM_b083b674-e22f-4d96-a4a5-5f9ee37b9f90"
      unitRef="usd">10583000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i63b7a92a09e442b3b15016267ea44e4c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfOC05LTEtMS00NjAxMw_01095698-75af-4c81-b257-3979a96c2ff6"
      unitRef="usd">-24000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfOC0xMS0xLTEtNDYwMTM_0544ed1b-3fd4-491e-9542-2e030fd260ba"
      unitRef="usd">-24000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i0c4c2b1d0a9e49ae81d18933f823dba9_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfOS0xLTEtMS00NjAxMw_6c4abd02-7145-4896-bd10-ae06e89c358a"
      unitRef="shares">3257430</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i6ebe0866adef47559cdc2ed65973c005_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfOS01LTEtMS00NjAxMw_731be14d-cdb9-4bc7-8f40-5d49efbe9932"
      unitRef="usd">21047000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfOS0xMS0xLTEtNDYwMTM_35df095c-6f55-4a0c-bbfc-65b7727a6e17"
      unitRef="usd">21047000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="icad9ba2326db486c889dd50988c4fef1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTEtNy0xLTEtNDYwMTM_57ecb558-f6e6-4781-855f-cafb1ff3f8d2"
      unitRef="usd">-94313000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTEtMTEtMS0xLTQ2MDEz_67999f09-91e5-4e4c-b7d9-9de5b462f46d"
      unitRef="usd">-94313000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i2aa43c785509442dbd5e3673f8823fe4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTItMS0xLTEtNDYwMTM_d97bf1b6-9ff9-43d6-9577-e0f74a634fc3"
      unitRef="shares">93599975</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i2aa43c785509442dbd5e3673f8823fe4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTItMy0xLTEtNDYwMTM_0d1c4760-7dee-4ee2-ba8b-fe8f309ce49b"
      unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia5a3476a21d74624862c1503a0509e16_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTItNS0xLTEtNDYwMTM_f91080e4-59b5-4eed-84ea-eabe84125617"
      unitRef="usd">680872000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i34d8d1400f4a4785ac6e2406ff8e5935_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTItNy0xLTEtNDYwMTM_574fdee4-6815-4d6e-8b9f-4bd785cce168"
      unitRef="usd">-554765000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i271432361a3c43cf9ae96050134ef2c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTItOS0xLTEtNDYwMTM_b18ce75b-7353-473d-8024-e66b8a42562a"
      unitRef="usd">-4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if0fdfe563b2749f3ad36d74c30c121dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTItMTEtMS0xLTQ2MDEz_17043b71-2b9c-40c9-a236-e5ec806a2f75"
      unitRef="usd">126112000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="iaeaeaa4c910f4ab5acf339a4968d2a9d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTMtMS0xLTEtNDYwMTM_af39a14a-2d48-4e5a-b7c0-ec058c367fdf"
      unitRef="shares">386664</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="id6cbb5f1b5224d25910844cbece963f3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTMtNS0xLTEtNDYwMTM_3b4edaa7-d23f-480b-899d-0b10ebd0b5a9"
      unitRef="usd">819000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTMtMTEtMS0xLTQ2MDEz_8adbb648-8043-4b59-bc25-423e1a17962b"
      unitRef="usd">819000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="iaeaeaa4c910f4ab5acf339a4968d2a9d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTQtMS0xLTEtNDYwMTM_6b91517f-2c21-4ab8-a50e-76d2f2985fe5"
      unitRef="shares">25989</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="id6cbb5f1b5224d25910844cbece963f3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTQtNS0xLTEtNDYwMTM_ee741453-c354-41a1-8569-21f6f45c9ac1"
      unitRef="usd">190000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTQtMTEtMS0xLTQ2MDEz_9da56eac-2568-4720-af9a-eaad71d7af88"
      unitRef="usd">190000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iaeaeaa4c910f4ab5acf339a4968d2a9d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTUtMS0xLTEtNDYwMTM_664b39bf-b3c5-4551-871a-7a16d28a08c8"
      unitRef="shares">331310</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id6cbb5f1b5224d25910844cbece963f3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTUtNS0xLTEtNDYwMTM_a8da4b1e-44ef-49f8-b6f7-a03f9ffe9faf"
      unitRef="usd">584000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTUtMTEtMS0xLTQ2MDEz_8f5b4c33-d17c-48a9-92b3-935e9ad82ccf"
      unitRef="usd">584000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="iaeaeaa4c910f4ab5acf339a4968d2a9d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTYtMS0xLTEtNDYwMTM_2c63773f-793e-4312-9819-a59f669a171c"
      unitRef="shares">167158</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="id6cbb5f1b5224d25910844cbece963f3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTctNS0xLTEtNDYwMTM_943e38c1-4e18-4c2f-8e0e-5eefe92c1f92"
      unitRef="usd">106000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTctMTEtMS0xLTQ2MDEz_c7036c18-c6af-4468-b6ff-d5e5d4d8edb9"
      unitRef="usd">106000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="iaeaeaa4c910f4ab5acf339a4968d2a9d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTgtMS0xLTEtNDYwMTM_9c860f94-34b6-46e1-b698-55e63b4f81ac"
      unitRef="shares">35671439</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iaeaeaa4c910f4ab5acf339a4968d2a9d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTgtMy0xLTEtNDYwMTM_eb9ead52-9091-4c64-9905-cdd98a7128ec"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id6cbb5f1b5224d25910844cbece963f3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTgtNS0xLTEtNDYwMTM_29ddbff0-208a-4d17-bf22-11a3314d2189"
      unitRef="usd">101142000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTgtMTEtMS0xLTQ2MDEz_64e39a5e-8445-4b44-8f50-2aca93d7bc30"
      unitRef="usd">101146000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id6cbb5f1b5224d25910844cbece963f3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTktNS0xLTEtNDYwMTM_d8f5b481-94a0-45dd-9289-6c384540cd71"
      unitRef="usd">12039000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMTktMTEtMS0xLTQ2MDEz_66847140-6fd7-4da2-b54f-5c84b0ddc12e"
      unitRef="usd">12039000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i7488244a81d34508944e33dfd4bdc232_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjAtOS0xLTEtNDY0MDM_a917c3e7-78e5-435b-919f-e317bb79a298"
      unitRef="usd">-2000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjAtMTEtMS0xLTQ2NDAz_7dace226-5741-426c-bb8d-e529d6ab2b88"
      unitRef="usd">-2000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i7ca2f91dea984f5fa2da91bc632532c1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjAtNy0xLTEtNDYwMTM_f576fa79-7eca-40f6-bf93-47fbd228ab91"
      unitRef="usd">-158165000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjAtMTEtMS0xLTQ2MDEz_101a36bc-769e-4adb-890e-a34added8036"
      unitRef="usd">-158165000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="id70cd43225df4f8fbf5df3ec715b334c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjEtMS0xLTEtNDYwMTM_3b016bd0-ce18-4f69-b1d8-150f3564399b"
      unitRef="shares">130182535</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id70cd43225df4f8fbf5df3ec715b334c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjEtMy0xLTEtNDYwMTM_17bce5f4-f8ba-45b5-b8cd-bd32ecb2813c"
      unitRef="usd">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie5bd779bf4924020b0765a5cc69ceba5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjEtNS0xLTEtNDYwMTM_52a423a0-03e0-4ab7-9885-df458d2ac82d"
      unitRef="usd">795540000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3c1428f4633d41e7a98d5a585209403f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjEtNy0xLTEtNDYwMTM_1d50b92d-0b72-488f-bd4c-e366a1bad373"
      unitRef="usd">-712930000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7c90b227c4764ac7987b4eef73eeb87d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjEtOS0xLTEtNDYwMTM_51ef055f-2f9c-4a1c-84cb-2076db873a47"
      unitRef="usd">-6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjEtMTEtMS0xLTQ2MDEz_9bb11fbc-ec18-4223-b7b6-ba666c71072f"
      unitRef="usd">82617000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="if786310abbc54aba91f5e0a5b90b7706_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjItMS0xLTEtNDYwMTM_3be824f0-fe6e-4d98-8d24-bbdedc2528c4"
      unitRef="shares">308356</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ic403adc07fe947369c966ca335e3f7c0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjItNS0xLTEtNDYwMTM_b1ca8a34-8e3a-4333-b2b9-0e239b2457b6"
      unitRef="usd">195000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjItMTEtMS0xLTQ2MDEz_3aaf37ac-4352-4e5e-a063-139ff70d088c"
      unitRef="usd">195000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="if786310abbc54aba91f5e0a5b90b7706_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjMtMS0xLTEtNDYwMTM_73896aee-f187-4af0-81f9-a3bc0eeddf1e"
      unitRef="shares">711675</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="ic403adc07fe947369c966ca335e3f7c0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjMtNS0xLTEtNDYwMTM_1a7ce295-1adc-4933-9e5b-2270a4e2ffcb"
      unitRef="usd">390000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjMtMTEtMS0xLTQ2MDEz_ade21742-2727-4fd5-bc0b-f4ee5d7c6e68"
      unitRef="usd">390000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="if786310abbc54aba91f5e0a5b90b7706_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjQtMS0xLTEtNDYwMTM_321a998e-3cee-448a-a3e8-add261a8335b"
      unitRef="shares">14080</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic403adc07fe947369c966ca335e3f7c0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjQtNS0xLTEtNDYwMTM_f21b2aab-3ba9-4d74-b515-8d63d7a93967"
      unitRef="usd">7000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjQtMTEtMS0xLTQ2MDEz_5d12bdd1-af9c-4c97-b8f4-11a1738aa91e"
      unitRef="usd">7000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="if786310abbc54aba91f5e0a5b90b7706_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjUtMS0xLTEtNDYwMTM_d2ae6657-9c56-4e2b-8786-e2ffb6b765ee"
      unitRef="shares">3243828</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="if786310abbc54aba91f5e0a5b90b7706_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjctMS0xLTEtNDYwMTM_c4cfe0bd-98d8-4a99-86cd-7d368baf335e"
      unitRef="shares">64114542</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if786310abbc54aba91f5e0a5b90b7706_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjctMy0xLTEtNDYwMTM_68191ab3-bad1-4c8c-b5a1-a918ad96c7fc"
      unitRef="usd">7000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic403adc07fe947369c966ca335e3f7c0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjctNS0xLTEtNDYwMTM_21ab3751-821c-4efe-9bd7-e32b7ac65660"
      unitRef="usd">71618000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjctMTEtMS0xLTQ2MDEz_872f9262-d212-49a8-87da-2adc30e81b4d"
      unitRef="usd">71625000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic403adc07fe947369c966ca335e3f7c0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjgtNS0xLTEtNDYwMTM_81f7e92f-9b36-4b8a-ba1e-899af4a0755a"
      unitRef="usd">10750000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjgtMTEtMS0xLTQ2MDEz_a4b3019f-c6ca-4587-b27c-997dcbcef033"
      unitRef="usd">10750000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="id792a81211054c6a9da992ae71d61ce3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjktOS0xLTEtNDYwMTM_a45dc4e2-f64a-4a30-8c1f-0b91881d7be7"
      unitRef="usd">-48000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMjktMTEtMS0xLTQ2MDEz_4b5c3b11-d219-4915-95af-25b1809a82b7"
      unitRef="usd">-48000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i3e05fc9654fc4f24b753405c6aae07a3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMzAtNy0xLTEtNDYwMTM_9b7388cb-67c5-4793-ac26-244fcae83ce6"
      unitRef="usd">-67207000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMzAtMTEtMS0xLTQ2MDEz_d6d2cb76-0cf5-4656-b826-327be3e2b73b"
      unitRef="usd">-67207000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i21472ed42ab040bba0bdd50fdd86e0c6_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMzEtMS0xLTEtNDYwMTM_2f92bb7b-fa1f-4fd7-8ed4-15dd5ddda987"
      unitRef="shares">198575016</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i21472ed42ab040bba0bdd50fdd86e0c6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMzEtMy0xLTEtNDYwMTM_e95efb3e-669a-4113-9003-a50ca30d0728"
      unitRef="usd">20000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2954e41000084c28b87d9af1f3c00c87_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMzEtNS0xLTEtNDYwMTM_e73c4205-a7d8-4913-bc06-89eb38d2c33e"
      unitRef="usd">878500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i236484790d154382b9ab018143306fb9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMzEtNy0xLTEtNDYwMTM_3bb9a6a8-d303-4629-a345-9c89b2109cf0"
      unitRef="usd">-780137000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7a16bb549f604ba4b134dd1fc542e6e0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMzEtOS0xLTEtNDYwMTM_965a1593-ad4c-4649-a059-8ba7187c8b1d"
      unitRef="usd">-54000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85MS9mcmFnOjliN2Q1NWQ3NjQzMzQ3MDg5Y2U5ODY4MTdmNzY3NjBkL3RhYmxlOjRhZGEwMDg2ZGZkMDQ3ODM4NTZhOGEyMzkwZGU2YWFiL3RhYmxlcmFuZ2U6NGFkYTAwODZkZmQwNDc4Mzg1NmE4YTIzOTBkZTZhYWJfMzEtMTEtMS0xLTQ2MDEz_ae51781b-7abd-41f4-8d96-042e8228f48b"
      unitRef="usd">98329000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMi0xLTEtMS00NjAxMw_04792a72-215c-4717-a281-933737108048"
      unitRef="usd">-67207000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMi0zLTEtMS00NjAxMw_9311f2f5-70ed-4b32-98e5-a5694658af20"
      unitRef="usd">-158165000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMi01LTEtMS00NjAxMw_b45174cb-68b5-4e46-9fb2-db326c36476b"
      unitRef="usd">-94313000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfNC0xLTEtMS00NjAxMw_cc690e7e-4b60-4dcd-87c1-b50489cff672"
      unitRef="usd">1144000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfNC0zLTEtMS00NjAxMw_4bf84a72-18fb-4c1d-8e0b-b8c67ee58ddd"
      unitRef="usd">2807000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfNC01LTEtMS00NjAxMw_7d10f70a-7566-482f-b8b5-9eff1b2453d5"
      unitRef="usd">2541000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfOC0xLTEtMS00NjAxMw_dc42fd05-fcdd-47eb-9ef0-727f90bc32fb"
      unitRef="usd">3457000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfOC0zLTEtMS00NjAxMw_6a9bac31-96cd-405c-a482-a99faf93a443"
      unitRef="usd">3085000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfOC01LTEtMS00NjAxMw_e94c63b3-abcf-4352-a088-abeeebf21d46"
      unitRef="usd">2147000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfOS0xLTEtMS00NjAxMw_d698e3e3-df08-418a-abc8-81c8e09c075f"
      unitRef="usd">10750000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfOS0zLTEtMS00NjAxMw_fea01690-4d7c-4af6-9493-c149b2507e56"
      unitRef="usd">12039000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfOS01LTEtMS00NjAxMw_1b0c6bf2-a545-43f9-88f9-746415ea8f88"
      unitRef="usd">10583000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTAtMS0xLTEtNDYwMTM_e1fa4215-2a63-4fea-ad7a-4d1a3ffa097a"
      unitRef="usd">583000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTAtMy0xLTEtNDYwMTM_9db5e511-48a5-43f2-8968-341359a46a53"
      unitRef="usd">-678000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTAtNS0xLTEtNDYwMTM_f26fba9e-a368-4a4a-a704-0ba9642ac480"
      unitRef="usd">407000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:GainsLossesOnRestructuringOfDebt
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfOC0xLTEtMS00NjUyNg_51b9aeae-29b7-409a-b85f-0234161180e0"
      unitRef="usd">-102000</us-gaap:GainsLossesOnRestructuringOfDebt>
    <us-gaap:GainsLossesOnRestructuringOfDebt
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfOC0zLTEtMS00NjUyNg_9c7b7ea6-1cce-43be-80dd-b500ff3a2094"
      unitRef="usd">0</us-gaap:GainsLossesOnRestructuringOfDebt>
    <us-gaap:GainsLossesOnRestructuringOfDebt
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfOC01LTEtMS00NjUyNg_850104bb-67fb-414b-80fe-86ddeff76126"
      unitRef="usd">0</us-gaap:GainsLossesOnRestructuringOfDebt>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfOS0xLTEtMS00NjUyNg_a29277c4-2dfd-40c5-ba0a-09cd328aadb4"
      unitRef="usd">1260000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfOS0zLTEtMS00NjUyNg_165fa40a-df75-4adb-b38f-9ebfe5829678"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfOS01LTEtMS00NjUyNg_3c23cb96-34fb-4a8b-862a-c19b098eab47"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTEtMS0xLTEtNDYwMTM_48388a43-1427-4f28-b289-427c8fa25853"
      unitRef="usd">1962000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTEtMy0xLTEtNDYwMTM_249fed15-9986-4103-ab7c-4ff8cc060bed"
      unitRef="usd">283000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTEtNS0xLTEtNDYwMTM_3db0cefe-8145-4956-b2f8-111c285bd71f"
      unitRef="usd">413000</us-gaap:AmortizationOfDebtDiscountPremium>
    <ardx:IncreaseDecreaseInUnbilledRevenue
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTMtMS0xLTEtNDYwMTM_bf719279-fabb-46c8-93df-1445ffd468d7"
      unitRef="usd">0</ardx:IncreaseDecreaseInUnbilledRevenue>
    <ardx:IncreaseDecreaseInUnbilledRevenue
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTMtMy0xLTEtNDYwMTM_941c9738-b051-4d61-afce-be02f348a31e"
      unitRef="usd">0</ardx:IncreaseDecreaseInUnbilledRevenue>
    <ardx:IncreaseDecreaseInUnbilledRevenue
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTMtNS0xLTEtNDYwMTM_d7ae3a73-a519-480f-9a44-5a6e011313f9"
      unitRef="usd">-750000</ardx:IncreaseDecreaseInUnbilledRevenue>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTQtMS0xLTEtNDYwMTM_59ad8f00-52fa-4cc5-8878-dd1fce29a9eb"
      unitRef="usd">7231000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTQtMy0xLTEtNDYwMTM_7718705e-5e8b-42a1-8a69-cc59ef9bea60"
      unitRef="usd">502000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTQtNS0xLTEtNDYwMTM_d53edba1-b6eb-44ed-8cbc-9db2dd6cfa77"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTQtMS0xLTEtNDY1NDQ_473e1cbc-c98c-4c91-97f1-dc15e1b495dc"
      unitRef="usd">28346000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTQtMy0xLTEtNDY1NDQ_330f3250-6617-4a34-9593-2f2b2b2ec614"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTQtNS0xLTEtNDY1NDQ_280ca846-3136-4955-8f07-2f92816c1cb8"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInInventories>
    <ardx:IncreaseDecreaseInPrepaidCommercialManufacturingExpense
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTUtMS0xLTEtNDY1NDQ_4a87605c-bb80-45b8-8d9a-e52796f93700"
      unitRef="usd">4161000</ardx:IncreaseDecreaseInPrepaidCommercialManufacturingExpense>
    <ardx:IncreaseDecreaseInPrepaidCommercialManufacturingExpense
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTUtMy0xLTEtNDY1NDQ_cb7fa451-4639-4546-8663-80799b0f2910"
      unitRef="usd">9406000</ardx:IncreaseDecreaseInPrepaidCommercialManufacturingExpense>
    <ardx:IncreaseDecreaseInPrepaidCommercialManufacturingExpense
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTUtNS0xLTEtNDY1NDQ_80900117-a811-4496-887e-460ddf7f271e"
      unitRef="usd">0</ardx:IncreaseDecreaseInPrepaidCommercialManufacturingExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTUtMS0xLTEtNDYwMTM_81d71ca3-0860-4d5f-a623-b2a78ad81ce4"
      unitRef="usd">-2299000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTUtMy0xLTEtNDYwMTM_8f742b17-da5a-4531-979b-b7f1c305d163"
      unitRef="usd">-502000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTUtNS0xLTEtNDYwMTM_e674962b-a4fc-43d2-affa-c26bc6635361"
      unitRef="usd">4653000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTYtMS0xLTEtNDYwMTM_ef76f930-e2e6-49c0-90cd-b5722c8ab482"
      unitRef="usd">6582000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTYtMy0xLTEtNDYwMTM_ad40a7bc-b55c-43b8-b89f-15e326d3a354"
      unitRef="usd">-1349000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTYtNS0xLTEtNDYwMTM_1f25a241-c678-45d1-8c51-e34f263da690"
      unitRef="usd">3439000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTctMS0xLTEtNDYwMTM_9ce5cd21-4155-4953-bc39-6748b02c1d88"
      unitRef="usd">2126000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTctMy0xLTEtNDYwMTM_99b4c0ca-f872-410e-ba2f-cfd55e440760"
      unitRef="usd">-250000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTctNS0xLTEtNDYwMTM_634274e5-9d36-493a-b393-148a4cca6c8b"
      unitRef="usd">1219000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTgtMS0xLTEtNDYwMTM_c0fd1a2c-df63-4f92-ab44-bc2e7de35edb"
      unitRef="usd">-3491000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTgtMy0xLTEtNDYwMTM_fbae1590-77bc-418a-aa8a-3ffda62d9eae"
      unitRef="usd">-2853000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTgtNS0xLTEtNDYwMTM_4b41375c-c8f2-43a4-a504-ce869fd56009"
      unitRef="usd">-2604000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTktMS0xLTEtNDYwMTM_fa546e1b-3230-46cb-a539-db35fa1061f9"
      unitRef="usd">4138000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTktMy0xLTEtNDYwMTM_93ccd218-312f-42a0-8255-9fcf29e91542"
      unitRef="usd">1386000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMTktNS0xLTEtNDYwMTM_0820f7cd-10ab-4f0a-a308-9c1f8362e868"
      unitRef="usd">-1000000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMjAtMS0xLTEtNDYwMTM_c9d3a7b9-c2ec-4ebd-9f69-3bd3dcee6e06"
      unitRef="usd">8509000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMjAtMy0xLTEtNDYwMTM_f2e47509-3853-4907-bc5a-e4b60a9bff09"
      unitRef="usd">550000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMjAtNS0xLTEtNDYwMTM_374a5296-776a-4c5d-aff5-4aeceb18e5eb"
      unitRef="usd">-364000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMjEtMS0xLTEtNDYwMTM_9fc2f5cb-eae6-439d-a216-7e80a2cbcebf"
      unitRef="usd">-70044000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMjEtMy0xLTEtNDYwMTM_07b2c3ad-fba7-4c0d-84de-15a3dc3151d4"
      unitRef="usd">-152551000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMjEtNS0xLTEtNDYwMTM_6a9b13a4-86d1-427e-b83b-6e4d086f665e"
      unitRef="usd">-81435000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMjMtMS0xLTEtNDYwMTM_96562ec3-d33b-4f01-9205-83033ebb1490"
      unitRef="usd">67000000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMjMtMy0xLTEtNDYwMTM_c2b01f0e-1507-44c3-94bd-c7ddc7d61a0f"
      unitRef="usd">125550000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMjMtNS0xLTEtNDYwMTM_b9d9b02e-e4cb-4f8b-b664-dee6d185c2f5"
      unitRef="usd">119734000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMjQtMS0xLTEtNDYwMTM_422c9009-2ee4-4f29-a2d0-5f857fd1f22e"
      unitRef="usd">50328000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMjQtMy0xLTEtNDYwMTM_b547d6c2-2084-40ce-8008-d64af48840b5"
      unitRef="usd">72735000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMjQtNS0xLTEtNDYwMTM_bb380152-e985-4fb6-a8a9-4cca0a2f929c"
      unitRef="usd">150852000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMjYtMS0xLTEtNDY1NjQ_027cd806-e7ab-4cd6-b314-c3309108f6b7"
      unitRef="usd">1798000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMjYtMy0xLTEtNDY1NjQ_d4ed27e6-5a3f-4e82-b824-23a02cf3451e"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMjYtNS0xLTEtNDY1NjQ_aeea019d-1165-4d2d-bcc8-8de6d35c4d05"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMjUtMS0xLTEtNDYwMTM_26f9ec35-4579-446a-988f-3386ee6c7817"
      unitRef="usd">55000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMjUtMy0xLTEtNDYwMTM_bf59ed11-266b-4dc3-b6d9-ab1e3ab9b657"
      unitRef="usd">1867000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMjUtNS0xLTEtNDYwMTM_0134fd99-8d19-4041-9a73-b8da4839512b"
      unitRef="usd">324000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMjYtMS0xLTEtNDYwMTM_0e8b3247-5ce6-43fe-b0f0-0ac01aec4627"
      unitRef="usd">18415000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMjYtMy0xLTEtNDYwMTM_cee5d14e-597e-48f1-afca-5ca9dd732aa9"
      unitRef="usd">50948000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMjYtNS0xLTEtNDYwMTM_157d5916-462f-415c-a331-9d45819e299b"
      unitRef="usd">-31442000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzAtMS0xLTEtNDY1OTU_f6fb0d8b-46b5-400d-a6a8-91d10d2e9197"
      unitRef="usd">26971000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzAtMy0xLTEtNDY1OTU_18786124-8923-4bcf-a834-5cb18cdcade2"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzAtNS0xLTEtNDY1OTU_dcccce43-8602-4f81-ab3c-cdee7fd0c0eb"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:RepaymentsOfSecuredDebt
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzEtMS0xLTEtNDY1NzQ_d1fdb94d-5c52-49ba-94c8-27f8f1715152"
      unitRef="usd">33038000</us-gaap:RepaymentsOfSecuredDebt>
    <us-gaap:RepaymentsOfSecuredDebt
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzEtMy0xLTEtNDY1NzQ_50381316-2f62-43d3-9096-1e84a958fabb"
      unitRef="usd">19444000</us-gaap:RepaymentsOfSecuredDebt>
    <us-gaap:RepaymentsOfSecuredDebt
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzEtNS0xLTEtNDY1NzQ_af2e843d-5649-4006-a704-42aec463c9d5"
      unitRef="usd">125000</us-gaap:RepaymentsOfSecuredDebt>
    <ardx:ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzItMS0xLTEtNDY2MTA_3da08441-b106-43ac-809a-31244a4312aa"
      unitRef="usd">9581000</ardx:ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts>
    <ardx:ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzItMy0xLTEtNDY2MTA_cba05705-cca3-4141-9d2e-074a0e6ef926"
      unitRef="usd">0</ardx:ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts>
    <ardx:ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzItNS0xLTEtNDY2MTA_dfed75eb-b76e-4813-916c-728e6349b21a"
      unitRef="usd">0</ardx:ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzAtMS0xLTEtNDYwMTM_3a420ecb-69ad-456c-b101-97d5be98b7af"
      unitRef="usd">71625000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzAtMy0xLTEtNDYwMTM_20a6b3b8-2e9b-4bb7-99d2-c1dd5d826093"
      unitRef="usd">101146000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzAtNS0xLTEtNDYwMTM_b7ac8591-105c-4c5a-b5db-28c0596c9fd7"
      unitRef="usd">21047000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzEtMS0xLTEtNDYwMTM_586a0e57-9d15-4d67-9fa8-2bf45e464ef0"
      unitRef="usd">202000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzEtMy0xLTEtNDYwMTM_36805d03-3f18-41a5-9658-ad3b10c20f64"
      unitRef="usd">1403000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzEtNS0xLTEtNDYwMTM_b2fef871-3678-428e-b8c0-c28814398653"
      unitRef="usd">1854000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzQtMS0xLTEtNDY0NDg_9bebf0e4-f1a3-4ac9-91e0-78baac6a74f0"
      unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzQtMy0xLTEtNDY0NDg_b00ef075-5676-4d95-b96e-88b63d91b052"
      unitRef="usd">106000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzQtNS0xLTEtNDY0NDg_0488a7f9-020e-44e6-9d8b-19295e03ec09"
      unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzUtMS0xLTEtNDYwMTM_d1e16111-3e21-4b32-b766-bdc47b917295"
      unitRef="usd">75341000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzUtMy0xLTEtNDYwMTM_dcd094d1-fd05-4406-a51e-bc2022b687cc"
      unitRef="usd">82999000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzUtNS0xLTEtNDYwMTM_2ee3ff29-c9ba-4043-8285-2aa70ba10156"
      unitRef="usd">22776000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzYtMS0xLTEtNDYwMTM_7e879894-ae10-4143-8997-4c53b76bd27e"
      unitRef="usd">23712000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzYtMy0xLTEtNDYwMTM_eeb5c331-9d19-40aa-89aa-62319c1c529e"
      unitRef="usd">-18604000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzYtNS0xLTEtNDYwMTM_357de69e-47cf-4885-83da-923b142b5021"
      unitRef="usd">-90101000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzctMS0xLTEtNDYwMTM_e28e0a51-2c9e-4974-9439-cbfe6e9e28cb"
      unitRef="usd">72428000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if0fdfe563b2749f3ad36d74c30c121dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzctMy0xLTEtNDYwMTM_a470bead-9e3f-43f9-b58d-56787a9f7d5a"
      unitRef="usd">91032000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3c73d82cd653451cb3c69d920ab3d8aa_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzctNS0xLTEtNDYwMTM_b40841ec-eee1-43fe-98d2-0905581d722a"
      unitRef="usd">181133000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzgtMS0xLTEtNDYwMTM_362b79c9-8db7-4b4e-837c-7a3245ee035d"
      unitRef="usd">96140000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzgtMy0xLTEtNDYwMTM_3a8da1cb-bca2-49e7-9554-215cc670fc05"
      unitRef="usd">72428000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if0fdfe563b2749f3ad36d74c30c121dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfMzgtNS0xLTEtNDYwMTM_e541ec53-2d6b-4e2a-8583-3c26f9a58320"
      unitRef="usd">91032000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfNDAtMS0xLTEtNDYwMTM_1916af19-c77f-41fb-9b22-7a261106a028"
      unitRef="usd">2901000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfNDAtMy0xLTEtNDYwMTM_5cde9fe9-45a7-4c98-b124-3436d5a16d6a"
      unitRef="usd">3469000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfNDAtNS0xLTEtNDYwMTM_2f512cf7-f53f-47fb-899a-267eeebbce8b"
      unitRef="usd">4200000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfNDEtMS0xLTEtNDYwMTM_a26e2123-53ef-4eb1-a236-ca011609bbaa"
      unitRef="usd">6000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfNDEtMy0xLTEtNDYwMTM_ac0d15d7-6587-4230-8210-6b25b46edd99"
      unitRef="usd">4000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfNDEtNS0xLTEtNDYwMTM_9751abdf-2130-4fb5-8931-f6c067204cd3"
      unitRef="usd">1000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfNDMtMS0xLTEtNDYwMTM_36f6217a-3062-4cc7-9cd2-317571aa19e8"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfNDMtMy0xLTEtNDYwMTM_53a65dc7-4e7f-4723-a055-827cbb9ee972"
      unitRef="usd">1604000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfNDMtNS0xLTEtNDYwMTM_fdcefd68-7d70-45a4-a447-2387372d3384"
      unitRef="usd">450000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:StockIssued1
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfNDQtMS0xLTEtNDYwMTM_337f5538-70bc-4e18-9b51-c81d57320a5e"
      unitRef="usd">390000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfNDQtMy0xLTEtNDYwMTM_40de8d0b-046b-4e1e-960d-509aeae5eb25"
      unitRef="usd">190000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfNDQtNS0xLTEtNDYwMTM_def833e0-a25f-43b3-9365-3959c56f6414"
      unitRef="usd">310000</us-gaap:StockIssued1>
    <ardx:DerivativeIssued
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfNDgtMS0xLTEtNDY2NDE_7e37e217-dabf-45e6-b583-364a65746267"
      unitRef="usd">375000</ardx:DerivativeIssued>
    <ardx:DerivativeIssued
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfNDgtMy0xLTEtNDY2NDE_28ef5a7c-36aa-4b05-aeb5-763beeefc96a"
      unitRef="usd">0</ardx:DerivativeIssued>
    <ardx:DerivativeIssued
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl85NC9mcmFnOjdjMWU1NTA4NmMwYTQzZjc5NWMwM2VjZTA2Mzk5MDM0L3RhYmxlOjczODFiZjcxMDc1YTRkZjZhNTdlODk1MjZmNjI3NzZlL3RhYmxlcmFuZ2U6NzM4MWJmNzEwNzVhNGRmNmE1N2U4OTUyNmY2Mjc3NmVfNDgtNS0xLTEtNDY2NDE_2cd005b9-93cd-4690-8eb5-7ccba446e668"
      unitRef="usd">0</ardx:DerivativeIssued>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDAvZnJhZzplMjE5NzRhNTgwMTk0NzZiYTI1MzIxZmJiYjBjYTdjOS90ZXh0cmVnaW9uOmUyMTk3NGE1ODAxOTQ3NmJhMjUzMjFmYmJiMGNhN2M5XzcwNg_0ee615a4-80aa-4b28-9cd6-45f0525f0334">ORGANIZATION AND BASIS OF PRESENTATION&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ardelyx, Inc. (&#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; or &#x201c;our&#x201d;) is a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs. We developed a unique and innovative platform that enabled the discovery of new biological mechanisms and pathways to develop potent, and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The first molecule we discovered and developed was tenapanor, a targeted, first-in-class, oral, small molecule therapy. Tenapanor, branded as IBSRELA, is approved in the U.S. for the treatment of adults with irritable bowel syndrome with constipation (&#x201c;IBS-C&#x201d;). Tenapanor is in development for the control of serum phosphorus in adult patients with chronic kidney disease (&#x201c;CKD&#x201d;) on dialysis under the brand name XPHOZAH. We also have a development stage asset, RDX013 for adult patients with CKD and/or heart failure with hyperkalemia, or elevated serum potassium, and a discovery phase asset, RDX020 for adult patients with metabolic acidosis, a serious electrolyte disorder, in patients with CKD.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate in one business segment, which is the development and commercialization of biopharmaceutical products.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDAvZnJhZzplMjE5NzRhNTgwMTk0NzZiYTI1MzIxZmJiYjBjYTdjOS90ZXh0cmVnaW9uOmUyMTk3NGE1ODAxOTQ3NmJhMjUzMjFmYmJiMGNhN2M5XzYwMA_dec8cebc-07af-4de9-8080-d756c27b08b7"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzMxOTA2_84ab844c-8ff5-4864-99da-7d418cb8c707">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the amounts reported in the financial statements and accompanying notes thereto. On an ongoing basis, management evaluates its estimates, including those related to recognition of revenue, clinical trial accruals, contract manufacturing accruals, fair value of assets and liabilities, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could materially differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, we had cash and short-term investments of approximately $123.9 million. We have incurred operating losses since inception in 2007 and our accumulated deficit as of December&#160;31, 2022 is $780.1&#160;million. Our current level of cash and short-term investments alone is not sufficient to meet our plans for the next twelve months following the issuance of these financial statements on March&#160;2, 2023. These factors raise substantial doubt regarding our ability to continue as a going concern for a period of one year from the issuance of these financial statements. We plan to address our operating cash flow requirements with our current cash and short-term investments, cash generated from product sales of IBSRELA, and if approved, cash generated from sales of XPHOZAH, our potential receipt of anticipated milestones payments from our collaboration partners, our potential receipt of anticipated payments from our Japanese collaboration partner under the second amendment to our License Agreement, with additional financing sources and through the implementation of cash preservation activities to reduce or defer discretionary spending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are no assurances that our efforts to meet our operating cash flow requirements will be successful. If our current cash and short-term investments as well as our plans to meet our operating cash flow requirements are not sufficient to fund necessary expenditures and meet our obligations for at least the next twelve months following the issuance of these financial statements, our liquidity, financial condition and business prospects will be materially affected. These financial statements have been prepared on a going concern basis and do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary in the event that we can no longer continue as a going concern. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid investments purchased with an original maturity date of 90 days or less on the date of purchase to be cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Short-Term Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term investments consist of debt securities classified as available-for-sale and have maturities greater than 90&#160;days, but less than one&#160;year, from the date of acquisition. Short-term investments are carried at fair value based upon quoted market prices. Unrealized gains and losses on available-for-sale securities are included in accumulated other comprehensive loss on our balance sheets. The cost of available-for-sale securities sold is based on the specific-identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents, short-term investments and accounts receivable. We are exposed to credit risks in the event of default by the counterparties to the extent of the amount recorded in its balance sheet. Cash, cash equivalents and short-term investments are invested through banks and other financial institutions in the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We manage our foreign currency exposures with the use of foreign currency purchases. We primarily conduct business in U.S. dollars; however, a portion of our expense and capital activities are transacted in foreign currencies which are subject to exchange rate fluctuations that can affect cash or earnings. We have been in a loss position and therefore our primary objective is to conserve and manage cash. There are generally two methods by which we may manage the cash flow risk of foreign exchange fluctuations when a contract is signed (i) we can purchase the foreign funds, in full or in part, upon the execution of the contract, or (ii) we can obtain the right to purchase such funds, in full or in part, at the execution of the contract, i.e., obtain a forward contract from an appropriate bank, that can be exercised to obtain the currency of interest at a particular point in time. The derivative instruments that we may use to hedge the exposure shall generally not be designated as cash flow hedges, and as a result, changes in their fair value would be recorded in other income (expense), net, in our statements of operations and comprehensive loss. The fair values of forward foreign currency exchange contracts would be estimated using current exchange rates and interest rates and the current creditworthiness of the counterparties is taken into consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets, with ranges generally from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzY3Mzg_4835439c-76eb-4d2f-801e-529f6574b0d2"&gt;three&lt;/span&gt; to five years. Leasehold improvements are amortized over the lesser of the estimated useful lives or the related remaining lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of long-lived assets, including property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the asset may not be recoverable. An impairment loss is recognized when the total of estimated future undiscounted cash flows, expected to result from the use of the asset and its eventual disposition, are less than the asset&#x2019;s carrying amount. Impairment, if any, would be assessed using discounted cash flows or other appropriate measures of fair value. For the years ending December&#160;31, 2022, 2021 and 2020 we have recognized no impairment losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable is reported net of allowances for returns, chargebacks and contractual off-invoice and prompt-pay discounts offered to our customers. Our estimate of the allowance for doubtful accounts is based on an evaluation of the aging of our receivables. Trade receivable balances are written off against the allowance when it is probable that the receivable will not be collected. To date, we have determined that an allowance for doubtful accounts is not required. As of December&#160;31, 2022 our accounts receivable balance was comprised of $0.7&#160;million from our collaboration agreements and $7.0&#160;million from commercial customers. As of December&#160;31, 2021 our accounts receivable balance was comprised of $0.5&#160;million from our collaborators.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We capitalize inventory costs associated with the production of our products after regulatory approval or when, based on management&#x2019;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Otherwise, such costs are expensed as research and development. Prior to the regulatory approval of drug product candidates, we incurred expenses for the manufacture of drug product that could potentially be available to support the commercial launch of our products or could be sold to our international partners under product supply agreements. We began to capitalize inventory costs associated with IBSRELA during the fourth quarter of 2021, when our intent to commercialize IBSRELA was established and we commenced preparation for the commercial launch of IBSRELA, which was when it was determined that the inventory had a probable future economic benefit.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory is stated at the lower of cost or estimated net realizable value with cost determined under the first-in first-out method. Inventory costs include the cost of materials, third-party contract manufacturing, third-party packaging services, freight, labor costs for personnel involved in the manufacturing process, and indirect overhead costs. We primarily use actual costs to determine the cost basis for inventory. The determination of whether inventory costs will be realizable requires management review of the expiration dates of IBSRELA compared to our forecasted sales. If actual market conditions are less favorable than projected by management, write-downs of inventory may be required, which would be recorded as cost of revenue in the statement of operations and comprehensive loss. As of December&#160;31, 2022, we have not recorded any write-offs for excess and obsolete inventory. A portion of inventory that represents product that is not expected to be sold or used within the next 12 months is classified as non-current on our balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Sales, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for our commercial product sales, net in accordance with Topic 606 - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We received approval from the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) in September 2019 to market IBSRELA in the U.S.. We began selling IBSRELA in the U.S. in March 2022. We distribute IBSRELA principally through major wholesalers, specialty pharmacies and group purchasing organizations ("GPOs") (collectively, our "Customers"). Our Customers subsequently sell IBSRELA to pharmacies and patients. Separately, we enter into arrangements with third parties that provide for government-mandated rebates, chargebacks and discounts. Revenue from product sales is recognized when our performance obligations are satisfied, which is when Customers obtain control of our product and occurs upon delivery.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reserves for Variable Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration which may be settled in the form of off-invoice discounts, chargebacks, or rebates. Variable consideration includes discounts to customers and government programs, wholesaler fees, group purchasing organization administrative fees, patient copay assistance programs, and estimated product returns. These estimates are based on the amounts earned or to be claimed for related sales and are classified as reductions of gross accounts receivable if settlement is expected to occur through a reduction in the amounts paid by our customers or a current liability if settlement is expected to occur through a payment from us. Where appropriate, these estimates are based on factors such as industry data and forecasted customer buying and payment patterns, our experience, current contractual and statutory requirements, specific known market events and trends. These reductions to gross sales reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. Variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we adjust these estimates, which would affect product revenue and earnings in the period such variances become known. As we gain more experience, estimates will be more heavily based on the expected utilization from historical data we have accumulated since the IBSRELA product launch.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rebates: Rebates include wholesaler fees, GPO fees, as well as mandated discounts under the Medicaid Drug Rebate Program ("Medicaid") and the Medicare Coverage Gap Program ("Medicare"). Estimates for rebates are recorded in the same period the related gross revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses on the balance sheets. We estimate our Medicaid and Medicare rebates based upon the estimated payor mix, and statutory discount rates. Our estimates for payor mix are guided by payor information received from specialty pharmacies, expected utilization for wholesaler sales to pharmacies, and available industry payor information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chargebacks: Chargebacks are discounts that occur when certain contracted purchasers purchase directly from our wholesalers at a discounted price. The wholesaler, in turn, charges back the difference between the price initially paid to us by the wholesaler and the discounted price paid to the wholesaler by the contracted purchaser. Amounts for estimated chargebacks are established in the same period that the related gross revenue is recognized, resulting in a reduction of product revenue and accounts receivable. The accrual for wholesaler chargebacks is estimated based on known chargeback rates, known sales to wholesalers, and estimated utilization by types of contracted purchasers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discounts and Fees: Our payment terms are generally 30 to 60 days. Wholesalers, GPOs and specialty pharmacies are offered various forms of consideration, including off-invoice discounts which may be paid to GPOs and specialty pharmacies. Wholesalers and GPOs may also receive prompt pay discounts for payment within a specified period. We expect discounts to be earned when offered and therefore, we deduct the full amount of these discounts from product sales when revenue is recognized, resulting in a reduction of product revenue and accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Reserves: Patients who have commercial insurance may receive copay assistance when product is dispensed by pharmacies to patients. We estimate the amount of copay assistance provided to eligible patients based on the terms of the program and redemption information provided by third-party claims processing organizations and are recorded in accounts payable and accrued expenses and other current liabilities on the balance sheets. Other reserves include estimated product returns which are recorded in the same period the related gross revenue is recognized, resulting in a reduction of product revenue as well as accounts receivable. We estimate our product returns reserve based upon our experience, and specific known market events and trends. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generate collaboration revenue primarily from research and collaboration and license agreements with customers. Goods and services in the agreements may include the grant of licenses for the use of our technology,&#160;the provision of services associated with the research and development of product candidates, manufacturing services, and participation in joint steering committees. The terms of these arrangements typically include payment to us of one or more of the following: non-refundable, up-front license fees; research, development, regulatory and commercial milestone payments; reimbursement of research and development services; option payments; reimbursement of certain costs; payments for manufacturing supply services; and future royalties on net sales of licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When two or more contracts are entered into with the same customer at or near the same time, we evaluate the contracts to determine whether the contracts should be accounted for as a single arrangement. Contracts are combined and accounted for as a single arrangement if one or more of the following criteria are met: (i) the contracts are negotiated as a package with a single commercial objective; (ii) the amount of consideration to be paid in one contract depends on the price or performance of the other contract; or (iii) the goods or services promised in the contracts (or some goods or services promised in each of the contracts) are a single performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under each of our agreements, management performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including any constraints on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) we satisfy each performance obligation. As part of the accounting for contracts with customers, we develop assumptions that require judgment to determine whether promised goods and services represent distinct performance obligations and the standalone selling price for each performance obligation identified in the contract. This evaluation is subjective and requires us to make judgments about the promised goods and services and whether those goods and services are separable from other aspects of the contract. Further, determining the standalone selling price for performance obligations requires significant judgment, and when an observable price of a promised good or service is not readily available, we consider relevant assumptions to estimate the standalone selling price, including, as applicable, market conditions, development timelines, probabilities of technical and regulatory success, reimbursement rates for personnel costs, forecasted revenues, potential limitations to the selling price of the product and discount rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We apply judgment in determining whether a combined performance obligation is satisfied at a point in time or over time, and, if over time, concluding upon the appropriate method of measuring progress to be applied for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, as estimates related to the measure of progress change, related revenue recognition is adjusted accordingly. Changes in our estimated measure of progress are accounted for prospectively as a change in accounting estimate. We recognize collaboration revenue by measuring the progress toward complete satisfaction of the performance obligation using an input measure. In order to recognize revenue over the research and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;development period, we measure actual costs incurred to date compared to the overall total expected costs to satisfy the performance obligation. Revenues are recognized as the program costs are incurred. We will re-evaluate the estimate of expected costs to satisfy the performance obligation each reporting period and make adjustments for any significant changes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts received prior to satisfying the revenue recognition criteria are recorded as contract liabilities in our Balance Sheets. If the related performance obligation is expected to be satisfied within the next twelve months it will be classified in current liabilities. Amounts recognized as revenue prior to receipt are recorded as contract assets in our Balance Sheets. If we expect to have an unconditional right to receive the consideration in the next twelve months, it will be classified in current assets. A net contract asset or liability is presented for each contract with a customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved. Milestone payments that are not within our control or the control of the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achievement of such development milestones and any related constraints, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Manufacturing supply services:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Arrangements that include a promise for future supply of drug substance or drug product for either clinical development or commercial supply at the customer&#x2019;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. If we are entitled to additional payments when the customer exercises these options, any payments are recorded in product supply revenue when the customer obtains control of the goods, which is upon delivery.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and where the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, royalty revenue resulting from licensing arrangements has not been material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses of intellectual property:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; If a license granted to a customer to use our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from consideration allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we apply judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, to conclude upon the appropriate method of measuring progress for purposes of recognizing revenue related to consideration allocated to the performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Options:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Customer options, such as options granted to allow a licensee to choose to research, develop and commercialize licensed compounds are evaluated at contract inception in order to determine whether those options provide a material right (i.e., an optional good or service offered for free or at a discount) to the customer. If the customer options represent a material right, the material right is treated as a separate performance obligation at the outset of the arrangement. We allocate the transaction price to material rights based on the standalone selling price, and revenue is recognized when or as the future goods or services are transferred or when the option expires. Customer options that are not material rights do not give rise to a separate performance obligation, and as such, the additional consideration that would result from a customer exercising an option in the future is not included in the transaction price for the current contract. Instead, the option is deemed a marketing offer, and additional option fee payments are recognized or being recognized as revenue when the licensee exercises the option. The exercise of an option that does not represent a material right is treated as a separate contract for accounting purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract modifications:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Contract modifications, defined as changes in the scope or price (or both) of a contract that are approved by the parties to the contract, such as a contract amendment, exist when the parties to a contract approve a modification that either creates new or changes existing enforceable rights and obligations of the parties to the contract. Depending on facts and circumstances, we account for a contract modification as one of the following: (i) a separate contract; (ii) a termination of the existing contract and a creation of a new contract; or (iii) a combination of the preceding treatments. A contract modification is accounted for as a separate contract if the scope of the contract increases because of the addition of promised goods or services that are distinct and the price of the contract increases by an amount of consideration that reflects &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;our standalone selling prices of the additional promised goods or services. When a contract modification is not considered a separate contract and the remaining goods or services are distinct from the goods or services transferred on or before the date of the contract modification, we account for the contract modification as a termination of the existing contract and a creation of a new contract. When a contract modification is not considered a separate contract and the remaining goods or services are not distinct, we account for the contract modification as an add-on to the existing contract and as an adjustment to revenue on a cumulative catch-up basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We receive payments from our licensees as established in each contract. Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until we perform our obligations under these arrangements. Where applicable, amounts are recorded as accounts receivable or unbilled revenue when our right to consideration is unconditional. We do not assess whether a contract with a customer has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of revenue consists of the cost of commercial goods sold to our Customers and international partners under product supply agreements as well as royalty expense based on sales of tenapanor. We capitalize inventory costs associated with the production of our products after regulatory approval or when, based on management&#x2019;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Otherwise, such costs are expensed as research and development. A portion of the costs of IBSRELA units recognized as revenue during the twelve months ended December&#160;31, 2022 were expensed prior to the fourth quarter of 2021, at which time our intent to commercialize IBSRELA was established and we commenced preparation for the commercial launch of IBSRELA. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of revenue includes payments due to AstraZeneca, which under the terms of a termination agreement entered into in 2015 ("AZ Termination Agreement") is entitled to (i) future royalties at a rate of 10% of net sales of tenapanor or other NHE3 products by us or our licensees, and (ii) 20% of non-royalty revenue received from our collaboration partners as a result of the development and commercialization of tenapanor or certain other NHE3 inhibitors.&#160;We have agreed to pay&#160;AstraZeneca up to a maximum of $75.0 million in the aggregate for (i) and (ii). We recognize these expenses as cost of revenue when we recognize the corresponding revenue that gives rise to payments due to AstraZeneca. To date, we have recognized an aggregate of $15.3 million as cost of revenue under the AZ Termination Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are charged to expense as incurred and consisted of costs incurred to further our research and development activities and include salaries and related employee benefits, costs associated with clinical trials, costs related to pre-commercialization manufacturing activities such as manufacturing process validation activities and the manufacturing of clinical drug supply, nonclinical research and development activities, regulatory activities, research-related overhead expenses and fees paid to external service providers and contract research and manufacturing organizations that conduct certain research and development activities on our behalf.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are required to estimate our accrued expenses at the end of each reporting period. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual costs. The majority of our service providers submit invoices in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with our service providers and make adjustments if necessary. Examples of estimated accrued research and development expenses include fees paid to:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;contract research organizations ("CROs") in connection with clinical studies;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;investigative sites in connection with clinical studies;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;vendors related to product manufacturing, development and distribution of clinical supplies; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;vendors in connection with preclinical development activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record expenses related to clinical studies and manufacturing development activities based on our estimates of the services received and efforts expended pursuant to contracts with multiple CROs and manufacturing vendors that conduct and manage these activities on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these contracts depend on factors such as the successful enrollment of subjects and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed, enrollment of subjects, number of sites activated and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we will adjust the accrued or prepaid expense balance accordingly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize compensation expense for all stock-based payment awards made to employees, non-employees and directors based on estimated fair values. For employee and non-employee stock options, we determine the grant date fair value of the awards using the Black-Scholes option-pricing model and generally recognize the fair value as stock-based compensation expense on a straight-line basis over the vesting period of the respective awards. For restricted stock and performance-based restricted stock, to the extent they are probable, the compensation cost for these awards is based on the closing price of our common stock on the date of grant and recognized as compensation expense on a straight-line basis over the requisite service period. Stock-based compensation expense is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. As such, our stock-based compensation is reduced for the estimated forfeitures at the date of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivatives and Hedging Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for our derivative instruments as either assets or liabilities on the balance sheet and measure them at fair value. Derivatives are adjusted to fair value through other income (expense), net in the statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Non-cash Interest Expense on Deferred Royalty Obligation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net proceeds we receive from the sale of certain future royalties are recorded as deferred royalty obligation related to the sale of future royalties on our balance sheets. As we earn royalties and remit those royalties pursuant to the agreement, the balance of the deferred royalty obligation will be effectively repaid over the life of agreement and non-cash interest expense related to the sale of future royalties is recorded using the effective interest method. To determine the amortization of our deferred royalty obligation, we are required to estimate the total amount of future royalty payments we expect to earn. There are a number of factors that could materially affect the amount and timing of royalty payments, most of which are not within our control. We periodically assess the amount of royalty payments we expect to receive which are subject to the agreement and, to the extent that the amount or timing of such payments is materially different than our original estimates, we prospectively adjust the imputed interest rate and the related amortization of the deferred royalty obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine if an arrangement is a lease at the inception of the arrangement. Operating leases are included in right-of-use assets, current portion of operating lease liability, and operating lease liability, net of current portion in our balance sheets. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. The operating lease right-of-use assets also include any lease payments made and exclude lease incentives. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise any such options. Lease expense is recognized on a straight-line basis over the expected lease term. We have elected not to separate lease and non-lease components, such as common area maintenance charges, and instead it accounts for these as a single lease component.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restructuring&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize restructuring charges related to reorganization plans that have been committed to by management when liabilities have been incurred. In connection with these activities, we record restructuring charges at fair value for, (a) contractual employee termination benefits when obligations are associated to services already rendered, rights to such benefits have vested, and payment of benefits is probable and can be reasonably estimated, (b) one-time employee termination benefits &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;when management has committed to a plan of termination, the plan identifies the employees and their expected termination dates, the details of termination benefits are complete, it is unlikely changes to the plan will be made or the plan will be withdrawn and communication to such employees has occurred, and (c) contract termination costs when a contract is terminated before the end of its term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;One-time employee termination benefits are recognized in their entirety when communication has occurred and future services are not required. If future services are required, the costs are recorded ratably over the remaining period of service. Contract termination costs to be incurred over the remaining contract term without economic benefit are recorded in their entirety when the contract is canceled.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration of potential shares of common stock. Diluted net loss per common share in the periods presented is the same as basic net loss per common share, since the effects of potentially dilutive securities are antidilutive due to the net loss for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;New Accounting Pronouncements - Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We adopted Accounting Standards Update 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASU 2016-13"), as of December 1, 2021 under the modified retrospective approach. ASU 2016-13 requires an entity to measure and recognize expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities with unrealized credit losses, the standard requires allowances to be recorded through net income instead of directly reducing the amortized cost of the investment under the previous other-than-temporary impairment model. The adoption of this standard did not have a material impact on our financial statements or a significant impact on our internal controls.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were various accounting standards and interpretations issued recently, none of which are expected to a have a material impact on our financial position, operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzMxODk2_46ceacd6-1441-4aa8-9a53-e3ba52256835">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;).&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzMxOTAy_d3f56543-8f82-4f6c-a679-da8b3c28c2f0">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the amounts reported in the financial statements and accompanying notes thereto. On an ongoing basis, management evaluates its estimates, including those related to recognition of revenue, clinical trial accruals, contract manufacturing accruals, fair value of assets and liabilities, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could materially differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:InvestmentsAndCash
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzIzNzQ_759dc7bc-62c3-4ad7-b5ba-da0c9e98e74b"
      unitRef="usd">123900000</us-gaap:InvestmentsAndCash>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzI0Njg_6954659c-e247-46bf-85c0-1d4bed297fb0"
      unitRef="usd">-780100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzMxOTAz_058cd634-5d3c-408c-b5d6-7f0a3130ca5e">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid investments purchased with an original maturity date of 90 days or less on the date of purchase to be cash equivalents.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <ardx:ShortTermInvestmentsPolicyTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzMxOTA3_8888fedc-6439-4c21-a765-28cd26612bde">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Short-Term Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term investments consist of debt securities classified as available-for-sale and have maturities greater than 90&#160;days, but less than one&#160;year, from the date of acquisition. Short-term investments are carried at fair value based upon quoted market prices. Unrealized gains and losses on available-for-sale securities are included in accumulated other comprehensive loss on our balance sheets. The cost of available-for-sale securities sold is based on the specific-identification method.&lt;/span&gt;&lt;/div&gt;</ardx:ShortTermInvestmentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzMxOTEz_46111201-0f27-41a1-963c-331edeee59a5">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents, short-term investments and accounts receivable. We are exposed to credit risks in the event of default by the counterparties to the extent of the amount recorded in its balance sheet. Cash, cash equivalents and short-term investments are invested through banks and other financial institutions in the U.S.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzMxOTA4_fb937a06-83c9-41e6-a624-7d56d228139c">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We manage our foreign currency exposures with the use of foreign currency purchases. We primarily conduct business in U.S. dollars; however, a portion of our expense and capital activities are transacted in foreign currencies which are subject to exchange rate fluctuations that can affect cash or earnings. We have been in a loss position and therefore our primary objective is to conserve and manage cash. There are generally two methods by which we may manage the cash flow risk of foreign exchange fluctuations when a contract is signed (i) we can purchase the foreign funds, in full or in part, upon the execution of the contract, or (ii) we can obtain the right to purchase such funds, in full or in part, at the execution of the contract, i.e., obtain a forward contract from an appropriate bank, that can be exercised to obtain the currency of interest at a particular point in time. The derivative instruments that we may use to hedge the exposure shall generally not be designated as cash flow hedges, and as a result, changes in their fair value would be recorded in other income (expense), net, in our statements of operations and comprehensive loss. The fair values of forward foreign currency exchange contracts would be estimated using current exchange rates and interest rates and the current creditworthiness of the counterparties is taken into consideration.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzMxODk4_edaf3b9e-2015-47f3-b873-30ad2b569f53">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets, with ranges generally from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzY3Mzg_4835439c-76eb-4d2f-801e-529f6574b0d2"&gt;three&lt;/span&gt; to five years. Leasehold improvements are amortized over the lesser of the estimated useful lives or the related remaining lease term.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i06f6392d8de34129a19422671d121309_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzY3NDQ_e96f135f-dc23-4aaa-a4b6-9081292a1374">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzMxOTE0_81d7c596-21f5-413e-90a7-1b63d350b4be">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of long-lived assets, including property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the asset may not be recoverable. An impairment loss is recognized when the total of estimated future undiscounted cash flows, expected to result from the use of the asset and its eventual disposition, are less than the asset&#x2019;s carrying amount. Impairment, if any, would be assessed using discounted cash flows or other appropriate measures of fair value. For the years ending December&#160;31, 2022, 2021 and 2020 we have recognized no impairment losses.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2Xzc0NzE_15af8d00-f774-4f33-b2ff-e24d7a873b02"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2Xzc0NzE_22fbe075-e505-48fb-b4e5-5f5a6bae7bd8"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2Xzc0NzE_2f75fe73-632b-4152-9605-aa9021b8a4de"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzMxOTA5_0c6e296f-4b95-40f1-87ab-f6e3517f48ed">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzIxOTkwMjMzMDczMTY_6a8c2c94-9413-47ce-8f6e-b7e83b1b84c6">Accounts ReceivableAccounts receivable is reported net of allowances for returns, chargebacks and contractual off-invoice and prompt-pay discounts offered to our customers. Our estimate of the allowance for doubtful accounts is based on an evaluation of the aging of our receivables. Trade receivable balances are written off against the allowance when it is probable that the receivable will not be collected. To date, we have determined that an allowance for doubtful accounts is not required.</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ieca82817eeaa4e6a9211772c02ceff0e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzU0OTc1NTg2NTYwMA_ed2be86b-5fbb-4844-82ab-822ea7a32d6e"
      unitRef="usd">700000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i3e0e80bb8eb7493a85b933d3d97f3803_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzU0OTc1NTg2NTYxNQ_4cb28ada-1dc3-4cb5-9943-4d3147a70330"
      unitRef="usd">7000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ia88c0559b8474f5190912f03388fc38d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzU0OTc1NTg2NTYzMA_d28785dd-9a1e-4a4b-9a4f-86c10ed15349"
      unitRef="usd">500000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzIxOTkwMjMzMDczMzA_cbde6073-2f03-40ab-a3c4-a4a6de96670c">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We capitalize inventory costs associated with the production of our products after regulatory approval or when, based on management&#x2019;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Otherwise, such costs are expensed as research and development. Prior to the regulatory approval of drug product candidates, we incurred expenses for the manufacture of drug product that could potentially be available to support the commercial launch of our products or could be sold to our international partners under product supply agreements. We began to capitalize inventory costs associated with IBSRELA during the fourth quarter of 2021, when our intent to commercialize IBSRELA was established and we commenced preparation for the commercial launch of IBSRELA, which was when it was determined that the inventory had a probable future economic benefit.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory is stated at the lower of cost or estimated net realizable value with cost determined under the first-in first-out method. Inventory costs include the cost of materials, third-party contract manufacturing, third-party packaging services, freight, labor costs for personnel involved in the manufacturing process, and indirect overhead costs. We primarily use actual costs to determine the cost basis for inventory. The determination of whether inventory costs will be realizable requires management review of the expiration dates of IBSRELA compared to our forecasted sales. If actual market conditions are less favorable than projected by management, write-downs of inventory may be required, which would be recorded as cost of revenue in the statement of operations and comprehensive loss. As of December&#160;31, 2022, we have not recorded any write-offs for excess and obsolete inventory. A portion of inventory that represents product that is not expected to be sold or used within the next 12 months is classified as non-current on our balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzMxODky_be7a16e3-4d23-417e-8658-6fad2e4cb409">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Sales, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for our commercial product sales, net in accordance with Topic 606 - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We received approval from the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) in September 2019 to market IBSRELA in the U.S.. We began selling IBSRELA in the U.S. in March 2022. We distribute IBSRELA principally through major wholesalers, specialty pharmacies and group purchasing organizations ("GPOs") (collectively, our "Customers"). Our Customers subsequently sell IBSRELA to pharmacies and patients. Separately, we enter into arrangements with third parties that provide for government-mandated rebates, chargebacks and discounts. Revenue from product sales is recognized when our performance obligations are satisfied, which is when Customers obtain control of our product and occurs upon delivery.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reserves for Variable Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration which may be settled in the form of off-invoice discounts, chargebacks, or rebates. Variable consideration includes discounts to customers and government programs, wholesaler fees, group purchasing organization administrative fees, patient copay assistance programs, and estimated product returns. These estimates are based on the amounts earned or to be claimed for related sales and are classified as reductions of gross accounts receivable if settlement is expected to occur through a reduction in the amounts paid by our customers or a current liability if settlement is expected to occur through a payment from us. Where appropriate, these estimates are based on factors such as industry data and forecasted customer buying and payment patterns, our experience, current contractual and statutory requirements, specific known market events and trends. These reductions to gross sales reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. Variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we adjust these estimates, which would affect product revenue and earnings in the period such variances become known. As we gain more experience, estimates will be more heavily based on the expected utilization from historical data we have accumulated since the IBSRELA product launch.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rebates: Rebates include wholesaler fees, GPO fees, as well as mandated discounts under the Medicaid Drug Rebate Program ("Medicaid") and the Medicare Coverage Gap Program ("Medicare"). Estimates for rebates are recorded in the same period the related gross revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses on the balance sheets. We estimate our Medicaid and Medicare rebates based upon the estimated payor mix, and statutory discount rates. Our estimates for payor mix are guided by payor information received from specialty pharmacies, expected utilization for wholesaler sales to pharmacies, and available industry payor information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chargebacks: Chargebacks are discounts that occur when certain contracted purchasers purchase directly from our wholesalers at a discounted price. The wholesaler, in turn, charges back the difference between the price initially paid to us by the wholesaler and the discounted price paid to the wholesaler by the contracted purchaser. Amounts for estimated chargebacks are established in the same period that the related gross revenue is recognized, resulting in a reduction of product revenue and accounts receivable. The accrual for wholesaler chargebacks is estimated based on known chargeback rates, known sales to wholesalers, and estimated utilization by types of contracted purchasers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discounts and Fees: Our payment terms are generally 30 to 60 days. Wholesalers, GPOs and specialty pharmacies are offered various forms of consideration, including off-invoice discounts which may be paid to GPOs and specialty pharmacies. Wholesalers and GPOs may also receive prompt pay discounts for payment within a specified period. We expect discounts to be earned when offered and therefore, we deduct the full amount of these discounts from product sales when revenue is recognized, resulting in a reduction of product revenue and accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Reserves: Patients who have commercial insurance may receive copay assistance when product is dispensed by pharmacies to patients. We estimate the amount of copay assistance provided to eligible patients based on the terms of the program and redemption information provided by third-party claims processing organizations and are recorded in accounts payable and accrued expenses and other current liabilities on the balance sheets. Other reserves include estimated product returns which are recorded in the same period the related gross revenue is recognized, resulting in a reduction of product revenue as well as accounts receivable. We estimate our product returns reserve based upon our experience, and specific known market events and trends. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generate collaboration revenue primarily from research and collaboration and license agreements with customers. Goods and services in the agreements may include the grant of licenses for the use of our technology,&#160;the provision of services associated with the research and development of product candidates, manufacturing services, and participation in joint steering committees. The terms of these arrangements typically include payment to us of one or more of the following: non-refundable, up-front license fees; research, development, regulatory and commercial milestone payments; reimbursement of research and development services; option payments; reimbursement of certain costs; payments for manufacturing supply services; and future royalties on net sales of licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When two or more contracts are entered into with the same customer at or near the same time, we evaluate the contracts to determine whether the contracts should be accounted for as a single arrangement. Contracts are combined and accounted for as a single arrangement if one or more of the following criteria are met: (i) the contracts are negotiated as a package with a single commercial objective; (ii) the amount of consideration to be paid in one contract depends on the price or performance of the other contract; or (iii) the goods or services promised in the contracts (or some goods or services promised in each of the contracts) are a single performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under each of our agreements, management performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including any constraints on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) we satisfy each performance obligation. As part of the accounting for contracts with customers, we develop assumptions that require judgment to determine whether promised goods and services represent distinct performance obligations and the standalone selling price for each performance obligation identified in the contract. This evaluation is subjective and requires us to make judgments about the promised goods and services and whether those goods and services are separable from other aspects of the contract. Further, determining the standalone selling price for performance obligations requires significant judgment, and when an observable price of a promised good or service is not readily available, we consider relevant assumptions to estimate the standalone selling price, including, as applicable, market conditions, development timelines, probabilities of technical and regulatory success, reimbursement rates for personnel costs, forecasted revenues, potential limitations to the selling price of the product and discount rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We apply judgment in determining whether a combined performance obligation is satisfied at a point in time or over time, and, if over time, concluding upon the appropriate method of measuring progress to be applied for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, as estimates related to the measure of progress change, related revenue recognition is adjusted accordingly. Changes in our estimated measure of progress are accounted for prospectively as a change in accounting estimate. We recognize collaboration revenue by measuring the progress toward complete satisfaction of the performance obligation using an input measure. In order to recognize revenue over the research and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;development period, we measure actual costs incurred to date compared to the overall total expected costs to satisfy the performance obligation. Revenues are recognized as the program costs are incurred. We will re-evaluate the estimate of expected costs to satisfy the performance obligation each reporting period and make adjustments for any significant changes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts received prior to satisfying the revenue recognition criteria are recorded as contract liabilities in our Balance Sheets. If the related performance obligation is expected to be satisfied within the next twelve months it will be classified in current liabilities. Amounts recognized as revenue prior to receipt are recorded as contract assets in our Balance Sheets. If we expect to have an unconditional right to receive the consideration in the next twelve months, it will be classified in current assets. A net contract asset or liability is presented for each contract with a customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved. Milestone payments that are not within our control or the control of the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achievement of such development milestones and any related constraints, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Manufacturing supply services:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Arrangements that include a promise for future supply of drug substance or drug product for either clinical development or commercial supply at the customer&#x2019;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. If we are entitled to additional payments when the customer exercises these options, any payments are recorded in product supply revenue when the customer obtains control of the goods, which is upon delivery.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and where the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, royalty revenue resulting from licensing arrangements has not been material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses of intellectual property:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; If a license granted to a customer to use our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from consideration allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we apply judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, to conclude upon the appropriate method of measuring progress for purposes of recognizing revenue related to consideration allocated to the performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Options:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Customer options, such as options granted to allow a licensee to choose to research, develop and commercialize licensed compounds are evaluated at contract inception in order to determine whether those options provide a material right (i.e., an optional good or service offered for free or at a discount) to the customer. If the customer options represent a material right, the material right is treated as a separate performance obligation at the outset of the arrangement. We allocate the transaction price to material rights based on the standalone selling price, and revenue is recognized when or as the future goods or services are transferred or when the option expires. Customer options that are not material rights do not give rise to a separate performance obligation, and as such, the additional consideration that would result from a customer exercising an option in the future is not included in the transaction price for the current contract. Instead, the option is deemed a marketing offer, and additional option fee payments are recognized or being recognized as revenue when the licensee exercises the option. The exercise of an option that does not represent a material right is treated as a separate contract for accounting purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract modifications:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Contract modifications, defined as changes in the scope or price (or both) of a contract that are approved by the parties to the contract, such as a contract amendment, exist when the parties to a contract approve a modification that either creates new or changes existing enforceable rights and obligations of the parties to the contract. Depending on facts and circumstances, we account for a contract modification as one of the following: (i) a separate contract; (ii) a termination of the existing contract and a creation of a new contract; or (iii) a combination of the preceding treatments. A contract modification is accounted for as a separate contract if the scope of the contract increases because of the addition of promised goods or services that are distinct and the price of the contract increases by an amount of consideration that reflects &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;our standalone selling prices of the additional promised goods or services. When a contract modification is not considered a separate contract and the remaining goods or services are distinct from the goods or services transferred on or before the date of the contract modification, we account for the contract modification as a termination of the existing contract and a creation of a new contract. When a contract modification is not considered a separate contract and the remaining goods or services are not distinct, we account for the contract modification as an add-on to the existing contract and as an adjustment to revenue on a cumulative catch-up basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We receive payments from our licensees as established in each contract. Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until we perform our obligations under these arrangements. Where applicable, amounts are recorded as accounts receivable or unbilled revenue when our right to consideration is unconditional. We do not assess whether a contract with a customer has a significant financing component if the expectation at contract inception is such that the period between payment by the licensees and the transfer of the promised goods or services to the licensees will be one year or less.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <ardx:RevenueGeneralPaymentTerms
      contextRef="i2de3a294b21b459b8c55c13b0a994e24_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzIxOTkwMjMzMDczMTg_d6fd4281-58e2-4d01-b782-a044db76d9d0">P30D</ardx:RevenueGeneralPaymentTerms>
    <ardx:RevenueGeneralPaymentTerms
      contextRef="i06f6392d8de34129a19422671d121309_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzIxOTkwMjMzMDczMjg_b2a29ae3-ef4d-40ae-b6ba-a07400d2d76a">P60D</ardx:RevenueGeneralPaymentTerms>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzIxOTkwMjMzMDczMzM_03b531be-e605-4a04-b817-a68cc6442a86">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of revenue consists of the cost of commercial goods sold to our Customers and international partners under product supply agreements as well as royalty expense based on sales of tenapanor. We capitalize inventory costs associated with the production of our products after regulatory approval or when, based on management&#x2019;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Otherwise, such costs are expensed as research and development. A portion of the costs of IBSRELA units recognized as revenue during the twelve months ended December&#160;31, 2022 were expensed prior to the fourth quarter of 2021, at which time our intent to commercialize IBSRELA was established and we commenced preparation for the commercial launch of IBSRELA. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of revenue includes payments due to AstraZeneca, which under the terms of a termination agreement entered into in 2015 ("AZ Termination Agreement") is entitled to (i) future royalties at a rate of 10% of net sales of tenapanor or other NHE3 products by us or our licensees, and (ii) 20% of non-royalty revenue received from our collaboration partners as a result of the development and commercialization of tenapanor or certain other NHE3 inhibitors.&#160;We have agreed to pay&#160;AstraZeneca up to a maximum of $75.0 million in the aggregate for (i) and (ii). We recognize these expenses as cost of revenue when we recognize the corresponding revenue that gives rise to payments due to AstraZeneca. To date, we have recognized an aggregate of $15.3 million as cost of revenue under the AZ Termination Agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <ardx:PercentageOfRoyaltyRevenue
      contextRef="i23a66360caef450d9534fe2775f21255_D20150601-20150630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzU0OTc1NTg2NTU2NA_f8f1354e-9995-450c-8bd2-4a412d52d809"
      unitRef="number">0.10</ardx:PercentageOfRoyaltyRevenue>
    <ardx:PercentageOfNonRoyaltyRevenue
      contextRef="i23a66360caef450d9534fe2775f21255_D20150601-20150630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzU0OTc1NTg2NTU2OA_602d4ed0-947c-4d9a-8f19-9596062c8979"
      unitRef="number">0.20</ardx:PercentageOfNonRoyaltyRevenue>
    <ardx:CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum
      contextRef="i8e9b10bffc104601b9077dcc9e1f4fa6_I20150630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzU0OTc1NTg2NTU3Mg_0faae7bc-afb8-461d-bd84-aff8c5abb61c"
      unitRef="usd">75000000</ardx:CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum>
    <ardx:CostOfRevenueAggregateAmountRecognized
      contextRef="i1d34215ee2e348899b09d93611aa94d9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzU0OTc1NTg2NTU3Ng_190f4fbd-92a5-4a2e-95e4-4a5af75c4dc8"
      unitRef="usd">15300000</ardx:CostOfRevenueAggregateAmountRecognized>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzMxOTA0_22c7182a-25f8-4342-b789-c9d9792f67ce">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are charged to expense as incurred and consisted of costs incurred to further our research and development activities and include salaries and related employee benefits, costs associated with clinical trials, costs related to pre-commercialization manufacturing activities such as manufacturing process validation activities and the manufacturing of clinical drug supply, nonclinical research and development activities, regulatory activities, research-related overhead expenses and fees paid to external service providers and contract research and manufacturing organizations that conduct certain research and development activities on our behalf.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <ardx:AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzMxODkz_6c2e8b2b-7b86-4ce9-9bf2-bfdeeda2cbf9">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are required to estimate our accrued expenses at the end of each reporting period. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual costs. The majority of our service providers submit invoices in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with our service providers and make adjustments if necessary. Examples of estimated accrued research and development expenses include fees paid to:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;contract research organizations ("CROs") in connection with clinical studies;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;investigative sites in connection with clinical studies;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;vendors related to product manufacturing, development and distribution of clinical supplies; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;vendors in connection with preclinical development activities.&lt;/span&gt;&lt;/div&gt;We record expenses related to clinical studies and manufacturing development activities based on our estimates of the services received and efforts expended pursuant to contracts with multiple CROs and manufacturing vendors that conduct and manage these activities on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these contracts depend on factors such as the successful enrollment of subjects and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed, enrollment of subjects, number of sites activated and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we will adjust the accrued or prepaid expense balance accordingly.</ardx:AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzMxODk1_c5a8f6a0-1cae-4138-a1c3-15c97c19bccf">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize compensation expense for all stock-based payment awards made to employees, non-employees and directors based on estimated fair values. For employee and non-employee stock options, we determine the grant date fair value of the awards using the Black-Scholes option-pricing model and generally recognize the fair value as stock-based compensation expense on a straight-line basis over the vesting period of the respective awards. For restricted stock and performance-based restricted stock, to the extent they are probable, the compensation cost for these awards is based on the closing price of our common stock on the date of grant and recognized as compensation expense on a straight-line basis over the requisite service period. Stock-based compensation expense is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. As such, our stock-based compensation is reduced for the estimated forfeitures at the date of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:DerivativesReportingOfDerivativeActivity
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzMxOTEw_d24e25e3-954b-4181-8c29-fbfecb2d5e6d">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivatives and Hedging Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for our derivative instruments as either assets or liabilities on the balance sheet and measure them at fair value. Derivatives are adjusted to fair value through other income (expense), net in the statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesReportingOfDerivativeActivity>
    <ardx:NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzIxOTkwMjMzMDczMzQ_d5947480-5811-4ffb-a382-bda155af572a">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Non-cash Interest Expense on Deferred Royalty Obligation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net proceeds we receive from the sale of certain future royalties are recorded as deferred royalty obligation related to the sale of future royalties on our balance sheets. As we earn royalties and remit those royalties pursuant to the agreement, the balance of the deferred royalty obligation will be effectively repaid over the life of agreement and non-cash interest expense related to the sale of future royalties is recorded using the effective interest method. To determine the amortization of our deferred royalty obligation, we are required to estimate the total amount of future royalty payments we expect to earn. There are a number of factors that could materially affect the amount and timing of royalty payments, most of which are not within our control. We periodically assess the amount of royalty payments we expect to receive which are subject to the agreement and, to the extent that the amount or timing of such payments is materially different than our original estimates, we prospectively adjust the imputed interest rate and the related amortization of the deferred royalty obligation.&lt;/span&gt;&lt;/div&gt;</ardx:NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzMxOTAw_fe77d5fb-1b84-47f5-9cfc-2226c82ffee7">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine if an arrangement is a lease at the inception of the arrangement. Operating leases are included in right-of-use assets, current portion of operating lease liability, and operating lease liability, net of current portion in our balance sheets. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. The operating lease right-of-use assets also include any lease payments made and exclude lease incentives. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise any such options. Lease expense is recognized on a straight-line basis over the expected lease term. We have elected not to separate lease and non-lease components, such as common area maintenance charges, and instead it accounts for these as a single lease component.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzMxOTAx_f2db1f29-992c-48b5-ae14-5f36e92901f6">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restructuring&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize restructuring charges related to reorganization plans that have been committed to by management when liabilities have been incurred. In connection with these activities, we record restructuring charges at fair value for, (a) contractual employee termination benefits when obligations are associated to services already rendered, rights to such benefits have vested, and payment of benefits is probable and can be reasonably estimated, (b) one-time employee termination benefits &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;when management has committed to a plan of termination, the plan identifies the employees and their expected termination dates, the details of termination benefits are complete, it is unlikely changes to the plan will be made or the plan will be withdrawn and communication to such employees has occurred, and (c) contract termination costs when a contract is terminated before the end of its term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;One-time employee termination benefits are recognized in their entirety when communication has occurred and future services are not required. If future services are required, the costs are recorded ratably over the remaining period of service. Contract termination costs to be incurred over the remaining contract term without economic benefit are recorded in their entirety when the contract is canceled.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzMxODk5_5bc21556-85f2-45a1-bd99-f2caecc9b8ef">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration of potential shares of common stock. Diluted net loss per common share in the periods presented is the same as basic net loss per common share, since the effects of potentially dilutive securities are antidilutive due to the net loss for all periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDMvZnJhZzplNjNhMmZiZDQ4YTk0ZTc4YTg5M2E1YjZjYWQ1YjhjNi90ZXh0cmVnaW9uOmU2M2EyZmJkNDhhOTRlNzhhODkzYTViNmNhZDViOGM2XzMxOTA1_92e37198-0962-4ba6-b677-cc403cb9ca33">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;New Accounting Pronouncements - Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We adopted Accounting Standards Update 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASU 2016-13"), as of December 1, 2021 under the modified retrospective approach. ASU 2016-13 requires an entity to measure and recognize expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities with unrealized credit losses, the standard requires allowances to be recorded through net income instead of directly reducing the amortized cost of the investment under the previous other-than-temporary impairment model. The adoption of this standard did not have a material impact on our financial statements or a significant impact on our internal controls.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were various accounting standards and interpretations issued recently, none of which are expected to a have a material impact on our financial position, operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90ZXh0cmVnaW9uOjc1YjMwNTI2NGY1ODQwZTlhNGIzNTNjMjM2ZmY3YmNlXzI1NzQ_05c1026e-6037-4b46-84e7-db3589e402c9">CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Securities classified as cash, cash equivalents and short-term investments as of December&#160;31, 2022 and 2021 are summarized below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial Paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents consist of money market funds with original maturities of three months or less at the time of purchase, and the carrying amount is a reasonable approximation of fair value. We invest our cash in high quality securities of financial and commercial institutions. These securities are carried at fair value, which is based on readily available market information, with unrealized gains and losses included in accumulated other comprehensive loss within stockholders&#x2019; equity on our balance sheets. We use the specific identification method to determine the amount of realized gains or losses on sales of marketable securities. Realized gains or losses have been insignificant and are included in other income, net, in the statement of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the short-term available-for sale securities held as of December&#160;31, 2022 and 2021 had contractual maturities of less than one year. Our available-for-sale securities are subject to a periodic impairment review. We consider a debt security to be impaired when its fair value is less than its carrying cost, in which case we would further review the investment to determine whether it is other-than-temporarily impaired. When we evaluate an investment for other-than-temporary impairment, we review factors such as the length of time and extent to which fair value has been below cost basis, the financial condition of the issuer and any changes thereto, intent to sell, and whether it is more likely than not we will be required to sell the investment before the recovery of its cost basis. If an investment is other-than-temporarily impaired or subject to credit losses, we write it down through the statement of operations and comprehensive loss to its fair value and establish that value as a new cost basis for the investment. Our unrealized losses as of December&#160;31, 2022 and 2021 were not material. We determined that none of our available-for-sale securities were other-than-temporarily impaired as of December&#160;31, 2022 and 2021, and no investment was in a continuous unrealized loss position for more than one year. As such, we believe that it is more likely than not that the investments will be held until maturity or a forecasted recovery of fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90ZXh0cmVnaW9uOjc1YjMwNTI2NGY1ODQwZTlhNGIzNTNjMjM2ZmY3YmNlXzI1NzI_2efb7b68-174a-490a-9001-9f5044f8543b">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Securities classified as cash, cash equivalents and short-term investments as of December&#160;31, 2022 and 2021 are summarized below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial Paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i72b7f1283e114d98b667e2d3b9d78c10_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzQtMS0xLTEtNDYwMTM_6a152e45-dc6f-415c-b68c-1487f34e7ea4"
      unitRef="usd">11827000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i72b7f1283e114d98b667e2d3b9d78c10_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzQtNy0xLTEtNDYwMTM_cc99f0cb-96d3-4c6d-b111-aa55710c166d"
      unitRef="usd">11827000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i82f59874748f487e829f759d2d2fe716_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzUtMS0xLTEtNDYwMTM_ccb81288-7c8d-4c85-bcb2-0913030255ae"
      unitRef="usd">84313000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i82f59874748f487e829f759d2d2fe716_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzUtNy0xLTEtNDYwMTM_49d5dd72-c0ea-471d-97f7-dc0802935dfc"
      unitRef="usd">84313000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzctMS0xLTEtNDYwMTM_66c8b2d7-3e7c-4c27-bd4c-5630bcab7bf0"
      unitRef="usd">96140000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzctNy0xLTEtNDYwMTM_2761c368-7baa-400b-9f0e-623d269d5724"
      unitRef="usd">96140000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ieabaefd41b574aa6b074694d974eb95a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzktMS0xLTEtNDYwMTM_0066e299-964d-4b44-bf03-fefd3525d365"
      unitRef="usd">25336000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ieabaefd41b574aa6b074694d974eb95a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzktMy0xLTEtNDYwMTM_c1931767-591a-4e77-97bd-b8bfe657240f"
      unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ieabaefd41b574aa6b074694d974eb95a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzktNS0xLTEtNDYwMTM_8a0f9333-e397-4d52-a2d2-8d9beff1c705"
      unitRef="usd">51000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ieabaefd41b574aa6b074694d974eb95a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzktNy0xLTEtNDYwMTM_c6dd404c-1221-4cb2-b453-7bcdf290872c"
      unitRef="usd">25291000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5cffd7fcbbc544939e32a7a8f34622be_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzEwLTEtMS0xLTQ2MDEz_f54883e7-8e54-417a-9ac4-412893b09308"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5cffd7fcbbc544939e32a7a8f34622be_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzEwLTMtMS0xLTQ2MDEz_20fc28d7-9003-4505-9e40-43e4b5e27190"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5cffd7fcbbc544939e32a7a8f34622be_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzEwLTUtMS0xLTQ2MDEz_d5e08417-8326-4f2b-ae01-c5bf9259d9d9"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5cffd7fcbbc544939e32a7a8f34622be_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzEwLTctMS0xLTQ2MDEz_7c4ef77b-ae70-4feb-b958-b1966012708b"
      unitRef="usd">999000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i91fc450e044e494a99d00262c55ee834_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzExLTEtMS0xLTQ2MDEz_3d2e2826-a4e2-4e76-83e8-f9fa96e09414"
      unitRef="usd">1487000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i91fc450e044e494a99d00262c55ee834_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzExLTMtMS0xLTQ2MDEz_140938d1-3310-4e1d-ad1b-a9169213339e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i91fc450e044e494a99d00262c55ee834_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzExLTUtMS0xLTQ2MDEz_27e9c492-a6a2-4c5d-a72f-2023ab5bb26d"
      unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i91fc450e044e494a99d00262c55ee834_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzExLTctMS0xLTQ2MDEz_4f72c904-cb05-410f-acae-b9b8695a89d1"
      unitRef="usd">1479000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzEzLTEtMS0xLTQ2MDEz_4daaf350-76b6-43e9-9501-ea389399f1df"
      unitRef="usd">27823000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzEzLTMtMS0xLTQ2MDEz_c0552182-8f85-490a-b697-845106966579"
      unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzEzLTUtMS0xLTQ2MDEz_c63f6c92-fbb2-484a-8cd3-bcae900b5952"
      unitRef="usd">60000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzEzLTctMS0xLTQ2MDEz_26e79629-1a0b-4516-91d3-69f0fb732304"
      unitRef="usd">27769000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ardx:InvestmentsAndCashAmortizedCost
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzE2LTEtMS0xLTQ2MDEz_f4c3cbce-4832-4dbf-b77f-3cbc6529b8c5"
      unitRef="usd">123963000</ardx:InvestmentsAndCashAmortizedCost>
    <ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedGains
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzE2LTMtMS0xLTQ2MDEz_0356c4dc-f4a3-4347-8788-0d4553d6063d"
      unitRef="usd">6000</ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedGains>
    <ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzE2LTUtMS0xLTQ2MDEz_fb2cf6a7-f885-4070-9e4e-99ad5f3eb3da"
      unitRef="usd">60000</ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses>
    <us-gaap:InvestmentsAndCash
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTo0ZTdhODMzMDIxY2I0OTFiYTJlMDM1NTI3NzAyODJiNC90YWJsZXJhbmdlOjRlN2E4MzMwMjFjYjQ5MWJhMmUwMzU1Mjc3MDI4MmI0XzE2LTctMS0xLTQ2MDEz_35e6b616-f9e2-45c6-af7d-5719e0f81d01"
      unitRef="usd">123909000</us-gaap:InvestmentsAndCash>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0604aebc55e7425795ca8e599d946833_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzQtMS0xLTEtNDYwMTM_44be9303-42cb-4e37-87c7-7aaf7df8f982"
      unitRef="usd">1253000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0604aebc55e7425795ca8e599d946833_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzQtNy0xLTEtNDYwMTM_e1cc4d17-cfbf-48d6-9775-785267689078"
      unitRef="usd">1253000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i98269013828c4cbf960fd07466f62e00_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzUtMS0xLTEtNDYwMTM_01ac6ba2-3e00-40c1-900c-15f5f64cfede"
      unitRef="usd">71175000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i98269013828c4cbf960fd07466f62e00_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzUtNy0xLTEtNDYwMTM_73a7b47a-471c-4f4f-9c4f-fbf7a8bcb6fe"
      unitRef="usd">71175000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ideed1df6eef44d1f8834a64175dd3912_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzYtMS0xLTEtNDYwMTM_0722f033-4ae4-44c9-a1d0-54dc56c8d03f"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ideed1df6eef44d1f8834a64175dd3912_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzYtNy0xLTEtNDYwMTM_95445235-10d5-4379-9d79-2410b3823f98"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idbbc030abf9e4d3a8044fd67d677deca_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzctMS0xLTEtNDYwMTM_b8a84590-ddee-4fa8-ad3b-448cf3e880bd"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idbbc030abf9e4d3a8044fd67d677deca_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzctNy0xLTEtNDYwMTM_a3afc646-e8b6-4078-9ae2-488037ff98d6"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzgtMS0xLTEtNDYwMTM_3b62e802-4dfc-489d-bb85-1de218f9be59"
      unitRef="usd">72428000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzgtNy0xLTEtNDYwMTM_8187ec12-01e0-4c29-8411-d615448561fc"
      unitRef="usd">72428000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i73a4c3bd901c4931af270d9b6aae48be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzEwLTEtMS0xLTQ2MDEz_34ad630b-8b53-44ea-b9e1-645d1e6c820e"
      unitRef="usd">31936000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i73a4c3bd901c4931af270d9b6aae48be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzEwLTMtMS0xLTQ2MDEz_15e49619-1ac5-43f2-ada9-23dad2521854"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i73a4c3bd901c4931af270d9b6aae48be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzEwLTUtMS0xLTQ2MDEz_d75198b1-dc0a-4e0b-a088-4e56b9950a00"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i73a4c3bd901c4931af270d9b6aae48be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzEwLTctMS0xLTQ2MDEz_c78937c5-9998-4fe8-bd2e-a6e5d9418b8d"
      unitRef="usd">31935000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie309689c7e5145568dac251da707114b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzExLTEtMS0xLTQ2MDEz_b406b07c-b147-4eee-aba4-1d3df52eb068"
      unitRef="usd">7025000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie309689c7e5145568dac251da707114b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzExLTMtMS0xLTQ2MDEz_da4b32d1-92fd-4134-b6c7-09a7d5b8166f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie309689c7e5145568dac251da707114b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzExLTUtMS0xLTQ2MDEz_9478477f-7a64-4f0d-9608-71ea640f90a5"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie309689c7e5145568dac251da707114b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzExLTctMS0xLTQ2MDEz_045e0617-7ba5-4a57-aa20-80417e522232"
      unitRef="usd">7022000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i197012cc5c3f4d0186f4f6f49afd9938_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzEzLTEtMS0xLTQ2MDEz_f2e7c37b-bb53-4ede-bf53-cbee24756646"
      unitRef="usd">5306000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i197012cc5c3f4d0186f4f6f49afd9938_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzEzLTMtMS0xLTQ2MDEz_0acbfc77-485e-4d63-a091-cfd1400a3d26"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i197012cc5c3f4d0186f4f6f49afd9938_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzEzLTUtMS0xLTQ2MDEz_8b21c7d1-dff9-496b-90c2-5c16ff2aa1b2"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i197012cc5c3f4d0186f4f6f49afd9938_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzEzLTctMS0xLTQ2MDEz_3d6fa584-56e5-4dd5-8ca0-93796b1f246a"
      unitRef="usd">5304000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzE0LTEtMS0xLTQ2MDEz_220856ef-22b2-46a7-8911-39ed0fc06a4a"
      unitRef="usd">44267000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzE0LTMtMS0xLTQ2MDEz_ca1c094d-d504-486e-b2f6-04fa3d4027a6"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzE0LTUtMS0xLTQ2MDEz_e50fac34-c88e-4fa6-9ae8-1f4cfec5e8dd"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzE0LTctMS0xLTQ2MDEz_7b26b488-0f21-4404-bd01-98c881af81c4"
      unitRef="usd">44261000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ardx:InvestmentsAndCashAmortizedCost
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzE3LTEtMS0xLTQ2MDEz_5ce3578f-4926-4af4-88a6-0f6ab6df9499"
      unitRef="usd">116695000</ardx:InvestmentsAndCashAmortizedCost>
    <ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedGains
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzE3LTMtMS0xLTQ2MDEz_af2d6705-9918-40e4-adeb-3d513e496fac"
      unitRef="usd">1000</ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedGains>
    <ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzE3LTUtMS0xLTQ2MDEz_c008e837-b7cb-4f37-996b-d0463bf478fe"
      unitRef="usd">7000</ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses>
    <us-gaap:InvestmentsAndCash
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90YWJsZTpkNDViMzFkNzhhYzk0ZDFlOTg3MGUyNGQ4ZjNiMGVjNS90YWJsZXJhbmdlOmQ0NWIzMWQ3OGFjOTRkMWU5ODcwZTI0ZDhmM2IwZWM1XzE3LTctMS0xLTQ2MDEz_79c49458-14b1-4265-b7f4-7dd8dd798dca"
      unitRef="usd">116689000</us-gaap:InvestmentsAndCash>
    <ardx:AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90ZXh0cmVnaW9uOjc1YjMwNTI2NGY1ODQwZTlhNGIzNTNjMjM2ZmY3YmNlXzc2OTY1ODE0MDMwOTc_893b6e37-0dd6-4b6f-9472-efd14569244c">P1Y</ardx:AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum>
    <ardx:AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90ZXh0cmVnaW9uOjc1YjMwNTI2NGY1ODQwZTlhNGIzNTNjMjM2ZmY3YmNlXzc2OTY1ODE0MDMwOTc_ea0295f9-cdb9-456c-8eb3-695517384fea">P1Y</ardx:AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90ZXh0cmVnaW9uOjc1YjMwNTI2NGY1ODQwZTlhNGIzNTNjMjM2ZmY3YmNlXzU0OTc1NTgxOTg4Mg_153c0635-56f2-437c-8570-b934d4908d68"
      unitRef="investment">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDYvZnJhZzo3NWIzMDUyNjRmNTg0MGU5YTRiMzUzYzIzNmZmN2JjZS90ZXh0cmVnaW9uOjc1YjMwNTI2NGY1ODQwZTlhNGIzNTNjMjM2ZmY3YmNlXzU0OTc1NTgxOTg4Mg_16f14a8d-f699-4d28-9042-2261f4598dfd"
      unitRef="investment">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90ZXh0cmVnaW9uOjA2NzI0MDE2MzE1MDQwZjlhOTVmNzhlMWZmMGQxYzZiXzMzMTQ_056acb24-3acb-4a41-8e7a-e0757c073cab">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1&#160;&#160;&#160;&#x2013;&#160;Valuations are based on quoted prices in active markets for identical assets or liabilities and readily accessible to us at the reporting date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2&#160;&#160;&#160;&#x2013;&#160;&#160;Valuations based on inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 &#160;&#x2013;&#160;&#160;Valuations based on unobservable inputs for which there is little or no market data, which require us to develop our own assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the fair value of our financial assets and liabilities that are measured or disclosed on a recurring basis by level within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liabilities for exit fees&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liability for exit fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Where quoted prices are available in an active market, securities are classified as Level 1. We classify money market funds as Level 1. When quoted market prices are not available for the specific security, we estimate fair value by using benchmark yields, reported trades, broker/dealer quotes and issuer spreads. We classify U.S. government-sponsored agency bonds, U.S. treasury notes, corporate bonds, commercial paper, and asset-backed securities as Level 2. In certain cases, where there is limited activity or less transparency around inputs to valuation, securities or derivative liabilities, such as the 2018 Exit Fee and 2022 Exit Fee, as defined and discussed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 10. Derivative Liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, are classified as Level 3.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts reflected in the balance sheets for cash equivalents, short-term investments, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values at both December&#160;31, 2022 and 2021, due to their short-term nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on our procedures under the expected credit loss model, including an assessment of unrealized losses in our portfolio, we concluded that any unrealized losses on our marketable securities were not attributable to credit and, therefore, we have not recorded an allowance for credit losses for these securities as of December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The principal amount outstanding under our term loan facilities is subject to a variable interest rate. Therefore, we believe the carrying amount of the term loan facility approximates fair value as of December&#160;31, 2022 and 2021. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 9. Borrowings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for a description of the Level 2 inputs used to estimate the fair value of the liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of the deferred royalty obligation related to the sale of future royalties approximates its fair value as of December&#160;31, 2022 and is based on our current estimates of future royalties and commercialization milestones expected to be &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;paid to us by Kyowa Kirin Co., Ltd. ("KKC") over the life of the agreement. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 8. Deferred Royalty Obligation Related to the Sale of Future Royalties&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for a description of the Level 3 inputs used to estimate the fair value of the liability.&lt;/span&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90ZXh0cmVnaW9uOjA2NzI0MDE2MzE1MDQwZjlhOTVmNzhlMWZmMGQxYzZiXzMzMTU_c6a56155-4de6-466e-988c-96788ecbb048">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the fair value of our financial assets and liabilities that are measured or disclosed on a recurring basis by level within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liabilities for exit fees&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liability for exit fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifce32edf589c43559645ca939f8321c0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzMtMS0xLTEtNDYwMTM_249d1c9f-1da7-4cbb-8a62-2535fbcd0b30"
      unitRef="usd">84313000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i800c2d8a407c4f52a90eac1ac7fa9c7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzMtMy0xLTEtNDYwMTM_822f73ba-0d90-46a2-9948-316727a2b26c"
      unitRef="usd">84313000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic862582842b14106872fa00b3bc1a179_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzMtNS0xLTEtNDYwMTM_35d52533-5a25-42b2-b87e-b494244c84a7"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8c1965f94e0f45c8ba92675a0a9e37a5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzMtNy0xLTEtNDYwMTM_4af955b1-2edb-4e08-860c-ac329c624af3"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibeba7a62348343fda259cc027ff9efaf_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzQtMS0xLTEtNDYwMTM_f520a4fe-810c-44ca-9a0a-94908cd87a15"
      unitRef="usd">25291000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5530fb3f55994ff9b89b29a90019a352_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzQtMy0xLTEtNDYwMTM_ff983083-bb53-4b14-ab95-55da18809e26"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i215440159e8b42d48ee9a7911b2b27ed_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzQtNS0xLTEtNDYwMTM_807e6703-368a-4e92-856c-a565d517b065"
      unitRef="usd">25291000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic020e23db5fa4fd392335d177235faab_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzQtNy0xLTEtNDYwMTM_f8efb0a1-78f8-4ca9-9dd7-67f4c3985b4e"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie6a449d340e445639849083309b50cfc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzYtMS0xLTEtNTE3ODM_ff9b88ef-4cd0-47a6-be75-397c0084bdde"
      unitRef="usd">1479000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4b017fd3d9ed45a686ed4da0c90e2b8a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzYtMy0xLTEtNTE3ODM_3dceb091-98a2-462c-a05f-aa9db1e352a1"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2189793c12b94eb5aea5349640fc8e74_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzYtNS0xLTEtNTE3ODM_8ba746dc-3912-4c48-8ddb-c89efac2ee27"
      unitRef="usd">1479000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4045d24f631d4b57b3bad1d73d787f3b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzYtNy0xLTEtNTE3ODM_2e7409f1-a55a-452c-b383-180686103641"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic0091d5584e742729920f89400c5a7ec_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzUtMS0xLTEtNDYwMTM_d953192c-9267-4368-899a-fb24d283c6c1"
      unitRef="usd">999000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i63caa9b53ecd4496aa9cbae0e6aebb0f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzUtMy0xLTEtNDYwMTM_aa7c2f2b-0813-4b9e-897a-2c4761ed0ebd"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2d651a762ddd4d42b1eb146a2f77667a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzUtNS0xLTEtNDYwMTM_806d0469-dec5-4974-9e32-383e2a1d3328"
      unitRef="usd">999000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i41b180661d604a9db63c4cc471ee7d76_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzUtNy0xLTEtNDYwMTM_e69bb65d-e79e-4875-94e6-c6fb2ed42e2c"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i691c998073704928ab9052cb14232a00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzgtMS0xLTEtNDYwMTM_3ad606eb-0dc0-418c-8a1f-f54c8bf982c4"
      unitRef="usd">112082000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i733e529140624718b49d4f80ac96a2d6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzgtMy0xLTEtNDYwMTM_e81ef220-f209-420c-9447-1d421d5c51c3"
      unitRef="usd">84313000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4139c0b0d3d942078ab8524d3ab1edfb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzgtNS0xLTEtNDYwMTM_a93e5840-ad21-43bb-860a-14020e24fafa"
      unitRef="usd">27769000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i663a0605660842e1b03f18928affeeff_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzgtNy0xLTEtNDYwMTM_f05081cd-a708-4ba4-b647-1ef959933f7e"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i6a2ed7629e8644ca88a18430d955a065_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzExLTEtMS0xLTQ2MDEz_e305adda-ac79-4b91-9cad-1e8611bc528f"
      unitRef="usd">1656000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i0b7cfff0602c4effac77d3fac445e8a0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzExLTMtMS0xLTQ2MDEz_74a93c89-fc99-462d-ac07-7391783d8dc0"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i9fb4cf2b13f04f7894360378ff59fdd1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzExLTUtMS0xLTQ2MDEz_17062dc3-3340-4fc4-9965-7796275555dd"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ib5ac62ac7b5c46bfa5e837d80abb240d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzExLTctMS0xLTQ2MDEz_bba6906a-f66d-48e5-bb6f-af57e1c415a4"
      unitRef="usd">1656000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i691c998073704928ab9052cb14232a00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzEyLTEtMS0xLTQ2MDEz_afab034b-afc4-4c85-960f-879dd5bc8a51"
      unitRef="usd">1656000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i733e529140624718b49d4f80ac96a2d6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzEyLTMtMS0xLTQ2MDEz_c945f3f3-2c3d-4400-aab2-a238da91d9a5"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i4139c0b0d3d942078ab8524d3ab1edfb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzEyLTUtMS0xLTQ2MDEz_5c376386-576c-4b5f-9eff-3178a97fcb30"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i663a0605660842e1b03f18928affeeff_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTo4ZTNkNTVkMjgzZjM0MjZjODU0ZmI2YmI3NGYwZDE0ZC90YWJsZXJhbmdlOjhlM2Q1NWQyODNmMzQyNmM4NTRmYjZiYjc0ZjBkMTRkXzEyLTctMS0xLTQ2MDEz_52913c66-628e-49af-b8a6-0972c508e134"
      unitRef="usd">1656000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibe6734a4d6234308b332b56b6c66f456_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzMtMS0xLTEtNDYwMTM_d3811811-eb24-4fbb-a6df-b344d08c9945"
      unitRef="usd">71175000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="icf63c7b0e2bd43fd95a03bb02babbf85_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzMtMy0xLTEtNDYwMTM_380d24e4-b24d-4b68-aa5a-1b1f50039671"
      unitRef="usd">71175000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i53e4cddaae814c21930efe5f393ab81c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzMtNS0xLTEtNDYwMTM_2fe969cb-59aa-43e5-b215-91349b63e38a"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2e79c3ee3bba453c95e397f21030d21e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzMtNy0xLTEtNDYwMTM_88002b6e-e714-4b32-a467-b75f4826ba5c"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i31e14a2329e641e4a02f507843106a3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzQtMS0xLTEtNDYwMTM_aecda001-7313-46cf-b05f-56b627a061d4"
      unitRef="usd">31935000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i39124c37d91d480fa7bfb56ae5e2f223_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzQtMy0xLTEtNDYwMTM_8d679b85-748a-4636-b447-9d99d6b786e9"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i49ea832c4a2441fa815b2b46be792d19_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzQtNS0xLTEtNDYwMTM_b01358d6-65e4-4666-949d-001c7b724a8e"
      unitRef="usd">31935000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia22881527d4b49cc88625aa8abc67b5c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzQtNy0xLTEtNDYwMTM_b28a6e7d-51ae-4246-8346-bd44011408fa"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i13616c69d6954d9dbcff580bb0481727_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzUtMS0xLTEtNDYwMTM_1b3a8e0e-4048-45e9-ba27-d5d54e163180"
      unitRef="usd">7022000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0cf9501a699e4a90b12f236486a35622_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzUtMy0xLTEtNDYwMTM_f8158b8f-0175-4ad5-bae1-77c598d88f46"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i16228cefd2e34ed3ad2ef7d53b54f81c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzUtNS0xLTEtNDYwMTM_fc120c24-8352-458b-b322-0176f1a39149"
      unitRef="usd">7022000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i132317a517fe469983d16efc145dde7b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzUtNy0xLTEtNDYwMTM_c9772b3c-f84a-4b33-b7e2-dad4781a1937"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if244d874422d4171840a2bb10d682a60_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzYtMS0xLTEtNDg1MDY_d65d22ff-142b-4a7f-8aef-8201654b8160"
      unitRef="usd">5304000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if834c52fad8d4fa786b3476c7c479709_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzYtMy0xLTEtNDg1MDY_69cee13a-b5e5-4614-ae9c-05c69747ed3f"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i243d57116a1a4a2abd6f7b0ba194d8ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzYtNS0xLTEtNDg1MDY_9f84a2a8-ef18-4b90-9518-a5ac6389ed2c"
      unitRef="usd">5304000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6c70318515a54462aad17c07ab4595b2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzYtNy0xLTEtNDg1MDY_a188c4bd-c3b7-4802-9b7f-c8f7766564e2"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i13f16a403b294350a327194d8765e8ef_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzgtMS0xLTEtNDYwMTM_99ffb22b-baf2-4303-aaa8-82451d9d1395"
      unitRef="usd">115436000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie065f8ba75da42ef8bfcb4016909b6aa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzgtMy0xLTEtNDYwMTM_bf253dc3-e4a8-4311-9dad-0f6402b2092d"
      unitRef="usd">71175000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifa8e2576d88e4d9f819b34c985d539dd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzgtNS0xLTEtNDYwMTM_5d73408a-86d3-4c3c-9f26-e7d75fde10f5"
      unitRef="usd">44261000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id1f7ed33632142769f453e0680a04d95_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzgtNy0xLTEtNDYwMTM_ca3b4265-4a36-4fee-88be-199fb7d18e0a"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="if07f3ef040004928a2a337f7a98fc44c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzExLTEtMS0xLTQ2MDEz_91d40288-1504-46a8-9dd7-683ccfa6dbd5"
      unitRef="usd">698000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="icc4e7bf5193a4086bed2f7af56d70ed0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzExLTMtMS0xLTQ2MDEz_c632fb27-a3b3-456b-8a16-bcd11f94c797"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i390e968f8ffa426689dcafbbec33f877_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzExLTUtMS0xLTQ2MDEz_b23918b9-862d-4fbc-8f49-f88aad479b74"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i9bc52b266a974dc1bf42493dfd520bfe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzExLTctMS0xLTQ2MDEz_498ed823-cc67-4442-9db1-7259864ff5aa"
      unitRef="usd">698000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i13f16a403b294350a327194d8765e8ef_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzEyLTEtMS0xLTQ2MDEz_39ed4a2b-edd6-4d3f-b629-4b39088aa41a"
      unitRef="usd">698000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ie065f8ba75da42ef8bfcb4016909b6aa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzEyLTMtMS0xLTQ2MDEz_7a9c1606-760f-49b1-8246-3394853339d9"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ifa8e2576d88e4d9f819b34c985d539dd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzEyLTUtMS0xLTQ2MDEz_1344f907-c34c-409a-8b2f-532b831427a3"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="id1f7ed33632142769f453e0680a04d95_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90YWJsZTpmODNlOTgwNWI5MWE0MGU1ODcxMWE5MWIwZGE0MGVhYS90YWJsZXJhbmdlOmY4M2U5ODA1YjkxYTQwZTU4NzExYTkxYjBkYTQwZWFhXzEyLTctMS0xLTQ2MDEz_9fb1804f-8bfe-4945-a760-222464edfd11"
      unitRef="usd">698000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90ZXh0cmVnaW9uOjA2NzI0MDE2MzE1MDQwZjlhOTVmNzhlMWZmMGQxYzZiXzMwMDI_95aa3fae-08f7-4c1d-8398-af6bb5015407"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMDkvZnJhZzowNjcyNDAxNjMxNTA0MGY5YTk1Zjc4ZTFmZjBkMWM2Yi90ZXh0cmVnaW9uOjA2NzI0MDE2MzE1MDQwZjlhOTVmNzhlMWZmMGQxYzZiXzMwMDI_b13e4ea4-ae3e-4ba9-a3d5-0d0ebf6bb5c2"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTU4L2ZyYWc6MTY0Y2M3ZDZlZWI5NGZkZTg0NjUzZDY0MjlkMWQ2ZDQvdGV4dHJlZ2lvbjoxNjRjYzdkNmVlYjk0ZmRlODQ2NTNkNjQyOWQxZDZkNF8yMTk5MDIzMjU2MzM3_3b3c8c6c-009a-4430-8178-c4a1d52a2701">INVENTORY&lt;div style="margin-bottom:3pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We began capitalizing inventory during the fourth quarter of 2021, at which time our intent to commercialize IBSRELA was established and we commenced preparation for the commercial launch of IBSRELA. Inventory as of December&#160;31, 2021 was not material. Inventory as of December&#160;31, 2022 consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reported as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;28,346&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Prepaid commercial manufacturing of $13.6&#160;million and $9.4&#160;million as of December&#160;31, 2022 and 2021, respectively, consisted of prepayments to third party contract manufacturing organizations for the manufacture of IBSRELA for production orders which we expect work to commence within the next 12 months.</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTU4L2ZyYWc6MTY0Y2M3ZDZlZWI5NGZkZTg0NjUzZDY0MjlkMWQ2ZDQvdGV4dHJlZ2lvbjoxNjRjYzdkNmVlYjk0ZmRlODQ2NTNkNjQyOWQxZDZkNF84Nzk2MDkzMDIzMzE4_c58b8d53-20c0-450b-a644-6eea945955c1">Inventory as of December&#160;31, 2022 consisted of the following (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reported as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;28,346&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTU4L2ZyYWc6MTY0Y2M3ZDZlZWI5NGZkZTg0NjUzZDY0MjlkMWQ2ZDQvdGV4dHJlZ2lvbjoxNjRjYzdkNmVlYjk0ZmRlODQ2NTNkNjQyOWQxZDZkNF8yMTk5MDIzMjU2MzM4_48fcbe0e-7eff-4194-aba9-4945a745c5ef">Inventory as of December&#160;31, 2022 consisted of the following (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reported as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;28,346&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTU4L2ZyYWc6MTY0Y2M3ZDZlZWI5NGZkZTg0NjUzZDY0MjlkMWQ2ZDQvdGFibGU6NTRlMTIwMzBhMGY5NDA3Mzg2OGE4ZDRmOGEwY2E5ZTUvdGFibGVyYW5nZTo1NGUxMjAzMGEwZjk0MDczODY4YThkNGY4YTBjYTllNV8xLTItMS0xLTUwMTE0_5495e3e7-5372-4735-9fd1-1df14b8a394b"
      unitRef="usd">22299000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTU4L2ZyYWc6MTY0Y2M3ZDZlZWI5NGZkZTg0NjUzZDY0MjlkMWQ2ZDQvdGFibGU6NTRlMTIwMzBhMGY5NDA3Mzg2OGE4ZDRmOGEwY2E5ZTUvdGFibGVyYW5nZTo1NGUxMjAzMGEwZjk0MDczODY4YThkNGY4YTBjYTllNV8yLTItMS0xLTUwMTE0_d46889ea-25a7-4478-9a8e-e70bb2caa258"
      unitRef="usd">5324000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTU4L2ZyYWc6MTY0Y2M3ZDZlZWI5NGZkZTg0NjUzZDY0MjlkMWQ2ZDQvdGFibGU6NTRlMTIwMzBhMGY5NDA3Mzg2OGE4ZDRmOGEwY2E5ZTUvdGFibGVyYW5nZTo1NGUxMjAzMGEwZjk0MDczODY4YThkNGY4YTBjYTllNV8zLTItMS0xLTUwMTE0_9a4c85b3-983e-4c2d-ab32-ece7ac1720c8"
      unitRef="usd">723000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTU4L2ZyYWc6MTY0Y2M3ZDZlZWI5NGZkZTg0NjUzZDY0MjlkMWQ2ZDQvdGFibGU6NTRlMTIwMzBhMGY5NDA3Mzg2OGE4ZDRmOGEwY2E5ZTUvdGFibGVyYW5nZTo1NGUxMjAzMGEwZjk0MDczODY4YThkNGY4YTBjYTllNV80LTItMS0xLTUwMTE0_db58c182-4722-4987-bfc0-cc9444b008f9"
      unitRef="usd">28346000</us-gaap:InventoryNet>
    <us-gaap:InventoryGross
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTU4L2ZyYWc6MTY0Y2M3ZDZlZWI5NGZkZTg0NjUzZDY0MjlkMWQ2ZDQvdGFibGU6NTRlMTIwMzBhMGY5NDA3Mzg2OGE4ZDRmOGEwY2E5ZTUvdGFibGVyYW5nZTo1NGUxMjAzMGEwZjk0MDczODY4YThkNGY4YTBjYTllNV82LTItMS0xLTUwMTE0_1f941a14-0263-4430-8bfd-2692ad54b057"
      unitRef="usd">3282000</us-gaap:InventoryGross>
    <us-gaap:InventoryNoncurrent
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTU4L2ZyYWc6MTY0Y2M3ZDZlZWI5NGZkZTg0NjUzZDY0MjlkMWQ2ZDQvdGFibGU6NTRlMTIwMzBhMGY5NDA3Mzg2OGE4ZDRmOGEwY2E5ZTUvdGFibGVyYW5nZTo1NGUxMjAzMGEwZjk0MDczODY4YThkNGY4YTBjYTllNV83LTItMS0xLTUwMTE0_047bbf71-30cd-4629-b24a-ab918ad3bce8"
      unitRef="usd">25064000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNet
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTU4L2ZyYWc6MTY0Y2M3ZDZlZWI5NGZkZTg0NjUzZDY0MjlkMWQ2ZDQvdGFibGU6NTRlMTIwMzBhMGY5NDA3Mzg2OGE4ZDRmOGEwY2E5ZTUvdGFibGVyYW5nZTo1NGUxMjAzMGEwZjk0MDczODY4YThkNGY4YTBjYTllNV84LTItMS0xLTUwMTE0_2e71ce33-481e-4d25-9b8d-b86b9a7baaf5"
      unitRef="usd">28346000</us-gaap:InventoryNet>
    <ardx:PrepaidCommercialManufacturingCurrent
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTU4L2ZyYWc6MTY0Y2M3ZDZlZWI5NGZkZTg0NjUzZDY0MjlkMWQ2ZDQvdGV4dHJlZ2lvbjoxNjRjYzdkNmVlYjk0ZmRlODQ2NTNkNjQyOWQxZDZkNF81NDk3NTU4MTQ2MzE_db3ae23a-b280-40bc-b560-49942620566c"
      unitRef="usd">13600000</ardx:PrepaidCommercialManufacturingCurrent>
    <ardx:PrepaidCommercialManufacturingCurrent
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTU4L2ZyYWc6MTY0Y2M3ZDZlZWI5NGZkZTg0NjUzZDY0MjlkMWQ2ZDQvdGV4dHJlZ2lvbjoxNjRjYzdkNmVlYjk0ZmRlODQ2NTNkNjQyOWQxZDZkNF81NDk3NTU4MTQ2Mzc_edfb73ca-af98-4e6b-bb9e-a5a47434f72f"
      unitRef="usd">9400000</ardx:PrepaidCommercialManufacturingCurrent>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGV4dHJlZ2lvbjo1ZDQ1MmY3OWRiNWM0Zjc4YTQyMGZhMjI0MWQ4YmRiZF8yMTk5MDIzMjU2NTAy_d11e92bc-2fe9-4ea8-8227-d6274f5535fc">PRODUCT REVENUE, NET&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We received approval from the FDA in September 2019 to market IBSRELA in the U.S. We began selling IBSRELA in the U.S. in March 2022. We recorded net revenue for IBSRELA of $15.6&#160;million during the twelve months ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales to AmerisourceBergen Drug Corporation, Cardinal Health, and McKesson Corporation made up 26.8%, 23.1%, and 21.6%, respectively, of our gross product revenue during the twelve months ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Discounts and Chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Rebates, Wholesaler and GPO Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Copay and Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Activity related to 2022 sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits/deductions issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(683)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,244)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no product sales or gross-to-net accruals during the twelve months ended December&#160;31, 2021 or 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0713ee81cc9747f9ae72ce305219dcfb_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGV4dHJlZ2lvbjo1ZDQ1MmY3OWRiNWM0Zjc4YTQyMGZhMjI0MWQ4YmRiZF81NDk3NTU4MTQ3MjU_98534e3f-422f-4e29-a651-97078101b767"
      unitRef="usd">15600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i71d12a4b8c5d41dd913f71f3f0c6a002_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGV4dHJlZ2lvbjo1ZDQ1MmY3OWRiNWM0Zjc4YTQyMGZhMjI0MWQ4YmRiZF81NDk3NTU4MTQ4MDQ_61ddbae7-e3dd-49a1-a263-7f2b179e127a"
      unitRef="number">0.268</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2cd807982655470294b4c867e9790f9f_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGV4dHJlZ2lvbjo1ZDQ1MmY3OWRiNWM0Zjc4YTQyMGZhMjI0MWQ4YmRiZF81NDk3NTU4MTQ4MDg_63d92a8c-cbd4-4a8b-bb6a-efaec1928a1b"
      unitRef="number">0.231</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia9f614394a884bf3935e5190b6e13cbc_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGV4dHJlZ2lvbjo1ZDQ1MmY3OWRiNWM0Zjc4YTQyMGZhMjI0MWQ4YmRiZF81NDk3NTU4MTQ4MTI_b8a15959-ce6b-49c8-be62-5d750eaeda3f"
      unitRef="number">0.216</us-gaap:ConcentrationRiskPercentage1>
    <ardx:ScheduleOfGrossToNetSalesAccrualsTableTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGV4dHJlZ2lvbjo1ZDQ1MmY3OWRiNWM0Zjc4YTQyMGZhMjI0MWQ4YmRiZF8yMTk5MDIzMjU2NTAz_fe801b3a-545d-4172-ba90-a2a2043c7926">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Discounts and Chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Rebates, Wholesaler and GPO Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Copay and Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Activity related to 2022 sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits/deductions issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(683)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,244)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ardx:ScheduleOfGrossToNetSalesAccrualsTableTextBlock>
    <ardx:ContractWithCustomerGrossToNetSalesAccruals
      contextRef="i2edca0d9c9d04eb4946163e30a07c874_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGFibGU6ZGE0ZWYwNDY4YjYxNDg1YmI3MWMwMzYxZTMxN2UxYzcvdGFibGVyYW5nZTpkYTRlZjA0NjhiNjE0ODViYjcxYzAzNjFlMzE3ZTFjN18xLTEtMS0xLTUwMTYz_21cef62b-39d4-4bd8-9007-0fd341911cb9"
      unitRef="usd">0</ardx:ContractWithCustomerGrossToNetSalesAccruals>
    <ardx:ContractWithCustomerGrossToNetSalesAccruals
      contextRef="i4364f4f8eb794e579c0d74bdcfc9a74d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGFibGU6ZGE0ZWYwNDY4YjYxNDg1YmI3MWMwMzYxZTMxN2UxYzcvdGFibGVyYW5nZTpkYTRlZjA0NjhiNjE0ODViYjcxYzAzNjFlMzE3ZTFjN18xLTMtMS0xLTUwMTYz_ef9ed1f6-6313-455c-9401-8b6184f87a9f"
      unitRef="usd">0</ardx:ContractWithCustomerGrossToNetSalesAccruals>
    <ardx:ContractWithCustomerGrossToNetSalesAccruals
      contextRef="i211614897cb84b21a3db4459c42a8128_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGFibGU6ZGE0ZWYwNDY4YjYxNDg1YmI3MWMwMzYxZTMxN2UxYzcvdGFibGVyYW5nZTpkYTRlZjA0NjhiNjE0ODViYjcxYzAzNjFlMzE3ZTFjN18xLTUtMS0xLTUwMTYz_cc525eba-c293-42b0-99d5-1477c340fef6"
      unitRef="usd">0</ardx:ContractWithCustomerGrossToNetSalesAccruals>
    <ardx:ContractWithCustomerGrossToNetSalesAccruals
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGFibGU6ZGE0ZWYwNDY4YjYxNDg1YmI3MWMwMzYxZTMxN2UxYzcvdGFibGVyYW5nZTpkYTRlZjA0NjhiNjE0ODViYjcxYzAzNjFlMzE3ZTFjN18xLTctMS0xLTUwMTYz_031d5298-a6f9-47f0-b93a-050c71cf0291"
      unitRef="usd">0</ardx:ContractWithCustomerGrossToNetSalesAccruals>
    <ardx:ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod
      contextRef="icbd146d95630481b89a9e53d21e7bfd0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGFibGU6ZGE0ZWYwNDY4YjYxNDg1YmI3MWMwMzYxZTMxN2UxYzcvdGFibGVyYW5nZTpkYTRlZjA0NjhiNjE0ODViYjcxYzAzNjFlMzE3ZTFjN18yLTEtMS0xLTUwMTYz_c5355d51-b408-4718-b366-336539952994"
      unitRef="usd">825000</ardx:ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod>
    <ardx:ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod
      contextRef="i378e9c4f2d8d414fb7b08c9fccc9c3c1_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGFibGU6ZGE0ZWYwNDY4YjYxNDg1YmI3MWMwMzYxZTMxN2UxYzcvdGFibGVyYW5nZTpkYTRlZjA0NjhiNjE0ODViYjcxYzAzNjFlMzE3ZTFjN18yLTMtMS0xLTUwMTYz_3ce1417a-eda5-4cf0-be58-7df29542d6dc"
      unitRef="usd">2721000</ardx:ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod>
    <ardx:ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod
      contextRef="i375a2ae60c4f4ac8bbe9ccc543f7a1c8_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGFibGU6ZGE0ZWYwNDY4YjYxNDg1YmI3MWMwMzYxZTMxN2UxYzcvdGFibGVyYW5nZTpkYTRlZjA0NjhiNjE0ODViYjcxYzAzNjFlMzE3ZTFjN18yLTUtMS0xLTUwMTYz_25b14907-e21d-4427-8fb7-483fe1d1e0b4"
      unitRef="usd">2502000</ardx:ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod>
    <ardx:ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGFibGU6ZGE0ZWYwNDY4YjYxNDg1YmI3MWMwMzYxZTMxN2UxYzcvdGFibGVyYW5nZTpkYTRlZjA0NjhiNjE0ODViYjcxYzAzNjFlMzE3ZTFjN18yLTctMS0xLTUwMTYz_be5e7bd8-6c1c-4fe5-acc1-cafc248986a7"
      unitRef="usd">6048000</ardx:ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod>
    <ardx:ContractWithCustomerGrossToCreditsOrDeductionsIssued
      contextRef="icbd146d95630481b89a9e53d21e7bfd0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGFibGU6ZGE0ZWYwNDY4YjYxNDg1YmI3MWMwMzYxZTMxN2UxYzcvdGFibGVyYW5nZTpkYTRlZjA0NjhiNjE0ODViYjcxYzAzNjFlMzE3ZTFjN18zLTEtMS0xLTUwMTYz_c695f651-7184-4af5-be88-85922d072cc4"
      unitRef="usd">-683000</ardx:ContractWithCustomerGrossToCreditsOrDeductionsIssued>
    <ardx:ContractWithCustomerGrossToCreditsOrDeductionsIssued
      contextRef="i378e9c4f2d8d414fb7b08c9fccc9c3c1_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGFibGU6ZGE0ZWYwNDY4YjYxNDg1YmI3MWMwMzYxZTMxN2UxYzcvdGFibGVyYW5nZTpkYTRlZjA0NjhiNjE0ODViYjcxYzAzNjFlMzE3ZTFjN18zLTMtMS0xLTUwMTYz_3412b431-12c0-426b-88c5-45ef3273e422"
      unitRef="usd">-1277000</ardx:ContractWithCustomerGrossToCreditsOrDeductionsIssued>
    <ardx:ContractWithCustomerGrossToCreditsOrDeductionsIssued
      contextRef="i375a2ae60c4f4ac8bbe9ccc543f7a1c8_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGFibGU6ZGE0ZWYwNDY4YjYxNDg1YmI3MWMwMzYxZTMxN2UxYzcvdGFibGVyYW5nZTpkYTRlZjA0NjhiNjE0ODViYjcxYzAzNjFlMzE3ZTFjN18zLTUtMS0xLTUwMTYz_8f06f1e1-e2d2-4150-a455-ad334f63def1"
      unitRef="usd">-1244000</ardx:ContractWithCustomerGrossToCreditsOrDeductionsIssued>
    <ardx:ContractWithCustomerGrossToCreditsOrDeductionsIssued
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGFibGU6ZGE0ZWYwNDY4YjYxNDg1YmI3MWMwMzYxZTMxN2UxYzcvdGFibGVyYW5nZTpkYTRlZjA0NjhiNjE0ODViYjcxYzAzNjFlMzE3ZTFjN18zLTctMS0xLTUwMTYz_c55a79d5-02d3-458c-9357-c9b33d214577"
      unitRef="usd">-3204000</ardx:ContractWithCustomerGrossToCreditsOrDeductionsIssued>
    <ardx:ContractWithCustomerGrossToNetSalesAccruals
      contextRef="i4459a35d21754ee897db3e8dbb29305d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGFibGU6ZGE0ZWYwNDY4YjYxNDg1YmI3MWMwMzYxZTMxN2UxYzcvdGFibGVyYW5nZTpkYTRlZjA0NjhiNjE0ODViYjcxYzAzNjFlMzE3ZTFjN180LTEtMS0xLTUwMTYz_1e86f0d8-134f-49de-a7b4-c36b6771102d"
      unitRef="usd">142000</ardx:ContractWithCustomerGrossToNetSalesAccruals>
    <ardx:ContractWithCustomerGrossToNetSalesAccruals
      contextRef="if2880e66b0644122b083edc9fd38c11d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGFibGU6ZGE0ZWYwNDY4YjYxNDg1YmI3MWMwMzYxZTMxN2UxYzcvdGFibGVyYW5nZTpkYTRlZjA0NjhiNjE0ODViYjcxYzAzNjFlMzE3ZTFjN180LTMtMS0xLTUwMTYz_c2c21d7c-74e7-4401-9842-61fe4aae07e8"
      unitRef="usd">1444000</ardx:ContractWithCustomerGrossToNetSalesAccruals>
    <ardx:ContractWithCustomerGrossToNetSalesAccruals
      contextRef="i855b02ed9cf247be9e99838bb95cb4ba_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGFibGU6ZGE0ZWYwNDY4YjYxNDg1YmI3MWMwMzYxZTMxN2UxYzcvdGFibGVyYW5nZTpkYTRlZjA0NjhiNjE0ODViYjcxYzAzNjFlMzE3ZTFjN180LTUtMS0xLTUwMTYz_a7c7b5d7-f56e-4ab8-a912-0c5733057326"
      unitRef="usd">1258000</ardx:ContractWithCustomerGrossToNetSalesAccruals>
    <ardx:ContractWithCustomerGrossToNetSalesAccruals
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGFibGU6ZGE0ZWYwNDY4YjYxNDg1YmI3MWMwMzYxZTMxN2UxYzcvdGFibGVyYW5nZTpkYTRlZjA0NjhiNjE0ODViYjcxYzAzNjFlMzE3ZTFjN180LTctMS0xLTUwMTYz_4a7bce54-65d7-4061-88ea-a09bdff75f68"
      unitRef="usd">2844000</ardx:ContractWithCustomerGrossToNetSalesAccruals>
    <ardx:ContractWithCustomerProductSalesGrossToNetAccruals
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGV4dHJlZ2lvbjo1ZDQ1MmY3OWRiNWM0Zjc4YTQyMGZhMjI0MWQ4YmRiZF81NDk3NTU4MTQ4MTY_0aa4aeff-4a6a-4356-803f-3387afb39d20"
      unitRef="usd">0</ardx:ContractWithCustomerProductSalesGrossToNetAccruals>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifee111286a5d4c6e8104da9cafffda38_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGV4dHJlZ2lvbjo1ZDQ1MmY3OWRiNWM0Zjc4YTQyMGZhMjI0MWQ4YmRiZF81NDk3NTU4MTQ4MTY_27dd7215-b769-4ef9-b9d9-c86fe6f9d74f"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ardx:ContractWithCustomerProductSalesGrossToNetAccruals
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGV4dHJlZ2lvbjo1ZDQ1MmY3OWRiNWM0Zjc4YTQyMGZhMjI0MWQ4YmRiZF81NDk3NTU4MTQ4MTY_b2a16909-1ec3-4a48-88d7-602d315e02f1"
      unitRef="usd">0</ardx:ContractWithCustomerProductSalesGrossToNetAccruals>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if6d0767c281240d4900cc0d8b9580230_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTY0L2ZyYWc6NWQ0NTJmNzlkYjVjNGY3OGE0MjBmYTIyNDFkOGJkYmQvdGV4dHJlZ2lvbjo1ZDQ1MmY3OWRiNWM0Zjc4YTQyMGZhMjI0MWQ4YmRiZF81NDk3NTU4MTQ4MTY_c76a64ef-54bf-452d-882a-46a851dcda2d"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzEzNzcz_f8dae5d5-79f3-4491-b29a-df5b77307391">COLLABORATION AND LICENSING AGREEMENTS&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Kyowa Kirin Co., Ltd. ("KKC")&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2019 KKC Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, we entered into a research collaboration and option agreement with KKC ("2019 KKC Agreement&#x201d;), to undergo research to identify two preclinical study-ready compounds for designation as development compounds, with one compound inhibiting the first undisclosed target (&#x201c;Program 1&#x201d;) and a second inhibiting the second undisclosed target (&#x201c;Program &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2&#x201d;). Pursuant to the 2019 KKC Agreement, upon completion of the research and designation by the research steering committee of one or more development candidates (&#x201c;DCs&#x201d;), KKC has the right to execute one or more separate collaborative agreements relating to the development and commercialization of one or both DCs in certain specified territories.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the 2019 KKC Agreement, KKC paid us a non-refundable, non-creditable upfront fee of $10.0 million, in two installments as follows: the first installment of $5.0 million within 30 days of November 11, 2019 ("Effective Date"), and the second installment of $5.0 million on the first anniversary of the Effective Date. The original term of the 2019 KKC Agreement commenced on the Effective Date and was to end on the earliest of: (i) two years following the Effective Date, (ii) the nomination of a program DC for both programs, (iii) the nomination of one program DC and the decision by the parties to cease research for the other program, or (iv) the decision by the parties to cease research for both programs. We entered into three amendments to the 2019 KKC Agreement, which have resulted in the extension of the original term. Under the third amendment to the 2019 KKC Agreement entered into on June 28, 2022, the 2019 KKC Agreement ended on February 28, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assessed the 2019 KKC Agreement in accordance with ASC 606 and concluded that the contract&#x2019;s counterparty, KKC, is a customer. We also considered the modification guidance prescribed in ASC 606 and concluded that the 2019 KKC Agreement should be accounted for as a separate contract from the 2017 KKC Agreement, as defined and discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We identified various promises in the 2019 KKC Agreement, including the grant of an initial research license, the Program 1 research, the Program 2 research, the right to obtain certain development and commercialization rights with Program 1 in certain territories and the right to obtain development and commercialization rights with Program 2 in certain territories, and participation in a joint steering committee&#160;(&#x201c;JSC&#x201d;) and determined that KKC could not benefit from either of the research programs without the research license and participation in the JSC. As such, the combined license, research programs and participation in the JSC were deemed to be the highest level of goods and services that can be deemed distinct for each of the Program 1 research and Program 2 research. We concluded that the options to obtain additional development and commercialization rights that are exercisable by KKC under certain circumstances are not performance obligations of the contract at inception because the option fees reflect the standalone selling price of the options, and therefore, the options are not considered to be material rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the outset of the 2019 KKC Agreement, we determined that the initial transaction price was $10.0 million and that revenue associated with the combined performance obligations should be recognized as services are provided using the input method. Since transfer of control occurs over time, in management&#x2019;s judgment this input method is the best measure of progress towards satisfying the performance obligations and reflects a faithful depiction of the transfer of goods and services. Revenue was recognized over the Program 1 and Program 2 research periods which concluded in 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2022 and 2021, we recognized zero and $4.2 million, respectively, as revenue under the 2019 KKC Agreement in the statement of operations and comprehensive loss. The transaction price had been fully allocated to revenue as of December&#160;31, 2021 and there was no associated deferred revenue presented on the balance sheet as of December&#160;31, 2022 or 2021. As of December&#160;31, 2022 and 2021, we had no material future obligations under the 2019 KKC Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2017 KKC Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2017, we entered into an exclusive license agreement with KKC (&#x201c;2017 KKC Agreement&#x201d;), under which we granted KKC an exclusive license to develop and commercialize certain NHE3 inhibitors including tenapanor in Japan for the treatment of cardiorenal diseases and conditions, excluding cancer. We retained the rights to tenapanor outside of Japan, and also retained the rights to tenapanor in Japan for indications other than those stated above. Pursuant to the 2017 KKC Agreement, KKC is responsible for all costs and expenses incurred in the development and commercialization of tenapanor for all licensed indications in Japan. We are responsible for supplying the tenapanor drug substance for KKC&#x2019;s use in development and commercialization throughout the term of the 2017 KKC Agreement, provided that KKC may exercise an option to manufacture the tenapanor drug substance under certain conditions. In October 2022, we entered into a Commercial Supply Agreement with KKC to further define the obligations of the parties with respect to the commercial supply of tenapanor drug substance (&#x201c;2022 KKC Supply Agreement&#x201d;). As detailed below under the heading &#x201c;Deferred revenue&#x2019; we have received advanced payments from KKC for the manufacturing of tenapanor drug substance that will be used to satisfy KKC needs. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assessed these arrangements in accordance with Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2014-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers (Topic 606) and related amendments (&#x201c;ASC 606&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and concluded that the contract counterparty, KKC, is a customer. Under the terms of the 2017 KKC Agreement, we received $30.0 million in up-front license fees, which was recognized as revenue when the agreement was executed. Based on our assessment, management determined that the &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;license and the manufacturing supply services were the material performance obligations at the inception of the 2017 KKC Agreement and, as such, each of the performance obligations is distinct. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the 2017 KKC Agreement, KKC paid us an up-front license fee of $30.0 million,. We may be entitled to receive up to $55.0 million in total development and regulatory milestones, of which $20.0 million has been received and recognized as revenue as of December&#160;31, 2022. We may also be eligible to receive approximately &#xa5;8.5&#160;billion for commercialization milestones, or approximately $64.6 million at the currency exchange rate on December&#160;31, 2022, as well as reimbursement of costs plus a reasonable overhead for the supply of product and royalties on net sales throughout the term of the agreement. As discussed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 8. Deferred Royalty Obligation Related to the Sale of Future Royalties&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the future royalties and commercial milestone payments we may receive under the 2017 KKC Agreement will be remitted to HealthCare Royalty Partners IV, L.P. pursuant to a Royalty and Sales Milestone Interest Acquisition Agreement. The variable consideration related to the remaining milestone payments was fully constrained at December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2022, we entered into a second amendment to the 2017 KKC Agreement ("2022 Amendment"). Under the terms of the 2022 Amendment, we and KKC have agreed to a reduction in the royalty rate payable to us by KKC upon net sales of tenapanor for hyperphosphatemia in Japan. The royalty rate will be reduced from the high teens to low double digits for a two-year period of time following the first commercial sale in Japan, and then to mid-single digits for the remainder of the royalty term. As discussed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 8. Deferred Royalty Obligation Related to the Sale of Future Royalties&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the future commercial milestones and royalties we may receive under the 2017 KKC Agreement will be remitted to HealthCare Royalty Partners IV, L.P. pursuant to a Royalty and Sales Milestone Interest Acquisition Agreement. As consideration for the reduction in the royalty rate, KKC agreed to pay us up to an additional $40.0 million payable in two tranches, with the first payment due following KKC's filing with the Japanese Ministry of Health, Labour and Welfare of its application for marketing approval for tenapanor and the second payment due following KKC&#x2019;s receipt of regulatory approval to market tenapanor for hyperphosphatemia in Japan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2022, we announced that KKC submitted an NDA to the Japanese Ministry of Health, Labour and Welfare for tenapanor for the improvement of hyperphosphatemia in adult patients with CKD on dialysis, which resulted in payment to us from KKC for an aggregate of $35.0 million for milestone payments and payments under the 2022 Amendment. We received these payments during the fourth quarter of 2022 and recorded them as licensing revenue on our statement of operations and comprehensive loss. The remaining variable consideration related to the reduction in the royalty rate was fully constrained at December&#160;31, 2022. For the year ended December&#160;31, 2021, $5.0 million of licensing revenue was recorded upon the initiation of phase 3 clinical studies by KKC in Japan to evaluate tenapanor for hyperphosphatemia.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2022 and 2021, $1.5 million and $0.9 million, respectively, of product supply revenue was recorded for manufacturing supply of tenapanor and other materials to KKC for product development and clinical trials in Japan, in accordance with our agreement with the 2017 KKC Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2022 and 2021, $35.0 million and $5.0 million, respectively, of licensing revenue was recorded. The 2022 licensing revenue was earned upon KKC's submission of an NDA to the Japanese Ministry of Health, Labour and Welfare for tenapanor for the improvement of hyperphosphatemia in adult patients with CKD on dialysis. The 2021 licensing revenue was recorded upon the initiation of Phase 3 clinical studies by KKC in Japan to evaluate tenapanor for hyperphosphatemia.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. ("Fosun Pharma")&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2017, we entered into an exclusive license agreement with Fosun Pharma ("Fosun Agreement") for the development, commercialization and distribution of tenapanor in China for both hyperphosphatemia and IBS-C. We assessed these arrangements in accordance with ASC 606 and concluded that the contract counterparty, Fosun Pharma, is a customer. Under the terms of the Fosun Agreement, we received $12.0 million in up-front license fees which was recognized as revenue when the agreement was executed. Based on our assessment, we determined that the license and the manufacturing supply services represented the material performance obligations at the inception of the agreement and, as such, each of the performance obligations are distinct.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may be entitled to additional development and commercialization milestones of up to $110.0 million, as well as reimbursement of cost plus a reasonable overhead for the supply of product and tiered royalties on net sales ranging from the mid-teens to 20%. The variable consideration related to the remaining development milestone payments was fully constrained at December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recorded no revenue related to the Fosun Agreement during the years ended December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Knight Therapeutics, Inc. ("Knight")&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2018, we entered into an exclusive license agreement with Knight Therapeutics, Inc., ("Knight Agreement") for the development, commercialization and distribution of tenapanor in Canada for hyperphosphatemia and IBS-C. We assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Knight, is a customer. Based on our assessment, we determined that the license and the manufacturing supply services were the material performance obligations at the inception of the agreement and, as such, each of the performance obligations are distinct.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Knight Agreement, we received a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$2.3 million non-refundable, one-time upfront payment in March 2018 and may be eligible to receive additional development and commercialization milestone payments worth up to CAD22.2, or approximately $16.3 million at the currency exchange rate on December&#160;31, 2022. We are also eligible to receive royalties ranging from the mid-single digits to the low twenties throughout the term of the agreement, and a transfer price for manufacturing services.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The variable consideration related to the remaining development milestone payments were fully constrained at December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2022 and 2021, $31 thousand and $13 thousand of licensing revenue was recorded, respectively, related to the Knight Agreement. For the years ended December&#160;31, 2022 and 2021, no product supply revenue was recorded, respectively, related to the Knight Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;AstraZeneca AB ("AstraZeneca")&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2015, we entered into a termination agreement with AstraZeneca ("AstraZeneca Termination Agreement") pursuant to which we have agreed to pay AstraZeneca (i) future royalties at a royalty rate of 10% of net sales of tenapanor or other NHE3 products by us or our licensees, and (ii) 20% of non-royalty revenue received from a new collaboration partner should we elect to license, or otherwise provide rights to develop and commercialize tenapanor or another NHE3 inhibitor, up to a maximum of $75.0 million in aggregate for (i) and (ii). For the years ended December&#160;31, 2022 and 2021, we recognized $3.6 million and $1.0 million, respectively, as cost of revenue related to the AstraZeneca Termination Agreement. To date in aggregate, we have recognized $15.3 million of the $75.0 million aggregate maximum related to the AstraZeneca Termination Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present changes in our current and non-current deferred revenue balances during the reporting period. The December&#160;31, 2022 deferred revenue current and non-current balances are attributable entirely to prepayments for product supply under the 2017 KKC Agreement, while the December&#160;31, 2021 current deferred revenue balance is attributable to the 2019 KKC Agreement and the December&#160;31, 2021 non-current deferred revenue balance is attributable prepayments for product supply under the 2017 KKC Agreement (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred revenue - current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at Balance at January 1,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases due to cash received, excluding amounts recognized as revenue during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases due to amounts reclassified from non-current, to be recognized in the next twelve months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases to amounts invoiced, for which cash has not yet been received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decreases due to revenue recognized in the period for which cash has been received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,177)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred revenue - non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at Balance at January 1,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases due to cash received during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases to amounts invoiced, for which cash has not yet been received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase due to unbilled prepayments recorded during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decreases due to amounts reclassified as current, to be recognized in the next twelve months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,961)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <ardx:NumberOfSeparateCollaborativeAgreements
      contextRef="i955167e463ef48678bbc1d03c4f4d412_D20191101-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzY1OA_35e80f2e-cde1-4c2e-89f8-c09570ed6b0a"
      unitRef="item">1</ardx:NumberOfSeparateCollaborativeAgreements>
    <ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees
      contextRef="i91c2203d38fd405d99bc3c88353bce51_D20191101-20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTgyOTcxOQ_fff60f5c-6ad6-4001-a639-b0ed67210c86"
      unitRef="usd">10000000</ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees>
    <ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment
      contextRef="i91c2203d38fd405d99bc3c88353bce51_D20191101-20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTgyOTcyNg_18443fba-2df3-40ac-8e4b-17b25dedcc0e"
      unitRef="usd">5000000</ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment>
    <ardx:TermOfPaymentOfLicenseFeeFirstInstallment
      contextRef="i91c2203d38fd405d99bc3c88353bce51_D20191101-20191130"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2Xzk4Nw_7f083c79-1467-4736-aeb7-3733ab3369a2">P30D</ardx:TermOfPaymentOfLicenseFeeFirstInstallment>
    <ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment
      contextRef="i91c2203d38fd405d99bc3c88353bce51_D20191101-20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTgyOTczMA_77721edb-b7c4-4462-aa7e-88de361446c6"
      unitRef="usd">5000000</ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment>
    <ardx:TermOfAgreement
      contextRef="i91c2203d38fd405d99bc3c88353bce51_D20191101-20191130"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzEzMDY_a861abd3-bad3-46ed-9120-70a3990aef58">P2Y</ardx:TermOfAgreement>
    <ardx:CollaborationAndLicensingAgreementsNumberOfAmendments
      contextRef="i91c2203d38fd405d99bc3c88353bce51_D20191101-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2Xzc2OTY1ODE0MTY4ODA_ecbea56e-d7d4-4b78-bbe1-7964e4e748ba"
      unitRef="segment">3</ardx:CollaborationAndLicensingAgreementsNumberOfAmendments>
    <ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees
      contextRef="i91c2203d38fd405d99bc3c88353bce51_D20191101-20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTgyOTczOQ_fff60f5c-6ad6-4001-a639-b0ed67210c86"
      unitRef="usd">10000000</ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia5096f6f9abe4dccb2dab386d07f22b0_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzM5Mzg_6e5edc43-e0a0-4b40-9a2e-e8c36bb9ea41"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ied48f951c2e54c4c9458741287f35022_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzM5NDU_77e24472-1170-4e68-8050-cf94932cbc6c"
      unitRef="usd">4200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="icfd7890f2ab641b689a46d3387cd65f5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTgzMDE2Ng_d8dd0d5e-a393-42e3-834f-3c96acf3c15d"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i317cad6de7604d25be88b176cb33baec_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTgzMDE2Ng_fd102e7a-e557-43d5-891e-ef510d815225"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees
      contextRef="i7f143c1e0eb144d6b655d94ab37c1a53_D20171101-20171130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTgzMTU4OQ_1fccd503-9b7b-459e-b101-952e69f4aa36"
      unitRef="usd">30000000</ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees>
    <ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees
      contextRef="i7f143c1e0eb144d6b655d94ab37c1a53_D20171101-20171130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTgzMjQwMQ_1fccd503-9b7b-459e-b101-952e69f4aa36"
      unitRef="usd">30000000</ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees>
    <ardx:CollaborativeArrangementPotentialDevelopmentMilestones
      contextRef="iff763b0fc4f84d4dac40730c49cc1731_I20171130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTgzMjQwOA_2f212d43-7039-47e6-919e-0b8e6d10b6ec"
      unitRef="usd">55000000</ardx:CollaborativeArrangementPotentialDevelopmentMilestones>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i687d24ba9ed84bf19bb4b4b49a494d08_D20171101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzcxOTI_42d24670-6ef1-4f08-b05c-c1f8e41b0d49"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ardx:CollaborativeArrangementPotentialCommercializationMilestones
      contextRef="ife00f72d231640e4becd88f58e11171e_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTgzMjQyOA_13be76eb-3653-4101-9e2a-bf638733a2ef"
      unitRef="jpy">8500000000</ardx:CollaborativeArrangementPotentialCommercializationMilestones>
    <ardx:CollaborativeArrangementPotentialCommercializationMilestones
      contextRef="ife00f72d231640e4becd88f58e11171e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzcyODk_e59eea0b-6caf-484f-9609-0ac5fc733b27"
      unitRef="usd">64600000</ardx:CollaborativeArrangementPotentialCommercializationMilestones>
    <ardx:CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate
      contextRef="if2637e6a1a82402793001d3d295bbbcd_I20220430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2Xzc2OTY1ODE0MjI1NTA_0b3870b7-fe37-4a05-bd8c-ab6ee37df0de"
      unitRef="usd">40000000</ardx:CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate>
    <ardx:CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches
      contextRef="if2637e6a1a82402793001d3d295bbbcd_I20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzQ0OTQ0_abefcc74-3567-452d-8da1-84e585452dbc"
      unitRef="payment_tranche">2</ardx:CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches>
    <ardx:RevenueRemainingPerformanceObligationVariableConsiderationAmount
      contextRef="i59072502f7a54137b0895e14bb4f6df8_I20221031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzQ0OTQ4_b5a66aff-cb85-4d0b-906e-2170d81a8eaf"
      unitRef="usd">35000000</ardx:RevenueRemainingPerformanceObligationVariableConsiderationAmount>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4dd8313c3e094ef89785a59b13d01eb7_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTg1NDM4MQ_0fc1244b-3d10-48c4-9984-f78e71accb48"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i60b13327723642e6932c3f852855047d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2Xzc2OTE_d00ecf86-4b7b-4b51-92ed-900fa9a368fb"
      unitRef="usd">1500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id10493b7130846e6b2a4742b479a65fe_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2Xzc2OTg_06720236-7375-4ded-bd88-528b0a6662e5"
      unitRef="usd">900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i715636a1b5ae4b288a29b92c2f3a54b3_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2Xzc5OTA_93b889db-f1f2-413e-8502-6a646ae68cbe"
      unitRef="usd">35000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4dd8313c3e094ef89785a59b13d01eb7_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2Xzc2OTY1ODE0MjcyNzQ_0fc1244b-3d10-48c4-9984-f78e71accb48"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="i274489be58ee4be5a06cb71683dc70e0_D20171201-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTgzMzQxMg_39bda077-68ef-43cb-a507-5a555f8cee0e"
      unitRef="usd">12000000</us-gaap:ProceedsFromLicenseFeesReceived>
    <ardx:CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones
      contextRef="i96f5a69e2c1547719e984c8ba3c41ff3_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTgzMzQ4Mg_fa058cde-deee-4af6-bf89-7ee0a8a578de"
      unitRef="usd">110000000</ardx:CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones>
    <ardx:ThresholdPercentageOfSalesForTieredRoyalties
      contextRef="i96f5a69e2c1547719e984c8ba3c41ff3_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTgzMzQ4OQ_68eab14d-fee0-4df9-b670-7af175e21c70"
      unitRef="number">0.20</ardx:ThresholdPercentageOfSalesForTieredRoyalties>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i99e3d63e61664f6bbfac5c19cb4294e3_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTgzMzU3OQ_07aa2c1c-2b29-4253-9f45-bd94b63d5ad0"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff2fbe5c1eb741e185c1d68735dd7502_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTgzMzU3OQ_eba602be-f669-4303-9139-078bbd61f8ce"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="i7523c9db4f3440e1bbc8ab0589ca11c5_D20180301-20180331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzEwNTc3_21bdc5b3-1d69-4ded-9501-ea80048e1e51"
      unitRef="usd">2300000</us-gaap:ProceedsFromLicenseFeesReceived>
    <ardx:CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones
      contextRef="if78e3d93318c461da96ac8c6973a6f76_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2Xzc2OTY1ODE0MTQyOTc_a0d0c053-11bd-4b1f-ae9e-fb38bb89b998"
      unitRef="cad">22200000</ardx:CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones>
    <ardx:CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones
      contextRef="if78e3d93318c461da96ac8c6973a6f76_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTgzMzc0Ng_3bd5a307-1ee9-46e9-bcdb-bf2ab3c8b8ff"
      unitRef="usd">16300000</ardx:CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieba6fa1b17514fa99298840f1171592e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzExMjA1_43889a03-9a0e-4c21-a964-0ff7f1ab2002"
      unitRef="usd">31000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i83f16a4b0497447dae41222920314fae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzExMjEy_9d6d6f45-424e-499f-88ac-93c451ac9db0"
      unitRef="usd">13000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0f4842d33b674e97bec5e1f35f13347e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzExMzI4_72a8898a-da10-4c51-bad4-95d5109a2361"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i85d4b734d53646fa9eece46433fcc33e_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzExMzI4_e07ff929-6a76-4231-8c9c-ee1217f6bd66"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ardx:PercentageOfRoyaltyRevenue
      contextRef="i23a66360caef450d9534fe2775f21255_D20150601-20150630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTg0NTUzMg_f8f1354e-9995-450c-8bd2-4a412d52d809"
      unitRef="number">0.10</ardx:PercentageOfRoyaltyRevenue>
    <ardx:PercentageOfNonRoyaltyRevenue
      contextRef="i23a66360caef450d9534fe2775f21255_D20150601-20150630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTg0NTUzNg_602d4ed0-947c-4d9a-8f19-9596062c8979"
      unitRef="number">0.20</ardx:PercentageOfNonRoyaltyRevenue>
    <ardx:CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum
      contextRef="i8e9b10bffc104601b9077dcc9e1f4fa6_I20150630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzEzMTg0_1733a871-e164-4593-944b-512c578139c9"
      unitRef="usd">75000000</ardx:CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum>
    <us-gaap:CostOfRevenue
      contextRef="if72c0334b4964673b5b1e29e363186db_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTg1NTY1MQ_36b185d9-107d-4365-9982-511a1bbfe345"
      unitRef="usd">3600000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="ifc0eee8426754521a747a26cbaedb831_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTg1NTY2Ng_a60bfc01-3133-4ef6-b81d-0f2f68771b2f"
      unitRef="usd">1000000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i1d7903c12c424b3ba490589eb00fd14d_D20150601-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTg1NTY4Mg_e14c5961-91f7-47c8-bb48-3510e3197fec"
      unitRef="usd">15300000</us-gaap:CostOfRevenue>
    <ardx:CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum
      contextRef="i8e9b10bffc104601b9077dcc9e1f4fa6_I20150630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzU0OTc1NTg1NTY5OA_1733a871-e164-4593-944b-512c578139c9"
      unitRef="usd">75000000</ardx:CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90ZXh0cmVnaW9uOmFjNmFlYWQwMGQyMTRmNmJhOTYxNjk1Nzk2OTI5ZDI2XzEzNzcy_e25552b1-4ad6-4ed4-a97a-8d342c36ea5e">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present changes in our current and non-current deferred revenue balances during the reporting period. The December&#160;31, 2022 deferred revenue current and non-current balances are attributable entirely to prepayments for product supply under the 2017 KKC Agreement, while the December&#160;31, 2021 current deferred revenue balance is attributable to the 2019 KKC Agreement and the December&#160;31, 2021 non-current deferred revenue balance is attributable prepayments for product supply under the 2017 KKC Agreement (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred revenue - current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at Balance at January 1,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases due to cash received, excluding amounts recognized as revenue during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases due to amounts reclassified from non-current, to be recognized in the next twelve months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases to amounts invoiced, for which cash has not yet been received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decreases due to revenue recognized in the period for which cash has been received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,177)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred revenue - non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at Balance at January 1,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases due to cash received during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases to amounts invoiced, for which cash has not yet been received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase due to unbilled prepayments recorded during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decreases due to amounts reclassified as current, to be recognized in the next twelve months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,961)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i7c98abb4d89044e0ab93ab428d564f5f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo2YjNlZTkxOWU3NWQ0MWIxYjJhZjZlYTUyY2VjMTJhYS90YWJsZXJhbmdlOjZiM2VlOTE5ZTc1ZDQxYjFiMmFmNmVhNTJjZWMxMmFhXzEtMS0xLTEtNDYwMTM_25439f70-11e0-4407-b0e0-d63117bfd97e"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ib952c4e7da01441388aaeecabdfe075a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo2YjNlZTkxOWU3NWQ0MWIxYjJhZjZlYTUyY2VjMTJhYS90YWJsZXJhbmdlOjZiM2VlOTE5ZTc1ZDQxYjFiMmFmNmVhNTJjZWMxMmFhXzEtMy0xLTEtNDYwMTM_b514d168-21b0-47c0-a9c7-1fc8d2ee5053"
      unitRef="usd">4177000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <ardx:ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenueDuringThePeriod
      contextRef="i236464e64f8d473283dc7641b1f31d01_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo2YjNlZTkxOWU3NWQ0MWIxYjJhZjZlYTUyY2VjMTJhYS90YWJsZXJhbmdlOjZiM2VlOTE5ZTc1ZDQxYjFiMmFmNmVhNTJjZWMxMmFhXzItMS0xLTEtNTM3NTM_fbe55d8f-3c86-4d3c-b054-bf4aea6584fc"
      unitRef="usd">42000</ardx:ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenueDuringThePeriod>
    <ardx:ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenueDuringThePeriod
      contextRef="ied48f951c2e54c4c9458741287f35022_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo2YjNlZTkxOWU3NWQ0MWIxYjJhZjZlYTUyY2VjMTJhYS90YWJsZXJhbmdlOjZiM2VlOTE5ZTc1ZDQxYjFiMmFmNmVhNTJjZWMxMmFhXzItMy0xLTEtNTM3NTM_51f233a6-c485-4dfd-8d61-9ef26768fe69"
      unitRef="usd">0</ardx:ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenueDuringThePeriod>
    <ardx:ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths
      contextRef="i236464e64f8d473283dc7641b1f31d01_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo2YjNlZTkxOWU3NWQ0MWIxYjJhZjZlYTUyY2VjMTJhYS90YWJsZXJhbmdlOjZiM2VlOTE5ZTc1ZDQxYjFiMmFmNmVhNTJjZWMxMmFhXzMtMS0xLTEtNTM3NTM_a9297b79-deec-4a30-bbb6-eb5489d53aaf"
      unitRef="usd">3961000</ardx:ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths>
    <ardx:ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths
      contextRef="ied48f951c2e54c4c9458741287f35022_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo2YjNlZTkxOWU3NWQ0MWIxYjJhZjZlYTUyY2VjMTJhYS90YWJsZXJhbmdlOjZiM2VlOTE5ZTc1ZDQxYjFiMmFmNmVhNTJjZWMxMmFhXzMtMy0xLTEtNTM3NTM_9c3a422b-0be6-4fdb-b5b8-7d7b1498d778"
      unitRef="usd">0</ardx:ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths>
    <ardx:ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived
      contextRef="i236464e64f8d473283dc7641b1f31d01_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo2YjNlZTkxOWU3NWQ0MWIxYjJhZjZlYTUyY2VjMTJhYS90YWJsZXJhbmdlOjZiM2VlOTE5ZTc1ZDQxYjFiMmFmNmVhNTJjZWMxMmFhXzQtMS0xLTEtNTM3NTM_6de5d365-534a-4d64-9ea6-d0b538a08833"
      unitRef="usd">208000</ardx:ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived>
    <ardx:ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived
      contextRef="ied48f951c2e54c4c9458741287f35022_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo2YjNlZTkxOWU3NWQ0MWIxYjJhZjZlYTUyY2VjMTJhYS90YWJsZXJhbmdlOjZiM2VlOTE5ZTc1ZDQxYjFiMmFmNmVhNTJjZWMxMmFhXzQtMy0xLTEtNTM3NTM_dcb31873-57b6-4ea9-9898-a1ddd1ce6a4d"
      unitRef="usd">0</ardx:ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived>
    <ardx:ContractWithCustomerLiabilityRevenueRecognizedCashReceived
      contextRef="i236464e64f8d473283dc7641b1f31d01_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo2YjNlZTkxOWU3NWQ0MWIxYjJhZjZlYTUyY2VjMTJhYS90YWJsZXJhbmdlOjZiM2VlOTE5ZTc1ZDQxYjFiMmFmNmVhNTJjZWMxMmFhXzItMS0xLTEtNDYwMTM_a9e043d2-3c1b-45c8-9795-f368a2b22381"
      unitRef="usd">0</ardx:ContractWithCustomerLiabilityRevenueRecognizedCashReceived>
    <ardx:ContractWithCustomerLiabilityRevenueRecognizedCashReceived
      contextRef="ied48f951c2e54c4c9458741287f35022_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo2YjNlZTkxOWU3NWQ0MWIxYjJhZjZlYTUyY2VjMTJhYS90YWJsZXJhbmdlOjZiM2VlOTE5ZTc1ZDQxYjFiMmFmNmVhNTJjZWMxMmFhXzItMy0xLTEtNDYwMTM_aa240402-d662-42b2-8952-36e645a4b679"
      unitRef="usd">4177000</ardx:ContractWithCustomerLiabilityRevenueRecognizedCashReceived>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i8366fe12a3334315af3ed1c7052d20c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo2YjNlZTkxOWU3NWQ0MWIxYjJhZjZlYTUyY2VjMTJhYS90YWJsZXJhbmdlOjZiM2VlOTE5ZTc1ZDQxYjFiMmFmNmVhNTJjZWMxMmFhXzUtMS0xLTEtNDYwMTM_c53d8123-24dc-4171-b375-d85dc0444358"
      unitRef="usd">4211000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="icfd7890f2ab641b689a46d3387cd65f5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo2YjNlZTkxOWU3NWQ0MWIxYjJhZjZlYTUyY2VjMTJhYS90YWJsZXJhbmdlOjZiM2VlOTE5ZTc1ZDQxYjFiMmFmNmVhNTJjZWMxMmFhXzUtMy0xLTEtNDYwMTM_58aecaa8-a10f-48b4-abc1-b26f1fa38ee3"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="icfd7890f2ab641b689a46d3387cd65f5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo0NTA2ZDMxZmU0Y2Y0MDQwODliNjNjNDFlZDg2YzEwMS90YWJsZXJhbmdlOjQ1MDZkMzFmZTRjZjQwNDA4OWI2M2M0MWVkODZjMTAxXzEtMS0xLTEtNDYwMTM_db465ff0-190b-4f13-80a0-4f5b5f200faf"
      unitRef="usd">4727000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ib8ee7345370441099ade9119306db79b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo0NTA2ZDMxZmU0Y2Y0MDQwODliNjNjNDFlZDg2YzEwMS90YWJsZXJhbmdlOjQ1MDZkMzFmZTRjZjQwNDA4OWI2M2M0MWVkODZjMTAxXzEtMy0xLTEtNDYwMTM_d64fe73e-a4d1-4779-8006-ad7442339890"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <ardx:ContractWithCustomerLiabilityIncreaseForCashReceived
      contextRef="ia5096f6f9abe4dccb2dab386d07f22b0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo0NTA2ZDMxZmU0Y2Y0MDQwODliNjNjNDFlZDg2YzEwMS90YWJsZXJhbmdlOjQ1MDZkMzFmZTRjZjQwNDA4OWI2M2M0MWVkODZjMTAxXzItMS0xLTEtNTM3Njc_d75c17aa-9e32-47c3-8b16-a8b911dab20e"
      unitRef="usd">7794000</ardx:ContractWithCustomerLiabilityIncreaseForCashReceived>
    <ardx:ContractWithCustomerLiabilityIncreaseForCashReceived
      contextRef="i0d56b583b1d146f7be5316e8e2d710b4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo0NTA2ZDMxZmU0Y2Y0MDQwODliNjNjNDFlZDg2YzEwMS90YWJsZXJhbmdlOjQ1MDZkMzFmZTRjZjQwNDA4OWI2M2M0MWVkODZjMTAxXzItMy0xLTEtNTM3Njc_4a5c88ac-5fe6-4dad-8ce6-a5a184ebca38"
      unitRef="usd">3242000</ardx:ContractWithCustomerLiabilityIncreaseForCashReceived>
    <ardx:ContractWithCustomerLiabilityIncreasesToAmountsInvoicedButCashNotReceived
      contextRef="ia5096f6f9abe4dccb2dab386d07f22b0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo0NTA2ZDMxZmU0Y2Y0MDQwODliNjNjNDFlZDg2YzEwMS90YWJsZXJhbmdlOjQ1MDZkMzFmZTRjZjQwNDA4OWI2M2M0MWVkODZjMTAxXzMtMS0xLTEtNTM3Njc_2ea3290b-0761-4a7c-8eba-28fe5deb84a6"
      unitRef="usd">465000</ardx:ContractWithCustomerLiabilityIncreasesToAmountsInvoicedButCashNotReceived>
    <ardx:ContractWithCustomerLiabilityIncreasesToAmountsInvoicedButCashNotReceived
      contextRef="i0d56b583b1d146f7be5316e8e2d710b4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo0NTA2ZDMxZmU0Y2Y0MDQwODliNjNjNDFlZDg2YzEwMS90YWJsZXJhbmdlOjQ1MDZkMzFmZTRjZjQwNDA4OWI2M2M0MWVkODZjMTAxXzMtMy0xLTEtNTM3Njc_405d6786-1401-4691-a490-491df65884cb"
      unitRef="usd">0</ardx:ContractWithCustomerLiabilityIncreasesToAmountsInvoicedButCashNotReceived>
    <ardx:ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded
      contextRef="ia5096f6f9abe4dccb2dab386d07f22b0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo0NTA2ZDMxZmU0Y2Y0MDQwODliNjNjNDFlZDg2YzEwMS90YWJsZXJhbmdlOjQ1MDZkMzFmZTRjZjQwNDA4OWI2M2M0MWVkODZjMTAxXzQtMS0xLTEtNTM3Njc_717e2d5a-c122-4974-9702-93e35e766a4a"
      unitRef="usd">0</ardx:ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded>
    <ardx:ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded
      contextRef="i0d56b583b1d146f7be5316e8e2d710b4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo0NTA2ZDMxZmU0Y2Y0MDQwODliNjNjNDFlZDg2YzEwMS90YWJsZXJhbmdlOjQ1MDZkMzFmZTRjZjQwNDA4OWI2M2M0MWVkODZjMTAxXzQtMy0xLTEtNTM3Njc_81a8ba8d-5cdd-4973-8a11-9108871b02b4"
      unitRef="usd">1485000</ardx:ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded>
    <ardx:ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths
      contextRef="ia5096f6f9abe4dccb2dab386d07f22b0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo0NTA2ZDMxZmU0Y2Y0MDQwODliNjNjNDFlZDg2YzEwMS90YWJsZXJhbmdlOjQ1MDZkMzFmZTRjZjQwNDA4OWI2M2M0MWVkODZjMTAxXzItMS0xLTEtNDYwMTM_fa558bf9-8646-4d96-9fd4-6d324e13fc28"
      unitRef="usd">3961000</ardx:ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths>
    <ardx:ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths
      contextRef="i0d56b583b1d146f7be5316e8e2d710b4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo0NTA2ZDMxZmU0Y2Y0MDQwODliNjNjNDFlZDg2YzEwMS90YWJsZXJhbmdlOjQ1MDZkMzFmZTRjZjQwNDA4OWI2M2M0MWVkODZjMTAxXzItMy0xLTEtNDYwMTM_d46b1632-86d7-421d-a935-852ff50c7fc3"
      unitRef="usd">0</ardx:ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i317cad6de7604d25be88b176cb33baec_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo0NTA2ZDMxZmU0Y2Y0MDQwODliNjNjNDFlZDg2YzEwMS90YWJsZXJhbmdlOjQ1MDZkMzFmZTRjZjQwNDA4OWI2M2M0MWVkODZjMTAxXzUtMS0xLTEtNDYwMTM_ab7665e3-f980-4f57-bded-fa14e4346668"
      unitRef="usd">9025000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i7c98abb4d89044e0ab93ab428d564f5f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTIvZnJhZzphYzZhZWFkMDBkMjE0ZjZiYTk2MTY5NTc5NjkyOWQyNi90YWJsZTo0NTA2ZDMxZmU0Y2Y0MDQwODliNjNjNDFlZDg2YzEwMS90YWJsZXJhbmdlOjQ1MDZkMzFmZTRjZjQwNDA4OWI2M2M0MWVkODZjMTAxXzUtMy0xLTEtNDYwMTM_a3999538-9997-4173-a57e-1210a510c897"
      unitRef="usd">4727000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:AssetRetirementObligationDisclosureTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTcxL2ZyYWc6Mzc0MTZhNTgwZjYxNGViM2IxZWQ4ZTExOWU5MzBjYTQvdGV4dHJlZ2lvbjozNzQxNmE1ODBmNjE0ZWIzYjFlZDhlMTE5ZTkzMGNhNF8yMTk5MDIzMjYwMjY2_438f7ee8-33e2-40fc-8315-4b5f2a3bf08f">DEFERRED ROYALTY OBLIGATION RELATED TO THE SALE OF FUTURE ROYALTIES&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, we and HealthCare Royalty Partners IV, L.P. (&#x201c;HCR&#x201d;) entered into a Royalty and Sales Milestone Interest Acquisition Agreement (&#x201c;HCR Agreement&#x201d;). Under the terms of the HCR Agreement, HCR has agreed to pay us up to $20.0 million in exchange for the royalty payments and commercial milestone payments (collectively the &#x201c;Royalty Interest Payments&#x201d;) that we may receive under our 2017 License Agreement with KKC based upon KKC's net sales of tenapanor in Japan for hyperphosphatemia. As consideration for the sale of the Royalty Interest Payments, HCR paid to us a $10.0 million upfront payment, and we are eligible to receive a $5.0 million payment following KKC's receipt of regulatory approval to market tenapanor for hyperphosphatemia in Japan, and another $5.0 million payment in the event net sales by KKC in Japan exceed a certain annual target level by the end of 2025.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The HCR Agreement is effective until terminated by the mutual agreement of the parties and contains customary representations and warranties and customary affirmative and negative covenants, including, among others, requirements as to prosecution, maintenance, defense and enforcement of certain patent rights in Japan, restrictions regarding our ability to forgive, release or reduce any Royalty Interest Payments due to us under the 2017 KKC Agreement, to create or incur any liens with respect to the Royalty Interest Payments, the 2017 KKC Agreement or certain patents, or to sell, license or transfer certain patents in the field and territory described in the 2017 KKC Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the HCR Agreement contains customary events of default with respect to which we may incur indemnification obligations to HCR for any losses incurred by HCR and related parties as a result of the event of default, subject to a specified limitation of liability cap. Under the HCR Agreement, an event of default will occur if, among other things, any of the representations and warranties included in the HCR Agreement proves not to have been true and correct in all material respects, at the time it was made, we breach any of our covenants under the HCR Agreement, subject to specified cure periods with respect to certain breaches, we are in breach or default under the 2017 KKC Agreement in any manner which is likely to cause a material adverse effect on the Royalty Interest Payments, the occurrence of a termination of the 2017 KKC Agreement under certain circumstances or we or our assets become subject to certain legal proceedings, such as bankruptcy proceedings, or we are unable to pay our debts as they become due.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We received the $10.0 million upfront payment from HCR during June 2022 and recorded it as a deferred royalty obligation related to the sale of future royalties ("deferred royalty obligation") on our balance sheet. Due to our ongoing manufacturing obligations under the 2017 KKC Agreement, we account for the proceeds as imputed debt and therefore will recognize royalties received under the arrangement as non-cash royalty revenue. Non-cash interest expense will be recognized over the life of the HCR Agreement using the effective interest method based on the imputed interest rate derived from estimated amounts and timing of future royalty payments to be received from KKC. As part of the sale, we incurred approximately $0.4 million in transaction costs, which, along with the deferred royalty obligation, are being amortized to non-cash interest expense over the estimated life of the HCR Agreement using the effective interest method. As future royalties are remitted to us by KKC, and subsequently from us to HCR, the balance of the deferred royalty obligation will be effectively repaid over the life of the HCR Agreement. There are a number of factors that could materially affect the fair value of the deferred royalty obligation. Such factors include, but are not limited to, the amount and timing of potential future royalty payments to be received from KKC under the 2017 KKC agreement, changing standards of care, the introduction of competing products, manufacturing or other delays, intellectual property matters, adverse events that result in governmental health authority imposed restrictions on the use of the drug products, significant changes in foreign exchange rates as the royalties remitted to HCR are made in U.S. dollars while the underlying sales of the products by KKC are made in Japanese yen, and other events or circumstances that could result in reduced royalty payments from KKC, which are not within our control, and all of which would result in a reduction of non-cash royalty revenues and the non-cash interest expense over the life of the deferred royalty obligation. We periodically assess the estimated royalty payments from KKC and, to the extent that the amount or timing of such payments is materially different than our original estimates, we prospectively adjust the imputed interest rate and &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the related amortization of the deferred royalty obligation. As of December&#160;31, 2022, our effective interest rate used to amortize the liability is 34.4%. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the twelve months ended December&#160;31, 2022, we recognized approximately $1.7 million of non-cash interest expense for the amortization of the deferred royalty obligation. As of December&#160;31, 2022, we have received no royalty payments from KKC and, therefore, the deferred royalty obligation has not begun to be reduced.&lt;/span&gt;&lt;/div&gt;</us-gaap:AssetRetirementObligationDisclosureTextBlock>
    <us-gaap:IncreaseDecreaseInRoyaltiesPayable
      contextRef="i4d7bf861c12549a792483e8efc814a9e_D20220601-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTcxL2ZyYWc6Mzc0MTZhNTgwZjYxNGViM2IxZWQ4ZTExOWU5MzBjYTQvdGV4dHJlZ2lvbjozNzQxNmE1ODBmNjE0ZWIzYjFlZDhlMTE5ZTkzMGNhNF81NDk3NTU4MTg1MDg_7ecb26e0-56b5-4c69-b668-eed16ecfeab6"
      unitRef="usd">20000000</us-gaap:IncreaseDecreaseInRoyaltiesPayable>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i41ff706f90cc43a59020a70376e95dd2_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTcxL2ZyYWc6Mzc0MTZhNTgwZjYxNGViM2IxZWQ4ZTExOWU5MzBjYTQvdGV4dHJlZ2lvbjozNzQxNmE1ODBmNjE0ZWIzYjFlZDhlMTE5ZTkzMGNhNF81NDk3NTU4MTg1MTU_b5c4c522-9884-456e-9884-0560c843d9c7"
      unitRef="usd">10000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i41ff706f90cc43a59020a70376e95dd2_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTcxL2ZyYWc6Mzc0MTZhNTgwZjYxNGViM2IxZWQ4ZTExOWU5MzBjYTQvdGV4dHJlZ2lvbjozNzQxNmE1ODBmNjE0ZWIzYjFlZDhlMTE5ZTkzMGNhNF81NDk3NTU4MTg1MjI_7fae8822-b041-47b3-952a-08d8a71cf4b5"
      unitRef="usd">5000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i41ff706f90cc43a59020a70376e95dd2_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTcxL2ZyYWc6Mzc0MTZhNTgwZjYxNGViM2IxZWQ4ZTExOWU5MzBjYTQvdGV4dHJlZ2lvbjozNzQxNmE1ODBmNjE0ZWIzYjFlZDhlMTE5ZTkzMGNhNF81NDk3NTU4MTg1MjY_796a52ab-f433-42be-9258-94870d621641"
      unitRef="usd">5000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i41ff706f90cc43a59020a70376e95dd2_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTcxL2ZyYWc6Mzc0MTZhNTgwZjYxNGViM2IxZWQ4ZTExOWU5MzBjYTQvdGV4dHJlZ2lvbjozNzQxNmE1ODBmNjE0ZWIzYjFlZDhlMTE5ZTkzMGNhNF81NDk3NTU4MTg1Mzg_b5c4c522-9884-456e-9884-0560c843d9c7"
      unitRef="usd">10000000</us-gaap:ContractWithCustomerLiability>
    <ardx:ContractWithCustomerLiabilityTransactionCosts
      contextRef="ia283d9f31c884152af9cfa5bfc1c18cc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTcxL2ZyYWc6Mzc0MTZhNTgwZjYxNGViM2IxZWQ4ZTExOWU5MzBjYTQvdGV4dHJlZ2lvbjozNzQxNmE1ODBmNjE0ZWIzYjFlZDhlMTE5ZTkzMGNhNF81NDk3NTU4MTg1NTU_e2f120f9-6392-44bf-81e6-7504b08b2087"
      unitRef="usd">400000</ardx:ContractWithCustomerLiabilityTransactionCosts>
    <ardx:ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent
      contextRef="i38d4c1dcbb354f1cb8f7b983e2aba1a6_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTcxL2ZyYWc6Mzc0MTZhNTgwZjYxNGViM2IxZWQ4ZTExOWU5MzBjYTQvdGV4dHJlZ2lvbjozNzQxNmE1ODBmNjE0ZWIzYjFlZDhlMTE5ZTkzMGNhNF81NDk3NTU4MTg1NzA_630894c9-9b78-4052-be8f-731c2f522741"
      unitRef="number">0.344</ardx:ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent>
    <us-gaap:AmortizationOfAdvanceRoyalty
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTcxL2ZyYWc6Mzc0MTZhNTgwZjYxNGViM2IxZWQ4ZTExOWU5MzBjYTQvdGV4dHJlZ2lvbjozNzQxNmE1ODBmNjE0ZWIzYjFlZDhlMTE5ZTkzMGNhNF81NDk3NTU4MTg1ODY_8766daef-005d-4e1d-a08c-a37ce3e4ec31"
      unitRef="usd">1700000</us-gaap:AmortizationOfAdvanceRoyalty>
    <us-gaap:ProceedsFromRoyaltiesReceived
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTcxL2ZyYWc6Mzc0MTZhNTgwZjYxNGViM2IxZWQ4ZTExOWU5MzBjYTQvdGV4dHJlZ2lvbjozNzQxNmE1ODBmNjE0ZWIzYjFlZDhlMTE5ZTkzMGNhNF81NDk3NTU4MTg1OTc_ac2d529c-8ce3-4d54-bd99-37625292dfe1"
      unitRef="usd">0</us-gaap:ProceedsFromRoyaltiesReceived>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzgxMjM_875d211a-970e-4f72-b939-0df7f451bd19">BORROWINGS&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Solar Capital and Western Alliance Bank Loan Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2018, we entered into a loan and security agreement ("2018 Loan Agreement"), with Solar Capital Ltd. and Western Alliance Bank ("Lenders&#x201d;). The 2018 Loan Agreement provided for a $50.0 million term loan facility with a maturity date of November&#160;1, 2022 ("2018 Term Loan&#x201d;). The full amount of the 2018 Term Loan was funded on May&#160;16, 2018. We received net proceeds from the loan of approximately $49.3 million, after deducting the closing fee, legal expenses and issuance costs. In October 2020, we and the Lenders entered into an amendment to the 2018 Loan Agreement (&#x201c;2020 Amendment&#x201d;) to extend the date through which we were permitted to make interest-only payments on the 2018 Term Loan by twelve months to December 1, 2021 subject to the repayment terms noted below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the 2018 Term Loan bore interest at a floating per annum rate equal to 7.45% plus the one-month London Inter-bank Offered Rate ("LIBOR"). We were permitted to make interest-only payments on the 2018 Term Loan through June 1, 2020, or until we achieved our primary endpoint in the Phase 3 study of tenapanor for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis prior to June&#160;1, 2020, in which case we would have been permitted to make interest-only payments on the 2018 Term Loan through December 1, 2020. In December 2019, we reported positive topline results for PHREEDOM, a long-term Phase 3 study evaluating the efficacy and safety of tenapanor as monotherapy for the treatment of hyperphosphatemia in adult patients with CKD on dialysis. The Lenders were in agreement that these positive data from the Phase 3 PHREEDOM study achieve the &#x201c;Phase 3 Endpoint&#x201d; required by the 2018 Term Loan to extend the interest only period by six months to December&#160;1, 2020. Subsequent to the 2020 Amendment, the interest only period was extended an additional twelve months to December 1, 2021. Accordingly, beginning on December&#160;1, 2021 through the maturity date, we would have been required to make monthly payments of interest plus repayment of the 2018 Term Loan in consecutive equal monthly installments of principal. If however, either the FDA did not approve our NDA for tenapanor for control of serum phosphorus in adult patients with CKD on dialysis on or before May 31, 2021 or the FDA issued a Complete Response Letter ("CRL") for tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis, then we would begin principal payments on the earlier of June 1, 2021 or the first day of the month immediately following the date that the FDA issued a CRL to us. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May and July 2021, we and the Lenders entered into additional amendments to the 2018 Loan Agreement (&#x201c;the 2021 Amendments&#x201d;) which together extended the period of time that we were permitted to make interest-only payments on the 2018 Term Loan to December 1, 2021; provided that if we had not received FDA approval for our NDA for tenapanor for the control of serum phosphorus in adult patients with CDK on dialysis on or before October 25, 2021, the interest-only period would expire and principal repayments would be required to begin on November 1, 2021. If principal repayments were required to begin prior to December 1, 2021 under the 2021 Amendments, then the first such repayment was required to include all payments that would have been due if monthly principal repayment had begun on June 1, 2021. Accordingly, during November 2021, in compliance with the terms of our 2018 Loan Agreement, we began to repay principal on the 2018 Term Loan. As of the Closing Date for the 2022 Loan, as discussed below, we owed $25.0&#160;million in principal payments from the 2018 Loan, which we repaid in full at that time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;SLR Investment Corp. Loan Agreement &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 23, 2022 (&#x201c;Closing Date&#x201d;), we entered into a loan and security agreement (&#x201c;2022 Loan Agreement&#x201d;) with SLR Investment Corp. as collateral agent (&#x201c;Agent&#x201d;), and the lenders listed in the 2022 Loan Agreement (collectively the &#x201c;2022 Lenders&#x201d;). The 2022 Loan Agreement provides for a senior secured loan facility, with $27.5 million (&#x201c;Term A Loan&#x201d;) funded on the Closing Date and an additional $22.5 million that we may borrow on or prior to July 25, 2023; provided that (i) we have received approval by the FDA for our NDA for XPHOZAH by December 31, 2022, and (ii) we have achieved certain product revenue milestone targets described in the 2022 Loan Agreement (&#x201c;Term B Loan&#x201d;, and collectively, the Term A Loan and the Term B Loan, the &#x201c;2022 Loan&#x201d;). On February 9, 2023, we entered into an amendment to the 2022 Loan Agreement with SLR Investment Corp. that extends the date by which we must receive approval by the FDA for our NDA for the control of serum phosphorus in adult patients with CKD on dialysis in order to borrow the additional $22.5 million from December 31, 2022 to November 30, 2023 and extended the period during which we are permitted to make interest only payments until March 31, &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025 if we receive approval by the FDA for our NDA for XPHOZAH on or prior to November 30, 2023 or achieve a defined net product revenue threshold for 2023. The 2022 Term A Loan funds were used to repay the 2018 Loan with the 2018 Lenders. The 2022 Loan has a maturity date of March 1, 2027.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the 2022 Loan bear interest at a floating per annum rate equal to 7.95% plus the greater of (i) one tenth percent (0.10%) and (ii) the one-month rate published by the Intercontinental Exchange Benchmark Administration Ltd or its successor. We are permitted to make interest-only payments on the 2022 Loan through March 31, 2024 or if certain conditions described above are achieved, through March 31, 2025. Accordingly, beginning on April 1, 2024 or April 1, 2025, we will be required to make monthly payments of interest plus repay the 2022 Loan in consecutive equal monthly installments of principal over 36 months or 24 months, respectively. We were obligated to pay $0.2 million, upon the closing of the Term A Loan, and we are obligated to pay $0.1 million on the earliest of (i) the funding date of the Term B Loan, (ii) July 25, 2023, and (iii) the prepayment, refinancing, substitution, or replacement of the Term A Loan on or prior to July 25, 2023. We are obligated to pay a final fee equal to 4.95% of the aggregate original principal amount of the 2022 Loan funded upon the earliest to occur of the maturity date, the acceleration of the 2022 Loan, and the prepayment, refinancing, substitution, or replacement of the 2022 Loan. We may voluntarily prepay the outstanding 2022 Loan balance, subject to a prepayment premium of (i) 3% of the outstanding principal amount of the 2022 Loan if prepaid prior to or on the first anniversary of the Closing Date, (ii) 2% of the outstanding principal amount of the 2022 Loan if prepaid after the first anniversary of the Closing Date through and including the second anniversary of the Closing Date, or (iii) 1% of the outstanding principal amount of the 2022 Loan if prepaid after the second anniversary of the Closing Date and prior to the maturity date. The 2022 Loan is secured by substantially all of our assets, except for our intellectual property and certain other customary exclusions. Additionally, in connection with the 2022 Loan, we entered into an agreement, whereby we agreed to pay an exit fee in the amount of 2% of the 2022 Loan funded (&#x201c;2022 Exit Fee&#x201d;) upon (i) any change of control transaction or (ii) our achievement of net revenue from the sale of any products equal to or greater than $100.0 million, measured on a six (6) months basis, tested monthly at the end of each month. Notwithstanding the prepayment or termination of the 2022 Loan, the 2022 Exit Fee will expire 10 years from the Closing Date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2022 Loan Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among others, requirements as to financial reporting and insurance and restrictions on our ability to dispose of our business or property, to change our line of business, to liquidate or dissolve, to enter into any change in control transaction, to merge or consolidate with any other entity or to acquire all or substantially all the capital stock or property of another entity, to incur additional indebtedness, to incur liens on our property, to pay any dividends or other distributions on capital stock other than dividends payable solely in capital stock or to redeem capital stock. We have agreed to not allow our cash and cash equivalents to be less than the eighty percent (80%) of the outstanding 2022 Term Loan balance for any period in which our net revenue from the sale of any products, calculated on a trailing six (6) month basis and tested monthly, is less than sixty percent (60%) of the outstanding 2022 Loan balance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the 2022 Loan Agreement contains customary events of default that entitle the Agent to cause our indebtedness under the 2022 Loan Agreement to become immediately due and payable, and to exercise remedies against us and the collateral securing the 2022 Term Loan, including our cash. Under the 2022 Loan Agreement, an event of default will occur if, among other things, we fail to make payments under the 2022 Loan Agreement, we breach any of our covenants under the 2022 Loan Agreement, subject to specified cure periods with respect to certain breaches, certain Lenders determine that a material adverse change has occurred, we or our assets become subject to certain legal proceedings, such as bankruptcy proceedings, we are unable to pay our debts as they become due or we default on contracts with third parties which would permit the holder of indebtedness to accelerate the maturity of such indebtedness or that could have a material adverse change on us. Upon the occurrence and for the duration of an event of default, an additional default interest rate equal to 4% per annum will apply to all obligations owed under the 2022 Loan Agreement. We have classified the 2022 Loan balance as a current liability as of December&#160;31, 2022 due to the determination of the existence of substantial doubt about our ability to continue operating as a going concern discussed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2. Summary of Significant Accounting Policies: Liquidity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and our assessment that the material adverse change clause under the 2022 Loan Agreement is not within our control. The lenders have not invoked the material adverse change clause as of the date of issuance of these financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 21. Subsequent Events&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on February 9, 2023, we entered into a second amendment (&#x201c;Second Amendment&#x201d;) to our Loan Agreement with the Lenders. The Second Amendment extends the interest-only term of the loan by twelve months to March 31, 2025 provided that we either (i) receive approval from the FDA for our NDA for the control of serum phosphorus in adult patients with CKD on dialysis on or prior to November 30, 2023 or (ii) achieve certain product revenue milestone targets as described in the Second Amendment for the year ending December 31, 2023. The Second Amendment also extends the period under which we may draw the Term B Loan from July 25, 2023 to December 20, 2023, and amends the milestone that we must achieve in order to draw the Term B Loan by extending the time period for the receipt of approval by the FDA of the NDA for the control of serum phosphorus in adult patients with CKD on dialysis until November 30, 2023. In addition, the Second Amendment replaces the floating per annum interest rate with 7.95% plus the greater of (a) one percent (1.00%) per annum and (b)(i) 0.022% plus (ii) 1-month CME Term SOFR reference rate as published by the CME Term SOFR Administrator on the CME Term SOFR Administrator&#x2019;s Website.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, our future payment obligations related to the 2022 Loan, excluding interest payments and the 2022 final fee, were as follows (in thousands) and may be condensed to the 24 months ending March 1, 2027 if certain conditions noted above to extend the interest-only period are achieved:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total repayment obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unamortized discount and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unaccreted value of final fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,040)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,711)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i933aaacf34f34a61bfa383d7cb1bb60d_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg1Njk0MQ_38e81747-f710-4f63-a213-dc6ee12797c1"
      unitRef="usd">50000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="if95076af06f24f2296cea9a5d6d76ff4_D20180501-20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzQ1NDEw_2e8f0fee-8345-4531-a604-acdb1794950a"
      unitRef="usd">49300000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <ardx:DebtInstrumentInterestPaymentExtensionTerm
      contextRef="i8733e6fccc254fd9bf95445ad142e86f_D20201001-20201031"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzQ1NDE0_6d4d00ef-b350-4805-9a0b-12facc48ec16">P12M</ardx:DebtInstrumentInterestPaymentExtensionTerm>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i95d5e831357142ff915c3c75ead6d520_D20180516-20180516"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg1Njk0OA_0b795889-e00c-4602-9633-84cad8aa3317"
      unitRef="number">0.0745</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <ardx:DebtInstrumentInterestPaymentExtensionTerm
      contextRef="i7c495d34647447ae8783de5a900a3e77_D20191201-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzQ1NDE4_0edac1e0-6c89-4913-9ecd-98e4bee884c9">P6M</ardx:DebtInstrumentInterestPaymentExtensionTerm>
    <ardx:DebtInstrumentInterestPaymentExtensionTerm
      contextRef="i69ee8e8bda5947d3a7b266f55eee864b_D20201009-20201009"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzQ1NDIy_f2fd08a7-1edb-40aa-ae4d-5ca52efcbb68">P12M</ardx:DebtInstrumentInterestPaymentExtensionTerm>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia1e9f731799b499eaf4aa779cb305fc6_I20180516"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg1Njg1Nw_51db30e9-a531-4b70-97fa-06771d1ba150"
      unitRef="usd">25000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="idaba5dc7a9024a1b89083ce66516cffd_D20220223-20220223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg0ODk0MQ_41d65aa5-ebaa-40dd-9057-fb2bb35009f8"
      unitRef="usd">27500000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <ardx:RemainingFundingBasedOnConditionalMilestoneAchievement
      contextRef="i4ed59bf2f32c4c919325b9d6800e3fad_I20220223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg0ODk0OA_ce424f42-357d-4424-8c2f-aa1784ed1729"
      unitRef="usd">22500000</ardx:RemainingFundingBasedOnConditionalMilestoneAchievement>
    <ardx:RemainingFundingBasedOnConditionalMilestoneAchievement
      contextRef="i4ed59bf2f32c4c919325b9d6800e3fad_I20220223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg0ODk1Mg_ce424f42-357d-4424-8c2f-aa1784ed1729"
      unitRef="usd">22500000</ardx:RemainingFundingBasedOnConditionalMilestoneAchievement>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i582ccc703db84580ad605cde3180b598_D20220223-20220223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg0ODk3Mg_95769b20-14c7-450c-8733-691ab10522b5"
      unitRef="number">0.0795</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <ardx:DebtInstrumentVariableRateBaseOption
      contextRef="i582ccc703db84580ad605cde3180b598_D20220223-20220223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg0ODk3Ng_cbeadd7d-8a36-48cf-89ff-0d3ab64e8a63"
      unitRef="number">0.0010</ardx:DebtInstrumentVariableRateBaseOption>
    <us-gaap:DebtInstrumentTerm
      contextRef="idaba5dc7a9024a1b89083ce66516cffd_D20220223-20220223"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzIxOTkwMjMyOTEwMDQ_ff2ee1bc-b2a5-4652-97cb-18a744c88017">P36M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm
      contextRef="i40c1281552f94064963e3bf9cbecc666_D20220223-20220223"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzIxOTkwMjMzMDA5NDQ_1e702658-fc24-4704-bff0-6920a6e80b79">P24M</us-gaap:DebtInstrumentTerm>
    <ardx:DebtInstrumentClosingFeeAmount
      contextRef="i62a2e82e4ddc4240896cf7fd6f83fbf6_I20220223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg0ODk4MA_730aee5b-bcf2-40ae-bfef-9b6157db0dd7"
      unitRef="usd">200000</ardx:DebtInstrumentClosingFeeAmount>
    <ardx:LoanAgreementFutureObligationUponFundingOrOtherEvents
      contextRef="i4ed59bf2f32c4c919325b9d6800e3fad_I20220223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg0ODk5Nw_675dba05-ac13-46ad-8dc5-11c3567496a3"
      unitRef="usd">100000</ardx:LoanAgreementFutureObligationUponFundingOrOtherEvents>
    <ardx:DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage
      contextRef="id31b250d8a3946278fda76b05ca4b4b1_I20220223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg0OTAwNA_71d25944-b242-4244-af23-391c4409e5e1"
      unitRef="number">0.0495</ardx:DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage>
    <ardx:DebtInstrumentPrepaymentFeePercentage
      contextRef="if668412fafc546cc955d0c29fa2f6c99_I20220223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg0OTAwOA_21cb6047-cb1c-4f0b-b48a-0d3573976766"
      unitRef="number">0.03</ardx:DebtInstrumentPrepaymentFeePercentage>
    <ardx:DebtInstrumentPrepaymentFeePercentage
      contextRef="i0f56c96387e743bbb3742ef501488a40_I20220223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg0OTAxOQ_eb1ea3c3-8a00-4267-af04-487a7d8429ee"
      unitRef="number">0.02</ardx:DebtInstrumentPrepaymentFeePercentage>
    <ardx:DebtInstrumentPrepaymentFeePercentage
      contextRef="i72298d93078c4637ab00517b03176997_I20220223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg0OTAyMw_02d6028a-5866-4da4-baa3-3ab48733ad82"
      unitRef="number">0.01</ardx:DebtInstrumentPrepaymentFeePercentage>
    <ardx:ExitFeePercentage
      contextRef="if0d290137b1441abbf8d0d36c58a8e95_I20220223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg0OTMxNQ_3db56add-e823-4af9-967a-60c729c630a8"
      unitRef="number">0.02</ardx:ExitFeePercentage>
    <ardx:LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum
      contextRef="i4584120047b3460da4d6b5a0f2eb0808_D20220223-20220223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg0OTMxOQ_0f87d771-a37b-4ba4-b9f5-1a0413caf14c"
      unitRef="usd">100000000</ardx:LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum>
    <ardx:LoanAgreementExitFeeTerm
      contextRef="i4584120047b3460da4d6b5a0f2eb0808_D20220223-20220223"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzIxOTkwMjMyOTEwMDU_9b4b7302-8171-45f4-80f9-49b1e2ddf409">P10Y</ardx:LoanAgreementExitFeeTerm>
    <ardx:LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum
      contextRef="id31b250d8a3946278fda76b05ca4b4b1_I20220223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg0OTAyNw_bf24e2af-3690-40d8-a663-ae8165d59fa3"
      unitRef="number">0.80</ardx:LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum>
    <ardx:LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod
      contextRef="iddc086b231bc43f99e47143a4bfb2914_D20220223-20220223"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg0OTAzNQ_45e9834d-45a8-4fd0-9347-0a8fe26a271f">P6M</ardx:LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod>
    <ardx:LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum
      contextRef="id31b250d8a3946278fda76b05ca4b4b1_I20220223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg0OTAzMQ_606ea207-3c76-464a-9fbe-5afbc26dc8af"
      unitRef="number">0.60</ardx:LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum>
    <ardx:DebtInstrumentInterestRateOnDefaultPercentage
      contextRef="id31b250d8a3946278fda76b05ca4b4b1_I20220223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg0OTAzOQ_8f586231-b738-4769-968d-049bb64f604b"
      unitRef="number">0.04</ardx:DebtInstrumentInterestRateOnDefaultPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ic957e7b2e6404684ab3ce4588e0747ed_D20230209-20230209"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg1ODgwMg_8558c00e-26e5-4608-a5f6-1304f05b61fa"
      unitRef="number">0.0795</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <ardx:DebtInstrumentVariableRateBaseOption
      contextRef="ic957e7b2e6404684ab3ce4588e0747ed_D20230209-20230209"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg1ODg0Mw_fbd702e0-e7d2-4b62-a06e-090be9e84594"
      unitRef="number">0.0100</ardx:DebtInstrumentVariableRateBaseOption>
    <ardx:DebtInstrumentVariableRatePlusOption
      contextRef="ic957e7b2e6404684ab3ce4588e0747ed_D20230209-20230209"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzU0OTc1NTg1ODg2OQ_e0c40463-b1e0-4520-89fa-851f08aecb84"
      unitRef="number">0.00022</ardx:DebtInstrumentVariableRatePlusOption>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90ZXh0cmVnaW9uOmQ0ZjJmOTNhODMxYTQ2YWJiNzI4ZWZkMjM0ODRmZjcyXzgxMjU_f5eaaf7c-1e3e-46b2-9b85-0c93ac2083bf">&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, our future payment obligations related to the 2022 Loan, excluding interest payments and the 2022 final fee, were as follows (in thousands) and may be condensed to the 24 months ending March 1, 2027 if certain conditions noted above to extend the interest-only period are achieved:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total repayment obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unamortized discount and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unaccreted value of final fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,040)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,711)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90YWJsZTpkZTQyOGVlYWE2ZGI0NTZlYTRhZDk5Y2IxMjRhYTdmYi90YWJsZXJhbmdlOmRlNDI4ZWVhYTZkYjQ1NmVhNGFkOTljYjEyNGFhN2ZiXzAtMS0xLTEtNDk0MzQ_9047ed40-c030-40af-ab4f-0bf8aabd9957"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90YWJsZTpkZTQyOGVlYWE2ZGI0NTZlYTRhZDk5Y2IxMjRhYTdmYi90YWJsZXJhbmdlOmRlNDI4ZWVhYTZkYjQ1NmVhNGFkOTljYjEyNGFhN2ZiXzEtMS0xLTEtNDk0MzQ_eb6f2001-0e9a-484f-9234-d605299e6f94"
      unitRef="usd">7639000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90YWJsZTpkZTQyOGVlYWE2ZGI0NTZlYTRhZDk5Y2IxMjRhYTdmYi90YWJsZXJhbmdlOmRlNDI4ZWVhYTZkYjQ1NmVhNGFkOTljYjEyNGFhN2ZiXzItMS0xLTEtNDk0MzQ_5db5411c-3e99-4862-8525-ffec9b7cd2bc"
      unitRef="usd">9167000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90YWJsZTpkZTQyOGVlYWE2ZGI0NTZlYTRhZDk5Y2IxMjRhYTdmYi90YWJsZXJhbmdlOmRlNDI4ZWVhYTZkYjQ1NmVhNGFkOTljYjEyNGFhN2ZiXzAtMS0xLTEtNDYwMTM_6f90704c-5285-4205-a395-6a22a142059d"
      unitRef="usd">9167000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90YWJsZTpkZTQyOGVlYWE2ZGI0NTZlYTRhZDk5Y2IxMjRhYTdmYi90YWJsZXJhbmdlOmRlNDI4ZWVhYTZkYjQ1NmVhNGFkOTljYjEyNGFhN2ZiXzEtMS0xLTEtNDYwMTM_94f8e216-ef31-4732-baa6-1882088d78bd"
      unitRef="usd">2888000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90YWJsZTpkZTQyOGVlYWE2ZGI0NTZlYTRhZDk5Y2IxMjRhYTdmYi90YWJsZXJhbmdlOmRlNDI4ZWVhYTZkYjQ1NmVhNGFkOTljYjEyNGFhN2ZiXzItMS0xLTEtNDYwMTM_29780f48-d1e5-4684-82d3-845ddf9a797b"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90YWJsZTpkZTQyOGVlYWE2ZGI0NTZlYTRhZDk5Y2IxMjRhYTdmYi90YWJsZXJhbmdlOmRlNDI4ZWVhYTZkYjQ1NmVhNGFkOTljYjEyNGFhN2ZiXzMtMS0xLTEtNDYwMTM_5a7190e2-2466-4e2f-9818-62a8a3887d9c"
      unitRef="usd">28861000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90YWJsZTpkZTQyOGVlYWE2ZGI0NTZlYTRhZDk5Y2IxMjRhYTdmYi90YWJsZXJhbmdlOmRlNDI4ZWVhYTZkYjQ1NmVhNGFkOTljYjEyNGFhN2ZiXzQtMS0xLTEtNDYwMTM_6f9d8685-b1a8-4390-bb5e-4039a90c96ca"
      unitRef="usd">1110000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90YWJsZTpkZTQyOGVlYWE2ZGI0NTZlYTRhZDk5Y2IxMjRhYTdmYi90YWJsZXJhbmdlOmRlNDI4ZWVhYTZkYjQ1NmVhNGFkOTljYjEyNGFhN2ZiXzUtMS0xLTEtNDYwMTM_f47d23d2-0b17-4fbf-81d5-18b0a26d3854"
      unitRef="usd">1040000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:LongTermDebt
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90YWJsZTpkZTQyOGVlYWE2ZGI0NTZlYTRhZDk5Y2IxMjRhYTdmYi90YWJsZXJhbmdlOmRlNDI4ZWVhYTZkYjQ1NmVhNGFkOTljYjEyNGFhN2ZiXzYtMS0xLTEtNDYwMTM_9764e245-b16a-4882-a4d6-7cb0e8e6c154"
      unitRef="usd">26711000</us-gaap:LongTermDebt>
    <us-gaap:LoansPayableCurrent
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90YWJsZTpkZTQyOGVlYWE2ZGI0NTZlYTRhZDk5Y2IxMjRhYTdmYi90YWJsZXJhbmdlOmRlNDI4ZWVhYTZkYjQ1NmVhNGFkOTljYjEyNGFhN2ZiXzctMS0xLTEtNDYwMTM_486713dc-0af6-4446-8080-39b791561ea0"
      unitRef="usd">26711000</us-gaap:LoansPayableCurrent>
    <us-gaap:LongTermLoansPayable
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTUvZnJhZzpkNGYyZjkzYTgzMWE0NmFiYjcyOGVmZDIzNDg0ZmY3Mi90YWJsZTpkZTQyOGVlYWE2ZGI0NTZlYTRhZDk5Y2IxMjRhYTdmYi90YWJsZXJhbmdlOmRlNDI4ZWVhYTZkYjQ1NmVhNGFkOTljYjEyNGFhN2ZiXzExLTEtMS0xLTQ5NDM0_3fbbcc08-07e3-46a8-a736-7a010c845a95"
      unitRef="usd">0</us-gaap:LongTermLoansPayable>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90ZXh0cmVnaW9uOjIwZjc5ODBmMzZhOTQxZDg4ODQ5NDhkNjFkN2EzZWQwXzI2MzY_42cb87c2-1ffe-468f-b1b5-7050d3973b37">DERIVATIVE LIABILITIES&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2018 Exit Fee&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2018, in connection with entering into the 2018 Loan Agreement, we entered into an agreement pursuant to which we agreed to pay $1.5 million in cash ("2018 Exit Fee") upon any change of control transaction in respect of the Company or if we obtain both (i) FDA approval of XPHOZAH and (ii) FDA approval of IBSRELA, which was obtained on September 12, 2019 (&#x201c;2018 Exit Fee Agreement&#x201d;). Notwithstanding the February 2022 prepayment of the 2018 Loan, our obligation to pay the 2018 Exit Fee will expire on May 16, 2028. We concluded that the 2018 Exit Fee is a freestanding derivative which should be accounted for at fair value on a recurring basis. The estimated fair value of the 2018 Exit Fee is recorded as a derivative liability and included in accrued expense and other current liabilities on the accompanying balance sheets. As of December&#160;31, 2022 and 2021, the estimated fair value of the 2018 Exit Fee was $1.2 million and $0.7 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the derivative liability was determined using a discounted cash flow analysis and is classified as a Level 3 measurement within the fair value hierarchy since our valuation utilized significant unobservable inputs. Specifically, the key assumptions included in the calculation of the estimated fair value of the derivative instrument include: (i) our estimates of both the probability and timing of a potential $1.5 million payment to Solar Capital Ltd. and Western Alliance Bank as a result of the FDA approvals, and (ii) a discount rate which was derived from our estimated cost of debt, adjusted with current LIBOR. Generally, increases or decreases in the probability of occurrence would result in a directionally similar impact in the fair value measurement of the derivative instrument and it is estimated that a 10% increase (decrease), not to exceed 100%, in the probability of occurrence would result in a fair value fluctuation of no more than $0.1 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2022 Exit Fee&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2022, in connection with entering into the 2022 Loan Agreement, we entered into an agreement, whereby we agreed to pay an exit fee in the amount of 2% of the 2022 Loan funded (&#x201c;2022 Exit Fee&#x201d;) upon (i) any change of control transaction or (ii) our achievement of net revenue from the sale of any products equal to or greater than $100.0 million, measured on a six (6) months basis ("Revenue Milestone"), tested monthly at the end of each month. Notwithstanding the prepayment or termination of the 2022 Loan, the 2022 Exit Fee will expire on February 23, 2032. We concluded that the 2022 Exit Fee is a freestanding derivative which should be accounted for at fair value on a recurring basis. The estimated fair value of the 2022 Exit Fee is recorded as a derivative liability and included in accrued expenses and other current liabilities on the accompanying balance sheets. As of December&#160;31, 2022, the estimated fair value of the 2022 Exit Fee is $0.4 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the derivative liability was determined using a discounted cash flow analysis and is classified as a Level 3 measurement within the fair value hierarchy since our valuation utilized significant unobservable inputs. Specifically, the key assumptions included in the calculation of the estimated fair value of the 2022 derivative liability include: (i) our estimates of both the probability and timing of achieving the Revenue Milestone and (ii) the probability and timing of funding the Term B Loan, which is dependent upon (a) approval by the FDA for our NDA for the control of serum phosphorus in adult patients with CKD on dialysis by December 31, 2022, and (b) achievement of certain product revenue milestone targets. Generally, increases or decreases in the probability of occurrence would result in a directionally similar impact in the fair value measurement of the derivative liability and it is estimated that a 10% increase (decrease) in the probability of occurrence would not result in a material fair value fluctuation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the fair value of recurring measurements included in Level 3 of the fair value hierarchy are presented as other income, net in our Statements of Operations and were as follows for the years ended December&#160;31, 2022, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 Exit Fee addition at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in estimated fair value:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018 Exit Fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(678)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 Exit Fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of exit fee derivative liabilities at December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i1b61195b8cbb43b4945e83216c7f171c_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90ZXh0cmVnaW9uOjIwZjc5ODBmMzZhOTQxZDg4ODQ5NDhkNjFkN2EzZWQwXzU0OTc1NTgxNzA1OA_c0b7ee30-e558-4eeb-be91-51d3e54aeca3"
      unitRef="usd">1500000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i829995ddccd34c45973808967c7cab51_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90ZXh0cmVnaW9uOjIwZjc5ODBmMzZhOTQxZDg4ODQ5NDhkNjFkN2EzZWQwXzU0OTc1NTgxNjk2Ng_8d9cbe36-6a99-480e-af0e-7241012850ee"
      unitRef="usd">1200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i23902f57514345efaefc7f6ed372683f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90ZXh0cmVnaW9uOjIwZjc5ODBmMzZhOTQxZDg4ODQ5NDhkNjFkN2EzZWQwXzU0OTc1NTgxNjk3MQ_176d214f-c27c-4c17-bc1f-3bc4cd561d3d"
      unitRef="usd">700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i1b61195b8cbb43b4945e83216c7f171c_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90ZXh0cmVnaW9uOjIwZjc5ODBmMzZhOTQxZDg4ODQ5NDhkNjFkN2EzZWQwXzE1Nzc_c0b7ee30-e558-4eeb-be91-51d3e54aeca3"
      unitRef="usd">1500000</us-gaap:DerivativeLiabilityNotionalAmount>
    <ardx:FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage
      contextRef="i73c09104400b4fc89c22d500c708517d_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90ZXh0cmVnaW9uOjIwZjc5ODBmMzZhOTQxZDg4ODQ5NDhkNjFkN2EzZWQwXzE5NzQ_72e6b105-58d9-4f02-a9c7-911514f87f54"
      unitRef="number">0.10</ardx:FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage>
    <ardx:FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation
      contextRef="i73c09104400b4fc89c22d500c708517d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90ZXh0cmVnaW9uOjIwZjc5ODBmMzZhOTQxZDg4ODQ5NDhkNjFkN2EzZWQwXzIxMDg_5b4d0a08-d20c-4834-8bf6-cea00d3a8821"
      unitRef="usd">100000</ardx:FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation>
    <ardx:ExitFeePercentage
      contextRef="if0d290137b1441abbf8d0d36c58a8e95_I20220223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90ZXh0cmVnaW9uOjIwZjc5ODBmMzZhOTQxZDg4ODQ5NDhkNjFkN2EzZWQwXzU0OTc1NTgxOTEzNA_3db56add-e823-4af9-967a-60c729c630a8"
      unitRef="number">0.02</ardx:ExitFeePercentage>
    <ardx:LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum
      contextRef="i4584120047b3460da4d6b5a0f2eb0808_D20220223-20220223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90ZXh0cmVnaW9uOjIwZjc5ODBmMzZhOTQxZDg4ODQ5NDhkNjFkN2EzZWQwXzU0OTc1NTgxNzQyOQ_327bd6bf-3006-447e-9b75-7c1df664af5c"
      unitRef="usd">100000000</ardx:LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i8a01e0a1633e4784b82496570aa01a7e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90ZXh0cmVnaW9uOjIwZjc5ODBmMzZhOTQxZDg4ODQ5NDhkNjFkN2EzZWQwXzU0OTc1NTgxOTEzOA_4c06f814-71df-49a2-a810-0ebeada1b8a5"
      unitRef="usd">400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <ardx:FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage
      contextRef="i3a1e94b571de450d80084e08a561e5cc_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90ZXh0cmVnaW9uOjIwZjc5ODBmMzZhOTQxZDg4ODQ5NDhkNjFkN2EzZWQwXzU0OTc1NTgxOTE0NQ_acbb2be9-db07-4e78-a2a4-6f1aa7265b77"
      unitRef="number">0.10</ardx:FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90ZXh0cmVnaW9uOjIwZjc5ODBmMzZhOTQxZDg4ODQ5NDhkNjFkN2EzZWQwXzI2MzU_c4cb7f11-f40b-4dff-ac05-c45c90de9da0">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the fair value of recurring measurements included in Level 3 of the fair value hierarchy are presented as other income, net in our Statements of Operations and were as follows for the years ended December&#160;31, 2022, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 Exit Fee addition at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in estimated fair value:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018 Exit Fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(678)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 Exit Fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of exit fee derivative liabilities at December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ia25f50b8fef94d1a9bc667f04f3a26ab_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90YWJsZTo5Nzk0MWY3ZGYwNzQ0YmI5OWZkYjczMzJhOTBiZmMwOC90YWJsZXJhbmdlOjk3OTQxZjdkZjA3NDRiYjk5ZmRiNzMzMmE5MGJmYzA4XzEtMS0xLTEtNDYwMTM_8ac83932-f642-4b2b-80a9-be62835e71c1"
      unitRef="usd">698000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i07e35ddf250a487cbae6c8e1f803a4b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90YWJsZTo5Nzk0MWY3ZGYwNzQ0YmI5OWZkYjczMzJhOTBiZmMwOC90YWJsZXJhbmdlOjk3OTQxZjdkZjA3NDRiYjk5ZmRiNzMzMmE5MGJmYzA4XzEtMy0xLTEtNDYwMTM_bd94b863-20f2-4621-b763-31a05a3eae9d"
      unitRef="usd">1376000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i0080f34bc4774f159a2fbc226bec7e75_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90YWJsZTo5Nzk0MWY3ZGYwNzQ0YmI5OWZkYjczMzJhOTBiZmMwOC90YWJsZXJhbmdlOjk3OTQxZjdkZjA3NDRiYjk5ZmRiNzMzMmE5MGJmYzA4XzEtNS0xLTEtNDYwMTM_2c08ee76-cc8f-4178-84e0-5f793a9ad508"
      unitRef="usd">969000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="ideeb597472c94a98a7ce7e756017a2b2_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90YWJsZTo5Nzk0MWY3ZGYwNzQ0YmI5OWZkYjczMzJhOTBiZmMwOC90YWJsZXJhbmdlOjk3OTQxZjdkZjA3NDRiYjk5ZmRiNzMzMmE5MGJmYzA4XzItMS0xLTEtNDY3ODk_cfb09343-1fc7-4dcb-861d-30cd7e918311"
      unitRef="usd">375000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="ib44009e3ef8846b299ee2faab0e9ac8c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90YWJsZTo5Nzk0MWY3ZGYwNzQ0YmI5OWZkYjczMzJhOTBiZmMwOC90YWJsZXJhbmdlOjk3OTQxZjdkZjA3NDRiYjk5ZmRiNzMzMmE5MGJmYzA4XzItMy0xLTEtNDY3ODk_3a25380c-375f-48fd-9d03-04d2af75c23c"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="i0921c20fa4634446aebe75988e9825d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90YWJsZTo5Nzk0MWY3ZGYwNzQ0YmI5OWZkYjczMzJhOTBiZmMwOC90YWJsZXJhbmdlOjk3OTQxZjdkZjA3NDRiYjk5ZmRiNzMzMmE5MGJmYzA4XzItNS0xLTEtNDY3ODk_759c0e9e-5e02-4e67-9c52-10171353d2a4"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i4aa9ee384f104add8be1fdc63cb9f8ce_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90YWJsZTo5Nzk0MWY3ZGYwNzQ0YmI5OWZkYjczMzJhOTBiZmMwOC90YWJsZXJhbmdlOjk3OTQxZjdkZjA3NDRiYjk5ZmRiNzMzMmE5MGJmYzA4XzQtMS0xLTEtNDY4MDA_c41c5940-a441-4932-9a0e-c70d05aae98d"
      unitRef="usd">510000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i74fef4adf9a14a308f8328b9570c5a83_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90YWJsZTo5Nzk0MWY3ZGYwNzQ0YmI5OWZkYjczMzJhOTBiZmMwOC90YWJsZXJhbmdlOjk3OTQxZjdkZjA3NDRiYjk5ZmRiNzMzMmE5MGJmYzA4XzQtMy0xLTEtNDY4MDA_261274a6-277a-4eb1-95a4-c498c33dc41a"
      unitRef="usd">-678000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ic44d3449c4204e78b2fb999f07d658ab_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90YWJsZTo5Nzk0MWY3ZGYwNzQ0YmI5OWZkYjczMzJhOTBiZmMwOC90YWJsZXJhbmdlOjk3OTQxZjdkZjA3NDRiYjk5ZmRiNzMzMmE5MGJmYzA4XzQtNS0xLTEtNDY4MDA_c4558f57-262d-4350-beb3-db313871186c"
      unitRef="usd">407000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ia0d3d90e1a504d63bd8c04dc4913b676_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90YWJsZTo5Nzk0MWY3ZGYwNzQ0YmI5OWZkYjczMzJhOTBiZmMwOC90YWJsZXJhbmdlOjk3OTQxZjdkZjA3NDRiYjk5ZmRiNzMzMmE5MGJmYzA4XzUtMS0xLTEtNDY4MDg_2326f03d-bb1e-4e09-9abd-d9a1cda25adb"
      unitRef="usd">73000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i04b8aa4c409143baabd2c14fa0c59341_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90YWJsZTo5Nzk0MWY3ZGYwNzQ0YmI5OWZkYjczMzJhOTBiZmMwOC90YWJsZXJhbmdlOjk3OTQxZjdkZjA3NDRiYjk5ZmRiNzMzMmE5MGJmYzA4XzUtMy0xLTEtNDY4MDg_f09327d6-6a7c-4d06-8d67-b96047dad942"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i60af5b7c588a4c7b92f37d85a0e4d590_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90YWJsZTo5Nzk0MWY3ZGYwNzQ0YmI5OWZkYjczMzJhOTBiZmMwOC90YWJsZXJhbmdlOjk3OTQxZjdkZjA3NDRiYjk5ZmRiNzMzMmE5MGJmYzA4XzUtNS0xLTEtNDY4MDg_757063a4-c2bb-4f0b-b931-349a5f9a0051"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i7aeaa47a07574280ba69e0812b3fc9c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90YWJsZTo5Nzk0MWY3ZGYwNzQ0YmI5OWZkYjczMzJhOTBiZmMwOC90YWJsZXJhbmdlOjk3OTQxZjdkZjA3NDRiYjk5ZmRiNzMzMmE5MGJmYzA4XzMtMS0xLTEtNDYwMTM_66235c55-3678-48fb-ba7c-0c32f8133537"
      unitRef="usd">1656000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ia25f50b8fef94d1a9bc667f04f3a26ab_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90YWJsZTo5Nzk0MWY3ZGYwNzQ0YmI5OWZkYjczMzJhOTBiZmMwOC90YWJsZXJhbmdlOjk3OTQxZjdkZjA3NDRiYjk5ZmRiNzMzMmE5MGJmYzA4XzMtMy0xLTEtNDYwMTM_30632ddd-a8f8-4c61-98c4-76caf4ded6c4"
      unitRef="usd">698000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i07e35ddf250a487cbae6c8e1f803a4b1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMTgvZnJhZzoyMGY3OTgwZjM2YTk0MWQ4ODg0OTQ4ZDYxZDdhM2VkMC90YWJsZTo5Nzk0MWY3ZGYwNzQ0YmI5OWZkYjczMzJhOTBiZmMwOC90YWJsZXJhbmdlOjk3OTQxZjdkZjA3NDRiYjk5ZmRiNzMzMmE5MGJmYzA4XzMtNS0xLTEtNDYwMTM_ddcd123f-7339-4f45-8a5b-b4ea6c597210"
      unitRef="usd">1376000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90ZXh0cmVnaW9uOjA4MzllYzIxNTcxYjQ1NTliN2JjMzRlNjZiNzMxMzgwXzM3Mzk_67dd489e-2368-4589-bfc0-e13724c5552d">LEASES&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have recorded right-of-use operating lease assets under three lease agreements. We have evaluated our facility leases and determined that, effective upon the adoption of Topic 842, the leases evaluated are all operating leases. We have performed an evaluation of our other contracts with suppliers and collaborators in accordance with Topic 842 and have determined that, except for the facility leases described below, none of our contracts contain a lease. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have recorded a right-of-use operating lease asset located in Fremont, California under a lease agreement entered into in September 2008 that was amended multiple times to add space and to extend the lease term through March 2025. The office space consists of 72,500 square feet. We do not have an option to renew the lease at our current Fremont location beyond March 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have recorded a right-of-use operating lease asset located in Waltham, Massachusetts under a lease agreement entered into in October 2018. The office space consisted of 3,520 square feet with the lease terminating in September 2021. We did not renew the lease at our original Waltham, Massachusetts facility. During April 2021 and May 2021, we recorded right-of-use operating lease assets for a new facility in Waltham, Massachusetts under a lease agreement entered into during December 2020 with lease commencement dates during April and May 2021. The office space consists of 12,864 square feet with the lease terminating in June 2026. We have an option to extend the lease term for one additional five year period. This option to extend the lease term has not been included in the calculation since currently the exercise of the option is uncertain and therefore deemed not probable. We recorded a $1.6 million right-of-use asset and lease liability for the Waltham lease upon commencement of the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have recorded a right-of-use operating lease asset located in Milwaukee, Wisconsin under a lease agreement entered into in October 2020 with a lease commencement date in November 2020. The office space consists of 4,768 square feet with the lease terminating in February 2026. We have an option to extend the lease term by one additional five-year period. This option to extend the lease term has not been included in the calculation since currently the exercise of the option is uncertain and therefore deemed not probable. We recorded a $0.4&#160;million right-of use asset and lease liability for the Milwaukee lease upon commencement of the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of our leases are operating leases and each contain customary rent escalation clauses. Certain of the leases have both lease and non-lease components. We have elected to account for each separate lease component and the non-lease components associated with that lease component as a single lease component for all classes of underlying assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides additional details of our facility leases presented in our balance sheets (dollars in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lease costs, which are included in operating expenses in our statements of operations, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for operating lease&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our undiscounted cash payment obligations for our operating lease liabilities as of December&#160;31, 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Imputed interest expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(853)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,894)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <ardx:NumberOfOperatingLeaseArrangements
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90ZXh0cmVnaW9uOjA4MzllYzIxNTcxYjQ1NTliN2JjMzRlNjZiNzMxMzgwXzc1_29310a97-6c34-486b-8519-85110e53b578"
      unitRef="lease_agreement">3</ardx:NumberOfOperatingLeaseArrangements>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i26bf80d609da4735913857489e4da748_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90ZXh0cmVnaW9uOjA4MzllYzIxNTcxYjQ1NTliN2JjMzRlNjZiNzMxMzgwXzEyMTc_e7ff74e3-0701-411f-803f-aeeca228fa92"
      unitRef="sqft">72500</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i335c2c940aa8413bb90dd9d65c09b3ba_I20181031"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90ZXh0cmVnaW9uOjA4MzllYzIxNTcxYjQ1NTliN2JjMzRlNjZiNzMxMzgwXzE1NTU_50214aa7-57de-4d3a-bcfb-dec19c517d2e"
      unitRef="sqft">3520</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="if84711cbb7fb484d9907b17e292a5c75_I20210531"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90ZXh0cmVnaW9uOjA4MzllYzIxNTcxYjQ1NTliN2JjMzRlNjZiNzMxMzgwXzE5NjE_8b5aad75-f805-40f4-bdc0-b040eed690ae"
      unitRef="sqft">12864</us-gaap:AreaOfRealEstateProperty>
    <ardx:LesseeOperatingLeaseNumberOfRenewalOptions
      contextRef="if84711cbb7fb484d9907b17e292a5c75_I20210531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90ZXh0cmVnaW9uOjA4MzllYzIxNTcxYjQ1NTliN2JjMzRlNjZiNzMxMzgwXzIwNjQ_7c137da7-231d-46f5-a9f6-d35b70765a2a"
      unitRef="renewal_option">1</ardx:LesseeOperatingLeaseNumberOfRenewalOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="if84711cbb7fb484d9907b17e292a5c75_I20210531"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90ZXh0cmVnaW9uOjA4MzllYzIxNTcxYjQ1NTliN2JjMzRlNjZiNzMxMzgwXzM3NDA_abb358fd-acc5-417f-a42a-cd79af292777">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ic02d026a5b904c17807bd479ea7d0b3e_D20210401-20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90ZXh0cmVnaW9uOjA4MzllYzIxNTcxYjQ1NTliN2JjMzRlNjZiNzMxMzgwXzIyNzc_9b510662-eefb-4032-976c-d764c9ef956e"
      unitRef="usd">1600000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i6c53895082604a918d0ac2f036a8236f_I20201130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90ZXh0cmVnaW9uOjA4MzllYzIxNTcxYjQ1NTliN2JjMzRlNjZiNzMxMzgwXzI1OTA_9a115951-01ce-440d-af2b-dcef36626923"
      unitRef="sqft">4768</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="i191e1bf76f4b440593cb3aed98e7c4e4_D20201101-20201130"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90ZXh0cmVnaW9uOjA4MzllYzIxNTcxYjQ1NTliN2JjMzRlNjZiNzMxMzgwXzM3NDE_75756013-2971-4863-9cf0-30e3b0ccc25c">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <ardx:LesseeOperatingLeaseNumberOfRenewalOptions
      contextRef="i6c53895082604a918d0ac2f036a8236f_I20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90ZXh0cmVnaW9uOjA4MzllYzIxNTcxYjQ1NTliN2JjMzRlNjZiNzMxMzgwXzI2OTY_e725197c-d4ec-4c7a-9f1b-51cced5bf0cf"
      unitRef="renewal_option">1</ardx:LesseeOperatingLeaseNumberOfRenewalOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i6c53895082604a918d0ac2f036a8236f_I20201130"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90ZXh0cmVnaW9uOjA4MzllYzIxNTcxYjQ1NTliN2JjMzRlNjZiNzMxMzgwXzM3NDI_19495bae-4fdc-4c67-9b90-290320ce8767">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i191e1bf76f4b440593cb3aed98e7c4e4_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90ZXh0cmVnaW9uOjA4MzllYzIxNTcxYjQ1NTliN2JjMzRlNjZiNzMxMzgwXzI5MDk_b8f6d63e-2646-4e18-92ef-b4880f42d771"
      unitRef="usd">400000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <ardx:ScheduleOfAdditionalDetailsOfLeasesTableTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90ZXh0cmVnaW9uOjA4MzllYzIxNTcxYjQ1NTliN2JjMzRlNjZiNzMxMzgwXzM3NDM_6e5507c6-46dc-431d-a236-42b7b9f5cd01">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides additional details of our facility leases presented in our balance sheets (dollars in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ardx:ScheduleOfAdditionalDetailsOfLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZToyZWJkNGU4MDhjNmY0ZTNmYmM1ZjJjOGE0YzRkM2VlMi90YWJsZXJhbmdlOjJlYmQ0ZTgwOGM2ZjRlM2ZiYzVmMmM4YTRjNGQzZWUyXzItMS0xLTEtNDYwMTM_606fdbfa-8aa4-4653-b2e3-683ecfd4822c"
      unitRef="usd">9295000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZToyZWJkNGU4MDhjNmY0ZTNmYmM1ZjJjOGE0YzRkM2VlMi90YWJsZXJhbmdlOjJlYmQ0ZTgwOGM2ZjRlM2ZiYzVmMmM4YTRjNGQzZWUyXzItMy0xLTEtNDYwMTM_97625e08-ef6c-42c0-a6f1-4dd420240c81"
      unitRef="usd">12752000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZToyZWJkNGU4MDhjNmY0ZTNmYmM1ZjJjOGE0YzRkM2VlMi90YWJsZXJhbmdlOjJlYmQ0ZTgwOGM2ZjRlM2ZiYzVmMmM4YTRjNGQzZWUyXzQtMS0xLTEtNDYwMTM_3c2c34d0-1715-4abc-a14f-543646fd453a"
      unitRef="usd">3894000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZToyZWJkNGU4MDhjNmY0ZTNmYmM1ZjJjOGE0YzRkM2VlMi90YWJsZXJhbmdlOjJlYmQ0ZTgwOGM2ZjRlM2ZiYzVmMmM4YTRjNGQzZWUyXzQtMy0xLTEtNDYwMTM_20a076fa-ac3c-4f0a-95b0-c02010feaf13"
      unitRef="usd">3492000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZToyZWJkNGU4MDhjNmY0ZTNmYmM1ZjJjOGE0YzRkM2VlMi90YWJsZXJhbmdlOjJlYmQ0ZTgwOGM2ZjRlM2ZiYzVmMmM4YTRjNGQzZWUyXzUtMS0xLTEtNDYwMTM_fe59d7cc-1252-45a2-8c5d-03797e8a96b4"
      unitRef="usd">5855000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZToyZWJkNGU4MDhjNmY0ZTNmYmM1ZjJjOGE0YzRkM2VlMi90YWJsZXJhbmdlOjJlYmQ0ZTgwOGM2ZjRlM2ZiYzVmMmM4YTRjNGQzZWUyXzUtMy0xLTEtNDYwMTM_af956ecd-ed2b-4111-98c2-dd9ebbb81a3b"
      unitRef="usd">9748000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZToyZWJkNGU4MDhjNmY0ZTNmYmM1ZjJjOGE0YzRkM2VlMi90YWJsZXJhbmdlOjJlYmQ0ZTgwOGM2ZjRlM2ZiYzVmMmM4YTRjNGQzZWUyXzYtMS0xLTEtNDYwMTM_77f657dd-3a06-4975-8267-6cb66cbd1b98"
      unitRef="usd">9749000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZToyZWJkNGU4MDhjNmY0ZTNmYmM1ZjJjOGE0YzRkM2VlMi90YWJsZXJhbmdlOjJlYmQ0ZTgwOGM2ZjRlM2ZiYzVmMmM4YTRjNGQzZWUyXzYtMy0xLTEtNDYwMTM_d22f07c0-a8c1-4dda-b509-c5318719d2b3"
      unitRef="usd">13240000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZToyZWJkNGU4MDhjNmY0ZTNmYmM1ZjJjOGE0YzRkM2VlMi90YWJsZXJhbmdlOjJlYmQ0ZTgwOGM2ZjRlM2ZiYzVmMmM4YTRjNGQzZWUyXzgtMS0xLTEtNDYwMTM_051d1645-4a9f-4568-9578-f8564af6281b">P2Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZToyZWJkNGU4MDhjNmY0ZTNmYmM1ZjJjOGE0YzRkM2VlMi90YWJsZXJhbmdlOjJlYmQ0ZTgwOGM2ZjRlM2ZiYzVmMmM4YTRjNGQzZWUyXzgtMy0xLTEtNDYwMTM_2c3e680b-8d54-437b-8c1e-4e0f9a8ef6c8">P3Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZToyZWJkNGU4MDhjNmY0ZTNmYmM1ZjJjOGE0YzRkM2VlMi90YWJsZXJhbmdlOjJlYmQ0ZTgwOGM2ZjRlM2ZiYzVmMmM4YTRjNGQzZWUyXzktMS0xLTEtNDYwMTM_b80cda89-d3ae-4e70-9c9f-e497c25189da"
      unitRef="number">0.068</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZToyZWJkNGU4MDhjNmY0ZTNmYmM1ZjJjOGE0YzRkM2VlMi90YWJsZXJhbmdlOjJlYmQ0ZTgwOGM2ZjRlM2ZiYzVmMmM4YTRjNGQzZWUyXzktMy0xLTEtNDYwMTM_64a29e68-a9c3-4db0-af5c-dadab61388c2"
      unitRef="number">0.069</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90ZXh0cmVnaW9uOjA4MzllYzIxNTcxYjQ1NTliN2JjMzRlNjZiNzMxMzgwXzM3NDQ_fd785c54-e756-45f4-87b7-2537e18b9e41">&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lease costs, which are included in operating expenses in our statements of operations, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for operating lease&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZTowMjAzN2ZjNTdiYTQ0ZjAxODg5NGJmM2U4M2JmYWU0ZS90YWJsZXJhbmdlOjAyMDM3ZmM1N2JhNDRmMDE4ODk0YmYzZTgzYmZhZTRlXzItMS0xLTEtNDYwMTM_24bcd240-9215-4b5a-a90d-ec29320ad32e"
      unitRef="usd">4257000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZTowMjAzN2ZjNTdiYTQ0ZjAxODg5NGJmM2U4M2JmYWU0ZS90YWJsZXJhbmdlOjAyMDM3ZmM1N2JhNDRmMDE4ODk0YmYzZTgzYmZhZTRlXzItMy0xLTEtNDYwMTM_7ac8b677-d87c-4554-a7f3-2f9bbdff341a"
      unitRef="usd">3671000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZTowMjAzN2ZjNTdiYTQ0ZjAxODg5NGJmM2U4M2JmYWU0ZS90YWJsZXJhbmdlOjAyMDM3ZmM1N2JhNDRmMDE4ODk0YmYzZTgzYmZhZTRlXzItNS0xLTEtNDYwMTM_bd0a4be8-1941-49a0-a5b6-c70072ae7a23"
      unitRef="usd">2608000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZTowMjAzN2ZjNTdiYTQ0ZjAxODg5NGJmM2U4M2JmYWU0ZS90YWJsZXJhbmdlOjAyMDM3ZmM1N2JhNDRmMDE4ODk0YmYzZTgzYmZhZTRlXzMtMS0xLTEtNDYwMTM_c2b9ef4a-6625-4735-b2e2-fbc7e1c69fac"
      unitRef="usd">4292000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZTowMjAzN2ZjNTdiYTQ0ZjAxODg5NGJmM2U4M2JmYWU0ZS90YWJsZXJhbmdlOjAyMDM3ZmM1N2JhNDRmMDE4ODk0YmYzZTgzYmZhZTRlXzMtMy0xLTEtNDYwMTM_db91f2c8-3c40-4131-b022-241dc73b549e"
      unitRef="usd">3438000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZTowMjAzN2ZjNTdiYTQ0ZjAxODg5NGJmM2U4M2JmYWU0ZS90YWJsZXJhbmdlOjAyMDM3ZmM1N2JhNDRmMDE4ODk0YmYzZTgzYmZhZTRlXzMtNS0xLTEtNDYwMTM_b97ebcf8-5b1e-46c6-9dc0-ca529a204e80"
      unitRef="usd">3065000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90ZXh0cmVnaW9uOjA4MzllYzIxNTcxYjQ1NTliN2JjMzRlNjZiNzMxMzgwXzM3Mzg_c1f99bec-f871-42f2-a3f0-df314b9cca68">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our undiscounted cash payment obligations for our operating lease liabilities as of December&#160;31, 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Imputed interest expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(853)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,894)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZTo3MTk0YWFhY2E2MjU0OWQ1OGYzMWRhMzk4ZTU2OTI0NC90YWJsZXJhbmdlOjcxOTRhYWFjYTYyNTQ5ZDU4ZjMxZGEzOThlNTY5MjQ0XzEtMi0xLTEtNDYwMTM_cba7cae9-a44c-445c-9d81-f47720db1547"
      unitRef="usd">4440000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZTo3MTk0YWFhY2E2MjU0OWQ1OGYzMWRhMzk4ZTU2OTI0NC90YWJsZXJhbmdlOjcxOTRhYWFjYTYyNTQ5ZDU4ZjMxZGEzOThlNTY5MjQ0XzItMi0xLTEtNDYwMTM_9a44b1a2-80e8-4709-a68b-6036592ff834"
      unitRef="usd">4589000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZTo3MTk0YWFhY2E2MjU0OWQ1OGYzMWRhMzk4ZTU2OTI0NC90YWJsZXJhbmdlOjcxOTRhYWFjYTYyNTQ5ZDU4ZjMxZGEzOThlNTY5MjQ0XzMtMi0xLTEtNDYwMTM_dffef324-4f2e-4a76-8be7-33ce853ac023"
      unitRef="usd">1321000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZTo3MTk0YWFhY2E2MjU0OWQ1OGYzMWRhMzk4ZTU2OTI0NC90YWJsZXJhbmdlOjcxOTRhYWFjYTYyNTQ5ZDU4ZjMxZGEzOThlNTY5MjQ0XzQtMi0xLTEtNDYwMTM_4154552c-e214-4731-95b6-338be6a73056"
      unitRef="usd">252000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <ardx:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZTo3MTk0YWFhY2E2MjU0OWQ1OGYzMWRhMzk4ZTU2OTI0NC90YWJsZXJhbmdlOjcxOTRhYWFjYTYyNTQ5ZDU4ZjMxZGEzOThlNTY5MjQ0XzYtMi0xLTEtNDYwMTM_84416f37-bc85-4e9d-8271-6cb14c0b1947"
      unitRef="usd">0</ardx:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZTo3MTk0YWFhY2E2MjU0OWQ1OGYzMWRhMzk4ZTU2OTI0NC90YWJsZXJhbmdlOjcxOTRhYWFjYTYyNTQ5ZDU4ZjMxZGEzOThlNTY5MjQ0XzctMi0xLTEtNDYwMTM_c3efc16c-fc29-4572-a443-5e8d1c1b9f22"
      unitRef="usd">10602000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZTo3MTk0YWFhY2E2MjU0OWQ1OGYzMWRhMzk4ZTU2OTI0NC90YWJsZXJhbmdlOjcxOTRhYWFjYTYyNTQ5ZDU4ZjMxZGEzOThlNTY5MjQ0XzgtMi0xLTEtNDYwMTM_31159865-f913-488e-a54d-94ef75b9b199"
      unitRef="usd">853000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZTo3MTk0YWFhY2E2MjU0OWQ1OGYzMWRhMzk4ZTU2OTI0NC90YWJsZXJhbmdlOjcxOTRhYWFjYTYyNTQ5ZDU4ZjMxZGEzOThlNTY5MjQ0XzktMi0xLTEtNDYwMTM_92eaaebd-f347-43b4-85c4-f0dbfa52bf59"
      unitRef="usd">9749000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZTo3MTk0YWFhY2E2MjU0OWQ1OGYzMWRhMzk4ZTU2OTI0NC90YWJsZXJhbmdlOjcxOTRhYWFjYTYyNTQ5ZDU4ZjMxZGEzOThlNTY5MjQ0XzEwLTItMS0xLTQ2MDEz_133a522c-c867-42a5-b384-46928b9f7f75"
      unitRef="usd">3894000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjEvZnJhZzowODM5ZWMyMTU3MWI0NTU5YjdiYzM0ZTY2YjczMTM4MC90YWJsZTo3MTk0YWFhY2E2MjU0OWQ1OGYzMWRhMzk4ZTU2OTI0NC90YWJsZXJhbmdlOjcxOTRhYWFjYTYyNTQ5ZDU4ZjMxZGEzOThlNTY5MjQ0XzExLTItMS0xLTQ2MDEz_0718a5bc-0fee-46dc-b807-8c42da92fc46"
      unitRef="usd">5855000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjQvZnJhZzplZTNjYjU1NjhkYjY0OThiYjQwNWNkMWE1MzhlNjA1Yi90ZXh0cmVnaW9uOmVlM2NiNTU2OGRiNjQ5OGJiNDA1Y2QxYTUzOGU2MDViXzM0OTg_b915cb1e-3e17-46a0-96a8-6b3f0994f800">STOCKHOLDERS&#x2019; EQUITY&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2020, we filed a Form S-3 registration statement, which became effective in August 2020 ("2020 Registration Statement"), containing (i) a base prospectus for the offering, issuance and sale by us of up to a maximum aggregate offering price of $250.0 million of our common stock, preferred stock, debt securities, warrants and/or units, from time to time in one or more offerings; and (ii) a prospectus supplement for the offering, issuance and sale by us of up to a maximum aggregate offering price of $100.0 million of our common stock that may be issued and sold, from time to time, under a sales agreement with Jefferies LLC ("Jefferies"), deemed to be &#x201c;at-the-market offerings&#x201d; ("2020 Open Market Sales Agreement").&#160;Pursuant to the 2020 Open Market Sales Agreement, Jefferies, as sales agent, received a commission of up to 3.0% of the gross sales price for shares of common stock sold under the 2020 Open Market Sales Agreement. As of December 31, 2021, we had sold 23.3 million shares and received the maximum gross proceeds of $100.0 million pursuant to the 2020 Open Market Sales Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, we filed an additional prospectus supplement under the 2020 Registration Statement for the offering, issuance and sale by us of up to a maximum aggregate offering price of $150.0 million of our common stock that may be issued and sold, from time to time, under an additional sales agreement we entered into with Jefferies ("2021 Open Market Sales Agreement"), pursuant to which we may, from time to time, sell up to $150.0 million in shares of our common stock through Jefferies. We are required to sell shares under the 2021 Open Market Sales Agreement. Pursuant to the 2021 Open Market Sales Agreement, Jefferies, as our sales agent, receives a commission of up to 3.0% of the gross sales price for shares of common stock sold under the 2021 Open Market Sales Agreement. During the twelve months ended December&#160;31, 2022, we sold 64.1 million shares and received gross proceeds of $73.1 million at a weighted average sales price of approximately $1.14 per share under the 2021 Open Market Sales Agreement. As of December&#160;31, 2022 we sold a total of 79.8 million shares and received gross proceeds of $98.1 million at a weighted average sales price of approximately $1.23 per share under the 2021 Open Market Sales Agreement. During the period January 1, 2023 to January 12, 2023, we received additional gross proceeds of $20.0 million for the sale of an additional 7.7 million shares which were sold at a weighted average sales price of approximately $2.60 per share under the 2021 Open Market Sales Agreement. There have been no other sales under the 2021 Open Market Sales Agreement after December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2023, we filed a Form S-3 registration statement, which became effective in January 2023 ("2023 Registration Statement"), containing (i) a base prospectus for the offering, issuance and sale by us of up to a maximum aggregate offering price of $250.0 million of our common stock, preferred stock, debt securities, warrants and/or units, from time to time in one or more offerings; and (ii) a prospectus supplement for the offering, issuance and sale by us of up to a maximum aggregate offering price of $150.0 million of our common stock that may be issued and sold, from time to time, under a sales agreement with Jefferies LLC ("Jefferies"), deemed to be &#x201c;at-the-market offerings&#x201d; ("2023 Open Market Sales Agreement").&#160;Pursuant to the 2023 Open Market Sales Agreement, Jefferies, as sales agent, may receive a commission of up to 3.0% of the gross sales price for shares of common stock sold under the 2023 Open Market Sales Agreement. There have been no sales of our common stock under the 2023 Open Market Sales Agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <ardx:MaximumAggregateOfferingPrice
      contextRef="if776a22c61a44a539fe0fe538eb2a3e2_I20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjQvZnJhZzplZTNjYjU1NjhkYjY0OThiYjQwNWNkMWE1MzhlNjA1Yi90ZXh0cmVnaW9uOmVlM2NiNTU2OGRiNjQ5OGJiNDA1Y2QxYTUzOGU2MDViXzI0OQ_796cf922-11cd-4168-ae97-c89ad5c74b47"
      unitRef="usd">250000000</ardx:MaximumAggregateOfferingPrice>
    <ardx:MaximumAggregateOfferingPrice
      contextRef="i6c0917f6cb2342afb6023949b42688ce_I20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjQvZnJhZzplZTNjYjU1NjhkYjY0OThiYjQwNWNkMWE1MzhlNjA1Yi90ZXh0cmVnaW9uOmVlM2NiNTU2OGRiNjQ5OGJiNDA1Y2QxYTUzOGU2MDViXzQ5Ng_c6109666-05d0-4dca-89df-bf664dc34ab0"
      unitRef="usd">100000000</ardx:MaximumAggregateOfferingPrice>
    <ardx:StockIssuanceCostCommissionPercent
      contextRef="ib4aee40b13b3480c9ac040be86a38b5d_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjQvZnJhZzplZTNjYjU1NjhkYjY0OThiYjQwNWNkMWE1MzhlNjA1Yi90ZXh0cmVnaW9uOmVlM2NiNTU2OGRiNjQ5OGJiNDA1Y2QxYTUzOGU2MDViXzgyOQ_45417bc2-cf95-4bfb-b24a-a8e1b6da33d4"
      unitRef="number">0.030</ardx:StockIssuanceCostCommissionPercent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i6e194876618f454a8e69ce8891915a74_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjQvZnJhZzplZTNjYjU1NjhkYjY0OThiYjQwNWNkMWE1MzhlNjA1Yi90ZXh0cmVnaW9uOmVlM2NiNTU2OGRiNjQ5OGJiNDA1Y2QxYTUzOGU2MDViXzExMjI_9f565c9e-9c25-41a5-a10c-2eaaeaa17981"
      unitRef="shares">23300000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i6e194876618f454a8e69ce8891915a74_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjQvZnJhZzplZTNjYjU1NjhkYjY0OThiYjQwNWNkMWE1MzhlNjA1Yi90ZXh0cmVnaW9uOmVlM2NiNTU2OGRiNjQ5OGJiNDA1Y2QxYTUzOGU2MDViXzExNTQ_ffadf2c5-2a0b-4195-9e81-7169e881457a"
      unitRef="usd">100000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ardx:MaximumAggregateOfferingPrice
      contextRef="i091722886b334fd9bde76bd765e73617_I20210831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjQvZnJhZzplZTNjYjU1NjhkYjY0OThiYjQwNWNkMWE1MzhlNjA1Yi90ZXh0cmVnaW9uOmVlM2NiNTU2OGRiNjQ5OGJiNDA1Y2QxYTUzOGU2MDViXzE1MTI_641ece77-6c72-4e61-81d1-a3132a97d6b8"
      unitRef="usd">150000000</ardx:MaximumAggregateOfferingPrice>
    <ardx:MaximumAggregateOfferingPrice
      contextRef="i091722886b334fd9bde76bd765e73617_I20210831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjQvZnJhZzplZTNjYjU1NjhkYjY0OThiYjQwNWNkMWE1MzhlNjA1Yi90ZXh0cmVnaW9uOmVlM2NiNTU2OGRiNjQ5OGJiNDA1Y2QxYTUzOGU2MDViXzE3NDg_641ece77-6c72-4e61-81d1-a3132a97d6b8"
      unitRef="usd">150000000</ardx:MaximumAggregateOfferingPrice>
    <ardx:StockIssuanceCostCommissionPercent
      contextRef="i387017f0cb654df1bee8547faa646789_D20210801-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjQvZnJhZzplZTNjYjU1NjhkYjY0OThiYjQwNWNkMWE1MzhlNjA1Yi90ZXh0cmVnaW9uOmVlM2NiNTU2OGRiNjQ5OGJiNDA1Y2QxYTUzOGU2MDViXzE5OTE_2c6849e3-05c1-4c41-9068-3e3d201a3897"
      unitRef="number">0.030</ardx:StockIssuanceCostCommissionPercent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="id010daff3c1947e29d8c5fd89ebaa449_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjQvZnJhZzplZTNjYjU1NjhkYjY0OThiYjQwNWNkMWE1MzhlNjA1Yi90ZXh0cmVnaW9uOmVlM2NiNTU2OGRiNjQ5OGJiNDA1Y2QxYTUzOGU2MDViXzU0OTc1NTgyMTE0NA_4c1bbc30-a9fe-474c-a3fe-f0607c5431c0"
      unitRef="shares">64100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ieeb64a378b284f01ba441778bf717ff2_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjQvZnJhZzplZTNjYjU1NjhkYjY0OThiYjQwNWNkMWE1MzhlNjA1Yi90ZXh0cmVnaW9uOmVlM2NiNTU2OGRiNjQ5OGJiNDA1Y2QxYTUzOGU2MDViXzU0OTc1NTgxOTg5OA_691bca29-b62c-4a20-96ff-a59b2bb0e3a5"
      unitRef="usd">73100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ardx:SaleOfStockWeightedAveragePricePerShare
      contextRef="ieeb64a378b284f01ba441778bf717ff2_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjQvZnJhZzplZTNjYjU1NjhkYjY0OThiYjQwNWNkMWE1MzhlNjA1Yi90ZXh0cmVnaW9uOmVlM2NiNTU2OGRiNjQ5OGJiNDA1Y2QxYTUzOGU2MDViXzU0OTc1NTgxOTkwMg_4732205e-9e7a-4c27-a328-a784059347a4"
      unitRef="usdPerShare">1.14</ardx:SaleOfStockWeightedAveragePricePerShare>
    <ardx:EquitySalesAgreementSharesIssuedSinceInception
      contextRef="i53cfbbd1366348c3a6a036a0048aed7a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjQvZnJhZzplZTNjYjU1NjhkYjY0OThiYjQwNWNkMWE1MzhlNjA1Yi90ZXh0cmVnaW9uOmVlM2NiNTU2OGRiNjQ5OGJiNDA1Y2QxYTUzOGU2MDViXzIxMTc_90e1911b-f1cd-464f-b243-e0f09c608926"
      unitRef="shares">79800000</ardx:EquitySalesAgreementSharesIssuedSinceInception>
    <ardx:EquitySalesAgreementProceedsFromSharesIssuedSinceInception
      contextRef="i53cfbbd1366348c3a6a036a0048aed7a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjQvZnJhZzplZTNjYjU1NjhkYjY0OThiYjQwNWNkMWE1MzhlNjA1Yi90ZXh0cmVnaW9uOmVlM2NiNTU2OGRiNjQ5OGJiNDA1Y2QxYTUzOGU2MDViXzIxNTg_a5bf7e82-c7ac-42c3-973c-d6a54abd09da"
      unitRef="usd">98100000</ardx:EquitySalesAgreementProceedsFromSharesIssuedSinceInception>
    <ardx:SaleOfStockWeightedAveragePricePerShare
      contextRef="i387017f0cb654df1bee8547faa646789_D20210801-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjQvZnJhZzplZTNjYjU1NjhkYjY0OThiYjQwNWNkMWE1MzhlNjA1Yi90ZXh0cmVnaW9uOmVlM2NiNTU2OGRiNjQ5OGJiNDA1Y2QxYTUzOGU2MDViXzIyMTI_43daec4d-dcfe-42b9-96f8-690afd8e48b4"
      unitRef="usdPerShare">1.23</ardx:SaleOfStockWeightedAveragePricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ic0543a071cf942e590a16ac2b267ca3a_D20230101-20230112"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjQvZnJhZzplZTNjYjU1NjhkYjY0OThiYjQwNWNkMWE1MzhlNjA1Yi90ZXh0cmVnaW9uOmVlM2NiNTU2OGRiNjQ5OGJiNDA1Y2QxYTUzOGU2MDViXzc2OTY1ODE0MDU4NjY_6cfc0390-2c5d-4ecf-991c-5d9a56ba1d28"
      unitRef="usd">20000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ic0543a071cf942e590a16ac2b267ca3a_D20230101-20230112"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjQvZnJhZzplZTNjYjU1NjhkYjY0OThiYjQwNWNkMWE1MzhlNjA1Yi90ZXh0cmVnaW9uOmVlM2NiNTU2OGRiNjQ5OGJiNDA1Y2QxYTUzOGU2MDViXzc2OTY1ODE0MDU5MTA_1243993b-1be8-4627-b97d-9cbe3008d5fe"
      unitRef="shares">7700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <ardx:SaleOfStockWeightedAveragePricePerShare
      contextRef="ic0543a071cf942e590a16ac2b267ca3a_D20230101-20230112"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjQvZnJhZzplZTNjYjU1NjhkYjY0OThiYjQwNWNkMWE1MzhlNjA1Yi90ZXh0cmVnaW9uOmVlM2NiNTU2OGRiNjQ5OGJiNDA1Y2QxYTUzOGU2MDViXzc2OTY1ODE0MDU4NzA_d0c8b514-a191-4622-bd2f-f3445e912e6a"
      unitRef="usdPerShare">2.60</ardx:SaleOfStockWeightedAveragePricePerShare>
    <ardx:MaximumAggregateOfferingPrice
      contextRef="i0edad5a730a244cba8f8a9819262823c_I20230131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjQvZnJhZzplZTNjYjU1NjhkYjY0OThiYjQwNWNkMWE1MzhlNjA1Yi90ZXh0cmVnaW9uOmVlM2NiNTU2OGRiNjQ5OGJiNDA1Y2QxYTUzOGU2MDViXzU0OTc1NTgyNDgyMQ_295510a4-7a74-4728-9fbe-ea57ba75958d"
      unitRef="usd">250000000</ardx:MaximumAggregateOfferingPrice>
    <ardx:MaximumAggregateOfferingPrice
      contextRef="id8349613f0ed462d8ac8ec08c2be4b51_I20230131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjQvZnJhZzplZTNjYjU1NjhkYjY0OThiYjQwNWNkMWE1MzhlNjA1Yi90ZXh0cmVnaW9uOmVlM2NiNTU2OGRiNjQ5OGJiNDA1Y2QxYTUzOGU2MDViXzU0OTc1NTgyNDgyNQ_9be593c4-93f8-4d02-86b5-a3c05b268ffd"
      unitRef="usd">150000000</ardx:MaximumAggregateOfferingPrice>
    <ardx:StockIssuanceCostCommissionPercent
      contextRef="i05cd4ea70ed4485589e755e460b69fd1_D20230101-20230131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjQvZnJhZzplZTNjYjU1NjhkYjY0OThiYjQwNWNkMWE1MzhlNjA1Yi90ZXh0cmVnaW9uOmVlM2NiNTU2OGRiNjQ5OGJiNDA1Y2QxYTUzOGU2MDViXzU0OTc1NTgyNDgyOQ_afb0af8d-ab5f-4df3-b4be-caea5167842f"
      unitRef="number">0.030</ardx:StockIssuanceCostCommissionPercent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzc3MjI_503777d4-a92c-4a65-80c8-4fa7f3e16aea">EQUITY INCENTIVE PLANS&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2008 Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We granted options under our 2008 Stock Incentive Plan (&#x201c;2008 Plan&#x201d;) until June&#160;2014 when it was terminated as to future awards, although it continues to govern the terms of options that remain outstanding under the 2008 Plan. The 2008 Plan provided for the granting of incentive and non-qualified stock options, and stock purchase rights to employees, directors and consultants at the discretion of the board of directors. Stock options granted generally vested over a period of four years from the date of grant. In connection with the board of directors and stockholders&#x2019; approval of the 2014 Plan, all remaining shares available for future award under the 2008 Plan were transferred to 2014 Plan, as discussed below, and the 2008 Plan was terminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2014 Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2014 Equity Incentive Award Plan (&#x201c;2014 Plan&#x201d;) became effective on June&#160;18, 2014. Under the 2014 Plan, 1.4 million shares of common stock were initially reserved for issuance pursuant to a variety of stock-based compensation awards, including stock options, stock appreciation rights ("SARs"), restricted stock awards, service-based restricted stock unit (&#x201c;RSU&#x201d;) awards, performance-based restricted stock unit (&#x201c;PRSU&#x201d;) awards, deferred stock awards, deferred stock unit awards, dividend equivalent awards, stock payment awards and performance awards. In addition, 35 thousand shares that had been available for future awards under the 2008 Plan as of June&#160;18, 2014, were added to the initial reserve available under the 2014 Plan, bringing the total reserve upon the effective date of the 2014 Plan to 1.5 million shares. The number of shares initially reserved for &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;issuance or transfer pursuant to awards under the 2014 Plan will be increased by (i)&#160;the number of shares represented by awards outstanding under 2008 Plan on June&#160;18, 2014, that are either forfeited or lapse unexercised or that are repurchased for the original purchase price thereof, up to a maximum of 1.2 million shares, and (ii)&#160;if approved by the administrator of the 2014 Plan, an annual increase on the first day of each fiscal&#160;year ending in 2024 equal to the lesser of (A)&#160;four&#160;percent (4.0%) of the shares of stock outstanding (on an as converted basis) on the last day of the immediately preceding fiscal&#160;year and (B)&#160;such smaller number of shares of stock as determined by our board of directors; provided, however, that no more than 10.7 million shares of stock may be issued upon the exercise of incentive stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2016 Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November&#160;2016, our board of directors approved the 2016 Employment Commencement Incentive Plan (&#x201c;Inducement Plan&#x201d;) under which 1.0 million shares were reserved. In January 2021, January 2022 and December 2022, 0.5&#160;million, 2.0&#160;million and 3.0&#160;million shares, respectively, were added to the Inducement Plan. As of December&#160;31, 2022, 2.1 million shares of our common stock were subject to inducement grants that were issued pursuant to the Inducement Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our stock option activity and related information during the twelve months ended December&#160;31, 2022 is as follows (in thousands, except per share dollar amounts and years):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.681%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.035%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Shares&#160;Available for&#160;Grant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Options&#160;Issued&#160;and&#160;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&#160;Term&lt;br/&gt;(in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:32pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number&#160;of&#160;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise&#160;Price&#160;&lt;br/&gt;per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,392)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,832)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issuance of common stock for services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(712)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value represents the difference between the total pre-tax value (i.e., the difference between our stock price and the exercise price) of stock options outstanding as of December&#160;31, 2022, based on our common stock closing price of $2.85 per share, which would have been received by the option holders if all their in-the-money options had been exercised as of that date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The intrinsic value of options exercised during the&#160;years ended December&#160;31, 2022, 2021 and 2020, was $30 thousand, $1.7&#160;million, and $2.7 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant-date estimated fair value of options granted during the&#160;years ended December&#160;31, 2022, 2021 and 2020 was $0.63, $3.92 and $4.82 per share, respectively. The estimated grant date fair value of employee stock options was calculated using the Black-Scholes option-pricing model, based on the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;We have limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock-option grants. As such, the expected term was initially estimated using the simplified method whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option. Beginning in 2021, we estimate the expected term of our options based upon historical exercises and post-vesting termination behavior, which has not resulted in a material difference as compared to using the simplified method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Since January 1, 2017, we use the historic volatility of our own stock over the retrospective period corresponding to the expected remaining term of the options, or the period since our shares were first quoted on The Nasdaq Global Market, if that is shorter, to compute our expected stock price volatility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The risk-free interest rate assumption is based on the zero-coupon U.S. treasury instruments on the date of grant with a maturity date consistent with the expected term of our stock option grants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Dividend Yield&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;To date, we have not declared or paid any cash dividends and does not have any plans to do so in the future. Therefore, we use an expected dividend yield of zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our RSUs activity and related information for the twelve months ended December&#160;31, 2022 is as follows (in thousands, except per share dollar amounts): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant&#160;Date&#160;Fair&lt;br/&gt;Value Per&#160;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested restricted stock units at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,956)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(362)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested restricted stock units at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total estimated fair value of RSUs vested during the years ended December&#160;31, 2022, 2021 and 2020 was $2.6 million, $0.8 million and zero, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2018, we granted 0.9 million PRSUs to our employees that vested upon the achievement of certain performance conditions, subject to the employees&#x2019; continued service relationship with us through the achievement date. During 2020, we granted an additional 30 thousand PRSUs subject to the same performance conditions. All 0.9&#160;million of these PRSUs vested in September 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Issuance of Common Stock for Services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the&#160;years ended December&#160;31, 2022, 2021 and 2020, we issued approximately 0.7 million, 26 thousand and 42 thousand shares, respectively, of common stock to members of the board of directors who elected to receive stock in lieu of their cash fees under our Non-Employee Director Compensation Program. The shares issued during the years ended December&#160;31, 2022, 2021 and 2020 were valued at $0.4 million, $0.2 million and $0.3 million for each year, respectively, based on the fair value of the common stock on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We adopted the 2014 Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;) and initially reserved approximately 0.2 million shares of common stock as of its effective date of June&#160;18, 2014. If approved by the administrator of the ESPP, on the first day of each calendar&#160;year, ending in 2024, the number of shares in the reserve will increase by an amount equal to the lesser of (i)&#160;one&#160;percent (1.0%) of the shares of common stock outstanding on the last day of the immediately preceding fiscal&#160;year and (ii)&#160;such number of shares of common stock as determined by the board of directors; provided, however, no more than 2.2 million shares of our common stock may be issued under the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our ESPP activity during the&#160;twelve months ended December&#160;31, 2022 is as follows (in thousands, except per share dollar amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&#160;Available&lt;br/&gt;for&#160;Grant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&#160;Shares&lt;br/&gt;Purchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average Purchase&#160;Price&lt;br/&gt;per&#160;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Proceeds&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares purchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(308)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table illustrates the weighted-average assumptions for the Black-Scholes option-pricing model used in determining the fair value of ESPP purchase rights granted to our employees:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense recognized for stock options, RSUs, PRSUs and our ESPP are recorded as operating expenses in our statements of operations and comprehensive loss, as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our total unrecognized stock-based compensation expense, net of estimated forfeitures, as of December&#160;31, 2022 is as follows (dollars in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.920%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.922%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrecognized Compensation Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average Remaining Vesting Period (Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options grant&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.55&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSU grants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.95&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i59e25fbea49d4656871685e6d2d6c76e_D20140101-20140630"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzUyNA_bffbe7a0-02d1-4c5d-8e47-2cc1d4675288">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i91127df0154643aeaa974e5370a0d08f_I20140618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzg5Mg_220d737f-6abe-4a89-8b4b-cba6bcf88b8c"
      unitRef="shares">1400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i3b2b0a1450e146dab1869a3c643a4b54_D20140618-20140618"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzEzNDU_a45d47de-419e-4ca6-aafe-1066d1f63a13"
      unitRef="shares">35000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i91127df0154643aeaa974e5370a0d08f_I20140618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzE1NzQ_6047eb90-afd4-4ae1-a1ab-6fe5daeed1af"
      unitRef="shares">1500000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <ardx:IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponInclusionOfForfeitedOrUnexercisedOptions
      contextRef="i91127df0154643aeaa974e5370a0d08f_I20140618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzE5MzQ_29436a1f-3f3a-442f-919d-1e78960f4d7f"
      unitRef="shares">1200000</ardx:IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponInclusionOfForfeitedOrUnexercisedOptions>
    <ardx:IncreaseInSharesReservedForIssuanceOptionForAnnualIncreaseAsPercentageOfSharesOutstanding
      contextRef="i91127df0154643aeaa974e5370a0d08f_I20140618"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzIxMTc_66336035-46c3-459f-84d0-7b348f263916"
      unitRef="number">0.040</ardx:IncreaseInSharesReservedForIssuanceOptionForAnnualIncreaseAsPercentageOfSharesOutstanding>
    <ardx:IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponExerciseOfStockOptions
      contextRef="i91127df0154643aeaa974e5370a0d08f_I20140618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzIzNjU_393c5966-8a2f-4878-b828-3e7c02d21815"
      unitRef="shares">10700000</ardx:IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponExerciseOfStockOptions>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ib434fa02b7f94f70a56b9427b8d40564_I20161130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzI1ODg_f0c9501e-5a1f-4a84-9b9a-5dca9dd7b7b4"
      unitRef="shares">1000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="id17ce6206b53406fae2405e677fe43ef_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzI2Mzk_eb47b726-b60a-4ee5-b40c-7518b19c6915"
      unitRef="shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i43e122158f0e415aa7661317d01ff3be_D20220101-20220131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzI2NDY_c7a38adf-3a81-44cc-bf61-40a165d64f8b"
      unitRef="shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i083ca43bb16849a593d6fe2102ad4aca_D20221201-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzIxOTkwMjMyNjYyMjA_c3e93ada-28eb-483c-b9f3-6549447d4a8f"
      unitRef="shares">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <ardx:CommonStockSubjectToIssuedInducementGrantsShares
      contextRef="if5d377e7e91446f9872db311ff7a998d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzI3MTY_3834dc15-4d42-4d62-b27c-70c5a0018f03"
      unitRef="shares">2100000</ardx:CommonStockSubjectToIssuedInducementGrantsShares>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzc3MjM_1b471a17-d1cc-41c3-bc5f-32751338c68b">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our stock option activity and related information during the twelve months ended December&#160;31, 2022 is as follows (in thousands, except per share dollar amounts and years):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.681%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.035%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Shares&#160;Available for&#160;Grant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Options&#160;Issued&#160;and&#160;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&#160;Term&lt;br/&gt;(in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:32pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number&#160;of&#160;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise&#160;Price&#160;&lt;br/&gt;per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,392)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,832)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issuance of common stock for services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(712)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i208be3295b5d448a8b943c647170b858_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzMtMS0xLTEtNDYwMTM_c35ed0d2-2143-40c2-b91e-35fc81149ce6"
      unitRef="shares">4974000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzMtMy0xLTEtNDYwMTM_6b5534a1-a27e-4141-926a-66cdc0c14a9c"
      unitRef="shares">10417000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzMtNS0xLTEtNDYwMTM_e262673b-6679-4491-9ccd-710c4c39a7e2"
      unitRef="usdPerShare">7.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <ardx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToAuthorizedInPeriod
      contextRef="i4d035ef039b9449f9a833a4878f300ef_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzQtMS0xLTEtNDYwMTM_87dd0b0b-4b5e-4ba3-8230-5c1480a17c02"
      unitRef="shares">10207000</ardx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToAuthorizedInPeriod>
    <ardx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToGrantedInPeriod
      contextRef="i4d035ef039b9449f9a833a4878f300ef_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzUtMS0xLTEtNDYwMTM_22cf97fc-53c7-4020-9c82-86d78f6d4d17"
      unitRef="shares">5392000</ardx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToGrantedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzUtMy0xLTEtNDYwMTM_25a8139e-855b-4bc5-99cd-3826f52d25f3"
      unitRef="shares">5392000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzUtNS0xLTEtNDYwMTM_72477ea2-8586-4295-bba5-e19c27985d0f"
      unitRef="usdPerShare">0.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzYtMy0xLTEtNDYwMTM_18db41e5-5589-4141-86cf-9c272a47df72"
      unitRef="shares">14000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzYtNS0xLTEtNDYwMTM_ab979727-3484-4b10-926f-6dad2131e810"
      unitRef="usdPerShare">0.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <ardx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToCanceledInPeriod
      contextRef="i4d035ef039b9449f9a833a4878f300ef_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzctMS0xLTEtNDYwMTM_f4b5af5f-16ff-4b35-89a3-ed8a18d1a0e0"
      unitRef="shares">1832000</ardx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToCanceledInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzctMy0xLTEtNDYwMTM_b7c830b3-448d-413b-9677-bfa3b5a4339b"
      unitRef="shares">1832000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzctNS0xLTEtNDYwMTM_91c62ea4-b62e-48cb-a719-f6916d056af8"
      unitRef="usdPerShare">5.80</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <ardx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToStockIssuedForServicesInPeriod
      contextRef="i4d035ef039b9449f9a833a4878f300ef_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzgtMS0xLTEtNDYwMTM_bd7d6530-3737-4947-b564-f8ed6c5685a0"
      unitRef="shares">712000</ardx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToStockIssuedForServicesInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ief16b3cbe3934dc98b9bc68d2856ca35_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzEwLTEtMS0xLTQ2MDEz_b02bd44e-d054-43d2-ab35-9b9d0e0c3db7"
      unitRef="shares">10909000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzEwLTMtMS0xLTQ2MDEz_05e0070e-7522-4433-b0b7-94d06c653965"
      unitRef="shares">13963000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzEwLTUtMS0xLTQ2MDEz_faaee074-5681-49ed-b639-fdf5dccf66da"
      unitRef="usdPerShare">4.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzEwLTctMS0xLTQ2MDEz_65ed7efc-0726-4c82-b2fa-77884e9806a8">P7Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzEwLTktMS0xLTQ2MDEz_219d80cb-0c13-4eed-8c6b-a7c6393edb6f"
      unitRef="usd">10156000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzExLTMtMS0xLTQ2MDEz_5d36ea73-9b79-4570-8cea-3c32b19b6cfa"
      unitRef="shares">13963000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzExLTUtMS0xLTQ2MDEz_19973268-2765-4a29-a04d-98185c148f6c"
      unitRef="usdPerShare">4.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzExLTctMS0xLTQ2MDEz_a05103a3-31b3-4157-8e16-7b0ee69608f3">P7Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzExLTktMS0xLTQ2MDEz_32de5e43-8091-4bb0-8597-45b0c69c5a5c"
      unitRef="usd">10156000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzEyLTMtMS0xLTQ2MDEz_6e8b6b40-d7fa-4569-8f31-c785b0ba6d17"
      unitRef="shares">8283000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzEyLTUtMS0xLTQ2MDEz_2323c280-1a51-4282-8b48-c2933abadc77"
      unitRef="usdPerShare">6.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzEyLTctMS0xLTQ2MDEz_c442fe69-e518-4ec3-b4cd-7bcd866c75fe">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkMDc1YzEyNDg1YmY0Y2FmYTYzY2I3MGNmNWZmYmM3Yi90YWJsZXJhbmdlOmQwNzVjMTI0ODViZjRjYWZhNjNjYjcwY2Y1ZmZiYzdiXzEyLTktMS0xLTQ2MDEz_ee668e7a-62c6-4719-ac63-b603eba71152"
      unitRef="usd">2727000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharePrice
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzMyMjg_1ee018f2-5b4f-4572-a537-2df5ec1fd5ab"
      unitRef="usdPerShare">2.85</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzM0NDU_5881d14c-9021-48a1-b572-ef76f56fe1b4"
      unitRef="usd">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzM0NDk_1f5de1e1-655c-49a0-9322-9b2678de6670"
      unitRef="usd">1700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzM0NTc_94312e07-1884-4a56-895b-3e13fd759658"
      unitRef="usd">2700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzM1ODg_1c305165-e721-434c-8814-ac91baad5e75"
      unitRef="usdPerShare">0.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzM1OTI_918d098d-571e-4b53-a136-4090045c2a3d"
      unitRef="usdPerShare">3.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzM1OTk_dd1f9f36-9d0d-468a-9ef4-254ef1a593d4"
      unitRef="usdPerShare">4.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzc3MjQ_2e071922-cb37-47fa-8f43-75af93d7678f">The estimated grant date fair value of employee stock options was calculated using the Black-Scholes option-pricing model, based on the following weighted-average assumptions:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i4d035ef039b9449f9a833a4878f300ef_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo0MzM3Mjg1M2YyZmI0ZDNjYTdmZTJiZDkyNDIyMTkxNy90YWJsZXJhbmdlOjQzMzcyODUzZjJmYjRkM2NhN2ZlMmJkOTI0MjIxOTE3XzItMS0xLTEtNDYwMTM_0b41406b-7994-4d7c-83ab-30a9e3143e7e">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ic5c3b975ccf642298e9ab071e46c4b8e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo0MzM3Mjg1M2YyZmI0ZDNjYTdmZTJiZDkyNDIyMTkxNy90YWJsZXJhbmdlOjQzMzcyODUzZjJmYjRkM2NhN2ZlMmJkOTI0MjIxOTE3XzItMy0xLTEtNDYwMTM_368188f9-08c8-478b-a98a-aeca6d726b07">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i7f8f14f6a5a441a4b8e90c587038294a_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo0MzM3Mjg1M2YyZmI0ZDNjYTdmZTJiZDkyNDIyMTkxNy90YWJsZXJhbmdlOjQzMzcyODUzZjJmYjRkM2NhN2ZlMmJkOTI0MjIxOTE3XzItNS0xLTEtNDYwMTM_a3a87f5b-5b7b-4daf-b470-0ea70fd1ce69">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i4d035ef039b9449f9a833a4878f300ef_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo0MzM3Mjg1M2YyZmI0ZDNjYTdmZTJiZDkyNDIyMTkxNy90YWJsZXJhbmdlOjQzMzcyODUzZjJmYjRkM2NhN2ZlMmJkOTI0MjIxOTE3XzMtMS0xLTEtNDYwMTM_294313d0-34ac-4478-a1f6-f201496684f9"
      unitRef="number">0.921</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ic5c3b975ccf642298e9ab071e46c4b8e_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo0MzM3Mjg1M2YyZmI0ZDNjYTdmZTJiZDkyNDIyMTkxNy90YWJsZXJhbmdlOjQzMzcyODUzZjJmYjRkM2NhN2ZlMmJkOTI0MjIxOTE3XzMtMy0xLTEtNDYwMTM_9558c00a-703d-4ca0-91ad-e592ede863db"
      unitRef="number">0.770</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i7f8f14f6a5a441a4b8e90c587038294a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo0MzM3Mjg1M2YyZmI0ZDNjYTdmZTJiZDkyNDIyMTkxNy90YWJsZXJhbmdlOjQzMzcyODUzZjJmYjRkM2NhN2ZlMmJkOTI0MjIxOTE3XzMtNS0xLTEtNDYwMTM_6d70a263-0749-40e7-9051-afed674a4852"
      unitRef="number">0.830</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i4d035ef039b9449f9a833a4878f300ef_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo0MzM3Mjg1M2YyZmI0ZDNjYTdmZTJiZDkyNDIyMTkxNy90YWJsZXJhbmdlOjQzMzcyODUzZjJmYjRkM2NhN2ZlMmJkOTI0MjIxOTE3XzQtMS0xLTEtNDYwMTM_e74af427-00fa-4854-ae0b-7e798749120c"
      unitRef="number">0.022</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ic5c3b975ccf642298e9ab071e46c4b8e_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo0MzM3Mjg1M2YyZmI0ZDNjYTdmZTJiZDkyNDIyMTkxNy90YWJsZXJhbmdlOjQzMzcyODUzZjJmYjRkM2NhN2ZlMmJkOTI0MjIxOTE3XzQtMy0xLTEtNDYwMTM_21dcf3a6-750e-485a-a0ad-0399945c58cb"
      unitRef="number">0.047</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i7f8f14f6a5a441a4b8e90c587038294a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo0MzM3Mjg1M2YyZmI0ZDNjYTdmZTJiZDkyNDIyMTkxNy90YWJsZXJhbmdlOjQzMzcyODUzZjJmYjRkM2NhN2ZlMmJkOTI0MjIxOTE3XzQtNS0xLTEtNDYwMTM_545bed16-517c-4138-b159-dff902f733b8"
      unitRef="number">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i4d035ef039b9449f9a833a4878f300ef_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo0MzM3Mjg1M2YyZmI0ZDNjYTdmZTJiZDkyNDIyMTkxNy90YWJsZXJhbmdlOjQzMzcyODUzZjJmYjRkM2NhN2ZlMmJkOTI0MjIxOTE3XzUtMS0xLTEtNDYwMTM_6d0a7a82-915d-43ff-8a21-f7ec860aa828"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ic5c3b975ccf642298e9ab071e46c4b8e_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo0MzM3Mjg1M2YyZmI0ZDNjYTdmZTJiZDkyNDIyMTkxNy90YWJsZXJhbmdlOjQzMzcyODUzZjJmYjRkM2NhN2ZlMmJkOTI0MjIxOTE3XzUtMy0xLTEtNDYwMTM_3fdbc56b-8512-42c0-a7a1-ea5d3e4a3d40"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i7f8f14f6a5a441a4b8e90c587038294a_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo0MzM3Mjg1M2YyZmI0ZDNjYTdmZTJiZDkyNDIyMTkxNy90YWJsZXJhbmdlOjQzMzcyODUzZjJmYjRkM2NhN2ZlMmJkOTI0MjIxOTE3XzUtNS0xLTEtNDYwMTM_c6d13002-9c4a-46e2-b04d-c5daa12bf407"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i4d035ef039b9449f9a833a4878f300ef_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzUxNDc_80430830-be96-4cf6-b646-5a972a827c41"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzc3MjU_c9062d6f-99c5-464b-a587-b7ba7d597552">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our RSUs activity and related information for the twelve months ended December&#160;31, 2022 is as follows (in thousands, except per share dollar amounts): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant&#160;Date&#160;Fair&lt;br/&gt;Value Per&#160;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested restricted stock units at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,956)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(362)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested restricted stock units at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="iad26c62e1f7040819c46ba8aaecbfdf7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTowZWEzMDZkMTg3Y2E0MGUzOGFmOTQ2YWM1ODA5ZDI2NC90YWJsZXJhbmdlOjBlYTMwNmQxODdjYTQwZTM4YWY5NDZhYzU4MDlkMjY0XzEtMS0xLTEtNDYwMTM_86cedb40-e78d-4728-b11c-081db83bb5c2"
      unitRef="shares">3529000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="iad26c62e1f7040819c46ba8aaecbfdf7_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTowZWEzMDZkMTg3Y2E0MGUzOGFmOTQ2YWM1ODA5ZDI2NC90YWJsZXJhbmdlOjBlYTMwNmQxODdjYTQwZTM4YWY5NDZhYzU4MDlkMjY0XzEtMy0xLTEtNDYwMTM_0e907a1c-8106-45ad-8779-a6f1118d7be2"
      unitRef="usdPerShare">2.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i5804b276fcba47ec9888f9294a058bd3_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTowZWEzMDZkMTg3Y2E0MGUzOGFmOTQ2YWM1ODA5ZDI2NC90YWJsZXJhbmdlOjBlYTMwNmQxODdjYTQwZTM4YWY5NDZhYzU4MDlkMjY0XzItMS0xLTEtNDYwMTM_dec5d11e-99bd-45b0-9ba0-9733126b6f7a"
      unitRef="shares">2195000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5804b276fcba47ec9888f9294a058bd3_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTowZWEzMDZkMTg3Y2E0MGUzOGFmOTQ2YWM1ODA5ZDI2NC90YWJsZXJhbmdlOjBlYTMwNmQxODdjYTQwZTM4YWY5NDZhYzU4MDlkMjY0XzItMy0xLTEtNDYwMTM_eec1228d-d02b-4f93-9dfd-69b8f7ca40f4"
      unitRef="usdPerShare">0.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i5804b276fcba47ec9888f9294a058bd3_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTowZWEzMDZkMTg3Y2E0MGUzOGFmOTQ2YWM1ODA5ZDI2NC90YWJsZXJhbmdlOjBlYTMwNmQxODdjYTQwZTM4YWY5NDZhYzU4MDlkMjY0XzMtMS0xLTEtNDYwMTM_05f2a706-80f6-4519-80ad-b71eff390bac"
      unitRef="shares">3956000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5804b276fcba47ec9888f9294a058bd3_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTowZWEzMDZkMTg3Y2E0MGUzOGFmOTQ2YWM1ODA5ZDI2NC90YWJsZXJhbmdlOjBlYTMwNmQxODdjYTQwZTM4YWY5NDZhYzU4MDlkMjY0XzMtMy0xLTEtNDYwMTM_22a3e2df-9416-4d7c-af4b-38e54c74cf66"
      unitRef="usdPerShare">1.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i5804b276fcba47ec9888f9294a058bd3_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTowZWEzMDZkMTg3Y2E0MGUzOGFmOTQ2YWM1ODA5ZDI2NC90YWJsZXJhbmdlOjBlYTMwNmQxODdjYTQwZTM4YWY5NDZhYzU4MDlkMjY0XzQtMS0xLTEtNDYwMTM_b458f8e9-5fdb-4684-9945-0f720f9fd25e"
      unitRef="shares">362000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i5804b276fcba47ec9888f9294a058bd3_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTowZWEzMDZkMTg3Y2E0MGUzOGFmOTQ2YWM1ODA5ZDI2NC90YWJsZXJhbmdlOjBlYTMwNmQxODdjYTQwZTM4YWY5NDZhYzU4MDlkMjY0XzQtMy0xLTEtNDYwMTM_a5ee53f7-e5fb-4fe1-adc3-4902855c7814"
      unitRef="usdPerShare">2.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i5c4f587701fb4044879019a9bdf73a97_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTowZWEzMDZkMTg3Y2E0MGUzOGFmOTQ2YWM1ODA5ZDI2NC90YWJsZXJhbmdlOjBlYTMwNmQxODdjYTQwZTM4YWY5NDZhYzU4MDlkMjY0XzUtMS0xLTEtNDYwMTM_3865c10f-a47e-4e46-a012-2d046b713ecb"
      unitRef="shares">1406000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i5c4f587701fb4044879019a9bdf73a97_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTowZWEzMDZkMTg3Y2E0MGUzOGFmOTQ2YWM1ODA5ZDI2NC90YWJsZXJhbmdlOjBlYTMwNmQxODdjYTQwZTM4YWY5NDZhYzU4MDlkMjY0XzUtMy0xLTEtNDYwMTM_70c0a021-5470-4c8c-91a3-72d3af1609b9"
      unitRef="usdPerShare">2.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i5804b276fcba47ec9888f9294a058bd3_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzU0OTc1NTgyMjU0NA_388f733b-883b-41b5-8e24-773cadc4e830"
      unitRef="usd">2600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="ic72722bcacf846aeae4e32bdaf25ad95_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzU0OTc1NTgyMjU0OQ_2aace4bb-4d7f-47ef-9224-6ea7f89608b5"
      unitRef="usd">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="ic0a3fa62b68c4a38948feeb7a5990743_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzU0OTc1NTgyMjU1Ng_e796f68b-9e14-45df-bd6b-501bbd25bdce"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i759c16cd46934957818cd44b6da608af_D20180701-20180731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzU0NDE_304e8a7c-de16-4c72-b45b-56925895b522"
      unitRef="shares">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i6a36013712a244a6857a4ef451619a76_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzU2Njg_712ef473-7ed0-4ab0-9725-39d5e9e13e92"
      unitRef="shares">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ia0963364402c4d97b8a169943f9ea6a8_D20200901-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzU3MjU_27d8d632-bb39-416f-95bd-2a07caecca50"
      unitRef="shares">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="i477da3d9a3ff40539adf947d1f500015_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzYxMzI_357cff0a-e3be-4517-a04f-508b3a9936a2"
      unitRef="shares">700000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="ie25852142a964d3188c11071355f91b7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzYxMzY_84e45c54-1981-45fb-a33e-1c2c3c4391f4"
      unitRef="shares">26000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="ib3f407a43bf14aab8924633cd249ade7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzYxNDM_f0538039-0ba9-401b-8010-e1b37a9b5892"
      unitRef="shares">42000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="i477da3d9a3ff40539adf947d1f500015_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzY0MDE_5f182f22-faca-44f4-9f06-1034cbc5107f"
      unitRef="usd">400000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="ie25852142a964d3188c11071355f91b7_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzY0MDU_e4773cf2-94da-4ca3-823d-1aac242a5b2d"
      unitRef="usd">200000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="ib3f407a43bf14aab8924633cd249ade7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzY0MTI_a6b51eb1-613d-43fa-b183-58608cc9e484"
      unitRef="usd">300000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i517e23fe4e2f4b29b85b4d380f6c2944_I20140618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzY2MzQ_12bbc3c7-2d03-407a-a611-b12397b65e93"
      unitRef="shares">200000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <ardx:IncreaseInSharesReservedForIssuanceOptionForAnnualIncreaseAsPercentageOfSharesOutstanding
      contextRef="i517e23fe4e2f4b29b85b4d380f6c2944_I20140618"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzY5MDg_cc641fec-a929-49dd-8b6b-b145b753b8f7"
      unitRef="number">0.010</ardx:IncreaseInSharesReservedForIssuanceOptionForAnnualIncreaseAsPercentageOfSharesOutstanding>
    <ardx:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesUnderEmployeeStockPurchasePlan
      contextRef="i517e23fe4e2f4b29b85b4d380f6c2944_I20140618"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzcxMzE_65c600b4-1ae5-4185-828a-26884b413fb3"
      unitRef="shares">2200000</ardx:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesUnderEmployeeStockPurchasePlan>
    <us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzc3MjY_c0a83a4a-1e29-4edd-8233-6f929beda7ba">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our ESPP activity during the&#160;twelve months ended December&#160;31, 2022 is as follows (in thousands, except per share dollar amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&#160;Available&lt;br/&gt;for&#160;Grant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&#160;Shares&lt;br/&gt;Purchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average Purchase&#160;Price&lt;br/&gt;per&#160;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Proceeds&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares purchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(308)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i180188a490a8459b9367c5d5573a5e16_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZToxZTJhMTc5YzEwZGE0MzNhOTNjMjFjNGMxYzdlY2EzOS90YWJsZXJhbmdlOjFlMmExNzljMTBkYTQzM2E5M2MyMWM0YzFjN2VjYTM5XzItMS0xLTEtNDYwMTM_d5c09586-e645-4560-b4d5-b2c97594932f"
      unitRef="shares">899000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <ardx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesStockPurchasePlanPurchasedNumber
      contextRef="i180188a490a8459b9367c5d5573a5e16_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZToxZTJhMTc5YzEwZGE0MzNhOTNjMjFjNGMxYzdlY2EzOS90YWJsZXJhbmdlOjFlMmExNzljMTBkYTQzM2E5M2MyMWM0YzFjN2VjYTM5XzItMy0xLTEtNDYwMTM_ef787b4d-7d2f-479d-b6c5-637dbaf4bc8e"
      unitRef="shares">1048000</ardx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesStockPurchasePlanPurchasedNumber>
    <ardx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsPurchases
      contextRef="i248a37dc8c184f47ac596a1ecc3f232f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZToxZTJhMTc5YzEwZGE0MzNhOTNjMjFjNGMxYzdlY2EzOS90YWJsZXJhbmdlOjFlMmExNzljMTBkYTQzM2E5M2MyMWM0YzFjN2VjYTM5XzMtMS0xLTEtNDYwMTM_bd747b84-057f-461a-b32c-9f86c5ed5d6d"
      unitRef="shares">308000</ardx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsPurchases>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i248a37dc8c184f47ac596a1ecc3f232f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZToxZTJhMTc5YzEwZGE0MzNhOTNjMjFjNGMxYzdlY2EzOS90YWJsZXJhbmdlOjFlMmExNzljMTBkYTQzM2E5M2MyMWM0YzFjN2VjYTM5XzMtMy0xLTEtNDYwMTM_142cf22e-728d-4ffd-8a34-dcb4c44da43e"
      unitRef="shares">308000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <ardx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare
      contextRef="i248a37dc8c184f47ac596a1ecc3f232f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZToxZTJhMTc5YzEwZGE0MzNhOTNjMjFjNGMxYzdlY2EzOS90YWJsZXJhbmdlOjFlMmExNzljMTBkYTQzM2E5M2MyMWM0YzFjN2VjYTM5XzMtNS0xLTEtNDYwMTM_53d184fc-c510-44aa-88ad-280695df0f6a"
      unitRef="usdPerShare">0.63</ardx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare>
    <ardx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanGrossProceeds
      contextRef="i248a37dc8c184f47ac596a1ecc3f232f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZToxZTJhMTc5YzEwZGE0MzNhOTNjMjFjNGMxYzdlY2EzOS90YWJsZXJhbmdlOjFlMmExNzljMTBkYTQzM2E5M2MyMWM0YzFjN2VjYTM5XzMtNy0xLTEtNDYwMTM_47dad088-a08f-495f-bef6-077078610952"
      unitRef="usd">195000</ardx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanGrossProceeds>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="id1fa16bad9884e0e9493c7512c233aa6_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZToxZTJhMTc5YzEwZGE0MzNhOTNjMjFjNGMxYzdlY2EzOS90YWJsZXJhbmdlOjFlMmExNzljMTBkYTQzM2E5M2MyMWM0YzFjN2VjYTM5XzQtMS0xLTEtNDYwMTM_31c59123-efad-43a5-b495-0371e74791b3"
      unitRef="shares">591000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <ardx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesStockPurchasePlanPurchasedNumber
      contextRef="id1fa16bad9884e0e9493c7512c233aa6_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZToxZTJhMTc5YzEwZGE0MzNhOTNjMjFjNGMxYzdlY2EzOS90YWJsZXJhbmdlOjFlMmExNzljMTBkYTQzM2E5M2MyMWM0YzFjN2VjYTM5XzQtMy0xLTEtNDYwMTM_ef00c3fb-f39b-4dc0-ae21-8109aa543f4f"
      unitRef="shares">1356000</ardx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesStockPurchasePlanPurchasedNumber>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzc3MTk_a7de4730-d5d8-4df5-a044-bdbfbf07b818">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table illustrates the weighted-average assumptions for the Black-Scholes option-pricing model used in determining the fair value of ESPP purchase rights granted to our employees:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i248a37dc8c184f47ac596a1ecc3f232f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo4Y2U3MGQ5Y2QxYzk0YmVkOGU1ZDE2YTYwMDEwZDA4Yy90YWJsZXJhbmdlOjhjZTcwZDljZDFjOTRiZWQ4ZTVkMTZhNjAwMTBkMDhjXzItMS0xLTEtNDYwMTM_b1c02aef-da07-445a-b2ae-40f47e79ec64">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="if8ec837e0d0b46c8864c912515db4ad0_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo4Y2U3MGQ5Y2QxYzk0YmVkOGU1ZDE2YTYwMDEwZDA4Yy90YWJsZXJhbmdlOjhjZTcwZDljZDFjOTRiZWQ4ZTVkMTZhNjAwMTBkMDhjXzItMy0xLTEtNDYwMTM_56945d15-672a-460e-8572-9a270e1c1f9f">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="id9c65dc81f5a450db626c1aa9194755f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo4Y2U3MGQ5Y2QxYzk0YmVkOGU1ZDE2YTYwMDEwZDA4Yy90YWJsZXJhbmdlOjhjZTcwZDljZDFjOTRiZWQ4ZTVkMTZhNjAwMTBkMDhjXzItNS0xLTEtNDYwMTM_f954c52c-2883-4301-a0c6-64338ea2bd19">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i248a37dc8c184f47ac596a1ecc3f232f_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo4Y2U3MGQ5Y2QxYzk0YmVkOGU1ZDE2YTYwMDEwZDA4Yy90YWJsZXJhbmdlOjhjZTcwZDljZDFjOTRiZWQ4ZTVkMTZhNjAwMTBkMDhjXzMtMS0xLTEtNDYwMTM_1767980e-c7ca-4ae6-8b1b-adbc41efc478"
      unitRef="number">0.972</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="if8ec837e0d0b46c8864c912515db4ad0_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo4Y2U3MGQ5Y2QxYzk0YmVkOGU1ZDE2YTYwMDEwZDA4Yy90YWJsZXJhbmdlOjhjZTcwZDljZDFjOTRiZWQ4ZTVkMTZhNjAwMTBkMDhjXzMtMy0xLTEtNDYwMTM_adefd4e9-31ab-4d57-b9cd-a12a06853a3c"
      unitRef="number">1.230</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="id9c65dc81f5a450db626c1aa9194755f_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo4Y2U3MGQ5Y2QxYzk0YmVkOGU1ZDE2YTYwMDEwZDA4Yy90YWJsZXJhbmdlOjhjZTcwZDljZDFjOTRiZWQ4ZTVkMTZhNjAwMTBkMDhjXzMtNS0xLTEtNDYwMTM_d1909ce2-2006-4021-af5f-b0ac2ab72ff7"
      unitRef="number">0.794</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i248a37dc8c184f47ac596a1ecc3f232f_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo4Y2U3MGQ5Y2QxYzk0YmVkOGU1ZDE2YTYwMDEwZDA4Yy90YWJsZXJhbmdlOjhjZTcwZDljZDFjOTRiZWQ4ZTVkMTZhNjAwMTBkMDhjXzQtMS0xLTEtNDYwMTM_1ccce258-4e6e-45e6-82ac-b2e5138573ed"
      unitRef="number">0.019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="if8ec837e0d0b46c8864c912515db4ad0_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo4Y2U3MGQ5Y2QxYzk0YmVkOGU1ZDE2YTYwMDEwZDA4Yy90YWJsZXJhbmdlOjhjZTcwZDljZDFjOTRiZWQ4ZTVkMTZhNjAwMTBkMDhjXzQtMy0xLTEtNDYwMTM_1833ca10-3c99-4a29-abb7-12f7eaf84aae"
      unitRef="number">0.007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="id9c65dc81f5a450db626c1aa9194755f_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo4Y2U3MGQ5Y2QxYzk0YmVkOGU1ZDE2YTYwMDEwZDA4Yy90YWJsZXJhbmdlOjhjZTcwZDljZDFjOTRiZWQ4ZTVkMTZhNjAwMTBkMDhjXzQtNS0xLTEtNDYwMTM_1d67b048-6c1f-42a3-bfb8-43161348a7b5"
      unitRef="number">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i248a37dc8c184f47ac596a1ecc3f232f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo4Y2U3MGQ5Y2QxYzk0YmVkOGU1ZDE2YTYwMDEwZDA4Yy90YWJsZXJhbmdlOjhjZTcwZDljZDFjOTRiZWQ4ZTVkMTZhNjAwMTBkMDhjXzUtMS0xLTEtNDYwMTM_4235a80f-1e9d-4d8b-94b2-1499f81a6efc"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="if8ec837e0d0b46c8864c912515db4ad0_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo4Y2U3MGQ5Y2QxYzk0YmVkOGU1ZDE2YTYwMDEwZDA4Yy90YWJsZXJhbmdlOjhjZTcwZDljZDFjOTRiZWQ4ZTVkMTZhNjAwMTBkMDhjXzUtMy0xLTEtNDYwMTM_0382b6ca-f600-44aa-a766-584ca5d13bf1"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="id9c65dc81f5a450db626c1aa9194755f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTo4Y2U3MGQ5Y2QxYzk0YmVkOGU1ZDE2YTYwMDEwZDA4Yy90YWJsZXJhbmdlOjhjZTcwZDljZDFjOTRiZWQ4ZTVkMTZhNjAwMTBkMDhjXzUtNS0xLTEtNDYwMTM_11bb6e66-94fc-4d0e-88fe-91002d6e8f7c"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzc3MjA_080c941e-d1d6-4da1-8814-734b8dafe02b">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense recognized for stock options, RSUs, PRSUs and our ESPP are recorded as operating expenses in our statements of operations and comprehensive loss, as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ieb74b9fdd27048e29f9e1520ac5e595e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkZWM4MmJkZWE5NWU0NzQyODljYWYwNzc3MmU0Mjg0My90YWJsZXJhbmdlOmRlYzgyYmRlYTk1ZTQ3NDI4OWNhZjA3NzcyZTQyODQzXzItMS0xLTEtNDk4OTQ_9e50782a-2a77-42ff-aa6a-97f602b29feb"
      unitRef="usd">7525000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2b365ae1dfda4e07a8271c22db477bea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkZWM4MmJkZWE5NWU0NzQyODljYWYwNzc3MmU0Mjg0My90YWJsZXJhbmdlOmRlYzgyYmRlYTk1ZTQ3NDI4OWNhZjA3NzcyZTQyODQzXzItMy0xLTEtNDk4OTQ_371124e5-ed42-4ce1-84ef-371eee84b1a8"
      unitRef="usd">7923000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie78b6836511840a480c1026e771997e3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkZWM4MmJkZWE5NWU0NzQyODljYWYwNzc3MmU0Mjg0My90YWJsZXJhbmdlOmRlYzgyYmRlYTk1ZTQ3NDI4OWNhZjA3NzcyZTQyODQzXzItNS0xLTEtNDk4OTQ_fcbe0a9c-f901-4454-938b-133014862d93"
      unitRef="usd">6522000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i48d97bd1c889443c8fee636ae7505dd3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkZWM4MmJkZWE5NWU0NzQyODljYWYwNzc3MmU0Mjg0My90YWJsZXJhbmdlOmRlYzgyYmRlYTk1ZTQ3NDI4OWNhZjA3NzcyZTQyODQzXzItMS0xLTEtNDYwMTM_af3058d5-225d-4633-bd3d-25bc2cc3706e"
      unitRef="usd">3225000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib0ec441698c9479d8b42818e25d70400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkZWM4MmJkZWE5NWU0NzQyODljYWYwNzc3MmU0Mjg0My90YWJsZXJhbmdlOmRlYzgyYmRlYTk1ZTQ3NDI4OWNhZjA3NzcyZTQyODQzXzItMy0xLTEtNDYwMTM_cf613d82-2dc6-4444-a3bd-de81636230f7"
      unitRef="usd">4116000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5830a4e62ed14db59de4465b18e9bdb9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkZWM4MmJkZWE5NWU0NzQyODljYWYwNzc3MmU0Mjg0My90YWJsZXJhbmdlOmRlYzgyYmRlYTk1ZTQ3NDI4OWNhZjA3NzcyZTQyODQzXzItNS0xLTEtNDYwMTM_155b1852-8678-490f-91d8-afbf3e154ad7"
      unitRef="usd">4061000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkZWM4MmJkZWE5NWU0NzQyODljYWYwNzc3MmU0Mjg0My90YWJsZXJhbmdlOmRlYzgyYmRlYTk1ZTQ3NDI4OWNhZjA3NzcyZTQyODQzXzQtMS0xLTEtNDYwMTM_77216b91-5d94-41e7-a2e3-e95d9cb28931"
      unitRef="usd">10750000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkZWM4MmJkZWE5NWU0NzQyODljYWYwNzc3MmU0Mjg0My90YWJsZXJhbmdlOmRlYzgyYmRlYTk1ZTQ3NDI4OWNhZjA3NzcyZTQyODQzXzQtMy0xLTEtNDYwMTM_fdffd318-05e5-457d-b0ed-99c2d6738597"
      unitRef="usd">12039000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZTpkZWM4MmJkZWE5NWU0NzQyODljYWYwNzc3MmU0Mjg0My90YWJsZXJhbmdlOmRlYzgyYmRlYTk1ZTQ3NDI4OWNhZjA3NzcyZTQyODQzXzQtNS0xLTEtNDYwMTM_04cd2658-523d-4c9d-a656-d5102b980f40"
      unitRef="usd">10583000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90ZXh0cmVnaW9uOjY4OTFlMGM4ZTAzMzQ4Mjg5ODg5N2FkMzA0NDJjMjgxXzc3MjE_4cd81845-61d2-4bb3-b533-79b51b81993e">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our total unrecognized stock-based compensation expense, net of estimated forfeitures, as of December&#160;31, 2022 is as follows (dollars in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.920%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.922%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrecognized Compensation Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average Remaining Vesting Period (Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options grant&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.55&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSU grants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.95&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ief16b3cbe3934dc98b9bc68d2856ca35_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZToxNTQ4NjFlODc1MGE0NDkzOTFlZTYxYTExZTdhNDMyZC90YWJsZXJhbmdlOjE1NDg2MWU4NzUwYTQ0OTM5MWVlNjFhMTFlN2E0MzJkXzItMS0xLTEtNDYwMTM_ea3aaaf5-71c2-4a82-bdca-e3c4f733dd2b"
      unitRef="usd">9434000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i4d035ef039b9449f9a833a4878f300ef_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZToxNTQ4NjFlODc1MGE0NDkzOTFlZTYxYTExZTdhNDMyZC90YWJsZXJhbmdlOjE1NDg2MWU4NzUwYTQ0OTM5MWVlNjFhMTFlN2E0MzJkXzItMy0xLTEtNDYwMTM_546381af-d43d-4084-b0b0-c1758b1af528">P2Y6M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i5c4f587701fb4044879019a9bdf73a97_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZToxNTQ4NjFlODc1MGE0NDkzOTFlZTYxYTExZTdhNDMyZC90YWJsZXJhbmdlOjE1NDg2MWU4NzUwYTQ0OTM5MWVlNjFhMTFlN2E0MzJkXzMtMS0xLTEtNDYwMTM_900e639f-de7f-449a-a7b5-73c1c42dcb64"
      unitRef="usd">2937000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i5804b276fcba47ec9888f9294a058bd3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZToxNTQ4NjFlODc1MGE0NDkzOTFlZTYxYTExZTdhNDMyZC90YWJsZXJhbmdlOjE1NDg2MWU4NzUwYTQ0OTM5MWVlNjFhMTFlN2E0MzJkXzMtMy0xLTEtNDYwMTM_0810c5d1-7d3c-4fe0-88ef-ea008ae8990d">P2Y11M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="id1fa16bad9884e0e9493c7512c233aa6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZToxNTQ4NjFlODc1MGE0NDkzOTFlZTYxYTExZTdhNDMyZC90YWJsZXJhbmdlOjE1NDg2MWU4NzUwYTQ0OTM5MWVlNjFhMTFlN2E0MzJkXzQtMS0xLTEtNDYwMTM_7e9d5a81-ab59-4028-a0ae-2019d87a8d21"
      unitRef="usd">22000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i248a37dc8c184f47ac596a1ecc3f232f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMjcvZnJhZzo2ODkxZTBjOGUwMzM0ODI4OTg4OTdhZDMwNDQyYzI4MS90YWJsZToxNTQ4NjFlODc1MGE0NDkzOTFlZTYxYTExZTdhNDMyZC90YWJsZXJhbmdlOjE1NDg2MWU4NzUwYTQ0OTM5MWVlNjFhMTFlN2E0MzJkXzQtMy0xLTEtNDYwMTM_fe9b7a86-962b-496d-a44d-885e8f7c4259">P0Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzAvZnJhZzplNDc3YmQ2ZGE0NjM0ZWQ2Yjk1YTFlNGM2ZmIwMDBhOC90ZXh0cmVnaW9uOmU0NzdiZDZkYTQ2MzRlZDZiOTVhMWU0YzZmYjAwMGE4XzMwMzk_1b953712-f904-4e78-a5fb-1c4427339145">RESTRUCTURING&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2021, we implemented restructuring plans in August and October following the receipt of a Complete Response Letter (&#x201c;CRL&#x201d;) from the U.S. FDA relating to our new drug application (&#x201c;NDA&#x201d;) for XPHOZAH and following the conclusion of an End of Review Type A meeting with the FDA, respectively. Both restructuring plans were substantially completed in December 2021 and most of the cash payments related to the reduction in workforce were disbursed prior to December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Impacted employees were eligible to receive severance benefits and additional Company funded COBRA premiums, contingent upon an impacted employee&#x2019;s execution (and non-revocation) of a separation agreement, which included a general release of claims against us. In connection with restructuring, we incurred restructuring charges of $6.2&#160;million, which were recorded during the twelve months ended December 31, 2021, related to one-time termination notice and severance payments and other employee-related costs. We did not incur any significant contract termination costs pursuant to restructuring. Of the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;charges, $2.7&#160;million was recorded in research and development expenses, and $3.5&#160;million was recorded in selling, general and administrative expense in the accompanying statements of operations and comprehensive loss. Most of the cash payments related to the reduction in workforce were disbursed during the twelve months ended December 31, 2021. We reported the remaining estimated restructuring liability of zero and $0.5&#160;million as accrued compensation and benefits in our balance sheet as of December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, in October, 2021, our Board approved, and management has implemented a retention program consisting of cash payments and grants of RSUs to our employees, including our executives, not impacted by the reduction in force.&lt;/span&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringCharges
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzAvZnJhZzplNDc3YmQ2ZGE0NjM0ZWQ2Yjk1YTFlNGM2ZmIwMDBhOC90ZXh0cmVnaW9uOmU0NzdiZDZkYTQ2MzRlZDZiOTVhMWU0YzZmYjAwMGE4XzIwOTk_66c4fb71-d9c3-4baa-ba4f-ea781e36317b"
      unitRef="usd">6200000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i48d97bd1c889443c8fee636ae7505dd3_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzAvZnJhZzplNDc3YmQ2ZGE0NjM0ZWQ2Yjk1YTFlNGM2ZmIwMDBhOC90ZXh0cmVnaW9uOmU0NzdiZDZkYTQ2MzRlZDZiOTVhMWU0YzZmYjAwMGE4XzIzNzI_c97337ee-f621-46bd-89aa-b4ef3e81ba7a"
      unitRef="usd">2700000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i431ed8f3e092438fbec58a56f0b02185_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzAvZnJhZzplNDc3YmQ2ZGE0NjM0ZWQ2Yjk1YTFlNGM2ZmIwMDBhOC90ZXh0cmVnaW9uOmU0NzdiZDZkYTQ2MzRlZDZiOTVhMWU0YzZmYjAwMGE4XzI0MzA_aff72729-5667-4c63-a5c2-c0aca49e1aaf"
      unitRef="usd">3500000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringReserveCurrent
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzAvZnJhZzplNDc3YmQ2ZGE0NjM0ZWQ2Yjk1YTFlNGM2ZmIwMDBhOC90ZXh0cmVnaW9uOmU0NzdiZDZkYTQ2MzRlZDZiOTVhMWU0YzZmYjAwMGE4XzU0OTc1NTgxOTI2Mw_38833fa9-7808-4b5b-b24c-8c13857b75f8"
      unitRef="usd">0</us-gaap:RestructuringReserveCurrent>
    <us-gaap:RestructuringReserveCurrent
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzAvZnJhZzplNDc3YmQ2ZGE0NjM0ZWQ2Yjk1YTFlNGM2ZmIwMDBhOC90ZXh0cmVnaW9uOmU0NzdiZDZkYTQ2MzRlZDZiOTVhMWU0YzZmYjAwMGE4XzI3MzU_2543aad8-c058-4b7b-93d8-6c40f6c64be9"
      unitRef="usd">500000</us-gaap:RestructuringReserveCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzMvZnJhZzo1ZmIwNDYwZjZmMzY0NGM5YTRlZTJmNWExN2I4MzI2Yy90ZXh0cmVnaW9uOjVmYjA0NjBmNmYzNjQ0YzlhNGVlMmY1YTE3YjgzMjZjXzIxOA_7613c9cd-a000-4c50-95be-893f71f20cf2">PROPERTY AND EQUIPMENT, NET&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment and furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,657)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,891)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized depreciation expense in the amount of $0.7 million, $1.4 million, and $1.8 million for the&#160;years ended December&#160;31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;During the year ended December 31, 2022, following the elimination of our internal research organization in the fourth quarter of 2021, we sold laboratory equipment with total net carrying value of $0.5 million and received cash proceeds of $1.8 million, resulting in a gain of $1.3 million which has been reported within other income, net on our statement of operations and comprehensive loss.</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzMvZnJhZzo1ZmIwNDYwZjZmMzY0NGM5YTRlZTJmNWExN2I4MzI2Yy90ZXh0cmVnaW9uOjVmYjA0NjBmNmYzNjQ0YzlhNGVlMmY1YTE3YjgzMjZjXzIxOQ_47096b84-d2ad-4075-a2a4-773a674faae1">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment and furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,657)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,891)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i09a681eff916461fb51eb3329131ce8c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzMvZnJhZzo1ZmIwNDYwZjZmMzY0NGM5YTRlZTJmNWExN2I4MzI2Yy90YWJsZTplMGJlOTZjN2Y0NmE0N2U5ODUxZTE5ZWJhNWEzZmNhMC90YWJsZXJhbmdlOmUwYmU5NmM3ZjQ2YTQ3ZTk4NTFlMTllYmE1YTNmY2EwXzItMS0xLTEtNDYwMTM_7a0f0f16-698b-4680-bbb9-c57bb2ddbfcd"
      unitRef="usd">46000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic11d410599a74593aa714291238376f7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzMvZnJhZzo1ZmIwNDYwZjZmMzY0NGM5YTRlZTJmNWExN2I4MzI2Yy90YWJsZTplMGJlOTZjN2Y0NmE0N2U5ODUxZTE5ZWJhNWEzZmNhMC90YWJsZXJhbmdlOmUwYmU5NmM3ZjQ2YTQ3ZTk4NTFlMTllYmE1YTNmY2EwXzItMy0xLTEtNDYwMTM_e47af40b-0154-47e4-a709-e2683bed1d95"
      unitRef="usd">7474000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibb22b29792e5485ebf185f5394ba3762_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzMvZnJhZzo1ZmIwNDYwZjZmMzY0NGM5YTRlZTJmNWExN2I4MzI2Yy90YWJsZTplMGJlOTZjN2Y0NmE0N2U5ODUxZTE5ZWJhNWEzZmNhMC90YWJsZXJhbmdlOmUwYmU5NmM3ZjQ2YTQ3ZTk4NTFlMTllYmE1YTNmY2EwXzMtMS0xLTEtNDYwMTM_af928756-6f8a-4dc8-84ba-cf9eee09b46d"
      unitRef="usd">2089000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="icc9a17e7794647c2bf47f0d17f42638a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzMvZnJhZzo1ZmIwNDYwZjZmMzY0NGM5YTRlZTJmNWExN2I4MzI2Yy90YWJsZTplMGJlOTZjN2Y0NmE0N2U5ODUxZTE5ZWJhNWEzZmNhMC90YWJsZXJhbmdlOmUwYmU5NmM3ZjQ2YTQ3ZTk4NTFlMTllYmE1YTNmY2EwXzMtMy0xLTEtNDYwMTM_5ab1164b-353f-4a75-8a5c-67d1629fdb81"
      unitRef="usd">2034000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i69f5495993474d55b708c186a11429b3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzMvZnJhZzo1ZmIwNDYwZjZmMzY0NGM5YTRlZTJmNWExN2I4MzI2Yy90YWJsZTplMGJlOTZjN2Y0NmE0N2U5ODUxZTE5ZWJhNWEzZmNhMC90YWJsZXJhbmdlOmUwYmU5NmM3ZjQ2YTQ3ZTk4NTFlMTllYmE1YTNmY2EwXzQtMS0xLTEtNDYwMTM_e289bc3e-86d7-4486-a363-22df92d67da8"
      unitRef="usd">8745000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id91a83781eeb4816af435aa999f55171_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzMvZnJhZzo1ZmIwNDYwZjZmMzY0NGM5YTRlZTJmNWExN2I4MzI2Yy90YWJsZTplMGJlOTZjN2Y0NmE0N2U5ODUxZTE5ZWJhNWEzZmNhMC90YWJsZXJhbmdlOmUwYmU5NmM3ZjQ2YTQ3ZTk4NTFlMTllYmE1YTNmY2EwXzQtMy0xLTEtNDYwMTM_63190361-28bf-4aa5-85d7-dca7f0802f51"
      unitRef="usd">8745000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzMvZnJhZzo1ZmIwNDYwZjZmMzY0NGM5YTRlZTJmNWExN2I4MzI2Yy90YWJsZTplMGJlOTZjN2Y0NmE0N2U5ODUxZTE5ZWJhNWEzZmNhMC90YWJsZXJhbmdlOmUwYmU5NmM3ZjQ2YTQ3ZTk4NTFlMTllYmE1YTNmY2EwXzUtMS0xLTEtNDYwMTM_c021fa6b-1d7d-43b8-9043-215ed98da63d"
      unitRef="usd">10880000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzMvZnJhZzo1ZmIwNDYwZjZmMzY0NGM5YTRlZTJmNWExN2I4MzI2Yy90YWJsZTplMGJlOTZjN2Y0NmE0N2U5ODUxZTE5ZWJhNWEzZmNhMC90YWJsZXJhbmdlOmUwYmU5NmM3ZjQ2YTQ3ZTk4NTFlMTllYmE1YTNmY2EwXzUtMy0xLTEtNDYwMTM_b7d1148c-8ea7-48aa-a3bc-1ad6d0419493"
      unitRef="usd">18253000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzMvZnJhZzo1ZmIwNDYwZjZmMzY0NGM5YTRlZTJmNWExN2I4MzI2Yy90YWJsZTplMGJlOTZjN2Y0NmE0N2U5ODUxZTE5ZWJhNWEzZmNhMC90YWJsZXJhbmdlOmUwYmU5NmM3ZjQ2YTQ3ZTk4NTFlMTllYmE1YTNmY2EwXzYtMS0xLTEtNDYwMTM_74250d1c-8c4b-4ee4-bfe2-3df6399e06c3"
      unitRef="usd">9657000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzMvZnJhZzo1ZmIwNDYwZjZmMzY0NGM5YTRlZTJmNWExN2I4MzI2Yy90YWJsZTplMGJlOTZjN2Y0NmE0N2U5ODUxZTE5ZWJhNWEzZmNhMC90YWJsZXJhbmdlOmUwYmU5NmM3ZjQ2YTQ3ZTk4NTFlMTllYmE1YTNmY2EwXzYtMy0xLTEtNDYwMTM_a301dc78-565c-4c20-80c5-fbcafd796b5f"
      unitRef="usd">15891000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzMvZnJhZzo1ZmIwNDYwZjZmMzY0NGM5YTRlZTJmNWExN2I4MzI2Yy90YWJsZTplMGJlOTZjN2Y0NmE0N2U5ODUxZTE5ZWJhNWEzZmNhMC90YWJsZXJhbmdlOmUwYmU5NmM3ZjQ2YTQ3ZTk4NTFlMTllYmE1YTNmY2EwXzctMS0xLTEtNDYwMTM_07ec0bd1-b961-48ba-8cea-550b4da4f126"
      unitRef="usd">1223000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzMvZnJhZzo1ZmIwNDYwZjZmMzY0NGM5YTRlZTJmNWExN2I4MzI2Yy90YWJsZTplMGJlOTZjN2Y0NmE0N2U5ODUxZTE5ZWJhNWEzZmNhMC90YWJsZXJhbmdlOmUwYmU5NmM3ZjQ2YTQ3ZTk4NTFlMTllYmE1YTNmY2EwXzctMy0xLTEtNDYwMTM_26f91363-eb2b-46f5-91c1-bba430a93a4e"
      unitRef="usd">2362000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzMvZnJhZzo1ZmIwNDYwZjZmMzY0NGM5YTRlZTJmNWExN2I4MzI2Yy90ZXh0cmVnaW9uOjVmYjA0NjBmNmYzNjQ0YzlhNGVlMmY1YTE3YjgzMjZjXzE1Ng_6c5861f8-cdc2-4c45-a826-61498482d2d3"
      unitRef="usd">700000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzMvZnJhZzo1ZmIwNDYwZjZmMzY0NGM5YTRlZTJmNWExN2I4MzI2Yy90ZXh0cmVnaW9uOjVmYjA0NjBmNmYzNjQ0YzlhNGVlMmY1YTE3YjgzMjZjXzE2MA_d6721bab-5a1d-4c44-9f0d-f2dad7e73c5c"
      unitRef="usd">1400000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzMvZnJhZzo1ZmIwNDYwZjZmMzY0NGM5YTRlZTJmNWExN2I4MzI2Yy90ZXh0cmVnaW9uOjVmYjA0NjBmNmYzNjQ0YzlhNGVlMmY1YTE3YjgzMjZjXzE2OA_74ffe3b0-7cd5-478b-a5a8-21a8a9e2b247"
      unitRef="usd">1800000</us-gaap:Depreciation>
    <us-gaap:PropertyPlantAndEquipmentDisposals
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzMvZnJhZzo1ZmIwNDYwZjZmMzY0NGM5YTRlZTJmNWExN2I4MzI2Yy90ZXh0cmVnaW9uOjVmYjA0NjBmNmYzNjQ0YzlhNGVlMmY1YTE3YjgzMjZjXzU0OTc1NTgxNDU3Nw_4205bb80-e134-4074-a42a-0363d7befe3f"
      unitRef="usd">500000</us-gaap:PropertyPlantAndEquipmentDisposals>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzMvZnJhZzo1ZmIwNDYwZjZmMzY0NGM5YTRlZTJmNWExN2I4MzI2Yy90ZXh0cmVnaW9uOjVmYjA0NjBmNmYzNjQ0YzlhNGVlMmY1YTE3YjgzMjZjXzU0OTc1NTgxNDU5Mg_eae15ad3-0b45-4839-acee-846a9e46562c"
      unitRef="usd">1800000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzMvZnJhZzo1ZmIwNDYwZjZmMzY0NGM5YTRlZTJmNWExN2I4MzI2Yy90ZXh0cmVnaW9uOjVmYjA0NjBmNmYzNjQ0YzlhNGVlMmY1YTE3YjgzMjZjXzU0OTc1NTgxNDYwNw_dcbb6983-2ed7-46a7-81d4-43b0a2004ba9"
      unitRef="usd">1300000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzYvZnJhZzpjZWQ5MWEzYWM4ODE0M2U0YjczNGFiYTExZWEzMjFjNS90ZXh0cmVnaW9uOmNlZDkxYTNhYzg4MTQzZTRiNzM0YWJhMTFlYTMyMWM1XzE0Nw_095d6099-96b9-4389-b64c-e56426c87cba">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payments due to AstraZeneca &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued gross to net revenue liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued contract manufacturing expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liability for exit fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued non-clinical research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional and consulting services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued sales and marketing expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzYvZnJhZzpjZWQ5MWEzYWM4ODE0M2U0YjczNGFiYTExZWEzMjFjNS90ZXh0cmVnaW9uOmNlZDkxYTNhYzg4MTQzZTRiNzM0YWJhMTFlYTMyMWM1XzE0OA_44881a31-2d7c-4885-aeec-b60d5a755c32">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payments due to AstraZeneca &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued gross to net revenue liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued contract manufacturing expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liability for exit fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued non-clinical research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional and consulting services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued sales and marketing expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <ardx:AccruedPaymentsDueToRelatedParty
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzYvZnJhZzpjZWQ5MWEzYWM4ODE0M2U0YjczNGFiYTExZWEzMjFjNS90YWJsZTplM2Y5M2ZmODQ5YjU0OTM5YWZlNzE3ZDQwNWQ3MzM4YS90YWJsZXJhbmdlOmUzZjkzZmY4NDliNTQ5MzlhZmU3MTdkNDA1ZDczMzhhXzItMS0xLTEtNTMzNDE_460b2140-0612-4925-93b1-8c19f1b67e1c"
      unitRef="usd">3385000</ardx:AccruedPaymentsDueToRelatedParty>
    <ardx:AccruedPaymentsDueToRelatedParty
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzYvZnJhZzpjZWQ5MWEzYWM4ODE0M2U0YjczNGFiYTExZWEzMjFjNS90YWJsZTplM2Y5M2ZmODQ5YjU0OTM5YWZlNzE3ZDQwNWQ3MzM4YS90YWJsZXJhbmdlOmUzZjkzZmY4NDliNTQ5MzlhZmU3MTdkNDA1ZDczMzhhXzItMy0xLTEtNTMzNDE_054483b2-6628-444e-a514-c5b2dcb2ec40"
      unitRef="usd">69000</ardx:AccruedPaymentsDueToRelatedParty>
    <ardx:AccruedGrossToNetRevenueLiabilities
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzYvZnJhZzpjZWQ5MWEzYWM4ODE0M2U0YjczNGFiYTExZWEzMjFjNS90YWJsZTplM2Y5M2ZmODQ5YjU0OTM5YWZlNzE3ZDQwNWQ3MzM4YS90YWJsZXJhbmdlOmUzZjkzZmY4NDliNTQ5MzlhZmU3MTdkNDA1ZDczMzhhXzItMS0xLTEtNDYwMTM_71b3e949-ff87-4460-b3f3-03abaeb4a7d1"
      unitRef="usd">1991000</ardx:AccruedGrossToNetRevenueLiabilities>
    <ardx:AccruedGrossToNetRevenueLiabilities
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzYvZnJhZzpjZWQ5MWEzYWM4ODE0M2U0YjczNGFiYTExZWEzMjFjNS90YWJsZTplM2Y5M2ZmODQ5YjU0OTM5YWZlNzE3ZDQwNWQ3MzM4YS90YWJsZXJhbmdlOmUzZjkzZmY4NDliNTQ5MzlhZmU3MTdkNDA1ZDczMzhhXzItMy0xLTEtNDYwMTM_50ca88d8-a532-4b6f-91db-27b65252006b"
      unitRef="usd">0</ardx:AccruedGrossToNetRevenueLiabilities>
    <ardx:AccruedContractManufacturingCosts
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzYvZnJhZzpjZWQ5MWEzYWM4ODE0M2U0YjczNGFiYTExZWEzMjFjNS90YWJsZTplM2Y5M2ZmODQ5YjU0OTM5YWZlNzE3ZDQwNWQ3MzM4YS90YWJsZXJhbmdlOmUzZjkzZmY4NDliNTQ5MzlhZmU3MTdkNDA1ZDczMzhhXzMtMS0xLTEtNDYwMTM_f9875057-d7b7-41d3-9e5f-1e61b77a7d3c"
      unitRef="usd">1657000</ardx:AccruedContractManufacturingCosts>
    <ardx:AccruedContractManufacturingCosts
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzYvZnJhZzpjZWQ5MWEzYWM4ODE0M2U0YjczNGFiYTExZWEzMjFjNS90YWJsZTplM2Y5M2ZmODQ5YjU0OTM5YWZlNzE3ZDQwNWQ3MzM4YS90YWJsZXJhbmdlOmUzZjkzZmY4NDliNTQ5MzlhZmU3MTdkNDA1ZDczMzhhXzMtMy0xLTEtNDYwMTM_473eae0f-9b6d-407e-81ae-be3311363f58"
      unitRef="usd">2485000</ardx:AccruedContractManufacturingCosts>
    <ardx:DerivativeLiabilityForExitFees
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzYvZnJhZzpjZWQ5MWEzYWM4ODE0M2U0YjczNGFiYTExZWEzMjFjNS90YWJsZTplM2Y5M2ZmODQ5YjU0OTM5YWZlNzE3ZDQwNWQ3MzM4YS90YWJsZXJhbmdlOmUzZjkzZmY4NDliNTQ5MzlhZmU3MTdkNDA1ZDczMzhhXzQtMS0xLTEtNDYwMTM_bf859605-0eb5-494f-baea-56e38749bcd8"
      unitRef="usd">1656000</ardx:DerivativeLiabilityForExitFees>
    <ardx:DerivativeLiabilityForExitFees
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzYvZnJhZzpjZWQ5MWEzYWM4ODE0M2U0YjczNGFiYTExZWEzMjFjNS90YWJsZTplM2Y5M2ZmODQ5YjU0OTM5YWZlNzE3ZDQwNWQ3MzM4YS90YWJsZXJhbmdlOmUzZjkzZmY4NDliNTQ5MzlhZmU3MTdkNDA1ZDczMzhhXzQtMy0xLTEtNDYwMTM_5301d8c4-beb0-465b-822c-63152b7a2420"
      unitRef="usd">698000</ardx:DerivativeLiabilityForExitFees>
    <ardx:AccruedNonClinicalResearchAndDevelopmentExpenses
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzYvZnJhZzpjZWQ5MWEzYWM4ODE0M2U0YjczNGFiYTExZWEzMjFjNS90YWJsZTplM2Y5M2ZmODQ5YjU0OTM5YWZlNzE3ZDQwNWQ3MzM4YS90YWJsZXJhbmdlOmUzZjkzZmY4NDliNTQ5MzlhZmU3MTdkNDA1ZDczMzhhXzYtMS0xLTEtNTUxMzc_67e726a4-fe5d-4e9d-b3ae-8fb4867a8617"
      unitRef="usd">1188000</ardx:AccruedNonClinicalResearchAndDevelopmentExpenses>
    <ardx:AccruedNonClinicalResearchAndDevelopmentExpenses
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzYvZnJhZzpjZWQ5MWEzYWM4ODE0M2U0YjczNGFiYTExZWEzMjFjNS90YWJsZTplM2Y5M2ZmODQ5YjU0OTM5YWZlNzE3ZDQwNWQ3MzM4YS90YWJsZXJhbmdlOmUzZjkzZmY4NDliNTQ5MzlhZmU3MTdkNDA1ZDczMzhhXzYtMy0xLTEtNTUxMzc_10d75e05-0754-4b6c-bd99-7656fe2fe39f"
      unitRef="usd">265000</ardx:AccruedNonClinicalResearchAndDevelopmentExpenses>
    <ardx:AccruedProfessionalAndConsultantFeesCurrent
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzYvZnJhZzpjZWQ5MWEzYWM4ODE0M2U0YjczNGFiYTExZWEzMjFjNS90YWJsZTplM2Y5M2ZmODQ5YjU0OTM5YWZlNzE3ZDQwNWQ3MzM4YS90YWJsZXJhbmdlOmUzZjkzZmY4NDliNTQ5MzlhZmU3MTdkNDA1ZDczMzhhXzUtMS0xLTEtNDYwMTM_5e051f10-c741-4f6a-8b4a-46764449f503"
      unitRef="usd">808000</ardx:AccruedProfessionalAndConsultantFeesCurrent>
    <ardx:AccruedProfessionalAndConsultantFeesCurrent
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzYvZnJhZzpjZWQ5MWEzYWM4ODE0M2U0YjczNGFiYTExZWEzMjFjNS90YWJsZTplM2Y5M2ZmODQ5YjU0OTM5YWZlNzE3ZDQwNWQ3MzM4YS90YWJsZXJhbmdlOmUzZjkzZmY4NDliNTQ5MzlhZmU3MTdkNDA1ZDczMzhhXzUtMy0xLTEtNDYwMTM_87c9b855-0893-4ae4-8535-235edc5b49b6"
      unitRef="usd">597000</ardx:AccruedProfessionalAndConsultantFeesCurrent>
    <ardx:AccruedSalesAndMarketingExpenses
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzYvZnJhZzpjZWQ5MWEzYWM4ODE0M2U0YjczNGFiYTExZWEzMjFjNS90YWJsZTplM2Y5M2ZmODQ5YjU0OTM5YWZlNzE3ZDQwNWQ3MzM4YS90YWJsZXJhbmdlOmUzZjkzZmY4NDliNTQ5MzlhZmU3MTdkNDA1ZDczMzhhXzctMS0xLTEtNTE0ODU_67959593-7f6d-4025-aa4f-659c476d2dd8"
      unitRef="usd">587000</ardx:AccruedSalesAndMarketingExpenses>
    <ardx:AccruedSalesAndMarketingExpenses
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzYvZnJhZzpjZWQ5MWEzYWM4ODE0M2U0YjczNGFiYTExZWEzMjFjNS90YWJsZTplM2Y5M2ZmODQ5YjU0OTM5YWZlNzE3ZDQwNWQ3MzM4YS90YWJsZXJhbmdlOmUzZjkzZmY4NDliNTQ5MzlhZmU3MTdkNDA1ZDczMzhhXzctMy0xLTEtNTE0ODU_7d101a95-004e-47bb-998a-1ac1e8d8a245"
      unitRef="usd">256000</ardx:AccruedSalesAndMarketingExpenses>
    <ardx:AccruedClinicalExpenses
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzYvZnJhZzpjZWQ5MWEzYWM4ODE0M2U0YjczNGFiYTExZWEzMjFjNS90YWJsZTplM2Y5M2ZmODQ5YjU0OTM5YWZlNzE3ZDQwNWQ3MzM4YS90YWJsZXJhbmdlOmUzZjkzZmY4NDliNTQ5MzlhZmU3MTdkNDA1ZDczMzhhXzYtMS0xLTEtNDYwMTM_04163c03-8102-4839-8dc3-2c34e1cd1226"
      unitRef="usd">223000</ardx:AccruedClinicalExpenses>
    <ardx:AccruedClinicalExpenses
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzYvZnJhZzpjZWQ5MWEzYWM4ODE0M2U0YjczNGFiYTExZWEzMjFjNS90YWJsZTplM2Y5M2ZmODQ5YjU0OTM5YWZlNzE3ZDQwNWQ3MzM4YS90YWJsZXJhbmdlOmUzZjkzZmY4NDliNTQ5MzlhZmU3MTdkNDA1ZDczMzhhXzYtMy0xLTEtNDYwMTM_d854b1dc-ca02-4a46-a1a5-09830e801e1f"
      unitRef="usd">2522000</ardx:AccruedClinicalExpenses>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzYvZnJhZzpjZWQ5MWEzYWM4ODE0M2U0YjczNGFiYTExZWEzMjFjNS90YWJsZTplM2Y5M2ZmODQ5YjU0OTM5YWZlNzE3ZDQwNWQ3MzM4YS90YWJsZXJhbmdlOmUzZjkzZmY4NDliNTQ5MzlhZmU3MTdkNDA1ZDczMzhhXzgtMS0xLTEtNDYwMTM_380efa5e-d812-46c6-9f43-abd7e32ca4d3"
      unitRef="usd">885000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzYvZnJhZzpjZWQ5MWEzYWM4ODE0M2U0YjczNGFiYTExZWEzMjFjNS90YWJsZTplM2Y5M2ZmODQ5YjU0OTM5YWZlNzE3ZDQwNWQ3MzM4YS90YWJsZXJhbmdlOmUzZjkzZmY4NDliNTQ5MzlhZmU3MTdkNDA1ZDczMzhhXzgtMy0xLTEtNDYwMTM_faa056f1-d3f8-4897-a1d9-1cf3fd430543"
      unitRef="usd">474000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzYvZnJhZzpjZWQ5MWEzYWM4ODE0M2U0YjczNGFiYTExZWEzMjFjNS90YWJsZTplM2Y5M2ZmODQ5YjU0OTM5YWZlNzE3ZDQwNWQ3MzM4YS90YWJsZXJhbmdlOmUzZjkzZmY4NDliNTQ5MzlhZmU3MTdkNDA1ZDczMzhhXzktMS0xLTEtNDYwMTM_b672bfae-71cb-43ea-adf8-ac26e30e2d95"
      unitRef="usd">12380000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzYvZnJhZzpjZWQ5MWEzYWM4ODE0M2U0YjczNGFiYTExZWEzMjFjNS90YWJsZTplM2Y5M2ZmODQ5YjU0OTM5YWZlNzE3ZDQwNWQ3MzM4YS90YWJsZXJhbmdlOmUzZjkzZmY4NDliNTQ5MzlhZmU3MTdkNDA1ZDczMzhhXzktMy0xLTEtNDYwMTM_5f269faa-c0b3-4caf-9569-07a46ae0e086"
      unitRef="usd">7366000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90ZXh0cmVnaW9uOjU5ZTk3ZjNhMDkyMDQ4ODRhZTE0NWMzZmVmZTIxMmUwXzU4NzU_92d47264-eb6c-43f0-8e59-ced343b1323b">INCOME TAXES&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of our provision for income taxes for the years ended December&#160;31, 2022, 2021 and 2020, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the statutory federal income tax rate to our effective tax rate is as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax at the federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Executive compensation disallowed under IRC Sec 162(m)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes reflect the tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets are as follows as of December&#160;31, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization and depreciation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(175,670)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(155,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets net of valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,689)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realization of deferred tax assets is dependent on future taxable income, if any, the timing and the amount of which are uncertain. We assess the available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit use of the existing deferred tax assets. A significant component of objective negative evidence evaluated was our cumulative loss incurred over the three-year period ended December&#160;31, 2022. Such objective evidence limits the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ability to consider other subjective evidence, such as our projections for future growth. On the basis of this evaluation, as of December&#160;31, 2022, December&#160;31, 2021 and December&#160;31, 2020, a full valuation allowance has been recorded against our net deferred tax asset. The valuation allowance increased by $20.5&#160;million in 2022 primarily due to increases in net operating losses. The amount of the deferred tax asset considered realizable, however, could be adjusted if estimates of future taxable income during the carryforward period are reduced or increased or if objective negative evidence in the form of cumulative losses is no longer present and additional weight is given to subjective evidence such as our projections for growth.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, we had net operating loss carryforwards for federal income tax purposes of approximately $433.6 million, of which approximately $283.4 million can be carried forward indefinitely and the remaining net operating losses expire beginning in 2030, if not utilized. Federal research and development tax credit carryforwards of approximately $17.2 million that expire beginning in 2027, if not utilized, and foreign tax credit carryforwards of approximately $1.2 million that expire in 2027, if not utilized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, we had net operating loss carryforwards for California income tax purposes of approximately $89.8&#160;million that expire beginning of 2030, if not utilized, and state research and development tax credit carryforwards of approximately $8.6 million which can be carried forward indefinitely. We had approximately $0.1 million of minimum tax credit carryovers for California income tax purposes. The minimum tax credits have no expiration date. We had other state net operating losses of approximately $19.0 million that begin to expire in 2031.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The future utilization of net operating loss and tax credit carryforwards and credits may be subject to an annual limitation, pursuant to Internal Revenue Code Sections 382 and 383, as a result of ownership changes that may have occurred previously or that could occur in the future. Due to the existence of the valuation allowance, limitations under Section 382 and 383 will not impact our effective tax rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Tax Cuts and Jobs Act of 2017, research and development costs are no longer fully deductible and are required to be capitalized and amortized for U.S. tax purposes effective January 1, 2022. The mandatory capitalization requirement did not have a material impact on our deferred tax assets and did not result in a cash tax liability as we have historically elected to capitalized research and development expenses for tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions related to current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtractions related to lapse of statute of limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(811)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtractions based on tax positions related to prior year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(811)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,388)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize a tax benefit from an uncertain tax position when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. Income tax positions must meet a more likely than not recognition at the effective date to be recognized. None of our unrecognized tax benefits would impact the effective tax rate if recognized, because the benefit would be offset by an increase in the valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have elected to include interest and penalties as a component of tax expense. During the years ended December&#160;31, 2022, 2021 and 2020, we did not recognize accrued interest and penalties related to unrecognized tax benefits. Although the timing and outcome of an income tax audit is highly uncertain, we do not anticipate that the amount of existing unrecognized tax benefits will significantly change during the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We file a U.S. federal income tax return and income tax returns in various state and local jurisdictions. Due to our net operating loss and tax credit carryforwards, the income tax returns remain open to U.S. federal and state tax examinations. We are not currently under examination in any tax jurisdiction.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90ZXh0cmVnaW9uOjU5ZTk3ZjNhMDkyMDQ4ODRhZTE0NWMzZmVmZTIxMmUwXzU4NzY_f82fd51c-5fb8-4fa8-adec-45052490b636">&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of our provision for income taxes for the years ended December&#160;31, 2022, 2021 and 2020, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1NjIxZTQwNDlmZWU0OGI4YjUzMDcwZDFhYWVhNGEwNi90YWJsZXJhbmdlOjU2MjFlNDA0OWZlZTQ4YjhiNTMwNzBkMWFhZWE0YTA2XzMtMS0xLTEtNDYwMTM_49a27cf2-12df-40b1-9a58-0d854f8766ce"
      unitRef="usd">8000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1NjIxZTQwNDlmZWU0OGI4YjUzMDcwZDFhYWVhNGEwNi90YWJsZXJhbmdlOjU2MjFlNDA0OWZlZTQ4YjhiNTMwNzBkMWFhZWE0YTA2XzMtMy0xLTEtNDYwMTM_0bdb320b-081e-478b-9c7f-4dd6ee941da8"
      unitRef="usd">4000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1NjIxZTQwNDlmZWU0OGI4YjUzMDcwZDFhYWVhNGEwNi90YWJsZXJhbmdlOjU2MjFlNDA0OWZlZTQ4YjhiNTMwNzBkMWFhZWE0YTA2XzMtNS0xLTEtNDYwMTM_54f5b0c4-ed9d-4bb1-b370-6560ebd74e86"
      unitRef="usd">2000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1NjIxZTQwNDlmZWU0OGI4YjUzMDcwZDFhYWVhNGEwNi90YWJsZXJhbmdlOjU2MjFlNDA0OWZlZTQ4YjhiNTMwNzBkMWFhZWE0YTA2XzQtMS0xLTEtNDYwMTM_8bc088de-da90-45d7-9b86-f00a76d36d73"
      unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1NjIxZTQwNDlmZWU0OGI4YjUzMDcwZDFhYWVhNGEwNi90YWJsZXJhbmdlOjU2MjFlNDA0OWZlZTQ4YjhiNTMwNzBkMWFhZWE0YTA2XzQtMy0xLTEtNDYwMTM_5f0cd6c4-44db-4378-b465-378ced6f5e6e"
      unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1NjIxZTQwNDlmZWU0OGI4YjUzMDcwZDFhYWVhNGEwNi90YWJsZXJhbmdlOjU2MjFlNDA0OWZlZTQ4YjhiNTMwNzBkMWFhZWE0YTA2XzQtNS0xLTEtNDYwMTM_3d8a9775-e3c9-43f1-9f62-1932900a2e6d"
      unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1NjIxZTQwNDlmZWU0OGI4YjUzMDcwZDFhYWVhNGEwNi90YWJsZXJhbmdlOjU2MjFlNDA0OWZlZTQ4YjhiNTMwNzBkMWFhZWE0YTA2XzUtMS0xLTEtNDYwMTM_bb3f7ed6-5d6c-4710-98bf-4120c05a50b6"
      unitRef="usd">8000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1NjIxZTQwNDlmZWU0OGI4YjUzMDcwZDFhYWVhNGEwNi90YWJsZXJhbmdlOjU2MjFlNDA0OWZlZTQ4YjhiNTMwNzBkMWFhZWE0YTA2XzUtMy0xLTEtNDYwMTM_8aa52c94-d75a-4357-ba5b-04425cdff54e"
      unitRef="usd">4000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1NjIxZTQwNDlmZWU0OGI4YjUzMDcwZDFhYWVhNGEwNi90YWJsZXJhbmdlOjU2MjFlNDA0OWZlZTQ4YjhiNTMwNzBkMWFhZWE0YTA2XzUtNS0xLTEtNDYwMTM_d2cb90ea-9ca7-4bba-91cf-c9981aa1548c"
      unitRef="usd">2000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1NjIxZTQwNDlmZWU0OGI4YjUzMDcwZDFhYWVhNGEwNi90YWJsZXJhbmdlOjU2MjFlNDA0OWZlZTQ4YjhiNTMwNzBkMWFhZWE0YTA2XzctMS0xLTEtNDYwMTM_7f0005b0-f264-42fa-a049-dc21263c0ff1"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1NjIxZTQwNDlmZWU0OGI4YjUzMDcwZDFhYWVhNGEwNi90YWJsZXJhbmdlOjU2MjFlNDA0OWZlZTQ4YjhiNTMwNzBkMWFhZWE0YTA2XzctMy0xLTEtNDYwMTM_0ea6f032-c0ed-49a3-a37b-33221067012f"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1NjIxZTQwNDlmZWU0OGI4YjUzMDcwZDFhYWVhNGEwNi90YWJsZXJhbmdlOjU2MjFlNDA0OWZlZTQ4YjhiNTMwNzBkMWFhZWE0YTA2XzctNS0xLTEtNDYwMTM_4158b94c-2059-4a81-8be5-f9773459a57e"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1NjIxZTQwNDlmZWU0OGI4YjUzMDcwZDFhYWVhNGEwNi90YWJsZXJhbmdlOjU2MjFlNDA0OWZlZTQ4YjhiNTMwNzBkMWFhZWE0YTA2XzgtMS0xLTEtNDYwMTM_b131d60a-b28e-4683-850f-ad4b1a147aaa"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1NjIxZTQwNDlmZWU0OGI4YjUzMDcwZDFhYWVhNGEwNi90YWJsZXJhbmdlOjU2MjFlNDA0OWZlZTQ4YjhiNTMwNzBkMWFhZWE0YTA2XzgtMy0xLTEtNDYwMTM_6e08490e-145e-4cfc-bd4d-95e75d49a465"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1NjIxZTQwNDlmZWU0OGI4YjUzMDcwZDFhYWVhNGEwNi90YWJsZXJhbmdlOjU2MjFlNDA0OWZlZTQ4YjhiNTMwNzBkMWFhZWE0YTA2XzgtNS0xLTEtNDYwMTM_1124980d-fb6a-49f4-880c-e8a4b975328b"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1NjIxZTQwNDlmZWU0OGI4YjUzMDcwZDFhYWVhNGEwNi90YWJsZXJhbmdlOjU2MjFlNDA0OWZlZTQ4YjhiNTMwNzBkMWFhZWE0YTA2XzktMS0xLTEtNDYwMTM_bb27ce59-365e-4749-a8b6-da2ba4d79448"
      unitRef="usd">8000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1NjIxZTQwNDlmZWU0OGI4YjUzMDcwZDFhYWVhNGEwNi90YWJsZXJhbmdlOjU2MjFlNDA0OWZlZTQ4YjhiNTMwNzBkMWFhZWE0YTA2XzktMy0xLTEtNDYwMTM_0e59a48f-f269-4991-ae49-c92850a26282"
      unitRef="usd">4000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1NjIxZTQwNDlmZWU0OGI4YjUzMDcwZDFhYWVhNGEwNi90YWJsZXJhbmdlOjU2MjFlNDA0OWZlZTQ4YjhiNTMwNzBkMWFhZWE0YTA2XzktNS0xLTEtNDYwMTM_c0b5fe95-65ed-4310-99fa-988f377fb456"
      unitRef="usd">2000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90ZXh0cmVnaW9uOjU5ZTk3ZjNhMDkyMDQ4ODRhZTE0NWMzZmVmZTIxMmUwXzU4Nzc_bee845ac-66e5-43d4-a218-99decd71b171">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the statutory federal income tax rate to our effective tax rate is as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax at the federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Executive compensation disallowed under IRC Sec 162(m)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzItMS0xLTEtNTY3ODU_eb823943-54a5-425a-ba94-66bc7ecd7072"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzItMy0xLTEtNTY3ODU_7a9613eb-134d-406c-9101-522a68cc17e5"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzItNS0xLTEtNTY3ODU_3caab700-aa21-4b46-92f4-38fc48e72c8d"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzUtMS0xLTEtNDYwMTM_c0f5288f-3be5-4ed8-8976-62b150ac50d8"
      unitRef="number">0.019</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzUtMy0xLTEtNDYwMTM_18c0420e-f4b9-470f-9b82-876bc26e4c73"
      unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzUtNS0xLTEtNDYwMTM_1eaaaf5d-5f85-4b01-bcfc-e7a29beb70fc"
      unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzYtMS0xLTEtNDYwMTM_4641fe0d-519d-43a5-a90f-54eb2234e62a"
      unitRef="number">0.015</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzYtMy0xLTEtNDYwMTM_49880835-1147-4494-9914-afc2f7b2d93f"
      unitRef="number">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzYtNS0xLTEtNDYwMTM_dac23bbb-dbe5-4af7-b3dc-2fbadde642c7"
      unitRef="number">0.013</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <ardx:EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitExecutiveCompensationDisallowedIRCSec162mPercent
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzctMS0xLTEtNDYwMTM_dc531326-b7c0-45cd-9096-5efd30699378"
      unitRef="number">-0.016</ardx:EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitExecutiveCompensationDisallowedIRCSec162mPercent>
    <ardx:EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitExecutiveCompensationDisallowedIRCSec162mPercent
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzctMy0xLTEtNDYwMTM_9c9a1e46-c6fb-4fad-9495-dc67eb81dedf"
      unitRef="number">-0.011</ardx:EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitExecutiveCompensationDisallowedIRCSec162mPercent>
    <ardx:EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitExecutiveCompensationDisallowedIRCSec162mPercent
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzctNS0xLTEtNDYwMTM_d8d58d90-f04c-4ebe-8db5-cd8e659a5cc8"
      unitRef="number">-0.005</ardx:EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitExecutiveCompensationDisallowedIRCSec162mPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzktMS0xLTEtNTY4MDk_b13d4189-caac-48c9-82d1-e80aa6b40836"
      unitRef="number">-0.023</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzktMy0xLTEtNTY4MDk_c468a1c0-fd20-4a87-8bbd-8d8ad83540f9"
      unitRef="number">-0.013</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzktNS0xLTEtNTY4MDk_5e8936b3-9eb7-4901-923a-8a2ad59872ba"
      unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzctMS0xLTEtNTY4Mzk_28757fde-a1c0-449f-89b5-c28fa772a53a"
      unitRef="number">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzctMy0xLTEtNTY4Mzk_6e14027e-eb48-4ae4-bd79-e11b463c19cf"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzctNS0xLTEtNTY4Mzk_9a6acc23-8f14-4caf-9439-bb0a4cc5ca88"
      unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzktMS0xLTEtNTY3OTg_b549af3b-6795-4ed9-9f41-6ca2370bb9ed"
      unitRef="number">-0.197</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzktMy0xLTEtNTY3OTg_a6c39229-e4a0-4643-be39-d01479c5c620"
      unitRef="number">-0.200</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzktNS0xLTEtNTY3OTg_262980a8-13c6-458d-9bbe-c31678c26c93"
      unitRef="number">-0.223</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzktMS0xLTEtNDYwMTM_91bb650d-d929-4e73-bea6-5779f3b6fd28"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzktMy0xLTEtNDYwMTM_4744c2bb-8cc5-4a9e-854c-2081d3bed155"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1YjVmNjE2OWUxMDU0OTNiYjdhOWRkMGYzYTQ0ZDc1Zi90YWJsZXJhbmdlOjViNWY2MTY5ZTEwNTQ5M2JiN2E5ZGQwZjNhNDRkNzVmXzktNS0xLTEtNDYwMTM_6f0f0c8b-a8c1-4985-94c0-96af5029f0b1"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90ZXh0cmVnaW9uOjU5ZTk3ZjNhMDkyMDQ4ODRhZTE0NWMzZmVmZTIxMmUwXzU4Nzg_481dbc74-dfbf-4263-8f14-26adbc3108f3">Significant components of our deferred tax assets are as follows as of December&#160;31, 2022 and 2021 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization and depreciation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(175,670)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(155,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets net of valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,689)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <ardx:DeferredTaxAssetsAmortizationAndDepreciation
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1ZThiNmFlMjQxZGY0ZTE3Yjc5ODVlMzdiZDIzYzNiNC90YWJsZXJhbmdlOjVlOGI2YWUyNDFkZjRlMTdiNzk4NWUzN2JkMjNjM2I0XzMtMS0xLTEtNDYwMTM_84719549-9a01-45e1-a10a-c318f8d45f69"
      unitRef="usd">64111000</ardx:DeferredTaxAssetsAmortizationAndDepreciation>
    <ardx:DeferredTaxAssetsAmortizationAndDepreciation
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1ZThiNmFlMjQxZGY0ZTE3Yjc5ODVlMzdiZDIzYzNiNC90YWJsZXJhbmdlOjVlOGI2YWUyNDFkZjRlMTdiNzk4NWUzN2JkMjNjM2I0XzMtMy0xLTEtNDYwMTM_13d52ca1-4b04-4dbf-a815-594cb802b569"
      unitRef="usd">61098000</ardx:DeferredTaxAssetsAmortizationAndDepreciation>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1ZThiNmFlMjQxZGY0ZTE3Yjc5ODVlMzdiZDIzYzNiNC90YWJsZXJhbmdlOjVlOGI2YWUyNDFkZjRlMTdiNzk4NWUzN2JkMjNjM2I0XzQtMS0xLTEtNDYwMTM_0f732002-e4b8-4050-aecf-df5aa36de912"
      unitRef="usd">86547000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1ZThiNmFlMjQxZGY0ZTE3Yjc5ODVlMzdiZDIzYzNiNC90YWJsZXJhbmdlOjVlOGI2YWUyNDFkZjRlMTdiNzk4NWUzN2JkMjNjM2I0XzQtMy0xLTEtNDYwMTM_f81a7d7c-792b-4880-a3bd-8df2c6dc8505"
      unitRef="usd">74989000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1ZThiNmFlMjQxZGY0ZTE3Yjc5ODVlMzdiZDIzYzNiNC90YWJsZXJhbmdlOjVlOGI2YWUyNDFkZjRlMTdiNzk4NWUzN2JkMjNjM2I0XzUtMS0xLTEtNDYwMTM_b10ae403-4e3e-46a8-9b19-83f7e7c29d6b"
      unitRef="usd">14411000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1ZThiNmFlMjQxZGY0ZTE3Yjc5ODVlMzdiZDIzYzNiNC90YWJsZXJhbmdlOjVlOGI2YWUyNDFkZjRlMTdiNzk4NWUzN2JkMjNjM2I0XzUtMy0xLTEtNDYwMTM_778c5d1f-fb65-47dc-8a69-d568572f1c02"
      unitRef="usd">13827000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1ZThiNmFlMjQxZGY0ZTE3Yjc5ODVlMzdiZDIzYzNiNC90YWJsZXJhbmdlOjVlOGI2YWUyNDFkZjRlMTdiNzk4NWUzN2JkMjNjM2I0XzYtMS0xLTEtNDYwMTM_fa9c04e2-4916-4ebe-a29f-09c1db05d401"
      unitRef="usd">5244000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1ZThiNmFlMjQxZGY0ZTE3Yjc5ODVlMzdiZDIzYzNiNC90YWJsZXJhbmdlOjVlOGI2YWUyNDFkZjRlMTdiNzk4NWUzN2JkMjNjM2I0XzYtMy0xLTEtNDYwMTM_ae0c4669-7b63-47fe-9193-08134926f50d"
      unitRef="usd">4054000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1ZThiNmFlMjQxZGY0ZTE3Yjc5ODVlMzdiZDIzYzNiNC90YWJsZXJhbmdlOjVlOGI2YWUyNDFkZjRlMTdiNzk4NWUzN2JkMjNjM2I0XzgtMS0xLTEtNDYwMTM_d203a4b5-905a-4031-9c9e-e90022dc974a"
      unitRef="usd">7486000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1ZThiNmFlMjQxZGY0ZTE3Yjc5ODVlMzdiZDIzYzNiNC90YWJsZXJhbmdlOjVlOGI2YWUyNDFkZjRlMTdiNzk4NWUzN2JkMjNjM2I0XzgtMy0xLTEtNDYwMTM_e25583f3-759e-42b1-b1f3-5e84c472f0e0"
      unitRef="usd">3867000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1ZThiNmFlMjQxZGY0ZTE3Yjc5ODVlMzdiZDIzYzNiNC90YWJsZXJhbmdlOjVlOGI2YWUyNDFkZjRlMTdiNzk4NWUzN2JkMjNjM2I0XzktMS0xLTEtNDYwMTM_ca18cd21-9d8c-473f-9f9a-ba41c7cddf4e"
      unitRef="usd">177799000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1ZThiNmFlMjQxZGY0ZTE3Yjc5ODVlMzdiZDIzYzNiNC90YWJsZXJhbmdlOjVlOGI2YWUyNDFkZjRlMTdiNzk4NWUzN2JkMjNjM2I0XzktMy0xLTEtNDYwMTM_83694f0f-c21c-44dd-b6ea-7044325cbaaa"
      unitRef="usd">157835000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1ZThiNmFlMjQxZGY0ZTE3Yjc5ODVlMzdiZDIzYzNiNC90YWJsZXJhbmdlOjVlOGI2YWUyNDFkZjRlMTdiNzk4NWUzN2JkMjNjM2I0XzEwLTEtMS0xLTQ2MDEz_ec3364ec-4269-4ec1-ad23-15bb52198bd7"
      unitRef="usd">175670000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1ZThiNmFlMjQxZGY0ZTE3Yjc5ODVlMzdiZDIzYzNiNC90YWJsZXJhbmdlOjVlOGI2YWUyNDFkZjRlMTdiNzk4NWUzN2JkMjNjM2I0XzEwLTMtMS0xLTQ2MDEz_5bdbcbe3-49a8-47a4-b1e4-65e08829d5d4"
      unitRef="usd">155141000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1ZThiNmFlMjQxZGY0ZTE3Yjc5ODVlMzdiZDIzYzNiNC90YWJsZXJhbmdlOjVlOGI2YWUyNDFkZjRlMTdiNzk4NWUzN2JkMjNjM2I0XzExLTEtMS0xLTQ2MDEz_61974c8f-6816-4c23-9a24-9709b233accc"
      unitRef="usd">2129000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1ZThiNmFlMjQxZGY0ZTE3Yjc5ODVlMzdiZDIzYzNiNC90YWJsZXJhbmdlOjVlOGI2YWUyNDFkZjRlMTdiNzk4NWUzN2JkMjNjM2I0XzExLTMtMS0xLTQ2MDEz_46dbfc83-8449-4b88-b5d7-0ea166de84db"
      unitRef="usd">2694000</us-gaap:DeferredTaxAssetsNet>
    <ardx:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1ZThiNmFlMjQxZGY0ZTE3Yjc5ODVlMzdiZDIzYzNiNC90YWJsZXJhbmdlOjVlOGI2YWUyNDFkZjRlMTdiNzk4NWUzN2JkMjNjM2I0XzEzLTEtMS0xLTQ2MDEz_173072bb-8f03-40c2-b806-cd7b90b1b9a5"
      unitRef="usd">2129000</ardx:DeferredTaxLiabilitiesRightOfUseAsset>
    <ardx:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1ZThiNmFlMjQxZGY0ZTE3Yjc5ODVlMzdiZDIzYzNiNC90YWJsZXJhbmdlOjVlOGI2YWUyNDFkZjRlMTdiNzk4NWUzN2JkMjNjM2I0XzEzLTMtMS0xLTQ2MDEz_d4089fc0-7104-433a-a38e-750b7f83927b"
      unitRef="usd">2689000</ardx:DeferredTaxLiabilitiesRightOfUseAsset>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1ZThiNmFlMjQxZGY0ZTE3Yjc5ODVlMzdiZDIzYzNiNC90YWJsZXJhbmdlOjVlOGI2YWUyNDFkZjRlMTdiNzk4NWUzN2JkMjNjM2I0XzE1LTEtMS0xLTQ2MDEz_e0a44173-32e6-4480-be9a-cf080a1c1c43"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1ZThiNmFlMjQxZGY0ZTE3Yjc5ODVlMzdiZDIzYzNiNC90YWJsZXJhbmdlOjVlOGI2YWUyNDFkZjRlMTdiNzk4NWUzN2JkMjNjM2I0XzE1LTMtMS0xLTQ2MDEz_ab8a8810-dd4b-4d21-8edb-905725b89c1e"
      unitRef="usd">5000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1ZThiNmFlMjQxZGY0ZTE3Yjc5ODVlMzdiZDIzYzNiNC90YWJsZXJhbmdlOjVlOGI2YWUyNDFkZjRlMTdiNzk4NWUzN2JkMjNjM2I0XzE2LTEtMS0xLTQ2MDEz_bb7b0271-4058-4aa1-a94a-87c55360fbe4"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo1ZThiNmFlMjQxZGY0ZTE3Yjc5ODVlMzdiZDIzYzNiNC90YWJsZXJhbmdlOjVlOGI2YWUyNDFkZjRlMTdiNzk4NWUzN2JkMjNjM2I0XzE2LTMtMS0xLTQ2MDEz_f10011bc-c0c0-40d4-81ab-d71d6e5bd120"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90ZXh0cmVnaW9uOjU5ZTk3ZjNhMDkyMDQ4ODRhZTE0NWMzZmVmZTIxMmUwXzU0OTc1NTgyMTc4NA_e2e9d509-0d1b-401f-95e8-907e98a1aa74"
      unitRef="usd">20500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="iac8bff27f31a4cdba6c1c3861745b2ef_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90ZXh0cmVnaW9uOjU5ZTk3ZjNhMDkyMDQ4ODRhZTE0NWMzZmVmZTIxMmUwXzE3MTA_b27f25f0-616a-4761-9cbf-29b20e8976e4"
      unitRef="usd">433600000</us-gaap:OperatingLossCarryforwards>
    <ardx:OperatingLossCarryforwardsWithoutExpiration
      contextRef="iac8bff27f31a4cdba6c1c3861745b2ef_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90ZXh0cmVnaW9uOjU5ZTk3ZjNhMDkyMDQ4ODRhZTE0NWMzZmVmZTIxMmUwXzE3Mzc_293da095-f4d8-4bc3-9b0b-48c1f5d67695"
      unitRef="usd">283400000</ardx:OperatingLossCarryforwardsWithoutExpiration>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="if0a0600f40b045c6b35e188f2f71061e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90ZXh0cmVnaW9uOjU5ZTk3ZjNhMDkyMDQ4ODRhZTE0NWMzZmVmZTIxMmUwXzE5MzM_8b46af5d-f250-4ddb-9090-9dd24db64215"
      unitRef="usd">17200000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i417d82d19f4a4fbcadb83d9e66e6fd76_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90ZXh0cmVnaW9uOjU5ZTk3ZjNhMDkyMDQ4ODRhZTE0NWMzZmVmZTIxMmUwXzIwMzg_8b7ee59a-a3ae-4607-9a2c-d96d63873e85"
      unitRef="usd">1200000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i888d6abdafc14bdab944dd9b5f92fa5f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90ZXh0cmVnaW9uOjU5ZTk3ZjNhMDkyMDQ4ODRhZTE0NWMzZmVmZTIxMmUwXzIxODQ_aa9fba54-c586-4fa8-9cfc-dfc0213b0d8d"
      unitRef="usd">89800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i4b6ecc5e16524d9ca5408690716f1a33_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90ZXh0cmVnaW9uOjU5ZTk3ZjNhMDkyMDQ4ODRhZTE0NWMzZmVmZTIxMmUwXzIzMTI_5ad2ac56-7b2e-4560-85f0-54f96cd0834b"
      unitRef="usd">8600000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="ib4ad706ca1134370ac1fdd46d324a005_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90ZXh0cmVnaW9uOjU5ZTk3ZjNhMDkyMDQ4ODRhZTE0NWMzZmVmZTIxMmUwXzIzNzk_911fa412-c8db-49b8-b75a-4b6a4f2f11ee"
      unitRef="usd">100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="if221b086648a41aab5554e1ca5f792ec_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90ZXh0cmVnaW9uOjU5ZTk3ZjNhMDkyMDQ4ODRhZTE0NWMzZmVmZTIxMmUwXzI1NTc_2b34f183-b49b-4038-80a8-4167c03db414"
      unitRef="usd">19000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90ZXh0cmVnaW9uOjU5ZTk3ZjNhMDkyMDQ4ODRhZTE0NWMzZmVmZTIxMmUwXzU4Nzk_27f95387-93d6-458d-913e-7ce4d4364a55">&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions related to current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtractions related to lapse of statute of limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(811)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtractions based on tax positions related to prior year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(811)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,388)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo0ODZlYTQ2YzFhNDM0MTA2YmM3YWVmYjZiNjVjODk2MS90YWJsZXJhbmdlOjQ4NmVhNDZjMWE0MzQxMDZiYzdhZWZiNmI2NWM4OTYxXzItMS0xLTEtNDYwMTM_b4f9e622-3026-46a6-8e53-9bf4cde63440"
      unitRef="usd">24426000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="if0fdfe563b2749f3ad36d74c30c121dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo0ODZlYTQ2YzFhNDM0MTA2YmM3YWVmYjZiNjVjODk2MS90YWJsZXJhbmdlOjQ4NmVhNDZjMWE0MzQxMDZiYzdhZWZiNmI2NWM4OTYxXzItMy0xLTEtNDYwMTM_b2e91cf1-aaf6-488c-ab7b-f4326db6b655"
      unitRef="usd">23624000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i3c73d82cd653451cb3c69d920ab3d8aa_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo0ODZlYTQ2YzFhNDM0MTA2YmM3YWVmYjZiNjVjODk2MS90YWJsZXJhbmdlOjQ4NmVhNDZjMWE0MzQxMDZiYzdhZWZiNmI2NWM4OTYxXzItNS0xLTEtNDYwMTM_6f182dad-6920-40d5-9292-826922e15890"
      unitRef="usd">24538000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo0ODZlYTQ2YzFhNDM0MTA2YmM3YWVmYjZiNjVjODk2MS90YWJsZXJhbmdlOjQ4NmVhNDZjMWE0MzQxMDZiYzdhZWZiNmI2NWM4OTYxXzMtMS0xLTEtNTQ0NTA_3d702717-80d6-4ec0-8a12-5cf1836ba095"
      unitRef="usd">460000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo0ODZlYTQ2YzFhNDM0MTA2YmM3YWVmYjZiNjVjODk2MS90YWJsZXJhbmdlOjQ4NmVhNDZjMWE0MzQxMDZiYzdhZWZiNmI2NWM4OTYxXzMtMy0xLTEtNTQ0NTA_23b9ecff-3ede-4de9-ad72-dd6f6ded4582"
      unitRef="usd">1613000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo0ODZlYTQ2YzFhNDM0MTA2YmM3YWVmYjZiNjVjODk2MS90YWJsZXJhbmdlOjQ4NmVhNDZjMWE0MzQxMDZiYzdhZWZiNmI2NWM4OTYxXzMtNS0xLTEtNTQ0NTA_56024be4-9018-4c3c-b5cc-b7df1360e572"
      unitRef="usd">474000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo0ODZlYTQ2YzFhNDM0MTA2YmM3YWVmYjZiNjVjODk2MS90YWJsZXJhbmdlOjQ4NmVhNDZjMWE0MzQxMDZiYzdhZWZiNmI2NWM4OTYxXzQtMS0xLTEtNTQ0NTk_0993d36b-2baa-46aa-a58e-f7aacbd908e4"
      unitRef="usd">811000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo0ODZlYTQ2YzFhNDM0MTA2YmM3YWVmYjZiNjVjODk2MS90YWJsZXJhbmdlOjQ4NmVhNDZjMWE0MzQxMDZiYzdhZWZiNmI2NWM4OTYxXzQtMy0xLTEtNTQ0NTk_2dc607b2-1c2b-46dc-b1b5-bac564c76325"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo0ODZlYTQ2YzFhNDM0MTA2YmM3YWVmYjZiNjVjODk2MS90YWJsZXJhbmdlOjQ4NmVhNDZjMWE0MzQxMDZiYzdhZWZiNmI2NWM4OTYxXzQtNS0xLTEtNTQ0NTk_748a07a0-e3f0-46b8-ae24-042414faa7eb"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo0ODZlYTQ2YzFhNDM0MTA2YmM3YWVmYjZiNjVjODk2MS90YWJsZXJhbmdlOjQ4NmVhNDZjMWE0MzQxMDZiYzdhZWZiNmI2NWM4OTYxXzMtMS0xLTEtNDYwMTM_6d4f074b-23e8-4400-9d9b-888423fdf3b1"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo0ODZlYTQ2YzFhNDM0MTA2YmM3YWVmYjZiNjVjODk2MS90YWJsZXJhbmdlOjQ4NmVhNDZjMWE0MzQxMDZiYzdhZWZiNmI2NWM4OTYxXzMtMy0xLTEtNDYwMTM_3224d9c6-9679-4c2d-a174-884a6211074b"
      unitRef="usd">811000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo0ODZlYTQ2YzFhNDM0MTA2YmM3YWVmYjZiNjVjODk2MS90YWJsZXJhbmdlOjQ4NmVhNDZjMWE0MzQxMDZiYzdhZWZiNmI2NWM4OTYxXzMtNS0xLTEtNDYwMTM_b851480b-2e33-416b-87bf-c6f33668c9e9"
      unitRef="usd">1388000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo0ODZlYTQ2YzFhNDM0MTA2YmM3YWVmYjZiNjVjODk2MS90YWJsZXJhbmdlOjQ4NmVhNDZjMWE0MzQxMDZiYzdhZWZiNmI2NWM4OTYxXzUtMS0xLTEtNDYwMTM_81d46404-25a8-4a8c-8478-120e237ea96c"
      unitRef="usd">24075000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i23bde0040cba4440804b10fdac242262_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo0ODZlYTQ2YzFhNDM0MTA2YmM3YWVmYjZiNjVjODk2MS90YWJsZXJhbmdlOjQ4NmVhNDZjMWE0MzQxMDZiYzdhZWZiNmI2NWM4OTYxXzUtMy0xLTEtNDYwMTM_b9c79786-6663-4506-978c-048090d396c1"
      unitRef="usd">24426000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="if0fdfe563b2749f3ad36d74c30c121dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xMzkvZnJhZzo1OWU5N2YzYTA5MjA0ODg0YWUxNDVjM2ZlZmUyMTJlMC90YWJsZTo0ODZlYTQ2YzFhNDM0MTA2YmM3YWVmYjZiNjVjODk2MS90YWJsZXJhbmdlOjQ4NmVhNDZjMWE0MzQxMDZiYzdhZWZiNmI2NWM4OTYxXzUtNS0xLTEtNDYwMTM_667393f2-231a-4a3a-ba5f-f393859a2e4b"
      unitRef="usd">23624000</us-gaap:UnrecognizedTaxBenefits>
    <ardx:GeographicInformationAndConcentrationsTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90ZXh0cmVnaW9uOjNiZjdlNzRjMWU3NzQyZTZiYmM3N2FmYWI2YjA3ODg0XzExNjg_6e6358f2-2501-47d2-8e57-b2891e7f8ec8">GEOGRAPHIC INFORMATION AND CONCENTRATIONS&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues are attributed to geographical areas based on the location at which we earned revenue for product sales of IBSRELA or the domicile of our collaboration partners. A summary of our revenue by geographic areas for the years ended December&#160;31, 2022, 2021 and 2020, is as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asia Pacific (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;North America (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Revenues from the United States are comprised of amounts earned from sales of IBSRELA.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Revenues from Asia Pacific are primarily comprised of amounts earned in accordance with the 2017 KKC Agreement and the 2019 KKC Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Revenues from North America are comprised of amounts earned from Canada in accordance with the Knight Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from Customers and collaboration partnerships accounting for more than 10% of total revenues during the years ended December&#160;31, 2022, 2021 and 2020 were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;KKC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Knight&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AmerisourceBergen Drug Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Historically, we have not experienced credit losses from our accounts receivable. We have not recorded a reserve for credit losses as of December&#160;31, 2022 and 2021.</ardx:GeographicInformationAndConcentrationsTextBlock>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90ZXh0cmVnaW9uOjNiZjdlNzRjMWU3NzQyZTZiYmM3N2FmYWI2YjA3ODg0XzExNjk_ba0b36f2-cec6-429b-a84c-ded3d346763f">A summary of our revenue by geographic areas for the years ended December&#160;31, 2022, 2021 and 2020, is as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asia Pacific (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;North America (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Revenues from the United States are comprised of amounts earned from sales of IBSRELA.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Revenues from Asia Pacific are primarily comprised of amounts earned in accordance with the 2017 KKC Agreement and the 2019 KKC Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Revenues from North America are comprised of amounts earned from Canada in accordance with the Knight Agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if59e9efdbe2d42718f4a91fe0b12275c_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90YWJsZTphY2Y1MDVlNjUyODA0MDNlODlkYWVmOGIzNWViZjczOC90YWJsZXJhbmdlOmFjZjUwNWU2NTI4MDQwM2U4OWRhZWY4YjM1ZWJmNzM4XzItMS0xLTEtNDYwMTM_2757d0d3-f3fd-40d2-837c-bb2e0d744139"
      unitRef="usd">15600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib44743fdc95f46f182f7c502b1cd9c4d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90YWJsZTphY2Y1MDVlNjUyODA0MDNlODlkYWVmOGIzNWViZjczOC90YWJsZXJhbmdlOmFjZjUwNWU2NTI4MDQwM2U4OWRhZWY4YjM1ZWJmNzM4XzItMy0xLTEtNDYwMTM_61aa4aae-83c5-452d-9bfa-1893b26c7794"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic04f77eb07ea4224a01520efa0f633d3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90YWJsZTphY2Y1MDVlNjUyODA0MDNlODlkYWVmOGIzNWViZjczOC90YWJsZXJhbmdlOmFjZjUwNWU2NTI4MDQwM2U4OWRhZWY4YjM1ZWJmNzM4XzItNS0xLTEtNDYwMTM_f1af9784-8f1e-4b9b-a840-e44b65515e06"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1746af5e54554e499e907d7129518fd0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90YWJsZTphY2Y1MDVlNjUyODA0MDNlODlkYWVmOGIzNWViZjczOC90YWJsZXJhbmdlOmFjZjUwNWU2NTI4MDQwM2U4OWRhZWY4YjM1ZWJmNzM4XzQtMS0xLTEtNTIxMjg_1037f081-012e-4373-a9b4-d223af043d8f"
      unitRef="usd">36527000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i511c3600481046ab8ea3a0188db062f2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90YWJsZTphY2Y1MDVlNjUyODA0MDNlODlkYWVmOGIzNWViZjczOC90YWJsZXJhbmdlOmFjZjUwNWU2NTI4MDQwM2U4OWRhZWY4YjM1ZWJmNzM4XzQtMy0xLTEtNTIxMjg_86f7a467-fb3f-4c32-8790-971dce2ef0d5"
      unitRef="usd">10084000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1b925d525dc749719f6bd325cefb8a1c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90YWJsZTphY2Y1MDVlNjUyODA0MDNlODlkYWVmOGIzNWViZjczOC90YWJsZXJhbmdlOmFjZjUwNWU2NTI4MDQwM2U4OWRhZWY4YjM1ZWJmNzM4XzQtNS0xLTEtNTIxMjg_89a88fdd-8951-4824-82bc-8e4fc8eb5c4a"
      unitRef="usd">6765000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iae0dc045d5b541dfa650458342fbe24a_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90YWJsZTphY2Y1MDVlNjUyODA0MDNlODlkYWVmOGIzNWViZjczOC90YWJsZXJhbmdlOmFjZjUwNWU2NTI4MDQwM2U4OWRhZWY4YjM1ZWJmNzM4XzQtMS0xLTEtNDYwMTM_f26e99b0-eb33-4219-8122-3373147080e5"
      unitRef="usd">31000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c3c4d25be5c41f2a23bc91cd0c77d25_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90YWJsZTphY2Y1MDVlNjUyODA0MDNlODlkYWVmOGIzNWViZjczOC90YWJsZXJhbmdlOmFjZjUwNWU2NTI4MDQwM2U4OWRhZWY4YjM1ZWJmNzM4XzQtMy0xLTEtNDYwMTM_8139c73f-59e0-46c4-9e9d-8c5d25ca604e"
      unitRef="usd">13000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5b4c067ab6484053a239a2ccd02d90d1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90YWJsZTphY2Y1MDVlNjUyODA0MDNlODlkYWVmOGIzNWViZjczOC90YWJsZXJhbmdlOmFjZjUwNWU2NTI4MDQwM2U4OWRhZWY4YjM1ZWJmNzM4XzQtNS0xLTEtNDYwMTM_69ae8791-f3de-4524-a1d1-b547918c0def"
      unitRef="usd">806000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90YWJsZTphY2Y1MDVlNjUyODA0MDNlODlkYWVmOGIzNWViZjczOC90YWJsZXJhbmdlOmFjZjUwNWU2NTI4MDQwM2U4OWRhZWY4YjM1ZWJmNzM4XzYtMS0xLTEtNDYwMTM_f51791b1-2610-4405-bb5e-4fff7b42d0a9"
      unitRef="usd">52158000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90YWJsZTphY2Y1MDVlNjUyODA0MDNlODlkYWVmOGIzNWViZjczOC90YWJsZXJhbmdlOmFjZjUwNWU2NTI4MDQwM2U4OWRhZWY4YjM1ZWJmNzM4XzYtMy0xLTEtNDYwMTM_9ec7f179-c0cb-4358-bd43-5285fcb4a297"
      unitRef="usd">10097000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90YWJsZTphY2Y1MDVlNjUyODA0MDNlODlkYWVmOGIzNWViZjczOC90YWJsZXJhbmdlOmFjZjUwNWU2NTI4MDQwM2U4OWRhZWY4YjM1ZWJmNzM4XzYtNS0xLTEtNDYwMTM_f89aaa2e-9d80-49a8-adc5-ed5e8e732049"
      unitRef="usd">7571000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90ZXh0cmVnaW9uOjNiZjdlNzRjMWU3NzQyZTZiYmM3N2FmYWI2YjA3ODg0XzExNzA_c666187c-a9f5-476e-ae41-54d159f723c2">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from Customers and collaboration partnerships accounting for more than 10% of total revenues during the years ended December&#160;31, 2022, 2021 and 2020 were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;KKC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Knight&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AmerisourceBergen Drug Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id19674491cd54b0c969b0e9bccb5521e_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90YWJsZTozYjZkNTI3Y2FiOWM0OTg5OWEzZjkyNWY4ZTAwNjExOC90YWJsZXJhbmdlOjNiNmQ1MjdjYWI5YzQ5ODk5YTNmOTI1ZjhlMDA2MTE4XzItMS0xLTEtNDYwMTM_74142af4-0b18-48e9-adbb-1e4eb43839ca"
      unitRef="number">0.700</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id3fb70f0cf0f4182806a3abc3d5b5b25_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90YWJsZTozYjZkNTI3Y2FiOWM0OTg5OWEzZjkyNWY4ZTAwNjExOC90YWJsZXJhbmdlOjNiNmQ1MjdjYWI5YzQ5ODk5YTNmOTI1ZjhlMDA2MTE4XzItMy0xLTEtNDYwMTM_792cffa8-6cde-4507-95b6-45fdca60b801"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8ac81d53477e44f6afab4b4e55da6c0b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90YWJsZTozYjZkNTI3Y2FiOWM0OTg5OWEzZjkyNWY4ZTAwNjExOC90YWJsZXJhbmdlOjNiNmQ1MjdjYWI5YzQ5ODk5YTNmOTI1ZjhlMDA2MTE4XzItNS0xLTEtNDYwMTM_e82c921d-fccc-4074-9191-3683880a1b02"
      unitRef="number">0.89</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2805b962ce1c4f33a04e27034cee3305_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90YWJsZTozYjZkNTI3Y2FiOWM0OTg5OWEzZjkyNWY4ZTAwNjExOC90YWJsZXJhbmdlOjNiNmQ1MjdjYWI5YzQ5ODk5YTNmOTI1ZjhlMDA2MTE4XzMtMS0xLTEtNDYwMTM_197798f4-cd83-47c9-a48f-f3e6d2a5833d"
      unitRef="number">0.001</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2d1f27a987ea46e4ac5004a0280afb04_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90YWJsZTozYjZkNTI3Y2FiOWM0OTg5OWEzZjkyNWY4ZTAwNjExOC90YWJsZXJhbmdlOjNiNmQ1MjdjYWI5YzQ5ODk5YTNmOTI1ZjhlMDA2MTE4XzMtMy0xLTEtNDYwMTM_b7ed3997-e1f3-4466-8404-c6b8c1c52077"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ifda028b327984abab2f5a8dc37dd7bf1_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90YWJsZTozYjZkNTI3Y2FiOWM0OTg5OWEzZjkyNWY4ZTAwNjExOC90YWJsZXJhbmdlOjNiNmQ1MjdjYWI5YzQ5ODk5YTNmOTI1ZjhlMDA2MTE4XzMtNS0xLTEtNDYwMTM_fe1f5f76-8d30-4fa6-9cd7-149328c2dc93"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iceaaa79f1b46468e9d5df39ac4e0e130_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90YWJsZTozYjZkNTI3Y2FiOWM0OTg5OWEzZjkyNWY4ZTAwNjExOC90YWJsZXJhbmdlOjNiNmQ1MjdjYWI5YzQ5ODk5YTNmOTI1ZjhlMDA2MTE4XzUtMS0xLTEtNDYwMTM_ccd39d62-3527-4a81-9428-3403b9e9f6fe"
      unitRef="number">0.111</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7f6e6bcfc89b4e3bbbf5ef1ab1cfa46c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90YWJsZTozYjZkNTI3Y2FiOWM0OTg5OWEzZjkyNWY4ZTAwNjExOC90YWJsZXJhbmdlOjNiNmQ1MjdjYWI5YzQ5ODk5YTNmOTI1ZjhlMDA2MTE4XzUtMy0xLTEtNDYwMTM_9cdf3c23-f6f9-4348-ba2c-9d1c69635d0a"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id58e400e1e524590b3c5cd7fe872d7d9_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDIvZnJhZzozYmY3ZTc0YzFlNzc0MmU2YmJjNzdhZmFiNmIwNzg4NC90YWJsZTozYjZkNTI3Y2FiOWM0OTg5OWEzZjkyNWY4ZTAwNjExOC90YWJsZXJhbmdlOjNiNmQ1MjdjYWI5YzQ5ODk5YTNmOTI1ZjhlMDA2MTE4XzUtNS0xLTEtNDYwMTM_6724d253-9d95-4ce5-a1a6-537a075fc644"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90ZXh0cmVnaW9uOjhhZTY1ODUzMmEwMjQ3NTdhZjRlZDk3ZTA2MWVmZjdkXzEzMjk_7e812903-4c3e-4056-a7a5-70d68c475c18">NET LOSS PER SHARE&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, less shares subject to repurchase, and excludes any dilutive effects of stock-based awards and warrants. Diluted net loss per common share is computed giving effect to all potential dilutive common shares, including common stock issuable upon exercise of stock options, and unvested restricted common stock and stock units. As we had net losses for the&#160;years ended December&#160;31, 2022, 2021 and 2020, all potential common shares were determined to be anti-dilutive. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of net loss per common share (in thousands, except per share dollar amounts):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(67,207)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(158,165)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(94,313)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;158,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;104,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;89,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the&#160;years ended December&#160;31, 2022, 2021 and 2020, the total numbers of securities that could potentially dilute net income per share in the future that were not considered in the diluted net loss per share calculations because the effect would have been anti-dilutive were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP shares issuable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The number of potential common shares that would have been included in diluted income per share had it not been for the anti-dilutive effect caused by the net loss, computed by converting these securities using the treasury stock method during the years ended December&#160;31, 2022, 2021 and 2020, was approximately 0.6 million, 1.1 million and 2.1 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90ZXh0cmVnaW9uOjhhZTY1ODUzMmEwMjQ3NTdhZjRlZDk3ZTA2MWVmZjdkXzEzMzA_09d5db2f-14ac-482d-803c-e7633bcdd7c8">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of net loss per common share (in thousands, except per share dollar amounts):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(67,207)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(158,165)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(94,313)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;158,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;104,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;89,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTo2ZDNmZTIyY2U4NTM0MjBlYmVjODllYWUwZmU0ZGU3NC90YWJsZXJhbmdlOjZkM2ZlMjJjZTg1MzQyMGViZWM4OWVhZTBmZTRkZTc0XzMtMS0xLTEtNDYwMTM_6e924cce-a135-4e5e-b390-4b4605679b15"
      unitRef="usd">-67207000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTo2ZDNmZTIyY2U4NTM0MjBlYmVjODllYWUwZmU0ZGU3NC90YWJsZXJhbmdlOjZkM2ZlMjJjZTg1MzQyMGViZWM4OWVhZTBmZTRkZTc0XzMtMy0xLTEtNDYwMTM_a36fe0de-4290-4a21-8c15-e8ed7de840d9"
      unitRef="usd">-158165000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTo2ZDNmZTIyY2U4NTM0MjBlYmVjODllYWUwZmU0ZGU3NC90YWJsZXJhbmdlOjZkM2ZlMjJjZTg1MzQyMGViZWM4OWVhZTBmZTRkZTc0XzMtNS0xLTEtNDYwMTM_c2931176-5c46-4ce5-90ee-7110edb1dddf"
      unitRef="usd">-94313000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTo2ZDNmZTIyY2U4NTM0MjBlYmVjODllYWUwZmU0ZGU3NC90YWJsZXJhbmdlOjZkM2ZlMjJjZTg1MzQyMGViZWM4OWVhZTBmZTRkZTc0XzUtMS0xLTEtNDYwMTM_12291c73-949d-4c4c-89bd-b33c52c3ad53"
      unitRef="shares">158690000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTo2ZDNmZTIyY2U4NTM0MjBlYmVjODllYWUwZmU0ZGU3NC90YWJsZXJhbmdlOjZkM2ZlMjJjZTg1MzQyMGViZWM4OWVhZTBmZTRkZTc0XzUtMS0xLTEtNDYwMTM_7fdf098b-ae33-4f0c-adc7-341f02b5ae61"
      unitRef="shares">158690000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTo2ZDNmZTIyY2U4NTM0MjBlYmVjODllYWUwZmU0ZGU3NC90YWJsZXJhbmdlOjZkM2ZlMjJjZTg1MzQyMGViZWM4OWVhZTBmZTRkZTc0XzUtMy0xLTEtNDYwMTM_1391c730-7703-4054-b088-ea1659f82f30"
      unitRef="shares">104206000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTo2ZDNmZTIyY2U4NTM0MjBlYmVjODllYWUwZmU0ZGU3NC90YWJsZXJhbmdlOjZkM2ZlMjJjZTg1MzQyMGViZWM4OWVhZTBmZTRkZTc0XzUtMy0xLTEtNDYwMTM_6aca9ca3-ac69-4160-b7a7-185503b94cf3"
      unitRef="shares">104206000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTo2ZDNmZTIyY2U4NTM0MjBlYmVjODllYWUwZmU0ZGU3NC90YWJsZXJhbmdlOjZkM2ZlMjJjZTg1MzQyMGViZWM4OWVhZTBmZTRkZTc0XzUtNS0xLTEtNDYwMTM_19185182-a45e-4201-a348-52c514403105"
      unitRef="shares">89582000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTo2ZDNmZTIyY2U4NTM0MjBlYmVjODllYWUwZmU0ZGU3NC90YWJsZXJhbmdlOjZkM2ZlMjJjZTg1MzQyMGViZWM4OWVhZTBmZTRkZTc0XzUtNS0xLTEtNDYwMTM_2f510e28-a546-4bce-9ec0-f920c7c65587"
      unitRef="shares">89582000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTo2ZDNmZTIyY2U4NTM0MjBlYmVjODllYWUwZmU0ZGU3NC90YWJsZXJhbmdlOjZkM2ZlMjJjZTg1MzQyMGViZWM4OWVhZTBmZTRkZTc0XzYtMS0xLTEtNDYwMTM_413d6136-69ca-4656-9909-d71b5ec3efcf"
      unitRef="usdPerShare">-0.42</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTo2ZDNmZTIyY2U4NTM0MjBlYmVjODllYWUwZmU0ZGU3NC90YWJsZXJhbmdlOjZkM2ZlMjJjZTg1MzQyMGViZWM4OWVhZTBmZTRkZTc0XzYtMS0xLTEtNDYwMTM_b9dc3948-e8cf-4c7c-84fe-f10de92917e1"
      unitRef="usdPerShare">-0.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTo2ZDNmZTIyY2U4NTM0MjBlYmVjODllYWUwZmU0ZGU3NC90YWJsZXJhbmdlOjZkM2ZlMjJjZTg1MzQyMGViZWM4OWVhZTBmZTRkZTc0XzYtMy0xLTEtNDYwMTM_a6067273-b87b-4269-bb28-8e87d9b24da3"
      unitRef="usdPerShare">-1.52</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTo2ZDNmZTIyY2U4NTM0MjBlYmVjODllYWUwZmU0ZGU3NC90YWJsZXJhbmdlOjZkM2ZlMjJjZTg1MzQyMGViZWM4OWVhZTBmZTRkZTc0XzYtMy0xLTEtNDYwMTM_f1049434-647e-4602-87c3-3bc04d88a8ee"
      unitRef="usdPerShare">-1.52</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTo2ZDNmZTIyY2U4NTM0MjBlYmVjODllYWUwZmU0ZGU3NC90YWJsZXJhbmdlOjZkM2ZlMjJjZTg1MzQyMGViZWM4OWVhZTBmZTRkZTc0XzYtNS0xLTEtNDYwMTM_9a373f0f-72a1-48e5-9e4d-70dac6a629bc"
      unitRef="usdPerShare">-1.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTo2ZDNmZTIyY2U4NTM0MjBlYmVjODllYWUwZmU0ZGU3NC90YWJsZXJhbmdlOjZkM2ZlMjJjZTg1MzQyMGViZWM4OWVhZTBmZTRkZTc0XzYtNS0xLTEtNDYwMTM_a8afb13b-07e5-4e18-96d8-677c9226c3d9"
      unitRef="usdPerShare">-1.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90ZXh0cmVnaW9uOjhhZTY1ODUzMmEwMjQ3NTdhZjRlZDk3ZTA2MWVmZjdkXzEzMzE_08c3006d-950c-42d4-ba87-f2f4f190df69">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the&#160;years ended December&#160;31, 2022, 2021 and 2020, the total numbers of securities that could potentially dilute net income per share in the future that were not considered in the diluted net loss per share calculations because the effect would have been anti-dilutive were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP shares issuable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib4411bca5f204674a4e725c73570e515_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTowZGVhZGU4NGY2ZWI0M2ZlYWY1ZjU4YzJmZTA2YTk0OS90YWJsZXJhbmdlOjBkZWFkZTg0ZjZlYjQzZmVhZjVmNThjMmZlMDZhOTQ5XzItMS0xLTEtNDYwMTM_3bacc153-477c-4d1e-b8c9-892b7b272f96"
      unitRef="shares">13522000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id664c0aa97b74d6b933633eb24bd7ffa_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTowZGVhZGU4NGY2ZWI0M2ZlYWY1ZjU4YzJmZTA2YTk0OS90YWJsZXJhbmdlOjBkZWFkZTg0ZjZlYjQzZmVhZjVmNThjMmZlMDZhOTQ5XzItMy0xLTEtNDYwMTM_0921cddf-c47f-45f9-bcbc-9112a5f68744"
      unitRef="shares">11871000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia1833de563c44c0a84b1e4c778b58c6d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTowZGVhZGU4NGY2ZWI0M2ZlYWY1ZjU4YzJmZTA2YTk0OS90YWJsZXJhbmdlOjBkZWFkZTg0ZjZlYjQzZmVhZjVmNThjMmZlMDZhOTQ5XzItNS0xLTEtNDYwMTM_9ae88707-ba42-4786-ba42-24666cad3555"
      unitRef="shares">9247000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i952c9b1adbbf4d96b9b3719a4c54ea85_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTowZGVhZGU4NGY2ZWI0M2ZlYWY1ZjU4YzJmZTA2YTk0OS90YWJsZXJhbmdlOjBkZWFkZTg0ZjZlYjQzZmVhZjVmNThjMmZlMDZhOTQ5XzMtMS0xLTEtNDYwMTM_10d07bd7-ea31-4448-9051-b7799864a8ab"
      unitRef="shares">2694000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iba8409a9d3074b558e62a6b388c3ab67_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTowZGVhZGU4NGY2ZWI0M2ZlYWY1ZjU4YzJmZTA2YTk0OS90YWJsZXJhbmdlOjBkZWFkZTg0ZjZlYjQzZmVhZjVmNThjMmZlMDZhOTQ5XzMtMy0xLTEtNDYwMTM_50f80741-c9de-49b7-ac50-562949d36799"
      unitRef="shares">1602000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i96a34e4ebc4c41b5b53c6de94e6f9347_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTowZGVhZGU4NGY2ZWI0M2ZlYWY1ZjU4YzJmZTA2YTk0OS90YWJsZXJhbmdlOjBkZWFkZTg0ZjZlYjQzZmVhZjVmNThjMmZlMDZhOTQ5XzMtNS0xLTEtNDYwMTM_1f7f7920-74d4-4664-8089-b194c1090fc1"
      unitRef="shares">26000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i538aeeb65eb843779d9a0e11b1e50104_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTowZGVhZGU4NGY2ZWI0M2ZlYWY1ZjU4YzJmZTA2YTk0OS90YWJsZXJhbmdlOjBkZWFkZTg0ZjZlYjQzZmVhZjVmNThjMmZlMDZhOTQ5XzQtMS0xLTEtNDYwMTM_3ea57153-7129-4d92-a826-8d9279fc0358"
      unitRef="shares">166000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ieb0f4765d39d45c69282d8ce87f604fc_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTowZGVhZGU4NGY2ZWI0M2ZlYWY1ZjU4YzJmZTA2YTk0OS90YWJsZXJhbmdlOjBkZWFkZTg0ZjZlYjQzZmVhZjVmNThjMmZlMDZhOTQ5XzQtMy0xLTEtNDYwMTM_415de0d5-891d-40e3-8b02-15e0dd875321"
      unitRef="shares">207000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1b5f3274350745bdba9cf5da71e8b2d5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTowZGVhZGU4NGY2ZWI0M2ZlYWY1ZjU4YzJmZTA2YTk0OS90YWJsZXJhbmdlOjBkZWFkZTg0ZjZlYjQzZmVhZjVmNThjMmZlMDZhOTQ5XzQtNS0xLTEtNDYwMTM_29b34cae-a5e8-43e1-9459-133b17db0cd8"
      unitRef="shares">94000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia6b3a9fd0ae14ddea562b4e1be92c9ca_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTowZGVhZGU4NGY2ZWI0M2ZlYWY1ZjU4YzJmZTA2YTk0OS90YWJsZXJhbmdlOjBkZWFkZTg0ZjZlYjQzZmVhZjVmNThjMmZlMDZhOTQ5XzUtMS0xLTEtNDYwMTM_2e10a545-f368-4608-9147-6878ebcc5c2f"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia8ac5065cbaa4252992fdf404620572d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTowZGVhZGU4NGY2ZWI0M2ZlYWY1ZjU4YzJmZTA2YTk0OS90YWJsZXJhbmdlOjBkZWFkZTg0ZjZlYjQzZmVhZjVmNThjMmZlMDZhOTQ5XzUtMy0xLTEtNDYwMTM_6614038e-6f56-490e-87dc-7dc1a9c69220"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if66074aa8b8c4eaf87dfdefd3d2725c2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTowZGVhZGU4NGY2ZWI0M2ZlYWY1ZjU4YzJmZTA2YTk0OS90YWJsZXJhbmdlOjBkZWFkZTg0ZjZlYjQzZmVhZjVmNThjMmZlMDZhOTQ5XzUtNS0xLTEtNDYwMTM_54525f1f-ae2d-4081-94d7-a459b00d729c"
      unitRef="shares">932000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTowZGVhZGU4NGY2ZWI0M2ZlYWY1ZjU4YzJmZTA2YTk0OS90YWJsZXJhbmdlOjBkZWFkZTg0ZjZlYjQzZmVhZjVmNThjMmZlMDZhOTQ5XzctMS0xLTEtNDYwMTM_4110e04e-ba53-47e1-adee-5c04a9ca2078"
      unitRef="shares">16382000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTowZGVhZGU4NGY2ZWI0M2ZlYWY1ZjU4YzJmZTA2YTk0OS90YWJsZXJhbmdlOjBkZWFkZTg0ZjZlYjQzZmVhZjVmNThjMmZlMDZhOTQ5XzctMy0xLTEtNDYwMTM_25b999c8-7c42-4d43-a1ab-2f311582e02f"
      unitRef="shares">13680000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90YWJsZTowZGVhZGU4NGY2ZWI0M2ZlYWY1ZjU4YzJmZTA2YTk0OS90YWJsZXJhbmdlOjBkZWFkZTg0ZjZlYjQzZmVhZjVmNThjMmZlMDZhOTQ5XzctNS0xLTEtNDYwMTM_17fe7a61-392f-4361-8c75-3a8b276e6391"
      unitRef="shares">10299000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <ardx:PotentialCommonSharesAntiDilutiveEffectOnSecurities
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90ZXh0cmVnaW9uOjhhZTY1ODUzMmEwMjQ3NTdhZjRlZDk3ZTA2MWVmZjdkXzEzMDI_4492d663-7c46-4405-85b6-8468576747e0"
      unitRef="shares">600000</ardx:PotentialCommonSharesAntiDilutiveEffectOnSecurities>
    <ardx:PotentialCommonSharesAntiDilutiveEffectOnSecurities
      contextRef="i45f1941f9fe64cf991b951806544dcae_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90ZXh0cmVnaW9uOjhhZTY1ODUzMmEwMjQ3NTdhZjRlZDk3ZTA2MWVmZjdkXzEzMDY_471be0d6-0838-4c4f-885f-c1aeea012850"
      unitRef="shares">1100000</ardx:PotentialCommonSharesAntiDilutiveEffectOnSecurities>
    <ardx:PotentialCommonSharesAntiDilutiveEffectOnSecurities
      contextRef="id1388a2db67242c6be93ba1db5eacd6a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDUvZnJhZzo4YWU2NTg1MzJhMDI0NzU3YWY0ZWQ5N2UwNjFlZmY3ZC90ZXh0cmVnaW9uOjhhZTY1ODUzMmEwMjQ3NTdhZjRlZDk3ZTA2MWVmZjdkXzEzMTM_ea6ca218-04a7-474d-affe-d8954072cce7"
      unitRef="shares">2100000</ardx:PotentialCommonSharesAntiDilutiveEffectOnSecurities>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDgvZnJhZzo3ZWYwMmVhMWYxNjk0N2RjYjVhYmEyYjU0MzhiYmZkNC90ZXh0cmVnaW9uOjdlZjAyZWExZjE2OTQ3ZGNiNWFiYTJiNTQzOGJiZmQ0XzE0MTU_dfdddd7f-6264-4cc1-82dc-10b26b16c5f0">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Guarantees and Indemnifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We indemnify each of our officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at our request in such capacity, as permitted under Delaware law and in accordance with our certificate of incorporation and bylaws. The term of the indemnification period lasts as long as an officer or director may be subject to any proceeding arising out of acts or omissions of such officer or director in such capacity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The maximum amount of potential future indemnification is unlimited; however, we currently hold director and officer liability insurance, which allows the transfer of risk associated with our exposure and may enable us to recover a portion of any future amounts paid. We believe that the fair value of these indemnification obligations is minimal. Accordingly, we have not recognized any liabilities relating to these obligations for any period presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings and Claims&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 30 and August 12, 2021, two putative securities class action lawsuits were commenced in the U.S. District Court for the Northern District of California naming as defendants Ardelyx and two current officers captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Strezsak v. Ardelyx, Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Case No. 4:21-cv-05868-HSG, and Siegel&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; v. Ardelyx, Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Case No. 5:21-cv-06228-HSG (together, the &#x201c;Securities Class Actions&#x201d;). The complaints allege that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 thereunder, by making false and misleading statements and omissions of material fact related to tenapanor. The plaintiffs seek to represent all persons who purchased or otherwise acquired Ardelyx securities between August 6, 2020, and July 19, 2021. The plaintiffs seek damages and interest, and an award of costs, including attorneys&#x2019; fees. On July 19, 2022, the court consolidated the two putative class actions and appointed a lead plaintiff and lead counsel. The lead plaintiff filed an amended complaint on September 29, 2022. Defendants filed a motion to dismiss the amended complaint on December 2, 2022. In January and February 2023, in lieu of filing a response to defendant&#x2019;s motion to dismiss, plaintiffs filed a motion seeking leave to further amend their compliant and defendants filed an opposition to the motion for leave to further amend the complaint. A hearing on the motion for leave to further amend the complaint is scheduled for mid-May 2023. We believe the plaintiff&#x2019;s claims are without merit and we have not recorded any accrual for a contingent liability associated with these legal proceedings.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 7, 2021 and March 29, 2022, two verified shareholders derivative lawsuits were filed in the U.S. District Court for the Northern District of California purportedly on behalf of Ardelyx against certain of Ardelyx&#x2019;s executive officers and members of our board of directors, captioned Go v. Raab, et al., Case No. 4:21-cv-09455-HSG, and Morris v. Raab, et al., Case No. 4:22-cv-01988-JSC. The complaints allege that the defendants violations of Section 14(a) of the Securities Exchange Act of 1934, as amended, breaches of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement, and waste of corporate assets, for personally making and/or causing Ardelyx to make materially false and misleading statements regarding the Company&#x2019;s business, operations and prospects. The complaint seeks contribution under Sections 10(b) and 21D of the Securities Exchange Act of 1934 from two executive officers. On January 19, and April 27, 2022, the court granted the parties&#x2019; stipulation to stay the Go and Morris actions, respectively, until resolution of the anticipated motion(s) to dismiss in the Securities Class Actions. On October 25, 2022, the parties filed a stipulation to consolidate and stay the Go and Morris actions, &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and on October 27, 2022, the court consolidated the Go and Morris action and stayed the consolidated action pending resolution of the anticipated motion(s) to dismiss in the Securities Class Action. We believe the plaintiff&#x2019;s claims are without merit and we have not recorded any accrual for a contingent liability associated with these legal proceedings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we may be involved in legal proceedings arising in the ordinary course of business. As of December&#160;31, 2022, there is no litigation pending that would reasonably be expected to have a material adverse effect on our results of operations and financial condition, and no contingent liabilities were accrued as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="ib374c30529ad46698e71cb3df47baab0_D20220730-20220812"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDgvZnJhZzo3ZWYwMmVhMWYxNjk0N2RjYjVhYmEyYjU0MzhiYmZkNC90ZXh0cmVnaW9uOjdlZjAyZWExZjE2OTQ3ZGNiNWFiYTJiNTQzOGJiZmQ0XzIxOTkwMjMyNzE1NTU_5b17b913-b5e1-42b8-bff7-3f315ab6dd9e"
      unitRef="claim">2</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNumberOfDefendants
      contextRef="ib374c30529ad46698e71cb3df47baab0_D20220730-20220812"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDgvZnJhZzo3ZWYwMmVhMWYxNjk0N2RjYjVhYmEyYjU0MzhiYmZkNC90ZXh0cmVnaW9uOjdlZjAyZWExZjE2OTQ3ZGNiNWFiYTJiNTQzOGJiZmQ0XzIxOTkwMjMyNzE1NjU_96035cd3-b08c-451c-be8d-598dca32dce4"
      unitRef="defendant">2</us-gaap:LossContingencyNumberOfDefendants>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i4720ecaa980849ecb662496f697442e6_D20220719-20220719"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDgvZnJhZzo3ZWYwMmVhMWYxNjk0N2RjYjVhYmEyYjU0MzhiYmZkNC90ZXh0cmVnaW9uOjdlZjAyZWExZjE2OTQ3ZGNiNWFiYTJiNTQzOGJiZmQ0XzIxOTkwMjMyNzE1NzQ_67c282d2-3734-46bd-b6da-28ae4efee47e"
      unitRef="claim">2</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i1fb81fa2f1994bbf9c437971dd33e52e_D20211207-20220329"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDgvZnJhZzo3ZWYwMmVhMWYxNjk0N2RjYjVhYmEyYjU0MzhiYmZkNC90ZXh0cmVnaW9uOjdlZjAyZWExZjE2OTQ3ZGNiNWFiYTJiNTQzOGJiZmQ0XzIxOTkwMjMyNzE1NzM_f62b9b45-5c16-41a3-866b-ab0e4611ce09"
      unitRef="claim">2</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNumberOfDefendants
      contextRef="i1fb81fa2f1994bbf9c437971dd33e52e_D20211207-20220329"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDgvZnJhZzo3ZWYwMmVhMWYxNjk0N2RjYjVhYmEyYjU0MzhiYmZkNC90ZXh0cmVnaW9uOjdlZjAyZWExZjE2OTQ3ZGNiNWFiYTJiNTQzOGJiZmQ0XzIxOTkwMjMyNzE1OTY_8da0e31f-ec50-45b0-9398-ca2515e9dc94"
      unitRef="defendant">2</us-gaap:LossContingencyNumberOfDefendants>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i776a810ab6f5478f91b8fbb19a6855bb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNDgvZnJhZzo3ZWYwMmVhMWYxNjk0N2RjYjVhYmEyYjU0MzhiYmZkNC90ZXh0cmVnaW9uOjdlZjAyZWExZjE2OTQ3ZGNiNWFiYTJiNTQzOGJiZmQ0XzIxOTkwMjMyNzE1ODg_0050fad5-e88b-4e23-bdf9-8b261cda5ae8"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTQvZnJhZzozMDdmYTE5YmM4YmQ0ZjE0OGRlYmViNzQ5NjVjM2JhMC90ZXh0cmVnaW9uOjMwN2ZhMTliYzhiZDRmMTQ4ZGViZWI3NDk2NWMzYmEwXzU2MzI_78ca9ae4-40bd-427e-a0f8-32e05f9e7d56">SUBSEQUENT EVENTS&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2023, we filed a Form S-3 registration statement, which became effective in January 2023 ("2023 Registration Statement"), containing (i) a base prospectus for the offering, issuance and sale by us of up to a maximum aggregate offering price of $250.0 million of our common stock, preferred stock, debt securities, warrants and/or units, from time to time in one or more offerings; and (ii) a prospectus supplement for the offering, issuance and sale by us of up to a maximum aggregate offering price of $150.0 million of our common stock that may be issued and sold, from time to time, under a sales agreement with Jefferies LLC ("Jefferies"), deemed to be &#x201c;at-the-market offerings&#x201d; ("2023 Open Market Sales Agreement").&#160;Pursuant to the 2023 Open Market Sales Agreement, Jefferies, as sales agent, may receive a commission of up to 3.0% of the gross sales price for shares of common stock sold under the 2023 Open Market Sales Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 9, 2023, we entered into a second amendment (&#x201c;Second Amendment&#x201d;) to our Loan Agreement with the Lenders. The Second Amendment extends the interest-only term of the loan by twelve months to March 31, 2025 provided that we either (i) receive approval from the FDA for our NDA for the control of serum phosphorus in adult patients with CKD on dialysis on or prior to November 30, 2023 or (ii) achieve certain product revenue milestone targets as described in the Second Amendment for the year ending December 31, 2023. The Second Amendment also extends the period under which we may draw the Term B Loan from July 25, 2023 to December 20, 2023, and amends the milestone that we must achieve in order to draw the Term B Loan by extending the time period for the receipt of approval by the FDA of the NDA for the control of serum phosphorus in adult patients with CKD on dialysis until November 30, 2023. In addition, the Second Amendment replaces the floating per annum interest rate with 7.95% plus the greater of (a) one percent (1.00%) per annum and (b)(i) 0.022% plus (ii) 1-month CME Term SOFR reference rate as published by the CME Term SOFR Administrator on the CME Term SOFR Administrator&#x2019;s Website.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <ardx:MaximumAggregateOfferingPrice
      contextRef="i0edad5a730a244cba8f8a9819262823c_I20230131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTQvZnJhZzozMDdmYTE5YmM4YmQ0ZjE0OGRlYmViNzQ5NjVjM2JhMC90ZXh0cmVnaW9uOjMwN2ZhMTliYzhiZDRmMTQ4ZGViZWI3NDk2NWMzYmEwXzU0OTc1NTgyNTQyNg_295510a4-7a74-4728-9fbe-ea57ba75958d"
      unitRef="usd">250000000</ardx:MaximumAggregateOfferingPrice>
    <ardx:MaximumAggregateOfferingPrice
      contextRef="id8349613f0ed462d8ac8ec08c2be4b51_I20230131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTQvZnJhZzozMDdmYTE5YmM4YmQ0ZjE0OGRlYmViNzQ5NjVjM2JhMC90ZXh0cmVnaW9uOjMwN2ZhMTliYzhiZDRmMTQ4ZGViZWI3NDk2NWMzYmEwXzU0OTc1NTgyNTY3NA_9be593c4-93f8-4d02-86b5-a3c05b268ffd"
      unitRef="usd">150000000</ardx:MaximumAggregateOfferingPrice>
    <ardx:StockIssuanceCostCommissionPercent
      contextRef="i05cd4ea70ed4485589e755e460b69fd1_D20230101-20230131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTQvZnJhZzozMDdmYTE5YmM4YmQ0ZjE0OGRlYmViNzQ5NjVjM2JhMC90ZXh0cmVnaW9uOjMwN2ZhMTliYzhiZDRmMTQ4ZGViZWI3NDk2NWMzYmEwXzU0OTc1NTgyNTk5Ng_afb0af8d-ab5f-4df3-b4be-caea5167842f"
      unitRef="number">0.030</ardx:StockIssuanceCostCommissionPercent>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ic957e7b2e6404684ab3ce4588e0747ed_D20230209-20230209"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTQvZnJhZzozMDdmYTE5YmM4YmQ0ZjE0OGRlYmViNzQ5NjVjM2JhMC90ZXh0cmVnaW9uOjMwN2ZhMTliYzhiZDRmMTQ4ZGViZWI3NDk2NWMzYmEwXzIxOTkwMjMyNjk3NTY_8558c00e-26e5-4608-a5f6-1304f05b61fa"
      unitRef="number">0.0795</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <ardx:DebtInstrumentVariableRateBaseOption
      contextRef="ic957e7b2e6404684ab3ce4588e0747ed_D20230209-20230209"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTQvZnJhZzozMDdmYTE5YmM4YmQ0ZjE0OGRlYmViNzQ5NjVjM2JhMC90ZXh0cmVnaW9uOjMwN2ZhMTliYzhiZDRmMTQ4ZGViZWI3NDk2NWMzYmEwXzIxOTkwMjMyNjk3NjM_fbd702e0-e7d2-4b62-a06e-090be9e84594"
      unitRef="number">0.0100</ardx:DebtInstrumentVariableRateBaseOption>
    <ardx:DebtInstrumentVariableRatePlusOption
      contextRef="ic957e7b2e6404684ab3ce4588e0747ed_D20230209-20230209"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNmVjY2EyN2I3YjQ2NTliZjFkNjFjZmI1NWRlOTk2L3NlYzo4YzZlY2NhMjdiN2I0NjU5YmYxZDYxY2ZiNTVkZTk5Nl8xNTQvZnJhZzozMDdmYTE5YmM4YmQ0ZjE0OGRlYmViNzQ5NjVjM2JhMC90ZXh0cmVnaW9uOjMwN2ZhMTliYzhiZDRmMTQ4ZGViZWI3NDk2NWMzYmEwXzIxOTkwMjMyNjk3NzA_e0c40463-b1e0-4520-89fa-851f08aecb84"
      unitRef="number">0.00022</ardx:DebtInstrumentVariableRatePlusOption>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>107
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M) T8AV%(U(B\0#,),QAB' U9EDK^!I^AGJ59?72O!6@L:@S0DEH9("X XCH
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M1M'/SJ4#V0NM*4=B1;@VJ9JUFS*UI59F6D0);#;[$.G#*%VBV5LR9[$6I5D
MDM??6DI6\X(MM3*E(B]@L[G?7VKH_C58D71)*W/J":''P6PT^$O+RVI"L*56
MYE4D!%PK(7RC<=S^D8(O@\%*!,QR(9H(D>FGN1.:CSI7/#07-<9VCEB BUB
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MM"EW-\Q-?P5I'<SZ40A],NP&7<>._P)02P,$%     @ LH!B5F?OE!*W!@
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M" (,HDV@75ZU[!)%9W!%_R&YR85FF59MN"C_8<M+*"%/5TLI-1=U%-0JJ>!
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MCX,^V<*^V-I!;*PD&?W"_+':T*/CUB=;V!=;^W%08T6IW8J^/W\HY#$)8"D
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M0[.+!\$(GEB,I%<[Q*UVCEE:L7K,5RI3+U^\=UW*_KE;GJ\X,@ T2TR1R16
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MS8)^TMWE2]B*+]FHFP 9&7&9MRT!UL6V)%N&_0Y0]GO?D&PG4PZ]"K*VWM<
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M>WWLR5#O+QX>1]WE-RL8SJT[)&C$F,7UZ'TS"S&CHXBJE^KE*>)7I9S4T_$
M.M7')I*,D2S&K.,<?+J'&=&KW3=,A UZGI+H3[(\ER'[H9"CV$)4O#PL0M9
M^P/JALXGZ8<"\#+1TJ+S<8CL6/NF^4X;A2@= :(D6A<?%.5D,6ZI%AQ+ U<T
M&$I$E[-SVU#;2$:AI0J8YV<3XDU:FG)IZJ)Y(XK$M-Z6E%@T,N1VD1B@H1AR
MZ!,.P&$SEN<1+D&VVU?!2+U#:?]6QQKI]W>C9E5=,"AA37=2C(C12/HH/LE-
M[J4#UM7&*7,=T>=UD CU!_3<O$$##QY0?:(=#F7UA.0#X5%JRUEKW-$B?*:A
M58W.U0)]UKC!X:W)T.]1V"[:X,212P]L8CO%JC6F.SODB!!)\FNG]X@\2;Y
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MJU[(#\8BHK)S_NL6 #5:T(L"8WW 3M%@).?0\K%I>&+TA&?T5.TM33##!XU
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M><N+NHY&;W_I>[I^Q<G4^':?E_KVK.>!EI]I NFM1.=>APH@-&IJ>I]F@_:
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MVQ)NG%[Z-QQ3[9PN_&6&D8 ,;\#SN=9N>\,&=J^\KO\'4$L#!!0    ( +*
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M;/A@&6Z\J?DC(0JP-R5?YI@/E*4%>+\T0+&](07]5^.+_P-02P,$%     @
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M5<<AKG'+)=#9(PK;)XUH?L5U5OCZ=@XLE*;F 4FX^E@NI4_N:@.ODUZG3\>
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MG:>NL.C1HU.Y,^2>5@.^MNW[<]H]O=Z3]M'ZU[Q]^NDFV K2K<0-N<:=\UX
MNGU.VX55M7_"ULK25>VG!?T#0>T,Z/M&*7M<N "G_S3C?P!02P,$%     @
MLH!B5F!R_@38$@  94(  !D   !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
MU5QY;]M(EO\J!8UGU@8469*OW(!BIZ?=29P@3D\#N]@_2F1)JFF*Q:XBK:@_
M_;[WZF#QD&([G<4NT.CH(-]]_-YCR2\W2O]N5D*4[.LZR\VKP:HLB^?'QR99
MB34W(U6('+Y9*+WF);S5RV-3:,%3NFF='4_'X_/C-9?YX/5+^NR3?OU2564F
M<_%),U.MUUQOWXA,;5X-)@/_P6>Y7)7XP?'KEP5?BEM1_EI\TO#N.%!)Y5KD
M1JJ<:;%X-9A-GK\YQ>OI@G])L3'1:X::S)7Z'=]<IZ\&8Q1(9"(ID0*'?^[$
MI<@R) 1B_.%H#@)+O#%^[:G_1+J#+G-NQ*7*?I-IN7HU>#I@J5CP*BL_J\W/
MPNESAO02E1GZ/]O8:\_& Y94IE1K=S-(L):Y_9=_=7:(;GBZZX:INV%*<EM&
M).45+_GKEUIMF,:K@1J^(%7I;A!.YNB4VU+#MQ+N*U^#-AF?*\VMC?*4O9<)
MVCQ?LME2"P$.*,W+XQ)XX1W'B:/[QM*=[J [F;(/*B]7AKW-4Y$V"1R#D$'2
MJ9?TS70OQ2N1C-C)9,BFX^ET#[V3H/D)T3OY+LW9?\WFIM00//_=9P3+XK2?
M!2;4<U/P1+P:0,88H>_$X/4__C8Y'[_8H\!I4.!T'_7O<-U>NOU27WY\_W[V
MYN/GV9?KCS=L=G/%WE]?OKVYO;[Y)YO]\_/;MQ_>WGRY9>^V:L/9.ZEESB[5
M:,C>E^F('0[>O;L<'('G)L\8O*S%8]<YNU%W8CT7FKX>LHU@\(70(F4R+Q7C
M#(7@.EFQI*.Q*NS+0&\CRQ6Q.!QTN?WC;T^GT\F+HR$#NA7$I5ZJFCI\)E.X
M2BZVK-PH!LHG8!N9\(R9LDJW3[#J;4&*=:'@;L.@)D(%,'*9.XD,O+V#0E>0
M+.'"H15+Y2)\!KJMY%R6Z*QR)=A":E.B3-(DF3*@?,GU$HKR(0D]?O%)JZ7F
M:S;Q2I#^G!F1J"XY]^D]Z$T]O1'[5&E3<1 <+(%$N@8<LJH /5&)3)#*:D&7
M!B.B4+%)YMOF]Z840J.40&,M2WB')- R8,NUTJ)I02 G4UX*$^2^NC2U&U&X
M%5B=6&#]1='%5Y%4I6@0-:+@$#8B#J$[4<>- 0DS;LUGE8_%0*507J$3R3/Y
M)_>J.Q9S!=X%P< ++!&ZA%[(3"$2N9!H>*&U+)66PHS8KQAUQ  ^7AMOOSY3
MX]N"2_"B 3_G*H?X6X!'^3P30WJ?0)+($M^#7Q8:ZBU;6(,>3,:C,?2++ -)
MAR@71K3,3<FSS"K,,7XS:,KF>12!T25$YZPF0T$,E$[&+.5;$CVD[H3J,NAP
M.'B[6 AJM0P:DAB E]!\45#N8P'_U;+P/ <RV@!8\'9J$A^Q+RMT@%S*')(4
M+;K;H-:#>0(><5R:Q$C,#083A% >+H*PS<!S*.IS=BB/R)!;^-2;SZ=<D]H0
MKL6+X8M<0=\.(<.AKMC,N[JD D+!XSXS=%OO?1AJT9W>IBE$F8D2#<*\!'%1
MB40 6JDS#WGA%< .'.9(#3%\#^7=T2.(-00?L=]:=;M<@>$9!Y.G-N#V5)7-
M2@+1%;\C%@"HB(BU_]?204#GV8:[&PFUDCJM&>[FUY03*/]2@7&G3RVT&.Z^
M*[6Q\Y.8ZPJ#TMUR0LIS8X2A0MM_NT0(FBB=<HA!VQ!FMY?L?'SNZDN>9%5*
M]_.2B,!'A#RPWDTN7ACXH$+)T2U;J@^0V5@;+$X4VLJ1&86W&FAFVHFS5BG4
MHL0&T[*25@;L[HF6<VOL;PC3HY%9J2I+V5R08BA:2H'!#?6E4'&M%@P*U-J3
MNFA' +7.!2"1U+80:%L567..<P,IYIHSEM0[KJ6"L@C1MY9@=A\L?;$E216?
MI1"LMNSP'+Z!A@F!%*(Z(_PD; 2$AAN^;WX^;7T>^H^:4P/PC>#;C83N-#8D
M:JX1B:B#A,1OLWL<F^D.-K9H4_XGLK#W8P"S?RN)GN]V<=^??[F];""45&">
MDF,IEM ["<5-KDKP;@Y>=[$A))6F-J3P)88DA[FR^:WS6;^\>"4(-&(S V.G
M]Q0(/2>!@K^[O/:1 XA*. 4"+$4/S 5]LP+[8J/(T!.HQ5*IU%)"$ V\C#4!
MH!J\QQ& 4 ?<@?D!J2,X".$,T U HM6-/\J.GI2UX-A$0<)3P OP&03]O>.%
MR'&-E1B_-P0WH$&@(PE#A_A)I$ZJ-33W'%7%6]#%A="T.\"*H^:97'(KE=,R
ME >.)3(1%M#/1<(K(R(U$-D@2EO@/&_A!#!*>8:-$:;\#,.QT#(1H5%8]0/^
M@'L!"@X;IO%"QO62' KS/D0X%@>R D20LVE5&E'N@VT;T8EYO-07&U V-]RN
M)*RXB#D:>,T)##=J<%)>46]1X!HLL)2^C2C>9>"Z/,,@HY:Y_!.+JZF#$96'
M@+^3&#65\252Y@4DV5I LL'L=HM.L5(O;'*2QQ1$>)+ P,   D+_E6M!,!/$
MX,LP;%'7^G>5+FU#7DG3H([="SG.,6W6@# J3=ZC+(1F"K[8< TY9$ EL]AZ
M"7=IC'9S$8(M:,'!5HL*8[V023RNQ.ITLW3$/CN[HVLBXUE5&ZG9GY$HH42R
M%MC4N0D6 L P&;&K2GMM+)BTZ.)*)!90^T4',<!;*+ B6?X46M&7!Z>C:8WT
M08+"PM!L2UW5AU 5<%(_-G$950J/RQ7H$-D59SXM5HC% *7!2&DL^N[&\XIC
MT G(V"K+MH!',I50Z)8J"FADT=9V4J<JF3Y7<>0#/H &)=) A+83A#H<5I_S
MC&+"KC/[>4P1\5H?S'9<T# Y:@-RA'JPJ$J*TBCL]IEVU(-VVDN/BYZE1P[E
M%F+&&MNWN)XMA^NZ72;UD&S%LY&X<0@(^.#5O6R O6L.G<8@0JV_^?GMB5\Z
M*&UBE"5R7O <K R7_8(OP^A1:L%+'U\)9+:$@DS-"$ <-\)'6FZ[%)1NDH[(
M)NA9BW"U0!%$A(/L<!$88Y&&HH9<2 #; @@8?_/>AM 2)$E\OR)P F498TT9
MERU =@ZN[%V>=$ NOI6&<A3[#392PLM9!DJ;TJHOOA;H!C)II74]"=UK(U$K
MXBD[MZ8-9;R6=F+0HB.3J8HB"P6WIIKJ:@E?SFV7ITM!JU#KL6??"XS"=*BJ
M98!SK=&]8[G0I@*&7/.M1R0(_CQ**#%5\VH!%0G3=*_P+?02PFZ$"?HQ*97-
M3QP)NTO)RZ 2NR5;1?D=TA.N7%2: L=.-Q9#=%&0G[3I3E?#?235QG->:?JY
MI51=$:"2H0QMZ>I]WPQG+M ]\V-65,E6@E/:^:U;J_8ZA]L"25-[(J"&0#:D
M=YQV+ 7?VK&?H#T*XJM [1]DL$\7<O8&6AN"F,K8%N*P )',A4A-9_K&@-!0
MY99NM=<W>=N!%06X)1B)*./7 E>-P8*SVU_#)'.CJ)"?/AD_&P9T0)I=.OSJ
M?'?I1G'##K\H0!TX4A\Y8)+9>E%O1&I.-'HWYJ8]^X![[ %VKQD[J;6)O'=P
M$L-0L%M5/+%[1=\<$(7[?4T+'45@8P,X@1A&+0N^=IM90)5ON+%M6U7:^<Y*
M4^/'7A0=3WO=6'+I$0 NS6GV,M>]=R)'#]+] ++38,B:@)6=)^.!;1=Q\(T?
M\A[DF<8"N-\7M$"-G3:D;,#B.*>2)<O,(R_R,5#!=P=G9TU'EZKL&0JU6%80
MM4IO\5I Z3!L@?N!J8V @VD<+[B))^!75P.BT1<A.\!9D)Z:-:H 9J2F%*G
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MII'#%[1*:D&,(_6%4@O/Q:NM4X#"52GID+>6.;J;26.U(ALEE7VHU#R-VVE
M6[- 5]J13-/4,@OCMNT.$\\'6Z0,?N!XLH=37<@I1(YW(W4<2)^?H#AKMA4I
MT\YP* F6]_EH>U]@4+.L;F6:"<LB[H*H*9N6_6"( Q^#!P@K*? $@S*OS%]]
MGSK$UYJ%$.8AC307?/6/3+M%Y[-E%N* _9J>F)2Y=-M(UQ!U4UIKQ(QR$\47
M9D8/3M_HBPR',&DWLG2B2_*+.H\S:ZR<Y'"WR'+/A!_BD60([II2H@MN;--
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MZ<82M%RH9LOL8"1 JL2SM:PVW^$%F4&OSN;,H=?_>!,;W]*B9PR&(2T,=-!
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MFW1A8$JB%L*343)<3ZIW7H%ND@^Y0HGHD ;]D:_6XPY]DLQLE!0Q!VDIW X
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M=Q\0.G3A^Z'=X0S@-[K:\&R[AJH:+]W=6=/"^*9CI=</?K'U*@D8G<JV[ZQ
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M@6XN?IH7JRIWV3)3UJK"_<Q04/@\@;[/E;+="SOH;]\._@)02P,$%     @
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M>^LY)[,PW31G<%Q(2&)O"]ZQOW,#EO]>..J#\7XXM='L"=PA[JIPG^>6+^;
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M[V$\>0:!3/:%\V]^R.II&H]XZ8B7@N ]E+5T/7_6N2_\<[V6U0H&K<2M+.I
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M6[^:A1-7F0]AE2#Z3\9.9EPS$>UJ$;43*.!4]KRF6LE%B2OA7[6VH3?DF-E
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MIJ0LUXUX!X+1K(9&FIL]!!+-)U\H52,%50Q:SD6$D1U%,[0Y=+Q@1V=5F+@
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M<@<K?$114IR80F#&*+XN#29@)&P;?BRSTTR[/9, D30I0B;CFK&!'5FEL$-
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MA,H:T/Q&2K/OV 6:]]?T'U!+ P04    " "R@&)6HSP_+A8%   /#   &0
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M(/VPI(X=M=M ZRM%&=!.W ';_P"S?P!02P,$%     @ LH!B5EXSI7@1"0
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M:=C* LPOC/'=0 ST7TD'_P!02P,$%     @ LH!B5H?0<*G-*P  QY@  !D
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MY2WP084P 2H"#BS@[$@U?[B /T^ LS8#B44X1OCJU[J4X&*+FW)Q4TO ^RH
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M"$B$\Y'L\OWF5U1R/0E$;ZS7K5V=K(@M+]_B\DKA0 - #65%QB\R\&K$QBO
MSS3)B9X4S;IU\ 0@[!R%$9(%Z(#&LWHSK_:J>U'%"8N1_Y!M3BR]<4'7@M%
MJ(:GZ=<?.OEYU.>D-5LA/-1&"4&=DY0<GX?5W#P7\;]QW_NVZ6_WL&K]GI]B
M@MXEJ"F[GB&LQAL8+@ND]H= :G]8) YPM\"9JK-7?=N"&CU-D=>GK8!H845*
MS+>3K[?Z-:&K1T.+% .>I6>#;O13%?R><!UI"*BJZ($:-[V'S7B""1ER15-5
M>>N?9_OF'O .0B[/T!(3PL?]H,50>Y:?V_Q8=F3N@+L:Y0P0,U@C6['?!KO"
M']WOR^V>?JI\ =3C/L!>:SAUB^)T5_5H#ACC KA%344B%5!V((9KL*;X>-'&
M1_'& @P@Q;8:[I8,0]P-G8.A ?Q$&T"15Q(1(\>A T2/"![P?23V6N:8Z!)T
M]XW(+8]\P0>[1P2>]&'B%=SPKD+20JXVN JG3@Y\#V(8SA",1]@:R@P Z*/R
M,:Z/P(AJ'2UD66\'YA79B_ 7V!< )/@3>73%JH5Y%"2TXI19F=^SPM\_*N,K
MFDV7"[^T&#)  (77^A[.NO"^O/O8V\IS=[[2E^1XAON\+>*Q2<,BVH_'M@&$
M(6$@EZ\B16SH!>VV% EF=AS8 -Y;HJ@"<8&;RFE_Y1:T'Y !. <=R83RX%BU
M@6T&,HA)8BC3!;4]&U-[5PB"E2E!8*%9%PD$?!+<8^$0?Z1MP1R)Y$ K /Q(
M1@/WB/4+TI"H0J45& G&4K@GRYBLZBA76>:)G_!(N/3Q*JM=1^A!FC?.$W(S
MF/Y";\3,(_W/X(@O]D*XA*0)N224K.CS<:-JJ(-]X]']X8>ZE.=Y&P%3\:.(
MS$XTU#W(I#V+KD!4B39"7@;'$V6!\#2:W.PA+4C]RXL8BKI8E-IO6P0?V."X
M0;3PCPC7R6#3YRR4)1^[\#')S([IJ",C;,6VJ;7G"@>(!,47)!^H80#+W\5!
M?&V_+CTAOH^X(1,-$(C\OL;=BH#+FCOQVRPV'; ]N"]W+F "D'<4B<K>[(H5
M5<L$'5E#[.?6N26,F.#@Y2(@WQR.0*D'L3Z^![]__3ULHLBN:1>3J/E-*[(=
M#+8\!1^""U_A[RKZG9X_!A2.DVA=$5Y;=U>Z>T>LE97QW:@,4!FS)49>GI$.
MB1,-'Q1H3CN65F2"X1Y(:(DH0J$!J[$)>%W;-Y'.++U&.=#3($V$ZW0-:GHX
M7\3^KN]0Y($&*#WS7Q%%&QP;A= V!$Y0KD6?24R6N$/B?8Q4X"$Q#@"+JOIF
M^$0?+#R%<;7+KY[[B :V.,^SB#L /[@I]6D5Q1$^ZWV@^,GM(YA9IEKM<W Y
MVUXH"8-@/,_ B*-=H6<(9Z@)V:_!UCYL8 4-_=)_+^FH\,<%:A.R6@R\ZV:(
MD.7HQN55Y(^K96IFU? 3AI FF>'ACZ.YU8OA$;&G :M3$!@[&U(EJC9A+'1H
M.1($%,=/K-#'<"V&9^$G,\$PHH7"H4]0HD64^)8<(W+$"QO7W3LW#"!R:)%(
M150+OHHC9;,!.):B;<"_E96N9E,7EXDZJ\KOU60HP2#8H"V1.39? T_9W8HG
M9A@&F-0CBV8<IR1A7@%IDNL$, .JO"L+Y=&2K,0#FK=5^=ZA;8JL@DQ/V_ (
M^&#+<_0)SSL!<MYR$!<<<U@DPIBXN%S,-&CFPF?O@A\Z28N?O,KUV,%E22:!
M9#"#Z+@*0$_TV#J08+4G<ZN]=9M\^UZ-(;9A>I)YNS4XFTTI05* ^^'8K8_Y
M*4@.)!W$))N@8&EQ-@P0>)[]B$Z3R,P@\@(><1=%TV\ZU*/!2[<A$T"BBQ2@
M"]PB^8E+%H^,)EN;%\Y"09QMIK#[MNS 0<?MPAH81>H&&S+$! ?=T!)!F9AE
M+8ULP6TDPH77-Q0.6P799CB5H_WU0TZ/"TM"89GR8A+J<CE]A.%$L 7;20_]
MH<]2_):=7N )"D'PYVB)>>2>!@TK#=IVE%=IT-<V'K1\ C_?8;"Q=;=HM^$J
MI&GN<G*C$ ^K2 4QM!YTGJ915JJ(0;8>T!7"S1GKCFU?5T1\JN23YT#[U,VA
MW (J:[=CW%M19*5 ]B/JQ'MPMU;L ,K)17K5GCT<3-'E[9:CX 6(LJHA2^<<
M#-L2=64C]#1Q]EU6M/VM@@F]O*(L.#-S3T',GL25O(X9&1>+&18W6H3]1=+_
M-BR'MH &,"DPUQ]17HA'H= $8=[7<)8A_M 04Y."(IW"_.3"U(0!>!A=$C!Y
MO20^=$?X*LPIWH+]2RX9!3$V[A;MF^93J.S-RYMWWWY_G16<6N)H0 \.4O:W
M'MX-[X2-H^&Q8N;6+7)^SA*-"VO=YY0S KB4?H\H!33>"TR <8LD7:@(F(28
MK+C2V$CN@XC!OX?B =>)!][G!;KK2K<S]'J>10;%2$GPCW Q$#4, 8Y8M\9^
M19W A$VKBW.-(*7?FJW%G-6N;'VWQG '_='TG<:MS2883Q)N%]!PN%S361Y#
M&&5;K)$Z3C-9PO0W1U!.+/8Q/H4I 4Q!4"4'^(#YAJ@1WXOH "?#-W7M,/9Y
MUU1W,96:YB$!M+"0!"#0>6C10$'_8._R@A<<! _1\!/-R.\#(@J@BH>E?*L8
M?0(7#:_P;X,^ W*0V$4*/S6<#(JF<LSL-JEB!*E0"ED6FI97HJ94L5'2&,(
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M<Y.ZT%/C."K%</XO1G:=CU@EI':#!BFX'O8:$SE_!<1M<XUGQV14J,I/#8/
M"&D5.*BMJXO++[-'9]=_S7XRO[_6WY\])MHP07XTJT?5Z13_:,6TN;SX-_Q?
M4JX>."J.>OWSG[[](K+&YD2- 6VJ9]D=)8/]2E;%SH!1\->VHG+"TY;S!"%A
MIGXK,=KLS3 4%8TJNWNM[#>G*.M]N2EQ^D*<CD\@+[B#ZF21!OJ=-?,A_U >
M>IH9\J]??7E^@:F#R@0!\EM8XI8&]).3\3@ 8U"\Q-HZ]BN-)UF1IKT?/ ._
M:G& =,.^6"BY1L5V2U.F-3*R0((34R@M(]?F%'C.RR_/OPCGG-AHI.0YBEQ4
M=?$*G<OENV_>67'UVM  LN'TR-[?LF#V;JYJ*TI3;D#E9+?>^V"JMF12*JI/
M5V0R8R^MZMIQZ:O,*9UYH;T_@M1IR&OEK7ZHL6-W.%;-R3G5$W3'UI3>2Z_D
M"C\S,6@0B.LQ;PTOZ@I;TUC'Y 0]G!Z(+4U$0^EQ.&AJGT%(A50M9W?1-EBA
M) E?/ !::5M1\C$_N];3AHE^20<AV?[:,HOE*"W:+QI4EH!TFT[$3?<U.%?2
MW2@S-_FJ$950#Z$!Z=7;N'U>[19Y*UX(=+E\A\^U-%#.LL2W I=)-OL'K:T7
M[NC@OZ1HFAI#1FV>XWJ-89&&E,8K&<JX1S)62D<-)'@KJFTAJF/G-V<GB#<.
MA[XFMQ;+CRG+U=OB:-3,G.<[#<(RYFY%]M\DQ! P:(NSU&Z*&6<EMO"LLHSA
M9Y+(0:JH[:*/JB()<PQ/KM.+8*A9O @*'DU&_ EG*T.G1:Q(Y9 OS7B3 A<*
M"HTXPO>; ]JH_ **LX)G2L/?=TF34@2)3GDP<XH&E6X'Q]F/P96)VC4T(@X?
MB"+I].5XCI193=Z<F,QGF@AT2C<L-T;F$A?F"U)^4>=2FBGQ/LBR/0@@ 4/Y
M-H#-3IT1@IJ6+:.:5UL)= [\DQ^.8K3%&FR%QZQ$"8!2?6+%W;.,!@P^?3XA
MV(93^EZ]HRE]/)JCEBMZ4QWCN[XHL5%25^7;J2B$@?5?9>?\IRT MD>!H[,2
M?<6>Y&!([-!<#(,,Q5*,[^BI4%_ZEX8OFM@=1HJG2HJBK%Z4SO$.K<OE*[!N
MZ#++ET25K\QEEI/"^/.6&I;6FV_4LME)?8B]6E,C)SF6UJ/J+\C85"/$D\I>
MAW\*_'% "X(T\)FY,R/>IL.U!L&>P4?M8KR/F-^^-[/4.<I+C=S$[.DEHL2+
MO.%8U_JRRN%4-UN:?"&KKC&T305"3>&X=296?*5VN7D#)AMG;A\-L*209GJ+
M# \$#CT#Q!ZQ]%V+<LSE,70"!A)>" 1;I3H@@@HIL9@0U>*GP<]6HU);*2_3
M(,1*G>!X M(UHF)\@./P#L-MU?BDY4='K&+(AO&6WL')R&)#UL84/A-Z9$*@
M5+$*E*R!FX^A9GB4A&Q,6&2!#71\KQFJ9D,UB%KJ9^2<-*=59G95RK1$H]<-
MLS3MSI4=7;@BIM 4/.\P5+D:E(^".#.EK0P=4BRB>^W:GWFS[%6\+>IJ^9*G
MU^%*,181?W(%3?*^#H)T2M3]YD6GY@#/W&Z&P2-.MDKK@^D@F!LIPKI;^GK@
MVT-ZHRDF5<T.6Q>[K- QC )%!TXN7&$VFGO]P!O,EK 7;Y:Z6KX'ZL\X6AHO
M!GJC=Y-]&QGUM:9*WDD$Z,>0N9C$Z3_G562VUG19+/@!KO 26:&D4<@+TO6L
M9A#$.&8VFP>2-YI"GD'SG:X]-25BZA)9'E>(E=7V_<3/:%G+S=OA&_!8?)_7
MH7HX1 ]7"5V&"-K\OC5?P9?Q<&\>1D9+<\-95>ZXWB/$*%4[$W+"'74J4Q\*
M"RDY(O":&X1T)W%A;3GY:3A;WU[EIGIGX;0KK8F>]#DI.DN==3%!GNS9%#\G
M#4^(-GLA9I[5/86\<0&9^6JNW#"7>(\N>V=_KSQ(7&3XWA4WY-"0 AU&--U)
M,O9-3 FFF>*P>#!EF<D;2A.ZXPK*B58>^[K6G(S"1^&M>%=3A(H.W:,E^%3A
MMN]TL.B@IS2,&<5;PWJ^<=7<GVCRWTR@0_+Y"+,LRL]X\]C5\M5AWU,IQJ0T
M?,B#E&$-3$"7N:5S53""7N%/U4A(NM1&]84_LM8 K%2\_K!KBU*_ZV:WIFIA
MN<-/R]CL=;CI0K'CCE,$"U_+;53#-<MI4?ENO!]3<98DJ[F^F4/6%4]1IGY
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M/[KFB$MB'UW7'.A/++!R+?X OM\UH#?D'_B"^Z9]3]M[\3]02P,$%     @
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M@\G( =5<R8U@9%E?@[$T=*G6RXS^8E!9 ]*OI30'P0;H_HM6_P%02P,$%
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M[0NY >SM!_2M,K(E3W$24"]8-(\8)!_>=0?1IP-T>RW=WB'TY(Y:+ZLD@E[
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M-3KI]P+035-N%E8M?2.<*TMMU4]+^H^A=@ Z+Y2RVX4ST/X9)W\!4$L#!!0
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M@\K!GX)OA!1.T.[;;WPCT;Y;Q(Z">XBXV >ZZ@.Q%P*E#&ZU<K6%CZK$\E>
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M0F4-:'\KI3E,;(#VRVKV#U!+ P04    " "R@&)6?&^'7P4$  !*"0  &0
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M ^SH8$ JAW1X3$YL'T;Y_VCGKV=D8(TY:PQZ'=QLJ/%03W*T2DHZVD7J0BY
MQ3Y WB8S7?V9M_7S\?+XO6[M6P5UH_.2NE2?WE;ECY ,PA%I)$DX&2<P#=/A
M&.Z0KCV>.[]:H49RJOJ4TGP(29C%9"&#[ZOE<E\CW)C&7P])EI'A,9#@ ].:
M?#IA^_.G29JDW_K_=)#"O8]FDH4#JB$BETU<987I= K'"B(ZZ&]T$6Q]%S<N
MY-*VK:Y?[1\*EVU_?!5O7QD_F-YR.BJ!&U*-S\>4Q;KMW.W$JMIWR[6RU'O]
ML*3'#FHG0/L;12G639R!_OFT^ ]02P,$%     @ LH!B5KRS5T _ @  X@0
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MX5B[GQ!H'^#N]TK9H^$3C+^U_!]02P,$%     @ LH!B5IU?8!%I @  UP4
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M)B\H&V#N"REQO['-W<_R] ]02P,$%     @ LH!B5AUN8N;+ @  ] H  !D
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M8O]ZYOY&\4WQAN,]5XJGQ>6:T243N8'^?\6Y^G63OS19O20[^Q]02P,$%
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M.^Z%T(M.Z,5)HN=&H7X(^KBJ=6VA5N2Q@O_&$H2V%M;:\N!C=!] :H/@*J9
M*SPF8=*</ PG>W/>Y,DHWNR+/+6CD1/O.85$LPH&:BG16KFFN;IHY]%7P9I>
MQ2?DW8W5/M,TQG_#S(HK"P*71)F<?Z"L3&.FS<3I=?"CA7;D;F%8T?\'C=]
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M_BN6-TVMM,0$VFS* "E-5&T/G:)&[1ZF/1BX!*L&,]N$[M_O;"A*I;3KPU[
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M_++$40;:.>#Y3BG[9+AN&8=C^A=02P,$%     @ LH!B5L]N=GJQ @  F @
M !D   !X;"]W;W)K<VAE971S+W-H965T-3(N>&ULK991;YLP%(7_BL6JJ97:
M0DP@M"-(;:)I?9A4->WZ,.W!@9M@U=C,-DG[[V=#BM*$LJS:2["-S[GG"S8F
M7@OYI'( C9X+QM78R;4N+UU7I3D41)V+$KBYLQ"R(-ITY=)5I022U:*"N=CS
M0K<@E#M)7(_=RB06E6:4PZU$JBH*(E^N@8GUV!DXKP-W=)EK.^ F<4F6, /]
M4-Y*TW-;EXP6P!45'$E8C)VKP>4DLO/K"3\HK-56&UF2N1!/MG.3C1W/!@(&
MJ;8.Q%Q6, '&K)&)\7OCZ;0EK7"[_>K^M68W+'.B8"+8(\UT/G8B!V6P(!73
M=V+]#38\@?5+!5/U+UHW<X/006FEM"@V8I.@H+RYDN?-_[ E& S?$>"- !\J
M\#<"OP9MDM584Z))$DNQ1M+.-FZV4?\WM=K04&Z?XDQ+<Y<:G4YN^ JX%O(%
MG:&962)9Q0 =3T$3RM2)&7R83='QT0DZ0I2C^UQ4BO!,Q:XVQ:V%FVX*73>%
M\#N%II">(W]PBK"'<8=\<KA\\%;N&N26&[?<N/;S_\H]I2IE0E42T,^KN=+2
MK*Q?77R-X;#;T.ZV2U62%,:.V4X*Y J<Y/.G0>A]Z:+]3V9OV/V6W>]S3^[(
MVBPA#9(2UODD&WE0R^UK8)5@C"\N8G>UC=!;Y(,(PQ9AV(OP:-X-=D&64J2@
M.B$:@W +(O#Q<(>AM\H'&8*6(>AE^$HY-1LW0TLANG=4L(<PPOX.06^-#Q*$
M+4'82]!NHJ[PX5YX'T=X)WVXM]*\=L:;2*,VTNBP2*>("WZ65E*:?E>^T5X^
M''CA[@(9'1HP:@-&O0'OA2:L*T^TO^DB?QCNY.DU_]?'[6Z=&_;,_D[DDG*%
M&"R,O7<^,FED<PXV'2W*^BB9"VT.IKJ9FT\'D':"N;\00K]V[.G4?HPD?P!0
M2P,$%     @ LH!B5CK:FS4O @  #P4  !D   !X;"]W;W)K<VAE971S+W-H
M965T-3,N>&ULK51-;]0P$/TKEJE0*\$Z'_L!)8G4[@K1 VC5I7! '+S)9&/5
ML8/M;-I_C^UDHZW80@]<8H\][\V\R8R33JI[70$8]%!SH5-<&=-<$J+S"FJJ
M)[(!86]*J6IJK*EV1#<*:.%!-2=1$,Q)39G 6>+/UBI+9&LX$[!62+=U3=7C
M-7#9I3C$AX-;MJN,.R!9TM =;,#<-6ME+3*R%*P&H9D42$&9XJOP<AD[?^_P
MC4&GC_;(*=E*>>^,FR+%@4L(..3&,5"[[&$)G#LBF\:O@1./(1WP>']@_^BU
M6RU;JF$I^7=6F"K%[S JH*0M-[>R^P2#GIGCRR77_HNZWG>VP"AOM9'U +89
MU$ST*WT8ZG $"*?/ *(!$+T4$ \ 7SG29^9EK:BA6:)DAY3SMFQNXVOCT58-
M$^XO;HRRM\SB3'8C]B",5(_H+?I"E:*NJNA\!88RKB_LZ=UFA<[/+M 98@)]
MK62KJ2AT0HR-[CA(/D2Z[B-%ST1:03Y!<?@&14$4G8 O7PX/G\*)U3P*CT;A
MD>>+_RE\Q73.I6X5H!]76VV4;:V?I_3UA-/3A&[<+G5#<TBQG2<-:@\X>_TJ
MG <?3JG]3V1/M,>C]OAO[-E:04-9@7)9UZ!R1KEM*=&65GBKF-B=$M\SSCRC
M>QKV61C/YHN$[(]5_>GU?AK,1Z<^6W+4KNZI^$S5C@F-.)06%DP6%J_Z\>L-
M(QO?P5MI[#SX;65?+%#.P=Z74IJ#X89B? .SWU!+ P04    " "R@&)6D1&D
MC5($   =&@  &0   'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6RUF6UOHS@0
MQ[^*Q9U.7:E7,$E(VDLB-6'WMKKM*FJU=R].]\*%"4$%G+--LB?MAS\;" \I
M]39:YTT X_F-YP_C,/9T3]DSWP (]#5-,CZS-D)L;VR;!QM(";^B6\CDG35E
M*1'RDD4VWS(@86&4)K;K.)Z=DCBSYM.B;<7F4YJ+),Y@Q1#/TY2P_Q:0T/W,
MPM:AX2&.-D(UV//IED3P".++=L7DE5U3PCB%C,<T0PS6,^L6W_BNHPR*'G_&
ML.>M<Z1">:+T65W<A3/+42."! *A$$0>=K"$)%$D.8Y_*ZA5^U2&[?,#_4,1
MO SFB7!8TN2O.!2;F36Q4 AKDB?B@>X_0A702/$"FO#B%^W+OF/'0D'.!4TK
M8SF"-,[*(_E:"=$RP-XK!FYEX!X;#%\Q&%0&@[<:#"N#8:%,&4JA@T\$F4\9
MW2.F>DN:.BG$+*QE^'&FGONC8/)N+.W$?,5HF <"/< .LAPNT6?YKOV*/A/&
MB'HBZ,('0>*$OY.M7QY]=/'SNZDMI&=E;P>5ET7IQ7W%"W;1/<W$AJ/W60AA
M%V#+(=?C=@_C7KA:H@_!%1K@2^0ZKMLSH.7;S7&/N?]V<T<3S:!^"H."-WB-
M%W,210PB4B0#71^>!_K[D^R*[@2D_)\^W4ONL)^K)HT;OB4!S"PY*W!@.[#F
MO_R$/>>W/LU,PGQ#L(Z>PUK/H8X^K]3K$ZPT'!6&:E+<S4<N'DT<1S['75N,
MEQVQXUR/7W3T7W8<C\:XW:\3PZB.8:2-82D3ALEI44X(8E--!<#0MDI83A+@
M*&*4<R0HRF3:DB!@.4EX7]A:7Z>^)R7,:T5\K(FN1T<-KU;#TZKQ>Q'H(7A6
M9<<WM#SH\@W=RD/,:<X"6 "+($,^RR.TI&Q+69%8?<)HW9XJC$F8;PC6D7M<
MRST^TX0T-JFG29AO"-;1<U+K.?E>,@>@\KF04[ZFS^AB"TRU]?Z=EC3LM!/H
MRO4F1W.4UNFI^AB"=?2YKO6Y_M'T7A(6QAE)T$<@B=CTJ:;U<>J[9Q+F&X)U
MM,5.\XWGG"F;*[ A28W2?%.TKJBM#V=L-*4KW'%.#_!13NO=GBR2(5I7)+<1
MR?W1O+X/_@#.I83?^:/6>SKY531)\TW1NBHWU0,^5_F C=8/1FF^*5I7U*:$
MP/H:XN3\'O;F-_:.\UOK]F21#-&Z(C4U"M87*7>+QX?WGVY[]3!:<ABE^:9H
M7=6:6@9[Y\I7H^6*49IOBM85M:E8L/8#7E?S5Y:=6G[D.<[+HE_OXV1%SE%R
MX*;FP/JB8]5>*KA42P2]XI@L(I9&:;XI6E? IBC!U^?*4Z.EB%&:;XK67;=M
MBA%7^UVNR]/*\@UYVM/S> E*VZ4<N]U:-T_5DI':?^ HH'DFRJ7HNK7>X[@M
M5O:/VA?XQB]W*AI,N7%R3U@49QPEL)9(YVHLQ\/*O8CR0M!ML3K_1(7\(BY.
M-T!"8*J#O+^F5!PNE(-Z1VC^/U!+ P04    " "R@&)6E?$U'=L#  !U$
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MMVW0X9IO-&I@BJVML_>JL_?N]_<S G$,99V%I(4$C"<)GK1P1M:8S8\D%GV
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M:'*S(0.K)?/K]6"'4S#4$X'2 B@MA-(HE,:@-(ZBZ8KM/!'O%$_$@WHB4%H
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MD*8#/L^$T"\-LX?OSFS)OU!+ P04    " "R@&)6 5;0&&($  "S'   &0
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M>%8>KH$N0)@!^OZ2<[4_,;M*S3[E[%]02P,$%     @ LH!B5H5/LY$Y!
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MV))LIW:[T:*Q<^Q1:)R*=EGB10?2).#Y7 B]V9@"_=69_@-02P,$%     @
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M7)N*9.L\6_S(I&1I7EP!C8#K#]3O"\;DOJ([*/]^,/\74$L#!!0    ( +*
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MPZGN0T&8#?K[F'.UGA@#96<;_P902P,$%     @ LH!B5FC*AT@P P  HPD
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M/J!L 'Z?26FV'9N@ODO%?P!02P,$%     @ LH!B5H:L!3]G P  ] T  !D
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M4#PO+MD95WAE%X\Q=F$@= "^GW.N-@.]0-77!?\ 4$L#!!0    ( +* 8E8
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M5>F:QTQ]O0#7 >I]RI@\-O0 S??0\B=02P,$%     @ LH!B5A)AD8.0 P
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MH%7XA.J\WTBN[A*%D]$_P%8<KS.2H M:;B.3#IJB!:,)4,G-C$"?T#5L@6X
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MK@W4_25C\G&@%Z@_A$2_ 5!+ P04    " "R@&)6-@TG,#H#  "S#@  &0
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ME9*,\;4U]\ PRWDN/:4O(1VP"Y;REX6[=@975\63,9%+$]M&L-_3:OD.4,]
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MJZ'(:BBR&HJLU_]3UN_C>/C'\<LS[:MV>,G/EC_8W/X$4$L! A0#%     @
MLH!B5@=!36*!    L0   !               ( !     &1O8U!R;W!S+V%P
M<"YX;6Q02P$"% ,4    " "R@&)6>R\:S.X    K @  $0
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M965T-"YX;6Q02P$"% ,4    " "R@&)6  RM0/<&  #N)0  &
M    @(&B'   >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @
MLH!B5M .@Q[,"0  358  !@              ("!SR,  'AL+W=O<FMS:&5E
M=',O<VAE970V+GAM;%!+ 0(4 Q0    ( +* 8E;$HS0OEPD  "TO   8
M          " @=$M  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M    " "R@&)6LBK!]]\$  "%"@  &               @(&>-P  >&PO=V]R
M:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ LH!B5CMW\&!#*   '84
M !@              ("!LSP  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+
M 0(4 Q0    ( +* 8E8:F,5P8 <  /X2   9              " @2QE  !X
M;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ LH!B5H8I$F:5
M"   018  !D              ("!PVP  'AL+W=O<FMS:&5E=',O<VAE970Q
M,2YX;6Q02P$"% ,4    " "R@&)6T$*X70$#  "5!@  &0
M@(&/=0  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( +*
M8E8B+&[=( 0  -\(   9              " @<=X  !X;"]W;W)K<VAE971S
M+W-H965T,3,N>&UL4$L! A0#%     @ LH!B5F!R_@38$@  94(  !D
M         ("!'GT  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
M    " "R@&)6&P""+/\)  "0&@  &0              @($MD   >&PO=V]R
M:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( +* 8E;;5NZ%G!$  /HU
M   9              " @6.:  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL
M4$L! A0#%     @ LH!B5J 'Q/;+!P  S!8  !D              ("!-JP
M 'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " "R@&)6F8Q]
M(",'   N%   &0              @($XM   >&PO=V]R:W-H965T<R]S:&5E
M=#$X+GAM;%!+ 0(4 Q0    ( +* 8E;R:AT 7 4  (D3   9
M  " @9*[  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @
MLH!B5LJHOW1)#P  S2L  !D              ("!)<$  'AL+W=O<FMS:&5E
M=',O<VAE970R,"YX;6Q02P$"% ,4    " "R@&)6KJRFATL%   $#   &0
M            @(&ET   >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4
M Q0    ( +* 8E; 4Y#(( ,  ,(&   9              " @2?6  !X;"]W
M;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ LH!B5KY=QDQ6 P
M8@<  !D              ("!?MD  'AL+W=O<FMS:&5E=',O<VAE970R,RYX
M;6Q02P$"% ,4    " "R@&)69CC+J14+  !3'@  &0              @($+
MW0  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( +* 8E:3
M% 79' 0  (L)   9              " @5?H  !X;"]W;W)K<VAE971S+W-H
M965T,C4N>&UL4$L! A0#%     @ LH!B5J,\/RX6!0  #PP  !D
M     ("!JNP  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +* 8E8><8M-G@,  ",)   9              "
M@2HQ 0!X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ LH!B
M5EBMV1RK @  4 <  !D              ("!_S0! 'AL+W=O<FMS:&5E=',O
M<VAE970S,BYX;6Q02P$"% ,4    " "R@&)6M*4&S"\#  #;!@  &0
M        @('A-P$ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0
M   ( +* 8E;&22@]\0,  .<*   9              " @4<[ 0!X;"]W;W)K
M<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ LH!B5C4K!&A9 P  /P<
M !D              ("!;S\! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q0
M2P$"% ,4    " "R@&)6+5';,#$#   E!P  &0              @('_0@$
M>&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( +* 8E8"L+:F
M,P0  )H*   9              " @6=& 0!X;"]W;W)K<VAE971S+W-H965T
M,S<N>&UL4$L! A0#%     @ LH!B5AA/ <<$!P  OQ0  !D
M ("!T4H! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " "R
M@&)6\?.B#LP"   G!@  &0              @($,4@$ >&PO=V]R:W-H965T
M<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( +* 8E97N%Y8/0,  $@'   9
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M970T-"YX;6Q02P$"% ,4    " "R@&)6G5]@$6D"  #7!0  &0
M    @('U: $ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    (
M +* 8E8=;F+FRP(  /0*   9              " @95K 0!X;"]W;W)K<VAE
M971S+W-H965T-#8N>&UL4$L! A0#%     @ LH!B5O"/-T^T!   =B   !D
M             ("!EVX! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"
M% ,4    " "R@&)6<)?F]"X&   P*P  &0              @(&"<P$ >&PO
M=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( +* 8E;I:31ZK (
M -T&   9              " @>=Y 0!X;"]W;W)K<VAE971S+W-H965T-#DN
M>&UL4$L! A0#%     @ LH!B5A5@@/NC"   #5$  !D              ("!
MRGP! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    " "R@&)6
MI_^8_C<"   H!0  &0              @(&DA0$ >&PO=V]R:W-H965T<R]S
M:&5E=#4Q+GAM;%!+ 0(4 Q0    ( +* 8E;/;G9ZL0(  )@(   9
M      " @1*( 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%
M  @ LH!B5CK:FS4O @  #P4  !D              ("!^HH! 'AL+W=O<FMS
M:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    " "R@&)6D1&DC5($   =&@
M&0              @(%@C0$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+
M 0(4 Q0    ( +* 8E:5\34=VP,  '40   9              " @>F1 0!X
M;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ LH!B5A)X[S1S
M$@  6T ! !D              ("!^Y4! 'AL+W=O<FMS:&5E=',O<VAE970U
M-BYX;6Q02P$"% ,4    " "R@&)639KAJ+8%  !B)   &0
M@(&EJ $ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( +*
M8E86[MT"*P0  %,4   9              " @9*N 0!X;"]W;W)K<VAE971S
M+W-H965T-3@N>&UL4$L! A0#%     @ LH!B5F[&%-LV"@  %'<  !D
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M=#8S+GAM;%!+ 0(4 Q0    ( +* 8E9H#"AS( ,  /$)   9
M  " @3[0 0!X;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @
MLH!B5K %IDR. @  1@<  !D              ("!E=,! 'AL+W=O<FMS:&5E
M=',O<VAE970V-2YX;6Q02P$"% ,4    " "R@&)62Z\(640#   )#   &0
M            @(%:U@$ >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4
M Q0    ( +* 8E:<  P"40D  /)[   9              " @=79 0!X;"]W
M;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @ LH!B5B7?30D>#
MJZ(  !D              ("!7>,! 'AL+W=O<FMS:&5E=',O<VAE970V."YX
M;6Q02P$"% ,4    " "R@&)6N=*$/3(%  !+&   &0              @(&R
M[P$ >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( +* 8E8&
M".RK'@,  '8)   9              " @1OU 0!X;"]W;W)K<VAE971S+W-H
M965T-S N>&UL4$L! A0#%     @ LH!B5O&4*4U" P  Y0H  !D
M     ("!</@! 'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +* 8E;'MH6:% ,  "@,   9              "
M@94) @!X;"]W;W)K<VAE971S+W-H965T-S8N>&UL4$L! A0#%     @ LH!B
M5JWQ7Z1: P  B@X  !D              ("!X P" 'AL+W=O<FMS:&5E=',O
M<VAE970W-RYX;6Q02P$"% ,4    " "R@&)6-\C*G 8#  #C"0  &0
M        @(%Q$ ( >&PO=V]R:W-H965T<R]S:&5E=#<X+GAM;%!+ 0(4 Q0
M   ( +* 8E8 ZOIGD@,  &D+   9              " @:X3 @!X;"]W;W)K
M<VAE971S+W-H965T-SDN>&UL4$L! A0#%     @ LH!B5N0>'+ * P  10L
M !D              ("!=Q<" 'AL+W=O<FMS:&5E=',O<VAE970X,"YX;6Q0
M2P$"% ,4    " "R@&)6>N3\_IX#   ;#0  &0              @(&X&@(
M>&PO=V]R:W-H965T<R]S:&5E=#@Q+GAM;%!+ 0(4 Q0    ( +* 8E8289&#
MD ,  '\,   9              " @8T> @!X;"]W;W)K<VAE971S+W-H965T
M.#(N>&UL4$L! A0#%     @ LH!B5L:+#D#= P  O!(  !D
M ("!5"(" 'AL+W=O<FMS:&5E=',O<VAE970X,RYX;6Q02P$"% ,4    " "R
M@&)6I5<-;S #  !#"@  &0              @(%H)@( >&PO=V]R:W-H965T
M<R]S:&5E=#@T+GAM;%!+ 0(4 Q0    ( +* 8E9$?Y$6G@,  !01   9
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M970X.2YX;6Q02P$"% ,4    " "R@&)6*1 9BR8$  "G&0  &0
M    @('</ ( >&PO=V]R:W-H965T<R]S:&5E=#DP+GAM;%!+ 0(4 Q0    (
M +* 8E;F*+=&;@,  + 6   -              "  3E! @!X;"]S='EL97,N
M>&UL4$L! A0#%     @ LH!B5I>*NQS     $P(   L              ( !
MTD0" %]R96QS+RYR96QS4$L! A0#%     @ LH!B5@5%!OS !@  ]3H   \
M             ( !NT4" 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( +*
M8E;FXJ30H (   4U   :              "  :A, @!X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( +* 8E;"@ QK.@(  &@S   3
M          "  8!/ @!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !B &(
*Y1H  .M1 @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>310</ContextCount>
  <ElementCount>440</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>105</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>15</UnitCount>
  <MyReports>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/BALANCESHEETS</Role>
      <ShortName>BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/BALANCESHEETSParenthetical</Role>
      <ShortName>BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/STATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS</Role>
      <ShortName>STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/OrganizationandBasisofPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Cash, Cash Equivalents and Short-Term Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestments</Role>
      <ShortName>Cash, Cash Equivalents and Short-Term Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Product Revenue, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/ProductRevenueNet</Role>
      <ShortName>Product Revenue, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Collaboration and Licensing Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CollaborationandLicensingAgreements</Role>
      <ShortName>Collaboration and Licensing Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Deferred Royalty Obligation Related To The Sale Of Future Royalties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyalties</Role>
      <ShortName>Deferred Royalty Obligation Related To The Sale Of Future Royalties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Borrowings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/Borrowings</Role>
      <ShortName>Borrowings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Derivative Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/DerivativeLiabilities</Role>
      <ShortName>Derivative Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Equity Incentive Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/EquityIncentivePlans</Role>
      <ShortName>Equity Incentive Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/Restructuring</Role>
      <ShortName>Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/AccruedExpensesandOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Geographic Information and Concentrations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/GeographicInformationandConcentrations</Role>
      <ShortName>Geographic Information and Concentrations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Cash, Cash Equivalents and Short-Term Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsTables</Role>
      <ShortName>Cash, Cash Equivalents and Short-Term Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestments</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/FairValueMeasurements</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/Inventory</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Product Revenue, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/ProductRevenueNetTables</Role>
      <ShortName>Product Revenue, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/ProductRevenueNet</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Collaboration and Licensing Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CollaborationandLicensingAgreementsTables</Role>
      <ShortName>Collaboration and Licensing Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/CollaborationandLicensingAgreements</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Borrowings (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/BorrowingsTables</Role>
      <ShortName>Borrowings (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/Borrowings</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Derivative Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/DerivativeLiabilitiesTables</Role>
      <ShortName>Derivative Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/DerivativeLiabilities</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/Leases</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Equity Incentive Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/EquityIncentivePlansTables</Role>
      <ShortName>Equity Incentive Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/EquityIncentivePlans</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/AccruedExpensesandOtherCurrentLiabilities</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/IncomeTaxes</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Geographic Information and Concentrations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/GeographicInformationandConcentrationsTables</Role>
      <ShortName>Geographic Information and Concentrations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/GeographicInformationandConcentrations</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/NetLossPerShare</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Organization and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails</Role>
      <ShortName>Organization and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/OrganizationandBasisofPresentation</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Summary of Significant Accounting Policies - Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesLiquidityDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Summary of Significant Accounting Policies - Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Cash, Cash Equivalents and Short-Term Investments - Securities Classified as Cash and Short-Term Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails</Role>
      <ShortName>Cash, Cash Equivalents and Short-Term Investments - Securities Classified as Cash and Short-Term Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Cash, Cash Equivalents and Short-Term Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsNarrativeDetails</Role>
      <ShortName>Cash, Cash Equivalents and Short-Term Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Measured on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Financial Assets and Liabilities Measured on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Inventory - Schedule (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/InventoryScheduleDetails</Role>
      <ShortName>Inventory - Schedule (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Inventory - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/InventoryNarrativeDetails</Role>
      <ShortName>Inventory - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Product Revenue, Net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails</Role>
      <ShortName>Product Revenue, Net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Product Revenue, Net - Gross-to-Net Sales Accruals (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails</Role>
      <ShortName>Product Revenue, Net - Gross-to-Net Sales Accruals (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Collaboration and Licensing Agreements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails</Role>
      <ShortName>Collaboration and Licensing Agreements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Collaboration and Licensing Agreements - Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails</Role>
      <ShortName>Collaboration and Licensing Agreements - Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Deferred Royalty Obligation Related To The Sale Of Future Royalties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails</Role>
      <ShortName>Deferred Royalty Obligation Related To The Sale Of Future Royalties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyalties</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Borrowings - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/BorrowingsNarrativeDetails</Role>
      <ShortName>Borrowings - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Borrowings - Future Payment Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/BorrowingsFuturePaymentObligationsDetails</Role>
      <ShortName>Borrowings - Future Payment Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Derivative Liabilities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/DerivativeLiabilitiesNarrativeDetails</Role>
      <ShortName>Derivative Liabilities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Derivative Liabilities - Changes in Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/DerivativeLiabilitiesChangesinFairValueDetails</Role>
      <ShortName>Derivative Liabilities - Changes in Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Leases - Additional Lease Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/LeasesAdditionalLeaseInformationDetails</Role>
      <ShortName>Leases - Additional Lease Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Leases - Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/LeasesLeaseCostsDetails</Role>
      <ShortName>Leases - Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Leases - Undiscounted Cash Payment Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails</Role>
      <ShortName>Leases - Undiscounted Cash Payment Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/StockholdersEquity</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - Equity Incentive Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails</Role>
      <ShortName>Equity Incentive Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - Equity Incentive Plans - Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails</Role>
      <ShortName>Equity Incentive Plans - Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - Equity Incentive Plans - Valuation Assumptions for Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/EquityIncentivePlansValuationAssumptionsforStockOptionsDetails</Role>
      <ShortName>Equity Incentive Plans - Valuation Assumptions for Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - Equity Incentive Plans - Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails</Role>
      <ShortName>Equity Incentive Plans - Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - Equity Incentive Plans - Employee Stock Purchase Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/EquityIncentivePlansEmployeeStockPurchasePlanDetails</Role>
      <ShortName>Equity Incentive Plans - Employee Stock Purchase Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0000074 - Disclosure - Equity Incentive Plans - Valuation Assumptions for ESPP (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/EquityIncentivePlansValuationAssumptionsforESPPDetails</Role>
      <ShortName>Equity Incentive Plans - Valuation Assumptions for ESPP (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>0000075 - Disclosure - Equity Incentive Plans - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails</Role>
      <ShortName>Equity Incentive Plans - Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>0000076 - Disclosure - Equity Incentive Plans - Unrecognized Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails</Role>
      <ShortName>Equity Incentive Plans - Unrecognized Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>0000077 - Disclosure - Restructuring (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/RestructuringDetails</Role>
      <ShortName>Restructuring (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/Restructuring</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>0000078 - Disclosure - Property and Equipment, Net - Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/PropertyandEquipmentNetBalancesDetails</Role>
      <ShortName>Property and Equipment, Net - Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>0000079 - Disclosure - Property and Equipment, Net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/PropertyandEquipmentNetNarrativeDetails</Role>
      <ShortName>Property and Equipment, Net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>0000080 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>0000081 - Disclosure - Income Taxes - Components of Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Components of Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>0000082 - Disclosure - Income Taxes - Reconciliation of Effective Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/IncomeTaxesReconciliationofEffectiveTaxRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Effective Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>0000083 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Components of Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>0000084 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>0000085 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>0000086 - Disclosure - Geographic Information and Concentrations - Revenue by Geographical Area (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/GeographicInformationandConcentrationsRevenuebyGeographicalAreaDetails</Role>
      <ShortName>Geographic Information and Concentrations - Revenue by Geographical Area (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>0000087 - Disclosure - Geographic Information and Concentrations - Concentration Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/GeographicInformationandConcentrationsConcentrationRiskDetails</Role>
      <ShortName>Geographic Information and Concentrations - Concentration Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>0000088 - Disclosure - Net Loss Per Share - Computation of Net Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails</Role>
      <ShortName>Net Loss Per Share - Computation of Net Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>0000089 - Disclosure - Net Loss Per Share - Anti-Dilutive Securities and Potential Common Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/NetLossPerShareAntiDilutiveSecuritiesandPotentialCommonSharesDetails</Role>
      <ShortName>Net Loss Per Share - Anti-Dilutive Securities and Potential Common Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>0000090 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/CommitmentsandContingencies</ParentRole>
      <Position>89</Position>
    </Report>
    <Report instance="ardx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>0000091 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/SubsequentEvents</ParentRole>
      <Position>90</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:PropertyPlantAndEquipmentUsefulLife -  ardx-20221231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="ardx-20221231.htm">ardx-20221231.htm</File>
    <File>ardelyx_psgxmsaamendment1.htm</File>
    <File>ardenwoodventurellc-leasea.htm</File>
    <File>ardx-20221231.xsd</File>
    <File>ardx-20221231_cal.xml</File>
    <File>ardx-20221231_def.xml</File>
    <File>ardx-20221231_lab.xml</File>
    <File>ardx-20221231_pre.xml</File>
    <File>ardx-20221231xex311.htm</File>
    <File>ardx-20221231xex312.htm</File>
    <File>ardx-20221231xex321.htm</File>
    <File>consentofindependentregist.htm</File>
    <File>kyowakirincoltdfkakyowahak.htm</File>
    <File>slr-ardelyxxsecondamendmen.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ardx-20221231_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="919">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>113
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ardx-20221231.htm": {
   "axisCustom": 2,
   "axisStandard": 34,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 919,
    "http://xbrl.sec.gov/dei/2022": 38
   },
   "contextCount": 310,
   "dts": {
    "calculationLink": {
     "local": [
      "ardx-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ardx-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ardx-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ardx-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ardx-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ardx-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 725,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 1,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 5
   },
   "keyCustom": 100,
   "keyStandard": 340,
   "memberCustom": 49,
   "memberStandard": 47,
   "nsprefix": "ardx",
   "nsuri": "http://www.ardelyx.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.ardelyx.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Cash, Cash Equivalents and Short-Term Investments",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestments",
     "shortName": "Cash, Cash Equivalents and Short-Term Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.ardelyx.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Inventory",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.ardelyx.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Product Revenue, Net",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.ardelyx.com/role/ProductRevenueNet",
     "shortName": "Product Revenue, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Collaboration and Licensing Agreements",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.ardelyx.com/role/CollaborationandLicensingAgreements",
     "shortName": "Collaboration and Licensing Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetRetirementObligationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Deferred Royalty Obligation Related To The Sale Of Future Royalties",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyalties",
     "shortName": "Deferred Royalty Obligation Related To The Sale Of Future Royalties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetRetirementObligationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Borrowings",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.ardelyx.com/role/Borrowings",
     "shortName": "Borrowings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Derivative Liabilities",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.ardelyx.com/role/DerivativeLiabilities",
     "shortName": "Derivative Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.ardelyx.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.ardelyx.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://www.ardelyx.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Equity Incentive Plans",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.ardelyx.com/role/EquityIncentivePlans",
     "shortName": "Equity Incentive Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Restructuring",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.ardelyx.com/role/Restructuring",
     "shortName": "Restructuring",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Property and Equipment, Net",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.ardelyx.com/role/PropertyandEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.ardelyx.com/role/AccruedExpensesandOtherCurrentLiabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.ardelyx.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ardx:GeographicInformationAndConcentrationsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Geographic Information and Concentrations",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://www.ardelyx.com/role/GeographicInformationandConcentrations",
     "shortName": "Geographic Information and Concentrations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ardx:GeographicInformationAndConcentrationsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Net Loss Per Share",
     "menuCat": "Notes",
     "order": "26",
     "role": "http://www.ardelyx.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "27",
     "role": "http://www.ardelyx.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "28",
     "role": "http://www.ardelyx.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "29",
     "role": "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i776a810ab6f5478f91b8fbb19a6855bb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.ardelyx.com/role/BALANCESHEETS",
     "shortName": "BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i776a810ab6f5478f91b8fbb19a6855bb_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Cash, Cash Equivalents and Short-Term Investments (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsTables",
     "shortName": "Cash, Cash Equivalents and Short-Term Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.ardelyx.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Inventory (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.ardelyx.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ardx:ScheduleOfGrossToNetSalesAccrualsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Product Revenue, Net (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.ardelyx.com/role/ProductRevenueNetTables",
     "shortName": "Product Revenue, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ardx:ScheduleOfGrossToNetSalesAccrualsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Collaboration and Licensing Agreements (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsTables",
     "shortName": "Collaboration and Licensing Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Borrowings (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.ardelyx.com/role/BorrowingsTables",
     "shortName": "Borrowings (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Derivative Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.ardelyx.com/role/DerivativeLiabilitiesTables",
     "shortName": "Derivative Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ardx:ScheduleOfAdditionalDetailsOfLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://www.ardelyx.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ardx:ScheduleOfAdditionalDetailsOfLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Equity Incentive Plans (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://www.ardelyx.com/role/EquityIncentivePlansTables",
     "shortName": "Equity Incentive Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Property and Equipment, Net (Tables)",
     "menuCat": "Tables",
     "order": "39",
     "role": "http://www.ardelyx.com/role/PropertyandEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i776a810ab6f5478f91b8fbb19a6855bb_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.ardelyx.com/role/BALANCESHEETSParenthetical",
     "shortName": "BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i776a810ab6f5478f91b8fbb19a6855bb_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "40",
     "role": "http://www.ardelyx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "41",
     "role": "http://www.ardelyx.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Geographic Information and Concentrations (Tables)",
     "menuCat": "Tables",
     "order": "42",
     "role": "http://www.ardelyx.com/role/GeographicInformationandConcentrationsTables",
     "shortName": "Geographic Information and Concentrations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Net Loss Per Share (Tables)",
     "menuCat": "Tables",
     "order": "43",
     "role": "http://www.ardelyx.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Organization and Basis of Presentation (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails",
     "shortName": "Organization and Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i776a810ab6f5478f91b8fbb19a6855bb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsAndCash",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Summary of Significant Accounting Policies - Liquidity (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesLiquidityDetails",
     "shortName": "Summary of Significant Accounting Policies - Liquidity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i776a810ab6f5478f91b8fbb19a6855bb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Summary of Significant Accounting Policies - Accounts Receivable (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails",
     "shortName": "Summary of Significant Accounting Policies - Accounts Receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "ieca82817eeaa4e6a9211772c02ceff0e_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "span",
       "div",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "span",
       "div",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i776a810ab6f5478f91b8fbb19a6855bb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Cash, Cash Equivalents and Short-Term Investments - Securities Classified as Cash and Short-Term Investments (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails",
     "shortName": "Cash, Cash Equivalents and Short-Term Investments - Securities Classified as Cash and Short-Term Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i776a810ab6f5478f91b8fbb19a6855bb_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "ardx:AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ardx:AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Cash, Cash Equivalents and Short-Term Investments - Narrative (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsNarrativeDetails",
     "shortName": "Cash, Cash Equivalents and Short-Term Investments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ardx:AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ardx:AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "shortName": "STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i691c998073704928ab9052cb14232a00_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Measured on a Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Financial Assets and Liabilities Measured on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i691c998073704928ab9052cb14232a00_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i776a810ab6f5478f91b8fbb19a6855bb_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.ardelyx.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i776a810ab6f5478f91b8fbb19a6855bb_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i776a810ab6f5478f91b8fbb19a6855bb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Inventory - Schedule (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.ardelyx.com/role/InventoryScheduleDetails",
     "shortName": "Inventory - Schedule (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i776a810ab6f5478f91b8fbb19a6855bb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i776a810ab6f5478f91b8fbb19a6855bb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ardx:PrepaidCommercialManufacturingCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Inventory - Narrative (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.ardelyx.com/role/InventoryNarrativeDetails",
     "shortName": "Inventory - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Product Revenue, Net - Narrative (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails",
     "shortName": "Product Revenue, Net - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i45f1941f9fe64cf991b951806544dcae_D20210101-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ardx:ContractWithCustomerProductSalesGrossToNetAccruals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ardx:ScheduleOfGrossToNetSalesAccrualsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i23bde0040cba4440804b10fdac242262_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ardx:ContractWithCustomerGrossToNetSalesAccruals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Product Revenue, Net - Gross-to-Net Sales Accruals (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails",
     "shortName": "Product Revenue, Net - Gross-to-Net Sales Accruals (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ardx:ScheduleOfGrossToNetSalesAccrualsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i23bde0040cba4440804b10fdac242262_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ardx:ContractWithCustomerGrossToNetSalesAccruals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Collaboration and Licensing Agreements - Narrative (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
     "shortName": "Collaboration and Licensing Agreements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "ia5096f6f9abe4dccb2dab386d07f22b0_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i23bde0040cba4440804b10fdac242262_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Collaboration and Licensing Agreements - Deferred Revenue (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails",
     "shortName": "Collaboration and Licensing Agreements - Deferred Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "ied48f951c2e54c4c9458741287f35022_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ardx:ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenueDuringThePeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfAdvanceRoyalty",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Deferred Royalty Obligation Related To The Sale Of Future Royalties (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails",
     "shortName": "Deferred Royalty Obligation Related To The Sale Of Future Royalties (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromRoyaltiesReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i776a810ab6f5478f91b8fbb19a6855bb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Borrowings - Narrative (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.ardelyx.com/role/BorrowingsNarrativeDetails",
     "shortName": "Borrowings - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i4584120047b3460da4d6b5a0f2eb0808_D20220223-20220223",
      "decimals": null,
      "lang": "en-US",
      "name": "ardx:LoanAgreementExitFeeTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i473a2780d03c4c7f8d5e27ab35bdee43_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.ardelyx.com/role/STATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i473a2780d03c4c7f8d5e27ab35bdee43_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i776a810ab6f5478f91b8fbb19a6855bb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Borrowings - Future Payment Obligations (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.ardelyx.com/role/BorrowingsFuturePaymentObligationsDetails",
     "shortName": "Borrowings - Future Payment Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i776a810ab6f5478f91b8fbb19a6855bb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i1b61195b8cbb43b4945e83216c7f171c_I20180531",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilityNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Derivative Liabilities - Narrative (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.ardelyx.com/role/DerivativeLiabilitiesNarrativeDetails",
     "shortName": "Derivative Liabilities - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i1b61195b8cbb43b4945e83216c7f171c_I20180531",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilityNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i23902f57514345efaefc7f6ed372683f_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Derivative Liabilities - Changes in Fair Value (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.ardelyx.com/role/DerivativeLiabilitiesChangesinFairValueDetails",
     "shortName": "Derivative Liabilities - Changes in Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i0080f34bc4774f159a2fbc226bec7e75_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ardx:NumberOfOperatingLeaseArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "lease_agreement",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Leases - Narrative (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.ardelyx.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ardx:NumberOfOperatingLeaseArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "lease_agreement",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ardx:ScheduleOfAdditionalDetailsOfLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i776a810ab6f5478f91b8fbb19a6855bb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Leases - Additional Lease Information (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.ardelyx.com/role/LeasesAdditionalLeaseInformationDetails",
     "shortName": "Leases - Additional Lease Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ardx:ScheduleOfAdditionalDetailsOfLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i776a810ab6f5478f91b8fbb19a6855bb_I20221231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Leases - Lease Costs (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.ardelyx.com/role/LeasesLeaseCostsDetails",
     "shortName": "Leases - Lease Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i776a810ab6f5478f91b8fbb19a6855bb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Leases - Undiscounted Cash Payment Obligations (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails",
     "shortName": "Leases - Undiscounted Cash Payment Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i776a810ab6f5478f91b8fbb19a6855bb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - Stockholders' Equity (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.ardelyx.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "ib4aee40b13b3480c9ac040be86a38b5d_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ardx:StockIssuanceCostCommissionPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i776a810ab6f5478f91b8fbb19a6855bb_I20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - Equity Incentive Plans - Narrative (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails",
     "shortName": "Equity Incentive Plans - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i23bde0040cba4440804b10fdac242262_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - Equity Incentive Plans - Stock Options (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails",
     "shortName": "Equity Incentive Plans - Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i23bde0040cba4440804b10fdac242262_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS",
     "shortName": "STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i4d035ef039b9449f9a833a4878f300ef_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - Equity Incentive Plans - Valuation Assumptions for Stock Options (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.ardelyx.com/role/EquityIncentivePlansValuationAssumptionsforStockOptionsDetails",
     "shortName": "Equity Incentive Plans - Valuation Assumptions for Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i4d035ef039b9449f9a833a4878f300ef_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "iad26c62e1f7040819c46ba8aaecbfdf7_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - Equity Incentive Plans - Restricted Stock Units (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails",
     "shortName": "Equity Incentive Plans - Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "iad26c62e1f7040819c46ba8aaecbfdf7_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i180188a490a8459b9367c5d5573a5e16_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - Equity Incentive Plans - Employee Stock Purchase Plan (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.ardelyx.com/role/EquityIncentivePlansEmployeeStockPurchasePlanDetails",
     "shortName": "Equity Incentive Plans - Employee Stock Purchase Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i180188a490a8459b9367c5d5573a5e16_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i248a37dc8c184f47ac596a1ecc3f232f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000074 - Disclosure - Equity Incentive Plans - Valuation Assumptions for ESPP (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.ardelyx.com/role/EquityIncentivePlansValuationAssumptionsforESPPDetails",
     "shortName": "Equity Incentive Plans - Valuation Assumptions for ESPP (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i248a37dc8c184f47ac596a1ecc3f232f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000075 - Disclosure - Equity Incentive Plans - Stock-Based Compensation (Details)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails",
     "shortName": "Equity Incentive Plans - Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "ief16b3cbe3934dc98b9bc68d2856ca35_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000076 - Disclosure - Equity Incentive Plans - Unrecognized Stock-Based Compensation (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails",
     "shortName": "Equity Incentive Plans - Unrecognized Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "ief16b3cbe3934dc98b9bc68d2856ca35_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i45f1941f9fe64cf991b951806544dcae_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000077 - Disclosure - Restructuring (Details)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://www.ardelyx.com/role/RestructuringDetails",
     "shortName": "Restructuring (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i45f1941f9fe64cf991b951806544dcae_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i776a810ab6f5478f91b8fbb19a6855bb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000078 - Disclosure - Property and Equipment, Net - Balances (Details)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://www.ardelyx.com/role/PropertyandEquipmentNetBalancesDetails",
     "shortName": "Property and Equipment, Net - Balances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i776a810ab6f5478f91b8fbb19a6855bb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000079 - Disclosure - Property and Equipment, Net - Narrative (Details)",
     "menuCat": "Details",
     "order": "78",
     "role": "http://www.ardelyx.com/role/PropertyandEquipmentNetNarrativeDetails",
     "shortName": "Property and Equipment, Net - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i776a810ab6f5478f91b8fbb19a6855bb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ardx:AccruedPaymentsDueToRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000080 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)",
     "menuCat": "Details",
     "order": "79",
     "role": "http://www.ardelyx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
     "shortName": "Accrued Expenses and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i776a810ab6f5478f91b8fbb19a6855bb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ardx:AccruedPaymentsDueToRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Organization and Basis of Presentation",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.ardelyx.com/role/OrganizationandBasisofPresentation",
     "shortName": "Organization and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000081 - Disclosure - Income Taxes - Components of Provision for Income Taxes (Details)",
     "menuCat": "Details",
     "order": "80",
     "role": "http://www.ardelyx.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails",
     "shortName": "Income Taxes - Components of Provision for Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000082 - Disclosure - Income Taxes - Reconciliation of Effective Tax Rate (Details)",
     "menuCat": "Details",
     "order": "81",
     "role": "http://www.ardelyx.com/role/IncomeTaxesReconciliationofEffectiveTaxRateDetails",
     "shortName": "Income Taxes - Reconciliation of Effective Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i776a810ab6f5478f91b8fbb19a6855bb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ardx:DeferredTaxAssetsAmortizationAndDepreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000083 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Details)",
     "menuCat": "Details",
     "order": "82",
     "role": "http://www.ardelyx.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails",
     "shortName": "Income Taxes - Components of Deferred Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i776a810ab6f5478f91b8fbb19a6855bb_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ardx:DeferredTaxAssetsAmortizationAndDepreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000084 - Disclosure - Income Taxes - Narrative (Details)",
     "menuCat": "Details",
     "order": "83",
     "role": "http://www.ardelyx.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i23bde0040cba4440804b10fdac242262_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000085 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)",
     "menuCat": "Details",
     "order": "84",
     "role": "http://www.ardelyx.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i3c73d82cd653451cb3c69d920ab3d8aa_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000086 - Disclosure - Geographic Information and Concentrations - Revenue by Geographical Area (Details)",
     "menuCat": "Details",
     "order": "85",
     "role": "http://www.ardelyx.com/role/GeographicInformationandConcentrationsRevenuebyGeographicalAreaDetails",
     "shortName": "Geographic Information and Concentrations - Revenue by Geographical Area (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "if59e9efdbe2d42718f4a91fe0b12275c_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "id19674491cd54b0c969b0e9bccb5521e_D20220101-20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000087 - Disclosure - Geographic Information and Concentrations - Concentration Risk (Details)",
     "menuCat": "Details",
     "order": "86",
     "role": "http://www.ardelyx.com/role/GeographicInformationandConcentrationsConcentrationRiskDetails",
     "shortName": "Geographic Information and Concentrations - Concentration Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "id19674491cd54b0c969b0e9bccb5521e_D20220101-20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000088 - Disclosure - Net Loss Per Share - Computation of Net Loss Per Common Share (Details)",
     "menuCat": "Details",
     "order": "87",
     "role": "http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails",
     "shortName": "Net Loss Per Share - Computation of Net Loss Per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000089 - Disclosure - Net Loss Per Share - Anti-Dilutive Securities and Potential Common Shares (Details)",
     "menuCat": "Details",
     "order": "88",
     "role": "http://www.ardelyx.com/role/NetLossPerShareAntiDilutiveSecuritiesandPotentialCommonSharesDetails",
     "shortName": "Net Loss Per Share - Anti-Dilutive Securities and Potential Common Shares (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i776a810ab6f5478f91b8fbb19a6855bb_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000090 - Disclosure - Commitments and Contingencies (Details)",
     "menuCat": "Details",
     "order": "89",
     "role": "http://www.ardelyx.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i776a810ab6f5478f91b8fbb19a6855bb_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.ardelyx.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "i6901aa5953694d66bf75924358ae9eb9_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "ic957e7b2e6404684ab3ce4588e0747ed_D20230209-20230209",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentBasisSpreadOnVariableRate1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000091 - Disclosure - Subsequent Events (Details)",
     "menuCat": "Details",
     "order": "90",
     "role": "http://www.ardelyx.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20221231.htm",
      "contextRef": "ic957e7b2e6404684ab3ce4588e0747ed_D20230209-20230209",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentBasisSpreadOnVariableRate1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 105,
   "tag": {
    "ardx_AccountsReceivableCollaboratorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Collaborator",
        "label": "Accounts Receivable, Collaborator [Member]",
        "terseLabel": "Collaborators"
       }
      }
     },
     "localname": "AccountsReceivableCollaboratorMember",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_AccountsReceivableCommercialCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Commercial Customer",
        "label": "Accounts Receivable, Commercial Customer [Member]",
        "terseLabel": "Commercial customers"
       }
      }
     },
     "localname": "AccountsReceivableCommercialCustomerMember",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_AccruedClinicalExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued clinical expenses.",
        "label": "Accrued Clinical Expenses",
        "terseLabel": "Accrued clinical expenses"
       }
      }
     },
     "localname": "AccruedClinicalExpenses",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_AccruedContractManufacturingCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued contract manufacturing costs.",
        "label": "Accrued Contract Manufacturing Costs",
        "terseLabel": "Accrued contract manufacturing expenses"
       }
      }
     },
     "localname": "AccruedContractManufacturingCosts",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_AccruedGrossToNetRevenueLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Gross To Net Revenue Liabilities",
        "label": "Accrued Gross To Net Revenue Liabilities",
        "terseLabel": "Accrued gross to net revenue liabilities"
       }
      }
     },
     "localname": "AccruedGrossToNetRevenueLiabilities",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_AccruedNonClinicalResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Non-Clinical Research And Development Expenses",
        "label": "Accrued Non-Clinical Research And Development Expenses",
        "terseLabel": "Accrued non-clinical research and development expenses"
       }
      }
     },
     "localname": "AccruedNonClinicalResearchAndDevelopmentExpenses",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_AccruedPaymentsDueToRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Payments Due To Related Party",
        "label": "Accrued Payments Due To Related Party",
        "terseLabel": "Accrued payments due to AstraZeneca"
       }
      }
     },
     "localname": "AccruedPaymentsDueToRelatedParty",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_AccruedProfessionalAndConsultantFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued professional and consultant fees current.",
        "label": "Accrued Professional And Consultant Fees Current",
        "terseLabel": "Accrued professional and consulting services"
       }
      }
     },
     "localname": "AccruedProfessionalAndConsultantFeesCurrent",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expenses policy.",
        "label": "Accrued Research and Development Expenses Policy [Policy Text Block]",
        "terseLabel": "Accrued Research and Development Expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpensesPolicyPolicyTextBlock",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ardx_AccruedSalesAndMarketingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued sales and marketing expenses.",
        "label": "Accrued Sales And Marketing Expenses",
        "terseLabel": "Accrued sales and marketing expenses"
       }
      }
     },
     "localname": "AccruedSalesAndMarketingExpenses",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_AmerisourceBergenDrugCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AmerisourceBergen Drug Corporation",
        "label": "AmerisourceBergen Drug Corporation [Member]",
        "terseLabel": "AmerisourceBergen Drug Corporation"
       }
      }
     },
     "localname": "AmerisourceBergenDrugCorporationMember",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/GeographicInformationandConcentrationsConcentrationRiskDetails",
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_AstraZenecaTerminationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AstraZeneca Termination Agreement",
        "label": "AstraZeneca Termination Agreement [Member]",
        "terseLabel": "AZ Termination Agreement"
       }
      }
     },
     "localname": "AstraZenecaTerminationAgreementMember",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_AstrazenecaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to AstraZeneca.",
        "label": "Astrazeneca [Member]",
        "terseLabel": "AstraZeneca"
       }
      }
     },
     "localname": "AstrazenecaMember",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.ardelyx.com/20221231",
     "xbrltype": "stringItemType"
    },
    "ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available-For-Sale Securities, Debt Securities, Current, Contractual Maturities, Maximum",
        "label": "Available-For-Sale Securities, Debt Securities, Current, Contractual Maturities, Maximum",
        "terseLabel": "Short-term securities, contractual maturities, maximum"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ardx_CardinalHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cardinal Health",
        "label": "Cardinal Health [Member]",
        "terseLabel": "Cardinal Health"
       }
      }
     },
     "localname": "CardinalHealthMember",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "ardx_InvestmentsAndCashAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, cash equivalents and investments gross unrealized gains.",
        "label": "Cash Cash Equivalents And Investments Gross Unrealized Gains",
        "terseLabel": "Total cash equivalents and investments, Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashCashEquivalentsAndInvestmentsGrossUnrealizedGains",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "ardx_InvestmentsAndCashAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, cash equivalents and investments gross unrealized losses.",
        "label": "Cash Cash Equivalents And Investments Gross Unrealized Losses",
        "negatedTerseLabel": "Total cash equivalents and investments, Gross Unrealized Losses"
       }
      }
     },
     "localname": "CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Contract With Customer Liability, Current, Rollforward",
        "label": "Change In Contract With Customer Liability, Current, Rollforward [Roll Forward]",
        "terseLabel": "Deferred revenue - current"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Contract With Customer Liability, Noncurrent, Rollforward",
        "label": "Change In Contract With Customer Liability, Noncurrent, Rollforward [Roll Forward]",
        "terseLabel": "Deferred revenue - non-current"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ardx_CollaborationAndLicensingAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "",
        "label": "Collaboration and Licensing Agreements [Abstract]",
        "terseLabel": "Collaboration and Licensing Agreements"
       }
      }
     },
     "localname": "CollaborationAndLicensingAgreementsAbstract",
     "nsuri": "http://www.ardelyx.com/20221231",
     "xbrltype": "stringItemType"
    },
    "ardx_CollaborationAndLicensingAgreementsNumberOfAmendments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration And Licensing Agreements, Number Of Amendments",
        "label": "Collaboration And Licensing Agreements, Number Of Amendments",
        "terseLabel": "Number of amendments"
       }
      }
     },
     "localname": "CollaborationAndLicensingAgreementsNumberOfAmendments",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration And Licensing Agreements, Upfront License Fees",
        "label": "Collaboration And Licensing Agreements, Upfront License Fees",
        "terseLabel": "Upfront license fees"
       }
      }
     },
     "localname": "CollaborationAndLicensingAgreementsUpfrontLicenseFees",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration And Licensing Agreements, Upfront License Fees, First Installment",
        "label": "Collaboration And Licensing Agreements, Upfront License Fees, First Installment",
        "terseLabel": "First installment of upfront license fees"
       }
      }
     },
     "localname": "CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration And Licensing Agreements, Upfront License Fees, Second Installment",
        "label": "Collaboration And Licensing Agreements, Upfront License Fees, Second Installment",
        "terseLabel": "Second installment of upfront license fees"
       }
      }
     },
     "localname": "CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CollaborationPartnershipConcentrationRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Partnership Concentration Risk",
        "label": "Collaboration Partnership Concentration Risk [Member]",
        "terseLabel": "Collaboration partnership concentration risk"
       }
      }
     },
     "localname": "CollaborationPartnershipConcentrationRiskMember",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/GeographicInformationandConcentrationsConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate",
        "label": "Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate",
        "terseLabel": "Fee receivable for reduction in royalty rate"
       }
      }
     },
     "localname": "CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate, Number Of Payment Tranches",
        "label": "Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate, Number Of Payment Tranches",
        "terseLabel": "Number of payment tranches for fee receivable for reduction in royalty rate"
       }
      }
     },
     "localname": "CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ardx_CollaborativeArrangementPotentialCommercializationMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Potential Commercialization Milestones",
        "label": "Collaborative Arrangement, Potential Commercialization Milestones",
        "terseLabel": "Potential commercialization milestones"
       }
      }
     },
     "localname": "CollaborativeArrangementPotentialCommercializationMilestones",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of future development and commercialization milestone under collaborative arrangements.",
        "label": "Collaborative Arrangement, Potential Development And Commercialization Milestones",
        "terseLabel": "Potential development and commercialization milestones"
       }
      }
     },
     "localname": "CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CollaborativeArrangementPotentialDevelopmentMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Potential Development Milestones",
        "label": "Collaborative Arrangement, Potential Development Milestones",
        "terseLabel": "Potential development milestones"
       }
      }
     },
     "localname": "CollaborativeArrangementPotentialDevelopmentMilestones",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Potential Payment Per Termination Agreement, Maximum",
        "label": "Collaborative Arrangement, Potential Payment Per Termination Agreement, Maximum",
        "terseLabel": "Maximum potential payment per agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CollaborativeDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Development [Member]",
        "label": "Collaborative Development [Member]",
        "terseLabel": "Collaborative development revenue"
       }
      }
     },
     "localname": "CollaborativeDevelopmentMember",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_CommonStockSubjectToIssuedInducementGrantsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Subject To Issued Inducement Grants, Shares",
        "label": "Common Stock Subject To Issued Inducement Grants, Shares",
        "terseLabel": "Share of common stock subject to issued inducement grants"
       }
      }
     },
     "localname": "CommonStockSubjectToIssuedInducementGrantsShares",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ardx_ContractWithCustomerCopayAndReturnsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Copay and Returns",
        "label": "Contract With Customer, Copay And Returns [Member]",
        "terseLabel": "Copay and Returns"
       }
      }
     },
     "localname": "ContractWithCustomerCopayAndReturnsMember",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_ContractWithCustomerDiscountsAndChargebacksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Discounts And Chargebacks",
        "label": "Contract With Customer, Discounts And Chargebacks [Member]",
        "terseLabel": "Discounts and Chargebacks"
       }
      }
     },
     "localname": "ContractWithCustomerDiscountsAndChargebacksMember",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Gross To Credits Or Deductions Issued",
        "label": "Contract With Customer, Gross To Credits Or Deductions Issued",
        "terseLabel": "Credits/deductions issued"
       }
      }
     },
     "localname": "ContractWithCustomerGrossToCreditsOrDeductionsIssued",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Gross To Net Sales, Accrual Activity During Current Period",
        "label": "Contract With Customer, Gross To Net Sales, Accrual Activity During Current Period",
        "terseLabel": "Activity related to 2022 sales"
       }
      }
     },
     "localname": "ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Gross To Net Sales Accrual",
        "label": "Contract With Customer, Gross To Net Sales Accrual [Roll Forward]",
        "terseLabel": "Gross-to-net sales accruals and reserves"
       }
      }
     },
     "localname": "ContractWithCustomerGrossToNetSalesAccrualRollForward",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ardx_ContractWithCustomerGrossToNetSalesAccruals": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Gross To Net Sales Accruals",
        "label": "Contract With Customer, Gross To Net Sales Accruals",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "ContractWithCustomerGrossToNetSalesAccruals",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Amortization, Effective Interest Rate, Percent",
        "label": "Contract With Customer, Liability, Amortization, Effective Interest Rate, Percent",
        "terseLabel": "Amortization, effective interest rate, percent"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Decrease In Revenue, To Be Recognized In Next Twelve Months",
        "label": "Contract With Customer, Liability, Decrease In Revenue, To Be Recognized In Next Twelve Months",
        "negatedTerseLabel": "Decreases due to amounts reclassified as current, to be recognized in the next twelve months"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Increase Due To Unbilled Prepayments Recorded",
        "label": "Contract With Customer, Liability, Increase Due To Unbilled Prepayments Recorded",
        "terseLabel": "Increase due to unbilled prepayments recorded during the period"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ContractWithCustomerLiabilityIncreaseForCashReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Increase For Cash Received",
        "label": "Contract With Customer, Liability, Increase For Cash Received",
        "terseLabel": "Increases due to cash received during the period"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityIncreaseForCashReceived",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenueDuringThePeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Increases Due To Cash Received, Excluding Amounts Recognized As Revenue During The Period",
        "label": "Contract With Customer, Liability, Increases Due To Cash Received, Excluding Amounts Recognized As Revenue During The Period",
        "terseLabel": "Increases due to cash received, excluding amounts recognized as revenue during the period"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenueDuringThePeriod",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ContractWithCustomerLiabilityIncreasesToAmountsInvoicedButCashNotReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Increases To Amounts Invoiced, But Cash Not Received",
        "label": "Contract With Customer, Liability, Increases To Amounts Invoiced, But Cash Not Received",
        "terseLabel": "Increases to amounts invoiced, for which cash has not yet been received"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityIncreasesToAmountsInvoicedButCashNotReceived",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Revenue Invoiced But Cash Not Received",
        "label": "Contract With Customer, Liability, Revenue Invoiced But Cash Not Received",
        "terseLabel": "Increases to amounts invoiced, for which cash has not yet been received"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received.",
        "label": "Contract with Customer Liability Revenue Recognized Cash Received",
        "negatedTerseLabel": "Decreases due to revenue recognized in the period for which cash has been received"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognizedCashReceived",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Revenue To Be Recognized In Next Twelve Months",
        "label": "Contract With Customer, Liability, Revenue To Be Recognized In Next Twelve Months",
        "terseLabel": "Increases due to amounts reclassified from non-current, to be recognized in the next twelve months"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ContractWithCustomerLiabilityTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Transaction Costs",
        "label": "Contract With Customer, Liability, Transaction Costs",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityTransactionCosts",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ContractWithCustomerProductSalesGrossToNetAccruals": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer Product Sales Gross To Net Accruals",
        "label": "Contract With Customer Product Sales Gross To Net Accruals",
        "terseLabel": "Contract with customer product sales gross to net accruals"
       }
      }
     },
     "localname": "ContractWithCustomerProductSalesGrossToNetAccruals",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ContractWithCustomerRebatesWholesalerAndGPOFeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Rebates, Wholesaler And GPO Fees",
        "label": "Contract With Customer, Rebates, Wholesaler And GPO Fees [Member]",
        "terseLabel": "Rebates, Wholesaler and GPO Fees"
       }
      }
     },
     "localname": "ContractWithCustomerRebatesWholesalerAndGPOFeesMember",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_CorporateBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Bonds",
        "label": "Corporate Bonds [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondsMember",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_CostOfRevenueAggregateAmountRecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of revenue, aggregate amount recognized.",
        "label": "Cost Of Revenue, Aggregate Amount Recognized",
        "terseLabel": "Aggregate cost of revenue recognized"
       }
      }
     },
     "localname": "CostOfRevenueAggregateAmountRecognized",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_DebtInstrumentClosingFeeAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Closing Fee Amount",
        "label": "Debt Instrument, Closing Fee Amount",
        "terseLabel": "Closing fee"
       }
      }
     },
     "localname": "DebtInstrumentClosingFeeAmount",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Fee Due Upon Maturity, Acceleration, Prepayment, Termination, Percentage",
        "label": "Debt Instrument, Fee Due Upon Maturity, Acceleration, Prepayment, Termination, Percentage",
        "terseLabel": "Final fee due upon maturity, acceleration, prepayment, or termination (percent)"
       }
      }
     },
     "localname": "DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_DebtInstrumentInterestPaymentExtensionTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of interest payment of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Interest Payment Extension Term",
        "terseLabel": "Interest-only payment extension term (in months)"
       }
      }
     },
     "localname": "DebtInstrumentInterestPaymentExtensionTerm",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ardx_DebtInstrumentInterestRateOnDefaultPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of additional default interest rate on the event of default.",
        "label": "Debt Instrument, Interest Rate On Default, Percentage",
        "terseLabel": "Additional default interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateOnDefaultPercentage",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_DebtInstrumentPrepaymentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of fee payable on prepayment of debt.",
        "label": "Debt Instrument, Prepayment Fee, Percentage",
        "terseLabel": "Prepayment premium (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentFeePercentage",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_DebtInstrumentVariableRateBaseOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Variable Rate, Base Option",
        "label": "Debt Instrument, Variable Rate, Base Option",
        "terseLabel": "Addition to floating per annum rate (percent)"
       }
      }
     },
     "localname": "DebtInstrumentVariableRateBaseOption",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails",
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_DebtInstrumentVariableRatePlusOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Variable Rate, Plus Option",
        "label": "Debt Instrument, Variable Rate, Plus Option",
        "terseLabel": "Addition plus to floating per annum rate (percent)"
       }
      }
     },
     "localname": "DebtInstrumentVariableRatePlusOption",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails",
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_DeferredRoyaltyObligationNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/BALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Royalty Obligation, Noncurrent",
        "label": "Deferred Royalty Obligation, Noncurrent",
        "terseLabel": "Deferred royalty obligation related to the sale of future royalties"
       }
      }
     },
     "localname": "DeferredRoyaltyObligationNoncurrent",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/BALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_DeferredTaxAssetsAmortizationAndDepreciation": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from amortization and depreciation.",
        "label": "Deferred Tax Assets, Amortization and Depreciation",
        "terseLabel": "Amortization and depreciation"
       }
      }
     },
     "localname": "DeferredTaxAssetsAmortizationAndDepreciation",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_DeferredTaxLiabilitiesRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from right of use asset.",
        "label": "Deferred Tax Liabilities, Right Of Use Asset",
        "negatedLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_DerivativeIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the non-cash issuance of derivative in connection with issuance of loan payable.",
        "label": "Derivative Issued",
        "terseLabel": "Issuance of derivative in connection with issuance of loan payable"
       }
      }
     },
     "localname": "DerivativeIssued",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_DerivativeLiabilityForExitFees": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of derivative liability for exit fee.",
        "label": "Derivative Liability for Exit Fees",
        "terseLabel": "Derivative liability for exit fees"
       }
      }
     },
     "localname": "DerivativeLiabilityForExitFees",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitExecutiveCompensationDisallowedIRCSec162mPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/IncomeTaxesReconciliationofEffectiveTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Executive Compensation Disallowed IRC Sec 162m, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Executive Compensation Disallowed IRC Sec 162m, Percent",
        "terseLabel": "Executive compensation disallowed under IRC Sec 162(m)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitExecutiveCompensationDisallowedIRCSec162mPercent",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan [Member]",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "ESPP",
        "verboseLabel": "ESPP shares issuable"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansEmployeeStockPurchasePlanDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansValuationAssumptionsforESPPDetails",
      "http://www.ardelyx.com/role/NetLossPerShareAntiDilutiveSecuritiesandPotentialCommonSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_EmployeeStockPurchasePlanSharesAvailableRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan, Shares Available",
        "label": "Employee Stock Purchase Plan, Shares Available [Roll Forward]",
        "terseLabel": "Shares\u00a0Available for\u00a0Grant"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanSharesAvailableRollForward",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ardx_EmployeeStockPurchasePlanSharesPurchasedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan, Shares Purchased",
        "label": "Employee Stock Purchase Plan, Shares Purchased [Roll Forward]",
        "terseLabel": "Number\u00a0of\u00a0Shares Purchased"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanSharesPurchasedRollForward",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ardx_EquitySalesAgreementProceedsFromSharesIssuedSinceInception": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Sales Agreement, Proceeds From Shares Issued Since Inception",
        "label": "Equity Sales Agreement, Proceeds From Shares Issued Since Inception",
        "terseLabel": "Total of gross proceeds"
       }
      }
     },
     "localname": "EquitySalesAgreementProceedsFromSharesIssuedSinceInception",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_EquitySalesAgreementSharesIssuedSinceInception": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Sales Agreement, Shares Issued Since Inception",
        "label": "Equity Sales Agreement, Shares Issued Since Inception",
        "terseLabel": "Total of shares sold"
       }
      }
     },
     "localname": "EquitySalesAgreementSharesIssuedSinceInception",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ardx_ExitFee2018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exit Fee 2018",
        "label": "Exit Fee 2018 [Member]",
        "terseLabel": "2018 Exit Fee"
       }
      }
     },
     "localname": "ExitFee2018Member",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilitiesChangesinFairValueDetails",
      "http://www.ardelyx.com/role/DerivativeLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_ExitFee2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exit Fee 2022",
        "label": "Exit Fee 2022 [Member]",
        "terseLabel": "2022 Exit Fee"
       }
      }
     },
     "localname": "ExitFee2022Member",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails",
      "http://www.ardelyx.com/role/DerivativeLiabilitiesChangesinFairValueDetails",
      "http://www.ardelyx.com/role/DerivativeLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_ExitFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exit Fee, Percentage",
        "label": "Exit Fee, Percentage",
        "terseLabel": "Exit fee (percent)"
       }
      }
     },
     "localname": "ExitFeePercentage",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails",
      "http://www.ardelyx.com/role/DerivativeLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_FacilityFremontCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility, Fremont California",
        "label": "Facility, Fremont California [Member]",
        "terseLabel": "Fremont facility"
       }
      }
     },
     "localname": "FacilityFremontCaliforniaMember",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_FacilityMilwaukeeWisconsinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility, Milwaukee Wisconsin",
        "label": "Facility, Milwaukee Wisconsin [Member]",
        "terseLabel": "Milwaukee facility"
       }
      }
     },
     "localname": "FacilityMilwaukeeWisconsinMember",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_FacilityOneWalthamMassachusettsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility One, Waltham Massachusetts",
        "label": "Facility One, Waltham Massachusetts [Member]",
        "terseLabel": "Original Waltham facility"
       }
      }
     },
     "localname": "FacilityOneWalthamMassachusettsMember",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_FacilityTwoWalthamMassachusettsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility Two, Waltham Massachusetts",
        "label": "Facility Two, Waltham Massachusetts [Member]",
        "terseLabel": "Waltham facility"
       }
      }
     },
     "localname": "FacilityTwoWalthamMassachusettsMember",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Sensitivity Analysis, Change In Probability Of Occurrence, Percentage",
        "label": "Fair Value Sensitivity Analysis, Change In Probability Of Occurrence, Percentage",
        "terseLabel": "Fair value analysis, percentage change in probability of occurrence"
       }
      }
     },
     "localname": "FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Sensitivity Analysis, Ten Percent Change In Probability Of Occurrence, Effect On Valuation",
        "label": "Fair Value Sensitivity Analysis, Ten Percent Change In Probability Of Occurrence, Effect On Valuation",
        "terseLabel": "Fair value analysis, effect on fair value based on 10% change in probability of occurrence"
       }
      }
     },
     "localname": "FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_GeographicInformationAndConcentrationsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure on geographic information and concentrations.",
        "label": "Geographic Information And Concentrations [Text Block]",
        "terseLabel": "Geographic Information and Concentrations"
       }
      }
     },
     "localname": "GeographicInformationAndConcentrationsTextBlock",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/GeographicInformationandConcentrations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ardx_GoVersusRaabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Go Versus Raab",
        "label": "Go Versus Raab [Member]",
        "terseLabel": "Go v. Raab"
       }
      }
     },
     "localname": "GoVersusRaabMember",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_GrossToNetSalesAccrualAndReserveClassificationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross To Net Sales Accrual And Reserve Classification",
        "label": "Gross To Net Sales Accrual And Reserve Classification [Axis]",
        "terseLabel": "Gross To Net Sales Accrual And Reserve Classification [Axis]"
       }
      }
     },
     "localname": "GrossToNetSalesAccrualAndReserveClassificationAxis",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ardx_GrossToNetSalesAccrualAndReserveClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross To Net Sales Accrual And Reserve Classification [Domain]",
        "label": "Gross To Net Sales Accrual And Reserve Classification [Domain]",
        "terseLabel": "Gross To Net Sales Accrual And Reserve Classification [Domain]"
       }
      }
     },
     "localname": "GrossToNetSalesAccrualAndReserveClassificationDomain",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_HealthCareRoyaltyPartnersIVLPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HealthCare Royalty Partners IV, L.P",
        "label": "HealthCare Royalty Partners IV, L.P [Member]",
        "terseLabel": "Healthcare royalty partners IV, L.P"
       }
      }
     },
     "localname": "HealthCareRoyaltyPartnersIVLPMember",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_IncomeTaxDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Disclosure [Line Items]",
        "label": "Income Tax Disclosure [Line Items]",
        "terseLabel": "Income Tax Disclosure [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureLineItems",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ardx_IncomeTaxDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Disclosure [Table]",
        "label": "Income Tax Disclosure [Table]",
        "terseLabel": "Income Tax Disclosure [Table]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTable",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Prepaid Commercial Manufacturing Expense",
        "label": "Increase (Decrease) In Prepaid Commercial Manufacturing Expense",
        "negatedLabel": "Prepaid commercial manufacturing"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidCommercialManufacturingExpense",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_IncreaseDecreaseInUnbilledRevenue": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase or decrease in unbilled revenue.",
        "label": "Increase (Decrease) In Unbilled Revenue",
        "negatedLabel": "Unbilled revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInUnbilledRevenue",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponExerciseOfStockOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase In Shares Reserved For Issuance, Maximum Shares To Be Issued Upon Exercise Of Stock Options",
        "label": "Increase In Shares Reserved For Issuance, Maximum Shares To Be Issued Upon Exercise Of Stock Options",
        "terseLabel": "Maximum shares to be issued upon exercise of incentive stock options"
       }
      }
     },
     "localname": "IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponExerciseOfStockOptions",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ardx_IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponInclusionOfForfeitedOrUnexercisedOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase In Shares Reserved For Issuance, Maximum Shares To Be Issued Upon Inclusion Of Forfeited Or Unexercised Options",
        "label": "Increase In Shares Reserved For Issuance, Maximum Shares To Be Issued Upon Inclusion Of Forfeited Or Unexercised Options",
        "terseLabel": "Potential increase to shares reserved for inclusion of forfeited or unexercised options from prior plan"
       }
      }
     },
     "localname": "IncreaseInSharesReservedForIssuanceMaximumSharesToBeIssuedUponInclusionOfForfeitedOrUnexercisedOptions",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ardx_IncreaseInSharesReservedForIssuanceOptionForAnnualIncreaseAsPercentageOfSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase In Shares Reserved For Issuance, Option For Annual Increase As Percentage Of Shares Outstanding",
        "label": "Increase In Shares Reserved For Issuance, Option For Annual Increase As Percentage Of Shares Outstanding",
        "terseLabel": "Potential increase in shares reserved as a percentage of shares outstanding"
       }
      }
     },
     "localname": "IncreaseInSharesReservedForIssuanceOptionForAnnualIncreaseAsPercentageOfSharesOutstanding",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_InvestmentsAndCashAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments And Cash, Amortized Cost",
        "label": "Investments And Cash, Amortized Cost",
        "totalLabel": "Total cash equivalents and investments, Cost"
       }
      }
     },
     "localname": "InvestmentsAndCashAmortizedCost",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_KkcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to KKC.",
        "label": "Kkc [Member]",
        "terseLabel": "KKC"
       }
      }
     },
     "localname": "KkcMember",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/GeographicInformationandConcentrationsConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_KnightTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Knight Therapeutics Inc.",
        "label": "Knight Therapeutics Inc [Member]",
        "terseLabel": "Knight"
       }
      }
     },
     "localname": "KnightTherapeuticsIncMember",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/GeographicInformationandConcentrationsConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_KyowaKirinCo.LtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Kyowa Kirin Co., Ltd.",
        "label": "Kyowa Kirin Co. Ltd [Member]",
        "terseLabel": "Kyowa Kirin Co. Ltd"
       }
      }
     },
     "localname": "KyowaKirinCo.LtdMember",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment [Member]",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/PropertyandEquipmentNetBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_LeaseArrangementsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Arrangements",
        "label": "Lease Arrangements [Axis]",
        "terseLabel": "Lease Arrangements [Axis]"
       }
      }
     },
     "localname": "LeaseArrangementsAxis",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ardx_LeaseArrangementsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Arrangements [Domain]",
        "label": "Lease Arrangements [Domain]",
        "terseLabel": "Lease Arrangements [Domain]"
       }
      }
     },
     "localname": "LeaseArrangementsDomain",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, to be Paid, after Year Four",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_LesseeOperatingLeaseNumberOfRenewalOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number Of Renewal Options",
        "label": "Lessee, Operating Lease, Number Of Renewal Options",
        "terseLabel": "Number of options to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfRenewalOptions",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement for the development, commercialization and distribution fo tenapanor in Canada. The Knight Agreement.",
        "label": "License Agreement Development Commercialization Distribution In Canada [Member]",
        "terseLabel": "Knight Agreement"
       }
      }
     },
     "localname": "LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement for the development, commercialization and distribution of tenapanor in China. The Fosun Agreement.",
        "label": "License Agreement Development Commercialization Distribution In China [Member]",
        "terseLabel": "Fosun Agreement"
       }
      }
     },
     "localname": "LicenseAgreementDevelopmentCommercializationDistributionInChinaMember",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement for the development, commercialization and distribution of tenapanor in Japan. The 2017 KKC Agreement.",
        "label": "License Agreement Development Commercialization Distribution In Japan [Member]",
        "terseLabel": "2017 KKC Agreement"
       }
      }
     },
     "localname": "LicenseAgreementDevelopmentCommercializationDistributionInJapanMember",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Agreement, Covenant, Cash And Cash Equivalents As Percentage Of Outstanding Loan Balance, Calculation Period",
        "label": "Loan Agreement, Covenant, Cash And Cash Equivalents As Percentage Of Outstanding Loan Balance, Calculation Period",
        "terseLabel": "Loan agreement, covenant, cash and cash equivalents as percentage of outstanding loan balance, calculation period"
       }
      }
     },
     "localname": "LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Agreement, Covenant, Cash And Cash Equivalents As Percentage Of Outstanding Loan Balance, Minimum",
        "label": "Loan Agreement, Covenant, Cash And Cash Equivalents As Percentage Of Outstanding Loan Balance, Minimum",
        "terseLabel": "Loan agreement covenant, cash and cash equivalents as percentage of outstanding loan balance, minimum"
       }
      }
     },
     "localname": "LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Agreement, Covenant, Net Product Revenue As Percentage Of Outstanding Loan Balance, Minimum",
        "label": "Loan Agreement, Covenant, Net Product Revenue As Percentage Of Outstanding Loan Balance, Minimum",
        "terseLabel": "Loan agreement covenant, net product revenue as percentage of outstanding loan balance, minimum"
       }
      }
     },
     "localname": "LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Agreement, Exit Fee, Net Product Revenue Threshold Metric, Trailing Six Month Basis, Minimum",
        "label": "Loan Agreement, Exit Fee, Net Product Revenue Threshold Metric, Trailing Six Month Basis, Minimum",
        "terseLabel": "Exit fee, net product revenue threshold"
       }
      }
     },
     "localname": "LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails",
      "http://www.ardelyx.com/role/DerivativeLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_LoanAgreementExitFeeTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Agreement, Exit Fee, Term",
        "label": "Loan Agreement, Exit Fee, Term",
        "terseLabel": "Exit fee, term (in years)"
       }
      }
     },
     "localname": "LoanAgreementExitFeeTerm",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Agreement, Future Obligation Upon Funding Or Other Events",
        "label": "Loan Agreement, Future Obligation Upon Funding Or Other Events",
        "terseLabel": "Future obligation upon loan funding or other events"
       }
      }
     },
     "localname": "LoanAgreementFutureObligationUponFundingOrOtherEvents",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_MaximumAggregateOfferingPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of maximum aggregate offering price.",
        "label": "Maximum Aggregate Offering Price",
        "terseLabel": "Maximum aggregate offering price"
       }
      }
     },
     "localname": "MaximumAggregateOfferingPrice",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails",
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_McKessonCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "McKesson Corporation",
        "label": "McKesson Corporation [Member]",
        "terseLabel": "McKesson Corporation"
       }
      }
     },
     "localname": "McKessonCorporationMember",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_MinimumTaxCreditCarryforwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum Tax Credit Carryforward [Member]",
        "label": "Minimum Tax Credit Carryforward [Member]",
        "terseLabel": "Minimum tax credit carryforwards"
       }
      }
     },
     "localname": "MinimumTaxCreditCarryforwardMember",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Cash Interest Expense On Deferred Royalty Obligation",
        "label": "Non Cash Interest Expense On Deferred Royalty Obligation [Policy Text Block]",
        "terseLabel": "Non-cash Interest Expense on Deferred Royalty Obligation"
       }
      }
     },
     "localname": "NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ardx_NumberOfOperatingLeaseArrangements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of operating lease arrangements.",
        "label": "Number of Operating Lease Arrangements",
        "terseLabel": "Number of lease agreements"
       }
      }
     },
     "localname": "NumberOfOperatingLeaseArrangements",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ardx_NumberOfSeparateCollaborativeAgreements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of separate collaborative agreements.",
        "label": "Number Of Separate Collaborative Agreements",
        "terseLabel": "Number of separate collaborative agreements"
       }
      }
     },
     "localname": "NumberOfSeparateCollaborativeAgreements",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ardx_OfficeEquipmentAndFurnitureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office Equipment And Furniture [Member]",
        "label": "Office Equipment And Furniture [Member]",
        "terseLabel": "Office equipment and furniture"
       }
      }
     },
     "localname": "OfficeEquipmentAndFurnitureMember",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/PropertyandEquipmentNetBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Open Market Sales Agreement 2020, At The Market Offering",
        "label": "Open Market Sales Agreement 2020, At The Market Offering [Member]",
        "terseLabel": "2020 Open Market Sales Agreement"
       }
      }
     },
     "localname": "OpenMarketSalesAgreement2020AtTheMarketOfferingMember",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Open Market Sales Agreement 2021, At The Market Offering",
        "label": "Open Market Sales Agreement 2021, At The Market Offering [Member]",
        "terseLabel": "2021 Open Market Sales Agreement"
       }
      }
     },
     "localname": "OpenMarketSalesAgreement2021AtTheMarketOfferingMember",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Open Market Sales Agreement 2023, At The Market Offering",
        "label": "Open Market Sales Agreement 2023, At The Market Offering [Member]",
        "terseLabel": "2023 Open Market Sales Agreement"
       }
      }
     },
     "localname": "OpenMarketSalesAgreement2023AtTheMarketOfferingMember",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails",
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_OperatingLossCarryforwardsWithoutExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws indefinitely.",
        "label": "Operating Loss Carryforwards, Without Expiration",
        "terseLabel": "Net operating loss carryforwards, indefinite"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsWithoutExpiration",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_PercentageOfNonRoyaltyRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents percentage of non-royalty revenue.",
        "label": "Percentage Of Non-Royalty Revenue",
        "terseLabel": "Percentage of non royalty revenue"
       }
      }
     },
     "localname": "PercentageOfNonRoyaltyRevenue",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_PercentageOfRoyaltyRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents percentage of royalty revenue.",
        "label": "Percentage Of Royalty Revenue",
        "terseLabel": "Percentage of royalty revenue"
       }
      }
     },
     "localname": "PercentageOfRoyaltyRevenue",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_PerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for performance-based restricted stock units.",
        "label": "Performance Based Restricted Stock Units [Member]",
        "verboseLabel": "PRSUs"
       }
      }
     },
     "localname": "PerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_PotentialCommonSharesAntiDilutiveEffectOnSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Common Shares, Anti-Dilutive Effect On Securities",
        "label": "Potential Common Shares, Anti-Dilutive Effect On Securities",
        "terseLabel": "Potential common shares that would have been included if not for anti-dilutive effect of securities"
       }
      }
     },
     "localname": "PotentialCommonSharesAntiDilutiveEffectOnSecurities",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/NetLossPerShareAntiDilutiveSecuritiesandPotentialCommonSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ardx_PrepaidCommercialManufacturingCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/BALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Commercial Manufacturing, Current",
        "label": "Prepaid Commercial Manufacturing, Current",
        "terseLabel": "Prepaid commercial manufacturing"
       }
      }
     },
     "localname": "PrepaidCommercialManufacturingCurrent",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/BALANCESHEETS",
      "http://www.ardelyx.com/role/InventoryNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Sale Of Future Royalties, Net Of Issuance Costs",
        "label": "Proceeds From Sale Of Future Royalties, Net Of Issuance Costs",
        "terseLabel": "Proceeds from the sale of future royalties, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ProductIBSRELAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product, IBSRELA",
        "label": "Product, IBSRELA [Member]",
        "terseLabel": "IBSRELA"
       }
      }
     },
     "localname": "ProductIBSRELAMember",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_ProductSupplyRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Supply Revenue",
        "label": "Product Supply Revenue [Member]",
        "terseLabel": "Product supply revenue"
       }
      }
     },
     "localname": "ProductSupplyRevenueMember",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_RemainingFundingBasedOnConditionalMilestoneAchievement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining Funding Based On Conditional Milestone Achievement",
        "label": "Remaining Funding Based On Conditional Milestone Achievement",
        "terseLabel": "Remaining funding based on milestone achievement"
       }
      }
     },
     "localname": "RemainingFundingBasedOnConditionalMilestoneAchievement",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ResearchCollaborationAndOptionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pertaining to the research collaboration and option agreement for research associated with identifying two pre-clinical compounds. The 2019 KKC AGreement.",
        "label": "Research Collaboration And Option Agreement [Member]",
        "terseLabel": "2019 KKC Agreement"
       }
      }
     },
     "localname": "ResearchCollaborationAndOptionAgreementMember",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_RevenueGeneralPaymentTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, General Payment Terms",
        "label": "Revenue, General Payment Terms",
        "terseLabel": "Payment terms"
       }
      }
     },
     "localname": "RevenueGeneralPaymentTerms",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ardx_RevenueRemainingPerformanceObligationVariableConsiderationAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Remaining Performance Obligation, Variable Consideration Amount",
        "label": "Revenue, Remaining Performance Obligation, Variable Consideration Amount",
        "terseLabel": "Proceeds from milestone payments"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationVariableConsiderationAmount",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_SaleOfStockWeightedAveragePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Weighted-Average Price Per Share",
        "label": "Sale Of Stock, Weighted-Average Price Per Share",
        "terseLabel": "Weighted-average share price (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockWeightedAveragePricePerShare",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of additional details of the leases.",
        "label": "Schedule of Additional Details of Leases [Table Text Block]",
        "terseLabel": "Summary of Additional Details of the Leases"
       }
      }
     },
     "localname": "ScheduleOfAdditionalDetailsOfLeasesTableTextBlock",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Gross To Net Sales Accruals",
        "label": "Schedule Of Gross To Net Sales Accruals [Table Text Block]",
        "terseLabel": "Schedule of Chargebacks, Discounts and Reserve Balances"
       }
      }
     },
     "localname": "ScheduleOfGrossToNetSalesAccrualsTableTextBlock",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Shanghai Fosun Pharmaceutical Industrial Development.",
        "label": "Shanghai Fosun Pharmaceutical Industrial Development [Member]",
        "terseLabel": "Fosun Pharma"
       }
      }
     },
     "localname": "ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanGrossProceeds": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of gross proceeds received from shares issued to employees under the plan.",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Employee Stock Purchase Plan, Gross Proceeds",
        "terseLabel": "Gross\u00a0Proceeds"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanGrossProceeds",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesStockPurchasePlanPurchasedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Employees Stock Purchase Plan, Purchased, Number",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Employees Stock Purchase Plan, Purchased, Number",
        "periodEndLabel": "Purchased, ending (shares)",
        "periodStartLabel": "Purchased, beginning (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeesStockPurchasePlanPurchasedNumber",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesUnderEmployeeStockPurchasePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Number Of Shares Under Employee Stock Purchase Plan",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Number Of Shares Under Employee Stock Purchase Plan",
        "terseLabel": "Maximum shares to be issued under ESPP"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesUnderEmployeeStockPurchasePlan",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToGrantedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Available For Grant, Decrease Due To Granted In Period",
        "label": "Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Available For Grant, Decrease Due To Granted In Period",
        "negatedTerseLabel": "Shares available for grant, effect of granted (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToGrantedInPeriod",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToStockIssuedForServicesInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Available For Grant, Decrease Due To Stock Issued For Services In Period",
        "label": "Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Available For Grant, Decrease Due To Stock Issued For Services In Period",
        "negatedTerseLabel": "Shares available for grant, effect of shares issued for services (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantDecreaseDueToStockIssuedForServicesInPeriod",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToAuthorizedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of shares available for grant options authorized.",
        "label": "Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Available For Grant, Increase Due To Authorized In Period",
        "terseLabel": "Shares available for grant, effect of authorized (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToAuthorizedInPeriod",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToCanceledInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Available For Grant, Increase Due To Canceled In Period",
        "label": "Share-Based Compensation Arrangement By Share Based Payment Award, Number Of Shares Available For Grant, Increase Due To Canceled In Period",
        "terseLabel": "Shares available for grant, effect of canceled (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDueToCanceledInPeriod",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsPurchases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents share based compensation arrangement by share based payment award number of shares available for grants options, purchase during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Options, Purchases",
        "negatedTerseLabel": "Shares purchased (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsPurchases",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the purchase price per share of shares issued to employees under the plan.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award, Purchased Price of Share",
        "terseLabel": "Purchase Price per Share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ardx_SharesAvailableForGrantRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Available For Grant",
        "label": "Shares Available For Grant [Roll Forward]",
        "terseLabel": "Shares\u00a0Available for\u00a0Grant"
       }
      }
     },
     "localname": "SharesAvailableForGrantRollForward",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ardx_ShortTermInvestmentsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short term investments.",
        "label": "Short Term Investments [Policy Text Block]",
        "terseLabel": "Short-Term Investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsPolicyTextBlock",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ardx_StockIssuanceCostCommissionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of commission given on gross proceeds from sale of securities.",
        "label": "Stock Issuance Cost, Commission, Percent",
        "terseLabel": "Offering sales commission (percent)"
       }
      }
     },
     "localname": "StockIssuanceCostCommissionPercent",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails",
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_StockOptionsAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Options, Aggregate Intrinsic Value",
        "label": "Stock Options, Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic\u00a0Value"
       }
      }
     },
     "localname": "StockOptionsAggregateIntrinsicValueAbstract",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ardx_StockOptionsWeightedAverageRemainingContractualTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Options, Weighted Average Remaining Contractual Term",
        "label": "Stock Options, Weighted Average Remaining Contractual Term [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual\u00a0Term (in Years)"
       }
      }
     },
     "localname": "StockOptionsWeightedAverageRemainingContractualTermAbstract",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ardx_StrezsakVersusArdelyxIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Strezsak Versus Ardelyx, Inc.",
        "label": "Strezsak Versus Ardelyx, Inc. [Member]",
        "terseLabel": "Strezsak v. Ardelyx, Inc."
       }
      }
     },
     "localname": "StrezsakVersusArdelyxIncMember",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_TaxAuthorityStatesOtherThanCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Authority, States Other Than California",
        "label": "Tax Authority, States Other Than California [Member]",
        "terseLabel": "Other states"
       }
      }
     },
     "localname": "TaxAuthorityStatesOtherThanCaliforniaMember",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_TermBLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term B Loan",
        "label": "Term B Loan [Member]",
        "terseLabel": "Term B Loan"
       }
      }
     },
     "localname": "TermBLoanMember",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_TermLoan2018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan 2018",
        "label": "Term Loan 2018 [Member]",
        "terseLabel": "2018 Term Loan"
       }
      }
     },
     "localname": "TermLoan2018Member",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_TermLoan2022AMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan 2022 A",
        "label": "Term Loan 2022 A [Member]",
        "terseLabel": "Term Loan A"
       }
      }
     },
     "localname": "TermLoan2022AMember",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_TermLoan2022BMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan 2022 B",
        "label": "Term Loan 2022 B [Member]",
        "terseLabel": "Term Loan B"
       }
      }
     },
     "localname": "TermLoan2022BMember",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_TermLoan2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan 2022",
        "label": "Term Loan 2022 [Member]",
        "terseLabel": "2022 Term Loan"
       }
      }
     },
     "localname": "TermLoan2022Member",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_TermOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of agreement.",
        "label": "Term Of Agreement",
        "terseLabel": "Term of agreement"
       }
      }
     },
     "localname": "TermOfAgreement",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ardx_TermOfPaymentOfLicenseFeeFirstInstallment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of payment of first installment fee.",
        "label": "Term Of Payment Of License Fee, First Installment",
        "terseLabel": "Term of payment of license fee, first installment"
       }
      }
     },
     "localname": "TermOfPaymentOfLicenseFeeFirstInstallment",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ardx_ThresholdPercentageOfSalesForTieredRoyalties": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the threshold percentage of net sales for tiered royalties.",
        "label": "Threshold Percentage of Sales For Tiered Royalties",
        "terseLabel": "Threshold percentage of net sales for tiered royalties"
       }
      }
     },
     "localname": "ThresholdPercentageOfSalesForTieredRoyalties",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_TwoThousandEightStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Eight Stock Incentive Plan [Member]",
        "label": "Two Thousand Eight Stock Incentive Plan [Member]",
        "terseLabel": "2008 Plan"
       }
      }
     },
     "localname": "TwoThousandEightStockIncentivePlanMember",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_TwoThousandFourteenEquityIncentiveAwardPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2014 Equity Incentive Award Plan [Member]",
        "label": "Two Thousand Fourteen Equity Incentive Award Plan [Member]",
        "terseLabel": "2014 Plan"
       }
      }
     },
     "localname": "TwoThousandFourteenEquityIncentiveAwardPlanMember",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_TwoThousandSixteenEmploymentCommencementIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2016 Employment commencement incentive plan.",
        "label": "Two Thousand Sixteen Employment Commencement Incentive Plan [Member]",
        "terseLabel": "Inducement Plan"
       }
      }
     },
     "localname": "TwoThousandSixteenEmploymentCommencementIncentivePlanMember",
     "nsuri": "http://www.ardelyx.com/20221231",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CANADA",
        "terseLabel": "North America"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.ardelyx.com/role/GeographicInformationandConcentrationsRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.ardelyx.com/role/GeographicInformationandConcentrationsRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r712",
      "r713",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r712",
      "r713",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r712",
      "r713",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r712",
      "r713",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r712",
      "r713",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_AsiaPacificMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asia Pacific [Member]",
        "terseLabel": "Asia Pacific"
       }
      }
     },
     "localname": "AsiaPacificMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/GeographicInformationandConcentrationsRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r236",
      "r237",
      "r365",
      "r394",
      "r672",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails",
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r744"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Board of directors"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r295",
      "r691",
      "r767",
      "r829"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r349",
      "r350",
      "r351",
      "r352",
      "r440",
      "r623",
      "r638",
      "r667",
      "r668",
      "r688",
      "r699",
      "r707",
      "r764",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails",
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r349",
      "r350",
      "r351",
      "r352",
      "r440",
      "r623",
      "r638",
      "r667",
      "r668",
      "r688",
      "r699",
      "r707",
      "r764",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r295",
      "r691",
      "r767",
      "r829"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r292",
      "r625",
      "r689",
      "r705",
      "r759",
      "r760",
      "r767",
      "r828"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails",
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails",
      "http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r292",
      "r625",
      "r689",
      "r705",
      "r759",
      "r760",
      "r767",
      "r828"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Products and Services [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails",
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails",
      "http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r349",
      "r350",
      "r351",
      "r352",
      "r433",
      "r440",
      "r467",
      "r468",
      "r469",
      "r599",
      "r623",
      "r638",
      "r667",
      "r668",
      "r688",
      "r699",
      "r707",
      "r753",
      "r764",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r349",
      "r350",
      "r351",
      "r352",
      "r433",
      "r440",
      "r467",
      "r468",
      "r469",
      "r599",
      "r623",
      "r638",
      "r667",
      "r668",
      "r688",
      "r699",
      "r707",
      "r753",
      "r764",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r236",
      "r237",
      "r365",
      "r394",
      "r673",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails",
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r293",
      "r294",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r690",
      "r706",
      "r767"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/GeographicInformationandConcentrationsRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r293",
      "r294",
      "r652",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r690",
      "r706",
      "r767"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/GeographicInformationandConcentrationsRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r744",
      "r817"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]",
        "terseLabel": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "verboseLabel": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/AccruedExpensesandOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r14",
      "r704"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r296",
      "r297"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BALANCESHEETS",
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ardelyx.com/role/BALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.ardelyx.com/role/BALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r86",
      "r201"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/PropertyandEquipmentNetBalancesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/PropertyandEquipmentNetBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r207",
      "r634",
      "r646",
      "r650"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r24",
      "r27",
      "r135",
      "r589",
      "r641",
      "r642",
      "r727",
      "r728",
      "r729",
      "r736",
      "r737",
      "r738"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive (Loss) Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r6"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r476",
      "r477",
      "r478",
      "r736",
      "r737",
      "r738",
      "r810"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Taxes paid for net share settlement of equity awards"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r121",
      "r122",
      "r442"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvanceRoyaltiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advance Royalties [Abstract]"
       }
      }
     },
     "localname": "AdvanceRoyaltiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r471"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfAdvanceRoyalty": {
     "auth_ref": [
      "r35",
      "r50"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expense charged against earnings for the periodic recognition of the advance royalties. These royalties are paid in one accounting period, but are deducted from earnings over time through amortization. For example, royalties that are required to be paid in advance of production from a mineral, oil, or gas property and amortized over the period of right to produce these items.",
        "label": "Amortization of Advance Royalty",
        "negatedLabel": "Non-cash interest expense related to the sale of future royalties",
        "terseLabel": "Amortization of the deferred royalty obligation"
       }
      }
     },
     "localname": "AmortizationOfAdvanceRoyalty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails",
      "http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r38",
      "r50",
      "r160",
      "r384"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Anti-dilutive securities not included in computation of diluted net loss per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/NetLossPerShareAntiDilutiveSecuritiesandPotentialCommonSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/NetLossPerShareAntiDilutiveSecuritiesandPotentialCommonSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/NetLossPerShareAntiDilutiveSecuritiesandPotentialCommonSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/NetLossPerShareAntiDilutiveSecuritiesandPotentialCommonSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Office space area (sq ft)"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/GeographicInformationandConcentrationsConcentrationRiskDetails",
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r696",
      "r745"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-Backed Securities [Member]",
        "terseLabel": "Asset backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetRetirementObligationDisclosureTextBlock": {
     "auth_ref": [
      "r331",
      "r332",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an asset retirement obligation and the associated long-lived asset. An asset retirement obligation is a legal obligation associated with the disposal or retirement from service of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees.",
        "label": "Asset Retirement Obligation Disclosure [Text Block]",
        "terseLabel": "Deferred Royalty Obligation Related To The Sale Of Future Royalties"
       }
      }
     },
     "localname": "AssetRetirementObligationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyalties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r165",
      "r177",
      "r203",
      "r233",
      "r283",
      "r286",
      "r290",
      "r309",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r520",
      "r522",
      "r546",
      "r704",
      "r762",
      "r763",
      "r818"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsAndLiabilitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets and Liabilities, Lessee [Abstract]",
        "verboseLabel": "Facilities - right-of-use assets and lease liabilities"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesAdditionalLeaseInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r196",
      "r210",
      "r233",
      "r309",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r520",
      "r522",
      "r546",
      "r704",
      "r762",
      "r763",
      "r818"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r151"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Assets, fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Short-term investments, Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Short-term investments, Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r304",
      "r321"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Short-term investments, Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Abstract]",
        "terseLabel": "Available-for-Sale Debt Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r78",
      "r303",
      "r321",
      "r629"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Short-term investments, Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r77",
      "r321"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]",
        "terseLabel": "Short-term investments:"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansValuationAssumptionsforStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CaliforniaFranchiseTaxBoardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of the state of California.",
        "label": "California Franchise Tax Board [Member]",
        "terseLabel": "California"
       }
      }
     },
     "localname": "CaliforniaFranchiseTaxBoardMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r52",
      "r199",
      "r670"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BALANCESHEETS",
      "http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value [Abstract]",
        "terseLabel": "Cash and cash equivalents:"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments [Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Short-Term Investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r45",
      "r52",
      "r58"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r45",
      "r159"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplementary disclosure of non-cash activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r233",
      "r258",
      "r259",
      "r261",
      "r263",
      "r271",
      "r272",
      "r309",
      "r353",
      "r355",
      "r356",
      "r357",
      "r360",
      "r361",
      "r392",
      "r393",
      "r396",
      "r400",
      "r407",
      "r546",
      "r669",
      "r718",
      "r732",
      "r739"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails",
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r517",
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration and Licensing Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails",
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r770",
      "r811"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.",
        "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r20",
      "r169",
      "r182"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r94",
      "r346",
      "r347",
      "r654",
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails",
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r736",
      "r737",
      "r810"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r5",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r5",
      "r704"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 300,000,000 shares authorized; 198,575,016 and 130,182,535 shares issued and outstanding as of December\u00a031, 2022 and December\u00a031, 2021, respectively."
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r28",
      "r212",
      "r214",
      "r220",
      "r630",
      "r635"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Comprehensive loss:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r66",
      "r67",
      "r156",
      "r157",
      "r295",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/GeographicInformationandConcentrationsConcentrationRiskDetails",
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r66",
      "r67",
      "r156",
      "r157",
      "r295",
      "r651",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/GeographicInformationandConcentrationsConcentrationRiskDetails",
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r66",
      "r67",
      "r156",
      "r157",
      "r295",
      "r653",
      "r831"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/GeographicInformationandConcentrationsConcentrationRiskDetails",
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r175",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/GeographicInformationandConcentrationsConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r66",
      "r67",
      "r156",
      "r157",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk (percent)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/GeographicInformationandConcentrationsConcentrationRiskDetails",
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r64",
      "r66",
      "r67",
      "r68",
      "r156",
      "r158",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/GeographicInformationandConcentrationsConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r66",
      "r67",
      "r156",
      "r157",
      "r295",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/GeographicInformationandConcentrationsConcentrationRiskDetails",
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r766"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of Deferred Revenue Balances"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r409",
      "r410",
      "r430"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r409",
      "r410",
      "r430"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BALANCESHEETS",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r409",
      "r410",
      "r430"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Deferred revenue, non-current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BALANCESHEETS",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r696",
      "r698",
      "r830"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r34",
      "r233",
      "r309",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r546",
      "r762"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r769"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Revenue"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock": {
     "auth_ref": [
      "r91",
      "r92",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations.",
        "label": "Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]",
        "terseLabel": "Restructuring"
       }
      }
     },
     "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r735",
      "r802"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r131",
      "r497",
      "r507",
      "r735"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r735",
      "r802",
      "r804"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r65",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r101",
      "r231",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r378",
      "r385",
      "r386",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Borrowings"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Borrowings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r166",
      "r167",
      "r176",
      "r238",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r368",
      "r374",
      "r375",
      "r376",
      "r377",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r566",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails",
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Floating per annum rate (percent)"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails",
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r3",
      "r167",
      "r176",
      "r389"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BorrowingsFuturePaymentObligationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Principal outstanding",
        "totalLabel": "Total repayment obligations"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsFuturePaymentObligationsDetails",
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r161",
      "r163",
      "r362",
      "r566",
      "r684",
      "r685"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Term loan amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BorrowingsFuturePaymentObligationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.",
        "label": "Debt Instrument, Fee Amount",
        "negatedTerseLabel": "Less: Unaccreted value of final fee"
       }
      }
     },
     "localname": "DebtInstrumentFeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsFuturePaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Term Loans"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r19",
      "r238",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r368",
      "r374",
      "r375",
      "r376",
      "r377",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r566",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails",
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Prior to first anniversary of closing date"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Three [Member]",
        "terseLabel": "After second anniversary to maturity date"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "After first anniversary through second anniversary of closing date"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r19",
      "r103",
      "r104",
      "r105",
      "r106",
      "r160",
      "r161",
      "r163",
      "r174",
      "r238",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r368",
      "r374",
      "r375",
      "r376",
      "r377",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r387",
      "r566",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Payment term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r162",
      "r374",
      "r390",
      "r684",
      "r685"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BorrowingsFuturePaymentObligationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Less: Unamortized discount and debt issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsFuturePaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r305",
      "r321",
      "r324",
      "r325"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss",
        "terseLabel": "Allowance for credit loss on available-for-sale debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": {
     "auth_ref": [
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions",
        "terseLabel": "Investment in continuous unrealized loss position for more than one year"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r735",
      "r803",
      "r804"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r50",
      "r131",
      "r498",
      "r506",
      "r507",
      "r735"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r492"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r800"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r800"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred tax assets net of valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r129",
      "r801"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r129",
      "r801"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r127",
      "r129",
      "r801"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r129",
      "r801"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r493"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r129",
      "r801"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r50",
      "r84"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/PropertyandEquipmentNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r50",
      "r281"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails",
      "http://www.ardelyx.com/role/DerivativeLiabilitiesChangesinFairValueDetails",
      "http://www.ardelyx.com/role/DerivativeLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect.",
        "label": "Derivative Financial Instruments, Liabilities [Member]",
        "terseLabel": "Derivative liabilities for exit fees",
        "verboseLabel": "Exit fee derivative liability"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilitiesChangesinFairValueDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r142",
      "r143",
      "r145",
      "r146",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails",
      "http://www.ardelyx.com/role/DerivativeLiabilitiesChangesinFairValueDetails",
      "http://www.ardelyx.com/role/DerivativeLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r150",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "Derivative Liabilities"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeLiabilityNotionalAmount": {
     "auth_ref": [
      "r807",
      "r808",
      "r809"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payments on the derivative liability.",
        "label": "Derivative Liability, Notional Amount",
        "terseLabel": "Agreed amount for exit fee upon change of control or regulatory approval"
       }
      }
     },
     "localname": "DerivativeLiabilityNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r144",
      "r145",
      "r147",
      "r148",
      "r149",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesReportingOfDerivativeActivity": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for derivatives entered into for trading purposes and those entered into for purposes other than trading including where and when derivative financial instruments and derivative commodity instruments and their related gains or losses are reported in the entity's statements of financial position, cash flows, and results of operations.",
        "label": "Derivatives, Reporting of Derivative Activity [Policy Text Block]",
        "terseLabel": "Derivatives and Hedging Activities"
       }
      }
     },
     "localname": "DerivativesReportingOfDerivativeActivity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails",
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r429",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails",
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r444",
      "r472",
      "r473",
      "r475",
      "r479",
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "verboseLabel": "Equity Incentive Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r221",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r256",
      "r258",
      "r261",
      "r262",
      "r263",
      "r267",
      "r535",
      "r536",
      "r631",
      "r636",
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share - basic (in dollars per share)",
        "verboseLabel": "Net loss per share of common stock - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails",
      "http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r221",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r258",
      "r261",
      "r262",
      "r263",
      "r267",
      "r535",
      "r536",
      "r631",
      "r636",
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share - diluted (in dollars per share)",
        "verboseLabel": "Net loss per share of common stock - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails",
      "http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r62",
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r484"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/IncomeTaxesReconciliationofEffectiveTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Income tax provision"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r234",
      "r484",
      "r508"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/IncomeTaxesReconciliationofEffectiveTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Income tax at the federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r798",
      "r805"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/IncomeTaxesReconciliationofEffectiveTaxRateDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r798",
      "r805"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/IncomeTaxesReconciliationofEffectiveTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "auth_ref": [
      "r797",
      "r798"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/IncomeTaxesReconciliationofEffectiveTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent",
        "verboseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r798",
      "r805"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/IncomeTaxesReconciliationofEffectiveTaxRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r798",
      "r805"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/IncomeTaxesReconciliationofEffectiveTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "terseLabel": "Tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r474"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized Compensation Expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Average Remaining Vesting Period (Years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options",
        "verboseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansValuationAssumptionsforStockOptionsDetails",
      "http://www.ardelyx.com/role/NetLossPerShareAntiDilutiveSecuritiesandPotentialCommonSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r102",
      "r192",
      "r216",
      "r217",
      "r218",
      "r239",
      "r240",
      "r241",
      "r244",
      "r252",
      "r254",
      "r270",
      "r313",
      "r408",
      "r476",
      "r477",
      "r478",
      "r502",
      "r503",
      "r534",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r589",
      "r641",
      "r642",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r538",
      "r539",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r151",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r376",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r539",
      "r596",
      "r597",
      "r598",
      "r684",
      "r685",
      "r696",
      "r697",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilitiesNarrativeDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r154",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilitiesChangesinFairValueDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r538",
      "r539",
      "r540",
      "r541",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r376",
      "r434",
      "r439",
      "r539",
      "r596",
      "r696",
      "r697",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r376",
      "r434",
      "r439",
      "r539",
      "r597",
      "r684",
      "r685",
      "r696",
      "r697",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r376",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r539",
      "r598",
      "r684",
      "r685",
      "r696",
      "r697",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilitiesNarrativeDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilitiesChangesinFairValueDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Change in Fair Value of Derivative Liability"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilitiesChangesinFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilitiesChangesinFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r152",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilitiesChangesinFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r152",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Changes in Fair Value of Derivative Liabilities"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r542"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Changes in estimated fair value:"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilitiesChangesinFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "auth_ref": [
      "r153"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "terseLabel": "2022 Exit Fee addition at fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilitiesChangesinFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r152"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Fair value of exit fee derivative liabilities, ending",
        "periodStartLabel": "Fair value of exit fee derivative liabilities, beginning",
        "terseLabel": "Estimated fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilitiesChangesinFairValueDetails",
      "http://www.ardelyx.com/role/DerivativeLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r376",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r596",
      "r597",
      "r598",
      "r684",
      "r685",
      "r696",
      "r697",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilitiesNarrativeDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r543",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r306",
      "r307",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r322",
      "r323",
      "r326",
      "r387",
      "r405",
      "r524",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r682",
      "r746",
      "r747",
      "r748",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "auth_ref": [
      "r731",
      "r751",
      "r752"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
        "negatedTerseLabel": "Gain on sale of equipment"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r50"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "terseLabel": "Gain on disposition of property plant equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/PropertyandEquipmentNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnRestructuringOfDebt": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete.",
        "label": "Gains (Losses) on Restructuring of Debt",
        "negatedTerseLabel": "Debt refinancing costs"
       }
      }
     },
     "localname": "GainsLossesOnRestructuringOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "verboseLabel": "General and administrative expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/RestructuringDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r50",
      "r83",
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment loss of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r82",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r30",
      "r164",
      "r170",
      "r185",
      "r283",
      "r285",
      "r289",
      "r291",
      "r632",
      "r681"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r330",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails",
      "http://www.ardelyx.com/role/RestructuringDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails",
      "http://www.ardelyx.com/role/RestructuringDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r234",
      "r485",
      "r490",
      "r496",
      "r504",
      "r509",
      "r511",
      "r512",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r235",
      "r253",
      "r254",
      "r282",
      "r483",
      "r505",
      "r510",
      "r637"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Provision for income taxes",
        "verboseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails",
      "http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Components of the provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r215",
      "r481",
      "r482",
      "r490",
      "r491",
      "r495",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r675"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDerivativeLiabilities": {
     "auth_ref": [
      "r730"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).",
        "label": "Increase (Decrease) in Derivative Liabilities",
        "terseLabel": "Change in derivative liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInDerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r730",
      "r814"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInRoyaltiesPayable": {
     "auth_ref": [
      "r49"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the obligations due for compensation payments related to the use of copyrights, patents, trade names, licenses, technology. Royalty payments are also paid by the lease holders for oil, gas, and mineral extraction.",
        "label": "Increase (Decrease) in Royalties Payable",
        "terseLabel": "Royalty payments and commercial milestone payments"
       }
      }
     },
     "localname": "IncreaseDecreaseInRoyaltiesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r162",
      "r172",
      "r219",
      "r280",
      "r565"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r226",
      "r228",
      "r229"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r722"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/InventoryScheduleDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/InventoryScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r725"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BALANCESHEETS",
      "http://www.ardelyx.com/role/InventoryScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r209",
      "r671",
      "r704"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/InventoryScheduleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/InventoryScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r720"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "terseLabel": "Inventory, non-current"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BALANCESHEETS",
      "http://www.ardelyx.com/role/InventoryScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r198",
      "r208",
      "r269",
      "r327",
      "r328",
      "r329",
      "r624",
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r724"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/InventoryScheduleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/InventoryScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r723"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/InventoryScheduleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/InventoryScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsAndCash": {
     "auth_ref": [
      "r183"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "ardx_InvestmentsAndCashAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of investments and unrestricted cash as of the balance sheet date.",
        "label": "Investments and Cash",
        "terseLabel": "Cash and short-term investments",
        "verboseLabel": "Total cash equivalents and investments, Fair Value"
       }
      }
     },
     "localname": "InvestmentsAndCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails",
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Lease costs"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r815"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "verboseLabel": "Summary of Lease Costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/PropertyandEquipmentNetBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "verboseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescriptionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Description [Abstract]",
        "terseLabel": "Additional details"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescriptionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesAdditionalLeaseInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease.",
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "verboseLabel": "Existence of option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r816"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "verboseLabel": "Summary of Undiscounted Cash Payment Obligations for Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r582"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted operating lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r582"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r582"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r582"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r582"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r582"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Imputed interest expenses"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Term of lease extension"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r15",
      "r233",
      "r309",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r521",
      "r522",
      "r523",
      "r546",
      "r680",
      "r762",
      "r818",
      "r819"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r10",
      "r168",
      "r180",
      "r704",
      "r734",
      "r749",
      "r812"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r17",
      "r197",
      "r233",
      "r309",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r521",
      "r522",
      "r523",
      "r546",
      "r704",
      "r762",
      "r818",
      "r819"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r151"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "terseLabel": "Liabilities, fair value"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "Licensing revenue",
        "verboseLabel": "License"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails",
      "http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LoansPayableCurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.ardelyx.com/role/BorrowingsFuturePaymentObligationsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.",
        "label": "Loans Payable, Current",
        "negatedTerseLabel": "Less: Current portion of long-term debt",
        "terseLabel": "Current portion of long-term debt"
       }
      }
     },
     "localname": "LoansPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BALANCESHEETS",
      "http://www.ardelyx.com/role/BorrowingsFuturePaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LoansPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing supported by a written promise to pay an obligation.",
        "label": "Loans Payable [Member]",
        "terseLabel": "Term loan",
        "verboseLabel": "Loan Agreement"
       }
      }
     },
     "localname": "LoansPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails",
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r3",
      "r167",
      "r178",
      "r375",
      "r391",
      "r684",
      "r685"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BorrowingsFuturePaymentObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ardelyx.com/role/BorrowingsFuturePaymentObligationsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "totalLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsFuturePaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Future payment obligations"
       }
      }
     },
     "localname": "LongTermDebtByMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsFuturePaymentObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r98",
      "r238",
      "r765"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BorrowingsFuturePaymentObligationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsFuturePaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r98",
      "r238",
      "r380"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BorrowingsFuturePaymentObligationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsFuturePaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r98",
      "r238",
      "r380"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BorrowingsFuturePaymentObligationsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsFuturePaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r98",
      "r238",
      "r380"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BorrowingsFuturePaymentObligationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsFuturePaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r98",
      "r238",
      "r380"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BorrowingsFuturePaymentObligationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsFuturePaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r98",
      "r238",
      "r380"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BorrowingsFuturePaymentObligationsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsFuturePaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermLoansPayable": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BorrowingsFuturePaymentObligationsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Loans Payable, Noncurrent",
        "terseLabel": "Long-term debt, net of current portion"
       }
      }
     },
     "localname": "LongTermLoansPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsFuturePaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails",
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r19",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails",
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r95",
      "r96",
      "r348",
      "r349",
      "r350",
      "r757",
      "r758"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r348",
      "r719"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Contingent liabilities"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r757",
      "r758"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "Number of lawsuits"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyNumberOfDefendants": {
     "auth_ref": [
      "r757",
      "r758"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of defendants named in a legal action.",
        "label": "Loss Contingency, Number of Defendants",
        "terseLabel": "Number of defendants"
       }
      }
     },
     "localname": "LossContingencyNumberOfDefendants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r770"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r227"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r227"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r45",
      "r48",
      "r51"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r31",
      "r51",
      "r171",
      "r184",
      "r195",
      "r211",
      "r213",
      "r218",
      "r233",
      "r243",
      "r247",
      "r248",
      "r249",
      "r250",
      "r253",
      "r254",
      "r260",
      "r283",
      "r285",
      "r289",
      "r291",
      "r309",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r536",
      "r546",
      "r681",
      "r762"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails",
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS",
      "http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/STATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "verboseLabel": "Summary of significant accounting policies"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r60",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r249",
      "r255",
      "r267",
      "r301",
      "r302",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r476",
      "r477",
      "r478",
      "r500",
      "r501",
      "r502",
      "r503",
      "r514",
      "r515",
      "r516",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r563",
      "r564",
      "r567",
      "r568",
      "r569",
      "r570",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r626",
      "r627",
      "r628",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r283",
      "r285",
      "r289",
      "r291",
      "r681"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r577",
      "r703"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "verboseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "verboseLabel": "Undiscounted cash payment obligations"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r572"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesAdditionalLeaseInformationDetails",
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r572"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedLabel": "Less: Current portion of operating lease liability",
        "terseLabel": "Current portion of lease liabilities",
        "verboseLabel": "Current portion of operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BALANCESHEETS",
      "http://www.ardelyx.com/role/LeasesAdditionalLeaseInformationDetails",
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r572"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, net of current portion",
        "verboseLabel": "Operating lease liability, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BALANCESHEETS",
      "http://www.ardelyx.com/role/LeasesAdditionalLeaseInformationDetails",
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r573",
      "r578"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "verboseLabel": "Cash paid for operating lease"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r571"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets",
        "verboseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BALANCESHEETS",
      "http://www.ardelyx.com/role/LeasesAdditionalLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r731"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r581",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "verboseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesAdditionalLeaseInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r580",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining life (years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesAdditionalLeaseInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r127"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r59",
      "r61",
      "r72",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "terseLabel": "Organization and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r202"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r132",
      "r133",
      "r134"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Unrealized losses on available-for-sale securities",
        "verboseLabel": "Unrealized losses on available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/STATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r16",
      "r704"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r225"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedTerseLabel": "Payments for taxes related to net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-Term Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansEmployeeStockPurchasePlanDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansValuationAssumptionsforESPPDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansEmployeeStockPurchasePlanDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansValuationAssumptionsforESPPDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r4",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r4",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r4",
      "r704"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of December\u00a031, 2022 and December\u00a031, 2021, respectively."
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r726"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r224"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "verboseLabel": "Net proceeds from loan"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock in at the market offering, net of issuance costs",
        "verboseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS",
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSecuredDebt": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.",
        "label": "Proceeds from Issuance of Secured Debt",
        "terseLabel": "Proceeds from 2022 Loan, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r42",
      "r119"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "verboseLabel": "Proceeds from issuance of common stock under equity incentive and stock purchase plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLicenseFeesReceived": {
     "auth_ref": [
      "r46"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from licensees for license fees during the current period.",
        "label": "Proceeds from License Fees Received",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "localname": "ProceedsFromLicenseFeesReceived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRoyaltiesReceived": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received for royalties during the current period.",
        "label": "Proceeds from Royalties Received",
        "terseLabel": "Proceeds from royalties received"
       }
      }
     },
     "localname": "ProceedsFromRoyaltiesReceived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r76",
      "r222",
      "r223"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "verboseLabel": "Proceeds from maturities and redemptions of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/PropertyandEquipmentNetNarrativeDetails",
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product sales, net"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails",
      "http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/PropertyandEquipmentNetBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r90",
      "r655",
      "r656",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/PropertyandEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisposals": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Disposals",
        "terseLabel": "Sale of property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisposals",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/PropertyandEquipmentNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r85",
      "r200"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/PropertyandEquipmentNetBalancesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/PropertyandEquipmentNetBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/PropertyandEquipmentNetBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r87",
      "r181",
      "r633",
      "r704"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.ardelyx.com/role/PropertyandEquipmentNetBalancesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BALANCESHEETS",
      "http://www.ardelyx.com/role/PropertyandEquipmentNetBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r87",
      "r655",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/PropertyandEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/PropertyandEquipmentNetBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]",
        "terseLabel": "Receivable [Domain]"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfSecuredDebt": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.",
        "label": "Repayments of Secured Debt",
        "negatedLabel": "Payments for 2018 Loan, net of costs"
       }
      }
     },
     "localname": "RepaymentsOfSecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r123",
      "r186",
      "r826"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails",
      "http://www.ardelyx.com/role/RestructuringDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research and development tax credit"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units",
        "verboseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails",
      "http://www.ardelyx.com/role/NetLossPerShareAntiDilutiveSecuritiesandPotentialCommonSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r334",
      "r336",
      "r339",
      "r344",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Restructuring"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r50",
      "r340",
      "r341",
      "r754"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring charges"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/RestructuringDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/RestructuringDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringReserveCurrent": {
     "auth_ref": [
      "r721",
      "r755",
      "r756"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.",
        "label": "Restructuring Reserve, Current",
        "terseLabel": "Estimated restructuring liability"
       }
      }
     },
     "localname": "RestructuringReserveCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/RestructuringDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r7",
      "r107",
      "r179",
      "r645",
      "r650",
      "r704"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BALANCESHEETS",
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r192",
      "r239",
      "r240",
      "r241",
      "r244",
      "r252",
      "r254",
      "r313",
      "r476",
      "r477",
      "r478",
      "r502",
      "r503",
      "r534",
      "r641",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r278",
      "r279",
      "r284",
      "r287",
      "r288",
      "r292",
      "r293",
      "r295",
      "r428",
      "r429",
      "r625"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenues",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/GeographicInformationandConcentrationsRevenuebyGeographicalAreaDetails",
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails",
      "http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r295",
      "r742"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/GeographicInformationandConcentrationsConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r432",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "verboseLabel": "Product Sales, Net and Reserves for Variable Consideration and Collaboration Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r418",
      "r419",
      "r431",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Product Revenue, Net"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Schedule of Revenue by Geographic Areas"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/GeographicInformationandConcentrationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r417"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Payment to be received"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]"
       }
      }
     },
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/GeographicInformationandConcentrationsRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r579",
      "r703"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesNarrativeDetails",
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks and Uncertainties [Abstract]"
       }
      }
     },
     "localname": "RisksAndUncertaintiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails",
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueProductLineMember": {
     "auth_ref": [
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from specified product or service, when it serves as benchmark in concentration of risk calculation. Includes, but is not limited to, revenue from contract with customer and other sources.",
        "label": "Revenue, Product and Service Benchmark [Member]",
        "terseLabel": "Gross product revenue"
       }
      }
     },
     "localname": "SalesRevenueProductLineMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/NetLossPerShareAntiDilutiveSecuritiesandPotentialCommonSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Anti-Dilutive Securities Not Considered in Diluted Net Loss Per Common Share Calculation"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Schedule of Securities Classified as Cash, Cash Equivalents and Short-Term Investments"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r806"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails",
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Provision for Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Components of Deferred Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Schedule of Computation of Net Loss Per Common Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Effective Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r116",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Recognized"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r538",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Financial Assets and Liabilities Measured on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r0",
      "r11",
      "r12",
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Current Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle including inventoried costs relating to long-term contracts or programs.",
        "label": "Schedule of Inventory, Noncurrent [Table Text Block]",
        "terseLabel": "Schedule of Noncurrent Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryNoncurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of Future Debt Payment Obligations"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/PropertyandEquipmentNetBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r335",
      "r336",
      "r337",
      "r338",
      "r341",
      "r342",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/RestructuringDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "auth_ref": [
      "r29",
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/GeographicInformationandConcentrationsRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r441",
      "r443",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansEmployeeStockPurchasePlanDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansValuationAssumptionsforESPPDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansValuationAssumptionsforStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of employee stock purchase plan activity.",
        "label": "Schedule of Share-Based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]",
        "terseLabel": "Schedule of Employee Stock Purchase Plan Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Units Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r110",
      "r111",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Valuation Assumptions for Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Valuation Assumptions for Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost [Table Text Block]",
        "terseLabel": "Schedule of Total Unrecognized Stock-Based Compensation Expense, Net of Estimated Forfeitures"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r702",
      "r799"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r64",
      "r66",
      "r67",
      "r68",
      "r156",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of Customers and Collaboration Partnerships"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/GeographicInformationandConcentrationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Disclosure [Abstract]",
        "terseLabel": "Equity Incentive Plans"
       }
      }
     },
     "localname": "ShareBasedArrangementsToObtainGoodsAndServicesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (shares)",
        "verboseLabel": "Number of shares granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r456",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Nonvested balance, ending (shares)",
        "periodStartLabel": "Nonvested balance, beginning (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number\u00a0of RSUs"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r456",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Nonvested balance, ending (in dollars per share)",
        "periodStartLabel": "Nonvested balance, beginning (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant\u00a0Date\u00a0Fair Value Per\u00a0Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (shares)",
        "terseLabel": "Number of shares vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r463"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Estimated fair value of RSUs vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansValuationAssumptionsforESPPDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansValuationAssumptionsforStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "verboseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansValuationAssumptionsforESPPDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansValuationAssumptionsforStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansValuationAssumptionsforESPPDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansValuationAssumptionsforStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansEmployeeStockPurchasePlanDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansValuationAssumptionsforESPPDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansValuationAssumptionsforStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of shares added to initial reserve"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares initially authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "periodEndLabel": "Shares available for grant, ending (shares)",
        "periodStartLabel": "Shares available for grant, beginning (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansEmployeeStockPurchasePlanDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r463"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Options canceled (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date estimated fair value of options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r118"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options issued and outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r448",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options issued and outstanding balance, ending (shares)",
        "periodStartLabel": "Options issued and outstanding balance, beginning (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number\u00a0of\u00a0Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r448",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options issued and outstanding balance, ending (in dollars per share)",
        "periodStartLabel": "Options issued and outstanding balance, beginning (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise\u00a0Price\u00a0 per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r464"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Options vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Options vested and expected to vest (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Options vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "terseLabel": "Shares purchased (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansValuationAssumptionsforStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options canceled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Common stock closing price (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansValuationAssumptionsforESPPDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansValuationAssumptionsforStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r118"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options issued and outstanding (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options vest and expected to vest (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r59",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r233",
      "r258",
      "r259",
      "r261",
      "r263",
      "r271",
      "r272",
      "r309",
      "r353",
      "r355",
      "r356",
      "r357",
      "r360",
      "r361",
      "r392",
      "r393",
      "r396",
      "r400",
      "r407",
      "r546",
      "r669",
      "r718",
      "r732",
      "r739"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails",
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r22",
      "r102",
      "r192",
      "r216",
      "r217",
      "r218",
      "r239",
      "r240",
      "r241",
      "r244",
      "r252",
      "r254",
      "r270",
      "r313",
      "r408",
      "r476",
      "r477",
      "r478",
      "r502",
      "r503",
      "r534",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r589",
      "r641",
      "r642",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/STATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r239",
      "r240",
      "r241",
      "r270",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/STATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r55",
      "r56",
      "r57"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "verboseLabel": "Issuance of common stock for services"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r4",
      "r5",
      "r102",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Issuance of common stock for services (in shares)",
        "verboseLabel": "Issuance of common stock for services (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.ardelyx.com/role/STATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r4",
      "r5",
      "r102",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Common stock sold and issued (in shares)",
        "verboseLabel": "Issuance of common stock in at the market offering (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r4",
      "r5",
      "r102",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "verboseLabel": "Issuance of common stock upon vesting of restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r4",
      "r5",
      "r102",
      "r107",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Options exercised (shares)",
        "terseLabel": "Issuance of common stock upon exercise of options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails",
      "http://www.ardelyx.com/role/STATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r4",
      "r5",
      "r102",
      "r107"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Issuance of common stock for services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.ardelyx.com/role/STATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r4",
      "r5",
      "r102",
      "r107"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock in at the market offering"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r22",
      "r102",
      "r107"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r5",
      "r8",
      "r9",
      "r75",
      "r704",
      "r734",
      "r749",
      "r812"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BALANCESHEETS",
      "http://www.ardelyx.com/role/STATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r108",
      "r232",
      "r393",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r406",
      "r408",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r561",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails",
      "http://www.ardelyx.com/role/StockholdersEquityDetails",
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r561",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r561",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails",
      "http://www.ardelyx.com/role/StockholdersEquityDetails",
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r561",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails",
      "http://www.ardelyx.com/role/StockholdersEquityDetails",
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r590",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails",
      "http://www.ardelyx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplementary disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/STATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r127"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r298",
      "r299",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r306",
      "r307",
      "r387",
      "r405",
      "r524",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r746",
      "r747",
      "r748",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r806"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/GeographicInformationandConcentrationsConcentrationRiskDetails",
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r678",
      "r696",
      "r827"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. government-sponsored agency bonds"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "auth_ref": [
      "r827"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "terseLabel": "U.S. government-sponsored agency bonds"
       }
      }
     },
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandShortTermInvestmentsSecuritiesClassifiedasCashandShortTermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r480",
      "r486"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at end of year",
        "periodStartLabel": "Balance at beginning of year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r487"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedTerseLabel": "Subtractions based on tax positions related to prior year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r488"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions based on tax positions related to current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r489"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedTerseLabel": "Subtractions related to lapse of statute of limitation"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r69",
      "r70",
      "r71",
      "r273",
      "r274",
      "r276",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r494"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants to purchase common stock"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/NetLossPerShareAntiDilutiveSecuritiesandPotentialCommonSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r257",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding - diluted (in shares)",
        "verboseLabel": "Shares used in computing net loss per share - diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails",
      "http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r256",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Shares used in computing net loss per share - basic",
        "verboseLabel": "Weighted average common shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails",
      "http://www.ardelyx.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 15
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=6402221&loc=d3e15743-112638",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "https://asc.fasb.org/topic&trid=2229140",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1,2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6392692&loc=d3e7535-110849",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6392692&loc=d3e7569-110849",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "410",
   "URI": "https://asc.fasb.org/subtopic&trid=2175671",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "https://asc.fasb.org/topic&trid=2175745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org/topic&trid=2122394",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r669": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r708": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r709": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r711": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r712": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r713": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r714": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r715": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r716": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r717": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "https://asc.fasb.org/topic&trid=2122478",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126970579&loc=d3e23163-113944",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r831": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r832": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r833": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r834": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r835": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r836": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r837": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r838": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>114
<FILENAME>0001628280-23-006041-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-006041-xbrl.zip
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MT(G4 F6\<O<K=_\C[JX7?^1E_]SL\"]02P,$%     @ LX!B5J;]$<"-$
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M>CKLK&5(GIFR92ZPLP8K5LD1=M:V86?%JEPD'$L7]S[%#SE:0F(: S+F,IP
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M,:/,W3[Y4-[<M,[7$RE&[$9"/&%+[K)[/ 5%Z+^C__^SZ+]H#O^G_PW!U?\
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MG2]3RL!.E-M"XU(_W3W#%2J2.6U=,$EQ4$K;LMV7XA$-,YR#OQ?HW;WNGAU
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MK9'=6(96UU/Q7MHM%KBP7"F1'3 -KNSU[C/)G12"UKI&M%U0UMR" 9L_;;1
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M25!1."]#&6K44F,RBJE8J]D9-X)Z.PU2V7"=0%XK&ZKW3\JY$X3OH]GV+ 4
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MI4Q*G*W>(QE!SQMC*46]L'S9/T-QF\S@K8L 7G"Y(7ZR*7X8OR?M3T^K=#;
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MVS_<^]PYIF<?;^V^X5MK?[+6Y]AM?3[^$%^^A?C['YU]T?G@C\KSUC]N?MZ
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M>8-N>+:XY*2LYB7W;/P)[201@U^'W>_)L8P5WMYZNG9^[N?^[! W;:\YE>_
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MUMUNR!,4"ZF-".+T_%JA2&NJ?11DE.7,3S0+(. ^+X6N:P>CEFCW_Z[MB'L
MDA* .-(APAY>)/I:LC_=!] G>6K#&TO3 [QK+4S"F@EVCD+H/8R<15&W]=S[
M]YY"2 ( :15?27[?I9;YE6+)/7'UC#+RY09>*AI$.O,'G=>##VJ3_8LV.Z9.
M4 .5@T&$HW!@ 1U3=ZMFQ>^M3@5PRMSM(B$=D^,]+?T;:=TJ8\@,U^<H4Y+
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MD"WNXG'7C$2VM=#0#@7A;.'6]P(;#"X93@,\KI^,[/5R]@;->4?LSX@IPJ]
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M-I;"IEDT66AFO-A03!A<@223^$0B[@#M1\O1U>O]Y>[3_4JXORRT])2;EQI
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M;#/J.\<#;ST*W"*;VT0\'<QHH1\(*79.7%%:21^H"ELV'[/:VK*<=QC K\/
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MY:1U\(U-,'BG*# P2*,,E\_T*&'53G"'GCT/G<GJO[$[B>6DZT38(]&#-G1
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M(&5:=_Q7QX_6;6G0F&U'D#Z#3B2T#+X)XB/9L+Y(),XW1R3.[7B6/PR)<UL
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MU(_0[JZUVD27<0H/*!1] 6?0\\A?%(VB\$<G&XMI42,8PMK;>!^3H&,*E:!
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M4+V&):6";9Z%A/'O9WME2Y\&(FQW?W_2Y#"0?X63H8A*+/2727? :QIQ):[
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M:?>MF!22F2YU],F8YSW*FF7,*Z-,[RE3;Y)I<#-X)TA-GF(6[S528BQVDEV
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M)2>#L"AX7C5SS)7*<,R(56)=+J@.DW 4FC^+7J<1VHO:#836\%RP$:H"O(1
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M9Y(1L)<SD(2W(MB@0^#S<"(/.S'1IO#SZF?SA,>S+83J\4H#&W./UA$AN;I
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ML;@*ZAI'!^=J#]X\PQKVTC8GCWA OJ,[VP$'QL5"=PQD5HWXL../3.043.'
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M041N(%Z19L-OL(>9C;5T2TRQ#Z'9G2858G-N$:<WB<ALV+3O^(&8\DV1DKF
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MCL-2:R)YL2YK\%)#JP5Z>T3!L%&E'!Z'AJ9 A6,G%$\V$P(I,:&Y#8C92AI
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M&I5]Y3%2:8J/RP\+*^92VDL91.HQ;WM].)>^>@-3WQ:5:SF')RHYTTE]T10
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MK2XAK0EFUB7@RE"<-RR[=KOQ?BBN7]C/R$ 6BU'^696N0V!/MD@H,N.TYE9
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M>+DAW^&_"BCA5RIM#(5B<9YY6>@0P"6BD\_K*;Q?!&&1BI3+4=<'N<.%E,B
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M:]XB?WWR.HF)-2>0<@+'WC"IY?'#11;7LXZ\HTSSP93F<QD6:C69&$UY1")
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MQ+<$##1710YA" )(,7&<T>)!/7'F+K-R(4MC;I8=?L#B![[9X0?NQUB^7/P
MFC6ZM3#>I_(9)M[ \*Z1.AL\<')Y(;D/!@%/.J4ZJ(L@^@6G^K3G5AG!C"5
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M^B1DX +>\B]HLC9D->G*0W<5OTB )@0Q5"/HO[+I48.%L,O2&]VC\QW<SN#
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M?>F8NP6%)UAB8K+YPS2N-Z:C?2-I9U9QUR7\QJ6A&0+.<"O\'_%J8F_ ](,
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M*^6S0;-WY8\@E6Z7=8[=4G22N3R!(.R%'T_(*=GN <QL80E#6Q[2+:D:VR5
MK?EQ!JXUQQ\&D&$;)85J3JKCB[@;=")I"*/,?5A*O#.8$H[N($.HP<"JS:2F
MZ1!OA#$(GQ=1W0#I8G=%.<&L:(@LQ%1P1E_"SU,C3%;:GCA%N. ;R#>-ON@"
MQ38Q>D>E(<8^S2]Q/-A=6U1R)!<^F*2/!B*YTO\=L7IAHFR3O(Y?KOV/('%S
M;Q!5MY4>,2!U*T-RV\SHA'XRVFGRS!0H5]B,]P;-HJAF97>2!=RGD49)Q+3.
MB$ +O;L=[U8HI]R)@6N\G7X/8W[P"8VY9+I,EUZ9>9_ATJBIX_(%N*0F?;;N
M$J6\?7%VJF[OF($[@"TC)WW;7F(F=%3[BP=EMM,MODW@/&\CG7"V3F6I3&+C
MOJ,5ZB-PD<'VHG'JRB3 P=R9H= %,B&CR]Z[D+[X+T"@,(-W;2+<^I3,?S25
MAB( \ RK)'4(G/*LR]1@RHW*1B"2Q4+Z0A^0=)=,6?7OWD^V#^69S5 H##"Q
M>\2YPT5M H7_S):K[\/8U$V6G7'TZEPV1AJU^K':$4T&,\93_M;O.;^=XM@C
M3,-+]I;A;U*>)'Q?*PFQ.>&F SM\%>]8HA)IN\&?_1#^"MX;.XE@ 40#*E*T
M4N49? 'ZHF"143>T;:5ND3$TB=.G$"SZ5ZB;QI$>!T3ME'[GL@>+4E M-"OG
M?01ICQ:?<-D0R<*'0*Z4SS]^N_]"G#%$SZYHC2']BH$'@UI)/P#_C,67X;!<
M0U[#AW%C;B*J.X::W:*>]ZU ';<I?AM],=QEMXW#F$LT#NK[=JH8"/<DSY=+
M_+J3=?GA-"6%U);81,U.&<HJX7).-XH-M<#$.$0*-L0/"FMNX?IXB07N*965
MY9;M"0T<Z^!. N\WR7X9FVR4#8S( P(S3= 33AA[HP-9%/$LJ/,#_0WI<U$?
M4PIM9/5L@J'PKKPA[D><=^!"!;M:UBWR$K.FD95,B2H)0[D65.N0ZSWT@!A1
M<#8_0P%P,T/3VD"_P[W_V3H0+P/70,A1,6M3='"(?R?<UWH-DT6'9.B$BW':
M^ZMI+F>=3[@63YX^>_R#1$G1':\V&O^"?ZC66GEN%D8;:N$W@M2!XPV[L8H\
MO7O?3?I*=B!R<D!R1Z^W@/[FESUSW(&.&TZ-VZ&14#'* C^=G1^&VS0+NFXM
M=T'X^Z*Y"+6K@CJ9D/I#3J-2WU4UIVO]'1-&ST^:.VI^Q3M,9*(G#[:X5OCI
MT4.4H-DV;H$;VE>HPDVS0!A>:Z7T"[A!G)!6_.<:C*.80ALLUN1&2JT\II9$
MN?L.M*BA6N<],4AX-^A8^@55%>ZROMZ#:WGI) '%;77TOG::,"4G]PP('#/S
ME!82P9[[7YJ=H9X;5BQ?G?*:HH^=+3'Q*9O33CHJ&ILGA9#.'S.\F]F_34-F
MP=P2AEPS]E#,T_WUQ[$\ I#@Y [TDR8FP'HEW#=#V5MS8^+9P<F=\$?'WXG;
M&O8]^:H#_Y0. ?YZU1/0IJ6^1/^IR1VY3W\-SA6$?J3Q8;.5@#EH5/EHPL^:
M>&_Q'V^GP3G&_.!>C+ECC<1?27<>G^W1$8,- F/:4TP-GTM]49)FU;=%1=1(
MH@FV?X^I&JSW(D\SLZQ+(INV[/0A-Y+LS#,C5Z]IOZN&-2RT)OI>VOUI'S>
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MZ)K2\(WX6H:X [C.@QE.E4/&*%K%A1/%,<3%3PTL_/KXW8>EV;[B$TO9@"9
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M8!O8V)_ 8'<A9S:=*Y?.]#49J+:=$B2ET$M<Z9IQKO$&OV:V*2;>!M$Y9C;
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M*!I<X(FDB0F 13]3'<,PY3OY$2L2C0QTEK4,D;+XUZ)8'^96(1/HHEX2E%+
M&48D5 *\B1<C0AK3Y3&:K;;K\S41)([>JF:0R8*6*Z8.UV<0?31E_C%)T.H"
M:EJ&YPYWJ%KWP)X';.%^_3&: OXMH:,R [>S<UTW[[E^8?]D^$X#R H6#>B%
MV%>V[R/K \M&+T;>_B #PG&RDC%K,]4D4BGBR-'IRMV$40IH/N; W.S"?Y'%
M\F>[8OG]&,L?7BR_6>/TOD2>&.>@8B/IUTB#I!5VHUX;+6KMA:*6K8&%^]A
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M\@77".](D]@,*#SYW6)$'I("N\@@1XJM?1'G"#ZA'1( LF :L,H#$U<.])Q
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M\86/1B-0C6:1H:!@@H-1XANT(;Y\8PL0<L(@=TSAT[A5)G:3!MN"W2PZV%M
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M.J"1<!=U5XALJ.NNG9M<=.FCBJ<RXB3I*R;1Z& 48+;\S3 #?/@EDL80 0N
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MY>;OJPP_LD^BNO[*L9_ ?06Y_R (;>UQ+/@ _LN>_]T>EY!TY"D+)HR&CP5
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M*8U4QO70X6 LUCB77Q#35W^$[6NZ3B0V%+R XP^IR*+TX+#\64Y,R4!B9*@
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MN?[2#;)?JMT[=)7W:2[;-!:OU0]O7"\&+3A[[06T7/K2&TE Z1.B$P0B*L&
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M_7P?5V3S?7!@BEB$;EF8Z8:3=R(1XV2Q<&3YX:V(\L-V9C0N*+9&H0]_]>0
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MDKM;V,!Q%@;[1TX\MHJ='-9%!L2"4O+28;"!=RDU-EV$,\='(*[MD&_W[/@
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MJ+R3[.O8V,EWY66S4Z_5=4.YZL +)Q/::#C\:B/?RLEC\A>N 'L@%B!:B*^
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MY0^@YBC8SO3Z1NV@Z(^%0R%<*6S0D<$7R/&7:-QBC2B[7*174O09[NMV_8B
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M)%)Q?"LX7C0[M.6">&^ \IA *&; 427!:T&3ILD(E7T-UN?J#L9".FU7?*F
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M<*EG[,;EG9V[YY7#WIL1N"8K!JX34J=B#(D(+@*/1A 3@S0$&8DZFM>/B]%
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MA<]PBFX2CII!V1=*"VM)X2UF[N8BV!G%QU\%L#L/'%0KHC6"6FY8\MR'Y'0
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MCA,=$[5H27+9#J N:6L]\TIYQR*GU1N]+0:3"PPFF#*1H(8D1;;7DE#@>53
MF38T,"XY*6W5I)IJE<'N-8,%S6-V1Z.27$@:?#;3;+2,N P7XUQU1SM!;Q\7
M.XMILI1(K8%[DODM)@.6LP21"N5E,I8KN[5-C>JK2UJ+.TIR+4V7:/ZVGE>P
M=YB=GDRGITTJ=)S*&M)2XS4M*.HU1>4]/#X9CC\AGOWPY'02CMP4>R=#-[K)
M%M*[G@@E003F:23.HK .#8TTPX$GPWCTSOY%%]IE&=$B@"(MC(]/)_G9/<VW
M,3[;Q[-[)J;F34_/A/0TR^B:<T!KWO0:!/AI*6^J-579J!-@)2D[N1V")RB
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MB<AD":H+$3R&[#7SQ/^"E%=K*[R2DJO9N2+I+B9#N!<8G=,0&4\@#/%@K(U
M/"7H(\G:UFYM&WKC;&^%<B7<*J4JI4V4T@IJ4625: 5--J$2(5E+O94T^^]2
MB!@<5K782;6X%(TQ+GJOLA]BB. @O+3@0]G3PSA21[55S'=-+]:!ADU<)?OH
MO>E\_\:/M5[?O:D@70BKS'_^ZWARMANE1E-:9+ _EJ(IRELJJ4[  J.0Y6O
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M)!3G45#4SIJ86<Y(1JP@/%W-<E<$SRK=K9GN%LVY*(FW+ +QFH$P)F5+3@1
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M%RYL=*ZYC-MR/)HAP/]:W*A=::DU6GJ^[%XH:Y CAYB( 4&-*P1EP-!@D-A
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M PE_@YI[]6(3MH(B9-]W,M\+'1)%;DP"Z@<D#5.?>)G'X%_)([<OH7\&Y/P
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M[R0DY6Z6^)$'MD:") Z'<3LBF,\LP&&+E7ZH0]Z3]8=LEUUA]V)E4ZV>,?T
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MPC1VS(<]$=,%&\FE+5OK+=V$Q_4YCW*3:#GQ?KSE8#G*NS6CP!,0+2<'<52
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M2 5E-&4NIS[W,]=-W'N+3JMJR0^H])V"SM=P</52$Z2F?Y; /YD4G$2!GY*
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MMB[Z&K3W5!%_P_AI5?+ !X@9-)?:&%-N4QR#LLF,I84V$3Q-NVT/)LTW*9=
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M>+Q&5YJ6-F:L?R6442=::&NMM*4@*N.H*MU<S=H[6]Y2[*IBDGH;UV:@FK
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M"!5 ?(Q&J#^$Y+2M)%^E0E>JG-# # >8^/@7'$!.;;Y2G;Q90?2T;8R*H-N
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MP7DJW2S(:'1VN.KDDK!U<!O(?U]E(Z'YG<5Q,,4_<, ;K+WB[$=ZZ"WPWQ=
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M(X(H(V:F>M?FL(S!-KA 3%*8'0B4QV$V*KOD>#IY1<N+0U5X4]I\DI/):U.
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MU8M\HA9 W?2+>98)KV,\^2N8#9CG;G9*[9#^VH2:TW0_=F*,-L\+^$_8%YM
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M^Z,&J;N"U.PV0V(845(A80CX7U$I9)0+R&F7HLS>%TYKFS4^U?CTI'W[;84
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MT$@UD S+(\UKPA(X1]0HF62-C-APDA,!KG.]3)EGGF#_?:W==<!@];1])F!
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MD+>PN>"F\)$)I1/BADK$;>)(:_!A<)+6R9 ,-V9MDQ"Y+LVB3MTN3I66/+-
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MI\^(;#EAO4R9FKW\2&"?PR\R46['R4DJY65Z5"H-G*"90V)U.SM_!I-73@,
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M$Q$<?$DXLM%XA(671G$%KEY:Q@6#6H47O9^7LR 4(=(2RRVU+LBD''; +,%
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MQFYVRKN=<]O*SJ^#;I=^+>!OR_:K(2UC"V#8\FUID.GT\(;F-'T'Q>O?30=
M4=TDJQUY$*-)[%W]RG:8" DT+ZH&P\C!;9TV7##FP=!X=ZE?EV&JS"6:[<J#
MGYJRX<!Q6IV,/>WTFOF:5^5H@'/[QUDS] ]'(=R)&X=!.'QYBW6]3FO0O_Z6
M"3GS,0/3$\F'5C,#-/'S<)STX=0>1.2 [A\#:X/&OK*M,WO>6_M]VL: @9D9
MP]GN7]O)E!ZLDY4"ATPIRCE_51J0?!6TR2Y-6XK#;F:W_]/47D;O+55..2Z%
M<8D$27QR0H1HC/P&;'FWM&B@'V\R,08W^Y^_V\VK9K+\,2/T%3^EBB?OA5=
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M=@: LZ'WCU?S]N=G]NAV@<;*T;W**%QISVX4^>OLX$UCM_G/X>+4R'LO]\J
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MKI*Q45'P;["@Q 3 I2M5^2K3?DO%?OMCF''Q=9EM,89=^V-5;/VC0\&DK6<
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MC;LB-RYRQZ1?;[(44PXT1!]43H7/)/;QMTSESG)N37 K&@9L#OB.#CAZ1K.
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MGGNI*2* /,$US*]N6A^QB^$T>/=>'4%KR9.S8!+;U54*<[*P.O!23*68L@N
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MQ:7W2M+LYABZ.?D[/?E@34XS&TC,<SAYCL7LC!>$XHAUGS,T1V[8:K2V,.8
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M>:F:/"X,]G#L)-?1J 5$J$J!,5N^#J";&>)JDOI7Z2[X:+CE*:P<+^^E-'N
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MV"+QTZ2V-4JEKL;-:E57(7:-+\T*>\F1@ &+ZW%FIW.,N)C6:SI ])@_C%
M!S,8CLH(#J LV*.UEMI+KH>D!**M:KK#S@?3F]QDK3N=EZ@9UC>O[(GMCIV,
MTPK0=DBV3]JT<B=*J)I#JHL!&LRH,J^)6<N$BID*E10MPV>@*NP!0Y(MZ6!M
MY6+@[(<#/W&U<@W*Z448XQ<NRK^/MN<%VK RMSP(ULODD@$LQ'C:I-2:P1 9
MHY$ E(*.F<8$*"W9M/^5%0D\<XHGVL>UPI?/4DR[8R9 AD,T#T$$#$:I\W_+
MZ5*)![0TZ@,:3MKK'8&^FXQ?-*E3M# Y(E!4PB?3$"+*DUHQGQ&:4RI/MO P
M)*,-[_%JY^5.Q^-8##AM8&[4],^J$&#O,NUS$\XKY7=:4^V-;-\J^9/ -NU<
MALJ_76YK;?$/YVR8%N%.MZ_T*?E%:JG)HX*@AA@1@[K]RMK$L^]5OG6TJF/M
M3)A[BBF?4]/(*IUA5*LE-P&K-@-?R6"O:],6<[>05=%A,9H#O)7OCTO:KG4_
MD,6(@6DG6YR(RE;#B,G2:V[3';51PG<!)H;5+<I-!#H%]@+:K==2VM?H>KQH
MP,MXM+ZN4&IPW^8FQ2R;F/1+#T7*YC9H,Q3IIQJ*M#3CZVLSN+X3K9:>QUYM
MF* 2-^.]NA+O=I/TJ$N?RDQ:SK:K["_$G"6:6T*1R:@46K7>6.%L[6L%+%MI
MKI1ZTGQEC/;",>^LY5)$YJR.RA::A\Q8 ^=R31WW&J6<NZU->ER_7>T=? 'O
M]BP,7<KXKHP6DOWJ5LOGW9.<4UT(5Y#"*DT$E1FQ04>BP,;,HLPRA4%4+I:8
M+?^]T_F5O8][TWY6,TT=,/(+/+2*^3[.^#R^W!7P12G35WDRV_QS%'?]!U09
M*R_[Q@MP$WXZVGMSHE6>>Q,BH51Z(@*6,5/MB.'*!1Y$<' .#]C.8KU#XP5H
M:\<+NF_MU;MED0!4F6)3C6GX[2AQ__#)/"D^JUR63T !;[)E;]QVD?[J9'CL
M3HS+O,P*A\V@.1%>"F)]41"N\@S^GOD8@ S[@T4JO,X*JAW&V]>Z8.HVQC:<
M3OJ-ZR'9FCLW,51N6-_"Y-;5E30L0_NFK.\A6"Z8I,:,&"'?1(XL+XTIFLWX
M'E*L4R+!XC^_S:*6;\D=EPKM!3N^?U5!!\>OZAJ_]X=_O;E\^^[]YS?'IY\/
M7C^FA^=/NF_>N<NCO_XY?[NW__EP[Y2^/8?5=0OZ]C]GU)W_TS>OB\G1^7/Z
M]MW?YT?'AV='>P>? %:R-Z__[AY^WA=O7[]]?_#N@![MO3A_"_?ZS^?33_ [
M2"SI,\8,MAT,1$0%&F#!"T)]5%%(9CTKYJMBHG!24U#G0VX 7+QFT4>J%7/P
M$^=ROA#HX=&+%T>O]P__NJ:>9ZD!=_W#9A?GX6H/P!0SKD2@W HAX"O.6S#]
MO+);5P+%MS0 TQW_Z([A<>X&;/%RT#/#SB-S@=](_I[7H!J$8;^S"YI#\HP_
M-/WWG:<#TRJQ6:E:7__F]T75WN]W#LPE^J9U4E7FRH]Z^+XI@!#<)/E\IRF&
MOVWAM^:V9.OW[3*0,KNC3\=^YXIM_6WK*:KVP]&T/.FX])C/WS]E_731"D@I
M4FOI]07GQA@7N8#_F9Q9G/;.O7*669M3CR$^IJF\5HE"E-OOCX !<4E/C ME
M1^L?0Y?_]FCXBH+BQ [1+G[WGAX\/^$Z:*:$(E$Q[ .1<V(RQHD'E22P3!7*
M87[QE3D)F'94TF<TKG2A),)+Z4TEK?J4@!D[AX,/+=6\TLQK^CW&^R"1S=)>
MG/1ZC0>ZR6IJ79ZRQ>(D6:2#Q$75[?/M=&5RC3=*/V8^-^D"2>]+WA^\#R91
M?;&M&@M)56XBS6,F8I85N0NF,-+G7N4QIH9>2--)9B\2]Z*MVC80D,X/P_@H
M[H]&$^36'RAN_>VI_#F8"H\_GF1!1QI#()H+201L.#$Y%<2 E&2J$'!@9NN!
M*';X2MK>[B3O.)Q3"NM4KA!4JO!GN/=VE017F:YE9*=;'5(9W-[I +0?N?$
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M3/JF71B2Y8TU\FT@W)Z;E".+D@HUKG3;4I>Z,N_%.ZISFP%9.L%C402AF.!
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MDVB]HEF@)"B?$6'SC!B:!T(+:D,1M)"%V'K =NA2O_\4'5*YF_U]_1J8KR2
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M_<'_C,OLL-I[AEH\2?'(BU'XH_[A3\SWZYG+/[K]=!;I2W]6'?0KEQOZF#[
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M;?KU*>VWG%N$X1'C$=G@S\DFKM7$I_L/CU[L=/X*?1SYE>8&]MT0F#ZDV4I
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M-<$'2 5X;;_^8G5S7&0UD07H%-^OZM(_FEQ<]+IA6*XYM0NV.!=O,!Q5HUV
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M@BX%SM74="PYB_ J1G$W'W8JHQ^K!#&G:_"PW_G2^/D?]8&PXUY_>*[UZL;
M33[NBR\S_#!L=;0_5B].@^.+P_'W$W25>>H9#Q@1103BUGED"4](<"8Y,%DN
MF,WGN;2Y;J.MJ1C^#%3Y81A9H\H/JLICE(QBBY4$S]-ZYG.);XN,<!CYG,B
M4[2)L*S*W"R*D3U"@>]E919;8[F_HTR#E=91+$D$_BKWF(%F/&\(>F VL=D[
M\@T*+1J%/DT0BA2%"<I[1*B@B M+D?8B(,R445%;(QU_]4:LP)K.AT(/QQOF
MH ?/6P4?F 4T*OA *CA&!&PY!.<#BH&Z7&2EE!BF* 03G7.:6.9R"%KQ.8L,
M/[5.AL0\<1:PW3NQW87%N5YZ-/SY!L0?F/LT<+LXN-V98#Q*)2E4"(A9+!$W
M2B!-92X/Z"3\'X@SNH);\]"1\.>RZ=<@W7-%N@>FF W2+13IQHAEH#1AE;?Z
MM"];?18Y@0WR@A&MB &ZR5Z](6R%\LGJ7T\4ZII]O\61\B?-Q3^7/V) %D9E
M]_(1LD/;.2HANDZ*K5_RV;C!K[/D>-YA.J9*XD^=CYN.H\S#1V_"Y>&<KU53
M_F$XX^7-?)J33#W.F5>B@>@9('IO@HQB00*1/&_EF82XD!H9H31*6DANDZ2:
M@.]/+X[-351_?XC]M9>D._,PG$9W?JKNC&^@>1:EQ@[I(#CB3,%OGD3$(T[&
MZISI!(X<NT5WEN&<QUU-9LA5:O+QRWSB\H7M6!V5,A,+"=S<XLV,:?YZ/>D?
M<EF<V/<E?EY[,H@VNCZ#KG^=L)-.8Q^L-BBP7#@A*HR,!XL9N5&>"J)-L*_>
MR-7'C9#_#('_GQDL_PO=(9NJ\G>+8#0J__@J/V;>@?]2 P8>6>,9XL%A9)/P
M*-@ ^$V8UIYFE9\S2KOT*C]#L[B'[@,&&O!';W#2E"A8?[^;@M+" P&-2DCP
MX!)'6CF%J& J$NU,Y/.7*'@:]0B&130&)X.5UO?]CM\OM48N5Q&ZJ#L2?QS'
MHUR"H"X\4,H"EIY)I59!];G>4;Y3S(V,!G6Y@T'KE_EK$8B?4(H ='$55P9H
MWEH$DJYBH1[B>#\H\@/4(A#L^B]]<H/5]&[E&&XKG(!GFX/[%DX@8O9.RS^Y
MI(*>Z13Y3K3]UD;I*'7?X@IW"E!=[>>ZB$/Y/W,V9ZUC</=I:"9YLO!!,\D/
M,LGX(:I+/.F0W'A>><V2?GZ.V4^=E9^9>?$4-B)FR;RX9P?9VU(PLO_V(K(O
MOK</ULXWZ9>#S6WXW/9[_.5@[<?6^I[8_/.OPS;]Q-OTK\.=SY_PEX_C\8NU
ML_9ZFWTY;!-P /<WUS\<MM<W^-;Z5PQC/?^RO7>^<_AE_\OVA^ZTRA*4.Q\H
MQ\C0?%3/"8NLP0%%3PVCV :66Z_Q%2K4TTV^&&E+DV>VE&CW- .UDVC'12*&
MDV12E-PG8X@S@F@L!>?!VV%#GQKMYDXX:]!NX6@W%JU5UFLGE4)!*X^X$!Q9
ME1BBR3@74F*<E(/)4I&GBW9-5FV#=H^!=B'O7E@:0&$HIUZZ:)BS)#@1K0_2
M5F7-\:BL>8-V/QGM-L>WHP.VW$6-LM%"W%B,K' 2>7!]%;51V=S(A:Y(/.>&
M]$]/K%U0'LQ/U<0_[&"_=6QA@G+9[['2Z#-/_)38ZW/SKJ<]8N- SP:R?]NS
MLKO5 .WB@+8]X41[ZDQ,W"(I*3C1BHE<GI&BY+R*Q$N3K"].]/V+9$S?:WE0
M/WGL*V=FCO>!IB4AAW>"IF7A?P_L[3;0]"#0-'ZZRAF2J->(>8X1)XP@!W8$
M44Z"5\P);F*IW\/NS0'O!4UW<VH;:'J9T/3 KFD#30\!31/NJ5'1^:21</D\
MA/02F> Q\E908RGF4>,,36!PGA T/8'$QLE6AJ.CRFU[<MJ'GR\^Z1%^[GK@
M+L9%CY+.+4IIHLBRA%%(C'!GO+=2/]^^3(/30W@ N,F@9#J"-M3YWQ&,:Q5[
M.*MZSSEXI"KML0I%G$Z$(RZ7KLU)D;TTRIJJ-)&1E=S'ERY+FJ0QJPJKNV1)
M:KG*F7R0=,:'R1!DLPUH&2)KLW42VCC*([T^K>_>V7P+/>T^3\CT25-34'_V
M$.=]YTFT>FXD?MHC/AL2OZCZ5#<2HB&57S^-F_#-V]]C]UMLPS#V7P:[9^UM
M8..?W^[#^&C[X!/>^OR>;/T)5WS^L-\^_\J_;'^B6]MPKS_&V;W_L;7]81^N
M/=C9WCG;W'XOOJQ_XE\.VC^^_+EQOK6]W]W<WA'M@_?XW^<;)^W.6$S46>6!
MU"++N4><"P_L7A.4N%(4!T=@S7-,E"^LJLM/*21X>^[[DX.?W$GC/GG$]RI\
M/FODI4&V.9 M'V;8_MYK &UQ@/9N M , )DCN?(PCAIQA0':I'9(8B;!AT])
M,YX!3>A[5^1;=+CBX=/7?S:@B0>M-//B.SG\%$#;[\?80-KB(*T] 6DAI9@8
MY8@G&A&W2B+MHD*,^:@%LQ[G!"&RPNBBTB$;CC8SI,F&HSTW2'O;.^TWH#47
M:+V? "T.GJ,0U*-("<_)-B1WI)$ 6H!=TBJ&A00%NG^'P(:%S5>6?C_VHTTG
ML=]PL:<,7+8??MR,6MN]W^/?MA/6\F)>X-9E)I8Z/V) Y['?:_!L+CS;F< S
MS3F1B2GDO!:(1Q.0IHKD2N^$>PP+FP-E_\]_:5C3WQH:]KB8EEMM7-TZ'=\9
MK7=1K^_H^4AL[7X'=%XT(LY+Y1JG='%XZ"<W#EA,GDB/DJ<&<:%HWD)@2$0=
MB"?.)$K!*<4K$B^*XOWL8RO/@O^].SP^/2GUMH UQ,')J-960P?GGLM?GAKZ
M?;ID C=^>/CHVF'^JT&[N=!N;P+M&"'":"D0K!M#7.N(K. !&1Z3$L[ .II7
M;[1@$U WT51@B4A?^6ZUJF9HN/H$^-\-R7 -ZUMZUO>2F_X\$NQ]G=Q,I=':
MZ )*C"O$F>-("\]1PL$E*ZA+PBRHO=F2<;R9>U#^5#W-9.%UZX^KW:8OE5"=
M;%'=L,"E8('7H.$?+ZC%[F.ES'W_O^UA/:[WM+V^<;Y+& /LHQYY+0$5J17(
M,<T1EX9J<'P54,)\(D8;_OSHX)/'O/$JB2-H6VD=Q9,,?OXJ'CX$.9S1S-5G
M(::T:GNQA7P6/T%/VWH\'>/QPEJT/Y;]^#%A/[ BV@KG$4XQGZ@,'CF-%=*>
MTV -39[+5V_$"BSJ8EGU K3I <]CYK^SO'>.3LLQMRL'T6J=X;2*1ASW!IW\
MF=?]V(4/?XL7=?7_Y^KIP/J9\<4EUL'CG9Y<?\E$Y>.?=%S0J*OG\B[_FX=;
MM$][&;VW5#GEN!3&)1(D\<D)$:(Q<I=0_FIXU?ZHU^FQW8O(]:/]BDHRP&O;
M_6[/!J_^=?7X7^<(C<W\^*1=.S4I/=C45+('>-2K^D"\!HF/_?PI&)-],F-I
M[?<S;O_7[6ND7KTI1X$S._DC0W[9J;1OIJW_#2=?:T5%V?R7<ZY7#KZB1SGY
M.G'8KX@RH:O#9_D9FM2J8'/RW\<9U/0Y>> #Z!]/>O[K?J\+TCC8^,]I,? G
MI;M4MS<X[3^A8^?O:S-^W/VRO7FP<_");![L?]TYV,%@2COP?=\W/V]^;7_>
M(.US,*T':V2G,W;L_/"?;IMNPGW!9/_YH;-Y\%YL_?E79W,=/DO?_]C9_G2^
M]><G,+__=/X-E&!K>V_7&2)\+FG (@$O3EJ,#/ K)!U+V!B>-,85 0.#%,-:
M9D,Q$,((T80[";::6QPB%9QJJ1/AS(X?4_^XO?7'__?_;OW?^L:'CR4U1/W6
MVGC_Z=WVSK5M)(N.CUG":H%N_?(E/17_[JCUUVGW+!],Q[FA3RMUNC&T;.LM
MD-#61\1:_;C7&9Q4^-H:]0(:MA%RT8/@M\!9CCY3@=PT:.UT#QZRW++URZOR
MX\/EFWP<WN35KRMEC>MNT+]T?H4O=B5CI-\;',,=3ZOC]B?[&9T3/.+1WDJK
M,QB<VB,?6_8(V!?0X98[:YV6$_>GQZV3'MSDT/[H')X>MNS>'HP?OFYT.=RZ
MXPO6__<<[#]E^D^IE\1R;@4S*0)_%$Q'1RV+5>\YC-55]O]N\^V5C+)V-:JU
MX:"VZC']G8<T&^^7+PXPWN&M][O*2)\,I8@0'Q GN9E<- IY;6P07G&7$\"H
MP*N3)R5;H#;=8>CUM \+>WA81!G@=P7$(<(B]&,8OA"B PX>?:X1THFYRY7M
M]VWN?@7B]J]>OX@)O)SZO</6">ABEKCR,_?+.@+1ZK<.>_T+B1O\5@3UETX1
M[TN2/3@]/NX617@:0BX]-D0EZ1UEG-KD)*;,<.,XE5K[V CY@PGY>[&YMPOH
M@HV4$F$1,,KUXY V(2&7I(2_&+<.YZR>>84<),N>@+2< 5H7N<H GZ4*^,D4
M.5YI%18- I;%#L0>%K*2TN^=D_W67[$L*+SQ?__W!^#[Z.^,YB%_,N0[P5=E
MHTOQ;_8$@6@CL(E?2PBPUHKR+OEM:"&VCN-1JUU]YF/YWK7A][[Z=;4BC'^?
M]K-2G)21@K;<=N'*Q6!7<DF6X?.4M_K11S!8V=;ER8)YJ:>O4J_Y>I,Z;F/D
MV!'F&-?8&^LQ_!FUM$P[$6XI43JN0X4^OJL1(!>!_F,TPB?8E?2QE67O#"P"
M%YPHYRD"NY";<B2''.4661V)D\$R%GCN&3ZI*O^3%SF+SQY \5 H*L#,,#S8
MM_U8</:*#F5EJ15C%M%;;:U=*0'4JJO_D$*R]FVE?==+636*<8".Q'"MI"0Z
MP?/#HTKCH]:& )VVBM]6;5),=5/>%418/RT@#<K2"Q_+EP/#+&_-6 3BY8'V
M!GSGNUV3A!3>1&1\+FQ+K$"68(_*[KVU1!E-@)JPU<GTI!%HUS*707D$2UG*
MAA:^DE2@#C[&,)C;KB]:;/ZN!_(63,<0I;;2'T5=BD@U$G.=Q&QNO]]-R89$
MO4#48@<2 _AEHB9($0D_P<44RMYJYX_GM(6KK5GJC#U];_7"N227_=6C5@Z_
MY2FRW6LX]AAX3W=)GP83SSR<4JVE8XRG8%R(2KJ@I(B*2:*J5N=8-TQ\\2I*
MVMOO=B4G@,-*(>D513Q*@C0)!%E&&+5&!>DTJ.C<_N9=J?@5\9Z@Y;%5=DJJ
MQ/+>.$TO!)O<3+!7KN!)%=KYGNW/V=11#6*W6PM_(];+(=9L<WUO,6+=.;K$
MD:<(>+]WNG=)_E9;GV/I-MZ/_SGM]"OOL A0?9<KN'RCG*ZVIGB -UXQ[@&6
M?N93O,#!0KQ IA4F*F'OI. A$1>C%EPE:R672IN::.G&"UR$1(NM[8U=ZJ7F
M)C*$A2>(>TZ0P5(C%ED ?QN\;Z,>U@V\16(KOZI\^*04UFL=ELIZ -F7&VM?
M+1%;F,T=',0 )#[8E)C/)V(C-4%[D8(VT5G+>;US!<SRFDXIC8.X4!']!/?U
M9'-[[ZR]O8$WUW:Y)\YYAI$U*2*NN,_5EB-*6&+E!6?$XU=O)%^=K"5SHZ]X
M/_\P1B>Y94H[JGG"Q(&H$ 5_)@5HENAM_74:_W#A O-C:WM/;*WM2D.<M]0@
M)ZE'W-*\3YH2LL(XZAR.S(I7;Q2[26" <-I6Y59EMODM]L'V7<$[D!=[#-(#
MO KX5/?L9ND!""CZOU@IHE=-'XQN*Q59^5R/?*T:>&%Y%T.H106_:%'Y^KV]
MM\L5@^D5$9FH+%A"J@!;J$96:8Z%85Q9#MQNE4SF1;>.8VWPYC)M:S<5.1\:
M, LTJAP02W/:,L%\<BX0)B7CVC,K+6;P/^;:QJ#L-0F7XHH<5;D79>2C@5?&
MJS)J'SL 3>_@_^,\H@:6KMF"_='>]KL&1V((<2B5/5C)4XZX,Q1QPL9+K V5
M@$5F=;)+S@,:KP<3D\M&K!&9^44&H&G7"D#_J"GRRH+YHIXAHYA'05K!K0O8
M!/OJC=%/P'S=TW=KS-><\G&6PVR<!1L]#RCXS(>I,YG>:"0-MN"V1*Y=L5ET
MRM[)W6S6)7?LN+@RK;_LT:GMG[4JP\6RUS]ZB5:O%7?L8K_X(A)W/^CR&!B_
MQ8KX9#B- AZ:2.NIHU)YRZH.36S(F. 70AO>_2#2Z.G6]@[96M_ [?5/'+YQ
M5_KD,3,842_ V$6?D#'$(Q&,%3+WT:(ZEZ"\*5 VW$HH>P89I*Y$<>=C0PN7
ME<:S7YC B/;V6L[T9\8PATCN)LTET&]G5$#&N\@PUD&D".QH5=U*CH;1]_Z0
M03^. ;RGA#4&\%Z0<[ZV&[#73A".+-#L+$$4N4!3/O[/132$1@EDB:[**9!S
M-V-8RE&V]D&D6D!WCEI'O58/KAR&R&>_5:L<8YE(=KDX=[#<>\Y#/C#B @M(
MDKY\SVJ+CBU]EC2.P0:1R\M:RKEW5B=MC2;@&%)-F2^^&"!'L[_W@*'FS?6]
ML_;[76J$(-ARI*S*)8"I1B:YB*(5REDEC-"AR9B^I\ 'S;B1A"60? #LH*W7
MT6,-5C-RP/)&X!])X#??[QH'G(5YC@P##Y('3)&63B#+@-D B=$IA<=,V7C$
M[&EVU^SI&R^\,7LZST?M$2]DZQP+'WBT*BL2UT)H$Y40D4OLI$F!3+#/9NM\
M4;JS]7[7)H=MT@%9)Q+H3F+(<3 6WH*Y(%)I3M/#[J+?*(E3F6KU5=,4=HX;
MCYWQG7H(?M:3WNK5W4\)7\]\?^K!8;9Z[=G=AST_>W%2ML2O<I'4LB(?<L6!
M&+)&#XH'^3OPX#"L._QT3M7Z87$,NK7^]<>7[=\/0/N^M_/IU_5W?&M[#_X/
M^U_6V]\WU]^?[9R_X^V/X\V<=^ S;[OM/]O\R_;:>?O\/6\?[(G2=9R^_=H^
M7\.;ZW\=P&L_P)MD.15=8*:4"N!!FK);+ 72X%0BGJQ*+((['^WXJ5HCG;-1
MT:A"X@8(?*()>X!A17G"UHV?JJU.T+;>;?ZQL;G][I^-UM__M[;Y\0XG:F__
MXJL#%51YL.H8' S)&2A=)$"Q*#=>.&*8F/<$[L/I5+GCZ\X)?)V?0<LHQKKU
M=]<>/0-G^7,V!+8N E^URZ[0.(-T>=!BF5MY_^RHN,+YP5N_U&1G-!4UO?D5
MKC[I=%M_G1[%"G< -CAXU8#H'6!4P$I.8O^P<V1+:&R0>4<Z/0'8:%EP0D(F
M+MW<:GMO/W]^*%#E<WN];[%_5"5FP3TJ4U*/N5"^?CRTV4$Y/0&'ONJ7?-FR
MU",MMNGBS^RM?.ODS*ZA@U+F(U\,]^^,'CLS2- 7])]36,?4&3I3PQ&L5!2S
MO'1\VO?[V=TOE5[*V./A<;=W%C,Q"QV@82>]?K6I"D\X..V>5,[72?G^7)2X
M'X>U!_,KK@=3D_\87;M:+\OP^8=K"%PO]FVW>];Z%@=E4;\5:EMOG5SLZ4^U
M \)$*L#GM-R =R2D5D1J$66@07HE8[8#A-=V 'Z1#$]$J4<8?]D*K&7W<J]8
M\-_/)LS 6E[Y\L\_,.A19)M<\:1 P/WK<-K_W@,IB4<OSF!\.MM<VW4)5D=9
MC# -.7E2!*0C5XAZ3V#%E*!:OWJ3LNZ>1=L?C*-\[?UD(:M\Z4IP5D&]LR0<
MQ8KY%\=GNN!=B'E=+&-8J*'$L[]5>2.5OH'>9P7+&MVM=3-KU3"CX)OM=$L5
MEZQWES%@FM)6T?43&.R@#F6 4EW^BD%1F],!2!40SF[O>Z608S>Y C_WB74^
M(5M4S\$SL$7;0[&ILCLNV9P"#N.6IW[PD>69"-KVCB[9(:)7RLU76Y\NB==(
M@.;;W#,$O(>0,!$<J$T^-6@4CX(I;'' .N4P4L9'HF_9T[LK6FX6EWPK5;M_
M:Z=@,OLPTV%9@D^/C9Y[HKVW"V(3%%,)2>MR9TAMD :O&7EGI?-):Z=]3EZ8
MDF\WMN,W[AX7= )X.^D4VPL?B?UO-:4813DO']BQK6^VWXD@Y'"K<@^4-P@R
M'[B0@Q$E A;2/2U\9HQS5']FZ(45KJZI.<<OKSZN?2@QJMRV K#_9,18AG?-
M8P2WO_[BB8]E#1AIVX>/GT9Z-KP>.$41MJ,9[_'WM)N$*Z'IZUXN]QF]U\E\
M#< ]'T\!BU.VLX;/5!&P2E/J5XLAN#38^N5B](;;^_," '/484NXP.#4R& =
MT=)8YC,:@)/#:Z8$ ("F(L%$E<E[(\':*%'A;ICP\^M3/C8F;)QOKG_:M5P$
MKD+,QWKA'V\ELC9%1+"4@23)+&&OWK#)VI*M[*8,"AVJ0*'X(+E00 EX7<]O
M!E,)CBVH,FFO5BIP 4&M2$^^JD::(<Y<^J[3:;;-Y0#TZ$Q+2>X=7GEZW*L\
MJ@NK.62&5VYR8WSX04WDI62H/^QQYD65?'^H,?9MK_^V3.XP>-R8P&O$G6R>
MO]^5F*OH#$8V!0XV,!)DB75(IBB"C3$0F[(-G"+O5VU@Y4976P/%B%5*<(T1
MG"5L^Y)KE^KK:Y<V54B7OPKIU'CJK?'1\7**PEI%"8G$!HZ3<S3XJ$G$S./$
M/7DZ\=0;97W$AW.XK7;HKW+C22,YM$+? 8+*KNZ1[\=".=U9SJ^I3.;)-$#J
MQ^.,1"4Z!A^N;SX9([RPQ%/=QI7*O.>$K=@I*5< :PE^S3&V?JMKCP?9^L8?
ML>\[@^K%T14PACHD>!%E!&X&ZY-K7PRCA=4F7+YW[*65B12(N<_CW-<"EWW9
M=_5,OSN:,+M#@UMG0U3OYS:[59+J)Z 6[[+CDO=PM]+;X71M]3]=3--6Y<DT
M-OL:FRW@_5UJ.).6),02LXASFI A)B 2E382=#^H8K,G.T>.V>R5499.)=R=
M.@WU6Z4;62QM /M1Y;3U^M-B><!4CP#&NB,=;-4,,G7Z@Q-@C\6EC=;OPRMY
MX:JORN'(?((Z*USG*._S\NR_P7UJ3MO-G?K*-_ZR5@\OQS&KWXZK%(#6]<UC
MIN8HW$T#QE,39E"!2HSAA;4R-\,KU@9U[@(8[F&L9NL">9Y21L-C2W9U0DU*
MQB1F G'I&>+")*3!)"*5B_(E*IDA\M4;/BV-X=>A<%Z$9.K@R"5H_R4'48IO
M!7*1*^YG0;>#SN#7H=1V[870%M?J\#"&3I64G:,JL=QG0I*+'OU>R^G@%(1]
M ,+3!0&>,$"C@>48=:S"SY6^Y3#]9(3]M]&.U$IKO_<]PK!KXW/4J[+NX(^C
MY;,%&S7FUUGF#?+?K!_G,)Y=9I@71DJD+8 ^UTHCIVDNEJ$\IH$2340N/#;#
M(861&%Y-C+L( -3+<W77\TJ\\;ELF,CGLF'R[JBU"<;[XC!W?KB5:W#EPM37
M)EVV-LJN= F5YC!+A&4O?URSV?_N*)S6GQC;\L\$NLJ<GP^6'&<\64R=2H8G
M ",AG>'@<VGP<(3D!98D(7F?N0D2/0;L$'A]-V%O!"81B<PZN=4<&6<L$L%;
M$T)QB3/AO"$O=W@T*A;WIUJ%$G&_=(R"K%S^BQ:C.CJ14E75F;.:#E$^2HJE
M$PR,6;*1@AA%J52*G,4T5C=S/"?U ?;G[AN5?X$22-OG7W>CXR!E5"(G,;@\
M,0KD./9(":(=,5Z:;/CPE#!E!82U&,XK0" D!#!-Z(0C)SG>(B4(B0J8I,1<
M'$N$; 3H20K0YOK.KE>6:1O 9[::@,_L?:[*#K_E0Y(B2)ZTRV?S)B'LB@ 5
M3)I/AK!FWG+F',F%SJPP+,@4 6VH#=QZ6Y?THK.7]&IDZ/&]TU*CYZ!]MGFP
M<]8^6-OU+!IF@T541P=,G($\F<20%-QPKF!E]34)]U?E:1B(@7^.JPVW[MFT
M+;XQKG5S[9YY82Z)P)2**AK"N4Q&*QH<(X!QRAJCPTPE6"YQKH^G[@ >9KM7
M>7L78_^SG"K[6(^AD;6ILL;:VSN[3#,>/!&(!T[A'TF1HPH,'O;"8DS (K&,
M5[?7F9MVP*(ZFUZM4I:PSH5T[54'_TJ H4ICJ1S#\7+5XP+Y''S!*H>VCD1,
M9, _9+<QOQ_#:7<8%)P ]\L1DK6,$IV3L[+9]+(/3+1W"?!"8HE"@8!%Y\0S
MY+P *T^!&3*FO=03!R"6T[=? WT]/,R^4:W0ET,Q+5L+15V8JYRQ :VN$#9_
M(-REBBGH?HY2IEZWV_L^:/W2.1HEN8#)BC]R":U+E0L"?"['0@][I_79X2KK
M^-?7LX"#*%-;>IQ>[."7OJH^W_=X$%\/?_DM= ;'77OVNG-4)JI<]%M]KWK;
M/^]SC_54+2M9O5UO@1NS*B3)N^!U?^_ZB^L-\M6R03[6)K9ZC\&52ES[-EXE
MU[YWTVT)7L7R^K=ONNW-[X$#_!"#E5PMSV IELLS6&7N=MN;WY/Z;E?>-%BS
MBMELFE#:&)^,\E>&^%8U?Q_K'=\'Q"F_TU$?^>O:Q<]XV91.[U62S^-T-%>W
MG=@LZ3@5-ZY@>.URRF#U4B'0X_VK+S__K%-EEG-Z:@Y434;E752_@[&I?KFT
MG[J(>7H&(C6LW_2_KO^O-W41I_+[A^$9G/)7SEG*/L3I<&-S._8/RSO9[N\4
M0][,:)G14:&/,CWO8-XZ1X..KZ;M']L]C5<F:CKL,3H-]N:8Q:LD::;F\T][
M6JOX5#6+O53]K/!P!KF;:1I>U'0.]1Y=UOGAKGM=422GF-7U /*[F<N7&5^0
MHM_TT5HKKET'Z[_N]<&3"*B>+^]C3&E\#5KYIZKR6B\M1R[/\#B+<;O_5E;C
M=]NM#IN<3+84O':VZ>W3,;.\XM84J2VG@Y[4/,T7N:18N\BH$4[DLC-6.\/S
MJ1M%%'9:Z*HAT0U]6A9]\FY(V=[V^H6K/>_#-CN?_QI\V3[^VE[W9.=\(U>C
M(? =>(>^/=S9WCG?@;&V_]P\W/S\Y7#GL,URU9MRS;__VG>'H;MU^/[[YOD_
M!^WM=_ ]_\#S?#C8^?QE?_,@5]'QWW?H#OER^*6S<QYRY_F3]D?\X_^V-TXV
MUW>^M[?;NYZ)&'"@B!+.$,>>(F=R4WJ1O":$&Q]SOMB*49-G^&K8&U.]A:G;
M$)KP[.IVDU6Z#0VO1>$&0FZ#$.9"Q!B$)S>\X%AC[@A.P7K**97TX2&D=FHN
M>2Z;=?9J@QT+Q(ZSJ]@AG1",6X(L5?FT7VX\1:5%4OK@L2?<FGSZ%Z]P,IE-
M][S!XV$!X\E1L_]^L'6<8_V>%%!>7V3Z;FA)'Q KQ\I3#QV<NO;FDRE/O1P@
MN3E&L"(LJ53, 2HJ@S@W )+>!Z0(]MPS8U6DN2@ZOB[/X;E"Y#SW6%AHXFD-
M<FX'/I7_IJXBH:OTJ7OP-?2T["A=ZDY^^Y19>):\F@<,WEG"S(!/SDTR5C-F
M\YF%Q#"NDV^O;R<W41#V@1STX2&6]=.XW;O(A'MW5!4=:SCXXLS+^PG_7:L0
ML,,.<2> @SO+D*8,(P'T6V-+\JF6PL$IOC<'OP%]'LJ&C'WEG7STY86+4@F.
M_K;TRW3OI7EREFQVAV?:(S92]ZC@L.SW6.0^SS+1Q+H$ZWWV=I80]*\_D;_,
M)'$]7B*)?U8+VS#$Q3/$3Q,,D5*?C$H>">85XCCWS_8Z=P8)(",R\$#4JS=B
MA9G):A<3Z2IW@9R?'5]XGC Q'TK<*</^0?=JJH,L0PCX,[?.:'!@H3@PMEM#
MA=6$F8BT$-E=] (9XP-BFLHD:* BL>MPX&Z1R"<$!O<&@"='DN;><EDB#^0.
MNRKW!+CYMU<&<^%;L\6R0&0;WV)1E"L5+5 :H27BU CDG!4H$N.I,EH$G/+1
M=B.?'[ ]FWN\U+V04>&^%[85\NRB3,]SF>:,1CR GW%3D_;+IWJ'-C4TGL)<
M]G1GPE,@.CA.HD"Y!V65UZ6E3RA;4VJY"DGE/:7)A-#9PP5/3X^;/8K&0WA<
M#V$(6(V3\!"@-NXD6&>4450AQC5'.>4N)ZLF)(,-E# 2-<'%23#/>)M\V>_Q
M4G?"?#[XU'UQ6V'/<B?L2KK4'_7"-EMAB[<!?F(K+'$G;!()$9D2V  FD#:6
MH1BT!=)++(Y@ \B*9L\P!/[,L>+G.ZKWW!"KVSF<]B\(88,&"T6#,3?7*:\9
M=@QQK@.XN<PA(Y5"+ED&.,$9&)+KT&"9-\:;O;#&TWU<3W<*M#6^[@*1;=S7
M-<1+&BU'#GX@KKU#5A&#DC1$!BRD3?K5&[&J%W7FZ FAV[.YQTO;$'LWZF(V
MU@HX]_>J.^M>7\:FV7U9'@_X2B[HI?T=>/]CO<X7#+@AN7.8@KT)E]<%%:1@
M&#'%%.*& [\5DJ.D8Y!>2"TLN+R*W(?B/N& Y_.$A>>R=][LN2V3)_)<I.[9
MW.,6AC@L\0R@'F_^VN:3#__)IEC?L%@??9!B?<MHQ^=C]S$1Z9AWD9G<V<)H
M9YR7.E MI+=,3.\QTE3J6THFO_$]L_B*S;^G[?6-\UV'J0N<1Q2PX(BS0)'-
M6UC@[ 4<L6?!J7+4W^![YS#,I6U/)>+3P,=-\*&4M)I@ZV027.EDB-/).6*L
MS">"W,/#1U.E[W%PHWT5-["(&"L<D1*4(LX90PX[A0P/6'HIF)&YY2U;,9*]
M)-QH]L&6R?N\PS[8W1"OJ;2W-$#WZ2K0)6MCQ(HC(7.'2A,#<I(9E$(2P?LD
M9;"OWO!5O2B8>T)@=@^7<BGT_L'ZQF7-=;<KMYM;N4>]02ZU!<D-0>@5N@/3
MXE^'TWYN\]7H_8QZ[Z_JO10QJ)@\PKF_,<_%+1Q-%BFE-8]&8S #N<3F2.UK
M87HS2U.,AE6\5%:Q$#:!V /2B5'?G-(QIW&C%HLR7Z^B#"4F:.P=PIZPW$ ]
M(.UESJSQ0#)8#" 8)?Q"Q%,Z9[Z@-)(GC5#_Q$'NUIG;9<8?N0ETU?7Y&[P\
M7P!ZAGFYY-HR6)+0.\WMY:[XM@^Z633#CO8,0VRB7 \=Y:ID<NTH;-02N=W+
M+S7!KX=$[1\3P2\1F(Q6,61<+K\N% ;4CA8QSRA(A9,^V44%O^93OR;WHLF]
M> '1K]MQL F*+10 QX)BQ!C%J-2(*BD0M]0@BWE 1A-=BH0GZ1<3%'L>F3[+
MQ(F>:E!L;IV_+E9&FEC9?>%@+%9FL2"86888R2??B%!(1R*1<CA&:236N0KD
MHF)E#0=Y(1SDB<;*;@>B42/J)I;VD"@T%DMC-$01.4,:&X*X<^"5":/ /W/8
M2^.%%7Y1L;0%TI(%Y7 ^:02KZ7?.ZUM<[.PQS]O-G@56S?.XDYZG]WH7O@FB
M/680[9(P-M&RA>/RV42T3$;MI.,8!94LH+$T"/@@05YI0&9G9>D5H%?HPE(H
M%JB*33I9L_'[ @)JES"QB9PM% S'(F>44>:IQHA8 225YIXICFODJ6',.AN\
M C"4J\^Z6%233O:HD;/KE;L)D3V8WH^%R#SG-$6@/E$0C7CT##F>.S8['[24
M7HD4B]XWZ60-JW@:(;+%(,[5$!AI?*W%PLQ8#"Q&*754%DGJ)>*Y/I/U$K!&
M8@:KI0@1]-4;NJ+HO1OW+CJ=[%\G65S@9^A\>S.!@O#B<"B'MK_7.:K. =&K
MN'1P.CCII+/JI<Y1 +%\373!OD?67)HU=WL_MNPP%MSJ##6A]2VK0JL?C_MQ
MD"N=M4[@@Z&34NS'?+[9Q9/O,1Z5ET]Z)[;;@D^B$_NCOO*7SFI<7;GNJMYI
MORYR=)PY>\E@RQ\=-@6I7OXUET2J/M:K"P+W+B+8+3O([P\#=95H#*-U*ZVB
M]ZU>]5U7ZBKY;F^0KZ^^&F[QWS_9*7H>?LN7?^]C?_C/D?UL3K<.=N S;[OM
M/]O\R_;:>?O\/6\?[(FM]3VQ2=]^;9^OX<WUOP[@M1__/F^?P<]=$B,F.E$D
M'$\Y8XDB*YA"-"01/4E!6 >XL*K%!"RTCB/(4Y[*E=;W_8[?;WWOG79#:]]^
MRS(' M<'*>E\ X%P9T70*GEJ[?>Z(?8'K4YJV6XWO]/IM[+B[D<$ A//1H*W
M;T-UIU'?FEK^3O;M22N \JR.8*F@P]*BP3@&P#/VQGOVM$)I29(GK-*[S+OA
M?7B <*U&PK^D:#K\@F&A8/YNU+S%5G=<_";;1!^#[8R#+VD_[1XJ#[]_VA5:
MDT"X1P9$ W%M"7)9[V-2 *LR1>+XJS=LLEHC"%[O% 0]K,PE0EPD8CA)!MP<
M[I,!T#;@ZV I. _>QB)"9"A"9$*$Q-,5(?DB1>CK+DDB1!()DD)XQ(W%R#!*
MD7%4*AV :ZI<VGSU.BX)(-J%OU8*,,TC2X$PK2T-3BK*@<FZ:)BS)#@1K0_2
M%EG"0UG"C2P]<5G:]KN&,T(C5HCHW"K%"HFT$0ZQ2%@*8&VDT)F!3,I2:R1&
M0)=SQ@5PC>[9<V$$W^N('+)52*YJ4(\RZ6E%&"T(%)C]9($[35"&NI?]_0G#
M[7SAJ52%OD^#U*I.*,SG6YC-6F5?KE] X/5=XAD61 H4528)#.@"T :.K ?S
M;6T048G<P&C*.89;V,$U G-/EM (S,\4F.UWNX;H@(T.2"@2$7>"(4N81!P;
MC+GPU+( K')U2K_OVUG -3)S3S;0R,Q/E9FONR%D?0<A,0$'Q*6VR,3$$14\
M)@+6@P5>3@M,D9E+P8<KUK_UT'MN?C^&TVZLZ])-B,+E)J%YE2L1&@Q.#ZO7
MMG,P<QM&]'L7/OCB%MZS]L'[W<SWB &'P;M<)SJG_^C$&5+")EAT!4Y$JG2]
M<W0*&I2ILU;6DQ0U<<ER&[53DB5*N/.:$)\_'T&=CF&I3OJ@6X5#7?"DPHA*
MQ&B,,L7#XV[O+,:QD&?F/:"<_K1;+C\=U#RJ]7O7^J\(I*#7!;Y7?1SEH&;^
MP&$OQ.ZE*&B^(/6ZW=[W_.X$H[,78O'ZVNV]&UBL* 05KJMGJLA:)5&WSM:;
M_RUA]5$8OTI\ H+;M<>#^'KXRV_#ZJ*=HT)3RT6_U6.H\ZAR=="Q,'[AT=7;
MOWWOA)/]O&6UBJMMJSJGM?[F^NW5\M;8YD+UGB2KDIAKW\:KY-KW;KHMP:N
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ML$' \50#QZ2PD804+(]864T5\90&QY5RT=ZRK=<@X)- P+.K",@4+!2/ L7
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M;XC]W3\/X;J+_1-HRW@F[LG.V=[)CFB<U-D^O-/>]F<&;>*-S-.VW6KMG6R
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MI$A39"8MK5)9[5N\4GIPMY-BKP<=#GY'6?O8'I7=PJU_-'VU@_%"V;'71@+
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MJ:@\-4&ZI57"E_E;W-&IC/O9/8_*N%_0N,>\#Z6T%X$DE)P4B*O@D;;2H"
ML15-Q&,(*PA;UO0-RHLNC/=1D&ZC=T^Z/2>NR.BSH3K ==+-M788TFWVIK-R
M?NCT^A6DS0[2)N5*DS4>\T@1-T26F@&6FH2P\20X+ +'9&E5+%/^9!GT:J-D
M?@'@.=V5"@#F"@#&?!H;L><2G!CE)$0M*D5DB&$(:\*XH; @X+"TRI>QF"<
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M9K=,*"F<CU,8C<*G+;]RTNGVB]_RDK*S\G7E9K!T-09_6IBIW?/:94Y'L;[
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M"<_MTJI<5G)6]!MS%-<N2A#2Z'3[A[6U(CW/UGYCCXM"%I<,[@&(92,.'G,
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M#T1GP^WV^NM Q2 Y>\Q024;I?/+:.!Z9<RZ)F(AUQ">(3'T5B,XEEHP7K7H
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M,*RX$T)'2:UT3&O/K).J"HK>@/6/!44")PVC39 WF:+5.(6L%Q@)23-I%),
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M!$15.]#=P-=-%;1F7;6,P%.#.'95,S9UFP1.%/D@;%8W^:R6QIT*UQ-F12"
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MAXRQMJT-C['6GRO&^F(0E!@0F54=%H"Y-N'4EW_5>^/7\6'4^WK9@7./K:]
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MY)F6[^AF#)1O.48$:J='0\T+C8!:@:U+@G\2@O]JGK2_^0&U?3.T5-\$=+0
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M7;P!GC-$E3E G3?/5\YF:KJL%C-)G D/8EW+ #<=S6I9CNL.HE$""N4%[Q#
MY'B2%$P,C%,,@$^R)K%&%.Z:CJLR-NM8@/A3"Q4CM8YGI38"6C!;],VF4\)\
M7KBNE' ;R^&)T!,K6=!&WDLYDM^'C'VQ,K!+\9O?X"P-)9+G7C G+2<R3-W
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MQ)*()1'K(1#KL?CO]B)6*!%K^Q'+-!W/PE@^S[&U"1?6!3P0\60A8EW0?M6
M+)LAEC7KRYH!)!Y:? N02<3:Z2P.?U\"EO1KK8A6CV4ME6BU/FCE.*ZMFZ!?
MH6ID.0RM3!%PT4V*V\"JW2\2T3/38-9 W9%()6,P?C\&P]MY3Y4IH6HUJ*(2
MJC8$JDC-]*\YST_34$T15DB=\#3 ACV+8>>8#!6#:4:&O@EX(T_= )[[WWE%
M!+>#-<:2-6X(:[R'%.\8GN%AJH^N6Y:S/V*NC*/&25QU1=OMVF,2;Q5OW0#.
MLLM6)V=?W_D\'VEU6@?-1X+5&H#5'7FINA;5%189*,V&0]<.?<5DOGSTZ"_
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MI'3:UR211IKRI"G/;SU2L<=M11E7^HQV 6@<U[$<V]R/#-<!U&% H]\&-(X
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MD+%Z+=_;E+':+5_?E+$Z+=.QE[JKT-^F\%(W.#.9A.$BO^&?C1$D"PXC> ;
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M[5X@9[TDS^NEDLCV5,BF&XZI[9=ID>8D TR!&PR*!(!-0)/0VN"@:%G&#\]
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M:J98FH0J"54SD_+PK$,BE42J>P052*RZ#:MFO?L;CDZWA2M(>)+P-#=29A,
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M+>KH*.A/AK4^D+0%O"%MUA]$%;41U(:[1*N?UW\B^4[_^,O_!U!+ P04
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M69'*69YCG)S-IB6.KKR(+G@:.,_)6D4@E"L2YQGQ23FBJ1>:ZZB%-Y4)L1?
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MWCA".35"!^!@:^=&W8;G%.7S3L2T+;MS'36UD88;SR'-!G"6*XAK<?&%VP^
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MIF@3E#O[>57'WR>09X.W_0P];:BWH"-!MQKEPD4JK3,<T5(Y0SE*1=2.B&L
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M/%HTV2! YH*I7>=N)Y@3Y-;455Q36NPE]1:\F&OKY+:Y2P:6,HGFB5;%QE5
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M,XQC\!.T@F;P>?3"3\Y7%;*N2HW/JZ^5REFC+\/^OR ]FZS.KMD8?_[Y'#[
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MT*@;_73J?E]>,GP>+2\3;C.M)5 T<#SAII2T*7TFO'*)T.1%5(%'1BOXX/M
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MC.CO,H0=?'F18^@*-ZLP>-#PCX 1[8M]DRBNXF: Y'TY@P+TG4?P)20_1AC
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MH*4G(7-TX5AY"PM1D>@CE3+X'/W4G/OV7+[NC&D!:=I6Z&,<S[(7DCJ:B="
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M:L+:L7=4&&;0.X[4Q>A\E E1(AU3P27&74Q:QP<+P\ZN.'IU6$@:DM!EG+=
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MW# UF,O:-W3.5?I, #EMU%&[*NAW\,M5^0??KRD[5+/@B1I8R1S(U!+II2!
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M4.:1G_HB$B2AS,8H&BS)3,TET&EB1U_#!\2,SR:!>62">XXPV-4"D!4'NWJ
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M8"L_:!2X (T*8R)NX249$_F)'![.1\#.83$4P5[?@W6CT[D1ANJ[YQ$8W,B
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MZ &88D;^O0^_V?0^HT$=V02H-05[JG;6P)O/:H#5]'^Y-[K?].AN]09;Q2^
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MX[G-9-_N\J*"E4X-E:T>Q>:\\#9NTC*VU'0 S)Q,8\ Z\LQ49]C:2G8!-CI
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M4W? 3^%T.0#[/MC6$\4)N..() B%VBL=ZDDZCG2B&@EY2 ,/A2'CJ;#+'.0
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ML+7D-T"HC_4SI"-#6R_IKQH<T*(S!^/]K&%];<-]F/"_#Z/]K(%Q9K"?)\7
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M:>I'%$'FJ1\(A3ZD2>!!'G'$,<9^9!;,=*JCN=% )Z>.W&EWDH8RP5%LS;C
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M4AG'2>3SQ/>-3D=.*//<R'0;_I%UM3RJO#OE4+00 )D7^N^-AG6@0:>C>B;
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M-EGGWW12_U&GG=QBW"0#WHCN].B#'5KN#C(8]COUL00[. X<,K!LX%P/J,X
MF:\T)U[)S=&%-L;O;7-2_)E#S/<IP41Z,,1<+7T#&D 2)P'T(QJ1( [BF!@M
M?1W(,C=6VW66;971OUWO'3G;/: TU+EI/W"VGLQ1AV-"M^7^2&RQWX0>OVFU
M^>-$'LK!P#IW1]I+\DJ^Q\&0'7<T#F]RZ@3P]8\;U:LR9*_58_Y%/?AM1"?Q
M0\12Z4..D( (TQ22-$T@)1$/<1)%L5T9W#&$G!M+UY("+:IEX.VH(VG(SJ\\
M/B/3MLW03)@5_31VKY[[O$?$WTF&\],@N\MC;M#7P+!A*85.%[P]!OR55.*K
MT.@IP[T6\-V=EN_3:B<*J3E%L]W86B[S[[HLTR*EQ MP%,!(UT%"44@@P2*$
MF'..(T$C'ML%&[N5;V[4WHBN%[^/FQUHT@EK&:WL>"3-^/T5QV=D:M]HMFN!
M:^7 OG878#N(>V&3C8Z[H06=EA<ZVIJYS<4USCBX"LIV+-VTH=SC0/LB 'RD
M;LY+6/A-%(\9$X=GKB_YZE&4NHR&GI[*&YT69_?ONA#QE[SZ3U%I-6Y7V3_4
MK%;7W_B8%^U7^CI_D88<^RQ*82I(J*8-+"%.I%0+!,+3Q",I0E;+@FG%G]NL
MTI7K^2JTA: =JG]5>M;YUVOQP9O_%*0H+:L_3?Q(&,X_LQWHL1U&AV+;MI9D
MG4:H4;H+>=-:ZJS9X$E48*OH1?=0:$??CK+N\T1..T:.DTY.)/RK9+"<=F".
MI<.<6(HSG&*T9PG7KN!H?R4J[:=[5H-J0]8Z59/.DK(FRQM1W/L+DD2>GP@,
M/4P)1+&DD.A=C$1-D;ZD1%(IK'UFT^HPMQGR67W$VHFN*R0^#9@77^.1L'"^
MS7>@)YPAC]5'M"R/J)$X4!9Q:V?MP $T'HZ=@:\SEBY]A1-K,+TK\76&Z*"G
M\95$&1##KAOXG).5?F;:Z%]!(HFE$.HYX@*BE*BU82K4LM!#28J\*/!"HQ7A
MD?;G-B%IR6K& %I.BUCJ ]#U3PX. !F9N#<P@!J5 0'F!T"QB"8_#YR)0L?W
M07(4)7Y<\]Z0\ .W31?_?5SFO6#OGLN&)E8HLD>B'78=$^K]F2YQ$8I3Z1$$
M ^G'$$41ACCU4ACBF/KZQ VE5OZLOL[F1F5;63?FT,!]ZUZ(S4Q@5\"-3'F#
M,!N0;.$T&,ZR+?1T-7&ZA=-*O\RW8'#/T-CK1S4YY,731V5%E7>"_R7/>;GP
M6)P@Z4=02IY E @&,<(4BBCQ!?)"S[?+5WJXF[E112<<N-72V092'P32C!;.
MAV=D0M@(> $V(-4R7H ZN9C+D.@^*)S%/Q_L9.)@YSY%7T8V]UYM]_)SD2T^
MK*JL>OHJ;C.=!'E5Z1".11BR1'H^A[&7>LI.B'V(6>K#.$Y2C_,T1 *;O/;'
M.IC;"]_("+9" BVEV8M_%,3^5]X%-&.'&MBA8OR*GU+]P,M="O:GV_SQ)W5K
M\UZK#]O7^6B#D[S(I]3I7N&3UYU1MN!36:X%?[\N= GE>G^A]J.47\3W^D_E
M(DA32I/(@SA"ZI7&Z@>EW(-Q&D61%*E:$/#%HRAH;E7$X&3'-L_S;O<CSF%*
M+AV*H*/867Y_GZ] 6:?=R%: 5*"Z$^">%+^)2ET@A5:L]L&7M5ZV3GBSP?&4
MI"%6H\'3E$&$/#5,24)A)!*1A@D)T8 ZU$Z'9IJ2LCN#4>9+7I\9S6HU1A\"
MPZT+Y\".O=M0@]E(#!J1VXWUBV:'05?V$=^;*QR:;W9 N2Q*<;K3Z0M4& -Q
ML%B%^=T#9Y#U_R7O79?<QI5TT5=!Q([8QRM"F"%!@)?9OZI]6>-SW*X*MWM-
M[.D?"EQMGE%)M43)[9JG/P ONI0D"J  %GN?B9EQ=15)9'X@$PEDYI>LDO_<
M:K_RO7$NJWVI4X2B(DL*HM<+*2!6,H8TR3!,I<REBCD2A=/V[^)(4S-%>T%!
M(ZFCS;F(J*69\8%3:,OR$J) #+U7L?!E/"Z.,ZZ]N*;NB8FX>L-PBI 7Y?YW
M2VUY5NN-.;3^6">^/!Z_W4+DDJ1,6PE94(@%TOM&P244*!>FAX3,['@Z;Y!A
M:I;$B#\[(;ZH/9M:#UA'3 XT<:<5<9TE.QL4&/O UND\[+,>W .9KQM@]$A%
MXBK!Z,0D R$Z1U,R]%&!RE$OU4Y]H.7:Y,?+ _H]4S;+-]K7*W^40BZ%2;6?
MRT0@K+11)2I2$!L^IB*+4D@*_7NB3:XVMEYK4V^5>&HFN),-/)=R(3S7J-X\
MO98>X90F+;1G>7N&G-&Z+G&2A\RI,]!I#G;OA-%]Q-I87],T5J'LS?).JVK6
M%_S.);3>!AZ0QC98N,];DY#2<LE6=S]HN3"I=Q]6Z[^;P^L=R\Y6?EW=;3=Z
ME37Y[1^7S2'%O"@RFM.B@+&0'&(2*\BP_DDO:'',$J%89A5%>DTEIK:6-5H
MVJE1E\=\,XK,@*Q+]<RQ-MWI =XX'9J^ZOO2OQ+^5=Z"*2R.O[2+(SB[.#98
M@/N6B;P".SB Q@/\O7F;=FQH&A/3^6V/BOY3>X;\%WBI'!(L_P(OUTA9G,W+
M4V=AFQ#9_B6CQQY8=7#=4_N2T9I[9-F\8]H651<M%EBUY2Y[<_4OGC)&7WDJ
M>]-27TNV\7)?7QG]HP3;UY9E:$;.G1!ZV.JM_O%^_77UYW).4QHS(1&DN<@A
MIJB 3* (9H*A5*8T(C%V2\HY&6-JWDZ;@=+*.0-&4HTC,+*Z9N>< MKO;WB"
M*; [, BA 9DZ%S&X(5GG])DCY^M<5.HT9>?RI<..#6L:TNJ.574:[UQ1J5*)
M".3,M#Q$C,(B3A4L(IHH3!@JJ-6W??[Q4_NL&^G 'YU\COGW+["S.T ;CDC@
M+]@>#.?3J/,Z>SHZ>O'P4<]YSBOV\E#FPE7#/M@=@7!+;;E__XHTDI06#,91
M3B&.(PDICE+(.,KUY-,,%4Y!SXLC3>TSWA-CRU;2?W/[D"]C:O=->T$J\.>]
M!ZD3,LBG?A4*3U_]Y7%&-0!7U7UI"Z[?<',?XX;R:D\TOM+N@MXO/^O];DT.
M,D]I)K)<,E@HFD(L2099E.J5GJ8)2;F4"#D%\AS&GIKI,#W05_O>!:8;.C^4
M=W#[XZN38&=9 D$;V-:<X?F;';8O,#"_M8+YEH;)MH#Y;Z!\=>37:JAL"TE/
M@V7K1TPH0-2U7ZC/2 Y26?7?6U:E:G=.R[E *4D3J+<]V'1_99#2--([(%*D
MJ"""I:IK^O[UE6-&#GI968?C]O)?)Q-&:H]NVPQ\<TG5JC>EL)++6_:*(2;?
M+\W_8>&F#IXNW'14N&"NZT":5/3)Y=V;0"0JT#LX9E3JK_8N3B-N-6#B7R6&
MY2+G7S^>-6!61HEM#9%K@-O9A= ^+ALYODCC7M3#=#6:#>^7_L7=<KFEB^Z.
MNZIE*J??NE;7U?UV4VWH4FCG>,YXCF*6<\@H1Q#G*(*Y("G43J3,BH+)(J/6
MF4?!Q)S:IOQAM=&REE1/4Y?[L2NZ!.M6:T"UVPB>=GH=^(FKO6H.2W.XM\#"
MV9O$W 9VX7:)/'JQ:E>]3LUZ,>L4[7@EZU\VRNZ3@.XJL-?W8/V\G]B<.SA9
MDYC[D5RG5W\'W-R@X%/3Z]R$&WT\ER4X@D>.2/C1AIW.'V972],ZG5;;M13W
MRR^2;]>FGEJ[1F7U^W+%C,#&!_JX?-INCMM;_/)<W_YV0:NJ97F+1<%BS FD
M,I$0$Y%#JH2"2-$,4U.2PX3+47XH0:?F8M3R@5K @>1[P:;4+C PA8D*["\X
MS9%SH" T@)ZB"L'$'#4$$1KLE_&*X.,-6P8>UBLNI:@^:(#>2;;Y+#?WJEN8
M3(N&2N\8F>0BB6 B4 :Q(#ED#!']8FA[SDFD[3EVHT>Z/JC+-S\.-9()RSZU
M<@/S.H&%->VS ]AVIM8O@(&-YL,1:D9<PZM31U%V?%.US/XLJ3T^GFRBQ8"C
M6C=[ %[:*8<[W2Q.M=[,?RV7Y>/VL27XSHE0A$H.64P%Q 6)(.-% 1.9LR@6
MF:*(V7B*)T^>FFO7"F=G+$YQZK<)-VD?^--OY;I."&_]A5_4MN]#UC<=?,3Z
MO_8?\.GS1OE.+ZK1?8Z7+QA*A4@W];GWO?I0+O6W7-+%PZJJ.RSM4@O37&41
M9A0J87KZB4C!'-$,QH03DE%5Y)G5!^DRZ-2^U9W,9GW:20TZL0=G9EM-@-WJ
M[QO6T''RVQ$=P+%G#Y$WACV+(4?FU[,'X91=S^'>H85<[Q_E^IO>^?Q]O?IS
M\]T$ZNCR>8Z*-!,B2V">,P8Q33)8*$(@PX10)%-$D%4GABOC3,WPM.5*G:R@
M$1:TTKJ6=)V'MM^^> 0LL$D9B-6 XJY>)&XH\#K_W)&+O'J5.RWTZK]\0)3[
M82V?:&DB](^F>15=_$J76V4Z5)GSD+?;]5H;H'D2I5F2(0FS2"&(D=XK% E*
M(,*BP 7#/%+V7!E60T[--+1"UY3,C=3@\5!LA_"B'>06X6'O0 8_A6@PW L,
MCB2>@59F[V ZQ%V]@SI2#/5V<-V"H$XX]08T[9XT7G#22;.C0*/;G0.)3VL:
M\CKMZ8&N[]>UERCJ8^T'N:Y#E/,D11E22D'#J0^QX@ED>9S  A%%F-Y.TI@[
M$9U>'W-J]OJ0K7T&GN@:_*CYU@Q1NU@M%G1=F32A)CG(D;/=9@KLMI&>@0UL
MOUM,?VLPU0*;4OY&Y);-3@O=I%UX9"BUA\@7(ZG%B.,RD-I#<,(XZG#K[=&K
M73:%^LU$U*0PI]=SK+3Q2?,8%H(HB%/3UD\5!-*,Y$G*"Q%'3M;HZHA3LT7'
MT9>Z/:=IJC@#RR8$4W8A&-X;@AD(OWLXZV901XUF'39,:>6M(UQA0EF]V 2(
M9)T?[]4"6;WJ]\6Q^F\<[@J5#5_RW5*8IH/:RY)+7LKJ75GQQ<J$]W<'NYC&
ML<0X@H7*]1Z6D1C2-*)04E2@+,:<9DY)44ZC3\TD'0A?DXX?B0_V\@\^:W>;
M&WMO*0CB(_A-OL >Y#\Y@^;1D[(?>W2?RAF6<]Z5^T/<C^KOMJ+4LUSW[6.8
MQ[Q("!19*B&FC.E=7E[ )&62HS11!;6B:7CQW*D9J%8TQTZ'AT!=/V@?J'Y@
M:V&EN=,Q^AD]!QV;'SYGM&/R,\(?'HN?^_. 8_ VSO^5_GRK?9-R<TA>T*:
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M,6G?[ERN?M:\R+!@(E8P(;* N$@Q9 3',$F*/.*8Y[%T*J<.(N74UJ$NPB*
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M)"JBI$BPL.,D=QS9Y5,;AYW\P9Z>W!5EB\4C#'*!5XP#H4'CZU]@V1ZP0CC
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M"UCD,8$J2@C26U5$E%->S#34FMZB6,LNA1?:SVE@_.HE/Z%>B/#+^4@E0 <
MS4 '$6@Q C5(P*#T%ZL,&C+ODZ\4<E+J_Y#*H2$3.5XET2#I!FP]38^[->6;
M_R@WW[OJX1U'0UMB_'7UB_PB^>K;TO#2?UQ^EC\W7_^4BQ^RZ7\WCT24HX(1
MR(F,FT93K,ABF*HDSPJ<H819'2Q[DVAJ*_#')5\;]HM=7QE:G]Y58"WY@E95
MJ4I3@VM*^I>K)>3;M8EE=TPHZYVFIL1%ORA@:<)'FUIA\%AK[+#3\C+E%EO?
ML2<R\,K9J0.,/CO"A2/BFE8ITZSE%PGV>NFU$AC-0*-:V]=T["ESV"J//74C
M;9S'FT*WG;1/N'OWU5X&&F^7[1.7HSVWUP>'Z%9^MUBL_C3I7_J_F]B/:3P[
M1WJ'G*4Q@X+JY153H6#!\AAR2DR()DURZL2",42(J:VM.RGK_D)MD+=N>Z%W
M-?2H^[1A,P3"]$&M=DK[;"=^8=9L<V+"SD7P7!B+QM_'<]6&F(TB8S7Q[H=Q
ME,[<%T284+OM?I#<>FA?>=90VZFD]I#%5_JS(3>J=T]SFE*6%(C!C&$.<80%
M9)(3*%A."APE:1([G2:>'V9J]J\6RM6*G<7/UD[=BDIP2]0(6#>V;42<@7Z4
M!EB9/A"\V9&S@XQL*?H4/;4%O5>[?>U"EO/WRTU]3J(_)&JRYN0[NJ%OF^WQ
M'*=Q5,2,0H)RTT@QQS#G.8$RHBS7OE#$I%51W+6!IO;%-[*" V'-02H%K;AV
MMN JNOW6P"=F@>W!4+BLC8(M%F?,@O9#_^7;ZL>_ZD<T%D'_L#<$5Q\\BBFP
M5:\S!M;7#VFM4G)#A[VKCSN(B[Y=/>I='"]-]\SZ'.%=6345(OKGC\NW=$D%
M;;,&$EZHE,="[Z,B"C%&"2QD3&%&29(+E!.9V?>Z]B/3U(S,_[,TI\Z#.GQY
MFB2+(\;QH0]LJUJ%#II,':;5G.@$#I4R1U2-6D/R;SQ-FDNCF=$G;ZPV"KO)
M,[M<<UXO]JK-ZM:GQ[-H"D;$X4RJ%=C()7VBR[IE<CNM_U(W&GOY8?I*Y_$[
M'?U=<?P,-6(/':_8''?<\?OH@>E _+L4VX6\5P_KU9-<;YX?]!N]N5O6@<I:
MF(9W3J1QRJE,8(IC0VR51C!720%IK#UN5:2"$^:4L&,Y\-16QT[:&:CEK;_@
MG<3#" &MY\ R\R4 LH$7O]M =<\1<43(5Q:'[;#CYEDX@G&2">%Z_U#&O2:0
M_DXV_WY<[MI+O*5/Y88N[EA5AW;FJ2R(D$4$$Q)+4R8<PX(F"B*<<YQ15A1<
MNG'PV0X]-6/5L"!6QI%8[=JNT*8Q@/G&%OM*X7]S)>ZSG@X[JQ4&Y,!VJQ,:
MO.G$_IO!>M_BIA4=_-$)[Y7JSQ4Q;^1_U@./3 ?H"L@I0:#S$X9R.F_T6*M'
M:6(BNR\%RP1EDD<P18:K.=6&*S=,!SG&29(RI'^V.ISH'65J-NJSWIBMS:ON
M:('.0VAG;&X&)K!=T?*!1D#PQHCXMPN<)T'L2B\XWKB+SXTQ,B=QCYJG7,-]
M%P^S ;LLS@.^CE^UU=FNI;A??C&!5=.5^A=:E=7ORQ6KY/J'F?Z/RZ?MQN2G
M++F^J]X>[EDXD.0JI5$"51%%>IM&&60RSF$A\SR2J<@+[D21$D+(J5F@SH,U
ME<$''M,^.]W\P0>_2I 9M[-XKSV/@0WF?JYFA],#.A5-1M!.25!K.0.'>H):
M47"L:;OS#,/4'')&/%GI("*.:N1#@OQRC0@ZUL#FKZOE-]/$VV3J_$HW;:;.
M%_G4MF T>_::%=]4')IFC!^T?9MC&G&4IQ$D+,<02Z(@10C!3-((8YQQQ9VR
M:09),;5%0G\<F6,3V$'@VYGSX)"&CG:9/H5& 6 TF(%6A^>V[:N1UF/7UUO
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M"I15M36OKD=X^XVE;\@"F\Z^NN A[16N@>>C\'JR#1%N ]-3;;5#?X)KSYA
MS71/1P';>T;. ;C:\OP?LMJ81JM-RN?5KN?S'.>4,U) O0(:GEPB8*&=6>W=
M9HB*+$NU<^ODV$Y%LZDMPXWXX$VY!&*U6-!U!9[DNEE)Q@HK>W][ L>A7_.=
MF'[@ND$'',#3-&@$&PT0:!&:@?;%T^]=@](,=#B!%J@FQFWZN<D#IM8)Q+Q#
MS?]K!\F]Z_77B*J'FDYO8?A@ @Y-'*XJ*7>T^74ZXA>YE'_2A3DBGR.,HT+J
M76V2YAG$%&-8))S# J=(24ZB6#B=35\9;VHK:AT56BFPJ#.(Y<^-GFD]2:Y9
MQ/T86P;:_"$7.IY62SH[Z*O1YAFWX@(CK\_D8BM@O"49]X\V<K*QE>JG2<=V
MMPTO]&^ZH3U0/<3GE>'B7VR%%/]1;KZ_I=7WNZ4P_QA3^(,NC!'LSM!(0J.<
M$,AI44"<)!Q2%440H21*I4 DCZU8_FX796J&:*\)>#*JN-,'#)P2.^,T#M"!
M[=8!QK46,Z#U )TBX$^M"3 ZM$6X^H<#;0(Q&-P&JD>J@X&"C,Z)<!M@Y\@3
M;GSBP-K7NNM7VXAYWW$HBF)5U,F3QAM#(H8%+R)8I)'@G!%!F--)RME1)F?Z
M&O':1FB.;8?.XVAGU&Y&)["]:N2;=?W1@W07ZL7 5]7HV3'&+0?M4_.DSK/W
MXF'?^[$SUK$N/7_6XC?CS%-58)XK"9,DPA!G+(6Y=HH@*Q*2%3FG#*=NI9Q7
MQYQ>9&R_I6AV9!UMW?.L9K/3.[56=/"T6F^<=VK79T$2(GB"4I@0)"#&20HI
ME0@RG%&D4H2BV*EAD]<Y&,,:O_H,V-ENK[@&MN,G^^1/>TSW ONSZ=;8>++O
MU\<;U=9;J__2[MO?.&P->">5U,\17^G/9HG1/[S5_UUNWM+U^EDU%,G5%UE)
M_>SO\SS'I,@DA@4JE$D8RR%-:0Z1S%B.)(IDEKO8(L?QIV:9M+2 U^(Z9I.Z
MXFYG@0*B&=@>=9*;[%/0.9GFYT9\<"2_.=5K-/!GH 9"Y\E<N8X^JO$:",U+
M4S;T,0/RYGZCAEFJSG%X$<QX6)=</LAU'2B9DTAQA#"',I6&I)UFD"6I@BA-
MD4@12>+<:F_K,NC43%@G*Z1MU+0.W8,G(_--87VGF>BW;Z'P#1T,UQ*#^[;*
M<!^?AEU\NI;;A*^;<'@ 6!TRQP+ .U(&F2^8W7+)'/'JS2FS?=9XN66.VAWE
MF+G>ZV;@J_5F_L5$O.N:9*%=4"D(AB(VO'L\(I#%.86,*)0K9:BHK"J]CYXZ
M-1-M$LK+:E-RNNC:U3:)^P[EW<>P]9O;P6"$MJ?#<+#^KL_JW>?AZ1L.O#O]
M7WO/[OA9HWRX9\7OOLSS?QS@6QGB*$/"65.UWWW[MI;?Z$8VE+![:LYYK+>"
MJ" 9Y")#YL/DD'']4Z+B.$M46J#(OO.%W9A3^VQW@@)NR,Y6:M?Y8NW(B^P"
MO(4GY1_.X%%2C9]>X5N19V /;<M%[,HT[8*H@Q/E']F1?*BWQV_H#- =PK1!
M>/_._HLG#\H-K%X'RO)1X_E/;KH=N4^.M]Y WOE]M1 ?'Y_6JQ_U.MJE7QB2
MSC3&!<R9*85B<0P+E!=0T"1G*>&*%T[QAIZQIF:R=Z*"\D#6 02>%Z"U.\;S
M!%A@H[S'ZE#, #DI%G#X9/.\,-+XC)[]*I]E];QRRR!W;UG'FNO<DVVU63W*
M];YCC]GJ574?'[JXXYOR1[EY?K==E\MO;:BZR2B>\X1*$FMK$N>9WJ81D\V;
MI @JGL<)R_-44N7@#7H0:6J6IQ-5K[--^\3-"ICW$U1&'R>GQL>$67F1(T]#
M<">ST0?\1YUTUVHT.^X-5JNE_<]&,;";M4:U75I,H]SHL^;DJ8X\>Z,YLJ/-
MHJNWZQ'P*\ZPCY'&])4](O/"E?;YY"$]0DVBUG_*I>349+F7RZ9D1_OT]?K<
M>H5$I%G"40S3B!"(\X)"JHH"HE21.&*IS'EFWR749LC)K7[_"0Z$!3MI7?I9
M6D%ML:YY!S#PNG4@[WD0AU 2V*'ITA_4-ZIC=0B]AJZOUJ N^/0W![5ZTHCM
M05TT.VX0ZG3GT/;M]3G+!RWS^Y_:U"WIHELIJE^>_RY7W];TZ7O)[]9Z?_6B
M)0>*4A8C$L$()13BA'!(*1,P*=("(\10&B5N/=X'RS(U@W[8'K#KI\N>P5X'
M4"OAVAQ^^%S9G;R,- .!5X0.</,A@DZ/G2]<G9N(H*U8/*#JK6_]<$E&;FY_
M,V0O#XA\/'*HC=W0<BG%>[HV?4:,S[U]W-;''.^D*GFYF2.BL$HYAI(5&<11
MP2&3VI[**$HQS92*W/JP7A]R:A;S0$(@&A%=K>-5E&V-H$_L@MNZ1EC020O>
M'"+9"GPY96V ,;-%QYO-NCK@R*;)%H!3"V1]YVW=._>][O0VO]W,SV.):*$P
M-JV>32$C*F!.<@3UYEO(0K(DP59GT#:#3="XU+*:*&XK[+#6FV>1M3,KOO *
MO9WNH-K+V9&RFRZT?U+]D=0==-K,]$^K:E\/Z;_#9A]:GCMHGAWJ53ID]BE]
MJ0-F[STWDB4W!#J&=6>U-&&U.H>.%B)/49$V"8>X2!$LBCB%E"0DSX7*1>%4
M"M,[VM0,2DO2M1?RMEXS9P&V,RO>8 ML5YP1&TZ[W(>$;Q;FLV.]#BESG]H7
M.9I[;QIF-G8\60<YJL8\:9NDO9[NS%_J?4VL,$2&; 83'L/"] K/,Q911+%(
M"R=OQ&;0J1F1G7AN5L,*7SOCX1NUP#9DSV)H2N!:*0-DW+C XLF@6 TYJEUQ
M >&E>7&ZU[W^X5.Y*;_5A^%O:57W\WZW>M1;J[DB*<\E3J'*$8$X*0@L9**W
M/%S;&Z2P2*05(7S?(%.S(GLY#4&2!'\T8CK415R$L]^(^ (IL-%PQL>I7N(:
M #>43UQ\]&C5%->4.RRNN'KMR)3:+;7G^Y^&2ZHR^Z(7Q5CM7YJBK'F!!.*F
ML)^G(H8X4A',8_T3B>(D3BE/%)&C$&:[R3TU8]1*#^1>_-?EQG9\#2SW7-.;
MW,!&U .O]8ZY^D#[,Z35'0)-V>H$V*J'S=EK<U$[2OW78)H>-A7>>*0'#C\@
M;^X#Y37/S0?M.J^6F[=T4:K5>EG2=G=7D)11%",88Y9 S',*<TYB*+@4<:0D
M3SBWSIB[,MC4EIA63*!:L1VRNJ[!VF_]?8,5?+/,6T*K#K&]L$-2XJZ!YY ,
MYQ'$D=+@^L#TE %G"4IO[MNU9XR7]6:IS5&^F^T] PSJYWI;\OWC4ELH66W>
M_S1V7]XO.U*>+ZMGNM@\W[-%NXEYV>44)51O!50")<*9L;@)9)A@*-,XSWF!
M$,7V.<JW2C,UDZSU@=R0,W<:@58EH#W$';55JQ78J^5@?6Z>0 O;/N:T!#;^
MGYO3CC,S<M\[(TX=;P/,DL,B,N9LC;3*#)TU3RN0+T1[EZB;!QEO#?.%Q]$B
MY^VA;JN@D.7\7?L6?R@K3A=UBW7]FVJ><I9D>9% Q;&$.(D(S&.90T1ID9 B
M$4Q:%;SWC#&U%:L3$S1R B,HJ"6ULW9]</:O-)Y "KQ^#,#'VM98('#F]*22
M_%^^K7[\J[Z[.3C1/^S/2_J>.8K!L%"J,P,VEPX[+#_+*%GGDC A4I%)#K&B
M&.(\2B&+,@%I(8A^ U2!A%.X_>)(4_O0+W"H#DK7N0ROW;&Q%] "?_@#\7(^
MCKV*A:<#U,OCC'KD>57=EX>4UV\89B),<J!V/Q[6JQ^ED.*7Y]\KT_ENQ[/=
M%@*7LMIU[E!2Y(DPS6.Y(:_0_Z-_*B0D.4&<Z%TQ2ITZ1+F+,#6CLF>/ISM9
MW4S)@&FPLS%AP0V]:Y6;9O_3B6]"2F^,!J!<_NV@N=U>BR =6(:#Z,EJ#1!@
M5',V'*"7=NZ&)]V8U/RI7,J/^L=JKJ*(123)()7,&+@\@H40'#*5T3B-*8\+
MI^*KTR&F9L!V$H(_C(R@%G)H\O(>2,OH^4WPA YTNR$S/$GY1'G?F<G[ 5XG
M'?E$P8LYR*=7#FWFL2Y_:*OQ0WXHEW1I6L@=-/WMFH=H4])&K%B$HUC&$D:Y
M:7V),@7SN" P1SBF>:J_?#M6KH'C3\TH[,7?=1@R"ZRI]9$_]7Y 25<OQW5"
M5$:*J,@EY 6+($Z1WJ!&2,%"%E&*68X9BMWZ;06<DG&Z;[UOD0?B='8L0]]#
M9\/.F@=$./09UQ[1G>C@0/9]4ZC:S_2>93X0.6\M5]Q&'[GERB!H3ENN#'O,
MR*FJ5_O3?UXM?]0MZC]O&SM)<Y47"8<2Y3'$,HIAGFN'52JEHB).,TS)_*EF
M[]*+['ICZ;:.);^+#7BI1=#@6R,D8'1AJEQG@,EOY=*4:H,W==)J-5;6JO,;
MP42D(JH$1(QRO86)":28:'\&H2Q+"IRF1+5OQ/NE^,N_#YT.H[X-<BG^"J^"
MY29LBI,;>F]W>Q)S6\5ZH#ZH]0<;#< ^Q7F'@?ZQ1F$"><Q#)^ZU,YF=Y?YK
MY#(/G0YOV<R#!1B0?O=QR0VKDGPGFW\_+G]?:M]K(47+RC1/>98)GD90F'[+
MF&AOABI%81(3(?3*%L<9FB_K5@!7EB^[ :W,4M&8I<-APUFG3L"N!X5#VM5U
M>/L7!8^0C6/).UG!FT[:OVF;#'80?@D H4-JFE<HQR+Z;-J<K!0H.W!7:R!:
M#?0OP?;%"^JK#XHU6KUY9=>?,E[BF+5&1YEA]G<-#/VNEJLNK*+'6CW*-OEL
MGDB!I$@49%FJ=P^)TOM)F4BHXHSD":.,I9%3A/?22%,[\FQ\M[(6L6ZF[AC%
MO8BH9;#6!TZA8[(',H)&2/"F%=,CK=Q5*'Q%5B^.,VX ]9JZ)W'2JS<,,PK_
MH.O25+)]T1Y.6_5/DX@F2KMBL> ,8IXR6%!60,RD3(HDEEGD% X]'6)J9J"3
M$!@1'0D4>H"T,P*WP1/XZW=$QOFSOZR\I^_]S "C?NB7%7SYA?=<>2,/TR_/
MNQ__O=0V9,V_/W_2+L6BSEU$"48\305,2!Q#3%4."Y)$,,4QX45!,X&=F _L
MAIV:"=A3"X&=L( N!?A\]X]!R:*6Z-O9"/^8!K8;M\ YG*[)"AW?A$W]@[X.
M99,5$!=)F^SN'MAX<555IBV-=F/DDI>R8=J>\RA7"2\(1*A )J)%(.7ZIX0F
MB%'"*&=6[7+[AYF:T3%2@B,Q6QYZ1UMS 50[VW([5(%MR0"4W'LL]H+@J[WB
M^4'&[:S8J^A)4\7^JP><!#](_58L-_2;O%=Z3]-6NW5G;"0I:%2DL=YZI)G)
MQ)2P2+,,QBC+,6.8Y=PJU?SZ4%,S!7MAS1'<<K4$Z[;,T_TXN!]CBZ-@;\@%
MM@P'H-TK$W2#76VL^P%P/V@.A[_>P!OIX/>+?-*/JT.93R]?0OCB)?1UY&N%
M4>]Q;_\3QCOJM=+DZ)C7[HYAWE7+^]T<$'VE/]LSHE_D4JIR,X^%]J98+""G
M/-5>%F&0Q40[7072+I=(N3)>UFI#%W9>5O]P3B9V-VBX%_VK&0/P*TSU0W"U
M<[3\H178K';]/]O37E,2V/$0O&FE]7CR:P>+)Q?LRF"CNF)VBK]TR2SO&MA
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MT=ZOWR70HY1K"419\<7*M.<S-.W?]M-2OGCO^9%VOF+  ['LC0J[/G.\./%
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M/L/B8Z'6N<UJ*9L,-1<.OZLGRL+;'A/^@2UGK<H,M,J CC9@I\X,- J!/8U
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M#G9FK*D=?.V)JG9SI7L+T).PVEDR3V -;*_V<:ISK'_2Z_[?JGX=:C%1$L_
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M0RS3MCJ# 8H3B#B/(,,,PXPG6808HM2N&\=@$D[-Q-0*@-)HH)-/F#0)C%*
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MFMSDA98?R$I*QT9&KI-@9\*&A'9@2]:*#HSL,V"DAZL<*OF!46 &NBJ CQ>
M=V\=U!,]7]V 7(<?M\%/3W .>O;T?<[(_8RK'6K5>;EM5LM%&.D:2[5[1.H_
M+-+>6YA ) 4*2( CCIS*8KQ*-S4[6?=D>%+/>S"M:4=N1GQT!AWB4V\Q+V/$
MMJYK*%S/:MU]?DK=@L]A_];]@(_*]M?H^'L.5F\]?<\.TK<!V[-<;F79,I_*
M- Y#W6@HXKK=/)8,8DR%\N5R+)3ESB(1N357VQ]@:O:WD>^_79NFO<+-SF1>
M@\; 5J\1S89LMT</L^-Z>^M/]NKQ(_<>.Z[<85^Q$]?UR '=.8BKLC1U;_EJ
MK6U$J<ND5]N-<@R+BIQ\'@<BYY0S&"+U'X0XAPR%%"8TC7! PT1&5I^TZ\!3
M^]0-B6"[@=(<CH!W%9BIA5K(O%@6&\N-JO-4G+<20P(\WL94X_I^']=:<K 3
M?2!\'?)(!\)Y+':D1]V157-BGGFC9X!)]:/)R@,RSR4WQ<W/M% H+-2?5V M
MQ99+D%>%'>HZ\P]U,M]6?0YK()?*5BDO5C]D0?\H.U_)XL57!FN/V3B;R>KR
MO/$R6GMHN9?9VN?^OF2:Y>8VUW4_![G:<2K2F 8"IC34G>1RK+;W.(9)A 5F
MA%"46/4HNCS4U!80+:G^Y.J%W)5?\R2B=KZC'YP&7@<:B'Y9K41IV!5^5'R#
M3D4$/5@X+V'CC8WSY$ CLW)>4OB0G?/B'3V#A\7]LL@+3M4N]72C\#FF$LLH
M#F#&(P11D$60!*&$(0FC*,\(RJ03Q;C=L%,S(3^VCX]T_:(_D8X"8*<!:%1P
MC/_938)E8,\[M$-'[,Y#.=39KA-,OH)K=H..&S5S N(@'.9V=S\C]?'Q:;%Z
MD;)>C8Z'X+ZN3,&0%";:5AHBA.Z_:Q/Z=;7Y7UWER5=*:MTN.B8Y0X1CF/,@
MABC"%.(\$LH=XE3]%A(:.+E#@TDZ-5/XVW+=RK8?9[]T9CGR#-L9S4G,VX@G
M(^V)QRYN/0.M?LU!B/$'E4;@Q12\-SJ90^JM3SJ-P>'W9+^'DW-4DS\XW*]7
MB>$''/GHO.[&U<GN_KY:+#Y5^_EY(HEDG#(8L8#I@_0 LB3#,$KC, X(CK+,
MS5L>1,RI+2E?MYK[L^KFN,JK_ZT.S48Z33\_J0,?JWN;JNF?K[<-"CO*@M^U
MNJ#6UZ>?/^B$O/6A^WDA_QJG[U9 >SN&MQNMYW+"'Z38+F1YF^]U&+[-=8_A
M=R_ZOY\H5R_L;E//<LYE&N50T#"%*"8(4BD%E"%+6"29C*E3ZFD/&::V$#0J
MZ#A+PQE=A2-/-MUV72)Z3)2E_1\6_J&->R.]@7ZOC[F.G"O99]JVFX;RE1;@
M]SMSZ#1,C*8_F+X,<P\)QK6Z_2$Z,*E7/*J?O?RVUN>?FY=O"QT^6@I=$_"D
M+?6Q"A<B1!"%60)93C*(=*\H1G,&14R92 4/DB1U,90N@T_-0C:R&Z/8"GZ>
MI.3Z&;"S@$/A.K#I:\2> 2/X/K+#EQKU0<V3C7,:>E3CU@>4UU:MUS-ZDIEV
M4OMO\P^2F3%TI.S;6CX6V\<Y3G$2I"*$@N08(IXJ9R]*<XARC+CD8< CMTZ]
MET:<FN%J"XN*I1I.EIM^M467D;:S55[Q&]A [14&*6],2PL:<<%/M<"G*P_<
MJ49MP?'%+WIQO'%)16W5/V 2M;ZQ1^KHWY>ZG.CN0:[ID]QN"EY^7O*Z0Q1*
MXCBE6003@:6R+ISJEIHAS B28<1YG&"KPNM+ TW-J%2B.B0EG@/QO.'P"<W
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M_"JAM9RGH6XJ$&$8H4@9T#RBD"&,(!<L$3R3"<=HOM%5SG8&]/4 3F:Q'6;
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ME^$P*LV&H5V3?Y54$W>+V^5W'>A>ZUW$4GQ=Z8S_ZE<E?U&:_/XY2W*9)BB
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M?O!830U[2QG1BM^0J%;@R^XR-"J 3H>P'0^\X O8!\%M_M&[(WC!<ZIG@M]
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MVYWVL*MR\9)[H*G'N_4>%KN]:_"!I_)P*[J(1U>Q\K'\O))/^DQ:MWY>F>Z
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MF75J9F(C=)V=N"/VOW4%5Q:[7H]%L#,BP:$=V*8$0=4]D=,%I5!)FE9SCIN
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M28P3"7DN(KTK8@9I7D20B#A)6,RE3*T(J<]-,+5MJY,/& &]<FZ.(+3;$?H
M,[#)=L+$V82>4SR0C3L:?E0C=$ZY0RMQ]G/]+KH_+6E9::-2-]8569(03/0I
M'^E#/\9Y"EE".(S3)"U0Q#%)4E=ZR\-)IO8Z;\DM17UI:EK5:T>S.W^:RA_G
M..%)<-WNHGTA&_R*68L%6KEV#^KA;Y9/(1#XPGAOBE>Y!SZEY+GKW9.?]4CV
M_]L_>)N:33$57- 49I%D$--,0*(BI'=RF>O-/*&9M$_RWPP[M3?\;W][ZY#
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MR&>9#' 9R<M[5#!\AMYVK*&QMCI6JE^*7>@!=N(6^E_;F,7EL4<Q'5;J==;
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M)!\=:<4-&"<CE+ YX5]S.+$<=\NBAP&B^=3C\8)L @>?KMQH].)Z-ARGV6S
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MIA__D= SRIFZDH\+4J![)'T"[T.$0#A3W$EJ68U2_HUE#X-&\\G-4X39R"/
M^Y>,;_ [LT$VE"J.GK(U>/H):2(XSM!3%LQ*285WZK2[T1T+'X:(AE.:-03:
M%":6KYZ73$2.Q!-O()K2"L%G7NYP2KVPXLG;A-[S:365.Y<^#!<-YS'K"+5G
M9%P@!W'!10F8C",Y*31NO#QS%EH42"/UQ@:.:-<FBM,**!\L=Q@"&DY<'B^\
M1NS![/Z56HHO;CX62M(XI,_IQ_P%_O _!XPJY[33("AEI2="!*.=!X)ND&4T
M9%NIO\23I!R&EH;3F]T(O1J2_O771X)]A]\XLG74(B/S=IPGTZO%1STD][ N
M4H\^HT9#J?V$G=A;JO PV%SA#C@V!L^]C\!13R",5^"%D9 DX5$;Z:2+3\ED
M[PHG'03+%-JR_(>)Q#R)X!U'2Y85 UL:KEGMK.4A&23]M&/@?K%^&DO54]2#
M\^!(&?;M RS)?K=J0S= SHD/-"RI%L@T>(FA+]=&6)^2R?:T;B$;"_;36:I3
M"!PERS9@\&8XO7H;!]%'S?%  Q4]!Q&T )\9?L6\EH(:[])I-Y@/ENNGH52G
M$#A"CHV>Y2\NWEV\?_GZT]]>O_[\Z9B#_.$'U#C%]Y!TXA%^/8,OSGT;+%[(
M%7?M,K\9CMTX##'&FRQ[ -U!A+/D' 9TY7$^_L$$ 1>YAZ =U:AY%NR^>"F[
MF5]H<K7H<J>DT7QV^YW[+?,<NHZU K=K7,QF:3Z[XS)IP3(-"C*3)9PU%)QP
M&="$*4)"]EGOBP&.X?(A!?WX")TAX=985!!WCT?&0^I7]5MW3"@6LHHF0P[E
M<EYQ"MZS ,99%BWE)(5]>:7C,;-!2+_0.46S6T%RBI@;P,I+-_MZ,8[E?U[_
MY_7PNQN5>/AB_M)-IS?#\9>_N]%U&B1E'&,"?65?:K_0EH-5D8+DQ"9"\>BU
M^S+5QV#G(,):P-)) )ATK8T&(';QW0WQVZ/T9C+]A!RMWK<,T^Q5\O/[O]T6
MG(;@D$&TU%9J H(FBE]%"S)(7=HC2";WQ;I'&:KGD=A/>-0=[+K44 L #*$T
M^II]3"'AGD(^WZ?Y+2\8\CFI@RB/)&S93 Y,:3J<+,L\XK:R9E]4=13:]M#3
M3]C5(;1JR;X!'+T=?T>J)].;WZ:3V6P0+;'1XBY0OA2Q!!/!$"TA&$Y]EABH
M<EL9.0\IZ*?!;W=8.4&^/:)CD;+X,$W?W#"6^I4T+>'([VY\G5$@:#G'7V[Q
M+ICBLI0]*>(#>ILJ@4\D@TJ6"J)YXG3#!=^1;CYHN7XZ_=:'1T<";L"@K)AZ
M_>-;&L\2.GZ7\Z]I^D!R QNEME9((%25-^":@<LQE#?@F9)@HQ.UK<P!9/73
M/[@[TU-;$PV ZR'Q,J'!E#Q ]#2#X)R#\=$ GK!>6^)T#OMZ<)P<_??3:KA#
MO^9HZ1X/C<G<C2K9G<FW-)W??!BY,GTCEECS6\FGH6\VL#1KAJX7Q"P\2B4O
MRG(I8CT[2AS)=F_3AN,,SFYZ6HBUJJ2+J@F] =MRYZF]GXS#:@]0'0GWIO2F
MLB@;5MX'$IE *T:T3_R)*^J3W.%[,EJ(GZK Y501-X"22\2[*X_-WR4W2Q_+
MG+G+_ <>KT5*@^@)MUDJ=,Y*L69Y7.R2X4!EYH3GB%:T-E[V$M1"-%4%.?7$
MW@*&[OVPM8T0E.-$4@)&I;(1F )/=4E N5SZY A!]]5#'(6=;82T$&+5P<S)
M8FX *TOZ!XEE=.M\ JK+K7XTZ-%Y71+EDAFBF19NWPNMXUW=%H*BBC=;SQ)D
M U[MNZ'SP]$B48WNU>(1T=?)"(4^*Z[6_.9.-(+&1$LQIU.6@G"!@W6$0%::
M4$ZM"J'V[?FAM/7K[79^K]Z)BAJP/&M\/0HR(^4FR@R\E!X*2Q5R(A1H8DU2
MY54"JWUUNIN:?N]+N]'^;HB=HHH&0'5[=?+!W91[DY=W04#2B\;@DFH-@MO%
M=&:T[LB%L3EYJZMG<K92T@R83M+SCONJ$X3> '1>7WT;36Y2^IA&Y4G#8UD-
M7'0H$FG!Z_*@(2E5OHJ0C/!.ZEC:2E=&T9-$]7OX=02HNJIH %L/P\M;?FX;
MS UB2BH4,:%H0LE1(#=.R]+<@3K#LS6D>FBVEZ)^,T(=H:JB$HZ&U/<T]9-:
M#M3$C3=MKE F\\60@U &Y^B2$S6: EOT"2%:*U'=<WI,1K]IH8[@<ZJX&S!#
M+R?CA1S^,9Q_?7D]FT^NTO31/C".,&&B 1EU*L]^'0;!1(+C0?E,'$UTW^"B
MH^H6#Z"KW[111YBJKI &0(;>X/3ZP:%]>S6\]JV!=E)F)B1(ZS@(PC489 B(
MY9J%X*+/^YJ/'NF1/TU8O_FH[ASTRBII &?;O,+@A$A10)9:@8A$@U=*@_:6
M1JTMMV)?)^PZ>8-^;^V[.OQ.$W8#F<X=WM]:YI[;[#Q'_%,>/#*D4AF&;H%X
MP8/F1@7;[>7:%J*:">^Z2S[554P3GOG>8WV-,<&8"%8+2!C/HOO(&%A%4FG1
M%5,,DK"];2FJNUJME 2<!7==**GODMI7JS4_3F[<:'YSZ4?#+\M9S/?\.*]C
M9,F!HMZ"$%*"E8Q"M-0:W&<NFXT0<4=![0&+-1,(UH=1)_)NRZU"PZLL"XR#
MDZD<\4:"\<Y#S,X*F:Q.J7;:_+FN^#DBOK-<O#Q+V WX4Z6J?#A?= (JK^_0
MF.(1GL:AL**(Y**TCXJN](R@,:-P8KD#B!$5KK,Q^YI['G>N[22GF9"NR[.L
MCC(:L#][)(01J'),.PQ@2C,:JREXB@&(L(E%W#S>Z=JOL4^L.CA'F-<=JBJI
MH@%0?;A==\'2\D6P=X0J%B)$*DU)JZ72VD@!8U(;CD+BJG[-]B,R^FX*44?#
MCU^&G"3N!A"SUE5Y13]/4EKE@"H72ZJ?@!$HE!BE#)):H4SM[, F#7T7.G6"
ME9,$W0!0+F)<U'JYT0<WC&_'+]VW(?I8:VP-,K-,2A&!18O0)V4D:7EFYSA:
M9Y*HH:+V]>[35/4;X7<$ILK*: !>']/<#<<IOG;3,?ITLXL0KJ^N%V41&'P.
MPW ^,-Z0;#.#0 1RE%.I.$:.+/4JEKE#L7I9RM-4]1OY=P2ORLIH %YK'"SN
M@\JXD6GZFL:SX?=4.KQ>I7>3V>Q]FE_FS^['(.9DJ<T9B)8>A+ 6C X.W4D9
MM21"^50;:\\DL=^L05=VK4,U-8#"QU(;1)TQ-E4&Z38*A(P*+ \9@HFDO-KB
M>>]\D#JQ7K^9@XZP=**P&T@]/17\#KBR@4=BP5E7>J1D#'HU]:!$R(RD,J'U
MW(\5#H)2]9%4?24S3U=+-9AUV$3TPT+V7]-\&-SH(>%'=!1]^&G5VXON(?:L
MO4;1N)AD-(04;ML7"<5 1>FD3EI27[ONYQR]1A]F/%#6E]/%LG$1TWY(T\5H
MIH$VCGJ'.RN(B+$M,P(\(0JRMXF&:*/BM4^UPRCK.PU5&3G[$U)5U-. V_20
MJ^7PKXOK^=?)=/A?*0ZDUTXZ)4 ZC4Z@2VAN*7Z5F><\DZP=[19LFQ3UG;\Z
M*\A.4D>CX'H[FUTC)]HJ@S0G"*YT;HG"@1=40S*&A(2.H\KR#,!:4M-W'JL'
M4!VAAD8!M3ZJ4$G+<VD5Q4H-JK"2@DFJ/+Y6-G/K,3;I]C[FN &1'>:P>H#6
ML0II %]K2=Z=!WR6Q&N6! :ZI"1_\0_G!8.,X:[QTF7":A<('T!6WRFKCG%6
M6S%M8>W1.1]=Z7"7,:RUY;D&\[0,UC(@<^:X:ZB-NO9MSQYR^DYAG0];)RFB
M14RMCGEK:? Q>/"*HWA*Z:"GTH%E,<A(C$RJ]G2.':3T6_)R?BP=H8 6<?1@
M'G1IT;@L86:X)Y+UQ<[2TBDX\!QDHM7[_)P\@KNSK.CY$76L*AH=J?3I\\7G
MU[^_?O_YT^6;RP^O/UY\?GOY_M/%^U<O+W__\/'UWUZ___3V[Z_?77XZ:M[2
M,SZ]1K;T6&8J94^7MWAWD+S#'U."(/PR.%XR\I):\$03H)0XRID1.M3>L3M(
M.?V6;_6!G\L3ZH%S+L5,/4B>=7'Y"'B?+$09/4=SZS#JZ"H3O*"@WYQG#7T_
MOMH[6L(]'ERSZ;PT>HW788[!09I^'X9T\6,X&ZC@(I,H"BI\!C2Z:'IEN31*
MV4A+A<OAH)([7& -'?BW>V3L6KN1?/@1>IQ4%&H;H%C<)BXYF+V:7+GA>" ,
M]Y%:"3F6UK\<O7H7%/*D@A7<HHC206TN#D/&8P+Z@4<=G3X&R(D";L#G73'R
M>[KR:3K(R6HGB0/.*2DU6!E\*!V"G @V24Y\JIWE>4! [^@X5:&/NW ?*=V^
MWT.N*/]T_>W;Z.9C^I[&UVG%1J14Q:31BK)2\T*5!).2@*"U\\98SS8;4.R<
M*[)KC7[NN^KCH*8H&S 6[U <X]DM\2$XJ5C4$%W)<F<KT&P:"5)ZSI)A2LG:
MCXH>$-#/_55WQN)XZ?9M+%Y.1OBM26E&\#V]0H2/)HM9 RM6G'><ABPQ2E=H
M]R3RXYS-(#6-6;! \V;J9(?!V+]./Y=.'1F-BB)MP'#<N>7OAN/T%K^<#5)2
MVE!:!FR5:6P!0S9+N8.D'%&:9\YD[>C\,16-U%4<'ZQ4$G #$%D=C/<MQ3DG
M@90@OG0P00/H/3A+*% 9N&4F"L=K9SDV:6@DECU2IX^>8)P@X'8 \@;EM*T!
MR>L?871=TL.EG3S^?RS5_-RZP)(00!3'\,YK#=YBH%>D1:(/+IC:X\R.(+-?
MF)V&B^T@ZTQ)#>#PKNO2:GS;O>"$429*PX!0)Y93<YR(!!2G/*>0"*>UT;:3
MF$9.MCJFJX[(&\#.R\EL?IE7FV2@F5/9Z0S:Y=)6CBBPVB5@Q<>75MC,Z_<+
M72.@7[M32:F/+@Z/E7 #\/B(&D "RE#V-9=_)9]!-MDH&@)$01V(Y,IS$$_
M&D^44SX'4QLN>PGJU\1T Y]Z&F@ 3K^E,<IHA+Q<Q*OA>%CD4\+)6W9$MB0Y
M$\&K,EB=N "V#.#A-EH,+KWPK/9CKR=(ZK<DN1M(U=1" Z J!K8D.FYE-%!1
ME%2E!:E+=;XN3S^4R&!M(#9K$RBMW>ILDX9^RXV[.\B.EG,#3TWOI'+_R'I
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M7Y'R"_Q0]R6]ORXE=)?YT</"Y;[PC.5HC(3D2_;,.@HN2@N*.*Z8"HJ[VH-
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M'L?UR5(8,V%D)+T%QUC&;8VACE>)@L>(J?C"0>7:54&'T-6OR>T?/9..5=D
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MYXSTG </UE",%7)$ZT*-0)=/))Z5Y([4SAE5(?SD66Z[B%BH[_*!^EY<S_#
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M!RT'@<O^;."J(?@& (0>04RWY>JW=>T?4T@81OM16G(W,%$KX9TKS>!Q:]B
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M#$*,R):U$;P*A4&FF:1"<DN.!LWV-7LN9>D<.A4DW< Q5L%OP# TO9VGJ]G
M<"E\F;VJ6/$8=$3?090:7A.)"RPS6WW 44WZ^T5L8[Y<;\!H8%,\WN[OTWSU
MQGN0%)>E-PXP+]!#07L"SFD+!(7*E4\LF=J/4?;1T^\)W1]*=H0>)ZOLI\Y:
MKN8E+P;&(O^=IRQWK'>^?.4A#'>?K%14>\E9@AAR+*_H-5B&GF/"B*5,QC0B
MG?L&KP_TO7?3Y4[O''>/5CH?XO8SV3W68I2!"&HAB5(5S13ZEZX824(Y38(8
M:VM7BG:7&'^?_ES[\.EDC%^&Y0%R.7WYM1P7;\?K/S$<AR&B:.G>,$*#3<:
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M'!WC"BF>TW5^D2;W)44%7EOIC-,RI-:^YVZ4=95%&M'&#:#'[M$YL5SPF+4
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MDF(Y@S-, 5->6W16"MWZ8?"C!/4&K&-T/Q]*$1V@ZIXM^)'^Z7KWF9!EB=E
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M_ VL;A#QZEXBKNYEN<G<9<Z LX)U\).%J(, 64+0,CFE=L["[[SHT:_P-X-
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MP%@T.)??73].3U*'>BU$Z]#9;+6!R"3M!B,8IJBM+*T;2[>D?]RL3">^TNC
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M>G8KD/^[7RVU5VT'T?3K^7)U-;AUPF/R(7 -*>@,*I&+ZKWBP(5)*+*5N-O
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M>W2/W1!@;92[G&1I7?:UEBUP!)6=(]FY ,D*8S$$GS >7QIS>]EQ:KFZ =_
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M&BCZ4? <*/4.T'.SH4CEZ3=<G96WR^5%[6QSV2!,%^\TEPRL-34];"G\2J%
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M4?)B?9)$O%2,')50P$630"!W.6@C;62-@7CTJ]/!+H<'!%LS)1P.J/DJG \
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MBJ<AC]$X[JUXE]C<6W4]/GB[8N[C_"=\'Z;Y5:'5KM@3SHK$D<Z%9#3MO)3
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M*=J"8AG!694A>13((@J9NQEALR-O)YH>\9KVX@%@>]57XE4=\HU<8DRQ!%Z
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M0T1M0!56:@F"AB0*1X]*)M&Z1\>S!'5>>')L%+93WFD7D=Q&]+DL+,KLP(3
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MC)=?+E=/6#]F(B).U[V1OI[GE<)FZ>S+?'$Q_<_JYQN9GQ3I/&U. T+84"/
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M2C7\4 7V3US\D2_H2K[9%]$9@K].P%,B9D*VX.H;)2LZ685.^[S3H;1QI:U
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M'/=1YW@8;*BH3G%X_;-UG/]NF)-._'6 <_ET'+1VBINX:(2K=1O:.E\;Q6E
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MIXGJ-\&U4>"V@2XZBM[>X>;#]-/GBW?E]V5>;9E)1A,YTOYSNFX7,@HAU$X
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M9?GS]#RGJPJ+"<J,(IH"07G:8=JOXL$95)2!<UX86>^#8NE)LCHS8?=$P+/
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M-$&\*KNI\ID[2?5GN"'E[VJ=_Q=02P,$%     @ LX!B5C>'.@CD!P  '"8
M !<   !A<F1X+3(P,C(Q,C,Q>&5X,S$R+FAT;>U:;6_;.!+^OK^"ZV"[">!W
M.YO&20.D28K+W6Y;!#D4^^E B2.;""5J2<J.]]??0U*.G3AIW6MWZP97H(XD
MS@R'G(?/#"D=_WC^[NSZ]_<7;.)RQ=[_^_6OEV>LT>IT/@S..IWSZW/VC^O?
M?F7#=K?'K@TOK'12%UQU.A=O&ZPQ<:X<=3JSV:P]&[2U&7>NKSK>U+"CM+;4
M%DXT3H[]$_P2%R<_'/_8:K%SG58Y%8ZEAK@CP2HKBS'[(,C>L%:KECK3Y=S(
M\<2Q?K<_8!^TN9%3'MN==(I.%G:.._'^N!,Z.4ZTF)\<"SEE4KQJR&%*_>1@
MR$D<#(9\_S!)#V@@AIQWNY0>#-+_].!D!^)1Q[JYHE>-7!:M"?G^1\-^^V"_
M=$<S*=QDU.MV?VH$T9/C3!<._1GHQ\MH9MT8-V/8<[J$.BPYNG4MKN2X&(4A
M-J*IA7BJE3:CG6[X=^1;6AG/I9J/?KZ6.5GVEF;L2N>\^+EI$9:6)2.S*&CE
MGQ0[";>S.(0#V%&RH,60>GT_B(O;B4RD8X->NW]_!)OYGF+RR7PCY\\NKJXO
MWUR>G5Y?OGN[J?=_N:_#1WV];+)_5M;)@EU1\6>3I62<S.;,3;A[L;/_\FCC
MV2^Y$%@L+449C+]<Q$,6 K$8M?R3;S3&7GLQB+^_]P?3TFWO^VFX9!,^)69H
M*FD&FG$3:=EI451<(0ZE-H[I@KW1)F>];NM?3&?LU A2\]LFNRS2-B)S^!PB
MT]^ZR+SF%O' Y.=S=E/HF2(QIF8,D(F1$1HN%!I) CUPK!Q>S%E5.%,11H"T
M$3((0L99CCLC$=2,IWADF,Y!:DY'N36!@E*REINY%\GY#:'?%9L6SP2<09<J
MI!_TX052:9!N(%9 '9X(,FPVD>F$V<K_+/5G9*@VX@>02ZN0EWR*FTDWP0!M
M26EPT-LMX9H6&.84:H(E\]5I>"X0''P_$"26R0)!]GA9!K4)_$$<S6:E7189
MV(/[J@C7J:H$; (X*Q%L G32J#DK$7</60]EI9:8K.%@'W0-V(M0;C6]1*4@
M "!JH"5T9X,_*;<3EBD]LPN4&AI+ZU"K.<;]P^@WO&RN@,TNG%GS]KG@;;AU
M>+N^%YP7.R_[O8,C6R.JK@<\1>@LD[C=M7LA<I>,&PH80<QEHLC'DA& F2AI
M)U[#B^5@2,^2_EY(FRIM*^AY[C1:1;"41J<D\-BR76!#$, 6 7!QFTYX,29V
M"EJZJA0D>@/>ZNWO4O2BMR_B7;R5ONPK(DB]?>:Y:P6[$4O>EXT[RNYUE*$C
M/\Z'B(:$3^E?4#+M#Q^B=/#+-T/I+M_;%ICVA^W#GI^(<[(H[1&ND-4^C:6F
M3[@IK^SF*C[S)01<U#W%7*HK P,@J*FT@?8@146PX\OD)6&NDJXAQ0/0ZF2Z
M!$NS)F3?*$&>\,5J)478<-HJL5)(;J0?@(PI/Z2!PENJK$_#86G:D+,#26)'
M"X>PU0Q*)0?"TTIQS^T85G!BF<ZA$8N#U9H&5PEY0= O]$E\ =UN%Y"3;0+R
M8+@.Y(TI:PW/FY/=QK#&4IA*X='*K2ZX9W5N@71?6GH(<R,6< + )4^DDF[N
M4_QCW?K%%9 70!77Q3W1E=(T)(_;>D!E94J VH:2)$VU$<&!4*2.J4"EH8!M
MM%#I%XT700$>\8O%)4OP][-!<+I-"(Y4?#'EJ@I\Y<-+688R44X1&/M(N7=7
M46S O_'V\0HP !:*X$X;Z\Q$5^YI#S;)$/Q.FGP1G7UZW\.217D>UB#%F8 _
M 6^^@^> .;%-F*M9,X9S'19^^UT7;Z'E4>Q]!E?ZE*[3M#(^^"OY\Q&KN;8.
MS_UI(VS9%(;^J)!^87KW"94,* :+/9"N'<>NB<+)@3]4"*=!T:^]Z-6$V[MB
MP_-?0#V)D!C"?-2D/6=*WI"JCQ$>R#>_>(J^$.E;M1W;_]ZW8_5>+)PGBL42
M:2Y9RI/F*DR7A.6!]AG%QUH=>^<:1RWKM+%W^3X\@,D\E\X1?20E)!H5A6\7
M$OX%([L ,QC8>H;'7U]1+U8@_5%)N!]66U6DX;1A[_];KK\NSY\JU&BH&26@
MYK>Y?L.<2@(VZEQ]M_69$;_QR3?6;"']AFHS''HNCH8^"W'U+B4>,CQ";%Q
MT=(=KSV)SKI&A0H@AE*R&2L B_1OJQP P2R%P=3YY-%#M&>5W;=P3W2*))X9
M$$<3<:? =4!..*2N(=:,.5 64ZVFY!-AP<?U6;NIZ9'R4NDYH74VT9$3^3T
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M[E*%)XA3Y=95/O&E4OT;OYL*7W"=_!=02P,$%     @ LX!B5@Z*;\E,!0
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M: N:$$6/#U[ WT&G><RY4R$3Q&\N'ZK\QSO[\EK\@J!_RSCY%U!+ P04
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M>/N2,&S^*P^6/6="*9'WO=LI>%8(5JJ[4QY48J>MBK:V?#SZ E!+ P04
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MV=SMM<B$*Z\]^O2.<.GVL3<1C!F4E7J> )YE2N>\I$OX>3(0LZY03J"!#4!
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M ]=00YI_Q-V9,#Y8U3TH).E0BF9S6CU)R@E=N\FOOJ7=3SS@ADU57=!:UP;
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MM-OHZ4O0)4ZZ;32-P8B'-\!88^F9@>D!3J(9"N8JQ7 HRSJ %Y%Q3/Z(CXM
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M!6[ / J(IO%4,GU))B!J6& 88!R$*48S,Y1<>"*S#<H"7#8X$D;?Q2EI.EC
M1DY,Y51"# B@B)=X*=IE$\T*K FEL]0X,@11,U2 2'<X%VNBPDCR.%(( H(%
M9D)B%R.OLD@J A>&74@KH1=QL$<9 ,$F@\T,.!3DS@!<DW!9C( O/A(].M!)
MZHF-]J;*[DHGEJW=G/N) @CA/,,@M:4SO4#X20SBE2B"T7SC>!,,RE!S;!&I
MHA59@,U&'^S2Z9H(5&<I[A5#=]#.W2++=%>;IIQ<L-&_PU#[,-05N46G?@(&
M?FM/CP54W 90)EY@.G8>"ICP9EEAHC0)=4.*G;2]"GXINBSQ%+17$G9= 40(
MDS%$)H'W*?3_9,:</*T8RCB/Y1A5M6 Q,L$-DFH&*UBF<#\B#<G:I!?B1WNS
M\2 J<T4:\F[M,I\H8"&-86K?'+[TQ"R2"HO*E%LD2 ]IE%@N9SG/\('I^9=$
M\9DP2?6 ) S\J"3=F</=-!?5=0]0M0%5PJ5:-%= F+',WXF9B1G/16X&DF:"
MA6](OG"R/FHOZ90-<67"?"ADEDLQ9"%P>"-'HY+?PP^S1&]]F;B(+H3(@9AH
M *4J#\SW+]#8+$EWDQEB %."V2VH#,0$T$R5.BF4$,B=ZA"/\?PK#AOU^3M]
M5I&KTP18% :,VKP,SD;V%/15P;25J6;5*919MIY&'B_J[N$PNO5#"=ZMV_*+
MG;OP@G8(BO*:";^Y:;ZM_7P(Q<V!?K]\)&/=6?DC^:#OPLI+\K@Y5CZ*2<TJ
MY2SDLD$KL.#WT8Q&%3R D2CKU,C5RC"6*V 8N?(7UY1,* B9LA=F-0_064'%
M=92)![;C7'WCY0$KQA,AK?3!L)8ZR21)]303TO=JIY8-2TJ=?$GWNNHC#A_V
MWTZLDE#3M95FT)Y 0T-7C,I33LXGH-%0+[]0Y(5&N?TKEQRC+UG\/XL/]G.N
M-/8LJ?00G22SO.&D9=ZBHD]6ZV4]XT)&:Z#]F*0Y'Y8_#_!,C0Q+<FS"G-#E
MIHS;2!7R2F,VN%24V)#?+1G$:8K/=\JQXK2AZR=*BIU4Z3;2#%T'@&"3K\S1
MFJIE1E3@8Y%.6TV6_1PWS)5F@2-NZB0[S![J7:HTV:Z<FHD;T_FZ"CUAKNU$
M.4\=9V8]%SJHG3Y0"*HC6RTMGD=.DR2>^>0:06;X'9UWC *V=,FB6B(28FP^
M.GY!RL[)/9>9/Y$R7U;/C0J6"J4$Y$=]7BCP2.>-=[/N_?#"])3K#@C93MD5
MT&F*(FK/V>A>D6G*E]9+K?_,[YX$7(LP7TT/\TU!^E&A0AX7F=*$+68/5%)0
MW:::XZ534&QNM>RCTO&NXZSXA4QJ=B"@3V%=Y<;TP)*TTE /1#R)6.9$KE4G
M&5N?#;KNU1%=F1,YOI?G10O$GA13"'-6>1.?2B%S(L?MTA,/PZ\,H!]",L28
M$##.DW1DA Z:5%:ZYA5CVH4Z3DC3/#DRS60Z@N]9%3>.-\Z/PF^PXH2E;QPZ
M>;,-XU"CXLB%P=1HN2,>/[3QVE^)?:%37&UI82DXY0NS_"2,T^*FXB*?XHKQ
M=)Q[C-U!:!%:?!@JQ1SHP*'8=%7JTBB?&\567[*^=1O61#3W7"AN_X7B[DUQ
M(1M4[-5E7%9.82,-'34$H*B$'PV-G^K("K .+CNV]@T3'DXI*M.@3.^0,96H
M-LN?Y&*A\"O :!ZD>> P@Y]$'4KE1X"X&$ZS(.6-))H_4<8'N9!M^;Q4I]?U
MHXP"OJ?;8"=@5BIUV<Y3#"-OH4:UBM!/=SH[+<@Q."P\0(H&<6GS C8YRH5*
MKSD95]ZX#%_((DM' LR.%W32D#M\@>E-3.];F 2QM4!3,/)=D&#X&5 RQXN1
MC(#8;/5E[E,ZG9/,,^D0P9BN&:*L(W8-JAIWTV"!D[(3)-J85J9.?EUMGU)\
MBU^4AR".; =>%:G#<#YQB1H_B.858?5^[?QX!8=%Q6Z[#/^O+5K+U6I589-R
M![=9=,0TA.BE9"&_HZ<D II=K>Q<5L-0B35&\B7_#K\PM17660E$I'X2<RV0
M5/YDM3@P"J%4F"Z]+_7RL/^'BC-FCG0\E4T44'3):U >8\5[P.X!F$I;JD0(
M3U[XL:-$L1_F'/)/TTG^NG;$A<5AT*F6DP(O<0L_*Y+Z9# 4'P:#+C5X^Z-]
M^KE]?-H3G<'9J-_M#=OC_N"LVN3IY3,$X!(2O6I81QX^T.D9X4O$CA2L@3$#
MI)"K65;,6W+1<J6E7S6OX)RI.=P&*JOK+R2^@7NP8*DDVT'_KH\?J?/5TC$>
MS0RXB!]Z<J&F1J]F=\W<X,00LBW5P:#EF@[J(K:<X&BNP^H''0+:$D!IXP0R
M0\#(U54'^Y8FHGD1ZO21.F8!UHVJ/-^5NKDM,\%P$[195=TFC.TDBR5>!*#X
M?P-Z,82'<5\2)Q!9H1-H)HP@AN>PJ1=(E,C'!['\&#?ZP@+K=%OBT4?T'A%\
M6>M.O/2K(70DA HK0?6%39'0H7:<R)MA9AS/P88]E4O+WJO/8F%P+IP6*L<]
M.>&F#!K+"4$<8!"@A9!PHBCAPU4O#M$$B="UAE.@30"8@?&B+!D]$VY,LN*_
MNR8R66>.9I;AJ@$(J\<#EI+#"345?+W,@4$'<-X=%*NB45>]M[#$.><E<+<'
MC%_&PVYU5^[4&=T=J61-]?<UL399=1R0F@J<[+!P+E1].B,O48U\<1SZ#GSC
MTJ&X90 OU79 *Y+5<UU,M/1-&_G^+75HW:+$&JAFM*\U2$]Z>KV/GLZ9T8+/
MQ56]/W52JB153JBAR^0"S$7,/4#5W%,,BREWZ7 2")^(7+-,S-I0J;R<B\@A
M<6G*!(I"Y&UJ2+S-5F%[;##:SI3*=,::M_G :?A8$P93;X>W(!./UMN.OUY<
MW.YM"><E+NZ)Q<55E/,&Q#A1"JTZ.^-CNDFBBI$ZL?:"86"_M^S\TMHQ*CQ@
M2R] O03YBH6QD3-HG1E,]]B5*M^0C2P5G! KG38*$JQ)RHKT5-7PA2NWU^A4
MCZ>T;"@K& 71IYIW6<I;C+-UIOD$(C]Q[=SI)ZPB964$#!3XR--2T) QH))U
MX/WK6:^X,M&!SL#U<\.14UWGB*3:!/%-? 3T.@[H6$ET4J'6N"4 6]*ST$-B
M8O'4XJLI  IK]66^:U!6S-"FDJ7Z\ @A1,5W00G"A"#X2$OU0WT>EH5C%Y3:
MG!I8R&S+VAU%>53BHP!W0553 ^5E1.^LNI#"DP*V"Z*(7/&Z="X7U"U+!X*[
MM$=J.0<E R[G3RY88\X!RP_U0P@A':ZN(V:H?6M6-(.<FUP5&.@/D5#Y.Y^+
M?E/#@(C<7BGW> #?;&ZG:+)'KQ!;8,LIFJ%Y/9[NM$(_BK;H-M!D8K8#$Z1@
MI@7MR2=369FJ4>)PE@'3 =C!EM29GF:L)X2/4;ENFTSE2-DJ5- NQG,HYE8H
MMK1AGJWJ>AKB*#=>_G+K,@X4IA='5-Y;'41S<*5N2[DVX/%VH95\-\SDQG&N
MB)LB57.];:Q1%/DD63#Y9&TIFJ5Q]$D">A,LQ0=H BJ0CF$!DZ3S054%*3N/
M47%P5/+KB7I*#VKG*4T=$1Y(D&JSSM<%S:L4I"SAJ3Q&DR0-!H#0A63M8?JJ
M_P0D#Y$O=_36'@P* [EAK'5$F.8>39$[@3SA9"A9T+>H\/P$12]F?;L+[7T@
MV=WV//E=]-5L,B^)JN0[PG"1V.3EI".RTP0/X(/0H<Q0#X59ZK #G@7KU X9
M[Y%*I]6PA"E'Y:P4^TOS['';/-_;"N44M L^#4[192I!\2,5&0-ZO;3[[Q)"
M&NQB4RG&658P-MM6%0O'H*9&N#%93:O]?:YGQ1I\A(G3-@ZAW($:L>Z1?OU$
M3V[?U(YE=EBU0&Y1>;Y%D9$II27O4D65QTNHYAJ@J)6;NI$>)K"[9IG?FI[V
ML;I&>L"@[S8$6A9HG5V0O][(3F1U?Q-=R!#1-@+JR;F#03'JYF*;J$IYZ'N.
MA?79O CL%HK/V9"-BX;VNS8">YHVC"9+)UMG;EEE[O&T\T5>@E#3E(3X;NDX
M$: ^'5QH4^N'NSU61$"'M2.@7K;?/2U7*R<DX*+ 3B.-;JG -W3-Q<*%K,6U
M^AG1!8R$I9M3)$HO4'H(O0@0U76^8;D9;+^#M%H\:D'*U<<D6AS02\I.2M:$
M!!(YZ2,[-#+P'))>H)P]&]EIDPZ5<+.\?["%X8U:7XBBA /O\$O:%E5G?:?M
MNRDY:W.%G<2^.MF2>7I/ :3.D7*7P.BQ9LJ3DDVDV"J<HG))9]+1%%Y^"%PK
M7HQ45.+Z3@B&/E;Z)F6@7LJQB"1K<V/B>&M9I]("B-VY\@)&9YYCL$F#@6#9
MV9,.#5O#C#(&I*:&I3=),PG,0(9;7.>$)ZEG'2VB& ^&59:)E9G6QM+QH$XV
MU;V8IMGI:"Y0V36OC*4#R1-I$]AR1#Q*-Q&'^.#Z$U53Y$R'$U/M( S-:2,L
M<!BDW*]^^$V,T NT9C0<8ZAV@9XLN*YTW!OYD3CZC6&B<B0^>PYIT[FQQWEZ
M:#_5I-3F3GU8NG+F<!,FQ)%3\PHD9:7:_?AC?R3:GWIG7?A_3&$IXX\],>Q_
M^#@>T=?!\6G_ T6FC,3@A*Z>MX?C?F\DL!7]Y[-N;RA&']NGIZ)_)O#/L#<Z
M[W7@\>.>^##XHS<\ZW7%\5<:#4-=QL//\ />W.D,AMWV6:<GOO3''ZFY/?P^
MAB?:I^*T_25]XVC<'O?PRUGOB_@Z&/ZOV, G!I_'\+8/[2',>D WPO@GI_W.
M&.^E <Z'_;-.__P4ICO^V!Z++X//IUV<XN?3,<X!'VJ?G\,SM$9\KGWV%9\5
M [@VQ*?X+OKI1(P^=S[R?#8-&*!S^KG;/_M "__4'L/<:=)JG1T<T\!(GWZW
M/V80G/>&)X/A)URVH68/LTN7>CK(9L(K.CV%EPW;IP8L9O!'O]OK&N+CX$L/
M(&OPHOHG>H8CO8!_?1[V1]U^AX?*5I("D+>,]P<!482CGK%!T^VI88:B=X)?
M\"7YWQ7,^CVZIS 83+G3ZWZ&Z:?@:=,8"+3>&4"BTR/4RPTRPB'RZR:8Z]71
M%UY1?I$CM2* /(S]N8<OQXW]RDL"*/7^',.+[E"Z^ %J$%OD5*R(^?W^V^%/
M[SU#(QYA0(MCW6)*QZ9KJG+NY]@?LJ^/UTB@GP+DQ3'<\:W:CCF'N^MS=WZ]
MX_>]E^-WO6['_N<K9V=G*N5D=V]J67+OX& R:=IOWAQ.]N"'UG3G8/)_>Z]^
MTI'],ZU* ]P>I/D9"L$OJ%,,3JH-@J4,,2PP*G60'A_F4!"GS0;D2&))F9P=
M"3>E!4/A(I?ORT+TV2K-,G"*;E"N+IK%^E/ILE5)]?X=)Z6D' 43RK8P],X,
M(GFD/[S%R +77!PY'BV/'GI;1 E01=]>HL/;,EV%%80-?#G#O,8.8U\,*!?;
M^LWJ<H,N;<?VZK6]P\;!P<':RSN-YMIKUPV[WSAL/ORH>]B#^?6MAMTF0# P
M -Y18'K_?+7[:DF'.&H%WT6S2'2H5JR W \JHKGCP7 (.N2P6.Y:K?Z:A>W@
MLE[=_58%MV4IVJ([?LXK[SZ[)[2KY;P+E.[>Z=<_R3!IO.SJ4YC=D\>Y8XSW
MWCMX&]&_XE^H6WAB*+W_/!X"/A 06?C]'!W\=L \,^>2"VV5P;&HKSZZKPA#
M[GARG9DCI^+$\<"8<Y0'<Q"HM,%(##AO9TE'_<4)O=ZS>T)L:$U'X-1?)-H?
MM"_SM(?NR1<=9^U&']9YH\O9T.@478Q_]$9C\AMV!L/SHJKS)+:AWK-[0MS@
M5DI)VXMGOK<0_VJ($=:$\/PGIYM4!\M,)WD&8*Q>Q<NI46U5[4?:ZBC7#Q?W
M<%P^MJAEJ3HJ[Y15Y737"XQ1[ZP_N$9N5#S#SCD>5/Z!AYR=8:_;QZ/)SN!3
M3YQ\!BUF=/Z'(4Y/.[6?[7&W@Y.MZUQAQP=#_(0(C.>/&KHUF_#H1'1[QV.>
MWFFC/F@*A/2Q4T^<Y*DA JZ?U'T/AFJKO#S^Y*[KR'=3_\"*H7HK-:8V'I8R
MU> ^!YZ/O82R+?^UK:EM.G[[L<B1!PM!>:2!GNY3+S$Z[].H4@[1B?V['G;7
M/GCGS5[C\/7/#=YYP""4AP]0.:@^0*4>]'>=.J/2"I\IW\F,(8X$0'.HTQN.
M^R<8"=N[243$?G#4;%86,52(7J@XA+IPYEYM#^UR8'5S^UF-2HB;="(G88)9
MN ?4>75]39]"&.Y!JH.H,+6M@U9E6)<[3:I?K_3R@Q'*;[DF[UK<1A_4Q+[<
MV+Y1WMF^(C=U7R=J<1+YPM#%_AQ/S.%7,S MG4/DZ=*2A9QP! M6;N 'L/SU
MI6-C*K)^ULBUPS*68_B6HO?*O:/K(%L;*#;7LK"^,.?+"?6Z)$@)-!OBTT)0
ME1XL4V'F&^A-) #PQGRBIX%UK;7P6DF9E]\Q X]SW3S*\HU60CYS)0^H6HL?
M!DHUR8ID9AT)=!ESVI58%4WH@BY[988EX:-/$L"[:P'<IA(-*D$3LT"C"O6
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MQ7/W_?\#4$L! A0#%     @ LX!B5E>S5-C%!P  R38  !T
M ( !     &%R9&5L>7A?<'-G>&US86%M96YD;65N=#$N:'1M4$L! A0#%
M  @ LX!B5J;]$<"-$   X6   !X              ( !  @  &%R9&5N=V]O
M9'9E;G1U<F5L;&,M;&5A<V5A+FAT;5!+ 0(4 Q0    ( +. 8E85^?2<:DL$
M !^7)P 1              "  <D8  !A<F1X+3(P,C(Q,C,Q+FAT;5!+ 0(4
M Q0    ( +. 8E:G2$Z"L1P  )!5 0 1              "  6)D! !A<F1X
M+3(P,C(Q,C,Q+GAS9%!+ 0(4 Q0    ( +. 8E;OJ9S#C20  /9C 0 5
M          "  4*!! !A<F1X+3(P,C(Q,C,Q7V-A;"YX;6Q02P$"% ,4
M" "S@&)65S"QSCZ%  #RZ 4 %0              @ $"I@0 87)D>"TR,#(R
M,3(S,5]D968N>&UL4$L! A0#%     @ LX!B5HB<G'7G"@  <PL  !0
M         ( !<RL% &%R9'@M,C R,C$R,S%?9S$N:G!G4$L! A0#%     @
MLX!B5I#WW"[T90$ )<D. !4              ( !C#8% &%R9'@M,C R,C$R
M,S%?;&%B+GAM;%!+ 0(4 Q0    ( +. 8E8I*^@-!=,  $B2"0 5
M      "  ;.<!@!A<F1X+3(P,C(Q,C,Q7W!R92YX;6Q02P$"% ,4    " "S
M@&)6>2Y/L.T'   &)@  %P              @ 'K;P< 87)D>"TR,#(R,3(S
M,7AE>#,Q,2YH=&U02P$"% ,4    " "S@&)6-X<Z".0'   <)@  %P
M        @ $-> < 87)D>"TR,#(R,3(S,7AE>#,Q,BYH=&U02P$"% ,4
M" "S@&)6#HIOR4P%   F&0  %P              @ $F@ < 87)D>"TR,#(R
M,3(S,7AE>#,R,2YH=&U02P$"% ,4    " "S@&)6 J971?P#  "9%@  '@
M            @ &GA0< 8V]N<V5N=&]F:6YD97!E;F1E;G1R96=I<W0N:'1M
M4$L! A0#%     @ LX!B5I>T8$EV$@  K 8! !X              ( !WXD'
M &MY;W=A:VER:6YC;VQT9&9K86MY;W=A:&%K+FAT;5!+ 0(4 Q0    ( +.
M8E9Z5L&R028  # 0 0 >              "  9&<!P!S;'(M87)D96QY>'AS
G96-O;F1A;65N9&UE;BYH=&U02P4&      \ #P 6!   #L,'

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
